PMID- 36875844
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240913
IS  - 2296-861X (Print)
IS  - 2296-861X (Electronic)
IS  - 2296-861X (Linking)
VI  - 10
DP  - 2023
TI  - Nutrition in the prevention and treatment of endometriosis: A review.
PG  - 1089891
LID - 10.3389/fnut.2023.1089891 [doi]
LID - 1089891
AB  - Endometriosis is characterized by the presence of endometrial tissues outside the 
      uterine lining, typically on the external surface of the uterus, the ovaries, 
      fallopian tubes, abdominal wall, or intestines. The prevalence of endometriosis 
      in North America, Australia, and Europe is ~1-5% in women of reproductive age. 
      Treatment options for endometriosis are limited. While over-the-counter 
      medications may be used to reduce acute pain, hormonal treatments are common and 
      may interfere with fertility. In more severe cases, laparoscopic excision 
      procedures and even hysterectomies are used to treat the pain associated with 
      endometriosis. Nutritional interventions may be helpful in the prevention and 
      treatment of endometriosis and associated pain. Reducing dietary fat and 
      increasing dietary fiber have been shown to reduce circulating estrogen 
      concentrations, suggesting a potential benefit for individuals with 
      endometriosis, as it is an estrogen-dependent disease. Meat consumption is 
      associated with greater risk of developing endometriosis. Anti-inflammatory 
      properties of plant-based diets may benefit women with endometriosis. 
      Additionally, seaweed holds estrogen-modulating properties that have benefitted 
      postmenopausal women and offers potential to reduce estradiol concentrations in 
      pre-menopausal women. Furthermore, consumption of vitamin D has been shown to 
      reduce endometrial pain via increased antioxidant capacity and supplementation 
      with vitamins C and E significantly reduced endometriosis symptoms, compared with 
      placebo. More randomized clinical trials are needed to elucidate the role of diet 
      in endometriosis.
CI  - Copyright © 2023 Barnard, Holtz, Schmidt, Kolipaka, Hata, Sutton, 
      Znayenko-Miller, Hazen, Cobb and Kahleova.
FAU - Barnard, Neal D
AU  - Barnard ND
AD  - Department of Clinical Research, Physicians Committee for Responsible Medicine, 
      Washington, DC, United States.
AD  - Adjunct Faculty, George Washington University School of Medicine and Health 
      Sciences, Washington, DC, United States.
FAU - Holtz, Danielle N
AU  - Holtz DN
AD  - Department of Clinical Research, Physicians Committee for Responsible Medicine, 
      Washington, DC, United States.
FAU - Schmidt, Natalie
AU  - Schmidt N
AD  - Department of Clinical Research, Physicians Committee for Responsible Medicine, 
      Washington, DC, United States.
AD  - Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, 
      FL, United States.
FAU - Kolipaka, Sinjana
AU  - Kolipaka S
AD  - Department of Clinical Research, Physicians Committee for Responsible Medicine, 
      Washington, DC, United States.
AD  - Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, 
      FL, United States.
FAU - Hata, Ellen
AU  - Hata E
AD  - Department of Clinical Research, Physicians Committee for Responsible Medicine, 
      Washington, DC, United States.
AD  - Milken Institute School of Public Health George Washington University, 
      Washington, DC, United States.
FAU - Sutton, Macy
AU  - Sutton M
AD  - Department of Clinical Research, Physicians Committee for Responsible Medicine, 
      Washington, DC, United States.
FAU - Znayenko-Miller, Tatiana
AU  - Znayenko-Miller T
AD  - Department of Clinical Research, Physicians Committee for Responsible Medicine, 
      Washington, DC, United States.
FAU - Hazen, Nicholas D
AU  - Hazen ND
AD  - Department of Obstetrics and Gynecology, Medstar Georgetown University Hospital, 
      Washington, DC, United States.
FAU - Cobb, Christie
AU  - Cobb C
AD  - Department of Obstetrics and Gynecology, Baptist Health Medical Center, Little 
      Rock, AR, United States.
FAU - Kahleova, Hana
AU  - Kahleova H
AD  - Department of Clinical Research, Physicians Committee for Responsible Medicine, 
      Washington, DC, United States.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230217
PL  - Switzerland
TA  - Front Nutr
JT  - Frontiers in nutrition
JID - 101642264
PMC - PMC9983692
OTO - NOTNLM
OT  - endometriosis
OT  - nutrients
OT  - nutrition
OT  - plant-based
OT  - vitamins
COIS- NB is an Adjunct Professor of Medicine at the George Washington University School 
      of Medicine. He serves without compensation as president of the Physicians 
      Committee for Responsible Medicine and Barnard Medical Center in Washington, DC, 
      nonprofit organizations providing educational, research, and medical services 
      related to nutrition. He writes books and articles and gives lectures related to 
      nutrition and health and has received royalties and honoraria from these sources. 
      DH, MS, TZ-M, and HK received financial compensation from the Physicians 
      Committee for Responsible Medicine for their work on this manuscript. The 
      remaining authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/03/07 06:00
MHDA- 2023/03/07 06:01
PMCR- 2023/01/01
CRDT- 2023/03/06 04:15
PHST- 2022/11/04 00:00 [received]
PHST- 2023/01/31 00:00 [accepted]
PHST- 2023/03/06 04:15 [entrez]
PHST- 2023/03/07 06:00 [pubmed]
PHST- 2023/03/07 06:01 [medline]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fnut.2023.1089891 [doi]
PST - epublish
SO  - Front Nutr. 2023 Feb 17;10:1089891. doi: 10.3389/fnut.2023.1089891. eCollection 
      2023.

PMID- 37755656
OWN - NLM
STAT- MEDLINE
DCOM- 20231107
LR  - 20240621
IS  - 1535-1645 (Electronic)
IS  - 1523-3812 (Print)
IS  - 1523-3812 (Linking)
VI  - 25
IP  - 10
DP  - 2023 Oct
TI  - Cognitive Problems in Perimenopause: A Review of Recent Evidence.
PG  - 501-511
LID - 10.1007/s11920-023-01447-3 [doi]
AB  - PURPOSE OF REVIEW: To review recent research regarding cognitive problems during 
      perimenopause, including which menopause-related symptoms, demographic variables, 
      stress exposures, and neural biomarkers are associated with cognitive problems 
      and which interventions demonstrate efficacy at improving cognitive performance. 
      RECENT FINDINGS: Cognitive problems are common during perimenopause and have a 
      significant impact on a substantial proportion of women. Evidence continues to 
      indicate that verbal learning and verbal memory are the cognitive functions that 
      are most negatively affected during perimenopause, and new research suggests that 
      perimenopause may also be associated with deficits in processing speed, 
      attention, and working memory. Recent research suggests that the cognitive 
      profiles of women transitioning through perimenopause are heterogenous - with 
      some showing strengths and others demonstrating weaknesses in particular 
      cognitive domains. Depression, sleep problems, and vasomotor symptoms in 
      perimenopause may be associated with cognitive difficulties. Recent neuroimaging 
      studies are identifying changes in activity patterns within brain regions that 
      correlate with cognitive performance in perimenopause, but future causal studies 
      are needed to understand the neural mechanisms of cognitive problems during this 
      time. Although clinical treatment studies for cognitive concerns have 
      historically focused on postmenopause, some small trials in perimenopausal 
      samples have been conducted recently but are frequently underpowered. Current 
      guidelines from the North American Menopause Society do not support the use of 
      hormone therapy at any age for cognitive problems. Animal research demonstrates 
      that estradiol and levonorgestrel combined may alleviate working memory problems. 
      Much progress has been made in understanding how perimenopause impacts cognition, 
      and more research is needed to better identify who is at highest risk and how to 
      meaningfully prevent and alleviate cognitive problems during this reproductive 
      stage. Larger-scale randomized intervention trials specifically during 
      perimenopause are urgently needed to address cognitive concerns in this 
      population of women. More consistent reproductive staging, inclusion of 
      covariates, and analyses examining perimenopause specifically would improve study 
      quality and the ability to draw clear conclusions from this research.
CI  - © 2023. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Metcalf, Christina A
AU  - Metcalf CA
AUID- ORCID: 0000-0003-1669-3561
AD  - Department of Psychiatry, University of Colorado Anschutz Medical Campus, 1890 N. 
      Revere Court MS F546, Aurora, CO, 80045, USA. christina.metcalf@cuanschutz.edu.
FAU - Duffy, Korrina A
AU  - Duffy KA
AUID- ORCID: 0000-0003-0377-0134
AD  - Department of Psychiatry, University of Colorado Anschutz Medical Campus, 1890 N. 
      Revere Court MS F546, Aurora, CO, 80045, USA.
FAU - Page, Chloe E
AU  - Page CE
AUID- ORCID: 0000-0001-5573-3760
AD  - Department of Psychiatry, University of Colorado Anschutz Medical Campus, 1890 N. 
      Revere Court MS F546, Aurora, CO, 80045, USA.
FAU - Novick, Andrew M
AU  - Novick AM
AUID- ORCID: 0000-0002-0995-5060
AD  - Department of Psychiatry, University of Colorado Anschutz Medical Campus, 1890 N. 
      Revere Court MS F546, Aurora, CO, 80045, USA.
LA  - eng
GR  - K23 HD110435/HD/NICHD NIH HHS/United States
GR  - L30 HD106379/HD/NICHD NIH HHS/United States
GR  - U54 AG062319/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20230927
PL  - United States
TA  - Curr Psychiatry Rep
JT  - Current psychiatry reports
JID - 100888960
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Female
MH  - Humans
MH  - *Perimenopause/psychology
MH  - *Menopause
MH  - Postmenopause/psychology
MH  - Estradiol
MH  - Cognition
PMC - PMC10842974
MID - NIHMS1935225
OTO - NOTNLM
OT  - Cognition
OT  - Hormone therapy
OT  - Interventions
OT  - Menopause transition
OT  - Perimenopause
OT  - Prevalence
COIS- Conflicts of Interest CAM, KAD, CEP, and AMN report no financial relationships 
      with commercial interests.
EDAT- 2023/09/27 12:42
MHDA- 2023/11/07 06:45
PMCR- 2024/02/05
CRDT- 2023/09/27 11:12
PHST- 2023/08/08 00:00 [accepted]
PHST- 2023/11/07 06:45 [medline]
PHST- 2023/09/27 12:42 [pubmed]
PHST- 2023/09/27 11:12 [entrez]
PHST- 2024/02/05 00:00 [pmc-release]
AID - 10.1007/s11920-023-01447-3 [pii]
AID - 10.1007/s11920-023-01447-3 [doi]
PST - ppublish
SO  - Curr Psychiatry Rep. 2023 Oct;25(10):501-511. doi: 10.1007/s11920-023-01447-3. 
      Epub 2023 Sep 27.

PMID- 38907632
OWN - NLM
STAT- MEDLINE
DCOM- 20240829
LR  - 20240901
IS  - 1477-0970 (Electronic)
IS  - 1352-4585 (Print)
IS  - 1352-4585 (Linking)
VI  - 30
IP  - 9
DP  - 2024 Aug
TI  - All women with multiple sclerosis should start hormone replacement therapy at 
      menopause unless contraindicated: Yes.
PG  - 1107-1109
LID - 10.1177/13524585241255002 [doi]
FAU - Voskuhl, Rhonda
AU  - Voskuhl R
AUID- ORCID: 0000-0003-2620-4346
AD  - UCLA Department of Neurology, UCLA Multiple Sclerosis Program, UCLA Comprehensive 
      Menopause Care Program, University of California, Los Angeles (UCLA), Los 
      Angeles, CA, USA.
LA  - eng
GR  - R35 NS132150/NS/NINDS NIH HHS/United States
PT  - Journal Article
DEP - 20240622
PL  - England
TA  - Mult Scler
JT  - Multiple sclerosis (Houndmills, Basingstoke, England)
JID - 9509185
SB  - IM
MH  - Humans
MH  - *Multiple Sclerosis/drug therapy
MH  - Female
MH  - *Menopause/drug effects
MH  - Hormone Replacement Therapy
MH  - Estrogen Replacement Therapy/adverse effects
PMC - PMC11363466
COIS- Declaration of Conflicting InterestsThe author(s) declared the following 
      potential conflicts of interest with respect to the research, authorship, and/or 
      publication of this article: Dr R.V. is an inventor on patents owned by the 
      University of California, Los Angeles (UCLA) which are licensed by CleopatraRX 
      and Dr R.V. is a consultant for CleopatraRX.
EDAT- 2024/06/22 19:45
MHDA- 2024/08/31 09:48
PMCR- 2024/08/30
CRDT- 2024/06/22 06:33
PHST- 2024/08/31 09:48 [medline]
PHST- 2024/06/22 19:45 [pubmed]
PHST- 2024/06/22 06:33 [entrez]
PHST- 2024/08/30 00:00 [pmc-release]
AID - 10.1177_13524585241255002 [pii]
AID - 10.1177/13524585241255002 [doi]
PST - ppublish
SO  - Mult Scler. 2024 Aug;30(9):1107-1109. doi: 10.1177/13524585241255002. Epub 2024 
      Jun 22.

PMID- 38907631
OWN - NLM
STAT- MEDLINE
DCOM- 20240829
LR  - 20240901
IS  - 1477-0970 (Electronic)
IS  - 1352-4585 (Print)
IS  - 1352-4585 (Linking)
VI  - 30
IP  - 9
DP  - 2024 Aug
TI  - All women with multiple sclerosis should start hormone replacement therapy at 
      menopause unless contraindicated: Commentary.
PG  - 1111-1112
LID - 10.1177/13524585241254989 [doi]
FAU - Petheram, Kate
AU  - Petheram K
AD  - Department of Neurology, South Tyneside and Sunderland NHS Foundation Trust, 
      South Shields, UK.
FAU - Dobson, Ruth
AU  - Dobson R
AUID- ORCID: 0000-0002-2993-585X
AD  - Centre for Preventive Neurology, Wolfson Institute of Population Health, Queen 
      Mary University London, London, UK.
AD  - Department of Neurology, Royal London Hospital, Barts Health NHS Trust, London, 
      UK.
LA  - eng
PT  - Journal Article
DEP - 20240622
PL  - England
TA  - Mult Scler
JT  - Multiple sclerosis (Houndmills, Basingstoke, England)
JID - 9509185
SB  - IM
MH  - Humans
MH  - *Multiple Sclerosis/drug therapy
MH  - Female
MH  - *Menopause/drug effects
MH  - Hormone Replacement Therapy
MH  - Estrogen Replacement Therapy/adverse effects
PMC - PMC11363460
COIS- Declaration of Conflicting InterestsThe author(s) declared no potential conflicts 
      of interest with respect to the research, authorship, and/or publication of this 
      article.
EDAT- 2024/06/22 19:45
MHDA- 2024/08/31 09:51
PMCR- 2024/08/30
CRDT- 2024/06/22 06:33
PHST- 2024/08/31 09:51 [medline]
PHST- 2024/06/22 19:45 [pubmed]
PHST- 2024/06/22 06:33 [entrez]
PHST- 2024/08/30 00:00 [pmc-release]
AID - 10.1177_13524585241254989 [pii]
AID - 10.1177/13524585241254989 [doi]
PST - ppublish
SO  - Mult Scler. 2024 Aug;30(9):1111-1112. doi: 10.1177/13524585241254989. Epub 2024 
      Jun 22.

PMID- 38907634
OWN - NLM
STAT- MEDLINE
DCOM- 20240829
LR  - 20240829
IS  - 1477-0970 (Electronic)
IS  - 1352-4585 (Linking)
VI  - 30
IP  - 9
DP  - 2024 Aug
TI  - All women with multiple sclerosis should start hormone replacement therapy at 
      menopause unless contraindicated: No.
PG  - 1109-1111
LID - 10.1177/13524585241254987 [doi]
FAU - Magyari, Melinda
AU  - Magyari M
AUID- ORCID: 0000-0002-0972-5222
AD  - The Danish Multiple Sclerosis Registry, Rigshospitalet, Copenhagen University 
      Hospital, Copenhagen, Denmark.
AD  - Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, 
      Copenhagen University Hospital, Copenhagen, Denmark.
AD  - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
LA  - eng
PT  - Journal Article
DEP - 20240622
PL  - England
TA  - Mult Scler
JT  - Multiple sclerosis (Houndmills, Basingstoke, England)
JID - 9509185
SB  - IM
MH  - Humans
MH  - *Multiple Sclerosis/drug therapy
MH  - Female
MH  - *Menopause/drug effects
MH  - Hormone Replacement Therapy
MH  - Estrogen Replacement Therapy/adverse effects
COIS- Declaration of Conflicting InterestsThe author declared the following potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article: None related to this article. The author has served 
      on scientific advisory board, as consultant for, received support for congress 
      participation or speaker honoraria from Biogen, Sanofi, Roche, Novartis, Merck, 
      Alexion, and Bristol Myers Squibb.
EDAT- 2024/06/22 19:45
MHDA- 2024/08/31 09:50
CRDT- 2024/06/22 06:33
PHST- 2024/08/31 09:50 [medline]
PHST- 2024/06/22 19:45 [pubmed]
PHST- 2024/06/22 06:33 [entrez]
AID - 10.1177/13524585241254987 [doi]
PST - ppublish
SO  - Mult Scler. 2024 Aug;30(9):1109-1111. doi: 10.1177/13524585241254987. Epub 2024 
      Jun 22.

PMID- 27557300
OWN - NLM
STAT- MEDLINE
DCOM- 20160901
LR  - 20220410
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 375
IP  - 8
DP  - 2016 Aug 25
TI  - 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
PG  - 717-29
LID - 10.1056/NEJMoa1602253 [doi]
AB  - BACKGROUND: The 70-gene signature test (MammaPrint) has been shown to improve 
      prediction of clinical outcome in women with early-stage breast cancer. We sought 
      to provide prospective evidence of the clinical utility of the addition of the 
      70-gene signature to standard clinical-pathological criteria in selecting 
      patients for adjuvant chemotherapy. METHODS: In this randomized, phase 3 study, 
      we enrolled 6693 women with early-stage breast cancer and determined their 
      genomic risk (using the 70-gene signature) and their clinical risk (using a 
      modified version of Adjuvant! Online). Women at low clinical and genomic risk did 
      not receive chemotherapy, whereas those at high clinical and genomic risk did 
      receive such therapy. In patients with discordant risk results, either the 
      genomic risk or the clinical risk was used to determine the use of chemotherapy. 
      The primary goal was to assess whether, among patients with high-risk clinical 
      features and a low-risk gene-expression profile who did not receive chemotherapy, 
      the lower boundary of the 95% confidence interval for the rate of 5-year survival 
      without distant metastasis would be 92% (i.e., the noninferiority boundary) or 
      higher. RESULTS: A total of 1550 patients (23.2%) were deemed to be at high 
      clinical risk and low genomic risk. At 5 years, the rate of survival without 
      distant metastasis in this group was 94.7% (95% confidence interval, 92.5 to 
      96.2) among those not receiving chemotherapy. The absolute difference in this 
      survival rate between these patients and those who received chemotherapy was 1.5 
      percentage points, with the rate being lower without chemotherapy. Similar rates 
      of survival without distant metastasis were reported in the subgroup of patients 
      who had estrogen-receptor-positive, human epidermal growth factor receptor 
      2-negative, and either node-negative or node-positive disease. CONCLUSIONS: Among 
      women with early-stage breast cancer who were at high clinical risk and low 
      genomic risk for recurrence, the receipt of no chemotherapy on the basis of the 
      70-gene signature led to a 5-year rate of survival without distant metastasis 
      that was 1.5 percentage points lower than the rate with chemotherapy. Given these 
      findings, approximately 46% of women with breast cancer who are at high clinical 
      risk might not require chemotherapy. (Funded by the European Commission Sixth 
      Framework Program and others; ClinicalTrials.gov number, NCT00433589; EudraCT 
      number, 2005-002625-31.).
FAU - Cardoso, Fatima
AU  - Cardoso F
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - van't Veer, Laura J
AU  - van't Veer LJ
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - Bogaerts, Jan
AU  - Bogaerts J
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - Slaets, Leen
AU  - Slaets L
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - Viale, Giuseppe
AU  - Viale G
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - Delaloge, Suzette
AU  - Delaloge S
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - Pierga, Jean-Yves
AU  - Pierga JY
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - Brain, Etienne
AU  - Brain E
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - Causeret, Sylvain
AU  - Causeret S
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - DeLorenzi, Mauro
AU  - DeLorenzi M
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - Glas, Annuska M
AU  - Glas AM
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - Golfinopoulos, Vassilis
AU  - Golfinopoulos V
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - Goulioti, Theodora
AU  - Goulioti T
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - Knox, Susan
AU  - Knox S
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - Matos, Erika
AU  - Matos E
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - Meulemans, Bart
AU  - Meulemans B
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - Neijenhuis, Peter A
AU  - Neijenhuis PA
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - Nitz, Ulrike
AU  - Nitz U
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - Passalacqua, Rodolfo
AU  - Passalacqua R
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - Ravdin, Peter
AU  - Ravdin P
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - Rubio, Isabel T
AU  - Rubio IT
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - Saghatchian, Mahasti
AU  - Saghatchian M
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - Smilde, Tineke J
AU  - Smilde TJ
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - Sotiriou, Christos
AU  - Sotiriou C
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - Stork, Lisette
AU  - Stork L
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - Straehle, Carolyn
AU  - Straehle C
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - Thomas, Geraldine
AU  - Thomas G
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - Thompson, Alastair M
AU  - Thompson AM
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - van der Hoeven, Jacobus M
AU  - van der Hoeven JM
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - Vuylsteke, Peter
AU  - Vuylsteke P
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - Bernards, René
AU  - Bernards R
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - Tryfonidis, Konstantinos
AU  - Tryfonidis K
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - Rutgers, Emiel
AU  - Rutgers E
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
FAU - Piccart, Martine
AU  - Piccart M
AD  - From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal 
      (F.C.); Helen Diller Family Comprehensive Cancer Center, University of 
      California, San Francisco (L.J.V.); European Organization for Research and 
      Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast 
      International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, 
      Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre 
      Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both 
      in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and 
      Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti 
      Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif 
      (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris 
      Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene 
      Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - 
      all in France; Swiss Institute of Bioinformatics and University of Lausanne, 
      Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands 
      Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp 
      (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum 
      Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, 
      Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany 
      (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital 
      Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London 
      (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).
CN  - MINDACT Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT00433589
SI  - EudraCT/2005-002625-31
GR  - 7714/CRUK_/Cancer Research UK/United Kingdom
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Antineoplastic Agents)
SB  - IM
CIN - N Engl J Med. 2016 Aug 25;375(8):790-1. doi: 10.1056/NEJMe1607947. PMID: 27557306
CIN - BMJ. 2016 Aug 24;354:i4635. doi: 10.1136/bmj.i4635. PMID: 27561820
CIN - Nat Rev Clin Oncol. 2016 Oct;13(10):589. doi: 10.1038/nrclinonc.2016.150. PMID: 
      27620708
CIN - N Engl J Med. 2016 Dec;375(22):2200-2201. doi: 10.1056/NEJMc1612048. PMID: 
      27959762
CIN - N Engl J Med. 2016 Dec;375(22):2199. doi: 10.1056/NEJMc1612048. PMID: 27959763
CIN - N Engl J Med. ;375(22):2199-2200. doi: 10.1056/NEJMc1612048. PMID: 28117957
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*therapeutic use
MH  - Breast Neoplasms/drug therapy/*genetics/mortality/surgery
MH  - *Chemotherapy, Adjuvant
MH  - Disease-Free Survival
MH  - Female
MH  - Gene Expression
MH  - *Gene Expression Profiling
MH  - *Genetic Predisposition to Disease
MH  - Genetic Testing
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Mastectomy
MH  - Middle Aged
MH  - Neoplasm Metastasis/*prevention & control
MH  - Neoplasm Staging
MH  - Oligonucleotide Array Sequence Analysis
MH  - Prospective Studies
MH  - Risk
MH  - Risk Assessment
FIR - Benn, Karen
IR  - Benn K
FIR - Bogaerts, Jan
IR  - Bogaerts J
FIR - Cardoso, Fatima
IR  - Cardoso F
FIR - Ciruelos, Eva
IR  - Ciruelos E
FIR - Corochan, Sabine
IR  - Corochan S
FIR - Cuny, Julia
IR  - Cuny J
FIR - de la Pena, Lorena
IR  - de la Pena L
FIR - Delaloge, Suzette
IR  - Delaloge S
FIR - DeLorenzi, Mauro
IR  - DeLorenzi M
FIR - Dudek-Peric, Aleksandra
IR  - Dudek-Peric A
FIR - Eekhout, Inge
IR  - Eekhout I
FIR - Gluz, Oleg
IR  - Gluz O
FIR - Golfinopoulos, Vassilis
IR  - Golfinopoulos V
FIR - Goulioti, Theodora
IR  - Goulioti T
FIR - Harbeck, Nadia
IR  - Harbeck N
FIR - Hilal, Valérie
IR  - Hilal V
FIR - Knox, Susan
IR  - Knox S
FIR - Lemonnier, Jerome
IR  - Lemonnier J
FIR - Ławniczak, Michał
IR  - Ławniczak M
FIR - Marini, Luca
IR  - Marini L
FIR - Matos, Erika
IR  - Matos E
FIR - Morales, Pepi
IR  - Morales P
FIR - Murray, Kirsten
IR  - Murray K
FIR - Nitz, Urlike
IR  - Nitz U
FIR - Passalaqua, Rodolfo
IR  - Passalaqua R
FIR - Piccart, Martine
IR  - Piccart M
FIR - Remmelzwaal, Jolanda
IR  - Remmelzwaal J
FIR - Rubio, Isabel
IR  - Rubio I
FIR - Rutgers, Emiel
IR  - Rutgers E
FIR - Saghatchian, Mahasti
IR  - Saghatchian M
FIR - Slaets, Leen
IR  - Slaets L
FIR - Sotiriou, Christos
IR  - Sotiriou C
FIR - Straehle, Carolyn
IR  - Straehle C
FIR - Straley, Mark
IR  - Straley M
FIR - Theron, Nathalie
IR  - Theron N
FIR - Thompson, Alastair
IR  - Thompson A
FIR - Tryfonidis, Konstantinos
IR  - Tryfonidis K
FIR - Todeschini, Renata
IR  - Todeschini R
FIR - Urunkar, Milanka
IR  - Urunkar M
FIR - van 't Veer, Laura
IR  - van 't Veer L
FIR - Viale, Giuseppe
IR  - Viale G
FIR - Aalders, Kim
IR  - Aalders K
FIR - Bines, Jacques
IR  - Bines J
FIR - Bedard, Philippe
IR  - Bedard P
FIR - Bozovic, Ivana
IR  - Bozovic I
FIR - Braga, Sofia
IR  - Braga S
FIR - Castaneda, Carlos
IR  - Castaneda C
FIR - Celebic, Aleksandar
IR  - Celebic A
FIR - Colichi, Camelia
IR  - Colichi C
FIR - Criscitiello, Carmen
IR  - Criscitiello C
FIR - Dal Lago, Lissandra
IR  - Dal Lago L
FIR - Demonty, Gaston
IR  - Demonty G
FIR - Drukker, Caroline
IR  - Drukker C
FIR - Fei, Fei
IR  - Fei F
FIR - Lia, Michela
IR  - Lia M
FIR - Loi, Sherene
IR  - Loi S
FIR - Messina, Carlo
IR  - Messina C
FIR - Mook, Stella
IR  - Mook S
FIR - Moulin, Camilo
IR  - Moulin C
FIR - Sreseli, Roman
IR  - Sreseli R
FIR - Therasse, Patrick
IR  - Therasse P
FIR - Werutsky, Gustavo
IR  - Werutsky G
FIR - Corachan, Sabine
IR  - Corachan S
FIR - Dudek-Peric, Aleksandra
IR  - Dudek-Peric A
FIR - Wheeler, Lorraine
IR  - Wheeler L
FIR - Dif, Nicolas
IR  - Dif N
FIR - Rizzetto, Giovanna
IR  - Rizzetto G
FIR - Beauvois, Melanie
IR  - Beauvois M
FIR - Meirsman, Livia
IR  - Meirsman L
FIR - Breyssens, Hilde
IR  - Breyssens H
FIR - Decker, Nuria
IR  - Decker N
FIR - Engelen, Kristel
IR  - Engelen K
FIR - Akropovic, Anita
IR  - Akropovic A
FIR - Harrison, Jillian
IR  - Harrison J
FIR - Henot, Frederic
IR  - Henot F
FIR - Celis, Miet
IR  - Celis M
FIR - De Jongh, Britt
IR  - De Jongh B
FIR - Delmotte, Inge
IR  - Delmotte I
FIR - Daubie, Valéry
IR  - Daubie V
FIR - Goossens, Roel
IR  - Goossens R
FIR - Helsen, Nils
IR  - Helsen N
FIR - Hourt, Laetitia
IR  - Hourt L
FIR - Janssen, Sven
IR  - Janssen S
FIR - Soete, Virginie
IR  - Soete V
FIR - Vansevenant, Kaat
IR  - Vansevenant K
FIR - Hermans, Catherine
IR  - Hermans C
FIR - Hart, Guus
IR  - Hart G
FIR - Brink, Guido
IR  - Brink G
FIR - Floore, Arno
IR  - Floore A
FIR - Sixt, Bernhard
IR  - Sixt B
FIR - Buyse, Marc
IR  - Buyse M
EDAT- 2016/08/25 06:00
MHDA- 2016/09/02 06:00
CRDT- 2016/08/25 06:00
PHST- 2016/08/25 06:00 [entrez]
PHST- 2016/08/25 06:00 [pubmed]
PHST- 2016/09/02 06:00 [medline]
AID - 10.1056/NEJMoa1602253 [doi]
PST - ppublish
SO  - N Engl J Med. 2016 Aug 25;375(8):717-29. doi: 10.1056/NEJMoa1602253.

PMID- 33133423
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240330
IS  - 2001-0370 (Print)
IS  - 2001-0370 (Electronic)
IS  - 2001-0370 (Linking)
VI  - 18
DP  - 2020
TI  - Deep metabolome: Applications of deep learning in metabolomics.
PG  - 2818-2825
LID - 10.1016/j.csbj.2020.09.033 [doi]
AB  - In the past few years, deep learning has been successfully applied to various 
      omics data. However, the applications of deep learning in metabolomics are still 
      relatively low compared to others omics. Currently, data pre-processing using 
      convolutional neural network architecture appears to benefit the most from deep 
      learning. Compound/structure identification and quantification using artificial 
      neural network/deep learning performed relatively better than traditional machine 
      learning techniques, whereas only marginally better results are observed in 
      biological interpretations. Before deep learning can be effectively applied to 
      metabolomics, several challenges should be addressed, including 
      metabolome-specific deep learning architectures, dimensionality problems, and 
      model evaluation regimes.
CI  - © 2020 The Author(s).
FAU - Pomyen, Yotsawat
AU  - Pomyen Y
AD  - Translational Research Unit, Chulabhorn Research Institute, Bangkok, Thailand.
FAU - Wanichthanarak, Kwanjeera
AU  - Wanichthanarak K
AD  - Metabolomics and Systems Biology, Department of Biochemistry, Faculty of Medicine 
      Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
AD  - Siriraj Metabolomics and Phenomics Center, Faculty of Medicine Siriraj Hospital, 
      Mahidol University, Bangkok 10700, Thailand.
FAU - Poungsombat, Patcha
AU  - Poungsombat P
AD  - Metabolomics and Systems Biology, Department of Biochemistry, Faculty of Medicine 
      Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
AD  - Siriraj Metabolomics and Phenomics Center, Faculty of Medicine Siriraj Hospital, 
      Mahidol University, Bangkok 10700, Thailand.
AD  - Center for Innovation in Chemistry (PERCH-CIC), Faculty of Science, Mahidol 
      University, Rama 6 Road, Bangkok 10400, Thailand.
FAU - Fahrmann, Johannes
AU  - Fahrmann J
AD  - Department of Clinical Cancer Prevention, The University of Texas MD Anderson 
      Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
FAU - Grapov, Dmitry
AU  - Grapov D
AD  - CDS- Creative Data Solutions LLC, https://creative-data.solutions, USA.
FAU - Khoomrung, Sakda
AU  - Khoomrung S
AD  - Metabolomics and Systems Biology, Department of Biochemistry, Faculty of Medicine 
      Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
AD  - Siriraj Metabolomics and Phenomics Center, Faculty of Medicine Siriraj Hospital, 
      Mahidol University, Bangkok 10700, Thailand.
AD  - Center for Innovation in Chemistry (PERCH-CIC), Faculty of Science, Mahidol 
      University, Rama 6 Road, Bangkok 10400, Thailand.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201001
PL  - Netherlands
TA  - Comput Struct Biotechnol J
JT  - Computational and structural biotechnology journal
JID - 101585369
PMC - PMC7575644
OTO - NOTNLM
OT  - AI, Artificial Intelligence
OT  - ANN, Artificial Neural Network
OT  - AUC, Area Under the receiver-operating characteristic Curve
OT  - Artificial neural network
OT  - CCS value, Collision Cross Section value
OT  - CFM-EI, Competitive Fragmentation Modeling-Electron Ionization
OT  - CNN, Convolutional Neural Network
OT  - DL, Deep Learning
OT  - DNN, Deep Neural Network
OT  - Deep learning
OT  - ECFP, Extended Circular Fingerprint
OT  - ER, Estrogen Receptor
OT  - FID, Free Induction Decay
OT  - FP score, Fingerprint correlation score
OT  - FTIR, Fourier Transform Infrared
OT  - GC–MS, Gas Chromatography-Mass Spectrometry
OT  - HDLSS data, High Dimensional Low Sample Size data
OT  - IST, Iterative Soft Thresholding
OT  - LC-MS, Liquid Chromatography-Mass Spectrometry
OT  - LSTM, Long Short-Term Memory
OT  - ML, Machine Learning
OT  - MLP, Multi-layered Perceptron
OT  - MS, Mass Spectrometry
OT  - Mass spectrometry
OT  - Metabolomics
OT  - NEIMS, Neural Electron-Ionization Mass Spectrometry
OT  - NMR
OT  - NMR, Nuclear Magnetic Resonance
OT  - NUS, Non-Uniformly Sampling
OT  - PARAFAC2, Parallel Factor Analysis 2
OT  - RF, Random Forest
OT  - RNN, Recurrent Neural Network
OT  - ReLU, Rectified Linear Unit
OT  - SMARTS, SMILES arbitrary target specification
OT  - SMILE, Sparse Multidimensional Iterative Lineshape-enhanced
OT  - SMILES, Simplified Molecular-Input Line-Entry System
OT  - SRA, Sequence Read Archive
OT  - VAE, Variational Autoencoder
OT  - istHMS, Implementation of IST at Harvard Medical School
OT  - m/z, mass/charge ratio
EDAT- 2020/11/03 06:00
MHDA- 2020/11/03 06:01
PMCR- 2020/10/01
CRDT- 2020/11/02 06:17
PHST- 2020/07/24 00:00 [received]
PHST- 2020/09/21 00:00 [revised]
PHST- 2020/09/21 00:00 [accepted]
PHST- 2020/11/02 06:17 [entrez]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2020/11/03 06:01 [medline]
PHST- 2020/10/01 00:00 [pmc-release]
AID - S2001-0370(20)30417-7 [pii]
AID - 10.1016/j.csbj.2020.09.033 [doi]
PST - epublish
SO  - Comput Struct Biotechnol J. 2020 Oct 1;18:2818-2825. doi: 
      10.1016/j.csbj.2020.09.033. eCollection 2020.

PMID- 38739921
OWN - NLM
STAT- MEDLINE
DCOM- 20240617
LR  - 20250121
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 177
IP  - 6
DP  - 2024 Jun
TI  - Associations of Testosterone and Related Hormones With All-Cause and 
      Cardiovascular Mortality and Incident Cardiovascular Disease in Men : Individual 
      Participant Data Meta-analyses.
PG  - 768-781
LID - 10.7326/M23-2781 [doi]
AB  - BACKGROUND: Whether circulating sex hormones modulate mortality and 
      cardiovascular disease (CVD) risk in aging men is controversial. PURPOSE: To 
      clarify associations of sex hormones with these outcomes. DATA SOURCES: 
      Systematic literature review to July 2019, with bridge searches to March 2024. 
      STUDY SELECTION: Prospective cohort studies of community-dwelling men with sex 
      steroids measured using mass spectrometry and at least 5 years of follow-up. DATA 
      EXTRACTION: Independent variables were testosterone, sex hormone-binding globulin 
      (SHBG), luteinizing hormone (LH), dihydrotestosterone (DHT), and estradiol 
      concentrations. Primary outcomes were all-cause mortality, CVD death, and 
      incident CVD events. Covariates included age, body mass index, marital status, 
      alcohol consumption, smoking, physical activity, hypertension, diabetes, 
      creatinine concentration, ratio of total to high-density lipoprotein cholesterol, 
      and lipid medication use. DATA SYNTHESIS: Nine studies provided individual 
      participant data (IPD) (255 830 participant-years). Eleven studies provided 
      summary estimates (n = 24 109). Two-stage random-effects IPD meta-analyses found 
      that men with baseline testosterone concentrations below 7.4 nmol/L (<213 ng/dL), 
      LH concentrations above 10 IU/L, or estradiol concentrations below 5.1 pmol/L had 
      higher all-cause mortality, and those with testosterone concentrations below 5.3 
      nmol/L (<153 ng/dL) had higher CVD mortality risk. Lower SHBG concentration was 
      associated with lower all-cause mortality (median for quintile 1 [Q1] vs. Q5, 
      20.6 vs. 68.3 nmol/L; adjusted hazard ratio [HR], 0.85 [95% CI, 0.77 to 0.95]) 
      and lower CVD mortality (adjusted HR, 0.81 [CI, 0.65 to 1.00]). Men with lower 
      baseline DHT concentrations had higher risk for all-cause mortality (median for 
      Q1 vs. Q5, 0.69 vs. 2.45 nmol/L; adjusted HR, 1.19 [CI, 1.08 to 1.30]) and CVD 
      mortality (adjusted HR, 1.29 [CI, 1.03 to 1.61]), and risk also increased with 
      DHT concentrations above 2.45 nmol/L. Men with DHT concentrations below 0.59 
      nmol/L had increased risk for incident CVD events. LIMITATIONS: Observational 
      study design, heterogeneity among studies, and imputation of missing data. 
      CONCLUSION: Men with low testosterone, high LH, or very low estradiol 
      concentrations had increased all-cause mortality. SHBG concentration was 
      positively associated and DHT concentration was nonlinearly associated with 
      all-cause and CVD mortality. PRIMARY FUNDING SOURCE: Medical Research Future 
      Fund, Government of Western Australia, and Lawley Pharmaceuticals. (PROSPERO: 
      CRD42019139668).
FAU - Yeap, Bu B
AU  - Yeap BB
AUID- ORCID: 0000-0002-7612-5892
AD  - Medical School, University of Western Australia, and Department of Endocrinology 
      and Diabetes, Fiona Stanley Hospital, Perth, Western Australia, Australia 
      (B.B.Y.).
FAU - Marriott, Ross J
AU  - Marriott RJ
AUID- ORCID: 0000-0002-8805-8498
AD  - School of Population and Global Health, University of Western Australia, Perth, 
      Western Australia, Australia (R.J.M., K.M.).
FAU - Dwivedi, Girish
AU  - Dwivedi G
AUID- ORCID: 0000-0003-0717-740X
AD  - Medical School, University of Western Australia; Harry Perkins Institute of 
      Medical Research; and Department of Cardiology, Fiona Stanley Hospital, Perth, 
      Western Australia, Australia (G.D.).
FAU - Adams, Robert J
AU  - Adams RJ
AUID- ORCID: 0000-0002-7572-0796
AD  - Adelaide Institute for Sleep Health, Flinders University, Bedford Park, South 
      Australia, Australia (R.J.A.).
FAU - Antonio, Leen
AU  - Antonio L
AUID- ORCID: 0000-0002-1079-2860
AD  - Laboratory of Clinical and Experimental Endocrinology, KU Leuven, Leuven, Belgium 
      (L.A., D.V.).
FAU - Ballantyne, Christie M
AU  - Ballantyne CM
AD  - Internal Medicine, Baylor College of Medicine, Houston, Texas (C.M.B.).
FAU - Bauer, Douglas C
AU  - Bauer DC
AUID- ORCID: 0000-0001-5261-7721
AD  - General Internal Medicine, University of California, San Francisco, San 
      Francisco, California (D.C.B.).
FAU - Bhasin, Shalender
AU  - Bhasin S
AUID- ORCID: 0000-0002-3982-6200
AD  - Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 
      (S.B.).
FAU - Biggs, Mary L
AU  - Biggs ML
AD  - Department of Biostatistics, School of Public Health, University of Washington, 
      Seattle, Washington (M.L.B.).
FAU - Cawthon, Peggy M
AU  - Cawthon PM
AD  - San Francisco Coordinating Center, California Pacific Medical Center Research 
      Institute, San Francisco, California (P.M.C.).
FAU - Couper, David J
AU  - Couper DJ
AUID- ORCID: 0000-0002-4313-9235
AD  - Gillings School of Global Public Health, University of North Carolina at Chapel 
      Hill, Chapel Hill, North Carolina (D.J.C.).
FAU - Dobs, Adrian S
AU  - Dobs AS
AD  - School of Medicine, Division of Endocrinology, Diabetes and Metabolism, Johns 
      Hopkins University, Baltimore, Maryland (A.S.D.).
FAU - Flicker, Leon
AU  - Flicker L
AUID- ORCID: 0000-0002-3650-0475
AD  - Medical School, University of Western Australia, and Western Australian Centre 
      for Healthy Ageing, University of Western Australia, Perth, Western Australia, 
      Australia (L.F.).
FAU - Handelsman, David J
AU  - Handelsman DJ
AUID- ORCID: 0000-0002-4200-7476
AD  - ANZAC Research Institute, University of Sydney, Sydney, New South Wales, 
      Australia (D.J.H.).
FAU - Hankey, Graeme J
AU  - Hankey GJ
AUID- ORCID: 0000-0002-6044-7328
AD  - Medical School, University of Western Australia, and Perron Institute for 
      Neurological and Translational Science, Perth, Western Australia, Australia 
      (G.J.H.).
FAU - Hannemann, Anke
AU  - Hannemann A
AUID- ORCID: 0000-0003-4420-5449
AD  - Institute of Clinical Chemistry and Laboratory Medicine, University Medicine 
      Greifswald, and German Centre for Cardiovascular Research, Partner Site 
      Greifswald, Greifswald, Germany (A.H.).
FAU - Haring, Robin
AU  - Haring R
AUID- ORCID: 0000-0002-8332-5016
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia, and European University of Applied Sciences, Faculty of 
      Applied Public Health, Rostock, Germany (R.H.).
FAU - Hsu, Benjumin
AU  - Hsu B
AD  - Centre for Big Data Research in Health, University of New South Wales, Sydney, 
      New South Wales, Australia (B.H.).
FAU - Martin, Sean A
AU  - Martin SA
AUID- ORCID: 0000-0001-8479-4992
AD  - Australian Institute of Family Studies, Southbank, Victoria, Australia (S.A.M.).
FAU - Matsumoto, Alvin M
AU  - Matsumoto AM
AUID- ORCID: 0000-0002-6506-8650
AD  - Department of Medicine, University of Washington School of Medicine, and 
      Geriatric Research, Education and Clinical Center, VA Puget Sound Health Care 
      System, Seattle, Washington (A.M.M.).
FAU - Mellström, Dan
AU  - Mellström D
AD  - Centre for Bone and Arthritis Research at the Sahlgrenska Academy, Institute of 
      Medicine, University of Gothenburg, Gothenburg, Sweden (D.M., C.O.).
FAU - Ohlsson, Claes
AU  - Ohlsson C
AD  - Centre for Bone and Arthritis Research at the Sahlgrenska Academy, Institute of 
      Medicine, University of Gothenburg, Gothenburg, Sweden (D.M., C.O.).
FAU - O'Neill, Terence W
AU  - O'Neill TW
AUID- ORCID: 0000-0002-8896-4677
AD  - Centre for Epidemiology Versus Arthritis, University of Manchester, and NIHR 
      Manchester Biomedical Research Centre, Manchester University NHS Foundation 
      Trust, Manchester, United Kingdom (T.W.O.).
FAU - Orwoll, Eric S
AU  - Orwoll ES
AUID- ORCID: 0000-0002-8520-7355
AD  - Oregon Health & Science University, Portland, Oregon (E.S.O.).
FAU - Quartagno, Matteo
AU  - Quartagno M
AUID- ORCID: 0000-0003-4446-0730
AD  - MRC Clinical Trials Unit, University College London, London, United Kingdom 
      (M.Q.).
FAU - Shores, Molly M
AU  - Shores MM
AUID- ORCID: 0000-0002-1235-2690
AD  - School of Medicine, Department of Psychiatry and Behavioral Sciences, University 
      of Washington, Seattle, Washington (M.M.S.).
FAU - Steveling, Antje
AU  - Steveling A
AUID- ORCID: 0000-0002-8397-0787
AD  - Department of Internal Medicine, University Medicine Greifswald, Greifswald, 
      Germany (A.S.).
FAU - Tivesten, Åsa
AU  - Tivesten Å
AUID- ORCID: 0000-0002-8318-0486
AD  - Wallenberg Laboratory for Cardiovascular and Metabolic Research, Department of 
      Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, 
      University of Gothenburg, and Department of Endocrinology, Sahlgrenska University 
      Hospital, Region Västra Götaland, Gothenburg, Sweden (Å.T.).
FAU - Travison, Thomas G
AU  - Travison TG
AUID- ORCID: 0000-0002-1030-7175
AD  - Brigham and Women's Hospital, Harvard Medical School, and Institute for Aging 
      Research, Hebrew Senior Life, Beth Israel Deaconess Medical Center, Boston, 
      Massachusetts (T.G.T.).
FAU - Vanderschueren, Dirk
AU  - Vanderschueren D
AUID- ORCID: 0000-0003-1395-0104
AD  - Laboratory of Clinical and Experimental Endocrinology, KU Leuven, Leuven, Belgium 
      (L.A., D.V.).
FAU - Wittert, Gary A
AU  - Wittert GA
AD  - Freemasons Centre for Men's Health and Wellbeing, School of Medicine, University 
      of Adelaide, Adelaide, South Australia, Australia (G.A.W.).
FAU - Wu, Frederick C W
AU  - Wu FCW
AUID- ORCID: 0000-0002-7005-4798
AD  - Division of Endocrinology, Diabetes & Gastroenterology, School of Medical 
      Sciences, University of Manchester, Manchester, United Kingdom (F.C.W.W.).
FAU - Murray, Kevin
AU  - Murray K
AUID- ORCID: 0000-0002-8856-6046
AD  - School of Population and Global Health, University of Western Australia, Perth, 
      Western Australia, Australia (R.J.M., K.M.).
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20240514
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 3XMK78S47O (Testosterone)
RN  - 0 (Sex Hormone-Binding Globulin)
RN  - 4TI98Z838E (Estradiol)
RN  - 9002-67-9 (Luteinizing Hormone)
RN  - 08J2K08A3Y (Dihydrotestosterone)
SB  - IM
MH  - Humans
MH  - Male
MH  - *Cardiovascular Diseases/mortality/blood
MH  - *Testosterone/blood
MH  - *Sex Hormone-Binding Globulin/analysis/metabolism
MH  - *Estradiol/blood
MH  - *Cause of Death
MH  - *Luteinizing Hormone/blood
MH  - *Dihydrotestosterone/blood
MH  - Incidence
MH  - Risk Factors
MH  - Aged
MH  - Middle Aged
COIS- Disclosures: Disclosures can be viewed at 
      www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M23-2781.
EDAT- 2024/05/13 18:46
MHDA- 2024/06/18 04:22
CRDT- 2024/05/13 17:03
PHST- 2024/06/18 04:22 [medline]
PHST- 2024/05/13 18:46 [pubmed]
PHST- 2024/05/13 17:03 [entrez]
AID - 10.7326/M23-2781 [doi]
PST - ppublish
SO  - Ann Intern Med. 2024 Jun;177(6):768-781. doi: 10.7326/M23-2781. Epub 2024 May 14.

PMID- 25905286
STAT- Publisher
CTDT- 20221221
PB  - MDText.com, Inc.
DP  - 2000
TI  - Ovarian Reserve Testing.
BTI - Endotext
AB  - The ovaries affect far more than reproductive health. Estrogen affects 
      cardiovascular, skeletal, mental health, and numerous other aspects of wellness. 
      Additionally, ovarian dysfunction can reflect disequilibrium relating to multiple 
      conditions. Efficient and effective ovarian testing can give women valuable 
      answers about their fertility, time to menopause, and other conditions and 
      symptoms they may face. Though no test is perfect, antral follicle count (AFC) 
      and anti- Müllerian hormone (AMH) provide more sensitive and specific results 
      that allow for the continuum of ovarian function, and have advantages over 
      classic tests such as follicle stimulating hormone (FSH), estradiol, the 
      clomiphene citrate challenge test (CCCT), and others. This chapter explores these 
      and additional ovarian assays, their underlying mechanisms, and limitations that 
      may favor one test over another depending on circumstances. Particular emphasis 
      is given to evaluating perimenopausal status, procreation, and etiologies for 
      amenorrhea. For complete coverage of all related areas of Endocrinology, please 
      visit our on-line FREE web-text, WWW.ENDOTEXT.ORG.
CI  - Copyright © 2000-2025, MDText.com, Inc.
FED - Feingold, Kenneth R
ED  - Feingold KR
AD  - Professor of Medicine Emeritus, University of California, San Francisco, CA
FED - Anawalt, Bradley
ED  - Anawalt B
AD  - Chief of Medicine at the University of Washington Medical Center and Professor 
      and Vice Chair of the Department of Medicine, University of Washington
FED - Blackman, Marc R
ED  - Blackman MR
AD  - Sr. Physician Scientist, Washington DC VA Medical Center; Professor of Medicine & 
      Rehabilitation Medicine, Georgetown University; Clinical Professor of Medicine, 
      Biochemistry and Molecular Medicine, George Washington University; and Professor 
      of Medicine (Part-time), Johns Hopkins University
FED - Boyce, Alison
ED  - Boyce A
AD  - Pediatric Endocrinologist and Associate Research Physician in the Skeletal 
      Diseases and Mineral Homeostasis Section, National Institute of Dental and 
      Craniofacial Research, National Institutes of Health
FED - Chrousos, George
ED  - Chrousos G
AD  - Professor of Pediatrics and Endocrinology, Division of Endocrinology, Metabolism 
      and Diabetes, First Department of Pediatrics, National and Kapodistrian 
      University of Athens Medical School, "Aghia Sophia" Children's Hospital, Athens, 
      Greece
FED - Corpas, Emiliano
ED  - Corpas E
AD  - M.D. Ph.D in Gerontology. Honorary Professor of Medicine, Universidad de Alcalá, 
      Madrid. Consultant in Endocrinology, Hospital HLA Guadalajara (Spain).
FED - de Herder, Wouter W
ED  - de Herder WW
AD  - Professor of Endocrine Oncology, Erasmus MC and Erasmus MC Cancer Center, 
      Rotterdam, the Netherlands
FED - Dhatariya, Ketan
ED  - Dhatariya K
AD  - Consultant in Diabetes, Endocrinology and General Medicine, Norfolk and Norwich 
      University Hospitals NHS Foundation Trust and University of East Anglia, Norwich, 
      UK.
FED - Dungan, Kathleen
ED  - Dungan K
AD  - Professor of Medicine, Division of Endocrinology, Diabetes, and Metabolism, Ohio 
      State University
FED - Hofland, Johannes
ED  - Hofland J
AD  - Consultant Endocrinologist, Erasmus MC and Erasmus MC Cancer Center, Rotterdam, 
      the Netherlands
FED - Kalra, Sanjay
ED  - Kalra S
AD  - Consultant Endocrinologist, Department of Endocrinology, Bharti Hospital, Karnal, 
      India
FED - Kaltsas, Gregory
ED  - Kaltsas G
AD  - Professor of General Medicine-Endocrinology, 1st Department of Propaedeutic 
      Medicine, National and Kapodistrian University of Athens, Athens, Greece
FED - Kapoor, Nitin
ED  - Kapoor N
AD  - Professor of Endocrinology, Department of Endocrinology, Diabetes and Metabolism, 
      Christian Medical College & Hospital, Vellore, Tamil Nadu, India, Melbourne 
      School of Population and Global Health, Faculty of Medicine, Dentistry and Health 
      Science, The University of Melbourne, Australia.
FED - Koch, Christian
ED  - Koch C
AD  - Professor, The University of Tennessee Health Science Center, Memphis, Tennessee
FED - Kopp, Peter
ED  - Kopp P
AD  - Professor of Medicine and Chief of the Division of Endocrinology, Diabetology and 
      Metabolism, University of Lausanne, Switzerland
FED - Korbonits, Márta
ED  - Korbonits M
AD  - Professor of Endocrinology and Metabolism, Centre Lead for Endocrinology and 
      Deputy Institute Director, William Harvey Research Institute, Barts and the 
      London School of Medicine and Dentistry, Queen Mary University of London, London, 
      England
FED - Kovacs, Christopher S
ED  - Kovacs CS
AD  - University Research Professor and Professor of Medicine (Endocrinology and 
      Metabolism), Obstetrics & Gynecology, and BioMedical Sciences, at Memorial 
      University of Newfoundland in St. John’s, Newfoundland, Canada.
FED - Kuohung, Wendy
ED  - Kuohung W
AD  - Director of the Division of Reproductive Endocrinology at Boston Medical Center 
      and an Associate Professor of Obstetrics and Gynecology at the Boston University 
      School of Medicine
FED - Laferrère, Blandine
ED  - Laferrère B
AD  - Professor of Medicine, New York Nutrition Obesity Research Center, Division of 
      Endocrinology, Department of Medicine, Columbia University Irving Medical Center, 
      New York, NY, USA.
FED - Levy, Miles
ED  - Levy M
AD  - Consultant endocrinologist at University Hospitals of Leicester and Honorary 
      Associate Professor at Leicester University
FED - McGee, Elizabeth A
ED  - McGee EA
AD  - Professor of Obstetrics and Gynecology at the University of Vermont and Director 
      of the Division of Reproductive Endocrinology and Infertility. Burlington, 
      Vermont
FED - McLachlan, Robert
ED  - McLachlan R
AD  - Director of Clinical Research, Hudson Institute of Medical Research; Consultant 
      Endocrinologist, Monash Medical Centre, Melbourne, Australia
FED - New, Maria
ED  - New M
AD  - Professor of Pediatrics, Professor of Genetics and Genomic Sciences, and Chief of 
      the Adrenal Steroid Disorders Program, Icahn School of Medicine, Mount Sinai 
      School of Medicine, New York, NY
FED - Purnell, Jonathan
ED  - Purnell J
AD  - Professor of Medicine, Knight Cardiovascular Institute and the Division of 
      Endocrinology, and Associate Director, Bob and Charlee Moore Institute for 
      Nutrition and Wellness, Oregon Health and Science University, Portland, OR
FED - Sahay, Rakesh
ED  - Sahay R
AD  - Professor and Head of Department of Endocrinology, Osmania Medical College and 
      Osmania General Hospital, Hyderabad, India.
FED - Shah, Amy S
ED  - Shah AS
AD  - Professor of Pediatrics, The University of Cincinnati, Department of Pediatrics 
      and Cincinnati Children’s Hospital Medical Center, Division of Endocrinology, 
      Cincinnati, OH, USA
FED - Singer, Frederick
ED  - Singer F
AD  - Director of the Endocrine/Bone Disease Program, Saint Johns Cancer Institute at 
      Saint John’s Health Center, Santa Monica, CA; Clinical Professor of Medicine, 
      UCLA School of Medicine, Los Angeles, CA
FED - Sperling, Mark A
ED  - Sperling MA
AD  - Professorial Lecturer, Division of Pediatric Endocrinology and Diabetes, Icahn 
      School of Medicine at Mount Sinai, New York, NY. Emeritus Professor and Chair, 
      Department of Pediatrics, University of Pittsburgh.
FED - Stratakis, Constantine A
ED  - Stratakis CA
AD  - CSO, ELPEN, Inc. & Director, Research Institute, Athens, Greece & Senior 
      Investigator, Human Genetics & Precision Medicine, FORTH (ITE), Heraklion, 
      Greece. Emeritus Scientific Director & Senior Investigator, NICHD, NIH, Bethesda, 
      MD, USA
FED - Trence, Dace L
ED  - Trence DL
AD  - Professor of Medicine, Emeritus, University of Washington, Seattle, WA
FED - Wilson, Don P
ED  - Wilson DP
AD  - Endowed Chair, Cardiovascular Health and Risk Prevention, Pediatric Endocrinology 
      and Diabetes, Cook Children's Medical Center, Fort Worth, TX
FAU - Deadmond, Amanda
AU  - Deadmond A
AD  - Positive Steps Fertility, Shreveport, LA
FAU - Koch, Christian A
AU  - Koch CA
AD  - Professor, Division of Endocrinology, Diabetes, Metabolism, Department of 
      Medicine, The University of Tennessee Health Science Center, Memphis, TN, Fox 
      Chase Cancer Center, Philadelphia, PA.
FAU - Parry, J Preston
AU  - Parry JP
AD  - Adjunct Professor, Department of Obstetrics and Gynecology, Louisiana State 
      University Health-Shreveport, Shreveport, LA, Positive Steps Fertility, Madison, 
      MS.
LA  - eng
PT  - Review
PT  - Book Chapter
PL  - South Dartmouth (MA)
EDAT- 2022/12/21 00:00
CRDT- 2022/12/21 00:00
AID - NBK279058 [bookaccession]

PMID- 27600178
OWN - NLM
STAT- MEDLINE
DCOM- 20180126
LR  - 20190816
IS  - 1524-4563 (Electronic)
IS  - 0194-911X (Linking)
VI  - 68
IP  - 4
DP  - 2016 Oct
TI  - Estrogen Signaling in the Adrenal Cortex: Implications for Blood Pressure Sex 
      Differences.
PG  - 840-8
LID - 10.1161/HYPERTENSIONAHA.116.07660 [doi]
FAU - Caroccia, Brasilina
AU  - Caroccia B
AD  - From the Molecular Internal Medicine, University of Zurich, Switzerland (M.B.); 
      and Department of Medicine-DIMED, University of Padua, Italy (B.C., T.M.S., 
      G.P.R.).
FAU - Seccia, Teresa M
AU  - Seccia TM
AD  - From the Molecular Internal Medicine, University of Zurich, Switzerland (M.B.); 
      and Department of Medicine-DIMED, University of Padua, Italy (B.C., T.M.S., 
      G.P.R.).
FAU - Barton, Matthias
AU  - Barton M
AD  - From the Molecular Internal Medicine, University of Zurich, Switzerland (M.B.); 
      and Department of Medicine-DIMED, University of Padua, Italy (B.C., T.M.S., 
      G.P.R.).
FAU - Rossi, Gian Paolo
AU  - Rossi GP
AD  - From the Molecular Internal Medicine, University of Zurich, Switzerland (M.B.); 
      and Department of Medicine-DIMED, University of Padua, Italy (B.C., T.M.S., 
      G.P.R.). gianpaolo.rossi@unipd.it.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Hypertension
JT  - Hypertension (Dallas, Tex. : 1979)
JID - 7906255
RN  - 0 (Estrogens)
RN  - 0 (GPER1 protein, human)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, G-Protein-Coupled)
SB  - IM
MH  - Adrenal Cortex/*metabolism
MH  - Disease Progression
MH  - Estrogen Replacement Therapy/*methods
MH  - Estrogens/*blood/metabolism
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Hypertension/drug therapy/epidemiology/*physiopathology
MH  - Male
MH  - Postmenopause/drug effects/physiology
MH  - Receptors, Estrogen/metabolism
MH  - Receptors, G-Protein-Coupled/metabolism
MH  - Renin-Angiotensin System/*physiology
MH  - Risk Assessment
MH  - Sex Characteristics
EDAT- 2016/09/08 06:00
MHDA- 2018/01/27 06:00
CRDT- 2016/09/08 06:00
PHST- 2016/09/08 06:00 [entrez]
PHST- 2016/09/08 06:00 [pubmed]
PHST- 2018/01/27 06:00 [medline]
AID - HYPERTENSIONAHA.116.07660 [pii]
AID - 10.1161/HYPERTENSIONAHA.116.07660 [doi]
PST - ppublish
SO  - Hypertension. 2016 Oct;68(4):840-8. doi: 10.1161/HYPERTENSIONAHA.116.07660.

PMID- 29270936
OWN - NLM
STAT- MEDLINE
DCOM- 20181024
LR  - 20181024
IS  - 1098-9021 (Electronic)
IS  - 0271-8235 (Linking)
VI  - 37
IP  - 6
DP  - 2017 Dec
TI  - Reproductive Issues in MS.
PG  - 632-642
LID - 10.1055/s-0037-1608925 [doi]
AB  - Multiple sclerosis (MS) is an autoimmune disease of the central nervous system, 
      predominantly affecting women of childbearing age. Therefore, issues of 
      conception, pregnancy, and delivery are of significant importance to patients and 
      treating physicians. We discuss immunologic and clinical effects of pregnancy on 
      the course of MS including both immunosuppression on a local level and a 
      heightened state of immunocompetence on a global level. Clinical outcomes of the 
      Pregnancy in Multiple Sclerosis trials are reported. We analyze and update the 
      available data on safety and efficacy of immunomodulating MS treatments and 
      symptomatic treatments for pregnant and lactating women, and address specific 
      issues of MS management at the time of pregnancy. We review the data related to 
      estrogen-based MS therapies currently or previously in trials. Pregnancy does not 
      appear to be associated with adverse outcomes in MS patients. Some evidence 
      suggests possible beneficial effects, although clear prospective data of 
      sufficient length and quality are limited. Long-term relapse rates or disability 
      progression do not seem to be affected by pregnancy in MS patients. The use of 
      immunosuppressive or immunomodulatory agents in pregnancy is not routinely 
      advisable but could be considered under special circumstances.
CI  - Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
FAU - Houtchens, Maria K
AU  - Houtchens MK
AD  - Department of Neurology, Partners Multiple Sclerosis Center, Brigham and Women's 
      Hospital, Harvard Medical School, Boston, Massachusetts.
FAU - Kaplan, Tamara B
AU  - Kaplan TB
AD  - Department of Neurology, Partners Multiple Sclerosis Center, Brigham and Women's 
      Hospital, Harvard Medical School, Boston, Massachusetts.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171221
PL  - United States
TA  - Semin Neurol
JT  - Seminars in neurology
JID - 8111343
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Adult
MH  - Animals
MH  - *Disease Progression
MH  - *Estrogen Replacement Therapy/adverse effects
MH  - Female
MH  - Humans
MH  - Immunologic Factors/*adverse effects
MH  - Menopause/*drug effects
MH  - Middle Aged
MH  - Multiple Sclerosis/blood/drug therapy/immunology
MH  - Pregnancy
MH  - Pregnancy Complications/blood/drug therapy/immunology
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2017/12/23 06:00
MHDA- 2018/10/26 06:00
CRDT- 2017/12/23 06:00
PHST- 2017/12/23 06:00 [entrez]
PHST- 2017/12/23 06:00 [pubmed]
PHST- 2018/10/26 06:00 [medline]
AID - 10.1055/s-0037-1608925 [doi]
PST - ppublish
SO  - Semin Neurol. 2017 Dec;37(6):632-642. doi: 10.1055/s-0037-1608925. Epub 2017 Dec 
      21.

PMID- 37611527
OWN - NLM
STAT- MEDLINE
DCOM- 20231003
LR  - 20241102
IS  - 1873-3360 (Electronic)
IS  - 0306-4530 (Print)
IS  - 0306-4530 (Linking)
VI  - 157
DP  - 2023 Nov
TI  - Effects of estrogen and progesterone on neuroactive steroids and cytokines in 
      patients with suicidality.
PG  - 106359
LID - S0306-4530(23)00337-2 [pii]
LID - 10.1016/j.psyneuen.2023.106359 [doi]
AB  - BACKGROUND: In ovulating psychiatric patients experiencing suicidality, suicidal 
      ideation (SI) often peaks perimenstrually. Our recent double-blind, 
      placebo-controlled, crossover randomized clinical trial (RCT; NCT03720847) showed 
      that perimenstrual administration of estradiol and progesterone (EP) can prevent 
      this peak in SI and depressed mood. In this pre-registered follow-up analysis, we 
      studied how the menstrual cycle and experimental manipulation affected two 
      neurobiological systems associated with the menstrual cycle and suicide risk: 
      GABAergic neuroactive steroids (NAS) and peripheral cytokines. METHODS: In 26 
      psychiatric outpatients with natural menstrual cycles and past-month SI, we 
      analyzed serum samples from three blood draws (midluteal, perimenstrual, 
      midfollicular) per experimental condition (EP vs placebo) timed to a luteinizing 
      hormone-surge ovulation test. Using gas chromatography/mass spectrometry (GC/MS), 
      we measured the progesterone (P4)-derived pregnane NAS 
      (3α,5α)- 3-hydroxypregnan20-one (3α,5α-THP), (3α,5β)- 3-hydroxypregnan-20-one 
      (3α,5β-THP), (3α,5α)- 3,21-dihydroxypregnan-20-one (3α,5α-THDOC), 
      (3α,5α)- 3-hydroxyandrostan-17-one (3α,5α-A), the androstane NAS 
      (3α,5β)- 3-hydroxyandrostan-17-one (3α,5β-A), (3α,5α,17β)-androstane-3,17-diol 
      (3α,5α-A-diol), (3α,5β,17β)-androstane-3,17-diol (3α,5β-A-diol), and their 
      precursor pregnenolone. High sensitivity multiplex assay kits quantified 
      peripheral cytokines IL-1β, IL-6, and TNF-α. RESULTS: P4-derived NAS fluctuated 
      in parallel with P4 and increased with exogenous perimenstrual administration of 
      EP. Conversely, androstane NAS either did not fluctuate or fluctuated inversely 
      from P4, and these NAS decreased with exogenous EP. Peripheral cytokines did not 
      show cyclical patterns, but each significantly predicted SI, depressed mood, or 
      anxiousness. Concomitant SSRI medication use predicted lower androstane NAS. 
      CONCLUSIONS: While preliminary and exploratory, our findings provide critical 
      descriptive context for future studies. Further, our work presents menstrual 
      cycle-related patterns for ten frequently-studied biomarkers, allowing for 
      improved quality of comparisons involving naturally-cycling populations in 
      research.
CI  - Copyright © 2023 Elsevier Ltd. All rights reserved.
FAU - Barone, Jordan C
AU  - Barone JC
AD  - University of Illinois at Chicago, Dept of Psychiatry, 912 S Wood St, Chicago, IL 
      60612, USA. Electronic address: jbarone2@uic.edu.
FAU - Wenzel, Elizabeth
AU  - Wenzel E
AD  - University of Illinois at Chicago, Dept of Psychiatry, 912 S Wood St, Chicago, IL 
      60612, USA.
FAU - Alluri, Viraja
AU  - Alluri V
AD  - University of Illinois at Chicago, Dept of Psychiatry, 912 S Wood St, Chicago, IL 
      60612, USA.
FAU - Moriarity, Daniel
AU  - Moriarity D
AD  - University of California, Los Angeles, Department of Psychiatry and Biobehavioral 
      Sciences, 757 Westwood Plaza #4, Los Angeles, CA 90095, USA; Stanford University, 
      Department of Genetics, 291 Campus Drive, Stanford, CA 94305, USA.
FAU - Pinna, Graziano
AU  - Pinna G
AD  - University of Illinois at Chicago, Dept of Psychiatry, 912 S Wood St, Chicago, IL 
      60612, USA.
FAU - Walsh, Erin
AU  - Walsh E
AD  - University of North Carolina-Chapel Hill, Department of Psychiatry, 101 Manning 
      Dr. #1, Chapel Hill, NC 27514, USA.
FAU - Rubinow, David R
AU  - Rubinow DR
AD  - University of North Carolina-Chapel Hill, Department of Psychiatry, 101 Manning 
      Dr. #1, Chapel Hill, NC 27514, USA.
FAU - Morrow, A Leslie
AU  - Morrow AL
AD  - University of North Carolina-Chapel Hill, Department of Psychiatry, 101 Manning 
      Dr. #1, Chapel Hill, NC 27514, USA.
FAU - Eisenlohr-Moul, Tory A
AU  - Eisenlohr-Moul TA
AD  - University of Illinois at Chicago, Dept of Psychiatry, 912 S Wood St, Chicago, IL 
      60612, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT03720847
GR  - RF1 MH120843/MH/NIMH NIH HHS/United States
GR  - F32 MH130149/MH/NIMH NIH HHS/United States
GR  - F31 MH130077/MH/NIMH NIH HHS/United States
GR  - R00 MH109667/MH/NIMH NIH HHS/United States
GR  - T32 MH067631/MH/NIMH NIH HHS/United States
GR  - K99 MH109667/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20230809
PL  - England
TA  - Psychoneuroendocrinology
JT  - Psychoneuroendocrinology
JID - 7612148
RN  - 4G7DS2Q64Y (Progesterone)
RN  - 0 (Neurosteroids)
RN  - 0 (Cytokines)
RN  - 25126-76-5 (Androstane-3,17-diol)
RN  - 0 (Androstanes)
RN  - 4TI98Z838E (Estradiol)
RN  - 0 (Estrogens)
SB  - IM
MH  - Female
MH  - Humans
MH  - Progesterone/pharmacology
MH  - *Neurosteroids
MH  - Cytokines
MH  - Androstane-3,17-diol/analysis
MH  - Suicidal Ideation
MH  - *Suicide
MH  - Androstanes
MH  - Estradiol
MH  - Estrogens
PMC - PMC10543480
MID - NIHMS1928315
OTO - NOTNLM
OT  - Clinical trial
OT  - Cytokines
OT  - Menstrual cycle
OT  - Neuroactive steroids
OT  - Premenstrual mood disorders
OT  - Suicidal ideation
COIS- Declaration of Competing Interest Dr. Pinna is a paid consultant to PureTech 
      Health (Boston, MA, USA), GABA Therapeutics, and NeuroTrauma Sciences 
      (Alpharetta, GA, USA). He has two patent applications, one on 
      N-palmitoylethanolamine (PEA) and peroxisome proliferator-activated receptor 
      alpha (PPAR-α) agonists US20180369171A1 allowed in May 16, 2023, and one on 
      allopregnanolone analogs US11266663B2 allowed in March 8, 2022, in the treatment 
      of neuropsychiatric disorders.
EDAT- 2023/08/24 00:42
MHDA- 2023/10/03 06:47
PMCR- 2024/11/01
CRDT- 2023/08/23 18:07
PHST- 2023/06/06 00:00 [received]
PHST- 2023/08/02 00:00 [revised]
PHST- 2023/08/07 00:00 [accepted]
PHST- 2023/10/03 06:47 [medline]
PHST- 2023/08/24 00:42 [pubmed]
PHST- 2023/08/23 18:07 [entrez]
PHST- 2024/11/01 00:00 [pmc-release]
AID - S0306-4530(23)00337-2 [pii]
AID - 10.1016/j.psyneuen.2023.106359 [doi]
PST - ppublish
SO  - Psychoneuroendocrinology. 2023 Nov;157:106359. doi: 
      10.1016/j.psyneuen.2023.106359. Epub 2023 Aug 9.

PMID- 27196727
OWN - NLM
STAT- MEDLINE
DCOM- 20171208
LR  - 20181113
IS  - 1945-7189 (Electronic)
IS  - 0163-769X (Print)
IS  - 0163-769X (Linking)
VI  - 37
IP  - 4
DP  - 2016 Aug
TI  - Estrogens, Neuroinflammation, and Neurodegeneration.
PG  - 372-402
LID - 10.1210/er.2016-1007 [doi]
AB  - Inflammatory activation of microglia is a hallmark of several disorders of the 
      central nervous system. In addition to protecting the brain against inflammatory 
      insults, microglia are neuroprotective and play a significant role in maintaining 
      neuronal connectivity, but the prolongation of an inflammatory status may limit 
      the beneficial functions of these immune cells. The finding that estrogen 
      receptors are present in monocyte-derived cells and that estrogens prevent and 
      control the inflammatory response raise the question of the role that this sex 
      steroid plays in the manifestation and progression of pathologies that have a 
      clear sex difference in prevalence, such as multiple sclerosis, Parkinson's 
      disease, and Alzheimer's disease. The present review aims to provide a critical 
      review of the current literature on the actions of estrogen in microglia and on 
      the involvement of estrogen receptors in the manifestation of selected 
      neurological disorders. This current understanding highlights a research area 
      that should be expanded to identify appropriate replacement therapies to slow the 
      progression of such diseases.
FAU - Villa, Alessandro
AU  - Villa A
AD  - Center of Excellence on Neurodegenerative Diseases and Department of 
      Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, 
      Italy.
FAU - Vegeto, Elisabetta
AU  - Vegeto E
AD  - Center of Excellence on Neurodegenerative Diseases and Department of 
      Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, 
      Italy.
FAU - Poletti, Angelo
AU  - Poletti A
AD  - Center of Excellence on Neurodegenerative Diseases and Department of 
      Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, 
      Italy.
FAU - Maggi, Adriana
AU  - Maggi A
AD  - Center of Excellence on Neurodegenerative Diseases and Department of 
      Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, 
      Italy.
LA  - eng
GR  - R01 AG027713/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20160519
PL  - United States
TA  - Endocr Rev
JT  - Endocrine reviews
JID - 8006258
RN  - 0 (Estrogens)
RN  - 0 (Receptors, Estrogen)
SB  - IM
MH  - Animals
MH  - *Demyelinating Diseases/immunology/metabolism
MH  - Estrogens/*metabolism
MH  - Humans
MH  - *Hypoxia, Brain/immunology/metabolism
MH  - *Inflammation/immunology/metabolism
MH  - *Microglia/immunology/metabolism
MH  - *Neurodegenerative Diseases/immunology/metabolism
MH  - Receptors, Estrogen/*metabolism
MH  - *Stroke/immunology/metabolism
PMC - PMC4971309
EDAT- 2016/05/20 06:00
MHDA- 2017/12/09 06:00
PMCR- 2017/08/01
CRDT- 2016/05/20 06:00
PHST- 2016/05/20 06:00 [entrez]
PHST- 2016/05/20 06:00 [pubmed]
PHST- 2017/12/09 06:00 [medline]
PHST- 2017/08/01 00:00 [pmc-release]
AID - ER-16-1007 [pii]
AID - 10.1210/er.2016-1007 [doi]
PST - ppublish
SO  - Endocr Rev. 2016 Aug;37(4):372-402. doi: 10.1210/er.2016-1007. Epub 2016 May 19.

PMID- 28375935
OWN - NLM
STAT- MEDLINE
DCOM- 20180508
LR  - 20180508
IS  - 1530-0374 (Electronic)
IS  - 1072-3714 (Linking)
VI  - 24
IP  - 9
DP  - 2017 Sep
TI  - Estriol: emerging clinical benefits.
PG  - 1081-1085
LID - 10.1097/GME.0000000000000855 [doi]
AB  - OBJECTIVE: Estriol is the main estrogen in pregnancy, but has received less 
      attention outside gestation. It is well known that pregnancy has an 
      immunosuppressive effect on many autoimmune diseases such as multiple sclerosis, 
      psoriasis, thyroiditis, uveitis, and rheumatoid arthritis. Emerging evidence 
      indicates that estriol has potential immunomodulatory benefits for many disease 
      states including autoimmune, inflammatory, and neurodegenerative conditions. In 
      this review, we discuss emerging roles for estriol in the treatment of menopausal 
      symptoms, osteoporosis, cancer, hyperlipidemia, vascular disease, and multiple 
      sclerosis. Estriol appears to offer a potentially cost-effective approach to a 
      variety of conditions and may offer a wide range of health benefits. METHODS: We 
      reviewed the English language MEDLINE literature with estriol in the title with 
      emphasis on publications including nonpregnant females between January 1974 and 
      August 2016. Approximately 393 such articles were considered and 72 articles have 
      been referenced in this review. RESULTS: Estriol offers considerable benefits for 
      postmenopausal women with reduced risks that are normally associated with 
      traditional hormone therapies. These benefits include improved control of 
      menopausal symptoms and better urogenital health. Moreover, the immunomodulatory 
      role of estriol in reducing proinflammatory cytokines may be an important new 
      therapeutic option for chronic autoimmune and neurodegenerative illnesses. Since 
      it is a relatively weak estrogen, there is potential for use in men for 
      conditions such as multiple sclerosis. CONCLUSIONS: We conclude transvaginal 
      estriol potentially offers a suitable physiologic delivery and cost-effective 
      alternative to currently available estrogen regimens in selected patients. 
      Additional studies on mode of delivery, safety, and efficacy merit further 
      investigation.
FAU - Ali, Emad S
AU  - Ali ES
AD  - 1Department of Internal Medicine 2School of Medicine 3Section of Endocrinology, 
      Texas Tech University Health Science Center, Lubbock, TX.
FAU - Mangold, Cheyenne
AU  - Mangold C
FAU - Peiris, Alan N
AU  - Peiris AN
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Menopause
JT  - Menopause (New York, N.Y.)
JID - 9433353
RN  - 0 (Immunologic Factors)
RN  - FB33469R8E (Estriol)
SB  - IM
MH  - Administration, Intravaginal
MH  - Bone Density/drug effects
MH  - Estriol/adverse effects/physiology/*therapeutic use
MH  - Estrogen Replacement Therapy/adverse effects
MH  - Female
MH  - Humans
MH  - Immunologic Factors
MH  - Inflammation/prevention & control
MH  - MEDLINE
MH  - Male
MH  - Multiple Sclerosis/drug therapy
MH  - Postmenopause/*drug effects
EDAT- 2017/04/05 06:00
MHDA- 2018/05/09 06:00
CRDT- 2017/04/05 06:00
PHST- 2017/04/05 06:00 [pubmed]
PHST- 2018/05/09 06:00 [medline]
PHST- 2017/04/05 06:00 [entrez]
AID - 10.1097/GME.0000000000000855 [doi]
PST - ppublish
SO  - Menopause. 2017 Sep;24(9):1081-1085. doi: 10.1097/GME.0000000000000855.

PMID- 32856989
OWN - NLM
STAT- MEDLINE
DCOM- 20220316
LR  - 20220531
IS  - 1477-0970 (Electronic)
IS  - 1352-4585 (Linking)
VI  - 28
IP  - 2
DP  - 2022 Feb
TI  - Menopause and multiple sclerosis: Influence on prognosis and role of 
      disease-modifying drugs and hormonal replacement therapy.
PG  - 173-182
LID - 10.1177/1352458520952022 [doi]
AB  - BACKGROUND: Sex hormones play a role in both the risk and the prognosis of 
      multiple sclerosis (MS). Considering all stages of women's reproductive life, 
      data regarding the influence of menopause on MS and vice versa are scarce. 
      OBJECTIVE: The aim of this study was to review the evidence addressing the 
      relationship between menopause and MS. METHODS: A literature search through 
      PubMed was conducted, selecting studies that assessed (1) the influence of 
      menopause in the MS course, (2) the influence of MS and disease-modifying drugs 
      (DMD) on the development of menopause and (3) the effect of hormone replacement 
      therapy (HRT) on symptoms of menopausal MS patients. RESULTS: (1) Most studies 
      suggest menopause may transitorily aggravate MS symptoms. Two studies found an 
      inflexion point on the Expanding Disability Status Scale (EDSS) with clinical 
      worsening during the menopausal transition. Another study considering full EDSS 
      trajectories from clinically isolated syndrome to postmenopause did not find such 
      an EDSS inflection; (2) MS and DMD do not seem to alter the age of menopause 
      onset; and (3) HRT in menopausal MS patients has not shown consistent benefits. 
      CONCLUSION: Menopause seems to be associated with transient symptom worsening, 
      but the existence of an inflection in disability progression is still 
      controversial. Properly designed studies are necessary to achieve conclusive 
      results.
FAU - Midaglia, Luciana
AU  - Midaglia L
AD  - Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia 
      (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 
      Barcelona, Spain.
FAU - Otero, Susana
AU  - Otero S
AD  - Department of Preventive Medicine and Epidemiology, Hospital Universitari Vall 
      d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
FAU - Baró, Francesc
AU  - Baró F
AD  - Department of Gynecology, Hospital Universitari Vall d'Hebron, Universitat 
      Autònoma de Barcelona, Barcelona, Spain.
FAU - Montalban, Xavier
AU  - Montalban X
AD  - Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia 
      (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 
      Barcelona, Spain.
FAU - Tintoré, Mar
AU  - Tintoré M
AUID- ORCID: 0000-0001-9999-5359
AD  - Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia 
      (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 
      Barcelona, Spain.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200828
PL  - England
TA  - Mult Scler
JT  - Multiple sclerosis (Houndmills, Basingstoke, England)
JID - 9509185
SB  - IM
MH  - Female
MH  - Hormone Replacement Therapy
MH  - Humans
MH  - Menopause
MH  - *Multiple Sclerosis/drug therapy
MH  - Postmenopause
MH  - Prognosis
OTO - NOTNLM
OT  - *Multiple sclerosis
OT  - *hormone replacement therapy
OT  - *low oestrogen levels
OT  - *menopause
OT  - *reproductive ageing
EDAT- 2020/08/29 06:00
MHDA- 2022/03/17 06:00
CRDT- 2020/08/29 06:00
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2022/03/17 06:00 [medline]
PHST- 2020/08/29 06:00 [entrez]
AID - 10.1177/1352458520952022 [doi]
PST - ppublish
SO  - Mult Scler. 2022 Feb;28(2):173-182. doi: 10.1177/1352458520952022. Epub 2020 Aug 
      28.

PMID- 31588832
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20201102
IS  - 1563-5279 (Electronic)
IS  - 0020-7454 (Linking)
VI  - 130
IP  - 3
DP  - 2020 Mar
TI  - Towards a comprehensive etiopathogenetic and pathophysiological theory of 
      multiple sclerosis.
PG  - 279-300
LID - 10.1080/00207454.2019.1677648 [doi]
AB  - Background: Multiple sclerosis (MS) is a neurodegenerative disease caused by 
      dysfunction of the immune system that affects the central nervous system (CNS). 
      It is characterized by demyelination, chronic inflammation, neuronal and 
      oligodendrocyte loss and reactive astrogliosis. It can result in physical 
      disability and acute neurological and cognitive problems. Despite the gains in 
      knowledge of immunology, cell biology, and genetics in the last five decades, the 
      ultimate etiology or specific elements that trigger MS remain unknown. The 
      objective of this review is to propose a theoretical basis for MS 
      etiopathogenesis.Methods: Search was done by accessing PubMed/Medline, EBSCO, and 
      PsycINFO databases. The search string used was "(multiple sclerosis* OR EAE) AND 
      (pathophysiology* OR etiopathogenesis)". The electronic databases were searched 
      for titles or abstracts containing these terms in all published articles between 
      January 1, 1960, and June 30, 2019. The search was filtered down to 362 articles 
      which were included in this review.Results: A framework to better understand the 
      etiopathogenesis and pathophysiology of MS can be derived from four essential 
      factors; mitochondria dysfunction (MtD) & oxidative stress (OS), vitamin D (VD), 
      sex hormones and thyroid hormones. These factors play a direct role in MS 
      etiopathogenesis and have a modulatory effect on many other factors involved in 
      the disease.Conclusions: For better MS prevention and treatment outcomes, efforts 
      should be geared towards treating thyroid problems, sex hormone alterations, VD 
      deficiency, sleep problems and melatonin alterations. MS patients should be 
      encouraged to engage in activities that boost total antioxidant capacity (TAC) 
      including diet and regular exercise and discouraged from activities that promote 
      OS including smoking and alcohol consumption.
FAU - Tobore, Tobore Onojighofia
AU  - Tobore TO
AUID- ORCID: 0000-0001-7334-2915
AD  - Johns Hopkins University, Baltimore, USA.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20191107
PL  - England
TA  - Int J Neurosci
JT  - The International journal of neuroscience
JID - 0270707
SB  - IM
MH  - Animals
MH  - Humans
MH  - *Multiple Sclerosis/etiology/metabolism/physiopathology
OTO - NOTNLM
OT  - Oxidative stress
OT  - ROS
OT  - axonal damage
OT  - blood–brain barrier
OT  - chronic inflammation
OT  - demyelinating diseases
OT  - estrogen
OT  - mitochondria dysfunction
OT  - neuronal loss
OT  - oligodendrocyte depletion
OT  - reactive astrogliosis
OT  - sex hormones
OT  - testosterone
OT  - thyroid hormones
OT  - vitamin D deficiency
EDAT- 2019/10/08 06:00
MHDA- 2020/11/03 06:00
CRDT- 2019/10/08 06:00
PHST- 2019/10/08 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
PHST- 2019/10/08 06:00 [entrez]
AID - 10.1080/00207454.2019.1677648 [doi]
PST - ppublish
SO  - Int J Neurosci. 2020 Mar;130(3):279-300. doi: 10.1080/00207454.2019.1677648. Epub 
      2019 Nov 7.

PMID- 25544310
OWN - NLM
STAT- MEDLINE
DCOM- 20160331
LR  - 20181202
IS  - 1873-4111 (Electronic)
IS  - 0378-5122 (Linking)
VI  - 80
IP  - 2
DP  - 2015 Feb
TI  - Multiple sclerosis at menopause: Potential neuroprotective effects of estrogen.
PG  - 133-9
LID - S0378-5122(14)00366-1 [pii]
LID - 10.1016/j.maturitas.2014.11.013 [doi]
AB  - Multiple sclerosis (MS) is an autoimmune demyelinating and neurodegenerative 
      condition of the central nervous system that preferentially afflicts women more 
      than men. Low estrogen states such as menopause and the postpartum period favor 
      exacerbations of multiple sclerosis in women with the disease. Existing and 
      emerging evidence suggests a role for estrogen in the alleviation of symptoms and 
      reversal of pathology associated with MS. While clinical evidence is sparse 
      regarding the benefit of estrogen therapy for women at risk for MS exacerbations, 
      scientific data demonstrates that estrogen potentiates numerous neuroprotective 
      effects on the central nervous system (CNS). Estrogens play a wide range of roles 
      involved in MS disease pathophysiology, including increasing antiinflammatory 
      cytokines, decreasing demyelination, and enhancing oxidative and energy producing 
      processes in CNS cells.
CI  - Copyright © 2014. Published by Elsevier Ireland Ltd.
FAU - Christianson, Mindy S
AU  - Christianson MS
AD  - Johns Hopkins University School of Medicine, Department of Gynecology and 
      Obstetrics, Division of Reproductive Endocrinology and Infertility, Lutherville, 
      MD 21093, United States. Electronic address: mchris21@jhmi.edu.
FAU - Mensah, Virginia A
AU  - Mensah VA
AD  - Brown Alpert Medical School, Women & Infants Hospital, Providence, RI, United 
      States.
FAU - Shen, Wen
AU  - Shen W
AD  - Johns Hopkins University School of Medicine, Department of Gynecology and 
      Obstetrics, Baltimore, MD, United States.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20141127
PL  - Ireland
TA  - Maturitas
JT  - Maturitas
JID - 7807333
RN  - 0 (Cytokines)
RN  - 0 (Estrogens)
RN  - 0 (Neuroprotective Agents)
SB  - IM
MH  - Cytokines
MH  - Disease Progression
MH  - Energy Metabolism
MH  - *Estrogen Replacement Therapy
MH  - Estrogens/*therapeutic use
MH  - Female
MH  - Humans
MH  - Menopause/*metabolism
MH  - Multiple Sclerosis/*drug therapy/metabolism
MH  - Neurons/*metabolism
MH  - Neuroprotective Agents/*therapeutic use
OTO - NOTNLM
OT  - Estradiol
OT  - Estrogen
OT  - Hormone therapy
OT  - Menopause
OT  - Multiple sclerosis
OT  - Neuroprotection
EDAT- 2014/12/30 06:00
MHDA- 2016/04/01 06:00
CRDT- 2014/12/30 06:00
PHST- 2014/10/16 00:00 [received]
PHST- 2014/11/19 00:00 [revised]
PHST- 2014/11/20 00:00 [accepted]
PHST- 2014/12/30 06:00 [entrez]
PHST- 2014/12/30 06:00 [pubmed]
PHST- 2016/04/01 06:00 [medline]
AID - S0378-5122(14)00366-1 [pii]
AID - 10.1016/j.maturitas.2014.11.013 [doi]
PST - ppublish
SO  - Maturitas. 2015 Feb;80(2):133-9. doi: 10.1016/j.maturitas.2014.11.013. Epub 2014 
      Nov 27.

PMID- 35734821
OWN - NLM
STAT- MEDLINE
DCOM- 20220729
LR  - 20230703
IS  - 1365-2826 (Electronic)
IS  - 0953-8194 (Print)
IS  - 0953-8194 (Linking)
VI  - 34
IP  - 7
DP  - 2022 Jul
TI  - Nuclear hormone receptors in demyelinating diseases.
PG  - e13171
LID - 10.1111/jne.13171 [doi]
AB  - Demyelination results from the pathological loss of myelin and is a hallmark of 
      many neurodegenerative diseases. Despite the prevalence of demyelinating 
      diseases, there are no disease modifying therapies that prevent the loss of 
      myelin or promote remyelination. This review aims to summarize studies in the 
      field that highlight the importance of nuclear hormone receptors in the promotion 
      and maintenance of myelination and the relevance of nuclear hormone receptors as 
      potential therapeutic targets for demyelinating diseases. These nuclear hormone 
      receptors include the estrogen receptor, progesterone receptor, androgen 
      receptor, vitamin D receptor, thyroid hormone receptor, peroxisome 
      proliferator-activated receptor, liver X receptor, and retinoid X receptor. 
      Pre-clinical studies in well-established animal models of demyelination have 
      shown a prominent role of these nuclear hormone receptors in myelination through 
      their promotion of oligodendrocyte maturation and development. The activation of 
      the nuclear hormone receptors by their ligands also promotes the synthesis of 
      myelin proteins and lipids in mouse models of demyelination. There are limited 
      clinical studies that focus on how the activation of these nuclear hormone 
      receptors could alleviate demyelination in patients with diseases such as 
      multiple sclerosis (MS). However, the completed clinical trials have reported 
      improved clinical outcome in MS patients treated with the ligands of some of 
      these nuclear hormone receptors. Together, the positive results from both 
      clinical and pre-clinical studies point to nuclear hormone receptors as promising 
      therapeutic targets to counter demyelination.
CI  - © 2022 British Society for Neuroendocrinology.
FAU - Zorrilla Veloz, Rocío I
AU  - Zorrilla Veloz RI
AD  - Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
AD  - Cancer Biology Program, The University of Texas MD Anderson Cancer Center 
      UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
FAU - McKenzie, Takese
AU  - McKenzie T
AUID- ORCID: 0000-0002-2337-1846
AD  - Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
AD  - Neuroscience Program, The University of Texas MD Anderson Cancer Center UTHealth 
      Graduate School of Biomedical Sciences, Houston, TX, USA.
FAU - Palacios, Bridgitte E
AU  - Palacios BE
AD  - Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
AD  - Cancer Biology Program, The University of Texas MD Anderson Cancer Center 
      UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
AD  - Neuroscience Program, The University of Texas MD Anderson Cancer Center UTHealth 
      Graduate School of Biomedical Sciences, Houston, TX, USA.
FAU - Hu, Jian
AU  - Hu J
AD  - Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
AD  - Cancer Biology Program, The University of Texas MD Anderson Cancer Center 
      UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
AD  - Neuroscience Program, The University of Texas MD Anderson Cancer Center UTHealth 
      Graduate School of Biomedical Sciences, Houston, TX, USA.
LA  - eng
GR  - R37 CA214800/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220622
PL  - United States
TA  - J Neuroendocrinol
JT  - Journal of neuroendocrinology
JID - 8913461
RN  - 0 (Receptors, Cytoplasmic and Nuclear)
SB  - IM
MH  - Animals
MH  - *Demyelinating Diseases/drug therapy/metabolism/pathology
MH  - Humans
MH  - Mice
MH  - *Multiple Sclerosis/metabolism
MH  - Myelin Sheath/metabolism
MH  - Oligodendroglia/metabolism/pathology
MH  - *Receptors, Cytoplasmic and Nuclear/metabolism
MH  - *Remyelination
PMC - PMC9339486
MID - NIHMS1811705
OTO - NOTNLM
OT  - demyelination
OT  - hormone receptors
OT  - myelin
OT  - nuclear receptors
OT  - steroid hormones
COIS- Conflict of Interest The authors declare no conflict of interest.
EDAT- 2022/06/24 06:00
MHDA- 2022/07/30 06:00
PMCR- 2023/07/01
CRDT- 2022/06/23 02:53
PHST- 2022/04/20 00:00 [revised]
PHST- 2022/01/21 00:00 [received]
PHST- 2022/05/27 00:00 [accepted]
PHST- 2022/06/24 06:00 [pubmed]
PHST- 2022/07/30 06:00 [medline]
PHST- 2022/06/23 02:53 [entrez]
PHST- 2023/07/01 00:00 [pmc-release]
AID - 10.1111/jne.13171 [doi]
PST - ppublish
SO  - J Neuroendocrinol. 2022 Jul;34(7):e13171. doi: 10.1111/jne.13171. Epub 2022 Jun 
      22.

PMID- 38561208
OWN - NLM
STAT- MEDLINE
DCOM- 20240403
LR  - 20240403
IS  - 1939-2869 (Electronic)
IS  - 0891-1150 (Linking)
VI  - 91
IP  - 4
DP  - 2024 Apr 1
TI  - Nonhormone therapies for vasomotor symptom management.
PG  - 237-244
LID - 10.3949/ccjm.91a.23067 [doi]
AB  - Vasomotor symptoms (VMS) are associated with adverse health consequences and can 
      cause significant morbidity for postmenopausal women. Although hormone therapy 
      remains the gold standard of VMS treatment in menopausal women, some women have 
      contraindications to or may choose not to take hormone therapy. This article 
      provides an up-to-date overview of the current evidence-based nonhormone 
      therapies available for managing VMS. Evidence supporting various treatment 
      options is reviewed, including lifestyle interventions, mind-body therapies, 
      procedures, pharmacologic agents, and emerging therapies, such as 
      neurokinin-receptor antagonists. The efficacy, safety, and clinical use of these 
      treatments are detailed, offering insights for clinicians to make informed 
      decisions in menopausal VMS management.
CI  - Copyright © 2024 The Cleveland Clinic Foundation. All Rights Reserved.
FAU - Iyer, Tara K
AU  - Iyer TK
AD  - Director, Menopause and Midlife Clinic, Division of Women's Health, Department of 
      Medicine, Brigham and Women's Hospital, Boston, MA; Instructor of Medicine, 
      Harvard Medical School, Boston, MA tiyer@bwh.harvard.edu.
FAU - Fiffick, Alexa N
AU  - Fiffick AN
AD  - CEO, Founder of Concierge Medicine of Westlake, Westlake, OH; Associate Director 
      of Education, Ms.Medicine; Menopause Expert, Menopause Mandate US.
FAU - Batur, Pelin
AU  - Batur P
AD  - Department of Subspecialty Care for Women's Health, Obstetrics and Gynecology 
      Institute, Cleveland Clinic, Cleveland, OH; Professor, OB/GYN and Reproductive 
      Biology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve 
      University, Cleveland, OH.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240401
PL  - United States
TA  - Cleve Clin J Med
JT  - Cleveland Clinic journal of medicine
JID - 8703441
RN  - 0 (Hormones)
SB  - IM
MH  - Female
MH  - Humans
MH  - *Hot Flashes/drug therapy
MH  - *Menopause
MH  - Estrogen Replacement Therapy/methods
MH  - Life Style
MH  - Hormones/pharmacology/therapeutic use
EDAT- 2024/04/02 00:42
MHDA- 2024/04/03 06:44
CRDT- 2024/04/01 20:33
PHST- 2024/04/03 06:44 [medline]
PHST- 2024/04/02 00:42 [pubmed]
PHST- 2024/04/01 20:33 [entrez]
AID - 91/4/237 [pii]
AID - 10.3949/ccjm.91a.23067 [doi]
PST - epublish
SO  - Cleve Clin J Med. 2024 Apr 1;91(4):237-244. doi: 10.3949/ccjm.91a.23067.

PMID- 27605175
OWN - NLM
STAT- MEDLINE
DCOM- 20170510
LR  - 20211216
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Print)
IS  - 0028-3878 (Linking)
VI  - 87
IP  - 14
DP  - 2016 Oct 4
TI  - Hormone therapy use and physical quality of life in postmenopausal women with 
      multiple sclerosis.
PG  - 1457-1463
AB  - OBJECTIVE: To determine the association between hormone therapy (HT) and physical 
      quality of life (QOL) in postmenopausal women with multiple sclerosis (MS). 
      METHODS: We included female participants from the prospective Nurses' Health 
      Study, with a diagnosis of definite or probable MS, who had completed a physical 
      functioning assessment (PF10; subscale of the 36-Item Short-Form Health Survey 
      QOL survey) at a time point between 3 and 10 years after their final menstrual 
      period (early postmenopause). We assessed the association between HT use at this 
      time point (never vs at least 12 months of systemic estrogen with/without 
      progestin) and both PF10 and the 36-Item Short-Form Health Survey Physical 
      Component Scale. We used a linear regression model adjusting for age, MS 
      duration, menopause type and duration, and further for additional covariates 
      (only ancestry was significant). RESULTS: Among 95 participants meeting all 
      inclusion criteria at their first postmenopausal assessment, 61 reported HT use 
      and 34 reported none. HT users differed from non-HT users in MS duration (p = 
      0.02) and menopause type (p = 0.01) but no other clinical or demographic 
      characteristics. HT users had average PF10 scores that were 23 points higher than 
      non-HT users (adjusted p = 0.004) and average Physical Component Scale scores 
      that were 9.1 points higher in the 59 women with these available (adjusted p = 
      0.02). Longer duration of HT use was also associated with higher PF10 scores (p = 
      0.02, adjusted p = 0.06). CONCLUSIONS: Systemic HT use was associated with better 
      physical QOL in postmenopausal women with MS in this observational study. Further 
      studies are necessary to investigate causality.
CI  - © 2016 American Academy of Neurology.
FAU - Bove, Riley
AU  - Bove R
AD  - From the UCSF MS Center (R.B.), Department of Neurology, UCSF, Sandler 
      Neurosciences Center, San Francisco, CA; Ann Romney Center for Neurologic 
      Diseases (C.C.W., T.C., L.C.), Harvard Medical School, Boston, MA; Johns Hopkins 
      Medical Institute (K.C.F.), Department of Neurology and Neuroimmunology, 
      Baltimore, MD; Partners Multiple Sclerosis Center (T.C.), Department of 
      Neurology, Brigham and Women's Hospital, Brookline; Harvard Medical School (T.C., 
      L.C.), Boston; Channing Division of Network Medicine (A.A.), Brigham and Women's 
      Hospital and Harvard Medical School, Boston; and Departments of Nutrition (A.A., 
      K.L.M.) and Epidemiology (L.C., A.A.), Harvard T.H. Chan School of Public Health, 
      Boston, MA. Riley.Bove@ucsf.edu.
FAU - White, Charles C
AU  - White CC
AD  - From the UCSF MS Center (R.B.), Department of Neurology, UCSF, Sandler 
      Neurosciences Center, San Francisco, CA; Ann Romney Center for Neurologic 
      Diseases (C.C.W., T.C., L.C.), Harvard Medical School, Boston, MA; Johns Hopkins 
      Medical Institute (K.C.F.), Department of Neurology and Neuroimmunology, 
      Baltimore, MD; Partners Multiple Sclerosis Center (T.C.), Department of 
      Neurology, Brigham and Women's Hospital, Brookline; Harvard Medical School (T.C., 
      L.C.), Boston; Channing Division of Network Medicine (A.A.), Brigham and Women's 
      Hospital and Harvard Medical School, Boston; and Departments of Nutrition (A.A., 
      K.L.M.) and Epidemiology (L.C., A.A.), Harvard T.H. Chan School of Public Health, 
      Boston, MA.
FAU - Fitzgerald, Kathryn C
AU  - Fitzgerald KC
AD  - From the UCSF MS Center (R.B.), Department of Neurology, UCSF, Sandler 
      Neurosciences Center, San Francisco, CA; Ann Romney Center for Neurologic 
      Diseases (C.C.W., T.C., L.C.), Harvard Medical School, Boston, MA; Johns Hopkins 
      Medical Institute (K.C.F.), Department of Neurology and Neuroimmunology, 
      Baltimore, MD; Partners Multiple Sclerosis Center (T.C.), Department of 
      Neurology, Brigham and Women's Hospital, Brookline; Harvard Medical School (T.C., 
      L.C.), Boston; Channing Division of Network Medicine (A.A.), Brigham and Women's 
      Hospital and Harvard Medical School, Boston; and Departments of Nutrition (A.A., 
      K.L.M.) and Epidemiology (L.C., A.A.), Harvard T.H. Chan School of Public Health, 
      Boston, MA.
FAU - Chitnis, Tanuja
AU  - Chitnis T
AD  - From the UCSF MS Center (R.B.), Department of Neurology, UCSF, Sandler 
      Neurosciences Center, San Francisco, CA; Ann Romney Center for Neurologic 
      Diseases (C.C.W., T.C., L.C.), Harvard Medical School, Boston, MA; Johns Hopkins 
      Medical Institute (K.C.F.), Department of Neurology and Neuroimmunology, 
      Baltimore, MD; Partners Multiple Sclerosis Center (T.C.), Department of 
      Neurology, Brigham and Women's Hospital, Brookline; Harvard Medical School (T.C., 
      L.C.), Boston; Channing Division of Network Medicine (A.A.), Brigham and Women's 
      Hospital and Harvard Medical School, Boston; and Departments of Nutrition (A.A., 
      K.L.M.) and Epidemiology (L.C., A.A.), Harvard T.H. Chan School of Public Health, 
      Boston, MA.
FAU - Chibnik, Lori
AU  - Chibnik L
AD  - From the UCSF MS Center (R.B.), Department of Neurology, UCSF, Sandler 
      Neurosciences Center, San Francisco, CA; Ann Romney Center for Neurologic 
      Diseases (C.C.W., T.C., L.C.), Harvard Medical School, Boston, MA; Johns Hopkins 
      Medical Institute (K.C.F.), Department of Neurology and Neuroimmunology, 
      Baltimore, MD; Partners Multiple Sclerosis Center (T.C.), Department of 
      Neurology, Brigham and Women's Hospital, Brookline; Harvard Medical School (T.C., 
      L.C.), Boston; Channing Division of Network Medicine (A.A.), Brigham and Women's 
      Hospital and Harvard Medical School, Boston; and Departments of Nutrition (A.A., 
      K.L.M.) and Epidemiology (L.C., A.A.), Harvard T.H. Chan School of Public Health, 
      Boston, MA.
FAU - Ascherio, Alberto
AU  - Ascherio A
AD  - From the UCSF MS Center (R.B.), Department of Neurology, UCSF, Sandler 
      Neurosciences Center, San Francisco, CA; Ann Romney Center for Neurologic 
      Diseases (C.C.W., T.C., L.C.), Harvard Medical School, Boston, MA; Johns Hopkins 
      Medical Institute (K.C.F.), Department of Neurology and Neuroimmunology, 
      Baltimore, MD; Partners Multiple Sclerosis Center (T.C.), Department of 
      Neurology, Brigham and Women's Hospital, Brookline; Harvard Medical School (T.C., 
      L.C.), Boston; Channing Division of Network Medicine (A.A.), Brigham and Women's 
      Hospital and Harvard Medical School, Boston; and Departments of Nutrition (A.A., 
      K.L.M.) and Epidemiology (L.C., A.A.), Harvard T.H. Chan School of Public Health, 
      Boston, MA.
FAU - Munger, Kassandra L
AU  - Munger KL
AD  - From the UCSF MS Center (R.B.), Department of Neurology, UCSF, Sandler 
      Neurosciences Center, San Francisco, CA; Ann Romney Center for Neurologic 
      Diseases (C.C.W., T.C., L.C.), Harvard Medical School, Boston, MA; Johns Hopkins 
      Medical Institute (K.C.F.), Department of Neurology and Neuroimmunology, 
      Baltimore, MD; Partners Multiple Sclerosis Center (T.C.), Department of 
      Neurology, Brigham and Women's Hospital, Brookline; Harvard Medical School (T.C., 
      L.C.), Boston; Channing Division of Network Medicine (A.A.), Brigham and Women's 
      Hospital and Harvard Medical School, Boston; and Departments of Nutrition (A.A., 
      K.L.M.) and Epidemiology (L.C., A.A.), Harvard T.H. Chan School of Public Health, 
      Boston, MA.
LA  - eng
GR  - K12 HD051959/HD/NICHD NIH HHS/United States
GR  - K25 AG041906/AG/NIA NIH HHS/United States
GR  - R01 NS071082/NS/NINDS NIH HHS/United States
GR  - UM1 CA186107/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Observational Study
DEP - 20160907
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
SB  - IM
CIN - Neurology. 2016 Oct 4;87(14):1430-1431. doi: 10.1212/WNL.0000000000003189. PMID: 
      27605172
MH  - *Estrogen Replacement Therapy
MH  - Female
MH  - Humans
MH  - Linear Models
MH  - Middle Aged
MH  - Multiple Sclerosis/drug therapy/*epidemiology
MH  - *Postmenopause
MH  - Prospective Studies
MH  - *Quality of Life
MH  - Surveys and Questionnaires
PMC - PMC5075979
EDAT- 2016/09/09 06:00
MHDA- 2017/05/11 06:00
PMCR- 2017/10/04
CRDT- 2016/09/09 06:00
PHST- 2016/01/27 00:00 [received]
PHST- 2016/05/12 00:00 [accepted]
PHST- 2016/09/09 06:00 [pubmed]
PHST- 2017/05/11 06:00 [medline]
PHST- 2016/09/09 06:00 [entrez]
PHST- 2017/10/04 00:00 [pmc-release]
AID - WNL.0000000000003176 [pii]
AID - NEUROLOGY2016721191 [pii]
AID - 10.1212/WNL.0000000000003176 [doi]
PST - ppublish
SO  - Neurology. 2016 Oct 4;87(14):1457-1463. doi: 10.1212/WNL.0000000000003176. Epub 
      2016 Sep 7.

PMID- 32373353
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2090-0422 (Print)
IS  - 2090-0430 (Electronic)
IS  - 2090-0430 (Linking)
VI  - 2020
DP  - 2020
TI  - Vitamin D and Demyelinating Diseases: Neuromyelitis Optica (NMO) and Multiple 
      Sclerosis (MS).
PG  - 8718736
LID - 10.1155/2020/8718736 [doi]
LID - 8718736
AB  - Vitamin D deficiency is prevalent in all ages regardless of climate or 
      geographical location and evidence is emerging that the incidence of autoimmune 
      diseases is increasing worldwide. Women make up a large proportion of autoimmune 
      disease diagnoses, underscoring the importance of fully elucidating the complex 
      synergistic relationships between estrogens and vitamin D. Vitamin D 
      receptor-activating drugs appear to enhance remyelination in patients diagnosed 
      with multiple sclerosis (MS) and other demyelinating diseases such as 
      neuromyelitis optica (NMO). This review is intended to update health 
      practitioners about the potential role of vitamin D deficiency demyelination and 
      to motivate future research on dietary recommendations for vitamin D in 
      preventing and treating demyel1nating diseases.
CI  - Copyright © 2020 Cady Rodney et al.
FAU - Rodney, Cady
AU  - Rodney C
AUID- ORCID: 0000-0003-1943-2092
AD  - Departments of Clinical Medicine and Pathophysiology, American University of 
      Antigua College of Medicine, Antigua and Barbuda.
FAU - Rodney, Sherriann
AU  - Rodney S
AD  - Departments of Clinical Medicine and Pathophysiology, American University of 
      Antigua College of Medicine, Antigua and Barbuda.
FAU - Millis, Richard M
AU  - Millis RM
AUID- ORCID: 0000-0002-7063-4338
AD  - Departments of Clinical Medicine and Pathophysiology, American University of 
      Antigua College of Medicine, Antigua and Barbuda.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200119
PL  - United States
TA  - Autoimmune Dis
JT  - Autoimmune diseases
JID - 101546750
PMC - PMC7187724
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/05/07 06:00
MHDA- 2020/05/07 06:01
PMCR- 2020/01/19
CRDT- 2020/05/07 06:00
PHST- 2019/09/25 00:00 [received]
PHST- 2019/11/30 00:00 [accepted]
PHST- 2020/05/07 06:00 [entrez]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2020/05/07 06:01 [medline]
PHST- 2020/01/19 00:00 [pmc-release]
AID - 10.1155/2020/8718736 [doi]
PST - epublish
SO  - Autoimmune Dis. 2020 Jan 19;2020:8718736. doi: 10.1155/2020/8718736. eCollection 
      2020.

PMID- 38277997
OWN - NLM
STAT- MEDLINE
DCOM- 20240223
LR  - 20240223
IS  - 1873-6750 (Electronic)
IS  - 0160-4120 (Linking)
VI  - 184
DP  - 2024 Feb
TI  - Benzo[a]pyrene exposure affects colorectal cancer susceptibility by regulating 
      ERβ-mediated LINC02977 transcription.
PG  - 108443
LID - S0160-4120(24)00029-1 [pii]
LID - 10.1016/j.envint.2024.108443 [doi]
AB  - Environmental pollutants known as polycyclic aromatic hydrocarbons (PAHs) are 
      produced through the incomplete combustion of organic material. While PAHs have 
      been investigated as genotoxicants, they can also operate through nongenotoxic 
      pathways in estrogen-dependent malignancies, such as breast, cervical and ovarian 
      cancer. However, whether PAHs induce colorectal cancer (CRC) risk through 
      estrogenic effects is still illusive. Here, we systematically investigated the 
      abnormal expression and activation of estrogen receptor beta (ERβ) regulated by 
      PAHs in CRC as well as the underlying mechanisms of ERβ-mediated CRC risk. Based 
      on the 300 plasma samples from CRC patients and healthy controls detected by 
      GC-MS/MS, we found that the plasma concentrations of benzo[a]pyrene (BaP) were 
      significantly higher in CRC cases than in healthy controls, with significant 
      estrogenic effects. Moreover, histone deacetylase 2 (HDAC2)-induced deacetylation 
      of the promoter decreases ERβ expression, which is associated with poor overall 
      survival and advanced tumor stage. The study also revealed that BaP and estradiol 
      (E(2)) had different carcinogenic effects, with BaP promoting cell proliferation 
      and inhibiting apoptosis, while E(2) had the opposite effects. Additionally, this 
      study mapped ERβ genomic binding regions by performing ChIP-seq and ATAC-seq and 
      identified genetic variants of rs1411680 and its high linkage disequilibrium SNP 
      rs6477937, which were significantly associated with CRC risk through 
      meta-analysis of two independent Chinese population genome-wide association 
      studies comprising 2,248 cases and 3,173 controls and then validation in a 
      large-scale European population. By integrating data from functional genomics, we 
      validated the regulatory effect of rs6477937 as an ERβ binding-disrupting SNP 
      that mediated allele-specific expression of LINC02977 in a long-range chromosomal 
      interaction manner, which was found to be highly expressed in CRC tissues. 
      Overall, this study suggests that the different active effects on ERβ by PAHs and 
      endogenous E(2) may play a crucial role in the development and progression of CRC 
      and highlights the potential of targeting ERβ and its downstream targets for CRC 
      prevention and treatment.
CI  - Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.
FAU - Ben, Shuai
AU  - Ben S
AD  - Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer 
      Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer 
      Personalized Medicine, School of Public Health, Nanjing Medical University, 
      Nanjing 211166, China; Department of Genetic Toxicology, The Key Laboratory of 
      Modern Toxicology of Ministry of Education, Center for Global Health, School of 
      Public Health, Nanjing Medical University, Nanjing 211166, China; Department of 
      Ophthalmology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong 
      University, Shanghai 200080, China.
FAU - Li, Shuwei
AU  - Li S
AD  - Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer 
      Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer 
      Personalized Medicine, School of Public Health, Nanjing Medical University, 
      Nanjing 211166, China; Department of Genetic Toxicology, The Key Laboratory of 
      Modern Toxicology of Ministry of Education, Center for Global Health, School of 
      Public Health, Nanjing Medical University, Nanjing 211166, China.
FAU - Gu, Dongying
AU  - Gu D
AD  - Department of Oncology, Nanjing First Hospital, Nanjing Medical University, 68 
      Changle Road, Nanjing 210000, Jiangsu, China.
FAU - Zhao, Lingyan
AU  - Zhao L
AD  - Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer 
      Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer 
      Personalized Medicine, School of Public Health, Nanjing Medical University, 
      Nanjing 211166, China; Department of Genetic Toxicology, The Key Laboratory of 
      Modern Toxicology of Ministry of Education, Center for Global Health, School of 
      Public Health, Nanjing Medical University, Nanjing 211166, China.
FAU - Xu, Shenya
AU  - Xu S
AD  - Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer 
      Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer 
      Personalized Medicine, School of Public Health, Nanjing Medical University, 
      Nanjing 211166, China; Department of Genetic Toxicology, The Key Laboratory of 
      Modern Toxicology of Ministry of Education, Center for Global Health, School of 
      Public Health, Nanjing Medical University, Nanjing 211166, China.
FAU - Ding, Zhutao
AU  - Ding Z
AD  - Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer 
      Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer 
      Personalized Medicine, School of Public Health, Nanjing Medical University, 
      Nanjing 211166, China; Department of Genetic Toxicology, The Key Laboratory of 
      Modern Toxicology of Ministry of Education, Center for Global Health, School of 
      Public Health, Nanjing Medical University, Nanjing 211166, China.
FAU - Chen, Silu
AU  - Chen S
AD  - Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer 
      Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer 
      Personalized Medicine, School of Public Health, Nanjing Medical University, 
      Nanjing 211166, China; Department of Genetic Toxicology, The Key Laboratory of 
      Modern Toxicology of Ministry of Education, Center for Global Health, School of 
      Public Health, Nanjing Medical University, Nanjing 211166, China.
FAU - Cheng, Yifei
AU  - Cheng Y
AD  - Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer 
      Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer 
      Personalized Medicine, School of Public Health, Nanjing Medical University, 
      Nanjing 211166, China; Department of Genetic Toxicology, The Key Laboratory of 
      Modern Toxicology of Ministry of Education, Center for Global Health, School of 
      Public Health, Nanjing Medical University, Nanjing 211166, China.
FAU - Xin, Junyi
AU  - Xin J
AD  - Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer 
      Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer 
      Personalized Medicine, School of Public Health, Nanjing Medical University, 
      Nanjing 211166, China; Department of Bioinformatics, School of Biomedical 
      Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, China.
FAU - Du, Mulong
AU  - Du M
AD  - Department of Biostatistics, Center for Global Health, School of Public Health, 
      Nanjing Medical University, Nanjing, China.
FAU - Wang, Meilin
AU  - Wang M
AD  - Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer 
      Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer 
      Personalized Medicine, School of Public Health, Nanjing Medical University, 
      Nanjing 211166, China; Department of Genetic Toxicology, The Key Laboratory of 
      Modern Toxicology of Ministry of Education, Center for Global Health, School of 
      Public Health, Nanjing Medical University, Nanjing 211166, China; The Affiliated 
      Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu 
      School, Nanjing Medical University, Suzhou 215008, China. Electronic address: 
      mwang@njmu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20240114
PL  - Netherlands
TA  - Environ Int
JT  - Environment international
JID - 7807270
RN  - 0 (Estrogen Receptor beta)
RN  - 3417WMA06D (Benzo(a)pyrene)
RN  - 0 (Polycyclic Aromatic Hydrocarbons)
RN  - 0 (Estrogens)
SB  - IM
MH  - Humans
MH  - Estrogen Receptor beta/genetics
MH  - Benzo(a)pyrene/toxicity
MH  - Genome-Wide Association Study
MH  - Tandem Mass Spectrometry
MH  - *Polycyclic Aromatic Hydrocarbons/toxicity/analysis
MH  - Estrogens
MH  - *Colorectal Neoplasms/genetics
OTO - NOTNLM
OT  - Benzo[a]pyrene
OT  - Colorectal cancer
OT  - Estrogen receptor beta
OT  - Genetic variants
OT  - Polycyclic aromatic hydrocarbons
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2024/01/27 12:42
MHDA- 2024/02/23 06:43
CRDT- 2024/01/26 18:13
PHST- 2023/09/27 00:00 [received]
PHST- 2023/12/04 00:00 [revised]
PHST- 2024/01/10 00:00 [accepted]
PHST- 2024/02/23 06:43 [medline]
PHST- 2024/01/27 12:42 [pubmed]
PHST- 2024/01/26 18:13 [entrez]
AID - S0160-4120(24)00029-1 [pii]
AID - 10.1016/j.envint.2024.108443 [doi]
PST - ppublish
SO  - Environ Int. 2024 Feb;184:108443. doi: 10.1016/j.envint.2024.108443. Epub 2024 
      Jan 14.

PMID- 37150421
OWN - NLM
STAT- MEDLINE
DCOM- 20230605
LR  - 20230605
IS  - 1872-7573 (Electronic)
IS  - 0378-8741 (Linking)
VI  - 314
DP  - 2023 Oct 5
TI  - Zigui-Yichong-Fang protects against cyclophosphamide-induced premature ovarian 
      insufficiency via the SIRT1/Foxo3a pathway.
PG  - 116608
LID - S0378-8741(23)00476-2 [pii]
LID - 10.1016/j.jep.2023.116608 [doi]
AB  - ETHNOPHARMACOLOGICAL RELEVANCE: Zigui-Yichong-Fang (ZGYCF) is a traditional 
      Chinese medicine prescription for the treatment of infertility and premature 
      ovarian insufficiency (POI). It is clinically used to regulate hormone levels, 
      improve ovarian reserve and increase pregnancy rate. However, the exact mechanism 
      of action is not yet clear. AIMS OF THE STUDY: This study aimed to explore the 
      potential impact and mechanism of ZGYCF on POI, and provide a scientific basis 
      for its clinical application. MATERIALS AND METHODS: UHPLC‒MS/MS was used to 
      identify the main compounds of ZGYCF. Female 8-week-old C57BL/6N mice were 
      randomized into four group containing the vehicle control (Veh) group, the 
      cyclophosphamide (CTX) model group, the low-dose ZGYCF (CTX-ZG-L) group and the 
      high-dose ZGYCF (CTX-ZG-H) group. A mouse POI model was induced with a single 
      intraperitoneal injection of CTX, and the therapeutic effects of different doses 
      of ZGYCF on POI were evaluated according to the ovarian weight coefficient, serum 
      AMH, serum E(2), ovarian histomorphology and follicle counts. After the dose 
      screening experiment, the CTX-ZG-L group was renamed the CTX-ZG group and 
      subjected to follow-up experiments. RNA-seq was used to explore the mechanism of 
      POI and the therapeutic mechanism of ZGYCF on POI in Veh group, CTX group and 
      CTX-ZG group. The mechanism of action of ZGYCF on POI were determined by 
      measuring serum hormone level, histomorphology, follicle counts, protein 
      expression and acetylation modification in groups of Veh, CTX, CTX-ZG and 
      CTX-ZG-Nam (SIRT1 inhibitor). RESULTS: A total of 37 compounds in ZGYCF were 
      identified. ZGYCF attenuated the morphological changes in ovarian tissue in POI 
      model mice, increased serum AMH and E(2) levels, reduced the damage to primordial 
      follicles and other follicles at all stages, and protected ovarian reserve. 
      RNA-seq results suggested that the genes expression of the PI3K signaling and 
      apoptosis signaling pathways was increased in POI mice, while ZGYCF upregulated 
      SIRT1 gene and the expression of estradiol, apoptosis inhibition and other 
      signaling pathway genes. Immunohistochemical staining, TUNEL staining, Western 
      blot analysis and immunoprecipitation results showed that in CTX group, SIRT1 
      expression and Foxo3a nuclei localization were decreased, while Ac-Foxo3a, p-AKT, 
      p-Foxo3a and apoptotic markers were upregulated. After administration of ZGYCF, 
      these conditions were reversed, however, after treatment with the SIRT1 
      inhibitor, the results were opposite to those of ZGYCF. CONCLUSIONS: Acetylated 
      Foxo3a plays an important role in the occurrence of POI. ZGYCF improves the 
      ovarian reserve of CTX-induced POI mice by activating SIRT1-mediated 
      deacetylation of Foxo3a, and played a role in the treatment of POI. SIRT1 may be 
      a novel target for ZGYCF to ameliorate POI.
CI  - Copyright © 2023 Elsevier B.V. All rights reserved.
FAU - Xiu, Zi
AU  - Xiu Z
AD  - Hebei Key Laboratory of Integrative Medicine on Liver-Kidney Patterns, Institute 
      of Integrative Medicine, College of Integrative Medicine, Hebei University of 
      Chinese Medicine, Shijiazhuang, 050200, China.
FAU - Tang, Siling
AU  - Tang S
AD  - Hebei Key Laboratory of Integrative Medicine on Liver-Kidney Patterns, Institute 
      of Integrative Medicine, College of Integrative Medicine, Hebei University of 
      Chinese Medicine, Shijiazhuang, 050200, China.
FAU - Kong, Peng
AU  - Kong P
AD  - Department of Biochemistry and Molecular Biology, College of Basic Medicine, Key 
      Laboratory of Medical Biotechnology of Hebei Province, Key Laboratory of Neural 
      and Vascular Biology of Ministry of Education, Hebei Medical University, 
      Shijiazhuang, 050017, China.
FAU - Yan, Mengxuan
AU  - Yan M
AD  - Hebei Key Laboratory of Integrative Medicine on Liver-Kidney Patterns, Institute 
      of Integrative Medicine, College of Integrative Medicine, Hebei University of 
      Chinese Medicine, Shijiazhuang, 050200, China.
FAU - Tong, Xue
AU  - Tong X
AD  - Hebei Key Laboratory of Integrative Medicine on Liver-Kidney Patterns, Institute 
      of Integrative Medicine, College of Integrative Medicine, Hebei University of 
      Chinese Medicine, Shijiazhuang, 050200, China.
FAU - Liu, Xueping
AU  - Liu X
AD  - Hebei Key Laboratory of Integrative Medicine on Liver-Kidney Patterns, Institute 
      of Integrative Medicine, College of Integrative Medicine, Hebei University of 
      Chinese Medicine, Shijiazhuang, 050200, China.
FAU - Liang, Xiao
AU  - Liang X
AD  - Hebei Key Laboratory of Integrative Medicine on Liver-Kidney Patterns, Institute 
      of Integrative Medicine, College of Integrative Medicine, Hebei University of 
      Chinese Medicine, Shijiazhuang, 050200, China.
FAU - Li, Rongxia
AU  - Li R
AD  - Hebei Key Laboratory of Integrative Medicine on Liver-Kidney Patterns, Institute 
      of Integrative Medicine, College of Integrative Medicine, Hebei University of 
      Chinese Medicine, Shijiazhuang, 050200, China; The Second Hospital of Hebei 
      Medicine University, Shijiazhuang, 050000, China.
FAU - Duan, Yancang
AU  - Duan Y
AD  - Hebei Key Laboratory of Integrative Medicine on Liver-Kidney Patterns, Institute 
      of Integrative Medicine, College of Integrative Medicine, Hebei University of 
      Chinese Medicine, Shijiazhuang, 050200, China. Electronic address: 
      duanyancang@163.com.
LA  - eng
PT  - Journal Article
DEP - 20230505
PL  - Ireland
TA  - J Ethnopharmacol
JT  - Journal of ethnopharmacology
JID - 7903310
RN  - EC 3.5.1.- (Sirtuin 1)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - 4TI98Z838E (Estradiol)
RN  - EC 3.5.1.- (SIRT1 protein, human)
RN  - EC 3.5.1.- (Sirt1 protein, mouse)
SB  - IM
MH  - Humans
MH  - Female
MH  - Mice
MH  - Animals
MH  - Sirtuin 1/metabolism
MH  - Phosphatidylinositol 3-Kinases
MH  - Tandem Mass Spectrometry
MH  - Mice, Inbred C57BL
MH  - *Primary Ovarian Insufficiency/chemically induced/drug therapy/prevention & 
      control
MH  - Cyclophosphamide/toxicity
MH  - *Menopause, Premature
MH  - Estradiol/therapeutic use
MH  - Disease Models, Animal
OTO - NOTNLM
OT  - Deacetylation
OT  - Foxo3a
OT  - Premature ovarian insufficiency
OT  - SIRT1
OT  - Zigui-Yichong-Fang
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/05/08 00:41
MHDA- 2023/06/05 06:42
CRDT- 2023/05/07 19:28
PHST- 2023/03/07 00:00 [received]
PHST- 2023/04/24 00:00 [revised]
PHST- 2023/05/04 00:00 [accepted]
PHST- 2023/06/05 06:42 [medline]
PHST- 2023/05/08 00:41 [pubmed]
PHST- 2023/05/07 19:28 [entrez]
AID - S0378-8741(23)00476-2 [pii]
AID - 10.1016/j.jep.2023.116608 [doi]
PST - ppublish
SO  - J Ethnopharmacol. 2023 Oct 5;314:116608. doi: 10.1016/j.jep.2023.116608. Epub 
      2023 May 5.

PMID- 38329326
OWN - NLM
STAT- MEDLINE
DCOM- 20240213
LR  - 20240213
IS  - 1530-6860 (Electronic)
IS  - 0892-6638 (Linking)
VI  - 38
IP  - 3
DP  - 2024 Feb 15
TI  - Sex-dependent expression of galectin-1, a cardioprotective β-galactoside-binding 
      lectin, in human calcific aortic stenosis.
PG  - e23447
LID - 10.1096/fj.202301832RR [doi]
AB  - We aimed to analyze sex-related differences in galectin-1 (Gal-1), a 
      β-galactoside-binding lectin, in aortic stenosis (AS) and its association with 
      the inflammatory and fibrocalcific progression of AS. Gal-1 was determined in 
      serum and aortic valves (AVs) from control and AS donors by western blot and 
      immunohistochemistry. Differences were validated by ELISA and qPCR in AS samples. 
      In vitro experiments were conducted in primary cultured valve interstitial cells 
      (VICs). Serum Gal-1 was not different neither between control and AS nor between 
      men and women. There was no association between circulating and valvular Gal-1 
      levels. The expression of Gal-1 in stenotic AVs was higher in men than women, 
      even after adjusting for confounding factors, and was associated with 
      inflammation, oxidative stress, extracellular matrix remodeling, fibrosis, and 
      osteogenesis. Gal-1 (LGALS1) mRNA was enhanced within fibrocalcific areas of 
      stenotic AVs, especially in men. Secretion of Gal-1 was up-regulated over a time 
      course of 2, 4, and 8 days in men's calcifying VICs, only peaking at day 4 in 
      women's VICs. In vitro, Gal-1 was associated with similar mechanisms to those in 
      our clinical cohort. β-estradiol significantly up-regulated the activity of an 
      LGALS1 promoter vector and the secretion of Gal-1, only in women's VICs. 
      Supplementation with rGal-1 prevented the effects elicited by calcific challenge 
      including the metabolic shift to glycolysis. In conclusion, Gal-1 is up-regulated 
      in stenotic AVs and VICs from men in association with inflammation, oxidative 
      stress, matrix remodeling, and osteogenesis. Estrogens can regulate Gal-1 
      expression with potential implications in post-menopause women. Exogenous rGal-1 
      can diminish calcific phenotypes in both women and men.
CI  - © 2024 Federation of American Societies for Experimental Biology.
FAU - Jover, Eva
AU  - Jover E
AUID- ORCID: 0000-0003-0628-9944
AD  - Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), 
      Instituto de Investigación Sanitaria de Navarra (IdiSNA), Hospital Universitario 
      de Navarra (HUN), Universidad Pública de Navarra (UPNA), Pamplona, Spain.
FAU - Martín-Núñez, Ernesto
AU  - Martín-Núñez E
AUID- ORCID: 0000-0003-0341-0956
AD  - Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), 
      Instituto de Investigación Sanitaria de Navarra (IdiSNA), Hospital Universitario 
      de Navarra (HUN), Universidad Pública de Navarra (UPNA), Pamplona, Spain.
FAU - Garaikoetxea, Mattie
AU  - Garaikoetxea M
AUID- ORCID: 0000-0001-7656-4046
AD  - Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), 
      Instituto de Investigación Sanitaria de Navarra (IdiSNA), Hospital Universitario 
      de Navarra (HUN), Universidad Pública de Navarra (UPNA), Pamplona, Spain.
FAU - Matilla, Lara
AU  - Matilla L
AUID- ORCID: 0000-0002-4234-8529
AD  - Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), 
      Instituto de Investigación Sanitaria de Navarra (IdiSNA), Hospital Universitario 
      de Navarra (HUN), Universidad Pública de Navarra (UPNA), Pamplona, Spain.
FAU - Blanco-Colio, Luis M
AU  - Blanco-Colio LM
AUID- ORCID: 0000-0002-1560-6609
AD  - IIS-Fundación Jiménez-Díaz-Autonoma University of Madrid (UAM), Madrid, Spain.
AD  - CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
FAU - Pérez-Sáez, Juan M
AU  - Pérez-Sáez JM
AUID- ORCID: 0000-0002-6722-5760
AD  - Laboratorio de Glicomedicina, Instituto de Biología y Medicina Experimental 
      (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), 
      Buenos Aires, Argentina.
FAU - Navarro, Adela
AU  - Navarro A
AUID- ORCID: 0000-0002-8508-9491
AD  - Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), 
      Instituto de Investigación Sanitaria de Navarra (IdiSNA), Hospital Universitario 
      de Navarra (HUN), Universidad Pública de Navarra (UPNA), Pamplona, Spain.
FAU - Fernández-Celis, Amaya
AU  - Fernández-Celis A
AUID- ORCID: 0000-0002-5627-7653
AD  - Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), 
      Instituto de Investigación Sanitaria de Navarra (IdiSNA), Hospital Universitario 
      de Navarra (HUN), Universidad Pública de Navarra (UPNA), Pamplona, Spain.
FAU - Gainza, Alicia
AU  - Gainza A
AUID- ORCID: 0000-0001-9726-734X
AD  - Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), 
      Instituto de Investigación Sanitaria de Navarra (IdiSNA), Hospital Universitario 
      de Navarra (HUN), Universidad Pública de Navarra (UPNA), Pamplona, Spain.
FAU - Álvarez, Virginia
AU  - Álvarez V
AUID- ORCID: 0000-0002-9899-9259
AD  - Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), 
      Instituto de Investigación Sanitaria de Navarra (IdiSNA), Hospital Universitario 
      de Navarra (HUN), Universidad Pública de Navarra (UPNA), Pamplona, Spain.
FAU - Sádaba, Rafael
AU  - Sádaba R
AUID- ORCID: 0000-0003-3776-4744
AD  - Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), 
      Instituto de Investigación Sanitaria de Navarra (IdiSNA), Hospital Universitario 
      de Navarra (HUN), Universidad Pública de Navarra (UPNA), Pamplona, Spain.
FAU - Tamayo, Ibai
AU  - Tamayo I
AUID- ORCID: 0000-0003-2860-3359
AD  - Research Methodology Unit, Navarrabiomed, Hospital Universitario de Navarra 
      (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain.
FAU - Rabinovich, Gabriel A
AU  - Rabinovich GA
AUID- ORCID: 0000-0002-0947-8735
AD  - Laboratorio de Glicomedicina, Instituto de Biología y Medicina Experimental 
      (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), 
      Buenos Aires, Argentina.
AD  - Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos 
      Aires, Argentina.
FAU - Martín-Ventura, José L
AU  - Martín-Ventura JL
AUID- ORCID: 0000-0003-2090-8641
AD  - IIS-Fundación Jiménez-Díaz-Autonoma University of Madrid (UAM), Madrid, Spain.
AD  - CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
FAU - López-Andrés, Natalia
AU  - López-Andrés N
AUID- ORCID: 0000-0003-3728-2606
AD  - Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), 
      Instituto de Investigación Sanitaria de Navarra (IdiSNA), Hospital Universitario 
      de Navarra (HUN), Universidad Pública de Navarra (UPNA), Pamplona, Spain.
LA  - eng
GR  - Miguel Servet CP13/00221 from Instituto de Salud Carlos III/MEC | Instituto de 
      Salud Carlos III (ISCIII)/
GR  - PI18/01875/MEC | Instituto de Salud Carlos III (ISCIII)/
GR  - PI19/00128/MEC | Instituto de Salud Carlos III (ISCIII)/
GR  - PI21/00280/MEC | Instituto de Salud Carlos III (ISCIII)/
GR  - PFIS (FI19/00302) PhD studentship/MEC | Instituto de Salud Carlos III (ISCIII)/
GR  - Sara Borrell postdoctoral fellowship CD19/00251/MEC | Instituto de Salud Carlos 
      III (ISCIII)/
GR  - Margarita Salas postdoctoral fellowship (ULL-MS-P14)/Universidad de La Laguna 
      (ULL)/
GR  - 'Stop Fuga de cerebros' postdoctoral fellowship/Roche España (Roche)/
PT  - Journal Article
PL  - United States
TA  - FASEB J
JT  - FASEB journal : official publication of the Federation of American Societies for 
      Experimental Biology
JID - 8804484
RN  - 0 (beta-galactoside)
RN  - 0 (Galectin 1)
RN  - 0 (LGALS1 protein, human)
RN  - Aortic Valve, Calcification of
SB  - IM
MH  - Male
MH  - *Galectin 1/genetics/metabolism
MH  - *Aortic Valve Stenosis/metabolism
MH  - Inflammation/metabolism
MH  - Female
MH  - Cells, Cultured
MH  - Aortic Valve/pathology
MH  - Humans
MH  - *Calcinosis
OTO - NOTNLM
OT  - calcification
OT  - galectin-1
OT  - sex differences
OT  - valve interstitial cells
OT  - valvular heart disease
EDAT- 2024/02/08 12:43
MHDA- 2024/02/09 06:42
CRDT- 2024/02/08 08:53
PHST- 2024/01/02 00:00 [revised]
PHST- 2023/09/07 00:00 [received]
PHST- 2024/01/10 00:00 [accepted]
PHST- 2024/02/09 06:42 [medline]
PHST- 2024/02/08 12:43 [pubmed]
PHST- 2024/02/08 08:53 [entrez]
AID - 10.1096/fj.202301832RR [doi]
PST - ppublish
SO  - FASEB J. 2024 Feb 15;38(3):e23447. doi: 10.1096/fj.202301832RR.

PMID- 29381664
OWN - NLM
STAT- MEDLINE
DCOM- 20190812
LR  - 20211204
IS  - 1530-0374 (Electronic)
IS  - 1072-3714 (Print)
IS  - 1072-3714 (Linking)
VI  - 25
IP  - 6
DP  - 2018 Jun
TI  - Hormone therapy and urine protein excretion: a multiracial cohort study, 
      systematic review, and meta-analysis.
PG  - 625-634
LID - 10.1097/GME.0000000000001062 [doi]
AB  - OBJECTIVE: Experimental models suggest estrogen has a renoprotective effect, but 
      human studies show variable results. Our objective was to study the association 
      of hormone therapy (HT) and albuminuria in postmenopausal women and to synthesize 
      the results with outcomes from prior studies. METHODS: We analyzed data from 
      postmenopausal women who participated in the second study visit (2000-2004) of 
      the Genetic Epidemiology Network of Arteriopathy (GENOA) study. The exposure was 
      self-reported HT use and the outcome was albuminuria (urine albumin-to-creatinine 
      ratio >25 mg/g creatinine). We also conducted a systematic review and 
      meta-analysis on the association of HT and urine protein in postmenopausal women. 
      Continuous and dichotomous measures of protein excretion were converted to a 
      standardized mean difference (SMD) for each study. RESULTS: In the GENOA cohort 
      (n = 2,217), there were fewer women with albuminuria among HT users than nonusers 
      (9% vs 19%, P < 0.001). HT use was associated with decreased odds of albuminuria 
      (odds ratio 0.65, 95% confidence interval (CI), 0.45-0.95), after adjusting for 
      significant differences in age, race, education, comorbidities, and the age at 
      and cause of menopause. The SMD of the effect of HT on urine 
      proteinuria/albuminuria in the randomized control trials (n = 3) was 0.02 (95% 
      CI, -0.29 to 0.33) and -0.13 (95% CI, -0.31 to 0.05) in the observational studies 
      (n = 9). There was significantly less albuminuria among HT users (SMD -0.15, 95% 
      CI, -0.27 to -0.04) in the 9 studies that only reported albuminuria as an outcome 
      and in the 10 studies with a comparator arm (SMD -0.15, 95% CI, -0.26 to -0.04). 
      CONCLUSIONS: HT is associated with decreased odds of albuminuria, but some of the 
      observed benefits may be related to reported outcomes, the presence of a 
      comparator arm, and the type of study design.
FAU - Kattah, Andrea G
AU  - Kattah AG
AD  - Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.
FAU - Suarez, Maria L G
AU  - Suarez MLG
AD  - Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.
FAU - Milic, Natasa
AU  - Milic N
AD  - Institute for Medical Statistics and Informatics, Faculty of Medicine, University 
      of Belgrade, Belgrade, Serbia.
FAU - Kantarci, Kejal
AU  - Kantarci K
AD  - Department of Neuroradiology, Mayo Clinic, Rochester, MN.
FAU - Zeydan, Burcu
AU  - Zeydan B
AD  - Department of Neuroradiology, Mayo Clinic, Rochester, MN.
FAU - Mosley, Thomas
AU  - Mosley T
AD  - Memory Impairment and Neurodegenerative Dementia Center, University of 
      Mississippi, Jackson, MS.
FAU - Turner, Stephen T
AU  - Turner ST
AD  - Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.
FAU - Ware, Erin B
AU  - Ware EB
AD  - Department of Epidemiology, School of Public Health, University of Michigan, Ann 
      Arbor, MI.
AD  - Survey Research Center, Institute for Social Research, University of Michigan, 
      Ann Arbor, MI.
FAU - Kardia, Sharon L R
AU  - Kardia SLR
AD  - Department of Epidemiology, School of Public Health, University of Michigan, Ann 
      Arbor, MI.
FAU - Garovic, Vesna D
AU  - Garovic VD
AD  - Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.
LA  - eng
GR  - R01 HL087660/HL/NHLBI NIH HHS/United States
GR  - U10 HL054464/HL/NHLBI NIH HHS/United States
GR  - U01 HL054464/HL/NHLBI NIH HHS/United States
GR  - R01 HL119443/HL/NHLBI NIH HHS/United States
GR  - RF1 AG057547/AG/NIA NIH HHS/United States
GR  - U10 HL054457/HL/NHLBI NIH HHS/United States
GR  - U10 HL054481/HL/NHLBI NIH HHS/United States
GR  - U01 HL054457/HL/NHLBI NIH HHS/United States
GR  - U01 HL054481/HL/NHLBI NIH HHS/United States
GR  - P50 AG044170/AG/NIA NIH HHS/United States
GR  - UL1 TR000135/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, N.I.H., Extramural
PT  - Systematic Review
PL  - United States
TA  - Menopause
JT  - Menopause (New York, N.Y.)
JID - 9433353
RN  - 0 (Biomarkers)
RN  - AYI8EX34EU (Creatinine)
CIN - Menopause. 2018 Jun;25(6):591-593. doi: 10.1097/GME.0000000000001111. PMID: 
      29664763
MH  - Albuminuria/metabolism
MH  - Biomarkers/urine
MH  - Cohort Studies
MH  - Creatinine/urine
MH  - *Estrogen Replacement Therapy
MH  - Ethnicity
MH  - Female
MH  - Humans
MH  - Hypertension/genetics
MH  - Menopause/ethnology/*urine
MH  - Middle Aged
MH  - Randomized Controlled Trials as Topic
MH  - Surveys and Questionnaires
PMC - PMC5970005
MID - NIHMS928459
EDAT- 2018/01/31 06:00
MHDA- 2019/08/14 06:00
PMCR- 2019/06/01
CRDT- 2018/01/31 06:00
PHST- 2018/01/31 06:00 [pubmed]
PHST- 2019/08/14 06:00 [medline]
PHST- 2018/01/31 06:00 [entrez]
PHST- 2019/06/01 00:00 [pmc-release]
AID - 10.1097/GME.0000000000001062 [doi]
PST - ppublish
SO  - Menopause. 2018 Jun;25(6):625-634. doi: 10.1097/GME.0000000000001062.

PMID- 38139092
OWN - NLM
STAT- MEDLINE
DCOM- 20231225
LR  - 20240102
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 24
IP  - 24
DP  - 2023 Dec 8
TI  - Sphingomyelin Metabolism Modifies Luminal A Breast Cancer Cell Line under a High 
      Dose of Vitamin C.
LID - 10.3390/ijms242417263 [doi]
LID - 17263
AB  - The role of sphingomyelin metabolism and vitamin C in cancer has been widely 
      described with conflicting results ranging from a total absence of effect to 
      possible preventive and/or protective effects. The aim of this study was to 
      establish the possible involvement of sphingomyelin metabolism in the changes 
      induced by vitamin C in breast cancer cells. The MCF7 cell line reproducing 
      luminal A breast cancer and the MDA-MB-231 cell line reproducing triple-negative 
      breast cancer were used. Cell phenotype was tested by estrogen receptor, 
      progesterone receptor, human epidermal growth factor receptor 2 expression, and 
      proliferation index percentage. Sphingomyelin was localized by an EGFP-NT-Lys 
      fluorescent probe. Sphingomyelin metabolism was analyzed by RT-PCR, Western 
      blotting and UFLC-MS/MS. The results showed that a high dose of vitamin C 
      produced reduced cell viability, modulated cell cycle related genes, and changed 
      the cell phenotype with estrogen receptor downregulation in MCF7 cell. In these 
      cells, the catabolism of sphingomyelin was promoted with a large increase in 
      ceramide content. No changes in viability and molecular expression were observed 
      in MB231 cells. In conclusion, a high dose of vitamin C induces changes in the 
      luminal A cell line involving sphingomyelin metabolism.
FAU - Codini, Michela
AU  - Codini M
AUID- ORCID: 0000-0002-1562-4495
AD  - Department of Pharmaceutical Sciences, University of Perugia, 06126 Perugia, 
      Italy.
FAU - Fiorani, Federico
AU  - Fiorani F
AD  - Department of Pharmaceutical Sciences, University of Perugia, 06126 Perugia, 
      Italy.
FAU - Mandarano, Martina
AU  - Mandarano M
AUID- ORCID: 0000-0001-5019-4825
AD  - Section of Anatomic Pathology and Histology, Department of Medicine and Surgery, 
      University of Perugia, 06126 Perugia, Italy.
FAU - Cataldi, Samuela
AU  - Cataldi S
AD  - Department of Pharmaceutical Sciences, University of Perugia, 06126 Perugia, 
      Italy.
FAU - Arcuri, Cataldo
AU  - Arcuri C
AUID- ORCID: 0000-0002-3114-8812
AD  - Section of Anatomy, Department of Medicine and Surgery, University of Perugia, 
      06126 Perugia, Italy.
FAU - Mirarchi, Alessandra
AU  - Mirarchi A
AD  - Section of Anatomy, Department of Medicine and Surgery, University of Perugia, 
      06126 Perugia, Italy.
FAU - Ceccarini, Maria Rachele
AU  - Ceccarini MR
AUID- ORCID: 0000-0002-5344-4890
AD  - Department of Pharmaceutical Sciences, University of Perugia, 06126 Perugia, 
      Italy.
FAU - Beccari, Tommaso
AU  - Beccari T
AUID- ORCID: 0000-0001-9637-6579
AD  - Department of Pharmaceutical Sciences, University of Perugia, 06126 Perugia, 
      Italy.
FAU - Kobayashi, Toshihide
AU  - Kobayashi T
AD  - UMR 7021 CNRS, Faculté de Pharmacie, Universitè de Strasbourg, 67401 Illkirch, 
      France.
AD  - Cellular Informatics Laboratory, RIKEN, Wako 351-0198, Saitama, Japan.
FAU - Tomishige, Nario
AU  - Tomishige N
AD  - UMR 7021 CNRS, Faculté de Pharmacie, Universitè de Strasbourg, 67401 Illkirch, 
      France.
AD  - Cellular Informatics Laboratory, RIKEN, Wako 351-0198, Saitama, Japan.
FAU - Sidoni, Angelo
AU  - Sidoni A
AD  - Section of Anatomic Pathology and Histology, Department of Medicine and Surgery, 
      University of Perugia, 06126 Perugia, Italy.
FAU - Albi, Elisabetta
AU  - Albi E
AUID- ORCID: 0000-0002-5745-5343
AD  - Department of Pharmaceutical Sciences, University of Perugia, 06126 Perugia, 
      Italy.
LA  - eng
PT  - Journal Article
DEP - 20231208
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Sphingomyelins)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - 0 (Vitamins)
SB  - IM
MH  - Humans
MH  - Female
MH  - MCF-7 Cells
MH  - *Breast Neoplasms/metabolism
MH  - Sphingomyelins
MH  - Ascorbic Acid/pharmacology
MH  - Tandem Mass Spectrometry
MH  - Vitamins/pharmacology
MH  - *Triple Negative Breast Neoplasms
MH  - Cell Line, Tumor
MH  - Cell Proliferation
PMC - PMC10743617
OTO - NOTNLM
OT  - HER-2
OT  - Ki-67
OT  - MB-231 cells
OT  - MCF7 cells
OT  - breast cancer
OT  - ceramide
OT  - estrogen receptor
OT  - progesterone receptor
OT  - sphingomyelin
OT  - vitamin C
COIS- The authors declare no conflict of interest.
EDAT- 2023/12/23 12:43
MHDA- 2023/12/25 06:41
PMCR- 2023/12/08
CRDT- 2023/12/23 01:20
PHST- 2023/10/30 00:00 [received]
PHST- 2023/12/01 00:00 [revised]
PHST- 2023/12/04 00:00 [accepted]
PHST- 2023/12/25 06:41 [medline]
PHST- 2023/12/23 12:43 [pubmed]
PHST- 2023/12/23 01:20 [entrez]
PHST- 2023/12/08 00:00 [pmc-release]
AID - ijms242417263 [pii]
AID - ijms-24-17263 [pii]
AID - 10.3390/ijms242417263 [doi]
PST - epublish
SO  - Int J Mol Sci. 2023 Dec 8;24(24):17263. doi: 10.3390/ijms242417263.

PMID- 35760047
OWN - NLM
STAT- MEDLINE
DCOM- 20230113
LR  - 20230225
IS  - 1423-0194 (Electronic)
IS  - 0028-3835 (Linking)
VI  - 113
IP  - 1
DP  - 2023
TI  - Progestogen-Mediated Neuroprotection in Central Nervous System Disorders.
PG  - 14-35
LID - 10.1159/000525677 [doi]
AB  - Neuroactive steroids can be synthetic or endogenous molecules produced by 
      neuronal and glial cells and peripheral glands. Examples include estrogens, 
      testosterone, progesterone and its reduced metabolites such as 
      5α-dihydro-progesterone and allopregnanolone. Steroids produced by neurons and 
      glia target the nervous system and are called neurosteroids. Progesterone and 
      analog molecules, known as progestogens, have been shown to exhibit neurotrophic, 
      neuroprotective, antioxidant, anti-inflammatory, glial modulatory, 
      promyelinating, and remyelinating effects in several experimental models of 
      neurodegenerative and injury conditions. Pleiotropic mechanisms of progestogens 
      may act synergistically to prevent neuron degeneration, astrocyte and microglial 
      reactivity, reducing morbidity and mortality. The aim of this review is to 
      summarize the significant findings related to the actions of progesterone and 
      other progestogens in experimental models and epidemiological and clinical trials 
      of some of the most prevalent and debilitating chronic neurodegenerative 
      disorders, namely, Alzheimer's disease, Parkinson's disease, Huntington's 
      disease, amyotrophic lateral sclerosis, and multiple sclerosis. We evaluated 
      progestogen alterations under pathological conditions, how pathology modifies 
      their levels, as well as the intracellular mechanisms and glial interactions 
      underlying their neuroprotective effects. Furthermore, an analysis of the 
      potential of natural progestogens and synthetic progestins as neuroprotective and 
      regenerative agents, when administered as hormone replacement therapy in 
      menopause, is also discussed.
CI  - © 2022 S. Karger AG, Basel.
FAU - Bassani, Taysa Bervian
AU  - Bassani TB
AD  - Department of Biological Sciences, Universidade Federal de São Paulo, Diadema, 
      Brazil.
AD  - Laboratory of Molecular and Translational Endocrinology, Escola Paulista de 
      Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.
FAU - Bartolomeo, Cynthia Silva
AU  - Bartolomeo CS
AD  - Department of Biosciences, Universidade Federal de São Paulo, Santos, Brazil.
FAU - Oliveira, Rafaela Brito
AU  - Oliveira RB
AD  - Department of Biological Sciences, Universidade Federal de São Paulo, Diadema, 
      Brazil.
AD  - Laboratory of Molecular and Translational Endocrinology, Escola Paulista de 
      Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.
FAU - Ureshino, Rodrigo Portes
AU  - Ureshino RP
AD  - Department of Biological Sciences, Universidade Federal de São Paulo, Diadema, 
      Brazil.
AD  - Laboratory of Molecular and Translational Endocrinology, Escola Paulista de 
      Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220627
PL  - Switzerland
TA  - Neuroendocrinology
JT  - Neuroendocrinology
JID - 0035665
RN  - 0 (Progestins)
RN  - 4G7DS2Q64Y (Progesterone)
SB  - IM
MH  - Female
MH  - Humans
MH  - *Progestins/pharmacology/therapeutic use/metabolism
MH  - Progesterone/pharmacology/therapeutic use/metabolism
MH  - Neuroprotection
MH  - *Alzheimer Disease/metabolism
MH  - Neurons/metabolism
OTO - NOTNLM
OT  - Allopregnanolone
OT  - Neurodegenerative disease
OT  - Neuroprotection
OT  - Progesterone
EDAT- 2022/06/28 06:00
MHDA- 2023/01/14 06:00
CRDT- 2022/06/27 18:30
PHST- 2021/12/13 00:00 [received]
PHST- 2022/06/17 00:00 [accepted]
PHST- 2022/06/28 06:00 [pubmed]
PHST- 2023/01/14 06:00 [medline]
PHST- 2022/06/27 18:30 [entrez]
AID - 000525677 [pii]
AID - 10.1159/000525677 [doi]
PST - ppublish
SO  - Neuroendocrinology. 2023;113(1):14-35. doi: 10.1159/000525677. Epub 2022 Jun 27.

PMID- 32168205
OWN - NLM
STAT- MEDLINE
DCOM- 20200908
LR  - 20210108
IS  - 1873-233X (Electronic)
IS  - 0029-7844 (Linking)
VI  - 135
IP  - 4
DP  - 2020 Apr
TI  - Clinical Effects of Early or Surgical Menopause.
PG  - 853-868
LID - 10.1097/AOG.0000000000003729 [doi]
AB  - Increasing numbers of women experience early menopause due in part to surgical 
      treatment for benign gynecologic disorders and the rise in risk-reducing 
      bilateral salpingo-oophorectomy in women with BRCA mutations. Unfortunately, the 
      adverse health consequences of early loss of ovarian function accelerate the 
      menopausal state and affect multiple systems, including cardiovascular, 
      neurologic, bone, and connective tissue, and affect quality of life owing to 
      vasomotor symptoms, mood, sleep, and sexual function. Yet many clinicians and 
      women remain reluctant to use hormone therapy because of the Women's Health 
      Initiative's adverse findings, even though they are not applicable to women with 
      early menopause. This review examines the effects of early menopause and 
      highlights the critical role of hormone therapy in this population.
FAU - Kingsberg, Sheryl A
AU  - Kingsberg SA
AD  - Department of Obstetrics and Gynecology, University Hospitals of Cleveland, 
      MacDonald Women's Hospital, Case Western Reserve University School of Medicine, 
      Cleveland, and Ms. Medicine, Cincinnati, Ohio.
FAU - Larkin, Lisa C
AU  - Larkin LC
FAU - Liu, James H
AU  - Liu JH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
SB  - IM
MH  - *Estrogen Replacement Therapy
MH  - Female
MH  - Genes, BRCA1
MH  - Genes, BRCA2
MH  - Humans
MH  - *Menopause, Premature
MH  - Ovarian Neoplasms/*genetics
MH  - Salpingo-oophorectomy/*adverse effects
EDAT- 2020/03/14 06:00
MHDA- 2020/09/09 06:00
CRDT- 2020/03/14 06:00
PHST- 2020/03/14 06:00 [pubmed]
PHST- 2020/09/09 06:00 [medline]
PHST- 2020/03/14 06:00 [entrez]
AID - 00006250-202004000-00015 [pii]
AID - 10.1097/AOG.0000000000003729 [doi]
PST - ppublish
SO  - Obstet Gynecol. 2020 Apr;135(4):853-868. doi: 10.1097/AOG.0000000000003729.

PMID- 35047868
OWN - NLM
STAT- MEDLINE
DCOM- 20220830
LR  - 20240405
IS  - 2666-7568 (Electronic)
IS  - 2666-7568 (Linking)
VI  - 3
IP  - 1
DP  - 2022 Jan
TI  - Personalising therapy for early-stage oestrogen receptor-positive breast cancer 
      in older women.
PG  - e54-e66
LID - 10.1016/s2666-7568(21)00280-4 [doi]
AB  - Age is one of the most important risk factors for the development of breast 
      cancer. Nearly a third of all breast cancer cases occur in older women (aged ≥70 
      years), with most cases being oestrogen receptor-positive (ER+). Such tumours are 
      often indolent and unlikely to be the ultimate cause of death for older women, 
      particularly when considering other comorbidities. This Review focuses on unique 
      clinical considerations for screening, detection, and treatment regimens for 
      older women who develop ER+ breast cancers-specifically, we focus on recent 
      trends for de-implementation of screening, staging, surgery, and adjuvant 
      therapies along the continuum of care. Additionally, we also review emerging 
      basic and translational research that will further uncover the unique underlying 
      biology of these tumours, which develop in the context of systemic age-related 
      inflammation and changing hormone profiles. With prevailing trends of clinical 
      de-implementation, new insights into mechanistic biology might provide an 
      opportunity for precision medicine approaches to treat patients with well 
      tolerated, low-toxicity agents to extend patients' lives with a higher quality of 
      life, prevent tumour recurrences, and reduce cancer-related burdens.
FAU - Carleton, Neil
AU  - Carleton N
AD  - (N Carleton BS, Prof S Oesterreich PhD, P F McAuliffe MD, Prof A V Lee PhD) (S 
      Beriwal MD, P N Barry MD), (N Carleton, Prof S Oesterreich, P F McAuliffe, Prof A 
      V Lee); (A Nasrazadani MD, K Gade MD, Prof A M Brufksy MD, G J van Londen MD), 
      (Prof R Bhargava MD), (D L Thull MS, P L Mai MD), (E J Diego MD, Prof M T Lotze 
      MD, P F McAuliffe), (Prof M T Lotze), (Prof M T Lotze), (Prof S Oesterreich, Prof 
      A V Lee), (Prof W A Berg MD, Prof M L Zuley MD); (O C Marroquin MD).
FAU - Nasrazadani, Azadeh
AU  - Nasrazadani A
AD  - (N Carleton BS, Prof S Oesterreich PhD, P F McAuliffe MD, Prof A V Lee PhD) (S 
      Beriwal MD, P N Barry MD), (N Carleton, Prof S Oesterreich, P F McAuliffe, Prof A 
      V Lee); (A Nasrazadani MD, K Gade MD, Prof A M Brufksy MD, G J van Londen MD), 
      (Prof R Bhargava MD), (D L Thull MS, P L Mai MD), (E J Diego MD, Prof M T Lotze 
      MD, P F McAuliffe), (Prof M T Lotze), (Prof M T Lotze), (Prof S Oesterreich, Prof 
      A V Lee), (Prof W A Berg MD, Prof M L Zuley MD); (O C Marroquin MD).
FAU - Gade, Kristine
AU  - Gade K
AD  - (N Carleton BS, Prof S Oesterreich PhD, P F McAuliffe MD, Prof A V Lee PhD) (S 
      Beriwal MD, P N Barry MD), (N Carleton, Prof S Oesterreich, P F McAuliffe, Prof A 
      V Lee); (A Nasrazadani MD, K Gade MD, Prof A M Brufksy MD, G J van Londen MD), 
      (Prof R Bhargava MD), (D L Thull MS, P L Mai MD), (E J Diego MD, Prof M T Lotze 
      MD, P F McAuliffe), (Prof M T Lotze), (Prof M T Lotze), (Prof S Oesterreich, Prof 
      A V Lee), (Prof W A Berg MD, Prof M L Zuley MD); (O C Marroquin MD).
FAU - Beriwal, Sushil
AU  - Beriwal S
AD  - (N Carleton BS, Prof S Oesterreich PhD, P F McAuliffe MD, Prof A V Lee PhD) (S 
      Beriwal MD, P N Barry MD), (N Carleton, Prof S Oesterreich, P F McAuliffe, Prof A 
      V Lee); (A Nasrazadani MD, K Gade MD, Prof A M Brufksy MD, G J van Londen MD), 
      (Prof R Bhargava MD), (D L Thull MS, P L Mai MD), (E J Diego MD, Prof M T Lotze 
      MD, P F McAuliffe), (Prof M T Lotze), (Prof M T Lotze), (Prof S Oesterreich, Prof 
      A V Lee), (Prof W A Berg MD, Prof M L Zuley MD); (O C Marroquin MD).
FAU - Barry, Parul N
AU  - Barry PN
AD  - (N Carleton BS, Prof S Oesterreich PhD, P F McAuliffe MD, Prof A V Lee PhD) (S 
      Beriwal MD, P N Barry MD), (N Carleton, Prof S Oesterreich, P F McAuliffe, Prof A 
      V Lee); (A Nasrazadani MD, K Gade MD, Prof A M Brufksy MD, G J van Londen MD), 
      (Prof R Bhargava MD), (D L Thull MS, P L Mai MD), (E J Diego MD, Prof M T Lotze 
      MD, P F McAuliffe), (Prof M T Lotze), (Prof M T Lotze), (Prof S Oesterreich, Prof 
      A V Lee), (Prof W A Berg MD, Prof M L Zuley MD); (O C Marroquin MD).
FAU - Brufsky, Adam M
AU  - Brufsky AM
AD  - (N Carleton BS, Prof S Oesterreich PhD, P F McAuliffe MD, Prof A V Lee PhD) (S 
      Beriwal MD, P N Barry MD), (N Carleton, Prof S Oesterreich, P F McAuliffe, Prof A 
      V Lee); (A Nasrazadani MD, K Gade MD, Prof A M Brufksy MD, G J van Londen MD), 
      (Prof R Bhargava MD), (D L Thull MS, P L Mai MD), (E J Diego MD, Prof M T Lotze 
      MD, P F McAuliffe), (Prof M T Lotze), (Prof M T Lotze), (Prof S Oesterreich, Prof 
      A V Lee), (Prof W A Berg MD, Prof M L Zuley MD); (O C Marroquin MD).
FAU - Bhargava, Rohit
AU  - Bhargava R
AD  - (N Carleton BS, Prof S Oesterreich PhD, P F McAuliffe MD, Prof A V Lee PhD) (S 
      Beriwal MD, P N Barry MD), (N Carleton, Prof S Oesterreich, P F McAuliffe, Prof A 
      V Lee); (A Nasrazadani MD, K Gade MD, Prof A M Brufksy MD, G J van Londen MD), 
      (Prof R Bhargava MD), (D L Thull MS, P L Mai MD), (E J Diego MD, Prof M T Lotze 
      MD, P F McAuliffe), (Prof M T Lotze), (Prof M T Lotze), (Prof S Oesterreich, Prof 
      A V Lee), (Prof W A Berg MD, Prof M L Zuley MD); (O C Marroquin MD).
FAU - Berg, Wendie A
AU  - Berg WA
AD  - (N Carleton BS, Prof S Oesterreich PhD, P F McAuliffe MD, Prof A V Lee PhD) (S 
      Beriwal MD, P N Barry MD), (N Carleton, Prof S Oesterreich, P F McAuliffe, Prof A 
      V Lee); (A Nasrazadani MD, K Gade MD, Prof A M Brufksy MD, G J van Londen MD), 
      (Prof R Bhargava MD), (D L Thull MS, P L Mai MD), (E J Diego MD, Prof M T Lotze 
      MD, P F McAuliffe), (Prof M T Lotze), (Prof M T Lotze), (Prof S Oesterreich, Prof 
      A V Lee), (Prof W A Berg MD, Prof M L Zuley MD); (O C Marroquin MD).
FAU - Zuley, Margarita L
AU  - Zuley ML
AD  - (N Carleton BS, Prof S Oesterreich PhD, P F McAuliffe MD, Prof A V Lee PhD) (S 
      Beriwal MD, P N Barry MD), (N Carleton, Prof S Oesterreich, P F McAuliffe, Prof A 
      V Lee); (A Nasrazadani MD, K Gade MD, Prof A M Brufksy MD, G J van Londen MD), 
      (Prof R Bhargava MD), (D L Thull MS, P L Mai MD), (E J Diego MD, Prof M T Lotze 
      MD, P F McAuliffe), (Prof M T Lotze), (Prof M T Lotze), (Prof S Oesterreich, Prof 
      A V Lee), (Prof W A Berg MD, Prof M L Zuley MD); (O C Marroquin MD).
FAU - van Londen, G J
AU  - van Londen GJ
AD  - (N Carleton BS, Prof S Oesterreich PhD, P F McAuliffe MD, Prof A V Lee PhD) (S 
      Beriwal MD, P N Barry MD), (N Carleton, Prof S Oesterreich, P F McAuliffe, Prof A 
      V Lee); (A Nasrazadani MD, K Gade MD, Prof A M Brufksy MD, G J van Londen MD), 
      (Prof R Bhargava MD), (D L Thull MS, P L Mai MD), (E J Diego MD, Prof M T Lotze 
      MD, P F McAuliffe), (Prof M T Lotze), (Prof M T Lotze), (Prof S Oesterreich, Prof 
      A V Lee), (Prof W A Berg MD, Prof M L Zuley MD); (O C Marroquin MD).
FAU - Marroquin, Oscar C
AU  - Marroquin OC
AD  - (N Carleton BS, Prof S Oesterreich PhD, P F McAuliffe MD, Prof A V Lee PhD) (S 
      Beriwal MD, P N Barry MD), (N Carleton, Prof S Oesterreich, P F McAuliffe, Prof A 
      V Lee); (A Nasrazadani MD, K Gade MD, Prof A M Brufksy MD, G J van Londen MD), 
      (Prof R Bhargava MD), (D L Thull MS, P L Mai MD), (E J Diego MD, Prof M T Lotze 
      MD, P F McAuliffe), (Prof M T Lotze), (Prof M T Lotze), (Prof S Oesterreich, Prof 
      A V Lee), (Prof W A Berg MD, Prof M L Zuley MD); (O C Marroquin MD).
FAU - Thull, Darcy L
AU  - Thull DL
AD  - (N Carleton BS, Prof S Oesterreich PhD, P F McAuliffe MD, Prof A V Lee PhD) (S 
      Beriwal MD, P N Barry MD), (N Carleton, Prof S Oesterreich, P F McAuliffe, Prof A 
      V Lee); (A Nasrazadani MD, K Gade MD, Prof A M Brufksy MD, G J van Londen MD), 
      (Prof R Bhargava MD), (D L Thull MS, P L Mai MD), (E J Diego MD, Prof M T Lotze 
      MD, P F McAuliffe), (Prof M T Lotze), (Prof M T Lotze), (Prof S Oesterreich, Prof 
      A V Lee), (Prof W A Berg MD, Prof M L Zuley MD); (O C Marroquin MD).
FAU - Mai, Phuong L
AU  - Mai PL
AD  - (N Carleton BS, Prof S Oesterreich PhD, P F McAuliffe MD, Prof A V Lee PhD) (S 
      Beriwal MD, P N Barry MD), (N Carleton, Prof S Oesterreich, P F McAuliffe, Prof A 
      V Lee); (A Nasrazadani MD, K Gade MD, Prof A M Brufksy MD, G J van Londen MD), 
      (Prof R Bhargava MD), (D L Thull MS, P L Mai MD), (E J Diego MD, Prof M T Lotze 
      MD, P F McAuliffe), (Prof M T Lotze), (Prof M T Lotze), (Prof S Oesterreich, Prof 
      A V Lee), (Prof W A Berg MD, Prof M L Zuley MD); (O C Marroquin MD).
FAU - Diego, Emilia J
AU  - Diego EJ
AD  - (N Carleton BS, Prof S Oesterreich PhD, P F McAuliffe MD, Prof A V Lee PhD) (S 
      Beriwal MD, P N Barry MD), (N Carleton, Prof S Oesterreich, P F McAuliffe, Prof A 
      V Lee); (A Nasrazadani MD, K Gade MD, Prof A M Brufksy MD, G J van Londen MD), 
      (Prof R Bhargava MD), (D L Thull MS, P L Mai MD), (E J Diego MD, Prof M T Lotze 
      MD, P F McAuliffe), (Prof M T Lotze), (Prof M T Lotze), (Prof S Oesterreich, Prof 
      A V Lee), (Prof W A Berg MD, Prof M L Zuley MD); (O C Marroquin MD).
FAU - Lotze, Michael T
AU  - Lotze MT
AD  - (N Carleton BS, Prof S Oesterreich PhD, P F McAuliffe MD, Prof A V Lee PhD) (S 
      Beriwal MD, P N Barry MD), (N Carleton, Prof S Oesterreich, P F McAuliffe, Prof A 
      V Lee); (A Nasrazadani MD, K Gade MD, Prof A M Brufksy MD, G J van Londen MD), 
      (Prof R Bhargava MD), (D L Thull MS, P L Mai MD), (E J Diego MD, Prof M T Lotze 
      MD, P F McAuliffe), (Prof M T Lotze), (Prof M T Lotze), (Prof S Oesterreich, Prof 
      A V Lee), (Prof W A Berg MD, Prof M L Zuley MD); (O C Marroquin MD).
FAU - Oesterreich, Steffi
AU  - Oesterreich S
AD  - (N Carleton BS, Prof S Oesterreich PhD, P F McAuliffe MD, Prof A V Lee PhD) (S 
      Beriwal MD, P N Barry MD), (N Carleton, Prof S Oesterreich, P F McAuliffe, Prof A 
      V Lee); (A Nasrazadani MD, K Gade MD, Prof A M Brufksy MD, G J van Londen MD), 
      (Prof R Bhargava MD), (D L Thull MS, P L Mai MD), (E J Diego MD, Prof M T Lotze 
      MD, P F McAuliffe), (Prof M T Lotze), (Prof M T Lotze), (Prof S Oesterreich, Prof 
      A V Lee), (Prof W A Berg MD, Prof M L Zuley MD); (O C Marroquin MD).
FAU - McAuliffe, Priscilla F
AU  - McAuliffe PF
AD  - (N Carleton BS, Prof S Oesterreich PhD, P F McAuliffe MD, Prof A V Lee PhD) (S 
      Beriwal MD, P N Barry MD), (N Carleton, Prof S Oesterreich, P F McAuliffe, Prof A 
      V Lee); (A Nasrazadani MD, K Gade MD, Prof A M Brufksy MD, G J van Londen MD), 
      (Prof R Bhargava MD), (D L Thull MS, P L Mai MD), (E J Diego MD, Prof M T Lotze 
      MD, P F McAuliffe), (Prof M T Lotze), (Prof M T Lotze), (Prof S Oesterreich, Prof 
      A V Lee), (Prof W A Berg MD, Prof M L Zuley MD); (O C Marroquin MD).
FAU - Lee, Adrian V
AU  - Lee AV
AD  - (N Carleton BS, Prof S Oesterreich PhD, P F McAuliffe MD, Prof A V Lee PhD) (S 
      Beriwal MD, P N Barry MD), (N Carleton, Prof S Oesterreich, P F McAuliffe, Prof A 
      V Lee); (A Nasrazadani MD, K Gade MD, Prof A M Brufksy MD, G J van Londen MD), 
      (Prof R Bhargava MD), (D L Thull MS, P L Mai MD), (E J Diego MD, Prof M T Lotze 
      MD, P F McAuliffe), (Prof M T Lotze), (Prof M T Lotze), (Prof S Oesterreich, Prof 
      A V Lee), (Prof W A Berg MD, Prof M L Zuley MD); (O C Marroquin MD).
LA  - eng
GR  - F30 CA264963/CA/NCI NIH HHS/United States
GR  - R01 CA187593/CA/NCI NIH HHS/United States
GR  - T32 CA082084/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220105
PL  - England
TA  - Lancet Healthy Longev
JT  - The lancet. Healthy longevity
JID - 101773309
RN  - 0 (Receptors, Estrogen)
MH  - Aged
MH  - *Breast Neoplasms
MH  - Combined Modality Therapy
MH  - Female
MH  - Humans
MH  - Neoplasm Recurrence, Local
MH  - Quality of Life
MH  - Receptors, Estrogen
PMC - PMC8765742
MID - NIHMS1770295
EDAT- 2022/01/21 06:00
MHDA- 2022/01/21 06:01
PMCR- 2022/01/18
CRDT- 2022/01/20 06:10
PHST- 2022/01/20 06:10 [entrez]
PHST- 2022/01/21 06:00 [pubmed]
PHST- 2022/01/21 06:01 [medline]
PHST- 2022/01/18 00:00 [pmc-release]
AID - 10.1016/s2666-7568(21)00280-4 [doi]
PST - ppublish
SO  - Lancet Healthy Longev. 2022 Jan;3(1):e54-e66. doi: 10.1016/s2666-7568(21)00280-4. 
      Epub 2022 Jan 5.

PMID- 39450958
OWN - NLM
STAT- MEDLINE
DCOM- 20241025
LR  - 20241105
IS  - 1958-5381 (Electronic)
IS  - 0767-0974 (Linking)
VI  - 40
IP  - 10
DP  - 2024 Oct
TI  - [Estrogen receptors and vascular aging].
PG  - 729-736
LID - 10.1051/medsci/2024115 [doi]
AB  - After years of studying cardiovascular diseases (CVD) in men due to their higher 
      incidence compared to women, attention is now being paid to female CVD and their 
      pathophysiology. Even though premenopausal women have a lower incidence of CVD, 
      this disparity progressively diminishes after menopause, highlighting the key 
      role of sex hormones. Many preclinical and fundamental studies have demonstrated 
      protective effects of estrogens on arterial endothelium, suggesting that hormone 
      therapy could improve cardiovascular health in menopausal women. However, 
      disappointing outcomes from a major clinical trial two decades ago questioned the 
      cardiovascular protection by estrogens with age. In this review, we will 
      summarize the main clinical and experimental studies reporting the effects of 
      estrogens on CVD, with a focus on their impact on endothelial function. Then, we 
      will present abnormalities in the expression and signaling of estrogen receptors 
      (ERs) in the arteries, and the contribution of conventional estrogens to arterial 
      protection during aging. Finally, we will examine how recent advances in the 
      mechanisms of action of ERa could help to optimize hormone therapy for menopause.
CI  - © 2024 médecine/sciences – Inserm.
FAU - Marjollet, Juline
AU  - Marjollet J
AD  - Inserm U1297, Institut des maladies métaboliques et cardiovasculaires (I2MC), 
      Université de Toulouse 3 Toulouse France.
FAU - Buscato, Mélissa
AU  - Buscato M
AD  - Inserm U1297, Institut des maladies métaboliques et cardiovasculaires (I2MC), 
      Université de Toulouse 3 Toulouse France.
FAU - Davezac, Morgane
AU  - Davezac M
AD  - Inserm U1297, Institut des maladies métaboliques et cardiovasculaires (I2MC), 
      Université de Toulouse 3 Toulouse France.
FAU - Vessieres, Emilie
AU  - Vessieres E
AD  - Université d'Angers, département MITOVASC, équipe CarMe, Inserm U1083, CNRS UMR 
      6015 Angers France.
FAU - Gosset, Anna
AU  - Gosset A
AD  - Inserm U1297, Institut des maladies métaboliques et cardiovasculaires (I2MC), 
      Université de Toulouse 3 Toulouse France.
FAU - Adlanmerini, Marine
AU  - Adlanmerini M
AD  - Inserm U1297, Institut des maladies métaboliques et cardiovasculaires (I2MC), 
      Université de Toulouse 3 Toulouse France.
FAU - Henrion, Daniel
AU  - Henrion D
AD  - Inserm U1297, Institut des maladies métaboliques et cardiovasculaires (I2MC), 
      Université de Toulouse 3 Toulouse France.
FAU - Lenfant, Francoise
AU  - Lenfant F
AD  - Inserm U1297, Institut des maladies métaboliques et cardiovasculaires (I2MC), 
      Université de Toulouse 3 Toulouse France.
FAU - Arnal, Jean-François
AU  - Arnal JF
AD  - Inserm U1297, Institut des maladies métaboliques et cardiovasculaires (I2MC), 
      Université de Toulouse 3 Toulouse France.
FAU - Fontaine, Coralie
AU  - Fontaine C
AD  - Inserm U1297, Institut des maladies métaboliques et cardiovasculaires (I2MC), 
      Université de Toulouse 3 Toulouse France.
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Récepteurs des œstrogènes et vieillissement artériel.
DEP - 20241025
PL  - France
TA  - Med Sci (Paris)
JT  - Medecine sciences : M/S
JID - 8710980
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Estrogens)
SB  - IM
MH  - Humans
MH  - *Aging/physiology
MH  - Female
MH  - *Receptors, Estrogen/physiology/metabolism
MH  - *Cardiovascular Diseases/etiology/metabolism
MH  - Estrogens/metabolism/physiology
MH  - Endothelium, Vascular/metabolism
MH  - Male
MH  - Menopause/physiology
MH  - Animals
MH  - Estrogen Replacement Therapy/methods
EDAT- 2024/10/25 12:24
MHDA- 2024/10/25 12:25
CRDT- 2024/10/25 08:33
PHST- 2024/10/25 12:25 [medline]
PHST- 2024/10/25 12:24 [pubmed]
PHST- 2024/10/25 08:33 [entrez]
AID - msc240150 [pii]
AID - 10.1051/medsci/2024115 [doi]
PST - ppublish
SO  - Med Sci (Paris). 2024 Oct;40(10):729-736. doi: 10.1051/medsci/2024115. Epub 2024 
      Oct 25.

PMID- 26799652
OWN - NLM
STAT- MEDLINE
DCOM- 20161019
LR  - 20241031
IS  - 1554-8635 (Electronic)
IS  - 1554-8627 (Print)
IS  - 1554-8627 (Linking)
VI  - 12
IP  - 1
DP  - 2016
TI  - Guidelines for the use and interpretation of assays for monitoring autophagy (3rd 
      edition).
PG  - 1-222
LID - 10.1080/15548627.2015.1100356 [doi]
FAU - Klionsky, Daniel J
AU  - Klionsky DJ
AD  - boc University of Michigan , Department of Molecular , Cellular, and 
      Developmental Biology , Ann Arbor , MI , USA.
AD  - bog University of Michigan, Life Sciences Institute , Ann Arbor , MI , USA.
FAU - Abdelmohsen, Kotb
AU  - Abdelmohsen K
AD  - afh National Institute on Aging, National Institutes of Health, Biomedical 
      Research Center, RNA Regulation Section, Laboratory of Genetics , Baltimore , MD 
      , USA.
FAU - Abe, Akihisa
AU  - Abe A
AD  - auo Tokyo Medical University , Department of Biochemistry , Tokyo , Japan.
FAU - Abedin, Md Joynal
AU  - Abedin MJ
AD  - bot University of Minnesota , Department of Lab Medicine and Pathology , 
      Minneapolis , MN , USA.
FAU - Abeliovich, Hagai
AU  - Abeliovich H
AD  - pi Hebrew University of Jerusalem, Faculty of Agriculture, Food, and Environment, 
      Biochemistry and Food Science , Rehovot , Israel.
FAU - Acevedo Arozena, Abraham
AU  - Acevedo Arozena A
AD  - adi MRC Harwell, Mammalian Genetics Unit , Oxfordshire , UK.
FAU - Adachi, Hiroaki
AU  - Adachi H
AD  - bqf University of Occupational and Environmental Health School of Medicine , 
      Department of Neurology , Fukuoka , Japan.
FAU - Adams, Christopher M
AU  - Adams CM
AD  - ble University of Iowa , Department of Internal Medicine , Iowa City , IA , USA.
FAU - Adams, Peter D
AU  - Adams PD
AD  - be Beatson Institute for Cancer Research, University of Glasgow , Glasgow , UK.
FAU - Adeli, Khosrow
AU  - Adeli K
AD  - bxe University of Toronto, Molecular Structure and Function, Research Institute, 
      Hospital for Sick Children , Toronto, ON , Canada.
FAU - Adhihetty, Peter J
AU  - Adhihetty PJ
AD  - bjm University of Florida , Department of Applied Physiology and Kinesiology , 
      Gainesville , FL , USA.
FAU - Adler, Sharon G
AU  - Adler SG
AD  - zx Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center , 
      Torrance , CA.
FAU - Agam, Galila
AU  - Agam G
AD  - bo Ben-Gurion University of the Negev and Mental Health Center , Department of 
      Clinical Biochemistry and Pharmacology and Psychiatry Research Unit , Beer-Sheva 
      , Israel.
FAU - Agarwal, Rajesh
AU  - Agarwal R
AD  - bia University of Colorado Denver, Skaggs School of Pharmacy and Pharmaceutical 
      Sciences , Department of Pharmaceutical Sciences , Aurora , CO , USA.
FAU - Aghi, Manish K
AU  - Aghi MK
AD  - bgc University of California San Francisco , Department of Neurological Surgery , 
      San Francisco , CA , USA.
FAU - Agnello, Maria
AU  - Agnello M
AD  - brf University of Palermo , Dipartimento di Scienze e Tecnologie Biologiche , 
      Chimiche e Farmaceutiche (STEBICEF) , Palermo , Italy.
FAU - Agostinis, Patrizia
AU  - Agostinis P
AD  - yn KU Leuven, Laboratory for Cell Death Research and Therapy , Department of 
      Cellular and Molecular Medicine , Campus Gasthuisberg , Leuven , Belgium.
FAU - Aguilar, Patricia V
AU  - Aguilar PV
AD  - bwj University of Texas, Medical Branch , Department of Pathology , Galveston , 
      TX , USA.
FAU - Aguirre-Ghiso, Julio
AU  - Aguirre-Ghiso J
AD  - add Icahn School of Medicine at Mount Sinai , Department of Otolaryngology , 
      Tisch Cancer Institute at Mount Sinai , New York , NY , USA.
AD  - adf Icahn School of Medicine at Mount Sinai, Division of Hematology and Oncology 
      , Department of Medicine , New York , NY , USA.
FAU - Airoldi, Edoardo M
AU  - Airoldi EM
AD  - ck Broad Institute of MIT and Harvard , Cambridge , MA , USA.
AD  - pf Harvard University , Department of Statistics , Cambridge , MA , USA.
FAU - Ait-Si-Ali, Slimane
AU  - Ait-Si-Ali S
AD  - azx Université Paris Diderot, Sorbonne Paris Cité, Centre Epigénétique et Destin 
      Cellulaire, UMR 7216, Centre National de la Recherche Scientifique CNRS , Paris , 
      France.
FAU - Akematsu, Takahiko
AU  - Akematsu T
AD  - byh University of Vienna , Department of Chromosome Biology , Max F. Perutz 
      Laboratories , Vienna , Austria.
FAU - Akporiaye, Emmanuel T
AU  - Akporiaye ET
AD  - ape Sidra Medical and Research Centre , Doha , Qatar.
FAU - Al-Rubeai, Mohamed
AU  - Al-Rubeai M
AD  - bap University College Dublin, School of Chemical and Bioprocess Engineering , 
      Dublin , Ireland.
FAU - Albaiceta, Guillermo M
AU  - Albaiceta GM
AD  - awt Universidad de Oviedo , Departamento de Biología Funcional , Oviedo , Spain.
FAU - Albanese, Chris
AU  - Albanese C
AD  - my Georgetown University, Lombardi Comprehensive Cancer Center , Departments of 
      Oncology and Pathology , Washington, DC , USA.
FAU - Albani, Diego
AU  - Albani D
AD  - uo IRCCS-Istituto di Ricerche Farmacologiche Mario Negri , Department of 
      Neuroscience , Milan , Italy.
FAU - Albert, Matthew L
AU  - Albert ML
AD  - sw Institut Pasteur , Department of Immunology , Paris , France.
FAU - Aldudo, Jesus
AU  - Aldudo J
AD  - dx Centro de Biologia Molecular "Severo Ochoa" (UAM/CSIC), Centro de 
      Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) , 
      Madrid , Spain.
FAU - Algül, Hana
AU  - Algül H
AD  - art Technische Universität München, II. Medizinische Klinik, Klinikum rechts der 
      Isar , Munich , Germany.
FAU - Alirezaei, Mehrdad
AU  - Alirezaei M
AD  - atb The Scripps Research Institute , Department of Immunology and Microbial 
      Science , La Jolla , CA , USA.
FAU - Alloza, Iraide
AU  - Alloza I
AD  - xr KERBASQUE, Basque Foundation for Sciences , Bilbao , Spain.
AD  - ahd Neurogenomiks , Neurosciences Department , Faculty of Medicine and 
      Odontology, University of Basque , Leioa , Spain.
FAU - Almasan, Alexandru
AU  - Almasan A
AD  - gx Cleveland Clinic , Department of Cancer Biology , Cleveland , OH , USA.
FAU - Almonte-Beceril, Maylin
AU  - Almonte-Beceril M
AD  - td Institute of Biomedical Investigation (INIBIC), Aging, Inflamation and 
      Regenerative Medicine , Coruña , Spain.
FAU - Alnemri, Emad S
AU  - Alnemri ES
AD  - atp Thomas Jefferson University , Department of Biochemistry and Molecular 
      Biology , Philadelphia , PA , USA.
FAU - Alonso, Covadonga
AU  - Alonso C
AD  - tx Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA) 
      , Departamento de Biotecnología , Madrid , Spain.
FAU - Altan-Bonnet, Nihal
AU  - Altan-Bonnet N
AD  - afp National Institutes of Health, National Heart, Lung, and Blood Institute , 
      Bethesda , MD , USA.
FAU - Altieri, Dario C
AU  - Altieri DC
AD  - ati The Wistar Institute , Philadelphia , PA , USA.
FAU - Alvarez, Silvia
AU  - Alvarez S
AD  - beo University of Buenos Aires, Institute of Biochemistry and Biophysics, School 
      of Pharmacy and Biochemistry , Buenos Aires , Argentina.
FAU - Alvarez-Erviti, Lydia
AU  - Alvarez-Erviti L
AD  - baq University College London , Department of Clinical Neurosciences , London , 
      UK.
FAU - Alves, Sandro
AU  - Alves S
AD  - dc CEA/DSV/12;BM, INSERM U1169, Gene Therapy for Neurodegenerative Diseases , 
      Fontenay-aux-Roses Cedex , France.
FAU - Amadoro, Giuseppina
AU  - Amadoro G
AD  - agb National Research Council (CNR), Institute of Translational Pharmacology 
      (IFT) , Rome , Italy.
FAU - Amano, Atsuo
AU  - Amano A
AD  - ait Osaka University Graduate School of Dentistry , Department of Preventive 
      Dentistry , Osaka , Japan.
FAU - Amantini, Consuelo
AU  - Amantini C
AD  - bgt University of Camerino, School of Biosciences and Veterinary Medicine , 
      Camerino , Italy.
FAU - Ambrosio, Santiago
AU  - Ambrosio S
AD  - bdb University of Barcelona, School of Medicine, Campus Bellvitge , Hospitalet 
      del Llobregat , Spain.
FAU - Amelio, Ivano
AU  - Amelio I
AD  - acb Medical Research Council (MRC), Toxicology Unit , Leicester , UK.
FAU - Amer, Amal O
AU  - Amer AO
AD  - aih Ohio State University , Department of Microbial Infection and Immunity , 
      Columbus , OH , USA.
FAU - Amessou, Mohamed
AU  - Amessou M
AD  - cbi Wayne State University, School of Medicine , Department of Pathology , 
      Karmanos Cancer Institute , Detroit , MI , USA.
FAU - Amon, Angelika
AU  - Amon A
AD  - aax Massachusetts Institute of Technology, Koch Institute for Integrative Cancer 
      Research , Cambridge , MA , USA.
FAU - An, Zhenyi
AU  - An Z
AD  - bgd University of California San Francisco , Department of Neurology , San 
      Francisco , CA , USA.
FAU - Anania, Frank A
AU  - Anania FA
AD  - ke Emory University, School of Medicine, Division of Digestive Diseases , Atlanta 
      , GA , USA.
FAU - Andersen, Stig U
AU  - Andersen SU
AD  - f Aarhus University , Department of Molecular Biology and Genetics , Aarhus , 
      Denmark.
FAU - Andley, Usha P
AU  - Andley UP
AD  - cay Washington University in St. Louis, School of Medicine , Department of 
      Ophthalmology and Visual Sciences , St. Louis , MO , USA.
FAU - Andreadi, Catherine K
AU  - Andreadi CK
AD  - blz University of Leicester , Department of Cancer Studies , Leicester , UK.
FAU - Andrieu-Abadie, Nathalie
AU  - Andrieu-Abadie N
AD  - sh INSERM UMR1037, Centre de Recherches en Cancérologie de Toulouse , Toulouse , 
      France.
FAU - Anel, Alberto
AU  - Anel A
AD  - byy University of Zaragoza , Department of Biochemistry and Molecular and Cell 
      Biology , Faculty of Sciences , Zaragoza , Spain.
FAU - Ann, David K
AU  - Ann DK
AD  - bf Beckman Research Institute, City of Hope , Department of Molecular 
      Pharmacology , Duarte , CA , USA.
FAU - Anoopkumar-Dukie, Shailendra
AU  - Anoopkumar-Dukie S
AD  - nx Griffith University, Menzies Health Institute Queensland , Australia.
FAU - Antonioli, Manuela
AU  - Antonioli M
AD  - aez National Institute for Infectious Diseases "L. Spallanzani" IRCCS , Rome , 
      Italy.
AD  - afz Freiburg Institute for Advanced Studies (FRIAS), University of Freiburg, 
      Germany.
FAU - Aoki, Hiroshi
AU  - Aoki H
AD  - bpw University of Niigata , Department of Neurosurgery , Brain Research Institute 
      , Niigata , Japan.
FAU - Apostolova, Nadezda
AU  - Apostolova N
AD  - bye University of Valencia , Department of Pharmacology , Valencia , Spain.
FAU - Aquila, Saveria
AU  - Aquila S
AD  - ber University of Calabria , Department of Pharmacy , Health and Nutritional 
      Sciences , Arcavacata di Rende (Cosenza) , Italy.
FAU - Aquilano, Katia
AU  - Aquilano K
AD  - btd University of Rome "Tor Vergata" , Department of Biology , Rome , Italy.
FAU - Araki, Koichi
AU  - Araki K
AD  - kf Emory University, School of Medicine , Emory Vaccine Center and Department of 
      Microbiology and Immunology , Atlanta , GA , USA.
FAU - Arama, Eli
AU  - Arama E
AD  - cbr Weizmann Institute of Science , Department of Molecular Genetics , Rehovot , 
      Israel.
FAU - Aranda, Agustin
AU  - Aranda A
AD  - qn IATA-CSIC, Institute of Agrochemistry and Food Technology , Paterna (Valencia) 
      , Spain.
FAU - Araya, Jun
AU  - Araya J
AD  - vs Jikei University School of Medicine, Divison of Respiratory Disease , 
      Department of Internal Medicine , Tokyo , Japan.
FAU - Arcaro, Alexandre
AU  - Arcaro A
AD  - bdp University of Bern, Division of Pediatric Hematology/Oncology , Department of 
      Clinical Research , Bern , Switzerland.
FAU - Arias, Esperanza
AU  - Arias E
AD  - z Albert Einstein College of Medicine , Department of Developmental and Molecular 
      Biology , Institute for Aging Studies , Bronx , NY , USA.
FAU - Arimoto, Hirokazu
AU  - Arimoto H
AD  - auc Tohoku University, Graduate School of Life Sciences, Sendai , Miyagi , Japan.
FAU - Ariosa, Aileen R
AU  - Ariosa AR
AD  - bog University of Michigan, Life Sciences Institute , Ann Arbor , MI , USA.
FAU - Armstrong, Jane L
AU  - Armstrong JL
AD  - bvf University of Sunderland , Department of Pharmacy , Health and Wellbeing, 
      Faculty of Applied Sciences , Sunderland , UK.
FAU - Arnould, Thierry
AU  - Arnould T
AD  - bpe University of Namur, Laboratory of Biochemistry and Cell Biology (URBC), 
      Namur Research Institute for Life Sciences (NARILIS) , Namur , Belgium.
FAU - Arsov, Ivica
AU  - Arsov I
AD  - ccn York College/The City University of New York , Department of Biology , 
      Jamaica , NY , USA.
FAU - Asanuma, Katsuhiko
AU  - Asanuma K
AD  - yy Kyoto University, Graduate School of Medicine, Medical Innocation Center (TMK 
      project) , Kyoto , Japan.
FAU - Askanas, Valerie
AU  - Askanas V
AD  - buz University of Southern California, Keck School of Medicine, Neurology and 
      Pathology , Los Angeles , CA , USA.
FAU - Asselin, Eric
AU  - Asselin E
AD  - bsu University of Quebec at Trois-Rivieres , Department of Biology and Medicine , 
      Trois-Rivieres, Quebec , Canada.
FAU - Atarashi, Ryuichiro
AU  - Atarashi R
AD  - adn Nagasaki University Graduate School of Biomedical Sciences , Department of 
      Molecular Microbiology and Immunology , Nagasaki , Japan.
FAU - Atherton, Sally S
AU  - Atherton SS
AD  - ne Georgia Regents University, Medical College of Georgia , Augusta , GA , USA.
FAU - Atkin, Julie D
AU  - Atkin JD
AD  - aak Macquarie University , Department of Biomedical Sciences , Faculty of 
      Medicine and Health Sciences , Sydney , NSW , Australia.
FAU - Attardi, Laura D
AU  - Attardi LD
AD  - aqm Stanford University, School of Medicine, Departments of Radiation Oncology 
      and Genetics , Stanford , CA , USA.
FAU - Auberger, Patrick
AU  - Auberger P
AD  - bps University of Nice, INSERM U1065, C3M , Nice , France.
FAU - Auburger, Georg
AU  - Auburger G
AD  - no Goethe University Medical School, Experimental Neurology , Frankfurt am Main , 
      Germany.
FAU - Aurelian, Laure
AU  - Aurelian L
AD  - bnk University of Maryland, School of Medicine , Department of Pharmacology , 
      Baltimore , MD , USA.
FAU - Autelli, Riccardo
AU  - Autelli R
AD  - bxp University of Turin , Department of Clinical and Biological Sciences , Turin 
      , TO , Italy.
FAU - Avagliano, Laura
AU  - Avagliano L
AD  - amo San Paolo Hospital Medical School, Unit of Obstetrics and Gynecology , Milano 
      , Italy.
AD  - bom University of Milan , Department of Health Sciences , Milan , Italy.
FAU - Avantaggiati, Maria Laura
AU  - Avantaggiati ML
AD  - mz Georgetown University, Lombardi Comprehensive Cancer Center , Washington, DC , 
      USA.
FAU - Avrahami, Limor
AU  - Avrahami L
AD  - arv Tel Aviv University , Department of Human Molecular Genetics and Biochemistry 
      , Sackler School of Medicine , Tel Aviv , Israel.
FAU - Awale, Suresh
AU  - Awale S
AD  - bxj University of Toyama, Division of Natural Drug Discovery, Institute of 
      Natural Medicine , Toyama , Japan.
FAU - Azad, Neelam
AU  - Azad N
AD  - on Hampton University , Department of Pharmaceutical Sciences , School of 
      Pharmacy , Hampton , VA , USA.
FAU - Bachetti, Tiziana
AU  - Bachetti T
AD  - uv Istituto Giannina Gaslini, UOC Medical Genetics , Genova , Italy.
FAU - Backer, Jonathan M
AU  - Backer JM
AD  - ab Albert Einstein College of Medicine , Department of Molecular Pharmacology , 
      Bronx , NY , USA.
FAU - Bae, Dong-Hun
AU  - Bae DH
AD  - bvi University of Sydney , Department of Pathology and Bosch Institute , Sydney, 
      New South Wales , Australia.
FAU - Bae, Jae-Sung
AU  - Bae JS
AD  - za Kyungpook National University , Department of Physiology , School of Medicine 
      , Jung-gu, Daegu , Korea.
FAU - Bae, Ok-Nam
AU  - Bae ON
AD  - os Hanyang University, College of Pharmacy , Ansan , Korea.
FAU - Bae, Soo Han
AU  - Bae SH
AD  - cck Yonsei University, College of Medicine, Severance Biomedical Science 
      Institute , Seoul , Korea.
FAU - Baehrecke, Eric H
AU  - Baehrecke EH
AD  - bnm University of Massachusetts, Medical School , Department of Molecular , Cell 
      and Cancer Biology , Worcester , MA , USA.
FAU - Baek, Seung-Hoon
AU  - Baek SH
AD  - q Ajou University, College of Pharmacy , Gyeonggido , Korea.
FAU - Baghdiguian, Stephen
AU  - Baghdiguian S
AD  - azp Université Montpellier 2, Institut des Sciences de l'Evolution - UMR CNRS 
      5554 , Montpellier, Languedoc-Roussillon , France.
FAU - Bagniewska-Zadworna, Agnieszka
AU  - Bagniewska-Zadworna A
AD  - b A. Mickiewicz University, Department of General Botany, Institute of 
      Experimental Biology, Faculty of Biology , Poznań , Poland.
FAU - Bai, Hua
AU  - Bai H
AD  - cl Brown University , Department of Ecology and Evolutionary Biology , Providence 
      , RI , USA.
FAU - Bai, Jie
AU  - Bai J
AD  - yq Kunming University of Science and Technology, Medical School , Kunmimg, Yunnan 
      , China.
FAU - Bai, Xue-Yuan
AU  - Bai XY
AD  - aqo State Key Laboratory of Kidney Diseases, National Clinical Research Center 
      for Kidney Diseases , Department of Nephrology , Chinese PLA General Hospital, 
      Chinese PLA Institute of Nephrology , Beijing , China.
FAU - Bailly, Yannick
AU  - Bailly Y
AD  - agz INCI, CNRS UPR3212, Institut des Neurosciences Cellulaires and Intégratives , 
      Strasbourg , France.
FAU - Balaji, Kithiganahalli Narayanaswamy
AU  - Balaji KN
AD  - re Indian Institute of Science , Department of Microbiology and Cell Biology , 
      Bangalore , India.
FAU - Balduini, Walter
AU  - Balduini W
AD  - bxz University of Urbino "Carlo Bo" , Department of Biomolecular Sciences , 
      Urbino , Italy.
FAU - Ballabio, Andrea
AU  - Ballabio A
AD  - ld Federico II University, Telethon Institute of Genetics and Medicine (TIGEM) , 
      Department of Medical and Translational Sciences , Naples , Italy.
FAU - Balzan, Rena
AU  - Balzan R
AD  - bmu University of Malta , Department of Physiology and Biochemistry , Faculty of 
      Medicine and Surgery , Msida , Malta.
FAU - Banerjee, Rajkumar
AU  - Banerjee R
AD  - ie CSIR, Indian Institute of Chemical Technology, Biomaterials Group , Hyderabad 
      , India.
FAU - Bánhegyi, Gábor
AU  - Bánhegyi G
AD  - anl Semmelweis University , Department of Medical Chemistry , Molecular Biology 
      and Pathobiochemistry , Budapest , Hungary.
FAU - Bao, Haijun
AU  - Bao H
AD  - ccc Xuzhou Medical College , Department of Pathology , Xuzhou, Jiangsu , China.
FAU - Barbeau, Benoit
AU  - Barbeau B
AD  - azk Université du Québec à Montréal , Département des Sciences Biologiques and 
      Centre de Recherche BioMed , Montréal, Québec , Canada.
FAU - Barrachina, Maria D
AU  - Barrachina MD
AD  - bye University of Valencia , Department of Pharmacology , Valencia , Spain.
FAU - Barreiro, Esther
AU  - Barreiro E
AD  - qy IMIM-Hospital del Mar CIBERES, Pompeu Fabra University, Barcelona Biomedical 
      Research Park , Respiratory Medicine Department , Lung Cancer and Muscle Research 
      Group , Barcelona , Spain.
FAU - Bartel, Bonnie
AU  - Bartel B
AD  - ali Rice University , Department of BioSciences , Houston , TX , USA.
FAU - Bartolomé, Alberto
AU  - Bartolomé A
AD  - hn Columbia University , Department of Medicine , New York , NY , USA.
FAU - Bassham, Diane C
AU  - Bassham DC
AD  - ud Iowa State University , Department of Genetics , Development and Cell Biology 
      , Ames , IA , USA.
FAU - Bassi, Maria Teresa
AU  - Bassi MT
AD  - anf Scientific Institute IRCCS Eugenio Medea, Laboratory of Molecular Biology , 
      Bosisio Parini, Lecco , Italy.
FAU - Bast, Robert C Jr
AU  - Bast RC Jr
AD  - avy University of Texas, MD Anderson Cancer Center , Department of Experimental 
      Therapeutics , Houston , TX , USA.
FAU - Basu, Alakananda
AU  - Basu A
AD  - bqd University of North Texas Health Science Center , Department of Molecular and 
      Medical Genetics , Fort Worth , TX , USA.
FAU - Batista, Maria Teresa
AU  - Batista MT
AD  - bhr University of Coimbra , Coimbra , Portugal.
FAU - Batoko, Henri
AU  - Batoko H
AD  - ayj Université Catholique de Louvain (UCL), Institut des Sciences de la Vie , 
      Louvain-la-Neuve , Belgium.
FAU - Battino, Maurizio
AU  - Battino M
AD  - akh Polytechnic University of Marche , Department of Clinical Science , Faculty 
      of Medicine , Ancona , Italy.
FAU - Bauckman, Kyle
AU  - Bauckman K
AD  - cbe Washington University, School of Medicine, Departments of Obstetrics and 
      Gynecology, and Pathology and Immunology , St. Louis , MO , USA.
FAU - Baumgarner, Bradley L
AU  - Baumgarner BL
AD  - buk University of South Carolina Upstate , Department of Biology , Division of 
      Natural Sciences and Engineering , Spartanburg, SC.
FAU - Bayer, K Ulrich
AU  - Bayer KU
AD  - bih University of Colorado, School of Medicine , Department of Pharmacology , 
      Aurora , CO , USA.
FAU - Beale, Rupert
AU  - Beale R
AD  - bgs University of Cambridge, Division of Virology , Department of Pathology , 
      Cambridge , UK.
FAU - Beaulieu, Jean-François
AU  - Beaulieu JF
AD  - azh Université de Sherbrooke , Department of Anatomy and Cell Biology , Faculty 
      of Medicine and Health Sciences , Sherbrooke, QC , Canada.
FAU - Beck, George R Jr
AU  - Beck GR Jr
AD  - av Atlanta Department of Veterans Affairs Medical Center , Decatur , GA.
AD  - kh Emory University, Division of Endocrinology, Metabolism, and Lipids , 
      Department of Medicine , Atlanta , GA , USA.
FAU - Becker, Christoph
AU  - Becker C
AD  - lx Friedrich-Alexander-University Erlangen-Nürnberg , Department of Medicine 1 , 
      Erlangen , Germany.
FAU - Beckham, J David
AU  - Beckham JD
AD  - bii University of Colorado, School of Medicine, Division of Infectious Diseases , 
      Aurora , CO , USA.
FAU - Bédard, Pierre-André
AU  - Bédard PA
AD  - abu McMaster University , Department of Biology , Hamilton, Ontario , Canada.
FAU - Bednarski, Patrick J
AU  - Bednarski PJ
AD  - ko Ernst-Moritz-Arndt University, Institute of Pharmacy , Greifswald , Germany.
FAU - Begley, Thomas J
AU  - Begley TJ
AD  - aqq State University of New York, College of Nanoscale Science and Engineering , 
      Albany , NY , USA.
FAU - Behl, Christian
AU  - Behl C
AD  - bbo University Medical Center of the Johannes Gutenberg-University, Institute for 
      Pathobiochemistry , Mainz , Germany.
FAU - Behrends, Christian
AU  - Behrends C
AD  - acc Medical School Goethe University, Institute of Biochemistry II , Frankfurt , 
      Germany.
FAU - Behrens, Georg Mn
AU  - Behrens GM
AD  - op Hannover Medical School , Department for Clinical Immunology and Rheumotology 
      , Hannover , Germany.
FAU - Behrns, Kevin E
AU  - Behrns KE
AD  - bjo University of Florida , Department of Surgery , Gainesville , FL , USA.
FAU - Bejarano, Eloy
AU  - Bejarano E
AD  - z Albert Einstein College of Medicine , Department of Developmental and Molecular 
      Biology , Institute for Aging Studies , Bronx , NY , USA.
FAU - Belaid, Amine
AU  - Belaid A
AD  - rv INSERM U1081, CNRS UMR7284, Institute of Research on Cancer and Ageing of Nice 
      (IRCAN) , Nice , France.
FAU - Belleudi, Francesca
AU  - Belleudi F
AD  - ana Sapienza University of Rome , Department of Clinical and Molecular Medicine , 
      Rome , Italy.
FAU - Bénard, Giovanni
AU  - Bénard G
AD  - sc INSERM U862, Neurocentre Magendie , Bordeaux , France.
FAU - Berchem, Guy
AU  - Berchem G
AD  - aad Luxembourg Institute of Health and Centre Hospitalier de Luxembourg , 
      Luxembourg.
FAU - Bergamaschi, Daniele
AU  - Bergamaschi D
AD  - aku Queen Mary University of London, Blizard Institute, Centre for Cell Biology 
      and Cutaneous Research , London , UK.
FAU - Bergami, Matteo
AU  - Bergami M
AD  - baw University Hospital Cologne, CECAD Research Center , Cologne , Germany.
FAU - Berkhout, Ben
AU  - Berkhout B
AD  - bck University of Amsterdam, Laboratory of Experimental Virology, Center for 
      Infection and Immunity Amsterdam (CINIMA), Academic Medical Center (AMC) , 
      Amsterdam , The Netherlands.
FAU - Berliocchi, Laura
AU  - Berliocchi L
AD  - aal Magna Graecia University , Department of Health Sciences , Catanzaro , Italy.
FAU - Bernard, Amélie
AU  - Bernard A
AD  - bog University of Michigan, Life Sciences Institute , Ann Arbor , MI , USA.
FAU - Bernard, Monique
AU  - Bernard M
AD  - azb Université de Montréal , Department of Medicine , Montréal, Quebec , Canada.
FAU - Bernassola, Francesca
AU  - Bernassola F
AD  - bth University of Rome "Tor Vergata" , Department of Experimental Medicine and 
      Surgery , Rome , Italy.
FAU - Bertolotti, Anne
AU  - Bertolotti A
AD  - adk MRC Laboratory of Molecular Biology , Cambridge , UK.
FAU - Bess, Amanda S
AU  - Bess AS
AD  - jl Duke University, Nicholas School of the Environment , Durham , NC , USA.
FAU - Besteiro, Sébastien
AU  - Besteiro S
AD  - ayy Université de Montpellier, DIMNP, UMR 5235, CNRS , Montpellier , France.
FAU - Bettuzzi, Saverio
AU  - Bettuzzi S
AD  - brh University of Parma , Department of Biomedicine , Biotechnology and 
      Translational Research , Parma , Italy.
FAU - Bhalla, Savita
AU  - Bhalla S
AD  - aic Northwestern University, Division of Hematology/Oncology , Chicago , IL , 
      USA.
FAU - Bhattacharyya, Shalmoli
AU  - Bhattacharyya S
AD  - akk Post Graduate Institute of Medical Education and Research (PGIMER) , 
      Department of Biophysics , Chandigarh , India.
FAU - Bhutia, Sujit K
AU  - Bhutia SK
AD  - aff National Institute of Technology Rourkela , Department of Life Science , 
      Rourkela, Odisha , India.
FAU - Biagosch, Caroline
AU  - Biagosch C
AD  - aro Technical University Munich, Institute of Human Genetics , Munich, Bavaria , 
      Germany.
FAU - Bianchi, Michele Wolfe
AU  - Bianchi MW
AD  - sz Institute for Integrative Biology of the Cell, Université Paris-Saclay , 
      Gif-sur-Yvette , France.
AD  - azz Université Paris-Est Créteil , Créteil , France.
AD  - bac Université Paris-Sud, CEA, CNRS , Paris , France.
FAU - Biard-Piechaczyk, Martine
AU  - Biard-Piechaczyk M
AD  - hb CNRS UM, Centre d'études d'agents Pathogènes et Biotechnologies pour la Santé 
      , Montpellier , France.
FAU - Billes, Viktor
AU  - Billes V
AD  - kl Eötvös Loránd University , Department of Genetics , Budapest , Hungary.
FAU - Bincoletto, Claudia
AU  - Bincoletto C
AD  - axn Universidade Federal de São Paulo (UNIFESP) , Departamento de Farmacologia , 
      Escola Paulista de Medicina , São Paulo, SP , Brazil.
FAU - Bingol, Baris
AU  - Bingol B
AD  - ml Genentech Inc. , Department of Neuroscience , South San Francisco , CA , USA.
FAU - Bird, Sara W
AU  - Bird SW
AD  - aqj Stanford University , Department of Microbiology and Immunology , Stanford , 
      CA , USA.
FAU - Bitoun, Marc
AU  - Bitoun M
AD  - apt Sorbonne Universités, UPMC Univ Paris 06, INSERM UMRS974, CNRS FRE 3617, 
      Center for Research in Myology , Paris , France.
FAU - Bjedov, Ivana
AU  - Bjedov I
AD  - avj UCL Cancer Institute , London , UK.
FAU - Blackstone, Craig
AU  - Blackstone C
AD  - afk National Institutes of Health, Cell Biology Section, Neurogenetics Branch, 
      National Institute of Neurological Disorders and Stroke , Bethesda , MD , USA.
FAU - Blanc, Lionel
AU  - Blanc L
AD  - asm The Feinstein Institute for Medical Research, Laboratory of Developmental 
      Erythropoiesis , Manhasset , NY.
FAU - Blanco, Guillermo A
AU  - Blanco GA
AD  - ben University of Buenos Aires, IDEHU-CONICET, Faculty of Pharmacy and 
      Biochemistry , Buenos Aires , Argentina.
FAU - Blomhoff, Heidi Kiil
AU  - Blomhoff HK
AD  - bqr University of Oslo, Institute of Basic Medical Sciences , Oslo , Norway.
FAU - Boada-Romero, Emilio
AU  - Boada-Romero E
AD  - aww Universidad de Salamanca, Campus Unamuno, Instituto de Biologia Molecular y 
      Celular del Cancer (IBMCC), Centro de Investigacion del Cancer , Salamanca , 
      Spain.
FAU - Böckler, Stefan
AU  - Böckler S
AD  - bdh University of Bayreuth, Cell Biology , Bayreuth , Germany.
FAU - Boes, Marianne
AU  - Boes M
AD  - bbs University Medical Centre Utrecht , Laboratory of Translational Immunology 
      and Department of Pediatric Immunology , Utrecht , The Netherlands.
FAU - Boesze-Battaglia, Kathleen
AU  - Boesze-Battaglia K
AD  - bro University of Pennsylvania , Department of Biochemistry , SDM , Philadelphia 
      , PA , USA.
FAU - Boise, Lawrence H
AU  - Boise LH
AD  - jz Emory University , Department of Cell Biology , Atlanta , GA , USA.
AD  - ka Emory University , Department of Hematology and Medical Oncology , Atlanta , 
      GA , USA.
FAU - Bolino, Alessandra
AU  - Bolino A
AD  - cai INSPE, Institute of Experimental Neurology, Division of Neuroscience , San 
      Raffaele Scientific Institute, Milan , Italy.
FAU - Boman, Andrea
AU  - Boman A
AD  - zq Linköping University, Experimental Pathology , Department of Clinical and 
      Experimental Medicine , Faculty of Health Sciences , Linköping , Sweden.
FAU - Bonaldo, Paolo
AU  - Bonaldo P
AD  - brc University of Padova , Department of Molecular Medicine , Padova , Italy.
FAU - Bordi, Matteo
AU  - Bordi M
AD  - ahm New York University , Department of Psychiatry , New York NY ; and Center for 
      Dementia Research, Nathan S. Kline Institute , Orangeburg , NY , USA.
FAU - Bosch, Jürgen
AU  - Bosch J
AD  - wj Johns Hopkins, Bloomberg School of Public Health , Department of Biochemistry 
      and Molecular Biology and Johns Hopkins Malaria Research Institute , Baltimore , 
      MD , USA.
FAU - Botana, Luis M
AU  - Botana LM
AD  - axh Universidade de Santiago de Compostela , Departamento Farmacoloxía , 
      Facultade de Veterinaria , Lugo , Spain.
FAU - Botti, Joelle
AU  - Botti J
AD  - azw Université Paris Descartes-Sorbonne Paris Cité, Institut Necker 
      Enfants-Malades (INEM), INSERM U1151-CNRS UMR 8253 , Paris , France.
FAU - Bou, German
AU  - Bou G
AD  - bba University Hospital La Coruña , Microbiology Department , La Coruña , Spain.
FAU - Bouché, Marina
AU  - Bouché M
AD  - amx Sapienza University of Rome, DAHFMO-Section of Histology , Rome , Italy.
FAU - Bouchecareilh, Marion
AU  - Bouchecareilh M
AD  - aye Université Bordeaux Segalen, Institut de Biochimie et Génétique Cellulaires, 
      CNRS UMR 5095 , Bordeaux , France.
FAU - Boucher, Marie-Josée
AU  - Boucher MJ
AD  - buc University of Sherbrooke, Faculté de Médecine et des Sciences de la Santé , 
      Department of Medicine/Gastroenterology Division , Sherbrooke, Québec , Canada.
FAU - Boulton, Michael E
AU  - Boulton ME
AD  - rm Indiana University School of Medicine , Department of Ophthalmology , 
      Indianapolis , IN , USA.
FAU - Bouret, Sebastien G
AU  - Bouret SG
AD  - bvb University of Southern California, The Saban Research Institute, 
      Developmental Neuroscience Program, Children's Hospital Los Angeles , Los Angeles 
      , CA , USA.
FAU - Boya, Patricia
AU  - Boya P
AD  - ec Centro de Investigaciones Biológicas (CSIC) , Department of Cellular and 
      Molecular Biology , Madrid , Spain.
FAU - Boyer-Guittaut, Michaël
AU  - Boyer-Guittaut M
AD  - ays Université de Franche-Comté, UFR Sciences et Techniques, Laboratoire de 
      Biochimie , Besançon , France.
FAU - Bozhkov, Peter V
AU  - Bozhkov PV
AD  - aqw Swedish University of Agricultural Sciences and Linnean Center for Plant 
      Biology, Department of Chemistry and Biotechnology, Uppsala BioCenter, Uppsala, 
      Sweden.
FAU - Brady, Nathan
AU  - Brady N
AD  - nj German Cancer Research Center (DKFZ), Systems Biology of Cell Death Mechanisms 
      , Heidelberg , Germany.
FAU - Braga, Vania Mm
AU  - Braga VM
AD  - ra Imperial College London, National Heart and Lung Institute , London , UK.
FAU - Brancolini, Claudio
AU  - Brancolini C
AD  - bxu University of Udine , Dipartimento di Scienze Mediche e Biologiche , Udine , 
      Italy.
FAU - Braus, Gerhard H
AU  - Braus GH
AD  - mo Georg-August-Universität Göttingen , Department of Molecular Microbiology and 
      Genetics , Institute of Microbiology and Genetics , Göttingen , Germany.
FAU - Bravo-San Pedro, José M
AU  - Bravo-San Pedro JM
AD  - km Centre de Recherche des Cordeliers, Equipe 11 labellisée par la Ligue 
      Nationale contre le Cancer , Paris , France.
AD  - oc Gustave Roussy Cancer Campus , Villejuif , France.
AD  - sn INSERM, U1138 , Paris , France.
AD  - azv Université Paris Descartes/Paris V , Paris , France.
FAU - Brennan, Lisa A
AU  - Brennan LA
AD  - lj Florida Atlantic University, Schmidt College of Medicine , Department of 
      Biomedical Sciences , Boca Raton , FL , USA.
FAU - Bresnick, Emery H
AU  - Bresnick EH
AD  - byt University of Wisconsin, School of Medicine and Public Health , Department of 
      Cell and Regenerative Biology , Carbone Cancer Center , Madison , WI , USA.
FAU - Brest, Patrick
AU  - Brest P
AD  - rv INSERM U1081, CNRS UMR7284, Institute of Research on Cancer and Ageing of Nice 
      (IRCAN) , Nice , France.
FAU - Bridges, Dave
AU  - Bridges D
AD  - bvo University of Tennessee Health Science Center , Department of Physiology , 
      Memphis , TN , USA.
FAU - Bringer, Marie-Agnès
AU  - Bringer MA
AD  - dt UMR 1324 INRA, 6265 CNRS, Université de Bourgogne Franche-Comté, Centre des 
      Sciences du Goût et de l'Alimentation, Dijon , France.
FAU - Brini, Marisa
AU  - Brini M
AD  - brb University of Padova , Department of Biology , Padova , Italy.
FAU - Brito, Glauber C
AU  - Brito GC
AD  - axk Universidade de São Paulo, Instituto do Cancer do Estado de São Paulo, 
      Faculdade de Medicina , São Paulo, SP , Brazil.
FAU - Brodin, Bertha
AU  - Brodin B
AD  - xg Karolinska Institute, Cancer Center Karolinska , Department of 
      Oncology-Pathology , Stockholm , Sweden.
FAU - Brookes, Paul S
AU  - Brookes PS
AD  - bsz University of Rochester Medical Center , Department of Anesthesiology , 
      Rochester , NY , USA.
FAU - Brown, Eric J
AU  - Brown EJ
AD  - mn Genentech Inc., Immunology and Infectious Diseases , South San Francisco , CA 
      , USA.
FAU - Brown, Karen
AU  - Brown K
AD  - blz University of Leicester , Department of Cancer Studies , Leicester , UK.
FAU - Broxmeyer, Hal E
AU  - Broxmeyer HE
AD  - rl Indiana University School of Medicine , Department of Microbiology and 
      Immunology , Indianapolis , IN , USA.
FAU - Bruhat, Alain
AU  - Bruhat A
AD  - rr INRA, UMR 1019 Nutrition Humaine , Centre de Clermont Theix, Saint Genès 
      Champanelle , France.
AD  - aym Université Clermont 1, UFR Médecine, UMR1019 Nutrition Humaine , 
      Clermont-Ferrand , France.
FAU - Brum, Patricia Chakur
AU  - Brum PC
AD  - btu University of São Paulo, School of Physical Education and Sport, Cellular and 
      Molecular Exercise Physiology Laboratory , São Paulo , Brazil.
FAU - Brumell, John H
AU  - Brumell JH
AD  - qd Hospital for Sick Children, Toronto , ON , Canada.
FAU - Brunetti-Pierri, Nicola
AU  - Brunetti-Pierri N
AD  - lc Federico II University , Department of Translational Medicine , Naples , 
      Italy.
AD  - asa Telethon Institute of Genetics and Medicine (TIGEM) , Pozzuoli, Naples , 
      Italy.
FAU - Bryson-Richardson, Robert J
AU  - Bryson-Richardson RJ
AD  - ada Monash University, School of Biological Sciences , Melbourne , Victoria , 
      Australia.
FAU - Buch, Shilpa
AU  - Buch S
AD  - bpi University of Nebraska Medical Center , Omaha , NE , USA.
FAU - Buchan, Alastair M
AU  - Buchan AM
AD  - bqy University of Oxford, Acute Stroke Programme, Radcliffe Department of 
      Medicine , Oxford , UK.
FAU - Budak, Hikmet
AU  - Budak H
AD  - amh Sabanci University, Molecular Biology, Genetics and Bioengineering Program , 
      Istanbul , Turkey.
FAU - Bulavin, Dmitry V
AU  - Bulavin DV
AD  - dn Centre Antoine Lacassagne , Nice , France.
AD  - sk INSERM, U1081-UMR CNRS 7284 , Nice , France.
AD  - bpu University of Nice-Sophia Antipolis, Institute for Research on Cancer and 
      Aging of Nice (IRCAN) , Nice , France.
FAU - Bultman, Scott J
AU  - Bultman SJ
AD  - bpx University of North Carolina , Department of Genetics , Chapel Hill , NC , 
      USA.
FAU - Bultynck, Geert
AU  - Bultynck G
AD  - yo KU Leuven, Laboratory of Molecular and Cellular Signaling , Department of 
      Cellular and Molecular Medicine , Leuven , Belgium.
FAU - Bumbasirevic, Vladimir
AU  - Bumbasirevic V
AD  - bdn University of Belgrade, School of Medicine, Institute of Histology and 
      Embryology , Belgrade , Serbia.
FAU - Burelle, Yan
AU  - Burelle Y
AD  - azd Université de Montréal, Faculty of Pharmacy , Montréal, Québec , Canada.
FAU - Burke, Robert E
AU  - Burke RE
AD  - hh Columbia University Medical Center , Department of Neurology , New York , NY , 
      USA.
AD  - hi Columbia University Medical Center , Department of Pathology and Cell Biology 
      , New York , NY , USA.
FAU - Burmeister, Margit
AU  - Burmeister M
AD  - boh University of Michigan, Molecular and Behavioral Neuroscience Institute , 
      Departments of Computational Medicine and Bioinformatics , Psychiatry, and Human 
      Genetics , Ann Arbor , MI , USA.
FAU - Bütikofer, Peter
AU  - Bütikofer P
AD  - bdq University of Bern, Institute of Biochemistry and Molecular Medicine , Bern , 
      Switzerland.
FAU - Caberlotto, Laura
AU  - Caberlotto L
AD  - bxk University of Trento, The Microsoft Research, Centre for Computational and 
      Systems Biology (COSBI) , Rovereto , TN , Italy.
FAU - Cadwell, Ken
AU  - Cadwell K
AD  - ahl New York University School of Medicine, Skirball Institute , Department of 
      Microbiology , New York , NY , USA.
FAU - Cahova, Monika
AU  - Cahova M
AD  - dh Center of Experimental Medicine, Institute for Clinical and Experimental 
      Medicine , Prague , Czech Republic.
FAU - Cai, Dongsheng
AU  - Cai D
AD  - x Albert Einstein College of Medicine , Bronx , NY , USA.
FAU - Cai, Jingjing
AU  - Cai J
AD  - cbs Wenzhou Medical University, School of Optometry and Ophthalmology and Eye 
      Hospital , Wenzhou, Zhejiang , China.
FAU - Cai, Qian
AU  - Cai Q
AD  - amd Rutgers University, The State University of New Jersey , Department of Cell 
      Biology and Neuroscience , Piscataway , NJ , USA.
FAU - Calatayud, Sara
AU  - Calatayud S
AD  - bye University of Valencia , Department of Pharmacology , Valencia , Spain.
FAU - Camougrand, Nadine
AU  - Camougrand N
AD  - ayq Université de Bordeaux, UMR 5095, CNRS, Institut de Biochimie et génétique 
      Cellulaires , Bordeaux , France.
FAU - Campanella, Michelangelo
AU  - Campanella M
AD  - bmj University of London , RVC Department of Comparative Biomedical Sciences , 
      UCL Consortium for Mitochondrial Research , London , UK.
FAU - Campbell, Grant R
AU  - Campbell GR
AD  - bfq University of California San Diego , Department of Pediatrics , La Jolla , CA 
      , USA.
FAU - Campbell, Matthew
AU  - Campbell M
AD  - ava Trinity College Dublin, Smurfit Institute of Genetics , Dublin , Ireland.
FAU - Campello, Silvia
AU  - Campello S
AD  - uj IRCCS Santa Lucia Foundation , Department of Experimental Neurosciences , Rome 
      , Italy.
AD  - btd University of Rome "Tor Vergata" , Department of Biology , Rome , Italy.
FAU - Candau, Robin
AU  - Candau R
AD  - bpa University of Montpellier, UMR 866, Dynamique Musculaire et Métabolisme , 
      Montpellier , France.
FAU - Caniggia, Isabella
AU  - Caniggia I
AD  - bxg University of Toronto/Lunenfeld-Tanenbaum Research Institute, Mount Sinai 
      Hospital , Department of Obstetrics and Gynecology , Toronto, Ontario , Canada.
FAU - Cantoni, Lavinia
AU  - Cantoni L
AD  - un IRCCS-Istituto di Ricerche Farmacologiche Mario Negri , Department of 
      Molecular Biochemistry and Pharmacology , Milan , Italy.
FAU - Cao, Lizhi
AU  - Cao L
AD  - dl Central South University , Department of Pediatrics , Xiangya Hospital , 
      Changsha, Hunan , China.
FAU - Caplan, Allan B
AU  - Caplan AB
AD  - bkr University of Idaho, Plant, Soil, and Entomological Sciences , Moscow , ID , 
      USA.
FAU - Caraglia, Michele
AU  - Caraglia M
AD  - ank Second University of Naples , Department of Biochemistry , Biophysics and 
      General Pathology , Naples , Italy.
FAU - Cardinali, Claudio
AU  - Cardinali C
AD  - anc Sapienza University of Rome , Department of Molecular Medicine , Rome , 
      Italy.
FAU - Cardoso, Sandra Morais
AU  - Cardoso SM
AD  - bhs University of Coimbra, Faculty of Medicine, Center for Neuroscience and Cell 
      Biology , Coimbra , Portugal.
FAU - Carew, Jennifer S
AU  - Carew JS
AD  - gz Cleveland Clinic, Taussig Cancer Institute , Cleveland , OH , USA.
FAU - Carleton, Laura A
AU  - Carleton LA
AD  - agp National University of Ireland, Apoptosis Research Centre , Galway , Ireland.
FAU - Carlin, Cathleen R
AU  - Carlin CR
AD  - cw Case Western Reserve University, Molecular Biology and Microbiology , 
      Cleveland , OH , USA.
FAU - Carloni, Silvia
AU  - Carloni S
AD  - bxz University of Urbino "Carlo Bo" , Department of Biomolecular Sciences , 
      Urbino , Italy.
FAU - Carlsson, Sven R
AU  - Carlsson SR
AD  - avs Umeå University , Department of Medical Biochemistry and Biophysics , Umeå , 
      Sweden.
FAU - Carmona-Gutierrez, Didac
AU  - Carmona-Gutierrez D
AD  - bke University of Graz, Institute of Molecular Biosciences, BioTechMed Graz , 
      Graz , Austria.
FAU - Carneiro, Leticia Am
AU  - Carneiro LA
AD  - kz Federal University of Rio de Janeiro, Insititute of Microbiology , Department 
      of Immunology , Rio de Janeiro , Brazil.
FAU - Carnevali, Oliana
AU  - Carnevali O
AD  - aki Polytechnic University of Marche , Department of Life and Environmental 
      Sciences , Ancona , Italy.
FAU - Carra, Serena
AU  - Carra S
AD  - axr Universita' degli Studi di Modena e Reggio Emilia , Dipartimento di Scienze 
      Biomediche , Metaboliche e Neuroscienze , Modena , Italy.
FAU - Carrier, Alice
AU  - Carrier A
AD  - dp Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS 
      UMR 7258, Aix-Marseille Université , Institut Paoli-Calmette, Parc Scientifique 
      et Technologique de Luminy, Marseille , France.
FAU - Carroll, Bernadette
AU  - Carroll B
AD  - ahp Newcastle University, Campus for Ageing and Vitality, Institute for Cell and 
      Molecular Biosciences and Institute for Ageing , Newcastle upon Tyne , UK.
FAU - Casas, Caty
AU  - Casas C
AD  - axx Universitat Autònoma de Barcelona , Department of Cell Biology , Physiology 
      and Immunology, Institut de Neurociències , Barcelona , Spain.
FAU - Casas, Josefina
AU  - Casas J
AD  - apx Spanish Council for Scientific Research, Institute for Advanced Chemistry of 
      Catalonia , Department of Biomedicinal Chemistry , Barcelona , Spain.
FAU - Cassinelli, Giuliana
AU  - Cassinelli G
AD  - ll Fondazione IRCCS Istituto Nazionale dei Tumori , Department of Experimental 
      Oncology and Molecular Medicine , Milan , Italy.
FAU - Castets, Perrine
AU  - Castets P
AD  - bdf University of Basel , Biozentrum, Basel, BS , Switzerland.
FAU - Castro-Obregon, Susana
AU  - Castro-Obregon S
AD  - hf Colonia Ciudad Universitaria , Neurodevelopment and Physiology Department , 
      Neuroscience Division, Instituto de Fisiologia Celular, UNAM , Mexico , DF , 
      Mexico.
FAU - Cavallini, Gabriella
AU  - Cavallini G
AD  - bru University of Pisa, Interdepartmental Research Centre on Biology and 
      Pathology of Aging , Pisa , Italy.
FAU - Ceccherini, Isabella
AU  - Ceccherini I
AD  - uv Istituto Giannina Gaslini, UOC Medical Genetics , Genova , Italy.
FAU - Cecconi, Francesco
AU  - Cecconi F
AD  - is Danish Cancer Society Research Center , Unit of Cell Stress and Survival (CSS) 
      , Copenhagen , Denmark.
AD  - ui IRCCS Santa Lucia Foundation , Rome , Italy.
AD  - btl University of Rome "Tor Vergata" , Department of Biology, Rome , Italy.
FAU - Cederbaum, Arthur I
AU  - Cederbaum AI
AD  - qq Icahn School of Medicine at Mount Sinai , Department of Pharmacology and 
      Systems Therapeutics , New York , NY , USA.
FAU - Ceña, Valentín
AU  - Ceña V
AD  - gq CIBERNED, ISCIII, Unidad Asociada Neurodeath , Madrid , Spain.
AD  - awg Universidad de Castilla-La Mancha , Albacete , Spain.
FAU - Cenci, Simone
AU  - Cenci S
AD  - axw Università Vita-Salute San Raffaele , Milan , Italy.
AD  - caj San Raffaele Scientific Institute , Milan , Italy.
FAU - Cerella, Claudia
AU  - Cerella C
AD  - qb Hôpital Kirchberg, Laboratoire de Biologie Moléculaire et Cellulaire du Cancer 
      , Luxembourg.
FAU - Cervia, Davide
AU  - Cervia D
AD  - bxt University of Tuscia , Department for Innovation in Biological , Agro-food 
      and Forest Systems (DIBAF) , Viterbo , Italy.
FAU - Cetrullo, Silvia
AU  - Cetrullo S
AD  - bdv University of Bologna , Dipartimento di Scienze Biomediche e Neuromotorie , 
      Bologna , Italy.
FAU - Chaachouay, Hassan
AU  - Chaachouay H
AD  - byz University of Zürich , Department of Radiation Oncology , Zurich , 
      Switzerland.
FAU - Chae, Han-Jung
AU  - Chae HJ
AD  - ge Chonbuk National University , Department of Pharmacology , Medical School , 
      Chonbuk , Korea.
FAU - Chagin, Andrei S
AU  - Chagin AS
AD  - xj Karolinska Institute , Department of Physiology and Pharmacology , Stockholm , 
      Sweden.
FAU - Chai, Chee-Yin
AU  - Chai CY
AD  - xb Kaohsiung Medical University Hospital , Department of Pathology , Kaohsiung 
      City , Taiwan.
AD  - xd Kaohsiung Medical University, Faculty of Medicine , Department of Pathology , 
      Kaohsiung City , Taiwan.
FAU - Chakrabarti, Gopal
AU  - Chakrabarti G
AD  - bet University of Calcutta , Department of Biotechnology , Dr.B.C. Guha Centre 
      for Genetic Engineering and Biotechnology , Kolkata , WB , India.
FAU - Chamilos, Georgios
AU  - Chamilos G
AD  - bio University of Crete, School of Medicine , Department of Infectious Diseases , 
      Heraklion, Crete , Greece.
FAU - Chan, Edmond Yw
AU  - Chan EY
AD  - aqx Strathclyde Institute of Pharmacy and Biomedical Sciences , Glasgow , UK.
FAU - Chan, Matthew Tv
AU  - Chan MT
AD  - fy Chinese University of Hong Kong , Department of Anaesthesia and Intensive Care 
      , Shatin, NT, Hong Kong.
FAU - Chandra, Dhyan
AU  - Chandra D
AD  - alo Roswell Park Cancer Institute , Department of Pharmacology and Therapeutics , 
      Buffalo , NY , USA.
FAU - Chandra, Pallavi
AU  - Chandra P
AD  - ub International Center for Genetic Engineering and Biotechnology, Immunology 
      Group , New Delhi , India.
FAU - Chang, Chih-Peng
AU  - Chang CP
AD  - ael National Cheng Kung University , Department of Microbiology and Immunology , 
      College of Medicine , Tainan , Taiwan.
FAU - Chang, Raymond Chuen-Chung
AU  - Chang RC
AD  - bko University of Hong Kong, Laboratory of Neurodegenerative Diseases , School of 
      Biomedical Sciences , LKS Faculty of Medicine , Hong Kong , China.
FAU - Chang, Ta Yuan
AU  - Chang TY
AD  - mg Geisel School of Medicine at Dartmouth , Department of Biochemistry , Hanover 
      , NH , USA.
FAU - Chatham, John C
AU  - Chatham JC
AD  - bcd University of Alabama at Birmingham, Division of Molecular and Cellular 
      Pathology , Department of Pathology , Birmingham , AL , USA.
FAU - Chatterjee, Saurabh
AU  - Chatterjee S
AD  - bul University of South Carolina, Environmental Health and Disease Laboratory , 
      Department of Environmental Health Sciences , Columbia , SC , USA.
FAU - Chauhan, Santosh
AU  - Chauhan S
AD  - tg Institute of Life Sciences , Bhubaneshwar , Odisa , India.
FAU - Che, Yongsheng
AU  - Che Y
AD  - bj Beijing Institute of Pharmacology and Toxicology, State Key Laboratory of 
      Toxicology and Medical Countermeasures , Beijing , China.
FAU - Cheetham, Michael E
AU  - Cheetham ME
AD  - avo UCL Institute of Ophthalmology , London , UK.
FAU - Cheluvappa, Rajkumar
AU  - Cheluvappa R
AD  - bpo University of New South Wales, Inflammation and Infection Research Centre, 
      School of Medical Sciences , Sydney, NSW , Australia.
FAU - Chen, Chun-Jung
AU  - Chen CJ
AD  - ari Taichung Veterans General Hospital , Department of Medical Research , 
      Taichung City , Taiwan.
FAU - Chen, Gang
AU  - Chen G
AD  - vz Jinshan Hospital of Fudan University , Department of Urology , Shanghai , 
      China.
AD  - bll University of Kentucky, College of Medicine , Department of Pharmacology and 
      Nutritional Sciences , Lexington , KY , USA.
FAU - Chen, Guang-Chao
AU  - Chen GC
AD  - i Academia Sinica, Institute of Biological Chemistry , Taipei , Taiwan.
FAU - Chen, Guoqiang
AU  - Chen G
AD  - aol Shanghai Jiao Tong University, School of Medicine, Key Laboratory of Cell 
      Differentiation and Apoptosis of Chinese Ministry of Education , Shanghai , 
      China.
FAU - Chen, Hongzhuan
AU  - Chen H
AD  - aok Shanghai Jiao Tong University, School of Medicine , Department of 
      Pharmacology and Chemical Biology , Shanghai , China.
FAU - Chen, Jeff W
AU  - Chen JW
AD  - bff University of California Irvine , Department of Neurosurgery , Irvine , CA , 
      USA.
FAU - Chen, Jian-Kang
AU  - Chen JK
AD  - nf Georgia Regents University, Medical College of Georgia , Department of 
      Cellular Biology and Anatomy , Augusta , GA , USA.
AD  - ng Georgia Regents University, Medical College of Georgia , Department of 
      Medicine , Augusta , GA , USA.
FAU - Chen, Min
AU  - Chen M
AD  - io Dalian Medical University , Department of Food Nutrition and Safety , Dalian , 
      China.
FAU - Chen, Mingzhou
AU  - Chen M
AD  - cbx Wuhan University, College of Life Science, State Key Laboratory of Virology , 
      Wuhan, Hubei , China.
FAU - Chen, Peiwen
AU  - Chen P
AD  - brc University of Padova , Department of Molecular Medicine , Padova , Italy.
FAU - Chen, Qi
AU  - Chen Q
AD  - blj University of Kansas Medical Center , Department of Pharmacology , Toxicology 
      and Therapeutics , Kansas City , KS , USA.
FAU - Chen, Quan
AU  - Chen Q
AD  - fp Chinese Academy of Sciences, Institute of Zoology , Beijing , China.
FAU - Chen, Shang-Der
AU  - Chen SD
AD  - eh Chang Gung University, College of Medicine , Department of Neurology , 
      Kaohsiung Chang Gung Memorial Hospital , Kaohsiung , Taiwan.
FAU - Chen, Si
AU  - Chen S
AD  - lm Food and Drug Administration (FDA), Division of Biochemical Toxicology, 
      National Center for Toxicological Research (NCTR) , Jefferson , AR , USA.
FAU - Chen, Steve S-L
AU  - Chen SS
AD  - j Academia Sinica, Institute of Biomedical Sciences , Taipei , Taiwan.
FAU - Chen, Wei
AU  - Chen W
AD  - ccs Zhejiang University , Department of Food Science and Nutrition , Hangzhou , 
      China.
FAU - Chen, Wei-Jung
AU  - Chen WJ
AD  - aew National Ilan University , Department of Biotechnology and Animal Science , 
      Yilan City , Taiwan.
FAU - Chen, Wen Qiang
AU  - Chen WQ
AD  - akq Qilu Hospital of Shandong University, Cardiology , Jinan, Shandong , China.
FAU - Chen, Wenli
AU  - Chen W
AD  - apu South China Normal University, College of Biophotonics , Guangdong , China.
FAU - Chen, Xiangmei
AU  - Chen X
AD  - aqo State Key Laboratory of Kidney Diseases, National Clinical Research Center 
      for Kidney Diseases , Department of Nephrology , Chinese PLA General Hospital, 
      Chinese PLA Institute of Nephrology , Beijing , China.
FAU - Chen, Yau-Hung
AU  - Chen YH
AD  - arm Tamkang University , Department of Chemistry , Tamsui, New Taipei City , 
      Taiwan.
FAU - Chen, Ye-Guang
AU  - Chen YG
AD  - avb Tsinghua University, School of Life Sciences , Beijing , China.
FAU - Chen, Yin
AU  - Chen Y
AD  - bcq University of Arizona , Department of Pharmacology and Toxicology , College 
      of Pharmacy , Tucson , AZ , USA.
FAU - Chen, Yingyu
AU  - Chen Y
AD  - ajq Peking University , Department of Immunology , Beijing , China.
AD  - ajs Peking University, Health Science Center, Center for Human Disease Genomics , 
      Beijing , China.
FAU - Chen, Yongshun
AU  - Chen Y
AD  - cdc Zhengzhou University Affiliated Cancer Hospital , Zhengzhou , China.
FAU - Chen, Yu-Jen
AU  - Chen YJ
AD  - aaj Mackay Memorial Hospital , Department of Radiation Oncology , Taipei , 
      Taiwan.
FAU - Chen, Yue-Qin
AU  - Chen YQ
AD  - ara Sun Yat-Sen University, Key Laboratory of Gene Engineering of the Ministry of 
      Education, School of Life Science , Guangzhou , China.
FAU - Chen, Yujie
AU  - Chen Y
AD  - atl Third Military Medical University , Department of Neurosurgery , Southwest 
      Hospital , Shapingba District, Chongqing , China.
FAU - Chen, Zhen
AU  - Chen Z
AD  - ma Fudan University, Cancer Center , Department of Integrative Oncology , 
      Shanghai , China.
FAU - Chen, Zhong
AU  - Chen Z
AD  - ccq Zhejiang University, Deparment of Pharmacology, College of Pharmaceutical 
      Sciences , Hangzhou, Zhejiang , China.
FAU - Cheng, Alan
AU  - Cheng A
AD  - bml University of Louisville , Department of Biochemistry and Molecular Genetics 
      , Louisville , KY , USA.
FAU - Cheng, Christopher Hk
AU  - Cheng CH
AD  - gb Chinese University of Hong Kong, School of Biomedical Sciences, Faculty of 
      Medicine , Shatin, NT, Hong Kong.
FAU - Cheng, Hua
AU  - Cheng H
AD  - bnl University of Maryland, School of Medicine, Institute of Human Virology , 
      Baltimore , MD , USA.
FAU - Cheong, Heesun
AU  - Cheong H
AD  - aeh National Cancer Center, Division of Cancer Biology, Research Institute , 
      Gyeonggi , Korea.
FAU - Cherry, Sara
AU  - Cherry S
AD  - brp University of Pennsylvania , Department of Microbiology , Philadelphia , PA , 
      USA.
FAU - Chesney, Jason
AU  - Chesney J
AD  - bmm University of Louisville , Department of Medicine (Hem-Onc) , Louisville , KY 
      , USA.
FAU - Cheung, Chun Hei Antonio
AU  - Cheung CH
AD  - aek National Cheng Kung University, College of Medicine , Department of 
      Pharmacology and Institute of Basic Medical Sciences , Tainan , Taiwan.
FAU - Chevet, Eric
AU  - Chevet E
AD  - azg Université de Rennes-1, Oncogenesis, stress, Signaling" (OSS), ERL 440 
      INSERM, Centre de Lutte Contre le Cancer Eugene Marquis , Rennes , France.
FAU - Chi, Hsiang Cheng
AU  - Chi HC
AD  - ej Chang Gung University , Department of Biochemistry , College of Medicine , 
      Taoyuan , Taiwan.
FAU - Chi, Sung-Gil
AU  - Chi SG
AD  - yf Korea University , Department of Life Science and Biotechnology , Seoul , 
      Korea.
FAU - Chiacchiera, Fulvio
AU  - Chiacchiera F
AD  - kv European Institute of Oncology (IEO) , Department of Experimental Oncology , 
      Milan , Italy.
FAU - Chiang, Hui-Ling
AU  - Chiang HL
AD  - ajv Pennsylvania State University, College of Medicine , Department of Cellular 
      and Molecular Physiology , Hershey , PA , USA.
FAU - Chiarelli, Roberto
AU  - Chiarelli R
AD  - brf University of Palermo , Dipartimento di Scienze e Tecnologie Biologiche , 
      Chimiche e Farmaceutiche (STEBICEF) , Palermo , Italy.
FAU - Chiariello, Mario
AU  - Chiariello M
AD  - ia Consiglio Nazionale delle Ricerche, Core Research Laboratory , Siena , Italy.
AD  - uu Istituto di Fisiologia Clinica , Siena , Italy.
AD  - ve Istituto Toscano Tumori , Siena , Italy.
FAU - Chieppa, Marcello
AU  - Chieppa M
AD  - afc National Institute of Gastoenterology, Laboratory of Experimental 
      Immunopathology , Castellana Grotte (BA) , Italy.
FAU - Chin, Lih-Shen
AU  - Chin LS
AD  - kd Emory University, School of Medicine , Department of Pharmacology , Atlanta , 
      GA , USA.
FAU - Chiong, Mario
AU  - Chiong M
AD  - awk Universidad de Chile, Advanced Center for Chronic Diseases (ACCDiS) , 
      Santiago , Chile.
FAU - Chiu, Gigi Nc
AU  - Chiu GN
AD  - agt National University of Singapore , Department of Pharmacy , Singapore.
FAU - Cho, Dong-Hyung
AU  - Cho DH
AD  - yz Kyung Hee University, Graduate School of East-West Medical Science , Seoul , 
      Korea.
FAU - Cho, Ssang-Goo
AU  - Cho SG
AD  - xz Konkuk University , Department of Animal Biotechnology , Seoul , Korea.
FAU - Cho, William C
AU  - Cho WC
AD  - akt Queen Elizabeth Hospital , Department of Clinical Oncology , Kowloon, Hong 
      Kong.
FAU - Cho, Yong-Yeon
AU  - Cho YY
AD  - da Catholic University of Korea, College of Pharmacy , Bucheon , Korea.
FAU - Cho, Young-Seok
AU  - Cho YS
AD  - anx Seoul St. Mary's Hospital , Department of Internal Medicine , Seoul, Korea.
FAU - Choi, Augustine Mk
AU  - Choi AM
AD  - cbo Weill Cornell Medical College , New York , NY , USA.
FAU - Choi, Eui-Ju
AU  - Choi EJ
AD  - yf Korea University , Department of Life Science and Biotechnology , Seoul , 
      Korea.
FAU - Choi, Eun-Kyoung
AU  - Choi EK
AD  - nw Graduate School of Hallym University , Chuncheon, Kangwon-do , Korea.
AD  - oj Hallym University , Department of Biomedical Gerontology , Chuncheon, 
      Kangwon-do, Korea; and Anyang, Gyeonggi-do , Korea.
AD  - zi Laboratory of Cellular Aging and Neurodegeneration, Ilsong Institute of Life 
      Science, Anyang , Gyeonggi-do , Korea.
FAU - Choi, Jayoung
AU  - Choi J
AD  - bhc University of Chicago , Department of Pathology , Chicago , IL , USA.
FAU - Choi, Mary E
AU  - Choi ME
AD  - cbm Weill Cornell Medical College, Division of Nephrology and Hypertension, Joan 
      and Sanford I . Weill Department of Medicine , New York , NY , USA.
FAU - Choi, Seung-Il
AU  - Choi SI
AD  - ccj Yonsei University, College of Medicine, Corneal Dystrophy Research Institute 
      ; and Department of Ophthalmology , Seoul , Korea.
FAU - Chou, Tsui-Fen
AU  - Chou TF
AD  - ov Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, 
      Division of Medical Genetics , Department of Pediatrics , Torrance , CA , USA.
FAU - Chouaib, Salem
AU  - Chouaib S
AD  - oe Gustave Roussy Institute , Villejuif , France.
FAU - Choubey, Divaker
AU  - Choubey D
AD  - bhn University of Cincinnati , Cincinnati , OH , USA.
FAU - Choubey, Vinay
AU  - Choubey V
AD  - bvl University of Tartu , Department of Pharmacology , Tartu , Estonia.
FAU - Chow, Kuan-Chih
AU  - Chow KC
AD  - aep National Chung Hsing University, Graduate Institute of Biomedical Sciences , 
      Taichung , Taiwan.
FAU - Chowdhury, Kamal
AU  - Chowdhury K
AD  - abb Max Planck Institute of Biophysical Chemistry , Department of Molecular Cell 
      Biology , Göttingen , Germany.
FAU - Chu, Charleen T
AU  - Chu CT
AD  - bsj University of Pittsburgh, School of Medicine , Department of Pathology and 
      Center for Neuroscience , Pittsburgh , PA , USA.
FAU - Chuang, Tsung-Hsien
AU  - Chuang TH
AD  - aeu National Health Research Institutes, Immunology Research Center , Miaoli , 
      Taiwan.
FAU - Chun, Taehoon
AU  - Chun T
AD  - yg Korea University, Department of Biotechnology, College of Life Sciences and 
      Biotechnology , Seoul , Korea.
FAU - Chung, Hyewon
AU  - Chung H
AD  - yb Konkuk University School of Medicine , Department of Ophthalmology , Seoul , 
      Korea.
FAU - Chung, Taijoon
AU  - Chung T
AD  - akp Pusan National University , Department of Biological Sciences , Busan , 
      Korea.
FAU - Chung, Yuen-Li
AU  - Chung YL
AD  - asx The Institute of Cancer Research, Cancer Research UK Cancer Imaging Centre, 
      Division of Radiotherapy and Imaging , Sutton, Surrey , UK.
FAU - Chwae, Yong-Joon
AU  - Chwae YJ
AD  - r Ajou University, School of Medicine , Department of Microbiology , Gyeonggi-do 
      , Korea.
FAU - Cianfanelli, Valentina
AU  - Cianfanelli V
AD  - it Danish Cancer Society Research Center, Unit of Cell Stress and Survival , 
      Copenhagen , Denmark.
FAU - Ciarcia, Roberto
AU  - Ciarcia R
AD  - bpg University of Naples Federico II , Department of Veterinary Medicine and 
      Animal Production , Naples , Italy.
FAU - Ciechomska, Iwona A
AU  - Ciechomska IA
AD  - ahb Nencki Institute of Experimental Biology, Neurobiology Center, Laboratory of 
      Molecular Neurobiology , Warsaw , Poland.
FAU - Ciriolo, Maria Rosa
AU  - Ciriolo MR
AD  - btd University of Rome "Tor Vergata" , Department of Biology , Rome , Italy.
FAU - Cirone, Mara
AU  - Cirone M
AD  - anb Sapienza University of Rome , Department of Experimental Medicine , Rome , 
      Italy.
FAU - Claerhout, Sofie
AU  - Claerhout S
AD  - bmd KU Leuven-University of Leuven, Center for Human Genetics; VIB Center for the 
      Biology of Disease , Leuven , Belgium.
FAU - Clague, Michael J
AU  - Clague MJ
AD  - bmh University of Liverpool, Cellular and Molecular Physiology, Institute of 
      Translational Medicine , Liverpool , UK.
FAU - Clària, Joan
AU  - Clària J
AD  - bda University of Barcelona , Department of Biochemistry and Molecular Genetics , 
      Hospital Clínic, IDIBAPS-CIBERehd , Barcelona , Spain.
FAU - Clarke, Peter Gh
AU  - Clarke PG
AD  - blw University of Lausanne , Department of Fundamental Neurosciences , Faculty of 
      Biology and Medicine , Lausanne , Switzerland.
FAU - Clarke, Robert
AU  - Clarke R
AD  - mw Georgetown University Medical Center , Department of Oncology , Washington, DC 
      , USA.
FAU - Clementi, Emilio
AU  - Clementi E
AD  - ane Scientific Institute IRCCS Eugenio Medea , Bosisio Parini , Italy.
AD  - bat University Hospital "Luigi Sacco", Università di Milano, Unit of Clinical 
      Pharmacology, National Research Council-Institute of Neuroscience , Department of 
      Biomedical and Clinical Sciences "Luigi Sacco" , Milano , Italy.
FAU - Cleyrat, Cédric
AU  - Cleyrat C
AD  - bpm University of New Mexico , Department of Pathology and Cancer Research and 
      Treatment Center , Albuquerque , NM , USA.
FAU - Cnop, Miriam
AU  - Cnop M
AD  - azn Universite Libre de Bruxelles, ULB Center for Diabetes Research , Brussels , 
      Belgium.
FAU - Coccia, Eliana M
AU  - Coccia EM
AD  - vb Istituto Superiore di Sanità , Department of Infectious , Parasitic and 
      Immunomediated Diseases , Rome , Italy.
FAU - Cocco, Tiziana
AU  - Cocco T
AD  - bdc University of Bari 'Aldo Moro' , Department of Basic Medical Sciences , 
      Neurosciences and Organs of Senses , Bari , Italy.
FAU - Codogno, Patrice
AU  - Codogno P
AD  - azw Université Paris Descartes-Sorbonne Paris Cité, Institut Necker 
      Enfants-Malades (INEM), INSERM U1151-CNRS UMR 8253 , Paris , France.
FAU - Coers, Jörn
AU  - Coers J
AD  - jk Duke University, Medical Center , Department of Molecular Genetics and 
      Microbiology , Durham , NC , USA.
FAU - Cohen, Ezra Ew
AU  - Cohen EE
AD  - bfy University of California San Diego, Moores Cancer Center , La Jolla , CA , 
      USA.
FAU - Colecchia, David
AU  - Colecchia D
AD  - ia Consiglio Nazionale delle Ricerche, Core Research Laboratory , Siena , Italy.
AD  - uu Istituto di Fisiologia Clinica , Siena , Italy.
AD  - ve Istituto Toscano Tumori , Siena , Italy.
FAU - Coletto, Luisa
AU  - Coletto L
AD  - y Albert Einstein College of Medicine , Department of Developmental and Molecular 
      Biology , Bronx , NY , USA.
FAU - Coll, Núria S
AU  - Coll NS
AD  - ds Centre for Research in Agricultural Genomics (CSIC-IRTA-UAB-UB) , Bellaterra , 
      Catalonia , Spain.
FAU - Colucci-Guyon, Emma
AU  - Colucci-Guyon E
AD  - sv Institut Pasteur, CNRS, URA2578, Unité Macrophages et Développement de 
      l'Immunité , Département de Biologie du Développement et des Cellules Souches , 
      Paris , France.
FAU - Comincini, Sergio
AU  - Comincini S
AD  - bri University of Pavia , Department of Biology and Biotechnology , Pavia , 
      Italy.
FAU - Condello, Maria
AU  - Condello M
AD  - vf Italian National Institute of Health , Department of Technology and Health, 
      Rome , Italy.
FAU - Cook, Katherine L
AU  - Cook KL
AD  - cas Wake Forest University , Department of Surgery , Hypertension and Vascular 
      Research Center, Wake Forest Comprehensive Cancer Center , Winston-Salem , NC , 
      USA.
FAU - Coombs, Graham H
AU  - Coombs GH
AD  - bve University of Strathclyde, Strathclyde Institute of Pharmacy and Biomedical 
      Sciences , Glasgow , UK.
FAU - Cooper, Cynthia D
AU  - Cooper CD
AD  - cav Washington State University Vancouver, School of Molecular Biosciences , 
      Vancouver , WA , USA.
FAU - Cooper, J Mark
AU  - Cooper JM
AD  - baq University College London , Department of Clinical Neurosciences , London , 
      UK.
FAU - Coppens, Isabelle
AU  - Coppens I
AD  - wc Johns Hopkins University, Bloomberg School of Public Health, Malaria Research 
      Institute , Department of Molecular Microbiology and Immunology , Baltimore , MD 
      , USA.
FAU - Corasaniti, Maria Tiziana
AU  - Corasaniti MT
AD  - bai University "Magna Graecia" of Catanzaro , Department of Health Sciences , 
      Catanzaro , Italy.
FAU - Corazzari, Marco
AU  - Corazzari M
AD  - rq INMI-IRCCS "L. Spallanzani" , Rome , Italy.
AD  - btl University of Rome "Tor Vergata" , Department of Biology, Rome , Italy.
FAU - Corbalan, Ramon
AU  - Corbalan R
AD  - bhf University of Chile, Advanced Center for Chronic Diseases (ACCDiS), Division 
      of Cardiovascular Diseases, Faculty of Medicine , Santiago , Chile.
FAU - Corcelle-Termeau, Elisabeth
AU  - Corcelle-Termeau E
AD  - iq Danish Cancer Society Research Center, Cell Death and Metabolism Unit, Center 
      for Autophagy, Recycling and Disease , Copenhagen , Denmark.
FAU - Cordero, Mario D
AU  - Cordero MD
AD  - bua University of Sevilla, Instituto de Biomedicina de Sevilla (IBIS) , Oral 
      Medicine Department , Sevilla , Spain.
FAU - Corral-Ramos, Cristina
AU  - Corral-Ramos C
AD  - awo Universidad de Córdoba, Campus de Excelencia Agroalimentario (ceiA3), 
      Departamento de Genética , Córdoba , Spain.
FAU - Corti, Olga
AU  - Corti O
AD  - sm INSERM, U1127, CNRS, UMR 7225 , Paris , France.
AD  - apq Sorbonne Universités, UMR S1127 , Paris , France.
FAU - Cossarizza, Andrea
AU  - Cossarizza A
AD  - boy University of Modena and Reggio Emilia, School of Medicine , Department of 
      Surgery , Medicine, Dentistry and Morphological Sciences , Modena , Italy.
FAU - Costelli, Paola
AU  - Costelli P
AD  - bxq University of Turin , Department of Clinical and Biological Sciences , Unit 
      of Experimental Medicine and Clinical Pathology , Turin , Italy.
FAU - Costes, Safia
AU  - Costes S
AD  - bfj University of California Los Angeles, Larry Hillblom Islet Research Center, 
      David Geffen School of Medicine , Los Angeles , CA , USA.
FAU - Cotman, Susan L
AU  - Cotman SL
AD  - aas Massachusetts General Hospital and Harvard Medical School, Center for Human 
      Genetic Research and Department of Neurology , Boston , MA , USA.
FAU - Coto-Montes, Ana
AU  - Coto-Montes A
AD  - ajj Oviedo University, Morphology and Cellular Biology Department , Oviedo , 
      Spain.
FAU - Cottet, Sandra
AU  - Cottet S
AD  - ut IRO, Institute for Research in Ophthalmology , Sion , Switzerland.
AD  - blx University of Lausanne , Department of Ophthalmology , Lausanne , 
      Switzerland.
FAU - Couve, Eduardo
AU  - Couve E
AD  - axa Universidad de Valparaíso, Instituto de Biología, Facultad de Ciencias , 
      Valparaíso , Chile.
FAU - Covey, Lori R
AU  - Covey LR
AD  - ama Rutgers University , Department of Cell Biology and Neuroscience , Piscataway 
      , NJ , USA.
FAU - Cowart, L Ashley
AU  - Cowart LA
AD  - ach Medical University of South Carolina, Biochemistry and Molecular Biology , 
      Charleston , SC , USA.
FAU - Cox, Jeffery S
AU  - Cox JS
AD  - bgb University of California San Francisco , Department of Microbiology and 
      Immunology , San Francisco , CA , USA.
FAU - Coxon, Fraser P
AU  - Coxon FP
AD  - bbw University of Aberdeen, Division of Applied Medicine , Aberdeen , UK.
FAU - Coyne, Carolyn B
AU  - Coyne CB
AD  - brz University of Pittsburgh , Department of Microbiology and Molecular Genetics 
      , Pittsburgh , PA , USA.
FAU - Cragg, Mark S
AU  - Cragg MS
AD  - buu University of Southampton, Cancer Sciences , Southampton , UK.
FAU - Craven, Rolf J
AU  - Craven RJ
AD  - blo University of Kentucky , Department of Pharmacology and Nutritional Sciences 
      , Lexington , KY , USA.
FAU - Crepaldi, Tiziana
AU  - Crepaldi T
AD  - bxs University of Turin , Turin , Italy.
FAU - Crespo, Jose L
AU  - Crespo JL
AD  - awz Universidad de Sevilla, Instituto de Bioquímica Vegetal y Fotosíntesis, CSIC 
      , Sevilla , Spain.
FAU - Criollo, Alfredo
AU  - Criollo A
AD  - awk Universidad de Chile, Advanced Center for Chronic Diseases (ACCDiS) , 
      Santiago , Chile.
FAU - Crippa, Valeria
AU  - Crippa V
AD  - ul IRCCS, "C. Mondino" National Neurological Institute, Experimental Neurobiology 
      Lab , Pavia , Italy.
FAU - Cruz, Maria Teresa
AU  - Cruz MT
AD  - bhp University of Coimbra, Center for Neuroscience and Cell Biology and Faculty 
      of Pharmacy , Coimbra , Portugal.
FAU - Cuervo, Ana Maria
AU  - Cuervo AM
AD  - z Albert Einstein College of Medicine , Department of Developmental and Molecular 
      Biology , Institute for Aging Studies , Bronx , NY , USA.
FAU - Cuezva, Jose M
AU  - Cuezva JM
AD  - awc Universidad Autonoma de Madrid, Departamento de Biologia Molecular , Madrid , 
      Spain.
FAU - Cui, Taixing
AU  - Cui T
AD  - bui University of South Carolina School of Medicine , Department of Cell Biology 
      and Anatomy , Columbia , SC , USA.
FAU - Cutillas, Pedro R
AU  - Cutillas PR
AD  - aky Queen Mary University of London, Centre for Haemato-Oncology, Barts Cancer 
      Institute , London , UK.
FAU - Czaja, Mark J
AU  - Czaja MJ
AD  - aa Albert Einstein College of Medicine , Department of Medicine , Bronx , NY , 
      USA.
FAU - Czyzyk-Krzeska, Maria F
AU  - Czyzyk-Krzeska MF
AD  - bhl University of Cincinnati College of Medicine , Department of Cancer Biology , 
      Cincinnati , OH , USA.
FAU - Dagda, Ruben K
AU  - Dagda RK
AD  - can University of Nevada School of Medicine, Department of Pharmacology, Reno, 
      NV, USA.
FAU - Dahmen, Uta
AU  - Dahmen U
AD  - baz University Hospital Jena , Department of General , Visceral and Vascular 
      Surgery, Experimental Transplantation Surgery , Jena , Germany.
FAU - Dai, Chunsun
AU  - Dai C
AD  - adt Nanjing Medical University, Center for Kidney Disease, 2nd Affiliated 
      Hospital , Jiangsu , China.
FAU - Dai, Wenjie
AU  - Dai W
AD  - asq The First Affiliated Hospital of Harbin Medical University, Key Laboratory of 
      Hepatosplenic Surgery , Department of General Surgery , Harbin , China.
FAU - Dai, Yun
AU  - Dai Y
AD  - cae Virginia Commonwealth University, Massey Cancer Center , Department of 
      Medicine , Richmond , VA , USA.
FAU - Dalby, Kevin N
AU  - Dalby KN
AD  - bvp University of Texas at Austin, College of Pharmacy, Division of Medicinal 
      Chemistry , Austin , TX , USA.
FAU - Dalla Valle, Luisa
AU  - Dalla Valle L
AD  - brb University of Padova , Department of Biology , Padova , Italy.
FAU - Dalmasso, Guillaume
AU  - Dalmasso G
AD  - ayn Université d'Auvergne, M2iSH "Microbes, Intestine, Inflammation, 
      Susceptibility of the Host", UMR 1071 INSERM, Centre Biomédical de Recherche et 
      Valorisation, Faculté de Médecine , Clermont-Ferrand , France.
FAU - D'Amelio, Marcello
AU  - D'Amelio M
AD  - uk IRCCS Santa Lucia Foundation , Rome , Italy.
FAU - Damme, Markus
AU  - Damme M
AD  - gf Christian Albrechts University, Institut für Biochemie , Kiel , Germany.
FAU - Darfeuille-Michaud, Arlette
AU  - Darfeuille-Michaud A
AD  - ayn Université d'Auvergne, M2iSH "Microbes, Intestine, Inflammation, 
      Susceptibility of the Host", UMR 1071 INSERM, Centre Biomédical de Recherche et 
      Valorisation, Faculté de Médecine , Clermont-Ferrand , France.
FAU - Dargemont, Catherine
AU  - Dargemont C
AD  - ajn Paris Diderot University, Sorbonne Paris Cité, INSERM, CNRS , Paris , France.
FAU - Darley-Usmar, Victor M
AU  - Darley-Usmar VM
AD  - bcc University of Alabama at Birmingham , Department of Pathology , Center for 
      Free Radical Biology , Birmingham , AL , USA.
FAU - Dasarathy, Srinivasan
AU  - Dasarathy S
AD  - gw Cleveland Clinic , Cleveland , OH , USA.
FAU - Dasgupta, Biplab
AU  - Dasgupta B
AD  - gt Cincinnati Children's Hospital Medical Center, Division of Oncology , 
      Cincinnati , OH , USA.
FAU - Dash, Srikanta
AU  - Dash S
AD  - avf Tulane University Health Sciences Center , Department of Pathology and 
      Laboratory Medicine , New Orleans , LA , USA.
FAU - Dass, Crispin R
AU  - Dass CR
AD  - ih Curtin University, School of Pharmacy , Bentley , Australia.
FAU - Davey, Hazel Marie
AU  - Davey HM
AD  - h Alberystwyth University, Institute of Biological, Environmental and Rural 
      Sciences , Penglais , Aberystwyth , Wales , UK.
FAU - Davids, Lester M
AU  - Davids LM
AD  - bgz University of Cape Town, Redox Laboratory , Department of Human Biology , 
      Cape Town , South Africa.
FAU - Dávila, David
AU  - Dávila D
AD  - hs Complutense University, Instituto de Investigaciones Sanitarias San Carlos 
      (IdISSC) , Department of Biochemistry and Molecular Biology I , School of Biology 
      , Madrid , Spain.
FAU - Davis, Roger J
AU  - Davis RJ
AD  - bno University of Massachusetts, Medical School, Howard Hughes Medical Institute 
      , Worcester , MA , USA.
FAU - Dawson, Ted M
AU  - Dawson TM
AD  - wf Johns Hopkins University, School of Medicine , Departments of Neurology , 
      Neuroscience and Pharmacology and Molecular Sciences ; Neuroregeneration Program, 
      Institute for Cell Engineering , Baltimore , MD , USA.
FAU - Dawson, Valina L
AU  - Dawson VL
AD  - wh Johns Hopkins University, School of Medicine, Neuroregeneration and Stem Cell 
      Programs, Institute for Cell Engineering , Department of Neurology , Department 
      of Physiology , Baltimore , MD , USA.
FAU - Daza, Paula
AU  - Daza P
AD  - btz University of Sevilla , Department of Cell Biology , Sevilla , Spain.
FAU - de Belleroche, Jackie
AU  - de Belleroche J
AD  - rb Imperial College London, Neurogenetics Group, Division of Brain Sciences , 
      London , UK.
FAU - de Figueiredo, Paul
AU  - de Figueiredo P
AD  - asj Texas A&M University , Department of Microbial Pathogenesis and Immunology , 
      Texas A&M Health Science Center , Bryan , TX , USA.
AD  - asl Texas A&M University, The Norman Borlaug Center , College Station , TX , USA.
FAU - de Figueiredo, Regina Celia Bressan Queiroz
AU  - de Figueiredo RC
AD  - ee Centro de Pesquisas Aggeu Magalhães/FIOCRUZ-PE , Departamento de Microbiologia 
      , Recife , PE , Brazil.
FAU - de la Fuente, José
AU  - de la Fuente J
AD  - ami SaBio, Instituto de Investigación en Recursos Cinegéticos IREC-CSIC-UCLM-JCCM 
      , Ciudad Real , Spain.
FAU - De Martino, Luisa
AU  - De Martino L
AD  - bpg University of Naples Federico II , Department of Veterinary Medicine and 
      Animal Production , Naples , Italy.
FAU - De Matteis, Antonella
AU  - De Matteis A
AD  - asa Telethon Institute of Genetics and Medicine (TIGEM) , Pozzuoli, Naples , 
      Italy.
FAU - De Meyer, Guido Ry
AU  - De Meyer GR
AD  - bcm University of Antwerp, Laboratory of Physiopharmacology, Wilrijk , Antwerp , 
      Belgium.
FAU - De Milito, Angelo
AU  - De Milito A
AD  - xg Karolinska Institute, Cancer Center Karolinska , Department of 
      Oncology-Pathology , Stockholm , Sweden.
FAU - De Santi, Mauro
AU  - De Santi M
AD  - bxz University of Urbino "Carlo Bo" , Department of Biomolecular Sciences , 
      Urbino , Italy.
FAU - de Souza, Wanderley
AU  - de Souza W
AD  - all Rio de Janeiro Federal University, Instituto de Biofísica Carlos Chagas Filho 
      , Rio de Janeiro , Brazil.
FAU - De Tata, Vincenzo
AU  - De Tata V
AD  - brt University of Pisa , Department of Translational Research and New 
      Technologies in Medicine and Surgery , Pisa , Italy.
FAU - De Zio, Daniela
AU  - De Zio D
AD  - ir Danish Cancer Society Research Center, Cell Stress and Survival Unit , 
      Copenhagen , Denmark.
FAU - Debnath, Jayanta
AU  - Debnath J
AD  - bgi University of California San Francisco, School of Medicine , Department of 
      Pathology , San Francisco , CA , USA.
FAU - Dechant, Reinhard
AU  - Dechant R
AD  - kq ETH Zurich, Institute of Biochemistry , Zurich , Switzerland.
FAU - Decuypere, Jean-Paul
AU  - Decuypere JP
AD  - yk KU Leuven , Department of Abdominal Transplant Surgery , Leuven , Belgium.
AD  - bbh University Hospitals Leuven , Department of Microbiology and Immunology , 
      Laboratory of Abdominal Transplantation , Leuven , Belgium.
FAU - Deegan, Shane
AU  - Deegan S
AD  - agp National University of Ireland, Apoptosis Research Centre , Galway , Ireland.
FAU - Dehay, Benjamin
AU  - Dehay B
AD  - ayp Université de Bordeaux, Institut des Maladies Neurodégénératives, CNRS UMR 
      5293 , Bordeaux , France.
FAU - Del Bello, Barbara
AU  - Del Bello B
AD  - bud University of Siena , Department of Molecular and Developmental Medicine , 
      Siena , Italy.
FAU - Del Re, Dominic P
AU  - Del Re DP
AD  - amc Rutgers University, New Jersey Medical School , Department of Cell Biology 
      and Molecular Medicine , Newark , NJ , USA.
FAU - Delage-Mourroux, Régis
AU  - Delage-Mourroux R
AD  - ayr Université de Franche-Comté, UFR Sciences et Techniques EA3922/SFR IBCT FED 
      4234, Estrogènes, Expression Génique et Pathologies du Système Nerveux Central , 
      Besançon , France.
FAU - Delbridge, Lea Md
AU  - Delbridge LM
AD  - bns University of Melbourne , Department of Physiology , Parkville , Australia.
FAU - Deldicque, Louise
AU  - Deldicque L
AD  - ayk Université Catholique de Louvain (UCL), Institute of Neuroscience , 
      Louvain-la-Neuve , Belgium.
FAU - Delorme-Axford, Elizabeth
AU  - Delorme-Axford E
AD  - bog University of Michigan, Life Sciences Institute , Ann Arbor , MI , USA.
FAU - Deng, Yizhen
AU  - Deng Y
AD  - asb Temasek Life Sciences Laboratory , Singapore.
FAU - Dengjel, Joern
AU  - Dengjel J
AD  - bjr University of Freiburg , Department of Dermatology , Medical Center, Center 
      for Biological Systems Analysis (ZBSA) , Freiburg , Germany.
FAU - Denizot, Melanie
AU  - Denizot M
AD  - blt University of La Réunion, CYROI, IRG Immunopathology and Infection Research 
      Grouping , Reunion , France.
FAU - Dent, Paul
AU  - Dent P
AD  - bzw Virginia Commonwealth University , Department of Biochemistry and Molecular 
      Biology , Richmond , VA , USA.
FAU - Der, Channing J
AU  - Der CJ
AD  - bpz University of North Carolina, Lineberger Comprehensive Cancer Center , Chapel 
      Hill , NC , USA.
FAU - Deretic, Vojo
AU  - Deretic V
AD  - bpn University of New Mexico, Health Sciences Center , Department of Molecular 
      Genetics and Microbiology , Albuquerque , NM , USA.
FAU - Derrien, Benoît
AU  - Derrien B
AD  - kt ETH Zürich, LFW D 18.1 , Zürich , Switzerland.
FAU - Deutsch, Eric
AU  - Deutsch E
AD  - bad Université Paris-Sud, INSERM 1030, Gustave Roussy Cancer Campus , Paris , 
      France.
FAU - Devarenne, Timothy P
AU  - Devarenne TP
AD  - asi Texas A&M University , Department of Biochemistry and Biophysics , College 
      Station , TX , USA.
FAU - Devenish, Rodney J
AU  - Devenish RJ
AD  - acx Monash University, Clayton Campus , Department of Biochemistry and Molecular 
      Biology , Melbourne , Victoria , Australia.
FAU - Di Bartolomeo, Sabrina
AU  - Di Bartolomeo S
AD  - btd University of Rome "Tor Vergata" , Department of Biology , Rome , Italy.
FAU - Di Daniele, Nicola
AU  - Di Daniele N
AD  - btj University of Rome "Tor Vergata" , Department of System Medicine , Rome , 
      Italy.
FAU - Di Domenico, Fabio
AU  - Di Domenico F
AD  - amz Sapienza University of Rome , Department of Biochemical Sciences "A. Rossi 
      Fanelli" , Rome , Italy.
FAU - Di Nardo, Alessia
AU  - Di Nardo A
AD  - ew Children's Hospital , Department of Neurology , Boston , MA , USA.
FAU - Di Paola, Simone
AU  - Di Paola S
AD  - asa Telethon Institute of Genetics and Medicine (TIGEM) , Pozzuoli, Naples , 
      Italy.
FAU - Di Pietro, Antonio
AU  - Di Pietro A
AD  - awo Universidad de Córdoba, Campus de Excelencia Agroalimentario (ceiA3), 
      Departamento de Genética , Córdoba , Spain.
FAU - Di Renzo, Livia
AU  - Di Renzo L
AD  - anb Sapienza University of Rome , Department of Experimental Medicine , Rome , 
      Italy.
FAU - DiAntonio, Aaron
AU  - DiAntonio A
AD  - cbb Washington University, School of Medicine , Department of Developmental 
      Biology , St. Louis , MO , USA.
FAU - Díaz-Araya, Guillermo
AU  - Díaz-Araya G
AD  - awl Universidad de Chile, Facultad de Ciencias Químicas y Farmacéuticas , Santos 
      Dumont , Santiago de Chile.
FAU - Díaz-Laviada, Ines
AU  - Díaz-Laviada I
AD  - bcg University of Alcala , Department of System Biology , Biochemistry and 
      Molecular Biology Unit, School of Medicine , Madrid , Spain.
FAU - Diaz-Meco, Maria T
AU  - Diaz-Meco MT
AD  - amt Sanford Burnham Prebys Medical Discovery Institute , La Jolla , CA , USA.
FAU - Diaz-Nido, Javier
AU  - Diaz-Nido J
AD  - awa Universidad Autónoma de Madrid, Centro de Biología Molecular Severo Ochoa, 
      CIBERER , Madrid , Spain.
FAU - Dickey, Chad A
AU  - Dickey CA
AD  - bup University of South Florida, Byrd Alzheimer's Institute , Tampa , FL , USA.
FAU - Dickson, Robert C
AU  - Dickson RC
AD  - bln University of Kentucky , Department of Molecular and Cellular Biochemistry , 
      Lexington , KY , USA.
FAU - Diederich, Marc
AU  - Diederich M
AD  - anu Seoul National University , College of Pharmacy , Seoul , Korea.
FAU - Digard, Paul
AU  - Digard P
AD  - biz University of Edinburgh, Easter Bush, The Roslin Insitute , Midlothian , UK.
FAU - Dikic, Ivan
AU  - Dikic I
AD  - nq Goethe University School of Medicine, Institute of Biochemistry II and 
      Buchmann Institute for Molecular Life Sciences , Frankfurt am Main , Germany.
FAU - Dinesh-Kumar, Savithrama P
AU  - Dinesh-Kumar SP
AD  - bfc University of California Davis , Department of Plant Biology and the Genome 
      Center , College of Biological Sciences , Davis , CA , USA.
FAU - Ding, Chan
AU  - Ding C
AD  - aov Shanghai Veterinary Research Institute , Shanghai , China.
FAU - Ding, Wen-Xing
AU  - Ding WX
AD  - blj University of Kansas Medical Center , Department of Pharmacology , Toxicology 
      and Therapeutics , Kansas City , KS , USA.
FAU - Ding, Zufeng
AU  - Ding Z
AD  - bcr University of Arkansas for Medical Sciences , Department of Cardiology , 
      Little Rock , AR , USA.
FAU - Dini, Luciana
AU  - Dini L
AD  - btn University of Salento , Department of Biological and Environmental Science 
      and Technology , Lecce , Italy.
FAU - Distler, Jörg Hw
AU  - Distler JH
AD  - bjc University of Erlangen-Nuremberg , Department of Internal Medicine 3 , 
      Erlangen , Germany.
FAU - Diwan, Abhinav
AU  - Diwan A
AD  - cbg Washington University, School of Medicine, John Cochran VA Medical Center, 
      Center for Cardiovascular Research , St. Louis , MO , USA.
FAU - Djavaheri-Mergny, Mojgan
AU  - Djavaheri-Mergny M
AD  - ayo Université de Bordeaux, INSERM U916, Institut Bergonié , Bordeaux cedex , 
      France.
FAU - Dmytruk, Kostyantyn
AU  - Dmytruk K
AD  - aeb NAS of Ukraine , Department of Molecular Genetics and Biotechnology , 
      Institute of Cell Biology , Lviv , Ukraine.
FAU - Dobson, Renwick Cj
AU  - Dobson RC
AD  - bgx University of Canterbury, Biomolecular Interaction Centre, School of 
      Biological Sciences , Christchurch , New Zealand.
FAU - Doetsch, Volker
AU  - Doetsch V
AD  - np Goethe University of Frankfurt, Institute of Biophysical Chemistry , Frankfurt 
      am Main , Germany.
FAU - Dokladny, Karol
AU  - Dokladny K
AD  - bpl University of New Mexico , Department of Internal Medicine , Albuquerque , NM 
      , USA.
FAU - Dokudovskaya, Svetlana
AU  - Dokudovskaya S
AD  - bae Université Paris-Sud, Institut Gustave Roussy, CNRS UMR 8126 , Villejuif , 
      France.
FAU - Donadelli, Massimo
AU  - Donadelli M
AD  - byg University of Verona , Department of Neurological, Biomedical and Movement 
      Sciences , Verona , Italy.
FAU - Dong, X Charlie
AU  - Dong XC
AD  - rj Indiana University School of Medicine , Department of Biochemistry and 
      Molecular Biology , Indianapolis , IN , USA.
FAU - Dong, Xiaonan
AU  - Dong X
AD  - bvr University of Texas , Southwestern Medical Center, Department of Internal 
      Medicine , Center for Autophagy Research, Dallas , TX , USA.
FAU - Dong, Zheng
AU  - Dong Z
AD  - nf Georgia Regents University, Medical College of Georgia , Department of 
      Cellular Biology and Anatomy , Augusta , GA , USA.
FAU - Donohue, Terrence M Jr
AU  - Donohue TM Jr
AD  - bph University of Nebraska Medical Center , Department of Internal Medicine , 
      Omaha , NE , USA.
AD  - bzj VA Nebraska-Western Iowa Health Care System , Omaha , NE , USA.
FAU - Doran, Kelly S
AU  - Doran KS
AD  - amm San Diego State University , Department of Biology and Center for Microbial 
      Sciences , San Diego , CA , USA.
FAU - D'Orazi, Gabriella
AU  - D'Orazi G
AD  - bah University "G. dAnnunzio" , Department of Medical , Oral and Biotechnological 
      Sciences , Chieti , Italy.
FAU - Dorn, Gerald W 2nd
AU  - Dorn GW 2nd
AD  - cax Washington University in St. Louis, School of Medicine , Department of 
      Internal Medicine , St. Louis , MO , USA.
FAU - Dosenko, Victor
AU  - Dosenko V
AD  - by Bogomoletz Institute of Physiology, National Academy of Sciences Ukraine , 
      General and Molecular Pathophysiology Department , Kiev , Ukraine.
FAU - Dridi, Sami
AU  - Dridi S
AD  - bcu University of Arkansas, Center of Excellence for Poultry Science , 
      Fayetteville , AR , USA.
FAU - Drucker, Liat
AU  - Drucker L
AD  - arx Tel Aviv University, Oncogenetic Laboratory, Meir Medical Center, Kfar Saba 
      and Sackler Faculty of Medicine , Tel Aviv , Israel.
FAU - Du, Jie
AU  - Du J
AD  - bi Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of 
      Heart, Lung, and Blood Vessel Diseases , Beijing , China.
FAU - Du, Li-Lin
AU  - Du LL
AD  - afb National Institute of Biological Sciences , Beijing , China.
FAU - Du, Lihuan
AU  - Du L
AD  - me Fujian Provincial Hospital, Department of Urology , Fuzhou , China.
FAU - du Toit, André
AU  - du Toit A
AD  - aqr Stellenbosch University , Department of Physiological Sciences , Stellenbosch 
      , South Africa.
FAU - Dua, Priyamvada
AU  - Dua P
AD  - akw Queen Mary University of London, Blizard Institute , Department of 
      Neuroscience and Trauma , London , UK.
FAU - Duan, Lei
AU  - Duan L
AD  - alx Rush University Medical Center , Department of Anatomy and Cell Biology , 
      Chicago , IL , USA.
FAU - Duann, Pu
AU  - Duann P
AD  - aim Ohio State University, DHLRI , Department of Medicine , Columbus , OH , USA.
FAU - Dubey, Vikash Kumar
AU  - Dubey VK
AD  - rg Indian Institute of Technology Guwahati , Department of Biosciences and 
      Bioengineering , Guwahati , Assam , India.
FAU - Duchen, Michael R
AU  - Duchen MR
AD  - bas University College London, UCL Consortium for Mitochondrial Research and 
      Department of Cell and Developmental Biology , London , UK.
FAU - Duchosal, Michel A
AU  - Duchosal MA
AD  - bbd University Hospital of Lausanne, Service and Central Laboratory of Hematology 
      , Lausanne , Switzerland.
FAU - Duez, Helene
AU  - Duez H
AD  - bbk University Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011, EGID , 
      Lille , France.
FAU - Dugail, Isabelle
AU  - Dugail I
AD  - si INSERM UMRS 1166, Unité de Recherche sur les Maladies Cardiovasculaires, du 
      Métabolisme et de la Nutrition , Paris , France.
FAU - Dumit, Verónica I
AU  - Dumit VI
AD  - lu Freiburg University, Center for Biological Systems Analysis (ZBSA), Core 
      Facility Proteomics , Freiburg , Germany.
FAU - Duncan, Mara C
AU  - Duncan MC
AD  - bnz University of Michigan , Department of Cell and Developmental Biology , Ann 
      Arbor , MI , USA.
FAU - Dunlop, Elaine A
AU  - Dunlop EA
AD  - ct Cardiff University, Institute of Cancer and Genetics , Cardiff , Wales, UK.
FAU - Dunn, William A Jr
AU  - Dunn WA Jr
AD  - bji University of Florida, College of Medicine , Department of Anatomy and Cell 
      Biology , Gainesville , FL , USA.
FAU - Dupont, Nicolas
AU  - Dupont N
AD  - azw Université Paris Descartes-Sorbonne Paris Cité, Institut Necker 
      Enfants-Malades (INEM), INSERM U1151-CNRS UMR 8253 , Paris , France.
FAU - Dupuis, Luc
AU  - Dupuis L
AD  - ry INSERM U1118, Mécanismes Centraux et Périphétiques de la Neurodégénérescence , 
      Strasbourg , France.
AD  - azi Université de Strasbourg, Faculté de Médecine, UMRS 1118 , Strasbourg , 
      France.
FAU - Durán, Raúl V
AU  - Durán RV
AD  - se INSERM U916, Université de Bordeaux, Institut Européen de Chimie et Biologie , 
      Pessac , France.
FAU - Durcan, Thomas M
AU  - Durcan TM
AD  - abt McGill University, Montreal Neurological Institute , Montreal, QC , Canada.
FAU - Duvezin-Caubet, Stéphane
AU  - Duvezin-Caubet S
AD  - ayg Université Bordeaux, CNRS, Institut de Biochimie et Génétique Cellulaires, 
      UMR 5095 , Bordeaux , France.
FAU - Duvvuri, Umamaheswar
AU  - Duvvuri U
AD  - bzk VA Pittsburgh Health System, University of Pittsburgh Medical Center , 
      Pittsburgh , PA , USA.
FAU - Eapen, Vinay
AU  - Eapen V
AD  - cd Brandeis University , Department of Biology , Waltham , MA , USA.
FAU - Ebrahimi-Fakhari, Darius
AU  - Ebrahimi-Fakhari D
AD  - alw Ruprecht-Karls-University Heidelberg, Division of Pediatric Neurology , 
      Department of Pediatrics , Heidelberg University Hospital , Heidelberg , Germany.
FAU - Echard, Arnaud
AU  - Echard A
AD  - st Institut Pasteur, CNRS URA2582 , Cell Biology and Infection Department , 
      Membrane Traffic and Cell Division Lab , Paris , France.
FAU - Eckhart, Leopold
AU  - Eckhart L
AD  - acn Medical University of Vienna , Department of Dermatology , Vienna , Austria.
FAU - Edelstein, Charles L
AU  - Edelstein CL
AD  - bhy University of Colorado Denver , Boulder , CO , USA.
FAU - Edinger, Aimee L
AU  - Edinger AL
AD  - bfe University of California Irvine , Department of Developmental and Cell 
      Biology , Irvine , CA , USA.
FAU - Eichinger, Ludwig
AU  - Eichinger L
AD  - bhx University of Cologne, Medical Faculty, Center for Biochemistry , Cologne , 
      Germany.
FAU - Eisenberg, Tobias
AU  - Eisenberg T
AD  - bke University of Graz, Institute of Molecular Biosciences, BioTechMed Graz , 
      Graz , Austria.
FAU - Eisenberg-Lerner, Avital
AU  - Eisenberg-Lerner A
AD  - cbq Weizmann Institute of Science , Department of Chemical Biology , Rehovot , 
      Israel.
FAU - Eissa, N Tony
AU  - Eissa NT
AD  - bb Baylor College of Medicine , Department of Medicine , Houston , TX , USA.
FAU - El-Deiry, Wafik S
AU  - El-Deiry WS
AD  - ajz Laboratory of Translational Oncology and Experimental Cancer Therapeutics, 
      Department of Hematology/Oncology and Molecular Therapeutics Program, Fox Chase 
      Cancer Center, Philadelphia, PA, USA.
FAU - El-Khoury, Victoria
AU  - El-Khoury V
AD  - aaf Luxembourg Institute of Health, Department of Oncology, Luxembourg City , 
      Luxembourg.
FAU - Elazar, Zvulun
AU  - Elazar Z
AD  - cbp Weizmann Institute of Science , Department of Biological Chemistry , Rehovot 
      , Israel.
FAU - Eldar-Finkelman, Hagit
AU  - Eldar-Finkelman H
AD  - arv Tel Aviv University , Department of Human Molecular Genetics and Biochemistry 
      , Sackler School of Medicine , Tel Aviv , Israel.
FAU - Elliott, Chris Jh
AU  - Elliott CJ
AD  - byx University of York , Department of Biology , Heslington, York , UK.
FAU - Emanuele, Enzo
AU  - Emanuele E
AD  - brj University of Pavia , Department of Health Sciences , Pavia , Italy.
FAU - Emmenegger, Urban
AU  - Emmenegger U
AD  - bxf University of Toronto, Sunnybrook Research Institute, Sunnybrook Health 
      Sciences Centre , Toronto, Ontario , Canada.
FAU - Engedal, Nikolai
AU  - Engedal N
AD  - bqs University of Oslo, Oslo University Hospital, Centre for Molecular Medicine 
      Norway, Nordic EMBL Partnership , Oslo , Norway.
FAU - Engelbrecht, Anna-Mart
AU  - Engelbrecht AM
AD  - aqr Stellenbosch University , Department of Physiological Sciences , Stellenbosch 
      , South Africa.
FAU - Engelender, Simone
AU  - Engelender S
AD  - arp Technion-Israel Institute of Technology, The Rappaport Faculty of Medicine 
      and Research Institute , Department of Biochemistry , Haifa , Israel.
FAU - Enserink, Jorrit M
AU  - Enserink JM
AD  - ajf Oslo University Hospital, Institute for Microbiology , Oslo , Norway.
FAU - Erdmann, Ralf
AU  - Erdmann R
AD  - alu Ruhr University Bochum, Medical Faculty, System Biochemistry , Bochum , 
      Germany.
FAU - Erenpreisa, Jekaterina
AU  - Erenpreisa J
AD  - zk Latvian Biomedical Research and Study Centre , Riga , Latvia.
FAU - Eri, Rajaraman
AU  - Eri R
AD  - bvn University of Tasmania, School of Health Sciences , Launceston , Tasmania.
FAU - Eriksen, Jason L
AU  - Eriksen JL
AD  - bkp University of Houston, College of Pharmacy, Pharmacological and 
      Pharmaceutical Sciences , Houston , TX , USA.
FAU - Erman, Andreja
AU  - Erman A
AD  - bmi University of Ljubljana, Institute of Cell Biology, Faculty of Medicine , 
      Ljubljana , Slovenia.
FAU - Escalante, Ricardo
AU  - Escalante R
AD  - co C.S.I.C./U.A.M., Instituto de Investigaciones Biomédicas Alberto Sols , Madrid 
      , Spain.
FAU - Eskelinen, Eeva-Liisa
AU  - Eskelinen EL
AD  - bkj University of Helsinki , Department of Biosciences , Helsinki , Finland.
FAU - Espert, Lucile
AU  - Espert L
AD  - hb CNRS UM, Centre d'études d'agents Pathogènes et Biotechnologies pour la Santé 
      , Montpellier , France.
FAU - Esteban-Martínez, Lorena
AU  - Esteban-Martínez L
AD  - ec Centro de Investigaciones Biológicas (CSIC) , Department of Cellular and 
      Molecular Biology , Madrid , Spain.
FAU - Evans, Thomas J
AU  - Evans TJ
AD  - bka University of Glasgow, Institute of Infection, Immunity and Inflammation , 
      Glasgow , UK.
FAU - Fabri, Mario
AU  - Fabri M
AD  - bhu University of Cologne , Department of Dermatology , Cologne , Germany.
FAU - Fabrias, Gemma
AU  - Fabrias G
AD  - apx Spanish Council for Scientific Research, Institute for Advanced Chemistry of 
      Catalonia , Department of Biomedicinal Chemistry , Barcelona , Spain.
FAU - Fabrizi, Cinzia
AU  - Fabrizi C
AD  - amy Sapienza University of Rome , DAHFMO-Section of Anatomy , Rome , Italy.
FAU - Facchiano, Antonio
AU  - Facchiano A
AD  - um IRCCS, Istituto Dermopatico dell'Immacolata , Rome , Italy.
FAU - Færgeman, Nils J
AU  - Færgeman NJ
AD  - bvc University of Southern Denmark, Villum Center for Bioanalytical Sciences , 
      Department of Biochemistry and Molecular Biology , Odense , Denmark.
FAU - Faggioni, Alberto
AU  - Faggioni A
AD  - anb Sapienza University of Rome , Department of Experimental Medicine , Rome , 
      Italy.
FAU - Fairlie, W Douglas
AU  - Fairlie WD
AD  - zc Olivia Newton-John Cancer Research Institute , Melbourne , Victoria , 
      Australia.
AD  - ze La Trobe University , Department of Chemistry and Physics , Melbourne , 
      Victoria , Australia.
AD  - zf La Trobe University, School of Cancer Medicine , Melbourne , Victoria , 
      Australia.
FAU - Fan, Chunhai
AU  - Fan C
AD  - fk Chinese Academy of Sciences, Division of Physical Biology and Bioimaging 
      Center, Shanghai Synchrotron Radiation Facility, Shanghai Institute of Applied 
      Physics , Shanghai , China.
FAU - Fan, Daping
AU  - Fan D
AD  - bui University of South Carolina School of Medicine , Department of Cell Biology 
      and Anatomy , Columbia , SC , USA.
FAU - Fan, Jie
AU  - Fan J
AD  - bsc University of Pittsburgh , Department of Surgery , Pittsburgh , PA , USA.
FAU - Fang, Shengyun
AU  - Fang S
AD  - bne University of Maryland, School of Medicine, Center for Biomedical Engineering 
      and Technology , Department of Physiology , Baltimore , MD , USA.
FAU - Fanto, Manolis
AU  - Fanto M
AD  - xu King's College London , Department of Basic and Clinical Neuroscience , IoPPN 
      , London , UK.
FAU - Fanzani, Alessandro
AU  - Fanzani A
AD  - bdz University of Brescia , Department of Molecular and Translational Medicine , 
      Brescia , Italy.
FAU - Farkas, Thomas
AU  - Farkas T
AD  - iq Danish Cancer Society Research Center, Cell Death and Metabolism Unit, Center 
      for Autophagy, Recycling and Disease , Copenhagen , Denmark.
FAU - Faure, Mathias
AU  - Faure M
AD  - ayw Université de Lyon, INSERM, U 1111, Centre International de Recherche en 
      Infectiologie (CIRI), Ecole Normale Supérieure de Lyon, CNRS, UMR 5308 , Lyon , 
      France.
FAU - Favier, Francois B
AU  - Favier FB
AD  - rs INRA, UMR866 Dynamique Musculaire et Métabolisme , Montpellier , France.
AD  - aza Université de Montpellier , Montpellier , France.
FAU - Fearnhead, Howard
AU  - Fearnhead H
AD  - agq National University of Ireland, Pharmacology and Therapeutics , Galway , 
      Ireland.
FAU - Federici, Massimo
AU  - Federici M
AD  - btk University of Rome "Tor Vergata" , Department of Systems Medicine , Rome , 
      Italy.
FAU - Fei, Erkang
AU  - Fei E
AD  - ads Nanchang University, Institute of Life Science , Nanchang , China.
FAU - Felizardo, Tania C
AU  - Felizardo TC
AD  - afl National Institutes of Health, Experimental Transplantation and Immunology 
      Branch, National Cancer Institute , Bethesda , MD , USA.
FAU - Feng, Hua
AU  - Feng H
AD  - atl Third Military Medical University , Department of Neurosurgery , Southwest 
      Hospital , Shapingba District, Chongqing , China.
FAU - Feng, Yibin
AU  - Feng Y
AD  - bkn University of Hong Kong , Hong Kong , China.
FAU - Feng, Yuchen
AU  - Feng Y
AD  - boc University of Michigan , Department of Molecular , Cellular, and 
      Developmental Biology , Ann Arbor , MI , USA.
AD  - bog University of Michigan, Life Sciences Institute , Ann Arbor , MI , USA.
FAU - Ferguson, Thomas A
AU  - Ferguson TA
AD  - cay Washington University in St. Louis, School of Medicine , Department of 
      Ophthalmology and Visual Sciences , St. Louis , MO , USA.
FAU - Fernández, Álvaro F
AU  - Fernández ÁF
AD  - awu Universidad de Oviedo, Instituto Universitario de Oncología , Departamento de 
      Bioquímica y Biología Molecular , Oviedo , Spain.
FAU - Fernandez-Barrena, Maite G
AU  - Fernandez-Barrena MG
AD  - aws Universidad de Navarra, Centro de Investigacion Medica Aplicada , Pamplona , 
      Spain.
FAU - Fernandez-Checa, Jose C
AU  - Fernandez-Checa JC
AD  - tr Instituto de Investigaciones Biomedicas de Barcelona, CSIC-IDIBAPS and Centro 
      de Investigacion en Red en enfermedades hepáticas y digestivas, CIBEREHD, ISCIII 
      , Barcelona , Spain.
AD  - bva University of Southern California, Research ALPD and Cirrhosis Center, Keck 
      School of Medicine , Los Angeles , CA , USA.
FAU - Fernández-López, Arsenio
AU  - Fernández-López A
AD  - awr Universidad de León, Área de Biología Celular, Instituto de Biomedicina , 
      León , Spain.
FAU - Fernandez-Zapico, Martin E
AU  - Fernandez-Zapico ME
AD  - abh Mayo Clinic, Schulze Center for Novel Therapeutics, Division of Oncology 
      Research , Department of Oncology , Rochester , MN , USA.
FAU - Feron, Olivier
AU  - Feron O
AD  - ayi Université Catholique de Louvain (UCL), Institut de Recherche Expérimentale 
      et Clinique (IREC) , Brussels , Belgium.
FAU - Ferraro, Elisabetta
AU  - Ferraro E
AD  - uh IRCCS San Raffaele Pisana, Laboratory of Skeletal Muscle Development and 
      Metabolism , Rome , Italy.
FAU - Ferreira-Halder, Carmen Veríssima
AU  - Ferreira-Halder CV
AD  - bgw University of Campinas , Department of Biochemistry and Tissue Biology , 
      Campinas, São Paulo , Brazil.
FAU - Fesus, Laszlo
AU  - Fesus L
AD  - biq University of Debrecen , Debrecen , Hungary.
FAU - Feuer, Ralph
AU  - Feuer R
AD  - amn San Diego State University , Department of Biology , San Diego , CA , USA.
FAU - Fiesel, Fabienne C
AU  - Fiesel FC
AD  - abe Mayo Clinic , Department of Neuroscience , Jacksonville , FL , USA.
FAU - Filippi-Chiela, Eduardo C
AU  - Filippi-Chiela EC
AD  - axc Universidad Federal do Rio Grande do Sul (UFRGS) , Department of Biophysics 
      and Center of Biotechnology , Porto Alegre , Brazil.
FAU - Filomeni, Giuseppe
AU  - Filomeni G
AD  - ir Danish Cancer Society Research Center, Cell Stress and Survival Unit , 
      Copenhagen , Denmark.
AD  - btd University of Rome "Tor Vergata" , Department of Biology , Rome , Italy.
FAU - Fimia, Gian Maria
AU  - Fimia GM
AD  - aez National Institute for Infectious Diseases "L. Spallanzani" IRCCS , Rome , 
      Italy.
AD  - bto University of Salento , Department of Biological and Environmental Sciences 
      and Technologies (DiSTeBA) , Lecce , Italy.
FAU - Fingert, John H
AU  - Fingert JH
AD  - aqs Stephen A. Wynn Institute for Vision Research , Iowa City , IA , USA.
AD  - blg University of Iowa , Department of Ophthalmology and Visual Sciences , Iowa 
      City , IA , USA.
FAU - Finkbeiner, Steven
AU  - Finkbeiner S
AD  - bgh University of California San Francisco, Departments of Neurology and 
      Physiology ; Gladstone Institute of Neurological Disease , San Francisco , CA , 
      USA.
FAU - Finkel, Toren
AU  - Finkel T
AD  - afp National Institutes of Health, National Heart, Lung, and Blood Institute , 
      Bethesda , MD , USA.
FAU - Fiorito, Filomena
AU  - Fiorito F
AD  - ss Istituto Zooprofilattico Sperimentale del Mezzogiorno, Department of 
      Chemistry, Portici (Naples), Italy.
AD  - bpg University of Naples Federico II , Department of Veterinary Medicine and 
      Animal Production , Naples , Italy.
FAU - Fisher, Paul B
AU  - Fisher PB
AD  - cab Virginia Commonwealth University, Institute of Molecular Medicine, Massey 
      Cancer Center, Virginia Commonwealth University, School of Medicine , Department 
      of Human and Molecular Genetics , Richmond , VA , USA.
FAU - Flajolet, Marc
AU  - Flajolet M
AD  - aln Rockefeller University , New York , NY , USA.
FAU - Flamigni, Flavio
AU  - Flamigni F
AD  - bdv University of Bologna , Dipartimento di Scienze Biomediche e Neuromotorie , 
      Bologna , Italy.
FAU - Florey, Oliver
AU  - Florey O
AD  - az Babraham Institute, Signalling Program , Cambridge , UK.
FAU - Florio, Salvatore
AU  - Florio S
AD  - bpg University of Naples Federico II , Department of Veterinary Medicine and 
      Animal Production , Naples , Italy.
FAU - Floto, R Andres
AU  - Floto RA
AD  - bgn University of Cambridge, Cambridge Institute for Medical Research , Cambridge 
      , UK.
FAU - Folini, Marco
AU  - Folini M
AD  - ll Fondazione IRCCS Istituto Nazionale dei Tumori , Department of Experimental 
      Oncology and Molecular Medicine , Milan , Italy.
FAU - Follo, Carlo
AU  - Follo C
AD  - axs Università del Piemonte Orientale "A. Avogadro" , Dipartimento di Scienze 
      della Salute , Novara , Italy.
FAU - Fon, Edward A
AU  - Fon EA
AD  - abs McGill University, McGill Parkinson Program , Department of Neurology and 
      Neurosurgery , Montreal, QC , Canada.
FAU - Fornai, Francesco
AU  - Fornai F
AD  - ug IRCCS Neuromed , Pozzilli, IS , Italy.
AD  - brt University of Pisa , Department of Translational Research and New 
      Technologies in Medicine and Surgery , Pisa , Italy.
FAU - Fortunato, Franco
AU  - Fortunato F
AD  - bal University Clinic Heidelberg , Department of Experimental Surgery , 
      Heidelberg , Germany.
FAU - Fraldi, Alessandro
AU  - Fraldi A
AD  - asa Telethon Institute of Genetics and Medicine (TIGEM) , Pozzuoli, Naples , 
      Italy.
FAU - Franco, Rodrigo
AU  - Franco R
AD  - bpj University of Nebraska-Lincoln, Redox Biology Center and School of Veterinary 
      Medicine and Biomedical Sciences , Lincoln , NE , USA.
FAU - Francois, Arnaud
AU  - Francois A
AD  - do Centre de Recherche du CHU de Québec, Faculty of Pharmacy , Québec , Canada.
AD  - azm Université Laval, Neurosciences Axis , Québec , Canada.
FAU - François, Aurélie
AU  - François A
AD  - sq Institut de Cancérologie de Lorraine , Vandoeuvre-Lès-Nancy Cedex , France.
FAU - Frankel, Lisa B
AU  - Frankel LB
AD  - bij University of Copenhagen, Biotech Research and Innovative Center (BRIC) , 
      Copenhagen , Denmark.
FAU - Fraser, Iain Dc
AU  - Fraser ID
AD  - aft National Institutes of Health, NIAID, Laboratory of Systems Biology , 
      Bethesda , MD , USA.
FAU - Frey, Norbert
AU  - Frey N
AD  - blq University of Kiel , Department of Cardiology , Kiel , Germany.
FAU - Freyssenet, Damien G
AU  - Freyssenet DG
AD  - ayv Université de Lyon, Faculty of Medicine , Saint Etienne , France.
FAU - Frezza, Christian
AU  - Frezza C
AD  - adh MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre , 
      Cambridge , UK.
FAU - Friedman, Scott L
AU  - Friedman SL
AD  - adg Icahn School of Medicine at Mount Sinai, Division of Liver Diseases , New 
      York , NY , USA.
FAU - Frigo, Daniel E
AU  - Frigo DE
AD  - qf Houston Methodist Research Institute, Genomic Medicine Program , Houston , TX 
      , USA.
AD  - bkq University of Houston , Department of Biology and Biochemistry , Center for 
      Nuclear Receptors and Cell Signaling , Houston , TX , USA.
FAU - Fu, Dongxu
AU  - Fu D
AD  - ala Queen's University of Belfast, Centre for Experimental Medicine , Belfast , 
      UK.
FAU - Fuentes, José M
AU  - Fuentes JM
AD  - awq Universidad de Extremadura, Centro de Investigación Biomédica en Red sobre 
      Enfermedades Neurodegenerativas (CIBERNED) , Departamento de Bioquímica y 
      Biología Molecular y Genética , Facultad de Enfermería y Terapia Ocupacional , 
      Cáceres , Spain.
FAU - Fueyo, Juan
AU  - Fueyo J
AD  - bwd University of Texas, MD Anderson Cancer Center , Department of Neuro-Oncology 
      , Houston , TX , USA.
FAU - Fujitani, Yoshio
AU  - Fujitani Y
AD  - wn Juntendo University, Graduate School of Medicine , Department of Metabolism 
      and Endocrinology , Tokyo , Japan.
FAU - Fujiwara, Yuuki
AU  - Fujiwara Y
AD  - afe National Institute of Neuroscience, National Center of Neurology and 
      Psychiatry , Department of Degenerative Neurological Diseases , Tokyo , Japan.
FAU - Fujiya, Mikihiro
AU  - Fujiya M
AD  - as Asahikawa Medical University, Division of Gastroenterology and 
      Hematology/Oncology , Department of Medicine , Hokkaido , Japan.
FAU - Fukuda, Mitsunori
AU  - Fukuda M
AD  - aty Tohoku University , Department of Developmental Biology and Neurosciences , 
      Graduate School of Life Sciences, Sendai , Miyagi , Japan.
FAU - Fulda, Simone
AU  - Fulda S
AD  - ns Goethe University, Institute for Experimental Cancer Research in Pediatrics , 
      Frankfurt , Germany.
FAU - Fusco, Carmela
AU  - Fusco C
AD  - uf IRCCS Casa Sollievo della Sofferenza, Medical Genetics Unit , San Giovanni 
      Rotondo (FG) , Italy.
FAU - Gabryel, Bozena
AU  - Gabryel B
AD  - acg Medical University of Silesia , Department of Pharmacology , Katowice , 
      Poland.
FAU - Gaestel, Matthias
AU  - Gaestel M
AD  - oq Hannover Medical School , Department of Biochemistry , Hannover , Germany.
FAU - Gailly, Philippe
AU  - Gailly P
AD  - ayl Université Catholique de Louvain (UCL), Laboratory of Cell Physiology , 
      Brussels , Belgium.
FAU - Gajewska, Malgorzata
AU  - Gajewska M
AD  - cau Warsaw University of Life Sciences (SGGW) , Department of Physiological 
      Sciences , Faculty of Veterinary Medicine , Warsaw , Poland.
FAU - Galadari, Sehamuddin
AU  - Galadari S
AD  - u Al Jalila Foundation Research Centre , Dubai , UAE.
AD  - avi UAE University, Cell Signaling Laboratory , Department of Biochemistry , 
      College of Medicine and Health Sciences , Al Ain, Abu Dhabi , UAE.
FAU - Galili, Gad
AU  - Galili G
AD  - ath The Weizmann Institute of Science , Department of Plant Sciences , Rehovot , 
      Israel.
FAU - Galindo, Inmaculada
AU  - Galindo I
AD  - tx Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA) 
      , Departamento de Biotecnología , Madrid , Spain.
FAU - Galindo, Maria F
AU  - Galindo MF
AD  - hr Complejo Hospitalario Universitario de Albacete, Unidad de 
      Neuropsicofarmacología , Albacete , Spain.
FAU - Galliciotti, Giovanna
AU  - Galliciotti G
AD  - bbn University Medical Center Hamburg-Eppendorf, Institute of Neuropathology , 
      Hamburg , Germany.
FAU - Galluzzi, Lorenzo
AU  - Galluzzi L
AD  - km Centre de Recherche des Cordeliers, Equipe 11 labellisée par la Ligue 
      Nationale contre le Cancer , Paris , France.
AD  - oc Gustave Roussy Cancer Campus , Villejuif , France.
AD  - sn INSERM, U1138 , Paris , France.
AD  - azv Université Paris Descartes/Paris V , Paris , France.
FAU - Galluzzi, Luca
AU  - Galluzzi L
AD  - bxz University of Urbino "Carlo Bo" , Department of Biomolecular Sciences , 
      Urbino , Italy.
FAU - Galy, Vincent
AU  - Galy V
AD  - app Sorbonne Universités, CNRS, UPMC, Univ Paris 06, UMR 7622, IBPS , Paris , 
      France.
FAU - Gammoh, Noor
AU  - Gammoh N
AD  - bja University of Edinburgh, Edinburgh Cancer Research Centre , Edinburgh , UK.
FAU - Gandy, Sam
AU  - Gandy S
AD  - qr Icahn School of Medicine at Mount Sinai , Departments of Neurology and 
      Psychiatry , Center for Cognitive Health, Mount Sinai Alzheimer's Disease 
      Research Center , New York , NY , USA.
AD  - vj James J. Peters VA Medical Center , Bronx , NY , USA.
FAU - Ganesan, Anand K
AU  - Ganesan AK
AD  - bfh University of California Irvine , Irvine , CA , USA.
FAU - Ganesan, Swamynathan
AU  - Ganesan S
AD  - bbx University of Adelaide, Alzheimer's Disease Genetics Laboratory , Adelaide , 
      Australia.
FAU - Ganley, Ian G
AU  - Ganley IG
AD  - biv University of Dundee, MRC Protein Phosphorylation and Ubiquitylation Unit, 
      School of Life Sciences , Dundee , UK.
FAU - Gannagé, Monique
AU  - Gannagé M
AD  - bjv University of Geneva, School of Medicine , Department of Pathology and 
      Immunology , Geneva , Switzerland.
FAU - Gao, Fen-Biao
AU  - Gao FB
AD  - bnn University of Massachusetts, Medical School , Department of Neurology , 
      Worcester , MA , USA.
FAU - Gao, Feng
AU  - Gao F
AD  - ass The Fourth Military Medical University, School of Basic Medical Sciences , 
      Department of Physiology , Xi'an , China.
FAU - Gao, Jian-Xin
AU  - Gao JX
AD  - aoq Shanghai Jiao Tong University, State Key Laboratory of Oncogenes and Related 
      Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of 
      Medicine , Shanghai , China.
FAU - García Nannig, Lorena
AU  - García Nannig L
AD  - bhf University of Chile, Advanced Center for Chronic Diseases (ACCDiS), Division 
      of Cardiovascular Diseases, Faculty of Medicine , Santiago , Chile.
FAU - García Véscovi, Eleonora
AU  - García Véscovi E
AD  - tn Instituto de Biología Molecular y Celular de Rosario (IBR-CONICET) , Rosario , 
      Argentina.
FAU - Garcia-Macía, Marina
AU  - Garcia-Macía M
AD  - ae Albert Einstein College of Medicine, Departments of Medicine (Endocrinology) 
      and Molecular Pharmacology , Bronx , NY , USA.
FAU - Garcia-Ruiz, Carmen
AU  - Garcia-Ruiz C
AD  - tv Instituto de Investigaciones Biomédicas de Barcelona IIBB-CSIC , Liver Unit, 
      Hospital Clinic de Barcelona-IDIBAPS and CIBEREHD, Barcelona , Spain.
FAU - Garg, Abhishek D
AU  - Garg AD
AD  - bmb University of Leuven, Campus Gasthuisberg , Department of Cellular and 
      Molecular Medicine , Laboratory for Cell Death Research and Therapy , Leuven , 
      Belgium.
FAU - Garg, Pramod Kumar
AU  - Garg PK
AD  - ak All India Institute of Medical Sciences , Department of Gastroenterology , New 
      Delhi , India.
FAU - Gargini, Ricardo
AU  - Gargini R
AD  - awb Universidad Autónoma de Madrid, Centro Nacional de Biotecnología (CNB-CSIC), 
      Centro de Biología Molecular Severo Ochoa, Departamento de Biología Molecular , 
      Madrid , Spain.
FAU - Gassen, Nils Christian
AU  - Gassen NC
AD  - abc Max Planck Institute of Psychiatry, Translational Research in Psychiatry , 
      Munich , Germany.
FAU - Gatica, Damián
AU  - Gatica D
AD  - boc University of Michigan , Department of Molecular , Cellular, and 
      Developmental Biology , Ann Arbor , MI , USA.
AD  - bog University of Michigan, Life Sciences Institute , Ann Arbor , MI , USA.
FAU - Gatti, Evelina
AU  - Gatti E
AD  - p Aix-Marseille Université, U2M, Centre d'Immunologie de Marseille-Luminy , 
      Marseille , France.
AD  - hd CNRS, UMR 7280 , Marseille , France.
AD  - sl INSERM, U1104 , Marseille , France.
FAU - Gavard, Julie
AU  - Gavard J
AD  - dq Centre de Recherche en Cancérologie de Nantes-Angers, CNRS UMR6299, INSERM 
      U892 , Nantes , France.
FAU - Gavathiotis, Evripidis
AU  - Gavathiotis E
AD  - ad Albert Einstein College of Medicine, Departments of Biochemistry and of 
      Medicine , Bronx , NY , USA.
FAU - Ge, Liang
AU  - Ge L
AD  - bex University of California Berkeley, Howard Hughes Medical Institute , 
      Department of Molecular and Cell Biology , Berkeley , CA , USA.
FAU - Ge, Pengfei
AU  - Ge P
AD  - lf First Hospital of Jilin University , Department of Neurosurgery , Changchun , 
      China.
FAU - Ge, Shengfang
AU  - Ge S
AD  - aoj Shanghai Jiao Tong University, School of Medicine , Department of 
      Biochemistry and Molecular Biology , Shanghai , China.
FAU - Gean, Po-Wu
AU  - Gean PW
AD  - aem National Cheng Kung University , Department of Pharmacology , Tainan , 
      Taiwan.
FAU - Gelmetti, Vania
AU  - Gelmetti V
AD  - if CSS-Mendel Institute, Neurogenetics Unit , Rome , Italy.
FAU - Genazzani, Armando A
AU  - Genazzani AA
AD  - axt Università del Piemonte Orientale , Novara , Italy.
FAU - Geng, Jiefei
AU  - Geng J
AD  - ox Harvard Medical School , Boston , MA , USA.
FAU - Genschik, Pascal
AU  - Genschik P
AD  - du Centre National de la Recherche Scientifique, Institut de Biologie Moléculaire 
      des Plantes, Unité Propre de Recherche , Strasbourg , France.
FAU - Gerner, Lisa
AU  - Gerner L
AD  - bqs University of Oslo, Oslo University Hospital, Centre for Molecular Medicine 
      Norway, Nordic EMBL Partnership , Oslo , Norway.
FAU - Gestwicki, Jason E
AU  - Gestwicki JE
AD  - bgf University of California San Francisco , Department of Pharmaceutical 
      Chemistry , San Francisco , CA , USA.
FAU - Gewirtz, David A
AU  - Gewirtz DA
AD  - caf Virginia Commonwealth University, Massey Cancer Center , Richmond , VA , USA.
FAU - Ghavami, Saeid
AU  - Ghavami S
AD  - bmz University of Manitoba , Department of Human Anatomy and Cell Science , 
      Winnipeg, Manitoba , Canada.
FAU - Ghigo, Eric
AU  - Ghigo E
AD  - o Aix-Marseille Université, CNRS UMR 7278, IRD198, INSERM U1095, Medicine Faculty 
      , Marseille , France.
FAU - Ghosh, Debabrata
AU  - Ghosh D
AD  - al All India Institute of Medical Sciences , Department of Physiology , New Delhi 
      , India.
FAU - Giammarioli, Anna Maria
AU  - Giammarioli AM
AD  - vd Istituto Superiore di Sanità , Rome , Italy.
AD  - amp San Raffaele Institute, Dept. of Therapeutic Research and Medicine Evaluation 
      , Sulmona, L'Aquila , Italy.
FAU - Giampieri, Francesca
AU  - Giampieri F
AD  - akh Polytechnic University of Marche , Department of Clinical Science , Faculty 
      of Medicine , Ancona , Italy.
FAU - Giampietri, Claudia
AU  - Giampietri C
AD  - amx Sapienza University of Rome, DAHFMO-Section of Histology , Rome , Italy.
FAU - Giatromanolaki, Alexandra
AU  - Giatromanolaki A
AD  - iv Democritus University of Thrace , Department of Pathology , Alexandroupolis , 
      Greece.
FAU - Gibbings, Derrick J
AU  - Gibbings DJ
AD  - bqw University of Ottawa , Department of Cellular and Molecular Medicine , 
      Ottawa, Ontario , Canada.
FAU - Gibellini, Lara
AU  - Gibellini L
AD  - box University of Modena and Reggio Emilia , Department of Surgery , Medicine, 
      Dentistry and Morphological Sciences , Modena , Italy.
FAU - Gibson, Spencer B
AU  - Gibson SB
AD  - bmy University of Manitoba, CancerCare Manitoba, Manitoba Institute of Cell 
      Biology , Departments of Biochemistry and Medical Genetics and Immunology , 
      Winnipeg, Manitoba , Canada.
FAU - Ginet, Vanessa
AU  - Ginet V
AD  - blw University of Lausanne , Department of Fundamental Neurosciences , Faculty of 
      Biology and Medicine , Lausanne , Switzerland.
FAU - Giordano, Antonio
AU  - Giordano A
AD  - asc Temple University, Sbarro Institute for Cancer Research and Molecular 
      Medicine, Center for Biotechnology, College of Science and Technology , 
      Philadelphia , PA , USA.
AD  - btb University of Siena, Department of Medicine, Surgery & Neuroscience, Siena, 
      Italy.
FAU - Giorgini, Flaviano
AU  - Giorgini F
AD  - bma University of Leicester , Department of Genetics , Leicester , UK.
FAU - Giovannetti, Elisa
AU  - Giovannetti E
AD  - ux Cancer Pharmacology Lab, AIRC Start-Up Unit, University of Pisa , Pisa , 
      Italy.
AD  - cak VU University Medical Center , Department of Medical Oncology , Amsterdam , 
      The Netherlands.
FAU - Girardin, Stephen E
AU  - Girardin SE
AD  - bxa University of Toronto , Department of Laboratory Medicine and Pathobiology , 
      Toronto, Ontario , Canada.
FAU - Gispert, Suzana
AU  - Gispert S
AD  - no Goethe University Medical School, Experimental Neurology , Frankfurt am Main , 
      Germany.
FAU - Giuliano, Sandy
AU  - Giuliano S
AD  - rw Centre Scientifique de Monaco, Biomedical Department, Monaco, Principality of 
      Monaco.
AD  - rx University of Nice Sophia Antipolis, Institute of Research on Cancer and 
      Ageing of Nice, CNRS UMR 7284/INSERM U1081 , Nice , France.
FAU - Gladson, Candece L
AU  - Gladson CL
AD  - gx Cleveland Clinic , Department of Cancer Biology , Cleveland , OH , USA.
FAU - Glavic, Alvaro
AU  - Glavic A
AD  - awm Universidad de Chile, Facultad de Ciencias , Departamento de Biología , 
      Centro de Regulación del Genoma , Santiago , Chile.
FAU - Gleave, Martin
AU  - Gleave M
AD  - bej University of British Columbia , Department of Urological Sciences , 
      Vancouver, BC , Canada.
FAU - Godefroy, Nelly
AU  - Godefroy N
AD  - bpb University of Montpellier, UMR 5554 , Montpellier , France.
FAU - Gogal, Robert M Jr
AU  - Gogal RM Jr
AD  - bjw University of Georgia, College of Veterinary Medicine , Department of 
      Biosciences and Diagnostic Imaging , Athens , GA , USA.
FAU - Gokulan, Kuppan
AU  - Gokulan K
AD  - bzh US Food and Drug Administration, National Center for Toxicology Research, 
      Division of Microbiology , Jefferson , AR , USA.
FAU - Goldman, Gustavo H
AU  - Goldman GH
AD  - axi Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São 
      Paulo (FCFRP, USP) , São Paulo , Brazil.
FAU - Goletti, Delia
AU  - Goletti D
AD  - afa National Institute for Infectious Diseases , Department of Epidemiology and 
      Preclinical Research , Translational Research Unit , Rome , Italy.
FAU - Goligorsky, Michael S
AU  - Goligorsky MS
AD  - ahi New York Medical College , Department of Medicine, Pharmacology, and 
      Physiology , Valhalla , NY , USA.
FAU - Gomes, Aldrin V
AU  - Gomes AV
AD  - bfb University of California Davis , Department of Neurobiology , Physiology, and 
      Behavior , Davis , CA , USA.
FAU - Gomes, Ligia C
AU  - Gomes LC
AD  - it Danish Cancer Society Research Center, Unit of Cell Stress and Survival , 
      Copenhagen , Denmark.
FAU - Gomez, Hernando
AU  - Gomez H
AD  - bry University of Pittsburgh , Department of Critical Care Medicine , Center for 
      Critical Care Nephrology, Clinical Research Investigation and Systems Modeling of 
      Acute Illness (CRISMA) Center , Pittsburgh , PA , USA.
FAU - Gomez-Manzano, Candelaria
AU  - Gomez-Manzano C
AD  - bwd University of Texas, MD Anderson Cancer Center , Department of Neuro-Oncology 
      , Houston , TX , USA.
FAU - Gómez-Sánchez, Rubén
AU  - Gómez-Sánchez R
AD  - awq Universidad de Extremadura, Centro de Investigación Biomédica en Red sobre 
      Enfermedades Neurodegenerativas (CIBERNED) , Departamento de Bioquímica y 
      Biología Molecular y Genética , Facultad de Enfermería y Terapia Ocupacional , 
      Cáceres , Spain.
FAU - Gonçalves, Dawit Ap
AU  - Gonçalves DA
AD  - bts University of São Paulo, Ribeirão Preto Medical School , Department of 
      Biochemistry and Immunology , Ribeirão Preto, São Paulo , Brazil.
FAU - Goncu, Ebru
AU  - Goncu E
AD  - jx Ege University, Faculty of Science , Department of Biology , Bornova , Izmir , 
      Turkey.
FAU - Gong, Qingqiu
AU  - Gong Q
AD  - ady Nankai University, College of Life Sciences , Tianjin , China.
FAU - Gongora, Céline
AU  - Gongora C
AD  - ur IRCM, INSERM, U896, Institut de Recherche en Cancérologie de Montpellier , 
      Montpellier , France.
FAU - Gonzalez, Carlos B
AU  - Gonzalez CB
AD  - avz Universidad Austral de Chile , Department of Physiology , Valdivia , Chile.
FAU - Gonzalez-Alegre, Pedro
AU  - Gonzalez-Alegre P
AD  - brm University of Pennsylvania, Center for Cell and Molecular Therapy, The 
      Children Hospital of Philadelphia , Department of Neurology , Perelman School of 
      Medicine , Philadelphia , PA , USA.
FAU - Gonzalez-Cabo, Pilar
AU  - Gonzalez-Cabo P
AD  - go CIBER de Enfermedades Raras (CIBERER) , Valencia , Spain.
AD  - akm Program in Rare and Genetic Diseases, Centro de Investigación Príncipe Felipe 
      (CIPF), IBV/CSIC Associated Unit at CIPF , Valencia , Spain.
FAU - González-Polo, Rosa Ana
AU  - González-Polo RA
AD  - awq Universidad de Extremadura, Centro de Investigación Biomédica en Red sobre 
      Enfermedades Neurodegenerativas (CIBERNED) , Departamento de Bioquímica y 
      Biología Molecular y Genética , Facultad de Enfermería y Terapia Ocupacional , 
      Cáceres , Spain.
FAU - Goping, Ing Swie
AU  - Goping IS
AD  - bcf University of Alberta , Department of Biochemistry , Edmonton, Alberta , 
      Canada.
FAU - Gorbea, Carlos
AU  - Gorbea C
AD  - bya University of Utah School of Medicine , Department of Biochemistry , Salt 
      Lake City , UT , USA.
FAU - Gorbunov, Nikolai V
AU  - Gorbunov NV
AD  - avw Uniformed Services University of the Health Sciences , Department of 
      Anesthesiology , Bethesda , MD , USA.
FAU - Goring, Daphne R
AU  - Goring DR
AD  - bwz University of Toronto , Department of Cell and Systems Biology , Toronto, 
      Ontario , Canada.
FAU - Gorman, Adrienne M
AU  - Gorman AM
AD  - agp National University of Ireland, Apoptosis Research Centre , Galway , Ireland.
FAU - Gorski, Sharon M
AU  - Gorski SM
AD  - ci British Columbia Cancer Agency , Genome Sciences Centre , Vancouver, BC , 
      Canada.
AD  - apf Simon Fraser University, Department of Molecular Biology and Biochemistry , 
      Burnaby, BC , Canada.
FAU - Goruppi, Sandro
AU  - Goruppi S
AD  - aat Massachusetts General Hospital and Harvard Medical School, Cutaneous Biology 
      Research Center , Charlestown , MA.
FAU - Goto-Yamada, Shino
AU  - Goto-Yamada S
AD  - yw Kyoto University , Department of Botany , Kyoto , Japan.
FAU - Gotor, Cecilia
AU  - Gotor C
AD  - hx Consejo Superior de Investigaciones Científicas (CSIC), Instituto de 
      Bioquímica Vegetal y Fotosíntesis , Sevilla , Spain.
FAU - Gottlieb, Roberta A
AU  - Gottlieb RA
AD  - dd Cedars-Sinai Heart Institute, Barbra Streisand Women's Heart Center , Los 
      Angeles , CA , USA.
FAU - Gozes, Illana
AU  - Gozes I
AD  - arz Tel Aviv University, Sackler Faculty of Medicine , Tel Aviv , Israel.
FAU - Gozuacik, Devrim
AU  - Gozuacik D
AD  - amh Sabanci University, Molecular Biology, Genetics and Bioengineering Program , 
      Istanbul , Turkey.
FAU - Graba, Yacine
AU  - Graba Y
AD  - n Aix Marseille Université, CNRS, IBDM, UMR 7288 , Campus de Luminy, Marseille , 
      France.
FAU - Graef, Martin
AU  - Graef M
AD  - aay Max Planck Institute for Biology of Ageing , Cologne , Germany.
FAU - Granato, Giovanna E
AU  - Granato GE
AD  - asc Temple University, Sbarro Institute for Cancer Research and Molecular 
      Medicine, Center for Biotechnology, College of Science and Technology , 
      Philadelphia , PA , USA.
FAU - Grant, Gary Dean
AU  - Grant GD
AD  - nx Griffith University, Menzies Health Institute Queensland , Australia.
FAU - Grant, Steven
AU  - Grant S
AD  - bzz Virginia Commonwealth University , Department of Internal Medicine , Richmond 
      , VA , USA.
FAU - Gravina, Giovanni Luca
AU  - Gravina GL
AD  - blu University of L'Aquila , Department of Biotechnological and Applied Clinical 
      Sciences , Division of Radiotherapy and Radiobiology , L'Aquila , Italy.
FAU - Green, Douglas R
AU  - Green DR
AD  - aqe St. Jude Children's Research Hospital , Memphis , TN , USA.
FAU - Greenhough, Alexander
AU  - Greenhough A
AD  - beb University of Bristol, School of Cellular and Molecular Medicine , Bristol , 
      UK.
FAU - Greenwood, Michael T
AU  - Greenwood MT
AD  - alq Royal Military College, Chemistry and Chemical Engineering, Kingston , ON , 
      Canada.
FAU - Grimaldi, Benedetto
AU  - Grimaldi B
AD  - uw Istituto Italiano di Tecnologia , Department of Drug Discovery and Development 
      , Laboratory of Molecular Medicine , Genoa , Italy.
FAU - Gros, Frédéric
AU  - Gros F
AD  - azj Université de Strasbourg/CNRS UPR3572, Immunopathologie et Chimie 
      Thérapeutique, IBMC , Strasbourg , France.
FAU - Grose, Charles
AU  - Grose C
AD  - blc University of Iowa, Children's Hospital , Iowa City , IA , USA.
FAU - Groulx, Jean-Francois
AU  - Groulx JF
AD  - ams Sanford Burnham Medical Research Institute, Cell Death and Survival Networks 
      Program , La Jolla , CA , USA.
FAU - Gruber, Florian
AU  - Gruber F
AD  - acm Medical University of Vienna , Department of Dermatology , CD Lab - Skin 
      Aging , Vienna , Austria.
FAU - Grumati, Paolo
AU  - Grumati P
AD  - nq Goethe University School of Medicine, Institute of Biochemistry II and 
      Buchmann Institute for Molecular Life Sciences , Frankfurt am Main , Germany.
AD  - brc University of Padova , Department of Molecular Medicine , Padova , Italy.
FAU - Grune, Tilman
AU  - Grune T
AD  - nl German Institute of Human Nutrition , Department of Molecular Toxicology , 
      Nuthetal , Germany.
FAU - Guan, Jun-Lin
AU  - Guan JL
AD  - bhl University of Cincinnati College of Medicine , Department of Cancer Biology , 
      Cincinnati , OH , USA.
FAU - Guan, Kun-Liang
AU  - Guan KL
AD  - bfr University of California San Diego , Department of Pharmacology and Moores 
      Cancer Center , La Jolla , CA , USA.
FAU - Guerra, Barbara
AU  - Guerra B
AD  - bvc University of Southern Denmark, Villum Center for Bioanalytical Sciences , 
      Department of Biochemistry and Molecular Biology , Odense , Denmark.
FAU - Guillen, Carlos
AU  - Guillen C
AD  - awe Universidad Complutense, School of Pharmacy , Madrid , Spain; and CIBER de 
      Diabetes y Enfermedades Metab olicas Asociadas (CIBERDEM), Instituto de Salud 
      Carlos III, Madrid, Spain.
FAU - Gulshan, Kailash
AU  - Gulshan K
AD  - gy Cleveland Clinic , Department of Cellular and Molecular Medicine , Cleveland , 
      OH , USA.
FAU - Gunst, Jan
AU  - Gunst J
AD  - yj KU Leuven , Clinical Division and Laboratory of Intensive Care Medicine , 
      Department Cellular and Molecular Medicine , Leuven , Belgium.
FAU - Guo, Chuanyong
AU  - Guo C
AD  - aus Tongji University School of Medicine , Department of Gastroenterology , 
      Shanghai Tenth People's Hospital , Shanghai , China.
FAU - Guo, Lei
AU  - Guo L
AD  - lm Food and Drug Administration (FDA), Division of Biochemical Toxicology, 
      National Center for Toxicological Research (NCTR) , Jefferson , AR , USA.
FAU - Guo, Ming
AU  - Guo M
AD  - avp UCLA David Geffen School of Medicine, Brain Research Institute , Los Angeles 
      , CA , USA.
FAU - Guo, Wenjie
AU  - Guo W
AD  - vr Jiangsu University, School of Pharmacy , Zhenjiang, Jiangsu , China.
FAU - Guo, Xu-Guang
AU  - Guo XG
AD  - atf The Third Affiliated Hospital of Guangzhou Medical University , Department of 
      Clinical Laboratory Medicine , Guangzhou, Guangdong , China.
FAU - Gust, Andrea A
AU  - Gust AA
AD  - bxn University of Tübingen, Center for Plant Molecular Biology (ZMBP) , 
      Department of Plant Biochemistry , Tübingen , Germany.
FAU - Gustafsson, Åsa B
AU  - Gustafsson ÅB
AD  - bga University of California San Diego, Skaggs School of Pharmacy and 
      Pharmaceutical Sciences , La Jolla , CA , USA.
FAU - Gutierrez, Elaine
AU  - Gutierrez E
AD  - bvi University of Sydney , Department of Pathology and Bosch Institute , Sydney, 
      New South Wales , Australia.
FAU - Gutierrez, Maximiliano G
AU  - Gutierrez MG
AD  - lt The Francis Crick Institute, Mill Hill Laboratory , London , UK.
FAU - Gwak, Ho-Shin
AU  - Gwak HS
AD  - nv Graduate School of Cancer Science and Policy , Department of System Cancer 
      Science , Goyang , Korea.
FAU - Haas, Albert
AU  - Haas A
AD  - bdx University of Bonn, Institute for Cell Biology , Bonn , Germany.
FAU - Haber, James E
AU  - Haber JE
AD  - cd Brandeis University , Department of Biology , Waltham , MA , USA.
FAU - Hadano, Shinji
AU  - Hadano S
AD  - auf Tokai University School of Medicine , Department of Molecular Life Sciences , 
      Kanagawa , Japan.
FAU - Hagedorn, Monica
AU  - Hagedorn M
AD  - bp Bernhard Nocht Institute for Tropical Medicine , Hamburg , Germany.
FAU - Hahn, David R
AU  - Hahn DR
AD  - gr Cincinnati Children's Hospital Medical Center, Division of Clinical 
      Pharmacology , Cincinnati , OH , USA.
FAU - Halayko, Andrew J
AU  - Halayko AJ
AD  - bna University of Manitoba , Department of Physiology and Pathophysiology , 
      Winnipeg, Manitoba , Canada.
FAU - Hamacher-Brady, Anne
AU  - Hamacher-Brady A
AD  - ni German Cancer Research Center (DKFZ), Lysosomal Systems Biology , Heidelberg , 
      Germany.
FAU - Hamada, Kozo
AU  - Hamada K
AD  - alj RIKEN Brain Science Institute, Laboratory for Developmental Neurobiology , 
      Saitama , Japan.
FAU - Hamai, Ahmed
AU  - Hamai A
AD  - azw Université Paris Descartes-Sorbonne Paris Cité, Institut Necker 
      Enfants-Malades (INEM), INSERM U1151-CNRS UMR 8253 , Paris , France.
FAU - Hamann, Andrea
AU  - Hamann A
AD  - nt Goethe University, Institute for Molecular Biosciences, Molecular 
      Developmental Biology , Frankfurt , Hesse , Germany.
FAU - Hamasaki, Maho
AU  - Hamasaki M
AD  - aix Osaka University , Department of Genetics , Graduate School of Medicine , 
      Osaka , Japan.
FAU - Hamer, Isabelle
AU  - Hamer I
AD  - bpf University of Namur, Research Unit in Molecular Physiology (URPhyM) , Namur , 
      Belgium.
FAU - Hamid, Qutayba
AU  - Hamid Q
AD  - aor University of Sharjah, College of Medicine, United Arab Emirates.
FAU - Hammond, Ester M
AU  - Hammond EM
AD  - bqz University of Oxford, CRUK/MRC Oxford Institute for Radiation Oncology , 
      Oxford , UK.
FAU - Han, Feng
AU  - Han F
AD  - ccx Zhejiang University, Institute of Pharmacology, Toxicology and Biochemical 
      Pharmaceutics , Hangzhou , China.
FAU - Han, Weidong
AU  - Han W
AD  - cda Zhejiang University, Sir Run Run Shaw Hospital, College of Medicine , 
      Hangzhou, Zhejiang , China.
FAU - Handa, James T
AU  - Handa JT
AD  - wk Johns Hopkins, School of Medicine, Wilmer Eye Institute , Baltimore , MD , 
      USA.
FAU - Hanover, John A
AU  - Hanover JA
AD  - afw National Institutes of Health, NIDDK, LCMB , Bethesda , MD , USA.
FAU - Hansen, Malene
AU  - Hansen M
AD  - amt Sanford Burnham Prebys Medical Discovery Institute , La Jolla , CA , USA.
FAU - Harada, Masaru
AU  - Harada M
AD  - bqg University of Occupational and Environmental Health , Third Department of 
      Internal Medicine , Kitakyushu , Japan.
FAU - Harhaji-Trajkovic, Ljubica
AU  - Harhaji-Trajkovic L
AD  - bdj University of Belgrade, Institute for Biological Research "Sinisa Stankovic" 
      , Belgrade , Serbia.
FAU - Harper, J Wade
AU  - Harper JW
AD  - pb Harvard Medical School , Department of Cell Biology , Boston , MA , USA.
FAU - Harrath, Abdel Halim
AU  - Harrath AH
AD  - xs King Saud University, College of Science , Department of Zoology , Riyadh , 
      Saudi Arabia.
FAU - Harris, Adrian L
AU  - Harris AL
AD  - ajk Oxford University, Department of Oncology , Weatherall Institute of Molecular 
      Medicine, John Radcliffe Hospital, Molecular Oncology Laboratories , Oxford , UK.
FAU - Harris, James
AU  - Harris J
AD  - acw Monash University, Centre for Inflammatory Diseases, Lupus Research 
      Laboratory , Clayton , Victoria , Australia.
FAU - Hasler, Udo
AU  - Hasler U
AD  - bju University of Geneva , Department of Cellular Physiology and Metabolism , 
      Geneva , Switzerland.
FAU - Hasselblatt, Peter
AU  - Hasselblatt P
AD  - bay University Hospital Freiburg , Department of Medicine II , Freiburg , 
      Germany.
FAU - Hasui, Kazuhisa
AU  - Hasui K
AD  - wt Kagoshima University, Graduate School of Medical and Dental Sciences, Division 
      of Human Pathology , Department of Oncology , Course of Advanced Therapeutics , 
      Kagoshima , Japan.
FAU - Hawley, Robert G
AU  - Hawley RG
AD  - mt George Washington University , Department of Anatomy and Regenerative Biology 
      , Washington, DC , USA.
FAU - Hawley, Teresa S
AU  - Hawley TS
AD  - mu George Washington University, Flow Cytometry Core Facility , Washington, DC , 
      USA.
FAU - He, Congcong
AU  - He C
AD  - aia Northwestern University , Department of Cell and Molecular Biology , Feinberg 
      School of Medicine , Chicago , IL , USA.
FAU - He, Cynthia Y
AU  - He CY
AD  - ags National University of Singapore , Department of Biological Sciences , 
      Singapore.
FAU - He, Fengtian
AU  - He F
AD  - atk Third Military Medical University , Department of Biochemistry and Molecular 
      Biology , Chongqing , China.
FAU - He, Gu
AU  - He G
AD  - apd Sichuan University, West China Hospital, State Key Labortary of Biotherapy , 
      Sichuan , China.
FAU - He, Rong-Rong
AU  - He RR
AD  - vv Jinan University, Anti-stress and Health Center, College of Pharmacy , 
      Guangzhou , China.
FAU - He, Xian-Hui
AU  - He XH
AD  - vw Jinan University , Department of Immunobiology , College of Life Science and 
      Technology , Guangzhou , China.
FAU - He, You-Wen
AU  - He YW
AD  - ji Duke University, Medical Center , Department of Immunology , Durham , NC , 
      USA.
FAU - He, Yu-Ying
AU  - He YY
AD  - bhb University of Chicago , Department of Medicine , Section of Dermatology , 
      Chicago , IL , USA.
FAU - Heath, Joan K
AU  - Heath JK
AD  - atg The Walter and Eliza Hall Institute of Medical Research, Development and 
      Cancer Division , Parkville , VIC , Australia.
FAU - Hébert, Marie-Josée
AU  - Hébert MJ
AD  - azb Université de Montréal , Department of Medicine , Montréal, Quebec , Canada.
FAU - Heinzen, Robert A
AU  - Heinzen RA
AD  - afx National Institutes of Health, Rocky Mountain Laboratories, NIAID, Coxiella 
      Pathogenesis Section , Hamilton , MT , USA.
FAU - Helgason, Gudmundur Vignir
AU  - Helgason GV
AD  - bkb University of Glasgow, Wolfson Wohl Cancer Research Centre, MVLS, Institute 
      of Cancer Sciences , Glasgow , UK.
FAU - Hensel, Michael
AU  - Hensel M
AD  - bqt University of Osnabrueck, Division of Microbiology , Osnabrueck , Germany.
FAU - Henske, Elizabeth P
AU  - Henske EP
AD  - cg Brigham and Women's Hospital, Harvard Medical School , Boston , MA , USA.
FAU - Her, Chengtao
AU  - Her C
AD  - caw Washington State University, School of Molecular Biosciences , Pullman , WA , 
      USA.
FAU - Herman, Paul K
AU  - Herman PK
AD  - aij Ohio State University , Department of Molecular Genetics , Columbus , OH , 
      USA.
FAU - Hernández, Agustín
AU  - Hernández A
AD  - axj Universidade de São Paulo , Departamento de Parasitología , Instituto de 
      Ciências Biomédicas , São Paulo , Brazil.
FAU - Hernandez, Carlos
AU  - Hernandez C
AD  - lg FISABIO, Hospital Dr. Peset , Valencia , Spain.
FAU - Hernández-Tiedra, Sonia
AU  - Hernández-Tiedra S
AD  - hs Complutense University, Instituto de Investigaciones Sanitarias San Carlos 
      (IdISSC) , Department of Biochemistry and Molecular Biology I , School of Biology 
      , Madrid , Spain.
FAU - Hetz, Claudio
AU  - Hetz C
AD  - bge FONDAP Center for Geroscience, Brain Health and Metabolism, Santiago, Chile.
AD  - bhj University of Chile, Institute of Biomedical Sciences, Center for Molecular 
      Studies of the Cell, Program of Cellular, Molecular Biology and Biomedical 
      Neuroscience Institute, Faculty of Medicine , Santiago , Chile.
FAU - Hiesinger, P Robin
AU  - Hiesinger PR
AD  - bwn University of Texas, Southwestern Medical Center , Dallas , TX , USA.
FAU - Higaki, Katsumi
AU  - Higaki K
AD  - auv Tottori University, Research Center for Bioscience and Technology , Yonago , 
      Japan.
FAU - Hilfiker, Sabine
AU  - Hilfiker S
AD  - hw Consejo Superior de Investigaciones Científicas (CSIC), Institute of 
      Parasitology and Biomedicine López-Neyra , Granada , Spain.
FAU - Hill, Bradford G
AU  - Hill BG
AD  - bmn University of Louisville , Department of Medicine , Institute of Molecular 
      Cardiology, Diabetes and Obesity Center , Louisville , KY , USA.
FAU - Hill, Joseph A
AU  - Hill JA
AD  - bwr University of Texas, Southwestern Medical Center, Medicine and Molecular 
      Biology , Dallas , TX.
FAU - Hill, William D
AU  - Hill WD
AD  - nb Georgia Regents University , Department of Neurology , Augusta , GA , USA.
AD  - nc Georgia Regents University , Department of Orthopaedic Surgery , Augusta , GA 
      , USA.
AD  - nd Georgia Regents University, Institute for Regenerative and Reparative Medicine 
      , Augusta , GA , USA.
AD  - nf Georgia Regents University, Medical College of Georgia , Department of 
      Cellular Biology and Anatomy , Augusta , GA , USA.
FAU - Hino, Keisuke
AU  - Hino K
AD  - xm Kawasaki Medical School , Department of Hepatology and Pancreatology , 
      Kurashiki, Okayama , Japan.
FAU - Hofius, Daniel
AU  - Hofius D
AD  - arh Swedish University of Agricultural Sciences and Linnean Center for Plant 
      Biology , Department of Plant Biology , Uppsala BioCenter , Uppsala , Sweden.
FAU - Hofman, Paul
AU  - Hofman P
AD  - bpt University of Nice-Sophia Antipolis, INSERM U1081, CNRS 7284, Faculty of 
      Medicine , Nice , France.
FAU - Höglinger, Günter U
AU  - Höglinger GU
AD  - nk German Center for Neurodegenerative Diseases (DZNE) , Munich , Germany.
AD  - ars Technische Universität München , Department of Neurology , Munich , Germany.
FAU - Höhfeld, Jörg
AU  - Höhfeld J
AD  - bdx University of Bonn, Institute for Cell Biology , Bonn , Germany.
FAU - Holz, Marina K
AU  - Holz MK
AD  - w Albert Einstein Cancer Center , New York , NY , USA.
AD  - ccg Yeshiva University , New York , NY , USA.
FAU - Hong, Yonggeun
AU  - Hong Y
AD  - rp Inje University , Department of Rehabilitation Science, College of Biomedical 
      Science & Engineering, u-Healthcare & Anti-aging Research Center (u-HARC), Gimhae 
      , Korea.
FAU - Hood, David A
AU  - Hood DA
AD  - cco York University, School of Kinesiology and Health Science , Toronto, Ontario 
      , Canada.
FAU - Hoozemans, Jeroen Jm
AU  - Hoozemans JJ
AD  - cam VU University Medical Center , Department of Pathology , Amsterdam , The 
      Netherlands.
FAU - Hoppe, Thorsten
AU  - Hoppe T
AD  - bhv University of Cologne, Institute for Genetics, CECAD Research Center , 
      Cologne , Germany.
FAU - Hsu, Chin
AU  - Hsu C
AD  - blk University of Kaohsiung Medical University , Department of Physiology , 
      Faculty of Medicine, College of Medicine , Kaohsiung , Taiwan.
FAU - Hsu, Chin-Yuan
AU  - Hsu CY
AD  - ek Chang Gung University , Department of Biomedical Sciences , College of 
      Medicine , Taoyuan , Taiwan.
FAU - Hsu, Li-Chung
AU  - Hsu LC
AD  - agk National Taiwan University, Institute of Molecular Medicine, College of 
      Medicine , Taipei , Taiwan.
FAU - Hu, Dong
AU  - Hu D
AD  - ao Anhui University of Science and Technology , Department of Immunology and 
      Medical Inspection , Huainan , Anhui , China.
FAU - Hu, Guochang
AU  - Hu G
AD  - bku University of Illinois at Chicago, Departments of Anesthesiology and 
      Pharmacology , Chicago , IL , USA.
FAU - Hu, Hong-Ming
AU  - Hu HM
AD  - akn Providence Portland Medical Center, Earle A. Chiles Research Institute , 
      Portland , OR , USA.
FAU - Hu, Hongbo
AU  - Hu H
AD  - fa China Agricultural University , Department of Nutrition and Food Safety , 
      Beijing , China.
FAU - Hu, Ming Chang
AU  - Hu MC
AD  - bwo University of Texas, Southwestern Medical Center , Department of Internal 
      Medicine , Center for Mineral Metabolism and Clinical Research , Dallas , TX , 
      USA.
FAU - Hu, Yu-Chen
AU  - Hu YC
AD  - agm National Tsing Hua University , Department of Chemical Engineering , Hsinchu 
      , Taiwan.
FAU - Hu, Zhuo-Wei
AU  - Hu ZW
AD  - fg Chinese Academy of Medical Sciences and Peking Union Medical College, 
      Molecular Immunology and Cancer Pharmacology Group, State Key Laboratory of 
      Bioactive Substance and Function of Natural Medicines, Institute of Materia 
      Medica , Beijing , China.
FAU - Hua, Fang
AU  - Hua F
AD  - fg Chinese Academy of Medical Sciences and Peking Union Medical College, 
      Molecular Immunology and Cancer Pharmacology Group, State Key Laboratory of 
      Bioactive Substance and Function of Natural Medicines, Institute of Materia 
      Medica , Beijing , China.
FAU - Hua, Ya
AU  - Hua Y
AD  - boi University of Michigan, Neurosurgery , Ann Arbor , MI , USA.
FAU - Huang, Canhua
AU  - Huang C
AD  - apc Sichuan University, State Key Laboratory of Biotherapy/Collaborative 
      Innovation Center of Biotherapy; West China Hospital , Chengdu , China.
FAU - Huang, Huey-Lan
AU  - Huang HL
AD  - em Chang Jung Christian University , Department of Bioscience Technology , Tainan 
      , Taiwan.
FAU - Huang, Kuo-How
AU  - Huang KH
AD  - agi National Taiwan University , Department of Urology , College of Medicine , 
      Taipei , Taiwan.
FAU - Huang, Kuo-Yang
AU  - Huang KY
AD  - el Chang Gung University, Molecular Regulation and Bioinformatics Laboratory , 
      Department of Parasitology , Taoyuan , Taiwan.
FAU - Huang, Shile
AU  - Huang S
AD  - zy Louisiana State University Health Sciences Center , Department of Biochemistry 
      and Molecular Biology , Shreveport , LA , USA.
FAU - Huang, Shiqian
AU  - Huang S
AD  - aoo Shanghai Jiao Tong University, School of Medicine, Shanghai Institute of 
      Immunology , Shanghai , China.
FAU - Huang, Wei-Pang
AU  - Huang WP
AD  - agg National Taiwan University , Department of Life Science , Taipei , Taiwan.
FAU - Huang, Yi-Ran
AU  - Huang YR
AD  - aom Shanghai Jiao Tong University, School of Medicine, Renji Hospital , Shanghai 
      , China.
FAU - Huang, Yong
AU  - Huang Y
AD  - qp Icahn School of Medicine at Mount Sinai , Department of Neuroscience , New 
      York , NY , USA.
FAU - Huang, Yunfei
AU  - Huang Y
AD  - v Albany Medical College, Center for Neuropharmacology and Neuroscience , Albany 
      , NY , USA.
FAU - Huber, Tobias B
AU  - Huber TB
AD  - ai Albert Ludwigs University, Renal Division , Freiburg , Germany.
AD  - bx BIOSS Centre for Biological Signalling Studies , Freiburg , Germany.
AD  - bbl University Medical Center Freiburg , Freiburg , Germany.
FAU - Huebbe, Patricia
AU  - Huebbe P
AD  - bls University of Kiel, Institute of Human Nutrition and Food Science , Kiel , 
      Germany.
FAU - Huh, Won-Ki
AU  - Huh WK
AD  - ant Seoul National University , Department of Biological Sciences , Seoul , 
      Korea.
FAU - Hulmi, Juha J
AU  - Hulmi JJ
AD  - bkk University of Helsinki , Department of Physiology , Faculty of Medicine , 
      Helsinki , Finland.
AD  - blh University of Jyväskylä , Department of Biology of Physical Activity , 
      Jyväskylä , Finland.
FAU - Hur, Gang Min
AU  - Hur GM
AD  - gk Chungnam National University, School of Medicine , Department of Pharmacology 
      , Daejeon , Korea.
FAU - Hurley, James H
AU  - Hurley JH
AD  - bew University of California Berkeley , Department of Molecular and Cell Biology 
      , Berkeley , CA , USA.
FAU - Husak, Zvenyslava
AU  - Husak Z
AD  - apz St. Anna Kinderkrebsforschung, Children's Cancer Research Institute, 
      Immunological Diagnostics , Vienna, Austria.
FAU - Hussain, Sabah Na
AU  - Hussain SN
AD  - abk McGill University , Department of Critical Care , Montreal, Quebec , Canada.
AD  - abp McGill University, Health Centre , Department of Medicine , Montreal, Quebec 
      , Canada.
FAU - Hussain, Salik
AU  - Hussain S
AD  - afr National Institutes of Health, National Institute of Environmental Health 
      Sciences, Clinical Research Program , Research Triangle Park , NC , USA.
FAU - Hwang, Jung Jin
AU  - Hwang JJ
AD  - at Asan Medical Center, Asan Institute for Life Sciences , Seoul , Korea.
FAU - Hwang, Seungmin
AU  - Hwang S
AD  - bhc University of Chicago , Department of Pathology , Chicago , IL , USA.
FAU - Hwang, Thomas Is
AU  - Hwang TI
AD  - aoy Shin Kong Wu Ho-Su Memorial Hospital , Department of Urology , Taipei , 
      Taiwan.
FAU - Ichihara, Atsuhiro
AU  - Ichihara A
AD  - aur Tokyo Women's Medical University , Department of Endocrinology and 
      Hypertension , Tokyo , Japan.
FAU - Imai, Yuzuru
AU  - Imai Y
AD  - wl Juntendo University , Department of Research for Parkinson's Disease , Tokyo , 
      Japan.
FAU - Imbriano, Carol
AU  - Imbriano C
AD  - bow University of Modena and Reggio Emilia , Department of Life Sciences , Modena 
      , Italy.
FAU - Inomata, Megumi
AU  - Inomata M
AD  - ar Asahi University, School of Dentistry , Department of Oral Microbiology , 
      Division of Oral Infections and Health Sciences , Mizuho , Gifu , Japan.
FAU - Into, Takeshi
AU  - Into T
AD  - ar Asahi University, School of Dentistry , Department of Oral Microbiology , 
      Division of Oral Infections and Health Sciences , Mizuho , Gifu , Japan.
FAU - Iovane, Valentina
AU  - Iovane V
AD  - btp University of Salerno , Department of Pharmacy , Fisciano, Salerno , Italy.
FAU - Iovanna, Juan L
AU  - Iovanna JL
AD  - dp Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS 
      UMR 7258, Aix-Marseille Université , Institut Paoli-Calmette, Parc Scientifique 
      et Technologique de Luminy, Marseille , France.
FAU - Iozzo, Renato V
AU  - Iozzo RV
AD  - atq Thomas Jefferson University , Department of Pathology , Anatomy and Cell 
      Biology , Philadelphia , PA , USA.
FAU - Ip, Nancy Y
AU  - Ip NY
AD  - py The Hong Kong University of Science and Technology, Clear Water Bay , Kowloon, 
      Hong Kong.
FAU - Irazoqui, Javier E
AU  - Irazoqui JE
AD  - pc Harvard Medical School, Laboratory of Comparative Immunology, Center for the 
      Study of Inflammatory Bowel Disease, Massachusetts General Hospital Research 
      Institute , Boston , MA , USA.
FAU - Iribarren, Pablo
AU  - Iribarren P
AD  - ed Centro de Investigaciones en Bioquímica Clínica e Inmunología 
      (CIBICI-CONICET), Universidad Nacional de Córdoba , Departamento de Bioquímica 
      Clínica , Facultad de Ciencias Químicas , Córdoba , Argentina.
FAU - Isaka, Yoshitaka
AU  - Isaka Y
AD  - aiu Osaka University Graduate School of Medicine , Department of Nephrology , 
      Osaka , Japan.
FAU - Isakovic, Aleksandra J
AU  - Isakovic AJ
AD  - baj University Belgrade, School of Medicine , Belgrade , Serbia.
FAU - Ischiropoulos, Harry
AU  - Ischiropoulos H
AD  - ev Children's Hospital of Philadelphia, Research Institute , Philadelphia , PA , 
      USA.
AD  - akd Perelman School of Medicine at the University of Pennsylvania , Departments 
      of Pediatrics and Systems Pharmacology and Translational Therapeutics , 
      Philadelphia , PA , USA.
FAU - Isenberg, Jeffrey S
AU  - Isenberg JS
AD  - bsn University of Pittsburgh, Vascular Medicine Institute , Pittsburgh , PA , 
      USA.
FAU - Ishaq, Mohammad
AU  - Ishaq M
AD  - th Institute of Microbial Technology (IMTECH), Cell Biology and Immunology 
      Division , Chandigarh , India.
FAU - Ishida, Hiroyuki
AU  - Ishida H
AD  - aub Tohoku University, Graduate School of Agricultural Sciences , Sendai , Japan.
FAU - Ishii, Isao
AU  - Ishii I
AD  - xp Keio University, Graduate School of Pharmaceutical Sciences , Department of 
      Biochemistry , Tokyo , Japan.
FAU - Ishmael, Jane E
AU  - Ishmael JE
AD  - air Oregon State University , Department of Pharmaceutical Sciences , College of 
      Pharmacy , Corvallis , OR , USA.
FAU - Isidoro, Ciro
AU  - Isidoro C
AD  - axs Università del Piemonte Orientale "A. Avogadro" , Dipartimento di Scienze 
      della Salute , Novara , Italy.
FAU - Isobe, Ken-Ichi
AU  - Isobe K
AD  - adq Nagoya University School of Medicine , Nagoya , Japan.
FAU - Isono, Erika
AU  - Isono E
AD  - aru Technische Universität München, Plant Systems Biology , Freising , Germany.
FAU - Issazadeh-Navikas, Shohreh
AU  - Issazadeh-Navikas S
AD  - bij University of Copenhagen, Biotech Research and Innovative Center (BRIC) , 
      Copenhagen , Denmark.
FAU - Itahana, Koji
AU  - Itahana K
AD  - jm Duke-NUS Graduate Medical School, Cancer and Stem Cell Biology Program , 
      Singapore.
FAU - Itakura, Eisuke
AU  - Itakura E
AD  - et Chiba University , Department of Nanobiology , Chiba , Japan.
FAU - Ivanov, Andrei I
AU  - Ivanov AI
AD  - bzx Virginia Commonwealth University , Department of Human and Molecular Genetics 
      , Richmond , VA , USA.
FAU - Iyer, Anand Krishnan V
AU  - Iyer AK
AD  - on Hampton University , Department of Pharmaceutical Sciences , School of 
      Pharmacy , Hampton , VA , USA.
FAU - Izquierdo, José M
AU  - Izquierdo JM
AD  - dy Centro de Biologia Molecular "Severo Ochoa" (UAM/CSIC), Consejo Superior de 
      Investigaciones Científicas, Universidad Autónoma de Madrid , Department of Cell 
      Biology and Immunology , Madrid , Spain.
FAU - Izumi, Yotaro
AU  - Izumi Y
AD  - amk Saitama Medical University, Saitama Medical Center , Department of General 
      Thoracic Surgery , Saitama , Japan.
FAU - Izzo, Valentina
AU  - Izzo V
AD  - km Centre de Recherche des Cordeliers, Equipe 11 labellisée par la Ligue 
      Nationale contre le Cancer , Paris , France.
AD  - oc Gustave Roussy Cancer Campus , Villejuif , France.
AD  - sn INSERM, U1138 , Paris , France.
AD  - azv Université Paris Descartes/Paris V , Paris , France.
FAU - Jäättelä, Marja
AU  - Jäättelä M
AD  - iq Danish Cancer Society Research Center, Cell Death and Metabolism Unit, Center 
      for Autophagy, Recycling and Disease , Copenhagen , Denmark.
FAU - Jaber, Nadia
AU  - Jaber N
AD  - aqu Stony Brook University , Department of Molecular Genetics and Microbiology , 
      Stony Brook , NY , USA.
FAU - Jackson, Daniel John
AU  - Jackson DJ
AD  - bkc University of Göttingen, Department of Geobiology , Göttingen , Germany.
FAU - Jackson, William T
AU  - Jackson WT
AD  - bni University of Maryland, School of Medicine , Department of Microbiology and 
      Immunology , Baltimore , MD , USA.
FAU - Jacob, Tony George
AU  - Jacob TG
AD  - aj All India Institute of Medical Sciences , Department of Anatomy , New Delhi , 
      India.
FAU - Jacques, Thomas S
AU  - Jacques TS
AD  - avl UCL Institute of Child Health and Great Ormond Street Hospital for Children 
      NHS Foundation Trust , London , UK.
FAU - Jagannath, Chinnaswamy
AU  - Jagannath C
AD  - bvt University of Texas, Health Science Center at Houston , Department of 
      Pathology and Laboratory Medicine , Houston , TX , USA.
FAU - Jain, Ashish
AU  - Jain A
AD  - aje Oslo University Hospital , Department of Molecular Cell Biology , Institute 
      for Cancer Research , Oslo , Norway.
AD  - bqk University of Oslo, Centre for Cancer Biomedicine , Oslo , Norway.
FAU - Jana, Nihar Ranjan
AU  - Jana NR
AD  - aef National Brain Research Centre , Manesar, Gurgaon , India.
FAU - Jang, Byoung Kuk
AU  - Jang BK
AD  - xo Keimyung University, School of Medicine, Division of Gastroenterology and 
      Hepatology , Department of Internal Medicine , Daegu , Korea.
FAU - Jani, Alkesh
AU  - Jani A
AD  - bib University of Colorado, Denver ; and Denver VAMC , Denver , CO , USA.
FAU - Janji, Bassam
AU  - Janji B
AD  - aae Luxembourg Institute of Health, Laboratory of Experimental Hemato-Oncology , 
      Department of Oncology , Luxembourg City , Luxembourg.
FAU - Jannig, Paulo Roberto
AU  - Jannig PR
AD  - btu University of São Paulo, School of Physical Education and Sport, Cellular and 
      Molecular Exercise Physiology Laboratory , São Paulo , Brazil.
FAU - Jansson, Patric J
AU  - Jansson PJ
AD  - bvi University of Sydney , Department of Pathology and Bosch Institute , Sydney, 
      New South Wales , Australia.
FAU - Jean, Steve
AU  - Jean S
AD  - azh Université de Sherbrooke , Department of Anatomy and Cell Biology , Faculty 
      of Medicine and Health Sciences , Sherbrooke, QC , Canada.
FAU - Jendrach, Marina
AU  - Jendrach M
AD  - ep Charité - Universitätsmedizin Berlin , Department of Neuropathology , Campus 
      Charité Mitte , Berlin , Germany.
FAU - Jeon, Ju-Hong
AU  - Jeon JH
AD  - anp Seoul National University College of Medicine , Department of Physiology and 
      Biomedical Sciences , Seoul , Korea.
FAU - Jessen, Niels
AU  - Jessen N
AD  - e Aarhus University , Department of Clinical Medicine , Aarhus , Denmark.
FAU - Jeung, Eui-Bae
AU  - Jeung EB
AD  - gi Chungbuk National University, College of Veterinary Medicine , Cheongju, 
      Chungbuk , Korea.
FAU - Jia, Kailiang
AU  - Jia K
AD  - li Florida Atlantic University , Department of Biological Sciences , Jupiter , FL 
      , USA.
FAU - Jia, Lijun
AU  - Jia L
AD  - mb Cancer Institute, Fudan University Shanghai Cancer Center , Collaborative 
      Innovation Center of Cancer Medicine, Department of Oncology , Shanghai Medical 
      College , Fudan University, Shanghai , China.
FAU - Jiang, Hong
AU  - Jiang H
AD  - bwd University of Texas, MD Anderson Cancer Center , Department of Neuro-Oncology 
      , Houston , TX , USA.
FAU - Jiang, Hongchi
AU  - Jiang H
AD  - asp The First Affiliated Hospital of Harbin Medical University , Department of 
      General Surgery , Harbin, Heilongjiang Province , China.
FAU - Jiang, Liwen
AU  - Jiang L
AD  - gd Chinese University of Hong Kong, School of Life Science, Centre for Cell and 
      Developmental Biology and State Key Laboratory of Agrobiotechnology , Sha Tin, 
      Hong Kong.
FAU - Jiang, Teng
AU  - Jiang T
AD  - adu Nanjing Medical University , Department of Neurology , Nanjing First Hospital 
      , Nanjing , China.
FAU - Jiang, Xiaoyan
AU  - Jiang X
AD  - bek University of British Columbia, Medical Genetics, and BC Cancer Agency, Terry 
      Fox Laboratory , Vancouver, BC , Canada.
FAU - Jiang, Xuejun
AU  - Jiang X
AD  - fu Chinese Academy of Sciences, State Key Laboratory of Mycology, Institute of 
      Microbiology , Beijing , China.
FAU - Jiang, Xuejun
AU  - Jiang X
AD  - adb Mossakowski Medical Research Centre, Polish Academy of Sciences, Electron 
      Microscopy Platform , Warsaw , Poland.
FAU - Jiang, Ying
AU  - Jiang Y
AD  - dg Center for Dementia Research, Nathan S. Kline Institute , Orangeburg , NY , 
      USA.
AD  - ahn New York University , Department of Psychiatry , New York , NY , USA.
FAU - Jiang, Yongjun
AU  - Jiang Y
AD  - lw Freshwater Aquaculture Collaborative Innovation Center of Hubei Province , 
      Wuhan , China.
AD  - qj Huazhong Agricultural University , Department of Aquatic Animal Medicine , 
      College of Fisheries , Wuhan , China.
FAU - Jiménez, Alberto
AU  - Jiménez A
AD  - awv Universidad de Salamanca, Campus Miguel de Unamuno , Departamento de 
      Microbiología y Genética , Salamanca , Spain.
FAU - Jin, Cheng
AU  - Jin C
AD  - fu Chinese Academy of Sciences, State Key Laboratory of Mycology, Institute of 
      Microbiology , Beijing , China.
FAU - Jin, Hongchuan
AU  - Jin H
AD  - cct Zhejiang University , Hangzhou , China.
FAU - Jin, Lei
AU  - Jin L
AD  - bpr University of Newcastle, School of Medicine and Public Health , Callaghan, 
      NSW , Australia.
FAU - Jin, Meiyan
AU  - Jin M
AD  - boc University of Michigan , Department of Molecular , Cellular, and 
      Developmental Biology , Ann Arbor , MI , USA.
AD  - bog University of Michigan, Life Sciences Institute , Ann Arbor , MI , USA.
FAU - Jin, Shengkan
AU  - Jin S
AD  - amf Rutgers University-Robert Wood Johnson Medical School , Pharmacology 
      Department , Piscataway , NJ , USA.
FAU - Jinwal, Umesh Kumar
AU  - Jinwal UK
AD  - but University of South Florida , Department of Pharmaceutical Sciences , College 
      of Pharmacy, Byrd Alzheimer's Institute , Tampa , FL , USA.
FAU - Jo, Eun-Kyeong
AU  - Jo EK
AD  - gl Chungnam National University, School of Medicine, Infection Signaling Network 
      Research Center , Daejeon , Korea.
FAU - Johansen, Terje
AU  - Johansen T
AD  - bxm University of Tromsø - The Arctic University of Norway, Molecular Cancer 
      Research Group, Institute of Medical Biology , Tromsø , Norway.
FAU - Johnson, Daniel E
AU  - Johnson DE
AD  - brw University of Pittsburgh Cancer Institute , Pittsburgh , PA , USA.
FAU - Johnson, Gail Vw
AU  - Johnson GV
AD  - bsz University of Rochester Medical Center , Department of Anesthesiology , 
      Rochester , NY , USA.
FAU - Johnson, James D
AU  - Johnson JD
AD  - bee University of British Columbia , Department of Cellular and Physiological 
      Sciences , Vancouver, BC , Canada.
FAU - Jonasch, Eric
AU  - Jonasch E
AD  - bwf University of Texas, MD Anderson Cancer Center , Houston , TX , USA.
FAU - Jones, Chris
AU  - Jones C
AD  - te Institute of Cancer Research, Divisions of Molecular Pathology and Cancer 
      Therapeutics , London , UK.
FAU - Joosten, Leo Ab
AU  - Joosten LA
AD  - alc Radboud University Nijmegen Medical Center , Department of Internal Medicine 
      , Nijmegen , The Netherlands.
FAU - Jordan, Joaquin
AU  - Jordan J
AD  - awh Universidad de Castilla-La Mancha, Facultad de Medicina , Departamento 
      Ciencias Medicas , Albacete , Spain.
FAU - Joseph, Anna-Maria
AU  - Joseph AM
AD  - bjk University of Florida , Department of Aging and Geriatric Research , 
      Gainesville , FL , USA.
FAU - Joseph, Bertrand
AU  - Joseph B
AD  - xg Karolinska Institute, Cancer Center Karolinska , Department of 
      Oncology-Pathology , Stockholm , Sweden.
FAU - Joubert, Annie M
AU  - Joubert AM
AD  - bst University of Pretoria , Department of Physiology , Pretoria, Gauteng , South 
      Africa.
FAU - Ju, Dianwen
AU  - Ju D
AD  - mc Fudan University , Department of Biosynthesis , Key Laboratory of Smart Drug 
      Delivery, Ministry of Education, School of Pharmacy , Shanghai , China.
FAU - Ju, Jingfang
AU  - Ju J
AD  - aqv Stony Brook University , Department of Pathology , Stony Brook , NY , USA.
FAU - Juan, Hsueh-Fen
AU  - Juan HF
AD  - agf National Taiwan University , Department of Life Science , Institute of 
      Molecular and Cellular Biology , Taipei , Taiwan.
FAU - Juenemann, Katrin
AU  - Juenemann K
AD  - bci University of Amsterdam , Department of Cellbiology and Histology , Academic 
      Medical Center , Amsterdam , The Netherlands.
FAU - Juhász, Gábor
AU  - Juhász G
AD  - kj Eötvös Loránd University , Department of Anatomy , Cell and Developmental 
      Biology , Budapest , Hungary.
FAU - Jung, Hye Seung
AU  - Jung HS
AD  - anr Seoul National University Hospital , Department of Internal Medicine , Seoul 
      , Korea.
FAU - Jung, Jae U
AU  - Jung JU
AD  - bux University of Southern California, Keck School of Medicine , Department of 
      Molecular Microbiology and Immunology , Los Angeles , CA , USA.
FAU - Jung, Yong-Keun
AU  - Jung YK
AD  - ant Seoul National University , Department of Biological Sciences , Seoul , 
      Korea.
FAU - Jungbluth, Heinz
AU  - Jungbluth H
AD  - kx Evelina's Children Hospital, Guy's and St. Thomas' Hospital NHS Foundation 
      Trust , Department of Paediatric Neurology , Neuromuscular Service , London , UK.
AD  - xu King's College London , Department of Basic and Clinical Neuroscience , IoPPN 
      , London , UK.
AD  - xv King's College, Randall Division of Cell and Molecular Biophysics, Muscle 
      Signalling Section , London , UK.
FAU - Justice, Matthew J
AU  - Justice MJ
AD  - ri Indiana University School of Medicine, Biochemistry and Molecular Biology , 
      Denver , CO , USA.
AD  - afy National Jewish Health , Denver , CO , USA.
FAU - Jutten, Barry
AU  - Jutten B
AD  - aag Maastricht University, Maastricht Radiation Oncology (MaastRO) Lab, GROW - 
      School for Oncology and Developmental Biology , Maastricht , The Netherlands.
FAU - Kaakoush, Nadeem O
AU  - Kaakoush NO
AD  - bpp University of New South Wales, School of Biotechnology and Biomolecular 
      Sciences , Sydney, NSW , Australia.
FAU - Kaarniranta, Kai
AU  - Kaarniranta K
AD  - biy University of Eastern Finland, Kuopio University Hospital , Department of 
      Ophthalmology , Kuopio , Finland.
FAU - Kaasik, Allen
AU  - Kaasik A
AD  - bvm University of Tartu, Institute of Biomedicine and Translational Medicine , 
      Tartu , Estonia.
FAU - Kabuta, Tomohiro
AU  - Kabuta T
AD  - afe National Institute of Neuroscience, National Center of Neurology and 
      Psychiatry , Department of Degenerative Neurological Diseases , Tokyo , Japan.
FAU - Kaeffer, Bertrand
AU  - Kaeffer B
AD  - avt UMR 1280 , Nantes , France.
FAU - Kågedal, Katarina
AU  - Kågedal K
AD  - zo Linköping University , Department of Clinical and Experimental Medicine , 
      Linköping , Sweden.
FAU - Kahana, Alon
AU  - Kahana A
AD  - boj University of Michigan, Ophthalmology and Visual Sciences, Kellogg Eye Center 
      , Ann Arbor , MI , USA.
FAU - Kajimura, Shingo
AU  - Kajimura S
AD  - bgj University of California San Francisco, UCSF Diabetes Center , Department of 
      Cell and Tissue Biology , San Francisco , CA , USA.
FAU - Kakhlon, Or
AU  - Kakhlon O
AD  - oh Hadassah Hebrew University Medical Center , Department of Neurology , 
      Jerusalem , Israel.
FAU - Kalia, Manjula
AU  - Kalia M
AD  - auw Translational Health Science and Technology Institute, Vaccine and Infectious 
      Disease Research Centre , Faridabad , India.
FAU - Kalvakolanu, Dhan V
AU  - Kalvakolanu DV
AD  - bni University of Maryland, School of Medicine , Department of Microbiology and 
      Immunology , Baltimore , MD , USA.
FAU - Kamada, Yoshiaki
AU  - Kamada Y
AD  - aey National Institute for Basic Biology, Sokendai , Okazaki , Japan.
FAU - Kambas, Konstantinos
AU  - Kambas K
AD  - iw Democritus University of Thrace, Laboratory of Molecular Hematology , 
      Alexandroupolis , Greece.
FAU - Kaminskyy, Vitaliy O
AU  - Kaminskyy VO
AD  - xk Karolinska Institute, Institute of Environmental Medicine , Stockholm , 
      Sweden.
FAU - Kampinga, Harm H
AU  - Kampinga HH
AD  - bcx University of Groningen, Department of Cell Biology, Groningen, The 
      Netherlands.
FAU - Kandouz, Mustapha
AU  - Kandouz M
AD  - cbi Wayne State University, School of Medicine , Department of Pathology , 
      Karmanos Cancer Institute , Detroit , MI , USA.
FAU - Kang, Chanhee
AU  - Kang C
AD  - oy Harvard Medical School, Brigham and Women's Hospital , Department of Genetics 
      , Division of Genetics , Boston , MA , USA.
AD  - qg Howard Hughes Medical Institute , Boston , MA , USA.
FAU - Kang, Rui
AU  - Kang R
AD  - bsb University of Pittsburgh , Department of Surgery , Hillman Cancer Center , 
      Pittsburgh , PA , USA.
FAU - Kang, Tae-Cheon
AU  - Kang TC
AD  - oi Hallym University , Department of Anatomy and Neurobiology , College of 
      Medicine , Kangwon-Do , Korea.
FAU - Kanki, Tomotake
AU  - Kanki T
AD  - ahs Niigata University Graduate School of Medical and Dental Sciences, Laboratory 
      of Biosignaling , Niigata , Japan.
FAU - Kanneganti, Thirumala-Devi
AU  - Kanneganti TD
AD  - aqb St. Jude Children's Research Hospital , Department of Immunology , Memphis , 
      TN , USA.
FAU - Kanno, Haruo
AU  - Kanno H
AD  - aue Tohoku University School of Medicine , Department of Orthopaedic Surgery , 
      Miyagi , Japan.
FAU - Kanthasamy, Anumantha G
AU  - Kanthasamy AG
AD  - uc Iowa State University , Department of Biomedical Science , Iowa Center for 
      Advanced Neurotoxiclogy , Ames , IA , USA.
FAU - Kantorow, Marc
AU  - Kantorow M
AD  - lj Florida Atlantic University, Schmidt College of Medicine , Department of 
      Biomedical Sciences , Boca Raton , FL , USA.
FAU - Kaparakis-Liaskos, Maria
AU  - Kaparakis-Liaskos M
AD  - ql Hudson Institute of Medical Research, Centre for Innate Immunity and 
      Infectious Diseases, Clayton , Melbourne , Victoria , Australia.
FAU - Kapuy, Orsolya
AU  - Kapuy O
AD  - jb Department of Medical Chemistry , Molecular Biology and Pathobiochemistry , 
      Budapest , Hungary.
FAU - Karantza, Vassiliki
AU  - Karantza V
AD  - act Merck Research Laboratories , Rahway , NJ , USA.
FAU - Karim, Md Razaul
AU  - Karim MR
AD  - bou University of Minnesota , Department of Neuroscience , Minneapolis , MN , 
      USA.
FAU - Karmakar, Parimal
AU  - Karmakar P
AD  - vi Jadavpur University, Life Science and Biotechnology, Kolkata , West Bengal , 
      India.
FAU - Kaser, Arthur
AU  - Kaser A
AD  - bgl University of Cambridge, Addenbrooke's Hospital , Department of Medicine , 
      Cambridge , UK.
FAU - Kaushik, Susmita
AU  - Kaushik S
AD  - y Albert Einstein College of Medicine , Department of Developmental and Molecular 
      Biology , Bronx , NY , USA.
FAU - Kawula, Thomas
AU  - Kawula T
AD  - bqb University of North Carolina, Microbiology and Immunology , Chapel Hill , NC 
      , USA.
FAU - Kaynar, A Murat
AU  - Kaynar AM
AD  - bsg University of Pittsburgh, School of Medicine , Department of Anesthesiology , 
      Pittsburgh , PA , USA.
AD  - bsh University of Pittsburgh, School of Medicine , Department of Critical Care 
      Medicine , Pittsburgh , PA , USA.
FAU - Ke, Po-Yuan
AU  - Ke PY
AD  - ei Chang Gung University , Department of Biochemistry and Molecular Biology and 
      Graduate Institute of Biomedical Sciences , College of Medicine , Taoyuan County 
      , Taiwan.
FAU - Ke, Zun-Ji
AU  - Ke ZJ
AD  - aou Shanghai University of Traditional Chinese Medicine , Department of 
      Biochemistry , Shanghai , China.
FAU - Kehrl, John H
AU  - Kehrl JH
AD  - afn National Institutes of Health, Laboratory of Immunoregulation, National 
      Institute of Allergy and Infectious Diseases , Bethesda , MD , USA.
FAU - Keller, Kate E
AU  - Keller KE
AD  - aip Oregon Health and Science University, Casey Eye Institute , Portland , OR , 
      USA.
FAU - Kemper, Jongsook Kim
AU  - Kemper JK
AD  - bky University of Illinois at Urbana-Champaign , Department of Molecular and 
      Integrative Physiology , Urbana , IL , USA.
FAU - Kenworthy, Anne K
AU  - Kenworthy AK
AD  - bzs Vanderbilt University, School of Medicine , Department of Molecular 
      Physiology and Biophysics , Nashville , TN , USA.
FAU - Kepp, Oliver
AU  - Kepp O
AD  - rz INSERM U1138 , Paris , France.
FAU - Kern, Andreas
AU  - Kern A
AD  - aby Medical Center of the Johannes Gutenberg University , Mainz , Germany.
FAU - Kesari, Santosh
AU  - Kesari S
AD  - wb John Wayne Cancer Institute , Department of Neurosciences , Santa Monica , CA 
      , USA.
FAU - Kessel, David
AU  - Kessel D
AD  - cbk Wayne State University, School of Medicine , Detroit , MI , USA.
FAU - Ketteler, Robin
AU  - Ketteler R
AD  - bar University College London, MRC Laboratory for Molecular Cell Biology , London 
      , UK.
FAU - Kettelhut, Isis do Carmo
AU  - Kettelhut Ido C
AD  - bts University of São Paulo, Ribeirão Preto Medical School , Department of 
      Biochemistry and Immunology , Ribeirão Preto, São Paulo , Brazil.
FAU - Khambu, Bilon
AU  - Khambu B
AD  - rn Indiana University School of Medicine , Department of Pathology and Laboratory 
      Medicine , Indianapolis , IN , USA.
FAU - Khan, Muzamil Majid
AU  - Khan MM
AD  - xf Karlsruhe Institute of Technology, Institute of Toxicology and Genetics , 
      Karlsruhe , Germany.
FAU - Khandelwal, Vinoth Km
AU  - Khandelwal VK
AD  - bzv Venus Medicine Research Center (VMRC) , Baddi , Himachal Pradesh , India.
FAU - Khare, Sangeeta
AU  - Khare S
AD  - bzh US Food and Drug Administration, National Center for Toxicology Research, 
      Division of Microbiology , Jefferson , AR , USA.
FAU - Kiang, Juliann G
AU  - Kiang JG
AD  - avx Uniformed Services University of the Health Sciences, Radiation Combined 
      Injury Program, Armed Forces Radiobiology Research Institute , Bethesda , MD , 
      USA.
FAU - Kiger, Amy A
AU  - Kiger AA
AD  - bfu University of California San Diego, Division of Biological Sciences , La 
      Jolla , CA , USA.
FAU - Kihara, Akio
AU  - Kihara A
AD  - pu Hokkaido University, Faculty of Pharmaceutical Sciences , Sapporo , Japan.
FAU - Kim, Arianna L
AU  - Kim AL
AD  - hj Columbia University Medical Center , New York , NY , USA.
FAU - Kim, Cheol Hyeon
AU  - Kim CH
AD  - yd Korea Cancer Center Hospital , Department of Internal Medicine , Seoul , 
      Korea.
FAU - Kim, Deok Ryong
AU  - Kim DR
AD  - of Gyeongsang National University School of Medicine , Department of Biochemistry 
      and Convergence Medical Science and Institute of Health Sciences , JinJu , Korea.
FAU - Kim, Do-Hyung
AU  - Kim DH
AD  - bor University of Minnesota , Department of Biochemistry , Molecular Biology and 
      Biophysics , Minneapolis , MN , USA.
FAU - Kim, Eung Kweon
AU  - Kim EK
AD  - ccj Yonsei University, College of Medicine, Corneal Dystrophy Research Institute 
      ; and Department of Ophthalmology , Seoul , Korea.
FAU - Kim, Hye Young
AU  - Kim HY
AD  - jc Dong-A University, College of Medicine and Mitochondria Hub Regulation Center 
      , Department of Anatomy and Cell Biology , Busan , Korea.
FAU - Kim, Hyung-Ryong
AU  - Kim HR
AD  - cbw Wonkwang University , Department of Dental Pharmacology , School of Dentistry 
      , Chonbuk , Korea.
FAU - Kim, Jae-Sung
AU  - Kim JS
AD  - bjp University of Florida , Gainesville , FL , USA.
FAU - Kim, Jeong Hun
AU  - Kim JH
AD  - ann Seoul National University College of Medicine , Department of Advanced 
      Education for Clinician-Scientists (AECS) , Seoul , Korea.
AD  - ano Seoul National University College of Medicine , Department of Ophthalmology , 
      Seoul , Korea.
FAU - Kim, Jin Cheon
AU  - Kim JC
AD  - bxx University of Ulsan College of Medicine, Asan Medical Center , Department of 
      Surgery , Seoul , Korea.
FAU - Kim, Jin Hyoung
AU  - Kim JH
AD  - ann Seoul National University College of Medicine , Department of Advanced 
      Education for Clinician-Scientists (AECS) , Seoul , Korea.
AD  - ano Seoul National University College of Medicine , Department of Ophthalmology , 
      Seoul , Korea.
FAU - Kim, Kwang Woon
AU  - Kim KW
AD  - bzq Vanderbilt University Medical Center , Department of Pediatric Surgery , 
      Nashville , TN , USA.
FAU - Kim, Michael D
AU  - Kim MD
AD  - bnu University of Miami, Miller School of Medicine , Department of Molecular and 
      Cellular Pharmacology , Miami , FL , USA.
FAU - Kim, Moon-Moo
AU  - Kim MM
AD  - jd Dong-Eui University , Department of Chemistry , Busan , Korea.
FAU - Kim, Peter K
AU  - Kim PK
AD  - bxd University of Toronto, Hospital for Sick Children , Toronto, Ontario , 
      Canada.
FAU - Kim, Seong Who
AU  - Kim SW
AD  - bxw University of Ulsan College of Medicine, Asan Medical Center , Department of 
      Biochemistry and Molecular Biology , Seoul , Korea.
FAU - Kim, Soo-Youl
AU  - Kim SY
AD  - aeg National Cancer Center, Cancer Cell and Molecular Biology Branch, Division of 
      Cancer Biology, Research Institute , Goyang , Korea.
FAU - Kim, Yong-Sun
AU  - Kim YS
AD  - ok Hallym University , Department of Microbiology , College of Medicine , 
      Chuncheon, Gangwon , Korea.
FAU - Kim, Yonghyun
AU  - Kim Y
AD  - bce University of Alabama , Department of Chemical and Biological Engineering , 
      Tuscaloosa , AL , USA.
FAU - Kimchi, Adi
AU  - Kimchi A
AD  - cbr Weizmann Institute of Science , Department of Molecular Genetics , Rehovot , 
      Israel.
FAU - Kimmelman, Alec C
AU  - Kimmelman AC
AD  - oz Harvard Medical School, Dana Farber Cancer Institute , Boston , MA , USA.
FAU - Kimura, Tomonori
AU  - Kimura T
AD  - bpn University of New Mexico, Health Sciences Center , Department of Molecular 
      Genetics and Microbiology , Albuquerque , NM , USA.
FAU - King, Jason S
AU  - King JS
AD  - bub University of Sheffield , Department of Biomedical Sciences , Sheffield , UK.
FAU - Kirkegaard, Karla
AU  - Kirkegaard K
AD  - aqj Stanford University , Department of Microbiology and Immunology , Stanford , 
      CA , USA.
FAU - Kirkin, Vladimir
AU  - Kirkin V
AD  - acs Merck KGaA, RandD Merck Serono , Darmstadt , Germany.
FAU - Kirshenbaum, Lorrie A
AU  - Kirshenbaum LA
AD  - bnb University of Manitoba, Institute of Cardiovascular Sciences, College of 
      Medicine, Faculty of Health Sciences , Winnipeg, Manitoba , Canada.
FAU - Kishi, Shuji
AU  - Kishi S
AD  - atc The Scripps Research Institute , Department of Metabolism and Aging , Jupiter 
      , FL , USA.
FAU - Kitajima, Yasuo
AU  - Kitajima Y
AD  - aua Tohoku University, Division of Biomedical Engineering for Health and Welfare 
      , Sendai , Japan.
FAU - Kitamoto, Katsuhiko
AU  - Kitamoto K
AD  - bww University of Tokyo , Department of Biotechnology , Tokyo , Japan.
FAU - Kitaoka, Yasushi
AU  - Kitaoka Y
AD  - aqg St. Marianna University School of Medicine , Department of Ophthalmology , 
      Kawasaki, Kanagawa , Japan.
FAU - Kitazato, Kaio
AU  - Kitazato K
AD  - ado Nagasaki University , Department of Molecular Microbiology and Immunology , 
      Graduate School of Biomedical Sciences , Nagasaki , Japan.
FAU - Kley, Rudolf A
AU  - Kley RA
AD  - alv Ruhr University Bochum, University Hospital Bergmannsheil , Department of 
      Neurology , Heimer Institute for Muscle Research , Bochum , Germany.
FAU - Klimecki, Walter T
AU  - Klimecki WT
AD  - bcq University of Arizona , Department of Pharmacology and Toxicology , College 
      of Pharmacy , Tucson , AZ , USA.
FAU - Klinkenberg, Michael
AU  - Klinkenberg M
AD  - no Goethe University Medical School, Experimental Neurology , Frankfurt am Main , 
      Germany.
FAU - Klucken, Jochen
AU  - Klucken J
AD  - bax University Hospital Erlangen, Friedrich-Alexander-Universität 
      Erlangen-Nürnberg (FAU) , Erlangen , Germany.
FAU - Knævelsrud, Helene
AU  - Knævelsrud H
AD  - aze Université de Montréal, Institute for Research in Immunology and Cancer , 
      Montréal, Québec , Canada.
FAU - Knecht, Erwin
AU  - Knecht E
AD  - ea Centro de Investigación Príncipe Felipe , Valencia , Spain.
FAU - Knuppertz, Laura
AU  - Knuppertz L
AD  - nt Goethe University, Institute for Molecular Biosciences, Molecular 
      Developmental Biology , Frankfurt , Hesse , Germany.
FAU - Ko, Jiunn-Liang
AU  - Ko JL
AD  - gm Chung-Shan Medical University, Institute of Medicine , Taichung , Taiwan.
FAU - Kobayashi, Satoru
AU  - Kobayashi S
AD  - ahh New York Institute of Technology , Department of Biomedical Sciences , 
      College of Osteopathic Medicine , Old Westbury , NY , USA.
FAU - Koch, Jan C
AU  - Koch JC
AD  - bbt University Medicine Göttingen , Department of Neurology , Göttingen , 
      Germany.
FAU - Koechlin-Ramonatxo, Christelle
AU  - Koechlin-Ramonatxo C
AD  - boz University of Montpellier, INRA, UMR 866, Dynamique Musculaire et Métabolisme 
      , Montpellier , France.
FAU - Koenig, Ulrich
AU  - Koenig U
AD  - cbu Westfälische Wilhelms-Universität Münster, Albert-Schweitzer-Campus 1, 
      Institute of Experimental Musculoskeletal Medicine , Münster , Germany.
FAU - Koh, Young Ho
AU  - Koh YH
AD  - ol Hallym University, Ilsong Institute of Life Science , Chuncheon , Korea.
FAU - Köhler, Katja
AU  - Köhler K
AD  - ks ETH Zurich, Institute of Molecular Systems Biology , Zurich , Switzerland.
FAU - Kohlwein, Sepp D
AU  - Kohlwein SD
AD  - bke University of Graz, Institute of Molecular Biosciences, BioTechMed Graz , 
      Graz , Austria.
FAU - Koike, Masato
AU  - Koike M
AD  - wm Juntendo University, Graduate School of Medicine , Department of Cell Biology 
      and Neuroscience , Tokyo , Japan.
FAU - Komatsu, Masaaki
AU  - Komatsu M
AD  - aht Niigata University, School of Medicine , Department of Biochemistry , Niigata 
      , Japan.
FAU - Kominami, Eiki
AU  - Kominami E
AD  - ws Juntendo University , Tokyo , Japan.
FAU - Kong, Dexin
AU  - Kong D
AD  - atw Tianjin Medical University, School of Pharmaceutical Sciences , Tianjin , 
      China.
FAU - Kong, Hee Jeong
AU  - Kong HJ
AD  - aes National Fisheries Research and Development Institute (NFRDI) , Busan , 
      Korea.
FAU - Konstantakou, Eumorphia G
AU  - Konstantakou EG
AD  - bcv University of Athens , Department of Cell Biology and Biophysics , Faculty of 
      Biology , Athens , Greece.
FAU - Kopp, Benjamin T
AU  - Kopp BT
AD  - agy Nationwide Children's Hospital, Center for Microbial Pathogenesis , Columbus 
      , OH , USA.
FAU - Korcsmaros, Tamas
AU  - Korcsmaros T
AD  - asu The Genome Analysis Centre (TGAC), Institute of Food Research, Gut Health and 
      Food Safety Programme , Norwich , UK.
FAU - Korhonen, Laura
AU  - Korhonen L
AD  - pp Helsinki University, Central Hospital, Medical Faculty, Division of Child 
      Psychiatry , Helsinki , Finland.
FAU - Korolchuk, Viktor I
AU  - Korolchuk VI
AD  - ahp Newcastle University, Campus for Ageing and Vitality, Institute for Cell and 
      Molecular Biosciences and Institute for Ageing , Newcastle upon Tyne , UK.
FAU - Koshkina, Nadya V
AU  - Koshkina NV
AD  - bwf University of Texas, MD Anderson Cancer Center , Houston , TX , USA.
FAU - Kou, Yanjun
AU  - Kou Y
AD  - asb Temasek Life Sciences Laboratory , Singapore.
FAU - Koukourakis, Michael I
AU  - Koukourakis MI
AD  - iy Democritus University of Thrace, School of Medicine , Alexandroupolis , 
      Greece.
FAU - Koumenis, Constantinos
AU  - Koumenis C
AD  - brk University of Pennsylvania Perelman School of Medicine , Department of 
      Radiation Oncology , Philadelphia , PA , USA.
FAU - Kovács, Attila L
AU  - Kovács AL
AD  - kj Eötvös Loránd University , Department of Anatomy , Cell and Developmental 
      Biology , Budapest , Hungary.
FAU - Kovács, Tibor
AU  - Kovács T
AD  - kl Eötvös Loránd University , Department of Genetics , Budapest , Hungary.
FAU - Kovacs, Werner J
AU  - Kovacs WJ
AD  - kp ETH Zurich , Department of Biology , Institute of Molecular Health Sciences , 
      Zurich , Switzerland.
FAU - Koya, Daisuke
AU  - Koya D
AD  - wx Kanazawa Medical University, Diabetology and Endocrinology , Ishikawa , Japan.
FAU - Kraft, Claudine
AU  - Kraft C
AD  - byi University of Vienna, Max F. Perutz Laboratories , Vienna , Austria.
FAU - Krainc, Dimitri
AU  - Krainc D
AD  - aid Northwestern University, Feinberg School of Medicine , Department of 
      Neurology , Chicago , IL , USA.
FAU - Kramer, Helmut
AU  - Kramer H
AD  - bwq University of Texas, Southwestern Medical Center , Department of Neuroscience 
      , Dallas , TX.
FAU - Kravic-Stevovic, Tamara
AU  - Kravic-Stevovic T
AD  - bdk University of Belgrade, Institute of Histology and Embryology, School of 
      Medicine , Belgrade , Serbia.
FAU - Krek, Wilhelm
AU  - Krek W
AD  - kr ETH Zurich, Institute of Molecular Health Sciences , Zurich , Switzerland.
FAU - Kretz-Remy, Carole
AU  - Kretz-Remy C
AD  - he CNRS, UMR 5534 , Villeurbanne , France.
AD  - ayu Université de Lyon, Lyon France; and Centre de Génétique et de Physiologie 
      Moléculaire et Cellulaire, Université Lyon 1, Villeurbanne , France.
FAU - Krick, Roswitha
AU  - Krick R
AD  - mr Georg-August-University Göttingen, Institute of Cellular Biochemistry , 
      Göttingen , Germany.
FAU - Krishnamurthy, Malathi
AU  - Krishnamurthy M
AD  - bwy University of Toledo , Department of Biological Sciences , Toledo , OH , USA.
FAU - Kriston-Vizi, Janos
AU  - Kriston-Vizi J
AD  - bar University College London, MRC Laboratory for Molecular Cell Biology , London 
      , UK.
FAU - Kroemer, Guido
AU  - Kroemer G
AD  - od Gustave Roussy Comprehensive Cancer Center , Villejuif , France.
AD  - qa Hôpital Européen Georges Pompidou, AP-HP , Paris , France.
AD  - sj INSERM, Cordeliers Research Cancer , Paris , France.
AD  - azr Université Paris Descartes, Apoptosis, Cancer and Immunity Laboratory, Team 
      11, Equipe Labellisée Ligue contre le Cancer and Cell Biology and Metabolomics 
      Platforms , Paris , France.
FAU - Kruer, Michael C
AU  - Kruer MC
AD  - bco University of Arizona College of Medicine, Barrow Neurological Institute, 
      Phoenix Children's Hospital , Department of Child Health , Phoenix , AZ , USA.
FAU - Kruger, Rejko
AU  - Kruger R
AD  - bms University of Luxembourg, Luxembourg Center for Systems Biomedicine , 
      Luxembourg.
FAU - Ktistakis, Nicholas T
AU  - Ktistakis NT
AD  - ay Babraham Institute , Cambridge , UK.
FAU - Kuchitsu, Kazuyuki
AU  - Kuchitsu K
AD  - auq Tokyo University of Science , Department of Applied Biological Science and 
      Imaging Frontier Center , Noda, Chiba , Japan.
FAU - Kuhn, Christian
AU  - Kuhn C
AD  - blq University of Kiel , Department of Cardiology , Kiel , Germany.
FAU - Kumar, Addanki Pratap
AU  - Kumar AP
AD  - bvy University of Texas, Health Science Center at San Antonio , Department of 
      Urology , San Antonio , TX , USA.
FAU - Kumar, Anuj
AU  - Kumar A
AD  - boc University of Michigan , Department of Molecular , Cellular, and 
      Developmental Biology , Ann Arbor , MI , USA.
FAU - Kumar, Ashok
AU  - Kumar A
AD  - bmq University of Louisville, School of Medicine , Department of Anatomical 
      Sciences and Neurobiology , Louisville , KY , USA.
FAU - Kumar, Deepak
AU  - Kumar D
AD  - bwt University of the District of Columbia, Cancer Research Laboratory , 
      Washington, DC , USA.
FAU - Kumar, Dhiraj
AU  - Kumar D
AD  - ub International Center for Genetic Engineering and Biotechnology, Immunology 
      Group , New Delhi , India.
FAU - Kumar, Rakesh
AU  - Kumar R
AD  - lo George Washington University, Department of Biochemistry and Molecular 
      Medicine, Washington, DC , USA.
FAU - Kumar, Sharad
AU  - Kumar S
AD  - bug University of South Australia and SA Pathology, Centre for Cancer Biology, 
      Adelaide , SA , Australia.
FAU - Kundu, Mondira
AU  - Kundu M
AD  - aqc St. Jude Children's Research Hospital , Department of Pathology , Memphis , 
      TN , USA.
FAU - Kung, Hsing-Jien
AU  - Kung HJ
AD  - aet National Health Research Institutes , Institute of Molecular and Genomic 
      Medicine, Miaoli , Taiwan.
AD  - bey University of California Davis, Cancer Center , Davis , CA , USA.
FAU - Kuno, Atsushi
AU  - Kuno A
AD  - and Sapporo Medical University School of Medicine , Department of Pharmacology , 
      Sapporo , Japan.
FAU - Kuo, Sheng-Han
AU  - Kuo SH
AD  - hh Columbia University Medical Center , Department of Neurology , New York , NY , 
      USA.
FAU - Kuret, Jeff
AU  - Kuret J
AD  - aii Ohio State University , Department of Molecular and Cellular Biochemistry , 
      Columbus , OH , USA.
FAU - Kurz, Tino
AU  - Kurz T
AD  - zp Linköping University , Department of Medical and Health Sciences , Linköping , 
      Sweden.
FAU - Kwok, Terry
AU  - Kwok T
AD  - acy Monash University , Department of Biochemistry and Molecular Biology , 
      Victoria , Australia.
AD  - acz Monash University , Department of Microbiology , Victoria , Australia.
FAU - Kwon, Taeg Kyu
AU  - Kwon TK
AD  - xn Keimyung University , Daegu , Korea.
FAU - Kwon, Yong Tae
AU  - Kwon YT
AD  - anw Seoul National University, Protein Metabolism Medical Research Center and 
      Department of Biomedical Sciences , College of Medicine , Seoul , Korea.
FAU - Kyrmizi, Irene
AU  - Kyrmizi I
AD  - bio University of Crete, School of Medicine , Department of Infectious Diseases , 
      Heraklion, Crete , Greece.
FAU - La Spada, Albert R
AU  - La Spada AR
AD  - amr Sanford Consortium for Regenerative Medicine , La Jolla , CA , USA.
AD  - bft University of California San Diego, Departments of Cellular and Molecular 
      Medicine, Neurosciences, and Pediatrics, Division of Biological Sciences 
      Institute for Genomic Medicine , La Jolla , CA , USA.
FAU - Lafont, Frank
AU  - Lafont F
AD  - su Center for Infection and Immunity of Lille, Institut Pasteur de Lille, CNRS, 
      INSERM, Lille Regional University Hospital Centre, Lille University , Lille , 
      France.
FAU - Lahm, Tim
AU  - Lahm T
AD  - ro Indiana University School of Medicine, Richard L. Roudebush VA Medical Center, 
      Division of Pulmonary, Critical Care, Sleep and Occupational Medicine , 
      Indianapolis , IN , USA.
FAU - Lakkaraju, Aparna
AU  - Lakkaraju A
AD  - bys University of Wisconsin , Department of Ophthalmology and Visual Sciences , 
      McPherson Eye Research Institute , Madison , WI , USA.
FAU - Lam, Truong
AU  - Lam T
AD  - bwl University of Texas, Medical School at Houston, Division of Cardiovascular 
      Medicine , Department of Medicine , Houston , TX , USA.
FAU - Lamark, Trond
AU  - Lamark T
AD  - bxl University of Tromsø - The Arctic University of Norway , Department of 
      Medical Biology , Tromsø , Norway.
FAU - Lancel, Steve
AU  - Lancel S
AD  - bbk University Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011, EGID , 
      Lille , France.
FAU - Landowski, Terry H
AU  - Landowski TH
AD  - bcn University of Arizona Cancer Center , Department of Medicine , Tucson , AZ , 
      USA.
FAU - Lane, Darius J R
AU  - Lane DJ
AD  - bvi University of Sydney , Department of Pathology and Bosch Institute , Sydney, 
      New South Wales , Australia.
FAU - Lane, Jon D
AU  - Lane JD
AD  - bea University of Bristol, School of Biochemistry , Bristol , UK.
FAU - Lanzi, Cinzia
AU  - Lanzi C
AD  - ll Fondazione IRCCS Istituto Nazionale dei Tumori , Department of Experimental 
      Oncology and Molecular Medicine , Milan , Italy.
FAU - Lapaquette, Pierre
AU  - Lapaquette P
AD  - ayh Université Bourgogne Franche-Comté, Agrosup Dijon, UMR PAM, Équipe Vin, 
      Aliment, Microbiologie, Stress , Dijon , France.
FAU - Lapierre, Louis R
AU  - Lapierre LR
AD  - cm Brown University , Department of Molecular Biology , Cell Biology and 
      Biochemistry , Providence , RI , USA.
FAU - Laporte, Jocelyn
AU  - Laporte J
AD  - sg INSERM U964, CNRS UMR7104, Université de Strasbourg , Department of 
      Translational Medecine , Institut de Génétique et de Biologie Moléculaire et 
      Cellulaire (IGBMC) , Illkirch , France.
FAU - Laukkarinen, Johanna
AU  - Laukkarinen J
AD  - arn Tampere University Hospital , Department of Gastroenterology and Alimentary 
      Tract Surgery , Tampere , Finland.
FAU - Laurie, Gordon W
AU  - Laurie GW
AD  - byk University of Virginia , Department of Cell Biology , Charlottesville , VA , 
      USA.
FAU - Lavandero, Sergio
AU  - Lavandero S
AD  - awk Universidad de Chile, Advanced Center for Chronic Diseases (ACCDiS) , 
      Santiago , Chile.
AD  - bwp University of Texas, Southwestern Medical Center , Department of Internal 
      Medicine , Dallas , TX.
FAU - Lavie, Lena
AU  - Lavie L
AD  - arq Technion-Israel Institute of Technology, Unit of Anatomy and Cell Biology, 
      The Ruth and Bruce Rappaport Faculty of Medicine , Haifa , Israel.
FAU - LaVoie, Matthew J
AU  - LaVoie MJ
AD  - cf Brigham and Women's Hospital, Ann Romney Center for Neurologic Diseases , 
      Department of Neurology , Harvard Medical School , Boston , MA , USA.
FAU - Law, Betty Yuen Kwan
AU  - Law BY
AD  - aai Macau University of Science and Technology, State Key Laboratory of Quality 
      Research in Chinese Medicine , Macau , China.
FAU - Law, Helen Ka-Wai
AU  - Law HK
AD  - px Hong Kong Polytechnic University , Department of Health Technology and 
      Informatics , Faculty of Health and Social Sciences , Kowloon, Hong Kong.
FAU - Law, Kelsey B
AU  - Law KB
AD  - bxd University of Toronto, Hospital for Sick Children , Toronto, Ontario , 
      Canada.
FAU - Layfield, Robert
AU  - Layfield R
AD  - bqe University of Nottingham, School of Life Sciences , Nottingham , UK.
FAU - Lazo, Pedro A
AU  - Lazo PA
AD  - hz Consejo Superior de Investigaciones Científicas (CSIC), Universidad de 
      Salamanca, Experimental Therapeutics and Translational Oncology Program, 
      Instituto de Biología Molecular y Celular del Cáncer , Salamanca , Spain.
AD  - to Instituto de Investigación Biomédica de Salamanca (IBSAL) , Hospital 
      Universitario de Salamanca, Salamanca , Spain.
FAU - Le Cam, Laurent
AU  - Le Cam L
AD  - qu ICM, Institut de Recherche en Cancérologie de Montpellier , Montpellier , 
      France.
AD  - sd INSERM U896 , Montpellier , France.
AD  - sr Institut du Cancer de Montpellier , Montpellier , France.
FAU - Le Roch, Karine G
AU  - Le Roch KG
AD  - bfk University of California Riverside , Department of Cell Biology and 
      Neuroscience , Riverside , CA , USA.
FAU - Le Stunff, Hervé
AU  - Le Stunff H
AD  - azy Université Paris Diderot, Unité Biologie Fonctionnelle et Adaptative - CNRS 
      UMR 8251 , Paris , France.
AD  - bab Université Paris-Sud, CEA, CNRS, Institute for Integrative Biology of the 
      Cell , Gif-sur-Yvette Cedex , France.
FAU - Leardkamolkarn, Vijittra
AU  - Leardkamolkarn V
AD  - aam Mahidol University , Department of Anatomy , Faculty of Science , Bangkok , 
      Thailand.
FAU - Lecuit, Marc
AU  - Lecuit M
AD  - sx Institut Pasteur, INSERM, Biology of Infection Unit , Paris , France.
FAU - Lee, Byung-Hoon
AU  - Lee BH
AD  - ans Seoul National University, College of Pharmacy and Research Institute of 
      Pharmaceutical Science , Seoul , Korea.
FAU - Lee, Che-Hsin
AU  - Lee CH
AD  - fb China Medical University , Department of Microbiology , Taichung , Taiwan.
FAU - Lee, Erinna F
AU  - Lee EF
AD  - zc Olivia Newton-John Cancer Research Institute , Melbourne , Victoria , 
      Australia.
AD  - ze La Trobe University , Department of Chemistry and Physics , Melbourne , 
      Victoria , Australia.
AD  - zf La Trobe University, School of Cancer Medicine , Melbourne , Victoria , 
      Australia.
FAU - Lee, Gyun Min
AU  - Lee GM
AD  - wv KAIST , Department of Biological Sciences , Daejon , Korea.
FAU - Lee, He-Jin
AU  - Lee HJ
AD  - yc Konkuk University, School of Medicine , Department of Anatomy , Seoul , Korea.
FAU - Lee, Hsinyu
AU  - Lee H
AD  - age National Taiwan University , Department of Life Science and Center for 
      Biotechnology , Taipei , Taiwan.
FAU - Lee, Jae Keun
AU  - Lee JK
AD  - yf Korea University , Department of Life Science and Biotechnology , Seoul , 
      Korea.
FAU - Lee, Jongdae
AU  - Lee J
AD  - bfm University of California San Diego , Department of Medicine , La Jolla , CA , 
      USA.
FAU - Lee, Ju-Hyun
AU  - Lee JH
AD  - ahm New York University , Department of Psychiatry , New York NY ; and Center for 
      Dementia Research, Nathan S. Kline Institute , Orangeburg , NY , USA.
FAU - Lee, Jun Hee
AU  - Lee JH
AD  - bob University of Michigan , Department of Molecular and Integrative Physiology , 
      Ann Arbor , MI , USA.
FAU - Lee, Michael
AU  - Lee M
AD  - rd Incheon National University, Division of Life Siences , Incheon , Korea.
FAU - Lee, Myung-Shik
AU  - Lee MS
AD  - arf Yonsei University College of Medicine, Severans Biomedical Science Institute 
      and Department of Internal Medicine , Seoul , Korea.
FAU - Lee, Patty J
AU  - Lee PJ
AD  - cce Yale University School of Medicine, Section of Pulmonary, Critical Care and 
      Sleep Medicine , New Haven , CT , USA.
FAU - Lee, Sam W
AU  - Lee SW
AD  - aat Massachusetts General Hospital and Harvard Medical School, Cutaneous Biology 
      Research Center , Charlestown , MA.
FAU - Lee, Seung-Jae
AU  - Lee SJ
AD  - anq Seoul National University College of Medicine, Neuroscience Research 
      Institute , Department of Medicine , Seoul , Korea.
FAU - Lee, Shiow-Ju
AU  - Lee SJ
AD  - aev National Health Research Institutes, Institute of Biotechnology and 
      Pharmaceutical Research , Miaoli County , Taiwan.
FAU - Lee, Stella Y
AU  - Lee SY
AD  - xa Kansas State University, Division of Biology , Manhattan , KS , USA.
FAU - Lee, Sug Hyung
AU  - Lee SH
AD  - db Catholic University of Korea , Seoul , Korea.
FAU - Lee, Sung Sik
AU  - Lee SS
AD  - kq ETH Zurich, Institute of Biochemistry , Zurich , Switzerland.
AD  - ku ETH Zurich, ScopeM (Scientific Center for Optical and Electron Microscopy) , 
      Zurich , Switzerland.
FAU - Lee, Sung-Joon
AU  - Lee SJ
AD  - ye Korea University , Department of Biotechnology , BK21-PLUS Graduate School of 
      Life Sciences and Biotechnology , Seoul , Korea.
FAU - Lee, Sunhee
AU  - Lee S
AD  - jf Duke University , Department of Medicine , Human Vaccine Institute , Durham , 
      NC , USA.
FAU - Lee, Ying-Ray
AU  - Lee YR
AD  - es Ditmanson Medical Foundation Chia-Yi Christian Hospital, Center for 
      Translational Medicine , Chiayi City , Taiwan.
FAU - Lee, Yong J
AU  - Lee YJ
AD  - bsc University of Pittsburgh , Department of Surgery , Pittsburgh , PA , USA.
FAU - Lee, Young H
AU  - Lee YH
AD  - afo National Institutes of Health, National Cancer Institute, Urologic Oncology 
      Branch , Bethesda , MD , USA.
FAU - Leeuwenburgh, Christiaan
AU  - Leeuwenburgh C
AD  - bjq University of Florida, Institute on Aging , Gainesville , FL , USA.
FAU - Lefort, Sylvain
AU  - Lefort S
AD  - cj British Columbia Cancer Agency, Terry Fox Laboratory , Vancouver, BC , Canada.
FAU - Legouis, Renaud
AU  - Legouis R
AD  - bab Université Paris-Sud, CEA, CNRS, Institute for Integrative Biology of the 
      Cell , Gif-sur-Yvette Cedex , France.
FAU - Lei, Jinzhi
AU  - Lei J
AD  - avd Tsinghua University, Zhou Pei-Yuan Center for Applied Mathematics , Beijing , 
      China.
FAU - Lei, Qun-Ying
AU  - Lei QY
AD  - ly Fudan University Shanghai Medical College , Department of Biochemistry and 
      Molecular Biology , School of Basic Medical Sciences, Institute of Biomedical 
      Sciences , Shanghai , China.
FAU - Leib, David A
AU  - Leib DA
AD  - mh Geisel School of Medicine at Dartmouth , Department of Microbiology and 
      Immunology , Lebanon , NH , USA.
FAU - Leibowitz, Gil
AU  - Leibowitz G
AD  - og Hadassah Hebrew University Medical Center, Endocrinology and Metabolism 
      Service , Department of Medicine , Jerusalem , Israel.
FAU - Lekli, Istvan
AU  - Lekli I
AD  - bir University of Debrecen, Faculty of Pharmacy , Department of Pharmacology , 
      Debrecen , Hungary.
FAU - Lemaire, Stéphane D
AU  - Lemaire SD
AD  - dv Centre National de la Recherche Scientifique, Sorbonne Universités UPMC Univ 
      Paris 06, UMR 8226, Laboratoire de Biologie Moléculaire et Cellulaire des 
      Eucaryotes, Institut de Biologie Physico-Chimique , Paris , France.
FAU - Lemasters, John J
AU  - Lemasters JJ
AD  - acl Medical University of South Carolina, Departments of Drug Discovery and 
      Biomedical Sciences , and Biochemistry and Molecular Biology , Charleston , SC , 
      USA.
FAU - Lemberg, Marius K
AU  - Lemberg MK
AD  - bkg University of Heidelberg, Center for Molecular Biology , Heidelberg , 
      Germany.
FAU - Lemoine, Antoinette
AU  - Lemoine A
AD  - qc Hôpital Paul Brousse - Hôpitaux Universitaires Paris-Sud, Biochimie et 
      Oncogénétique , Villejuif , France.
FAU - Leng, Shuilong
AU  - Leng S
AD  - ny Guangzhou Medical University , Department of Human Anatomy , School of Basic 
      Science , Guangzhou, Guangdong , China.
FAU - Lenz, Guido
AU  - Lenz G
AD  - axc Universidad Federal do Rio Grande do Sul (UFRGS) , Department of Biophysics 
      and Center of Biotechnology , Porto Alegre , Brazil.
FAU - Lenzi, Paola
AU  - Lenzi P
AD  - brt University of Pisa , Department of Translational Research and New 
      Technologies in Medicine and Surgery , Pisa , Italy.
FAU - Lerman, Lilach O
AU  - Lerman LO
AD  - abf Mayo Clinic, Division of Nephrology and Hypertension , Rochester , MN , USA.
FAU - Lettieri Barbato, Daniele
AU  - Lettieri Barbato D
AD  - btd University of Rome "Tor Vergata" , Department of Biology , Rome , Italy.
FAU - Leu, Julia I-Ju
AU  - Leu JI
AD  - akc Perelman School of Medicine at the University of Pennsylvania , Department of 
      Genetics , Philadelphia , PA , USA.
FAU - Leung, Hing Y
AU  - Leung HY
AD  - bjy University of Glasgow, Cancer Research UK Beatson Institute , Glasgow , UK.
AD  - bjz University of Glasgow, Institute of Cancer Sciences , Glasgow , UK.
FAU - Levine, Beth
AU  - Levine B
AD  - qh Howard Hughes Medical Institute , Dallas , TX.
AD  - bvr University of Texas , Southwestern Medical Center, Department of Internal 
      Medicine , Center for Autophagy Research, Dallas , TX , USA.
FAU - Lewis, Patrick A
AU  - Lewis PA
AD  - avm UCL Institute of Neurology , Department of Molecular Neuroscience , London , 
      UK.
AD  - bsy University of Reading, School of Pharmacy, Whiteknights , Reading , UK.
FAU - Lezoualc'h, Frank
AU  - Lezoualc'h F
AD  - bzd University Paul Sabatier, INSERM U1048 , Toulouse , France.
FAU - Li, Chi
AU  - Li C
AD  - bmp University of Louisville, James Graham Brown Cancer Center , Department of 
      Medicine , Department of Pharmacology and Toxicology , Louisville , KY , USA.
FAU - Li, Faqiang
AU  - Li F
AD  - byq Washington University in St Louis, Department of Biology, St. Louis, MO , 
      USA.
FAU - Li, Feng-Jun
AU  - Li FJ
AD  - ags National University of Singapore , Department of Biological Sciences , 
      Singapore.
FAU - Li, Jun
AU  - Li J
AD  - bzr Vanderbilt University , Department of Neurology , Nashville , TN , USA.
FAU - Li, Ke
AU  - Li K
AD  - fe Chinese Academy of Medical Sciences and Peking Union Medical College, 
      Institute of Medicinal Biotechnology , Beijing , China.
FAU - Li, Lian
AU  - Li L
AD  - kd Emory University, School of Medicine , Department of Pharmacology , Atlanta , 
      GA , USA.
FAU - Li, Min
AU  - Li M
AD  - pw Hong Kong Baptist University, School of Chinese Medicine , Kowloon Tong, Hong 
      Kong.
FAU - Li, Min
AU  - Li M
AD  - aqz Sun Yat-Sen University , Department of Pharmacology and Toxicology , School 
      of Pharmaceutical Sciences , Guangzhou , China.
FAU - Li, Qiang
AU  - Li Q
AD  - fj Chinese Academy of Sciences, Division of Medical Physics, Institute of Modern 
      Physics , Lanzhou, Gansu Province , China.
FAU - Li, Rui
AU  - Li R
AD  - abl McGill University , Department of Neuroscience , Montreal Neurological 
      Institute , Montreal, QC , Canada.
FAU - Li, Sheng
AU  - Li S
AD  - fq Chinese Academy of Sciences, Key Laboratory of Developmental and Evolutionary 
      Biology, Institute of Plant Physiology and Ecology, Shanghai Institutes for 
      Biological Sciences , Shanghai , China.
FAU - Li, Wei
AU  - Li W
AD  - cq Capital Medical University, Center for Medical Genetics, Beijing Children's 
      Hospital , Beijing , China.
FAU - Li, Wei
AU  - Li W
AD  - fv Chinese Academy of Sciences, State Key Laboratory of Stem Cell and 
      Reproductive Biology, Institute of Zoology , Beijing , China.
FAU - Li, Xiaotao
AU  - Li X
AD  - jr East China Normal University , Shanghai , China.
FAU - Li, Yumin
AU  - Li Y
AD  - ang Second Hospital of Lanzhou University, Key Laboratory of Digestive System 
      Tumors , Gansu , China.
FAU - Lian, Jiqin
AU  - Lian J
AD  - atk Third Military Medical University , Department of Biochemistry and Molecular 
      Biology , Chongqing , China.
FAU - Liang, Chengyu
AU  - Liang C
AD  - bux University of Southern California, Keck School of Medicine , Department of 
      Molecular Microbiology and Immunology , Los Angeles , CA , USA.
FAU - Liang, Qiangrong
AU  - Liang Q
AD  - ahh New York Institute of Technology , Department of Biomedical Sciences , 
      College of Osteopathic Medicine , Old Westbury , NY , USA.
FAU - Liao, Yulin
AU  - Liao Y
AD  - apv Southern Medical University , Department of Cardiology , Nanfang Hospital , 
      Guangzhou , China.
FAU - Liberal, Joana
AU  - Liberal J
AD  - bhp University of Coimbra, Center for Neuroscience and Cell Biology and Faculty 
      of Pharmacy , Coimbra , Portugal.
FAU - Liberski, Pawel P
AU  - Liberski PP
AD  - acf Medical University of Lodz , Department of Molecular Pathology and 
      Neuropathology , Lodz , Poland.
FAU - Lie, Pearl
AU  - Lie P
AD  - dg Center for Dementia Research, Nathan S. Kline Institute , Orangeburg , NY , 
      USA.
FAU - Lieberman, Andrew P
AU  - Lieberman AP
AD  - bnx University of Michigan Medical School , Department of Pathology , Ann Arbor , 
      MI , USA.
FAU - Lim, Hyunjung Jade
AU  - Lim HJ
AD  - ya Konkuk University , Department of Veterinary Medicine , Seoul , Korea.
FAU - Lim, Kah-Leong
AU  - Lim KL
AD  - aga National Neuroscience Institute , Singapore.
AD  - agv National University of Singapore , Department of Physiology , Yong Loo Lin 
      School of Medicine , Singapore.
FAU - Lim, Kyu
AU  - Lim K
AD  - gj Chungnam National University, School of Medicine , Department of Biochemistry 
      , Infection Signaling Network Research Center, Cancer Research Institute , 
      Daejeon , Korea.
FAU - Lima, Raquel T
AU  - Lima RT
AD  - bsp University of Porto, Cancer Drug Resistance Group, IPATIMUP - Institute of 
      Molecular Pathology and Immunology , Porto , Portugal.
AD  - bsr University of Porto , Department of Pathology and Oncology , Faculty of 
      Medicine , Porto , Portugal.
AD  - bss University of Porto, i3S-Instituto de Investigação e Inovação em Saúde , 
      Porto , Portugal.
FAU - Lin, Chang-Shen
AU  - Lin CS
AD  - xc Kaohsiung Medical University , Graduate Institute of Medicine , Kaohsiung , 
      Taiwan.
AD  - agd National Sun Yat-Sen University, Department of Biological Sciences , 
      Kaohsiung , Taiwan.
FAU - Lin, Chiou-Feng
AU  - Lin CF
AD  - ark Taipei Medical University , Department of Microbiology and Immunology , 
      Institute of Medical Sciences , Taipei , Taiwan.
FAU - Lin, Fang
AU  - Lin F
AD  - apn Soochow University, School of Pharmaceutical Science , Department of 
      Pharmacology , Laboratory of Aging and Nervous Diseases , Su Zhou, Jiangsu 
      Province , China.
FAU - Lin, Fangming
AU  - Lin F
AD  - hk Columbia University, College of Physicians and Surgeons , Department of 
      Pediatrics , New York , NY , USA.
FAU - Lin, Fu-Cheng
AU  - Lin FC
AD  - ccu Zhejiang University, Institute of Agriculture and Biotechnology , Hangzhou , 
      China.
FAU - Lin, Kui
AU  - Lin K
AD  - mm Genentech Inc. , Department of Translational Oncology , South San Francisco , 
      CA , USA.
FAU - Lin, Kwang-Huei
AU  - Lin KH
AD  - ej Chang Gung University , Department of Biochemistry , College of Medicine , 
      Taoyuan , Taiwan.
FAU - Lin, Pei-Hui
AU  - Lin PH
AD  - aik Ohio State University , Department of Surgery , Davis Heart and Lung Research 
      Institute , Columbus , OH , USA.
FAU - Lin, Tianwei
AU  - Lin T
AD  - cby Xiamen University, School of Life Sciences , Fujian , China.
FAU - Lin, Wan-Wan
AU  - Lin WW
AD  - agh National Taiwan University , Department of Pharmacology , College of Medicine 
      , Taipei , Taiwan.
FAU - Lin, Yee-Shin
AU  - Lin YS
AD  - ael National Cheng Kung University , Department of Microbiology and Immunology , 
      College of Medicine , Tainan , Taiwan.
FAU - Lin, Yong
AU  - Lin Y
AD  - aaa Lovelace Respiratory Research Institute, Molecular Biology and Lung Cancer 
      Program , Albuquerque , NM , USA.
FAU - Linden, Rafael
AU  - Linden R
AD  - avq UFRJ, Instituto de Biofisica Carlos Chagas Filho , Rio de Janeiro , Brazil.
FAU - Lindholm, Dan
AU  - Lindholm D
AD  - bki University of Helsinki, Biomedicum , Helsinki , Finland.
FAU - Lindqvist, Lisa M
AU  - Lindqvist LM
AD  - bnq Cell Signalling and Cell Death Division, and University of Melbourne, Walter 
      and Eliza Hall Institute of Medical Research , Department of Medical Biology , 
      Parkville , Victoria , Australia.
FAU - Lingor, Paul
AU  - Lingor P
AD  - bkd University of Göttingen , Department of Neurology , Göttingen , Germany.
FAU - Linkermann, Andreas
AU  - Linkermann A
AD  - gg Christian-Albrechts-University of Kiel , Department of Nephrology and 
      Hypertension , Kiel , Germany.
FAU - Liotta, Lance A
AU  - Liotta LA
AD  - ms George Mason University , Manassas , VA , USA.
FAU - Lipinski, Marta M
AU  - Lipinski MM
AD  - bng University of Maryland, School of Medicine , Department of Anesthesiology , 
      Baltimore , MD , USA.
FAU - Lira, Vitor A
AU  - Lira VA
AD  - bld University of Iowa , Department of Health and Human Physiology , Iowa City , 
      IA , USA.
FAU - Lisanti, Michael P
AU  - Lisanti MP
AD  - bmv University of Manchester, Breakthrough Breast Cancer Research Unit, 
      Manchester Centre for Cellular Metabolism , UK.
FAU - Liton, Paloma B
AU  - Liton PB
AD  - jh Duke University , Department of Ophthalmology , Durham , NC , USA.
FAU - Liu, Bo
AU  - Liu B
AD  - apb Sichuan University, State Key Laboratory of Biotherapy/Collaborative 
      Innovation Center of Biotherapy, West China Hospital , Chengdu , China.
FAU - Liu, Chong
AU  - Liu C
AD  - ani Second Military Medical University , Department of Pharmacology , Shanghai , 
      China.
FAU - Liu, Chun-Feng
AU  - Liu CF
AD  - apk Soochow University , Department of Neurology , Second Affiliated Hospital of 
      Soochow University and Institute of Neuroscience , Suzhou , China.
FAU - Liu, Fei
AU  - Liu F
AD  - bok University of Michigan, School of Dentistry , Department of Biologic and 
      Materials Sciences , Ann Arbor , MI , USA.
FAU - Liu, Hung-Jen
AU  - Liu HJ
AD  - aeq National Chung Hsing University, Institute of Molecular Biology , Taichung , 
      Taiwan.
FAU - Liu, Jianxun
AU  - Liu J
AD  - ex China Academy of Chinese Medical Sciences, Institute of Basic Medical Sciences 
      of Xiyuan Hospital , Beijing , China.
FAU - Liu, Jing-Jing
AU  - Liu JJ
AD  - bfw University of California San Diego, Division of Biological Sciences, Section 
      of Molecular Biology , La Jolla , CA , USA.
FAU - Liu, Jing-Lan
AU  - Liu JL
AD  - ef Chang Gung Memorial Hospital , Department of Pathology , Chiayi , Taiwan.
FAU - Liu, Ke
AU  - Liu K
AD  - apa Sichuan University, Key Laboratory of Bio-Resources and Eco-Environment of 
      Ministry of Education, College of Life Science , Chengdu, Sichuan , China.
FAU - Liu, Leyuan
AU  - Liu L
AD  - asf Texas A&M Health Science Center, Institute of Biosciences and Technology , 
      Houston , TX , USA.
FAU - Liu, Liang
AU  - Liu L
AD  - aai Macau University of Science and Technology, State Key Laboratory of Quality 
      Research in Chinese Medicine , Macau , China.
FAU - Liu, Quentin
AU  - Liu Q
AD  - ip Dalian Medical University, Institute of Cancer Stem Cell , Dalian , China.
FAU - Liu, Rong-Yu
AU  - Liu RY
AD  - aso The First Affiliated Hospital of Anhui Medical University , Department of 
      Pulmonary , Anhui Geriatric Institute , Anhui , China.
FAU - Liu, Shiming
AU  - Liu S
AD  - ate The Second Hospital Affiliated to Guangzhou Medical University, Guangzhou 
      Institute of Cardiovascular Disease , Guangzhou, Guangdong Province , China.
FAU - Liu, Shuwen
AU  - Liu S
AD  - apw Southern Medical University, School of Pharmaceutical Sciences, Guangzhou , 
      Guangdong , China.
FAU - Liu, Wei
AU  - Liu W
AD  - ccz Zhejiang University, School of Medicine , Department of Biochemistry , 
      Hangzhou, Zhejiang , China.
FAU - Liu, Xian-De
AU  - Liu XD
AD  - bwb University of Texas, MD Anderson Cancer Center , Department of Genitourinary 
      Medical Oncology , Houston , TX , USA.
FAU - Liu, Xiangguo
AU  - Liu X
AD  - aob Shandong University, School of Life Sciences , Jinan , China.
FAU - Liu, Xiao-Hong
AU  - Liu XH
AD  - ccu Zhejiang University, Institute of Agriculture and Biotechnology , Hangzhou , 
      China.
FAU - Liu, Xinfeng
AU  - Liu X
AD  - adv Nanjing University School of Medicine, Jinling Hospital , Department of 
      Neurology , Nanjing , China.
FAU - Liu, Xu
AU  - Liu X
AD  - boc University of Michigan , Department of Molecular , Cellular, and 
      Developmental Biology , Ann Arbor , MI , USA.
AD  - bog University of Michigan, Life Sciences Institute , Ann Arbor , MI , USA.
FAU - Liu, Xueqin
AU  - Liu X
AD  - lw Freshwater Aquaculture Collaborative Innovation Center of Hubei Province , 
      Wuhan , China.
AD  - qj Huazhong Agricultural University , Department of Aquatic Animal Medicine , 
      College of Fisheries , Wuhan , China.
FAU - Liu, Yang
AU  - Liu Y
AD  - bvr University of Texas , Southwestern Medical Center, Department of Internal 
      Medicine , Center for Autophagy Research, Dallas , TX , USA.
FAU - Liu, Yule
AU  - Liu Y
AD  - avb Tsinghua University, School of Life Sciences , Beijing , China.
FAU - Liu, Zexian
AU  - Liu Z
AD  - qk Huazhong University of Science and Technology , Department of Biomedical 
      Engineering , College of Life Science and Technology , Wuhan, Hubei , China.
FAU - Liu, Zhe
AU  - Liu Z
AD  - atv Tianjin Medical University , Department of Immunology , Tianjin Key 
      Laboratory of Medical Epigenetics , Tianjin , China.
FAU - Liuzzi, Juan P
AU  - Liuzzi JP
AD  - lk Florida International University , Department of Dietetics and Nutrition , 
      Miami , FL , USA.
FAU - Lizard, Gérard
AU  - Lizard G
AD  - bak University Bourgogne Franche Comté, EA 7270/INSERM , Dijon , France.
FAU - Ljujic, Mila
AU  - Ljujic M
AD  - agp National University of Ireland, Apoptosis Research Centre , Galway , Ireland.
FAU - Lodhi, Irfan J
AU  - Lodhi IJ
AD  - cbf Washington University, School of Medicine, Division of Endocrinology, 
      Metabolism and Lipid Research , Department of Medicine , St. Louis , MO , USA.
FAU - Logue, Susan E
AU  - Logue SE
AD  - agp National University of Ireland, Apoptosis Research Centre , Galway , Ireland.
FAU - Lokeshwar, Bal L
AU  - Lokeshwar BL
AD  - na Georgia Regents University, Cancer Center , Department of Medicine , Augusta , 
      GA , USA.
FAU - Long, Yun Chau
AU  - Long YC
AD  - agw National University of Singapore, Yong Loo Lin School of Medicine , 
      Department of Biochemistry , Singapore.
FAU - Lonial, Sagar
AU  - Lonial S
AD  - ki Emory University, Winship Cancer Institute , Department of Hematology and 
      Medical Oncology , Atlanta , GA , USA.
FAU - Loos, Benjamin
AU  - Loos B
AD  - aqr Stellenbosch University , Department of Physiological Sciences , Stellenbosch 
      , South Africa.
FAU - López-Otín, Carlos
AU  - López-Otín C
AD  - awu Universidad de Oviedo, Instituto Universitario de Oncología , Departamento de 
      Bioquímica y Biología Molecular , Oviedo , Spain.
FAU - López-Vicario, Cristina
AU  - López-Vicario C
AD  - bda University of Barcelona , Department of Biochemistry and Molecular Genetics , 
      Hospital Clínic, IDIBAPS-CIBERehd , Barcelona , Spain.
FAU - Lorente, Mar
AU  - Lorente M
AD  - hs Complutense University, Instituto de Investigaciones Sanitarias San Carlos 
      (IdISSC) , Department of Biochemistry and Molecular Biology I , School of Biology 
      , Madrid , Spain.
FAU - Lorenzi, Philip L
AU  - Lorenzi PL
AD  - bwa University of Texas, MD Anderson Cancer Center , Department of Bioinformatics 
      and Computational Biology , Houston , TX , USA.
AD  - bwg University of Texas, MD Anderson Cancer Center, The Proteomics and 
      Metabolomics Core Facility , Houston , TX , USA.
FAU - Lõrincz, Péter
AU  - Lõrincz P
AD  - kj Eötvös Loránd University , Department of Anatomy , Cell and Developmental 
      Biology , Budapest , Hungary.
FAU - Los, Marek
AU  - Los M
AD  - zn Medical University of Silesia, ENT Department, School of Medicine, Katowice, 
      Poland.
FAU - Lotze, Michael T
AU  - Lotze MT
AD  - bsd University of Pittsburgh , Department of Surgery , University of Pittsburgh 
      Cancer Institute , Pittsburgh , PA , USA.
FAU - Lovat, Penny E
AU  - Lovat PE
AD  - ahq Newcastle University, The Medical School, Institute of Cellular Medicine , 
      Newcastle upon Tyne , UK.
FAU - Lu, Binfeng
AU  - Lu B
AD  - bsi University of Pittsburgh, School of Medicine , Department of Immunology , 
      Pittsburgh , PA , USA.
FAU - Lu, Bo
AU  - Lu B
AD  - ato Thomas Jefferson University Hospitals , Department of Radiation Oncology , 
      Philadelphia , PA , USA.
FAU - Lu, Jiahong
AU  - Lu J
AD  - bmt University of Macau, State Key Lab of Quality Research in Chinese Medicine, 
      Institute of Chinese Medical Sciences , Macao , China.
FAU - Lu, Qing
AU  - Lu Q
AD  - am Alpert Medical School of Brown University, Vascular Research Laboratory, 
      Providence Veterans Affairs Medical Center , Department of Medicine , Providence 
      , RI , USA.
FAU - Lu, She-Min
AU  - Lu SM
AD  - cca Xi'an Jiaotong University Health Science Center , Department of Biochemistry 
      and Molecular Biology , School of Basic Medical Sciences , Shaanxi , China.
FAU - Lu, Shuyan
AU  - Lu S
AD  - ake Pfizer Inc., Drug Safety Research and Development , San Diego , CA , USA.
FAU - Lu, Yingying
AU  - Lu Y
AD  - gu City University of Hong Kong , Department of Biomedical Sciences , Kowloon 
      Tong, Hong Kong , China.
FAU - Luciano, Frédéric
AU  - Luciano F
AD  - ru INSERM U1065, C3M, Team 2 , Nice , France.
FAU - Luckhart, Shirley
AU  - Luckhart S
AD  - bez University of California Davis , Department of Medical Microbiology and 
      Immunology , School of Medicine , Davis , CA , USA.
FAU - Lucocq, John Milton
AU  - Lucocq JM
AD  - bvd University of St Andrews, School of Medicine , St Andrews, Fife , UK.
FAU - Ludovico, Paula
AU  - Ludovico P
AD  - boo Life and Health Sciences Research Institute (ICVS), School of Health 
      Sciences, University of Minho, Braga, Portugal.
AD  - boq ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal.
FAU - Lugea, Aurelia
AU  - Lugea A
AD  - df Cedars-Sinai Medical Center, VAGLAHS-UCLA, Pancreatic Research Group , Los 
      Angeles , CA , USA.
FAU - Lukacs, Nicholas W
AU  - Lukacs NW
AD  - bnx University of Michigan Medical School , Department of Pathology , Ann Arbor , 
      MI , USA.
FAU - Lum, Julian J
AU  - Lum JJ
AD  - aux Trev and Joyce Deeley Research Centre; and University of Victoria, BC Cancer 
      Agency; and Department of Biochemistry and Microbiology , Victoria, BC , Canada.
FAU - Lund, Anders H
AU  - Lund AH
AD  - bij University of Copenhagen, Biotech Research and Innovative Center (BRIC) , 
      Copenhagen , Denmark.
FAU - Luo, Honglin
AU  - Luo H
AD  - beg University of British Columbia , Department of Pathology and Laboratory 
      Medicine , James Hogg Research Centre , Vancouver, BC , Canada.
FAU - Luo, Jia
AU  - Luo J
AD  - bll University of Kentucky, College of Medicine , Department of Pharmacology and 
      Nutritional Sciences , Lexington , KY , USA.
FAU - Luo, Shouqing
AU  - Luo S
AD  - akf Plymouth University, Peninsula School of Medicine and Dentistry , Plymouth , 
      UK.
FAU - Luparello, Claudio
AU  - Luparello C
AD  - brf University of Palermo , Dipartimento di Scienze e Tecnologie Biologiche , 
      Chimiche e Farmaceutiche (STEBICEF) , Palermo , Italy.
FAU - Lyons, Timothy
AU  - Lyons T
AD  - ala Queen's University of Belfast, Centre for Experimental Medicine , Belfast , 
      UK.
FAU - Ma, Jianjie
AU  - Ma J
AD  - aik Ohio State University , Department of Surgery , Davis Heart and Lung Research 
      Institute , Columbus , OH , USA.
FAU - Ma, Yi
AU  - Ma Y
AD  - aoi Shanghai Jiao Tong University, School of Medicine, Center for Reproductive 
      Medicine, Renji Hospital , Shanghai , China.
FAU - Ma, Yong
AU  - Ma Y
AD  - asp The First Affiliated Hospital of Harbin Medical University , Department of 
      General Surgery , Harbin, Heilongjiang Province , China.
FAU - Ma, Zhenyi
AU  - Ma Z
AD  - atu Tianjin Medical University , Department of Biochemistry and Molecular Biology 
      , School of Basic Medical Sciences, Tianjin Key Laboratory of Medical Epigenetics 
      , Tianjin , China.
FAU - Machado, Juliano
AU  - Machado J
AD  - bts University of São Paulo, Ribeirão Preto Medical School , Department of 
      Biochemistry and Immunology , Ribeirão Preto, São Paulo , Brazil.
FAU - Machado-Santelli, Glaucia M
AU  - Machado-Santelli GM
AD  - btr University of São Paulo, Institute of Biomedical Science , Department of Cell 
      and Developmental Biology , São Paulo, SP , Brazil.
FAU - Macian, Fernando
AU  - Macian F
AD  - ac Albert Einstein College of Medicine , Department of Pathology , Bronx , NY , 
      USA.
FAU - MacIntosh, Gustavo C
AU  - MacIntosh GC
AD  - ue Iowa State University, Roy J. Carver Department of Biochemistry, Biophysics, 
      and Molecular Biology , Ames , IA , USA.
FAU - MacKeigan, Jeffrey P
AU  - MacKeigan JP
AD  - bzo Van Andel Research Institute, Laboratory of Systems Biology , Grand Rapids , 
      MI , USA.
FAU - Macleod, Kay F
AU  - Macleod KF
AD  - bhe University of Chicago , The Ben May Department for Cancer Research , Chicago 
      , IL , USA.
FAU - MacMicking, John D
AU  - MacMicking JD
AD  - ccd Yale University School of Medicine , Department of Microbial Pathogenesis and 
      Howard Hughes Medical Institute , New Haven , CT , USA.
FAU - MacMillan-Crow, Lee Ann
AU  - MacMillan-Crow LA
AD  - bct University of Arkansas for Medical Sciences , Department of 
      Pharmacology/Toxicology , Little Rock , AR , USA.
FAU - Madeo, Frank
AU  - Madeo F
AD  - bke University of Graz, Institute of Molecular Biosciences, BioTechMed Graz , 
      Graz , Austria.
FAU - Madesh, Muniswamy
AU  - Madesh M
AD  - asd Temple University, School of Medicine , Department of Biochemistry ; and 
      Center for Translational Medicine , Philadelphia , PA , USA.
FAU - Madrigal-Matute, Julio
AU  - Madrigal-Matute J
AD  - y Albert Einstein College of Medicine , Department of Developmental and Molecular 
      Biology , Bronx , NY , USA.
FAU - Maeda, Akiko
AU  - Maeda A
AD  - cv Case Western Reserve University , Department of Ophthalmology and Visual 
      Sciences , Cleveland , OH , USA.
FAU - Maeda, Tatsuya
AU  - Maeda T
AD  - bwx University of Tokyo, Institute of Molecular and Cellular Biosciences , Tokyo 
      , Japan.
FAU - Maegawa, Gustavo
AU  - Maegawa G
AD  - bjn University of Florida , Department of Pediatrics/Genetics and Metabolism , 
      Gainesville , FL , USA.
FAU - Maellaro, Emilia
AU  - Maellaro E
AD  - bud University of Siena , Department of Molecular and Developmental Medicine , 
      Siena , Italy.
FAU - Maes, Hannelore
AU  - Maes H
AD  - yn KU Leuven, Laboratory for Cell Death Research and Therapy , Department of 
      Cellular and Molecular Medicine , Campus Gasthuisberg , Leuven , Belgium.
FAU - Magariños, Marta
AU  - Magariños M
AD  - awd Universidad Autónoma de Madrid , Departamento de Biología , Madrid , Spain.
FAU - Maiese, Kenneth
AU  - Maiese K
AD  - bnp University of Medicine and Dentistry of New Jersey, Cellular and Molecular 
      Signaling , Newark , NJ , USA.
FAU - Maiti, Tapas K
AU  - Maiti TK
AD  - rh Indian Institute of Technology Kharagpur , Department of Biotechnology , 
      Kharagpur , India.
FAU - Maiuri, Luigi
AU  - Maiuri L
AD  - cah San Raffaele Scientific Institute, European Institute for Research in Cystic 
      Fibrosis , Milan , Italy.
FAU - Maiuri, Maria Chiara
AU  - Maiuri MC
AD  - avv UMRS 1138, Centre de Recherche des Cordeliers , Paris , France.
FAU - Maki, Carl G
AU  - Maki CG
AD  - alx Rush University Medical Center , Department of Anatomy and Cell Biology , 
      Chicago , IL , USA.
FAU - Malli, Roland
AU  - Malli R
AD  - ace Medical University of Graz, Institute of Molecular Biology and Biochemistry, 
      Centre of Molecular Medicine , Graz , Austria.
FAU - Malorni, Walter
AU  - Malorni W
AD  - vd Istituto Superiore di Sanità , Rome , Italy.
AD  - amp San Raffaele Institute, Dept. of Therapeutic Research and Medicine Evaluation 
      , Sulmona, L'Aquila , Italy.
FAU - Maloyan, Alina
AU  - Maloyan A
AD  - aiq Oregon Health and Science University, Knight Cardiovascular Institute , 
      Portland , OR , USA.
FAU - Mami-Chouaib, Fathia
AU  - Mami-Chouaib F
AD  - oe Gustave Roussy Institute , Villejuif , France.
FAU - Man, Na
AU  - Man N
AD  - bnv University of Miami, Miller School of Medicine, Sylvester Comprehensive 
      Cancer Center , Miami , FL , USA.
AD  - btv University of Science and Technology of China , Anhui , China.
FAU - Mancias, Joseph D
AU  - Mancias JD
AD  - pa Harvard Medical School, Dana Farber Cancer Institute and Beth Israel Deaconess 
      Medical Center , Department of Radiation Oncology , Boston , MA , USA.
FAU - Mandelkow, Eva-Maria
AU  - Mandelkow EM
AD  - jp DZNE, German Center for Neurodegenerative Diseases, and CAESAR Research Center 
      , Bonn , Germany.
FAU - Mandell, Michael A
AU  - Mandell MA
AD  - bpn University of New Mexico, Health Sciences Center , Department of Molecular 
      Genetics and Microbiology , Albuquerque , NM , USA.
FAU - Manfredi, Angelo A
AU  - Manfredi AA
AD  - caj San Raffaele Scientific Institute , Milan , Italy.
FAU - Manié, Serge N
AU  - Manié SN
AD  - avu UMR CNRS 5286, INSERM 1052, Cancer Research Center of Lyon , Lyon , France.
FAU - Manzoni, Claudia
AU  - Manzoni C
AD  - avn UCL Institute of Neurology , London , UK.
AD  - bsx University of Reading, School of Pharmacy , Reading , UK.
FAU - Mao, Kai
AU  - Mao K
AD  - aau Massachusetts General Hospital and Harvard Medical School , Department of 
      Molecular Biology ; Department of Genetics , Boston , MA , USA.
FAU - Mao, Zixu
AU  - Mao Z
AD  - kc Emory University, School of Medicine , Department of Pharmacology and 
      Neurology , Atlanta , GA , USA.
FAU - Mao, Zong-Wan
AU  - Mao ZW
AD  - arb Sun Yat-Sen University, School of Chemistry and Chemical Engineering , 
      Guangzhou , China.
FAU - Marambaud, Philippe
AU  - Marambaud P
AD  - asn The Feinstein Institute for Medical Research, North Shore LIJ Health System, 
      Litwin-Zucker Research Center for the Study of Alzheimer's Disease , New York , 
      NY , USA.
FAU - Marconi, Anna Maria
AU  - Marconi AM
AD  - bom University of Milan , Department of Health Sciences , Milan , Italy.
FAU - Marelja, Zvonimir
AU  - Marelja Z
AD  - ajm Paris Descartes University-Sorbonne Paris Cité, Imagine Institute , Paris , 
      France.
FAU - Marfe, Gabriella
AU  - Marfe G
AD  - anj Second University of Naples , Department of Biochemistry and Biophysics , 
      Naples , Italy.
FAU - Margeta, Marta
AU  - Margeta M
AD  - bgi University of California San Francisco, School of Medicine , Department of 
      Pathology , San Francisco , CA , USA.
FAU - Margittai, Eva
AU  - Margittai E
AD  - anm Semmelweis University, Institute of Human Physiology and Clinical 
      Experimental Research , Budapest , Hungary.
FAU - Mari, Muriel
AU  - Mari M
AD  - bbp University Medical Center Utrecht , Department of Cell Biology , Groningen , 
      The Netherlands.
FAU - Mariani, Francesca V
AU  - Mariani FV
AD  - buy University of Southern California, Keck School of Medicine, Eli and Edythe 
      Broad CIRM Center for Regenerative Medicine and Stem Cell Research , Department 
      of Cell and Neurobiology , Los Angeles , CA , USA.
FAU - Marin, Concepcio
AU  - Marin C
AD  - uq IRCE, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) , 
      Barcelona , Spain.
FAU - Marinelli, Sara
AU  - Marinelli S
AD  - ha CNR, Institute of Cell Biology and Neurobiology and IRCCS Santa Lucia 
      Foundation , Rome , Italy.
FAU - Mariño, Guillermo
AU  - Mariño G
AD  - bqx University of Oviedo , Department of Animal Physiology , Faculty of Medicine, 
      Campus del Cristo , Oviedo , Spain.
FAU - Markovic, Ivanka
AU  - Markovic I
AD  - bdl University of Belgrade, Institute of Medical and Clinical Biochemistry, 
      Faculty of Medicine , Belgrade , Serbia.
FAU - Marquez, Rebecca
AU  - Marquez R
AD  - bli University of Kansas and University of Kansas Cancer Center , Departments of 
      Molecular Biosciences and Radiation Oncology , Lawrence , KS , USA.
FAU - Martelli, Alberto M
AU  - Martelli AM
AD  - bdu University of Bologna , Department of Biomedical and Neuromotor Sciences , 
      Bologna , Italy.
FAU - Martens, Sascha
AU  - Martens S
AD  - byi University of Vienna, Max F. Perutz Laboratories , Vienna , Austria.
FAU - Martin, Katie R
AU  - Martin KR
AD  - bzo Van Andel Research Institute, Laboratory of Systems Biology , Grand Rapids , 
      MI , USA.
FAU - Martin, Seamus J
AU  - Martin SJ
AD  - auy Trinity College Dublin , Department of Genetics , The Smurfit Institute , 
      Dublin , Ireland.
FAU - Martin, Shaun
AU  - Martin S
AD  - yl KU Leuven , Department of Cellular and Molecular Medicine , Leuven , Belgium.
FAU - Martin-Acebes, Miguel A
AU  - Martin-Acebes MA
AD  - dz Centro de Biologia Molecular "Severo Ochoa" (UAM/CSIC) , Department of 
      Virology and Microbiology , Madrid , Spain.
FAU - Martín-Sanz, Paloma
AU  - Martín-Sanz P
AD  - tp Instituto de Investigaciones Biomédicas Alberto Sols, CSIC/UAM, Centro de 
      Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) 
      , Madrid , Spain.
FAU - Martinand-Mari, Camille
AU  - Martinand-Mari C
AD  - bpb University of Montpellier, UMR 5554 , Montpellier , France.
FAU - Martinet, Wim
AU  - Martinet W
AD  - bcm University of Antwerp, Laboratory of Physiopharmacology, Wilrijk , Antwerp , 
      Belgium.
FAU - Martinez, Jennifer
AU  - Martinez J
AD  - bbj National Institute of Environmental Health Sciences, Immunity, Inflammation, 
      and Disease Laboratory, Research Triangle Park, NC, USA.
FAU - Martinez-Lopez, Nuria
AU  - Martinez-Lopez N
AD  - af Albert Einstein College of Medicine, Departments of Medicine and Molecular 
      Pharmacology , Bronx , NY , USA.
FAU - Martinez-Outschoorn, Ubaldo
AU  - Martinez-Outschoorn U
AD  - ats Thomas Jefferson University , Philadelphia , PA , USA.
FAU - Martínez-Velázquez, Moisés
AU  - Martínez-Velázquez M
AD  - eb Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de 
      Jalisco, AC, Unidad de Biotecnología Médica y Farmacéutica , Guadalajara , 
      Jalisco , México.
FAU - Martinez-Vicente, Marta
AU  - Martinez-Vicente M
AD  - bzm Vall d'Hebron Research Institute-CIBERNED, Neurodegenerative Diseases 
      Research Group , Barcelona , Spain.
FAU - Martins, Waleska Kerllen
AU  - Martins WK
AD  - amw São Paulo University , Biochemistry Department ; and Santo Amaro University, 
      Life Sciences , São Paulo , Brazil.
FAU - Mashima, Hirosato
AU  - Mashima H
AD  - t Akita University, Graduate School of Medicine , Akita , Japan.
FAU - Mastrianni, James A
AU  - Mastrianni JA
AD  - bhd University of Chicago, Pritzker School of Medicine , Department of Neurology 
      , Chicago , IL , USA.
FAU - Matarese, Giuseppe
AU  - Matarese G
AD  - up IRCCS-MultiMedica , Milan , Italy.
AD  - axu Università di Salerno , Dipartimento di Medicina e Chirurgia , Baronissi, 
      Salerno , Italy.
FAU - Matarrese, Paola
AU  - Matarrese P
AD  - vc Istituto Superiore di Sanità , Department of Therapeutic Research and Medicine 
      , Evaluation Section of Cell Aging, Degeneration and Gender Medicine , Rome , 
      Italy.
FAU - Mateo, Roberto
AU  - Mateo R
AD  - aqj Stanford University , Department of Microbiology and Immunology , Stanford , 
      CA , USA.
FAU - Matoba, Satoaki
AU  - Matoba S
AD  - ys Kyoto Prefectural University of Medicine , Department of Cardiovascular 
      Medicine , Graduate School of Medical Science , Kyoto , Japan.
FAU - Matsumoto, Naomichi
AU  - Matsumoto N
AD  - cch Yokohama City University Graduate School of Medicine , Department of Human 
      Genetics , Yokohama , Japan.
FAU - Matsushita, Takehiko
AU  - Matsushita T
AD  - xx Kobe University, Graduate School of Medicine , Department of Orthopaedic 
      Surgery , Hyogo , Japan.
FAU - Matsuura, Akira
AU  - Matsuura A
AD  - et Chiba University , Department of Nanobiology , Chiba , Japan.
FAU - Matsuzawa, Takeshi
AU  - Matsuzawa T
AD  - ais Osaka Prefecture University, Graduate School of Life and Environmental 
      Science , Osaka , Japan.
FAU - Mattson, Mark P
AU  - Mattson MP
AD  - afg National Institute on Aging, Intramural Research Program, Laboratory of 
      Neurosciences , Baltimore , MD , USA.
FAU - Matus, Soledad
AU  - Matus S
AD  - ahf Neurounion Biomedical Foundation , Santiago , Chile.
AD  - bge FONDAP Center for Geroscience, Brain Health and Metabolism, Santiago, Chile.
AD  - bhh University of Chile, Biomedical Neuroscience Institute , Santiago , Chile.
FAU - Maugeri, Norma
AU  - Maugeri N
AD  - cag Vita-Salute San Raffaele University, San Raffaele Scientific Institute, 
      Autoimmunity and Vascular Inflammation Unit , Milan , Italy.
FAU - Mauvezin, Caroline
AU  - Mauvezin C
AD  - bos University of Minnesota , Department of Genetics , Cell Biology and 
      Development , Minneapolis , MN , USA.
FAU - Mayer, Andreas
AU  - Mayer A
AD  - blv University of Lausanne , Department of Biochemistry , Epalinges , 
      Switzerland.
FAU - Maysinger, Dusica
AU  - Maysinger D
AD  - abm McGill University , Department of Pharmacology and Therapeutics , Montreal, 
      Quebec , Canada.
FAU - Mazzolini, Guillermo D
AU  - Mazzolini GD
AD  - aw Austral University-CONICET, Gene and Cell Therapy Laboratory , Pilar , Buenos 
      Aires , Argentina.
FAU - McBrayer, Mary Kate
AU  - McBrayer MK
AD  - dg Center for Dementia Research, Nathan S. Kline Institute , Orangeburg , NY , 
      USA.
FAU - McCall, Kimberly
AU  - McCall K
AD  - cb Boston University , Department of Biology , Boston , MA , USA.
FAU - McCormick, Craig
AU  - McCormick C
AD  - ij Dalhousie University , Department of Microbiology and Immunology , Halifax, 
      Nova Scotia , Canada.
FAU - McInerney, Gerald M
AU  - McInerney GM
AD  - xi Karolinska Institute , Department of Microbiology , Tumor and Cell Biology , 
      Stockholm , Sweden.
FAU - McIver, Skye C
AU  - McIver SC
AD  - byt University of Wisconsin, School of Medicine and Public Health , Department of 
      Cell and Regenerative Biology , Carbone Cancer Center , Madison , WI , USA.
FAU - McKenna, Sharon
AU  - McKenna S
AD  - ban University College Cork, Cork Cancer Research Centre, BioSciences Institute, 
      Co. Cork , Ireland.
FAU - McMahon, John J
AU  - McMahon JJ
AD  - jg Duke University , Department of Molecular Genetics and Microbiology , Durham , 
      NC , USA.
FAU - McNeish, Iain A
AU  - McNeish IA
AD  - bjz University of Glasgow, Institute of Cancer Sciences , Glasgow , UK.
FAU - Mechta-Grigoriou, Fatima
AU  - Mechta-Grigoriou F
AD  - sb INSERM U830, Stress and Cancer Laboratory, Institut Curie , Paris , France.
FAU - Medema, Jan Paul
AU  - Medema JP
AD  - bch University of Amsterdam, Academic Medical Center, Laboratory of Experimental 
      Oncology and Radiobiology , Amsterdam, North Holland , The Netherlands.
FAU - Medina, Diego L
AU  - Medina DL
AD  - asa Telethon Institute of Genetics and Medicine (TIGEM) , Pozzuoli, Naples , 
      Italy.
FAU - Megyeri, Klara
AU  - Megyeri K
AD  - bvj University of Szeged , Department of Medical Microbiology and Immunobiology , 
      Szeged, Csongrád , Hungary.
FAU - Mehrpour, Maryam
AU  - Mehrpour M
AD  - azw Université Paris Descartes-Sorbonne Paris Cité, Institut Necker 
      Enfants-Malades (INEM), INSERM U1151-CNRS UMR 8253 , Paris , France.
FAU - Mehta, Jawahar L
AU  - Mehta JL
AD  - bcr University of Arkansas for Medical Sciences , Department of Cardiology , 
      Little Rock , AR , USA.
FAU - Mei, Yide
AU  - Mei Y
AD  - btw University of Science and Technology of China, CAS Key Laboratory of Innate 
      Immunity and Chronic Disease, School of Lifesciences , Hefei, Anhui , China.
FAU - Meier, Ute-Christiane
AU  - Meier UC
AD  - akw Queen Mary University of London, Blizard Institute , Department of 
      Neuroscience and Trauma , London , UK.
FAU - Meijer, Alfred J
AU  - Meijer AJ
AD  - bcj University of Amsterdam , Department of Medical Biochemistry , Academic 
      Medical Center , Amsterdam , The Netherlands.
FAU - Meléndez, Alicia
AU  - Meléndez A
AD  - gv City University of New York , Department of Biology , Queens College and The 
      Graduate Center , Flushing , NY , USA.
FAU - Melino, Gerry
AU  - Melino G
AD  - adm MRC Toxicology Unit , Leicester , UK.
AD  - bti University of Rome "Tor Vergata" , Department of Surgery and Experimental 
      Medicine , Rome , Italy.
FAU - Melino, Sonia
AU  - Melino S
AD  - btf University of Rome "Tor Vergata" , Department of Chemistry , Rome , Italy.
FAU - de Melo, Edesio Jose Tenorio
AU  - de Melo EJ
AD  - axl Universidade Estadual do Norte Fluminense Darcy Ribeiro, Centro de 
      Biociencias e Biotecnologia, Lab Biologia Celular e Tecidual, Setor de 
      Toxicologia Celular, Campos dos Goytacazes , Rio de Janeiro , Brazil.
FAU - Mena, Maria A
AU  - Mena MA
AD  - qe Hospital Universitario Ramón y Cajal, CIBERNED , Neurobiology Department , 
      Madrid , Spain.
FAU - Meneghini, Marc D
AU  - Meneghini MD
AD  - bxb University of Toronto , Department of Molecular Genetics , Toronto, Ontario , 
      Canada.
FAU - Menendez, Javier A
AU  - Menendez JA
AD  - nn Girona Biomedical Research Institute (IDIBGI), Catalan Institute of Oncology 
      (ICO) , Catalonia , Spain.
FAU - Menezes, Regina
AU  - Menezes R
AD  - qo iBET, Instituto de Biologia Experimental e Tecnológica , Oeiras , Portugal.
AD  - tt Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova 
      de Lisboa , Oeiras , Portugal.
FAU - Meng, Liesu
AU  - Meng L
AD  - cca Xi'an Jiaotong University Health Science Center , Department of Biochemistry 
      and Molecular Biology , School of Basic Medical Sciences , Shaanxi , China.
FAU - Meng, Ling-Hua
AU  - Meng LH
AD  - aod Shanghai Institute of Materia Medica, Division of Antitumor Pharmacology , 
      Shanghai , China.
FAU - Meng, Songshu
AU  - Meng S
AD  - im Dalian Medical University, Cancer Center, Institute of Cancer Stem Cell , 
      Dalian, Liaoning Province , China.
FAU - Menghini, Rossella
AU  - Menghini R
AD  - btk University of Rome "Tor Vergata" , Department of Systems Medicine , Rome , 
      Italy.
FAU - Menko, A Sue
AU  - Menko AS
AD  - atr Thomas Jefferson University , Department of Pathology, Anatomy, and Cell 
      Biology , Sydney Kimmel Medical College , Philadelphia , PA , USA.
FAU - Menna-Barreto, Rubem Fs
AU  - Menna-Barreto RF
AD  - ua Instituto Oswaldo Cruz, FIOCRUZ, Laboratório de Biologia Celular , Rio de 
      Janeiro , Brazil.
FAU - Menon, Manoj B
AU  - Menon MB
AD  - oq Hannover Medical School , Department of Biochemistry , Hannover , Germany.
FAU - Meraz-Ríos, Marco A
AU  - Meraz-Ríos MA
AD  - di Center of Investigation and Advanced Studies, Cinvestav-IPN , Mexico City , 
      Mexico.
FAU - Merla, Giuseppe
AU  - Merla G
AD  - uf IRCCS Casa Sollievo della Sofferenza, Medical Genetics Unit , San Giovanni 
      Rotondo (FG) , Italy.
FAU - Merlini, Luciano
AU  - Merlini L
AD  - uy Istituto Ortopedico Rizzoli IOR-IRCCS, Laboratory of Musculoskeletal Cell 
      Biology , Bologna , Italy.
FAU - Merlot, Angelica M
AU  - Merlot AM
AD  - bvi University of Sydney , Department of Pathology and Bosch Institute , Sydney, 
      New South Wales , Australia.
FAU - Meryk, Andreas
AU  - Meryk A
AD  - bla University of Innsbruck, Institute for Biomedical Aging Research , Innsbruck 
      , Austria.
FAU - Meschini, Stefania
AU  - Meschini S
AD  - vf Italian National Institute of Health , Department of Technology and Health, 
      Rome , Italy.
FAU - Meyer, Joel N
AU  - Meyer JN
AD  - jl Duke University, Nicholas School of the Environment , Durham , NC , USA.
FAU - Mi, Man-Tian
AU  - Mi MT
AD  - atn Third Military Medical University, Research Center for Nutrition and Food 
      Safety, Institute of Military Preventive Medicine , Chongqing , China.
FAU - Miao, Chao-Yu
AU  - Miao CY
AD  - ani Second Military Medical University , Department of Pharmacology , Shanghai , 
      China.
FAU - Micale, Lucia
AU  - Micale L
AD  - uf IRCCS Casa Sollievo della Sofferenza, Medical Genetics Unit , San Giovanni 
      Rotondo (FG) , Italy.
FAU - Michaeli, Simon
AU  - Michaeli S
AD  - bt Biochimie et Physiologie Moléculaire des Plantes, UMR5004 
      CNRS/INRA/UM2/SupAgro, Institut de Biologie Intégrative des Plantes , Montpellier 
      , France.
FAU - Michiels, Carine
AU  - Michiels C
AD  - bpe University of Namur, Laboratory of Biochemistry and Cell Biology (URBC), 
      Namur Research Institute for Life Sciences (NARILIS) , Namur , Belgium.
FAU - Migliaccio, Anna Rita
AU  - Migliaccio AR
AD  - adc Icahn School of Medicine at Mount Sinai , Department of Medicine , New York , 
      NY , USA.
FAU - Mihailidou, Anastasia Susie
AU  - Mihailidou AS
AD  - alr Royal North Shore Hospital, Cardiovascular and Hormonal Research Laboratory, 
      Royal North Shore Hospital and Kolling Institute, Sydney , NSW , Australia.
AD  - bvg University of Sydney , Department of Cardiology , Sydney, NSW , Australia.
FAU - Mijaljica, Dalibor
AU  - Mijaljica D
AD  - acx Monash University, Clayton Campus , Department of Biochemistry and Molecular 
      Biology , Melbourne , Victoria , Australia.
FAU - Mikoshiba, Katsuhiko
AU  - Mikoshiba K
AD  - alj RIKEN Brain Science Institute, Laboratory for Developmental Neurobiology , 
      Saitama , Japan.
FAU - Milan, Enrico
AU  - Milan E
AD  - axw Università Vita-Salute San Raffaele , Milan , Italy.
AD  - caj San Raffaele Scientific Institute , Milan , Italy.
FAU - Miller-Fleming, Leonor
AU  - Miller-Fleming L
AD  - bgp University of Cambridge , Department of BIochemistry , Cambridge , UK.
FAU - Mills, Gordon B
AU  - Mills GB
AD  - bwe University of Texas, MD Anderson Cancer Center , Department of Systems 
      Biology , Houston , TX , USA.
FAU - Mills, Ian G
AU  - Mills IG
AD  - ajg University of Oslo and Oslo University Hospital, Prostate Cancer Research 
      Group, Centre for Molecular Medicine (Norway) , Oslo , Norway.
AD  - bqn University of Oslo , Department of Molecular Oncology , Department of Urology 
      , Oslo , Norway.
AD  - bqq Centre for Cancer Research and Cell Biology, Queen's University Belfast, 
      Lisburn Road, Belfast, UK.
FAU - Minakaki, Georgia
AU  - Minakaki G
AD  - bax University Hospital Erlangen, Friedrich-Alexander-Universität 
      Erlangen-Nürnberg (FAU) , Erlangen , Germany.
FAU - Minassian, Berge A
AU  - Minassian BA
AD  - asw The Hospital for Sick Children , Department of Paediatrics , Toronto, Ontario 
      , Canada.
FAU - Ming, Xiu-Fen
AU  - Ming XF
AD  - bjt University of Fribourg , Department of Medicine , Division of Physiology , 
      Fribourg , Switzerland.
FAU - Minibayeva, Farida
AU  - Minibayeva F
AD  - aly Russian Academy of Sciences, Kazan Institute of Biochemistry and Biophysics , 
      Kazan, Tatarstan , Russia.
FAU - Minina, Elena A
AU  - Minina EA
AD  - aqw Swedish University of Agricultural Sciences and Linnean Center for Plant 
      Biology, Department of Chemistry and Biotechnology, Uppsala BioCenter, Uppsala, 
      Sweden.
FAU - Mintern, Justine D
AU  - Mintern JD
AD  - bs Bio21 Molecular Science and Biotechnology Institute , Department of 
      Biochemistry and Molecular Biology , Parkville , Victoria , Australia.
FAU - Minucci, Saverio
AU  - Minucci S
AD  - bol University of Milan , Department of Experimental Oncology , European 
      Institute of Oncology and Department of Biosciences , Milan , Italy.
FAU - Miranda-Vizuete, Antonio
AU  - Miranda-Vizuete A
AD  - awx Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, 
      Consejo Superior de Investigaciones Científicas, Universidad de Sevilla , Sevilla 
      , Spain.
FAU - Mitchell, Claire H
AU  - Mitchell CH
AD  - brn University of Pennsylvania , Department of Anatomy and Cell Biology , 
      Philadelphia , PA , USA.
FAU - Miyamoto, Shigeki
AU  - Miyamoto S
AD  - bfs University of California San Diego , Department of Pharmacology , La Jolla , 
      CA , USA.
FAU - Miyazawa, Keisuke
AU  - Miyazawa K
AD  - auo Tokyo Medical University , Department of Biochemistry , Tokyo , Japan.
FAU - Mizushima, Noboru
AU  - Mizushima N
AD  - bwv University of Tokyo , Department of Biochemistry and Molecular Biology , 
      Graduate School and Faculty of Medicine , Tokyo , Japan.
FAU - Mnich, Katarzyna
AU  - Mnich K
AD  - agp National University of Ireland, Apoptosis Research Centre , Galway , Ireland.
FAU - Mograbi, Baharia
AU  - Mograbi B
AD  - rv INSERM U1081, CNRS UMR7284, Institute of Research on Cancer and Ageing of Nice 
      (IRCAN) , Nice , France.
FAU - Mohseni, Simin
AU  - Mohseni S
AD  - zo Linköping University , Department of Clinical and Experimental Medicine , 
      Linköping , Sweden.
FAU - Moita, Luis Ferreira
AU  - Moita LF
AD  - tu Instituto Gulbenkian de Ciência , Oeiras , Portugal.
FAU - Molinari, Marco
AU  - Molinari M
AD  - uk IRCCS Santa Lucia Foundation , Rome , Italy.
FAU - Molinari, Maurizio
AU  - Molinari M
AD  - jt Institute for Research in Biomedicine, Bellinzona, Switzerland, Università 
      Svizzera italiana, Lugano , Switzerland.
AD  - ju Ecole Polytechnique Federale de Lausanne, Global Health Institute, School of 
      Life Sciences , Lausanne , Switzerland.
FAU - Møller, Andreas Buch
AU  - Møller AB
AD  - g Aarhus University, Medical Research Laboratory, Institute for Clinical Medicine 
      , Aarhus , Denmark.
FAU - Mollereau, Bertrand
AU  - Mollereau B
AD  - ayx Université de Lyon, UMR 5239 CNRS, Laboratory of Molecular Biology of the 
      Cell, Ecole Normale Supérieure de Lyon , Lyon , France.
FAU - Mollinedo, Faustino
AU  - Mollinedo F
AD  - hy Consejo Superior de Investigaciones Científicas (CSIC), Universidad de 
      Salamanca, Campus Miguel de Unamuno, Instituto de Biología Molecular y Celular 
      del Cáncer, Centro de Investigación del Cáncer , Salamanca , Spain.
FAU - Mongillo, Marco
AU  - Mongillo M
AD  - bre University of Padova, Venetian Institute of Molecular Medicine , Department 
      of Biomedical Science , Padova , Italy.
FAU - Monick, Martha M
AU  - Monick MM
AD  - blf University of Iowa , Department of Medicine , Iowa City , IA , USA.
FAU - Montagnaro, Serena
AU  - Montagnaro S
AD  - bpg University of Naples Federico II , Department of Veterinary Medicine and 
      Animal Production , Naples , Italy.
FAU - Montell, Craig
AU  - Montell C
AD  - ahe Neuroscience Research Institute , Santa Barbara , CA , USA.
AD  - bgk University of California Santa Barbara , Department of Molecular , Cellular, 
      and Developmental Biology , Santa Barbara , CA , USA.
FAU - Moore, Darren J
AU  - Moore DJ
AD  - bzn Van Andel Institute, Center for Neurodegenerative Science , Grand Rapids , MI 
      , USA.
FAU - Moore, Michael N
AU  - Moore MN
AD  - bjd University of Exeter Medical School, European Centre for Environment and 
      Human Health (ECEHH), Truro , Cornwall , UK.
FAU - Mora-Rodriguez, Rodrigo
AU  - Mora-Rodriguez R
AD  - awp Universidad de Costa Rica, CIET , San José , Costa Rica.
FAU - Moreira, Paula I
AU  - Moreira PI
AD  - bho University of Coimbra, CNC - Center for Neuroscience and Cell Biology and 
      Faculty of Medicine , Coimbra , Portugal.
FAU - Morel, Etienne
AU  - Morel E
AD  - azw Université Paris Descartes-Sorbonne Paris Cité, Institut Necker 
      Enfants-Malades (INEM), INSERM U1151-CNRS UMR 8253 , Paris , France.
FAU - Morelli, Maria Beatrice
AU  - Morelli MB
AD  - anc Sapienza University of Rome , Department of Molecular Medicine , Rome , 
      Italy.
FAU - Moreno, Sandra
AU  - Moreno S
AD  - bzf University Roma Tre , Department of Science , LIME, Rome , Italy.
FAU - Morgan, Michael J
AU  - Morgan MJ
AD  - bih University of Colorado, School of Medicine , Department of Pharmacology , 
      Aurora , CO , USA.
FAU - Moris, Arnaud
AU  - Moris A
AD  - aps Sorbonne Universités, UPMC Univ Paris 06, INSERM U1135, CNRS ERL 8255, Center 
      for Immunology and Microbial Infections - CIMI-Paris , Paris , France.
FAU - Moriyasu, Yuji
AU  - Moriyasu Y
AD  - aml Saitama University, Graduate School of Science and Engineering , Saitama , 
      Japan.
FAU - Morrison, Janna L
AU  - Morrison JL
AD  - buh University of South Australia, Early Origins of Adult Health Research Group, 
      School of Pharmacy and Medical Sciences, Sansom Institute for Health Research, 
      Adelaide , SA , Australia.
FAU - Morrison, Lynda A
AU  - Morrison LA
AD  - amj Saint Louis University School of Medicine , Department of Molecular 
      Microbiology and Immunology , St. Louis , MO , USA.
FAU - Morselli, Eugenia
AU  - Morselli E
AD  - akj Pontificia Universidad Católica de Chile , Physiology Department , Santiago , 
      Chile.
FAU - Moscat, Jorge
AU  - Moscat J
AD  - amq Sanford Burnham Prebys NCI-Cancer Center, Cell Death and Survival Networks 
      Program , La Jolla , CA , USA.
FAU - Moseley, Pope L
AU  - Moseley PL
AD  - bpl University of New Mexico , Department of Internal Medicine , Albuquerque , NM 
      , USA.
FAU - Mostowy, Serge
AU  - Mostowy S
AD  - rc Imperial College London, Section of Microbiology, MRC Centre for Molecular 
      Bacteriology and Infection , London , UK.
FAU - Motori, Elisa
AU  - Motori E
AD  - aay Max Planck Institute for Biology of Ageing , Cologne , Germany.
FAU - Mottet, Denis
AU  - Mottet D
AD  - bme University of Liege , GIGA-Signal Transduction Department , Protein 
      Signalisation and Interaction Laboratory , Liège , Belgium.
FAU - Mottram, Jeremy C
AU  - Mottram JC
AD  - byw University of York, Centre for Immunology and Infection , Department of 
      Biology , Hull York Medical School , York , UK.
FAU - Moussa, Charbel E-H
AU  - Moussa CE
AD  - mv Georgetown University Medical Center , Department of Neuroscience , 
      Washington, DC , USA.
FAU - Mpakou, Vassiliki E
AU  - Mpakou VE
AD  - bcw University of Athens, Medical School , Second Department of Internal Medicine 
      and Research Institute , Attikon University General Hospital , Athens , Greece.
FAU - Mukhtar, Hasan
AU  - Mukhtar H
AD  - byp University of Wisconsin , Department of Dermatology , Madison , WI , USA.
FAU - Mulcahy Levy, Jean M
AU  - Mulcahy Levy JM
AD  - bic University of Colorado , Department of Pediatrics , Center for Cancer and 
      Blood Disorders , Aurora , CO , USA.
FAU - Muller, Sylviane
AU  - Muller S
AD  - hc CNRS, Immunopathology and Therapeutic Chemistry, Institut de Biologie 
      Moléculaire et Cellulaire , Strasbourg , France.
FAU - Muñoz-Moreno, Raquel
AU  - Muñoz-Moreno R
AD  - tx Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA) 
      , Departamento de Biotecnología , Madrid , Spain.
FAU - Muñoz-Pinedo, Cristina
AU  - Muñoz-Pinedo C
AD  - bl Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Cell Death 
      Regulation Group , Barcelona , Spain.
FAU - Münz, Christian
AU  - Münz C
AD  - bzb University of Zurich, Institute of Experimental Immunology , Zurich , 
      Switzerland.
FAU - Murphy, Maureen E
AU  - Murphy ME
AD  - atj The Wistar Institute, Program in Molecular and Cellular Oncogenesis , 
      Philadelphia , PA , USA.
FAU - Murray, James T
AU  - Murray JT
AD  - auz Trinity College Dublin, School of Biochemistry and Immunology, Trinity 
      Biomedical Sciences Institute , Dublin , Ireland.
FAU - Murthy, Aditya
AU  - Murthy A
AD  - mj Genentech Inc. , Department of Cancer Immunology , South San Francisco , CA , 
      USA.
FAU - Mysorekar, Indira U
AU  - Mysorekar IU
AD  - cbe Washington University, School of Medicine, Departments of Obstetrics and 
      Gynecology, and Pathology and Immunology , St. Louis , MO , USA.
FAU - Nabi, Ivan R
AU  - Nabi IR
AD  - bee University of British Columbia , Department of Cellular and Physiological 
      Sciences , Vancouver, BC , Canada.
FAU - Nabissi, Massimo
AU  - Nabissi M
AD  - bgu University of Camerino, School of Pharmacy , Camerino , Italy.
FAU - Nader, Gustavo A
AU  - Nader GA
AD  - xj Karolinska Institute , Department of Physiology and Pharmacology , Stockholm , 
      Sweden.
FAU - Nagahara, Yukitoshi
AU  - Nagahara Y
AD  - aui Tokyo Denki University, Division of Life Science and Engineering , Hatoyama, 
      Hiki-gun, Saitama , Japan.
FAU - Nagai, Yoshitaka
AU  - Nagai Y
AD  - aei National Center of Neurology and Psychiatry , Department of Degenerative 
      Neurological Diseases , Kodaira, Tokyo , Japan.
FAU - Nagata, Kazuhiro
AU  - Nagata K
AD  - yu Kyoto Sangyo University , Department of Life Sciences , Kyoto , Japan.
FAU - Nagelkerke, Anika
AU  - Nagelkerke A
AD  - ale Radboud University, Institute for Molecules and Materials , Department of 
      Molecular Materials , Nijmegen , The Netherlands.
FAU - Nagy, Péter
AU  - Nagy P
AD  - kj Eötvös Loránd University , Department of Anatomy , Cell and Developmental 
      Biology , Budapest , Hungary.
FAU - Naidu, Samisubbu R
AU  - Naidu SR
AD  - rk Indiana University School of Medicine , Department of Dermatology , 
      Indianapolis , IN , USA.
FAU - Nair, Sreejayan
AU  - Nair S
AD  - byv University of Wyoming, School of Pharmacy, College of Health Sciences , 
      Laramie , WY , USA.
FAU - Nakano, Hiroyasu
AU  - Nakano H
AD  - atx Toho University, School of Medicine , Department of Biochemistry , Tokyo , 
      Japan.
FAU - Nakatogawa, Hitoshi
AU  - Nakatogawa H
AD  - auk Tokyo Institute of Technology, Graduate School of Bioscience and 
      Biotechnology , Tokyo , Japan.
FAU - Nanjundan, Meera
AU  - Nanjundan M
AD  - buq University of South Florida , Department of Cell Biology , Microbiology, and 
      Molecular Biology , Tampa , FL , USA.
FAU - Napolitano, Gennaro
AU  - Napolitano G
AD  - asa Telethon Institute of Genetics and Medicine (TIGEM) , Pozzuoli, Naples , 
      Italy.
FAU - Naqvi, Naweed I
AU  - Naqvi NI
AD  - asb Temasek Life Sciences Laboratory , Singapore.
FAU - Nardacci, Roberta
AU  - Nardacci R
AD  - aez National Institute for Infectious Diseases "L. Spallanzani" IRCCS , Rome , 
      Italy.
FAU - Narendra, Derek P
AU  - Narendra DP
AD  - pd Harvard Medical School, Neurology Residency Program, Brigham and Women's 
      Hospital and Massachusetts General Hospital , Boston , MA , USA.
FAU - Narita, Masashi
AU  - Narita M
AD  - bgo University of Cambridge, Cancer Research UK Cambridge Institute, Li Ka Shing 
      Centre , Cambridge , UK.
FAU - Nascimbeni, Anna Chiara
AU  - Nascimbeni AC
AD  - azw Université Paris Descartes-Sorbonne Paris Cité, Institut Necker 
      Enfants-Malades (INEM), INSERM U1151-CNRS UMR 8253 , Paris , France.
FAU - Natarajan, Ramesh
AU  - Natarajan R
AD  - bzy Virginia Commonwealth University , Department of Internal Medicine , Division 
      of Pulmonary Disease and Critical Care Medicine , Richmond , VA , USA.
FAU - Navegantes, Luiz C
AU  - Navegantes LC
AD  - btt University of São Paulo, Ribeirão Preto Medical School , Department of 
      Physiology , Ribeirão Preto, São Paulo , Brazil.
FAU - Nawrocki, Steffan T
AU  - Nawrocki ST
AD  - bvv University of Texas, Health Science Center at San Antonio, CTRC Institute for 
      Drug Development , San Antonio , TX , USA.
FAU - Nazarko, Taras Y
AU  - Nazarko TY
AD  - bfv University of California San Diego, Division of Biological Sciences, Section 
      of Molecular Biology , La Jolla, CA , USA.
FAU - Nazarko, Volodymyr Y
AU  - Nazarko VY
AD  - bkw University of Illinois at Chicago, Deprtment of Biochemistry and Molecular 
      Genetics , Chicago , IL , USA.
FAU - Neill, Thomas
AU  - Neill T
AD  - atq Thomas Jefferson University , Department of Pathology , Anatomy and Cell 
      Biology , Philadelphia , PA , USA.
FAU - Neri, Luca M
AU  - Neri LM
AD  - bjg University of Ferrara , Department of Morphology , Surgery and Experimental 
      Medicine , Ferrara , Italy.
FAU - Netea, Mihai G
AU  - Netea MG
AD  - alc Radboud University Nijmegen Medical Center , Department of Internal Medicine 
      , Nijmegen , The Netherlands.
FAU - Netea-Maier, Romana T
AU  - Netea-Maier RT
AD  - alb Radboud University Nijmegen Medical Center , Department of Internal Medicine 
      , Division of Endocrinology , Nijmegen , The Netherlands.
FAU - Neves, Bruno M
AU  - Neves BM
AD  - bcz University of Aveiro/QOPNA , Department of Chemistry , Aveiro , Portugal.
FAU - Ney, Paul A
AU  - Ney PA
AD  - ahg New York Blood Center, Lindsley F. Kimball Research Institute , New York , NY 
      , USA.
FAU - Nezis, Ioannis P
AU  - Nezis IP
AD  - byl University of Warwick, Life Sciences , Coventry , UK.
FAU - Nguyen, Hang Tt
AU  - Nguyen HT
AD  - ayn Université d'Auvergne, M2iSH "Microbes, Intestine, Inflammation, 
      Susceptibility of the Host", UMR 1071 INSERM, Centre Biomédical de Recherche et 
      Valorisation, Faculté de Médecine , Clermont-Ferrand , France.
FAU - Nguyen, Huu Phuc
AU  - Nguyen HP
AD  - bxo University of Tübingen, Institute of Medical Genetics and Applied Genomics , 
      Tübingen , Germany.
FAU - Nicot, Anne-Sophie
AU  - Nicot AS
AD  - sg INSERM U964, CNRS UMR7104, Université de Strasbourg , Department of 
      Translational Medecine , Institut de Génétique et de Biologie Moléculaire et 
      Cellulaire (IGBMC) , Illkirch , France.
FAU - Nilsen, Hilde
AU  - Nilsen H
AD  - s Akershus University Hospital , Oslo , Norway.
AD  - bqo University of Oslo , Department of Clinical Molecular Biology , Oslo , 
      Norway.
FAU - Nilsson, Per
AU  - Nilsson P
AD  - xh Karolinska Institute, Center for Alzheimer Research , Department of 
      Neurobiology , Care Sciences and Society, Division for Neurogeriatrics , Huddinge 
      , Sweden.
AD  - zh Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, Wako , 
      Saitama , Japan.
FAU - Nishimura, Mikio
AU  - Nishimura M
AD  - aex National Institute for Basic Biology , Department of Cell Biology , Okazaki , 
      Japan.
FAU - Nishino, Ichizo
AU  - Nishino I
AD  - aej National Center of Neurology and Psychiatry , Department of Neuromuscular 
      Research , National Institute of Neuroscience , Tokyo , Japan.
FAU - Niso-Santano, Mireia
AU  - Niso-Santano M
AD  - awq Universidad de Extremadura, Centro de Investigación Biomédica en Red sobre 
      Enfermedades Neurodegenerativas (CIBERNED) , Departamento de Bioquímica y 
      Biología Molecular y Genética , Facultad de Enfermería y Terapia Ocupacional , 
      Cáceres , Spain.
FAU - Niu, Hua
AU  - Niu H
AD  - apl Soochow University , Department of Pathogenic Biology , Suzhou, Jiangsu , 
      China.
FAU - Nixon, Ralph A
AU  - Nixon RA
AD  - aho New York University, Nathan Kline Institute , Orangeburg , NY , USA.
FAU - Njar, Vincent Co
AU  - Njar VC
AD  - bnh University of Maryland, School of Medicine , Department of Chemistry , 
      Baltimore , MD , USA.
FAU - Noda, Takeshi
AU  - Noda T
AD  - aiy Osaka University, Graduate School of Dentistry , Osaka , Japan.
FAU - Noegel, Angelika A
AU  - Noegel AA
AD  - bhw University of Cologne, Institute of Biochemistry I, Medical Faculty , Koeln , 
      Germany.
FAU - Nolte, Elsie Magdalena
AU  - Nolte EM
AD  - bst University of Pretoria , Department of Physiology , Pretoria, Gauteng , South 
      Africa.
FAU - Norberg, Erik
AU  - Norberg E
AD  - xj Karolinska Institute , Department of Physiology and Pharmacology , Stockholm , 
      Sweden.
FAU - Norga, Koenraad K
AU  - Norga KK
AD  - bcl University of Antwerp , Department of Paediatric Oncology , Antwerp , 
      Belgium.
FAU - Noureini, Sakineh Kazemi
AU  - Noureini SK
AD  - bly Hakim Sabzevari University, Department of Biology, Faculty of Basic Sciences, 
      Sabzevar, Iran.
FAU - Notomi, Shoji
AU  - Notomi S
AD  - pe Harvard Medical School, Ophthalmology , Boston , MA , USA.
FAU - Notterpek, Lucia
AU  - Notterpek L
AD  - bjj University of Florida, College of Medicine , Department of Neuroscience , 
      Gainesville , FL , USA.
FAU - Nowikovsky, Karin
AU  - Nowikovsky K
AD  - aco Medical University of Vienna, Internal Medicine I , Vienna , Austria.
FAU - Nukina, Nobuyuki
AU  - Nukina N
AD  - wo Juntendo University, Graduate School of Medicine , Department of Neuroscience 
      for Neurodegenerative Disorders , Tokyo , Japan.
FAU - Nürnberger, Thorsten
AU  - Nürnberger T
AD  - bxn University of Tübingen, Center for Plant Molecular Biology (ZMBP) , 
      Department of Plant Biochemistry , Tübingen , Germany.
FAU - O'Donnell, Valerie B
AU  - O'Donnell VB
AD  - cu Cardiff University, Systems Immunity Research Institute , Cardiff , Wales, UK.
FAU - O'Donovan, Tracey
AU  - O'Donovan T
AD  - ban University College Cork, Cork Cancer Research Centre, BioSciences Institute, 
      Co. Cork , Ireland.
FAU - O'Dwyer, Peter J
AU  - O'Dwyer PJ
AD  - brl University of Pennsylvania, Abramson Cancer Center , Philadelphia , PA , USA.
FAU - Oehme, Ina
AU  - Oehme I
AD  - nh German Cancer Research Center (DKFZ), Clinical Cooperation Unit (CCU) 
      Pediatric Oncology , Heidelberg , Germany.
FAU - Oeste, Clara L
AU  - Oeste CL
AD  - hv Consejo Superior de Investigaciones Científicas (CSIC), Centro de 
      Investigaciones Biológicas , Madrid , Spain.
FAU - Ogawa, Michinaga
AU  - Ogawa M
AD  - afd National Institute of Infectious Diseases , Department of Bacteriology I , 
      Tokyo , Japan.
FAU - Ogretmen, Besim
AU  - Ogretmen B
AD  - aci Medical University of South Carolina , Department of Biochemistry and 
      Molecular Biology , Hollings Cancer Center , Charleston , SC , USA.
FAU - Ogura, Yuji
AU  - Ogura Y
AD  - aqh St. Marianna University School of Medicine , Department of Physiology , 
      Kanagawa , Japan.
FAU - Oh, Young J
AU  - Oh YJ
AD  - cci Yonsei University, College of Life Science and Biotechnology , Department of 
      Systems Biology , Seoul , Korea.
FAU - Ohmuraya, Masaki
AU  - Ohmuraya M
AD  - yp Kumamoto University, Institute of Resource Development and Analysis , Kumamoto 
      , Japan.
FAU - Ohshima, Takayuki
AU  - Ohshima T
AD  - aug Tokushima Bunri University, Faculty of Pharmaceutical Sciences at Kagawa 
      Campus, Sanuki City , Kagawa , Japan.
FAU - Ojha, Rani
AU  - Ojha R
AD  - akl Post Graduate Institute of Medical Education and Research (PGIMER) , 
      Department of Urology , Chandigarh , India.
FAU - Okamoto, Koji
AU  - Okamoto K
AD  - aiz Osaka University, Graduate School of Frontier Biosciences , Osaka , Japan.
FAU - Okazaki, Toshiro
AU  - Okazaki T
AD  - ww Kanazawa Medical University , Department of Medicine , Ishikawa , Japan.
FAU - Oliver, F Javier
AU  - Oliver FJ
AD  - ts Instituto de Parasitología y Biomedicina López Neyra (IPBLN), CSIC , Granada , 
      Spain.
FAU - Ollinger, Karin
AU  - Ollinger K
AD  - zo Linköping University , Department of Clinical and Experimental Medicine , 
      Linköping , Sweden.
FAU - Olsson, Stefan
AU  - Olsson S
AD  - bil University of Copenhagen , Department of Plant and Environmental Sciences , 
      Section for Genetics and Microbiology , Copenhagen , Denmark.
FAU - Orban, Daniel P
AU  - Orban DP
AD  - boc University of Michigan , Department of Molecular , Cellular, and 
      Developmental Biology , Ann Arbor , MI , USA.
AD  - bog University of Michigan, Life Sciences Institute , Ann Arbor , MI , USA.
FAU - Ordonez, Paulina
AU  - Ordonez P
AD  - bfq University of California San Diego , Department of Pediatrics , La Jolla , CA 
      , USA.
FAU - Orhon, Idil
AU  - Orhon I
AD  - azw Université Paris Descartes-Sorbonne Paris Cité, Institut Necker 
      Enfants-Malades (INEM), INSERM U1151-CNRS UMR 8253 , Paris , France.
FAU - Orosz, Laszlo
AU  - Orosz L
AD  - bvj University of Szeged , Department of Medical Microbiology and Immunobiology , 
      Szeged, Csongrád , Hungary.
FAU - O'Rourke, Eyleen J
AU  - O'Rourke EJ
AD  - bws University of Virginia, Departments of Biology and Cell Biology, 
      Charlottesville, VA, USA.
FAU - Orozco, Helena
AU  - Orozco H
AD  - byc University of Valencia , Departamento de Bioquimica y Biologia Molecular , 
      IATA-CSIC , Valencia , Spain.
AD  - byd University of Valencia , Departamento de Biotecnología , IATA-CSIC , Valencia 
      , Spain.
FAU - Ortega, Angel L
AU  - Ortega AL
AD  - byf University of Valencia , Department of Physiology , Burjassot, Valencia , 
      Spain.
FAU - Ortona, Elena
AU  - Ortona E
AD  - uz Istituto Superiore di Sanità , Department of Cell Biology and Neurosciences , 
      Rome , Italy.
FAU - Osellame, Laura D
AU  - Osellame LD
AD  - acx Monash University, Clayton Campus , Department of Biochemistry and Molecular 
      Biology , Melbourne , Victoria , Australia.
FAU - Oshima, Junko
AU  - Oshima J
AD  - bym University of Washington , Department of Pathology , Seattle , WA.
FAU - Oshima, Shigeru
AU  - Oshima S
AD  - aum Tokyo Medical and Dental University , Department of Gastroenterology and 
      Hepatology , Tokyo , Japan.
FAU - Osiewacz, Heinz D
AU  - Osiewacz HD
AD  - nt Goethe University, Institute for Molecular Biosciences, Molecular 
      Developmental Biology , Frankfurt , Hesse , Germany.
FAU - Otomo, Takanobu
AU  - Otomo T
AD  - aiv Osaka University Graduate School of Medicine , Department of Pediatrics , 
      Osaka , Japan.
FAU - Otsu, Kinya
AU  - Otsu K
AD  - xt King's College London, Cardiovascular Division , London , UK.
FAU - Ou, Jing-Hsiung James
AU  - Ou JH
AD  - bux University of Southern California, Keck School of Medicine , Department of 
      Molecular Microbiology and Immunology , Los Angeles , CA , USA.
FAU - Outeiro, Tiago F
AU  - Outeiro TF
AD  - bbr University Medical Centre Göttingen , Department of Neurodegeneration and 
      Restorative Research , Göttingen , Germany.
FAU - Ouyang, Dong-Yun
AU  - Ouyang DY
AD  - vw Jinan University , Department of Immunobiology , College of Life Science and 
      Technology , Guangzhou , China.
FAU - Ouyang, Hongjiao
AU  - Ouyang H
AD  - bsf University of Pittsburgh, School of Dental Medicine , Department of 
      Endodontics , Pittsburgh , PA , USA.
FAU - Overholtzer, Michael
AU  - Overholtzer M
AD  - acr Memorial Sloan Kettering Cancer Center , New York , NY , USA.
FAU - Ozbun, Michelle A
AU  - Ozbun MA
AD  - bpk University of New Mexico, Comprehensive Cancer Center , Department of 
      Molecular Genetics and Microbiology , Albuquerque , NM , USA.
FAU - Ozdinler, P Hande
AU  - Ozdinler PH
AD  - aib Northwestern University , Department of Neurology , Feinberg School of 
      Medicine , Chicago , IL , USA.
FAU - Ozpolat, Bulent
AU  - Ozpolat B
AD  - avy University of Texas, MD Anderson Cancer Center , Department of Experimental 
      Therapeutics , Houston , TX , USA.
FAU - Pacelli, Consiglia
AU  - Pacelli C
AD  - azc Université de Montréal , Department of Pharmacology , Faculty of Medicine , 
      Montreal, QC , Canada.
FAU - Paganetti, Paolo
AU  - Paganetti P
AD  - zg Laboratory for Biomedical Neurosciences NSI/EOC, Neurodegeneration Group , 
      Torricella-Taverne , Switzerland.
FAU - Page, Guylène
AU  - Page G
AD  - bso University of Poitiers, EA3808 Molecular Targets and Therapeutics in 
      Alzheimer's Disease , Poitiers , France.
FAU - Pages, Gilles
AU  - Pages G
AD  - rx University of Nice Sophia Antipolis, Institute of Research on Cancer and 
      Ageing of Nice, CNRS UMR 7284/INSERM U1081 , Nice , France.
FAU - Pagnini, Ugo
AU  - Pagnini U
AD  - bpg University of Naples Federico II , Department of Veterinary Medicine and 
      Animal Production , Naples , Italy.
FAU - Pajak, Beata
AU  - Pajak B
AD  - adb Mossakowski Medical Research Centre, Polish Academy of Sciences, Electron 
      Microscopy Platform , Warsaw , Poland.
AD  - cat Warsaw University of Life Sciences - SGGW, Faculty of Veterinary Medicine , 
      Department of Physiological Sciences , Warsaw , Poland.
FAU - Pak, Stephen C
AU  - Pak SC
AD  - bsk University of Pittsburgh, School of Medicine , Department of Pediatrics , 
      Pittsburgh , PA , USA.
FAU - Pakos-Zebrucka, Karolina
AU  - Pakos-Zebrucka K
AD  - agp National University of Ireland, Apoptosis Research Centre , Galway , Ireland.
FAU - Pakpour, Nazzy
AU  - Pakpour N
AD  - bez University of California Davis , Department of Medical Microbiology and 
      Immunology , School of Medicine , Davis , CA , USA.
FAU - Palková, Zdena
AU  - Palková Z
AD  - er Charles University in Prague, Faculty of Science , Department of Genetics and 
      Microbiology , Prague , Czech Republic.
FAU - Palladino, Francesca
AU  - Palladino F
AD  - azo Université Lyon, Ecole Normale Supérieure de Lyon , Lyon , France.
FAU - Pallauf, Kathrin
AU  - Pallauf K
AD  - bls University of Kiel, Institute of Human Nutrition and Food Science , Kiel , 
      Germany.
FAU - Pallet, Nicolas
AU  - Pallet N
AD  - sa INSERM U1147 , Paris , France.
FAU - Palmieri, Marta
AU  - Palmieri M
AD  - byg University of Verona , Department of Neurological, Biomedical and Movement 
      Sciences , Verona , Italy.
FAU - Paludan, Søren R
AU  - Paludan SR
AD  - d Aarhus University, Department of Biomedicine , Aarhus , Denmark.
FAU - Palumbo, Camilla
AU  - Palumbo C
AD  - btg University of Rome "Tor Vergata" , Department of Clinical Sciences and 
      Translational Medicine , Rome , Italy.
FAU - Palumbo, Silvia
AU  - Palumbo S
AD  - bri University of Pavia , Department of Biology and Biotechnology , Pavia , 
      Italy.
FAU - Pampliega, Olatz
AU  - Pampliega O
AD  - z Albert Einstein College of Medicine , Department of Developmental and Molecular 
      Biology , Institute for Aging Studies , Bronx , NY , USA.
FAU - Pan, Hongming
AU  - Pan H
AD  - cdb Zhejiang University, Sir Run Run Shaw Hospital , Department of Medical 
      Oncology , Hangzhou, Zhejiang , China.
FAU - Pan, Wei
AU  - Pan W
AD  - agl Department of Cardiology, Nanhai Hospital Affiliated to Southern Medical 
      University, Foshan, Guangdong Province, China.
FAU - Panaretakis, Theocharis
AU  - Panaretakis T
AD  - xg Karolinska Institute, Cancer Center Karolinska , Department of 
      Oncology-Pathology , Stockholm , Sweden.
FAU - Pandey, Aseem
AU  - Pandey A
AD  - asj Texas A&M University , Department of Microbial Pathogenesis and Immunology , 
      Texas A&M Health Science Center , Bryan , TX , USA.
AD  - asl Texas A&M University, The Norman Borlaug Center , College Station , TX , USA.
FAU - Pantazopoulou, Areti
AU  - Pantazopoulou A
AD  - ec Centro de Investigaciones Biológicas (CSIC) , Department of Cellular and 
      Molecular Biology , Madrid , Spain.
FAU - Papackova, Zuzana
AU  - Papackova Z
AD  - sy Institute for Clinical and Experimental Medicine, Centre for Experimental 
      Medicine , Department of Metabolism and Diabetes , Prague , Czech Republic.
FAU - Papademetrio, Daniela L
AU  - Papademetrio DL
AD  - awf Universidad de Buenos Aires, Inmunología, Facultad de Farmacia y Bioquímica , 
      Buenos Aires , Argentina.
FAU - Papassideri, Issidora
AU  - Papassideri I
AD  - aee National and Kapodistrian University of Athens , Department of Cell Biology 
      and Biophysics , Faculty of Biology , Athens , Greece.
FAU - Papini, Alessio
AU  - Papini A
AD  - bjh University of Florence , Department of Biology , Florence , Italy.
FAU - Parajuli, Nirmala
AU  - Parajuli N
AD  - bct University of Arkansas for Medical Sciences , Department of 
      Pharmacology/Toxicology , Little Rock , AR , USA.
FAU - Pardo, Julian
AU  - Pardo J
AD  - axb IIS Aragon, Universidad de Zaragoza/Araid, Centro de Investigación Biomédica 
      de Aragón , Zaragoza , Spain.
FAU - Parekh, Vrajesh V
AU  - Parekh VV
AD  - bzu Vanderbilt University, School of Medicine, Pathology Microbiology and 
      Immunology , Nashville , TN , USA.
FAU - Parenti, Giancarlo
AU  - Parenti G
AD  - ld Federico II University, Telethon Institute of Genetics and Medicine (TIGEM) , 
      Department of Medical and Translational Sciences , Naples , Italy.
FAU - Park, Jong-In
AU  - Park JI
AD  - abz Medical College of Wisconsin , Department of Biochemistry , Milwaukee , WI , 
      USA.
FAU - Park, Junsoo
AU  - Park J
AD  - ccm Yonsei University, Division of Biological Science and Technology , Wonju , 
      Korea.
FAU - Park, Ohkmae K
AU  - Park OK
AD  - yh Korea University, Division of Life Sciences , Seoul , Korea.
FAU - Parker, Roy
AU  - Parker R
AD  - bid University of Colorado, HHMI , Department of Chemistry and Biochemistry , 
      Aurora , CO , USA.
FAU - Parlato, Rosanna
AU  - Parlato R
AD  - bkh University of Heidelberg, Institute of Anatomy and Cell Biology , Heidelberg 
      , Germany.
AD  - bxv University of Ulm, Institute of Applied Physiology , Ulm , Germany.
FAU - Parys, Jan B
AU  - Parys JB
AD  - yo KU Leuven, Laboratory of Molecular and Cellular Signaling , Department of 
      Cellular and Molecular Medicine , Leuven , Belgium.
FAU - Parzych, Katherine R
AU  - Parzych KR
AD  - boc University of Michigan , Department of Molecular , Cellular, and 
      Developmental Biology , Ann Arbor , MI , USA.
AD  - bog University of Michigan, Life Sciences Institute , Ann Arbor , MI , USA.
FAU - Pasquet, Jean-Max
AU  - Pasquet JM
AD  - ayf Université Bordeaux Segalen, U1035 INSERM, Hématopoïèse Leucémique et Cibles 
      Thérapeutiques , Bordeaux , France.
FAU - Pasquier, Benoit
AU  - Pasquier B
AD  - amv Sanofi , Vitry Sur Seine , France.
FAU - Pasumarthi, Kishore Bs
AU  - Pasumarthi KB
AD  - il Dalhousie University , Department of Pharmacology , Halifax, Nova Scotia , 
      Canada.
FAU - Patschan, Daniel
AU  - Patschan D
AD  - bbc University Hospital of Göttingen , Department of Nephrology and Rheumatology 
      , Göttingen , Germany.
FAU - Patterson, Cam
AU  - Patterson C
AD  - ahr New York-Presbyterian Hospital/Weill-Cornell Medical Center , New York , NY , 
      USA.
FAU - Pattingre, Sophie
AU  - Pattingre S
AD  - us IRCM, Institut de Recherche en Cancérologie de Montpellier , Montpellier , 
      France.
AD  - ayz Université de Montpellier, Institut régional du Cancer de Montpellier, 
      INSERM, U 1194 , Montpellier , France.
FAU - Pattison, Scott
AU  - Pattison S
AD  - bum University of South Dakota, Division of Basic Biomedical Sciences , 
      Vermillion , SD , USA.
FAU - Pause, Arnim
AU  - Pause A
AD  - abn McGill University , Goodman Cancer Research Centre and Department of 
      Biochemistry , Montreal, Quebec , Canada.
FAU - Pavenstädt, Hermann
AU  - Pavenstädt H
AD  - bbb University Hospital Muenster Albert-Schweitzer-Campus, Internal Medicine D , 
      Department of Nephrology , Hypertension and Rheumatology , Münster , Germany.
FAU - Pavone, Flaminia
AU  - Pavone F
AD  - ha CNR, Institute of Cell Biology and Neurobiology and IRCCS Santa Lucia 
      Foundation , Rome , Italy.
FAU - Pedrozo, Zully
AU  - Pedrozo Z
AD  - bhg P Catholic University of Chile, Advanced Center for Chronic Diseases 
      (ACCDiS), Faculty of Medicine , Santiago , Chile.
FAU - Peña, Fernando J
AU  - Peña FJ
AD  - bjf University of Extremadura , Department of Medicine , Faculty of Veterinary 
      Medicine , Cáceres , Spain.
FAU - Peñalva, Miguel A
AU  - Peñalva MA
AD  - ec Centro de Investigaciones Biológicas (CSIC) , Department of Cellular and 
      Molecular Biology , Madrid , Spain.
FAU - Pende, Mario
AU  - Pende M
AD  - azt Université Paris Descartes, Institut Necker-Enfants Malades, INSERM, U1151 , 
      Paris , France.
FAU - Peng, Jianxin
AU  - Peng J
AD  - dj College of Science, Central China Normal University , Wuhan , China.
FAU - Penna, Fabio
AU  - Penna F
AD  - bxq University of Turin , Department of Clinical and Biological Sciences , Unit 
      of Experimental Medicine and Clinical Pathology , Turin , Italy.
FAU - Penninger, Josef M
AU  - Penninger JM
AD  - tj Institute of Molecular Biotechnology of the Austrian Academy of Sciences 
      (IMBA) , Vienna , Austria.
FAU - Pensalfini, Anna
AU  - Pensalfini A
AD  - dg Center for Dementia Research, Nathan S. Kline Institute , Orangeburg , NY , 
      USA.
FAU - Pepe, Salvatore
AU  - Pepe S
AD  - bnt Murdoch Childrens Research Institute, University of Melbourne , Department of 
      Paediatrics , Royal Children's Hospital , Melbourne , Victoria , Australia.
FAU - Pereira, Gustavo Js
AU  - Pereira GJ
AD  - lb Federal University of São Paulo , Department of Pharmacology , Paulista School 
      of Medicine , São Paulo , Brazil.
FAU - Pereira, Paulo C
AU  - Pereira PC
AD  - bht University of Coimbra, IBILI, Faculty of Medicine , Coimbra , Portugal.
FAU - Pérez-de la Cruz, Verónica
AU  - Pérez-de la Cruz V
AD  - ty Instituto Nacional de Neurología y Neurocirugía, Neurochemistry Unit , Mexico 
      City , Mexico.
FAU - Pérez-Pérez, María Esther
AU  - Pérez-Pérez ME
AD  - awz Universidad de Sevilla, Instituto de Bioquímica Vegetal y Fotosíntesis, CSIC 
      , Sevilla , Spain.
FAU - Pérez-Rodríguez, Diego
AU  - Pérez-Rodríguez D
AD  - awr Universidad de León, Área de Biología Celular, Instituto de Biomedicina , 
      León , Spain.
FAU - Pérez-Sala, Dolores
AU  - Pérez-Sala D
AD  - hv Consejo Superior de Investigaciones Científicas (CSIC), Centro de 
      Investigaciones Biológicas , Madrid , Spain.
FAU - Perier, Celine
AU  - Perier C
AD  - bzl Vall d'Hebron Research Institute, Neurodegenerative Diseases Lab , Barcelona 
      , Spain.
FAU - Perl, Andras
AU  - Perl A
AD  - aqp State University of New York, College of Medicine , Departments of Medicine , 
      Microbiology and Immunology, Biochemistry and Molecular Biology , Syracuse , NY , 
      USA.
FAU - Perlmutter, David H
AU  - Perlmutter DH
AD  - bse University of Pittsburgh , Pittsburgh , PA , USA.
FAU - Perrotta, Ida
AU  - Perrotta I
AD  - beq University of Calabria , Department of Biology , Ecology and Earth Science, 
      Laboratory of Electron Microscopy , Cosenza , Italy.
FAU - Pervaiz, Shazib
AU  - Pervaiz S
AD  - ig Curtin University, School of Biomedical Sciences , Perth , Australia.
AD  - ago National University Cancer Institute, National University Health System , 
      Singapore.
AD  - agv National University of Singapore , Department of Physiology , Yong Loo Lin 
      School of Medicine , Singapore.
FAU - Pesonen, Maija
AU  - Pesonen M
AD  - bix University of Eastern Finland, Faculty of Health Science, School of 
      Pharmacy/Toxicology , Kuopio , Finland.
FAU - Pessin, Jeffrey E
AU  - Pessin JE
AD  - af Albert Einstein College of Medicine, Departments of Medicine and Molecular 
      Pharmacology , Bronx , NY , USA.
FAU - Peters, Godefridus J
AU  - Peters GJ
AD  - cak VU University Medical Center , Department of Medical Oncology , Amsterdam , 
      The Netherlands.
FAU - Petersen, Morten
AU  - Petersen M
AD  - bik University of Copenhagen , Department of Biology , Copenhagen , Denmark.
FAU - Petrache, Irina
AU  - Petrache I
AD  - afy National Jewish Health , Denver , CO , USA.
FAU - Petrof, Basil J
AU  - Petrof BJ
AD  - abo McGill University, Health Centre Research Institute, Meakins Christie 
      Laboratories , Montreal, Quebec , Canada.
FAU - Petrovski, Goran
AU  - Petrovski G
AD  - aja Oslo University Hospital, Center for Eye Research , Oslo , Norway.
AD  - bqp University of Oslo , Department of Ophthalmology , Oslo , Norway.
AD  - bvk University of Szeged , Department of Ophthalmology , Faculty of Medicine , 
      Szeged , Hungary.
FAU - Phang, James M
AU  - Phang JM
AD  - aha NCI/CCR, Basic Research Laboratory , Frederick , MD , USA.
FAU - Piacentini, Mauro
AU  - Piacentini M
AD  - btd University of Rome "Tor Vergata" , Department of Biology , Rome , Italy.
FAU - Pierdominici, Marina
AU  - Pierdominici M
AD  - uz Istituto Superiore di Sanità , Department of Cell Biology and Neurosciences , 
      Rome , Italy.
FAU - Pierre, Philippe
AU  - Pierre P
AD  - p Aix-Marseille Université, U2M, Centre d'Immunologie de Marseille-Luminy , 
      Marseille , France.
AD  - hd CNRS, UMR 7280 , Marseille , France.
AD  - sl INSERM, U1104 , Marseille , France.
AD  - bcy University of Aveiro, Institute for Research in Biomedicine - iBiMED, Aveiro 
      Health Sciences Program , Aveiro , Portugal.
FAU - Pierrefite-Carle, Valérie
AU  - Pierrefite-Carle V
AD  - azq Université Nice Sophia Antipolis, UMR E-4320TIRO-MATOs CEA/iBEB, Faculté de 
      Médecine , Nice , France.
FAU - Pietrocola, Federico
AU  - Pietrocola F
AD  - km Centre de Recherche des Cordeliers, Equipe 11 labellisée par la Ligue 
      Nationale contre le Cancer , Paris , France.
AD  - oc Gustave Roussy Cancer Campus , Villejuif , France.
AD  - sn INSERM, U1138 , Paris , France.
AD  - azv Université Paris Descartes/Paris V , Paris , France.
FAU - Pimentel-Muiños, Felipe X
AU  - Pimentel-Muiños FX
AD  - aww Universidad de Salamanca, Campus Unamuno, Instituto de Biologia Molecular y 
      Celular del Cancer (IBMCC), Centro de Investigacion del Cancer , Salamanca , 
      Spain.
FAU - Pinar, Mario
AU  - Pinar M
AD  - ec Centro de Investigaciones Biológicas (CSIC) , Department of Cellular and 
      Molecular Biology , Madrid , Spain.
FAU - Pineda, Benjamin
AU  - Pineda B
AD  - tz Instituto Nacional de Neurología y Neurocirugía, Neuroimmunology and 
      Neuro-Oncology Unit , Mexico City , Mexico.
FAU - Pinkas-Kramarski, Ronit
AU  - Pinkas-Kramarski R
AD  - arw Tel Aviv University , Department of Neurobiology , Tel-Aviv , Israel.
FAU - Pinti, Marcello
AU  - Pinti M
AD  - bow University of Modena and Reggio Emilia , Department of Life Sciences , Modena 
      , Italy.
FAU - Pinton, Paolo
AU  - Pinton P
AD  - bjg University of Ferrara , Department of Morphology , Surgery and Experimental 
      Medicine , Ferrara , Italy.
FAU - Piperdi, Bilal
AU  - Piperdi B
AD  - ah Albert Einstein College of Medicine, Montefiore Medical Center , Bronx , NY , 
      USA.
FAU - Piret, James M
AU  - Piret JM
AD  - bel University of British Columbia, Michael Smith Laboratories , Department of 
      Chemical and Biological Engineering , Vancouver, BC , Canada.
FAU - Platanias, Leonidas C
AU  - Platanias LC
AD  - vl Jesse Brown VA Medical Center , Department of Medicine , Chicago , IL , USA.
AD  - aie Northwestern University, Robert H. Lurie Comprehensive Cancer Center , 
      Chicago , IL , USA.
FAU - Platta, Harald W
AU  - Platta HW
AD  - als Ruhr University Bochum, Biochemie Intrazellulärer Transportprozesse , Bochum 
      , Germany.
FAU - Plowey, Edward D
AU  - Plowey ED
AD  - aql Stanford University, School of Medicine , Department of Pathology , Stanford 
      , CA , USA.
FAU - Pöggeler, Stefanie
AU  - Pöggeler S
AD  - mp Georg-August-Universität Göttingen, Institute of Microbiology and Genetics , 
      Department of Genetics of Eukaryotic Microorganisms , Göttingen , Germany.
FAU - Poirot, Marc
AU  - Poirot M
AD  - bxh University of Toulouse, INSERM UMR 1037, Cancer Research Center of Toulouse , 
      Toulouse , France.
FAU - Polčic, Peter
AU  - Polčic P
AD  - hq Comenius University in Bratislava , Department of Biochemistry , Faculty of 
      Natural Sciences , Bratislava , Slovak Republic.
FAU - Poletti, Angelo
AU  - Poletti A
AD  - axq Universita' degli Studi di Milano , Dipartimento di Scienze Farmacologiche e 
      Biomolecolari , Milan , Italy.
FAU - Poon, Audrey H
AU  - Poon AH
AD  - abq McGill University, Health Centre Research Institute, Meakins-Christie 
      Laboratories , Montreal, Quebec, Canada.
FAU - Popelka, Hana
AU  - Popelka H
AD  - bog University of Michigan, Life Sciences Institute , Ann Arbor , MI , USA.
FAU - Popova, Blagovesta
AU  - Popova B
AD  - mo Georg-August-Universität Göttingen , Department of Molecular Microbiology and 
      Genetics , Institute of Microbiology and Genetics , Göttingen , Germany.
FAU - Poprawa, Izabela
AU  - Poprawa I
AD  - bue University of Silesia , Department of Animal Histology and Embryology , 
      Katowice , Poland.
FAU - Poulose, Shibu M
AU  - Poulose SM
AD  - bzi USDA-Human Nutrition Research Center on Aging at Tufts University , 
      Department of Neuroscience and Aging , Boston , MA , USA.
FAU - Poulton, Joanna
AU  - Poulton J
AD  - bra University of Oxford , Nuffield Department of Obstetrics and Gynaecology , 
      Oxford , UK.
FAU - Powers, Scott K
AU  - Powers SK
AD  - bjm University of Florida , Department of Applied Physiology and Kinesiology , 
      Gainesville , FL , USA.
FAU - Powers, Ted
AU  - Powers T
AD  - bfa University of California Davis , Department of Molecular and Cellular Biology 
      , Davis , CA , USA.
FAU - Pozuelo-Rubio, Mercedes
AU  - Pozuelo-Rubio M
AD  - dw Centro Andaluz de Biología Molecular y Medicina Regenerativa, Consejo Superior 
      de Investigaciones Científicas , Sevilla , Spain.
FAU - Prak, Krisna
AU  - Prak K
AD  - bar University College London, MRC Laboratory for Molecular Cell Biology , London 
      , UK.
FAU - Prange, Reinhild
AU  - Prange R
AD  - wa Johannes Gutenberg University Mainz, University Medical Center , Department of 
      Medical Microbiology and Hygiene , Mainz , Germany.
FAU - Prescott, Mark
AU  - Prescott M
AD  - acx Monash University, Clayton Campus , Department of Biochemistry and Molecular 
      Biology , Melbourne , Victoria , Australia.
FAU - Priault, Muriel
AU  - Priault M
AD  - ayd Université Bordeaux Ségalen, Institut de Biochimie et de Génétique 
      Cellulaires, CNRS, UMR 5095 , Bordeaux , France.
FAU - Prince, Sharon
AU  - Prince S
AD  - bgy University of Cape Town , Department of Human Biology , Cape Town, Western 
      Province , South Africa.
FAU - Proia, Richard L
AU  - Proia RL
AD  - afv National Institutes of Health, NIDDK, Genetics of Development and Disease 
      Branch , Bethesda , MD , USA.
FAU - Proikas-Cezanne, Tassula
AU  - Proikas-Cezanne T
AD  - js Eberhard Karls University Tübingen, Interfaculty Institute of Cell Biology , 
      Tübingen , Germany.
FAU - Prokisch, Holger
AU  - Prokisch H
AD  - aro Technical University Munich, Institute of Human Genetics , Munich, Bavaria , 
      Germany.
FAU - Promponas, Vasilis J
AU  - Promponas VJ
AD  - bip University of Cyprus , Department of Biological Sciences , Bioinformatics 
      Research Laboratory , Nicosia , Cyprus.
FAU - Przyklenk, Karin
AU  - Przyklenk K
AD  - cbh Wayne State University, School of Medicine, Cardiovascular Research Institute 
      , Detroit , MI , USA.
FAU - Puertollano, Rosa
AU  - Puertollano R
AD  - afj National Institutes of Health, Cell Biology and Physiology Center, National 
      Heart, Lung, and Blood Institute , Bethesda , MD , USA.
FAU - Pugazhenthi, Subbiah
AU  - Pugazhenthi S
AD  - bie University of Colorado, School of Medicine, Anschutz Medical Campus , Aurora 
      , CO , USA.
FAU - Puglielli, Luigi
AU  - Puglielli L
AD  - byr University of Wisconsin , Department of Medicine , Madison , WI , USA.
FAU - Pujol, Aurora
AU  - Pujol A
AD  - bm Bellvitge Biomedical Research Institute (IDIBELL), Neurometabolic Diseases 
      Laboratory , Barcelona , Spain.
AD  - gp CIBERER Spanish Network for Rare Diseases , Madrid , Spain.
AD  - qv ICREA Catalan Institution for Research and Advanced Studies , Catalonia , 
      Spain.
FAU - Puyal, Julien
AU  - Puyal J
AD  - bav University Hospital Center, University of Lausanne, Clinic of Neonatology , 
      Department of Pediatrics and Pediatric Surgery , Lausanne , Switzerland.
AD  - blw University of Lausanne , Department of Fundamental Neurosciences , Faculty of 
      Biology and Medicine , Lausanne , Switzerland.
FAU - Pyeon, Dohun
AU  - Pyeon D
AD  - big University of Colorado, School of Medicine , Department of Immunology and 
      Microbiology , Aurora , CO , USA.
FAU - Qi, Xin
AU  - Qi X
AD  - cx Case Western Reserve University, School of Medicine , Department of Physiology 
      and Biophysics , Cleveland , OH , USA.
FAU - Qian, Wen-Bin
AU  - Qian WB
AD  - ccv Zhejiang University, Institute of Hematology, First Affiliated Hospital, 
      College of Medicine , Hangzhou , China.
FAU - Qin, Zheng-Hong
AU  - Qin ZH
AD  - apo Soochow University, School of Pharmaceutical Science , Department of 
      Pharmacology , Suzhou , China.
FAU - Qiu, Yu
AU  - Qiu Y
AD  - aqd St. Jude Children's Research Hospital , Department of Structural Biology , 
      Memphis , TN , USA.
FAU - Qu, Ziwei
AU  - Qu Z
AD  - asb Temasek Life Sciences Laboratory , Singapore.
FAU - Quadrilatero, Joe
AU  - Quadrilatero J
AD  - byo University of Waterloo , Department of Kinesiology , Waterloo, Ontario , 
      Canada.
FAU - Quinn, Frederick
AU  - Quinn F
AD  - bjx University of Georgia , Department of Infectious Diseases , Athens , GA , 
      USA.
FAU - Raben, Nina
AU  - Raben N
AD  - afu National Institutes of Health, NIAMS, Laboratory of Muscle Stem Cells and 
      Gene Regulation , Bethesda , MD , USA.
FAU - Rabinowich, Hannah
AU  - Rabinowich H
AD  - bsa University of Pittsburgh , Department of Pathology , Pittsburgh , PA , USA.
FAU - Radogna, Flavia
AU  - Radogna F
AD  - qb Hôpital Kirchberg, Laboratoire de Biologie Moléculaire et Cellulaire du Cancer 
      , Luxembourg.
FAU - Ragusa, Michael J
AU  - Ragusa MJ
AD  - iu Dartmouth College , Department of Chemistry , Hanover , NH , USA.
FAU - Rahmani, Mohamed
AU  - Rahmani M
AD  - cad Virginia Commonwealth University, Massey Cancer Center , Department of 
      Internal Medicine , Richmond , VA , USA.
FAU - Raina, Komal
AU  - Raina K
AD  - bia University of Colorado Denver, Skaggs School of Pharmacy and Pharmaceutical 
      Sciences , Department of Pharmaceutical Sciences , Aurora , CO , USA.
FAU - Ramanadham, Sasanka
AU  - Ramanadham S
AD  - bbz University of Alabama at Birmingham , Department of Cell , Developmental, and 
      Integrative Biology (CDIB), Comprehensive Diabetes Center (UCDC) , Birmingham , 
      AL , USA.
FAU - Ramesh, Rajagopal
AU  - Ramesh R
AD  - bqi University of Oklahoma Health Sciences Center , Department of Pathology , 
      Oklahoma City , OK , USA.
FAU - Rami, Abdelhaq
AU  - Rami A
AD  - bam University Clinics, Institute of Cellular and Molecular Anatomy (Anatomie 3) 
      , Frankfurt , Germany.
FAU - Randall-Demllo, Sarron
AU  - Randall-Demllo S
AD  - bvn University of Tasmania, School of Health Sciences , Launceston , Tasmania.
FAU - Randow, Felix
AU  - Randow F
AD  - adk MRC Laboratory of Molecular Biology , Cambridge , UK.
AD  - bgr University of Cambridge , Department of Medicine , Addenbrooke's Hospital , 
      Cambridge , UK.
FAU - Rao, Hai
AU  - Rao H
AD  - bvw University of Texas, Health Science Center at San Antonio , Department of 
      Molecular Medicine , San Antonio , TX , USA.
FAU - Rao, V Ashutosh
AU  - Rao VA
AD  - avh U.S. Food and Drug Administration, Center for Drug Evaluation and Research , 
      Silver Spring , MD , USA.
FAU - Rasmussen, Blake B
AU  - Rasmussen BB
AD  - bwi University of Texas, Medical Branch , Department of Nutrition and Metabolism 
      , Galveston , TX , USA.
FAU - Rasse, Tobias M
AU  - Rasse TM
AD  - pj Heidelberg University, Deutsches Krebsforschungszentrum, Proteostasis in 
      Neurodegenerative Disease (B180), CHS Research Group at CellNetworks , Heidelberg 
      , Germany.
FAU - Ratovitski, Edward A
AU  - Ratovitski EA
AD  - wd Johns Hopkins University, School of Medicine , Baltimore , MD , USA.
FAU - Rautou, Pierre-Emmanuel
AU  - Rautou PE
AD  - pz Hôpital Beaujon , Paris , France.
AD  - so INSERM, U970 , Paris , France.
AD  - ajl Paris Cardiovascular Research Center - PARCC , Clichy , France.
AD  - azu Université Paris Descartes , Paris , France.
FAU - Ray, Swapan K
AU  - Ray SK
AD  - buj University of South Carolina School of Medicine , Department of Pathology , 
      Microbiology, and Immunology , Columbia , SC , USA.
FAU - Razani, Babak
AU  - Razani B
AD  - cba Washington University, School of Medicine, Cardiovascular Division , 
      Department of Medicine , St. Louis , MO , USA.
AD  - cbd Washington University, School of Medicine , Department of Pathology and 
      Immunology , St. Louis , MO , USA.
FAU - Reed, Bruce H
AU  - Reed BH
AD  - byn University of Waterloo , Department of Biology , Waterloo, Ontario , Canada.
FAU - Reggiori, Fulvio
AU  - Reggiori F
AD  - bbp University Medical Center Utrecht , Department of Cell Biology , Groningen , 
      The Netherlands.
FAU - Rehm, Markus
AU  - Rehm M
AD  - alp Royal College of Surgeons in Ireland , Department of Physiology and Medical 
      Physics , Dublin , Ireland.
FAU - Reichert, Andreas S
AU  - Reichert AS
AD  - ayc Universitätsklinikum Düsseldorf, Institute for Biochemistry and Molecular 
      Biology I , Düsseldorf , Germany.
FAU - Rein, Theo
AU  - Rein T
AD  - abc Max Planck Institute of Psychiatry, Translational Research in Psychiatry , 
      Munich , Germany.
FAU - Reiner, David J
AU  - Reiner DJ
AD  - ask Texas A&M University, Texas A&M Health Science Center, College of Medicine, 
      Institute of Biosciences and Technology , Houston , TX , USA.
FAU - Reits, Eric
AU  - Reits E
AD  - m Academic Medical Center, University of Amsterdam , Department of Cell Biology 
      and Histology , Amsterdam , The Netherlands.
FAU - Ren, Jun
AU  - Ren J
AD  - byv University of Wyoming, School of Pharmacy, College of Health Sciences , 
      Laramie , WY , USA.
FAU - Ren, Xingcong
AU  - Ren X
AD  - ajx Pennsylvania State University, College of Medicine , Department of 
      Pharmacology , Hershey , PA , USA.
FAU - Renna, Maurizio
AU  - Renna M
AD  - bgq University of Cambridge , Department of Medical Genetics , Cambridge 
      Institute for Medical Research , Cambridge , UK.
FAU - Reusch, Jane Eb
AU  - Reusch JE
AD  - iz Denver VAMC , Denver , CO , USA.
AD  - bif University of Colorado, School of Medicine , Aurora , CO , USA.
FAU - Revuelta, Jose L
AU  - Revuelta JL
AD  - axp Universidal de Salamanca, Campus Miguel de Unamuno , Departamento de 
      Microbiologia y Genetica , Salamanca , Spain.
FAU - Reyes, Leticia
AU  - Reyes L
AD  - byu University of Wisconsin, School of Veterinary Medicine , Department of 
      Pathobiological Sciences , Madison , WI , USA.
FAU - Rezaie, Alireza R
AU  - Rezaie AR
AD  - aqf St. Louis University School of Medicine , Department of Biochemistry and 
      Molecular Biology , St. Louis , MO , USA.
FAU - Richards, Robert I
AU  - Richards RI
AD  - bby University of Adelaide , Department of Genetics and Evolution , School of 
      Biological Sciences , Adelaide , SA , Australia.
FAU - Richardson, Des R
AU  - Richardson DR
AD  - bvi University of Sydney , Department of Pathology and Bosch Institute , Sydney, 
      New South Wales , Australia.
FAU - Richetta, Clémence
AU  - Richetta C
AD  - aps Sorbonne Universités, UPMC Univ Paris 06, INSERM U1135, CNRS ERL 8255, Center 
      for Immunology and Microbial Infections - CIMI-Paris , Paris , France.
FAU - Riehle, Michael A
AU  - Riehle MA
AD  - bcp University of Arizona , Department of Entomology , Tucson , AZ , USA.
FAU - Rihn, Bertrand H
AU  - Rihn BH
AD  - zw Lorraine University, CITHéFOR EA3452, Faculté de Pharmacie , Nancy , France.
FAU - Rikihisa, Yasuko
AU  - Rikihisa Y
AD  - ail Ohio State University , Department of Veterinary Biosciences , College of 
      Veterinary Medicine , Columbus , OH , USA.
FAU - Riley, Brigit E
AU  - Riley BE
AD  - amu Sangamo Biosciences , Richmond , CA , USA.
FAU - Rimbach, Gerald
AU  - Rimbach G
AD  - bls University of Kiel, Institute of Human Nutrition and Food Science , Kiel , 
      Germany.
FAU - Rippo, Maria Rita
AU  - Rippo MR
AD  - axv Università Politecnica delle Marche , Department of Clinical and Molecular 
      Sciences , Ancona , Italy.
FAU - Ritis, Konstantinos
AU  - Ritis K
AD  - iw Democritus University of Thrace, Laboratory of Molecular Hematology , 
      Alexandroupolis , Greece.
FAU - Rizzi, Federica
AU  - Rizzi F
AD  - brg University of Parma , Department of Biomedical , Biotechnological and 
      Translational Sciences , Parma , Italy.
FAU - Rizzo, Elizete
AU  - Rizzo E
AD  - axm Universidade Federal de Minas Gerais, UFMG , Departamento de Morfologia , 
      Instituto de Ciências Biológicas , Belo Horizonte , Minas Gerais , Brazil.
FAU - Roach, Peter J
AU  - Roach PJ
AD  - rj Indiana University School of Medicine , Department of Biochemistry and 
      Molecular Biology , Indianapolis , IN , USA.
FAU - Robbins, Jeffrey
AU  - Robbins J
AD  - bhm University of Cincinnati, Cincinnati Children's Hospital , Cincinnati , OH , 
      USA.
FAU - Roberge, Michel
AU  - Roberge M
AD  - bec University of British Columbia , Department of Biochemistry and Molecular 
      Biology , Vancouver, BC Canada.
FAU - Roca, Gabriela
AU  - Roca G
AD  - arr Technische Universität Braunschweig, Biozentrum , Braunschweig , Germany.
FAU - Roccheri, Maria Carmela
AU  - Roccheri MC
AD  - brf University of Palermo , Dipartimento di Scienze e Tecnologie Biologiche , 
      Chimiche e Farmaceutiche (STEBICEF) , Palermo , Italy.
FAU - Rocha, Sonia
AU  - Rocha S
AD  - biu University of Dundee, Centre for Gene Regulation and Expression, College of 
      Life Sciences , UK.
FAU - Rodrigues, Cecilia M P
AU  - Rodrigues CMP
AD  - axg Universidade de Lisboa, Research Institute for Medicines (iMed.ULisboa), 
      Faculty of Pharmacy , Lisboa , Portugal.
FAU - Rodríguez, Clara I
AU  - Rodríguez CI
AD  - ib BioCruces Health Research Institute, Cruces University Hospital, Stem Cells 
      and Cell Therapy Laboratory , Barakaldo , Spain.
FAU - de Cordoba, Santiago Rodriguez
AU  - de Cordoba SR
AD  - ja Department of Cellular and Molecular Medicine , Center for Biological Research 
      and Center for Biomedical Network Research on Rare Diseases , Madrid , Spain.
FAU - Rodriguez-Muela, Natalia
AU  - Rodriguez-Muela N
AD  - ec Centro de Investigaciones Biológicas (CSIC) , Department of Cellular and 
      Molecular Biology , Madrid , Spain.
FAU - Roelofs, Jeroen
AU  - Roelofs J
AD  - xa Kansas State University, Division of Biology , Manhattan , KS , USA.
FAU - Rogov, Vladimir V
AU  - Rogov VV
AD  - np Goethe University of Frankfurt, Institute of Biophysical Chemistry , Frankfurt 
      am Main , Germany.
FAU - Rohn, Troy T
AU  - Rohn TT
AD  - bz Boise State University , Department of Biological Sciences, Boise , ID , USA.
FAU - Rohrer, Bärbel
AU  - Rohrer B
AD  - ack Medical University of South Carolina , Department of Ophthalmology , 
      Charleston , SC , USA.
FAU - Romanelli, Davide
AU  - Romanelli D
AD  - blb University of Insubria , Department of Biotechnology and Life Sciences , 
      Varese , Italy.
FAU - Romani, Luigina
AU  - Romani L
AD  - brs University of Perugia , Department of Experimental Medicine , Perugia , 
      Italy.
FAU - Romano, Patricia Silvia
AU  - Romano PS
AD  - axd Universidad Nacional de Cuyo (FCM-UNCUYO), Instituto de Histologia y 
      Embriologia (IHEM-CONICET), Facultad de Ciencias Medicas , Mendoza , Argentina.
FAU - Roncero, M Isabel G
AU  - Roncero MI
AD  - awo Universidad de Córdoba, Campus de Excelencia Agroalimentario (ceiA3), 
      Departamento de Genética , Córdoba , Spain.
FAU - Rosa, Jose Luis
AU  - Rosa JL
AD  - aya Universitat de Barcelona, L'Hospitalet de Llobregat , Departament de Ciències 
      Fisiol∫giques II , Campus de Bellvitge, Institut d'Investigació Biomèdica de 
      Bellvitge (IDIBELL) , Barcelona , Spain.
FAU - Rosello, Alicia
AU  - Rosello A
AD  - ako Public Health England, Health Protection Services, Modelling and Economics 
      Unit, Colindale , London , UK.
FAU - Rosen, Kirill V
AU  - Rosen KV
AD  - ii Dalhousie University, Biochemistry and Molecular Biology , Halifax, NS , 
      Canada.
AD  - ik Dalhousie University , Department of Pediatrics , Halifax, Nova Scotia , 
      Canada.
FAU - Rosenstiel, Philip
AU  - Rosenstiel P
AD  - blr University of Kiel, Institute of Clinical Molecular Biology , Kiel , Germany.
FAU - Rost-Roszkowska, Magdalena
AU  - Rost-Roszkowska M
AD  - bue University of Silesia , Department of Animal Histology and Embryology , 
      Katowice , Poland.
FAU - Roth, Kevin A
AU  - Roth KA
AD  - bcb University of Alabama at Birmingham , Department of Pathology , Birmingham , 
      AL , USA.
FAU - Roué, Gael
AU  - Roué G
AD  - sp Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS) , 
      Hemato-oncology Department , Barcelona , Spain.
FAU - Rouis, Mustapha
AU  - Rouis M
AD  - bze University Pierre et Marie Curie, UMR8256/INSERM U-1164, Biological 
      Adaptation and Ageing (B2A) , Paris , France.
FAU - Rouschop, Kasper M
AU  - Rouschop KM
AD  - aag Maastricht University, Maastricht Radiation Oncology (MaastRO) Lab, GROW - 
      School for Oncology and Developmental Biology , Maastricht , The Netherlands.
FAU - Ruan, Daniel T
AU  - Ruan DT
AD  - bq Beth Israel Deaconess Medical Center, Medical Genetics , Boston , MA , USA.
FAU - Ruano, Diego
AU  - Ruano D
AD  - awy Universidad de Sevilla, Instituto de Biomedicina de Sevilla , Sevilla , 
      Spain.
FAU - Rubinsztein, David C
AU  - Rubinsztein DC
AD  - bgm University of Cambridge, Cambridge Institute for Medical Research, 
      Addenbrooke's Hospital , Department of Medical Genetics , Cambridge , UK.
FAU - Rucker, Edmund B 3rd
AU  - Rucker EB 3rd
AD  - blm University of Kentucky , Department of Biology , Lexington , KY , USA.
FAU - Rudich, Assaf
AU  - Rudich A
AD  - bn Ben-Gurion University , Department of Clinical Biochemistry and the National 
      Institute of Biotechnology in the Negev , Beer-Sheva , Israel.
FAU - Rudolf, Emil
AU  - Rudolf E
AD  - eq Charles University in Prague, Faculty of Medicine in Hradec Kralove , 
      Department of Medical Biology and Genetics , Hradec Kralove , Czech Republic.
FAU - Rudolf, Ruediger
AU  - Rudolf R
AD  - aaq Mannheim University of Applied Sciences, Institute of Molecular and Cell 
      Biology , Mannheim , Germany.
FAU - Ruegg, Markus A
AU  - Ruegg MA
AD  - bdf University of Basel , Biozentrum, Basel, BS , Switzerland.
FAU - Ruiz-Roldan, Carmen
AU  - Ruiz-Roldan C
AD  - awo Universidad de Córdoba, Campus de Excelencia Agroalimentario (ceiA3), 
      Departamento de Genética , Córdoba , Spain.
FAU - Ruparelia, Avnika Ashok
AU  - Ruparelia AA
AD  - ada Monash University, School of Biological Sciences , Melbourne , Victoria , 
      Australia.
FAU - Rusmini, Paola
AU  - Rusmini P
AD  - axq Universita' degli Studi di Milano , Dipartimento di Scienze Farmacologiche e 
      Biomolecolari , Milan , Italy.
FAU - Russ, David W
AU  - Russ DW
AD  - aio Ohio University, Division of Physical Therapy , Athens , OH , USA.
FAU - Russo, Gian Luigi
AU  - Russo GL
AD  - agc National Research Council, Institute of Food Sciences , Avellino , Italy.
FAU - Russo, Giuseppe
AU  - Russo G
AD  - asc Temple University, Sbarro Institute for Cancer Research and Molecular 
      Medicine, Center for Biotechnology, College of Science and Technology , 
      Philadelphia , PA , USA.
FAU - Russo, Rossella
AU  - Russo R
AD  - bes University of Calabria , Department of Pharmacy , Health and Nutritional 
      Sciences, Section of Preclinical and Translational Pharmacology , Rende (Cosenza) 
      , Italy.
FAU - Rusten, Tor Erik
AU  - Rusten TE
AD  - aje Oslo University Hospital , Department of Molecular Cell Biology , Institute 
      for Cancer Research , Oslo , Norway.
AD  - bqk University of Oslo, Centre for Cancer Biomedicine , Oslo , Norway.
FAU - Ryabovol, Victoria
AU  - Ryabovol V
AD  - tc Institute of Biochemistry and Biophysics , Kazan , Russia.
FAU - Ryan, Kevin M
AU  - Ryan KM
AD  - bjy University of Glasgow, Cancer Research UK Beatson Institute , Glasgow , UK.
FAU - Ryter, Stefan W
AU  - Ryter SW
AD  - cbn Weill Cornell Medical College , Joan and Sanford I. Weill Department of 
      Medicine , New York , NY , USA.
FAU - Sabatini, David M
AU  - Sabatini DM
AD  - cbv Whitehead Institute, HHMI and Massachusetts Institute of Technology , 
      Cambridge , MA , USA.
FAU - Sacher, Michael
AU  - Sacher M
AD  - hu Concordia University , Department of Biology , Montreal , Canada.
AD  - abi McGill University , Department of Anatomy and Cell Biology , Montreal , 
      Canada.
FAU - Sachse, Carsten
AU  - Sachse C
AD  - kw European Molecular Biology Laboratory (EMBL), Structural and Computational 
      Biology Unit , Heidelberg , Germany.
FAU - Sack, Michael N
AU  - Sack MN
AD  - afi National Institutes of Health, Cardiovascular Branch, NHLB , Bethesda , MD , 
      USA.
FAU - Sadoshima, Junichi
AU  - Sadoshima J
AD  - alz Rutgers New Jersey Medical School , Department of Cell Biology and Molecular 
      Medicine , Newark , NJ , USA.
FAU - Saftig, Paul
AU  - Saftig P
AD  - gf Christian Albrechts University, Institut für Biochemie , Kiel , Germany.
FAU - Sagi-Eisenberg, Ronit
AU  - Sagi-Eisenberg R
AD  - ary Tel Aviv University, Sackler Faculty of Medicine , Department of Cell and 
      Developmental Biology , Tel Aviv , Israel.
FAU - Sahni, Sumit
AU  - Sahni S
AD  - bvi University of Sydney , Department of Pathology and Bosch Institute , Sydney, 
      New South Wales , Australia.
FAU - Saikumar, Pothana
AU  - Saikumar P
AD  - bvx University of Texas, Health Science Center at San Antonio , Department of 
      Pathology , San Antonio , TX , USA.
FAU - Saito, Tsunenori
AU  - Saito T
AD  - ahv Nippon Medical School , Department of Cardiovascular Medicine , Tokyo , 
      Japan.
FAU - Saitoh, Tatsuya
AU  - Saitoh T
AD  - auh Tokushima University, Division of Molecular Genetics, Institute for Enzyme 
      Research , Tokushima , Japan.
FAU - Sakakura, Koichi
AU  - Sakakura K
AD  - nz Gunma University Graduate School of Medicine , Department of 
      Otolaryngology-Head and Neck Surgery , Gunma , Japan.
FAU - Sakoh-Nakatogawa, Machiko
AU  - Sakoh-Nakatogawa M
AD  - auj Tokyo Institute of Technology, Frontier Research Center , Yokohama , Japan.
FAU - Sakuraba, Yasuhito
AU  - Sakuraba Y
AD  - anv Seoul National University , Department of Plant Science , Seoul , Korea.
FAU - Salazar-Roa, María
AU  - Salazar-Roa M
AD  - apy Spanish National Cancer Research Centre (CNIO), Cell Division and Cancer 
      Group , Madrid , Spain.
FAU - Salomoni, Paolo
AU  - Salomoni P
AD  - avk UCL Cancer Institute, Samantha Dickson Brain Cancer Unit , London , UK.
FAU - Saluja, Ashok K
AU  - Saluja AK
AD  - bov University of Minnesota , Department of Surgery , Minneapolis , MN , USA.
FAU - Salvaterra, Paul M
AU  - Salvaterra PM
AD  - bg Beckman Research Institute, City of Hope , Department of Neuroscience , Irell 
      and Manella Graduate School of Biological Science , Duarte , CA , USA.
FAU - Salvioli, Rosa
AU  - Salvioli R
AD  - va Istituto Superiore di Sanità , Department of Haematology , Oncology and 
      Molecular Medicine , Rome , Italy.
FAU - Samali, Afshin
AU  - Samali A
AD  - agp National University of Ireland, Apoptosis Research Centre , Galway , Ireland.
FAU - Sanchez, Anthony Mj
AU  - Sanchez AM
AD  - brr Laboratoire Européen Performance Santé Altitude, EA 4604, University of 
      Perpignan Via Domitia , Font-Romeu , France.
FAU - Sánchez-Alcázar, José A
AU  - Sánchez-Alcázar JA
AD  - axe Universidad Pablo de Olavide, Centro Andaluz de Biología del Desarrollo 
      (CABD), Consejo Superior de Investigaciones Científicas-Junta de Andalucía , 
      Sevilla , Spain.
FAU - Sanchez-Prieto, Ricardo
AU  - Sanchez-Prieto R
AD  - awi Universidad de Castilla-La Mancha, Laboratorio de Oncología Molecular, Centro 
      Regional de Investigaciones Biomédicas , Albacete , Spain.
FAU - Sandri, Marco
AU  - Sandri M
AD  - bre University of Padova, Venetian Institute of Molecular Medicine , Department 
      of Biomedical Science , Padova , Italy.
FAU - Sanjuan, Miguel A
AU  - Sanjuan MA
AD  - acp MedImmune, Respiratory, Inflammation and Autoimmunity Research Department , 
      Gaithersburg , MD , USA.
FAU - Santaguida, Stefano
AU  - Santaguida S
AD  - aax Massachusetts Institute of Technology, Koch Institute for Integrative Cancer 
      Research , Cambridge , MA , USA.
FAU - Santambrogio, Laura
AU  - Santambrogio L
AD  - ag Albert Einstein College of Medicine, Departments of Pathology, Microbiology 
      and Immunology , New York , NY , USA.
FAU - Santoni, Giorgio
AU  - Santoni G
AD  - bgv University of Camerino, School of Pharmacy, Section of Experimental Medicine 
      , Camerino, MC , Italy.
FAU - Dos Santos, Claudia Nunes
AU  - Dos Santos CN
AD  - qo iBET, Instituto de Biologia Experimental e Tecnológica , Oeiras , Portugal.
AD  - tt Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova 
      de Lisboa , Oeiras , Portugal.
FAU - Saran, Shweta
AU  - Saran S
AD  - vk Jawaharlal Nehru University, School of Life Sciences , New Delhi , India.
FAU - Sardiello, Marco
AU  - Sardiello M
AD  - bc Baylor College of Medicine , Department of Molecular and Human Genetics , 
      Houston , TX , USA.
FAU - Sargent, Graeme
AU  - Sargent G
AD  - bxd University of Toronto, Hospital for Sick Children , Toronto, Ontario , 
      Canada.
FAU - Sarkar, Pallabi
AU  - Sarkar P
AD  - dg Center for Dementia Research, Nathan S. Kline Institute , Orangeburg , NY , 
      USA.
FAU - Sarkar, Sovan
AU  - Sarkar S
AD  - bds University of Birmingham, Institute of Biomedical Research, Institute of 
      Cancer and Genomic Sciences, College of Medical and Dental Sciences , Edgbaston, 
      Birmingham , UK.
FAU - Sarrias, Maria Rosa
AU  - Sarrias MR
AD  - ph Health Research Institute Germans Trias i Pujol , Badalona , Spain.
FAU - Sarwal, Minnie M
AU  - Sarwal MM
AD  - bgg University of California San Francisco , Department of Surgery , San 
      Francisco , CA , USA.
FAU - Sasakawa, Chihiro
AU  - Sasakawa C
AD  - eu Chiba University, Medical Mycology Research Center , Chiba , Japan.
FAU - Sasaki, Motoko
AU  - Sasaki M
AD  - wy Kanazawa University Graduate School of Medical Sciences , Department of Human 
      Pathology , Kanazawa , Japan.
FAU - Sass, Miklos
AU  - Sass M
AD  - kj Eötvös Loránd University , Department of Anatomy , Cell and Developmental 
      Biology , Budapest , Hungary.
FAU - Sato, Ken
AU  - Sato K
AD  - ob Gunma University, Laboratory of Molecular Traffic, Institute for Moleclualr 
      and Cellular Regulation , Gunma , Japan.
FAU - Sato, Miyuki
AU  - Sato M
AD  - oa Gunma University, Laboratory of Molecular Membrane Biology, Institute for 
      Moleclualr and Cellular Regulation , Gunma , Japan.
FAU - Satriano, Joseph
AU  - Satriano J
AD  - bfn University of California San Diego , Department of Medicine , San Diego , CA 
      , USA.
FAU - Savaraj, Niramol
AU  - Savaraj N
AD  - acu Miami VA Healthcare System and University of Miami Miller School of Medicine, 
      Oncology/Hematology , Miami , FL , USA.
FAU - Saveljeva, Svetlana
AU  - Saveljeva S
AD  - cp Cambridge University , Department of Medicine , Cambridge , UK.
FAU - Schaefer, Liliana
AU  - Schaefer L
AD  - nr Goethe University, Institue of Pharmacology and Toxicology , Frankfurt am Main 
      , Germany.
FAU - Schaible, Ulrich E
AU  - Schaible UE
AD  - alg Research Center Borstel , Borstel , Germany.
FAU - Scharl, Michael
AU  - Scharl M
AD  - bbg University Hospital Zürich, Division of Gastroenterology and Hepatolog , 
      Zürich , Switzerland.
FAU - Schatzl, Hermann M
AU  - Schatzl HM
AD  - bev University of Calgary, Faculty of Veterinary Medicine , Calgary, AB , Canada.
FAU - Schekman, Randy
AU  - Schekman R
AD  - bex University of California Berkeley, Howard Hughes Medical Institute , 
      Department of Molecular and Cell Biology , Berkeley , CA , USA.
FAU - Scheper, Wiep
AU  - Scheper W
AD  - cao VU University, Medical Center , Academic Medical Center, Department of 
      Clinical Genetics and Alzheimer Center , Amsterdam , Netherlands.
AD  - cap Department of Genome Analysis , Amsterdam , Netherlands.
AD  - caq VU University, Departments of Functional Genomics and Molecular and Cellular 
      Neuroscience, Center for Neurogenomics and Cognitive Research , Amsterdam , 
      Netherlands.
FAU - Schiavi, Alfonso
AU  - Schiavi A
AD  - vg IUF-Leibniz Research Institute for Environmental Medicine , Duesseldorf , 
      Germany.
AD  - bte University of Rome "Tor Vergata" , Department of Biomedicine and Prevention , 
      Rome , Italy.
FAU - Schipper, Hyman M
AU  - Schipper HM
AD  - vn Jewish General Hospital , Department of Neurology and Neurosurgery , 
      Department of Medicine , Montreal, Quebec , Canada.
AD  - abr McGill University, Lady Davis Institute for Medical Research , Montreal, 
      Quebec , Canada.
FAU - Schmeisser, Hana
AU  - Schmeisser H
AD  - afq National Institutes of Health, National Institute of Allergy and Infectious 
      Disease, Cytokine Biology Section , Bethesda , MD , USA.
FAU - Schmidt, Jens
AU  - Schmidt J
AD  - bbq University Medical Centre Göttingen , Clinic for Neurology and Department of 
      Neuroimmunology , Göttingen , Germany.
FAU - Schmitz, Ingo
AU  - Schmitz I
AD  - po Systems-oriented Immunology and Inflammation Research, Helmholtz Centre for 
      Infection Research , Braunschweig , Germany.
AD  - aji Otto-von-Guericke-University Magdeburg, Institute of Molecular and Clinical 
      Immunology , Magdeburg , Germany.
FAU - Schneider, Bianca E
AU  - Schneider BE
AD  - alg Research Center Borstel , Borstel , Germany.
FAU - Schneider, E Marion
AU  - Schneider EM
AD  - bbf University Hospital Ulm, Sektion Experimentelle Anaestesiologie , Ulm , 
      Germany.
FAU - Schneider, Jaime L
AU  - Schneider JL
AD  - z Albert Einstein College of Medicine , Department of Developmental and Molecular 
      Biology , Institute for Aging Studies , Bronx , NY , USA.
FAU - Schon, Eric A
AU  - Schon EA
AD  - hj Columbia University Medical Center , New York , NY , USA.
FAU - Schönenberger, Miriam J
AU  - Schönenberger MJ
AD  - bzc University of Zürich, Institute of Physiology , Zürich , Switzerland.
FAU - Schönthal, Axel H
AU  - Schönthal AH
AD  - buw University of Southern California , Department of Molecular Microbiology and 
      Immunology , Keck School of Medicine , Los Angeles , CA , USA.
FAU - Schorderet, Daniel F
AU  - Schorderet DF
AD  - ut IRO, Institute for Research in Ophthalmology , Sion , Switzerland.
AD  - blx University of Lausanne , Department of Ophthalmology , Lausanne , 
      Switzerland.
FAU - Schröder, Bernd
AU  - Schröder B
AD  - gf Christian Albrechts University, Institut für Biochemie , Kiel , Germany.
FAU - Schuck, Sebastian
AU  - Schuck S
AD  - pk Heidelberg University, Zentrum für Molekulare Biologie der Universität 
      Heidelberg (ZMBH) , Heidelberg , Germany.
FAU - Schulze, Ryan J
AU  - Schulze RJ
AD  - abd Mayo Clinic , Department of Biochemistry , Rochester , MN , USA.
FAU - Schwarten, Melanie
AU  - Schwarten M
AD  - ln Forschungszentrum Juelich, ICS-6/Structural Biochemistry , Juelich , Germany.
FAU - Schwarz, Thomas L
AU  - Schwarz TL
AD  - ca Boston Children's Hospital, F.M. Kirby Neuroscience Center , Boston , MA , 
      USA.
FAU - Sciarretta, Sebastiano
AU  - Sciarretta S
AD  - ug IRCCS Neuromed , Pozzilli, IS , Italy.
AD  - alz Rutgers New Jersey Medical School , Department of Cell Biology and Molecular 
      Medicine , Newark , NJ , USA.
AD  - btc University of Rome "Sapienza" , Department of Medical-Surgical Sciences and 
      Biotechnologies , Latina , Italy.
FAU - Scotto, Kathleen
AU  - Scotto K
AD  - amg Rutgers University-Robert Wood Johnson Medical School, Rutgers Cancer 
      Institute of New Jersey , Piscataway , NJ , USA.
FAU - Scovassi, A Ivana
AU  - Scovassi AI
AD  - tk Institute of Molecular Genetics, National Research Council , Pavia , Italy.
FAU - Screaton, Robert A
AU  - Screaton RA
AD  - arg Sunnybrook Research Institute; and University of Toronto , Department of 
      Biochemistry , Toronto, Ontario , Canada.
FAU - Screen, Mark
AU  - Screen M
AD  - pq Helsinki University , Department of Medical Genetics , Helsinki , Finland.
FAU - Seca, Hugo
AU  - Seca H
AD  - bsp University of Porto, Cancer Drug Resistance Group, IPATIMUP - Institute of 
      Molecular Pathology and Immunology , Porto , Portugal.
AD  - bsq University of Porto , Department of Biological Sciences , Faculty of Pharmacy 
      , Porto , Portugal.
AD  - bss University of Porto, i3S-Instituto de Investigação e Inovação em Saúde , 
      Porto , Portugal.
FAU - Sedej, Simon
AU  - Sedej S
AD  - acd Medical University of Graz, Division of Cardiology , Graz , Austria.
FAU - Segatori, Laura
AU  - Segatori L
AD  - alh Rice University, Chemical and Biomolecular Engineering , Houston , TX , USA.
AD  - ali Rice University , Department of BioSciences , Houston , TX , USA.
FAU - Segev, Nava
AU  - Segev N
AD  - bkw University of Illinois at Chicago, Deprtment of Biochemistry and Molecular 
      Genetics , Chicago , IL , USA.
FAU - Seglen, Per O
AU  - Seglen PO
AD  - bql University of Oslo, Centre for Molecular Medicine Norway (NCMM) , Oslo , 
      Norway.
FAU - Seguí-Simarro, Jose M
AU  - Seguí-Simarro JM
AD  - ayb Universitat Politècnica de València, COMAV Institute , Valencia , Spain.
FAU - Segura-Aguilar, Juan
AU  - Segura-Aguilar J
AD  - bhi University of Chile, Faculty of Medicine, ICBM, Molecular and Clinical 
      Pharmacology , Santiago , Chile.
FAU - Seki, Ekihiro
AU  - Seki E
AD  - de Cedars-Sinai Medical Center , Department of Medicine , Los Angeles , CA , USA.
FAU - Sell, Christian
AU  - Sell C
AD  - je Drexel University, College of Medicine , Department of Pathology , 
      Philadelphia , PA , USA.
FAU - Seiliez, Iban
AU  - Seiliez I
AD  - rt INRA, UR1067, Nutrion Métabolisme Aquaculture , St-Pée-sur-Nivelle , France.
FAU - Semenkovich, Clay F
AU  - Semenkovich CF
AD  - caz Washington University , Department of Medicine , St. Louis , MO , USA.
FAU - Semenza, Gregg L
AU  - Semenza GL
AD  - wg Johns Hopkins University, School of Medicine, Institute for Cell Engineering 
      and McKusick-Nathans Institute of Genetic Medicine , Baltimore , MD , USA.
FAU - Sen, Utpal
AU  - Sen U
AD  - bmo University of Louisville , Department of Physiology , Louisville , KY , USA.
FAU - Serra, Andreas L
AU  - Serra AL
AD  - bza University of Zurich, Epidemiology, Biostatistics and Prevention Institute , 
      Zurich , Switzerland.
FAU - Serrano-Puebla, Ana
AU  - Serrano-Puebla A
AD  - ec Centro de Investigaciones Biológicas (CSIC) , Department of Cellular and 
      Molecular Biology , Madrid , Spain.
FAU - Sesaki, Hiromi
AU  - Sesaki H
AD  - wd Johns Hopkins University, School of Medicine , Baltimore , MD , USA.
FAU - Setoguchi, Takao
AU  - Setoguchi T
AD  - wu Kagoshima University, The Near-Future Locomoter Organ Medicine Creation 
      Course, Graduate School of Medical and Dental Sciences , Kagoshima , Japan.
FAU - Settembre, Carmine
AU  - Settembre C
AD  - jn Dulbecco Telethon Institute and Telethon Institute of Genetics and Medicine 
      (TIGEM) , Naples , Italy.
FAU - Shacka, John J
AU  - Shacka JJ
AD  - bcb University of Alabama at Birmingham , Department of Pathology , Birmingham , 
      AL , USA.
FAU - Shajahan-Haq, Ayesha N
AU  - Shajahan-Haq AN
AD  - zs Lombardi Comprehensive Cancer Center, Georgetown University Medical Center , 
      Department of Oncology , Washington, DC , USA.
FAU - Shapiro, Irving M
AU  - Shapiro IM
AD  - att Thomas Jefferson University, Sidney Kimmel Medical College , Philadelphia , 
      PA , USA.
FAU - Sharma, Shweta
AU  - Sharma S
AD  - bnc University of Maryland , Department of Nutrition and Food Science , College 
      Park , MD , USA.
FAU - She, Hua
AU  - She H
AD  - kd Emory University, School of Medicine , Department of Pharmacology , Atlanta , 
      GA , USA.
FAU - Shen, C-K James
AU  - Shen CK
AD  - k Academia Sinica, Institute of Molecular Biology , Taipei , Taiwan.
FAU - Shen, Chiung-Chyi
AU  - Shen CC
AD  - qm Hungkuang University , Department of Physical Therapy , Taichung , Taiwan.
FAU - Shen, Han-Ming
AU  - Shen HM
AD  - agv National University of Singapore , Department of Physiology , Yong Loo Lin 
      School of Medicine , Singapore.
FAU - Shen, Sanbing
AU  - Shen S
AD  - agr National University of Ireland, Regenerative Medicine Institute , Galway , 
      Ireland.
FAU - Shen, Weili
AU  - Shen W
AD  - aon Shanghai Jiao Tong University, School of Medicine, Shanghai Institute of 
      Hypertension , Shanghai , China.
FAU - Sheng, Rui
AU  - Sheng R
AD  - apm Soochow University, School of Pharmaceutical Science , Department of 
      Pharmacology and Laboratory of Aging and Nervous Diseases , Suzhou , China.
FAU - Sheng, Xianyong
AU  - Sheng X
AD  - cr Capital Normal University , Beijing , China.
FAU - Sheng, Zu-Hang
AU  - Sheng ZH
AD  - ahu NINDS, National Institutes of Health, Synaptic Function Section , Bethesda , 
      MD , USA.
FAU - Shepherd, Trevor G
AU  - Shepherd TG
AD  - cbt Western University , Department of Obstetrics and Gynaecology , London, ON , 
      Canada.
FAU - Shi, Junyan
AU  - Shi J
AD  - aqi St. Paul's Hospital, Centre for Heart Lung Innovation , Vancouver, BC , 
      Canada.
AD  - beh University of British Columbia , Department of Pathology and Laboratory 
      Medicine , Vancouver, BC , Canada.
FAU - Shi, Qiang
AU  - Shi Q
AD  - bzg US Food and Drug Administration, National Center for Toxicological Research, 
      Division of Systems Biology , Jefferson , AR , USA.
FAU - Shi, Qinghua
AU  - Shi Q
AD  - btx University of Science and Technology of China, School of Life Sciences, and 
      Hefei National Laboratory for Physical Sciences at Microscale , Hefei, Anhui , 
      China.
FAU - Shi, Yuguang
AU  - Shi Y
AD  - ajv Pennsylvania State University, College of Medicine , Department of Cellular 
      and Molecular Physiology , Hershey , PA , USA.
FAU - Shibutani, Shusaku
AU  - Shibutani S
AD  - ccf Yamaguchi University, Joint Faculty of Veterinary Medicine, Laboratory of 
      Veterinary Hygiene , Yamaguchi , Japan.
FAU - Shibuya, Kenichi
AU  - Shibuya K
AD  - aea NARO Institute of Floricultural Science , Tsukuba , Japan.
FAU - Shidoji, Yoshihiro
AU  - Shidoji Y
AD  - bpd University of Nagasaki, Molecular and Cellular Biology, Graduate School of 
      Human Health Science , Nagasaki , Japan.
FAU - Shieh, Jeng-Jer
AU  - Shieh JJ
AD  - aer National Chung-Hsing University, Institute of Biomedical Sciences, College of 
      Life Sciences , Taichung , Taiwan.
FAU - Shih, Chwen-Ming
AU  - Shih CM
AD  - arj Taipei Medical University , Department of Biochemistry , College of Medicine 
      , Taipei City , Taiwan.
FAU - Shimada, Yohta
AU  - Shimada Y
AD  - vt Jikei University School of Medicine, Research Center for Medical Sciences, 
      Division of Gene Therapy , Tokyo , Japan.
FAU - Shimizu, Shigeomi
AU  - Shimizu S
AD  - aun Tokyo Medical and Dental University, Medical Research Institute, Pathological 
      Cell Biology , Tokyo , Japan.
FAU - Shin, Dong Wook
AU  - Shin DW
AD  - an Amorepacific Corporation RandD Center, Bioscience Research Institute , 
      Gyeonggi , Korea.
FAU - Shinohara, Mari L
AU  - Shinohara ML
AD  - ji Duke University, Medical Center , Department of Immunology , Durham , NC , 
      USA.
FAU - Shintani, Michiko
AU  - Shintani M
AD  - xw Kobe University, Graduate School of Health Sciences, Laboratory of Pathology, 
      Division of Medical Biophysics , Hyogo , Japan.
FAU - Shintani, Takahiro
AU  - Shintani T
AD  - aud Tohoku University, Laboratory of Bioindustrial Genomics, Graduate School of 
      Agricultural Science , Miyagi , Japan.
FAU - Shioi, Tetsuo
AU  - Shioi T
AD  - yx Kyoto University , Department of Cardiovascular Medicine , Kyoto , Japan.
FAU - Shirabe, Ken
AU  - Shirabe K
AD  - zb Kyushu University , Department of Surgery and Science , Fukuoka , Japan.
FAU - Shiri-Sverdlov, Ronit
AU  - Shiri-Sverdlov R
AD  - aah Maastricht University, Medical Centre, NUTRIM , Department of Molecular 
      Genetics , Maastricht , The Netherlands.
FAU - Shirihai, Orian
AU  - Shirihai O
AD  - cc Boston University , Department of Medicine , Boston , MA , USA.
FAU - Shore, Gordon C
AU  - Shore GC
AD  - abj McGill University , Department of Biochemistry , Montreal, Quebec , Canada.
FAU - Shu, Chih-Wen
AU  - Shu CW
AD  - xe Kaohsiung Veterans General Hospital , Department of Medical Education and 
      Research , Kaohsiung , Taiwan.
FAU - Shukla, Deepak
AU  - Shukla D
AD  - bkv University of Illinois at Chicago, Departments of Ophthalmology and 
      Microbiology and Immunology , Chicago , IL , USA.
FAU - Sibirny, Andriy A
AU  - Sibirny AA
AD  - aed National Academy of Sciences of Ukraine , Department of Biotechnology and 
      Microbiology , Lviv , Ukraine.
AD  - btm University of Rzeszow, Institute of Cell Biology , Rzeszow , Poland.
FAU - Sica, Valentina
AU  - Sica V
AD  - km Centre de Recherche des Cordeliers, Equipe 11 labellisée par la Ligue 
      Nationale contre le Cancer , Paris , France.
AD  - oc Gustave Roussy Cancer Campus , Villejuif , France.
AD  - sn INSERM, U1138 , Paris , France.
AD  - azv Université Paris Descartes/Paris V , Paris , France.
FAU - Sigurdson, Christina J
AU  - Sigurdson CJ
AD  - bfo University of California San Diego , Department of Pathology , La Jolla , CA 
      , USA.
FAU - Sigurdsson, Einar M
AU  - Sigurdsson EM
AD  - ahk New York University School of Medicine, Departments of Neuroscience and 
      Physiology, and Psychiatry , New York , NY , USA.
FAU - Sijwali, Puran Singh
AU  - Sijwali PS
AD  - id CSIR - Centre for Cellular and Molecular Biology , Hyderabad , India.
FAU - Sikorska, Beata
AU  - Sikorska B
AD  - acf Medical University of Lodz , Department of Molecular Pathology and 
      Neuropathology , Lodz , Poland.
FAU - Silveira, Wilian A
AU  - Silveira WA
AD  - btt University of São Paulo, Ribeirão Preto Medical School , Department of 
      Physiology , Ribeirão Preto, São Paulo , Brazil.
FAU - Silvente-Poirot, Sandrine
AU  - Silvente-Poirot S
AD  - bxh University of Toulouse, INSERM UMR 1037, Cancer Research Center of Toulouse , 
      Toulouse , France.
FAU - Silverman, Gary A
AU  - Silverman GA
AD  - bsk University of Pittsburgh, School of Medicine , Department of Pediatrics , 
      Pittsburgh , PA , USA.
FAU - Simak, Jan
AU  - Simak J
AD  - avg U.S. Food and Drug Administration, Center for Biologics Evaluation and 
      Research , Silver Spring , MD , USA.
FAU - Simmet, Thomas
AU  - Simmet T
AD  - avr Ulm University, Institute of Pharmacology of Natural Compounds and Clinical 
      Pharmacology , Ulm , Germany.
FAU - Simon, Anna Katharina
AU  - Simon AK
AD  - adj MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine and BRC 
      Translational Immunology Lab, NDM , Oxford , UK.
FAU - Simon, Hans-Uwe
AU  - Simon HU
AD  - bdr University of Bern, Institute of Pharmacology , Bern , Switzerland.
FAU - Simone, Cristiano
AU  - Simone C
AD  - bde University of Bari 'Aldo Moro', Division of Medical Genetics, DIMO, School of 
      Medicine , Bari , Italy.
FAU - Simons, Matias
AU  - Simons M
AD  - ajm Paris Descartes University-Sorbonne Paris Cité, Imagine Institute , Paris , 
      France.
FAU - Simonsen, Anne
AU  - Simonsen A
AD  - bqr University of Oslo, Institute of Basic Medical Sciences , Oslo , Norway.
FAU - Singh, Rajat
AU  - Singh R
AD  - x Albert Einstein College of Medicine , Bronx , NY , USA.
FAU - Singh, Shivendra V
AU  - Singh SV
AD  - brv University of Pittsburgh Cancer Institute, Hillman Cancer Center Research 
      Pavilion , Pittsburgh , PA , USA.
FAU - Singh, Shrawan K
AU  - Singh SK
AD  - akl Post Graduate Institute of Medical Education and Research (PGIMER) , 
      Department of Urology , Chandigarh , India.
FAU - Sinha, Debasish
AU  - Sinha D
AD  - wi Johns Hopkins University, School of Medicine, Wilmer Eye Institute , Baltimore 
      , MD , USA.
FAU - Sinha, Sangita
AU  - Sinha S
AD  - ahw North Dakota State University , Department of Chemistry and Biochemistry , 
      Fargo , ND , USA.
FAU - Sinicrope, Frank A
AU  - Sinicrope FA
AD  - abg Mayo Clinic , Rochester , MN , USA.
FAU - Sirko, Agnieszka
AU  - Sirko A
AD  - akg Polish Academy of Sciences, Institute of Biochemistry and Biophysics , Warsaw 
      , Poland.
FAU - Sirohi, Kapil
AU  - Sirohi K
AD  - dr Centre for Cellular and Molecular Biology, Council of Scientific and 
      Industrial Research , Hyderabad , India.
FAU - Sishi, Balindiwe Jn
AU  - Sishi BJ
AD  - aqr Stellenbosch University , Department of Physiological Sciences , Stellenbosch 
      , South Africa.
FAU - Sittler, Annie
AU  - Sittler A
AD  - apr Sorbonne Universités, University Pierre and Marie Curie, Paris 6, Brain and 
      Spine Institute, INSERM U1127, CNRS UMR722 , Paris , France.
FAU - Siu, Parco M
AU  - Siu PM
AD  - px Hong Kong Polytechnic University , Department of Health Technology and 
      Informatics , Faculty of Health and Social Sciences , Kowloon, Hong Kong.
FAU - Sivridis, Efthimios
AU  - Sivridis E
AD  - ix Democritus University of Thrace, Medical School , Department of Pathology , 
      Alexandroupolis , Greece.
FAU - Skwarska, Anna
AU  - Skwarska A
AD  - mf Gdansk University of Technology , Department of Pharmaceutical Technology and 
      Biochemistry , Gdansk , Poland.
FAU - Slack, Ruth
AU  - Slack R
AD  - bqv University of Ottawa , Department of Cellular and Molecular Medicine , 
      Faculty of Medicine , Ottawa, Ontario , Canada.
FAU - Slaninová, Iva
AU  - Slaninová I
AD  - aar Masaryk University , Department of Biology , Faculty of Medicine , Brno , 
      Czech Republic.
FAU - Slavov, Nikolai
AU  - Slavov N
AD  - ahy Northeastern University , Department of Bioengineering , Boston , MA , USA.
FAU - Smaili, Soraya S
AU  - Smaili SS
AD  - lb Federal University of São Paulo , Department of Pharmacology , Paulista School 
      of Medicine , São Paulo , Brazil.
FAU - Smalley, Keiran Sm
AU  - Smalley KS
AD  - acv Moffitt Cancer Center , Department of Tumor Biology , Tampa , FL , USA.
FAU - Smith, Duncan R
AU  - Smith DR
AD  - aao Mahidol University, Salaya Campus, Institute of Molecular Biosciences , 
      Nakorn Pathom , Thailand.
FAU - Soenen, Stefaan J
AU  - Soenen SJ
AD  - ym KU Leuven , Department of Imaging and Pathology , Leuven , Belgium.
FAU - Soleimanpour, Scott A
AU  - Soleimanpour SA
AD  - bnw University of Michigan Medical School , Department of Internal Medicine , Ann 
      Arbor , MI , USA.
FAU - Solhaug, Anita
AU  - Solhaug A
AD  - aif Norwegian Veterinary Institute , Oslo , Norway.
FAU - Somasundaram, Kumaravel
AU  - Somasundaram K
AD  - rf Indian Institute of Science, Microbiology and Cell Biology , Bangalore , 
      India.
FAU - Son, Jin H
AU  - Son JH
AD  - ky Ewha W. University, Brain and Cognitive Sciences/Pharmacy , Seoul , Korea.
FAU - Sonawane, Avinash
AU  - Sonawane A
AD  - qx IIT University, School of Biotechnology , Orissa , India.
FAU - Song, Chunjuan
AU  - Song C
AD  - ap Applied Genetic Technologies Corporation , Alachua , FL , USA.
FAU - Song, Fuyong
AU  - Song F
AD  - anz Shandong University , Department of Toxicology , Jinan, Shandong , China.
FAU - Song, Hyun Kyu
AU  - Song HK
AD  - yh Korea University, Division of Life Sciences , Seoul , Korea.
FAU - Song, Ju-Xian
AU  - Song JX
AD  - pw Hong Kong Baptist University, School of Chinese Medicine , Kowloon Tong, Hong 
      Kong.
FAU - Song, Wei
AU  - Song W
AD  - vm Jewish General Hospital, Bloomfield Centre for Research in Aging, Lady Davis 
      Institute for Medical Research , Montreal, Quebec , Canada.
FAU - Soo, Kai Y
AU  - Soo KY
AD  - zd La Trobe University , Department of Biochemistry and Genetics , La Trobe 
      Institute for Molecular Science , Melbourne , Victoria , Australia.
FAU - Sood, Anil K
AU  - Sood AK
AD  - abv MD Anderson Cancer Center , Department of Cancer Biology , Houston , TX , 
      USA.
AD  - abx MD Anderson Cancer Center , Department of Gynecologic Oncology and 
      Reproductive Medicine , Houston , TX , USA.
FAU - Soong, Tuck Wah
AU  - Soong TW
AD  - agu National University of Singapore , Department of Physiology , Singapore.
FAU - Soontornniyomkij, Virawudh
AU  - Soontornniyomkij V
AD  - bfz University of California San Diego, School of Medicine , Department of 
      Psychiatry , La Jolla , CA , USA.
FAU - Sorice, Maurizio
AU  - Sorice M
AD  - anb Sapienza University of Rome , Department of Experimental Medicine , Rome , 
      Italy.
FAU - Sotgia, Federica
AU  - Sotgia F
AD  - bmx University of Manchester, Institute of Cancer Sciences, Faculty of Medical 
      and Human Sciences , Manchester , UK.
FAU - Soto-Pantoja, David R
AU  - Soto-Pantoja DR
AD  - car Wake Forest University , Department of Surgery and Cancer Biology , 
      Winston-Salem , NC , USA.
FAU - Sotthibundhu, Areechun
AU  - Sotthibundhu A
AD  - aan Chulabhorn International College of Medicine, Thammasat University, Pathum 
      Thani, Thailand.
FAU - Sousa, Maria João
AU  - Sousa MJ
AD  - bop University of Minho, Molecular and Environmental Biology Centre 
      (CBMA)/Department of Biology , Braga , Portugal.
FAU - Spaink, Herman P
AU  - Spaink HP
AD  - zl Leiden University, Institute of Biology , Leiden , The Netherlands.
FAU - Span, Paul N
AU  - Span PN
AD  - ald Radboud University Nijmegen Medical Center , Department of Radiation Oncology 
      , Nijmegen , The Netherlands.
FAU - Spang, Anne
AU  - Spang A
AD  - bdg University of Basel , Biozentrum, Basel , Switzerland.
FAU - Sparks, Janet D
AU  - Sparks JD
AD  - bta University of Rochester Medical Center , Department of Pathology and 
      Laboratory Medicine , Rochester , NY , USA.
FAU - Speck, Peter G
AU  - Speck PG
AD  - lh Flinders University, School of Biological Sciences, Bedford Park , South 
      Australia , Australia.
FAU - Spector, Stephen A
AU  - Spector SA
AD  - bfp University of California San Diego , Department of Pediatrics , Division of 
      Infectious Diseases , La Jolla , CA , USA.
FAU - Spies, Claudia D
AU  - Spies CD
AD  - eo Charité - Universitätsmedizin Berlin , Department of Anesthesiology and 
      Intensive Care Medicine , Campus Charité Mitte and Campus Virchow-Klinikum , 
      Berlin , Germany.
FAU - Springer, Wolfdieter
AU  - Springer W
AD  - abe Mayo Clinic , Department of Neuroscience , Jacksonville , FL , USA.
FAU - Clair, Daret St
AU  - Clair DS
AD  - blp University of Kentucky , Department of Toxicology and Cancer Biology, 
      Lexington , KY , USA.
FAU - Stacchiotti, Alessandra
AU  - Stacchiotti A
AD  - ce Brescia University , Department of Clinical and Experimental Sciences , 
      Brescia , Italy.
FAU - Staels, Bart
AU  - Staels B
AD  - bmf University of Lille, INSERM UMR1011, Institut Pasteur de Lille, EGID , Lille 
      , France.
FAU - Stang, Michael T
AU  - Stang MT
AD  - bsm University of Pittsburgh, School of Medicine , Department of Surgery , 
      Division of Endocrine Surgery , Pittsburgh , PA , USA.
FAU - Starczynowski, Daniel T
AU  - Starczynowski DT
AD  - gs Cincinnati Children's Hospital Medical Center, Division of Experimental 
      Hematology and Cancer Biology , Cincinnati , OH , USA.
FAU - Starokadomskyy, Petro
AU  - Starokadomskyy P
AD  - bwp University of Texas, Southwestern Medical Center , Department of Internal 
      Medicine , Dallas , TX.
FAU - Steegborn, Clemens
AU  - Steegborn C
AD  - bdi University of Bayreuth , Department of Biochemistry , Bayreuth , Germany.
FAU - Steele, John W
AU  - Steele JW
AD  - bfl University of California San Diego , Department of Cellular and Molecular 
      Medicine , La Jolla , CA , USA.
FAU - Stefanis, Leonidas
AU  - Stefanis L
AD  - bv Biomedical Research Foundation of the Academy of Athens, Laboratory of 
      Neurodegenerative Diseases , Athens , Attiki , Greece.
FAU - Steffan, Joan
AU  - Steffan J
AD  - bfg University of California Irvine , Department of Psychiatry and Human Behavior 
      , Irvine , CA , USA.
FAU - Stellrecht, Christine M
AU  - Stellrecht CM
AD  - avy University of Texas, MD Anderson Cancer Center , Department of Experimental 
      Therapeutics , Houston , TX , USA.
FAU - Stenmark, Harald
AU  - Stenmark H
AD  - ajd Oslo University Hospital , Department of Biochemistry , Institute for Cancer 
      Research , Oslo , Norway.
FAU - Stepkowski, Tomasz M
AU  - Stepkowski TM
AD  - tm Institute of Nuclear Chemistry and Technology, Centre for Radiobiology and 
      Biological Dosimetry , Dorodna , Poland.
FAU - Stern, Stęphan T
AU  - Stern ST
AD  - zm Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer 
      Research, Nanotechnology Characterization Lab, Cancer Research Technology Program 
      , Frederick , MD , USA.
FAU - Stevens, Craig
AU  - Stevens C
AD  - jv Edinburgh Napier University, School of Life, Sport and Social Sciences , 
      Edinburgh , UK.
FAU - Stockwell, Brent R
AU  - Stockwell BR
AD  - hl Columbia University , Department of Biological Sciences , New York , NY , USA.
AD  - hm Columbia University , Department of Chemistry , New York , NY , USA.
FAU - Stoka, Veronika
AU  - Stoka V
AD  - vh J. Stefan Institute , Department of Biochemistry and Molecular and Structural 
      Biology , Ljubljana , Slovenia.
FAU - Storchova, Zuzana
AU  - Storchova Z
AD  - aaz Max Planck Institute of Biochemistry, Group Maintenance of Genome Stability , 
      Martinsried , Germany.
FAU - Stork, Björn
AU  - Stork B
AD  - pn Heinrich-Heine-University, Institute of Molecular Medicine , Düsseldorf , 
      Germany.
FAU - Stratoulias, Vassilis
AU  - Stratoulias V
AD  - bkj University of Helsinki , Department of Biosciences , Helsinki , Finland.
FAU - Stravopodis, Dimitrios J
AU  - Stravopodis DJ
AD  - aee National and Kapodistrian University of Athens , Department of Cell Biology 
      and Biophysics , Faculty of Biology , Athens , Greece.
AD  - bcv University of Athens , Department of Cell Biology and Biophysics , Faculty of 
      Biology , Athens , Greece.
FAU - Strnad, Pavel
AU  - Strnad P
AD  - bau University Hospital Aachen , IZKF and Department of Internal Medicine III , 
      Aachen , Germany.
FAU - Strohecker, Anne Marie
AU  - Strohecker AM
AD  - ain Ohio State University, The James Comprehensive Cancer Center . Department of 
      Molecular Virology , Immunology and Medical Genetics and Department of Surgery , 
      Division of Surgical Oncology , Columbus , OH , USA.
FAU - Ström, Anna-Lena
AU  - Ström AL
AD  - aqt Stockholm University , Department of Neurochemistry , Stockholm , Sweden.
FAU - Stromhaug, Per
AU  - Stromhaug P
AD  - br Binghamton University, State University of New York , Binghamton , NY , USA.
FAU - Stulik, Jiri
AU  - Stulik J
AD  - tl Institute of Molecular Pathology and Biology, FMHS UO , Hradec Kralove , Czech 
      Republic.
FAU - Su, Yu-Xiong
AU  - Su YX
AD  - bkm University of Hong Kong, Division of Oral and Maxillofacial Surgery, Faculty 
      of Dentistry , Hong Kong.
FAU - Su, Zhaoliang
AU  - Su Z
AD  - vq Jiangsu University , Department of Immunology , Zhenjiang, Jiangsu , China.
FAU - Subauste, Carlos S
AU  - Subauste CS
AD  - cy Case Western Reserve University, School of Medicine, Division of Infectious 
      Diseases and HIV Medicine , Department of Medicine , Cleveland , OH , USA.
FAU - Subramaniam, Srinivasa
AU  - Subramaniam S
AD  - atd The Scripps Research Institute , Department of Neuroscience , Jupiter , FL , 
      USA.
FAU - Sue, Carolyn M
AU  - Sue CM
AD  - bvh University of Sydney , Department of Neurogenetics , Kolling Institute , St 
      Leonards, NSW , Australia.
FAU - Suh, Sang Won
AU  - Suh SW
AD  - om Hallym University, School of Medicine , Department of Physiology , Chuncheon , 
      Korea.
FAU - Sui, Xinbing
AU  - Sui X
AD  - cdb Zhejiang University, Sir Run Run Shaw Hospital , Department of Medical 
      Oncology , Hangzhou, Zhejiang , China.
FAU - Sukseree, Supawadee
AU  - Sukseree S
AD  - acn Medical University of Vienna , Department of Dermatology , Vienna , Austria.
FAU - Sulzer, David
AU  - Sulzer D
AD  - hh Columbia University Medical Center , Department of Neurology , New York , NY , 
      USA.
FAU - Sun, Fang-Lin
AU  - Sun FL
AD  - aut Tongji University, School of Life Science and Technology , Shanghai , China.
FAU - Sun, Jiaren
AU  - Sun J
AD  - bwh University of Texas, Medical Branch , Department of Microbiology and 
      Immunology , Galveston , TX , USA.
FAU - Sun, Jun
AU  - Sun J
AD  - bkx University of Illinois at Chicago, Division of Gastroenterology and 
      Hepatology , Department of Medicine , Chicago , IL , USA.
FAU - Sun, Shi-Yong
AU  - Sun SY
AD  - kg Emory University, School of Medicine, Winship Cancer Institute , Atlanta , GA 
      , USA.
FAU - Sun, Yang
AU  - Sun Y
AD  - adx Nanjing University, School of Life Sciences, State Key Laboratory of 
      Pharmaceutical Biotechnology , Nanjing, Jiangsu , China.
FAU - Sun, Yi
AU  - Sun Y
AD  - bof University of Michigan , Department of Radiation Oncology , Division of 
      Radiation and Cancer Biology , Ann Arbor , MI , USA.
FAU - Sun, Yingjie
AU  - Sun Y
AD  - aov Shanghai Veterinary Research Institute , Shanghai , China.
FAU - Sundaramoorthy, Vinod
AU  - Sundaramoorthy V
AD  - aak Macquarie University , Department of Biomedical Sciences , Faculty of 
      Medicine and Health Sciences , Sydney , NSW , Australia.
FAU - Sung, Joseph
AU  - Sung J
AD  - ga Chinese University of Hong Kong, Institute of Digestive Diseases , Shatin, 
      Hong Kong.
FAU - Suzuki, Hidekazu
AU  - Suzuki H
AD  - xq Keio University, School of Medicine , Medical Education Center , Tokyo , 
      Japan.
FAU - Suzuki, Kuninori
AU  - Suzuki K
AD  - bwu University of Tokyo, Bioimaging Center, Graduate School of Frontier Sciences 
      , Chiba , Japan.
FAU - Suzuki, Naoki
AU  - Suzuki N
AD  - atz Tohoku University , Department of Neurology , Sendai , Japan.
FAU - Suzuki, Tadashi
AU  - Suzuki T
AD  - alk RIKEN Global Research Cluster, Glycometabolome Team, Systems Glycobiology 
      Research Group , Saitama , Japan.
FAU - Suzuki, Yuichiro J
AU  - Suzuki YJ
AD  - mx Georgetown University , Department of Pharmacology and Physiology , 
      Washington, DC , USA.
FAU - Swanson, Michele S
AU  - Swanson MS
AD  - boa University of Michigan , Department of Microbiology and Immunology , Ann 
      Arbor , MI , USA.
FAU - Swanton, Charles
AU  - Swanton C
AD  - zv University College London Cancer Institute , London , UK.
FAU - Swärd, Karl
AU  - Swärd K
AD  - aac Lund University, Biomedical Centre , Department of Experimental Medical 
      Science , Lund , Sweden.
FAU - Swarup, Ghanshyam
AU  - Swarup G
AD  - dr Centre for Cellular and Molecular Biology, Council of Scientific and 
      Industrial Research , Hyderabad , India.
FAU - Sweeney, Sean T
AU  - Sweeney ST
AD  - byx University of York , Department of Biology , Heslington, York , UK.
FAU - Sylvester, Paul W
AU  - Sylvester PW
AD  - bmk University of Louisiana at Monroe, School of Pharmacy , Monroe , LA , USA.
FAU - Szatmari, Zsuzsanna
AU  - Szatmari Z
AD  - kj Eötvös Loránd University , Department of Anatomy , Cell and Developmental 
      Biology , Budapest , Hungary.
FAU - Szegezdi, Eva
AU  - Szegezdi E
AD  - agp National University of Ireland, Apoptosis Research Centre , Galway , Ireland.
FAU - Szlosarek, Peter W
AU  - Szlosarek PW
AD  - akv Queen Mary University of London, Barts Cancer Institute, Center for Molecular 
      Oncology , London , UK.
FAU - Taegtmeyer, Heinrich
AU  - Taegtmeyer H
AD  - bwl University of Texas, Medical School at Houston, Division of Cardiovascular 
      Medicine , Department of Medicine , Houston , TX , USA.
FAU - Tafani, Marco
AU  - Tafani M
AD  - anb Sapienza University of Rome , Department of Experimental Medicine , Rome , 
      Italy.
FAU - Taillebourg, Emmanuel
AU  - Taillebourg E
AD  - azl Université Grenoble-Alpes, CEA-DSV-iRTSV-BGE-GenandChem, INSERM, U1038 , 
      Grenoble , France.
FAU - Tait, Stephen Wg
AU  - Tait SW
AD  - bjy University of Glasgow, Cancer Research UK Beatson Institute , Glasgow , UK.
FAU - Takacs-Vellai, Krisztina
AU  - Takacs-Vellai K
AD  - kk Eötvös Loránd University , Department of Biological Anthropology , Budapest , 
      Hungary.
FAU - Takahashi, Yoshinori
AU  - Takahashi Y
AD  - aka Pennsylvania State University, College of Medicine , Hershey Cancer Institute 
      and Department of Pediatrics , Hershey , PA , USA.
FAU - Takáts, Szabolcs
AU  - Takáts S
AD  - kj Eötvös Loránd University , Department of Anatomy , Cell and Developmental 
      Biology , Budapest , Hungary.
FAU - Takemura, Genzou
AU  - Takemura G
AD  - aq Asahi University , Department of Internal Medicine , Gifu , Japan.
FAU - Takigawa, Nagio
AU  - Takigawa N
AD  - xl Kawasaki Medical School , Department of General Internal Medicine 4 , Okayama 
      , Japan.
FAU - Talbot, Nicholas J
AU  - Talbot NJ
AD  - bje University of Exeter, School of Biosciences , Exeter , UK.
FAU - Tamagno, Elena
AU  - Tamagno E
AD  - bxr University of Turin, Neuroscience Institute Cavalieri Ottolenghi , Turin , 
      Italy.
FAU - Tamburini, Jerome
AU  - Tamburini J
AD  - azs Université Paris Descartes, Institut Cochin, Faculté de Médecine Sorbonne 
      Paris Cité , Paris , France.
FAU - Tan, Cai-Ping
AU  - Tan CP
AD  - arb Sun Yat-Sen University, School of Chemistry and Chemical Engineering , 
      Guangzhou , China.
FAU - Tan, Lan
AU  - Tan L
AD  - aks Qingdao University , Department of Neurology , Qingdao Municipal Hospital, 
      School of Medicine , Qingdao, Shandong Province , China.
FAU - Tan, Mei Lan
AU  - Tan ML
AD  - aap Malaysian Institute of Pharmaceuticals and Nutraceuticals , Pulau Pinang , 
      Malaysia.
AD  - bag Universiti Sains Malaysia, Advanced Medical and Dental Institute, Ministry of 
      Science, Technology and Innovation , Pulau Pinang , Malaysia.
FAU - Tan, Ming
AU  - Tan M
AD  - buf University of South Alabama, Mitchell Cancer Institute , Mobile , AL , USA.
FAU - Tan, Yee-Joo
AU  - Tan YJ
AD  - a A*STAR (Agency for Science, Technology and Research), Institute of Molecular 
      and Cell Biology , Singapore.
AD  - agx National University of Singapore, Department of Microbiology and Immunology, 
      Yong Loo Lin School of Medicine, National University Health System (NUHS) , 
      Singapore.
FAU - Tanaka, Keiji
AU  - Tanaka K
AD  - aup Tokyo Metropolitan Institute of Medical Science, Laboratory of Protein 
      Metabolism , Tokyo , Japan.
FAU - Tanaka, Masaki
AU  - Tanaka M
AD  - yr Kyoto Prefectural University of Medicine , Department of Basic Geriatrics , 
      Kyoto , Japan.
FAU - Tang, Daolin
AU  - Tang D
AD  - bsb University of Pittsburgh , Department of Surgery , Hillman Cancer Center , 
      Pittsburgh , PA , USA.
FAU - Tang, Dingzhong
AU  - Tang D
AD  - fw Chinese Academy of Sciences, State Key Laboratory of Plant Cell and Chromosome 
      Engineering, Institute of Genetics and Developmental Biology , Beijing , China.
FAU - Tang, Guomei
AU  - Tang G
AD  - hh Columbia University Medical Center , Department of Neurology , New York , NY , 
      USA.
FAU - Tanida, Isei
AU  - Tanida I
AD  - wq Juntendo University, School of Medicine , Department of Cell Biology and 
      Neuroscience , Tokyo , Japan.
FAU - Tanji, Kunikazu
AU  - Tanji K
AD  - ps Hirosaki University Graduate School of Medicine , Hirosaki , Japan.
FAU - Tannous, Bakhos A
AU  - Tannous BA
AD  - aav Massachusetts General Hospital and Harvard Medical School, Experimental 
      Therapeutics and Molecular Imaging Laboratory, Neuroscience Center , Charlestown 
      , MA , USA.
FAU - Tapia, Jose A
AU  - Tapia JA
AD  - bjf University of Extremadura , Department of Medicine , Faculty of Veterinary 
      Medicine , Cáceres , Spain.
FAU - Tasset-Cuevas, Inmaculada
AU  - Tasset-Cuevas I
AD  - z Albert Einstein College of Medicine , Department of Developmental and Molecular 
      Biology , Institute for Aging Studies , Bronx , NY , USA.
FAU - Tatar, Marc
AU  - Tatar M
AD  - cl Brown University , Department of Ecology and Evolutionary Biology , Providence 
      , RI , USA.
FAU - Tavassoly, Iman
AU  - Tavassoly I
AD  - ade Icahn School of Medicine at Mount Sinai , Department of Pharmacology and 
      Systems Therapeutics , New York , NY , USA.
FAU - Tavernarakis, Nektarios
AU  - Tavernarakis N
AD  - lp Foundation for Research and Technology - Hellas , Heraklion, Crete , Greece.
AD  - bim University of Crete , Department of Basic Sciences , Faculty of Medicine , 
      Heraklion, Crete , Greece.
AD  - bin University of Crete, Institute of Molecular Biology and Biotechnology , 
      Heraklion, Crete , Greece.
FAU - Taylor, Allen
AU  - Taylor A
AD  - ave Tufts University, USDA Human Nutrition Research Center on Aging , Boston , MA 
      , USA.
FAU - Taylor, Graham S
AU  - Taylor GS
AD  - bdt University of Birmingham, Institute of Immunology and Immunotherapy , 
      Birmingham, West Midlands , UK.
FAU - Taylor, Gregory A
AU  - Taylor GA
AD  - ji Duke University, Medical Center , Department of Immunology , Durham , NC , 
      USA.
AD  - jj Duke University, Medical Center , Department of Medicine , Durham , NC , USA.
AD  - jk Duke University, Medical Center , Department of Molecular Genetics and 
      Microbiology , Durham , NC , USA.
AD  - jo Durham VA Medical Center, GRECC , Durham , NC , USA.
FAU - Taylor, J Paul
AU  - Taylor JP
AD  - aqa Howard Hughes Medical Institute, St. Jude Children's Research Hospital, Cell 
      and Molecular Biology , Memphis , TN , USA.
FAU - Taylor, Mark J
AU  - Taylor MJ
AD  - zr Liverpool School of Tropical Medicine , Department of Parasitology , 
      Liverpool, Merseyside , UK.
FAU - Tchetina, Elena V
AU  - Tchetina EV
AD  - aec Nasonova Research Institute of Rheumatology, Immunology and Molecular Biology 
      Laboratory , Moscow , Russia.
FAU - Tee, Andrew R
AU  - Tee AR
AD  - cs Cardiff University, Heath Park, Institute of Cancer and Genetics , Cardiff , 
      Wales , UK.
FAU - Teixeira-Clerc, Fatima
AU  - Teixeira-Clerc F
AD  - sf INSERM U955, Faculté de Médecine de Créteil, UMR-S955 , Créteil , France.
AD  - baa Université Paris-Est, Institut Mondor de Recherche Biomédicale , Paris , 
      France.
FAU - Telang, Sucheta
AU  - Telang S
AD  - bmm University of Louisville , Department of Medicine (Hem-Onc) , Louisville , KY 
      , USA.
FAU - Tencomnao, Tewin
AU  - Tencomnao T
AD  - gh Chulalongkorn University , Department of Clinical Chemistry , Faculty of 
      Allied Health Sciences , Bangkok , Thailand.
FAU - Teng, Ba-Bie
AU  - Teng BB
AD  - bvs University of Texas, Health Science Center at Houston, Center for Human 
      Genetics, Institute of Molecular Medicine , Houston , TX , USA.
FAU - Teng, Ru-Jeng
AU  - Teng RJ
AD  - aca Medical College of Wisconsin , Department of Pediatrics , Milwaukee , WI , 
      USA.
FAU - Terro, Faraj
AU  - Terro F
AD  - bmg University of Limoges , Department of Histology and Cell Biology , Limoges , 
      France.
FAU - Tettamanti, Gianluca
AU  - Tettamanti G
AD  - blb University of Insubria , Department of Biotechnology and Life Sciences , 
      Varese , Italy.
FAU - Theiss, Arianne L
AU  - Theiss AL
AD  - bd Baylor University Medical Center , Department of Internal Medicine , Division 
      of Gastroenterology, Baylor Research Institute , Dallas , TX.
FAU - Theron, Anne E
AU  - Theron AE
AD  - bst University of Pretoria , Department of Physiology , Pretoria, Gauteng , South 
      Africa.
FAU - Thomas, Kelly Jean
AU  - Thomas KJ
AD  - hg Colorado Mesa University , Department of Biological Sciences , Grand Junction 
      , CO , USA.
FAU - Thomé, Marcos P
AU  - Thomé MP
AD  - axc Universidad Federal do Rio Grande do Sul (UFRGS) , Department of Biophysics 
      and Center of Biotechnology , Porto Alegre , Brazil.
FAU - Thomes, Paul G
AU  - Thomes PG
AD  - bph University of Nebraska Medical Center , Department of Internal Medicine , 
      Omaha , NE , USA.
FAU - Thorburn, Andrew
AU  - Thorburn A
AD  - bih University of Colorado, School of Medicine , Department of Pharmacology , 
      Aurora , CO , USA.
FAU - Thorner, Jeremy
AU  - Thorner J
AD  - bew University of California Berkeley , Department of Molecular and Cell Biology 
      , Berkeley , CA , USA.
FAU - Thum, Thomas
AU  - Thum T
AD  - or Hannover Medical School, Institute of Molecular and Translational Therapeutic 
      Strategies (IMTTS) , Hannover , Germany.
FAU - Thumm, Michael
AU  - Thumm M
AD  - mr Georg-August-University Göttingen, Institute of Cellular Biochemistry , 
      Göttingen , Germany.
FAU - Thurston, Teresa Lm
AU  - Thurston TL
AD  - qz Imperial College London, MRC Centre for Molecular Bacteriology and Infection , 
      London , UK.
FAU - Tian, Ling
AU  - Tian L
AD  - fq Chinese Academy of Sciences, Key Laboratory of Developmental and Evolutionary 
      Biology, Institute of Plant Physiology and Ecology, Shanghai Institutes for 
      Biological Sciences , Shanghai , China.
FAU - Till, Andreas
AU  - Till A
AD  - bdy University of Bonn, Institute of Reconstructive Neurobiology , Bonn , 
      Germany.
AD  - bfx University of California San Diego, San Diego Center for Systems Biology , La 
      Jolla , CA , USA.
FAU - Ting, Jenny Pan-Yun
AU  - Ting JP
AD  - bpy University of North Carolina , Department of Microbiology-Immunology , Chapel 
      Hill , NC , USA.
AD  - bqa University of North Carolina, Lineberger Comprehensive Cancer Center, 
      Institute of Inflammatory Diseases, Center for Translational Immunology , Chapel 
      Hill , NC , USA.
FAU - Titorenko, Vladimir I
AU  - Titorenko VI
AD  - ht Concordia University , Biology Department , Montreal, Quebec , Canada.
FAU - Toker, Lilach
AU  - Toker L
AD  - bei University of British Columbia , Department of Psychiatry , Vancouver, BC , 
      Canada.
FAU - Toldo, Stefano
AU  - Toldo S
AD  - cac Virginia Commonwealth University, Internal Medicine, VCU Pauley Heart Center 
      , Richmond , VA , USA.
FAU - Tooze, Sharon A
AU  - Tooze SA
AD  - zu London Research Institute, Cancer Research UK , London , UK.
FAU - Topisirovic, Ivan
AU  - Topisirovic I
AD  - vo Jewish General Hospital , Department of Oncology , Montreal, Quebec , Canada.
AD  - abr McGill University, Lady Davis Institute for Medical Research , Montreal, 
      Quebec , Canada.
FAU - Torgersen, Maria Lyngaas
AU  - Torgersen ML
AD  - ajb Oslo University Hospital, Centre for Cancer Biomedicine , Oslo , Norway.
AD  - asy The Norwegian Radium Hospital, Faculty of Medicine , Oslo , Norway.
AD  - bqm University of Oslo , Department of Biochemistry , Institute for Cancer 
      Research , Oslo , Norway.
FAU - Torosantucci, Liliana
AU  - Torosantucci L
AD  - if CSS-Mendel Institute, Neurogenetics Unit , Rome , Italy.
FAU - Torriglia, Alicia
AU  - Torriglia A
AD  - rz INSERM U1138 , Paris , France.
FAU - Torrisi, Maria Rosaria
AU  - Torrisi MR
AD  - ana Sapienza University of Rome , Department of Clinical and Molecular Medicine , 
      Rome , Italy.
FAU - Tournier, Cathy
AU  - Tournier C
AD  - bmw University of Manchester, Faculty of Life Sciences , Manchester , UK.
FAU - Towns, Roberto
AU  - Towns R
AD  - bny University of Michigan , Ann Arbor , MI , USA.
FAU - Trajkovic, Vladimir
AU  - Trajkovic V
AD  - bdm University of Belgrade, School of Medicine , Belgrade , Serbia.
FAU - Travassos, Leonardo H
AU  - Travassos LH
AD  - la Federal University of Rio de Janeiro, Institute of Biophysics Carlos Chagas 
      Filho, Laboratory of Immunoreceptors and Signaling , Rio de Janeiro , Brazil.
FAU - Triola, Gemma
AU  - Triola G
AD  - tb Institute of Advanced Chemistry of Catalonia, Spanish Research Council 
      (IQAC-CSIC) , Department of Biomedicinal Chemistry , Barcelona , Spain.
FAU - Tripathi, Durga Nand
AU  - Tripathi DN
AD  - asg Texas A&M University Health Science Center, Center for Translational Cancer 
      Research, Institute of Bioscience and Technology , Houston , TX , USA.
FAU - Trisciuoglio, Daniela
AU  - Trisciuoglio D
AD  - alf Regina Elena National Cancer Institute, Experimental Chemotherapy Laboratory 
      , Rome , Italy.
FAU - Troncoso, Rodrigo
AU  - Troncoso R
AD  - awj Universidad de Chile, Advanced Center for Chronic Diseases (ACCDiS), Facultad 
      de Ciencias Químicas y Farmacéuticas , Santiago , Chile.
AD  - awn Universidad de Chile, Instituto de Nutrición y Tecnología de los Alimentos 
      (INTA) , Santiago , Chile.
FAU - Trougakos, Ioannis P
AU  - Trougakos IP
AD  - bcv University of Athens , Department of Cell Biology and Biophysics , Faculty of 
      Biology , Athens , Greece.
FAU - Truttmann, Anita C
AU  - Truttmann AC
AD  - bav University Hospital Center, University of Lausanne, Clinic of Neonatology , 
      Department of Pediatrics and Pediatric Surgery , Lausanne , Switzerland.
FAU - Tsai, Kuen-Jer
AU  - Tsai KJ
AD  - aen National Cheng Kung University, Institute of Clinical Medicine , Tainan , 
      Taiwan.
FAU - Tschan, Mario P
AU  - Tschan MP
AD  - bdo University of Bern, Division of Experimental Pathology, Institute of 
      Pathology , Bern , Switzerland.
FAU - Tseng, Yi-Hsin
AU  - Tseng YH
AD  - ej Chang Gung University , Department of Biochemistry , College of Medicine , 
      Taoyuan , Taiwan.
FAU - Tsukuba, Takayuki
AU  - Tsukuba T
AD  - adp Nagasaki University, Division of Dental Pharmacology, Graduate School of 
      Biomedical Sciences , Nagasaki , Japan.
FAU - Tsung, Allan
AU  - Tsung A
AD  - brx University of Pittsburgh Medical Center , Department of Surgery , Pittsburgh 
      , PA , USA.
FAU - Tsvetkov, Andrey S
AU  - Tsvetkov AS
AD  - bwk University of Texas, Medical School at Houston , Department of Neurobiology 
      and Anatomy , Houston , TX , USA.
FAU - Tu, Shuiping
AU  - Tu S
AD  - aos Shanghai Jiao Tong University, School of Medicine, Renji Hospital , Shanghai 
      , China.
FAU - Tuan, Hsing-Yu
AU  - Tuan HY
AD  - agm National Tsing Hua University , Department of Chemical Engineering , Hsinchu 
      , Taiwan.
FAU - Tucci, Marco
AU  - Tucci M
AD  - bdd University of Bari 'Aldo Moro' , Department of Biomedical Sciences and 
      Clinical Oncology , Bari , Italy.
FAU - Tumbarello, David A
AU  - Tumbarello DA
AD  - buv University of Southampton, Centre for Biological Sciences, Highfield Campus , 
      Southampton , UK.
FAU - Turk, Boris
AU  - Turk B
AD  - vh J. Stefan Institute , Department of Biochemistry and Molecular and Structural 
      Biology , Ljubljana , Slovenia.
FAU - Turk, Vito
AU  - Turk V
AD  - vh J. Stefan Institute , Department of Biochemistry and Molecular and Structural 
      Biology , Ljubljana , Slovenia.
FAU - Turner, Robin Fb
AU  - Turner RF
AD  - bem University of British Columbia, Michael Smith Laboratories , Vancouver, 
      British Columbia , Canada.
FAU - Tveita, Anders A
AU  - Tveita AA
AD  - ajc Oslo University Hospital, Centre for Immune Regulation , Oslo , Norway.
FAU - Tyagi, Suresh C
AU  - Tyagi SC
AD  - bmr University of Louisville, School of Medicine , Department of Physiology and 
      Biophysics , Louisville , KY , USA.
FAU - Ubukata, Makoto
AU  - Ubukata M
AD  - pv Hokkaido University, Research Faculty of Agriculture , Sapporo , Japan.
FAU - Uchiyama, Yasuo
AU  - Uchiyama Y
AD  - wq Juntendo University, School of Medicine , Department of Cell Biology and 
      Neuroscience , Tokyo , Japan.
FAU - Udelnow, Andrej
AU  - Udelnow A
AD  - ajh Otto-von-Guericke-University Magdeburg , Department of General , Visceral and 
      Vascular Surgery , Magdeburg , Germany.
FAU - Ueno, Takashi
AU  - Ueno T
AD  - wp Juntendo University, Graduate School of Medicine, Laboratory of Proteomics and 
      Biomolecular Science , Tokyo , Japan.
FAU - Umekawa, Midori
AU  - Umekawa M
AD  - alm Ritsumeikan University , Department of Biotechnology , Shiga , Japan.
FAU - Umemiya-Shirafuji, Rika
AU  - Umemiya-Shirafuji R
AD  - aig Obihiro University of Agriculture and Veterinary Medicine, National Research 
      Center for Protozoan Diseases , Obihiro, Hokkaido , Japan.
FAU - Underwood, Benjamin R
AU  - Underwood BR
AD  - bh Beechcroft, Fulbourn Hospital , Cambridge , UK.
FAU - Ungermann, Christian
AU  - Ungermann C
AD  - bqu University of Osnabrueck, Fachbereich Biologie/Chemie , Osnabrueck , Germany.
FAU - Ureshino, Rodrigo P
AU  - Ureshino RP
AD  - lb Federal University of São Paulo , Department of Pharmacology , Paulista School 
      of Medicine , São Paulo , Brazil.
FAU - Ushioda, Ryo
AU  - Ushioda R
AD  - yv Kyoto Sangyo University , Department of Molecular Biosciences , Faculty of 
      Life Sciences , Kyoto , Japan.
FAU - Uversky, Vladimir N
AU  - Uversky VN
AD  - bur University of South Florida , Department of Molecular Medicine , Tampa , FL , 
      USA.
FAU - Uzcátegui, Néstor L
AU  - Uzcátegui NL
AD  - dm Central University of Venezuela, Institute for Anatomy , Caracas , Venezuela.
FAU - Vaccari, Thomas
AU  - Vaccari T
AD  - qw IFOM - The FIRC Institute of Molecular Oncology , Milan , Italy.
FAU - Vaccaro, Maria I
AU  - Vaccaro MI
AD  - bep University of Buenos Aires, National Council for Scientific and Technical 
      Research (CONICET), Institute for Biochemistry and Molecular Medicine , 
      Department of Pathophysiology , School of Pharmacy and Biochemistry , Buenos 
      Aires , Argentina.
FAU - Váchová, Libuše
AU  - Váchová L
AD  - ti Institute of Microbiology ASCR, v.v.i. , Prague , Czech Republic.
FAU - Vakifahmetoglu-Norberg, Helin
AU  - Vakifahmetoglu-Norberg H
AD  - xj Karolinska Institute , Department of Physiology and Pharmacology , Stockholm , 
      Sweden.
FAU - Valdor, Rut
AU  - Valdor R
AD  - bpc University of Murcia-IMIB Virgen de la Arrixaca Hospital, Human Anatomy and 
      Psycobiology Department, Cell Therapy and Hematopoietic Transplantation Unit , 
      Murcia , Spain.
FAU - Valente, Enza Maria
AU  - Valente EM
AD  - btq University of Salerno, Section of Neurosciences , Department of Medicine and 
      Surgery , Salerno , Italy.
FAU - Vallette, Francois
AU  - Vallette F
AD  - azf Université de Nantes, CRCNA, UMRINSERM 892/CNRS 6299 , Nantes , France.
FAU - Valverde, Angela M
AU  - Valverde AM
AD  - tq Instituto de Investigaciones Biomédicas Alberto Sols, CSIC/UAM , Madrid , 
      Spain.
FAU - Van den Berghe, Greet
AU  - Van den Berghe G
AD  - yj KU Leuven , Clinical Division and Laboratory of Intensive Care Medicine , 
      Department Cellular and Molecular Medicine , Leuven , Belgium.
FAU - Van Den Bosch, Ludo
AU  - Van Den Bosch L
AD  - yi KU Leuven and VIB, Vesalius Research Center, Laboratory of Neurobiology , 
      Leuven , Belgium.
FAU - van den Brink, Gijs R
AU  - van den Brink GR
AD  - l Academic Medical Center , Department of Gastroenterology and Hepatology , 
      Amsterdam , The Netherlands.
FAU - van der Goot, F Gisou
AU  - van der Goot FG
AD  - ju Ecole Polytechnique Federale de Lausanne, Global Health Institute, School of 
      Life Sciences , Lausanne , Switzerland.
FAU - van der Klei, Ida J
AU  - van der Klei IJ
AD  - bkf University of Groningen, Molecular Cell Biology , Groningen , The 
      Netherlands.
FAU - van der Laan, Luc Jw
AU  - van der Laan LJ
AD  - kn Erasmus MC-University Medical Center Rotterdam , Department of Surgery , 
      Rotterdam , The Netherlands.
FAU - van Doorn, Wouter G
AU  - van Doorn WG
AD  - bfd University of California Davis, Mann Laboratory , Department of Plant 
      Sciences , Davis , CA , USA.
FAU - van Egmond, Marjolein
AU  - van Egmond M
AD  - cal VU University Medical Center , Department of Molecular Cell Biology and 
      Immunology , Amsterdam , The Netherlands.
FAU - van Golen, Kenneth L
AU  - van Golen KL
AD  - asv The Helen F. Graham Cancer Center , Newark , DE , USA.
AD  - bis University of Delaware , Department of Biological Sciences , Newark , DE , 
      USA.
AD  - bit University of Delaware, The Center for Translational Cancer Research , Newark 
      , DE , USA.
FAU - Van Kaer, Luc
AU  - Van Kaer L
AD  - bzt Vanderbilt University, School of Medicine , Department of Pathology , 
      Microbiology and Immunology , Nashville , TN , USA.
FAU - van Lookeren Campagne, Menno
AU  - van Lookeren Campagne M
AD  - mk Genentech Inc. , Department of Immunology , South San Francisco , CA , USA.
FAU - Vandenabeele, Peter
AU  - Vandenabeele P
AD  - nm Ghent University , Department of Biomedical Molecular Biology , Inflammation 
      Research Center, VIB, Methusalem Program , Gent , Belgium.
FAU - Vandenberghe, Wim
AU  - Vandenberghe W
AD  - bbi University Hospitals Leuven , Department of Neurology , Leuven , Belgium.
AD  - bmc University of Leuven , Department of Neurosciences , Leuven , Belgium.
FAU - Vanhorebeek, Ilse
AU  - Vanhorebeek I
AD  - yj KU Leuven , Clinical Division and Laboratory of Intensive Care Medicine , 
      Department Cellular and Molecular Medicine , Leuven , Belgium.
FAU - Varela-Nieto, Isabel
AU  - Varela-Nieto I
AD  - ic CSIC-UAM and CIBERER, Institute for Biomedical Research "Alberto Sols" , 
      Madrid , Spain.
FAU - Vasconcelos, M Helena
AU  - Vasconcelos MH
AD  - bsp University of Porto, Cancer Drug Resistance Group, IPATIMUP - Institute of 
      Molecular Pathology and Immunology , Porto , Portugal.
AD  - bsq University of Porto , Department of Biological Sciences , Faculty of Pharmacy 
      , Porto , Portugal.
AD  - bss University of Porto, i3S-Instituto de Investigação e Inovação em Saúde , 
      Porto , Portugal.
FAU - Vasko, Radovan
AU  - Vasko R
AD  - mq Georg-August-University Göttingen , Department of Nephrology and Rheumatology 
      , Göttingen , Germany.
FAU - Vavvas, Demetrios G
AU  - Vavvas DG
AD  - pe Harvard Medical School, Ophthalmology , Boston , MA , USA.
FAU - Vega-Naredo, Ignacio
AU  - Vega-Naredo I
AD  - bhq University of Coimbra, CNC-Center for Neuroscience and Cell Biology , 
      Cantanhede , Portugal.
FAU - Velasco, Guillermo
AU  - Velasco G
AD  - hs Complutense University, Instituto de Investigaciones Sanitarias San Carlos 
      (IdISSC) , Department of Biochemistry and Molecular Biology I , School of Biology 
      , Madrid , Spain.
FAU - Velentzas, Athanassios D
AU  - Velentzas AD
AD  - bcv University of Athens , Department of Cell Biology and Biophysics , Faculty of 
      Biology , Athens , Greece.
FAU - Velentzas, Panagiotis D
AU  - Velentzas PD
AD  - bnm University of Massachusetts, Medical School , Department of Molecular , Cell 
      and Cancer Biology , Worcester , MA , USA.
FAU - Vellai, Tibor
AU  - Vellai T
AD  - kl Eötvös Loránd University , Department of Genetics , Budapest , Hungary.
FAU - Vellenga, Edo
AU  - Vellenga E
AD  - bbm University Medical Center Groningen, University of Groningen , Department of 
      Hematology , Groningen , The Netherlands.
FAU - Vendelbo, Mikkel Holm
AU  - Vendelbo MH
AD  - c Aarhus University Hospital, Department of Nuclear Medicine and PET Center , 
      Aarhus , Denmark.
FAU - Venkatachalam, Kartik
AU  - Venkatachalam K
AD  - bvz University of Texas, Health Sciences Center-Houston (UTHSC) , Department of 
      Integrative Biology and Pharmacology , Houston , TX , USA.
FAU - Ventura, Natascia
AU  - Ventura N
AD  - pl Heinrich Heine University, Institute of Clinical Chemistry and Laboratory 
      Diagnostic, Medical Faculty , Duesseldorf , Germany.
AD  - vg IUF-Leibniz Research Institute for Environmental Medicine , Duesseldorf , 
      Germany.
FAU - Ventura, Salvador
AU  - Ventura S
AD  - axy Universitat Autònoma de Barcelona, Institut de Biotecnologia i Biomedicina 
      and Departament de Bioquímica i Biologia Molecular , Bellaterra (Barcelona) , 
      Spain.
FAU - Veras, Patrícia St
AU  - Veras PS
AD  - nu Gonçalo Moniz Research Center, Oswaldo Cruz Foundation, FIOCRUZ-BA, Laboratory 
      of Pathology and Biointervention , Salvador, BA , Brazil.
FAU - Verdier, Mireille
AU  - Verdier M
AD  - ayt Université de Limoges, EA 3842, LHCP, Faculté de Médecine , Limoges , France.
FAU - Vertessy, Beata G
AU  - Vertessy BG
AD  - cn Budapest University of Technology and Economics, Institute of Enzymology, RCNC 
      , HAS and Department of Applied Biotechnology , Budapest , Hungary.
FAU - Viale, Andrea
AU  - Viale A
AD  - abw MD Anderson Cancer Center , Department of Genomic Medicine , Houston , TX , 
      USA.
FAU - Vidal, Michel
AU  - Vidal M
AD  - bbv University Montpellier, UMR5235 , Montpellier , France.
FAU - Vieira, Helena L A
AU  - Vieira HL
AD  - axo Universidade Nova de Lisboa, CEDOC, NOVA Medical School , Lisboa , Portugal.
FAU - Vierstra, Richard D
AU  - Vierstra RD
AD  - byq Washington University in St Louis, Department of Biology, St. Louis, MO , 
      USA.
FAU - Vigneswaran, Nadarajah
AU  - Vigneswaran N
AD  - bvu University of Texas, Health Science Center at Houston, School of Dentistry , 
      Houston , TX , USA.
FAU - Vij, Neeraj
AU  - Vij N
AD  - dk Central Michigan University, College of Medicine , Mt. Pleasant , MI , USA.
FAU - Vila, Miquel
AU  - Vila M
AD  - ax Autonomous University of Barcelona (UAB) , Department of Biochemistry and 
      Molecular Biology , Barcelona , Spain.
AD  - cz Catalan Institution for Research and Advanced Studies (ICREA) , Barcelona , 
      Spain.
AD  - ahc Neurodegenerative Diseases Research Group, Vall d'Hebron Research 
      Institute-CIBERNED , Barcelona , Spain.
FAU - Villar, Margarita
AU  - Villar M
AD  - ami SaBio, Instituto de Investigación en Recursos Cinegéticos IREC-CSIC-UCLM-JCCM 
      , Ciudad Real , Spain.
FAU - Villar, Victor H
AU  - Villar VH
AD  - se INSERM U916, Université de Bordeaux, Institut Européen de Chimie et Biologie , 
      Pessac , France.
FAU - Villarroya, Joan
AU  - Villarroya J
AD  - z Albert Einstein College of Medicine , Department of Developmental and Molecular 
      Biology , Institute for Aging Studies , Bronx , NY , USA.
FAU - Vindis, Cécile
AU  - Vindis C
AD  - bxi University of Toulouse, INSERM UMR 1048 , Toulouse , France.
FAU - Viola, Giampietro
AU  - Viola G
AD  - brd University of Padova , Department of Woman's and Child's Health , Laboratory 
      of Oncohematology , Padova , Italy.
FAU - Viscomi, Maria Teresa
AU  - Viscomi MT
AD  - uk IRCCS Santa Lucia Foundation , Rome , Italy.
FAU - Vitale, Giovanni
AU  - Vitale G
AD  - bon University of Milan, Istituto Auxologico Italiano , Department of Clinical 
      Sciences and Community Health , Milan , Italy.
FAU - Vogl, Dan T
AU  - Vogl DT
AD  - brl University of Pennsylvania, Abramson Cancer Center , Philadelphia , PA , USA.
FAU - Voitsekhovskaja, Olga V
AU  - Voitsekhovskaja OV
AD  - xy Komarov Botanical Institute RAS, Plant Ecological Physiology Laboratory , 
      Saint Petersburg , Russian Federation.
FAU - von Haefen, Clarissa
AU  - von Haefen C
AD  - eo Charité - Universitätsmedizin Berlin , Department of Anesthesiology and 
      Intensive Care Medicine , Campus Charité Mitte and Campus Virchow-Klinikum , 
      Berlin , Germany.
FAU - von Schwarzenberg, Karin
AU  - von Schwarzenberg K
AD  - aab Ludwig-Maximilians-University Munich , Department of Pharmacy , Munich , 
      Germany.
FAU - Voth, Daniel E
AU  - Voth DE
AD  - bcs University of Arkansas for Medical Sciences , Department of Microbiology and 
      Immunology , Little Rock , AR , USA.
FAU - Vouret-Craviari, Valérie
AU  - Vouret-Craviari V
AD  - bpv University of Nice-Sophia Antipolis, IRCAN , Nice , France.
FAU - Vuori, Kristina
AU  - Vuori K
AD  - amt Sanford Burnham Prebys Medical Discovery Institute , La Jolla , CA , USA.
FAU - Vyas, Jatin M
AU  - Vyas JM
AD  - aaw Massachusetts General Hospital, Division of Infectious Disease , Boston , MA 
      , USA.
FAU - Waeber, Christian
AU  - Waeber C
AD  - bao University College Cork, School of Pharmacy , Department of Pharmacology and 
      Therapeutics , Cork , Ireland.
FAU - Walker, Cheryl Lyn
AU  - Walker CL
AD  - asf Texas A&M Health Science Center, Institute of Biosciences and Technology , 
      Houston , TX , USA.
FAU - Walker, Mark J
AU  - Walker MJ
AD  - bsv University of Queensland, Australian Infectious Diseases Research Centre and 
      School of Chemistry and Molecular Biosciences , Brisbane , Queensland , 
      Australia.
FAU - Walter, Jochen
AU  - Walter J
AD  - bdw University of Bonn , Department of Neurology , Bonn , Germany.
FAU - Wan, Lei
AU  - Wan L
AD  - au Asia University , Department of Biotechnology , Taichung , Taiwan.
AD  - fc China Medical University, School of Chinese Medicine , Taichung , Taiwan.
FAU - Wan, Xiangbo
AU  - Wan X
AD  - api Sixth Affiliated Hospital of Sun Yat-Sen University, Gastrointestinal 
      Institute , Department of Radiation Oncology , Guangzhou, Guangdong , China.
FAU - Wang, Bo
AU  - Wang B
AD  - akr Qilu Hospital of Shandong University , Department of Traditional Chinese 
      Medicine , Jinan , China.
FAU - Wang, Caihong
AU  - Wang C
AD  - cbe Washington University, School of Medicine, Departments of Obstetrics and 
      Gynecology, and Pathology and Immunology , St. Louis , MO , USA.
FAU - Wang, Chao-Yung
AU  - Wang CY
AD  - eg Chang Gung University, Chang Gung Memorial Hospital , Department of Cardiology 
      , Internal Medicine , Taoyuan , Taiwan.
FAU - Wang, Chengshu
AU  - Wang C
AD  - fo Chinese Academy of Sciences, Institute of Plant Physiology and Ecology, 
      Shanghai Institutes for Biological Sciences , Shanghai , China.
FAU - Wang, Chenran
AU  - Wang C
AD  - bhl University of Cincinnati College of Medicine , Department of Cancer Biology , 
      Cincinnati , OH , USA.
FAU - Wang, Chuangui
AU  - Wang C
AD  - jq East China Normal University, School of Life Science , Shanghai , China.
FAU - Wang, Dong
AU  - Wang D
AD  - ot Harbin Medical University, College of Bioinformatics Science and Technology , 
      Harbin, Heilongjiang , China.
FAU - Wang, Fen
AU  - Wang F
AD  - ase Texas A&M Health Science Center, Center for Cancer and Stem Cell Biology, 
      Institute of Biosciences and Technology , Houston , TX , USA.
FAU - Wang, Fuxin
AU  - Wang F
AD  - fn Chinese Academy of Sciences, Institute of Microbiology , Beijing , China.
FAU - Wang, Guanghui
AU  - Wang G
AD  - apj Soochow University, College of Pharmaceutical Sciences , Jiangsu , China.
FAU - Wang, Hai-Jie
AU  - Wang HJ
AD  - aot Shanghai Medical School of Fudan University , Department of Anatomy , 
      Histology and Embryology , Shanghai , China.
FAU - Wang, Haichao
AU  - Wang H
AD  - ahx North Shore University Hospital , Department of Emergency Medicine , 
      Manhasset , NY , USA.
FAU - Wang, Hong-Gang
AU  - Wang HG
AD  - ajw Pennsylvania State University, College of Medicine , Department of Pediatrics 
      , Hershey , PA , USA.
FAU - Wang, Hongmin
AU  - Wang H
AD  - bun University of South Dakota, Sanford School of Medicine, Division of Basic 
      Biomedical Sciences , Vermillion , SD , USA.
FAU - Wang, Horng-Dar
AU  - Wang HD
AD  - agn National Tsing Hua University, Institute of Biotechnology, Institute of 
      Systems Neuroscience , and Department of Life Science , HsinChu City , Taiwan.
FAU - Wang, Jing
AU  - Wang J
AD  - bbu University Montpellier 1, INSERM U1051 , Montpellier , France.
FAU - Wang, Junjun
AU  - Wang J
AD  - ey China Agricultural University, College of Animal Science and Technology, State 
      Key Laboratory of Animal Nutrition , Beijing , China.
FAU - Wang, Mei
AU  - Wang M
AD  - jm Duke-NUS Graduate Medical School, Cancer and Stem Cell Biology Program , 
      Singapore.
FAU - Wang, Mei-Qing
AU  - Wang MQ
AD  - lr Fourth Military Medical University , Department of Oral Anatomy and Physiology 
      and TMD , College of Stomatology , Xi'an , China.
FAU - Wang, Pei-Yu
AU  - Wang PY
AD  - agj National Taiwan University, Graduate Institute of Brain and Mind Sciences, 
      College of Medicine , Taipei , Taiwan.
FAU - Wang, Peng
AU  - Wang P
AD  - ma Fudan University, Cancer Center , Department of Integrative Oncology , 
      Shanghai , China.
FAU - Wang, Richard C
AU  - Wang RC
AD  - bwm University of Texas, Southwestern Medical Center at Dallas , Department of 
      Dermatology , Dallas , TX.
FAU - Wang, Shuo
AU  - Wang S
AD  - fi Chinese Academy of Sciences, CAS Key Laboratory of Infection and Immunity, 
      Institute of Biophysics , Beijing , China.
FAU - Wang, Ting-Fang
AU  - Wang TF
AD  - k Academia Sinica, Institute of Molecular Biology , Taipei , Taiwan.
FAU - Wang, Xian
AU  - Wang X
AD  - aph Sir Runrun Shaw Hospital, Medical School of Zhejiang University , Department 
      of Medical Oncology , Hangzhou , China.
FAU - Wang, Xiao-Jia
AU  - Wang XJ
AD  - ccp Zhejiang Cancer Hospital , Department of Medical Oncology , Hangzhou , China.
FAU - Wang, Xiao-Wei
AU  - Wang XW
AD  - ccw Zhejiang University, Institute of Insect Science , Hangzhou , China.
FAU - Wang, Xin
AU  - Wang X
AD  - ch Brigham and Women's Hospital, Harvard Medical School , Department of 
      Neurosurgery , Boston MA.
FAU - Wang, Xuejun
AU  - Wang X
AD  - buo University of South Dakota , Vermillion , SD , USA.
FAU - Wang, Yan
AU  - Wang Y
AD  - avb Tsinghua University, School of Life Sciences , Beijing , China.
FAU - Wang, Yanming
AU  - Wang Y
AD  - akb Pennsylvania State University , Department of Biochemistry and Molecular 
      Biology , Center for Eukaryotic Gene Regulation , University Park , PA , USA.
FAU - Wang, Ying
AU  - Wang Y
AD  - bk Beijing Jishuitan Hospital , Department of Molecular Orthopedics , Beijing 
      Institute of Traumatology and Orthopedics , Beijing , China.
FAU - Wang, Ying-Jan
AU  - Wang YJ
AD  - aeo National Cheng Kung University, Medical College , Department of Environmental 
      and Occupational Health , Tainan , Taiwan.
FAU - Wang, Yipeng
AU  - Wang Y
AD  - jp DZNE, German Center for Neurodegenerative Diseases, and CAESAR Research Center 
      , Bonn , Germany.
FAU - Wang, Yu
AU  - Wang Y
AD  - bkl University of Hong Kong , Department of Pharmacology and Pharmacy , Hong Kong 
      , China.
FAU - Wang, Yu Tian
AU  - Wang YT
AD  - bef University of British Columbia , Department of Medicine and Brain Research 
      Center , Vancouver, BC , Canada.
FAU - Wang, Yuqing
AU  - Wang Y
AD  - bxd University of Toronto, Hospital for Sick Children , Toronto, Ontario , 
      Canada.
FAU - Wang, Zhi-Nong
AU  - Wang ZN
AD  - en Changzheng Hospital, The Second Military Medical University , Department of 
      Cardiothoracic Surgery , Shanghai , China.
FAU - Wappner, Pablo
AU  - Wappner P
AD  - tw Instituto Leloir , Buenos Aires , Argentina.
FAU - Ward, Carl
AU  - Ward C
AD  - bds University of Birmingham, Institute of Biomedical Research, Institute of 
      Cancer and Genomic Sciences, College of Medical and Dental Sciences , Edgbaston, 
      Birmingham , UK.
FAU - Ward, Diane McVey
AU  - Ward DM
AD  - byb University of Utah, School of Medicine , Department of Pathology , Salt Lake 
      City , UT , USA.
FAU - Warnes, Gary
AU  - Warnes G
AD  - akx Queen Mary University of London, Blizard Institute, Flow Cytometry Core 
      Facility , London , UK.
FAU - Watada, Hirotaka
AU  - Watada H
AD  - wn Juntendo University, Graduate School of Medicine , Department of Metabolism 
      and Endocrinology , Tokyo , Japan.
FAU - Watanabe, Yoshihisa
AU  - Watanabe Y
AD  - yt Kyoto Prefectural University of Medicine , Department of Basic Geriatrics, 
      Kyoto , Japan.
FAU - Watase, Kei
AU  - Watase K
AD  - aul Tokyo Medical and Dental University, Center for Brain Integration Research, 
      Bunkyo , Tokyo , Japan.
FAU - Weaver, Timothy E
AU  - Weaver TE
AD  - bhk University of Cincinnati College of Medicine, Cincinnati Children's Research 
      Foundation and Department of Pediatrics , Cincinnati , OH , USA.
FAU - Weekes, Colin D
AU  - Weekes CD
AD  - bhz University of Colorado Denver, Division of Medical Oncology , Department of 
      Medicine , Aurora , CO , USA.
FAU - Wei, Jiwu
AU  - Wei J
AD  - adw Nanjing University, Jiangsu Key Laboratory of Molecular Medicine, Medical 
      School and the State Key Laboratory of Pharmaceutical Biotechnology , Nanjing, 
      Jiangsu Province , China.
FAU - Weide, Thomas
AU  - Weide T
AD  - bbe University Hospital of Muenster , Department of Internal Medicine D , 
      Molecular Nephrology , Muenster , Germany.
FAU - Weihl, Conrad C
AU  - Weihl CC
AD  - cbc Washington University, School of Medicine , Department of Neurology , St. 
      Louis , MO , USA.
FAU - Weindl, Günther
AU  - Weindl G
AD  - lv Freie Universität Berlin, Institute of Pharmacy (Pharmacology and Toxicology) 
      , Berlin , Germany.
FAU - Weis, Simone Nardin
AU  - Weis SN
AD  - axf Universidade de Brasília , Departamento de Biologia Celular , Brasília, DF , 
      Brazil.
FAU - Wen, Longping
AU  - Wen L
AD  - btv University of Science and Technology of China , Anhui , China.
FAU - Wen, Xin
AU  - Wen X
AD  - boc University of Michigan , Department of Molecular , Cellular, and 
      Developmental Biology , Ann Arbor , MI , USA.
AD  - bog University of Michigan, Life Sciences Institute , Ann Arbor , MI , USA.
FAU - Wen, Yunfei
AU  - Wen Y
AD  - abv MD Anderson Cancer Center , Department of Cancer Biology , Houston , TX , 
      USA.
AD  - abx MD Anderson Cancer Center , Department of Gynecologic Oncology and 
      Reproductive Medicine , Houston , TX , USA.
FAU - Westermann, Benedikt
AU  - Westermann B
AD  - bdh University of Bayreuth, Cell Biology , Bayreuth , Germany.
FAU - Weyand, Cornelia M
AU  - Weyand CM
AD  - aqn Stanford University, School of Medicine , Stanford , CA , USA.
FAU - White, Anthony R
AU  - White AR
AD  - bnr University of Melbourne , Department of Pathology , Parkville , Victoria , 
      Australia.
FAU - White, Eileen
AU  - White E
AD  - ame Rutgers University, The State University of New Jersey, Rutgers Cancer 
      Institute of New Jersey , New Brunswick , NJ , USA.
FAU - Whitton, J Lindsay
AU  - Whitton JL
AD  - atb The Scripps Research Institute , Department of Immunology and Microbial 
      Science , La Jolla , CA , USA.
FAU - Whitworth, Alexander J
AU  - Whitworth AJ
AD  - adl MRC Mitochondrial Biology Unit , Cambridge , UK.
FAU - Wiels, Joëlle
AU  - Wiels J
AD  - baf Université Paris-Sud, Université Paris-Saclay, UMR 8126CNRS, Institut Gustave 
      Roussy , Villejuif , France.
FAU - Wild, Franziska
AU  - Wild F
AD  - aaq Mannheim University of Applied Sciences, Institute of Molecular and Cell 
      Biology , Mannheim , Germany.
FAU - Wildenberg, Manon E
AU  - Wildenberg ME
AD  - l Academic Medical Center , Department of Gastroenterology and Hepatology , 
      Amsterdam , The Netherlands.
FAU - Wileman, Tom
AU  - Wileman T
AD  - biw University of East Anglia, Norwich Medical School , Norfolk , UK.
FAU - Wilkinson, Deepti Srinivas
AU  - Wilkinson DS
AD  - amt Sanford Burnham Prebys Medical Discovery Institute , La Jolla , CA , USA.
FAU - Wilkinson, Simon
AU  - Wilkinson S
AD  - bjb University of Edinburgh, Edinburgh Cancer Research UK Centre, MRC Institute 
      of Genetics and Molecular Medicine , Edinburgh , UK.
FAU - Willbold, Dieter
AU  - Willbold D
AD  - ln Forschungszentrum Juelich, ICS-6/Structural Biochemistry , Juelich , Germany.
AD  - pm Heinrich-Heine-University , Institut für Physikalische Biologie, Duesseldorf , 
      Germany.
FAU - Williams, Chris
AU  - Williams C
AD  - bw Biomolecular Sciences and Biotechnology Institute (GBB) , Groningen , The 
      Netherlands.
AD  - bkf University of Groningen, Molecular Cell Biology , Groningen , The 
      Netherlands.
FAU - Williams, Katherine
AU  - Williams K
AD  - bzh US Food and Drug Administration, National Center for Toxicology Research, 
      Division of Microbiology , Jefferson , AR , USA.
FAU - Williamson, Peter R
AU  - Williamson PR
AD  - afm National Institutes of Health, Laboratory of Clinical Infectious Diseases, 
      National Institute of Allergy and Infectious Diseases , Bethesda , MD , USA.
FAU - Winklhofer, Konstanze F
AU  - Winklhofer KF
AD  - alt Ruhr University Bochum , Department of Molecular Cell Biology , Institute of 
      Biochemistry and Pathobiochemistry , Bochum , Germany.
FAU - Witkin, Steven S
AU  - Witkin SS
AD  - cbl Weill Cornell Medical College , Department of Obstetrics and Gynecology , New 
      York , NY , USA.
FAU - Wohlgemuth, Stephanie E
AU  - Wohlgemuth SE
AD  - bjl University of Florida , Department of Animal Sciences , IFAS/College of 
      Agriculture and Life Science , Gainesville , FL , USA.
FAU - Wollert, Thomas
AU  - Wollert T
AD  - aba Max Planck Institute of Biochemistry, Molecular Membrane and Organelle 
      Biology , Martinsried , Germany.
FAU - Wolvetang, Ernst J
AU  - Wolvetang EJ
AD  - bsw University of Queensland, Australian Institute for Bioengineering and 
      Nanotechnology (AIBN) , Brisbane , Australia.
FAU - Wong, Esther
AU  - Wong E
AD  - adz Nanyang Technological University, School of Biological Sciences , Singapore.
FAU - Wong, G William
AU  - Wong GW
AD  - we Johns Hopkins University, School of Medicine , Department of Physiology and 
      Center for Metabolism and Obesity Research , Baltimore , MD , USA.
FAU - Wong, Richard W
AU  - Wong RW
AD  - wz Kanazawa University, Cell-bionomics Unit and Laboratory of Molecular and 
      Cellular Biology , Department of Biology , Faculty of Natural Systems, Institute 
      of Science and Engineering , Ishikawa , Japan.
FAU - Wong, Vincent Kam Wai
AU  - Wong VK
AD  - aai Macau University of Science and Technology, State Key Laboratory of Quality 
      Research in Chinese Medicine , Macau , China.
FAU - Woodcock, Elizabeth A
AU  - Woodcock EA
AD  - ba Baker IDI Heart and Diabetes Institute, Molecular Cardiology Laboratory , 
      Melbourne , Australia.
FAU - Wright, Karen L
AU  - Wright KL
AD  - zj Lancaster University, Faculty of Health and Medicine, Division of Biomedical 
      and Life Sciences , Lancaster , UK.
FAU - Wu, Chunlai
AU  - Wu C
AD  - zz Louisiana State University Health Sciences Center, Neuroscience Center of 
      Excellence , New Orleans , LA , USA.
FAU - Wu, Defeng
AU  - Wu D
AD  - qt Icahn School of Medicine at Mount Sinai , New York , NY , USA.
FAU - Wu, Gen Sheng
AU  - Wu GS
AD  - cbj Wayne State University, School of Medicine , Departments of Oncology and 
      Pathology , Detroit , MI , USA.
FAU - Wu, Jian
AU  - Wu J
AD  - lz Fudan University Shanghai Medical College, Key Laboratory of Molecular 
      Virology , Shanghai , China.
FAU - Wu, Junfang
AU  - Wu J
AD  - bnf University of Maryland, School of Medicine , Department of Anesthesiology and 
      Center for Shock , Trauma and Anesthesiology Research (STAR), National Study 
      Center for Trauma and EMS , Baltimore , MD , USA.
FAU - Wu, Mian
AU  - Wu M
AD  - bty University of Science and Technology of China, School of Life Sciences , 
      Hefei, Anhui , China.
FAU - Wu, Min
AU  - Wu M
AD  - bqc University of North Dakota , Department of Biomedical Sciences , School of 
      Medicine and Health Sciences , Grand Forks , ND , USA.
FAU - Wu, Shengzhou
AU  - Wu S
AD  - cbs Wenzhou Medical University, School of Optometry and Ophthalmology and Eye 
      Hospital , Wenzhou, Zhejiang , China.
FAU - Wu, William Kk
AU  - Wu WK
AD  - fx Chinese University of Hong Kong , Department of Anaesthesia and Intensive Care 
      , Hong Kong.
FAU - Wu, Yaohua
AU  - Wu Y
AD  - asq The First Affiliated Hospital of Harbin Medical University, Key Laboratory of 
      Hepatosplenic Surgery , Department of General Surgery , Harbin , China.
FAU - Wu, Zhenlong
AU  - Wu Z
AD  - ez China Agricultural University , Department of Animal Nutrition and Feed 
      Science , Beijing , China.
FAU - Xavier, Cristina Pr
AU  - Xavier CP
AD  - bsp University of Porto, Cancer Drug Resistance Group, IPATIMUP - Institute of 
      Molecular Pathology and Immunology , Porto , Portugal.
AD  - bss University of Porto, i3S-Instituto de Investigação e Inovação em Saúde , 
      Porto , Portugal.
FAU - Xavier, Ramnik J
AU  - Xavier RJ
AD  - ow Harvard Medical School and Broad Institute , Boston , MA , USA.
FAU - Xia, Gui-Xian
AU  - Xia GX
AD  - fn Chinese Academy of Sciences, Institute of Microbiology , Beijing , China.
FAU - Xia, Tian
AU  - Xia T
AD  - bfi University of California Los Angeles , Department of Medicine , Los Angeles , 
      CA , USA.
FAU - Xia, Weiliang
AU  - Xia W
AD  - aog Shanghai Jiao Tong University, School of Biomedical Engineering and Med-X 
      Research Institute , Shanghai , China.
AD  - aoq Shanghai Jiao Tong University, State Key Laboratory of Oncogenes and Related 
      Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of 
      Medicine , Shanghai , China.
FAU - Xia, Yong
AU  - Xia Y
AD  - atf The Third Affiliated Hospital of Guangzhou Medical University , Department of 
      Clinical Laboratory Medicine , Guangzhou, Guangdong , China.
FAU - Xiao, Hengyi
AU  - Xiao H
AD  - aoz Sichuan University, Aging Research Group, State Key Lab for Biotherapy, West 
      China Hospital , Chengdu , China.
FAU - Xiao, Jian
AU  - Xiao J
AD  - anh Second Military Medical University , Department of Cardiothoracic Surgery , 
      Changzheng Hospital , Shanghai , China.
FAU - Xiao, Shi
AU  - Xiao S
AD  - ard Sun Yat-Sen University, State Key Laboratory of Biocontrol, School of Life 
      Sciences , Guangzhou , China.
FAU - Xiao, Wuhan
AU  - Xiao W
AD  - fm Chinese Academy of Sciences, Institute of Hydrobiology , Wuhan, Hubei , China.
FAU - Xie, Chuan-Ming
AU  - Xie CM
AD  - boe University of Michigan , Department of Radiation Oncology , Ann Arbor , MI , 
      USA.
FAU - Xie, Zhiping
AU  - Xie Z
AD  - aoh Shanghai Jiao Tong University, School of Life Sciences and Biotechnology , 
      Shanghai , China.
FAU - Xie, Zhonglin
AU  - Xie Z
AD  - bqj University of Oklahoma, Health Sciences Center, Section of Molecular Medicine 
      , Department of Medicine , Oklahoma City , OK , USA.
FAU - Xilouri, Maria
AU  - Xilouri M
AD  - bu Biomedical Research Foundation of the Academy of Athens, Center of Clinical, 
      Experimental Surgery and Translational Research , Athens , Greece.
FAU - Xiong, Yuyan
AU  - Xiong Y
AD  - bjt University of Fribourg , Department of Medicine , Division of Physiology , 
      Fribourg , Switzerland.
FAU - Xu, Chuanshan
AU  - Xu C
AD  - gc Chinese University of Hong Kong, School of Chinese Medicine, Faculty of 
      Medicine , Shatin, NT, Hong Kong.
FAU - Xu, Congfeng
AU  - Xu C
AD  - aoo Shanghai Jiao Tong University, School of Medicine, Shanghai Institute of 
      Immunology , Shanghai , China.
FAU - Xu, Feng
AU  - Xu F
AD  - md Fudan University , Department of Neurosugery , Shanghai , China.
FAU - Xu, Haoxing
AU  - Xu H
AD  - boc University of Michigan , Department of Molecular , Cellular, and 
      Developmental Biology , Ann Arbor , MI , USA.
FAU - Xu, Hongwei
AU  - Xu H
AD  - ou Harbin Medical University , Department of Immunology , Heilongjiang Provincial 
      Key Laboratory for Infection and Immunity , Harbin , China.
FAU - Xu, Jian
AU  - Xu J
AD  - bqh University of Oklahoma Health Sciences Center , Department of Medicine , 
      Oklahoma City , OK , USA.
FAU - Xu, Jianzhen
AU  - Xu J
AD  - aox Shantou University Medical College , Department of Biochemistry and Molecular 
      Biology , Shantou , China.
FAU - Xu, Jinxian
AU  - Xu J
AD  - nf Georgia Regents University, Medical College of Georgia , Department of 
      Cellular Biology and Anatomy , Augusta , GA , USA.
AD  - ng Georgia Regents University, Medical College of Georgia , Department of 
      Medicine , Augusta , GA , USA.
FAU - Xu, Liang
AU  - Xu L
AD  - bli University of Kansas and University of Kansas Cancer Center , Departments of 
      Molecular Biosciences and Radiation Oncology , Lawrence , KS , USA.
FAU - Xu, Xiaolei
AU  - Xu X
AD  - abg Mayo Clinic , Rochester , MN , USA.
FAU - Xu, Yangqing
AU  - Xu Y
AD  - pb Harvard Medical School , Department of Cell Biology , Boston , MA , USA.
FAU - Xu, Ye
AU  - Xu Y
AD  - vu Jilin Medical University, Medical Research Laboratory , Jilin City, Jilin 
      Province , China.
FAU - Xu, Zhi-Xiang
AU  - Xu ZX
AD  - bca University of Alabama at Birmingham , Department of Medicine , Division of 
      Hematology and Oncology, Comprehensive Cancer Center , Birmingham , AL , USA.
FAU - Xu, Ziheng
AU  - Xu Z
AD  - boc University of Michigan , Department of Molecular , Cellular, and 
      Developmental Biology , Ann Arbor , MI , USA.
AD  - bog University of Michigan, Life Sciences Institute , Ann Arbor , MI , USA.
FAU - Xue, Yu
AU  - Xue Y
AD  - qk Huazhong University of Science and Technology , Department of Biomedical 
      Engineering , College of Life Science and Technology , Wuhan, Hubei , China.
FAU - Yamada, Takahiro
AU  - Yamada T
AD  - pt Hokkaido University Graduate School of Medicine , Department of Obstetrics and 
      Gynecology , Sapporo , Hokkaido , Japan.
FAU - Yamamoto, Ai
AU  - Yamamoto A
AD  - ho Columbia University , Department of Neurology , New York , NY , USA.
FAU - Yamanaka, Koji
AU  - Yamanaka K
AD  - adr Nagoya University, Research Institute of Environmental Medicine, Nagoya , 
      Aichi , Japan.
FAU - Yamashina, Shunhei
AU  - Yamashina S
AD  - wr Juntendo University, School of Medicine , Department of Gastroenterology , 
      Tokyo , Japan.
FAU - Yamashiro, Shigeko
AU  - Yamashiro S
AD  - amb Rutgers University, Molecular Biology and Biochemistry , Piscataway , NJ , 
      USA.
FAU - Yan, Bing
AU  - Yan B
AD  - aoa Shandong University, School of Chemistry and Chemical Engineering, Jinan , 
      Shandong , China.
FAU - Yan, Bo
AU  - Yan B
AD  - vy Jining Medical University, Shandong Provincial Sino-US Cooperation Research 
      Center for Translational Medicine , Shandong , China.
FAU - Yan, Xianghua
AU  - Yan X
AD  - qi Huazhong Agricultural University, College of Animal Sciences and Technology, 
      Wuhan , Hubei , China.
FAU - Yan, Zhen
AU  - Yan Z
AD  - byj University of Virginia , Charlottesville , VA , USA.
FAU - Yanagi, Yasuo
AU  - Yanagi Y
AD  - apg Singapore Eye Research Institute, Singapore National Eye Center , Singapore.
FAU - Yang, Dun-Sheng
AU  - Yang DS
AD  - ahj New York University Langone Medical Center, Nathan Kline Institute for 
      Psychiatric Research , Orangeburg , NY , USA.
FAU - Yang, Jin-Ming
AU  - Yang JM
AD  - ajy Pennsylvania State University, College of Medicine , Department of 
      Pharmacology , Pennsylvania State University Hershey Cancer Institute , Hershey , 
      PA , USA.
FAU - Yang, Liu
AU  - Yang L
AD  - asr The Fourth Military Medical University, Institute of Orthopaedics, Xijing 
      Hospital , Xi'an, Shanxi , China.
FAU - Yang, Minghua
AU  - Yang M
AD  - dl Central South University , Department of Pediatrics , Xiangya Hospital , 
      Changsha, Hunan , China.
FAU - Yang, Pei-Ming
AU  - Yang PM
AD  - arl Taipei Medical University, Graduate Institute of Cancer Biology and Drug 
      Discovery, College of Medical Science and Technology , Taipei , Taiwan.
FAU - Yang, Peixin
AU  - Yang P
AD  - bnj University of Maryland, School of Medicine , Department of Obstetrics , 
      Gynecology and Reproductive Sciences , Baltimore , MD , USA.
FAU - Yang, Qian
AU  - Yang Q
AD  - ast The Fourth Military Medical University , Xi'an , China.
FAU - Yang, Wannian
AU  - Yang W
AD  - mi Geisinger Clinic, Weis Center for Research , Danville , PA , USA.
FAU - Yang, Wei Yuan
AU  - Yang WY
AD  - i Academia Sinica, Institute of Biological Chemistry , Taipei , Taiwan.
FAU - Yang, Xuesong
AU  - Yang X
AD  - vx Jinan University, Medical College, Division of Histology and Embryology , 
      Guangzhou, Guangdong , China.
FAU - Yang, Yi
AU  - Yang Y
AD  - oo Hangzhou Normal University , Department of Pharmacology , School of Medicine , 
      Hangzhou , China.
FAU - Yang, Ying
AU  - Yang Y
AD  - aof Shanghai Jiao Tong University , Department of Endocrinology and Metabolism , 
      Affiliated Sixth People's Hospital, Shanghai Diabetes Institute, Shanghai Key 
      Laboratory of Diabetes Mellitus, Shanghai Clinical Center for Diabetes , Shanghai 
      , China.
FAU - Yang, Zhifen
AU  - Yang Z
AD  - aqk Stanford University , Department of Radiation Oncology , Stanford , CA , USA.
FAU - Yang, Zhihong
AU  - Yang Z
AD  - bjs University of Fribourg , Department of Medicine , Division of Physiology, 
      Faculty of Science , Fribourg , Switzerland.
FAU - Yao, Meng-Chao
AU  - Yao MC
AD  - k Academia Sinica, Institute of Molecular Biology , Taipei , Taiwan.
FAU - Yao, Pamela J
AU  - Yao PJ
AD  - afs National Institutes of Health, National Institute on Aging, Biomedical 
      Research Center, Laboratory of Neurosciences , Baltimore , MD , USA.
FAU - Yao, Xiaofeng
AU  - Yao X
AD  - in Dalian Medical University , Department of Environmental and Occupational 
      Hygiene , Dalian , China.
FAU - Yao, Zhenyu
AU  - Yao Z
AD  - fr Chinese Academy of Sciences, Shenzhen Institutes of Advanced Technology , 
      Guangdong , China.
FAU - Yao, Zhiyuan
AU  - Yao Z
AD  - boc University of Michigan , Department of Molecular , Cellular, and 
      Developmental Biology , Ann Arbor , MI , USA.
AD  - bog University of Michigan, Life Sciences Institute , Ann Arbor , MI , USA.
FAU - Yasui, Linda S
AU  - Yasui LS
AD  - ahz Northern Illinois University , Department of Biological Sciences , DeKalb , 
      IL , USA.
FAU - Ye, Mingxiang
AU  - Ye M
AD  - lq Fourth Military Medical University , Department of Biochemistry and Molecular 
      Biology , Xi'an , China.
FAU - Yedvobnick, Barry
AU  - Yedvobnick B
AD  - jy Emory University , Department of Biology , Atlanta , GA , USA.
FAU - Yeganeh, Behzad
AU  - Yeganeh B
AD  - bxc University of Toronto, Hospital for Sick Children Research Institute , 
      Department of Physiology and Experimental Medicine , Toronto , Canada.
FAU - Yeh, Elizabeth S
AU  - Yeh ES
AD  - acj Medical University of South Carolina , Department of Cell and Molecular 
      Pharmacology and Experimental Therapeutics , Charleston , SC , USA.
FAU - Yeyati, Patricia L
AU  - Yeyati PL
AD  - jw Edinburgh University, MRC Human Genetics Unit , Edinburgh , UK.
FAU - Yi, Fan
AU  - Yi F
AD  - aoc Shandong University, School of Medicine , Department of Pharmacology , Jinan, 
      Shandong Province , China.
FAU - Yi, Long
AU  - Yi L
AD  - atn Third Military Medical University, Research Center for Nutrition and Food 
      Safety, Institute of Military Preventive Medicine , Chongqing , China.
FAU - Yin, Xiao-Ming
AU  - Yin XM
AD  - rn Indiana University School of Medicine , Department of Pathology and Laboratory 
      Medicine , Indianapolis , IN , USA.
FAU - Yip, Calvin K
AU  - Yip CK
AD  - bed University of British Columbia , Department of Biochemistry and Molecular 
      Biology , Vancouver, British Columbia , Canada.
FAU - Yoo, Yeong-Min
AU  - Yoo YM
AD  - ccl Yonsei University , Department of Biomedical Engineering , College of Health 
      Science , Seoul , Korea.
FAU - Yoo, Young Hyun
AU  - Yoo YH
AD  - jc Dong-A University, College of Medicine and Mitochondria Hub Regulation Center 
      , Department of Anatomy and Cell Biology , Busan , Korea.
FAU - Yoon, Seung-Yong
AU  - Yoon SY
AD  - bxy University of Ulsan College of Medicine , Department of Brain Science , Seoul 
      , Korea.
FAU - Yoshida, Ken-Ichi
AU  - Yoshida K
AD  - acq Meiji University , Department of Life Sciences , Kanagawa , Japan.
FAU - Yoshimori, Tamotsu
AU  - Yoshimori T
AD  - aiw Osaka University , Department of Genetics , Graduate School of Medicine, 
      Laboratory of Intracellular Membrane Dynamics, Graduate School of Frontier 
      Biosciences , Osaka , Japan.
FAU - Young, Ken H
AU  - Young KH
AD  - bwc University of Texas, MD Anderson Cancer Center , Department of 
      Hematopathology , Houston , TX , USA.
FAU - Yu, Huixin
AU  - Yu H
AD  - vp Jiangsu Institute of Nuclear Medicine , Wuxi, Jiangsu , China.
FAU - Yu, Jane J
AU  - Yu JJ
AD  - cg Brigham and Women's Hospital, Harvard Medical School , Boston , MA , USA.
FAU - Yu, Jin-Tai
AU  - Yu JT
AD  - aks Qingdao University , Department of Neurology , Qingdao Municipal Hospital, 
      School of Medicine , Qingdao, Shandong Province , China.
FAU - Yu, Jun
AU  - Yu J
AD  - fz Chinese University of Hong Kong, Institute of Digestive Diseases , Department 
      of Medicine and Therapeutics , State Key Laboratory of Digestive Disease , Hong 
      Kong.
FAU - Yu, Li
AU  - Yu L
AD  - avc Tsinghua University, State Key Laboratory of Biomembrane and Membrane 
      Biotechnology, Tsinghua University-Peking University Joint Center for Life 
      Sciences, School of Life Science , Beijing , China.
FAU - Yu, W Haung
AU  - Yu WH
AD  - hp Columbia University, Taub Institute for Alzheimer's Disease Research , 
      Department of Pathology and Cell Biology , New York , NY , USA.
FAU - Yu, Xiao-Fang
AU  - Yu XF
AD  - le First Hospital of Jilin University , Changchun, Jilin , China.
FAU - Yu, Zhengping
AU  - Yu Z
AD  - atm Third Military Medical University , Department of Occupational Health , 
      Chongqing , China.
FAU - Yuan, Junying
AU  - Yuan J
AD  - pb Harvard Medical School , Department of Cell Biology , Boston , MA , USA.
FAU - Yuan, Zhi-Min
AU  - Yuan ZM
AD  - pg Harvard University, School of Public Health , Department of Genetics and 
      Complex Diseases , Boston , MA , USA.
FAU - Yue, Beatrice Yjt
AU  - Yue BY
AD  - bks University of Illinois at Chicago, College of Medicine , Department of 
      Ophthalmology and Visual Sciences , Chicago , IL , USA.
FAU - Yue, Jianbo
AU  - Yue J
AD  - gu City University of Hong Kong , Department of Biomedical Sciences , Kowloon 
      Tong, Hong Kong , China.
FAU - Yue, Zhenyu
AU  - Yue Z
AD  - qs Icahn School of Medicine at Mount Sinai, Friedman Brain Institute , New York , 
      NY , USA.
FAU - Zacks, David N
AU  - Zacks DN
AD  - bod University of Michigan , Department of Ophthalmology and Visual Sciences , 
      Ann Arbor , MI , USA.
FAU - Zacksenhaus, Eldad
AU  - Zacksenhaus E
AD  - auu Toronto General Research Institute - University Health Network, Division of 
      Advanced Diagnostics , Toronto, Ontario , Canada.
FAU - Zaffaroni, Nadia
AU  - Zaffaroni N
AD  - ll Fondazione IRCCS Istituto Nazionale dei Tumori , Department of Experimental 
      Oncology and Molecular Medicine , Milan , Italy.
FAU - Zaglia, Tania
AU  - Zaglia T
AD  - bre University of Padova, Venetian Institute of Molecular Medicine , Department 
      of Biomedical Science , Padova , Italy.
FAU - Zakeri, Zahra
AU  - Zakeri Z
AD  - akz Queens College of the City University of New York , Department of Biology , 
      Flushing , NY , USA.
FAU - Zecchini, Vincent
AU  - Zecchini V
AD  - adh MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre , 
      Cambridge , UK.
FAU - Zeng, Jinsheng
AU  - Zeng J
AD  - aqy Sun Yat-Sen University , Department of Neurology and Stroke Center , The 
      First Affiliated Hospital , Guangzhou , China.
FAU - Zeng, Min
AU  - Zeng M
AD  - ata The People's Hospital of Hainan Province, Medical Care Center, Haikou , 
      Hainan , China.
FAU - Zeng, Qi
AU  - Zeng Q
AD  - a A*STAR (Agency for Science, Technology and Research), Institute of Molecular 
      and Cell Biology , Singapore.
FAU - Zervos, Antonis S
AU  - Zervos AS
AD  - bha University of Central Florida College of Medicine, Burnett School of 
      Biomedical Sciences , Orlando , FL , USA.
FAU - Zhang, Donna D
AU  - Zhang DD
AD  - bcq University of Arizona , Department of Pharmacology and Toxicology , College 
      of Pharmacy , Tucson , AZ , USA.
FAU - Zhang, Fan
AU  - Zhang F
AD  - bzp Vancouver Prostate Centre , Vancouver, BC , Canada.
FAU - Zhang, Guo
AU  - Zhang G
AD  - asz The People's Hospital of Guangxi Zhuang Autonomous Region , Department of 
      Gastroenterology , Nanning , Guangxi , China.
FAU - Zhang, Guo-Chang
AU  - Zhang GC
AD  - bkz University of Illinois at Urbana-Champaign, Institute for Genomic Biology , 
      Urbana , IL , USA.
FAU - Zhang, Hao
AU  - Zhang H
AD  - aow Shantou University Medical College, Cancer Research Center, Shantou , 
      Guangdong , China.
FAU - Zhang, Hong
AU  - Zhang H
AD  - fl Chinese Academy of Sciences, Institute of Biophysics, State Key Laboratory of 
      Biomacromolecules , Beijing , China.
FAU - Zhang, Hong
AU  - Zhang H
AD  - ajp Peking University First Hospital, Renal Division , Beijing , China.
FAU - Zhang, Hongbing
AU  - Zhang H
AD  - fd Chinese Academy of Medical Sciences and Peking Union Medical College , 
      Department of Physiology , Institute of Basic Medical Sciences , Beijing , China.
AD  - ajo Peking University First Hospital , Department of Internal Medicine , Beijing 
      , China.
FAU - Zhang, Jian
AU  - Zhang J
AD  - lq Fourth Military Medical University , Department of Biochemistry and Molecular 
      Biology , Xi'an , China.
FAU - Zhang, Jian
AU  - Zhang J
AD  - ls Fourth Military Medical University , Department of Pulmonary Medicine , Xijing 
      Hospital , Xi'an, Shaanxi Province , China.
FAU - Zhang, Jiangwei
AU  - Zhang J
AD  - ash Texas A&M University Health Science Center, Center for Translational Cancer 
      Research, Institute of Biosciences and Technology , Houston , TX , USA.
FAU - Zhang, Jianhua
AU  - Zhang J
AD  - bcb University of Alabama at Birmingham , Department of Pathology , Birmingham , 
      AL , USA.
FAU - Zhang, Jing-Pu
AU  - Zhang JP
AD  - fe Chinese Academy of Medical Sciences and Peking Union Medical College, 
      Institute of Medicinal Biotechnology , Beijing , China.
FAU - Zhang, Li
AU  - Zhang L
AD  - vp Jiangsu Institute of Nuclear Medicine , Wuxi, Jiangsu , China.
FAU - Zhang, Lin
AU  - Zhang L
AD  - brq University of Pennsylvania , Department of Obstetrics and Gynecology ; 
      Perelman School of Medicine , Philadelphia , PA , USA.
FAU - Zhang, Lin
AU  - Zhang L
AD  - bsl University of Pittsburgh, School of Medicine , Department of Pharmacology and 
      Chemical Biology , Pittsburgh , PA , USA.
FAU - Zhang, Long
AU  - Zhang L
AD  - ccy Zhejiang University, Life Sciences Institute , Zhejiang , China.
FAU - Zhang, Ming-Yong
AU  - Zhang MY
AD  - fs Chinese Academy of Sciences, South China Botanical Garden , Guangzhou , China.
FAU - Zhang, Xiangnan
AU  - Zhang X
AD  - ma Fudan University, Cancer Center , Department of Integrative Oncology , 
      Shanghai , China.
FAU - Zhang, Xu Dong
AU  - Zhang XD
AD  - bpq University of Newcastle, School of Biomedical Sciences and Pharmacy , 
      Newcastle, NSW , Australia.
FAU - Zhang, Yan
AU  - Zhang Y
AD  - any Shandong Agricultural University, State Key Laboratory of Crop Science , 
      Tai'an , China.
FAU - Zhang, Yang
AU  - Zhang Y
AD  - bkp University of Houston, College of Pharmacy, Pharmacological and 
      Pharmaceutical Sciences , Houston , TX , USA.
FAU - Zhang, Yanjin
AU  - Zhang Y
AD  - bnd University of Maryland , Department of Veterinary Medicine , College Park , 
      MD , USA.
FAU - Zhang, Yingmei
AU  - Zhang Y
AD  - byv University of Wyoming, School of Pharmacy, College of Health Sciences , 
      Laramie , WY , USA.
AD  - ccb Xijing Hospital, The Fourth Military Medical University , Xi'an , China.
FAU - Zhang, Yunjiao
AU  - Zhang Y
AD  - btv University of Science and Technology of China , Anhui , China.
FAU - Zhao, Mei
AU  - Zhao M
AD  - cbz Xi'an Jiaotong University Health Center , Department of Pharmacology , Xi'an, 
      Shaanxi , China.
FAU - Zhao, Wei-Li
AU  - Zhao WL
AD  - aop Shanghai Jiao Tong University, School of Medicine, State Key Laboratory of 
      Medical Genomics; Shanghai Institute of Hematology; Shanghai Rui Jin Hospital , 
      Shanghai , China.
FAU - Zhao, Xiaonan
AU  - Zhao X
AD  - aoo Shanghai Jiao Tong University, School of Medicine, Shanghai Institute of 
      Immunology , Shanghai , China.
FAU - Zhao, Yan G
AU  - Zhao YG
AD  - ft Chinese Academy of Sciences, State Key Laboratory of Biomacromolecules, 
      Institute of Biophysics , Beijing , China.
FAU - Zhao, Ying
AU  - Zhao Y
AD  - ajt Peking University, Health Science Center , Department of Biochemistry and 
      Molecular Biology , Beijing , China.
FAU - Zhao, Yongchao
AU  - Zhao Y
AD  - bof University of Michigan , Department of Radiation Oncology , Division of 
      Radiation and Cancer Biology , Ann Arbor , MI , USA.
FAU - Zhao, Yu-Xia
AU  - Zhao YX
AD  - akr Qilu Hospital of Shandong University , Department of Traditional Chinese 
      Medicine , Jinan , China.
FAU - Zhao, Zhendong
AU  - Zhao Z
AD  - ff Chinese Academy of Medical Sciences and Peking Union Medical College, MOH Key 
      Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology , 
      Beijing , China.
FAU - Zhao, Zhizhuang J
AU  - Zhao ZJ
AD  - bqi University of Oklahoma Health Sciences Center , Department of Pathology , 
      Oklahoma City , OK , USA.
FAU - Zheng, Dexian
AU  - Zheng D
AD  - fh Chinese Academy of Medical Sciences and Peking Union Medical College, National 
      Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences , 
      Beijing , China.
FAU - Zheng, Xi-Long
AU  - Zheng XL
AD  - beu University of Calgary , Department of Biochemistry and Molecular Biology , 
      Libin Cardiovascular Institute of Alberta , Calgary, AB , Canada.
FAU - Zheng, Xiaoxiang
AU  - Zheng X
AD  - ccr Zhejiang University , Department of Biomedical Engineering , Qiushi Academy 
      for Advanced Studies , Hangzhou , China.
FAU - Zhivotovsky, Boris
AU  - Zhivotovsky B
AD  - tf Institute of Environmental Medicine, Division of Toxicology, Karolinska 
      Institute , Stockholm , Sweden.
AD  - zt Lomonosov Moscow State University, Faculty of Basic Medicine , Moscow , 
      Russia.
FAU - Zhong, Qing
AU  - Zhong Q
AD  - bvq University of Texas , Department of Biochemistry , Dallas , TX , USA.
AD  - bvr University of Texas , Southwestern Medical Center, Department of Internal 
      Medicine , Center for Autophagy Research, Dallas , TX , USA.
FAU - Zhou, Guang-Zhou
AU  - Zhou GZ
AD  - pr Henan University of Technology, College of Bioengineering , Zhengzhou, Henan 
      Province , China.
FAU - Zhou, Guofei
AU  - Zhou G
AD  - bkt University of Illinois at Chicago, College of Medicine , Department of 
      Pediatrics , Chicago , IL , USA.
FAU - Zhou, Huiping
AU  - Zhou H
AD  - caa Virginia Commonwealth University , Department of Microbiology and Immunology 
      , Richmond , VA , USA.
FAU - Zhou, Shu-Feng
AU  - Zhou SF
AD  - bus University of South Florida , Department of Pharmaceutical Science , Tampa , 
      FL , USA.
FAU - Zhou, Xu-Jie
AU  - Zhou XJ
AD  - ajp Peking University First Hospital, Renal Division , Beijing , China.
AD  - ajr Peking University , Department of Medicine , Beijing , China.
AD  - aju Peking University, Institute of Nephrology, Key Laboratory of Renal Disease, 
      Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention 
      and Treatment, Ministry of Education , Beijing , China.
FAU - Zhu, Hongxin
AU  - Zhu H
AD  - aoe Shanghai Jiao Tong University, Bio-X Institutes , Shanghai , China.
FAU - Zhu, Hua
AU  - Zhu H
AD  - aik Ohio State University , Department of Surgery , Davis Heart and Lung Research 
      Institute , Columbus , OH , USA.
FAU - Zhu, Wei-Guo
AU  - Zhu WG
AD  - ajt Peking University, Health Science Center , Department of Biochemistry and 
      Molecular Biology , Beijing , China.
FAU - Zhu, Wenhua
AU  - Zhu W
AD  - cca Xi'an Jiaotong University Health Science Center , Department of Biochemistry 
      and Molecular Biology , School of Basic Medical Sciences , Shaanxi , China.
FAU - Zhu, Xiao-Feng
AU  - Zhu XF
AD  - are Sun Yat-Sen University, State Key Laboratory of Oncology in South China, 
      Cancer Center , Guangzhou , China.
FAU - Zhu, Yuhua
AU  - Zhu Y
AD  - ey China Agricultural University, College of Animal Science and Technology, State 
      Key Laboratory of Animal Nutrition , Beijing , China.
FAU - Zhuang, Shi-Mei
AU  - Zhuang SM
AD  - arc Sun Yat-Sen University, School of Life Sciences , Guangzhou , China.
FAU - Zhuang, Xiaohong
AU  - Zhuang X
AD  - gd Chinese University of Hong Kong, School of Life Science, Centre for Cell and 
      Developmental Biology and State Key Laboratory of Agrobiotechnology , Sha Tin, 
      Hong Kong.
FAU - Ziparo, Elio
AU  - Ziparo E
AD  - amx Sapienza University of Rome, DAHFMO-Section of Histology , Rome , Italy.
FAU - Zois, Christos E
AU  - Zois CE
AD  - ajk Oxford University, Department of Oncology , Weatherall Institute of Molecular 
      Medicine, John Radcliffe Hospital, Molecular Oncology Laboratories , Oxford , UK.
FAU - Zoladek, Teresa
AU  - Zoladek T
AD  - akg Polish Academy of Sciences, Institute of Biochemistry and Biophysics , Warsaw 
      , Poland.
FAU - Zong, Wei-Xing
AU  - Zong WX
AD  - aqu Stony Brook University , Department of Molecular Genetics and Microbiology , 
      Stony Brook , NY , USA.
FAU - Zorzano, Antonio
AU  - Zorzano A
AD  - gn CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto 
      de Salud Carlos III , Barcelona , Spain.
AD  - ta Institute for Research in Biomedicine (IRB Barcelona) , The Barcelona 
      Institute of Science and Technology, Barcelona , Spain.
AD  - axz Universitat de Barcelona , Departament de Bioquímica i Biologia Molecular , 
      Facultat de Biologia , Barcelona , Spain.
FAU - Zughaier, Susu M
AU  - Zughaier SM
AD  - kb Emory University, School of Medicine , Department of Microbiology and 
      Immunology , Atlanta , GA , USA.
LA  - eng
GR  - R01 GM116908/GM/NIGMS NIH HHS/United States
GR  - I01 BX001110/BX/BLRD VA/United States
GR  - R01 CA078810/CA/NCI NIH HHS/United States
GR  - R15 AI089518/AI/NIAID NIH HHS/United States
GR  - R03 DK092434/DK/NIDDK NIH HHS/United States
GR  - R01 EY026171/EY/NEI NIH HHS/United States
GR  - I01 BX000976/BX/BLRD VA/United States
GR  - R01 CA187305/CA/NCI NIH HHS/United States
GR  - R01 AI091968/AI/NIAID NIH HHS/United States
GR  - R01 NS078072/NS/NINDS NIH HHS/United States
GR  - R01 HL126711/HL/NHLBI NIH HHS/United States
GR  - R01 EY010199/EY/NEI NIH HHS/United States
GR  - R01 DK044234/DK/NIDDK NIH HHS/United States
GR  - R01 AR050429/AR/NIAMS NIH HHS/United States
GR  - R01 HL072844/HL/NHLBI NIH HHS/United States
GR  - MC_UU_12016/4/MRC_/Medical Research Council/United Kingdom
GR  - R01 DK083575/DK/NIDDK NIH HHS/United States
GR  - P20 RR024489/RR/NCRR NIH HHS/United States
GR  - R21 AI115286/AI/NIAID NIH HHS/United States
GR  - 11359/CRUK_/Cancer Research UK/United Kingdom
GR  - 13101/CRUK_/Cancer Research UK/United Kingdom
GR  - MC_UP_A390_1106/MRC_/Medical Research Council/United Kingdom
GR  - K08 DK089117/DK/NIDDK NIH HHS/United States
GR  - R01 GM021841/GM/NIGMS NIH HHS/United States
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - R01 NS065789/NS/NINDS NIH HHS/United States
GR  - R01 CA159314/CA/NCI NIH HHS/United States
GR  - R56 DK108921/DK/NIDDK NIH HHS/United States
GR  - R01 CA140964/CA/NCI NIH HHS/United States
GR  - R01 AI087669/AI/NIAID NIH HHS/United States
GR  - MR/J010448/1/MRC_/Medical Research Council/United Kingdom
GR  - R01 CA132136/CA/NCI NIH HHS/United States
GR  - R01 EY024327/EY/NEI NIH HHS/United States
GR  - MC_U132670600/MRC_/Medical Research Council/United Kingdom
GR  - 145505/SNSF_/Swiss National Science Foundation/Switzerland
GR  - R01 DK097441/DK/NIDDK NIH HHS/United States
GR  - I01 BX001969/BX/BLRD VA/United States
GR  - R03 DK106304/DK/NIDDK NIH HHS/United States
GR  - R01 EY018884/EY/NEI NIH HHS/United States
GR  - G0300648/MRC_/Medical Research Council/United Kingdom
GR  - U54 CA149147/CA/NCI NIH HHS/United States
GR  - R01 NS069566/NS/NINDS NIH HHS/United States
GR  - R01 AG032611/AG/NIA NIH HHS/United States
GR  - R01 DK076685/DK/NIDDK NIH HHS/United States
GR  - R01 AG039756/AG/NIA NIH HHS/United States
GR  - R01 CA138441/CA/NCI NIH HHS/United States
GR  - U01 DK127747/DK/NIDDK NIH HHS/United States
GR  - 14BGIA20030027/AHA/American Heart Association-American Stroke Association/United 
      States
GR  - R01 HL107594/HL/NHLBI NIH HHS/United States
GR  - 16337/CRUK_/Cancer Research UK/United Kingdom
GR  - K12 GM068524/GM/NIGMS NIH HHS/United States
GR  - K08 CA193982/CA/NCI NIH HHS/United States
GR  - K02 AG042095/AG/NIA NIH HHS/United States
GR  - P01 DK098108/DK/NIDDK NIH HHS/United States
GR  - P30 ES006694/ES/NIEHS NIH HHS/United States
GR  - R01 AG020197/AG/NIA NIH HHS/United States
GR  - R01 HL071158/HL/NHLBI NIH HHS/United States
GR  - GM053396/GM/NIGMS NIH HHS/United States
GR  - BBS/E/B/000C0413/BB_/Biotechnology and Biological Sciences Research 
      Council/United Kingdom
GR  - R01 GM097355/GM/NIGMS NIH HHS/United States
GR  - P01 CA108671/CA/NCI NIH HHS/United States
GR  - R01 HL130230/HL/NHLBI NIH HHS/United States
GR  - R01 DK079879/DK/NIDDK NIH HHS/United States
GR  - 16466/CRUK_/Cancer Research UK/United Kingdom
GR  - I01 BX002363/BX/BLRD VA/United States
GR  - P42 ES027723/ES/NIEHS NIH HHS/United States
GR  - K08 CA164047/CA/NCI NIH HHS/United States
GR  - R01 HL079669/HL/NHLBI NIH HHS/United States
GR  - R01 AR042527/AR/NIAMS NIH HHS/United States
GR  - R01 AA022601/AA/NIAAA NIH HHS/United States
GR  - R01 EY026885/EY/NEI NIH HHS/United States
GR  - R01 DK090115/DK/NIDDK NIH HHS/United States
GR  - K-1202/PUK_/Parkinson's UK/United Kingdom
GR  - K01 DK075386/DK/NIDDK NIH HHS/United States
GR  - P30 CA010815/CA/NCI NIH HHS/United States
GR  - R01 AR060837/AR/NIAMS NIH HHS/United States
GR  - G0801936/MRC_/Medical Research Council/United Kingdom
GR  - R01 HL077328/HL/NHLBI NIH HHS/United States
GR  - R15 GM102846/GM/NIGMS NIH HHS/United States
GR  - R01 NS073813/NS/NINDS NIH HHS/United States
GR  - R01 NS076896/NS/NINDS NIH HHS/United States
GR  - 11975/CRUK_/Cancer Research UK/United Kingdom
GR  - K01 AA019996/AA/NIAAA NIH HHS/United States
GR  - R01 HL116329/HL/NHLBI NIH HHS/United States
GR  - R01 DK033823/DK/NIDDK NIH HHS/United States
GR  - R01 CA089121/CA/NCI NIH HHS/United States
GR  - R00 DK094980/DK/NIDDK NIH HHS/United States
GR  - NC/L000199/1/NC3RS_/National Centre for the Replacement, Refinement and Reduction 
      of Animals in Research/United Kingdom
GR  - R01 DK098331/DK/NIDDK NIH HHS/United States
GR  - R01 NS091218/NS/NINDS NIH HHS/United States
GR  - R01 GM096193/GM/NIGMS NIH HHS/United States
GR  - R03 DK089010/DK/NIDDK NIH HHS/United States
GR  - R01 AT005076/AT/NCCIH NIH HHS/United States
GR  - R01 CA184137/CA/NCI NIH HHS/United States
GR  - R01 EY024581/EY/NEI NIH HHS/United States
GR  - R01 GM053396/GM/NIGMS NIH HHS/United States
GR  - I01 RX000444/RX/RRD VA/United States
GR  - R01 HL117233/HL/NHLBI NIH HHS/United States
GR  - R21 DK075494/DK/NIDDK NIH HHS/United States
GR  - R01 HL114697/HL/NHLBI NIH HHS/United States
GR  - MC_UU_12022/6/MRC_/Medical Research Council/United Kingdom
GR  - R01 EY009083/EY/NEI NIH HHS/United States
GR  - R01 CA178394/CA/NCI NIH HHS/United States
GR  - G12 MD007595/MD/NIMHD NIH HHS/United States
GR  - 087518/WT_/Wellcome Trust/United Kingdom
GR  - R01 HL085629/HL/NHLBI NIH HHS/United States
GR  - R01 HL117913/HL/NHLBI NIH HHS/United States
GR  - R37 AG021904/AG/NIA NIH HHS/United States
GR  - R00 AG042494/AG/NIA NIH HHS/United States
GR  - P20 GM104934/GM/NIGMS NIH HHS/United States
GR  - R01 AR062030/AR/NIAMS NIH HHS/United States
GR  - R01 NS062792/NS/NINDS NIH HHS/United States
GR  - P30 AG028740/AG/NIA NIH HHS/United States
GR  - R01 HL059888/HL/NHLBI NIH HHS/United States
GR  - P01 CA163200/CA/NCI NIH HHS/United States
GR  - R01 EY028559/EY/NEI NIH HHS/United States
GR  - R01 AG045223/AG/NIA NIH HHS/United States
GR  - R21 DA029249/DA/NIDA NIH HHS/United States
GR  - R56 DK037034/DK/NIDDK NIH HHS/United States
GR  - R01 EY022633/EY/NEI NIH HHS/United States
GR  - R15 CA151112/CA/NCI NIH HHS/United States
GR  - MR/M019217/1/MRC_/Medical Research Council/United Kingdom
GR  - R03 DK106344/DK/NIDDK NIH HHS/United States
GR  - H-1201/PUK_/Parkinson's UK/United Kingdom
GR  - R56 NS065789/NS/NINDS NIH HHS/United States
GR  - R01 EY026979/EY/NEI NIH HHS/United States
GR  - P20 GM103554/GM/NIGMS NIH HHS/United States
GR  - R01 CA109182/CA/NCI NIH HHS/United States
GR  - R01 CA184208/CA/NCI NIH HHS/United States
GR  - K08 NS085324/NS/NINDS NIH HHS/United States
GR  - R01 CA175120/CA/NCI NIH HHS/United States
GR  - R01 AI146180/AI/NIAID NIH HHS/United States
GR  - R01 CA193698/CA/NCI NIH HHS/United States
GR  - F-1002/PUK_/Parkinson's UK/United Kingdom
GR  - R01 CA122346/CA/NCI NIH HHS/United States
GR  - R01 AI108906/AI/NIAID NIH HHS/United States
GR  - 14-1328/AICR_/Worldwide Cancer Research/United Kingdom
GR  - R37 AI042999/AI/NIAID NIH HHS/United States
GR  - MC_UP_A500_1019/MRC_/Medical Research Council/United Kingdom
GR  - R01 CA143811/CA/NCI NIH HHS/United States
GR  - R01 AI137198/AI/NIAID NIH HHS/United States
GR  - R01 DK100163/DK/NIDDK NIH HHS/United States
GR  - P20 GM103492/GM/NIGMS NIH HHS/United States
GR  - R01 EY015537/EY/NEI NIH HHS/United States
GR  - 12918/CRUK_/Cancer Research UK/United Kingdom
GR  - R01 AI139675/AI/NIAID NIH HHS/United States
GR  - MR/N004434/1/MRC_/Medical Research Council/United Kingdom
GR  - P20 GM103652/GM/NIGMS NIH HHS/United States
GR  - K22 CA181274/CA/NCI NIH HHS/United States
GR  - R01 AI111935/AI/NIAID NIH HHS/United States
GR  - K08 NS083739/NS/NINDS NIH HHS/United States
GR  - MC_U105185860/MRC_/Medical Research Council/United Kingdom
GR  - R03 NS087338/NS/NINDS NIH HHS/United States
GR  - MC_U105170648/MRC_/Medical Research Council/United Kingdom
GR  - P30 DK020541/DK/NIDDK NIH HHS/United States
GR  - P30 DK020593/DK/NIDDK NIH HHS/United States
GR  - I01 BX001746/BX/BLRD VA/United States
GR  - R01 DK073336/DK/NIDDK NIH HHS/United States
GR  - 16464/CRUK_/Cancer Research UK/United Kingdom
GR  - R01 NS075685/NS/NINDS NIH HHS/United States
GR  - R01 NS057553/NS/NINDS NIH HHS/United States
GR  - R01 NS089737/NS/NINDS NIH HHS/United States
GR  - P30 ES023512/ES/NIEHS NIH HHS/United States
GR  - 15816/CRUK_/Cancer Research UK/United Kingdom
GR  - T32 CA009686/CA/NCI NIH HHS/United States
GR  - R01 EY027733/EY/NEI NIH HHS/United States
GR  - R00 DK087928/DK/NIDDK NIH HHS/United States
GR  - R01 HL056416/HL/NHLBI NIH HHS/United States
GR  - R01 AA019954/AA/NIAAA NIH HHS/United States
GR  - U54 HD090255/HD/NICHD NIH HHS/United States
GR  - R01 HL130845/HL/NHLBI NIH HHS/United States
GR  - R35 CA220446/CA/NCI NIH HHS/United States
GR  - R01 AA021751/AA/NIAAA NIH HHS/United States
GR  - R03 NS090939/NS/NINDS NIH HHS/United States
GR  - R01 GM061766/GM/NIGMS NIH HHS/United States
GR  - T32 AI007538/AI/NIAID NIH HHS/United States
GR  - R01 NS085070/NS/NINDS NIH HHS/United States
GR  - R01 AG026389/AG/NIA NIH HHS/United States
GR  - R01 NS077239/NS/NINDS NIH HHS/United States
GR  - 12825/CRUK_/Cancer Research UK/United Kingdom
GR  - 18974/CRUK_/Cancer Research UK/United Kingdom
GR  - P30 DK020579/DK/NIDDK NIH HHS/United States
GR  - R01 DK062777/DK/NIDDK NIH HHS/United States
GR  - R21 NS091928/NS/NINDS NIH HHS/United States
GR  - R01 DK062092/DK/NIDDK NIH HHS/United States
GR  - R01 GM060574/GM/NIGMS NIH HHS/United States
GR  - I01 RX001477/RX/RRD VA/United States
GR  - P30 DK020572/DK/NIDDK NIH HHS/United States
GR  - R01 DK105118/DK/NIDDK NIH HHS/United States
GR  - R01 HL130174/HL/NHLBI NIH HHS/United States
GR  - R01 GM089919/GM/NIGMS NIH HHS/United States
GR  - MR/M00869X/1/MRC_/Medical Research Council/United Kingdom
GR  - G0601891/MRC_/Medical Research Council/United Kingdom
GR  - R37 AI103197/AI/NIAID NIH HHS/United States
GR  - R01 CA142862/CA/NCI NIH HHS/United States
GR  - R01 CA149646/CA/NCI NIH HHS/United States
GR  - R01 HL072166/HL/NHLBI NIH HHS/United States
GR  - R01 HL098216/HL/NHLBI NIH HHS/United States
GR  - R21 AR060444/AR/NIAMS NIH HHS/United States
GR  - R01 EY005681/EY/NEI NIH HHS/United States
GR  - R01 NS079697/NS/NINDS NIH HHS/United States
GR  - 19276/CRUK_/Cancer Research UK/United Kingdom
GR  - R01 AG038664/AG/NIA NIH HHS/United States
GR  - R01 AR064420/AR/NIAMS NIH HHS/United States
GR  - R01 GM114840/GM/NIGMS NIH HHS/United States
GR  - R01 EY025362/EY/NEI NIH HHS/United States
GR  - G1002186/MRC_/Medical Research Council/United Kingdom
GR  - 2014112/DDCF/Doris Duke Charitable Foundation/United States
GR  - R15 AI119980/AI/NIAID NIH HHS/United States
GR  - R00 AG048016/AG/NIA NIH HHS/United States
GR  - MR/K019384/1/MRC_/Medical Research Council/United Kingdom
GR  - R01 DK061498/DK/NIDDK NIH HHS/United States
GR  - MR/L010933/1/MRC_/Medical Research Council/United Kingdom
GR  - R01 DK107220/DK/NIDDK NIH HHS/United States
GR  - R01 CA162405/CA/NCI NIH HHS/United States
GR  - R01 EY010577/EY/NEI NIH HHS/United States
GR  - 10SDG2600164/AHA/American Heart Association-American Stroke Association/United 
      States
GR  - RF1 AG043517/AG/NIA NIH HHS/United States
GR  - R01 AI092084/AI/NIAID NIH HHS/United States
GR  - R01 GM117466/GM/NIGMS NIH HHS/United States
GR  - P01 AG031782/AG/NIA NIH HHS/United States
GR  - R21 AI113526/AI/NIAID NIH HHS/United States
GR  - R01 CA130893/CA/NCI NIH HHS/United States
GR  - R01 EY013434/EY/NEI NIH HHS/United States
GR  - R01 CA129536/CA/NCI NIH HHS/United States
GR  - R56 HL122580/HL/NHLBI NIH HHS/United States
GR  - R01 GM101056/GM/NIGMS NIH HHS/United States
GR  - R01 GM063075/GM/NIGMS NIH HHS/United States
GR  - R01 AG031867/AG/NIA NIH HHS/United States
GR  - P20 GM103625/GM/NIGMS NIH HHS/United States
GR  - G1000089/MRC_/Medical Research Council/United Kingdom
GR  - R01 NS078560/NS/NINDS NIH HHS/United States
GR  - R01 AI104928/AI/NIAID NIH HHS/United States
GR  - 15890/CRUK_/Cancer Research UK/United Kingdom
GR  - R01 AR059115/AR/NIAMS NIH HHS/United States
GR  - R01 DK094652/DK/NIDDK NIH HHS/United States
GR  - R01 DK095842/DK/NIDDK NIH HHS/United States
PT  - Guideline
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Autophagy
JT  - Autophagy
JID - 101265188
SB  - IM
EIN - Autophagy. 2016;12(2):443. doi: 10.1080/15548627.2016.1147886. Selliez, Iban 
      [corrected to Seiliez, Iban]. PMID: 26902590
MH  - Animals
MH  - *Autophagy/physiology
MH  - Biological Assay/methods/*standards
MH  - Computer Simulation
MH  - Humans
PMC - PMC4835977
OTO - NOTNLM
OT  - LC3
OT  - autolysosome
OT  - autophagosome
OT  - chaperone-mediated autophagy
OT  - flux
OT  - lysosome
OT  - macroautophagy
OT  - phagophore
OT  - stress
OT  - vacuole
EDAT- 2016/01/23 06:00
MHDA- 2016/10/26 06:00
PMCR- 2017/01/21
CRDT- 2016/01/23 06:00
PHST- 2016/01/23 06:00 [entrez]
PHST- 2016/01/23 06:00 [pubmed]
PHST- 2016/10/26 06:00 [medline]
PHST- 2017/01/21 00:00 [pmc-release]
AID - 1100356 [pii]
AID - 10.1080/15548627.2015.1100356 [doi]
PST - ppublish
SO  - Autophagy. 2016;12(1):1-222. doi: 10.1080/15548627.2015.1100356.

PMID- 20301592
STAT- Publisher
DRDT- 20170803
CTDT- 20050908
PB  - University of Washington, Seattle
DP  - 1993
TI  - Cytochrome P450 Oxidoreductase Deficiency.
BTI - GeneReviews(®)
AB  - CLINICAL CHARACTERISTICS: Cytochrome P450 oxidoreductase deficiency (PORD) is a 
      disorder of steroidogenesis with a broad phenotypic spectrum including cortisol 
      deficiency, altered sex steroid synthesis, disorders of sex development (DSD), 
      and skeletal malformations of the Antley-Bixler syndrome (ABS) phenotype. 
      Cortisol deficiency is usually partial, with some baseline cortisol production 
      but failure to mount an adequate cortisol response in stress. Mild 
      mineralocorticoid excess can be present and causes arterial hypertension, usually 
      presenting in young adulthood. Manifestations of altered sex steroid synthesis 
      include ambiguous genitalia/DSD in both males and females, large ovarian cysts in 
      females, poor masculinization and delayed puberty in males, and maternal 
      virilization during pregnancy with an affected fetus. Skeletal malformations can 
      manifest as craniosynostosis, mid-face retrusion with proptosis and choanal 
      stenosis or atresia, low-set dysplastic ears with stenotic external auditory 
      canals, hydrocephalus, radiohumeral synostosis, neonatal fractures, congenital 
      bowing of the long bones, joint contractures, arachnodactyly, and clubfeet; other 
      anomalies observed include urinary tract anomalies (renal pelvic dilatation, 
      vesicoureteral reflux). Cognitive impairment is of minor concern and likely 
      associated with the severity of malformations; studies of developmental outcomes 
      are lacking. DIAGNOSIS/TESTING: The diagnosis of PORD can be established by 
      urinary steroid profiling using gas chromatography / mass spectrometry (GC/MS), 
      which documents combined impairment of 17α-hydroxylase (CYP17A1) and 
      21-hydroxylase (CYP21A2) enzymatic activity located at key branch points of 
      cortisol, aldosterone, and sex steroid synthesis. Identification of biallelic POR 
      pathogenic variants on molecular genetic testing confirms the diagnosis. 
      Molecular genetic testing is desirable for all individuals affected by PORD to 
      confirm the diagnosis, but is mandatory if clinical and laboratory features are 
      inconclusive. MANAGEMENT: Treatment of manifestations: Glucocorticoid replacement 
      therapy for cortisol deficiency including stress-dose cover in intercurrent 
      illness; surgery as needed for craniosynostosis, hypospadias, and cryptorchidism 
      in males and clitoromegaly and vaginal hypoplasia in females; dihydrotestosterone 
      treatment has been successful in some males with micropenis; testosterone 
      replacement in males in whom testosterone levels remain relatively low after 
      onset of puberty; females with absent pubertal development may require estrogen 
      replacement therapy; treatment with estradiol to reduce the size of ovarian 
      cysts; endotracheal intubation, nasal stints or tracheotomy, and tracheostomy as 
      needed; physical and occupational therapy for joint contractures and help with 
      fine and gross motor skills. Prevention of secondary complications: 
      Supplementation with appropriate steroid hormones in individuals who are 
      deficient has helped alleviate adrenal crisis, lack of or poor pubertal 
      development in males and females, sleepiness, and fatigue. Early intervention 
      services may improve the outcome for individuals at risk for developmental delays 
      and learning difficulties. Surveillance: Evaluations with a specialist tertiary 
      pediatric endocrine service throughout childhood to closely monitor development 
      and adjust steroid supplementation. Periodic formal developmental assessments in 
      centers with expertise and experience in developmental testing. Evaluation of 
      relatives at risk: It is appropriate to evaluate apparently asymptomatic older 
      and younger sibs of a proband in order to identify as early as possible those who 
      would benefit from initiation of treatment and preventive measures. GENETIC 
      COUNSELING: PORD is inherited in an autosomal recessive manner. At conception, 
      each sib of an affected individual has a 25% chance of being affected, a 50% 
      chance of being an asymptomatic carrier, and a 25% chance of being unaffected and 
      not a carrier. Carrier testing for at-risk family members and prenatal genetic 
      testing for pregnancies at increased risk are possible if the POR pathogenic 
      variants have been identified in the family. In addition, noninvasive testing of 
      maternal urine steroid excretion by GC/MS can indicate whether the unborn child 
      is affected by PORD from gestational week 12 onwards.
CI  - Copyright © 1993-2025, University of Washington, Seattle. GeneReviews is a 
      registered trademark of the University of Washington, Seattle. All rights 
      reserved.
FED - Adam, Margaret P
ED  - Adam MP
FED - Feldman, Jerry
ED  - Feldman J
FED - Mirzaa, Ghayda M
ED  - Mirzaa GM
FED - Pagon, Roberta A
ED  - Pagon RA
FED - Wallace, Stephanie E
ED  - Wallace SE
FED - Amemiya, Anne
ED  - Amemiya A
FAU - Idkowiak, Jan
AU  - Idkowiak J
AD  - Institute of Metabolism and Systems Research, University of Birmingham, 
      Birmingham, United Kingdom
FAU - Cragun, Deborah
AU  - Cragun D
AD  - University of Tampa, Tampa, Florida
FAU - Hopkin, Robert J
AU  - Hopkin RJ
AD  - Clinical Geneticist, Children's Hospital Medical Center and University of 
      Cincinnati College of Medicine, Cincinnati, Ohio
FAU - Arlt, Wiebke
AU  - Arlt W
AD  - Institute of Metabolism and Systems Research, University of Birmingham, 
      Birmingham, United Kingdom
LA  - eng
PT  - Review
PT  - Book Chapter
PL  - Seattle (WA)
OTO - NLM
OT  - POR Deficiency
OT  - PORD
OT  - POR Deficiency
OT  - PORD
OT  - Antley-Bixler Syndrome
OT  - Congenital Adrenal Hyperplasia due to Apparent Combined CYP17A1 and CYP21A2 
      Enzymatic Deficiency
OT  - NADPH--cytochrome P450 reductase
OT  - POR
OT  - Cytochrome P450 Oxidoreductase Deficiency
EDAT- 2017/08/03 00:00
CRDT- 2017/08/03 00:00
AID - NBK1419 [bookaccession]

PMID- 26370920
OWN - NLM
STAT- MEDLINE
DCOM- 20160926
LR  - 20221207
IS  - 1873-1708 (Electronic)
IS  - 0890-6238 (Linking)
VI  - 58
DP  - 2015 Dec
TI  - Ozone treatment prevents the toxicity of an environmental mixture of estrogens on 
      rat fetal testicular development.
PG  - 85-92
LID - S0890-6238(15)30019-8 [pii]
LID - 10.1016/j.reprotox.2015.09.001 [doi]
AB  - Effluents from wastewater treatment plants contain a mixture of estrogens (MIX: 
      17β-estradiol: E2, estrone: E1, estriol: E3 and 17α-ethinylestradiol EE2). High 
      doses of estrogens have been shown to negatively impact fetal testicular 
      development, but the impact of low doses of estrogens in mixture have yet to be 
      elucidated. Using an organ culture system in which embryonic 15.5 day-old rat 
      testes were grown ex vivo, we showed that exposure to the MIX at environmentally 
      relevant concentrations reduces testis growth. No effect was observed on 
      testosterone secretion, but we quantified a significant decrease in the number of 
      Sertoli cells and gonocytes because of higher rates of apoptosis. As ozone (O3) 
      can be used as a disinfectant during wastewater treatment, we confirmed by 
      HPLC-MS analysis that it removes the four parent compounds. Interestingly, the 
      negative effects of the MIX were not observed when testes were exposed to the MIX 
      treated with O3.
CI  - Copyright © 2015 Elsevier Inc. All rights reserved.
FAU - Lassonde, Guylaine
AU  - Lassonde G
AD  - INRS-Institut Armand Frappier, Laval, Quebec, Canada.
FAU - Nasuhoglu, Deniz
AU  - Nasuhoglu D
AD  - Department of Chemical Engineering, McGill University, Montreal, Quebec, Canada.
FAU - Pan, Jun Feng
AU  - Pan JF
AD  - INRS-Institut Armand Frappier, Laval, Quebec, Canada.
FAU - Gaye, Bintou
AU  - Gaye B
AD  - INRS-Institut Armand Frappier, Laval, Quebec, Canada.
FAU - Yargeau, Viviane
AU  - Yargeau V
AD  - Department of Chemical Engineering, McGill University, Montreal, Quebec, Canada.
FAU - Delbes, Geraldine
AU  - Delbes G
AD  - INRS-Institut Armand Frappier, Laval, Quebec, Canada. Electronic address: 
      geraldine.delbes@iaf.inrs.ca.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150911
PL  - United States
TA  - Reprod Toxicol
JT  - Reproductive toxicology (Elmsford, N.Y.)
JID - 8803591
RN  - 0 (Disinfectants)
RN  - 0 (Estrogens)
RN  - 0 (Waste Water)
RN  - 0 (Water Pollutants, Chemical)
RN  - 66H7ZZK23N (Ozone)
SB  - IM
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Chromatography, High Pressure Liquid
MH  - Disinfectants/*chemistry
MH  - Estrogens/chemistry/*toxicity
MH  - Female
MH  - Leydig Cells/drug effects/pathology
MH  - Male
MH  - Mass Spectrometry
MH  - Organ Culture Techniques
MH  - Organogenesis/*drug effects
MH  - Ozone/*chemistry
MH  - Pregnancy
MH  - Rats, Sprague-Dawley
MH  - Sertoli Cells/drug effects/pathology
MH  - Testis/*drug effects/embryology
MH  - *Wastewater
MH  - Water Pollutants, Chemical/chemistry/*toxicity
MH  - Water Purification/*methods
OTO - NOTNLM
OT  - Estrogen
OT  - Fetal testis
OT  - Low doses
OT  - Mixtures
OT  - Organ culture
OT  - Ozone
OT  - Water treatment
EDAT- 2015/09/16 06:00
MHDA- 2016/09/27 06:00
CRDT- 2015/09/16 06:00
PHST- 2015/07/13 00:00 [received]
PHST- 2015/08/24 00:00 [revised]
PHST- 2015/09/09 00:00 [accepted]
PHST- 2015/09/16 06:00 [entrez]
PHST- 2015/09/16 06:00 [pubmed]
PHST- 2016/09/27 06:00 [medline]
AID - S0890-6238(15)30019-8 [pii]
AID - 10.1016/j.reprotox.2015.09.001 [doi]
PST - ppublish
SO  - Reprod Toxicol. 2015 Dec;58:85-92. doi: 10.1016/j.reprotox.2015.09.001. Epub 2015 
      Sep 11.

PMID- 35767133
OWN - NLM
STAT- MEDLINE
DCOM- 20220712
LR  - 20230802
IS  - 1573-7225 (Electronic)
IS  - 0957-5243 (Print)
IS  - 0957-5243 (Linking)
VI  - 33
IP  - 8
DP  - 2022 Aug
TI  - Risk of clear-cell adenocarcinoma of the vagina and cervix among US women with 
      potential exposure to diethylstilbestrol in utero.
PG  - 1121-1124
LID - 10.1007/s10552-022-01598-3 [doi]
AB  - PURPOSE: Women exposed to diethylstilbestrol (DES) in utero were at elevated risk 
      of clear-cell adenocarcinoma of the vagina and cervix (CCA) as young women. 
      Previous research suggested that this elevated risk of CCA may persist into 
      adulthood. We extended a published analysis to measure CCA risk as these women 
      aged. METHODS: Standardized incidence ratios (SIR) compared CCA risk among women 
      born from 1947 through 1971 (the DES-era) to CCA risk among the comparison group 
      of women born prior to 1947, using registry data that covered the US population. 
      RESULTS: Incidence rates of CCA among both cohorts increased with age. Among the 
      DES-era birth cohort, higher rates of CCA were observed across all age groups 
      except 55-59 years. SIR estimates had wide confidence intervals that often 
      included the null value. CONCLUSIONS: Results are consistent with prior research 
      and suggest an elevated risk of CCA in midlife and at older ages among women 
      exposed in utero to DES. These results highlight unresolved issues regarding 
      cancer risk among aging DES daughters and appropriate screening guidance. The 
      examination of population-based cancer surveillance data may be a useful tool for 
      monitoring trends in the incidence of other rare cancers over time among specific 
      birth cohorts.
CI  - © 2022. This is a U.S. Government work and not under copyright protection in the 
      US; foreign copyright protection may apply.
FAU - White, Mary C
AU  - White MC
AUID- ORCID: 0000-0002-9826-3962
AD  - Division of Cancer Prevention and Control, Centers for Disease Control and 
      Prevention, Atlanta, GA, USA. mxw5@cdc.gov.
AD  - Epidemiology and Applied Research Branch, Division of Cancer Prevention and 
      Control, Centers for Disease Control and Prevention, 4770 Buford Highway NE, MS 
      S107-4, Chamblee, GA, 30341, USA. mxw5@cdc.gov.
FAU - Weir, Hannah K
AU  - Weir HK
AUID- ORCID: 0000-0001-6568-9708
AD  - Division of Cancer Prevention and Control, Centers for Disease Control and 
      Prevention, Atlanta, GA, USA.
FAU - Soman, Ashwini V
AU  - Soman AV
AD  - Cyberdata Technologies, Inc., Herndon, VA, USA.
FAU - Peipins, Lucy A
AU  - Peipins LA
AUID- ORCID: 0000-0003-2409-3638
AD  - Division of Cancer Prevention and Control, Centers for Disease Control and 
      Prevention, Atlanta, GA, USA.
FAU - Thompson, Trevor D
AU  - Thompson TD
AD  - Division of Cancer Prevention and Control, Centers for Disease Control and 
      Prevention, Atlanta, GA, USA.
LA  - eng
GR  - CC999999/ImCDC/Intramural CDC HHS/United States
GR  - HHSN31620120007W 200-2017-F-94805/CC/CDC HHS/United States
PT  - Journal Article
DEP - 20220629
PL  - Netherlands
TA  - Cancer Causes Control
JT  - Cancer causes & control : CCC
JID - 9100846
RN  - 731DCA35BT (Diethylstilbestrol)
SB  - IM
MH  - *Adenocarcinoma, Clear Cell/chemically induced/epidemiology
MH  - Adult
MH  - Cervix Uteri
MH  - Diethylstilbestrol/adverse effects
MH  - Female
MH  - Humans
MH  - *Prenatal Exposure Delayed Effects/chemically induced/epidemiology
MH  - *Uterine Cervical Neoplasms/chemically induced/epidemiology
MH  - Vagina
MH  - *Vaginal Neoplasms/chemically induced/diagnosis/epidemiology
PMC - PMC9377316
MID - NIHMS1820146
OTO - NOTNLM
OT  - Cancer registries
OT  - Cancer surveillance
OT  - DES
OT  - Diethylstilbestrol
OT  - Gynecologic cancer
OT  - Prenatal exposure
COIS- Conflict of interest The authors have no relevant financial or non-financial 
      interests to disclose.
EDAT- 2022/06/30 06:00
MHDA- 2022/07/14 06:00
PMCR- 2023/08/01
CRDT- 2022/06/29 11:18
PHST- 2021/12/30 00:00 [received]
PHST- 2022/06/13 00:00 [accepted]
PHST- 2022/06/30 06:00 [pubmed]
PHST- 2022/07/14 06:00 [medline]
PHST- 2022/06/29 11:18 [entrez]
PHST- 2023/08/01 00:00 [pmc-release]
AID - 10.1007/s10552-022-01598-3 [pii]
AID - 10.1007/s10552-022-01598-3 [doi]
PST - ppublish
SO  - Cancer Causes Control. 2022 Aug;33(8):1121-1124. doi: 10.1007/s10552-022-01598-3. 
      Epub 2022 Jun 29.

PMID- 39098088
OWN - NLM
STAT- MEDLINE
DCOM- 20240827
LR  - 20250103
IS  - 1873-6750 (Electronic)
IS  - 0160-4120 (Linking)
VI  - 190
DP  - 2024 Aug
TI  - Bisphenol mixtures, metal mixtures and type 2 diabetes mellitus: Insights from 
      metabolite profiling.
PG  - 108921
LID - S0160-4120(24)00507-5 [pii]
LID - 10.1016/j.envint.2024.108921 [doi]
AB  - BACKGROUND: Little is known about the combined effect of bisphenol mixtures and 
      metal mixtures on type 2 diabetes mellitus (T2DM) risk, and the mediating roles 
      of metabolites. METHODS: The study included 606 pairs of T2DM cases and controls 
      matched by age and sex, and information of participants was collected through 
      questionnaires and laboratory tests. Serum bisphenol and plasma metal 
      concentrations were measured using ultra-performance liquid chromatography-mass 
      spectrometry (UPLC-MS/MS) and inductively coupled plasma-mass spectrometry 
      (ICP-MS), respectively. Widely targeted metabolomics was employed to obtain the 
      serum metabolomic profiles. Conditional logistic regression models were used to 
      assess the single associations of bisphenols and metals with T2DM risk after 
      multivariable adjustment. Additionally, the joint effects of bisphenol mixtures 
      and metal mixtures were examined using quantile-based g-computation (QG-C) 
      models. Furthermore, differential metabolites associated with T2DM were 
      identified, and mediation analyses were performed to explore the role of 
      metabolites in the associations of bisphenols and metals with T2DM risk. RESULTS: 
      The results showed bisphenol mixtures were associated with an increased T2DM 
      risk, with bisphenol A (BPA) identified as the primary contributor. While the 
      association between metal mixtures and T2DM remained inconclusive, cobalt (Co), 
      iron (Fe), and zinc (Zn) showed the highest weight indices for T2DM risk. A total 
      of 154 differential metabolites were screened between the T2DM cases and 
      controls. Mediation analyses indicated that 9 metabolites mediated the 
      association between BPA and T2DM, while L-valine mediated the association between 
      Zn and T2DM risk. CONCLUSIONS: The study indicated that BPA, Co, Fe, and Zn were 
      the primary contributors to increased T2DM risk, and metabolites played a 
      mediating role in the associations of BPA and Zn with the risk of T2DM. Our 
      findings contribute to a better understanding of the mechanisms underlying the 
      associations of bisphenols and metals with T2DM.
CI  - Copyright © 2024. Published by Elsevier Ltd.
FAU - Yang, Ze
AU  - Yang Z
AD  - Department of Occupational and Environmental Health, School of Public Health, 
      Tianjin Medical University, Tianjin 300070, China; Tianjin Key Laboratory of 
      Environment, Nutrition, and Public Health, Tianjin Medical University, Tianjin 
      300070, China; Center for International Collaborative Research on Environment, 
      Nutrition and Public Health, Tianjin 300070, China; Key Laboratory of Prevention 
      and Control of Major Diseases in the Population, Ministry of Education, Tianjin 
      Medical University, Tianjin 300070, China; Department of Occupational Health and 
      Environmental Health, Hebei Medical University, Shijiazhuang 050017, China.
FAU - Liu, Hongbo
AU  - Liu H
AD  - Department of Occupational and Environmental Health, School of Public Health, 
      Tianjin Medical University, Tianjin 300070, China; Tianjin Key Laboratory of 
      Environment, Nutrition, and Public Health, Tianjin Medical University, Tianjin 
      300070, China; Center for International Collaborative Research on Environment, 
      Nutrition and Public Health, Tianjin 300070, China; Key Laboratory of Prevention 
      and Control of Major Diseases in the Population, Ministry of Education, Tianjin 
      Medical University, Tianjin 300070, China.
FAU - Wei, Jiemin
AU  - Wei J
AD  - Department of Occupational and Environmental Health, School of Public Health, 
      Tianjin Medical University, Tianjin 300070, China; Tianjin Key Laboratory of 
      Environment, Nutrition, and Public Health, Tianjin Medical University, Tianjin 
      300070, China; Center for International Collaborative Research on Environment, 
      Nutrition and Public Health, Tianjin 300070, China; Key Laboratory of Prevention 
      and Control of Major Diseases in the Population, Ministry of Education, Tianjin 
      Medical University, Tianjin 300070, China.
FAU - Liu, Ruifang
AU  - Liu R
AD  - Department of Occupational and Environmental Health, School of Public Health, 
      Tianjin Medical University, Tianjin 300070, China; Tianjin Key Laboratory of 
      Environment, Nutrition, and Public Health, Tianjin Medical University, Tianjin 
      300070, China; Center for International Collaborative Research on Environment, 
      Nutrition and Public Health, Tianjin 300070, China; Key Laboratory of Prevention 
      and Control of Major Diseases in the Population, Ministry of Education, Tianjin 
      Medical University, Tianjin 300070, China.
FAU - Zhang, Jingyun
AU  - Zhang J
AD  - NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of 
      Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of 
      Endocrinology, Tianjin Medical University, Tianjin 300134, China.
FAU - Sun, Meiqing
AU  - Sun M
AD  - Wuqing District Center for Disease Control and Prevention, Tianjin 301700, China.
FAU - Shen, Changkun
AU  - Shen C
AD  - Wuqing District Center for Disease Control and Prevention, Tianjin 301700, China.
FAU - Liu, Jian
AU  - Liu J
AD  - Wuqing District Center for Disease Control and Prevention, Tianjin 301700, China.
FAU - Men, Kun
AU  - Men K
AD  - Department of Laboratory, The Second Hospital of Tianjin Medical University, 
      Tianjin 300202, China.
FAU - Chen, Yu
AU  - Chen Y
AD  - Department of Endocrinology, The Second Hospital of Tianjin Medical University, 
      Tianjin 300202, China.
FAU - Yang, Xueli
AU  - Yang X
AD  - Department of Occupational and Environmental Health, School of Public Health, 
      Tianjin Medical University, Tianjin 300070, China; Tianjin Key Laboratory of 
      Environment, Nutrition, and Public Health, Tianjin Medical University, Tianjin 
      300070, China; Center for International Collaborative Research on Environment, 
      Nutrition and Public Health, Tianjin 300070, China; Key Laboratory of Prevention 
      and Control of Major Diseases in the Population, Ministry of Education, Tianjin 
      Medical University, Tianjin 300070, China.
FAU - Yu, Pei
AU  - Yu P
AD  - NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of 
      Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of 
      Endocrinology, Tianjin Medical University, Tianjin 300134, China.
FAU - Chen, Liming
AU  - Chen L
AD  - NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of 
      Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of 
      Endocrinology, Tianjin Medical University, Tianjin 300134, China.
FAU - Tang, Nai-Jun
AU  - Tang NJ
AD  - Department of Occupational and Environmental Health, School of Public Health, 
      Tianjin Medical University, Tianjin 300070, China; Tianjin Key Laboratory of 
      Environment, Nutrition, and Public Health, Tianjin Medical University, Tianjin 
      300070, China; Center for International Collaborative Research on Environment, 
      Nutrition and Public Health, Tianjin 300070, China; Key Laboratory of Prevention 
      and Control of Major Diseases in the Population, Ministry of Education, Tianjin 
      Medical University, Tianjin 300070, China. Electronic address: 
      tangnaijun@tmu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20240730
PL  - Netherlands
TA  - Environ Int
JT  - Environment international
JID - 7807270
RN  - 0 (Phenols)
RN  - 0 (Benzhydryl Compounds)
RN  - RW57K3X12M (bisphenol A)
RN  - 0 (Metals)
RN  - 0 (Environmental Pollutants)
SB  - IM
MH  - *Diabetes Mellitus, Type 2/chemically induced
MH  - *Phenols
MH  - Humans
MH  - *Benzhydryl Compounds/blood
MH  - Female
MH  - Male
MH  - Middle Aged
MH  - *Metals/blood
MH  - Case-Control Studies
MH  - Metabolomics
MH  - Adult
MH  - Environmental Exposure
MH  - Environmental Pollutants/blood
MH  - Aged
OTO - NOTNLM
OT  - Bisphenol
OT  - Mediation effect
OT  - Metabolomics
OT  - Metal
OT  - T2DM
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2024/08/05 00:42
MHDA- 2024/08/27 09:48
CRDT- 2024/08/04 21:57
PHST- 2024/04/16 00:00 [received]
PHST- 2024/06/22 00:00 [revised]
PHST- 2024/07/29 00:00 [accepted]
PHST- 2024/08/27 09:48 [medline]
PHST- 2024/08/05 00:42 [pubmed]
PHST- 2024/08/04 21:57 [entrez]
AID - S0160-4120(24)00507-5 [pii]
AID - 10.1016/j.envint.2024.108921 [doi]
PST - ppublish
SO  - Environ Int. 2024 Aug;190:108921. doi: 10.1016/j.envint.2024.108921. Epub 2024 
      Jul 30.

PMID- 32913138
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20211102
IS  - 1521-0111 (Electronic)
IS  - 0026-895X (Print)
IS  - 0026-895X (Linking)
VI  - 98
IP  - 5
DP  - 2020 Nov
TI  - Regulation of Kappa Opioid Receptor Inactivation Depends on Sex and Cellular Site 
      of Antagonist Action.
PG  - 548-558
LID - 10.1124/molpharm.120.000124 [doi]
AB  - The prototypical member of the receptor-inactivating kappa opioid receptor (KOR) 
      antagonists, norbinaltorphimine (norBNI), produces prolonged receptor 
      inactivation by a cJun kinase mechanism. These antagonists have potential 
      therapeutic utility in the treatment of stress disorders; however, additional 
      preclinical characterization is necessary to understand important aspects of 
      their action. In this study, we report that norBNI does not work as effectively 
      in female mice as in males because of estrogen regulation of G protein receptor 
      kinase (GRK); pretreatment of ovary-intact female mice with the selective GRK2/3 
      inhibitor, Compound 101, made females equally sensitive to norBNI as males. Prior 
      observations suggested that in vivo treatment with norBNI does not produce 
      long-lasting inhibition of KOR regulation of dopamine release in the nucleus 
      accumbens. We assessed the persistence of norBNI receptor inactivation in 
      subcellular compartments. Fast-scan cyclic voltammetry recordings confirmed that 
      presynaptic inhibition of dopamine release by the KOR agonist U69,593 was not 
      blocked by in vivo pretreatment with norBNI under conditions that prevented 
      KOR-mediated aversion and analgesia. We employed a novel in vivo proxy sensor of 
      KOR activation, adenovirus associated double floxed inverted-HyPerRed, and 
      demonstrated that KOR activation stimulates cJun kinase-dependent reactive oxygen 
      species (ROS) production in somatic regions of ventral tegmental area dopamine 
      neurons, but did not activate ROS production in dopamine terminals. The 
      compartment selective action helps explain how dopamine somatic, but not 
      terminally expressed, KORs are inactivated by norBNI. These results further 
      elucidate molecular signaling mechanisms mediating receptor-inactivating KOR 
      antagonist action and advance medication development for this novel class of 
      stress-resilience medications. SIGNIFICANCE STATEMENT: Kappa opioid receptor 
      (KOR) antagonists are being developed as novel proresilience therapeutics for the 
      treatment of mood and substance use disorders. This study showed that the 
      long-acting KOR antagonists are affected by both the sex of the animal and the 
      subcellular compartment in which the receptor is expressed.
CI  - Copyright © 2020 by The American Society for Pharmacology and Experimental 
      Therapeutics.
FAU - Reichard, Kathryn L
AU  - Reichard KL
AD  - Neurobiology of Addiction, Pain, and Emotion (K.L.R., K.A.N., Z.M.G.R., P.M.S. ., 
      S.S.S., B.B.L., C.C.), University of Washington Department of Pharmacology 
      (K.L.R., K.A.N., Z.M.G.R., P.M.S.M. S.S.S., B.B.L., C.C.), University of 
      Washington Graduate Program in Neuroscience (K.L.R., C.C.), Seattle, Washington.
FAU - Newton, Keionna A
AU  - Newton KA
AD  - Neurobiology of Addiction, Pain, and Emotion (K.L.R., K.A.N., Z.M.G.R., P.M.S. ., 
      S.S.S., B.B.L., C.C.), University of Washington Department of Pharmacology 
      (K.L.R., K.A.N., Z.M.G.R., P.M.S.M. S.S.S., B.B.L., C.C.), University of 
      Washington Graduate Program in Neuroscience (K.L.R., C.C.), Seattle, Washington.
FAU - Rivera, Zeena M G
AU  - Rivera ZMG
AD  - Neurobiology of Addiction, Pain, and Emotion (K.L.R., K.A.N., Z.M.G.R., P.M.S. ., 
      S.S.S., B.B.L., C.C.), University of Washington Department of Pharmacology 
      (K.L.R., K.A.N., Z.M.G.R., P.M.S.M. S.S.S., B.B.L., C.C.), University of 
      Washington Graduate Program in Neuroscience (K.L.R., C.C.), Seattle, Washington.
FAU - Sotero de Menezes, Paulo M
AU  - Sotero de Menezes PM
AD  - Neurobiology of Addiction, Pain, and Emotion (K.L.R., K.A.N., Z.M.G.R., P.M.S. ., 
      S.S.S., B.B.L., C.C.), University of Washington Department of Pharmacology 
      (K.L.R., K.A.N., Z.M.G.R., P.M.S.M. S.S.S., B.B.L., C.C.), University of 
      Washington Graduate Program in Neuroscience (K.L.R., C.C.), Seattle, Washington.
FAU - Schattauer, Selena S
AU  - Schattauer SS
AD  - Neurobiology of Addiction, Pain, and Emotion (K.L.R., K.A.N., Z.M.G.R., P.M.S. ., 
      S.S.S., B.B.L., C.C.), University of Washington Department of Pharmacology 
      (K.L.R., K.A.N., Z.M.G.R., P.M.S.M. S.S.S., B.B.L., C.C.), University of 
      Washington Graduate Program in Neuroscience (K.L.R., C.C.), Seattle, Washington.
FAU - Land, Benjamin B
AU  - Land BB
AD  - Neurobiology of Addiction, Pain, and Emotion (K.L.R., K.A.N., Z.M.G.R., P.M.S. ., 
      S.S.S., B.B.L., C.C.), University of Washington Department of Pharmacology 
      (K.L.R., K.A.N., Z.M.G.R., P.M.S.M. S.S.S., B.B.L., C.C.), University of 
      Washington Graduate Program in Neuroscience (K.L.R., C.C.), Seattle, Washington.
FAU - Chavkin, Charles
AU  - Chavkin C
AD  - Neurobiology of Addiction, Pain, and Emotion (K.L.R., K.A.N., Z.M.G.R., P.M.S. ., 
      S.S.S., B.B.L., C.C.), University of Washington Department of Pharmacology 
      (K.L.R., K.A.N., Z.M.G.R., P.M.S.M. S.S.S., B.B.L., C.C.), University of 
      Washington Graduate Program in Neuroscience (K.L.R., C.C.), Seattle, Washington 
      cchavkin@uw.edu.
LA  - eng
GR  - P30 DA048736/DA/NIDA NIH HHS/United States
GR  - R01 DA030074/DA/NIDA NIH HHS/United States
GR  - T32 DA007278/DA/NIDA NIH HHS/United States
GR  - T32 NS099578/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200910
PL  - United States
TA  - Mol Pharmacol
JT  - Molecular pharmacology
JID - 0035623
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Narcotic Antagonists)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (Receptors, Opioid, kappa)
RN  - 36OOQ86QM1 (norbinaltorphimine)
RN  - 5S6W795CQM (Naltrexone)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Analgesics, Opioid/pharmacology
MH  - Animals
MH  - Dopamine/metabolism
MH  - Dopaminergic Neurons/drug effects/metabolism
MH  - Female
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Naltrexone/analogs & derivatives/pharmacology
MH  - Narcotic Antagonists/*pharmacology
MH  - Phosphorylation/drug effects
MH  - Reactive Oxygen Species/metabolism
MH  - Receptors, Opioid, kappa/*metabolism
MH  - Signal Transduction/drug effects
PMC - PMC7569314
EDAT- 2020/09/12 06:00
MHDA- 2020/11/11 06:00
PMCR- 2021/11/01
CRDT- 2020/09/11 05:39
PHST- 2020/07/21 00:00 [received]
PHST- 2020/08/27 00:00 [accepted]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2020/09/11 05:39 [entrez]
PHST- 2021/11/01 00:00 [pmc-release]
AID - molpharm.120.000124 [pii]
AID - MOL_AR2020000124 [pii]
AID - 10.1124/molpharm.120.000124 [doi]
PST - ppublish
SO  - Mol Pharmacol. 2020 Nov;98(5):548-558. doi: 10.1124/molpharm.120.000124. Epub 
      2020 Sep 10.

PMID- 28285016
OWN - NLM
STAT- MEDLINE
DCOM- 20171208
LR  - 20240326
IS  - 1879-1220 (Electronic)
IS  - 0960-0760 (Print)
IS  - 0960-0760 (Linking)
VI  - 176
DP  - 2018 Feb
TI  - GPER modulators: Opportunity Nox on the heels of a class Akt.
PG  - 73-81
LID - S0960-0760(17)30070-5 [pii]
LID - 10.1016/j.jsbmb.2017.03.005 [doi]
AB  - The (patho)physiology of estrogen and its receptors is complex. It is therefore 
      not surprising that therapeutic approaches targeting this hormone include 
      stimulation of its activity through supplementation with either the hormone 
      itself or natural or synthetic agonists, inhibition of its activity through the 
      use of antagonists or inhibitors of its synthesis, and tissue-selective 
      modulation of its activity with biased ligands. The physiology of this hormone is 
      further complicated by the existence of at least three receptors, the classical 
      nuclear estrogen receptors α and β (ERα and ERβ), and the 7-transmembrane G 
      protein-coupled estrogen receptor (GPER/GPR30), with overlapping but distinct 
      pharmacologic profiles, particularly of anti-estrogenic ligands. GPER-selective 
      ligands, as well as GPER knockout mice, have greatly aided our understanding of 
      the physiological roles of GPER. Such ligands have revealed that GPER activation 
      mediates many of the rapid cellular signaling events (including Ca(2+) 
      mobilization, ERK and PI3K/Akt activation) associated with estrogen activity, as 
      opposed to the nuclear ERs that are traditionally described to function as 
      ligand-induced transcriptional factors. Many of the salutary effects of estrogen 
      throughout the body are reproduced by the GPER-selective agonist G-1, which, 
      owing to its minimal effects on reproductive tissues, can be considered a 
      non-feminizing estrogenic compound, and thus of potential therapeutic use in both 
      women and men. On the contrary, until recently GPER-selective antagonists had 
      predominantly found preclinical application in cancer models where estrogen 
      stimulates cell growth and survival. This viewpoint changed recently with the 
      discovery that GPER is associated with aging, particularly that of the 
      cardiovascular system, where the GPER antagonist G36 reduced hypertension and 
      GPER deficiency prevented cardiac fibrosis and vascular dysfunction with age, 
      through the downregulation of Nox1 and as a consequence superoxide production. 
      Thus, similar to the classical ERs, both agonists and antagonists of GPER may be 
      of therapeutic benefit depending on the disease or condition to be treated.
CI  - Copyright © 2017 Elsevier Ltd. All rights reserved.
FAU - Prossnitz, Eric R
AU  - Prossnitz ER
AD  - Division of Molecular Medicine, Department of Internal Medicine, University of 
      New Mexico Comprehensive Cancer Center, University of New Mexico Health Sciences 
      Center, Albuquerque, NM 87131, United States. Electronic address: 
      eprossnitz@salud.unm.edu.
LA  - eng
GR  - P30 CA118100/CA/NCI NIH HHS/United States
GR  - R01 CA127731/CA/NCI NIH HHS/United States
GR  - R01 CA163890/CA/NCI NIH HHS/United States
GR  - R01 CA194496/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20170308
PL  - England
TA  - J Steroid Biochem Mol Biol
JT  - The Journal of steroid biochemistry and molecular biology
JID - 9015483
RN  - 0 (Estrogens)
RN  - 0 (Receptors, G-Protein-Coupled)
RN  - EC 1.6.3.- (NADPH Oxidases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
SB  - IM
MH  - Animals
MH  - Estrogens/*pharmacology
MH  - Gene Expression Regulation/*drug effects
MH  - Humans
MH  - NADPH Oxidases/*metabolism
MH  - Proto-Oncogene Proteins c-akt/*metabolism
MH  - Receptors, G-Protein-Coupled/*metabolism
PMC - PMC5591048
MID - NIHMS863466
OTO - NOTNLM
OT  - Cancer
OT  - Diabetes
OT  - Estrogen
OT  - GPER
OT  - Inflammation
OT  - Multiple sclerosis
OT  - Obesity
OT  - Vascular
COIS- Competing interests: E.R.P. is an inventor on a U.S. patent application for the 
      therapeutic use of compounds targeting GPER and on U.S. patent Nos. 7,875,721 and 
      8,487,100 for GPER-selective ligands and imaging agents.
EDAT- 2017/03/13 06:00
MHDA- 2017/12/09 06:00
PMCR- 2019/02/01
CRDT- 2017/03/13 06:00
PHST- 2017/02/21 00:00 [received]
PHST- 2017/03/03 00:00 [revised]
PHST- 2017/03/06 00:00 [accepted]
PHST- 2017/03/13 06:00 [pubmed]
PHST- 2017/12/09 06:00 [medline]
PHST- 2017/03/13 06:00 [entrez]
PHST- 2019/02/01 00:00 [pmc-release]
AID - S0960-0760(17)30070-5 [pii]
AID - 10.1016/j.jsbmb.2017.03.005 [doi]
PST - ppublish
SO  - J Steroid Biochem Mol Biol. 2018 Feb;176:73-81. doi: 10.1016/j.jsbmb.2017.03.005. 
      Epub 2017 Mar 8.

PMID- 38430617
OWN - NLM
STAT- MEDLINE
DCOM- 20240505
LR  - 20240505
IS  - 1873-4111 (Electronic)
IS  - 0378-5122 (Linking)
VI  - 184
DP  - 2024 Jun
TI  - Menopause hormone therapy and physical performance: The Canadian Longitudinal 
      Study on Aging.
PG  - 107959
LID - S0378-5122(24)00054-9 [pii]
LID - 10.1016/j.maturitas.2024.107959 [doi]
AB  - OBJECTIVE: To examine the association between menopause hormone therapy (MHT) and 
      physical performance among women from the Canadian Longitudinal Study on Aging. 
      STUDY DESIGN: Cross-sectional study of 12,506 postmenopausal Canadian women. MAIN 
      OUTCOME MEASURES: Grip strength (kg), gait speed (m/s), timed up and go (s), 
      chair rise (s), and balance (s) were assessed following standard procedures. The 
      association between MHT and physical performance was evaluated using linear 
      regression models adjusted for age, education, study site, smoking, alcohol 
      consumption, body mass index, diabetes, hypertension, and hysterectomy. 
      Sensitivity analyses were conducted according to age at study visit (<65 vs. 
      ≥65 years), body mass index (<25 kg/m(2) vs. ≥25 kg/m(2)), physical activity 
      level (less vs. more active), duration and type of MHT, and time of starting MHT 
      after menopause. RESULTS: Compared with those who never used MHT, prior or 
      current use was associated with better performance on the timed up and go test 
      (β: -0.19; 95%CI: -0.28; -0.11) and faster gait speed (β = 0.01, 95%CI = 0.00; 
      0.02). No association was found for grip strength, balance, and chair rise. 
      Results did not change by body mass index, physical activity, or duration of MHT 
      use. When stratified by age at study visit, the effect remained significant only 
      in among those aged 65 years or more. Starting MHT <5 years after menopause was 
      associated with better physical performance. CONCLUSIONS: MHT was associated with 
      better physical performance in gait speed and timed up and go tests. The 
      cross-sectional design of the study limits causal interpretation. Prospective 
      studies are needed to confirm our results.
CI  - Copyright © 2024 Elsevier B.V. All rights reserved.
FAU - Macêdo, Pedro R S
AU  - Macêdo PRS
AD  - Postgraduate Program in Physiotherapy, Federal University of Rio Grande do Norte, 
      Campus Universitário - Avenida Senador Salgado Filho, 3000, Lagoa Nova, CEP 
      59078-970 Natal, RN, Brazil. Electronic address: p.rafael2012@hotmail.com.
FAU - Macêdo, Sabrina G G F
AU  - Macêdo SGGF
AD  - Postgraduate Program in Physiotherapy, Federal University of Rio Grande do Norte, 
      Campus Universitário - Avenida Senador Salgado Filho, 3000, Lagoa Nova, CEP 
      59078-970 Natal, RN, Brazil. Electronic address: sabrinaggf@hotmail.com.
FAU - Velez, Maria P
AU  - Velez MP
AD  - Department of Obstetrics and Gynaecology, Queen's University, Victory 4, Kingston 
      General Hospital, Kingston, Ontario K7L 2V7, Canada. Electronic address: 
      maria.velez@queensu.ca.
FAU - Câmara, Saionara M A
AU  - Câmara SMA
AD  - Postgraduate Program in Physiotherapy, Federal University of Rio Grande do Norte, 
      Campus Universitário - Avenida Senador Salgado Filho, 3000, Lagoa Nova, CEP 
      59078-970 Natal, RN, Brazil; Department of Obstetrics and Gynaecology, Queen's 
      University, Victory 4, Kingston General Hospital, Kingston, Ontario K7L 2V7, 
      Canada. Electronic address: saionara.aires@ufrn.br.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20240301
PL  - Ireland
TA  - Maturitas
JT  - Maturitas
JID - 7807333
SB  - IM
MH  - Humans
MH  - Female
MH  - Cross-Sectional Studies
MH  - Middle Aged
MH  - Longitudinal Studies
MH  - Canada
MH  - Aged
MH  - *Hand Strength
MH  - *Physical Functional Performance
MH  - *Walking Speed
MH  - Aging/physiology
MH  - Menopause
MH  - Estrogen Replacement Therapy
MH  - Postural Balance
MH  - Body Mass Index
MH  - Exercise
MH  - Postmenopause/physiology
OTO - NOTNLM
OT  - CLSA
OT  - Menopause hormone therapy
OT  - Physical functional performance
OT  - Postmenopausal women
COIS- Declaration of competing interest MPV declares financial support of the Pfizer 
      Canada ULC for the present manuscript as payment made to Queen's University. 
      PRSM, SGGFM and SMAC declare that they have no competing interests.
EDAT- 2024/03/03 17:42
MHDA- 2024/05/06 00:52
CRDT- 2024/03/02 18:02
PHST- 2023/08/21 00:00 [received]
PHST- 2024/02/15 00:00 [revised]
PHST- 2024/02/21 00:00 [accepted]
PHST- 2024/05/06 00:52 [medline]
PHST- 2024/03/03 17:42 [pubmed]
PHST- 2024/03/02 18:02 [entrez]
AID - S0378-5122(24)00054-9 [pii]
AID - 10.1016/j.maturitas.2024.107959 [doi]
PST - ppublish
SO  - Maturitas. 2024 Jun;184:107959. doi: 10.1016/j.maturitas.2024.107959. Epub 2024 
      Mar 1.

PMID- 39423480
OWN - NLM
STAT- MEDLINE
DCOM- 20241130
LR  - 20241130
IS  - 1618-095X (Electronic)
IS  - 0944-7113 (Linking)
VI  - 135
DP  - 2024 Dec
TI  - Formononetin alleviates ulcerative colitis via reshaping the balance of M1/M2 
      macrophage polarization in a gut microbiota-dependent manner.
PG  - 156153
LID - S0944-7113(24)00810-9 [pii]
LID - 10.1016/j.phymed.2024.156153 [doi]
AB  - BACKGROUND: Ulcerative colitis (UC), a type of inflammatory bowel disease, 
      presents substantial challenges in clinical treatment due to the limitations of 
      current medications. Formononetin (FN), a naturally compound with widespread 
      availability, exhibits anti-inflammatory, antioxidant, and immunomodulatory 
      properties. PURPOSE: This study aimed to investigate the efficacy of FN against 
      UC and its potential regulatory mechanism. METHODS: Here, dextran sulfate sodium 
      (DSS) was employed to replicate experimental colitis in mice with concomitant FN 
      treatment. The distribution and localisation of CD68 and F4/80 macrophages in 
      colonic tissues were visualized by immunofluorescence, their chemokine and 
      inflammatory cytokine concentrations were determined by ELISA, and macrophages 
      and M1/M2 subpopulations were determined by flow cytometry. Additionally, 16 s 
      rRNA and LC-MS techniques were used to detect the colonic intestinal microbiota 
      and metabolite profiles, respectively. Correlation analyses was performed to 
      clarify the interactions between differential bacteria, metabolites and M1/M2 
      macrophages, and pseudo sterile mice were constructed by depletion of gut flora 
      with quadruple antibiotics, followed by faecal microbial transplantation to 
      evaluate its effects on colitis and M1/M2 macrophage polarisation. RESULTS: FN 
      dose-dependently alleviated clinical symptoms and inflammatory injury in colonic 
      tissues of colitis mice, with its high-dose efficacy comparable to that of 5-ASA. 
      Concurrently, FN not only inhibited inflammatory infiltration of macrophages and 
      their M1/M2 polarisation balance in colitis mice, but also improved the 
      composition of colonic microbiota and metabolite profiles. However, FN lost its 
      protective effects against DSS-induced colitis and failed to restore the 
      equilibrium of M1/M2 macrophage differentiation following intestinal flora 
      depletion through quadruple antibiotic treatment. Importantly, fecal microbiota 
      transplantation from FN-treated mice restored FN's protective effects against 
      DSS-induced colitis and reestablished its regulatory role in M1/M2 macrophage 
      polarization. CONCLUSION: Collectively, FN ameliorated UC through modulating the 
      balance of M1/M2 macrophage polarization in a gut microbiota-dependent manner.
CI  - Copyright © 2024 Elsevier GmbH. All rights reserved.
FAU - Xiao, Qiuping
AU  - Xiao Q
AD  - College of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang 330004, 
      Jiangxi Province, China; Key Laboratory of Effective Material Basis of TCM, 
      Jiangxi Province, Jiangxi University of Chinese Medicine, Nanchang, China.
FAU - Luo, Lin
AU  - Luo L
AD  - College of Acupuncture and Tuina, Jiangxi University of Chinese Medicine, 
      Nanchang 330004, Jiangxi Province, China.
FAU - Zhu, Xiyan
AU  - Zhu X
AD  - College of Traditional Chinese Medicine, Jiangxi University of Chinese Medicine, 
      Nanchang 330004, Jiangxi Province, China.
FAU - Yan, Yuhao
AU  - Yan Y
AD  - College of Acupuncture and Tuina, Jiangxi University of Chinese Medicine, 
      Nanchang 330004, Jiangxi Province, China.
FAU - Li, Shanshan
AU  - Li S
AD  - Laboratory Animal Science and Technology Center, Jiangxi University of Chinese 
      Medicine, Nanchang 330004, Jiangxi Province, China.
FAU - Chen, Liling
AU  - Chen L
AD  - Laboratory Animal Science and Technology Center, Jiangxi University of Chinese 
      Medicine, Nanchang 330004, Jiangxi Province, China.
FAU - Wang, Xiaomin
AU  - Wang X
AD  - College of Traditional Chinese Medicine, Jiangxi University of Chinese Medicine, 
      Nanchang 330004, Jiangxi Province, China.
FAU - Zhang, Jie
AU  - Zhang J
AD  - Laboratory Animal Science and Technology Center, Jiangxi University of Chinese 
      Medicine, Nanchang 330004, Jiangxi Province, China.
FAU - Liu, Duanyong
AU  - Liu D
AD  - Jiangxi Provincial Engineering Research Center of Development and Evaluation of 
      TCM classic prescriptions, Jiangxi University of Chinese Medicine, Nanchang 
      330004, Jiangxi Province, China; College of Nursing, Jiangxi University of 
      Chinese Medicine, Nanchang 330004, Jiangxi Province, China; Key Laboratory of 
      Prevention and Treatment of Immunological and Metabolic Diseases Related to 
      Prescription and Syndrome, Jiangxi University of Chinese Medicine, Nanchang 
      330004, Jiangxi Province, China.
FAU - Liu, Ronghua
AU  - Liu R
AD  - College of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang 330004, 
      Jiangxi Province, China; Key Laboratory of Effective Material Basis of TCM, 
      Jiangxi Province, Jiangxi University of Chinese Medicine, Nanchang, China.
FAU - Zhong, Youbao
AU  - Zhong Y
AD  - College of Acupuncture and Tuina, Jiangxi University of Chinese Medicine, 
      Nanchang 330004, Jiangxi Province, China; College of Traditional Chinese 
      Medicine, Jiangxi University of Chinese Medicine, Nanchang 330004, Jiangxi 
      Province, China; Laboratory Animal Science and Technology Center, Jiangxi 
      University of Chinese Medicine, Nanchang 330004, Jiangxi Province, China; Key 
      Laboratory of Prevention and Treatment of Immunological and Metabolic Diseases 
      Related to Prescription and Syndrome, Jiangxi University of Chinese Medicine, 
      Nanchang 330004, Jiangxi Province, China. Electronic address: 
      20171006@jxutcm.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20241012
PL  - Germany
TA  - Phytomedicine
JT  - Phytomedicine : international journal of phytotherapy and phytopharmacology
JID - 9438794
RN  - 295DQC67BJ (formononetin)
RN  - 0 (Isoflavones)
RN  - 9042-14-2 (Dextran Sulfate)
RN  - 0 (Cytokines)
RN  - 0 (Anti-Inflammatory Agents)
SB  - IM
MH  - Animals
MH  - *Colitis, Ulcerative/drug therapy/chemically induced
MH  - *Gastrointestinal Microbiome/drug effects
MH  - *Macrophages/drug effects
MH  - *Isoflavones/pharmacology
MH  - Mice
MH  - *Dextran Sulfate
MH  - Male
MH  - *Colon/drug effects/microbiology
MH  - Mice, Inbred C57BL
MH  - Disease Models, Animal
MH  - Cytokines/metabolism
MH  - Anti-Inflammatory Agents/pharmacology
MH  - Fecal Microbiota Transplantation
OTO - NOTNLM
OT  - Formononetin
OT  - Gut microbiota
OT  - Inflammatory cytokines
OT  - M1/M2 macrophage
OT  - Ulcerative colitis
COIS- Declaration of competing interest The authors declare no competing financial 
      interests or personal relationships that could have potentially influenced the 
      work presented in this paper.
EDAT- 2024/10/19 16:23
MHDA- 2024/11/30 12:42
CRDT- 2024/10/18 18:01
PHST- 2024/08/04 00:00 [received]
PHST- 2024/09/18 00:00 [revised]
PHST- 2024/10/11 00:00 [accepted]
PHST- 2024/11/30 12:42 [medline]
PHST- 2024/10/19 16:23 [pubmed]
PHST- 2024/10/18 18:01 [entrez]
AID - S0944-7113(24)00810-9 [pii]
AID - 10.1016/j.phymed.2024.156153 [doi]
PST - ppublish
SO  - Phytomedicine. 2024 Dec;135:156153. doi: 10.1016/j.phymed.2024.156153. Epub 2024 
      Oct 12.

PMID- 26614639
OWN - NLM
STAT- MEDLINE
DCOM- 20161013
LR  - 20161230
IS  - 1521-6551 (Electronic)
IS  - 1521-6543 (Linking)
VI  - 68
IP  - 1
DP  - 2016 Jan
TI  - Nuclear selenoproteins and genome maintenance.
PG  - 5-12
LID - 10.1002/iub.1455 [doi]
AB  - Selenium is an essential metalloid required for the expression of selenoproteins. 
      While cells are constantly challenged by clastogens of endogenous and exogenous 
      origins, genome integrity is maintained by direct repair of DNA damage, redox 
      balance, and epigenetic regulation. To date, only five selenoproteins are 
      experimentally demonstrated to reside in nucleus, exclusively or partially, 
      including selenoprotein H, methionine-R-sulfoxide reductase 1, glutathione 
      peroxidase-4, thioredoxin reductase-1, and thioredoxin glutathione reductase. All 
      these five selenoproteins have demonstrated or potential roles in redox 
      regulation and genome maintenance. Selenoprotein H is known to transactivate the 
      expression of a couple of genes against oxidative stress. The thioredoxin 
      reductase-1b isoform delivers estrogen receptor-α and -β to the nucleus. Nuclear 
      glutathione peroxidase-4 epigenetically and globally inhibits gene expression 
      through the maintenance of chromatin compactness in testes. Continued studies on 
      how these and additional nuclear selenoproteins regulate genome stability will 
      have profound impact on advancing our understanding in selenium regulation of 
      optimal health. © 2015 IUBMB Life, 68(1):5-12, 2016.
CI  - © 2015 International Union of Biochemistry and Molecular Biology.
FAU - Zhang, Xiong
AU  - Zhang X
AD  - Department of Geriatrics & Neurology, The Second Affiliated Hospital, Wenzhou 
      Medical University, Wenzhou, Zhejiang, China.
FAU - Zhang, Li
AU  - Zhang L
AD  - Department of Food Science, Nutrition and Health Promotion, Mississippi State 
      University, Mississippi State, MS, USA.
FAU - Zhu, Jian-Hong
AU  - Zhu JH
AD  - Department of Preventive Medicine, Wenzhou Medical University, Wenzhou, Zhejiang, 
      China.
FAU - Cheng, Wen-Hsing
AU  - Cheng WH
AD  - Department of Food Science, Nutrition and Health Promotion, Mississippi State 
      University, Mississippi State, MS, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
DEP - 20151128
PL  - England
TA  - IUBMB Life
JT  - IUBMB life
JID - 100888706
RN  - 0 (Nuclear Localization Signals)
RN  - 0 (Selenoproteins)
SB  - IM
MH  - Amino Acid Sequence
MH  - Animals
MH  - Cell Nucleus/*enzymology
MH  - *Epigenesis, Genetic
MH  - Gene Expression
MH  - Genomic Instability
MH  - Humans
MH  - Molecular Sequence Data
MH  - Nuclear Localization Signals
MH  - Oxidation-Reduction
MH  - Oxidative Stress
MH  - Selenoproteins/chemistry/*physiology
OTO - NOTNLM
OT  - DNA damage
OT  - genome maintenance
OT  - selenium
OT  - selenoproteins
EDAT- 2015/11/29 06:00
MHDA- 2016/10/14 06:00
CRDT- 2015/11/29 06:00
PHST- 2015/09/08 00:00 [received]
PHST- 2015/10/26 00:00 [accepted]
PHST- 2015/11/29 06:00 [entrez]
PHST- 2015/11/29 06:00 [pubmed]
PHST- 2016/10/14 06:00 [medline]
AID - 10.1002/iub.1455 [doi]
PST - ppublish
SO  - IUBMB Life. 2016 Jan;68(1):5-12. doi: 10.1002/iub.1455. Epub 2015 Nov 28.

PMID- 37527476
OWN - NLM
STAT- MEDLINE
DCOM- 20230828
LR  - 20240904
IS  - 1530-0374 (Electronic)
IS  - 1072-3714 (Print)
IS  - 1072-3714 (Linking)
VI  - 30
IP  - 9
DP  - 2023 Sep 1
TI  - Menopausal hormone therapy and change in physical activity in the Women's Health 
      Initiative hormone therapy clinical trials.
PG  - 898-905
LID - 10.1097/GME.0000000000002231 [doi]
AB  - OBJECTIVE: The menopausal transition results in a progressive decrease in 
      circulating estrogen levels. Experimental evidence in rodents has indicated that 
      estrogen depletion leads to a reduction of energy expenditure and physical 
      activity. It is unclear whether treatment with estrogen therapy increases 
      physical activity level in postmenopausal women. METHODS: A total of 27,327 
      postmenopausal women aged 50-79 years enrolled in the Women's Health Initiative 
      randomized double-blind trials of menopausal hormone therapy. Self-reported 
      leisure-time physical activity at baseline, and years 1, 3, and 6 was quantified 
      as metabolic equivalents (MET)-h/wk. In each trial, comparison between 
      intervention and placebo groups of changes in physical activity levels from 
      baseline to follow-up assessment was examined using linear regression models. 
      RESULTS: In the CEE-alone trial, the increase in MET-h/wk was greater in the 
      placebo group compared with the intervention group at years 3 ( P = 0.002) and 6 
      ( P < 0.001). Similar results were observed when analyses were restricted to 
      women who maintained an adherence rate ≥80% during the trial or who were 
      physically active at baseline. In the CEE + MPA trial, the primary analyses did 
      not show significant differences between groups, but the increase of MET-h/wk was 
      greater in the placebo group compared with the intervention group at year 3 ( P = 
      0.004) among women with an adherence rate ≥80%. CONCLUSIONS: The results from 
      this clinical trial do not support the hypothesis that estrogen treatment 
      increases physical activity among postmenopausal women.
CI  - Copyright © 2023 by The North American Menopause Society.
FAU - Peila, Rita
AU  - Peila R
AD  - From the Department of Epidemiology and Population Health, Albert Einstein 
      College of Medicine, Bronx, New York, NY.
FAU - Xue, Xiaonan
AU  - Xue X
AD  - From the Department of Epidemiology and Population Health, Albert Einstein 
      College of Medicine, Bronx, New York, NY.
FAU - LaMonte, Michael J
AU  - LaMonte MJ
AD  - Department of Epidemiology and Environmental Health, University of Buffalo, 
      Buffalo, NY.
FAU - Shadyab, Aladdin H
AU  - Shadyab AH
AD  - Herbert Wertheim School of Public Health and Human Longevity Science, University 
      of California, San Diego, La Jolla, CA.
FAU - Wactawski-Wende, Jean
AU  - Wactawski-Wende J
AD  - Department of Epidemiology and Environmental Health, School of Public Health and 
      Health Professions, University at Buffalo, Buffalo, NY.
FAU - Jung, Su Yon
AU  - Jung SY
AD  - Translational Sciences Section, Jonsson Comprehensive Cancer Center, School of 
      Nursing, University of California, Los Angeles, Los Angeles, CA.
FAU - Johnson, Karen C
AU  - Johnson KC
AD  - Department of Preventive Medicine, College of Medicine, University of Tennessee, 
      Health Science Center, Memphis, TN.
FAU - Coday, Mace
AU  - Coday M
AD  - Department of Preventive Medicine, College of Medicine, University of Tennessee, 
      Health Science Center, Memphis, TN.
FAU - Richey, Phyllis
AU  - Richey P
AD  - Department of Preventive Medicine, College of Medicine, University of Tennessee, 
      Health Science Center, Memphis, TN.
FAU - Mouton, Charles P
AU  - Mouton CP
AD  - Department of Family Medicine, University of Texas Medical Branch, Galveston, TX.
FAU - Saquib, Nazums
AU  - Saquib N
AD  - College of Medicine, Sulaiman Al Rajhi University, Al Bukayriyah, Saudi Arabia.
FAU - Chlebowski, Rowan T
AU  - Chlebowski RT
AD  - Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, 
      Torrance, CA.
FAU - Pan, Kathy
AU  - Pan K
AD  - Department of Hematology/Oncology, Kaiser Permanente Southern California, Downey, 
      CA.
FAU - Michael, Yvonne L
AU  - Michael YL
AD  - Department of Epidemiology and Biostatistics, Dornsife School of Public Health, 
      Drexel University, Philadelphia, PA.
FAU - LeBoff, Meryl S
AU  - LeBoff MS
AD  - Division of Endocrinology, Diabetes, and Hypertension, Brigham's and Women's 
      Hospital, Harvard Medical School, Boston, MA.
FAU - Manson, JoAnn E
AU  - Manson JE
AD  - Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 
      Boston, MA.
FAU - Rohan, Thomas E
AU  - Rohan TE
AD  - From the Department of Epidemiology and Population Health, Albert Einstein 
      College of Medicine, Bronx, New York, NY.
LA  - eng
GR  - HHSN268201600002C/HL/NHLBI NIH HHS/United States
GR  - HHSN268201600018C/HL/NHLBI NIH HHS/United States
GR  - HHSN268201600003C/HL/NHLBI NIH HHS/United States
GR  - HHSN268201600004C/HL/NHLBI NIH HHS/United States
GR  - HHSN268201600001C/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20230801
PL  - United States
TA  - Menopause
JT  - Menopause (New York, N.Y.)
JID - 9433353
RN  - 0 (Estrogens, Conjugated (USP))
RN  - 0 (Estrogens)
RN  - C2QI4IOI2G (Medroxyprogesterone Acetate)
SB  - IM
CIN - Menopause. 2023 Sep 1;30(9):883-884. doi: 10.1097/GME.0000000000002242. PMID: 
      37625085
MH  - Female
MH  - Humans
MH  - *Estrogens, Conjugated (USP)
MH  - *Estrogens
MH  - Women's Health
MH  - Menopause
MH  - Exercise
MH  - Estrogen Replacement Therapy
MH  - Medroxyprogesterone Acetate
PMC - PMC10527163
MID - NIHMS1906618
COIS- Conflict of interest/financial disclosures: R.T.C. receives ongoing funding from 
      UpToDate . M.S.L. received $1000 honorarium from the New England Bone Club for a 
      plenary lecture at the 2022 New England Bone Club meeting. The other authors have 
      nothing to disclose.
EDAT- 2023/08/01 19:12
MHDA- 2023/08/28 06:42
PMCR- 2024/09/01
CRDT- 2023/08/01 16:03
PHST- 2023/08/28 06:42 [medline]
PHST- 2023/08/01 19:12 [pubmed]
PHST- 2023/08/01 16:03 [entrez]
PHST- 2024/09/01 00:00 [pmc-release]
AID - 00042192-990000000-00221 [pii]
AID - 10.1097/GME.0000000000002231 [doi]
PST - ppublish
SO  - Menopause. 2023 Sep 1;30(9):898-905. doi: 10.1097/GME.0000000000002231. Epub 2023 
      Aug 1.

PMID- 35084436
OWN - NLM
STAT- MEDLINE
DCOM- 20220401
LR  - 20230315
IS  - 2374-2445 (Electronic)
IS  - 2374-2437 (Print)
IS  - 2374-2437 (Linking)
VI  - 8
IP  - 3
DP  - 2022 Mar 1
TI  - Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast 
      Cancer Susceptibility Genes.
PG  - e216744
LID - 10.1001/jamaoncol.2021.6744 [doi]
LID - e216744
AB  - IMPORTANCE: Rare germline genetic variants in several genes are associated with 
      increased breast cancer (BC) risk, but their precise contributions to different 
      disease subtypes are unclear. This information is relevant to guidelines for gene 
      panel testing and risk prediction. OBJECTIVE: To characterize tumors associated 
      with BC susceptibility genes in large-scale population- or hospital-based 
      studies. DESIGN, SETTING, AND PARTICIPANTS: The multicenter, international 
      case-control analysis of the BRIDGES study included 42 680 patients and 46 387 
      control participants, comprising women aged 18 to 79 years who were sampled 
      independently of family history from 38 studies. Studies were conducted between 
      1991 and 2016. Sequencing and analysis took place between 2016 and 2021. 
      EXPOSURES: Protein-truncating variants and likely pathogenic missense variants in 
      ATM, BARD1, BRCA1, BRCA2, CHEK2, PALB2, RAD51C, RAD51D, and TP53. MAIN OUTCOMES 
      AND MEASURES: The intrinsic-like BC subtypes as defined by estrogen receptor, 
      progesterone receptor, and ERBB2 (formerly known as HER2) status, and tumor 
      grade; morphology; size; stage; lymph node involvement; subtype-specific odds 
      ratios (ORs) for carrying protein-truncating variants and pathogenic missense 
      variants in the 9 BC susceptibility genes. RESULTS: The mean (SD) ages at 
      interview (control participants) and diagnosis (cases) were 55.1 (11.9) and 55.8 
      (10.6) years, respectively; all participants were of European or East Asian 
      ethnicity. There was substantial heterogeneity in the distribution of intrinsic 
      subtypes by gene. RAD51C, RAD51D, and BARD1 variants were associated mainly with 
      triple-negative disease (OR, 6.19 [95% CI, 3.17-12.12]; OR, 6.19 [95% CI, 
      2.99-12.79]; and OR, 10.05 [95% CI, 5.27-19.19], respectively). CHEK2 variants 
      were associated with all subtypes (with ORs ranging from 2.21-3.17) except for 
      triple-negative disease. For ATM variants, the association was strongest for the 
      hormone receptor (HR)+ERBB2- high-grade subtype (OR, 4.99; 95% CI, 3.68-6.76). 
      BRCA1 was associated with increased risk of all subtypes, but the ORs varied 
      widely, being highest for triple-negative disease (OR, 55.32; 95% CI, 
      40.51-75.55). BRCA2 and PALB2 variants were also associated with triple-negative 
      disease. TP53 variants were most strongly associated with HR+ERBB2+ and HR-ERBB2+ 
      subtypes. Tumors occurring in pathogenic variant carriers were of higher grade. 
      For most genes and subtypes, a decline in ORs was observed with increasing age. 
      Together, the 9 genes were associated with 27.3% of all triple-negative tumors in 
      women 40 years or younger. CONCLUSIONS AND RELEVANCE: The results of this 
      case-control study suggest that variants in the 9 BC risk genes differ 
      substantially in their associated pathology but are generally associated with 
      triple-negative and/or high-grade disease. Knowing the age and tumor subtype 
      distributions associated with individual BC genes can potentially aid guidelines 
      for gene panel testing, risk prediction, and variant classification and guide 
      targeted screening strategies.
CN  - Breast Cancer Association Consortium
FAU - Mavaddat, Nasim
AU  - Mavaddat N
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, England.
FAU - Dorling, Leila
AU  - Dorling L
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, England.
FAU - Carvalho, Sara
AU  - Carvalho S
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, England.
FAU - Allen, Jamie
AU  - Allen J
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, England.
FAU - González-Neira, Anna
AU  - González-Neira A
AD  - Human Cancer Genetics Programme, Spanish National Cancer Research Centre, Madrid, 
      Spain.
FAU - Keeman, Renske
AU  - Keeman R
AD  - Division of Molecular Pathology, the Netherlands Cancer Institute-Antoni van 
      Leeuwenhoek Hospital, Amsterdam, the Netherlands.
FAU - Bolla, Manjeet K
AU  - Bolla MK
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, England.
FAU - Dennis, Joe
AU  - Dennis J
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, England.
FAU - Wang, Qin
AU  - Wang Q
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, England.
FAU - Ahearn, Thomas U
AU  - Ahearn TU
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, National 
      Institutes of Health, Department of Health and Human Services, Bethesda, 
      Maryland.
FAU - Andrulis, Irene L
AU  - Andrulis IL
AD  - Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute 
      of Mount Sinai Hospital, Toronto, Ontario, Canada.
AD  - Department of Molecular Genetics, University of Toronto, Toronto, Ontario, 
      Canada.
FAU - Beckmann, Matthias W
AU  - Beckmann MW
AD  - Department of Gynecology and Obstetrics, Comprehensive Cancer Center 
      Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander University 
      Erlangen-Nuremberg, Erlangen, Germany.
FAU - Behrens, Sabine
AU  - Behrens S
AD  - Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, 
      Germany.
FAU - Benitez, Javier
AU  - Benitez J
AD  - Human Cancer Genetics Programme, Spanish National Cancer Research Centre, Madrid, 
      Spain.
AD  - Biomedical Network on Rare Diseases, Madrid, Spain.
FAU - Bermisheva, Marina
AU  - Bermisheva M
AD  - Institute of Biochemistry and Genetics, Ufa Federal Research Centre of the 
      Russian Academy of Sciences, Ufa, Russia.
FAU - Blomqvist, Carl
AU  - Blomqvist C
AD  - Department of Oncology, Helsinki University Hospital, University of Helsinki, 
      Helsinki, Finland.
FAU - Bogdanova, Natalia V
AU  - Bogdanova NV
AD  - Department of Radiation Oncology, Hannover Medical School, Hannover, Germany.
AD  - Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
AD  - N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, 
      Belarus.
FAU - Bojesen, Stig E
AU  - Bojesen SE
AD  - Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen 
      University Hospital, Herlev, Denmark.
AD  - Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen 
      University Hospital, Herlev, Denmark.
AD  - Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, 
      Denmark.
FAU - Briceno, Ignacio
AU  - Briceno I
AD  - Medical Faculty, Universidad de La Sabana, Bogota, Colombia.
FAU - Brüning, Thomas
AU  - Brüning T
AD  - Institute for Prevention and Occupational Medicine of the German Social Accident 
      Insurance, Institute of the Ruhr University Bochum, Bochum, Germany.
FAU - Camp, Nicola J
AU  - Camp NJ
AD  - Department of Internal Medicine and Huntsman Cancer Institute, University of 
      Utah, Salt Lake City.
FAU - Campbell, Archie
AU  - Campbell A
AD  - Centre for Genomic and Experimental Medicine, Institute of Genetics & Cancer, 
      University of Edinburgh, Edinburgh, Scotland.
AD  - Usher Institute of Population Health Sciences and Informatics, University of 
      Edinburgh, Edinburgh, Scotland.
FAU - Castelao, Jose E
AU  - Castelao JE
AD  - Oncology and Genetics Unit, Instituto de Investigación Sanitaria Galicia Sur, 
      Xerencia de Xestion Integrada de Vigo-SERGAS, Vigo, Spain.
FAU - Chang-Claude, Jenny
AU  - Chang-Claude J
AD  - Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, 
      Germany.
AD  - Cancer Epidemiology Group, University Cancer Center Hamburg, University Medical 
      Center Hamburg-Eppendorf, Hamburg, Germany.
FAU - Chanock, Stephen J
AU  - Chanock SJ
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, National 
      Institutes of Health, Department of Health and Human Services, Bethesda, 
      Maryland.
FAU - Chenevix-Trench, Georgia
AU  - Chenevix-Trench G
AD  - Department of Genetics and Computational Biology, QIMR Berghofer Medical Research 
      Institute, Brisbane, Queensland, Australia.
FAU - Christiansen, Hans
AU  - Christiansen H
AD  - Department of Radiation Oncology, Hannover Medical School, Hannover, Germany.
FAU - Czene, Kamila
AU  - Czene K
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 
      Stockholm, Sweden.
FAU - Dörk, Thilo
AU  - Dörk T
AD  - Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
FAU - Eriksson, Mikael
AU  - Eriksson M
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 
      Stockholm, Sweden.
FAU - Evans, D Gareth
AU  - Evans DG
AD  - Division of Evolution and Genomic Sciences, School of Biological Sciences, 
      Faculty of Biology, Medicine and Health, University of Manchester, Manchester 
      Academic Health Science Centre, Manchester, England.
AD  - North West Genomics Laboratory Hub, Manchester Centre for Genomic Medicine, St 
      Mary's Hospital, Manchester University National Health Service Foundation Trust, 
      Manchester Academic Health Science Centre, Manchester, England.
FAU - Fasching, Peter A
AU  - Fasching PA
AD  - Department of Gynecology and Obstetrics, Comprehensive Cancer Center 
      Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander University 
      Erlangen-Nuremberg, Erlangen, Germany.
AD  - David Geffen School of Medicine, Department of Medicine Division of Hematology 
      and Oncology, University of California at Los Angeles.
FAU - Figueroa, Jonine D
AU  - Figueroa JD
AD  - Usher Institute of Population Health Sciences and Informatics, University of 
      Edinburgh, Edinburgh, Scotland.
AD  - Cancer Research UK Edinburgh Centre, University of Edinburgh, Edinburgh, 
      Scotland.
FAU - Flyger, Henrik
AU  - Flyger H
AD  - Department of Breast Surgery, Herlev and Gentofte Hospital, Copenhagen University 
      Hospital, Herlev, Denmark.
FAU - Gabrielson, Marike
AU  - Gabrielson M
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 
      Stockholm, Sweden.
FAU - Gago-Dominguez, Manuela
AU  - Gago-Dominguez M
AD  - Fundación Pública Galega de Medicina Xenómica, Instituto de Investigación 
      Sanitaria de Santiago de Compostela, Complejo Hospitalario Universitario de 
      Santiago, SERGAS, Santiago de Compostela, Spain.
AD  - Moores Cancer Center, University of California San Diego, La Jolla.
FAU - Geisler, Jürgen
AU  - Geisler J
AD  - Department of Oncology, Akershus University Hospital, Lørenskog, Norway.
AD  - Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Campus 
      at Akershus University Hospital, Norway.
FAU - Giles, Graham G
AU  - Giles GG
AD  - Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, 
      Australia.
AD  - Centre for Epidemiology and Biostatistics, Melbourne School of Population and 
      Global Health, The University of Melbourne, Melbourne, Victoria, Australia.
AD  - Precision Medicine, School of Clinical Sciences at Monash Health, Monash 
      University, Clayton, Victoria, Australia.
FAU - Guénel, Pascal
AU  - Guénel P
AD  - Paris-Saclay University, UVSQ, Gustave Roussy, Inserm, CESP, Villejuif, France.
FAU - Hadjisavvas, Andreas
AU  - Hadjisavvas A
AD  - Department of Cancer Genetics, Therapeutics and Ultrastructural Pathology, The 
      Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus.
AD  - Cyprus School of Molecular Medicine, The Cyprus Institute of Neurology & 
      Genetics, Nicosia, Cyprus.
FAU - Hahnen, Eric
AU  - Hahnen E
AD  - Center for Familial Breast and Ovarian Cancer, Faculty of Medicine and University 
      Hospital Cologne, University of Cologne, Cologne, Germany.
AD  - Center for Integrated Oncology, Faculty of Medicine and University Hospital 
      Cologne, University of Cologne, Cologne, Germany.
FAU - Hall, Per
AU  - Hall P
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 
      Stockholm, Sweden.
AD  - Department of Oncology, Södersjukhuset, Stockholm, Sweden.
FAU - Hamann, Ute
AU  - Hamann U
AD  - Molecular Genetics of Breast Cancer, German Cancer Research Center, Heidelberg, 
      Germany.
FAU - Hartikainen, Jaana M
AU  - Hartikainen JM
AD  - Translational Cancer Research Area, University of Eastern Finland, Kuopio, 
      Finland.
AD  - Institute of Clinical Medicine, Pathology and Forensic Medicine, University of 
      Eastern Finland, Kuopio, Finland.
FAU - Hartman, Mikael
AU  - Hartman M
AD  - Saw Swee Hock School of Public Health, National University of Singapore and 
      National University Health System, Singapore, Singapore.
AD  - Department of Medicine, Yong Loo Lin School of Medicine, National University of 
      Singapore and National University Health System, Singapore, Singapore.
AD  - Department of Surgery, National University Health System, Singapore, Singapore.
FAU - Hoppe, Reiner
AU  - Hoppe R
AD  - Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, 
      Germany.
AD  - University of Tübingen, Tübingen, Germany.
FAU - Howell, Anthony
AU  - Howell A
AD  - Division of Cancer Sciences, University of Manchester, Manchester, England.
FAU - Jakubowska, Anna
AU  - Jakubowska A
AD  - Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, 
      Poland.
AD  - Independent Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian 
      Medical University, Szczecin, Poland.
FAU - Jung, Audrey
AU  - Jung A
AD  - Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, 
      Germany.
FAU - Khusnutdinova, Elza K
AU  - Khusnutdinova EK
AD  - Institute of Biochemistry and Genetics, Ufa Federal Research Centre of the 
      Russian Academy of Sciences, Ufa, Russia.
AD  - Department of Genetics and Fundamental Medicine, Bashkir State University, Ufa, 
      Russia.
FAU - Kristensen, Vessela N
AU  - Kristensen VN
AD  - Department of Medical Genetics, Oslo University Hospital and University of Oslo, 
      Oslo, Norway.
AD  - Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, 
      Norway.
FAU - Li, Jingmei
AU  - Li J
AD  - Department of Medicine, Yong Loo Lin School of Medicine, National University of 
      Singapore and National University Health System, Singapore, Singapore.
AD  - Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore.
FAU - Lim, Swee Ho
AU  - Lim SH
AD  - Breast Department, KK Women's and Children's Hospital, Singapore, Singapore.
AD  - SingHealth Duke-NUS Breast Centre, Singapore, Singapore.
FAU - Lindblom, Annika
AU  - Lindblom A
AD  - Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, 
      Sweden.
AD  - Department of Clinical Genetics, Karolinska University Hospital, Stockholm, 
      Sweden.
FAU - Loizidou, Maria A
AU  - Loizidou MA
AD  - Department of Cancer Genetics, Therapeutics and Ultrastructural Pathology, The 
      Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus.
AD  - Cyprus School of Molecular Medicine, The Cyprus Institute of Neurology & 
      Genetics, Nicosia, Cyprus.
FAU - Lophatananon, Artitaya
AU  - Lophatananon A
AD  - Division of Population Health, Health Services Research and Primary Care, School 
      of Health Sciences, Faculty of Biology, Medicine and Health, University of 
      Manchester, Manchester, England.
FAU - Lubinski, Jan
AU  - Lubinski J
AD  - Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, 
      Poland.
FAU - Madsen, Michael J
AU  - Madsen MJ
AD  - Department of Internal Medicine and Huntsman Cancer Institute, University of 
      Utah, Salt Lake City.
FAU - Mannermaa, Arto
AU  - Mannermaa A
AD  - Translational Cancer Research Area, University of Eastern Finland, Kuopio, 
      Finland.
AD  - Institute of Clinical Medicine, Pathology and Forensic Medicine, University of 
      Eastern Finland, Kuopio, Finland.
AD  - Biobank of Eastern Finland, Kuopio University Hospital, Kuopio, Finland.
FAU - Manoochehri, Mehdi
AU  - Manoochehri M
AD  - Molecular Genetics of Breast Cancer, German Cancer Research Center, Heidelberg, 
      Germany.
FAU - Margolin, Sara
AU  - Margolin S
AD  - Department of Oncology, Södersjukhuset, Stockholm, Sweden.
AD  - Department of Clinical Science and Education, Södersjukhuset, Karolinska 
      Institutet, Stockholm, Sweden.
FAU - Mavroudis, Dimitrios
AU  - Mavroudis D
AD  - Department of Medical Oncology, University Hospital of Heraklion, Heraklion, 
      Greece.
FAU - Milne, Roger L
AU  - Milne RL
AD  - Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, 
      Australia.
AD  - Centre for Epidemiology and Biostatistics, Melbourne School of Population and 
      Global Health, The University of Melbourne, Melbourne, Victoria, Australia.
AD  - Precision Medicine, School of Clinical Sciences at Monash Health, Monash 
      University, Clayton, Victoria, Australia.
FAU - Mohd Taib, Nur Aishah
AU  - Mohd Taib NA
AD  - Department of Surgery, Faculty of Medicine University of Malaya, UM Cancer 
      Research Institute, Kuala Lumpur, Malaysia.
FAU - Morra, Anna
AU  - Morra A
AD  - Division of Molecular Pathology, the Netherlands Cancer Institute-Antoni van 
      Leeuwenhoek Hospital, Amsterdam, the Netherlands.
FAU - Muir, Kenneth
AU  - Muir K
AD  - Division of Population Health, Health Services Research and Primary Care, School 
      of Health Sciences, Faculty of Biology, Medicine and Health, University of 
      Manchester, Manchester, England.
FAU - Obi, Nadia
AU  - Obi N
AD  - Institute for Medical Biometry and Epidemiology, University Medical Center 
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Osorio, Ana
AU  - Osorio A
AD  - Human Cancer Genetics Programme, Spanish National Cancer Research Centre, Madrid, 
      Spain.
AD  - Centro de Investigación en Red de Enfermedades Raras, Madrid, Spain.
FAU - Park-Simon, Tjoung-Won
AU  - Park-Simon TW
AD  - Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
FAU - Peterlongo, Paolo
AU  - Peterlongo P
AD  - Genome Diagnostics Program, IFOM-the FIRC Institute of Molecular Oncology, Milan, 
      Italy.
FAU - Radice, Paolo
AU  - Radice P
AD  - Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of 
      Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
FAU - Saloustros, Emmanouil
AU  - Saloustros E
AD  - Department of Oncology, University Hospital of Larissa, Larissa, Greece.
FAU - Sawyer, Elinor J
AU  - Sawyer EJ
AD  - School of Cancer & Pharmaceutical Sciences, Comprehensive Cancer Centre, Guy's 
      Campus, King's College London, London, England.
FAU - Schmutzler, Rita K
AU  - Schmutzler RK
AD  - Center for Familial Breast and Ovarian Cancer, Faculty of Medicine and University 
      Hospital Cologne, University of Cologne, Cologne, Germany.
AD  - Center for Integrated Oncology, Faculty of Medicine and University Hospital 
      Cologne, University of Cologne, Cologne, Germany.
AD  - Center for Molecular Medicine Cologne, Faculty of Medicine and University 
      Hospital Cologne, University of Cologne, Cologne, Germany.
FAU - Shah, Mitul
AU  - Shah M
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of 
      Cambridge, Cambridge, England.
FAU - Sim, Xueling
AU  - Sim X
AD  - Saw Swee Hock School of Public Health, National University of Singapore and 
      National University Health System, Singapore, Singapore.
FAU - Southey, Melissa C
AU  - Southey MC
AD  - Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, 
      Australia.
AD  - Precision Medicine, School of Clinical Sciences at Monash Health, Monash 
      University, Clayton, Victoria, Australia.
AD  - Department of Clinical Pathology, University of Melbourne, Melbourne, Victoria, 
      Australia.
FAU - Thorne, Heather
AU  - Thorne H
AD  - Research Department, Peter MacCallum Cancer Center, Melbourne, Victoria, 
      Australia.
AD  - Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, 
      Victoria, Australia.
FAU - Tomlinson, Ian
AU  - Tomlinson I
AD  - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, 
      England.
AD  - Wellcome Trust Centre for Human Genetics and Oxford National Institute for Health 
      Research Biomedical Research Centre, University of Oxford, Oxford, England.
FAU - Torres, Diana
AU  - Torres D
AD  - Molecular Genetics of Breast Cancer, German Cancer Research Center, Heidelberg, 
      Germany.
AD  - Institute of Human Genetics, Pontificia Universidad Javeriana, Bogota, Colombia.
FAU - Truong, Thérèse
AU  - Truong T
AD  - Paris-Saclay University, UVSQ, Gustave Roussy, Inserm, CESP, Villejuif, France.
FAU - Yip, Cheng Har
AU  - Yip CH
AD  - Department of Surgery, Faculty of Medicine University of Malaya, UM Cancer 
      Research Institute, Kuala Lumpur, Malaysia.
AD  - Subang Jaya Medical Centre, Subang Jaya, Selangor, Malaysia.
FAU - Spurdle, Amanda B
AU  - Spurdle AB
AD  - Department of Genetics and Computational Biology, QIMR Berghofer Medical Research 
      Institute, Brisbane, Queensland, Australia.
FAU - Vreeswijk, Maaike P G
AU  - Vreeswijk MPG
AD  - Department of Human Genetics, Leiden University Medical Center, Leiden, the 
      Netherlands.
FAU - Dunning, Alison M
AU  - Dunning AM
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of 
      Cambridge, Cambridge, England.
FAU - García-Closas, Montserrat
AU  - García-Closas M
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, National 
      Institutes of Health, Department of Health and Human Services, Bethesda, 
      Maryland.
FAU - Pharoah, Paul D P
AU  - Pharoah PDP
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, England.
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of 
      Cambridge, Cambridge, England.
FAU - Kvist, Anders
AU  - Kvist A
AD  - Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund 
      University, Lund, Sweden.
FAU - Muranen, Taru A
AU  - Muranen TA
AD  - Department of Obstetrics and Gynecology, Helsinki University Hospital, University 
      of Helsinki, Helsinki, Finland.
FAU - Nevanlinna, Heli
AU  - Nevanlinna H
AD  - Department of Obstetrics and Gynecology, Helsinki University Hospital, University 
      of Helsinki, Helsinki, Finland.
FAU - Teo, Soo Hwang
AU  - Teo SH
AD  - Department of Surgery, Faculty of Medicine University of Malaya, UM Cancer 
      Research Institute, Kuala Lumpur, Malaysia.
AD  - Breast Cancer Research Programme, Cancer Research Malaysia, Subang Jaya, 
      Selangor, Malaysia.
FAU - Devilee, Peter
AU  - Devilee P
AD  - Department of Human Genetics, Leiden University Medical Center, Leiden, the 
      Netherlands.
AD  - Department of Pathology, Leiden University Medical Center, Leiden, the 
      Netherlands.
FAU - Schmidt, Marjanka K
AU  - Schmidt MK
AD  - Division of Molecular Pathology, the Netherlands Cancer Institute-Antoni van 
      Leeuwenhoek Hospital, Amsterdam, the Netherlands.
AD  - Department of Clinical Genetics, Leiden University Medical Center, Leiden, the 
      Netherlands.
FAU - Easton, Douglas F
AU  - Easton DF
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, England.
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of 
      Cambridge, Cambridge, England.
LA  - eng
GR  - 203477/Z/16/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Multicenter Study
DEP - 20220317
PL  - United States
TA  - JAMA Oncol
JT  - JAMA oncology
JID - 101652861
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - *Breast Neoplasms/genetics
MH  - Case-Control Studies
MH  - Female
MH  - Genes, BRCA2
MH  - Genetic Predisposition to Disease
MH  - Germ Cells
MH  - Germ-Line Mutation
MH  - Humans
MH  - Middle Aged
MH  - Young Adult
PMC - PMC8796069
COIS- Conflict of Interest Disclosures: Dr Mavaddat reported grants from the University 
      of Cambridge, European Union Horizon 2020, Wellcome Trust, Genome Canada, 
      Canadian Institutes of Health Research, and National Cancer Institute during the 
      conduct of the study. Dr Allen reported grants from EU Horizons 2020 during the 
      conduct of the study. Dr Bolla reported grants from Cancer Research UK and the 
      National Institutes of Health (NIH) during the conduct of the study. Dr Andrulis 
      reported grants from NIH during the conduct of the study. Dr Briceno reported 
      grants from Universidad de la Sabana during the conduct of the study. Dr Fasching 
      reported personal fees from Roche, Lilly, Novartis, Pierre Fabre, Gilead, Seagen, 
      Eisai, Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme, and Pfizer and grants 
      from Cepheid and BioNtech during the conduct of the study. Dr Giles reported 
      grants from National Health and Medical Research Council during the conduct of 
      the study. Dr Hahnen reported personal fees from AstraZeneca outside the 
      submitted work. Dr Hartikainen reported grants from Cancer Foundation Finland 
      during the conduct of the study. Ms Morra reported being paid by an EU grant 
      during the conduct of the study. Dr Park-Simon reported being a recipient of the 
      Claudia von Schilling Stiftung Award during the conduct of the study. Dr 
      Schmutzler reported grants from German Cancer Aid during the conduct of the 
      study. Dr Southey reported grants from National Health and Medical Research 
      Council (NHMRC) (Australia) during the conduct of the study. Dr Spurdle reported 
      grants from the NHMRC during the conduct of the study. Dr Pharoah reported grants 
      from Cancer Research UK during the conduct of the study. Dr Kvist reported grants 
      from European Union Horizon 2020 research and innovation program BRIDGES during 
      the conduct of the study. Dr Nevanlinna reported grants from Helsinki University 
      Hospital, Sigrid Juselius Foundation, and Cancer Foundation Finland during the 
      conduct of the study as well as honorarium from AstraZeneca outside the submitted 
      work. Dr Camp reported grants from the University of Utah, Huntsman Cancer 
      Foundation, and the National Cancer Institute. Dr Schmidt reported grants from EU 
      during the conduct of the study. Dr Easton reported grants from the European 
      Commission and Wellcome Trust outside the submitted work. No other disclosures 
      were reported.
EDAT- 2022/01/28 06:00
MHDA- 2022/04/02 06:00
PMCR- 2022/01/27
CRDT- 2022/01/27 12:15
PHST- 2022/01/28 06:00 [pubmed]
PHST- 2022/04/02 06:00 [medline]
PHST- 2022/01/27 12:15 [entrez]
PHST- 2022/01/27 00:00 [pmc-release]
AID - 2788577 [pii]
AID - coi210095 [pii]
AID - 10.1001/jamaoncol.2021.6744 [doi]
PST - ppublish
SO  - JAMA Oncol. 2022 Mar 1;8(3):e216744. doi: 10.1001/jamaoncol.2021.6744. Epub 2022 
      Mar 17.

PMID- 32173578
OWN - NLM
STAT- MEDLINE
DCOM- 20210204
LR  - 20210204
IS  - 1553-4669 (Electronic)
IS  - 1553-4650 (Linking)
VI  - 27
IP  - 7
DP  - 2020 Nov-Dec
TI  - Hormone Replacement Therapy Prescription after Premature Surgical Menopause.
PG  - 1618-1623
LID - S1553-4650(20)30124-2 [pii]
LID - 10.1016/j.jmig.2020.03.002 [doi]
AB  - STUDY OBJECTIVE: To assess hormone replacement therapy (HRT) prescription pattern 
      in patients undergoing premature surgical menopause on the basis of surgical 
      indication. DESIGN: Retrospective cohort study. SETTING: Academic tertiary care 
      center. PATIENTS: Surgically menopausal patients aged ≤45 years who underwent a 
      minimally invasive hysterectomy with salpingo-oophorectomy. INTERVENTIONS: HRT 
      prescription in the 6-week postoperative period. MEASUREMENTS AND MAIN RESULTS: A 
      total of 63 patients met inclusion criteria. Of these, 52% (n = 33) were 
      prescribed HRT in the 6-week postoperative period. Indications for surgical 
      menopause included pelvic pain or endometriosis (31.7%), gynecologic malignancy 
      (20.6%), BRCA gene mutation (17.4%), breast cancer (9.5%), Lynch syndrome (4.8%), 
      and other (15.8%). In total, 80% of patients with pelvic pain, 25% with 
      gynecologic malignancies, 45% with BRCA gene mutations, 33.3% with breast cancer, 
      and 66.6% with Lynch syndrome used HRT postoperatively. In patients who used HRT 
      postoperatively, 76% were offered preoperative HRT counseling. This is in 
      contrast with those patients who did not use HRT postoperatively, of whom only 
      33% were offered HRT counseling (p <.001). Perioperative complications were not 
      predictive of HRT use postoperatively. In patients who did not use HRT 
      postoperatively, 13.3% used alternative nonhormonal therapy. CONCLUSION: In 
      patients who underwent premature surgical menopause, 52% used HRT 
      postoperatively. Patients with pelvic pain and Lynch syndrome were more likely to 
      use HRT, whereas those with gynecologic or breast malignancies and BRCA gene 
      mutations were less likely to use HRT. Preoperative HRT counseling was associated 
      with postoperative HRT use.
CI  - Copyright © 2020. Published by Elsevier Inc.
FAU - Garg, Nisha
AU  - Garg N
AD  - Department of Obstetrics and Gynecology, University of California, Irvine (Dr. 
      Garg).
FAU - Behbehani, Sadikah
AU  - Behbehani S
AD  - Department of Obstetrics and Gynecology, University of California, Riverside (Dr. 
      Behbehani), California. Electronic address: Sadikah.behbehani@mail.mcgill.ca.
FAU - Kosiorek, Heidi
AU  - Kosiorek H
AD  - Department of Health Sciences Research, Mayo Clinic Arizona, Scottsdale (Ms. 
      Kosiorek).
FAU - Wasson, Megan
AU  - Wasson M
AD  - Department of Gynecology, Mayo Clinic Arizona, Phoenix (Dr. Wasson), Arizona.
LA  - eng
PT  - Journal Article
DEP - 20200313
PL  - United States
TA  - J Minim Invasive Gynecol
JT  - Journal of minimally invasive gynecology
JID - 101235322
SB  - IM
CIN - J Minim Invasive Gynecol. 2020 Sep - Oct;27(6):1425. doi: 
      10.1016/j.jmig.2020.04.025. PMID: 32344026
CIN - J Minim Invasive Gynecol. 2020 Sep - Oct;27(6):1426. doi: 
      10.1016/j.jmig.2020.04.024. PMID: 32344033
MH  - Adult
MH  - Breast Neoplasms/genetics/prevention & control
MH  - Cohort Studies
MH  - Endometriosis/epidemiology/surgery
MH  - Female
MH  - Gynecologic Surgical Procedures/*adverse effects
MH  - *Hormone Replacement Therapy/statistics & numerical data
MH  - Humans
MH  - *Menopause, Premature/drug effects/physiology
MH  - Middle Aged
MH  - Mutation
MH  - Ovarian Diseases/epidemiology/surgery
MH  - Ovarian Neoplasms/genetics/prevention & control
MH  - Postoperative Complications/*drug therapy/epidemiology
MH  - Practice Patterns, Physicians'/*statistics & numerical data
MH  - Retrospective Studies
MH  - Syndrome
OTO - NOTNLM
OT  - BRCA
OT  - Endometriosis
OT  - Estrogen replacement
OT  - Pelvic pain
EDAT- 2020/03/17 06:00
MHDA- 2021/02/05 06:00
CRDT- 2020/03/17 06:00
PHST- 2019/12/20 00:00 [received]
PHST- 2020/03/05 00:00 [revised]
PHST- 2020/03/05 00:00 [accepted]
PHST- 2020/03/17 06:00 [pubmed]
PHST- 2021/02/05 06:00 [medline]
PHST- 2020/03/17 06:00 [entrez]
AID - S1553-4650(20)30124-2 [pii]
AID - 10.1016/j.jmig.2020.03.002 [doi]
PST - ppublish
SO  - J Minim Invasive Gynecol. 2020 Nov-Dec;27(7):1618-1623. doi: 
      10.1016/j.jmig.2020.03.002. Epub 2020 Mar 13.

PMID- 38287805
OWN - NLM
STAT- MEDLINE
DCOM- 20240131
LR  - 20240220
IS  - 2768-6698 (Electronic)
IS  - 2768-6698 (Linking)
VI  - 29
IP  - 1
DP  - 2024 Jan 24
TI  - Early Estrogen Replacement Therapy Attenuates Cardiac Dysfunction Caused by Aging 
      and Ovariectomy in Female Wistar Rats.
PG  - 46
LID - 10.31083/j.fbl2901046 [doi]
AB  - BACKGROUND: Cardiovascular diseases (CVDs) are the leading cause of women's 
      mortality, linked to aging and reduced estrogen during menopause. Estrogen 
      replacement therapy (ERT) is suggested for CVDs prevention. Yet, its timing 
      initiation remains contentious. Thus, we aimed to evaluate the effect of early 
      and late estrogen therapy on cardiac function and lipid metabolism in 
      ovariectomized old female Wistar rats. METHODS: Fifty randomized female Wistar 
      rats were included in 5 groups (n = 10, 18 months old): (1) Sham, (2) 10 weeks 
      post ovariectomy (Ovx-10 w), (3) 10 weeks post Ovx + early estrogen replacement 
      therapy (Ovx 10 w-early ERT), (4) 20 weeks post Ovx (Ovx-20 w) and (5) Ovx 20 
      w-late ERT. Three days (early ERT) or 10 weeks (late ERT) after surgery 17-β 
      estradiol was given (5 µg/kg/day), and 10 weeks after the start of ERT, we 
      assessed cardiac function by echocardiography, electrocardiography, and cardiac 
      catheterization. Estradiol, cholesterol, triglyceride (TG), high-density 
      lipoprotein (HDL) and low-density lipoprotein (LDL) levels were determined. 
      Cardiac histology was performed with Masson's staining. RESULTS: Ovariectomy 
      (Ovx) increases left ventricle internal systolic diameter (0.4 vs 0.3 cm, *p = 
      0.020) and decreases shortening fraction (40 vs 54 %, *p = 0.030) regardless of 
      therapy. ERT prevents the increase in left ventricle mass after 10 weeks post-Ovx 
      and the ejection fractionreduction after 20 weeks. Lower P wave amplitudes (18.8 
      vs 24.2 ms, *p = 0.013) were found in the Ovx-20 w group. A longer duration of 
      the QRS complex after 20 weeks post-Ovx with and without ERT was found (32.5 and 
      32.1 vs 28.3 ms, *p = 0.003; *p = 0.007). Diastolic blood pressure was higher 20 
      weeks post-Ovx (86 vs 76 mmHg, *p = 0.047), regardless of ERT. The left ventricle 
      (LV) -dP/dt was decreased in Ovx groups without ERT (-750 vs -1320 mmHg, *p = 
      0.034). An increase in LV collagen deposition was found in the Ovx 10 w group vs 
      Sham (9.58 vs 4.54 %, *p = 0.028). Early ERT avoids the increase in body weight, 
      cholesterol and LDL caused by Ovx. CONCLUSIONS: Ovariectomy causes time-dependent 
      alterations in lipid metabolism, morphology, electrical activity, and heart 
      contractile function. Early but not late ERT prevents some of these effects.
CI  - © 2024 The Author(s). Published by IMR Press.
FAU - Ramírez-Hernández, Diana
AU  - Ramírez-Hernández D
AD  - Laboratorio de Farmacología del Miocardio, Facultad de Estudios Superiores 
      Cuautitlán, Universidad Nacional Autónoma de México, 54740 Estado de México, 
      Mexico.
AD  - Laboratorio de Farmacología Molecular, Escuela Superior de Medicina, Instituto 
      Politécnico Nacional, 11340 Ciudad de México, Mexico.
FAU - López-Sanchez, Pedro
AU  - López-Sanchez P
AD  - Laboratorio de Farmacología Molecular, Escuela Superior de Medicina, Instituto 
      Politécnico Nacional, 11340 Ciudad de México, Mexico.
FAU - Lezama-Martínez, Diego
AU  - Lezama-Martínez D
AD  - Laboratorio de Farmacología del Miocardio, Facultad de Estudios Superiores 
      Cuautitlán, Universidad Nacional Autónoma de México, 54740 Estado de México, 
      Mexico.
FAU - Pérez-García, Erik
AU  - Pérez-García E
AD  - Laboratorio de Farmacología del Miocardio, Facultad de Estudios Superiores 
      Cuautitlán, Universidad Nacional Autónoma de México, 54740 Estado de México, 
      Mexico.
FAU - Montoya-Hernández, M Fernanda Skat
AU  - Montoya-Hernández MFS
AD  - Laboratorio de Farmacología del Miocardio, Facultad de Estudios Superiores 
      Cuautitlán, Universidad Nacional Autónoma de México, 54740 Estado de México, 
      Mexico.
FAU - Aranda-Fraustro, Alberto
AU  - Aranda-Fraustro A
AD  - Laboratorio de Patología, Instituto Nacional de Cardiología Dr. Ignacio Chávez. 
      CDMX. Tlalpan, 14080 Ciudad de México, Mexico.
FAU - Flores-Monroy, Jazmin
AU  - Flores-Monroy J
AD  - Laboratorio de Farmacología del Miocardio, Facultad de Estudios Superiores 
      Cuautitlán, Universidad Nacional Autónoma de México, 54740 Estado de México, 
      Mexico.
LA  - eng
GR  - IN202022/UNAM-PAPIIT/
GR  - IN217122I/UNAM-PAPIIT/
GR  - CI2211/FES Cuautitlán/
GR  - CI2259/FES Cuautitlán/
GR  - A1-S-8958/CONACYT/
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Singapore
TA  - Front Biosci (Landmark Ed)
JT  - Frontiers in bioscience (Landmark edition)
JID - 101612996
RN  - 4TI98Z838E (Estradiol)
RN  - 0 (Estrogens)
RN  - 97C5T2UQ7J (Cholesterol)
SB  - IM
MH  - Humans
MH  - Rats
MH  - Animals
MH  - Female
MH  - Infant
MH  - *Estrogen Replacement Therapy
MH  - Rats, Wistar
MH  - Ovariectomy
MH  - Estradiol/pharmacology
MH  - Aging
MH  - Blood Pressure
MH  - Estrogens
MH  - *Heart Diseases
MH  - Cholesterol
OTO - NOTNLM
OT  - aging
OT  - echocardiography
OT  - electrocardiography
OT  - estrogen-replacement-therapy
OT  - fibrosis
OT  - lipid-metabolism
OT  - ovariectomy
COIS- The authors declare no conflict of interest.
EDAT- 2024/01/30 06:42
MHDA- 2024/01/31 06:43
CRDT- 2024/01/30 02:53
PHST- 2023/06/15 00:00 [received]
PHST- 2023/08/31 00:00 [revised]
PHST- 2023/10/08 00:00 [accepted]
PHST- 2024/01/31 06:43 [medline]
PHST- 2024/01/30 06:42 [pubmed]
PHST- 2024/01/30 02:53 [entrez]
AID - S2768-6701(23)01070-5 [pii]
AID - 10.31083/j.fbl2901046 [doi]
PST - ppublish
SO  - Front Biosci (Landmark Ed). 2024 Jan 24;29(1):46. doi: 10.31083/j.fbl2901046.

PMID- 36615537
OWN - NLM
STAT- MEDLINE
DCOM- 20230110
LR  - 20230111
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 28
IP  - 1
DP  - 2023 Jan 1
TI  - Interplay between Lignans and Gut Microbiota: Nutritional, Functional and 
      Methodological Aspects.
LID - 10.3390/molecules28010343 [doi]
LID - 343
AB  - Lignans are non-flavonoid polyphenols present in a wide range of foods frequently 
      consumed in the Western world, such as seeds, vegetables and fruits, and 
      beverages such as coffee, tea and wine. In particular, the human gut microbiota 
      (GM) can convert dietary lignans into biologically active compounds, especially 
      enterolignans (i.e., enterolactone and enterodiol), which play anti-inflammatory 
      and anti-oxidant roles, act as estrogen receptor activators and modulate gene 
      expression and/or enzyme activity. Interestingly, recent evidence documenting 
      those dietary interventions involving foods enriched in lignans have shown 
      beneficial and protective effects on various human pathologies, including 
      colorectal and breast cancer and cardiovascular diseases. However, considering 
      that more factors (e.g., diet, food transit time and intestinal redox state) can 
      modulate the lignans bioactivation by GM, there are usually remarkable 
      inter-individual differences in urine, fecal and blood concentrations of 
      enterolignans; hence, precise and validated analytical methods, especially 
      gas/liquid chromatography coupled to mass spectrometry, are needed for their 
      accurate quantification. Therefore, this review aims to summarize the beneficial 
      roles of enterolignans, their interaction with GM and the new methodological 
      approaches developed for their evaluation in different biological samples, since 
      they could be considered future promising nutraceuticals for the prevention of 
      human chronic disorders.
FAU - Baldi, Simone
AU  - Baldi S
AUID- ORCID: 0000-0002-5151-2618
AD  - Department of Experimental and Clinical Medicine, University of Florence, 50134 
      Florence, Italy.
FAU - Tristán Asensi, Marta
AU  - Tristán Asensi M
AD  - Department of Experimental and Clinical Medicine, University of Florence, 50134 
      Florence, Italy.
FAU - Pallecchi, Marco
AU  - Pallecchi M
AUID- ORCID: 0000-0002-0057-6531
AD  - Department of Neurosciences, Psychology, Drug Research and Child Health, 
      University of Florence, 50139 Florence, Italy.
FAU - Sofi, Francesco
AU  - Sofi F
AUID- ORCID: 0000-0001-7113-7424
AD  - Department of Experimental and Clinical Medicine, University of Florence, 50134 
      Florence, Italy.
AD  - Unit of Clinical Nutrition, Careggi University Hospital, 50134 Florence, Italy.
FAU - Bartolucci, Gianluca
AU  - Bartolucci G
AUID- ORCID: 0000-0002-5631-8769
AD  - Department of Neurosciences, Psychology, Drug Research and Child Health, 
      University of Florence, 50139 Florence, Italy.
FAU - Amedei, Amedeo
AU  - Amedei A
AUID- ORCID: 0000-0002-6797-9343
AD  - Department of Experimental and Clinical Medicine, University of Florence, 50134 
      Florence, Italy.
AD  - Interdisciplinary Internal Medicine Unit, Careggi University Hospital, 50134 
      Florence, Italy.
LA  - eng
GR  - 696295/European Union/
PT  - Journal Article
PT  - Review
DEP - 20230101
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Lignans)
SB  - IM
MH  - Humans
MH  - *Gastrointestinal Microbiome
MH  - Gas Chromatography-Mass Spectrometry
MH  - Vegetables/chemistry
MH  - Diet
MH  - *Lignans/chemistry
PMC - PMC9822457
OTO - NOTNLM
OT  - GC-MS
OT  - HPLC
OT  - enterolignans
OT  - gut microbiota
OT  - lignans
OT  - phytoestrogens
COIS- The authors declare no conflict of interest.
EDAT- 2023/01/09 06:00
MHDA- 2023/01/11 06:00
PMCR- 2023/01/01
CRDT- 2023/01/08 01:35
PHST- 2022/10/31 00:00 [received]
PHST- 2022/12/27 00:00 [revised]
PHST- 2022/12/28 00:00 [accepted]
PHST- 2023/01/08 01:35 [entrez]
PHST- 2023/01/09 06:00 [pubmed]
PHST- 2023/01/11 06:00 [medline]
PHST- 2023/01/01 00:00 [pmc-release]
AID - molecules28010343 [pii]
AID - molecules-28-00343 [pii]
AID - 10.3390/molecules28010343 [doi]
PST - epublish
SO  - Molecules. 2023 Jan 1;28(1):343. doi: 10.3390/molecules28010343.

PMID- 25681847
OWN - NLM
STAT- MEDLINE
DCOM- 20151221
LR  - 20220410
IS  - 1558-0474 (Electronic)
IS  - 0889-8545 (Linking)
VI  - 42
IP  - 1
DP  - 2015 Mar
TI  - Hormonal and nonhormonal treatment of vasomotor symptoms.
PG  - 163-79
LID - S0889-8545(14)00080-1 [pii]
LID - 10.1016/j.ogc.2014.09.008 [doi]
AB  - This article focuses on the cause, pathophysiology, differential diagnosis of, 
      and treatment options for vasomotor symptoms. In addition, it summarizes 
      important points for health care providers caring for perimenopausal and 
      postmenopausal women with regard to health maintenance, osteoporosis, 
      cardiovascular disease, and vaginal atrophy. Treatment options for hot flashes 
      with variable effectiveness include systemic hormone therapy 
      (estrogen/progestogen), nonhormonal pharmacologic therapies (selective serotonin 
      reuptake inhibitors, selective norepinephrine reuptake inhibitors, clonidine, 
      gabapentin), and nonpharmacologic therapy options (behavioral changes, 
      acupuncture). Risks and benefits as well as contraindications for hormone therapy 
      are further discussed.
CI  - Copyright © 2015 Elsevier Inc. All rights reserved.
FAU - Krause, Miriam S
AU  - Krause MS
AD  - Fertility and Endocrine Associates, 4121 Dutchman's Lane, Suite 414, Louisville, 
      KY 40207, USA. Electronic address: ms.krause@yahoo.de.
FAU - Nakajima, Steven T
AU  - Nakajima ST
AD  - Stanford Fertility and Reproductive Medicine Center, 900 Welch Road, Suite 20, 
      Palo Alto, CA 94304, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20141202
PL  - United States
TA  - Obstet Gynecol Clin North Am
JT  - Obstetrics and gynecology clinics of North America
JID - 8709551
RN  - 0 (Adrenergic alpha-Agonists)
RN  - 0 (Cyclohexanecarboxylic Acids)
RN  - 0 (Progestins)
SB  - IM
MH  - Adrenergic alpha-Agonists/therapeutic use
MH  - Cyclohexanecarboxylic Acids/therapeutic use
MH  - Estrogen Replacement Therapy/*methods
MH  - Evidence-Based Medicine
MH  - Female
MH  - Hot Flashes/etiology/physiopathology/*therapy
MH  - Humans
MH  - Menopause/drug effects/*physiology
MH  - Progestins/therapeutic use
MH  - Vasomotor System/*drug effects/physiopathology
MH  - Women's Health
OTO - NOTNLM
OT  - Estrogen
OT  - Menopause
OT  - Progestogen
OT  - SNRI
OT  - SSRI
OT  - Vasomotor symptoms
EDAT- 2015/02/16 06:00
MHDA- 2015/12/22 06:00
CRDT- 2015/02/16 06:00
PHST- 2015/02/16 06:00 [entrez]
PHST- 2015/02/16 06:00 [pubmed]
PHST- 2015/12/22 06:00 [medline]
AID - S0889-8545(14)00080-1 [pii]
AID - 10.1016/j.ogc.2014.09.008 [doi]
PST - ppublish
SO  - Obstet Gynecol Clin North Am. 2015 Mar;42(1):163-79. doi: 
      10.1016/j.ogc.2014.09.008. Epub 2014 Dec 2.

PMID- 38518096
OWN - NLM
STAT- MEDLINE
DCOM- 20240405
LR  - 20240405
IS  - 1477-0393 (Electronic)
IS  - 0748-2337 (Linking)
VI  - 40
IP  - 5
DP  - 2024 May
TI  - Triclosan, an antimicrobial drug, induced reproductive impairment in the 
      freshwater fish, Anabas testudineus (Bloch, 1792).
PG  - 254-271
LID - 10.1177/07482337241242510 [doi]
AB  - Triclosan (TCS), an antimicrobial drug, is known to occupy different compartments 
      in aquatic ecosystems. The present study focused to evaluate the reproductive 
      toxicity of triclosan, at environmentally relevant (0.009 and 9 μg L(-1)) and 
      sublethal (176.7 μg L(-1)) concentrations for 90 days in the pre-spawning phase 
      of the fish, Anabas testudineus. The reproductive biomarkers, namely, gonadal 
      steroidogenic enzymes, expression of aromatic genes, levels of serum 
      gonadotropins, sex hormones, and histology of gonads were analyzed. The weight of 
      the animal, brain weights along with gonadosomatic index decreased while mucus 
      deposition increased significantly at all concentrations of triclosan as the 
      primary defensive mechanism to prevent the entry of toxicants. Triclosan 
      disrupted gonadal steroidogenesis as evidenced by a reduction in the activities 
      of gonadal steroidogenic enzymes. The expressions of cyp19a1a and cyp19a1b genes 
      were up-regulated in the brain of both sexes and testis, while down-regulated in 
      the ovary indicating estrogenic effects of the compound. The endocrine-disrupting 
      effects of triclosan were confirmed. The current results suggest that chronic 
      exposure to triclosan altered reproductive endpoints thereby impairing normal 
      reproductive functions in fish.
FAU - Chokki Veettil, Priyatha
AU  - Chokki Veettil P
AUID- ORCID: 0000-0002-6950-9062
AD  - Research and Post-Graduation Department of Zoology, St. Thomas College, Thrissur, 
      India. RINGGOLD: 561604
FAU - Nikarthil Sidhick, Jeena
AU  - Nikarthil Sidhick J
AD  - Marine Biotechnology Division, Central Marine Fisheries Research Institute, 
      Kochi, India. RINGGOLD: 29300
FAU - Kavungal Abdulkhader, Sajeela
AU  - Kavungal Abdulkhader S
AD  - Marine Biotechnology Division, Central Marine Fisheries Research Institute, 
      Kochi, India. RINGGOLD: 29300
FAU - Ms, Siva Prasad
AU  - Ms SP
AD  - Department of Forensic Science, University of Calicut, Kerala Police Academy, 
      Thrissur, India.
FAU - Kumari Chidambaran, Chitra
AU  - Kumari Chidambaran C
AD  - Endocrinology and Toxicology Laboratory, Department of Zoology, University of 
      Calicut, Malappuram, India. RINGGOLD: 29279
LA  - eng
PT  - Journal Article
DEP - 20240322
PL  - England
TA  - Toxicol Ind Health
JT  - Toxicology and industrial health
JID - 8602702
RN  - 4NM5039Y5X (Triclosan)
RN  - 0 (Anti-Infective Agents)
SB  - IM
MH  - Male
MH  - Female
MH  - Animals
MH  - *Triclosan/toxicity
MH  - Ecosystem
MH  - Fishes
MH  - *Anti-Infective Agents/toxicity
MH  - Fresh Water
OTO - NOTNLM
OT  - Triclosan
OT  - aromatase
OT  - histology
OT  - reproductive toxicity
OT  - serum hormones
OT  - steroidogenesis
COIS- Declaration of conflicting interestsThe author(s) declared no potential conflicts 
      of interest with respect to the research, authorship, and/or publication of this 
      article.
EDAT- 2024/03/22 18:44
MHDA- 2024/04/05 06:44
CRDT- 2024/03/22 15:03
PHST- 2024/04/05 06:44 [medline]
PHST- 2024/03/22 18:44 [pubmed]
PHST- 2024/03/22 15:03 [entrez]
AID - 10.1177/07482337241242510 [doi]
PST - ppublish
SO  - Toxicol Ind Health. 2024 May;40(5):254-271. doi: 10.1177/07482337241242510. Epub 
      2024 Mar 22.

PMID- 38521431
OWN - NLM
STAT- MEDLINE
DCOM- 20240415
LR  - 20240626
IS  - 1872-7573 (Electronic)
IS  - 0378-8741 (Linking)
VI  - 328
DP  - 2024 Jun 28
TI  - Qixian granule inhibits ferroptosis in vascular endothelial cells by modulating 
      TRPML1 in the lysosome to prevent postmenopausal atherosclerosis.
PG  - 118076
LID - S0378-8741(24)00375-1 [pii]
LID - 10.1016/j.jep.2024.118076 [doi]
AB  - ETHNOPHARMACOLOGICAL RELEVANCE: QiXian Granule (QXG) is an integrated traditional 
      Chinese medicine formula used to treat postmenopausal atherosclerotic (AS) 
      cardiovascular diseases. The previous studies have found that QXG inhibited 
      isoproterenol (ISO)-induced myocardial remodeling. And its active ingredient, 
      Icraiin, can inhibit ferroptosis by promoting oxidized low-density lipoprotein 
      (xo-LDL)-induced vascular endothelial cell injury and autophagy in 
      atherosclerotic mice. Another active ingredient, Salvianolic Acid B, can suppress 
      ferroptosis and apoptosis during myocardial ischemia/reperfusion injury by 
      reducing ubiquitin-proteasome degradation of Glutathione Peroxidase 4 (GPX4) and 
      down-regulating the reactive oxygen species (ROS)- c-Jun N-terminal kinases 
      (JNK)/mitogen-activated protein kinase (MAPK) pathway. AIM OF THE STUDY: The 
      objective of this research was to assess the possible impact of QXG on 
      atherosclerosis in postmenopausal individuals and investigate its underlying 
      mechanisms. MATERIALS AND METHODS: Female ApoE(-/-) mice underwent ovariectomy 
      and were subjected to a high-fat diet (HFD) to establish a postmenopausal 
      atherosclerosis model. The therapeutic effects of QXG were observed in vivo and 
      in vitro through intraperitoneal injection of erastin, G-protein Coupled Estrogen 
      Receptor (GPER) inhibitor (G15), and silent Mucolipin Transient Receptor 
      Potential Channel 1 (TRPML1) adenovirus injection via tail vein. UPLC-MS and 
      molecular docking techniques identified and evaluated major QXG components, 
      contributing to the investigation of QXG's anti-postmenopausal atherosclerotic 
      effects. RESULTS: QXG increased serum Estradiol levels, decreased 
      follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels, which 
      indicated QXG had estrogen-like effects in Ovx/ApoE(-/-) mice. Furthermore, QXG 
      demonstrated the potential to impede the progression of AS in Ovx/ApoE(-/-) mice, 
      as evidenced by reductions in serum triglycerides (TG), total cholesterol (TC), 
      and low-density lipoprotein-cholesterol (LDL-C) levels. Additionally, QXG 
      inhibited ferroptosis in Ovx/ApoE(-/-) mice. Notably, UPLC-MS analysis identified 
      a total of 106 active components in QXG. The results of molecular docking 
      analysis demonstrated that Epmedin B, Astragaloside II, and Orientin exhibit 
      strong binding affinity towards TRPML1. QXG alleviates the progression of 
      atherosclerosis by activating TRPML1 through the GPER pathway or directly 
      activating TRPML1, thereby inhibiting GPX4 and ferritin heavy chain 
      (FTH1)-mediated iron pendant disease. In vitro, QXG-treated serum suppressed 
      proliferation, migration, and ox-LDL-induced MMP and ROS elevation in HAECs. 
      CONCLUSION: QXG inhibited GPX4 and FTH1-mediated ferroptosis in vascular 
      endothelial cells through up-regulating GPER/TRPML1 signaling, providing a 
      potential therapeutic option for postmenopausal females seeking a safe and 
      effective medication to prevent atherosclerosis. The study highlights QXG's 
      estrogenic properties and its promising role in combating postmenopausal 
      atherosclerosis.
CI  - Copyright © 2024 Elsevier B.V. All rights reserved.
FAU - Zhang, Meng
AU  - Zhang M
AD  - Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese 
      Medicine, Shanghai, 201203, China.
FAU - Mao, Chenhan
AU  - Mao C
AD  - Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, 
      Nanjing University of Chinese Medicine, Nanjing, 210028, China.
FAU - Dai, Yang
AU  - Dai Y
AD  - The Third Clinical Medical College, Nanjing University of Chinese Medicine, 
      Nanjing, 210028, China.
FAU - Xu, Xiaojin
AU  - Xu X
AD  - Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, 
      Nanjing University of Chinese Medicine, Nanjing, 210028, China.
FAU - Wang, Xindong
AU  - Wang X
AD  - Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, 
      Nanjing University of Chinese Medicine, Nanjing, 210028, China. Electronic 
      address: wangxd@njucm.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20240322
PL  - Ireland
TA  - J Ethnopharmacol
JT  - Journal of ethnopharmacology
JID - 7903310
RN  - 0 (qixian)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (Receptors, G-Protein-Coupled)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Estrogens)
RN  - 0 (Apolipoproteins E)
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
EIN - J Ethnopharmacol. 2024 Oct 28;333:118495. doi: 10.1016/j.jep.2024.118495. PMID: 
      38926012
MH  - Female
MH  - Animals
MH  - Mice
MH  - Endothelial Cells
MH  - Reactive Oxygen Species/metabolism
MH  - Signal Transduction
MH  - Postmenopause
MH  - Chromatography, Liquid
MH  - *Ferroptosis
MH  - Molecular Docking Simulation
MH  - Tandem Mass Spectrometry
MH  - *Atherosclerosis/drug therapy/prevention & control/metabolism
MH  - Receptors, G-Protein-Coupled/metabolism
MH  - Cholesterol, LDL/metabolism
MH  - Estrogens/metabolism
MH  - Apolipoproteins E
MH  - Lysosomes/metabolism
MH  - *Drugs, Chinese Herbal
OTO - NOTNLM
OT  - Ferroptosis
OT  - GPER
OT  - GPX4
OT  - Post-menopausal atherosclerotic
OT  - TRPML1
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2024/03/24 00:42
MHDA- 2024/04/15 06:44
CRDT- 2024/03/23 20:42
PHST- 2024/01/16 00:00 [received]
PHST- 2024/02/29 00:00 [revised]
PHST- 2024/03/18 00:00 [accepted]
PHST- 2024/04/15 06:44 [medline]
PHST- 2024/03/24 00:42 [pubmed]
PHST- 2024/03/23 20:42 [entrez]
AID - S0378-8741(24)00375-1 [pii]
AID - 10.1016/j.jep.2024.118076 [doi]
PST - ppublish
SO  - J Ethnopharmacol. 2024 Jun 28;328:118076. doi: 10.1016/j.jep.2024.118076. Epub 
      2024 Mar 22.

PMID- 32209333
OWN - NLM
STAT- MEDLINE
DCOM- 20210119
LR  - 20210119
IS  - 1873-2933 (Electronic)
IS  - 0009-9120 (Linking)
VI  - 82
DP  - 2020 Aug
TI  - Advancements in the gold standard: Measuring steroid sex hormones by mass 
      spectrometry.
PG  - 21-32
LID - S0009-9120(19)31411-0 [pii]
LID - 10.1016/j.clinbiochem.2020.03.008 [doi]
AB  - Sex hormones, such as testosterone and estrogens, play an essential role in 
      regulating physiological and reproductive development throughout the lifetime of 
      the individual. Although variation in levels of these hormones are observed 
      throughout the distinct stages in life, significant deviations from reference 
      ranges can result in detrimental effects to the individual. Alterations, by 
      either an increase or decrease, in hormone levels are associated with 
      physiological changes, decreased reproductive capabilities, and increased risk 
      for diseases. Hormone therapies (HTs) and assisted reproductive technologies 
      (ARTs) are commonly used to address these factors. In addition to these 
      treatments, gender-affirming therapies, an iteration of HTs, are also a prominent 
      treatment for transgender individuals. Considering that the effectiveness of 
      these treatments relies on achieving therapeutic hormone levels, monitoring of 
      hormones has served as a way of assessing therapeutic efficay. The need for 
      reliable methods to achieve this task has led to great advancements in methods 
      for evaluating hormone concentrations in biological matrices. Although 
      immunoassays are the more widely used method, mass spectrometry (MS)-based 
      methods have proven to be more sensitive, specific, and reliable. Advances in MS 
      technology and its applications for therapeutic hormone monitoring have been 
      significant, hence integration of these methods in the clinical setting is 
      desired. Here, we provide a general overview of HT and ART, and the immunoassay 
      and MS-based methods currently utilized for monitoring sex hormones. 
      Additionally, we highlight recent advances in MS-based methods and discuss future 
      applications and considerations for MS-based hormone assays.
CI  - Copyright © 2020 The Canadian Society of Clinical Chemists. Published by Elsevier 
      Inc. All rights reserved.
FAU - Conklin, Steven E
AU  - Conklin SE
AD  - Department of Pathology, The Johns Hopkins University School of Medicine, 1800 
      Orleans St. Zayed B1020, Baltimore, MD 21287, USA. Electronic address: 
      sconkli2@jhmi.edu.
FAU - Knezevic, Claire E
AU  - Knezevic CE
AD  - Department of Pathology, The Johns Hopkins University School of Medicine, 1800 
      Orleans St. Zayed B1020, Baltimore, MD 21287, USA. Electronic address: 
      cknezev1@jhmi.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200321
PL  - United States
TA  - Clin Biochem
JT  - Clinical biochemistry
JID - 0133660
RN  - 0 (Gonadal Steroid Hormones)
SB  - IM
MH  - Adult
MH  - Chromatography, Liquid/methods
MH  - Drug Monitoring/*methods/trends
MH  - Estrogen Replacement Therapy
MH  - Female
MH  - Gas Chromatography-Mass Spectrometry/*methods/trends
MH  - Gonadal Steroid Hormones/*blood/*chemistry/therapeutic use
MH  - Humans
MH  - Immunoassay/methods
MH  - Male
MH  - Middle Aged
MH  - Reproductive Techniques, Assisted
MH  - Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/*methods/trends
MH  - Tandem Mass Spectrometry/*methods/trends
MH  - Transgender Persons
EDAT- 2020/03/27 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/03/27 06:00
PHST- 2019/12/31 00:00 [received]
PHST- 2020/03/16 00:00 [revised]
PHST- 2020/03/16 00:00 [accepted]
PHST- 2020/03/27 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
PHST- 2020/03/27 06:00 [entrez]
AID - S0009-9120(19)31411-0 [pii]
AID - 10.1016/j.clinbiochem.2020.03.008 [doi]
PST - ppublish
SO  - Clin Biochem. 2020 Aug;82:21-32. doi: 10.1016/j.clinbiochem.2020.03.008. Epub 
      2020 Mar 21.

PMID- 37817434
OWN - NLM
STAT- MEDLINE
DCOM- 20240329
LR  - 20240331
IS  - 1976-670X (Electronic)
IS  - 1976-6696 (Print)
IS  - 1976-6696 (Linking)
VI  - 57
IP  - 3
DP  - 2024 Mar
TI  - Genistein alleviates pulmonary fibrosis by inactivating lung fibroblasts.
PG  - 143-148
AB  - Pulmonary fibrosis is a serious lung disease that occurs predominantly in men. 
      Genistein is an important natural soybeanderived phytoestrogen that affects 
      various biological functions, such as cell migration and fibrosis. However, the 
      antifibrotic effects of genistein on pulmonary fibrosis are largely unknown. The 
      antifibrotic effects of genistein were evaluated using in vitro and in vivo 
      models of lung fibrosis. Proteomic data were analyzed using nano-LC-ESI-MS/MS. 
      Genistein significantly reduced transforming growth factor (TGF)-β1-induced 
      expression of collagen type I and α-smooth muscle actin (SMA) in MRC-5 cells and 
      primary fibroblasts from patients with idiopathic pulmonary fibrosis (IPF). 
      Genistein also reduced TGF-β1-induced expression of p-Smad2/3 and p-p38 MAPK in 
      fibroblast models. Comprehensive protein analysis confirmed that genistein 
      exerted an anti-fibrotic effect by regulating various molecular mechanisms, such 
      as unfolded protein response, epithelial mesenchymal transition (EMT), mammalian 
      target of rapamycin complex 1 (mTORC1) signaling, cell death, and several 
      metabolic pathways. Genistein was also found to decrease hydroxyproline levels in 
      the lungs of BLM-treated mice. Genistein exerted an anti-fibrotic effect by 
      preventing fibroblast activation, suggesting that genistein could be developed as 
      a pharmacological agent for the prevention and treatment of pulmonary fibrosis. 
      [BMB Reports 2024; 57(3): 143-148].
FAU - Kwon, Seung-Hyun
AU  - Kwon SH
AD  - Veterans Medical Research Institute, Veterans Health Service Medical Center, 
      Seoul 05368, Korea.
FAU - Chung, Hyunju
AU  - Chung H
AD  - Core Research Laboratory, Medical Science Research Institute, Kyung Hee 
      University Hospital at Gangdong, Seoul 05278, Korea.
FAU - Seo, Jung-Woo
AU  - Seo JW
AD  - Core Research Laboratory, Medical Science Research Institute, Kyung Hee 
      University Hospital at Gangdong, Seoul 05278, Korea.
FAU - Kim, Hak Su
AU  - Kim HS
AD  - Veterans Medical Research Institute, Veterans Health Service Medical Center, 
      Seoul 05368, Korea.
LA  - eng
PT  - News
PL  - Korea (South)
TA  - BMB Rep
JT  - BMB reports
JID - 101465334
RN  - DH2M523P0H (Genistein)
RN  - 0 (Transforming Growth Factor beta1)
SB  - IM
MH  - Male
MH  - Humans
MH  - Mice
MH  - Animals
MH  - *Pulmonary Fibrosis/drug therapy/chemically induced/metabolism
MH  - Genistein/pharmacology/therapeutic use/metabolism
MH  - Proteomics
MH  - Tandem Mass Spectrometry
MH  - Lung/metabolism
MH  - Fibroblasts/metabolism
MH  - Fibrosis
MH  - Transforming Growth Factor beta1/metabolism
MH  - Mammals/metabolism
PMC - PMC10979345
COIS- CONFLICTS OF INTEREST The authors have no conflicting interests.
EDAT- 2023/10/11 06:45
MHDA- 2024/03/29 06:45
PMCR- 2023/10/13
CRDT- 2023/10/11 01:58
PHST- 2023/06/15 00:00 [received]
PHST- 2024/03/29 06:45 [medline]
PHST- 2023/10/11 06:45 [pubmed]
PHST- 2023/10/11 01:58 [entrez]
PHST- 2023/10/13 00:00 [pmc-release]
AID - 5967 [pii]
AID - bmb-57-3-143 [pii]
AID - 10.5483/BMBRep.2023-0099 [doi]
PST - ppublish
SO  - BMB Rep. 2024 Mar;57(3):143-148. doi: 10.5483/BMBRep.2023-0099.

PMID- 34893532
OWN - NLM
STAT- MEDLINE
DCOM- 20220504
LR  - 20240801
IS  - 1940-6215 (Electronic)
IS  - 1940-6207 (Print)
IS  - 1940-6215 (Linking)
VI  - 15
IP  - 3
DP  - 2022 Mar 1
TI  - Analgesic Use and Circulating Estrogens, Androgens, and Their Metabolites in the 
      Women's Health Initiative Observational Study.
PG  - 173-183
LID - 10.1158/1940-6207.CAPR-21-0264 [doi]
AB  - Though studies have observed inverse associations between use of analgesics 
      (aspirin, NSAIDs, and acetaminophen) and the risk of several cancers, the 
      potential biological mechanisms underlying these associations are unclear. We 
      investigated the relationship between analgesic use and serum concentrations of 
      estrogens, androgens, and their metabolites among postmenopausal women to provide 
      insights on whether analgesic use might influence endogenous hormone levels, 
      which could in turn influence hormone-related cancer risk. The study included 
      1,860 postmenopausal women from two case-control studies nested within the 
      Women's Health Initiative Observational Study. Analgesic use was reported at 
      study baseline. Fifteen estrogens and estrogen metabolites and 12 androgens and 
      androgen metabolites were quantified in baseline serum by LC/MS-MS. Linear 
      regression with inverse probability weighting, stratified by menopausal hormone 
      therapy (MHT) use, was used to estimate adjusted geometric mean concentrations of 
      each hormone by analgesic use. Among women not currently using MHT (n = 951), 
      low-dose aspirin (<100 mg) use was associated with a higher serum concentration 
      of estrone, estradiol, and 2, 4, and 16 hydroxylated metabolites. Use of 
      regular-dose aspirin (≥100 mg), non-aspirin NSAIDs, and acetaminophen was not 
      associated with serum concentrations of estrogens, androgens, or their 
      metabolites. This study highlights the importance of examining aspirin use by 
      dose and suggests that low-dose aspirin may influence endogenous estrogen 
      concentrations. PREVENTION RELEVANCE: This study explores a potential pathway by 
      which analgesic medications such as aspirin may prevent hormone-related cancers. 
      The findings support a positive association between low-dose aspirin use and 
      endogenous estrogens, indicating that further elucidation of the interplay 
      between low-dose aspirin, estrogen concentrations, and cancer risk is needed.
CI  - ©2021 American Association for Cancer Research.
FAU - Hurwitz, Lauren M
AU  - Hurwitz LM
AUID- ORCID: 0000-0001-8932-5028
AD  - Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.
FAU - Shadyab, Aladdin H
AU  - Shadyab AH
AD  - Herbert Wertheim School of Public Health and Human Longevity Science, University 
      of California San Diego, La Jolla, California.
FAU - Tabung, Fred K
AU  - Tabung FK
AUID- ORCID: 0000-0001-8193-7150
AD  - Division of Medical Oncology, Department of Internal Medicine, The Ohio State 
      University College of Medicine and Comprehensive Cancer Center, Columbus, Ohio.
FAU - Anderson, Garnet L
AU  - Anderson GL
AUID- ORCID: 0000-0001-5087-7837
AD  - Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, 
      Washington.
FAU - Saquib, Nazmus
AU  - Saquib N
AUID- ORCID: 0000-0002-2819-2839
AD  - Research Unit, College of Medicine, Sulaiman Al Rajhi University, Al Bukayriyah, 
      Saudi Arabia.
FAU - Wallace, Robert B
AU  - Wallace RB
AD  - Department of Epidemiology, University of Iowa College of Public Health, Iowa 
      City, Iowa.
FAU - Wild, Robert A
AU  - Wild RA
AD  - Department of Obstetrics and Gynecology, University of Oklahoma College of 
      Medicine, Oklahoma City, Oklahoma.
FAU - Pfeiffer, Ruth M
AU  - Pfeiffer RM
AUID- ORCID: 0000-0001-7791-2698
AD  - Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.
FAU - Xu, Xia
AU  - Xu X
AD  - Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick 
      National Laboratory for Cancer Research, Frederick, Maryland.
FAU - Trabert, Britton
AU  - Trabert B
AUID- ORCID: 0000-0002-1539-6090
AD  - Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.
LA  - eng
GR  - Z01 CP010126/ImNIH/Intramural NIH HHS/United States
GR  - HHSN268201100001I/HL/NHLBI NIH HHS/United States
GR  - HHSN268201100004I/HL/NHLBI NIH HHS/United States
GR  - HHSN268201100046C/HL/NHLBI NIH HHS/United States
GR  - P30 CA086862/CA/NCI NIH HHS/United States
GR  - HHSN268201100003C/WH/WHI NIH HHS/United States
GR  - HHSN271201100004C/AG/NIA NIH HHS/United States
GR  - HHSN268201100002C/WH/WHI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - HHSN268201100003I/HL/NHLBI NIH HHS/United States
GR  - HHSN268201100002I/HL/NHLBI NIH HHS/United States
GR  - HHSN268201100001C/WH/WHI NIH HHS/United States
GR  - HHSN268201100004C/WH/WHI NIH HHS/United States
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, N.I.H., Intramural
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer Prev Res (Phila)
JT  - Cancer prevention research (Philadelphia, Pa.)
JID - 101479409
RN  - 0 (Analgesics)
RN  - 0 (Androgens)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - 4TI98Z838E (Estradiol)
RN  - 0 (Estrogens)
SB  - IM
MH  - Female
MH  - Humans
MH  - Analgesics/therapeutic use
MH  - *Androgens
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin
MH  - Estradiol
MH  - *Estrogens/metabolism
MH  - Postmenopause
MH  - Women's Health
PMC - PMC8898279
MID - NIHMS1762911
COIS- Conflict of interest disclosure statement: The authors declare no potential 
      conflicts of interest.
EDAT- 2021/12/12 06:00
MHDA- 2022/05/06 06:00
PMCR- 2022/09/01
CRDT- 2021/12/11 05:37
PHST- 2021/06/30 00:00 [received]
PHST- 2021/09/27 00:00 [revised]
PHST- 2021/11/29 00:00 [accepted]
PHST- 2021/12/12 06:00 [pubmed]
PHST- 2022/05/06 06:00 [medline]
PHST- 2021/12/11 05:37 [entrez]
PHST- 2022/09/01 00:00 [pmc-release]
AID - 1940-6207.CAPR-21-0264 [pii]
AID - 10.1158/1940-6207.CAPR-21-0264 [doi]
PST - ppublish
SO  - Cancer Prev Res (Phila). 2022 Mar 1;15(3):173-183. doi: 
      10.1158/1940-6207.CAPR-21-0264.

PMID- 26776441
OWN - NLM
STAT- MEDLINE
DCOM- 20170612
LR  - 20211204
IS  - 1879-1220 (Electronic)
IS  - 0960-0760 (Print)
IS  - 0960-0760 (Linking)
VI  - 160
DP  - 2016 Jun
TI  - Nudging oligodendrocyte intrinsic signaling to remyelinate and repair: Estrogen 
      receptor ligand effects.
PG  - 43-52
LID - S0960-0760(16)30006-1 [pii]
LID - 10.1016/j.jsbmb.2016.01.006 [doi]
AB  - Demyelination in multiple sclerosis (MS) leads to significant, progressive axonal 
      and neuronal degeneration. Currently existing immunosuppressive and 
      immunomodulatory therapies alleviate MS symptoms and slow, but fail to prevent or 
      reverse, disease progression. Restoration of damaged myelin sheath by 
      replenishment of mature oligodendrocytes (OLs) should not only restore saltatory 
      axon conduction, but also provide a major boost to axon survival. Our previous 
      work has shown that therapeutic treatment with the modestly selective generic 
      estrogen receptor (ER) β agonist diarylpropionitrile (DPN) confers functional 
      neuroprotection in a chronic experimental autoimmune encephalomyelitis (EAE) 
      mouse model of MS by stimulating endogenous remyelination. Recently, we found 
      that the more potent, selective ERβ agonist indazole-chloride (Ind-Cl) improves 
      clinical disease and motor performance. Importantly, electrophysiological 
      measures revealed improved corpus callosal conduction and reduced axon 
      refractoriness. This Ind-Cl treatment-induced functional remyelination was 
      attributable to increased OL progenitor cell (OPC) and mature OL numbers. At the 
      intracellular signaling level, transition of early to late OPCs requires ERK1/2 
      signaling, and transition of immature to mature OLs requires mTOR signaling; 
      thus, the PI3K/Akt/mTOR pathway plays a major role in the late stages of OL 
      differentiation and myelination. Indeed, therapeutic treatment of EAE mice with 
      various ERβ agonists results in increased brain-derived neurotrophic factor 
      (BDNF) and phosphorylated (p) Akt and p-mTOR levels. It is notable that while 
      DPN's neuroprotective effects occur in the presence of peripheral and central 
      inflammation, Ind-Cl is directly neuroprotective, as demonstrated by 
      remyelination effects in the cuprizone-induced demyelination model, as well as 
      immunomodulatory. Elucidating the mechanisms by which ER agonists and other 
      directly remyelinating agents modulate endogenous OPC and OL regulatory signaling 
      is critical to the development of effective remyelinating drugs. The discovery of 
      signaling targets to induce functional remyelination will valuably contribute to 
      the treatment of demyelinating neurological diseases, including MS, stroke, and 
      traumatic brain and spinal cord injury.
CI  - Published by Elsevier Ltd.
FAU - Khalaj, Anna J
AU  - Khalaj AJ
AD  - Division of Biomedical Sciences, School of Medicine at the University of 
      California, Riverside, United States.
FAU - Hasselmann, Jonathan
AU  - Hasselmann J
AD  - Division of Biomedical Sciences, School of Medicine at the University of 
      California, Riverside, United States.
FAU - Augello, Catherine
AU  - Augello C
AD  - Division of Biomedical Sciences, School of Medicine at the University of 
      California, Riverside, United States.
FAU - Moore, Spencer
AU  - Moore S
AD  - Division of Biomedical Sciences, School of Medicine at the University of 
      California, Riverside, United States.
FAU - Tiwari-Woodruff, Seema K
AU  - Tiwari-Woodruff SK
AD  - Division of Biomedical Sciences, School of Medicine at the University of 
      California, Riverside, United States; Neuroscience Graduate Program, University 
      of California, Riverside, United States. Electronic address: 
      seema.tiwari-woodruff@ucr.edu.
LA  - eng
GR  - R01 NS081141/NS/NINDS NIH HHS/United States
GR  - R21 NS075198/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20160114
PL  - England
TA  - J Steroid Biochem Mol Biol
JT  - The Journal of steroid biochemistry and molecular biology
JID - 9015483
RN  - 0 (Estrogen Receptor beta)
RN  - 0 (Estrogens)
RN  - 0 (Ligands)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Drug Discovery/methods
MH  - Encephalomyelitis, Autoimmune, Experimental/*drug therapy/metabolism/pathology
MH  - Estrogen Receptor beta/*agonists/*metabolism
MH  - Estrogens/metabolism
MH  - Humans
MH  - Ligands
MH  - Multiple Sclerosis/*drug therapy/metabolism/pathology
MH  - Myelin Sheath/*drug effects/metabolism/pathology
MH  - Oligodendroglia/*drug effects/metabolism/pathology
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - Signal Transduction/*drug effects
MH  - TOR Serine-Threonine Kinases/metabolism
PMC - PMC5233753
MID - NIHMS760208
OTO - NOTNLM
OT  - Axon degeneration
OT  - Demyelination
OT  - Estrogen receptor ligands
OT  - Experimental autoimmune encephalomyelitis
OT  - Multiple sclerosis
OT  - Remyelination
EDAT- 2016/01/19 06:00
MHDA- 2017/06/13 06:00
PMCR- 2017/06/01
CRDT- 2016/01/19 06:00
PHST- 2015/08/27 00:00 [received]
PHST- 2016/01/08 00:00 [revised]
PHST- 2016/01/11 00:00 [accepted]
PHST- 2016/01/19 06:00 [entrez]
PHST- 2016/01/19 06:00 [pubmed]
PHST- 2017/06/13 06:00 [medline]
PHST- 2017/06/01 00:00 [pmc-release]
AID - S0960-0760(16)30006-1 [pii]
AID - 10.1016/j.jsbmb.2016.01.006 [doi]
PST - ppublish
SO  - J Steroid Biochem Mol Biol. 2016 Jun;160:43-52. doi: 10.1016/j.jsbmb.2016.01.006. 
      Epub 2016 Jan 14.

PMID- 37847876
OWN - NLM
STAT- MEDLINE
DCOM- 20231030
LR  - 20240417
IS  - 1530-0374 (Electronic)
IS  - 1072-3714 (Linking)
VI  - 30
IP  - 11
DP  - 2023 Nov 1
TI  - Comparative estrogen exposure from compounded transdermal estradiol creams and 
      Food and Drug Administration-approved transdermal estradiol gels and patches.
PG  - 1098-1105
LID - 10.1097/GME.0000000000002266 [doi]
AB  - OBJECTIVE: The aim of this study was to evaluate the amount of estrogen exposure 
      associated with the use of compounded transdermal estradiol (E2) creams and 
      compare it with estrogen exposure associated with the use of Food and Drug 
      Administration (FDA)-approved transdermal E2 patches and gels. METHODS: This was 
      a retrospective cohort study that used clinical laboratory data collected from 
      January 1, 2016, to December 31, 2019. Participants were first divided into three 
      groups: postmenopausal women on no menopausal hormone therapy (n = 8,720); 
      postmenopausal women using either a transdermal E2 patch, gel, or cream (n = 
      1,062); and premenopausal women on no hormonal therapy (n = 16,308). The 
      postmenopausal menopausal hormone therapy group was further subdivided by 
      formulation (patch [n = 777], gel [n = 132], or cream [n = 153]) and dose range 
      (low, mid, or high). The Jonckheere-Terpstra trend test was used to determine if 
      there was a dose-dependent trend in urinary E2 with increasing dose of compounded 
      E2 cream (dose categories for E2 cream subanalysis, <0.5 mg [n = 49], ≥0.5-≤1.0 
      mg [n = 50], ≥1.0-≤1.5 mg [n = 58], and >1.5-≤3.0 mg [n = 46]). Urinary E2 and 
      other characteristics were compared across formulations (within each dose range) 
      using Kruskal-Wallis one-way analysis of variance. RESULTS: A dose-dependent, 
      ordered trend existed for urinary E2 with increasing doses of compounded E2 cream 
      (urinary E2 medians [ng/mg-Cr], 0.80 for <0.5 mg, 0.73 for ≥0.5-≤1.0 mg, 1.39 for 
      ≥1.0-≤1.5 mg, and 1.74 for >1.5-≤3.0 mg; Jonckheere-Terpstra trend test, P < 
      0.001). Significant differences in urinary E2 concentrations were observed in all 
      three dose ranges (Kruskal-Wallis one-way analysis of variance, P = 0.013 for low 
      dose, P < 0.001 for mid dose, P = 0.009 for high dose). Comparison of E2 
      concentrations of compounded creams to E2 concentrations obtained with similar 
      doses of FDA-approved patches and gels showed that the creams had significantly 
      lower values than the patches and gels. CONCLUSIONS: Estrogen exposure from 
      compounded transdermal E2 creams increases in a dose-dependent manner; however, 
      the amount of estrogen exposure associated with compounded creams is 
      significantly lower than estrogen exposure associated with FDA-approved 
      transdermal E2 patches and gels. Clinicians should be aware of the direction and 
      magnitude of these potential differences in estrogen exposure when encountering 
      women who have either previously used or are currently using compounded E2 
      creams.
CI  - Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on 
      behalf of The Menopause Society.
FAU - Newman, Mark S
AU  - Newman MS
AD  - From the Precision Analytical, Inc, McMinnville, OR.
FAU - Saltiel, Doreen
AU  - Saltiel D
AD  - Biote Medical, LLC, Irving, TX.
FAU - Smeaton, Jaclyn
AU  - Smeaton J
AD  - From the Precision Analytical, Inc, McMinnville, OR.
FAU - Stanczyk, Frank Z
AU  - Stanczyk FZ
AD  - Department of Obstetrics and Gynecology, Keck School of Medicine, University of 
      Southern California, Los Angeles, CA.
LA  - eng
PT  - Journal Article
DEP - 20231018
PL  - United States
TA  - Menopause
JT  - Menopause (New York, N.Y.)
JID - 9433353
RN  - 4TI98Z838E (Estradiol)
RN  - 0 (Estrogens)
RN  - 0 (Gels)
SB  - IM
MH  - United States
MH  - Female
MH  - Humans
MH  - *Estradiol
MH  - Retrospective Studies
MH  - United States Food and Drug Administration
MH  - *Estrogens
MH  - Administration, Cutaneous
MH  - Gels
MH  - Estrogen Replacement Therapy
COIS- Financial disclosure/conflicts of interest: M.S.N. is president and CEO of 
      Precision Analytical, Inc. D.S. was previously a consultant for Precision 
      Analytical, Inc. J.S. is an employee of Precision Analytical. F.Z.S. has nothing 
      to disclose.
EDAT- 2023/10/17 18:43
MHDA- 2023/10/30 06:47
CRDT- 2023/10/17 16:03
PHST- 2023/10/30 06:47 [medline]
PHST- 2023/10/17 18:43 [pubmed]
PHST- 2023/10/17 16:03 [entrez]
AID - 00042192-202311000-00005 [pii]
AID - 10.1097/GME.0000000000002266 [doi]
PST - ppublish
SO  - Menopause. 2023 Nov 1;30(11):1098-1105. doi: 10.1097/GME.0000000000002266. Epub 
      2023 Oct 18.

PMID- 34027024
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240402
IS  - 2352-8737 (Electronic)
IS  - 2352-8737 (Linking)
VI  - 7
IP  - 1
DP  - 2021
TI  - Association between menopausal hormone therapy and risk of neurodegenerative 
      diseases: Implications for precision hormone therapy.
PG  - e12174
LID - 10.1002/trc2.12174 [doi]
LID - e12174
AB  - INTRODUCTION: The impact of menopausal hormone therapy (HT) on age-associated 
      Alzheimer's and neurodegenerative diseases (NDDs) remains unresolved. To 
      determine the effect of HT, formulation, type, and duration on risk of NDDs, a 
      retrospective analysis was performed using a 10-year Humana claims dataset. 
      METHODS: Study population included women aged 45 years or older with or without 
      claim records of HT medications. Patients diagnosed with NDDs including 
      Alzheimer's disease (AD), Parkinson's disease (PD), dementia, multiple sclerosis 
      (MS), and amyotrophic lateral sclerosis (ALS) were identified. Relative risk (RR) 
      ratios and 95% confidence intervals (CI) for combined NDDs, or AD, PD, dementia, 
      MS, and ALS were determined. Cumulative hazard ratios were determined to 
      investigate the association between HT and NDDs at different age groups. RESULTS: 
      In 379,352 women with or without claim records of HT, use of HT was associated 
      with significantly reduced risk for combined NDDs (RR 0.42, 95% CI 0.40-0.43, 
      P < 0.001). Average follow-up time was 5.1 [2.3] years. Formulations containing 
      natural steroids 17β-estradiol and/or progesterone were associated with greater 
      reduction in NDD risk. Oral- HT users showed significantly reduced RRs (0.42, 
      0.41-0.44, P < 0.001) for combined NDDs compared to non-HT users. The RRs for 
      transdermal-HT users were significantly decreased for all-cause dementia (0.73, 
      0.60-0.88, P = 0.001) and MS (0.55, 0.36-0.84, P = 0.005). Greatest reduction in 
      risk of NDD, AD, and dementia emerged in patients aged 65 years or older. 
      Further, the protective effect of long-term therapy (>1 year) on combined NDDs, 
      AD, PD, and dementia was greater compared to short-term therapy (≤1 year). 
      DISCUSSION: HT was associated with reduced risk of all NDDs including AD and 
      dementia, with greater duration of therapy and natural steroid formulations 
      associated with greater efficacy. These findings advance precision HT to prevent 
      NDDs including AD.
CI  - © 2021 The Authors. Alzheimer's & Dementia: Translational Research & Clinical 
      Interventions published by Wiley Periodicals, Inc. on behalf of Alzheimer's 
      Association.
FAU - Kim, Yu Jin
AU  - Kim YJ
AD  - Center for Innovation in Brain Science University of Arizona Tucson Arizona USA.
FAU - Soto, Maira
AU  - Soto M
AD  - Center for Innovation in Brain Science University of Arizona Tucson Arizona USA.
AD  - College of Medicine, Department of Pharmacology University of Arizona Tucson 
      Arizona USA.
FAU - Branigan, Gregory L
AU  - Branigan GL
AD  - Center for Innovation in Brain Science University of Arizona Tucson Arizona USA.
AD  - College of Medicine, Department of Pharmacology University of Arizona Tucson 
      Arizona USA.
AD  - College of Medicine MD-PhD Training Program University of Arizona Tucson Arizona 
      USA.
FAU - Rodgers, Kathleen
AU  - Rodgers K
AD  - Center for Innovation in Brain Science University of Arizona Tucson Arizona USA.
AD  - College of Medicine, Department of Pharmacology University of Arizona Tucson 
      Arizona USA.
FAU - Brinton, Roberta Diaz
AU  - Brinton RD
AD  - Center for Innovation in Brain Science University of Arizona Tucson Arizona USA.
AD  - College of Medicine, Department of Pharmacology University of Arizona Tucson 
      Arizona USA.
AD  - College of Medicine, Department of Neurology University of Arizona Tucson Arizona 
      USA.
LA  - eng
GR  - P01 AG026572/AG/NIA NIH HHS/United States
GR  - R01 AG057931/AG/NIA NIH HHS/United States
GR  - R37 AG053589/AG/NIA NIH HHS/United States
GR  - T32 AG061897/AG/NIA NIH HHS/United States
PT  - Journal Article
DEP - 20210513
PL  - United States
TA  - Alzheimers Dement (N Y)
JT  - Alzheimer's & dementia (New York, N. Y.)
JID - 101650118
PMC - PMC8118114
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - age‐associated neurodegenerative diseases
OT  - dementia
OT  - estrogen
OT  - menopausal hormone therapy
OT  - precision hormone therapy
OT  - progestin
OT  - retrospective analysis
COIS- Dr. Brinton reported receiving grants from the Women's Alzheimer's Movement and 
      the National Institute on Aging during the conduct of the study. No other 
      disclosures were reported.
EDAT- 2021/05/25 06:00
MHDA- 2021/05/25 06:01
PMCR- 2021/05/13
CRDT- 2021/05/24 08:16
PHST- 2020/11/24 00:00 [received]
PHST- 2021/02/18 00:00 [revised]
PHST- 2021/03/12 00:00 [accepted]
PHST- 2021/05/24 08:16 [entrez]
PHST- 2021/05/25 06:00 [pubmed]
PHST- 2021/05/25 06:01 [medline]
PHST- 2021/05/13 00:00 [pmc-release]
AID - TRC212174 [pii]
AID - 10.1002/trc2.12174 [doi]
PST - epublish
SO  - Alzheimers Dement (N Y). 2021 May 13;7(1):e12174. doi: 10.1002/trc2.12174. 
      eCollection 2021.

PMID- 35086823
OWN - NLM
STAT- MEDLINE
DCOM- 20220405
LR  - 20240324
IS  - 1538-7755 (Electronic)
IS  - 1055-9965 (Print)
IS  - 1055-9965 (Linking)
VI  - 31
IP  - 4
DP  - 2022 Apr 1
TI  - Circulating Sex Hormone Levels and Colon Cancer Risk in Men: A Nested 
      Case-Control Study and Meta-Analysis.
PG  - 793-803
LID - 10.1158/1055-9965.EPI-21-0996 [doi]
AB  - BACKGROUND: Endogenous sex hormones may contribute to higher colorectal cancer 
      incidence rates in men compared with women, but despite an increased number of 
      studies, clear evidence is lacking. METHODS: We conducted a comprehensive nested 
      case-control study of circulating concentrations of sex hormones, sex hormone 
      precursors, and sex hormone binding globulin (SHBG) in relation to subsequent 
      colon cancer risk in European men. Concentrations were measured using liquid 
      LC/MS-MS in prospectively collected plasma samples from 690 cases and 690 matched 
      controls from the European Prospective Investigation into Cancer and Nutrition 
      (EPIC) and the Northern Sweden Health and Disease Study (NSHDS) cohorts. 
      Multivariable conditional logistic regression was used to estimate odds ratios 
      (OR) and 95% confidence intervals (CI). In addition, we conducted a meta-analysis 
      of previous studies on men. RESULTS: Circulating levels of testosterone (OR, 
      0.68; 95% CI, 0.51-0.89) and SHBG (OR, 0.77; 95% CI, 0.62-0.96) were inversely 
      associated with colon cancer risk. For free testosterone, there was a 
      nonsignificant inverse association (OR, 0.83; 95% CI, 0.58-1.18). In a 
      dose-response meta-analysis of endogenous sex hormone levels, inverse 
      associations with colorectal/colon cancer risk were found for testosterone 
      [relative risks (RR) per 100 ng/dL = 0.98; 95% CI, 0.96-1.00; I2 = 22%] and free 
      testosterone (RR per 1 ng/dL = 0.98; 95% CI, 0.95-1.00; I2 = 0%). CONCLUSIONS: 
      Our results provide suggestive evidence for the association between testosterone, 
      SHBG, and male colon cancer development. IMPACT: Additional support for the 
      involvement of sex hormones in male colon cancer.
CI  - ©2022 The Authors; Published by the American Association for Cancer Research.
FAU - Harbs, Justin
AU  - Harbs J
AD  - Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.
FAU - Rinaldi, Sabina
AU  - Rinaldi S
AD  - International Agency for Research on Cancer, World Health Organization, Lyon, 
      France.
FAU - Gicquiau, Audrey
AU  - Gicquiau A
AD  - International Agency for Research on Cancer, World Health Organization, Lyon, 
      France.
FAU - Keski-Rahkonen, Pekka
AU  - Keski-Rahkonen P
AD  - International Agency for Research on Cancer, World Health Organization, Lyon, 
      France.
FAU - Mori, Nagisa
AU  - Mori N
AD  - International Agency for Research on Cancer, World Health Organization, Lyon, 
      France.
FAU - Liu, Xijia
AU  - Liu X
AD  - Department of Statistics, Umeå University, Umeå, Sweden.
FAU - Kaaks, Rudolf
AU  - Kaaks R
AUID- ORCID: 0000-0003-3751-3929
AD  - Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 
      Heidelberg, Germany.
FAU - Katzke, Verena
AU  - Katzke V
AUID- ORCID: 0000-0002-6509-6555
AD  - Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 
      Heidelberg, Germany.
FAU - Schulze, Matthias B
AU  - Schulze MB
AUID- ORCID: 0000-0002-0830-5277
AD  - Department of Molecular Epidemiology, German Institute of Human Nutrition 
      Potsdam-Rehbruecke, Nuthetal, Germany.
AD  - Institute of Nutritional Science, University of Potsdam, Potsdam, Germany.
FAU - Agnoli, Claudia
AU  - Agnoli C
AUID- ORCID: 0000-0003-4472-1179
AD  - Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori 
      di Milano, Milan, Italy.
FAU - Tumino, Rosario
AU  - Tumino R
AUID- ORCID: 0000-0003-2666-414X
AD  - Cancer Registry and Histopathology Department, Provincial Health Authority (ASP 
      7), Ragusa, Italy.
FAU - Bueno-de-Mesquita, Bas
AU  - Bueno-de-Mesquita B
AD  - Centre for Nutrition, Prevention and Health Services, National Institute for 
      Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
FAU - Crous-Bou, Marta
AU  - Crous-Bou M
AD  - Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan 
      Institute of Oncology (ICO) - Bellvitge Biomedical Research Institute (IDIBELL), 
      L'Hospitalet de Llobregat, Barcelona, Spain.
AD  - Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, 
      Massachusetts.
FAU - Sánchez, Maria-Jose
AU  - Sánchez MJ
AUID- ORCID: 0000-0003-4817-0757
AD  - Escuela Andaluza de Salud Pública (EASP), Granada, Spain.
AD  - Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain.
AD  - Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública 
      (CIBERESP), Madrid, Spain.
AD  - Department of Preventive Medicine and Public Health, University of Granada, 
      Granada, Spain.
FAU - Aizpurua, Amaia
AU  - Aizpurua A
AD  - Ministry of Health of the Basque Government, Sub-Directorate for Public Health 
      and Addictions of Gipuzkoa, San Sebastián, Spain.
FAU - Chirlaque, María-Dolores
AU  - Chirlaque MD
AD  - Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública 
      (CIBERESP), Madrid, Spain.
AD  - Department of Epidemiology, Regional Health Council, IMIB-Arrixaca, Murcia 
      University, Murcia, Spain.
FAU - Gurrea, Aurelio Barricarte
AU  - Gurrea AB
AD  - Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública 
      (CIBERESP), Madrid, Spain.
AD  - Navarra Public Health Institute, Pamplona, Spain.
AD  - Navarra Institute for Health Research (IdiSNA) Pamplona, Spain.
FAU - Travis, Ruth C
AU  - Travis RC
AUID- ORCID: 0000-0002-9571-0763
AD  - Cancer Epidemiology Unit, Nuffield Department of Population Health, University of 
      Oxford, Oxford, United Kingdom.
FAU - Watts, Eleanor L
AU  - Watts EL
AUID- ORCID: 0000-0001-9229-2589
AD  - Cancer Epidemiology Unit, Nuffield Department of Population Health, University of 
      Oxford, Oxford, United Kingdom.
FAU - Christakoudi, Sofia
AU  - Christakoudi S
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Imperial 
      College London, London, United Kingdom.
AD  - MRC Centre for Transplantation, Division of Transplantation Immunology and 
      Mucosal Biology, Faculty of Life Sciences & Medicine, King's College London, 
      London, United Kingdom.
FAU - Tsilidis, Konstantinos K
AU  - Tsilidis KK
AUID- ORCID: 0000-0002-8452-8472
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Imperial 
      College London, London, United Kingdom.
AD  - Department of Hygiene and Epidemiology, Faculty of Medicine, University of 
      Ioannina School of Medicine, Ioannina, Greece.
FAU - Weiderpass, Elisabete
AU  - Weiderpass E
AUID- ORCID: 0000-0003-2237-0128
AD  - International Agency for Research on Cancer, World Health Organization, Lyon, 
      France.
FAU - Gunter, Marc J
AU  - Gunter MJ
AUID- ORCID: 0000-0001-5472-6761
AD  - International Agency for Research on Cancer, World Health Organization, Lyon, 
      France.
FAU - Van Guelpen, Bethany
AU  - Van Guelpen B
AUID- ORCID: 0000-0002-9692-101X
AD  - Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.
AD  - Wallenberg Centre for Molecular Medicine, Umeå University, Umeå, Sweden.
FAU - Murphy, Neil
AU  - Murphy N
AD  - International Agency for Research on Cancer, World Health Organization, Lyon, 
      France.
FAU - Harlid, Sophia
AU  - Harlid S
AUID- ORCID: 0000-0001-8540-6891
AD  - Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.
LA  - eng
GR  - 29017/CRUK_/Cancer Research UK/United Kingdom
GR  - DH_/Department of Health/United Kingdom
GR  - MR/N003284/1/MRC_/Medical Research Council/United Kingdom
GR  - G0401527/MRC_/Medical Research Council/United Kingdom
GR  - G1000143/MRC_/Medical Research Council/United Kingdom
GR  - 14136/CRUK_/Cancer Research UK/United Kingdom
GR  - 001/WHO_/World Health Organization/International
GR  - MR/M012190/1/MRC_/Medical Research Council/United Kingdom
GR  - 1000143/MRC_/Medical Research Council/United Kingdom
GR  - C8221/A29017/CRUK_/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Epidemiol Biomarkers Prev
JT  - Cancer epidemiology, biomarkers & prevention : a publication of the American 
      Association for Cancer Research, cosponsored by the American Society of 
      Preventive Oncology
JID - 9200608
RN  - 0 (Gonadal Steroid Hormones)
RN  - 0 (Sex Hormone-Binding Globulin)
RN  - 3XMK78S47O (Testosterone)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Case-Control Studies
MH  - *Colonic Neoplasms/epidemiology
MH  - Estradiol
MH  - Female
MH  - Gonadal Steroid Hormones
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Prospective Studies
MH  - Risk Factors
MH  - *Sex Hormone-Binding Globulin/metabolism
MH  - Testosterone
PMC - PMC9381125
EDAT- 2022/01/29 06:00
MHDA- 2022/04/06 06:00
PMCR- 2022/08/16
CRDT- 2022/01/28 05:51
PHST- 2021/08/18 00:00 [received]
PHST- 2021/11/05 00:00 [revised]
PHST- 2022/01/21 00:00 [accepted]
PHST- 2022/01/29 06:00 [pubmed]
PHST- 2022/04/06 06:00 [medline]
PHST- 2022/01/28 05:51 [entrez]
PHST- 2022/08/16 00:00 [pmc-release]
AID - 1055-9965.EPI-21-0996 [pii]
AID - EPI-21-0996 [pii]
AID - 10.1158/1055-9965.EPI-21-0996 [doi]
PST - ppublish
SO  - Cancer Epidemiol Biomarkers Prev. 2022 Apr 1;31(4):793-803. doi: 
      10.1158/1055-9965.EPI-21-0996.

PMID- 34961984
OWN - NLM
STAT- MEDLINE
DCOM- 20220318
LR  - 20220318
IS  - 1365-2826 (Electronic)
IS  - 0953-8194 (Linking)
VI  - 34
IP  - 1
DP  - 2022 Jan
TI  - Tibolone restrains neuroinflammation in mouse experimental autoimmune 
      encephalomyelitis.
PG  - e13078
LID - 10.1111/jne.13078 [doi]
AB  - Multiple sclerosis (MS) is an immune-mediated and degenerating disease in which 
      myelin sheaths are damaged as a result of chronic progressive inflammation of the 
      central nervous system. Tibolone 
      [(7α,17α)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-in-3-one], a synthetic 
      estrogenic compound with tissue-specific actions and used for menopausal hormone 
      therapy, shows neuroprotective and antioxidant properties both in vivo and in 
      vitro. In the present study, we analyzed whether tibolone plays a therapeutic 
      role in experimental autoimmune encephalomyelitis (EAE) mice, a commonly used 
      model of MS. Female C57BL/6 mice were induced with the myelin oligodendrocyte 
      glycoprotein MOG(35-55) and received s.c. tibolone (0.08 mg kg(-1) ) injection 
      every other day from the day of induction until death on the acute phase of the 
      disease. Reactive gliosis, Toll like receptor 4 (TLR4), high mobility group box 
      protein 1 (HMGB1), inflammasome parameters, activated Akt levels and myelin were 
      assessed by a real-time polymerase chain reaction, immunohistochemistry, and 
      western blot analysis. Our findings indicated that, in the EAE spinal cord, 
      tibolone reversed the astrocytic and microglial reaction, and reduced the 
      hyperexpression of TLR4 and HMGB1, as well as NLR family pyrin domain containing 
      3-caspase 1-interleukin-1β inflammasome activation. At the same time, tibolone 
      attenuated the Akt/nuclear factor kappa B pathway and limited the white matter 
      demyelination area. Estrogen receptor expression was unaltered with tibolone 
      treatment. Clinically, tibolone improved neurological symptoms without uterine 
      compromise. Overall, our data suggest that tibolone may serve as a promising 
      agent for the attenuation of MS-related inflammation.
CI  - © 2021 British Society for Neuroendocrinology.
FAU - Mancino, Dalila N J
AU  - Mancino DNJ
AD  - Laboratory of Neuroendocrine Biochemistry, Instituto de Biologia y Medicina 
      Experimental - CONICET, Buenos Aires, Argentina.
FAU - Lima, Analia
AU  - Lima A
AD  - Laboratory of Neuroendocrine Biochemistry, Instituto de Biologia y Medicina 
      Experimental - CONICET, Buenos Aires, Argentina.
FAU - Roig, Paulina
AU  - Roig P
AD  - Laboratory of Neuroendocrine Biochemistry, Instituto de Biologia y Medicina 
      Experimental - CONICET, Buenos Aires, Argentina.
FAU - García Segura, Luis M
AU  - García Segura LM
AD  - Instituto Cajal, Consejo Superior de Investigaciones Cientificas, Madrid, Spain.
FAU - De Nicola, Alejandro F
AU  - De Nicola AF
AUID- ORCID: 0000-0002-3523-9148
AD  - Laboratory of Neuroendocrine Biochemistry, Instituto de Biologia y Medicina 
      Experimental - CONICET, Buenos Aires, Argentina.
AD  - Department of Human Biochemistry, University of Buenos Aires, Buenos Aires, 
      Argentina.
FAU - Garay, Laura I
AU  - Garay LI
AUID- ORCID: 0000-0003-2929-6346
AD  - Laboratory of Neuroendocrine Biochemistry, Instituto de Biologia y Medicina 
      Experimental - CONICET, Buenos Aires, Argentina.
AD  - Department of Human Biochemistry, University of Buenos Aires, Buenos Aires, 
      Argentina.
LA  - eng
SI  - RefSeq/NM_001025612
SI  - RefSeq/NM_021297
SI  - RefSeq/NM_145827.4
SI  - RefSeq/NM_008361.4
SI  - RefSeq/NM_008689
SI  - RefSeq/NM_008401
SI  - RefSeq/NM_001025100
SI  - RefSeq/NM_001302532.1
SI  - RefSeq/NM_207707.1
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20211227
PL  - United States
TA  - J Neuroendocrinol
JT  - Journal of neuroendocrinology
JID - 8913461
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Norpregnenes)
RN  - FF9X0205V2 (tibolone)
SB  - IM
MH  - Animals
MH  - Disease Models, Animal
MH  - Disease Progression
MH  - Encephalomyelitis, Autoimmune, Experimental/*drug therapy/pathology
MH  - Female
MH  - Inflammation/pathology/prevention & control
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Neuritis/pathology/*prevention & control
MH  - Neuroprotective Agents/therapeutic use
MH  - Norpregnenes/*therapeutic use
MH  - Remission Induction
OTO - NOTNLM
OT  - experimental autoimmune encephalomyelitis
OT  - inflammasome
OT  - microglia
OT  - tibolone
EDAT- 2021/12/29 06:00
MHDA- 2022/03/19 06:00
CRDT- 2021/12/28 06:46
PHST- 2021/11/03 00:00 [revised]
PHST- 2021/08/18 00:00 [received]
PHST- 2021/12/03 00:00 [accepted]
PHST- 2021/12/29 06:00 [pubmed]
PHST- 2022/03/19 06:00 [medline]
PHST- 2021/12/28 06:46 [entrez]
AID - 10.1111/jne.13078 [doi]
PST - ppublish
SO  - J Neuroendocrinol. 2022 Jan;34(1):e13078. doi: 10.1111/jne.13078. Epub 2021 Dec 
      27.

PMID- 36517463
OWN - NLM
STAT- MEDLINE
DCOM- 20230302
LR  - 20230321
IS  - 1940-6215 (Electronic)
IS  - 1940-6215 (Linking)
VI  - 16
IP  - 3
DP  - 2023 Mar 1
TI  - Estrogen-DNA Adducts and Breast Cancer Risk in Premenopausal Asian Women.
PG  - 153-161
LID - 10.1158/1940-6207.CAPR-22-0415 [doi]
AB  - The incidence of breast cancer among premenopausal women has been increasing 
      rapidly in recent decades in East Asia. This case-control study investigated 
      whether estrogen-DNA adducts were associated with breast cancer risk in Taiwan. 
      The control group (n = 146) comprised healthy female volunteers and women with 
      non-proliferative breast disease. The case group (n = 221) comprised women either 
      with proliferative benign breast disease or breast cancer. The ratios of 
      estrogen-DNA adducts to their respective metabolites and conjugates in plasma 
      were analyzed using ultraperformance LC/MS-MS. The SNPs of CYP1A1, CYP1B1, and 
      COMT were genotyped. Logistic regression model was used to compare the 
      estrogen-DNA adduct ratios between the two groups. The estrogen-DNA adduct ratio 
      in the case group was significantly higher than that in the control group (median 
      ratio: 58.52 vs. 29.36, P = 0.004). A multiple logistic regression model 
      demonstrated that a unit increase in the natural log of the estrogen-DNA adduct 
      ratio in premenopausal women was a significant predictor of breast cancer risk, 
      with an estimated hazard ratio of 1.718 (1.444-2.046, P < 0.001). However, the 
      CYP1A1, CYP1B1, and COMT SNPs were not associated with the estrogen-DNA adduct 
      ratios. In conclusion, plasma estrogen-DNA adduct ratio was associated with the 
      presence of breast cancer or proliferating benign breast disease in premenopausal 
      women in Taiwan. PREVENTION RELEVANCE: This study provides evidence that 
      endogenous estrogen-induced genotoxicity may contribute to the carcinogenesis of 
      breast cancer in premenopausal Asian women. This work could have important 
      preventive implication for the emerging disease in East Asia.
CI  - ©2022 American Association for Cancer Research.
FAU - Lin, Ching-Hung
AU  - Lin CH
AUID- ORCID: 0000-0003-2403-4056
AD  - Department of Medical Oncology, National Taiwan University Hospital, Cancer 
      Center Branch, Taipei, Taiwan.
AD  - Department of Internal Medicine, National Taiwan University Hospital, Taipei, 
      Taiwan.
FAU - Zahid, Muhammad
AU  - Zahid M
AUID- ORCID: 0000-0002-9975-9476
AD  - Department of Environmental, Agricultural and Occupational Health, University of 
      Nebraska Medical Center, Omaha, Nebraska.
FAU - Kuo, Wen-Hung
AU  - Kuo WH
AUID- ORCID: 0000-0002-9881-4605
AD  - Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan.
FAU - Hu, Fu-Chang
AU  - Hu FC
AUID- ORCID: 0000-0002-9060-0506
AD  - Graduate Institute of Clinical Medicine and School of Nursing, College of 
      Medicine, National Taiwan University, Taipei, Taiwan.
AD  - Statistical Consulting Clinic, International-Harvard Statistical Consulting 
      Company, Taipei, Taiwan.
FAU - Wang, Ming-Yang
AU  - Wang MY
AUID- ORCID: 0000-0001-8941-010X
AD  - Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan.
FAU - Chen, I-Chun
AU  - Chen IC
AUID- ORCID: 0000-0001-9342-7596
AD  - Department of Medical Oncology, National Taiwan University Hospital, Cancer 
      Center Branch, Taipei, Taiwan.
AD  - Graduate Institute of Oncology, National Taiwan University, Taipei, Taiwan.
FAU - Beseler, Cheryl L
AU  - Beseler CL
AUID- ORCID: 0000-0002-2135-3839
AD  - Department of Environmental, Agricultural and Occupational Health, University of 
      Nebraska Medical Center, Omaha, Nebraska.
FAU - Mondal, Bodhisattwa
AU  - Mondal B
AUID- ORCID: 0000-0001-9515-3154
AD  - Department of Biology, Briar Cliff University, Sioux City, Iowa.
FAU - Lu, Yen-Shen
AU  - Lu YS
AUID- ORCID: 0000-0001-7461-1291
AD  - Department of Internal Medicine, National Taiwan University Hospital, Taipei, 
      Taiwan.
FAU - Rogan, Eleanor G
AU  - Rogan EG
AUID- ORCID: 0000-0002-6260-4390
AD  - Department of Environmental, Agricultural and Occupational Health, University of 
      Nebraska Medical Center, Omaha, Nebraska.
FAU - Cheng, Ann-Lii
AU  - Cheng AL
AUID- ORCID: 0000-0002-9152-6512
AD  - Department of Medical Oncology, National Taiwan University Hospital, Cancer 
      Center Branch, Taipei, Taiwan.
AD  - Department of Internal Medicine, National Taiwan University Hospital, Taipei, 
      Taiwan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Prev Res (Phila)
JT  - Cancer prevention research (Philadelphia, Pa.)
JID - 101479409
RN  - 0 (DNA Adducts)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP1A1)
RN  - 0 (Estrogens)
SB  - IM
MH  - Female
MH  - Humans
MH  - *Breast Neoplasms/etiology/genetics
MH  - DNA Adducts
MH  - Cytochrome P-450 CYP1A1
MH  - Case-Control Studies
MH  - Estrogens/metabolism
EDAT- 2022/12/15 06:00
MHDA- 2023/03/03 06:00
CRDT- 2022/12/14 23:02
PHST- 2022/09/22 00:00 [received]
PHST- 2022/11/23 00:00 [revised]
PHST- 2022/12/12 00:00 [accepted]
PHST- 2022/12/15 06:00 [pubmed]
PHST- 2023/03/03 06:00 [medline]
PHST- 2022/12/14 23:02 [entrez]
AID - 711668 [pii]
AID - 10.1158/1940-6207.CAPR-22-0415 [doi]
PST - ppublish
SO  - Cancer Prev Res (Phila). 2023 Mar 1;16(3):153-161. doi: 
      10.1158/1940-6207.CAPR-22-0415.

PMID- 38020654
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240130
IS  - 1664-2295 (Print)
IS  - 1664-2295 (Electronic)
IS  - 1664-2295 (Linking)
VI  - 14
DP  - 2023
TI  - Sex differences in the neuronal transcriptome and synaptic mitochondrial function 
      in the cerebral cortex of a multiple sclerosis model.
PG  - 1268411
LID - 10.3389/fneur.2023.1268411 [doi]
LID - 1268411
AB  - INTRODUCTION: Multiple sclerosis (MS) affects the cerebral cortex, inducing 
      cortical atrophy and neuronal and synaptic pathology. Despite the fact that women 
      are more susceptible to getting MS, men with MS have worse disability 
      progression. Here, sex differences in neurodegenerative mechanisms are determined 
      in the cerebral cortex using the MS model, chronic experimental autoimmune 
      encephalomyelitis (EAE). METHODS: Neurons from cerebral cortex tissues of chronic 
      EAE, as well as age-matched healthy control, male and female mice underwent RNA 
      sequencing and gene expression analyses using RiboTag technology. The morphology 
      of mitochondria in neurons of cerebral cortex was assessed using Thy1-CFP-MitoS 
      mice. Oxygen consumption rates were determined using mitochondrial respirometry 
      assays from intact as well as permeabilized synaptosomes. RESULTS: RNA sequencing 
      of neurons in cerebral cortex during chronic EAE in C57BL/6 mice showed robust 
      differential gene expression in male EAE compared to male healthy controls. In 
      contrast, there were few differences in female EAE compared to female healthy 
      controls. The most enriched differential gene expression pathways in male mice 
      during EAE were mitochondrial dysfunction and oxidative phosphorylation. 
      Mitochondrial morphology in neurons showed significant abnormalities in the 
      cerebral cortex of EAE males, but not EAE females. Regarding function, 
      synaptosomes isolated from cerebral cortex of male, but not female, EAE mice 
      demonstrated significantly decreased oxygen consumption rates during respirometry 
      assays. DISCUSSION: Cortical neuronal transcriptomics, mitochondrial morphology, 
      and functional respirometry assays in synaptosomes revealed worse 
      neurodegeneration in male EAE mice. This is consistent with worse 
      neurodegeneration in MS men and reveals a model and a target to develop 
      treatments to prevent cortical neurodegeneration and mitigate disability 
      progression in MS men.
CI  - Copyright © 2023 Itoh, Itoh, Stiles and Voskuhl.
FAU - Itoh, Noriko
AU  - Itoh N
AD  - Department of Neurology, David Geffen School of Medicine, University of 
      California, Los Angeles, Los Angeles, CA, United States.
FAU - Itoh, Yuichiro
AU  - Itoh Y
AD  - Department of Neurology, David Geffen School of Medicine, University of 
      California, Los Angeles, Los Angeles, CA, United States.
FAU - Stiles, Linsey
AU  - Stiles L
AD  - Department of Endocrinology, David Geffen School of Medicine, University of 
      California, Los Angeles, Los Angeles, CA, United States.
AD  - Department of Molecular and Medical Pharmacology, David Geffen School of 
      Medicine, University of California, Los Angeles, Los Angeles, CA, United States.
FAU - Voskuhl, Rhonda
AU  - Voskuhl R
AD  - Department of Neurology, David Geffen School of Medicine, University of 
      California, Los Angeles, Los Angeles, CA, United States.
LA  - eng
GR  - R01 NS096748/NS/NINDS NIH HHS/United States
GR  - R01 NS109670/NS/NINDS NIH HHS/United States
GR  - R35 NS132150/NS/NINDS NIH HHS/United States
PT  - Journal Article
DEP - 20231102
PL  - Switzerland
TA  - Front Neurol
JT  - Frontiers in neurology
JID - 101546899
PMC - PMC10654219
OTO - NOTNLM
OT  - RNA sequencing
OT  - cerebral cortex
OT  - estrogen
OT  - experimental autoimmune encephalomyelitis
OT  - mitochondria
OT  - multiple sclerosis
OT  - sex chromosomes
OT  - sex differences
COIS- RV is an inventor of UCLA’s patents pertaining to estriol, is a consultant with 
      equity in CleopatraRX, the licensee, and is also an inventor on UCLA’s patents 
      pertaining to novel estrogen receptor beta ligands which are unlicensed. The 
      remaining authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/11/29 18:42
MHDA- 2023/11/29 18:43
PMCR- 2023/11/02
CRDT- 2023/11/29 14:48
PHST- 2023/07/28 00:00 [received]
PHST- 2023/10/09 00:00 [accepted]
PHST- 2023/11/29 18:43 [medline]
PHST- 2023/11/29 18:42 [pubmed]
PHST- 2023/11/29 14:48 [entrez]
PHST- 2023/11/02 00:00 [pmc-release]
AID - 10.3389/fneur.2023.1268411 [doi]
PST - epublish
SO  - Front Neurol. 2023 Nov 2;14:1268411. doi: 10.3389/fneur.2023.1268411. eCollection 
      2023.

PMID- 31728944
OWN - NLM
STAT- MEDLINE
DCOM- 20200228
LR  - 20250103
IS  - 1614-7499 (Electronic)
IS  - 0944-1344 (Linking)
VI  - 26
IP  - 36
DP  - 2019 Dec
TI  - Catalytic degradation of organic pollutants in Fe(III)/peroxymonosulfate (PMS) 
      system: performance, influencing factors, and pathway.
PG  - 36410-36422
LID - 10.1007/s11356-019-06657-y [doi]
AB  - This study demonstrated, for the first time, Fe(III)/peroximonosulphate (PMS) 
      could be an efficient advanced oxidation process (AOP) for wastewater treatment. 
      Bisphenol A (BPA) was chosen as a model pollutant in the present study. 
      Fe(III)-activated PMS system proved very effective to eliminate 92.18% of BPA (20 
      mg/L) for 30-min reaction time at 0.50 mM PMS, 1.5 g/L Fe(III), pH 7.0. The 
      maximum degradation of BPA occurred at neutral pH, while it was suppressed at 
      both strongly acidic and alkaline conditions. Organic and inorganic ions can 
      interfere with system efficiency either positively or negatively, so their 
      interaction was thoroughly investigated. Furthermore, the presence of organic 
      acids also affected BPA degradation rate, especially the addition of 10 mM citric 
      acid decreased the degradation rate from 92.18 to 66.08%. Radical scavenging 
      experiments showed that SO(4)(•-) was the dominant reactive species in 
      Fe(III)/PMS system. A total of 5 BPA intermediates were found by using LC/MS. A 
      possible degradation pathway was proposed which underwent through bridge cleavage 
      and hydroxylation processes. Acute toxicity of the BPA degradation products was 
      assessed using Escherichia coli growth inhibition test. These findings proved to 
      be promising and economical to deal with wastewater using iron mineral for the 
      elimination of organic pollutants. Graphical abstract.
FAU - Latif, Abdul
AU  - Latif A
AD  - Anhui Province Key Laboratory of Farmland Ecological Conservation and Pollution 
      Prevention, School of Resources and Environment, Anhui Agricultural University, 
      Hefei, 230036, China.
FAU - Kai, Sun
AU  - Kai S
AD  - Anhui Province Key Laboratory of Farmland Ecological Conservation and Pollution 
      Prevention, School of Resources and Environment, Anhui Agricultural University, 
      Hefei, 230036, China.
FAU - Si, Youbin
AU  - Si Y
AUID- ORCID: 0000-0002-5983-2560
AD  - Anhui Province Key Laboratory of Farmland Ecological Conservation and Pollution 
      Prevention, School of Resources and Environment, Anhui Agricultural University, 
      Hefei, 230036, China. youbinsi@ahau.edu.cn.
LA  - eng
GR  - 41471405/National Natural Science Foundation of China/
GR  - 1808085QD104, 1908085MD111/Natural Science Foundation of Anhui Province/
PT  - Journal Article
DEP - 20191114
PL  - Germany
TA  - Environ Sci Pollut Res Int
JT  - Environmental science and pollution research international
JID - 9441769
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Ferric Compounds)
RN  - 0 (Peroxides)
RN  - 0 (Phenols)
RN  - 0 (Waste Water)
RN  - 0 (Water Pollutants, Chemical)
RN  - 22047-43-4 (peroxymonosulfate)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - Benzhydryl Compounds/*analysis
MH  - Catalysis
MH  - Ferric Compounds/*chemistry
MH  - Oxidation-Reduction
MH  - Peroxides/*chemistry
MH  - Phenols/*analysis
MH  - Wastewater/*chemistry
MH  - Water Pollutants, Chemical/*analysis
MH  - Water Purification/*methods
OTO - NOTNLM
OT  - Advanced oxidation process (AOP)
OT  - BPA degradation
OT  - Fe(III)/PMS system
OT  - Influencing factors
OT  - Reaction pathway
EDAT- 2019/11/16 06:00
MHDA- 2020/02/29 06:00
CRDT- 2019/11/16 06:00
PHST- 2019/06/19 00:00 [received]
PHST- 2019/09/30 00:00 [accepted]
PHST- 2019/11/16 06:00 [pubmed]
PHST- 2020/02/29 06:00 [medline]
PHST- 2019/11/16 06:00 [entrez]
AID - 10.1007/s11356-019-06657-y [pii]
AID - 10.1007/s11356-019-06657-y [doi]
PST - ppublish
SO  - Environ Sci Pollut Res Int. 2019 Dec;26(36):36410-36422. doi: 
      10.1007/s11356-019-06657-y. Epub 2019 Nov 14.

PMID- 36157343
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220928
IS  - 2666-4984 (Electronic)
IS  - 2096-9643 (Print)
IS  - 2666-4984 (Linking)
VI  - 12
DP  - 2022 Oct
TI  - Organophosphate esters cause thyroid dysfunction via multiple signaling pathways 
      in zebrafish brain.
PG  - 100198
LID - 10.1016/j.ese.2022.100198 [doi]
LID - 100198
AB  - Organophosphate esters (OPEs) are widespread in various environmental media, and 
      can disrupt thyroid endocrine signaling pathways. Mechanisms by which OPEs 
      disrupt thyroid hormone (TH) signal transduction are not fully understood. Here, 
      we present in vivo-in vitro-in silico evidence establishing OPEs as environmental 
      THs competitively entering the brain to inhibit growth of zebrafish via multiple 
      signaling pathways. OPEs can bind to transthyretin (TTR) and thyroxine-binding 
      globulin, thereby affecting the transport of TH in the blood, and to the brain by 
      TTR through the blood-brain barrier. When GH3 cells were exposed to OPEs, cell 
      proliferation was significantly inhibited given that OPEs are competitive 
      inhibitors of TH. Cresyl diphenyl phosphate was shown to be an effective 
      antagonist of TH. Chronic exposure to OPEs significantly inhibited the growth of 
      zebrafish by interfering with thyroperoxidase and thyroglobulin to inhibit TH 
      synthesis. Based on comparisons of modulations of gene expression with the Gene 
      Ontology and Kyoto Encyclopedia of Genes and Genomes databases, signaling 
      pathways related to thyroid endocrine functions, such as receptor-ligand binding 
      and regulation of hormone levels, were identified as being affected by exposure 
      to OPEs. Effects were also associated with the biosynthesis and metabolism of 
      lipids, and neuroactive ligand-receptor interactions. These findings provide a 
      comprehensive understanding of the mechanisms by which OPEs disrupt thyroid 
      pathways in zebrafish.
CI  - © 2022 The Authors.
FAU - Yan, Zhenfei
AU  - Yan Z
AD  - State Key Laboratory of Environmental Criteria and Risk Assessment, Chinese 
      Research Academy of Environmental Sciences, Beijing, 100012, China.
AD  - College of Environment, Hohai University, Nanjing, 210098, China.
FAU - Feng, Chenglian
AU  - Feng C
AD  - State Key Laboratory of Environmental Criteria and Risk Assessment, Chinese 
      Research Academy of Environmental Sciences, Beijing, 100012, China.
FAU - Jin, Xiaowei
AU  - Jin X
AD  - China National Environmental Monitoring Centre, Beijing, 100012, China.
FAU - Wang, Fangkun
AU  - Wang F
AD  - Department of Preventive Veterinary Medicine, College of Veterinary Medicine, 
      Shandong Agricultural University, Taian, 271018, China.
FAU - Liu, Cong
AU  - Liu C
AD  - Department of Preventive Veterinary Medicine, College of Veterinary Medicine, 
      Shandong Agricultural University, Taian, 271018, China.
FAU - Li, Na
AU  - Li N
AD  - Key Laboratory of Drinking Water Science and Technology, Research Center for 
      Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing, 100085, China.
FAU - Qiao, Yu
AU  - Qiao Y
AD  - State Key Laboratory of Environmental Criteria and Risk Assessment, Chinese 
      Research Academy of Environmental Sciences, Beijing, 100012, China.
FAU - Bai, Yingchen
AU  - Bai Y
AD  - State Key Laboratory of Environmental Criteria and Risk Assessment, Chinese 
      Research Academy of Environmental Sciences, Beijing, 100012, China.
FAU - Wu, Fengchang
AU  - Wu F
AD  - State Key Laboratory of Environmental Criteria and Risk Assessment, Chinese 
      Research Academy of Environmental Sciences, Beijing, 100012, China.
AD  - College of Environment, Hohai University, Nanjing, 210098, China.
FAU - Giesy, John P
AU  - Giesy JP
AD  - Department of Veterinary Biomedical Sciences, University of Saskatchewan, 
      Saskatoon, SK, Canada.
AD  - Toxicology Centre, University of Saskatchewan, Saskatoon, SK, Canada.
AD  - Department of Environmental Sciences, Baylor University, Waco, TX, USA.
LA  - eng
PT  - Journal Article
DEP - 20220606
PL  - Netherlands
TA  - Environ Sci Ecotechnol
JT  - Environmental science and ecotechnology
JID - 9918453988906676
PMC - PMC9500371
OTO - NOTNLM
OT  - AChE, acetylcholinesterase
OT  - ANOVA, analysis of variance
OT  - BCF, bioconcentration factor
OT  - BFR, brominated flame retardant
OT  - CD-FBS, charcoal-dextran-treated fetal bovine serum
OT  - CDP, cresyl diphenyl phosphate
OT  - Competitive inhibition assay
OT  - DEG, differentially expressed gene
OT  - DKA, β-diketone antibiotic
OT  - DMSO, dimethyl sulfoxide
OT  - EAS, estrogen
OT  - FBS, fetal bovine serum
OT  - GAPDH, glyceraldehyde-3-phosphate dehydrogenase
OT  - GO, Gene Ontology
OT  - HPLC-MS/MS, high-performance liquid chromatograph interfaced with a mass 
      spectrometer
OT  - HPT, hypothalamic–pituitary–thyroid
OT  - HS, horse serum
OT  - KEGG, Kyoto Encyclopedia of Genes and Genomes
OT  - MAPK, mitogen-activated protein kinase
OT  - Molecular docking simulation
OT  - NIS, Na+/I− symporter
OT  - OD490, optical density
OT  - OPE, organophosphate ester
OT  - OPFR, organophosphate flame retardant
OT  - Organophosphate ester
OT  - P/S, penicillin–streptomycin
OT  - PBDE, polybrominated diphenyl ether
OT  - PBS, phosphate-buffered saline
OT  - RIC20/50, concentration inhibiting 20%/50%
OT  - T4, thyroxin
OT  - TBG, thyroxine-binding globulin
OT  - TCIPP, tris(2-chloroisopropyl) phosphate
OT  - TDCIPP, tris(1,3-dichloro-2-propyl) phosphate (TDCIPP)
OT  - TDCIPP-d15, tris(1,3-dichloroisopropyl) phosphate-D15
OT  - TG, thyroglobulin
OT  - TH, thyroid hormone
OT  - THR, thyroid hormone receptor
OT  - TIPP, tris(isopropyl) phosphate
OT  - TPHP, triphenyl phosphate
OT  - TPO, thyroperoxidase
OT  - TRβ, thyroid hormone receptor β
OT  - TTR, transthyretin
OT  - Thyroid endocrine function
OT  - Transcriptome sequencing
OT  - androgen, and steroidogenesis
OT  - cga, glycoprotein hormone
OT  - qRT-PCR, quantitative real-time PCR
OT  - tshβa, thyroid-stimulating hormone beta subunit a
COIS- The authors declare that there were no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2022/09/27 06:00
MHDA- 2022/09/27 06:01
PMCR- 2022/06/06
CRDT- 2022/09/26 17:07
PHST- 2022/03/21 00:00 [received]
PHST- 2022/06/01 00:00 [revised]
PHST- 2022/06/01 00:00 [accepted]
PHST- 2022/09/26 17:07 [entrez]
PHST- 2022/09/27 06:00 [pubmed]
PHST- 2022/09/27 06:01 [medline]
PHST- 2022/06/06 00:00 [pmc-release]
AID - S2666-4984(22)00054-0 [pii]
AID - 100198 [pii]
AID - 10.1016/j.ese.2022.100198 [doi]
PST - epublish
SO  - Environ Sci Ecotechnol. 2022 Jun 6;12:100198. doi: 10.1016/j.ese.2022.100198. 
      eCollection 2022 Oct.

PMID- 34102661
OWN - NLM
STAT- MEDLINE
DCOM- 20211026
LR  - 20211026
IS  - 1473-5598 (Electronic)
IS  - 0263-6352 (Linking)
VI  - 39
IP  - 10
DP  - 2021 Oct 1
TI  - Effects of hormone replacement therapy on endothelial function, arterial 
      stiffness and myocardial deformation in women with Turner syndrome.
PG  - 2051-2057
LID - 10.1097/HJH.0000000000002903 [doi]
AB  - OBJECTIVES: Turner syndrome (TS) is associated with increased cardiovascular 
      risk. We investigated whether hormone replacement therapy (HRT) affects 
      endothelial function, arterial stiffness and myocardial deformation in women with 
      TS. METHODS: Twenty-five women with TS were studied in the estrogen phase of the 
      HRT and two months after discontinuation of HRT. The following measurements were 
      made: flow-mediated dilation (FMD) of the brachial artery, pulse wave velocity 
      (PWV-Complior) and central systolic blood pressure (cSBP), carotid intima-media 
      thickness (cIMT), aortic (Ao) elastic indexes - namely Ao strain, distensibility, 
      stiffness index and pressure strain modulus (Ep) - and left ventricular (LV) 
      global longitudinal strain (GLS) using speckle-tracking echocardiography. Ten 
      healthy female of similar age and BMI served as a control group. RESULTS: 
      Compared to controls, women with TS on HRT had higher PWV (9.1 ± 2.4 vs. 
      7.5 ± 0.5 m/s), cSBP (130 ± 15 vs. 121 ± 6 mmHg), cIMT (0.66 ± 0.06 vs. 
      0.55 ± 0.05 mm), aortic stiffness index, Ep and LA strain, and lower FMD (7.2 ± 4 
      vs. 10.5 ± 2.3%), Ao strain, Ao distensibility and GLS (-18.8 ± 2.7 vs. 
      -21.9 ± 1.5%) (P < 0.05 for all comparisons). Two months after discontinuation of 
      HRT, all women increased FMD (11.7 ± 6 vs. 7.2 ± 4%) and reduced PWV (7.8 ± 1.7 
      vs. 9.1 ± 2.4 m/s) and cSBP (123 ± 14 vs. 130 ± 15 mmHg). There were no 
      statistically significant changes in BMI, cIMT and GLS (P > 0.05 for all 
      comparisons). The percentage decrease of cSBP was associated with the percentage 
      decrease of PWV (r = 0.54) and reversely related with the percentage increase of 
      FMD (r = -0.57; P < 0.05 for all comparisons). CONCLUSIONS: HRT in women with TS 
      may deteriorate endothelial function contributing to increased arterial stiffness 
      and central arterial blood pressure.
CI  - Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Peppa, Melpomeni
AU  - Peppa M
AD  - Endocrine Unit, 2nd Department of Internal Medicine Propaedeutic, Research 
      Institute and Diabetes Center.
FAU - Pavlidis, George
AU  - Pavlidis G
AD  - 2nd Department of Cardiology.
FAU - Mavroeidi, Ioanna
AU  - Mavroeidi I
AD  - Endocrine Unit, 2nd Department of Internal Medicine Propaedeutic, Research 
      Institute and Diabetes Center.
FAU - Katogiannis, Konstantinos
AU  - Katogiannis K
AD  - 2nd Department of Cardiology.
FAU - Varoudi, Maria
AU  - Varoudi M
AD  - 2nd Department of Cardiology.
FAU - Thymis, John
AU  - Thymis J
AD  - 2nd Department of Cardiology.
FAU - Kostelli, Gavriella
AU  - Kostelli G
AD  - 2nd Department of Cardiology.
FAU - Vlastos, Dimitrios
AU  - Vlastos D
AD  - 2nd Department of Cardiology.
FAU - Plotas, Panagiotis
AU  - Plotas P
AD  - 2nd Department of Cardiology.
FAU - Bamias, Aristotelis
AU  - Bamias A
AD  - 2nd Department of Internal Medicine Propaedeutic, Research Institute and Diabetes 
      Center, Attikon University Hospital, National and Kapodistrian University of 
      Athens, Athens, Greece.
FAU - Parissis, John
AU  - Parissis J
AD  - 2nd Department of Cardiology.
FAU - Ikonomidis, Ignatios
AU  - Ikonomidis I
AD  - 2nd Department of Cardiology.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Hypertens
JT  - Journal of hypertension
JID - 8306882
SB  - IM
MH  - Carotid Intima-Media Thickness
MH  - Female
MH  - Hormone Replacement Therapy
MH  - Humans
MH  - Pulse Wave Analysis
MH  - *Turner Syndrome/drug therapy
MH  - *Vascular Stiffness
EDAT- 2021/06/09 06:00
MHDA- 2021/10/27 06:00
CRDT- 2021/06/08 20:59
PHST- 2021/06/09 06:00 [pubmed]
PHST- 2021/10/27 06:00 [medline]
PHST- 2021/06/08 20:59 [entrez]
AID - 00004872-202110000-00015 [pii]
AID - 10.1097/HJH.0000000000002903 [doi]
PST - ppublish
SO  - J Hypertens. 2021 Oct 1;39(10):2051-2057. doi: 10.1097/HJH.0000000000002903.

PMID- 27771476
OWN - NLM
STAT- MEDLINE
DCOM- 20170928
LR  - 20240425
IS  - 1879-0518 (Electronic)
IS  - 0010-7824 (Print)
IS  - 0010-7824 (Linking)
VI  - 95
IP  - 2
DP  - 2017 Feb
TI  - Nonoral combined hormonal contraceptives and thromboembolism: a systematic 
      review.
PG  - 130-139
LID - S0010-7824(16)30455-3 [pii]
LID - 10.1016/j.contraception.2016.10.005 [doi]
AB  - BACKGROUND: Combined hormonal contraceptives (CHCs), containing estrogen and 
      progestin, are associated with an increased risk of venous thromboembolism (VTE) 
      and arterial thromboembolism (ATE) compared with nonuse. Few studies have 
      examined whether nonoral formulations (including the combined hormonal patch, 
      combined vaginal ring and combined injectable contraceptives) increase the risk 
      of thrombosis compared with combined oral contraceptives (COCs). OBJECTIVES: The 
      objectives were to examine the risk of VTE and ATE among women using nonoral CHCs 
      compared to women using COCs. METHODS: We searched the PubMed database for all 
      English language articles published from database inception through May 2016. We 
      included primary research studies that examined women using the patch, ring or 
      combined injectables compared with women using levonorgestrel-containing or 
      norgestimate-containing COCs. Outcomes of interest included VTE (deep venous 
      thrombosis or pulmonary embolism) or ATE (acute myocardial infarction or ischemic 
      stroke). We assessed the quality of each individual piece of evidence using the 
      system developed by the United States Preventive Services Task Force. RESULTS: 
      Eight studies were identified that met inclusion criteria. Of seven analyses from 
      six studies examining VTE among patch users compared with levonorgestrel- or 
      norgestimate-containing COC users, two found a statistically significantly 
      elevated risk among patch users (risk estimates 2.2-2.3), one found an elevated 
      risk that did not meet statistical significance (risk estimate 2.0), and four 
      found no increased risk. Of three studies examining VTE among ring users compared 
      with levonorgestrel COC users, one found a statistically significantly elevated 
      risk among patch users (risk estimate 1.9) and two did not. Two studies did not 
      find an increased risk for ATE among women using the patch compared with 
      norgestimate COCs. We did not identify any studies examining combined injectable 
      contraceptives. CONCLUSION: Limited Level II-2 good to fair evidence demonstrated 
      conflicting results on whether women using the patch or the ring have a higher 
      risk of VTE than women using COCs. Evidence did not demonstrate an increased risk 
      of ATE among women using the patch. Overall, any potential elevated risk likely 
      represents a small number of events on a population level. Additional studies 
      with standard methodology are needed to further clarify any associations and 
      better understand mechanisms of hormone-induced thrombosis among users of nonoral 
      combined hormonal contraception.
CI  - Published by Elsevier Inc.
FAU - Tepper, Naomi K
AU  - Tepper NK
AD  - Division of Reproductive Health, US Centers for Disease Control and Prevention, 
      4770 Buford Hwy, MS F-74, Atlanta, GA 30341. Electronic address: ntepper@cdc.gov.
FAU - Dragoman, Monica V
AU  - Dragoman MV
AD  - Department of Reproductive Health and Research, World Health Organization, 
      Geneva, Switzerland.
FAU - Gaffield, Mary E
AU  - Gaffield ME
AD  - Department of Reproductive Health and Research, World Health Organization, 
      Geneva, Switzerland.
FAU - Curtis, Kathryn M
AU  - Curtis KM
AD  - Division of Reproductive Health, US Centers for Disease Control and Prevention, 
      4770 Buford Hwy, MS F-74, Atlanta, GA 30341.
LA  - eng
GR  - 001/WHO_/World Health Organization/International
GR  - CC999999/ImCDC/Intramural CDC HHS/United States
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20161019
PL  - United States
TA  - Contraception
JT  - Contraception
JID - 0234361
RN  - 0 (Contraceptives, Oral, Combined)
RN  - 0 (Contraceptives, Oral, Hormonal)
RN  - 0 (Estrogens)
RN  - 0 (Progestins)
RN  - 3J8Q1747Z2 (Norgestrel)
RN  - 5W7SIA7YZW (Levonorgestrel)
RN  - C291HFX4DY (norgestimate)
SB  - IM
MH  - Administration, Cutaneous
MH  - Adolescent
MH  - Adult
MH  - Contraceptive Devices, Female
MH  - Contraceptives, Oral, Combined/*administration & dosage/*adverse effects
MH  - Contraceptives, Oral, Hormonal/adverse effects
MH  - Estrogens/adverse effects
MH  - Female
MH  - Humans
MH  - Levonorgestrel/adverse effects
MH  - Norgestrel/adverse effects/analogs & derivatives
MH  - Progestins/adverse effects
MH  - Risk Factors
MH  - Thromboembolism/*chemically induced
MH  - Venous Thromboembolism/chemically induced
MH  - Young Adult
PMC - PMC11025291
MID - NIHMS1982361
OTO - NOTNLM
OT  - Arterial thromboembolism
OT  - Nonoral combined hormonal contraception
OT  - Patch
OT  - Ring
OT  - Venous thromboembolism
EDAT- 2016/10/25 06:00
MHDA- 2017/09/29 06:00
PMCR- 2024/04/18
CRDT- 2016/11/08 06:00
PHST- 2016/08/09 00:00 [received]
PHST- 2016/10/13 00:00 [accepted]
PHST- 2016/10/25 06:00 [pubmed]
PHST- 2017/09/29 06:00 [medline]
PHST- 2016/11/08 06:00 [entrez]
PHST- 2024/04/18 00:00 [pmc-release]
AID - S0010-7824(16)30455-3 [pii]
AID - 10.1016/j.contraception.2016.10.005 [doi]
PST - ppublish
SO  - Contraception. 2017 Feb;95(2):130-139. doi: 10.1016/j.contraception.2016.10.005. 
      Epub 2016 Oct 19.

PMID- 38643322
OWN - NLM
STAT- MEDLINE
DCOM- 20241014
LR  - 20241108
IS  - 1720-8386 (Electronic)
IS  - 0391-4097 (Print)
IS  - 0391-4097 (Linking)
VI  - 47
IP  - 11
DP  - 2024 Nov
TI  - Sarcopenic obesity and reduced BMD in young men living with HIV: body composition 
      and sex steroids interplay.
PG  - 2715-2730
LID - 10.1007/s40618-024-02375-6 [doi]
AB  - PURPOSE: Sex steroids play a key role on male bone homeostasis and body 
      composition (BC), their role in men living with HIV (MLWH) is less recognized. 
      This study aimed at investigating the prevalence of low BMD, sarcopenia, and 
      sarcopenic obesity (SO) and their relationship with sex steroids in MLWH 
      aged < 50. METHODS: Prospective, cross-sectional, observational study on MLWH 
      younger than 50 (median age 47.0 years). BC and BMD were evaluated with DXA. Two 
      different definitions of sarcopenia were applied: appendicular lean 
      mass/height(2) (ALMI) < 7.26 kg/m(2) or appendicular lean mass/body weight 
      (ALM/W) < 28.27%. Low BMD was defined for Z-score < -2.0. Sarcopenia coupled with 
      obesity identified SO. Serum total testosterone (T) and estradiol (E2) were 
      measured by LC-MS/MS; free testosterone (cFT) was calculated by Vermeulen 
      equation. RESULTS: Sarcopenia was detected in 107 (34.9%) and 44 (14.3%) out of 
      307 MLWH according to ALMI and ALM/W, respectively. The prevalence of SO was 
      similar by using both ALMI (11.4%) and ALM/W (12.4%). Sarcopenic and SO MLWH had 
      lower total T and cFT in both the definition for sarcopenia. BMD was reduced in 
      43/307 (14.0%). Serum E2 < 18 pg/mL was an independent contributing factor for 
      sarcopenia, SO, and low BMD. CONCLUSIONS: T and E2 are important determinants of 
      BC even in MLWH. This is among the first studies investigating the distribution 
      of obesity phenotypes and the prevalence of SO among MLWH showing that SO is 
      present in 11-12% of enrolled MLWH regardless of the definition used. However, 
      deep differences emerged using two different diagnostic definitions.
CI  - © 2024. The Author(s).
FAU - De Vincentis, S
AU  - De Vincentis S
AUID- ORCID: 0000-0002-9582-5683
AD  - Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, 
      University of Modena and Reggio Emilia, Via Giardini, 1355, 41126, Modena, Italy. 
      sara.devincentis@unimore.it.
AD  - Unit of Endocrinology, Department of Medical Specialties, Azienda 
      Ospedaliero-Universitaria of Modena, Modena, Italy. sara.devincentis@unimore.it.
FAU - Greco, C
AU  - Greco C
AUID- ORCID: 0000-0002-9675-3677
AD  - Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, 
      University of Modena and Reggio Emilia, Via Giardini, 1355, 41126, Modena, Italy.
AD  - Unit of Endocrinology, Department of Medical Specialties, Azienda 
      Ospedaliero-Universitaria of Modena, Modena, Italy.
FAU - Fanelli, F
AU  - Fanelli F
AUID- ORCID: 0000-0003-2601-2694
AD  - Endocrinology Research Group, Department of Medical and Surgical Sciences, Center 
      for Applied Biomedical Research, Alma Mater Studiorum University of Bologna, 
      Bologna, Italy.
FAU - Decaroli, M C
AU  - Decaroli MC
AUID- ORCID: 0000-0002-9727-1135
AD  - Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, 
      University of Modena and Reggio Emilia, Via Giardini, 1355, 41126, Modena, Italy.
AD  - Unit of Endocrinology, Department of Medical Specialties, Azienda 
      Ospedaliero-Universitaria of Modena, Modena, Italy.
FAU - Diazzi, C
AU  - Diazzi C
AUID- ORCID: 0000-0002-6259-2481
AD  - Unit of Endocrinology, Department of Medical Specialties, Azienda 
      Ospedaliero-Universitaria of Modena, Modena, Italy.
FAU - Mezzullo, M
AU  - Mezzullo M
AUID- ORCID: 0000-0001-6748-3041
AD  - Endocrinology Research Group, Department of Medical and Surgical Sciences, Center 
      for Applied Biomedical Research, Alma Mater Studiorum University of Bologna, 
      Bologna, Italy.
FAU - Milic, J
AU  - Milic J
AD  - Multidisciplinary Metabolic Clinic, Unit of Infectious Diseases, University of 
      Modena and Reggio Emilia, Modena, Italy.
FAU - De Santis, M C
AU  - De Santis MC
AUID- ORCID: 0000-0002-2169-3921
AD  - Department of Laboratory Medicine and Pathology, Azienda USL of Modena, Modena, 
      Italy.
FAU - Roli, L
AU  - Roli L
AUID- ORCID: 0000-0001-7154-189X
AD  - Department of Laboratory Medicine and Pathology, Azienda USL of Modena, Modena, 
      Italy.
FAU - Pagotto, U
AU  - Pagotto U
AUID- ORCID: 0000-0003-4182-3110
AD  - Endocrinology Research Group, Department of Medical and Surgical Sciences, Center 
      for Applied Biomedical Research, Alma Mater Studiorum University of Bologna, 
      Bologna, Italy.
AD  - Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda 
      Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
FAU - Guaraldi, G
AU  - Guaraldi G
AUID- ORCID: 0000-0002-5724-3914
AD  - Multidisciplinary Metabolic Clinic, Unit of Infectious Diseases, University of 
      Modena and Reggio Emilia, Modena, Italy.
FAU - Rochira, V
AU  - Rochira V
AUID- ORCID: 0000-0001-8169-0696
AD  - Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, 
      University of Modena and Reggio Emilia, Via Giardini, 1355, 41126, Modena, Italy.
AD  - Unit of Endocrinology, Department of Medical Specialties, Azienda 
      Ospedaliero-Universitaria of Modena, Modena, Italy.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20240420
PL  - Italy
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
RN  - 0 (Gonadal Steroid Hormones)
RN  - 3XMK78S47O (Testosterone)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Humans
MH  - Male
MH  - *Sarcopenia/epidemiology/blood/diagnosis
MH  - *Body Composition/physiology
MH  - Cross-Sectional Studies
MH  - *Obesity/epidemiology/complications/physiopathology
MH  - Middle Aged
MH  - Adult
MH  - *HIV Infections/complications/epidemiology
MH  - Prospective Studies
MH  - *Bone Density/physiology
MH  - Gonadal Steroid Hormones/blood
MH  - Testosterone/blood
MH  - Prevalence
MH  - Estradiol/blood
PMC - PMC11473605
OTO - NOTNLM
OT  - Androgen
OT  - Bone mass
OT  - Comorbidity
OT  - Estradiol/testosterone ratio
OT  - Estrogen
OT  - Sarcopenia
OT  - Visceral fat
COIS- The authors have no relevant financial or non-financial interests to disclose.
EDAT- 2024/04/21 00:43
MHDA- 2024/10/14 12:22
PMCR- 2024/04/20
CRDT- 2024/04/20 23:30
PHST- 2024/01/24 00:00 [received]
PHST- 2024/04/09 00:00 [accepted]
PHST- 2024/10/14 12:22 [medline]
PHST- 2024/04/21 00:43 [pubmed]
PHST- 2024/04/20 23:30 [entrez]
PHST- 2024/04/20 00:00 [pmc-release]
AID - 10.1007/s40618-024-02375-6 [pii]
AID - 2375 [pii]
AID - 10.1007/s40618-024-02375-6 [doi]
PST - ppublish
SO  - J Endocrinol Invest. 2024 Nov;47(11):2715-2730. doi: 10.1007/s40618-024-02375-6. 
      Epub 2024 Apr 20.

PMID- 33896600
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20250103
IS  - 1879-0097 (Electronic)
IS  - 0109-5641 (Linking)
VI  - 37
IP  - 6
DP  - 2021 Jun
TI  - Bisphenol A as degradation product of monomers used in resin-based dental 
      materials.
PG  - 1020-1029
LID - S0109-5641(21)00108-1 [pii]
LID - 10.1016/j.dental.2021.03.005 [doi]
AB  - OBJECTIVE: There is still much debate about the release of bisphenol-A (BPA) from 
      dental materials. Therefore, this study aimed to quantify BPA present as an 
      impurity in both BPA-based and non-BPA-based monomers and to evaluate whether 
      these monomers may degrade to BPA upon salivary, bacterial, and chemical 
      challenges. METHODS: BPA was determined in three different amounts (1, 2, and 3 
      μmol) of each monomer (TEGDMA, UDMA, mUDMA, BisGMA, BisEMA-3, -6, -10, -30, 
      BisPMA, EBPADMA urethane, BADGE, and BisDMA). Next, the monomers (3 μmol) were 
      immersed in whole human pooled saliva collected from adults, Streptococcus mutans 
      (2 × 10(7) CFU/mL), and acidic (0.1 M HCl), alkaline (0.1 M NaOH), and control 
      media. The amount of BPA was quantified using a specific and highly sensitive 
      UPLC-MS/MS method including derivatization of BPA by pyridine-3-sulfonyl 
      chloride. RESULTS: The monomers BisGMA and BisEMA-3 contained trace amounts 
      (0.0006% and 0.0025%, respectively) of BPA as impurities of their synthesis 
      process. BPA concentrations increased when the monomers BisGMA, BisEMA-3, 
      BisEMA-6, BisEMA-10, BisPMA and BADGE were exposed to saliva and S. mutans, 
      indicating degradation of a small amount of monomer into BPA. In addition, BisPMA 
      and BADGE degraded into BPA under alkaline conditions. The conversion rate of the 
      monomers into BPA ranged between 0.0003% and 0.0025%. SIGNIFICANCE: Impurities 
      and degradation of BPA-based monomers may account for the release of BPA from 
      resin-based dental materials. Even though the detected amounts of BPA due to 
      monomer impurity were small, manufacturers of dental materials can reduce the BPA 
      content by using only monomers of the highest purity. Considering the overall 
      current trend towards BPA-free materials, it may be recommendable to investigate 
      whether non-BPA based monomers can be used in dental resin-based materials.
CI  - Copyright © 2021 The Academy of Dental Materials. Published by Elsevier Inc. All 
      rights reserved.
FAU - De Nys, Siemon
AU  - De Nys S
AD  - KU Leuven (University of Leuven), Department of Oral Health Sciences, BIOMAT & 
      University Hospitals Leuven (UZ Leuven), Dentistry, 3000 Leuven, Belgium.
FAU - Duca, Radu Corneliu
AU  - Duca RC
AD  - Environment and Health, Department of Public Health and Primary Care, KU Leuven, 
      Kapucijnenvoer 35, 3000 Leuven, Belgium; Unit Environmental Hygiene and Human 
      Biological Monitoring, Department of Health Protection, National Health 
      Laboratory (LNS), 3555 Dudelange, Luxembourg.
FAU - Vervliet, Philippe
AU  - Vervliet P
AD  - Toxicological Centre, University of Antwerp, Universiteitsplein 1, D.S.551, 2610 
      Wilrijk, Belgium.
FAU - Covaci, Adrian
AU  - Covaci A
AD  - Toxicological Centre, University of Antwerp, Universiteitsplein 1, D.S.551, 2610 
      Wilrijk, Belgium.
FAU - Boonen, Imke
AU  - Boonen I
AD  - Laboratory of Analytical, Environmental and Geo-Chemistry, Vrije Universiteit 
      Brussel, Pleinlaan 2, 1050 Ixelles, Belgium.
FAU - Elskens, Marc
AU  - Elskens M
AD  - Laboratory of Analytical, Environmental and Geo-Chemistry, Vrije Universiteit 
      Brussel, Pleinlaan 2, 1050 Ixelles, Belgium.
FAU - Vanoirbeek, Jeroen
AU  - Vanoirbeek J
AD  - Environment and Health, Department of Public Health and Primary Care, KU Leuven, 
      Kapucijnenvoer 35, 3000 Leuven, Belgium.
FAU - Godderis, Lode
AU  - Godderis L
AD  - Environment and Health, Department of Public Health and Primary Care, KU Leuven, 
      Kapucijnenvoer 35, 3000 Leuven, Belgium; IDEWE, External Service for Prevention 
      and Protection at Work, 3001 Heverlee, Belgium.
FAU - Van Meerbeek, Bart
AU  - Van Meerbeek B
AD  - KU Leuven (University of Leuven), Department of Oral Health Sciences, BIOMAT & 
      University Hospitals Leuven (UZ Leuven), Dentistry, 3000 Leuven, Belgium.
FAU - Van Landuyt, Kirsten L
AU  - Van Landuyt KL
AD  - KU Leuven (University of Leuven), Department of Oral Health Sciences, BIOMAT & 
      University Hospitals Leuven (UZ Leuven), Dentistry, 3000 Leuven, Belgium. 
      Electronic address: kirsten.vanlanduyt@kuleuven.be.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210423
PL  - England
TA  - Dent Mater
JT  - Dental materials : official publication of the Academy of Dental Materials
JID - 8508040
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Composite Resins)
RN  - 0 (Dental Materials)
RN  - 0 (Methacrylates)
RN  - 0 (Phenols)
RN  - 0 (Polymethacrylic Acids)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 454I75YXY0 (Bisphenol A-Glycidyl Methacrylate)
RN  - RW57K3X12M (bisphenol A)
MH  - Benzhydryl Compounds
MH  - Bisphenol A-Glycidyl Methacrylate
MH  - Chromatography, Liquid
MH  - *Composite Resins
MH  - Dental Materials
MH  - Humans
MH  - Materials Testing
MH  - Methacrylates
MH  - Phenols
MH  - Polyethylene Glycols
MH  - Polymethacrylic Acids
MH  - *Tandem Mass Spectrometry
OTO - NOTNLM
OT  - Bisphenol A
OT  - Degradation
OT  - Dental monomer
OT  - Impurity
EDAT- 2021/04/27 06:00
MHDA- 2021/06/30 06:00
CRDT- 2021/04/26 05:34
PHST- 2020/06/09 00:00 [received]
PHST- 2021/03/09 00:00 [revised]
PHST- 2021/03/28 00:00 [accepted]
PHST- 2021/04/27 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
PHST- 2021/04/26 05:34 [entrez]
AID - S0109-5641(21)00108-1 [pii]
AID - 10.1016/j.dental.2021.03.005 [doi]
PST - ppublish
SO  - Dent Mater. 2021 Jun;37(6):1020-1029. doi: 10.1016/j.dental.2021.03.005. Epub 
      2021 Apr 23.

PMID- 34465793
OWN - NLM
STAT- MEDLINE
DCOM- 20210915
LR  - 20240202
IS  - 2041-1723 (Electronic)
IS  - 2041-1723 (Linking)
VI  - 12
IP  - 1
DP  - 2021 Aug 31
TI  - Exosomal miR-19a and IBSP cooperate to induce osteolytic bone metastasis of 
      estrogen receptor-positive breast cancer.
PG  - 5196
LID - 10.1038/s41467-021-25473-y [doi]
LID - 5196
AB  - Bone metastasis is an incurable complication of breast cancer. In advanced 
      stages, patients with estrogen-positive tumors experience a significantly higher 
      incidence of bone metastasis (>87%) compared to estrogen-negative patients 
      (<56%). To understand the mechanism of this bone-tropism of ER(+) tumor, and to 
      identify liquid biopsy biomarkers for patients with high risk of bone metastasis, 
      the secreted extracellular vesicles and cytokines from bone-tropic breast cancer 
      cells are examined in this study. Both exosomal miR-19a and Integrin-Binding 
      Sialoprotein (IBSP) are found to be significantly upregulated and secreted from 
      bone-tropic ER(+) breast cancer cells, increasing their levels in the circulation 
      of patients. IBSP is found to attract osteoclast cells and create an 
      osteoclast-enriched environment in the bone, assisting the delivery of exosomal 
      miR-19a to osteoclast to induce osteoclastogenesis. Our findings reveal a 
      mechanism by which ER(+) breast cancer cells create a microenvironment favorable 
      for colonization in the bone. These two secreted factors can also serve as 
      effective biomarkers for ER(+) breast cancer to predict their risks of bone 
      metastasis. Furthermore, our screening of a natural compound library identifies 
      chlorogenic acid as a potent inhibitor for IBSP-receptor binding to suppress bone 
      metastasis of ER(+) tumor, suggesting its preventive use for bone recurrence in 
      ER(+) patients.
CI  - © 2021. The Author(s).
FAU - Wu, Kerui
AU  - Wu K
AD  - Department of Cancer Biology, Wake Forest University School of Medicine, 
      Winston-Salem, NC, USA.
FAU - Feng, Jiamei
AU  - Feng J
AD  - Department of Cancer Biology, Wake Forest University School of Medicine, 
      Winston-Salem, NC, USA.
AD  - Mammary Department, Shuguang Hospital Affiliated to Shanghai University of 
      Traditional Chinese Medicine, Shanghai, China.
FAU - Lyu, Feng
AU  - Lyu F
AD  - Department of Cancer Biology, Wake Forest University School of Medicine, 
      Winston-Salem, NC, USA.
AD  - Department of Breast Surgery, Henan Provincial People's Hospital, People's 
      Hospital of Zhengzhou University, People's Hospital of Henan University, 
      Zhengzhou, Henan, China.
FAU - Xing, Fei
AU  - Xing F
AUID- ORCID: 0000-0001-6350-0764
AD  - Department of Cancer Biology, Wake Forest University School of Medicine, 
      Winston-Salem, NC, USA.
FAU - Sharma, Sambad
AU  - Sharma S
AD  - Department of Cancer Biology, Wake Forest University School of Medicine, 
      Winston-Salem, NC, USA.
FAU - Liu, Yin
AU  - Liu Y
AD  - Department of Cancer Biology, Wake Forest University School of Medicine, 
      Winston-Salem, NC, USA.
FAU - Wu, Shih-Ying
AU  - Wu SY
AD  - Department of Cancer Biology, Wake Forest University School of Medicine, 
      Winston-Salem, NC, USA.
FAU - Zhao, Dan
AU  - Zhao D
AUID- ORCID: 0000-0002-5120-6725
AD  - Department of Cancer Biology, Wake Forest University School of Medicine, 
      Winston-Salem, NC, USA.
FAU - Tyagi, Abhishek
AU  - Tyagi A
AUID- ORCID: 0000-0002-0155-2099
AD  - Department of Cancer Biology, Wake Forest University School of Medicine, 
      Winston-Salem, NC, USA.
FAU - Deshpande, Ravindra Pramod
AU  - Deshpande RP
AD  - Department of Cancer Biology, Wake Forest University School of Medicine, 
      Winston-Salem, NC, USA.
FAU - Pei, Xinhong
AU  - Pei X
AD  - Department of Cancer Biology, Wake Forest University School of Medicine, 
      Winston-Salem, NC, USA.
AD  - Department of Breast Surgery, The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou, Henan, China.
FAU - Ruiz, Marco Gabril
AU  - Ruiz MG
AD  - Department of Cancer Biology, Wake Forest University School of Medicine, 
      Winston-Salem, NC, USA.
FAU - Takahashi, Hiroyuki
AU  - Takahashi H
AD  - Department of Pathology, Jikei University School of Medicine, Minato City, Tokyo, 
      Japan.
FAU - Tsuzuki, Shunsuke
AU  - Tsuzuki S
AD  - Department of Pathology, Jikei University School of Medicine, Minato City, Tokyo, 
      Japan.
FAU - Kimura, Takahiro
AU  - Kimura T
AD  - Department of Pathology, Jikei University School of Medicine, Minato City, Tokyo, 
      Japan.
FAU - Mo, Yin-Yuan
AU  - Mo YY
AD  - Cancer Institute, University of Mississippi Medical Center, Jackson, MS, USA.
FAU - Shiozawa, Yusuke
AU  - Shiozawa Y
AUID- ORCID: 0000-0001-9814-9230
AD  - Department of Cancer Biology, Wake Forest University School of Medicine, 
      Winston-Salem, NC, USA.
FAU - Singh, Ravi
AU  - Singh R
AUID- ORCID: 0000-0003-0750-1804
AD  - Department of Cancer Biology, Wake Forest University School of Medicine, 
      Winston-Salem, NC, USA.
FAU - Watabe, Kounosuke
AU  - Watabe K
AUID- ORCID: 0000-0001-7441-6322
AD  - Department of Cancer Biology, Wake Forest University School of Medicine, 
      Winston-Salem, NC, USA. kwatabe@wakehealth.edu.
LA  - eng
GR  - P30 CA012197/CA/NCI NIH HHS/United States
GR  - R01 CA185650/CA/NCI NIH HHS/United States
GR  - R01 CA173499/CA/NCI NIH HHS/United States
GR  - T32 CA247819/CA/NCI NIH HHS/United States
GR  - R01 CA207222/CA/NCI NIH HHS/United States
GR  - R01 CA205067/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20210831
PL  - England
TA  - Nat Commun
JT  - Nature communications
JID - 101528555
RN  - 0 (Integrin-Binding Sialoprotein)
RN  - 0 (MIRN19a microRNA, mouse)
RN  - 0 (MicroRNAs)
RN  - 0 (Receptors, Estrogen)
SB  - IM
MH  - Animals
MH  - Bone Neoplasms/genetics/metabolism/*secondary
MH  - Breast Neoplasms/genetics/*metabolism/pathology
MH  - Exosomes/genetics/*metabolism
MH  - Female
MH  - Humans
MH  - Integrin-Binding Sialoprotein/genetics/*metabolism
MH  - Mice
MH  - Mice, Knockout
MH  - Mice, Nude
MH  - MicroRNAs/genetics/*metabolism
MH  - Neoplasm Metastasis
MH  - Osteoclasts/metabolism
MH  - Receptors, Estrogen/metabolism
PMC - PMC8408156
COIS- The authors declare no competing interests.
EDAT- 2021/09/02 06:00
MHDA- 2021/09/16 06:00
PMCR- 2021/08/31
CRDT- 2021/09/01 06:51
PHST- 2019/10/30 00:00 [received]
PHST- 2021/08/10 00:00 [accepted]
PHST- 2021/09/01 06:51 [entrez]
PHST- 2021/09/02 06:00 [pubmed]
PHST- 2021/09/16 06:00 [medline]
PHST- 2021/08/31 00:00 [pmc-release]
AID - 10.1038/s41467-021-25473-y [pii]
AID - 25473 [pii]
AID - 10.1038/s41467-021-25473-y [doi]
PST - epublish
SO  - Nat Commun. 2021 Aug 31;12(1):5196. doi: 10.1038/s41467-021-25473-y.

PMID- 24965919
OWN - NLM
STAT- MEDLINE
DCOM- 20151023
LR  - 20150203
IS  - 1098-2787 (Electronic)
IS  - 0277-7037 (Linking)
VI  - 34
IP  - 2
DP  - 2015 Mar-Apr
TI  - Bringing GC-MS profiling of steroids into clinical applications.
PG  - 219-36
LID - 10.1002/mas.21436 [doi]
AB  - Abnormalities of steroid biosynthesis and excretion are responsible for the 
      development and prevention of endocrine disorders, such as metabolic syndromes, 
      cancers, and neurodegenerative diseases. Due to their biochemical roles in 
      endocrine system, qualitative and quantitative analysis of steroid hormones in 
      various biological specimens is needed to elucidate their altered expression. 
      Mass spectrometry (MS)-based steroid profiling can reveal the states of 
      metabolites in biological systems and provide comprehensive insights by allowing 
      comparisons between metabolites present in cells, tissues, or organisms. In 
      addition, the activities of many enzymes related to steroid metabolism often lead 
      to hormonal imbalances that have serious consequences, and which are responsible 
      for the progress of hormone-dependent diseases. In contrast to 
      immunoaffinity-based enzyme assays, MS-based methods are more reproducible in 
      quantification. In particular, high-resolution gas chromatographic (GC) 
      separation of steroids with similar chemical structures can be achieved to 
      provide rapid and reproducible results with excellent purification. GC-MS 
      profiling therefore has been widely used for steroid analysis, and offers the 
      basis for techniques that can be applied to large-scale clinical studies. Recent 
      advances in analytical technologies combined with inter-disciplinary strategies, 
      such as physiology and bioinformatics, will help in understanding the biochemical 
      roles of steroid hormones. Therefore, comprehensive analytical protocols in 
      steroid analysis for different research purposes may contribute to the 
      elucidation of complex metabolic processes relevant to steroid function in many 
      endocrine disorders, and in the identification of diagnostic biomarkers.
CI  - © 2014 Wiley Periodicals, Inc.
FAU - Choi, Man Ho
AU  - Choi MH
AD  - Future Convergence Research Division, Korea Institute of Science and Technology, 
      Seoul, 136-791, Korea.
FAU - Chung, Bong Chul
AU  - Chung BC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20140625
PL  - United States
TA  - Mass Spectrom Rev
JT  - Mass spectrometry reviews
JID - 8219702
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Androgens)
RN  - 0 (Estrogens)
RN  - 0 (Isoenzymes)
RN  - 0 (Progestins)
RN  - 0 (Sterols)
RN  - 9035-51-2 (Cytochrome P-450 Enzyme System)
RN  - EC 1.1.- (Hydroxysteroid Dehydrogenases)
SB  - IM
MH  - Adrenal Cortex Hormones/blood/*isolation & purification
MH  - Androgens/blood/*isolation & purification
MH  - Cardiovascular Diseases/blood/diagnosis
MH  - Cytochrome P-450 Enzyme System/metabolism
MH  - Estrogens/blood/*isolation & purification
MH  - Gas Chromatography-Mass Spectrometry
MH  - Humans
MH  - Hydroxysteroid Dehydrogenases/metabolism
MH  - Isoenzymes/metabolism
MH  - Neoplasms/blood/diagnosis
MH  - Progestins/blood/*isolation & purification
MH  - Solid Phase Extraction
MH  - Sterols/blood/*isolation & purification
OTO - NOTNLM
OT  - diagnostic biomarker
OT  - endocrine disorder
OT  - gas chromatography
OT  - profiling
OT  - steroid
EDAT- 2014/06/27 06:00
MHDA- 2015/10/24 06:00
CRDT- 2014/06/27 06:00
PHST- 2012/06/24 00:00 [received]
PHST- 2013/12/05 00:00 [revised]
PHST- 2014/03/26 00:00 [accepted]
PHST- 2014/06/27 06:00 [entrez]
PHST- 2014/06/27 06:00 [pubmed]
PHST- 2015/10/24 06:00 [medline]
AID - 10.1002/mas.21436 [doi]
PST - ppublish
SO  - Mass Spectrom Rev. 2015 Mar-Apr;34(2):219-36. doi: 10.1002/mas.21436. Epub 2014 
      Jun 25.

PMID- 35483542
OWN - NLM
STAT- MEDLINE
DCOM- 20220628
LR  - 20220921
IS  - 1878-5867 (Electronic)
IS  - 0039-128X (Linking)
VI  - 184
DP  - 2022 Aug
TI  - Assessment of estrogen exposure from transdermal estradiol gel therapy with a 
      dried urine assay.
PG  - 109038
LID - S0039-128X(22)00076-9 [pii]
LID - 10.1016/j.steroids.2022.109038 [doi]
AB  - Transdermal estradiol gel is a commonly used menopausal hormone therapy. In 
      research studies investigating the pharmacokinetics and clinical utility of 
      transdermal estradiol gels, serum is often used to measure estradiol levels. 
      Serum results only represent a moment in time during phlebotomy and thus provide 
      little information and allow for limited inference unless serial measurements are 
      performed. In contrast, dried urine may provide a representation of serum 
      estradiol levels over a longer period of time, while also being non-invasive and 
      easier to collect. The primary aim of this study was to evaluate a dried urine 
      method to determine if it may be a viable option for evaluating estrogen exposure 
      resulting from transdermal estradiol gel use. A secondary aim was to explore 
      differences in the urinary estrogen profiles of premenopausal women on no therapy 
      and postmenopausal women who were either on transdermal estradiol gel therapy or 
      no therapy at all. The results of this study demonstrated that the expected 
      dose-proportional changes in estrogen exposure can be observed in the urinary 
      estrogen profile using a GC-MS/MS dried urine assay. The GC-MS/MS assay also 
      showed the differences in the urinary estrogen profiles of premenopausal women, 
      postmenopausal women on estrogen replacement therapy, and postmenopausal women on 
      no therapy.
CI  - Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
FAU - Newman, Mark S
AU  - Newman MS
AD  - Precision Analytical, Inc 3138 NE Rivergate St., Suite 301C, McMinnville, OR 
      97128, USA.
FAU - Curran, Desmond A
AU  - Curran DA
AD  - Precision Analytical, Inc 3138 NE Rivergate St., Suite 301C, McMinnville, OR 
      97128, USA.
FAU - Mayfield, Bryan P
AU  - Mayfield BP
AD  - Precision Analytical, Inc 3138 NE Rivergate St., Suite 301C, McMinnville, OR 
      97128, USA; Department of Pharmacy Practice, Texas Tech University Health 
      Sciences Center Jerry H. Hodge School of Pharmacy, 5920 Forest Park Road, Dallas, 
      TX 75235, USA.
FAU - Saltiel, Doreen
AU  - Saltiel D
AD  - Precision Analytical, Inc 3138 NE Rivergate St., Suite 301C, McMinnville, OR 
      97128, USA.
FAU - Stanczyk, Frank Z
AU  - Stanczyk FZ
AD  - Departments of Obstetrics and Gynecology, and Population and Public Health 
      Sciences, University of Southern California, LRB 1321 N. Mission Road, Los 
      Angeles, CA, USA.
LA  - eng
PT  - Journal Article
DEP - 20220426
PL  - United States
TA  - Steroids
JT  - Steroids
JID - 0404536
RN  - 0 (Estrogens)
RN  - 0 (Gels)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - *Estradiol
MH  - Estrogen Replacement Therapy
MH  - Estrogens
MH  - Female
MH  - Gels
MH  - Humans
MH  - *Tandem Mass Spectrometry
OTO - NOTNLM
OT  - Dried Urine
OT  - Estradiol
OT  - Estrone
OT  - Gas Chromatography
OT  - Sex Hormones
OT  - Steroid Hormones
OT  - Tandem Mass Spectrometry
OT  - Transdermal Estradiol Gel
OT  - Urinary Estradiol
OT  - Urinary Estrogen
EDAT- 2022/04/29 06:00
MHDA- 2022/06/29 06:00
CRDT- 2022/04/28 19:25
PHST- 2022/01/28 00:00 [received]
PHST- 2022/04/06 00:00 [revised]
PHST- 2022/04/20 00:00 [accepted]
PHST- 2022/04/29 06:00 [pubmed]
PHST- 2022/06/29 06:00 [medline]
PHST- 2022/04/28 19:25 [entrez]
AID - S0039-128X(22)00076-9 [pii]
AID - 10.1016/j.steroids.2022.109038 [doi]
PST - ppublish
SO  - Steroids. 2022 Aug;184:109038. doi: 10.1016/j.steroids.2022.109038. Epub 2022 Apr 
      26.

PMID- 36414155
OWN - NLM
STAT- MEDLINE
DCOM- 20221230
LR  - 20230216
IS  - 1878-5867 (Electronic)
IS  - 0039-128X (Linking)
VI  - 189
DP  - 2023 Jan
TI  - Assessing estrogen exposure from transdermal estradiol patch therapy using a 
      dried urine collection and a GC-MS/MS assay.
PG  - 109149
LID - S0039-128X(22)00188-X [pii]
LID - 10.1016/j.steroids.2022.109149 [doi]
AB  - BACKGROUND: Transdermal estradiol patch therapy is often dosed based on patient 
      reported symptoms. Although dosing based on serum estradiol concentrations has 
      been considered, serum sampling is too invasive and inconvenient to use in 
      real-world settings. The primary aim of this study was to determine if a dried 
      urine assay could be used to assess estrogen exposure resulting from transdermal 
      estradiol patch therapy at increasing doses. METHODS: This was a retrospective 
      analysis of clinical laboratory data. Urinary estrogen profiles of postmenopausal 
      women being treated with transdermal estradiol patches at differing doses 
      (age = 56.8 ± 7.5) were selected from the database along with the profiles of 
      women on no therapy for comparison (age = 55.1 ± 9.5). Metabolite concentrations 
      were obtained using a multi-spot dried urine collection and a gas 
      chromatography-tandem mass spectrometry assay. The Jonckheere-Terpstra test was 
      used to assess for ordered differences across dose groups to determine if 
      dose-dependent increases in urinary estrogens occurred with increasing doses. 
      RESULTS: Median concentrations of estradiol and other estrogen metabolites 
      increased with increasing doses of transdermal estradiol patch therapy 
      (p < 0.001; Jonckheere-Terpstra test). For women who collected samples before and 
      after initiating therapy, there were significant differences between before and 
      after concentrations of estradiol and other estrogen metabolites. CONCLUSION: 
      This large study conducted using real-world data demonstrated that a dried urine 
      assay offers a viable method of assessing estrogen exposure differences that 
      occur with the use of differing doses of transdermal estradiol patches. Further 
      studies with prospective designs that include outcome measures are needed to 
      confirm the findings of this study.
CI  - Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Newman, Mark S
AU  - Newman MS
AD  - Precision Analytical, Inc 3138 NE Rivergate St., Suite 301C, McMinnville, OR 
      97128, USA.
FAU - Mayfield, Bryan P
AU  - Mayfield BP
AD  - Precision Analytical, Inc 3138 NE Rivergate St., Suite 301C, McMinnville, OR 
      97128, USA; Department of Pharmacy Practice, Texas Tech University Health 
      Sciences Center Jerry H. Hodge School of Pharmacy, 5920 Forest Park Road, Dallas, 
      TX 75235, USA. Electronic address: bryan.mayfield@ttuhsc.edu.
FAU - Saltiel, Doreen
AU  - Saltiel D
AD  - Precision Analytical, Inc 3138 NE Rivergate St., Suite 301C, McMinnville, OR 
      97128, USA.
FAU - Stanczyk, Frank Z
AU  - Stanczyk FZ
AD  - Departments of Obstetrics and Gynecology, and Population and Public Health 
      Sciences, University of Southern California, LRB 1321 N. Mission Road, Los 
      Angeles, CA, USA.
LA  - eng
PT  - Journal Article
DEP - 20221119
PL  - United States
TA  - Steroids
JT  - Steroids
JID - 0404536
RN  - 4TI98Z838E (Estradiol)
RN  - 0 (Estrogens)
SB  - IM
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - *Estradiol
MH  - *Tandem Mass Spectrometry
MH  - Gas Chromatography-Mass Spectrometry
MH  - Urine Specimen Collection
MH  - Retrospective Studies
MH  - Estrogens/metabolism
MH  - Estrogen Replacement Therapy/methods
OTO - NOTNLM
OT  - Dried urine
OT  - Gas chromatography
OT  - Tandem mass spectrometry
OT  - Transdermal estradiol patch
OT  - Urinary estradiol
OT  - Urinary estrone
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2022/11/23 06:00
MHDA- 2022/12/31 06:00
CRDT- 2022/11/22 19:25
PHST- 2022/09/20 00:00 [received]
PHST- 2022/11/07 00:00 [revised]
PHST- 2022/11/17 00:00 [accepted]
PHST- 2022/11/23 06:00 [pubmed]
PHST- 2022/12/31 06:00 [medline]
PHST- 2022/11/22 19:25 [entrez]
AID - S0039-128X(22)00188-X [pii]
AID - 10.1016/j.steroids.2022.109149 [doi]
PST - ppublish
SO  - Steroids. 2023 Jan;189:109149. doi: 10.1016/j.steroids.2022.109149. Epub 2022 Nov 
      19.

PMID- 30890053
OWN - NLM
STAT- MEDLINE
DCOM- 20200520
LR  - 20200520
IS  - 1742-5662 (Electronic)
IS  - 1742-5689 (Print)
IS  - 1742-5662 (Linking)
VI  - 16
IP  - 152
DP  - 2019 Mar 29
TI  - Mechanical regulation of bone formation and resorption around implants in a mouse 
      model of osteopenic bone.
PG  - 20180667
LID - 10.1098/rsif.2018.0667 [doi]
LID - 20180667
AB  - Although mechanical stimulation is considered a promising approach to accelerate 
      implant integration, our understanding of load-driven bone formation and 
      resorption around implants is still limited. This lack of knowledge may delay the 
      development of effective loading protocols to prevent implant loosening, 
      especially in osteoporosis. In healthy bone, formation and resorption are 
      mechanoregulated processes. In the intricate context of peri-implant bone 
      regeneration, it is not clear whether bone (re)modelling can still be 
      load-driven. Here, we investigated the mechanical control of peri-implant bone 
      (re)modelling with a well-controlled mechanobiological experiment. We applied 
      cyclic mechanical loading after implant insertion in tail vertebrae of oestrogen 
      depleted mice and we monitored peri-implant bone response by in vivo micro-CT. 
      Experimental data were combined with micro-finite element simulations to estimate 
      local tissue strains in (re)modelling locations. We demonstrated that a 
      substantial increase in bone mass around the implant could be obtained by loading 
      the entire bone. This augmentation could be attributed to a large reduction in 
      bone resorption rather than to an increase in bone formation. We also showed that 
      following implantation, mechanical regulation of bone (re)modelling was 
      transiently lost. Our findings should help to clarify the role of mechanical 
      stimulation on the maintenance of peri-implant bone mass.
FAU - Li, Zihui
AU  - Li Z
AD  - 1 Institute for Biomechanics, ETH Zurich , Zurich , Switzerland.
FAU - Betts, Duncan
AU  - Betts D
AD  - 1 Institute for Biomechanics, ETH Zurich , Zurich , Switzerland.
FAU - Kuhn, Gisela
AU  - Kuhn G
AD  - 1 Institute for Biomechanics, ETH Zurich , Zurich , Switzerland.
FAU - Schirmer, Michael
AU  - Schirmer M
AD  - 2 pfm medical titanium gmbh , Nuremberg , Germany.
FAU - Müller, Ralph
AU  - Müller R
AD  - 1 Institute for Biomechanics, ETH Zurich , Zurich , Switzerland.
FAU - Ruffoni, Davide
AU  - Ruffoni D
AD  - 1 Institute for Biomechanics, ETH Zurich , Zurich , Switzerland.
AD  - 3 Mechanics of Biological and Bioinspired Materials Laboratory, Department of 
      Aerospace and Mechanical Engineering, University of Liège , Liège , Belgium.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J R Soc Interface
JT  - Journal of the Royal Society, Interface
JID - 101217269
SB  - IM
MH  - Animals
MH  - *Bone Density
MH  - Bone Diseases, Metabolic/diagnostic imaging/*metabolism/pathology
MH  - *Bone Resorption
MH  - *Bone-Implant Interface
MH  - Disease Models, Animal
MH  - Female
MH  - *Implants, Experimental
MH  - Mice
MH  - *Osteogenesis
MH  - X-Ray Microtomography
PMC - PMC6451400
OTO - NOTNLM
OT  - bone remodelling
OT  - implant integration
OT  - in vivo micro-CT
OT  - mechanical loading
OT  - mechanobiology
OT  - osteoporosis
COIS- M.S. is an employee of pfm medical titanium. All other authors have declared that 
      no competing interests exist.
EDAT- 2019/03/21 06:00
MHDA- 2020/05/21 06:00
PMCR- 2020/03/01
CRDT- 2019/03/21 06:00
PHST- 2019/03/21 06:00 [entrez]
PHST- 2019/03/21 06:00 [pubmed]
PHST- 2020/05/21 06:00 [medline]
PHST- 2020/03/01 00:00 [pmc-release]
AID - rsif20180667 [pii]
AID - 10.1098/rsif.2018.0667 [doi]
PST - ppublish
SO  - J R Soc Interface. 2019 Mar 29;16(152):20180667. doi: 10.1098/rsif.2018.0667.

PMID- 26654821
OWN - NLM
STAT- MEDLINE
DCOM- 20161219
LR  - 20250103
IS  - 1872-9711 (Electronic)
IS  - 0161-813X (Linking)
VI  - 53
DP  - 2016 Mar
TI  - Exposure to bisphenol A and behavior in school-age children.
PG  - 12-19
LID - S0161-813X(15)30035-8 [pii]
LID - 10.1016/j.neuro.2015.12.001 [doi]
AB  - INTRODUCTION: Bisphenol A (BPA) exposure has been shown to affect human brain 
      neurodevelopment and behavior. OBJECTIVE: We aimed to investigate whether 
      environmental exposure to BPA in children was associated with their childhood 
      behavior. METHODS: Urinary BPA concentrations and behavioral characteristics were 
      assessed in 300 children belonging to the INMA "Environment and Childhood" 
      Granada birth cohort in their follow-up at 9-11 years of age. BPA concentrations 
      were quantified in urine using liquid chromatography-tandem mass spectrometry 
      (LC-MS-MS), and child behavior reported by parents using the Child Behavior 
      Checklist (CBCL/6-18) under supervision of a psychologist. The association 
      between BPA concentrations and CBCL standardized scores was analyzed using linear 
      regression models, adjusted for important covariates. RESULTS: Median (P25, P75) 
      BPA concentration was 4.76 (2.77, 9.03)μg/L. Mean (±SD) CBCL externalizing and 
      internalizing scores were 56.35 (±8.06) and 51.36 (±9.22), respectively. In 
      multivariate regression analyses, adjusted for maternal and child 
      characteristics, higher BPA concentrations were associated with worse behavioral 
      scores on all scales. Children with BPA concentrations in the 4th quartile had 
      more somatic complaints (β=2.35; 95% CI: 0.25, 4.46) and social (β=1.71; 95% CI: 
      0.19, 3.22) and thought problems (β=2.58; 95% CI: 0.66, 4.51) in comparison to 
      those in the 1st quartile. Children with values in the 3rd quartile of BPA 
      concentrations also showed greater social problems (β=1.94; 95% CI: 0.43, 3.45). 
      CONCLUSIONS: Our results suggest that exposure to BPA in childhood may affect 
      children's behavior. Although further investigations are required, preventive 
      measures should be undertaken to reduce inadvertent exposure to BPA.
CI  - Copyright © 2015 Elsevier Inc. All rights reserved.
FAU - Perez-Lobato, R
AU  - Perez-Lobato R
AD  - Instituto de Investigación Biosanitaria ibs.GRANADA, University of Granada, Av. 
      Madrid s/n, Granada 18071, Spain.
FAU - Mustieles, V
AU  - Mustieles V
AD  - Instituto de Investigación Biosanitaria ibs.GRANADA, University of Granada, Av. 
      Madrid s/n, Granada 18071, Spain.
FAU - Calvente, I
AU  - Calvente I
AD  - Instituto de Investigación Biosanitaria ibs.GRANADA, University of Granada, Av. 
      Madrid s/n, Granada 18071, Spain.
FAU - Jimenez-Diaz, I
AU  - Jimenez-Diaz I
AD  - Instituto de Investigación Biosanitaria ibs.GRANADA, University of Granada, Av. 
      Madrid s/n, Granada 18071, Spain.
FAU - Ramos, R
AU  - Ramos R
AD  - Instituto de Investigación Biosanitaria ibs.GRANADA, University of Granada, Av. 
      Madrid s/n, Granada 18071, Spain.
FAU - Caballero-Casero, N
AU  - Caballero-Casero N
AD  - University of Córdoba, Institute of Fine Chemistry and Nanochemistry, 14017 
      Córdoba, Spain.
FAU - López-Jiménez, F J
AU  - López-Jiménez FJ
AD  - University of Córdoba, Institute of Fine Chemistry and Nanochemistry, 14017 
      Córdoba, Spain.
FAU - Rubio, S
AU  - Rubio S
AD  - University of Córdoba, Institute of Fine Chemistry and Nanochemistry, 14017 
      Córdoba, Spain.
FAU - Olea, N
AU  - Olea N
AD  - Instituto de Investigación Biosanitaria ibs.GRANADA, University of Granada, Av. 
      Madrid s/n, Granada 18071, Spain; CIBER en Epidemiología y Salud Pública 
      (CIBERESP), Madrid, Spain.
FAU - Fernandez, M F
AU  - Fernandez MF
AD  - Instituto de Investigación Biosanitaria ibs.GRANADA, University of Granada, Av. 
      Madrid s/n, Granada 18071, Spain; CIBER en Epidemiología y Salud Pública 
      (CIBERESP), Madrid, Spain. Electronic address: marieta@ugr.es.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151204
PL  - Netherlands
TA  - Neurotoxicology
JT  - Neurotoxicology
JID - 7905589
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Environmental Pollutants)
RN  - 0 (Phenols)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - Benzhydryl Compounds/*toxicity/urine
MH  - Checklist
MH  - Child
MH  - Child Behavior Disorders/*epidemiology/*urine
MH  - Chromatography, Liquid
MH  - Cohort Studies
MH  - Community Health Planning
MH  - Environmental Pollutants/*toxicity/urine
MH  - Female
MH  - Humans
MH  - Male
MH  - Mass Spectrometry
MH  - Mood Disorders/*epidemiology/*urine
MH  - Phenols/*toxicity/urine
MH  - Pregnancy
MH  - Prenatal Exposure Delayed Effects/epidemiology/physiopathology
MH  - Psychiatric Status Rating Scales
OTO - NOTNLM
OT  - BPA exposure
OT  - Birth cohort
OT  - Cognitive and behavior functioning
OT  - Healthy children
EDAT- 2015/12/15 06:00
MHDA- 2016/12/20 06:00
CRDT- 2015/12/15 06:00
PHST- 2015/09/09 00:00 [received]
PHST- 2015/11/12 00:00 [revised]
PHST- 2015/12/01 00:00 [accepted]
PHST- 2015/12/15 06:00 [entrez]
PHST- 2015/12/15 06:00 [pubmed]
PHST- 2016/12/20 06:00 [medline]
AID - S0161-813X(15)30035-8 [pii]
AID - 10.1016/j.neuro.2015.12.001 [doi]
PST - ppublish
SO  - Neurotoxicology. 2016 Mar;53:12-19. doi: 10.1016/j.neuro.2015.12.001. Epub 2015 
      Dec 4.

PMID- 30377972
OWN - NLM
STAT- MEDLINE
DCOM- 20190221
LR  - 20240109
IS  - 1614-7499 (Electronic)
IS  - 0944-1344 (Linking)
VI  - 25
IP  - 36
DP  - 2018 Dec
TI  - Natural and synthetic estrogens in leafy vegetable and their risk associated to 
      human health.
PG  - 36712-36723
LID - 10.1007/s11356-018-3588-4 [doi]
AB  - Since the inception of global industrialization, the growth of steroid estrogens 
      becomes a matter of emerging serious concern for the rapid population. Steroidal 
      estrogens are potent endocrine-upsetting chemicals that are excreted naturally by 
      vertebrates (e.g., humans and fish) and can enter natural waters through the 
      discharge of treated and raw sewage. Steroidal estrogens in plants may enter the 
      food web and become a serious threat to human health. We evaluated the uptake and 
      accumulation of ethinylestradiol (EE2) and 17β-estradiol (17β-E2) in lettuce 
      plants (Lactuca sativa) grown under controlled environmental condition over 
      21 days growth period. An effective analytical method based on ultrasonic liquid 
      extraction (ULE) for solid samples and solid phase extraction (SPE) for liquid 
      samples with gas chromatography-mass spectrometry (GC/MS) has been developed to 
      determine the steroid estrogens in lettuce plants. The extent of uptake and 
      accumulation was observed in a dose-dependent manner and roots were major organs 
      for estrogen deposition. Unlike the 17β-E2, EE2 was less accumulated and 
      translocated from root to leaves. For 17β-E2, the distribution in lettuce was 
      primarily to roots after the second week (13%), whereas in leaves it was (10%) 
      over the entire study period. The distribution of EE2 at 2000 μg L(-1) in roots 
      and leaves was very low (3.07% and 0.54%) during the first week and then was 
      highest (12% in roots and 8% in leaves) in last week. Bioaccumulation factor 
      values of 17β-E2 and EE2 in roots were 0.33 and 0.29 at 50 μg L(-1) concentration 
      as maximum values were found at 50 μg L(-1) rather than 500 and 2000 in all 
      observed plant tissues. Similar trend was noticed in roots than leaves for 
      bioconcentration factor as the highest bioconcentration values were observed at 
      50 μg L(-1) concentration instead of 500 and 2000 μg L(-1) spiked concentration. 
      These findings mainly indicate the potential for uptake and bioaccumulation of 
      estrogens in lettuce plants. Overall, the estrogen contents in lettuce were 
      compared to the FAO/WHO recommended toxic level and were found to be higher than 
      the toxic level which is of serious concern to the public health. This analytical 
      procedure may aid in future studies on risks associated with uptake of 
      endocrine-disrupting chemicals in lettuce plants.
FAU - Adeel, Muhammad
AU  - Adeel M
AD  - Beijing Key Laboratory of Farmland Soil Pollution Prevention and Remediation, 
      College of Resources and Environmental Sciences, China Agricultural University, 
      Beijing, 100094, People's Republic of China.
FAU - Zain, Muhammad
AU  - Zain M
AD  - Key Laboratory of Crop Water Use and Regulation, Ministry of Agriculture, 
      Farmland Irrigation Research Institute, Chinese Academy of Agricultural Sciences 
      (CAAS), Xinxiang, 453003, Henan, People's Republic of China.
FAU - Fahad, Shah
AU  - Fahad S
AD  - College of Plant Science and Technology, Huazhong Agricultural University, Wuhan, 
      China.
AD  - Department of Agriculture, The University of Swabi, Swabi, Kyber Pakhtunkhwa, 
      Pakistan.
AD  - College of Life Science, Linyi University, Linyi, 276000, Shandong, China.
FAU - Rizwan, Muhammad
AU  - Rizwan M
AD  - Microelement Research Center, College of Resources and Environment, Huazhong 
      Agricultural University, Wuhan, 430070, People's Republic of China.
FAU - Ameen, Asif
AU  - Ameen A
AD  - College of Agronomy and Biotechnology, China Agricultural University, Beijing, 
      100193, China.
AD  - Department of Agronomy, Faculty of Agriculture, Gomal University, Dera Ismail 
      Khan, Pakistan.
FAU - Yi, Hao
AU  - Yi H
AD  - Beijing Key Laboratory of Farmland Soil Pollution Prevention and Remediation, 
      College of Resources and Environmental Sciences, China Agricultural University, 
      Beijing, 100094, People's Republic of China.
FAU - Baluch, Mansoor A
AU  - Baluch MA
AD  - University of Engineering and Technology, Taxila, 47050, Pakistan.
FAU - Lee, Jie Yinn
AU  - Lee JY
AD  - Institute for Tropical Biology and Conservation (ITBC), University of Malaysia 
      Sabah, 88400, Kota Kinabalu, Sabah, Malaysia.
FAU - Rui, Yukui
AU  - Rui Y
AD  - Beijing Key Laboratory of Farmland Soil Pollution Prevention and Remediation, 
      College of Resources and Environmental Sciences, China Agricultural University, 
      Beijing, 100094, People's Republic of China. ruiyukui@163.com.
LA  - eng
PT  - Journal Article
DEP - 20181030
PL  - Germany
TA  - Environ Sci Pollut Res Int
JT  - Environmental science and pollution research international
JID - 9441769
RN  - 0 (Endocrine Disruptors)
RN  - 0 (Estradiol Congeners)
RN  - 0 (Sewage)
RN  - 0 (Water Pollutants, Chemical)
RN  - 423D2T571U (Ethinyl Estradiol)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Endocrine Disruptors/*analysis/toxicity
MH  - Estradiol/analysis/toxicity
MH  - Estradiol Congeners/*analysis/toxicity
MH  - Ethinyl Estradiol/analysis/toxicity
MH  - Humans
MH  - Lactuca/*chemistry
MH  - Plant Leaves/chemistry
MH  - Risk Assessment
MH  - Sewage/chemistry
MH  - Vegetables/*chemistry
MH  - Water Pollutants, Chemical/*analysis/toxicity
OTO - NOTNLM
OT  - 17β-E2
OT  - Bioaccumulation
OT  - EE2
OT  - Lettuce plants
OT  - Plant uptake
EDAT- 2018/11/01 06:00
MHDA- 2019/02/23 06:00
CRDT- 2018/11/01 06:00
PHST- 2018/09/07 00:00 [received]
PHST- 2018/10/23 00:00 [accepted]
PHST- 2018/11/01 06:00 [pubmed]
PHST- 2019/02/23 06:00 [medline]
PHST- 2018/11/01 06:00 [entrez]
AID - 10.1007/s11356-018-3588-4 [pii]
AID - 10.1007/s11356-018-3588-4 [doi]
PST - ppublish
SO  - Environ Sci Pollut Res Int. 2018 Dec;25(36):36712-36723. doi: 
      10.1007/s11356-018-3588-4. Epub 2018 Oct 30.

PMID- 36308941
OWN - NLM
STAT- MEDLINE
DCOM- 20221130
LR  - 20221130
IS  - 1873-2542 (Electronic)
IS  - 0378-1135 (Linking)
VI  - 275
DP  - 2022 Dec
TI  - RNA-seq and LC-MS/MS analysis of antiviral effects mediated by cold stress and 
      stress hormone corticosterone in chicken DF-1 cells.
PG  - 109580
LID - S0378-1135(22)00249-8 [pii]
LID - 10.1016/j.vetmic.2022.109580 [doi]
AB  - Cold stress in poultry is a global problem that causes huge economic losses and 
      threatens the health and welfare of poultry. However, knowledge of chicken 
      responses to virus infection under cold stress is limited. The purpose of this 
      research was to investigate the effects of cold stress on gene expression and 
      viral replication in chicken DF-1 cells in hypothermia. In addition, the 
      characterization of circulating steroid hormone profiles in the plasma of 
      chickens under cold stress was analyzed by liquid chromatography-tandem mass 
      spectrometry. Herein, we performed RNA sequencing to obtain DF-1 cell 
      transcriptional profiles under cold stress. A total of 9499 differentially 
      expressed genes (DEGs) were identified in DF-1 cells. Overexpressed DEGs were 
      related to the proteasome, cell cycle, spliceosome, ribosome biogenesis, and 
      mammalian target of rapamycin (mTOR). Down-regulated DEGs were related to 
      ribosomes, oxidative phosphorylation, apoptosis, and the p53 signaling pathway. 
      Gene set enrichment analysis showed that the DEGs mainly affect host ribosome 
      translation and mitochondrial respiratory electron transport. The principal 
      steroid hormone alterations in chickens subjected to cold stress included 
      dihydrotestosterone, testosterone, β-sitosterol, androstenedione, 
      7a,27-dihydroxycholesterol,7-ketocholesterol, and desmosterol, which are 
      associated with endocrine resistance, ovarian steroidogenesis, and steroid 
      hormone biosynthesis. In addition, Infectious bronchitis virus (IBV), Newcastle 
      disease virus (NDV), and Influenza A (H9N2) Virus replication in DF-1 cells is 
      significantly inhibited by cold stress. Moreover, the plasma concentrations of 
      corticosterone, an important stress hormone in poultry, were significantly 
      elevated in chickens subjected to cold stress, and we found that IBV and 
      vesicular stomatitis virus (VSV) replication were strongly inhibited in DF-1 
      cells pretreated with CORT, but NDV and H9N2 replication were unaffected. In 
      conclusion, in response to cold stress, the translation efficiency and 
      mitochondrial respiratory chain are temporarily weakened in DF-1 cells, which 
      affects virus replication. Chickens may regulate aromatase deficiency, 
      androstenedione metabolism, androgen and estrogen metabolism, and 17-beta 
      hydroxysteroid dehydrogenase III deficiency through steroid hormones in response 
      to cold stress. This study provides valuable insights into the molecular 
      regulatory mechanisms of poultry under cold stress and may support further 
      research on the intrinsic link between steroid hormones and virus replication 
      under stress.
CI  - Copyright © 2022 Elsevier B.V. All rights reserved.
FAU - Dai, Jun
AU  - Dai J
AD  - Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, 
      Shanghai 200241, China; Laboratory of Veterinary Microbiology and Animal 
      Infectious Diseases, College of Animal Sciences and Veterinary Medicine, Guangxi 
      University, Nanning 530004 Guangxi China. Electronic address: 1341481255@qq.com.
FAU - Wang, Huan
AU  - Wang H
AD  - Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, 
      Shanghai 200241, China. Electronic address: 592622864@qq.com.
FAU - Liao, Ying
AU  - Liao Y
AD  - Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, 
      Shanghai 200241, China. Electronic address: liaoying@shvri.ac.cn.
FAU - Tan, Lei
AU  - Tan L
AD  - Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, 
      Shanghai 200241, China. Electronic address: tanlei@shvri.ac.cn.
FAU - Sun, Yingjie
AU  - Sun Y
AD  - Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, 
      Shanghai 200241, China. Electronic address: sunyingjie@shvri.ac.cn.
FAU - Song, Cuiping
AU  - Song C
AD  - Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, 
      Shanghai 200241, China. Electronic address: scp@shvri.ac.cn.
FAU - Liu, Weiwei
AU  - Liu W
AD  - Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, 
      Shanghai 200241, China. Electronic address: liuweiwei@shvri.ac.cn.
FAU - Qiu, Xusheng
AU  - Qiu X
AD  - Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, 
      Shanghai 200241, China. Electronic address: xsqiu1981@shvri.ac.cn.
FAU - Ding, Chan
AU  - Ding C
AD  - Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, 
      Shanghai 200241, China; Jiangsu Co-innovation Center for Prevention and Control 
      of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, 
      Yangzhou 225009, China. Electronic address: shoveldeen@shvri.ac.cn.
LA  - eng
PT  - Journal Article
DEP - 20221021
PL  - Netherlands
TA  - Vet Microbiol
JT  - Veterinary microbiology
JID - 7705469
RN  - W980KJ009P (Corticosterone)
RN  - 0 (Antiviral Agents)
RN  - 409J2J96VR (Androstenedione)
SB  - IM
MH  - Animals
MH  - Chickens
MH  - *Newcastle Disease
MH  - *Influenza A Virus, H9N2 Subtype/genetics
MH  - Corticosterone
MH  - *Poultry Diseases
MH  - RNA-Seq/veterinary
MH  - Cold-Shock Response
MH  - Antiviral Agents
MH  - Chromatography, Liquid/veterinary
MH  - Androstenedione
MH  - Tandem Mass Spectrometry/veterinary
MH  - Newcastle disease virus/genetics
MH  - *Infectious bronchitis virus/genetics
MH  - Mammals
OTO - NOTNLM
OT  - Antiviral
OT  - Cold stress
OT  - Corticosterone
OT  - Plasma
OT  - Poultry
COIS- Conflict of interest This is the first submission of this manuscript and no parts 
      of this manuscript are being considered for publication elsewhere. All authors 
      have approved this manuscript. No author has financial or other contractual 
      agreements that might cause conflicts of interest.
EDAT- 2022/10/30 06:00
MHDA- 2022/12/01 06:00
CRDT- 2022/10/29 18:28
PHST- 2022/08/05 00:00 [received]
PHST- 2022/09/28 00:00 [revised]
PHST- 2022/10/01 00:00 [accepted]
PHST- 2022/10/30 06:00 [pubmed]
PHST- 2022/12/01 06:00 [medline]
PHST- 2022/10/29 18:28 [entrez]
AID - S0378-1135(22)00249-8 [pii]
AID - 10.1016/j.vetmic.2022.109580 [doi]
PST - ppublish
SO  - Vet Microbiol. 2022 Dec;275:109580. doi: 10.1016/j.vetmic.2022.109580. Epub 2022 
      Oct 21.

PMID- 36006202
OWN - NLM
STAT- MEDLINE
DCOM- 20220829
LR  - 20220920
IS  - 2072-6651 (Electronic)
IS  - 2072-6651 (Linking)
VI  - 14
IP  - 8
DP  - 2022 Aug 8
TI  - Application of an In Vitro Digestion Model for Wheat and Red Beetroot Bread to 
      Assess the Bioaccessibility of Aflatoxin B(1), Ochratoxin A and Zearalenone and 
      Betalains.
LID - 10.3390/toxins14080540 [doi]
LID - 540
AB  - Nowadays, the bakery industry includes different bioactive ingredients to enrich 
      the nutritional properties of its products, such as betalains from red beetroot 
      (Beta vulgaris). However, cereal products are considered a major route of 
      exposure to many mycotoxins, both individually and in combination, due to their 
      daily consumption, if the cereals used contain these toxins. Only the fraction of 
      the contaminant that is released from the food is bioaccessible and bioavailable 
      to produce toxic effects. Foods with bioactive compounds vary widely in chemical 
      structure and function, and some studies have demonstrated their protective 
      effects against toxics. In this study the bioaccessibility and bioavailability of 
      three legislated mycotoxins (AFB(1), OTA and ZEN), individual and combined, in 
      two breads, one with wheat flour and the other with wheat flour enriched with 20% 
      Beta vulgaris, were evaluated. Bioaccessibility of these three mycotoxins from 
      wheat bread and red beet bread enriched individually at 100 ng/g was similar 
      between the breads: 16% and 14% for AFB1, 16% and 17% for OTA and 26% and 22% for 
      ZEN, respectively. Whereas, when mycotoxins were co-present these values varied 
      with a decreasing tendency: 9% and 15% for AFB1, 13% and 9% for OTA, 4% and 25% 
      for ZEN in wheat bread and in red beet bread, respectively. These values reveal 
      that the presence of other components and the co-presence of mycotoxins can 
      affect the final bioavailability; however, it is necessary to assess this process 
      with in vivo studies to complete the studies.
FAU - Llorens Castelló, Paula
AU  - Llorens Castelló P
AD  - Laboratory of Food Chemistry and Toxicology, Faculty of Pharmacy, University of 
      Valencia, 46100 Burjassot, Spain.
FAU - Juan-García, Ana
AU  - Juan-García A
AUID- ORCID: 0000-0002-5988-0490
AD  - Laboratory of Food Chemistry and Toxicology, Faculty of Pharmacy, University of 
      Valencia, 46100 Burjassot, Spain.
FAU - Cortés, Juan Carlos Moltó
AU  - Cortés JCM
AD  - Laboratory of Food Chemistry and Toxicology, Faculty of Pharmacy, University of 
      Valencia, 46100 Burjassot, Spain.
FAU - Mañes Vinuesa, Jordi
AU  - Mañes Vinuesa J
AUID- ORCID: 0000-0002-0289-4752
AD  - Laboratory of Food Chemistry and Toxicology, Faculty of Pharmacy, University of 
      Valencia, 46100 Burjassot, Spain.
FAU - Juan García, Cristina
AU  - Juan García C
AUID- ORCID: 0000-0002-8923-3219
AD  - Laboratory of Food Chemistry and Toxicology, Faculty of Pharmacy, University of 
      Valencia, 46100 Burjassot, Spain.
LA  - eng
PT  - Journal Article
DEP - 20220808
PL  - Switzerland
TA  - Toxins (Basel)
JT  - Toxins
JID - 101530765
RN  - 0 (Mycotoxins)
RN  - 0 (Ochratoxins)
RN  - 1779SX6LUY (ochratoxin A)
RN  - 37279-84-8 (Betalains)
RN  - 5W827M159J (Zearalenone)
RN  - 9N2N2Y55MH (Aflatoxin B1)
SB  - IM
MH  - Aflatoxin B1/analysis
MH  - Betalains/analysis
MH  - Bread/analysis
MH  - Digestion
MH  - Edible Grain/chemistry
MH  - Flour/analysis
MH  - Food Contamination/analysis/prevention & control
MH  - *Mycotoxins/analysis
MH  - Ochratoxins
MH  - Triticum
MH  - Vegetables
MH  - *Zearalenone/analysis
PMC - PMC9414101
OTO - NOTNLM
OT  - LC-Q-TOF-MS
OT  - aflatoxin B1
OT  - beetroot
OT  - bioaccessibility
OT  - bread
OT  - ochratoxin A
OT  - zearalenone
COIS- The authors declare no conflict of interest.
EDAT- 2022/08/26 06:00
MHDA- 2022/08/30 06:00
PMCR- 2022/08/08
CRDT- 2022/08/25 10:32
PHST- 2022/06/28 00:00 [received]
PHST- 2022/07/28 00:00 [revised]
PHST- 2022/08/01 00:00 [accepted]
PHST- 2022/08/25 10:32 [entrez]
PHST- 2022/08/26 06:00 [pubmed]
PHST- 2022/08/30 06:00 [medline]
PHST- 2022/08/08 00:00 [pmc-release]
AID - toxins14080540 [pii]
AID - toxins-14-00540 [pii]
AID - 10.3390/toxins14080540 [doi]
PST - epublish
SO  - Toxins (Basel). 2022 Aug 8;14(8):540. doi: 10.3390/toxins14080540.

PMID- 25514104
OWN - NLM
STAT- MEDLINE
DCOM- 20150512
LR  - 20181202
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 100
IP  - 3
DP  - 2015 Mar
TI  - Effects of low-dose versus placebo or conventional-dose postmenopausal hormone 
      therapy on variables related to cardiovascular risk: a systematic review and 
      meta-analyses of randomized clinical trials.
PG  - 1028-37
LID - 10.1210/jc.2014-3301 [doi]
AB  - CONTEXT: Hormone therapy (HT), the most efficient treatment for menopausal 
      symptoms, might have deleterious cardiovascular (CV) effects. OBJECTIVE: This 
      study aimed to evaluate the effects of low-dose estrogen HT on CV risk factors vs 
      conventional-dose HT and placebo in postmenopausal women with no established CV 
      disease. DATA SOURCES: MEDLINE, Cochrane Central, and EMBASE were searched for 
      trials published in 1990-2013; a hand search of reference lists of selected 
      articles was performed; and ClinicalTrials.gov was searched for unpublished 
      trials. STUDY SELECTION: Within randomized controlled trials of healthy 
      postmenopausal women comparing low-dose HT to placebo or conventional-dose HT, 11 
      418 studies were initially identified. DATA EXTRACTION: Data were independently 
      extracted by two investigators. Disagreements were resolved by a third author. 
      DATA SYNTHESIS: Twenty-eight trials (3360 patients) were included. Low-dose HT vs 
      placebo or conventional-dose HT did not effect weight, body mass index (BMI), 
      blood pressure, C-reactive protein, or high-density lipoprotein cholesterol 
      (HDL-C). Low-dose HT was associated with lower levels of total cholesterol 
      (-12.16 mg/dL, 95% confidence interval [CI], -17.41 - -6.92) and low-density 
      lipoprotein cholesterol (LDL-C) (-12.16 mg/dL; 95% CI, -16.55 - -7.77) vs 
      placebo. Compared with conventional-dose HT, low-dose HT was associated with 
      higher total cholesterol (5.05 mg/dL; 95% CI, 0.88-9.21) and LDL-C (4.49 mg/dL; 
      95% CI, 0.59-8.39). Low-dose HT was not associated with differences in 
      triglycerides vs placebo. Oral, low-dose HT was associated with lower 
      triglycerides vs conventional-dose HT (-14.09 mg/dL; 95% CI, -24.2 - -3.93). 
      CONCLUSION: In this population of apparently healthy postmenopausal women, the 
      effect of low-dose HT did not differ from that of placebo or conventional-dose HT 
      regarding weight, BMI, blood pressure, CRP, or HDL-C. In contrast, low-dose HT 
      was associated with better lipid profile vs placebo, and induced higher total and 
      LDL-C and lower triglycerides vs conventional-dose HT.
FAU - Casanova, Gislaine
AU  - Casanova G
AD  - Gynecological Endocrinology Unit, Division of Endocrinology (G.C., R.B.R., 
      P.M.S.), Hospital de Clínicas de Porto Alegre, 90035-003 Porto Alegre, Brazil; 
      Department of Statistics (P.Z.), Universidade Federal do Rio Grande do Sul 
      (UFRGS), 90035-003 Porto Alegre, Brazil; and Laboratory of Molecular 
      Endocrinology, Department of Physiology (P.M.S.), UFRGS, 90035-003, Porto Alegre, 
      Brazil.
FAU - Bossardi Ramos, Ramon
AU  - Bossardi Ramos R
FAU - Ziegelmann, Patrícia
AU  - Ziegelmann P
FAU - Spritzer, Poli Mara
AU  - Spritzer PM
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20141216
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Lipids)
RN  - 0 (Placebos)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Blood Pressure/drug effects
MH  - C-Reactive Protein/metabolism
MH  - Cardiovascular Diseases/epidemiology/*etiology
MH  - Cardiovascular System/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - *Estrogen Replacement Therapy/adverse effects/methods
MH  - Female
MH  - Humans
MH  - Lipids/blood
MH  - Placebos
MH  - Postmenopause/*drug effects
MH  - Randomized Controlled Trials as Topic/statistics & numerical data
MH  - Risk Factors
EDAT- 2014/12/17 06:00
MHDA- 2015/05/13 06:00
CRDT- 2014/12/17 06:00
PHST- 2014/12/17 06:00 [entrez]
PHST- 2014/12/17 06:00 [pubmed]
PHST- 2015/05/13 06:00 [medline]
AID - 10.1210/jc.2014-3301 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2015 Mar;100(3):1028-37. doi: 10.1210/jc.2014-3301. Epub 
      2014 Dec 16.

PMID- 28690253
OWN - NLM
STAT- MEDLINE
DCOM- 20180806
LR  - 20250103
IS  - 1348-2246 (Electronic)
IS  - 0910-6340 (Linking)
VI  - 33
IP  - 7
DP  - 2017
TI  - Infant Exposure to Bisphenol A Can Be Quantitatively Assessed by a Simply 
      Improved High-Performance Liquid Chromatography-Tandem Mass-Spectrometry Method.
PG  - 777-781
LID - 10.2116/analsci.33.777 [doi]
AB  - To quantitatively measure trace levels of bisphenol A (BPA) in infant urine, a 
      simply improved high-performance liquid chromatography (HPLC)-tandem 
      mass-spectrometry method was developed and validated. In the present work, a 
      ZORBAX SB-C(18) column (2.1 × 30 mm, 3.5 μm) was used for trapping and isolating 
      BPA from the HPLC mobile phase. The result showed that the trapping column can 
      provide effective separation from the background BPA to the sample BPA. This 
      method has a limit of detection (LOD) of 0.048 μg/L, spiked recoveries 85.4% 
      (0.50 - 10.0 μg/L), and relative standard deviations of 1.8 - 15.9%. By using its 
      low-LOD advantage, we firstly reported that Chinese infants (n = 48 with age <6 
      months) have been ubiquitously exposed to BPA (detection frequency of 93%) with 
      an median level of 0.13 μg/L (ranging from below LOD to 5.04 μg/L).
FAU - Wang, Heng
AU  - Wang H
AD  - Key Laboratory of Urban Environment and Health, Institute of Urban Environment, 
      Chinese Academy of Sciences.
AD  - University of Chinese Academy of Sciences.
AD  - Key Laboratory of Health Risk Factors for Seafood of Zhejiang Province, Zhoushan 
      Municipal Center for Disease Control and Prevention.
FAU - Liu, Liangpo
AU  - Liu L
AD  - Key Laboratory of Urban Environment and Health, Institute of Urban Environment, 
      Chinese Academy of Sciences.
AD  - University of Chinese Academy of Sciences.
FAU - Eqani, Syed Ali Musstjab Akber Shah
AU  - Eqani SAMAS
AD  - Key Laboratory of Urban Environment and Health, Institute of Urban Environment, 
      Chinese Academy of Sciences.
FAU - Shen, Heqing
AU  - Shen H
AD  - Key Laboratory of Urban Environment and Health, Institute of Urban Environment, 
      Chinese Academy of Sciences.
AD  - University of Chinese Academy of Sciences.
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Anal Sci
JT  - Analytical sciences : the international journal of the Japan Society for 
      Analytical Chemistry
JID - 8511078
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Environmental Pollutants)
RN  - 0 (Phenols)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - Benzhydryl Compounds/*urine
MH  - Chromatography, High Pressure Liquid
MH  - *Environmental Exposure
MH  - Environmental Pollutants/*urine
MH  - Humans
MH  - Infant
MH  - Phenols/*urine
MH  - Tandem Mass Spectrometry
OTO - NOTNLM
OT  - HPLC-MS/MS
OT  - Infant urine
OT  - trace level BPA
OT  - trapping column
EDAT- 2017/07/12 06:00
MHDA- 2018/08/07 06:00
CRDT- 2017/07/11 06:00
PHST- 2017/07/11 06:00 [entrez]
PHST- 2017/07/12 06:00 [pubmed]
PHST- 2018/08/07 06:00 [medline]
AID - 10.2116/analsci.33.777 [doi]
PST - ppublish
SO  - Anal Sci. 2017;33(7):777-781. doi: 10.2116/analsci.33.777.

PMID- 36038500
OWN - NLM
STAT- MEDLINE
DCOM- 20221118
LR  - 20221229
IS  - 1365-2362 (Electronic)
IS  - 0014-2972 (Print)
IS  - 0014-2972 (Linking)
VI  - 52
IP  - 12
DP  - 2022 Dec
TI  - Sex steroids and sex steroid-binding globulin levels amongst middle-aged and 
      elderly men and women from general population.
PG  - e13866
LID - 10.1111/eci.13866 [doi]
LID - e13866
AB  - BACKGROUND AND AIMS: Availability of age- and sex-specific reference values for 
      sex steroids and sex steroid-binding globulin (SHBG) levels allows for 
      appropriate interpretation of research findings and their clinical applications. 
      We report the sex-specific distribution and reference levels of sex steroids, 
      including total estradiol, total testosterone and (calculated) free androgen 
      index (cFAI), SHBG and other androgens dehydroepiandrosterone (DHEA), 
      dehydroepiandrosterone sulphate (DHEAS) and androstenedione across age. METHODS: 
      Using data from 3291 participants from the prospective population-based Rotterdam 
      Study (2006-2008), we visualised the distribution of sex steroids and SHBG levels 
      by calculating and depicting the 5th, 25th, 50th, 75th and 95th percentiles per 
      year and per age-year across 5-year age bands to provide reference value ranges 
      in men and women. Total estradiol and SHBG were measured using automated 
      immunoassay and androgens using liquid chromatography-mass spectrometry 
      (LC-MS/MS). RESULT: Mean age was 56.8 (range 45.6-79.9) years in men and 56.9 
      (range 45.7-79.9) years in women. Amongst men, total estradiol and SHBG showed an 
      increasing trend from 45 years onwards. In women, total estradiol and SHBG showed 
      a decreasing trend from 45 years until the age of 60. From 60 years onwards, SHBG 
      showed an increasing trend. For total testosterone, a clear declining trend was 
      observed amongst men but not women. Other androgens showed a similar decreasing 
      trend in both sexes from 45 years onwards. DISCUSSION AND CONCLUSION: Our study 
      underlines sex-specific trends in sex steroids and SHBG levels with ageing. This 
      warrants taking into account sex- and age-specific reference values for sex 
      steroids and SHBG when investigating their impact on health outcomes to prevent 
      controversial results and allow for their appropriate clinical application.
CI  - © 2022 The Authors. European Journal of Clinical Investigation published by John 
      Wiley & Sons Ltd on behalf of Stichting European Society for Clinical 
      Investigation Journal Foundation.
FAU - Aribas, Elif
AU  - Aribas E
AUID- ORCID: 0000-0003-2736-7542
AD  - Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, 
      Rotterdam, the Netherlands.
FAU - Roeters van Lennep, Jeanine E
AU  - Roeters van Lennep JE
AD  - Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, 
      Rotterdam, the Netherlands.
FAU - De Rijke, Yolanda B
AU  - De Rijke YB
AD  - Department of Clinical Chemistry, Erasmus MC, University Medical Center 
      Rotterdam, Rotterdam, the Netherlands.
FAU - Laven, Joop S E
AU  - Laven JSE
AD  - Division of Reproductive Endocrinology and Infertility, Department of Obstetrics 
      and Gynecology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the 
      Netherlands.
FAU - Ikram, Mohammad Arfan
AU  - Ikram MA
AD  - Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, 
      Rotterdam, the Netherlands.
FAU - Peeters, Robin P
AU  - Peeters RP
AD  - Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, 
      Rotterdam, the Netherlands.
FAU - Kavousi, Maryam
AU  - Kavousi M
AD  - Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, 
      Rotterdam, the Netherlands.
LA  - eng
GR  - 555003017/ZonMw Gender and Prevention/
GR  - NKI-20157737/The Dutch Cancer Society/
GR  - 2012 T008/The Dutch Heart Foundation/
GR  - The Netherlands Consortium for Healthy Aging/
GR  - The Municipality of Rotterdam/
GR  - The European Commission (DGXII)/
GR  - The Dutch Ministry for Health, Welfare and Sports/
GR  - The Dutch Ministry of Education, Culture and Science/
GR  - The Research Institute for Diseases in the Elderly (RIDE)/
GR  - The Netherlands Organization for the Health Research and Development (ZonMw)/
GR  - Erasmus Medical Center and Erasmus University Rotterdam/
PT  - Journal Article
DEP - 20220908
PL  - England
TA  - Eur J Clin Invest
JT  - European journal of clinical investigation
JID - 0245331
RN  - 0 (Sex Hormone-Binding Globulin)
RN  - 0 (Androgens)
RN  - 0 (Gonadal Steroid Hormones)
RN  - 3XMK78S47O (Testosterone)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Middle Aged
MH  - Aged
MH  - Male
MH  - Female
MH  - Humans
MH  - *Sex Hormone-Binding Globulin/analysis
MH  - Prospective Studies
MH  - Chromatography, Liquid
MH  - *Tandem Mass Spectrometry
MH  - Androgens
MH  - Gonadal Steroid Hormones
MH  - Testosterone
MH  - Estradiol
PMC - PMC9787498
OTO - NOTNLM
OT  - epidemiology
OT  - reference values
OT  - sex steroid-binding globulin
OT  - sex steroids
COIS- EA, JERL, YBR, MAI, RPP and MK have nothing to disclose. JSEL reports grants from 
      fAstellas (Tokyo, Japan), Dutch Heart Association (Utrecht, the Netherlands), 
      ZonMw (Amsterdam, the Netherlands), personal fees from Titus Healthcare 
      (Hoofddorp, the Netherlands) and grants and personal fees from Ferring 
      (Hoofddorp, the Netherlands), Ansh Labs (Webster, Tx, USA), outside the submitted 
      work.
EDAT- 2022/08/30 06:00
MHDA- 2022/11/19 06:00
PMCR- 2022/12/23
CRDT- 2022/08/29 22:12
PHST- 2022/07/20 00:00 [revised]
PHST- 2022/05/20 00:00 [received]
PHST- 2022/08/06 00:00 [accepted]
PHST- 2022/08/30 06:00 [pubmed]
PHST- 2022/11/19 06:00 [medline]
PHST- 2022/08/29 22:12 [entrez]
PHST- 2022/12/23 00:00 [pmc-release]
AID - ECI13866 [pii]
AID - 10.1111/eci.13866 [doi]
PST - ppublish
SO  - Eur J Clin Invest. 2022 Dec;52(12):e13866. doi: 10.1111/eci.13866. Epub 2022 Sep 
      8.

PMID- 34521477
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210918
IS  - 2056-5909 (Print)
IS  - 2056-5909 (Electronic)
IS  - 2056-5909 (Linking)
VI  - 27
IP  - 1
DP  - 2021 Sep 15
TI  - Effects of menopausal hormone therapy on ambulatory blood pressure and arterial 
      stiffness in postmenopausal Korean women with grade 1 hypertension: a randomized, 
      placebo-controlled trial.
PG  - 18
LID - 10.1186/s40885-021-00175-1 [doi]
LID - 18
AB  - BACKGROUND: Estrogen therapy in early menopausal women decreases the risk of 
      coronary heart disease and parenteral, but not oral, estrogen is reported to 
      reduce blood pressure (BP). Progestogens are typically added to estrogens to 
      prevent unopposed endometrial stimulation. The effects of progestogen on BP have 
      been less well studied to date. This study was conducted to explore the impacts 
      of micronized progesterone (MP4) combined with percutaneous estradiol gel (PEG) 
      on hemodynamics in postmenopausal Korean women with grade 1 hypertension. 
      METHODS: Fifty-two postmenopausal women (aged 49-75 years) with systolic BP (SBP) 
      of 140-160 mmHg or diastolic BP (DBP) of 90-100 mmHg were randomly assigned for 
      12 weeks to placebo (n = 16), estrogen therapy (ET) (n = 19) with PEG (0.1 %, 
      1 g./d), or estrogen + progestogen therapy (EPT, n = 17) with PEG and MP4 
      (100 mg/d). The primary endpoint was ambulatory BP and the secondary endpoints 
      were arterial stiffness as brachial-ankle pulse-wave velocity (baPWV) and aortic 
      parameters on applanation tonometry. RESULTS: One woman in the ET group dropped 
      out, so 51 participants were finally analyzed. Outcome measures for ambulatory BP 
      and arterial stiffness were not different between groups. Within-group 
      comparisons showed that EPT significantly decreased daytime heart rate and baPWV: 
      the changes from baseline (mean ± standard deviation) were - 2.5 ± 5.7 bpm 
      (P = 0.03) and - 0.6 ± 1.4 m/s (P = 0.04), respectively. After adjusting for 
      baseline, linear regression analysis revealed a significant difference in the 
      relationship between baseline and 12-week baPWV among groups (P = 0.02). The 
      relationship was significantly different between placebo and ET (P = 0.03) and 
      EPT (P = 0.01), respectively, but not between ET and EPT. Additionally, pooled 
      results of active treatments disclosed that SBP, DBP, PWV, and augmentation index 
      at the aorta were significantly reduced relative to baseline. CONCLUSIONS: There 
      was no difference in ambulatory BP between ET and EPT in postmenopausal Korean 
      women with grade 1 hypertension. Further, ET and EPT similarly decreased baPWV 
      from baseline as compared with placebo. MP4 might not adversely influence 
      estrogen effects on ambulatory BP and arterial stiffness. TRIAL REGISTRATION: 
      Clinical Research Information Registry, KCT0005405, Registered 22 September 2020 
      - Retrospectively registered, 
      https://cris.nih.go.kr/cris/search/detailSearch.do?all_type=Y&search_page=L&pageSize=10&page=1&seq=17608&search_lang=E 
      .
CI  - © 2021. The Author(s).
FAU - Yoon, Byung-Koo
AU  - Yoon BK
AUID- ORCID: 0000-0002-1326-6102
AD  - Department of Obstetrics, Gynecology, and Women's Health, Samsung Medical Center, 
      Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 
      bkyoon@skku.edu.
FAU - Sung, Jidong
AU  - Sung J
AUID- ORCID: 0000-0002-1006-5727
AD  - Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of 
      Medicine, Seoul, Republic of Korea. jidong.sung@samsung.com.
FAU - Song, Yun-Mi
AU  - Song YM
AUID- ORCID: 0000-0001-9232-5563
AD  - Department of Family Medicine, Samsung Medical Center, Sungkyunkwan University 
      School of Medicine, Seoul, Republic of Korea.
FAU - Kim, Soo-Min
AU  - Kim SM
AUID- ORCID: 0000-0002-2368-3057
AD  - Department of Obstetrics, Gynecology, and Women's Health, Samsung Medical Center, 
      Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
FAU - Son, Kyung-A
AU  - Son KA
AUID- ORCID: 0000-0003-1164-8534
AD  - Department of Obstetrics, Gynecology, and Women's Health, Samsung Medical Center, 
      Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
FAU - Yoo, Jun Hyun
AU  - Yoo JH
AUID- ORCID: 0000-0002-0344-5123
AD  - Department of Family Medicine, Samsung Medical Center, Sungkyunkwan University 
      School of Medicine, Seoul, Republic of Korea.
FAU - Park, Sung-Ji
AU  - Park SJ
AUID- ORCID: 0000-0002-7075-847X
AD  - Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of 
      Medicine, Seoul, Republic of Korea.
FAU - Kim, Duk-Kyung
AU  - Kim DK
AUID- ORCID: 0000-0002-2348-8948
AD  - Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of 
      Medicine, Seoul, Republic of Korea.
LA  - eng
GR  - PH01095291 and PH01095801/the Samsung Medical Center Research Fund/
GR  - C-A5-811-1/the IN-SUNG Foundation for Medical Research/
PT  - Journal Article
DEP - 20210915
PL  - England
TA  - Clin Hypertens
JT  - Clinical hypertension
JID - 101669508
PMC - PMC8442403
OTO - NOTNLM
OT  - Estradiol
OT  - Hormone replacement therapy
OT  - Hypertension
OT  - Progestins
OT  - Vascular stiffness
COIS- The authors declare that they have no competing interests.
EDAT- 2021/09/16 06:00
MHDA- 2021/09/16 06:01
PMCR- 2021/09/15
CRDT- 2021/09/15 05:49
PHST- 2020/09/26 00:00 [received]
PHST- 2021/06/15 00:00 [accepted]
PHST- 2021/09/15 05:49 [entrez]
PHST- 2021/09/16 06:00 [pubmed]
PHST- 2021/09/16 06:01 [medline]
PHST- 2021/09/15 00:00 [pmc-release]
AID - 10.1186/s40885-021-00175-1 [pii]
AID - 175 [pii]
AID - 10.1186/s40885-021-00175-1 [doi]
PST - epublish
SO  - Clin Hypertens. 2021 Sep 15;27(1):18. doi: 10.1186/s40885-021-00175-1.

PMID- 34482962
OWN - NLM
STAT- MEDLINE
DCOM- 20211018
LR  - 20250103
IS  - 1879-0097 (Electronic)
IS  - 0109-5641 (Linking)
VI  - 37
IP  - 10
DP  - 2021 Oct
TI  - Long-term elution of bisphenol A from dental composites.
PG  - 1561-1568
LID - S0109-5641(21)00227-X [pii]
LID - 10.1016/j.dental.2021.08.005 [doi]
AB  - OBJECTIVES: BPA release from composites on the short term has been reported in 
      several in-vitro and in-vivo studies. However, it remains unclear whether these 
      materials also leach BPA on the long term. Even though composites may release 
      various (BPA-based) methacrylate monomers up to one year, quantitative data about 
      BPA have not been reported due to the lack of a sensitive method to accurately 
      quantify low levels of BPA. In this context, the aim of the study was to quantify 
      the one-year release of BPA with an optimized analytical method. METHODS: 
      Composite disks (n = 6, 6 mm diameter and 2 mm height) from four commercial 
      materials (G-ӕnial Posterior, Venus, Ceram.x mono and Filtek Supreme XTE) were 
      immersed in 1 mL of water or ethanol as extraction solvent and stored in the dark 
      at 37 °C. The extraction solvent was renewed weekly for a period of 52 weeks. 
      Samples were derivatized with pyridine-3-sulfonyl chloride before analysis with 
      ultra-pressure liquid chromatography tandem mass spectrometry (UPLC-MS/MS). 
      RESULTS: Derivatizing BPA increased the sensitivity of the analytical method and 
      allowed accurate quantification of very low levels of BPA (i.e. 0.78 pmol BPA). 
      BPA eluted continuously in ethanol from all four tested composites over a period 
      of one year. BPA elution was clearly higher when ethanol was used as extraction 
      solution. In water, BPA eluted could be detected up to one year, but levels could 
      not be accurately quantified anymore after several weeks. SIGNIFICANCE: 
      Composites can be considered as a potential long-term source of BPA, and thus 
      should not be neglected when assessing the overall exposure to endocrine 
      disrupting chemicals.
CI  - Copyright © 2021 The Academy of Dental Materials. Published by Elsevier Inc. All 
      rights reserved.
FAU - De Nys, Siemon
AU  - De Nys S
AD  - KU Leuven (University of Leuven), Department of Oral Health Sciences, BIOMAT & 
      University Hospitals Leuven (UZ Leuven), Dentistry, Leuven, Belgium.
FAU - Putzeys, Eveline
AU  - Putzeys E
AD  - KU Leuven (University of Leuven), Department of Oral Health Sciences, BIOMAT & 
      University Hospitals Leuven (UZ Leuven), Dentistry, Leuven, Belgium.
FAU - Duca, Radu Corneliu
AU  - Duca RC
AD  - Environment and Health, Department of Public Health and Primary Care, KU Leuven, 
      Kapucijnenvoer 35, 3000 Leuven, Belgium; Unit Environmental Hygiene and Human 
      Biological Monitoring, Department of Health Protection, National Health 
      Laboratory (LNS), 3555 Dudelange, Luxembourg.
FAU - Vervliet, Philippe
AU  - Vervliet P
AD  - Toxicological Centre, University of Antwerp, Universiteitsplein 1, D.S.551, 2610 
      Wilrijk, Belgium.
FAU - Covaci, Adrian
AU  - Covaci A
AD  - Toxicological Centre, University of Antwerp, Universiteitsplein 1, D.S.551, 2610 
      Wilrijk, Belgium.
FAU - Boonen, Imke
AU  - Boonen I
AD  - Laboratory of Analytical, Environmental and Geo-Chemistry, Vrije Universiteit 
      Brussel, Pleinlaan 2, 1050 Ixelles, Belgium.
FAU - Elskens, Marc
AU  - Elskens M
AD  - Laboratory of Analytical, Environmental and Geo-Chemistry, Vrije Universiteit 
      Brussel, Pleinlaan 2, 1050 Ixelles, Belgium.
FAU - Vanoirbeek, Jeroen
AU  - Vanoirbeek J
AD  - Environment and Health, Department of Public Health and Primary Care, KU Leuven, 
      Kapucijnenvoer 35, 3000 Leuven, Belgium.
FAU - Godderis, Lode
AU  - Godderis L
AD  - Environment and Health, Department of Public Health and Primary Care, KU Leuven, 
      Kapucijnenvoer 35, 3000 Leuven, Belgium; IDEWE, External Service for Prevention 
      and Protection at Work, Heverlee, Belgium.
FAU - Van Meerbeek, Bart
AU  - Van Meerbeek B
AD  - KU Leuven (University of Leuven), Department of Oral Health Sciences, BIOMAT & 
      University Hospitals Leuven (UZ Leuven), Dentistry, Leuven, Belgium.
FAU - Van Landuyt, Kirsten L
AU  - Van Landuyt KL
AD  - KU Leuven (University of Leuven), Department of Oral Health Sciences, BIOMAT & 
      University Hospitals Leuven (UZ Leuven), Dentistry, Leuven, Belgium. Electronic 
      address: kirsten.vanlanduyt@uzleuven.be.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210903
PL  - England
TA  - Dent Mater
JT  - Dental materials : official publication of the Academy of Dental Materials
JID - 8508040
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Composite Resins)
RN  - 0 (Dental Materials)
RN  - 0 (Phenols)
RN  - RW57K3X12M (bisphenol A)
MH  - Benzhydryl Compounds/analysis
MH  - Chromatography, Liquid
MH  - Composite Resins
MH  - *Dental Materials
MH  - Materials Testing
MH  - Phenols
MH  - *Tandem Mass Spectrometry
OTO - NOTNLM
OT  - BPA
OT  - Elution
OT  - Endocrine disruptor
OT  - Monomers
OT  - Resin-based dental composite
EDAT- 2021/09/07 06:00
MHDA- 2021/10/21 06:00
CRDT- 2021/09/06 05:33
PHST- 2021/03/16 00:00 [received]
PHST- 2021/07/20 00:00 [revised]
PHST- 2021/08/04 00:00 [accepted]
PHST- 2021/09/07 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
PHST- 2021/09/06 05:33 [entrez]
AID - S0109-5641(21)00227-X [pii]
AID - 10.1016/j.dental.2021.08.005 [doi]
PST - ppublish
SO  - Dent Mater. 2021 Oct;37(10):1561-1568. doi: 10.1016/j.dental.2021.08.005. Epub 
      2021 Sep 3.

PMID- 31720688
OWN - NLM
STAT- MEDLINE
DCOM- 20201105
LR  - 20231113
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Print)
IS  - 0021-972X (Linking)
VI  - 105
IP  - 3
DP  - 2020 Mar 1
TI  - Sex-specific Estrogen Levels and Reference Intervals from Infancy to Late 
      Adulthood Determined by LC-MS/MS.
PG  - 754-68
LID - dgz196 [pii]
LID - 10.1210/clinem/dgz196 [doi]
AB  - CONTEXT: The lack of sensitive and robust analytical methods has hindered the 
      reliable quantification of estrogen metabolites in subjects with low 
      concentrations. OBJECTIVE: To establish sex-specific reference ranges for estrone 
      (E1) and estradiol (E2) throughout life and to evaluate sex-differences using the 
      state-of-the-art liquid chromatography tandem mass spectrometry (LC-MS/MS) method 
      for quantification of E1, E2, and estriol (E3). DESIGN: LC-MS/MS method 
      development and construction of estrogen reference ranges. SETTINGS: 
      Population-based cross-sectional cohorts from the greater Copenhagen and Aarhus 
      areas. PARTICIPANTS: Healthy participants aged 3 months to 61 years (n = 1838). 
      RESULTS: An isotope diluted LC-MS/MS method was developed and validated for 
      measurements of serum E1, E2, and E3. Limits of detections (LODs) were 3 pmol/L 
      (E1), 4 pmol/L (E2), and 12 pmol/L (E3), respectively. This sensitive method made 
      it possible to differentiate between male and female concentration levels of E1 
      and E2 in children. In girls, E2 levels ranged from <LOD to 100 pmol/L during 
      mini-puberty, whereas it was ≤20 pmol/L during childhood. E1 and E2 increased 
      with age and pubertal breast stage and varied during the menstrual cycle; E1 was 
      lower than E2 in girls and premenopausal women, and higher than E2 in 
      postmenopausal women. In boys, E1 and E2 increased with age and pubertal stage, 
      whereas little changes with age were observed in men. High E3 concentrations were 
      confirmed in pregnant women. CONCLUSION: Reference ranges of simultaneous 
      quantification of E1 and E2 by this novel specific and highly sensitive LC-MS/MS 
      method provide an invaluable tool in clinical practice and in future research 
      studies.
CI  - © Endocrine Society 2019.
FAU - Frederiksen, Hanne
AU  - Frederiksen H
AD  - Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, 
      Copenhagen, Denmark.
AD  - International Center for Research and Research Training in Endocrine Disruption 
      of Male Reproduction and Child Health (EDMaRC), University of Copenhagen, 
      Copenhagen, Denmark.
FAU - Johannsen, Trine Holm
AU  - Johannsen TH
AD  - Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, 
      Copenhagen, Denmark.
AD  - International Center for Research and Research Training in Endocrine Disruption 
      of Male Reproduction and Child Health (EDMaRC), University of Copenhagen, 
      Copenhagen, Denmark.
FAU - Andersen, Stine Ehlern
AU  - Andersen SE
AD  - Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, 
      Copenhagen, Denmark.
FAU - Albrethsen, Jakob
AU  - Albrethsen J
AD  - Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, 
      Copenhagen, Denmark.
AD  - International Center for Research and Research Training in Endocrine Disruption 
      of Male Reproduction and Child Health (EDMaRC), University of Copenhagen, 
      Copenhagen, Denmark.
FAU - Landersoe, Selma Kløve
AU  - Landersoe SK
AD  - The Fertility Clinic, Rigshospitalet, University of Copenhagen, Copenhagen, 
      Denmark.
FAU - Petersen, Jørgen Holm
AU  - Petersen JH
AD  - Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, 
      Copenhagen, Denmark.
AD  - International Center for Research and Research Training in Endocrine Disruption 
      of Male Reproduction and Child Health (EDMaRC), University of Copenhagen, 
      Copenhagen, Denmark.
AD  - Department of Biostatistics, University of Copenhagen, Copenhagen, Denmark.
FAU - Andersen, Anders Nyboe
AU  - Andersen AN
AD  - The Fertility Clinic, Rigshospitalet, University of Copenhagen, Copenhagen, 
      Denmark.
FAU - Vestergaard, Esben Thyssen
AU  - Vestergaard ET
AD  - Paediatrics and Adolescent Medicine, Aarhus University Hospital, Aahus, Denmark.
FAU - Schorring, Mia Elbek
AU  - Schorring ME
AD  - Paediatrics and Adolescent Medicine, Aarhus University Hospital, Aahus, Denmark.
FAU - Linneberg, Allan
AU  - Linneberg A
AD  - Center for Clinical Research and Disease Prevention, Bispebjerg and Frederiksberg 
      Hospital, University of Copenhagen, Copenhagen, Denmark.
AD  - Department of Clinical Medicine, Faculty of Health and Medical Sciences, 
      University of Copenhagen, Copenhagen, Denmark.
FAU - Main, Katharina M
AU  - Main KM
AD  - Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, 
      Copenhagen, Denmark.
AD  - International Center for Research and Research Training in Endocrine Disruption 
      of Male Reproduction and Child Health (EDMaRC), University of Copenhagen, 
      Copenhagen, Denmark.
FAU - Andersson, Anna-Maria
AU  - Andersson AM
AD  - Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, 
      Copenhagen, Denmark.
AD  - International Center for Research and Research Training in Endocrine Disruption 
      of Male Reproduction and Child Health (EDMaRC), University of Copenhagen, 
      Copenhagen, Denmark.
FAU - Juul, Anders
AU  - Juul A
AD  - Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, 
      Copenhagen, Denmark.
AD  - International Center for Research and Research Training in Endocrine Disruption 
      of Male Reproduction and Child Health (EDMaRC), University of Copenhagen, 
      Copenhagen, Denmark.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 2DI9HA706A (Estrone)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Child, Preschool
MH  - Chromatography, Liquid/methods/*statistics & numerical data
MH  - Estradiol/*blood
MH  - Estrone/*blood
MH  - Female
MH  - Healthy Volunteers
MH  - Humans
MH  - Infant
MH  - Male
MH  - Middle Aged
MH  - Reference Values
MH  - Sensitivity and Specificity
MH  - *Sex Factors
MH  - Tandem Mass Spectrometry/methods/*statistics & numerical data
MH  - Young Adult
PMC - PMC7007877
OTO - NOTNLM
OT  - LC-MS/MS
OT  - childhood
OT  - estradiol
OT  - estrone
OT  - menopause
OT  - menstrual cycle
OT  - mini-puberty
OT  - pubertal development
OT  - reference range
EDAT- 2019/11/14 06:00
MHDA- 2020/11/06 06:00
PMCR- 2019/11/13
CRDT- 2019/11/14 06:00
PHST- 2019/09/19 00:00 [received]
PHST- 2019/11/11 00:00 [accepted]
PHST- 2019/11/14 06:00 [pubmed]
PHST- 2020/11/06 06:00 [medline]
PHST- 2019/11/14 06:00 [entrez]
PHST- 2019/11/13 00:00 [pmc-release]
AID - 5624050 [pii]
AID - dgz196 [pii]
AID - 10.1210/clinem/dgz196 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2020 Mar 1;105(3):754-68. doi: 10.1210/clinem/dgz196.

PMID- 29407362
OWN - NLM
STAT- MEDLINE
DCOM- 20190624
LR  - 20240611
IS  - 1879-0518 (Electronic)
IS  - 0010-7824 (Print)
IS  - 0010-7824 (Linking)
VI  - 97
IP  - 4
DP  - 2018 Apr
TI  - Simultaneous quantitation of multiple contraceptive hormones in human serum by 
      LC-MS/MS.
PG  - 363-369
LID - S0010-7824(18)30037-4 [pii]
LID - 10.1016/j.contraception.2018.01.015 [doi]
AB  - OBJECTIVE: The objective was to develop a method to simultaneously quantify five 
      commonly used hormonal contraceptives (HCs) and two endogenous sex steroids by 
      liquid chromatography-tandem triple quadrupole mass spectrometry (LC-MS/MS) and 
      apply this method to human serum samples. STUDY DESIGN: We developed a method to 
      simultaneously analyze ethinyl estradiol (EE2), etonogestrel (ENG), 
      levonorgestrel (LNG), medroxyprogesterone acetate (MPA) and norethisterone (NET), 
      along with estradiol (E2) and progesterone (P4), in human serum for a Shimadzu 
      Nexera-LCMS-8050 LC-MS/MS platform. We analyzed serum collected from women 
      self-reporting use of oral contraceptives, contraceptive implants or injectable 
      contraceptives (n=14) and normally cycling women using no HC (n=15) as well as 
      pooled samples from women administered various HCs (ENG, n=6; LNG, n=14; MPA, 
      n=7; NET, n=5). RESULTS: Limits of quantitation were 0.010ng/mL for E2, EE2 and 
      P4; 0.020ng/mL for ENG, LNG and MPA; and 0.040ng/mL for NET. Precisions for all 
      assays, as indicated by coefficient of variation, were less than or equal to 
      12.1%. Accuracies for all assays were in the range of 95%-108%. Endogenous 
      hormone values obtained from analysis of human serum samples are in agreement 
      with levels previously reported in the literature for normally cycling women as 
      well as for women taking the appropriate HC. CONCLUSIONS: We have developed a 
      robust, accurate and sensitive method for simultaneously analyzing commonly used 
      contraceptive steroids and endogenous sex steroids in human serum. IMPLICATIONS: 
      This analytical method can be used for quantitating contraceptive steroid levels 
      in women for monitoring systemic exposure to determine drug interactions, 
      nonadherence, misreporting and proper dosing.
CI  - Copyright © 2018 Elsevier Inc. All rights reserved.
FAU - Blue, Steven W
AU  - Blue SW
AD  - Endocrine Technologies Support Core, Oregon National Primate Research Center, 
      Beaverton, OR.
FAU - Winchell, Andrea J
AU  - Winchell AJ
AD  - Endocrine Technologies Support Core, Oregon National Primate Research Center, 
      Beaverton, OR.
FAU - Kaucher, Amy V
AU  - Kaucher AV
AD  - Endocrine Technologies Support Core, Oregon National Primate Research Center, 
      Beaverton, OR.
FAU - Lieberman, Rachel A
AU  - Lieberman RA
AD  - Shimadzu Scientific Instruments, Columbia, MD.
FAU - Gilles, Christopher T
AU  - Gilles CT
AD  - Shimadzu Scientific Instruments, Columbia, MD.
FAU - Pyra, Maria N
AU  - Pyra MN
AD  - Department of Epidemiology, University of Washington, Seattle, WA.
FAU - Heffron, Renee
AU  - Heffron R
AD  - Department of Epidemiology, University of Washington, Seattle, WA; Department of 
      Global Health, University of Washington, Seattle, WA.
FAU - Hou, Xuanlin
AU  - Hou X
AD  - Department of Global Health, University of Washington, Seattle, WA.
FAU - Coombs, Robert W
AU  - Coombs RW
AD  - Department of Medicine, University of Washington, Seattle, WA.
FAU - Nanda, Kavita
AU  - Nanda K
AD  - FHI 360, Durham, NC.
FAU - Davis, Nicole L
AU  - Davis NL
AD  - Division of Reproductive Health, National Center for Chronic Disease Prevention 
      and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA.
FAU - Kourtis, Athena P
AU  - Kourtis AP
AD  - Division of Reproductive Health, National Center for Chronic Disease Prevention 
      and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA.
FAU - Herbeck, Joshua T
AU  - Herbeck JT
AD  - Department of Global Health, University of Washington, Seattle, WA.
FAU - Baeten, Jared M
AU  - Baeten JM
AD  - Department of Epidemiology, University of Washington, Seattle, WA; Department of 
      Global Health, University of Washington, Seattle, WA; Department of Medicine, 
      University of Washington, Seattle, WA.
FAU - Lingappa, Jairam R
AU  - Lingappa JR
AD  - Department of Global Health, University of Washington, Seattle, WA; Department of 
      Medicine, University of Washington, Seattle, WA; Department of Pediatrics, 
      University of Washington, Seattle, WA.
FAU - Erikson, David W
AU  - Erikson DW
AD  - Endocrine Technologies Support Core, Oregon National Primate Research Center, 
      Beaverton, OR. Electronic address: erikson@ohsu.edu.
LA  - eng
GR  - P51 OD011092/OD/NIH HHS/United States
GR  - P51 RR000163/RR/NCRR NIH HHS/United States
GR  - R01 AI111738/AI/NIAID NIH HHS/United States
GR  - U48 DP005013/DP/NCCDPHP CDC HHS/United States
GR  - P30 AI027757/AI/NIAID NIH HHS/United States
GR  - U48DP005013/ACL/ACL HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20180131
PL  - United States
TA  - Contraception
JT  - Contraception
JID - 0234361
RN  - 0 (Contraceptives, Oral)
RN  - 0 (Contraceptives, Oral, Combined)
RN  - 0 (Steroids)
RN  - 4G7DS2Q64Y (Progesterone)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Adult
MH  - Chromatography, Liquid
MH  - Contraceptives, Oral/*blood
MH  - Contraceptives, Oral, Combined/*blood
MH  - Estradiol/*blood
MH  - Female
MH  - Humans
MH  - Progesterone/*blood
MH  - Steroids/blood
MH  - Tandem Mass Spectrometry
PMC - PMC5840044
MID - NIHMS945332
OTO - NOTNLM
OT  - Hormonal contraceptive
OT  - LC–MS/MS
OT  - Liquid chromatography
OT  - Mass spectrometry
OT  - Steroid
EDAT- 2018/02/07 06:00
MHDA- 2019/06/25 06:00
PMCR- 2019/04/01
CRDT- 2018/02/07 06:00
PHST- 2017/07/28 00:00 [received]
PHST- 2017/12/13 00:00 [revised]
PHST- 2018/01/24 00:00 [accepted]
PHST- 2018/02/07 06:00 [pubmed]
PHST- 2019/06/25 06:00 [medline]
PHST- 2018/02/07 06:00 [entrez]
PHST- 2019/04/01 00:00 [pmc-release]
AID - S0010-7824(18)30037-4 [pii]
AID - 10.1016/j.contraception.2018.01.015 [doi]
PST - ppublish
SO  - Contraception. 2018 Apr;97(4):363-369. doi: 10.1016/j.contraception.2018.01.015. 
      Epub 2018 Jan 31.

PMID- 33408073
OWN - NLM
STAT- MEDLINE
DCOM- 20220307
LR  - 20240808
IS  - 1940-6215 (Electronic)
IS  - 1940-6207 (Print)
IS  - 1940-6215 (Linking)
VI  - 14
IP  - 4
DP  - 2021 Apr
TI  - Circulating 27-hydroxycholesterol and Risk of Colorectal Adenomas and Serrated 
      Polyps.
PG  - 479-488
LID - 10.1158/1940-6207.CAPR-20-0414 [doi]
AB  - The oxysterol 27-hydroxycholesterol (27-OHC) is an endogenous selective estrogen 
      receptor modulator implicated in breast cancer etiology. It is unknown whether 
      circulating 27-OHC is associated with colorectal neoplasia risk. Circulating 
      27-OHC was measured using LC/MS in fasting plasma collected at baseline from 
      participants of the Vitamin D/Calcium Polyp Prevention Study, a completed 
      randomized clinical trial. Participants were between 45 and 75 years old, 
      recently diagnosed with ≥1 colorectal adenoma, and followed for new colorectal 
      polyps during colonoscopic surveillance. Adjusted risk ratios (RR) with 95% 
      confidence intervals (CI) of new colorectal polyps were estimated for quartiles 
      of circulating 27-OHC using log-linear regression for repeated outcomes. Polyp 
      phenotypes included any adenomas, advanced adenomas, hyperplastic polyps, and 
      sessile serrated adenomas/polyps. Circulating 27-OHC was measured at baseline for 
      1,246 participants. Compared with participants with circulating 27-OHC below the 
      first quartile (<138 ng/mL), those with circulating 27-OHC at or above the fourth 
      quartile (≥201 ng/mL) had 24% higher risk of adenomas (RR, 1.24; 95% CI, 
      1.05-1.47) and 89% higher risk of advanced adenomas (RR, 1.89; 95% CI, 
      1.17-3.06). Stronger associations were observed among participants with advanced 
      adenomas at baseline. Circulating 27-OHC was not associated with risk of 
      hyperplastic polyps (RR, 0.90; 95% CI, 0.66-1.22) or sessile serrated 
      adenomas/polyps (RR, 1.02; 95% CI, 0.50-2.07). Circulating 27-OHC may be a risk 
      factor for colorectal adenomas but not serrated polyps. PREVENTION RELEVANCE: 
      This study found that plasma concentration of 27-hydroxycholesterol, a metabolite 
      of cholesterol that regulates lipid metabolism and acts as a selective estrogen 
      receptor modulator, is associated with the risk of developing precursor lesions 
      for colorectal cancer.
CI  - ©2021 American Association for Cancer Research.
FAU - Passarelli, Michael N
AU  - Passarelli MN
AD  - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, New 
      Hampshire. michael.n.passarelli@dartmouth.edu.
FAU - Thompson, Bonne M
AU  - Thompson BM
AD  - Department of Molecular Genetics, University of Texas Southwestern Medical 
      Center, Dallas, Texas.
AD  - Center for Human Nutrition, University of Texas Southwestern Medical Center, 
      Dallas, Texas.
FAU - McDonald, Jeffrey G
AU  - McDonald JG
AD  - Department of Molecular Genetics, University of Texas Southwestern Medical 
      Center, Dallas, Texas.
AD  - Center for Human Nutrition, University of Texas Southwestern Medical Center, 
      Dallas, Texas.
FAU - Snover, Dale C
AU  - Snover DC
AD  - Department of Pathology, Fairview Southdale Hospital, Edina, Minnesota.
FAU - Palys, Thomas J
AU  - Palys TJ
AD  - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, New 
      Hampshire.
FAU - Rees, Judy R
AU  - Rees JR
AD  - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, New 
      Hampshire.
FAU - Barry, Elizabeth L
AU  - Barry EL
AUID- ORCID: 0000-0001-9637-3036
AD  - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, New 
      Hampshire.
FAU - Baron, John A
AU  - Baron JA
AUID- ORCID: 0000-0003-3461-1056
AD  - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, New 
      Hampshire.
AD  - Department of Medicine, University of North Carolina School of Medicine, Chapel 
      Hill, North Carolina.
AD  - Department of Epidemiology, Gillings School of Global Public Health, University 
      of North Carolina, Chapel Hill, North Carolina.
LA  - eng
GR  - P01 HL020948/HL/NHLBI NIH HHS/United States
GR  - P20 GM104416/GM/NIGMS NIH HHS/United States
GR  - R01 CA098286/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20210106
PL  - United States
TA  - Cancer Prev Res (Phila)
JT  - Cancer prevention research (Philadelphia, Pa.)
JID - 101479409
RN  - 0 (Biomarkers)
RN  - 0 (Hydroxycholesterols)
RN  - 0 (Vitamins)
RN  - 1406-16-2 (Vitamin D)
RN  - 6T2NA6P5SQ (27-hydroxycholesterol)
SB  - IM
MH  - Adenoma/blood/drug therapy/epidemiology/*pathology
MH  - Biomarkers/*blood
MH  - Colonic Polyps/blood/drug therapy/epidemiology/*pathology
MH  - Colorectal Neoplasms/blood/drug therapy/epidemiology/*pathology
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Hydroxycholesterols/*blood
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Risk Factors
MH  - United States/epidemiology
MH  - Vitamin D/*administration & dosage
MH  - Vitamins/administration & dosage
PMC - PMC8026496
MID - NIHMS1659033
COIS- Disclosure of Potential Conflicts of Interest: Together with the Trustees of 
      Dartmouth College, J. A. Baron holds a patent, currently not licensed, for the 
      chemopreventive use of calcium for colorectal cancer. All other authors declare 
      no potential conflicts of interest.
EDAT- 2021/01/08 06:00
MHDA- 2022/03/08 06:00
PMCR- 2021/10/01
CRDT- 2021/01/07 05:59
PHST- 2020/08/05 00:00 [received]
PHST- 2020/11/16 00:00 [revised]
PHST- 2020/12/23 00:00 [accepted]
PHST- 2021/01/08 06:00 [pubmed]
PHST- 2022/03/08 06:00 [medline]
PHST- 2021/01/07 05:59 [entrez]
PHST- 2021/10/01 00:00 [pmc-release]
AID - 1940-6207.CAPR-20-0414 [pii]
AID - 10.1158/1940-6207.CAPR-20-0414 [doi]
PST - ppublish
SO  - Cancer Prev Res (Phila). 2021 Apr;14(4):479-488. doi: 
      10.1158/1940-6207.CAPR-20-0414. Epub 2021 Jan 6.

PMID- 39694337
OWN - NLM
STAT- Publisher
LR  - 20241222
IS  - 1095-6808 (Electronic)
IS  - 0091-3022 (Linking)
VI  - 76
DP  - 2024 Dec 16
TI  - Revisiting the role of sexual hormones in the demyelinated central nervous 
      system.
PG  - 101172
LID - S0091-3022(24)00052-9 [pii]
LID - 10.1016/j.yfrne.2024.101172 [doi]
AB  - Sex-related differences characterize multiple sclerosis, an autoimmune, 
      inflammatory and neurodegenerative disease displaying higher incidence in females 
      as well as discrepancies in susceptibility and progression. Besides clinical 
      specificities, molecular and cellular differences related to sex hormones were 
      progressively uncovered improving our understanding of the mechanisms involved in 
      this disabling disease. The most recent findings may give rise to the 
      identification of novel therapeutic perspectives that could meet the urgent need 
      for a treatment preventing the transition from the recurrent- to the progressive 
      form of the disease. The present review is an update of our current knowledge 
      about progestagens, androgens and estrogens in the context of CNS demyelination 
      including their synthesis, the impact of their dysregulation, the preclinical and 
      clinical data presently available, the main molecular dimorphisms related to 
      these hormones and their age-related changes and relationship with failure of 
      spontaneous remyelination, likely impacting the inexorable progression of 
      multiple sclerosis towards irreversible disabilities.
CI  - Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Traiffort, Elisabeth
AU  - Traiffort E
AD  - U1195 Inserm, Paris-Saclay University, Kremlin-Bicêtre, France. Electronic 
      address: elisabeth.traiffort@inserm.fr.
FAU - Kassoussi, Abdelmoumen
AU  - Kassoussi A
AD  - U1195 Inserm, Paris-Saclay University, Kremlin-Bicêtre, France.
FAU - Zahaf, Amina
AU  - Zahaf A
AD  - U1195 Inserm, Paris-Saclay University, Kremlin-Bicêtre, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20241216
PL  - United States
TA  - Front Neuroendocrinol
JT  - Frontiers in neuroendocrinology
JID - 7513292
SB  - IM
OTO - NOTNLM
OT  - Androgen
OT  - CNS demyelination
OT  - Estrogen
OT  - Microglia
OT  - Multiple sclerosis
OT  - Neuroinflammation
OT  - Progestagen
OT  - Remyelination
OT  - Sexual dimorphism
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2024/12/19 00:20
MHDA- 2024/12/19 00:20
CRDT- 2024/12/18 19:17
PHST- 2024/07/03 00:00 [received]
PHST- 2024/12/09 00:00 [revised]
PHST- 2024/12/15 00:00 [accepted]
PHST- 2024/12/19 00:20 [pubmed]
PHST- 2024/12/19 00:20 [medline]
PHST- 2024/12/18 19:17 [entrez]
AID - S0091-3022(24)00052-9 [pii]
AID - 10.1016/j.yfrne.2024.101172 [doi]
PST - aheadofprint
SO  - Front Neuroendocrinol. 2024 Dec 16;76:101172. doi: 10.1016/j.yfrne.2024.101172.

PMID- 34798152
OWN - NLM
STAT- MEDLINE
DCOM- 20220301
LR  - 20250103
IS  - 1879-176X (Electronic)
IS  - 0300-5712 (Linking)
VI  - 116
DP  - 2022 Jan
TI  - Bisphenol A release from short-term degraded resin-based dental materials.
PG  - 103894
LID - S0300-5712(21)00316-X [pii]
LID - 10.1016/j.jdent.2021.103894 [doi]
AB  - OBJECTIVES: There is still much debate about the release of bisphenol A (BPA) 
      from resin-based dental materials. Therefore, this study aimed to quantify BPA 
      present as an impurity and to evaluate whether their degradation by salivary, 
      bacterial, and chemical challenges could increase its release. METHODS: BPA was 
      determined in three different amounts (300, 400, and 500 µg) of eight 
      unpolymerized resin-based materials (four composites, one fissure sealant, two 
      adhesives and one root canal sealer). Next, polymerized samples (n = 5) of each 
      material were immersed in 1 mL of whole human pooled saliva collected from 
      adults, Streptococcus mutans (2 × 10(7) CFU/mL), and acidic (0.1 M HCl), alkaline 
      (0.1 M NaOH), and control media, respectively. The amount of BPA was quantified 
      using an UPLC-MS/MS method including derivatization of BPA by pyridine-3-sulfonyl 
      chloride. RESULTS: Only the composites contained trace amounts of BPA above the 
      limit of quantification (ranging from 301±32 pg PBA/mg to 1534±62 pg BPA/mg), 
      most likely as impurity from the synthesis of the monomers. The amounts of BPA 
      released from polymerized materials upon salivary and bacterial degradation were 
      too low for accurate quantification, but in water, quantifiable amounts of BPA 
      were released from all materials. In alkaline media, the BPA release from two 
      composites was significantly decreased, while the release from one adhesive was 
      significantly increased, compared to water. CONCLUSIONS: BPA already present in 
      unpolymerized resin-based materials may account for the release of BPA after 
      polymerization. There was no clear indication that short-term material 
      degradation leads to increased release of BPA.
CI  - Copyright © 2021 Elsevier Ltd. All rights reserved.
FAU - De Nys, Siemon
AU  - De Nys S
AD  - KU Leuven (University of Leuven), Department of Oral Health Sciences, BIOMAT & 
      University Hospitals Leuven (UZ Leuven), Dentistry, Leuven, Belgium; IDEWE, 
      External service for prevention and protection at work, Heverlee, Belgium.
FAU - Duca, Radu Corneliu
AU  - Duca RC
AD  - Environment and Health, Department of Public Health and Primary Care, KU Leuven, 
      Kapucijnenvoer 35, 3000 Leuven, Belgium; Unit Environmental Hygiene and Human 
      Biological Monitoring, Department of Health Protection, National Health 
      Laboratory (LNS), 3555 Dudelange, Luxembourg; IDEWE, External service for 
      prevention and protection at work, Heverlee, Belgium.
FAU - Vervliet, Philippe
AU  - Vervliet P
AD  - Toxicological Centre, University of Antwerp, Universiteitsplein 1, D.S.551, 2610 
      Wilrijk, Belgium.
FAU - Covaci, Adrian
AU  - Covaci A
AD  - Toxicological Centre, University of Antwerp, Universiteitsplein 1, D.S.551, 2610 
      Wilrijk, Belgium.
FAU - Boonen, Imke
AU  - Boonen I
AD  - Laboratory of Analytical, Environmental and GeoChemistry, Vrije Universiteit 
      Brussel, Pleinlaan 2, 1050 Ixelles, Belgium.
FAU - Elskens, Marc
AU  - Elskens M
AD  - Laboratory of Analytical, Environmental and GeoChemistry, Vrije Universiteit 
      Brussel, Pleinlaan 2, 1050 Ixelles, Belgium.
FAU - Vanoirbeek, Jeroen
AU  - Vanoirbeek J
AD  - Environment and Health, Department of Public Health and Primary Care, KU Leuven, 
      Kapucijnenvoer 35, 3000 Leuven, Belgium; IDEWE, External service for prevention 
      and protection at work, Heverlee, Belgium.
FAU - Godderis, Lode
AU  - Godderis L
AD  - Environment and Health, Department of Public Health and Primary Care, KU Leuven, 
      Kapucijnenvoer 35, 3000 Leuven, Belgium; Laboratory of Analytical, Environmental 
      and GeoChemistry, Vrije Universiteit Brussel, Pleinlaan 2, 1050 Ixelles, Belgium; 
      IDEWE, External service for prevention and protection at work, Heverlee, Belgium.
FAU - Van Meerbeek, Bart
AU  - Van Meerbeek B
AD  - KU Leuven (University of Leuven), Department of Oral Health Sciences, BIOMAT & 
      University Hospitals Leuven (UZ Leuven), Dentistry, Leuven, Belgium; IDEWE, 
      External service for prevention and protection at work, Heverlee, Belgium.
FAU - Van Landuyt, Kirsten L
AU  - Van Landuyt KL
AD  - KU Leuven (University of Leuven), Department of Oral Health Sciences, BIOMAT & 
      University Hospitals Leuven (UZ Leuven), Dentistry, Leuven, Belgium; IDEWE, 
      External service for prevention and protection at work, Heverlee, Belgium. 
      Electronic address: kirsten.vanlanduyt@uzleuven.be.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20211117
PL  - England
TA  - J Dent
JT  - Journal of dentistry
JID - 0354422
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Composite Resins)
RN  - 0 (Dental Cements)
RN  - 0 (Dental Materials)
RN  - 0 (Phenols)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - Adult
MH  - Benzhydryl Compounds
MH  - Chromatography, Liquid
MH  - *Composite Resins
MH  - Dental Cements
MH  - Dental Materials
MH  - Humans
MH  - Phenols
MH  - *Tandem Mass Spectrometry
OTO - NOTNLM
OT  - Bisphenol A
OT  - Composite
OT  - Degradation
OT  - Endocrine disruptor
OT  - Resin-based dental materials
EDAT- 2021/11/20 06:00
MHDA- 2022/03/03 06:00
CRDT- 2021/11/19 20:16
PHST- 2021/06/25 00:00 [received]
PHST- 2021/11/10 00:00 [revised]
PHST- 2021/11/14 00:00 [accepted]
PHST- 2021/11/20 06:00 [pubmed]
PHST- 2022/03/03 06:00 [medline]
PHST- 2021/11/19 20:16 [entrez]
AID - S0300-5712(21)00316-X [pii]
AID - 10.1016/j.jdent.2021.103894 [doi]
PST - ppublish
SO  - J Dent. 2022 Jan;116:103894. doi: 10.1016/j.jdent.2021.103894. Epub 2021 Nov 17.

PMID- 29545367
OWN - NLM
STAT- MEDLINE
DCOM- 20190919
LR  - 20221109
IS  - 1524-4571 (Electronic)
IS  - 0009-7330 (Print)
IS  - 0009-7330 (Linking)
VI  - 122
IP  - 12
DP  - 2018 Jun 8
TI  - Dominant Role for Regulatory T Cells in Protecting Females Against Pulmonary 
      Hypertension.
PG  - 1689-1702
LID - 10.1161/CIRCRESAHA.117.312058 [doi]
AB  - RATIONALE: Pulmonary arterial hypertension (PH) is a life-threatening condition 
      associated with immune dysregulation and abnormal regulatory T cell (Treg) 
      activity, but it is currently unknown whether and how abnormal Treg function 
      differentially affects males and females. OBJECTIVE: To evaluate whether and how 
      Treg deficiency differentially affects male and female rats in experimental PH. 
      METHODS AND RESULTS: Male and female athymic rnu/rnu rats, lacking Tregs, were 
      treated with the VEGFR2 (vascular endothelial growth factor receptor 2) inhibitor 
      SU5416 or chronic hypoxia and evaluated for PH; some animals underwent Treg 
      immune reconstitution before SU5416 administration. Plasma PGI(2) (prostacyclin) 
      levels were measured. Lung and right ventricles were assessed for the expression 
      of the vasoprotective proteins COX-2 (cyclooxygenase 2), PTGIS (prostacyclin 
      synthase), PDL-1 (programmed death ligand 1), and HO-1 (heme oxygenase 1). 
      Inhibitors of these pathways were administered to athymic rats undergoing Treg 
      immune reconstitution. Finally, human cardiac microvascular endothelial cells 
      cocultured with Tregs were evaluated for COX-2, PDL-1, HO-1, and ER (estrogen 
      receptor) expression, and culture supernatants were assayed for PGI(2) and IL 
      (interleukin)-10. SU5416-treatment and chronic hypoxia produced more severe PH in 
      female than male athymic rats. Females were distinguished by greater pulmonary 
      inflammation, augmented right ventricular fibrosis, lower plasma PGI(2) levels, 
      decreased lung COX-2, PTGIS, HO-1, and PDL-1 expression and reduced right 
      ventricular PDL-1 levels. In both sexes, Treg immune reconstitution protected 
      against PH development and raised levels of plasma PGI(2) and cardiopulmonary 
      COX-2, PTGIS, PDL-1, and HO-1. Inhibiting COX-2, HO-1, and PD-1 (programmed death 
      1)/PDL-1 pathways abrogated Treg protection. In vitro, human Tregs directly 
      upregulated endothelial COX-2, PDL-1, HO-1, ERs and increased supernatant levels 
      of PGI(2) and IL-10. CONCLUSIONS: In 2 animal models of PH based on Treg 
      deficiency, females developed more severe PH than males. The data suggest that 
      females are especially reliant on the normal Treg function to counteract the 
      effects of pulmonary vascular injury leading to PH.
CI  - © 2018 American Heart Association, Inc.
FAU - Tamosiuniene, Rasa
AU  - Tamosiuniene R
AD  - From the Stanford University School of Medicine, Department of Medicine, CA 
      (R.T., P.M., T.S., J.Q., M.S., L.P.N., A.L., M.R., A.H., L.A., M.R.N.).
FAU - Manouvakhova, Olga
AU  - Manouvakhova O
AD  - VA Palo Alto Health Care System, CA (O.M., Y.-C.L., A.L., A.B.T., J.M.S., 
      M.R.N.).
FAU - Mesange, Paul
AU  - Mesange P
AD  - From the Stanford University School of Medicine, Department of Medicine, CA 
      (R.T., P.M., T.S., J.Q., M.S., L.P.N., A.L., M.R., A.H., L.A., M.R.N.).
FAU - Saito, Toshie
AU  - Saito T
AD  - From the Stanford University School of Medicine, Department of Medicine, CA 
      (R.T., P.M., T.S., J.Q., M.S., L.P.N., A.L., M.R., A.H., L.A., M.R.N.).
FAU - Qian, Jin
AU  - Qian J
AD  - From the Stanford University School of Medicine, Department of Medicine, CA 
      (R.T., P.M., T.S., J.Q., M.S., L.P.N., A.L., M.R., A.H., L.A., M.R.N.).
FAU - Sanyal, Mrinmoy
AU  - Sanyal M
AD  - From the Stanford University School of Medicine, Department of Medicine, CA 
      (R.T., P.M., T.S., J.Q., M.S., L.P.N., A.L., M.R., A.H., L.A., M.R.N.).
FAU - Lin, Yu-Chun
AU  - Lin YC
AD  - VA Palo Alto Health Care System, CA (O.M., Y.-C.L., A.L., A.B.T., J.M.S., 
      M.R.N.).
FAU - Nguyen, Linh P
AU  - Nguyen LP
AD  - From the Stanford University School of Medicine, Department of Medicine, CA 
      (R.T., P.M., T.S., J.Q., M.S., L.P.N., A.L., M.R., A.H., L.A., M.R.N.).
FAU - Luria, Amir
AU  - Luria A
AD  - From the Stanford University School of Medicine, Department of Medicine, CA 
      (R.T., P.M., T.S., J.Q., M.S., L.P.N., A.L., M.R., A.H., L.A., M.R.N.).
AD  - VA Palo Alto Health Care System, CA (O.M., Y.-C.L., A.L., A.B.T., J.M.S., 
      M.R.N.).
FAU - Tu, Allen B
AU  - Tu AB
AD  - VA Palo Alto Health Care System, CA (O.M., Y.-C.L., A.L., A.B.T., J.M.S., 
      M.R.N.).
FAU - Sante, Joshua M
AU  - Sante JM
AD  - VA Palo Alto Health Care System, CA (O.M., Y.-C.L., A.L., A.B.T., J.M.S., 
      M.R.N.).
FAU - Rabinovitch, Marlene
AU  - Rabinovitch M
AD  - From the Stanford University School of Medicine, Department of Medicine, CA 
      (R.T., P.M., T.S., J.Q., M.S., L.P.N., A.L., M.R., A.H., L.A., M.R.N.).
FAU - Fitzgerald, Desmond J
AU  - Fitzgerald DJ
AD  - University of Limerick, President, Ireland (D.J.F.).
FAU - Graham, Brian B
AU  - Graham BB
AD  - University of Colorado Denver, School of Medicine, Department of Medicine, Aurora 
      (B.B.G.).
FAU - Habtezion, Aida
AU  - Habtezion A
AD  - From the Stanford University School of Medicine, Department of Medicine, CA 
      (R.T., P.M., T.S., J.Q., M.S., L.P.N., A.L., M.R., A.H., L.A., M.R.N.).
FAU - Voelkel, Norbert F
AU  - Voelkel NF
AD  - Virginia Commonwealth University School of Medicine, Department of Internal 
      Medicine, Richmond (N.F.V.).
FAU - Aurelian, Laure
AU  - Aurelian L
AD  - From the Stanford University School of Medicine, Department of Medicine, CA 
      (R.T., P.M., T.S., J.Q., M.S., L.P.N., A.L., M.R., A.H., L.A., M.R.N.).
AD  - University of Maryland School of Medicine, Baltimore (L.A.).
FAU - Nicolls, Mark R
AU  - Nicolls MR
AD  - From the Stanford University School of Medicine, Department of Medicine, CA 
      (R.T., P.M., T.S., J.Q., M.S., L.P.N., A.L., M.R., A.H., L.A., M.R.N.) 
      mnicolls@stanford.edu.
AD  - VA Palo Alto Health Care System, CA (O.M., Y.-C.L., A.L., A.B.T., J.M.S., 
      M.R.N.).
LA  - eng
GR  - R01 HL138473/HL/NHLBI NIH HHS/United States
GR  - R56 HL082662/HL/NHLBI NIH HHS/United States
GR  - P01 HL108797/HL/NHLBI NIH HHS/United States
GR  - K12 HL120001/HL/NHLBI NIH HHS/United States
GR  - R01 HL122887/HL/NHLBI NIH HHS/United States
GR  - T32 GM099608/GM/NIGMS NIH HHS/United States
GR  - T32 HL098049/HL/NHLBI NIH HHS/United States
GR  - T32 HL129970/HL/NHLBI NIH HHS/United States
GR  - R01 HL125739/HL/NHLBI NIH HHS/United States
GR  - R01 HL082662/HL/NHLBI NIH HHS/United States
GR  - P01 HL014985/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20180315
PL  - United States
TA  - Circ Res
JT  - Circulation research
JID - 0047103
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Indoles)
RN  - 0 (Prostaglandins I)
RN  - 0 (Pyrroles)
RN  - 0 (Receptors, Estrogen)
RN  - 71IA9S35AJ (Semaxinib)
RN  - 9035-51-2 (Cytochrome P-450 Enzyme System)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - EC 1.14.14.18 (Heme Oxygenase (Decyclizing))
RN  - EC 1.14.14.18 (Hmox1 protein, rat)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (Ptgs2 protein, rat)
RN  - EC 2.7.10.1 (Kdr protein, rat)
RN  - EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-2)
RN  - EC 5.3.- (Intramolecular Oxidoreductases)
RN  - EC 5.3.99.4 (prostacyclin synthetase)
SB  - IM
CIN - Circ Res. 2018 Jun 8;122(12):1635-1637. doi: 10.1161/CIRCRESAHA.118.313075. PMID: 
      29880496
MH  - Angiogenesis Inhibitors/pharmacology
MH  - Animals
MH  - B7-H1 Antigen/analysis/antagonists & inhibitors/metabolism
MH  - Chronic Disease
MH  - Cyclooxygenase 2/analysis/metabolism
MH  - Cytochrome P-450 Enzyme System/analysis/metabolism
MH  - Epoprostenol/antagonists & inhibitors/blood/metabolism
MH  - Female
MH  - Heme Oxygenase (Decyclizing)/analysis/antagonists & inhibitors/metabolism
MH  - Hypertension, Pulmonary/blood/chemically induced/etiology/*prevention & control
MH  - Hypoxia/complications
MH  - Indoles/pharmacology
MH  - Intramolecular Oxidoreductases/analysis/antagonists & inhibitors/metabolism
MH  - Lung/metabolism
MH  - Male
MH  - Prostaglandins I/biosynthesis
MH  - Pyrroles/pharmacology
MH  - Rats
MH  - Rats, Nude
MH  - Receptors, Estrogen/analysis/antagonists & inhibitors/metabolism
MH  - *Sex Factors
MH  - T-Lymphocytes, Regulatory/immunology/*physiology
MH  - Vascular Endothelial Growth Factor Receptor-2/antagonists & inhibitors
PMC - PMC5993601
MID - NIHMS951527
OTO - NOTNLM
OT  - hypertension
OT  - prostacyclin
OT  - pulmonary sex
OT  - regulatory T cells
EDAT- 2018/03/17 06:00
MHDA- 2019/09/20 06:00
PMCR- 2019/06/08
CRDT- 2018/03/17 06:00
PHST- 2017/09/12 00:00 [received]
PHST- 2018/03/09 00:00 [revised]
PHST- 2018/03/13 00:00 [accepted]
PHST- 2018/03/17 06:00 [pubmed]
PHST- 2019/09/20 06:00 [medline]
PHST- 2018/03/17 06:00 [entrez]
PHST- 2019/06/08 00:00 [pmc-release]
AID - CIRCRESAHA.117.312058 [pii]
AID - 10.1161/CIRCRESAHA.117.312058 [doi]
PST - ppublish
SO  - Circ Res. 2018 Jun 8;122(12):1689-1702. doi: 10.1161/CIRCRESAHA.117.312058. Epub 
      2018 Mar 15.

PMID- 30623764
OWN - NLM
STAT- MEDLINE
DCOM- 20190521
LR  - 20190521
IS  - 1958-5381 (Electronic)
IS  - 0767-0974 (Linking)
VI  - 34
IP  - 12
DP  - 2018 Dec
TI  - [Towards an optimization of the modulation of the estrogen receptor during 
      menopausal hormonal therapy].
PG  - 1056-1062
LID - 10.1051/medsci/2018297 [doi]
AB  - Women now live more than a third of their lives after the onset of menopause. The 
      decline in endogenous estrogen production during this period is accompanied by 
      functional disorders that affect quality of life. These symptoms may be relieved 
      by menopausal hormone therapy (MHT) initially based on the administration of 
      equine conjugated estrogens (mainly in the United States, oral route) or the 
      natural estrogen, 17β-estradiol (in Europe, transdermal route). Estrogen receptor 
      α (ERα), but not ERβ, mediates most of the physiological effects of estrogens. 
      ERα belongs to the superfamily of nuclear receptors and regulates the 
      transcription of genes via its activation functions AF1 and AF2. In addition to 
      these classical genomic actions, estrogens can activate a subpopulation of ERα 
      present at the cell membrane and thereby induce rapid signals. In this review, we 
      will summarize the evolution of MHTs in last decades, as well as treatments that 
      use various selective estrogen receptor modulators (SERMs). Next, we will 
      describe recent advances in the understanding of the mechanisms of estrogen 
      action, in particular the respective roles of nuclear and membrane ERα as well as 
      the potential implications for future therapies.
CI  - © 2018 médecine/sciences – Inserm.
FAU - Valéra, Marie-Cécile
AU  - Valéra MC
AD  - Inserm U1048 et université Toulouse III, I2MC, CHU Rangueil, BP 84225, 31432 
      Toulouse Cedex 4, France.
FAU - Fontaine, Coralie
AU  - Fontaine C
AD  - Inserm U1048 et université Toulouse III, I2MC, CHU Rangueil, BP 84225, 31432 
      Toulouse Cedex 4, France.
FAU - Noirrit-Esclassan, Emmanuelle
AU  - Noirrit-Esclassan E
AD  - Inserm U1048 et université Toulouse III, I2MC, CHU Rangueil, BP 84225, 31432 
      Toulouse Cedex 4, France.
FAU - Boudou, Frédéric
AU  - Boudou F
AD  - Inserm U1048 et université Toulouse III, I2MC, CHU Rangueil, BP 84225, 31432 
      Toulouse Cedex 4, France.
FAU - Buscato, Melissa
AU  - Buscato M
AD  - Inserm U1048 et université Toulouse III, I2MC, CHU Rangueil, BP 84225, 31432 
      Toulouse Cedex 4, France.
FAU - Adlanmerini, Marine
AU  - Adlanmerini M
AD  - Inserm U1048 et université Toulouse III, I2MC, CHU Rangueil, BP 84225, 31432 
      Toulouse Cedex 4, France.
FAU - Trémollières, Florence
AU  - Trémollières F
AD  - Inserm U1048 et université Toulouse III, I2MC, CHU Rangueil, BP 84225, 31432 
      Toulouse Cedex 4, France.
FAU - Gourdy, Pierre
AU  - Gourdy P
AD  - Inserm U1048 et université Toulouse III, I2MC, CHU Rangueil, BP 84225, 31432 
      Toulouse Cedex 4, France.
FAU - Lenfant, Françoise
AU  - Lenfant F
AD  - Inserm U1048 et université Toulouse III, I2MC, CHU Rangueil, BP 84225, 31432 
      Toulouse Cedex 4, France.
FAU - Arnal, Jean-François
AU  - Arnal JF
AD  - Inserm U1048 et université Toulouse III, I2MC, CHU Rangueil, BP 84225, 31432 
      Toulouse Cedex 4, France.
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Vers une optimisation de la modulation du récepteur des œstrogènes dans le 
      traitement hormonal de la ménopause.
DEP - 20190109
PL  - France
TA  - Med Sci (Paris)
JT  - Medecine sciences : M/S
JID - 8710980
RN  - 0 (Estrogen Receptor alpha)
RN  - 0 (Selective Estrogen Receptor Modulators)
SB  - IM
MH  - Animals
MH  - Calibration
MH  - Estrogen Receptor alpha/metabolism
MH  - Estrogen Replacement Therapy/methods/standards/*trends
MH  - Female
MH  - Humans
MH  - Menopause/*drug effects/physiology
MH  - Quality of Life
MH  - Selective Estrogen Receptor Modulators/administration & dosage/*therapeutic use
EDAT- 2019/01/10 06:00
MHDA- 2019/05/22 06:00
CRDT- 2019/01/10 06:00
PHST- 2019/01/10 06:00 [entrez]
PHST- 2019/01/10 06:00 [pubmed]
PHST- 2019/05/22 06:00 [medline]
AID - msc180187 [pii]
AID - 10.1051/medsci/2018297 [doi]
PST - ppublish
SO  - Med Sci (Paris). 2018 Dec;34(12):1056-1062. doi: 10.1051/medsci/2018297. Epub 
      2019 Jan 9.

PMID- 33685991
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20221005
IS  - 1538-7445 (Electronic)
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 81
IP  - 9
DP  - 2021 May 1
TI  - Genomic Alterations in PIK3CA-Mutated Breast Cancer Result in mTORC1 Activation 
      and Limit the Sensitivity to PI3Kα Inhibitors.
PG  - 2470-2480
LID - 10.1158/0008-5472.CAN-20-3232 [doi]
AB  - PI3Kα inhibitors have shown clinical activity in PIK3CA-mutated estrogen 
      receptor-positive (ER(+)) patients with breast cancer. Using whole genome 
      CRISPR/Cas9 sgRNA knockout screens, we identified and validated several negative 
      regulators of mTORC1 whose loss confers resistance to PI3Kα inhibition. Among the 
      top candidates were TSC1, TSC2, TBC1D7, AKT1S1, STK11, MARK2, PDE7A, DEPDC5, 
      NPRL2, NPRL3, C12orf66, SZT2, and ITFG2. Loss of these genes invariably results 
      in sustained mTOR signaling under pharmacologic inhibition of the PI3K-AKT 
      pathway. Moreover, resistance could be prevented or overcome by mTOR inhibition, 
      confirming the causative role of sustained mTOR activity in limiting the 
      sensitivity to PI3Kα inhibition. Cumulatively, genomic alterations affecting 
      these genes are identified in about 15% of PIK3CA-mutated breast tumors and 
      appear to be mutually exclusive. This study improves our understanding of the 
      role of mTOR signaling restoration in leading to resistance to PI3Kα inhibition 
      and proposes therapeutic strategies to prevent or revert this resistance. 
      SIGNIFICANCE: These findings show that genetic lesions of multiple negative 
      regulators of mTORC1 could limit the efficacy of PI3Kα inhibitors in breast 
      cancer, which may guide patient selection strategies for future clinical trials.
CI  - ©2021 American Association for Cancer Research.
FAU - Cai, Yanyan
AU  - Cai Y
AD  - Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer 
      Center, New York, New York. maurizio.scaltriti@astrazeneca.com caiy@mskcc.org.
FAU - Xu, Guotai
AU  - Xu G
AD  - Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer 
      Center, New York, New York.
AD  - National Institute of Biological Sciences (NIBS), Beijing, China.
FAU - Wu, Fan
AU  - Wu F
AUID- ORCID: 0000-0002-3960-320X
AD  - Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer 
      Center, New York, New York.
FAU - Michelini, Flavia
AU  - Michelini F
AD  - Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer 
      Center, New York, New York.
AD  - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New 
      York.
FAU - Chan, Carmen
AU  - Chan C
AUID- ORCID: 0000-0001-9086-6622
AD  - Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer 
      Center, New York, New York.
FAU - Qu, Xuan
AU  - Qu X
AD  - Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer 
      Center, New York, New York.
FAU - Selenica, Pier
AU  - Selenica P
AD  - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New 
      York.
FAU - Ladewig, Erik
AU  - Ladewig E
AD  - Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer 
      Center, New York, New York.
AD  - Computational and Systems Biology Program, Memorial Sloan Kettering Cancer 
      Center, New York, New York.
FAU - Castel, Pau
AU  - Castel P
AUID- ORCID: 0000-0002-4972-4347
AD  - Helen Diller Family Comprehensive Cancer Center, University of California, San 
      Francisco, California.
FAU - Cheng, Yuanming
AU  - Cheng Y
AD  - Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, 
      New York.
FAU - Zhao, Alison
AU  - Zhao A
AUID- ORCID: 0000-0002-5479-2686
AD  - Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer 
      Center, New York, New York.
FAU - Jhaveri, Komal
AU  - Jhaveri K
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New 
      York.
FAU - Toska, Eneda
AU  - Toska E
AD  - Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer 
      Center, New York, New York.
AD  - Department of Oncology, Sidney Kimmel Cancer Center, Johns Hopkins University 
      School of Medicine, Baltimore, Maryland.
AD  - Department of Biochemistry and Molecular Biology, Johns Hopkins School of Public 
      Health, Baltimore, Maryland.
FAU - Jimenez, Marta
AU  - Jimenez M
AD  - Unicancer, Paris, France.
FAU - Jacquet, Alexandra
AU  - Jacquet A
AUID- ORCID: 0000-0001-9244-5370
AD  - Unicancer, Paris, France.
FAU - Tran-Dien, Alicia
AU  - Tran-Dien A
AD  - INSERM UMR981 and Department of Medical Oncology, Gustave Roussy Cancer Campus, 
      Villejuif, France.
AD  - Université Paris Saclay, Le Kremlin-Bicetre, France.
FAU - Andre, Fabrice
AU  - Andre F
AUID- ORCID: 0000-0001-5795-8357
AD  - INSERM UMR981 and Department of Medical Oncology, Gustave Roussy Cancer Campus, 
      Villejuif, France.
AD  - Université Paris Saclay, Le Kremlin-Bicetre, France.
AD  - Department of Medical Oncology, Gustave Roussy, Université Paris Saclay, 
      Villejuif, France.
FAU - Chandarlapaty, Sarat
AU  - Chandarlapaty S
AUID- ORCID: 0000-0003-4532-8053
AD  - Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer 
      Center, New York, New York.
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New 
      York.
FAU - Reis-Filho, Jorge S
AU  - Reis-Filho JS
AD  - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New 
      York.
FAU - Razavi, Pedram
AU  - Razavi P
AD  - Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer 
      Center, New York, New York.
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New 
      York.
FAU - Scaltriti, Maurizio
AU  - Scaltriti M
AUID- ORCID: 0000-0002-5522-1447
AD  - Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer 
      Center, New York, New York. maurizio.scaltriti@astrazeneca.com caiy@mskcc.org.
AD  - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New 
      York.
LA  - eng
GR  - K00 CA212478/CA/NCI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - R01 CA190642/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20210308
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (Phosphoinositide-3 Kinase Inhibitors)
RN  - 0 (Thiazoles)
RN  - 08W5N2C97Q (Alpelisib)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.1.137 (PIK3CA protein, human)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 1)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Breast Neoplasms/*drug therapy/*genetics/metabolism/pathology
MH  - Cell Survival/drug effects
MH  - Class I Phosphatidylinositol 3-Kinases/antagonists & inhibitors/*genetics
MH  - Cohort Studies
MH  - Drug Resistance, Neoplasm/*drug effects
MH  - Female
MH  - HEK293 Cells
MH  - Humans
MH  - *Loss of Function Mutation
MH  - MCF-7 Cells
MH  - Mechanistic Target of Rapamycin Complex 1/*metabolism
MH  - Mice
MH  - Phosphoinositide-3 Kinase Inhibitors/*administration & dosage
MH  - Signal Transduction/*genetics
MH  - TOR Serine-Threonine Kinases/metabolism
MH  - Thiazoles/*administration & dosage
MH  - Transduction, Genetic
MH  - Tumor Burden/drug effects/genetics
MH  - Xenograft Model Antitumor Assays
PMC - PMC8137641
MID - NIHMS1682852
COIS- Conflicts of Interest Statement M.S. has received funds from Puma Biotechnology, 
      AstraZeneca, Daiichi-Sankio, Immunomedics, Targimmune and Menarini Ricerche, is a 
      cofounder of Medendi.org and is an employee of AstraZeneca. P.R. has received 
      consultation fees from Novartis, AstraZeneca, Foundation Medicine, Inivata, 
      Tempus, Neetera, Epic Sciences and institutional research funds from Grail Inc, 
      Illumina, Novartis, and Epic Sciences. J.S.R.-F. is a consultant of Goldman Sachs 
      and REPARE Therapeutics, a member of the Scientific Advisory Board of VolitionRx 
      and Paige.AI, and an ad hoc member of the Scientific Advisory Board of Ventana 
      Medical Systems, Roche, Genentech, Novartis and InviCRO. S.C. has performed 
      consulting for Novartis, Lilly, and Paige.ai and receives institutional research 
      support from Daiichi Sankyo, Sanofi, Novartis, and Lilly. K.J. has performed 
      consulting for AstraZeneca, Novartis, Pfizer, Genentech, Lilly Pharmaceuticals, 
      Taiho Oncology, AbbVie, Jounce Therapeutics, and received institutional research 
      funding from Novartis, Genentech, Pfizer, AstraZeneca, Lilly Pharmaceuticals, 
      Debio Pharmaceuticals, Zymeworks, Novita Pharmaceuticals, PUMA Biotechnology, 
      Immunomedics. F.A. received research funding and served as speaker/advisor 
      (compensated to the hospital) for Roche, AstraZeneca, Daiichi Sankyo, Pfizer, 
      Novartis and Lilly. The other authors declare no competing interests.
EDAT- 2021/03/10 06:00
MHDA- 2021/09/18 06:00
PMCR- 2021/11/01
CRDT- 2021/03/09 06:02
PHST- 2020/09/23 00:00 [received]
PHST- 2021/02/02 00:00 [revised]
PHST- 2021/03/02 00:00 [accepted]
PHST- 2021/03/10 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2021/03/09 06:02 [entrez]
PHST- 2021/11/01 00:00 [pmc-release]
AID - 0008-5472.CAN-20-3232 [pii]
AID - 10.1158/0008-5472.CAN-20-3232 [doi]
PST - ppublish
SO  - Cancer Res. 2021 May 1;81(9):2470-2480. doi: 10.1158/0008-5472.CAN-20-3232. Epub 
      2021 Mar 8.

PMID- 37958751
OWN - NLM
STAT- MEDLINE
DCOM- 20231115
LR  - 20231117
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 24
IP  - 21
DP  - 2023 Oct 30
TI  - Molecular Action of Tamoxifen in the Ovaries of Rats with Mammary Neoplasia.
LID - 10.3390/ijms242115767 [doi]
LID - 15767
AB  - Tamoxifen (TAM) is a drug commonly used in patients with breast cancer. The 
      anticancer effect of TAM occurs via its ability to antagonize estrogen-dependent 
      growth of mammary epithelial cells. Previously, we demonstrated that TAM 
      prevented the chemotherapy-induced loss of ovarian follicular reserves in both 
      cancer-free rats and rats with cancer. Such follicular loss is a main cause of 
      infertility in young women treated for cancer. The current study was undertaken 
      to discover the molecules and intracellular pathways involved in the action of 
      TAM in the ovaries of rats with mammary tumors. To meet this goal we used 
      transcriptomic (RNA-Seq) and proteomic (2D-DIGE/MS) approaches. TAM inhibited the 
      expression of genes and lncRNAs involved in ovarian steroidogenesis. Moreover, 
      TAM altered the expression of genes related to primordial follicle activation or 
      arrest. In addition, proteomic screening indicated the importance of basic 
      metabolic processes in the ovarian actions of TAM. Although simple extrapolation 
      of these data to humans is not possible, the results of this study emphasize the 
      need to explore the ability of TAM to affect ovarian function in women undergoing 
      cancer treatment.
FAU - Nynca, Anna
AU  - Nynca A
AUID- ORCID: 0000-0002-1807-6148
AD  - Department of Animal Anatomy and Physiology, University of Warmia and Mazury in 
      Olsztyn, Oczapowskiego 1A, 10-719 Olsztyn, Poland.
FAU - Swigonska, Sylwia
AU  - Swigonska S
AD  - Laboratory of Molecular Diagnostics, University of Warmia and Mazury in Olsztyn, 
      10-720 Olsztyn, Poland.
FAU - Molcan, Tomasz
AU  - Molcan T
AUID- ORCID: 0000-0002-0380-0156
AD  - Molecular Biology Laboratory, Institute of Animal Reproduction and Food Research, 
      Polish Academy of Sciences, 10-243 Olsztyn, Poland.
FAU - Petroff, Brian K
AU  - Petroff BK
AD  - Department of Pathobiology and Diagnostic Investigation, Michigan State 
      University, East Lansing, MI 48910, USA.
FAU - Ciereszko, Renata E
AU  - Ciereszko RE
AUID- ORCID: 0000-0002-6896-5023
AD  - Department of Animal Anatomy and Physiology, University of Warmia and Mazury in 
      Olsztyn, Oczapowskiego 1A, 10-719 Olsztyn, Poland.
AD  - Laboratory of Molecular Diagnostics, University of Warmia and Mazury in Olsztyn, 
      10-720 Olsztyn, Poland.
LA  - eng
GR  - 2016/21/B/NZ4/00202/National Science Centre, Poland/
PT  - Journal Article
DEP - 20231030
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 094ZI81Y45 (Tamoxifen)
SB  - IM
MH  - Rats
MH  - Female
MH  - Humans
MH  - Animals
MH  - Tamoxifen/therapeutic use
MH  - Ovary/metabolism
MH  - Proteomics
MH  - *Breast Neoplasms/metabolism
MH  - *Mammary Neoplasms, Animal/metabolism
PMC - PMC10649132
OTO - NOTNLM
OT  - breast cancer
OT  - ovary
OT  - proteome
OT  - tamoxifen
OT  - transcriptome
OT  - tumor-bearing rats
COIS- The authors declare no conflict of interest.
EDAT- 2023/11/14 06:43
MHDA- 2023/11/15 06:43
PMCR- 2023/10/30
CRDT- 2023/11/14 02:09
PHST- 2023/09/07 00:00 [received]
PHST- 2023/10/20 00:00 [revised]
PHST- 2023/10/27 00:00 [accepted]
PHST- 2023/11/15 06:43 [medline]
PHST- 2023/11/14 06:43 [pubmed]
PHST- 2023/11/14 02:09 [entrez]
PHST- 2023/10/30 00:00 [pmc-release]
AID - ijms242115767 [pii]
AID - ijms-24-15767 [pii]
AID - 10.3390/ijms242115767 [doi]
PST - epublish
SO  - Int J Mol Sci. 2023 Oct 30;24(21):15767. doi: 10.3390/ijms242115767.

PMID- 34180240
OWN - NLM
STAT- MEDLINE
DCOM- 20210708
LR  - 20210708
IS  - 1520-5118 (Electronic)
IS  - 0021-8561 (Linking)
VI  - 69
IP  - 26
DP  - 2021 Jul 7
TI  - New Biotransformation Mode of Zearalenone Identified in Bacillus subtilis Y816 
      Revealing a Novel ZEN Conjugate.
PG  - 7409-7419
LID - 10.1021/acs.jafc.1c01817 [doi]
AB  - An increasing number of Bacillus strains have been identified, and the removal 
      capacity of zearalenone (ZEN) was determined; however, they failed to reveal the 
      detoxification mechanism and transformation product. Here, Bacillus subtilis 
      Y816, which could transform 40 mg/L of ZEN within 7 h of fermentation, was 
      identified and studied. First, the biotransformation products of ZEN and 
      17-β-estradiol (E2) were identified as ZEN-14-phosphate and E2-3-phosphate by 
      HPLC-TOF-MS and NMR, respectively. An intracellular zearalenone 
      phosphotransferase (ZPH) was found through transcriptome sequencing analysis of 
      B. subtilis Y816. The phosphorylated reaction conditions of ZEN by ZPH were 
      further revealed in this work. Furthermore, the phosphorylated conjugates showed 
      reduced estrogenic toxicity compared with their original substances (ZEN and 
      α/β-zearalenol) using an engineered yeast biosensor system. The first report on 
      the phosphorylated conjugated mode of ZEN in B. subtilis Y816 will inspire new 
      perspectives on the biotransformation of ZEN in Bacillus strains.
FAU - Yang, Shi Bin
AU  - Yang SB
AD  - University of Chinese Academy of Sciences, Beijing 100049, China.
AD  - Industrial Enzymes National Engineering Laboratory, Tianjin Institute of 
      Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China.
FAU - Zheng, Hong Chen
AU  - Zheng HC
AUID- ORCID: 0000-0001-7780-0784
AD  - University of Chinese Academy of Sciences, Beijing 100049, China.
AD  - National Technology Innovation Center of Synthetic Biology, Tianjin Institute of 
      Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China.
AD  - Industrial Enzymes National Engineering Laboratory, Tianjin Institute of 
      Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China.
AD  - Tianjin Key Laboratory for Industrial Biological Systems and Bioprocessing 
      Engineering, Tianjin Institute of Industrial Biotechnology, Chinese Academy of 
      Sciences, Tianjin 300308, China.
FAU - Xu, Jian Yong
AU  - Xu JY
AD  - National Technology Innovation Center of Synthetic Biology, Tianjin Institute of 
      Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China.
AD  - Industrial Enzymes National Engineering Laboratory, Tianjin Institute of 
      Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China.
FAU - Zhao, Xing Ya
AU  - Zhao XY
AD  - Industrial Enzymes National Engineering Laboratory, Tianjin Institute of 
      Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China.
AD  - Tianjin Key Laboratory for Industrial Biological Systems and Bioprocessing 
      Engineering, Tianjin Institute of Industrial Biotechnology, Chinese Academy of 
      Sciences, Tianjin 300308, China.
FAU - Shu, Wen Ju
AU  - Shu WJ
AD  - Industrial Enzymes National Engineering Laboratory, Tianjin Institute of 
      Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China.
AD  - Tianjin Key Laboratory for Industrial Biological Systems and Bioprocessing 
      Engineering, Tianjin Institute of Industrial Biotechnology, Chinese Academy of 
      Sciences, Tianjin 300308, China.
FAU - Li, Xiang Ming
AU  - Li XM
AD  - Preventive Medicine Department, Medical College, Yangzhou University, Yangzhou, 
      Jiangsu 225001, China.
FAU - Song, Hui
AU  - Song H
AD  - University of Chinese Academy of Sciences, Beijing 100049, China.
AD  - National Technology Innovation Center of Synthetic Biology, Tianjin Institute of 
      Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China.
AD  - Industrial Enzymes National Engineering Laboratory, Tianjin Institute of 
      Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China.
AD  - Tianjin Key Laboratory for Industrial Biological Systems and Bioprocessing 
      Engineering, Tianjin Institute of Industrial Biotechnology, Chinese Academy of 
      Sciences, Tianjin 300308, China.
FAU - Ma, Yan He
AU  - Ma YH
AD  - National Technology Innovation Center of Synthetic Biology, Tianjin Institute of 
      Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China.
AD  - Industrial Enzymes National Engineering Laboratory, Tianjin Institute of 
      Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China.
LA  - eng
PT  - Journal Article
DEP - 20210628
PL  - United States
TA  - J Agric Food Chem
JT  - Journal of agricultural and food chemistry
JID - 0374755
RN  - 5W827M159J (Zearalenone)
SB  - IM
MH  - *Bacillus/metabolism
MH  - Bacillus subtilis/genetics/metabolism
MH  - Biotransformation
MH  - Fermentation
MH  - *Zearalenone/metabolism
OTO - NOTNLM
OT  - E2-3-phosphate
OT  - ZEN-14-phosphate
OT  - biotransformation
OT  - estrogenic toxicity
OT  - zearalenone phosphotransferase
EDAT- 2021/06/29 06:00
MHDA- 2021/07/09 06:00
CRDT- 2021/06/28 08:43
PHST- 2021/06/29 06:00 [pubmed]
PHST- 2021/07/09 06:00 [medline]
PHST- 2021/06/28 08:43 [entrez]
AID - 10.1021/acs.jafc.1c01817 [doi]
PST - ppublish
SO  - J Agric Food Chem. 2021 Jul 7;69(26):7409-7419. doi: 10.1021/acs.jafc.1c01817. 
      Epub 2021 Jun 28.

PMID- 35710396
OWN - NLM
STAT- MEDLINE
DCOM- 20220620
LR  - 20220716
IS  - 2662-7671 (Electronic)
IS  - 2662-7671 (Linking)
VI  - 22
IP  - 1
DP  - 2022 Jun 16
TI  - Investigation into the protective effects of hypaconitine and glycyrrhetinic acid 
      against chronic heart failure of the rats.
PG  - 160
LID - 10.1186/s12906-022-03632-y [doi]
LID - 160
AB  - BACKGROUND: The present study aimed to determine the protective effects of 
      hypaconitine (HA) and glycyrrhetinic acid (GA) against chronic heart failure 
      (CHF) in the rats and to explore the underlying molecular mechanisms. METHODS: 
      The CHF rat model was established by transverse-aortic constriction (TAC) 
      operation. Transthoracic echocardiography and hematoxylin eosin (HE) staining 
      were used to evaluate the pathophysiological and histopathological changes of CHF 
      model. The total cholesterol (TCHO) and triglyceride (TG) levels were determined 
      by ELISA assay. The protein expression of fibroblast growth factor 2 (FGF2), 
      vascular endothelial growth factor A (VEGFA) and endothelial nitric oxide 
      synthase (eNOS) in the rat ventricular tissues was determined by 
      immunohistochemistry. The serum metabolites were determined by LC-MS/MS assay. 
      RESULTS: After applied the HA + GA, the cardiac tissue and structure were 
      obviously improved, and the HA + GA treatment also significantly reduced the 
      plasma levels of TCHO and TG in the CHF rats. The expression of FGF2 and VEGFA 
      protein was up-regulated and the expression of eNOS protein was down-regulated in 
      the ventricular tissues of CHF rats, which was significantly restored after 
      HA + GA treatment. HA + GA treatment down-regulated serum isonicotinic acid, 
      phosphatidylcholine, cardiolipin, estrogen glucuronide, and glycocholic acid, 
      up-regulated serum sphingosine and deoxycholic acid in the CHF rats. CONCLUSIONS: 
      In conclusion, HA + GA showed protective effects on CHF in the rats, and the 
      HA + GA may exert protective effects by reducing lipid levels, up-regulating the 
      expression of FGF2 and VEGFA proteins, attenuating eNOS protein expression, and 
      modulating metabolic pathways. However, the molecular mechanisms underlying 
      HA + GA-mediated effects still require further examination.
CI  - © 2022. The Author(s).
FAU - Wang, Liqin
AU  - Wang L
AD  - Preventive Treatment Center, The First Affiliated Hospital of Nanchang 
      University, Nanchang, Jiangxi Province, China.
AD  - Institute of Shiceng Pulse, Nanchang University, Nanchang, Jiangxi Province, 
      China.
FAU - Deng, Haiming
AU  - Deng H
AD  - Department of Cardiology, The First Affiliated Hospital of Nanchang University, 
      Nanchang, Jiangxi Province, China.
FAU - Wang, Tengyu
AU  - Wang T
AD  - Preventive Treatment Center, The First Affiliated Hospital of Nanchang 
      University, Nanchang, Jiangxi Province, China.
AD  - Institute of Shiceng Pulse, Nanchang University, Nanchang, Jiangxi Province, 
      China.
FAU - Qiao, Yun
AU  - Qiao Y
AD  - Jiangxi University of Chinese Medicine, Nanchang, Jiangxi Province, China.
FAU - Zhu, Jianbing
AU  - Zhu J
AD  - Department of Cardiology, The First Affiliated Hospital of Nanchang University, 
      Nanchang, Jiangxi Province, China.
FAU - Xiong, Mingfeng
AU  - Xiong M
AD  - Preventive Treatment Center, The First Affiliated Hospital of Nanchang 
      University, Nanchang, Jiangxi Province, China. ncxmf1213@126.com.
AD  - Institute of Shiceng Pulse, Nanchang University, Nanchang, Jiangxi Province, 
      China. ncxmf1213@126.com.
LA  - eng
GR  - 81904087; 81800324 and 81960061/National Science Foundation of China/
GR  - 81904087; 81800324 and 81960061/National Science Foundation of China/
GR  - 20181BAB215036 and 20192ACBL21040/National Science Foundation of Jiangxi 
      Province/
GR  - 20181BAB215036 and 20192ACBL21040/National Science Foundation of Jiangxi 
      Province/
GR  - 2019/2019 National Training Program for Innovative Talents of Traditional Chinese 
      Medicine/
GR  - 2020/2020 Training Program for Youth Backbone Talents of Traditional Chinese 
      Medicine of Jiangxi Province/
GR  - [Jiangxi Traditional Chinese Medicine Comprehensive (2021) No.12]./Xiong Monian 
      Famous Chinese Medicine Teacher Inheritance Construction Project/
GR  - 20203BBE52W010/Key project of Jiangxi Science and Technology Department/
PT  - Journal Article
DEP - 20220616
PL  - England
TA  - BMC Complement Med Ther
JT  - BMC complementary medicine and therapies
JID - 101761232
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 103107-01-3 (Fibroblast Growth Factor 2)
RN  - 5207313N6E (hypaconitine)
RN  - P540XA09DR (Glycyrrhetinic Acid)
RN  - X8YN71D5WC (Aconitine)
SB  - IM
MH  - Aconitine/analogs & derivatives
MH  - Animals
MH  - Chromatography, Liquid
MH  - Fibroblast Growth Factor 2
MH  - *Glycyrrhetinic Acid/pharmacology
MH  - *Heart Failure/drug therapy
MH  - Rats
MH  - Tandem Mass Spectrometry
MH  - Vascular Endothelial Growth Factor A
PMC - PMC9202221
OTO - NOTNLM
OT  - Chronic heart failure
OT  - Glycyrrhetinic acid
OT  - Hypaconitine
OT  - Immunohistochemistry
OT  - Metabolites
COIS- The authors declare that there is no conflict of interests regarding the 
      publication of this paper.
EDAT- 2022/06/17 06:00
MHDA- 2022/06/22 06:00
PMCR- 2022/06/16
CRDT- 2022/06/16 23:38
PHST- 2021/11/25 00:00 [received]
PHST- 2022/05/24 00:00 [accepted]
PHST- 2022/06/16 23:38 [entrez]
PHST- 2022/06/17 06:00 [pubmed]
PHST- 2022/06/22 06:00 [medline]
PHST- 2022/06/16 00:00 [pmc-release]
AID - 10.1186/s12906-022-03632-y [pii]
AID - 3632 [pii]
AID - 10.1186/s12906-022-03632-y [doi]
PST - epublish
SO  - BMC Complement Med Ther. 2022 Jun 16;22(1):160. doi: 10.1186/s12906-022-03632-y.

PMID- 29475970
OWN - NLM
STAT- MEDLINE
DCOM- 20190522
LR  - 20240620
IS  - 1538-7755 (Electronic)
IS  - 1055-9965 (Print)
IS  - 1055-9965 (Linking)
VI  - 27
IP  - 4
DP  - 2018 Apr
TI  - Neonatal Hormone Concentrations and Risk of Testicular Germ Cell Tumors (TGCT).
PG  - 488-495
LID - 10.1158/1055-9965.EPI-17-0879 [doi]
AB  - Background: Testicular germ cell tumor (TGCT) incidence has increased over the 
      last 40 years in the United States. In contrast to TGCT among infants, it is 
      hypothesized that TGCT in adolescents and young men is the result of sex steroid 
      hormone imbalance during early fetal development. However, little is known about 
      the neonatal period when abrupt hormonal changes occur, and direct supporting 
      evidence is scarce due to the difficulties in obtaining prediagnostic 
      specimens.Methods: We conducted a population-based case-control study examining 
      hormone levels at birth among 91 infants (0-4 years) and 276 adolescents (15-19 
      years) diagnosed with TGCT, and 344 matched controls. Estrogen and androgen 
      levels were quantified using liquid chromatography-tandem mass spectrometry 
      (LC-MS/MS) from archived newborn dried blood spots. Logistic regression models 
      were used to estimate the association between each hormone level and TGCT 
      risk.Results: Higher levels of androstenedione were associated with increased 
      TGCT risk among adolescents [odds ratio (OR): 2.33, 95% confidence interval (CI): 
      1.37-3.97 for highest vs. lowest quartile; P trend = 0.003] but not among infants 
      (OR: 0.70, 95% CI: 0.28-1.77). A similar pattern was observed for testosterone 
      (OR: 1.73, 95% CI: 1.00-3.00,) although the trend was not significant (P trend = 
      0.12). Associations were stronger among non-Hispanic white subjects, relative to 
      Hispanics. There was no difference by tumor histologic subtype. Estriol (the only 
      detectable estrogen) was not associated with TGCT risk in either age 
      group.Conclusions: Higher levels of neonatal androgens were associated with 
      increased risk of TGCT among adolescents, suggesting that early life hormone 
      levels are related to the later development of TGCT.Impact: This is the first 
      study with direct measures of sex steroid hormones to examine the relationship 
      between estrogens and androgens at birth and risk of adolescent TGCT. Cancer 
      Epidemiol Biomarkers Prev; 27(4); 488-95. ©2018 AACR.
CI  - ©2018 American Association for Cancer Research.
FAU - Morimoto, Libby M
AU  - Morimoto LM
AD  - Division of Epidemiology, School of Public Health, University of California, 
      Berkeley, California. libbym@berkeley.edu.
FAU - Zava, David
AU  - Zava D
AD  - ZRT Laboratory, Beaverton, Oregon.
FAU - McGlynn, Katherine A
AU  - McGlynn KA
AD  - Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Bethesda, Maryland.
FAU - Stanczyk, Frank Z
AU  - Stanczyk FZ
AD  - Department of Obstetrics and Gynecology, Keck School of Medicine, University of 
      Southern California, Los Angeles, California.
FAU - Kang, Alice Y
AU  - Kang AY
AD  - Division of Epidemiology, School of Public Health, University of California, 
      Berkeley, California.
FAU - Ma, Xiaomei
AU  - Ma X
AD  - Yale School of Public Health, New Haven, Connecticut.
FAU - Wiemels, Joseph L
AU  - Wiemels JL
AD  - Department of Preventative Medicine, University of Southern California, Los 
      Angeles, California.
FAU - Metayer, Catherine
AU  - Metayer C
AD  - Division of Epidemiology, School of Public Health, University of California, 
      Berkeley, California.
LA  - eng
GR  - R21 CA185725/CA/NCI NIH HHS/United States
GR  - U58 DP003862/DP/NCCDPHP CDC HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20180223
PL  - United States
TA  - Cancer Epidemiol Biomarkers Prev
JT  - Cancer epidemiology, biomarkers & prevention : a publication of the American 
      Association for Cancer Research, cosponsored by the American Society of 
      Preventive Oncology
JID - 9200608
RN  - 0 (Androgens)
RN  - 0 (Estrogens)
RN  - Testicular Germ Cell Tumor
SB  - IM
MH  - Adolescent
MH  - Androgens/*blood
MH  - Case-Control Studies
MH  - Child, Preschool
MH  - Chromatography, High Pressure Liquid
MH  - Estrogens/*blood
MH  - Humans
MH  - Incidence
MH  - Infant
MH  - Infant, Newborn
MH  - Male
MH  - Neoplasms, Germ Cell and Embryonal/*epidemiology
MH  - Risk Factors
MH  - Tandem Mass Spectrometry
MH  - Testicular Neoplasms/*epidemiology
MH  - United States/epidemiology
PMC - PMC5884718
MID - NIHMS940383
COIS- Conflict of Interest: The authors declare no potential conflicts of interest.
EDAT- 2018/02/25 06:00
MHDA- 2019/05/23 06:00
PMCR- 2019/04/01
CRDT- 2018/02/25 06:00
PHST- 2017/10/02 00:00 [received]
PHST- 2017/12/06 00:00 [revised]
PHST- 2018/01/29 00:00 [accepted]
PHST- 2018/02/25 06:00 [pubmed]
PHST- 2019/05/23 06:00 [medline]
PHST- 2018/02/25 06:00 [entrez]
PHST- 2019/04/01 00:00 [pmc-release]
AID - 1055-9965.EPI-17-0879 [pii]
AID - 10.1158/1055-9965.EPI-17-0879 [doi]
PST - ppublish
SO  - Cancer Epidemiol Biomarkers Prev. 2018 Apr;27(4):488-495. doi: 
      10.1158/1055-9965.EPI-17-0879. Epub 2018 Feb 23.

PMID- 35318882
OWN - NLM
STAT- MEDLINE
DCOM- 20220324
LR  - 20220531
IS  - 1473-0790 (Electronic)
IS  - 1368-5538 (Linking)
VI  - 25
IP  - 1
DP  - 2022 Dec
TI  - Primary, secondary and compensated male biochemical hypogonadism in people living 
      with HIV (PLWH): relevance of sex hormone-binding globulin (SHBG) measurement and 
      comparison between liquid chromatography-tandem mass spectrometry (LC-MS/MS) and 
      chemiluminescent immunoassay for sex steroids assay.
PG  - 41-53
LID - 10.1080/13685538.2022.2039116 [doi]
AB  - BACKGROUND: Data about classification of hypogonadism and estrogen deficiency in 
      male people living with HIV (PLWH) are scanty. AIM: To investigate the prevalence 
      and characterization of biochemical hypogonadism and relative estrogen deficiency 
      in male PLWH aged < 50 comparing liquid chromatography-tandem mass spectrometry 
      (LC-MS/MS) with chemiluminescent immunoassay (CI), and combining gonadotropin, 
      sex hormone-binding globulin (SHBG) and serum estradiol (E2) measurements. 
      METHODS: Prospective, cross-sectional, observational study. Serum total 
      testosterone (TT), E2, gonadotropins, SHBG were measured by CI. TT and E2 were 
      also assessed by LC-MS/MS. Free testosterone (cFT) was calculated by Vermeulen 
      equation. RESULTS: A total of 316 PLWH (45.3 ± 5.3 years) were enrolled. TT and 
      cFT by LC-MS/MS were lower compared to CI (p < 0.0001). The prevalence of 
      biochemical hypogonadism was higher with LC-MS/MS than CI, both for TT (5.1% vs 
      3.2%, p < 0.0001) or cFT (9.5% vs 7%, p < 0.0001). The prevalence of hypogonadism 
      (overt + compensated) was 17.1% for cFT using LC-MS/MS. Secondary form of 
      hypogonadism was more prevalent than primary. The prevalence of relative estrogen 
      deficiency was of 30.0% among hypogonadal patients and 15.5% among eugonadal. 
      CONCLUSIONS: The prevalence of male hypogonadism results underestimated by CI 
      compared to LC-MS/MS in PLWH, both for TT and cFT. SHBG and gonadotropins are 
      essential for detecting T deficiency.
FAU - De Vincentis, Sara
AU  - De Vincentis S
AUID- ORCID: 0000-0002-9582-5683
AD  - Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, 
      University of Modena and Reggio Emilia, Modena, Italy.
AD  - Unit of Endocrinology, Department of Medical Specialties, Azienda 
      Ospedaliero-Universitaria of Modena, Modena, Italy.
AD  - Clinical and Experimental Medicine PhD Program, University of Modena and Reggio 
      Emilia, Modena, Italy.
FAU - Decaroli, Maria Chiara
AU  - Decaroli MC
AUID- ORCID: 0000-0002-9727-1135
AD  - Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, 
      University of Modena and Reggio Emilia, Modena, Italy.
AD  - Unit of Endocrinology, Department of Medical Specialties, Azienda 
      Ospedaliero-Universitaria of Modena, Modena, Italy.
FAU - Fanelli, Flaminia
AU  - Fanelli F
AUID- ORCID: 0000-0003-2601-2694
AD  - Unit of Endocrinology and Prevention and Care of Diabetes, Centre for Applied 
      Biomedical Research, Department of Medical and Surgical Sciences, University of 
      Bologna, Sant'Orsola Policlinic Bologna, Italy.
FAU - Diazzi, Chiara
AU  - Diazzi C
AUID- ORCID: 0000-0002-6259-2481
AD  - Unit of Endocrinology, Department of Medical Specialties, Azienda 
      Ospedaliero-Universitaria of Modena, Modena, Italy.
FAU - Mezzullo, Marco
AU  - Mezzullo M
AUID- ORCID: 0000-0001-6748-3041
AD  - Unit of Endocrinology and Prevention and Care of Diabetes, Centre for Applied 
      Biomedical Research, Department of Medical and Surgical Sciences, University of 
      Bologna, Sant'Orsola Policlinic Bologna, Italy.
FAU - Tartaro, Giulia
AU  - Tartaro G
AD  - Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, 
      University of Modena and Reggio Emilia, Modena, Italy.
AD  - Unit of Endocrinology, Department of Medical Specialties, Azienda 
      Ospedaliero-Universitaria of Modena, Modena, Italy.
FAU - Tagliavini, Simonetta
AU  - Tagliavini S
AD  - Department of Laboratory Medicine and Pathology, Azienda USL of Modena, Modena, 
      Italy.
FAU - De Santis, Maria Cristina
AU  - De Santis MC
AUID- ORCID: 0000-0002-2169-3921
AD  - Department of Laboratory Medicine and Pathology, Azienda USL of Modena, Modena, 
      Italy.
FAU - Roli, Laura
AU  - Roli L
AUID- ORCID: 0000-0001-7154-189X
AD  - Department of Laboratory Medicine and Pathology, Azienda USL of Modena, Modena, 
      Italy.
FAU - Milic, Jovana
AU  - Milic J
AUID- ORCID: 0000-0002-9806-8470
AD  - Multidisciplinary Metabolic Clinic, Unit of Infectious Diseases, University of 
      Modena and Reggio Emilia, Modena, Italy.
FAU - Trenti, Tommaso
AU  - Trenti T
AUID- ORCID: 0000-0001-8093-4011
AD  - Department of Laboratory Medicine and Pathology, Azienda USL of Modena, Modena, 
      Italy.
FAU - Pagotto, Uberto
AU  - Pagotto U
AUID- ORCID: 0000-0003-4182-3110
AD  - Unit of Endocrinology and Prevention and Care of Diabetes, Centre for Applied 
      Biomedical Research, Department of Medical and Surgical Sciences, University of 
      Bologna, Sant'Orsola Policlinic Bologna, Italy.
FAU - Guaraldi, Giovanni
AU  - Guaraldi G
AUID- ORCID: 0000-0002-5724-3914
AD  - Multidisciplinary Metabolic Clinic, Unit of Infectious Diseases, University of 
      Modena and Reggio Emilia, Modena, Italy.
FAU - Rochira, Vincenzo
AU  - Rochira V
AUID- ORCID: 0000-0001-8169-0696
AD  - Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, 
      University of Modena and Reggio Emilia, Modena, Italy.
AD  - Unit of Endocrinology, Department of Medical Specialties, Azienda 
      Ospedaliero-Universitaria of Modena, Modena, Italy.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - England
TA  - Aging Male
JT  - The aging male : the official journal of the International Society for the Study 
      of the Aging Male
JID - 9808210
RN  - 0 (Sex Hormone-Binding Globulin)
RN  - 3XMK78S47O (Testosterone)
SB  - IM
MH  - Chromatography, Liquid
MH  - Cross-Sectional Studies
MH  - *HIV Infections/complications
MH  - Humans
MH  - *Hypogonadism/complications
MH  - Immunoassay
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Sex Hormone-Binding Globulin/*analysis
MH  - Tandem Mass Spectrometry
MH  - Testosterone
OTO - NOTNLM
OT  - HIV
OT  - SHBG
OT  - hypogonadism
OT  - sex steroids
OT  - testosterone
EDAT- 2022/03/24 06:00
MHDA- 2022/03/25 06:00
CRDT- 2022/03/23 08:40
PHST- 2022/03/23 08:40 [entrez]
PHST- 2022/03/24 06:00 [pubmed]
PHST- 2022/03/25 06:00 [medline]
AID - 10.1080/13685538.2022.2039116 [doi]
PST - ppublish
SO  - Aging Male. 2022 Dec;25(1):41-53. doi: 10.1080/13685538.2022.2039116.

PMID- 34201250
OWN - NLM
STAT- MEDLINE
DCOM- 20210726
LR  - 20220128
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 22
IP  - 12
DP  - 2021 Jun 8
TI  - Cumin Prevents 17β-Estradiol-Associated Breast Cancer in ACI Rats.
LID - 10.3390/ijms22126194 [doi]
LID - 6194
AB  - Breast cancer (BC) is a leading cause of cancer deaths in women in less developed 
      countries and the second leading cause of cancer death in women in the U.S. In 
      this study, we report the inhibition of E2-mediated mammary tumorigenesis by 
      Cuminum cyminum (cumin) administered via the diet as cumin powder, as well as 
      dried ethanolic extract. Groups of female ACI rats were given either an AIN-93M 
      diet or a diet supplemented with cumin powder (5% and 7.5%, w/w) or dried 
      ethanolic cumin extract (1%, w/w), and then challenged with subcutaneous E2 
      silastic implants (1.2 cm; 9 mg). The first appearance of a palpable mammary 
      tumor was significantly delayed by both the cumin powder and extract. At the end 
      of the study, the tumor incidence was 96% in the control group, whereas only 55% 
      and 45% animals had palpable tumors in the cumin powder and extract groups, 
      respectively. Significant reductions in tumor volume (660 ± 122 vs. 138 ± 49 and 
      75 ± 46 mm(3)) and tumor multiplicity (4.21 ± 0.43 vs. 1.16 ± 0.26 and 0.9 ± 0.29 
      tumors/animal) were also observed by the cumin powder and cumin extract groups, 
      respectively. The cumin powder diet intervention dose- and time-dependently 
      offset E2-related pituitary growth, and reduced the levels of circulating 
      prolactin and the levels of PCNA in the mammary tissues. Mechanistically, the 
      cumin powder diet resulted in a significant reversal of E2-associated modulation 
      in ERα, CYP1A1 and CYP1B1. Further, the cumin powder diet reversed the expression 
      levels of miRNAs (miR-182, miR-375, miR-127 and miR-206) that were highly 
      modulated by E2 treatment. We analyzed the composition of the extract by GC/MS 
      and established cymene and cuminaldehyde as major components, and further 
      detected no signs of gross or systemic toxicity. Thus, cumin bioactives can 
      significantly delay and prevent E2-mediated mammary tumorigenesis in a safe and 
      effective manner, and warrant continued efforts to develop these clinically 
      translatable spice bioactives as chemopreventives and therapeutics against BC.
FAU - Aqil, Farrukh
AU  - Aqil F
AUID- ORCID: 0000-0002-0081-7251
AD  - James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202, 
      USA.
AD  - Department of Medicine, University of Louisville, Louisville, KY 40202, USA.
FAU - Jeyabalan, Jeyaprakash
AU  - Jeyabalan J
AD  - James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202, 
      USA.
FAU - Munagala, Radha
AU  - Munagala R
AD  - James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202, 
      USA.
AD  - Department of Medicine, University of Louisville, Louisville, KY 40202, USA.
FAU - Ahmad, Iqbal
AU  - Ahmad I
AD  - Department of Ag Microbiology, Aligarh Muslim University, Aligarh 202002, India.
FAU - Schultz, David J
AU  - Schultz DJ
AD  - Department of Biology, University of Louisville, Louisville, KY 40208, USA.
FAU - Gupta, Ramesh C
AU  - Gupta RC
AD  - James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202, 
      USA.
AD  - Department of Pharmacology and Toxicology, 580 S. Preston St. Rm 304E, Baxter II 
      Research Building, University of Louisville, Louisville, KY 40202, USA.
LA  - eng
GR  - R01 CA125152/CA/NCI NIH HHS/United States
GR  - CA-125152/NH/NIH HHS/United States
PT  - Journal Article
DEP - 20210608
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Estrogens)
RN  - 0 (MicroRNAs)
RN  - 0 (Plant Extracts)
RN  - 4TI98Z838E (Estradiol)
RN  - EC 1.14.14.1 (Cyp1b1 protein, rat)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP1A1)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP1B1)
SB  - IM
MH  - Animals
MH  - Cuminum/*chemistry
MH  - Cytochrome P-450 CYP1A1/genetics/metabolism
MH  - Cytochrome P-450 CYP1B1/genetics/metabolism
MH  - Estradiol/*toxicity
MH  - Estrogens/*toxicity
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/*drug effects
MH  - Mammary Neoplasms, Experimental/chemically induced/pathology/*prevention & 
      control
MH  - MicroRNAs/genetics
MH  - Plant Extracts/*pharmacology
MH  - Rats
MH  - Rats, Inbred ACI
PMC - PMC8228322
OTO - NOTNLM
OT  - ACI rats
OT  - Cuminum cyminum
OT  - breast cancer
OT  - cumin
OT  - estradiol
COIS- The authors declare no conflict of interest.
EDAT- 2021/07/03 06:00
MHDA- 2021/07/27 06:00
PMCR- 2021/06/08
CRDT- 2021/07/02 01:10
PHST- 2021/04/30 00:00 [received]
PHST- 2021/05/28 00:00 [revised]
PHST- 2021/06/04 00:00 [accepted]
PHST- 2021/07/02 01:10 [entrez]
PHST- 2021/07/03 06:00 [pubmed]
PHST- 2021/07/27 06:00 [medline]
PHST- 2021/06/08 00:00 [pmc-release]
AID - ijms22126194 [pii]
AID - ijms-22-06194 [pii]
AID - 10.3390/ijms22126194 [doi]
PST - epublish
SO  - Int J Mol Sci. 2021 Jun 8;22(12):6194. doi: 10.3390/ijms22126194.

PMID- 33493605
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 596
DP  - 2021 Mar 1
TI  - Optimization of sulfobutyl-ether-β-cyclodextrin levels in oral formulations to 
      enhance progesterone bioavailability.
PG  - 120212
LID - S0378-5173(21)00016-8 [pii]
LID - 10.1016/j.ijpharm.2021.120212 [doi]
AB  - Progesterone oral dose regimens are indicated for the treatment of luteal phase 
      deficiency and estrogen dominance. The poor aqueous solubility of progesterone 
      leads to erratic oral absorption, resulting in suboptimal or excessive plasma 
      levels. Developing a formulation to enhance the solubility of progesterone in the 
      gastrointestinal tract would be beneficial to decrease drug absorption 
      variability and increase bioavailability. The solubility of progesterone at 
      400 mM sulfobutyl-ether-β-cyclodextrin (SBE-β-CD) concentration was ~7000-fold 
      greater than its intrinsic solubility, aided by the formation of 
      SBE-β-CD-progesterone complex. The complex was characterized using differential 
      scanning colorimeter, Fourier-transform infrared (FTIR) and nuclear magnetic 
      resonance (NMR) spectroscopy techniques. FTIR and NMR studies of the complex 
      confirm the interaction between functional groups of SBE-β-CD and progesterone to 
      form an inclusion complex. Molecular modeling studies demonstrated progesterone 
      binding poses with four probable SBE-β-CD isomers and these results matched with 
      NMR and FTIR data. The progesterone oral formulations were optimized by 
      increasing the levels of SBE-β-CD in the formulation to prevent the displacement 
      of progesterone from the complex by gastrointestinal contents. The oral 
      bioavailability of progesterone in rats was increased 5-fold when administered 
      with the optimized formulation compared to administration with progesterone API 
      capsules. Studies demonstrated that the optimized formulation prevents 
      precipitation of progesterone in the intestinal tract and increases progesterone 
      oral bioavailability in rats.
CI  - Copyright © 2021 Elsevier B.V. All rights reserved.
FAU - Shankar, Vijay Kumar
AU  - Shankar VK
AD  - Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University 
      of Mississippi, University, MS 38677, USA. Electronic address: 
      vshankar@olemiss.edu.
FAU - Police, Anitha
AU  - Police A
AD  - Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University 
      of Mississippi, University, MS 38677, USA. Electronic address: 
      apolice@go.olemiss.edu.
FAU - Pandey, Pankaj
AU  - Pandey P
AD  - Department of BioMolecular Sciences, Division of Medicinal Chemistry, School of 
      Pharmacy, The University of Mississippi, University, MS 38677, USA. Electronic 
      address: ppandey@olemiss.edu.
FAU - Cuny, Zachary G
AU  - Cuny ZG
AD  - Department of BioMolecular Sciences, Division of Medicinal Chemistry, School of 
      Pharmacy, The University of Mississippi, University, MS 38677, USA. Electronic 
      address: zgcuny@gmail.com.
FAU - Repka, Michael A
AU  - Repka MA
AD  - Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University 
      of Mississippi, University, MS 38677, USA. Electronic address: 
      marepka@olemiss.edu.
FAU - Doerksen, Robert J
AU  - Doerksen RJ
AD  - Department of BioMolecular Sciences, Division of Medicinal Chemistry, School of 
      Pharmacy, The University of Mississippi, University, MS 38677, USA. Electronic 
      address: rjd@olemiss.edu.
FAU - Murthy, S Narasimha
AU  - Murthy SN
AD  - Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University 
      of Mississippi, University, MS 38677, USA; Institute for Drug Delivery and 
      Biomedical Research, Bangalore, India. Electronic address: murthy@olemiss.edu.
LA  - eng
PT  - Journal Article
DEP - 20210123
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Ethers)
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (beta-Cyclodextrins)
RN  - 2PP9364507 (SBE4-beta-cyclodextrin)
RN  - 4G7DS2Q64Y (Progesterone)
SB  - IM
MH  - Animals
MH  - Biological Availability
MH  - Ethers
MH  - Female
MH  - *Pharmaceutical Preparations
MH  - Progesterone
MH  - Rats
MH  - Solubility
MH  - *beta-Cyclodextrins
OTO - NOTNLM
OT  - Docking
OT  - Intestinal permeation
OT  - Oral bioavailability
OT  - Progesterone
OT  - Simulated intestinal fluids
OT  - Sulfobutyl-ether-β-cyclodextrin
EDAT- 2021/01/26 06:00
MHDA- 2021/06/22 06:00
CRDT- 2021/01/25 20:11
PHST- 2020/06/26 00:00 [received]
PHST- 2020/12/07 00:00 [revised]
PHST- 2020/12/19 00:00 [accepted]
PHST- 2021/01/26 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2021/01/25 20:11 [entrez]
AID - S0378-5173(21)00016-8 [pii]
AID - 10.1016/j.ijpharm.2021.120212 [doi]
PST - ppublish
SO  - Int J Pharm. 2021 Mar 1;596:120212. doi: 10.1016/j.ijpharm.2021.120212. Epub 2021 
      Jan 23.

PMID- 32666001
OWN - NLM
STAT- MEDLINE
DCOM- 20210604
LR  - 20220310
IS  - 2466-054X (Electronic)
IS  - 2466-0493 (Print)
IS  - 2466-0493 (Linking)
VI  - 61
IP  - 4
DP  - 2020 Jul
TI  - Estrogen replacement is protective to the effect of in vitro hypoxia on female 
      rabbit bladder and pelvic floor contractile response.
PG  - 432-440
LID - 10.4111/icu.2020.61.4.432 [doi]
AB  - PURPOSE: To explore the effect of estrogen replacement on pelvic floor and 
      bladder contractile response to electrical field stimulation, following in vitro 
      hypoxia in an animal model of surgical menopause. MATERIALS AND METHODS: Twelve 
      female adult rabbits were divided into three groups: control, ovariectomy, and 
      ovariectomy with estradiol replacement. At 4 weeks animals were euthanized. 
      Bladder, coccygeus, and pubococcygeus were isolated. Tissues were equilibrated 
      with oxygenated Tyrodes containing glucose and stimulated with electrical field 
      stimulation. Tissues were then stimulated under hypoxic conditions for 1 hour 
      using nitrogenated Tyrodes without glucose. Tissues were then re-oxygenated for 2 
      hours and stimulated. RESULTS: Pelvic floor required 10 times the stimulation 
      duration (power) to achieve maximum contraction at 2 g baseline tension (10 ms 
      duration) when compared to bladder (1 ms duration). Maximal tension generated was 
      significantly greater for bladder than pelvic floor. Coccygeus and pubococcygeus 
      were significantly less sensitive to the effects of hypoxia and had stable 
      contractile response to field stimulation throughout the hour of hypoxia. Hypoxia 
      resulted in progressive and rapid decline of bladder contractile strength. 
      Following hypoxia, pelvic floor contractile recovery was superior to bladder. 
      Improvement in the contractile response of both bladder and pelvic floor, during 
      the period of post-hypoxia re-oxygenation, was significantly greater in 
      ovariectomy animals treated with estradiol replacement. CONCLUSIONS: Replacement 
      of estradiol at time of ovariectomy reduced oxidative stress on tissue and was 
      protective to the effects of hypoxia on pelvic floor and bladder contractile 
      function.
CI  - © The Korean Urological Association, 2020.
FAU - Dobberfuhl, Amy D
AU  - Dobberfuhl AD
AUID- ORCID: 0000-0003-3451-3878
AD  - Department of Urology, Stanford University School of Medicine, Stanford, CA, USA.
FAU - Schuler, Catherine
AU  - Schuler C
AD  - Stratton VA Medical Center, Albany, NY, USA.
FAU - Leggett, Robert E
AU  - Leggett RE
AD  - Stratton VA Medical Center, Albany, NY, USA.
FAU - De, Elise J B
AU  - De EJB
AUID- ORCID: 0000-0003-0730-9038
AD  - Department of Urology, Massachusetts General Hospital, Boston, MA, USA.
FAU - Levin, Robert M
AU  - Levin RM
AUID- ORCID: 0000-0003-1578-6870
AD  - Stratton VA Medical Center, Albany, NY, USA.
LA  - eng
GR  - KL2 TR003143/TR/NCATS NIH HHS/United States
GR  - L30 DK115056/DK/NIDDK NIH HHS/United States
GR  - KL2 TR001083/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20200514
PL  - Korea (South)
TA  - Investig Clin Urol
JT  - Investigative and clinical urology
JID - 101674989
RN  - 0 (Estrogens)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Animals
MH  - Estradiol/*pharmacology
MH  - *Estrogen Replacement Therapy
MH  - Estrogens/*pharmacology
MH  - Female
MH  - *Hypoxia/physiopathology
MH  - In Vitro Techniques
MH  - Muscle Contraction/*drug effects
MH  - Pelvic Floor/*physiology
MH  - Rabbits
MH  - Urinary Bladder/*drug effects/*physiology
PMC - PMC7329650
OTO - NOTNLM
OT  - Estrogen replacement therapy
OT  - Hypoxia
OT  - Models, animal
OT  - Pelvic floor
OT  - Urinary bladder
COIS- CONFLICTS OF INTEREST: The authors have nothing to disclose.
EDAT- 2020/07/16 06:00
MHDA- 2021/06/05 06:00
PMCR- 2020/07/01
CRDT- 2020/07/16 06:00
PHST- 2019/06/27 00:00 [received]
PHST- 2020/02/05 00:00 [accepted]
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2021/06/05 06:00 [medline]
PHST- 2020/07/01 00:00 [pmc-release]
AID - 10.4111/icu.2020.61.4.432 [doi]
PST - ppublish
SO  - Investig Clin Urol. 2020 Jul;61(4):432-440. doi: 10.4111/icu.2020.61.4.432. Epub 
      2020 May 14.

PMID- 30506492
OWN - NLM
STAT- MEDLINE
DCOM- 20190304
LR  - 20231002
IS  - 1573-7225 (Electronic)
IS  - 0957-5243 (Print)
IS  - 0957-5243 (Linking)
VI  - 30
IP  - 1
DP  - 2019 Jan
TI  - Comparability of serum, plasma, and urinary estrogen and estrogen metabolite 
      measurements by sex and menopausal status.
PG  - 75-86
LID - 10.1007/s10552-018-1105-1 [doi]
AB  - PURPOSE: The comparability between serum, plasma, and urinary measurements of 
      estrogen metabolites via liquid chromatography-tandem mass spectrometry 
      (LC-MS/MS) has not been largely explored, and it is unclear if urinary LC-MS/MS 
      measurements are suitable surrogates of circulating levels. METHODS: Serum, 
      plasma (EDTA and heparin), and urinary estrogen/estrogen metabolite levels were 
      measured via LC-MS/MS in paired samples from 64 healthy volunteers (18 men, 20 
      premenopausal women, 26 postmenopausal women). Geometric means and Spearman 
      correlation coefficients were used to compare individual and combined pathway 
      levels of estrogens/estrogen metabolites across biologic matrices by 
      sex/menopausal status. RESULTS: Measured concentrations of estrogens/estrogen 
      metabolites across blood matrices were almost identical (percent 
      differences < 4.8%). Parent estrogen concentrations measured in serum and urine 
      were moderately correlated in postmenopausal women (estrone: r = 0.69, estradiol: 
      r = 0.69). Correlations were similar comparing unconjugated serum estradiol to 
      urinary estrone (r = 0.76) and urinary estradiol (r = 0.65) in postmenopausal 
      women but were moderate to low in premenopausal women (r = 0.60, 0.40, 
      respectively)/men (r = 0.33, 0.53, respectively). Comparing metabolite ratios, 
      proportionally higher concentrations of 16-pathway metabolites were measured in 
      urine versus serum across sex/menopausal status groups (e.g., postmenopausal 
      women: 50.3% 16-pathway metabolites/total in urine versus 35.3% in serum). 
      CONCLUSIONS: There is strong agreement between estrogen/estrogen metabolites 
      measurements in serum, heparin plasma, and EDTA plasma. Individual estrogen 
      metabolite concentrations were moderately correlated between urine and serum, but 
      were not well correlated when evaluating pathway- or relative estrogen 
      concentrations. Differences between serum and urine are likely explained by 
      differences in metabolism and/or excretion.
FAU - Coburn, Sally B
AU  - Coburn SB
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, 
      DHHS, Bethesda, MD, USA.
FAU - Stanczyk, Frank Z
AU  - Stanczyk FZ
AD  - Departments of Obstetrics and Gynecology, and Preventive Medicine, University of 
      Southern California Keck School of Medicine, Los Angeles, CA, USA.
FAU - Falk, Roni T
AU  - Falk RT
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, 
      DHHS, Bethesda, MD, USA.
FAU - McGlynn, Katherine A
AU  - McGlynn KA
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, 
      DHHS, Bethesda, MD, USA.
FAU - Brinton, Louise A
AU  - Brinton LA
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, 
      DHHS, Bethesda, MD, USA.
FAU - Sampson, Joshua
AU  - Sampson J
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, 
      DHHS, Bethesda, MD, USA.
FAU - Bradwin, Gary
AU  - Bradwin G
AD  - Department of Laboratory Medicine, Harvard Medical School and Children's 
      Hospital, Boston, MA, USA.
FAU - Xu, Xia
AU  - Xu X
AD  - Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick 
      National Laboratory for Cancer Research, Frederick, MD, USA.
FAU - Trabert, Britton
AU  - Trabert B
AUID- ORCID: 0000-0002-1539-6090
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, 
      DHHS, Bethesda, MD, USA. britton.trabert@nih.gov.
LA  - eng
GR  - R01 DK115648/DK/NIDDK NIH HHS/United States
GR  - T32 DK062707/DK/NIDDK NIH HHS/United States
GR  - ZIA CP010126-21/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
DEP - 20181201
PL  - Netherlands
TA  - Cancer Causes Control
JT  - Cancer causes & control : CCC
JID - 9100846
RN  - 0 (Estrogens)
RN  - 2DI9HA706A (Estrone)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Chromatography, Liquid
MH  - Estradiol/metabolism
MH  - Estrogens/*metabolism
MH  - Estrone/metabolism
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Postmenopause
MH  - *Premenopause
MH  - Tandem Mass Spectrometry
PMC - PMC6447065
MID - NIHMS1524869
OTO - NOTNLM
OT  - Comparison
OT  - Estrogen metabolites
OT  - Estrogens
OT  - Plasma
OT  - Serum
OT  - Urine
COIS- Conflicts of interest: All authors declare they have no conflicts of interest.
EDAT- 2018/12/07 06:00
MHDA- 2019/03/05 06:00
PMCR- 2020/01/01
CRDT- 2018/12/04 06:00
PHST- 2018/07/19 00:00 [received]
PHST- 2018/11/26 00:00 [accepted]
PHST- 2018/12/07 06:00 [pubmed]
PHST- 2019/03/05 06:00 [medline]
PHST- 2018/12/04 06:00 [entrez]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.1007/s10552-018-1105-1 [pii]
AID - 10.1007/s10552-018-1105-1 [doi]
PST - ppublish
SO  - Cancer Causes Control. 2019 Jan;30(1):75-86. doi: 10.1007/s10552-018-1105-1. Epub 
      2018 Dec 1.

PMID- 26246394
OWN - NLM
STAT- MEDLINE
DCOM- 20160518
LR  - 20221207
IS  - 1745-5065 (Electronic)
IS  - 1745-5057 (Linking)
VI  - 11
IP  - 4
DP  - 2015 Jul
TI  - The menopause transition: interview with Ellen W Freeman.
PG  - 441-3
LID - 10.2217/whe.15.33 [doi]
AB  - Ellen W Freeman is a Research Professor in the Department of 
      Obstetrics/Gynecology and the Department of Psychiatry at the University of 
      Pennsylvania School of Medicine in Philadelphia (PA, USA). She directs the PMS 
      research program and is co-director of the Human Behavior and Reproduction unit 
      in the Department of Obstetrics and Gynecology. She received her AB in history in 
      Smith College in Northampton, Massachusetts and her MS and PhD in social research 
      from Bryn Mawr College in Bryn Mawr, Pennsylvania. She has published more than 
      200 scientific articles, book chapters, reviews and abstracts on premenstrual 
      syndromes, perimenopause, adolescent pregnancy, infertility and related topics as 
      well as a book on teenage pregnancy. In addition, she has lectured extensively 
      worldwide on mood disorders and menopause in women. She is also a member of the 
      editorial boards of Medscape, Archives of Women's Mental Health and Mental 
      Fitness: Psychiatry, OB/GYN, Primary Care and is a Fellow in the College of 
      Physicians of Philadelphia.
FAU - Freeman, Ellen W
AU  - Freeman EW
AD  - Department of Obstetrics & Gynecology, University of Pennsylvania School of 
      Medicine, Mudd Professorship Suite, 3701 Market Street, 8th Floor, Philadelphia, 
      PA 19104-5509, USA.
LA  - eng
PT  - Interview
DEP - 20150806
PL  - United States
TA  - Womens Health (Lond)
JT  - Women's health (London, England)
JID - 101271249
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Climacteric/drug effects/physiology
MH  - Depressive Disorder/*epidemiology/physiopathology
MH  - Estradiol/metabolism
MH  - Estrogen Replacement Therapy
MH  - Female
MH  - Humans
MH  - Menopause/drug effects/*physiology
MH  - Prevalence
MH  - Selective Serotonin Reuptake Inhibitors/therapeutic use
MH  - *Women's Health
EDAT- 2015/08/08 06:00
MHDA- 2016/05/19 06:00
CRDT- 2015/08/07 06:00
PHST- 2015/08/07 06:00 [entrez]
PHST- 2015/08/08 06:00 [pubmed]
PHST- 2016/05/19 06:00 [medline]
AID - 10.2217/whe.15.33 [doi]
PST - ppublish
SO  - Womens Health (Lond). 2015 Jul;11(4):441-3. doi: 10.2217/whe.15.33. Epub 2015 Aug 
      6.

PMID- 28778445
OWN - NLM
STAT- MEDLINE
DCOM- 20170822
LR  - 20240326
IS  - 1872-8421 (Electronic)
IS  - 0165-5728 (Print)
IS  - 0165-5728 (Linking)
VI  - 310
DP  - 2017 Sep 15
TI  - Estrogen protection against EAE modulates the microbiota and mucosal-associated 
      regulatory cells.
PG  - 51-59
LID - S0165-5728(17)30252-7 [pii]
LID - 10.1016/j.jneuroim.2017.06.007 [doi]
AB  - Sex hormones promote immunoregulatory effects on multiple sclerosis. In the 
      current study we evaluated the composition of the gut microbiota and the 
      mucosal-associated regulatory cells in estrogen or sham treated female mice 
      before and after autoimmune encephalomyelitis (EAE) induction. Treatment with 
      pregnancy levels of estrogen induces changes in the composition and diversity of 
      gut microbiota. Additionally, estrogen prevents EAE-associated changes in the gut 
      microbiota and might promote the enrichment of bacteria that are associated with 
      immune regulation. Our results point to a possible cross-talk between the sex 
      hormones and the gut microbiota, which could promote neuroprotection.
CI  - Copyright © 2017 Elsevier B.V. All rights reserved.
FAU - Benedek, Gil
AU  - Benedek G
AD  - Neuroimmunology Research, VA Portland Health Care System, 3710 SW U.S. Veterans 
      Hospital Rd, Portland, OR 97239, USA; Department of Neurology, Oregon Health & 
      Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA.
FAU - Zhang, Jun
AU  - Zhang J
AD  - Neuroimmunology Research, VA Portland Health Care System, 3710 SW U.S. Veterans 
      Hospital Rd, Portland, OR 97239, USA; Department of Neurology, Oregon Health & 
      Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA.
FAU - Nguyen, Ha
AU  - Nguyen H
AD  - Neuroimmunology Research, VA Portland Health Care System, 3710 SW U.S. Veterans 
      Hospital Rd, Portland, OR 97239, USA; Department of Neurology, Oregon Health & 
      Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA.
FAU - Kent, Gail
AU  - Kent G
AD  - Neuroimmunology Research, VA Portland Health Care System, 3710 SW U.S. Veterans 
      Hospital Rd, Portland, OR 97239, USA; Department of Neurology, Oregon Health & 
      Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA.
FAU - Seifert, Hilary A
AU  - Seifert HA
AD  - Neuroimmunology Research, VA Portland Health Care System, 3710 SW U.S. Veterans 
      Hospital Rd, Portland, OR 97239, USA; Department of Neurology, Oregon Health & 
      Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA.
FAU - Davin, Sean
AU  - Davin S
AD  - Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, 
      3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA.
FAU - Stauffer, Patrick
AU  - Stauffer P
AD  - Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, 
      3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA.
FAU - Vandenbark, Arthur A
AU  - Vandenbark AA
AD  - Neuroimmunology Research, VA Portland Health Care System, 3710 SW U.S. Veterans 
      Hospital Rd, Portland, OR 97239, USA; Department of Neurology, Oregon Health & 
      Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA; 
      Department of Molecular Microbiology & Immunology, Oregon Health & Science 
      University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA.
FAU - Karstens, Lisa
AU  - Karstens L
AD  - Division of Bioinformatics and Computational Biology, Oregon Health & Science 
      University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA; Division of 
      Urogynecology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, 
      Portland, OR 97239, USA.
FAU - Asquith, Mark
AU  - Asquith M
AD  - Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, 
      3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA.
FAU - Offner, Halina
AU  - Offner H
AD  - Neuroimmunology Research, VA Portland Health Care System, 3710 SW U.S. Veterans 
      Hospital Rd, Portland, OR 97239, USA; Department of Neurology, Oregon Health & 
      Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA; 
      Department of Anesthesiology and Perioperative Medicine, Oregon Health & Science 
      University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA. Electronic 
      address: offnerva@ohsu.edu.
LA  - eng
GR  - R01 NS080890/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20170621
PL  - Netherlands
TA  - J Neuroimmunol
JT  - Journal of neuroimmunology
JID - 8109498
RN  - 0 (Antigens, CD)
RN  - 0 (Estrogens)
RN  - 0 (Myelin-Oligodendrocyte Glycoprotein)
RN  - 0 (Peptide Fragments)
RN  - 0 (RNA, Ribosomal, 16S)
RN  - 0 (myelin oligodendrocyte glycoprotein (35-55))
RN  - 130068-27-8 (Interleukin-10)
SB  - IM
MH  - Animals
MH  - Antigens, CD/metabolism
MH  - Disease Models, Animal
MH  - Encephalomyelitis, Autoimmune, Experimental/chemically induced/*drug 
      therapy/pathology
MH  - Estrogens/*therapeutic use
MH  - Feces/microbiology
MH  - Female
MH  - Interleukin-10/genetics/metabolism
MH  - Intestines/drug effects/*microbiology
MH  - Leukocytes/drug effects
MH  - Lymph Nodes/drug effects/pathology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Transgenic
MH  - Microbiota/*drug effects
MH  - Mucous Membrane/*drug effects/*pathology
MH  - Myelin-Oligodendrocyte Glycoprotein/toxicity
MH  - Peptide Fragments/toxicity
MH  - RNA, Ribosomal, 16S/genetics/metabolism
MH  - Spinal Cord/pathology
MH  - Time Factors
PMC - PMC5570519
MID - NIHMS889588
OTO - NOTNLM
OT  - EAE
OT  - Estrogen
OT  - M2-like macrophage/microglia
OT  - Microbiota
OT  - Regulatory B cell
COIS- Competing interests The authors declare that they have no conflict of interest.
EDAT- 2017/08/06 06:00
MHDA- 2017/08/23 06:00
PMCR- 2018/09/15
CRDT- 2017/08/06 06:00
PHST- 2017/06/08 00:00 [received]
PHST- 2017/06/19 00:00 [accepted]
PHST- 2017/08/06 06:00 [entrez]
PHST- 2017/08/06 06:00 [pubmed]
PHST- 2017/08/23 06:00 [medline]
PHST- 2018/09/15 00:00 [pmc-release]
AID - S0165-5728(17)30252-7 [pii]
AID - 10.1016/j.jneuroim.2017.06.007 [doi]
PST - ppublish
SO  - J Neuroimmunol. 2017 Sep 15;310:51-59. doi: 10.1016/j.jneuroim.2017.06.007. Epub 
      2017 Jun 21.

PMID- 30108098
OWN - NLM
STAT- MEDLINE
DCOM- 20191112
LR  - 20210223
IS  - 1538-7755 (Electronic)
IS  - 1055-9965 (Print)
IS  - 1055-9965 (Linking)
VI  - 27
IP  - 12
DP  - 2018 Dec
TI  - Effects of Exercise and Cardiorespiratory Fitness on Estrogen Metabolism in 
      Postmenopausal Women.
PG  - 1480-1482
LID - 10.1158/1055-9965.EPI-17-0900 [doi]
AB  - BACKGROUND: Lowering endogenous estrogen levels is one mechanism whereby physical 
      activity may lower postmenopausal breast cancer risk. Several prospective studies 
      have suggested that increased 2-hydroxylation of estrogens may also reduce 
      postmenopausal breast cancer risk, but whether or not exercise alters estrogen 
      metabolism through this mechanism is unclear. METHODS: We measured total 
      circulating concentrations of parent estrogens (estrone and estradiol) and 13 
      estrogen metabolites, including glucuronidated, sulfated, and unconjugated forms, 
      by stable isotope dilution LC/MS-MS in 153 postmenopausal women randomized to 12 
      months of moderate-to-vigorous exercise and 153 controls. We also explored 
      associations with cardiorespiratory fitness measured by treadmill. RESULTS: 
      Although women randomized to exercise averaged 178 minutes/week of exercise over 
      12 months, their cardiorespiratory fitness was 13% greater than controls at 12 
      months (P = 0.0001), and total estradiol was reduced by 10% (P = 0.04); there 
      were no statistically significant effects of exercise on circulating 
      concentrations of estrogen metabolites in the 2-, 4-, or 16-pathways, or on the 
      2-pathway/parent estrogens ratio. However, we observed a statistically 
      significant association between increased fitness and reduced concentration of 
      2-pathway metabolites (P < 0.05). CONCLUSIONS: We found no evidence that 12 
      months of moderate-to-vigorous exercise or increased fitness changed estrogen 
      metabolism in a way that might reduce breast cancer risk. IMPACT: The protective 
      effect of exercise on postmenopausal breast cancer is unlikely to be mediated by 
      changes in estrogen metabolism.
CI  - ©2018 American Association for Cancer Research.
FAU - Matthews, Charles E
AU  - Matthews CE
AD  - Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, NCI, 
      Bethesda, Maryland. matthewsce@mail.nih.gov.
FAU - Sampson, Joshua N
AU  - Sampson JN
AUID- ORCID: 0000-0003-2875-3365
AD  - Biostatistics Branch, Division of Cancer Epidemiology and Genetics, NCI, 
      Bethesda, Maryland.
FAU - Brenner, Darren R
AU  - Brenner DR
AD  - Departments of Cancer Epidemiology and Prevention Research and Oncology and 
      Community Health Sciences, Cumming School of Medicine, University of Calgary, 
      Calgary, Alberta, Canada.
FAU - Moore, Steven C
AU  - Moore SC
AD  - Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, NCI, 
      Bethesda, Maryland.
FAU - Courneya, Kerry S
AU  - Courneya KS
AD  - Faculty of Physical Education and Recreation, University of Alberta, Edmonton, 
      Alberta, Canada.
FAU - Ziegler, Regina G
AU  - Ziegler RG
AUID- ORCID: 0000-0002-5100-9852
AD  - Epidemiology and Biostatistics Program, Division of Cancer Epidemiology and 
      Genetics, NCI, Bethesda, Maryland.
FAU - Friedenreich, Christine M
AU  - Friedenreich CM
AUID- ORCID: 0000-0002-4783-1966
AD  - Departments of Cancer Epidemiology and Prevention Research, Oncology, and 
      Community Health Sciences, Cumming School of Medicine, University of Calgary, 
      Calgary, Alberta, Canada.
AD  - Department of Kinesiology, University of Calgary, Calgary, Alberta, Canada.
LA  - eng
GR  - Z99 CA999999/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20180814
PL  - United States
TA  - Cancer Epidemiol Biomarkers Prev
JT  - Cancer epidemiology, biomarkers & prevention : a publication of the American 
      Association for Cancer Research, cosponsored by the American Society of 
      Preventive Oncology
JID - 9200608
RN  - 0 (Estrogens)
SB  - IM
MH  - Cardiorespiratory Fitness/*physiology
MH  - Estrogens/*metabolism
MH  - Exercise/*physiology
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Postmenopause
MH  - Risk Factors
PMC - PMC7899052
MID - NIHMS1669775
COIS- The authors declare no potential conflicts of interest.
EDAT- 2018/08/16 06:00
MHDA- 2019/11/13 06:00
PMCR- 2021/02/22
CRDT- 2018/08/16 06:00
PHST- 2017/10/10 00:00 [received]
PHST- 2017/12/12 00:00 [revised]
PHST- 2018/08/10 00:00 [accepted]
PHST- 2018/08/16 06:00 [pubmed]
PHST- 2019/11/13 06:00 [medline]
PHST- 2018/08/16 06:00 [entrez]
PHST- 2021/02/22 00:00 [pmc-release]
AID - 1055-9965.EPI-17-0900 [pii]
AID - 10.1158/1055-9965.EPI-17-0900 [doi]
PST - ppublish
SO  - Cancer Epidemiol Biomarkers Prev. 2018 Dec;27(12):1480-1482. doi: 
      10.1158/1055-9965.EPI-17-0900. Epub 2018 Aug 14.

PMID- 29092787
OWN - NLM
STAT- MEDLINE
DCOM- 20190501
LR  - 20190501
IS  - 1879-1220 (Electronic)
IS  - 0960-0760 (Linking)
VI  - 178
DP  - 2018 Apr
TI  - Estradiol metabolites as biomarkers of endometrial cancer prognosis after 
      surgery.
PG  - 45-54
LID - S0960-0760(17)30318-7 [pii]
LID - 10.1016/j.jsbmb.2017.10.021 [doi]
AB  - Endometrial cancer (EC) is the most common gynecologic malignancy prevailing 
      after menopause. Defining steroid profiles may help predict the risk of 
      recurrence after hysterectomy, which remains limited due to the lack of reliable 
      markers. Adrenal precursors, androgens, parent estrogens and catechol estrogen 
      metabolites were measured by mass spectrometry (MS) in preoperative serums and 
      those collected one month after hysterectomy from 246 newly diagnosed 
      postmenopausal EC cases. We also examined the associations between steroid 
      hormones and EC status by including 110 healthy postmenopausal women. Steroid 
      concentrations were analyzed in relation to clinicopathological features, 
      recurrence and overall survival (OS). The mean follow-up time was 65.5 months and 
      26 patients experienced relapse after surgery for a recurrence incidence of 10.6% 
      (6.4% Type I and 29.5% Type II). Recurrence and OS were related to a more 
      aggressive disease but not linked to body mass index. Preoperative levels of 
      estriol (E(3)) and estrone-sulfate (E(1)-S) were inversely associated with 
      recurrence in a multivariate logistic regression analysis (Hazard ratios (HRs) of 
      0.31, P=0.039 and 3.01, P=0.024; respectively). All circulating steroids declined 
      considerably after surgery almost reaching those of healthy women, except 
      4-methoxy-E(2) (4MeO-E(2)) for which postoperative levels increased by 35% and 
      were associated to a 68% decreased risk of recurrence (HR=0.32, P=0.015). Women 
      diagnosed with both histological types of EC present significantly higher levels 
      of steroids, in support of their mitogenic effects. The estrogen precursor 
      E(1)-S, the anticancer metabolite 4MeO-E(2), and E(3) that exert mixed antagonist 
      and agonist estrogenic activities and immunological effects, are potential 
      independent prognostic factors.
CI  - Copyright © 2017 Elsevier Ltd. All rights reserved.
FAU - Audet-Delage, Yannick
AU  - Audet-Delage Y
AD  - Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center and 
      Faculty of Pharmacy, Laval University, Québec, Canada.
FAU - Grégoire, Jean
AU  - Grégoire J
AD  - Gynecologic Oncology Service, CHU de Québec, and Department of Obstetrics, 
      Gynecology, and Reproduction, Faculty of Medicine, Laval University, Québec, 
      Canada.
FAU - Caron, Patrick
AU  - Caron P
AD  - Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center and 
      Faculty of Pharmacy, Laval University, Québec, Canada.
FAU - Turcotte, Véronique
AU  - Turcotte V
AD  - Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center and 
      Faculty of Pharmacy, Laval University, Québec, Canada.
FAU - Plante, Marie
AU  - Plante M
AD  - Gynecologic Oncology Service, CHU de Québec, and Department of Obstetrics, 
      Gynecology, and Reproduction, Faculty of Medicine, Laval University, Québec, 
      Canada.
FAU - Ayotte, Pierre
AU  - Ayotte P
AD  - CHU de Québec Research Center, and Department of Social and Preventive Medicine, 
      Faculty of Medicine, Laval University, Québec, Canada.
FAU - Simonyan, David
AU  - Simonyan D
AD  - Statistical and Clinical Research Platform, CHU de Québec Research Center, 
      Québec, Canada.
FAU - Villeneuve, Lyne
AU  - Villeneuve L
AD  - Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center and 
      Faculty of Pharmacy, Laval University, Québec, Canada.
FAU - Guillemette, Chantal
AU  - Guillemette C
AD  - Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center and 
      Faculty of Pharmacy, Laval University, Québec, Canada; Canada Research Chair in 
      Pharmacogenomics, Canada. Electronic address: 
      chantal.guillemette@crchudequebec.ulaval.ca.
LA  - eng
GR  - MOP-68964/CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20171029
PL  - England
TA  - J Steroid Biochem Mol Biol
JT  - The Journal of steroid biochemistry and molecular biology
JID - 9015483
RN  - 0 (Biomarkers, Tumor)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Adenocarcinoma/*metabolism/pathology/surgery
MH  - Aged
MH  - Biomarkers, Tumor/*metabolism
MH  - Case-Control Studies
MH  - Endometrial Neoplasms/*metabolism/pathology/surgery
MH  - Estradiol/analysis/*metabolism
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - *Metabolomics
MH  - Neoplasm Invasiveness
MH  - Neoplasm Recurrence, Local/*metabolism/pathology/surgery
MH  - Postmenopause
MH  - Prognosis
MH  - Prospective Studies
MH  - Survival Rate
OTO - NOTNLM
OT  - Catechol estrogens
OT  - Endometrial cancer
OT  - Mass spectrometry
OT  - Recurrence
EDAT- 2017/11/03 06:00
MHDA- 2019/05/02 06:00
CRDT- 2017/11/03 06:00
PHST- 2017/06/29 00:00 [received]
PHST- 2017/10/23 00:00 [revised]
PHST- 2017/10/26 00:00 [accepted]
PHST- 2017/11/03 06:00 [pubmed]
PHST- 2019/05/02 06:00 [medline]
PHST- 2017/11/03 06:00 [entrez]
AID - S0960-0760(17)30318-7 [pii]
AID - 10.1016/j.jsbmb.2017.10.021 [doi]
PST - ppublish
SO  - J Steroid Biochem Mol Biol. 2018 Apr;178:45-54. doi: 10.1016/j.jsbmb.2017.10.021. 
      Epub 2017 Oct 29.

PMID- 32069802
OWN - NLM
STAT- MEDLINE
DCOM- 20200918
LR  - 20250103
IS  - 1660-4601 (Electronic)
IS  - 1661-7827 (Print)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Feb 13
TI  - Assessing Endogenous and Exogenous Hormone Exposures and Breast Development in a 
      Migrant Study of Bangladeshi and British Girls.
LID - 10.3390/ijerph17041185 [doi]
LID - 1185
AB  - Timing of breast development (or thelarche) and its endogenous and exogenous 
      determinants may underlie global variation in breast cancer incidence. The study 
      objectives were to characterize endogenous estrogen levels and bisphenol A (BPA) 
      exposure using a migrant study of adolescent girls and test whether 
      concentrations explained differences in thelarche by birthplace and growth 
      environment. Estrogen metabolites (EM) and BPA-glucuronide (BPA-G) were 
      quantified in urine spot samples using liquid chromatography tandem mass 
      spectrometry (LC-MS/MS) from a cross-sectional study of Bangladeshi, first- and 
      second-generation Bangladeshi migrants to the UK, and white British girls aged 
      5-16 years (n = 348). Thelarche status at the time of interview was self-reported 
      and defined equivalent to Tanner Stage ≥2. We compared geometric means (and 95% 
      confidence interval (CIs)) of EM and BPA-G using linear regression and assessed 
      whether EM and BPA-G explained any of the association between exposure to the UK 
      and the age at thelarche using hazard ratios and 95% confidence intervals. 
      Average EM decreased with exposure to the UK, whereas BPA-G increased and was 
      significantly higher among white British (0.007 ng/mL, 95% CI: 0.0024-0.0217) and 
      second-generation British-Bangladeshi girls (0.009 ng/mL, 95% CI: 0.0040-0.0187) 
      compared to Bangladeshi girls (0.002 ng/mL, 95% CI: 0.0018-0.0034). Two of four 
      EM ratios (16-pathway/parent and parent/all pathways) were significantly 
      associated with thelarche. The relationship between exposure to the UK and 
      thelarche did not change appreciably after adding EM and BPA-G to the models. 
      While BPA-G is often considered a ubiquitous exposure, our findings suggest it 
      can vary based on birthplace and growth environment, with increasing levels for 
      girls who were born in or moved to the UK. Our study did not provide 
      statistically significant evidence that BPA-G or EM concentrations explained 
      earlier thelarche among girls who were born or raised in the UK.
FAU - Howland, Renata E
AU  - Howland RE
AUID- ORCID: 0000-0002-1506-2568
AD  - Department of Epidemiology, Mailman School of Public Health, New York, NY 10032, 
      USA.
FAU - Deziel, Nicole C
AU  - Deziel NC
AUID- ORCID: 0000-0002-5751-9191
AD  - Yale School of Public Health, Yale University, New Haven, CT 06510, USA.
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, 
      Bethseda, MD 20892, USA.
FAU - Bentley, Gillian R
AU  - Bentley GR
AUID- ORCID: 0000-0002-2009-5540
AD  - Department of Anthropology, Durham University, Durham DH13LE, UK.
FAU - Booth, Mark
AU  - Booth M
AD  - Faculty of Medical Sciences, Newcastle University, Newcastle NE24HH, UK.
FAU - Choudhury, Osul A
AU  - Choudhury OA
AD  - Sylhet MAG Osmani Medical College, Sylhet WV23JH, Bangladesh.
FAU - Hofmann, Jonathan N
AU  - Hofmann JN
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, 
      Bethseda, MD 20892, USA.
FAU - Hoover, Robert N
AU  - Hoover RN
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, 
      Bethseda, MD 20892, USA.
FAU - Katki, Hormuzd A
AU  - Katki HA
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, 
      Bethseda, MD 20892, USA.
FAU - Trabert, Britton
AU  - Trabert B
AUID- ORCID: 0000-0002-1539-6090
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, 
      Bethseda, MD 20892, USA.
FAU - Fox, Stephen D
AU  - Fox SD
AD  - Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick 
      National Laboratory for Cancer Research, Frederick, MD 21702, USA.
FAU - Troisi, Rebecca
AU  - Troisi R
AD  - Faculty of Medical Sciences, Newcastle University, Newcastle NE24HH, UK.
FAU - Houghton, Lauren C
AU  - Houghton LC
AD  - Department of Epidemiology, Mailman School of Public Health, New York, NY 10032, 
      USA.
LA  - eng
GR  - K07 CA218166/CA/NCI NIH HHS/United States
GR  - 5K017CA218166-02/Division of Cancer Prevention, National Cancer 
      Institute/International
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200213
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Estrogens)
RN  - 0 (Phenols)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - Adolescent
MH  - Bangladesh
MH  - *Benzhydryl Compounds/toxicity
MH  - *Breast/growth & development
MH  - Child
MH  - Child, Preschool
MH  - Chromatography, Liquid
MH  - Cross-Sectional Studies
MH  - *Estrogens/metabolism
MH  - Female
MH  - Humans
MH  - Menarche
MH  - *Phenols/toxicity
MH  - *Tandem Mass Spectrometry
MH  - United Kingdom
MH  - White People
PMC - PMC7068451
OTO - NOTNLM
OT  - BPA
OT  - adolescents
OT  - cancer
OT  - environmental exposure
OT  - estrogen
OT  - migrant study
COIS- The authors declare no conflict of interest. The funders had no role in the 
      design of the study, in the collection, analyses, or interpretation of data, in 
      the writing of the manuscript, or in the decision to publish the results.
EDAT- 2020/02/20 06:00
MHDA- 2020/09/20 06:00
PMCR- 2020/02/01
CRDT- 2020/02/20 06:00
PHST- 2019/10/09 00:00 [received]
PHST- 2020/01/17 00:00 [revised]
PHST- 2020/02/08 00:00 [accepted]
PHST- 2020/02/20 06:00 [entrez]
PHST- 2020/02/20 06:00 [pubmed]
PHST- 2020/09/20 06:00 [medline]
PHST- 2020/02/01 00:00 [pmc-release]
AID - ijerph17041185 [pii]
AID - ijerph-17-01185 [pii]
AID - 10.3390/ijerph17041185 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Feb 13;17(4):1185. doi: 
      10.3390/ijerph17041185.

PMID- 28697043
OWN - NLM
STAT- MEDLINE
DCOM- 20180726
LR  - 20180726
IS  - 1530-0374 (Electronic)
IS  - 1072-3714 (Linking)
VI  - 24
IP  - 12
DP  - 2017 Dec
TI  - Vasomotor hot flashes and cardiac repolarization: a randomized placebo-controlled 
      trial of postmenopausal hormone therapy.
PG  - 1386-1391
LID - 10.1097/GME.0000000000000932 [doi]
AB  - OBJECTIVE: The aim of the study was to compare the effects of different hormone 
      therapies on cardiac repolarization in recently postmenopausal women with and 
      without hot flashes. METHODS: We recruited 150 healthy women: 72 with and 78 
      without hot flashes. They were randomized and treated for 6 months with 
      transdermal estradiol (1 mg/day), oral estradiol (OE) alone (2 mg/day) or 
      combined with medroxyprogesterone acetate (MPA; 5 mg/day), or placebo. Cardiac 
      repolarization was assessed by measuring QT intervals, rate-dependence of QT-end 
      interval, and T waves from 24-hour electrocardiographic recording before and 
      during hormone therapy, comprising a total of over 20 million QT-interval 
      measurements. RESULTS: Hot flashes were accompanied with shortened median T-peak 
      - T-end interval (at RR interval of 700, 800, and 900 ms; P = 0.040, 0.020, and 
      0.032; η = 0.35, 0.39, and 0.37; respectively) during the use of OE but not 
      transdermal estradiol. In contrast, the addition of MPA to OE lengthened the 
      maximal QT-end (at RR interval of 500 ms, P = 0.016, η = 0.27) and the maximal 
      T-peak - T-end interval (at RR interval of 500 and 600 ms; P = 0.016 and 0.032; 
      η = 0.25 and 0.22, respectively). These effects were not seen in women without 
      hot flashes. CONCLUSIONS: Hot flashes predict beneficial shortening in cardiac 
      repolarization during OE, but not if MPA is combined with OE. These data may 
      provide one explanation for MPA-related cardiac hazards in epidemiological 
      studies.
FAU - Lantto, Hanna
AU  - Lantto H
AD  - Division of Clinical Physiology and Nuclear Medicine, HUS Medical Imaging Center, 
      Helsinki University Hospital.
FAU - Haapalahti, Petri
AU  - Haapalahti P
AD  - Division of Clinical Physiology and Nuclear Medicine, HUS Medical Imaging Center, 
      Helsinki University Hospital.
FAU - Viitasalo, Matti
AU  - Viitasalo M
AD  - Department of Cardiology, Heart and Lung Center, Helsinki University Hospital, 
      Helsinki.
FAU - Väänänen, Heikki
AU  - Väänänen H
AD  - Aalto University, Espoo.
FAU - Sovijärvi, Anssi R A
AU  - Sovijärvi ARA
AD  - Division of Clinical Physiology and Nuclear Medicine, HUS Medical Imaging Center, 
      Helsinki University Hospital.
FAU - Ylikorkala, Olavi
AU  - Ylikorkala O
AD  - Department of Obstetrics and Gynecology, Women's Hospital, Helsinki University 
      Hospital, Helsinki, Finland.
FAU - Mikkola, Tomi S
AU  - Mikkola TS
AD  - Department of Obstetrics and Gynecology, Women's Hospital, Helsinki University 
      Hospital, Helsinki, Finland.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Menopause
JT  - Menopause (New York, N.Y.)
JID - 9433353
RN  - 0 (Placebos)
RN  - 4TI98Z838E (Estradiol)
RN  - C2QI4IOI2G (Medroxyprogesterone Acetate)
SB  - IM
MH  - Arrhythmias, Cardiac/prevention & control
MH  - Double-Blind Method
MH  - *Electrocardiography
MH  - Estradiol/administration & dosage
MH  - Estrogen Replacement Therapy/*methods
MH  - Female
MH  - Heart/physiopathology
MH  - Heart Diseases/physiopathology/*prevention & control
MH  - Heart Rate
MH  - Hot Flashes/*drug therapy
MH  - Humans
MH  - Medroxyprogesterone Acetate/administration & dosage
MH  - Middle Aged
MH  - Placebos
MH  - Postmenopause/*physiology
EDAT- 2017/07/12 06:00
MHDA- 2018/07/27 06:00
CRDT- 2017/07/12 06:00
PHST- 2017/07/12 06:00 [pubmed]
PHST- 2018/07/27 06:00 [medline]
PHST- 2017/07/12 06:00 [entrez]
AID - 10.1097/GME.0000000000000932 [doi]
PST - ppublish
SO  - Menopause. 2017 Dec;24(12):1386-1391. doi: 10.1097/GME.0000000000000932.

PMID- 36442995
OWN - NLM
STAT- MEDLINE
DCOM- 20230724
LR  - 20230912
IS  - 1468-6244 (Electronic)
IS  - 0022-2593 (Linking)
VI  - 60
IP  - 8
DP  - 2023 Aug
TI  - Differential involvement of germline pathogenic variants in breast cancer genes 
      between DCIS and low-grade invasive cancers.
PG  - 740-746
LID - 10.1136/jmg-2022-108790 [doi]
AB  - PURPOSE: To investigate frequency of germline pathogenic variants (PVs) in women 
      with ductal carcinoma in situ (DCIS) and grade 1 invasive breast cancer (G1BC). 
      METHODS: We undertook BRCA1/2 analysis in 311 women with DCIS and 392 with G1BC 
      and extended panel testing (non-BRCA1/2) in 176/311 with DCIS and 156/392 with 
      G1BC. We investigated PV detection by age at diagnosis, Manchester Score (MS), 
      DCIS grade and receptor status. RESULTS: 30/311 (9.6%) with DCIS and 16/392 with 
      G1BC (4.1%) had a BRCA1/2 PV (p=0.003), and 24/176-(13.6%) and 7/156-(4.5%), 
      respectively, a non-BRCA1/2 PV (p=0.004). Increasing MS was associated with 
      increased likelihood of BRCA1/2 PV in both DCIS and G1BC, although the 10% 
      threshold was not predictive for G1GB. 13/32 (40.6%) DCIS and 0/17 with G1BC 
      <40 years had a non-BRCA1/2 PV (p<0.001). 0/16 DCIS G1 had a PV. For G2 and G3 
      DCIS, PV rates were 10/98 (BRCA1/2) and 9/90 (non-BRCA1/2), and 8/47 (BRCA1/2) 
      and 8/45 (non-BRCA1/2), respectively. 6/9 BRCA1 and 3/26 BRCA2-associated DCIS 
      were oestrogen receptor negative-(p=0.003). G1BC population testing showed no 
      increased PV rate (OR=1.16, 95% CI 0.28 to 4.80). CONCLUSION: DCIS is more likely 
      to be associated with both BRCA1/2 and non-BRCA1/2 PVs than G1BC. Extended panel 
      testing ought to be offered in young-onset DCIS where PV detection rates are 
      highest.
CI  - © Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and 
      permissions. Published by BMJ.
FAU - Evans, D Gareth
AU  - Evans DG
AUID- ORCID: 0000-0002-8482-5784
AD  - Division of Evolution and Genomic Science, The University of Manchester School of 
      Health Sciences, Manchester, UK gareth.evans@mft.nhs.uk.
FAU - Sithambaram, Siva
AU  - Sithambaram S
AD  - Manchester Univerities Hospital NHS Foundation Trust, Manchester, UK.
FAU - van Veen, Elke Maria
AU  - van Veen EM
AUID- ORCID: 0000-0001-8618-2332
AD  - Division of Evolution and Genomic Sciences, The University of Manchester, 
      Manchester, UK.
FAU - Burghel, George J
AU  - Burghel GJ
AUID- ORCID: 0000-0001-9360-8194
AD  - Genomic Diagnostic Laboratory, MFT, Manchester, UK.
FAU - Schlecht, Helene
AU  - Schlecht H
AD  - North West Genomic Laboratory Hub, Central Manchester University Hospitals NHS 
      Foundation Trust, Manchester, UK.
FAU - Harkness, Elaine F
AU  - Harkness EF
AD  - Division of Evolution and Genomic Sciences, The University of Manchester, 
      Manchester, UK.
FAU - Byers, Helen
AU  - Byers H
AD  - Genomic Medicine, The University of Manchester School of Health Sciences, 
      Manchester, UK.
FAU - Ellingford, Jamie M
AU  - Ellingford JM
AUID- ORCID: 0000-0003-1137-9768
AD  - Institute of Human Development, The University of Manchester School of Health 
      Sciences, Manchester, UK.
FAU - Gandhi, Ashu
AU  - Gandhi A
AUID- ORCID: 0000-0002-7264-6201
AD  - Prevent Breast Cancer Centre, Wythenshawe Hospital Manchester Universities 
      Foundation Trust, Manchester, UK.
FAU - Howell, Sacha J
AU  - Howell SJ
AD  - Manchester Univerities Hospital NHS Foundation Trust, Manchester, UK.
AD  - Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, 
      UK.
FAU - Howell, Anthony
AU  - Howell A
AD  - Manchester Foundation Trust, Prevent Breast Cancer Centre, Manchester, UK.
FAU - Forde, Claire
AU  - Forde C
AUID- ORCID: 0000-0001-8035-4471
AD  - Clinical Genetics Service, Central Manchester University Hospitals NHS Foundation 
      Trust, Manchester, UK.
FAU - Lalloo, Fiona
AU  - Lalloo F
AD  - Clinical Genetics Service, Manchester Centre for Genomic Medicine, Central 
      Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
FAU - Newman, William G
AU  - Newman WG
AD  - Genetics, The University of Manchester School of Health Sciences, Manchester, UK.
FAU - Smith, Miriam Jane
AU  - Smith MJ
AUID- ORCID: 0000-0002-3184-0817
AD  - Genetic Medicine, The University of Manchester School of Health Sciences, 
      Manchester, UK.
FAU - Woodward, Emma Roisin
AU  - Woodward ER
AUID- ORCID: 0000-0002-6297-2855
AD  - Manchester Centre for Genomic Medicine, MFT, Manchester, UK.
LA  - eng
GR  - IS-BRC-1215-20007/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221128
PL  - England
TA  - J Med Genet
JT  - Journal of medical genetics
JID - 2985087R
RN  - 0 (BRCA1 Protein)
RN  - 0 (BRCA2 Protein)
SB  - IM
MH  - Female
MH  - Humans
MH  - *Carcinoma, Intraductal, Noninfiltrating/diagnosis/genetics/pathology
MH  - *Breast Neoplasms/diagnosis/genetics/epidemiology
MH  - BRCA1 Protein/genetics
MH  - BRCA2 Protein/genetics
MH  - Germ-Line Mutation/genetics
MH  - Genes, BRCA2
MH  - Germ Cells/pathology
OTO - NOTNLM
OT  - Genetics, Medical
COIS- Competing interests: None declared.
EDAT- 2022/11/29 06:00
MHDA- 2023/07/24 06:42
CRDT- 2022/11/28 21:12
PHST- 2022/06/28 00:00 [received]
PHST- 2022/11/14 00:00 [accepted]
PHST- 2023/07/24 06:42 [medline]
PHST- 2022/11/29 06:00 [pubmed]
PHST- 2022/11/28 21:12 [entrez]
AID - jmg-2022-108790 [pii]
AID - 10.1136/jmg-2022-108790 [doi]
PST - ppublish
SO  - J Med Genet. 2023 Aug;60(8):740-746. doi: 10.1136/jmg-2022-108790. Epub 2022 Nov 
      28.

PMID- 35134918
OWN - NLM
STAT- MEDLINE
DCOM- 20220509
LR  - 20240627
IS  - 1460-2350 (Electronic)
IS  - 0268-1161 (Print)
IS  - 0268-1161 (Linking)
VI  - 37
IP  - 5
DP  - 2022 May 3
TI  - Incidence and familial risk of premature ovarian insufficiency in the Finnish 
      female population.
PG  - 1030-1036
LID - 10.1093/humrep/deac014 [doi]
AB  - STUDY QUESTION: What is the incidence of premature ovarian insufficiency (POI), 
      has the incidence of POI changed over time, and what is the risk of POI among 
      relatives of POI women? SUMMARY ANSWER: The incidence of POI increased among 
      females aged 15-19 years from 2007 onwards and decreased in older age groups, and 
      among relatives of women with POI the risk of POI is significantly increased. 
      WHAT IS KNOWN ALREADY: So far, there has been no good quality, nationwide studies 
      of the incidence of POI. Early menopause has been associated with the elevated 
      risk of early menopause among relatives, but the knowledge of the familial risk 
      of POI is scarce. Lower socioeconomic status has been associated with lower age 
      at natural menopause. STUDY DESIGN, SIZE, DURATION: Population-based study with 
      5011 women diagnosed with POI in 1988-2017. The data were collected from national 
      registries and covers POI subjects in entire Finland. PARTICIPANTS/MATERIALS, 
      SETTING, METHODS: Women with hormone replacement therapy reimbursement for POI 
      were identified from Social Insurance Institution (SII). We calculated POI 
      incidence in different age groups and studied the changes in the incidence rate 
      over time in 5-year segments. Four population-based controls were selected from 
      the Digital and Population Data Services Agency (DVV) for each POI woman. Family 
      members of the POI cases and controls were identified from the DVV and linked to 
      SII reimbursement data to identify POI diagnoses among them. The familial risk of 
      POI was estimated with a logistical regression model. MAIN RESULTS AND THE ROLE 
      OF CHANCE: The incidence was highest in the 35-39 age group, ranging from 
      73.8/100 000 women-years in 1993-1997 to 39.9/100 000 women-years in 2013-2017. 
      From 2007, the incidence among 15- to 19-year-olds rose from 7.0 to 10.0/100 000 
      women-years in 2015-2017. Cumulative incidence of POI for women under 40 years in 
      1988-2017 was 478/100 000 women. The relative risk of POI among relatives of 
      women with POI was 4.6 (95% CI 3.3-6.5) compared to relatives of women without 
      POI. POI women tended to have slightly lower socioeconomic status and level of 
      education compared to controls. LIMITATIONS, REASONS FOR CAUTION: For some women 
      with POI, diagnosis or reimbursement may be lacking. However, we presume that 
      these women represent a minority due to the nature of the disease and the 
      economic benefits of reimbursement. Some changes in the incidence of POI can 
      reflect changes in clinical practice and changing treatments and reimbursement 
      criteria. WIDER IMPLICATIONS OF THE FINDINGS: The risk of developing POI is 
      significantly higher in women who have first-degree relatives diagnosed with POI. 
      Raising awareness of the increased risk might lead to earlier diagnosis and 
      initiation of hormonal replacement therapy, possibly preventing adverse effects 
      of low oestrogen levels, such as osteoporosis. STUDY FUNDING/COMPETING 
      INTEREST(S): This work was financially supported by the Oulu University Hospital. 
      H.S. received a grant from Finnish Menopause Society. S.M.S. received a grant 
      from the Finnish Menopause Society, the Finnish Medical Foundation and the Juho 
      Vainio Foundation. The authors do not have any competing interests to declare. 
      TRIAL REGISTRATION NUMBER: N/A.
CI  - © The Author(s) 2022. Published by Oxford University Press on behalf of European 
      Society of Human Reproduction and Embryology.
FAU - Silvén, H
AU  - Silvén H
AUID- ORCID: 0000-0001-6820-5705
AD  - Department of Obstetrics and Gynecology, Oulu University Hospital, Oulu, Finland.
AD  - PEDEGO Research Unit, University of Oulu, Oulu, Finland.
AD  - Medical Research Center, Oulu University Hospital and University of Oulu, Oulu, 
      Finland.
FAU - Savukoski, S M
AU  - Savukoski SM
AUID- ORCID: 0000-0003-2491-0458
AD  - Department of Obstetrics and Gynecology, Oulu University Hospital, Oulu, Finland.
AD  - PEDEGO Research Unit, University of Oulu, Oulu, Finland.
AD  - Medical Research Center, Oulu University Hospital and University of Oulu, Oulu, 
      Finland.
FAU - Pesonen, P
AU  - Pesonen P
AUID- ORCID: 0000-0002-4215-3430
AD  - Northern Finland Birth Cohorts, Arctic Biobank, Infrastructure for Population 
      Studies, Faculty of Medicine, University of Oulu, Oulu, Finland.
FAU - Pukkala, E
AU  - Pukkala E
AUID- ORCID: 0000-0001-9536-6440
AD  - Faculty of Social Sciences, Tampere University, Tampere, Finland.
AD  - Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer 
      Research, Helsinki, Finland.
FAU - Gissler, M
AU  - Gissler M
AUID- ORCID: 0000-0001-8254-7525
AD  - Information Services Department, THL Finnish Institute for Health and Welfare, 
      Helsinki, Finland.
AD  - Academic Primary Health Care Centre, Stockholm, Sweden.
AD  - Department of Molecular Medicine and Surgery, 171 76, Karolinska Institute, 
      Stockholm, Sweden.
FAU - Suvanto, E
AU  - Suvanto E
AD  - Department of Obstetrics and Gynecology, Oulu University Hospital, Oulu, Finland.
AD  - PEDEGO Research Unit, University of Oulu, Oulu, Finland.
AD  - Medical Research Center, Oulu University Hospital and University of Oulu, Oulu, 
      Finland.
FAU - Niinimäki, M
AU  - Niinimäki M
AUID- ORCID: 0000-0003-0927-0472
AD  - Department of Obstetrics and Gynecology, Oulu University Hospital, Oulu, Finland.
AD  - PEDEGO Research Unit, University of Oulu, Oulu, Finland.
AD  - Medical Research Center, Oulu University Hospital and University of Oulu, Oulu, 
      Finland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Reprod
JT  - Human reproduction (Oxford, England)
JID - 8701199
SB  - IM
MH  - Adult
MH  - Aged
MH  - Female
MH  - Finland/epidemiology
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Incidence
MH  - *Menopause, Premature
MH  - *Primary Ovarian Insufficiency/epidemiology/genetics
PMC - PMC9071220
OTO - NOTNLM
OT  - early menopause
OT  - familial risk
OT  - genetic risk
OT  - hormone replacement therapy
OT  - menopause
OT  - premature ovarian insufficiency
EDAT- 2022/02/09 06:00
MHDA- 2022/05/10 06:00
PMCR- 2022/02/04
CRDT- 2022/02/08 20:22
PHST- 2021/09/09 00:00 [received]
PHST- 2021/12/21 00:00 [revised]
PHST- 2022/02/09 06:00 [pubmed]
PHST- 2022/05/10 06:00 [medline]
PHST- 2022/02/08 20:22 [entrez]
PHST- 2022/02/04 00:00 [pmc-release]
AID - 6521741 [pii]
AID - deac014 [pii]
AID - 10.1093/humrep/deac014 [doi]
PST - ppublish
SO  - Hum Reprod. 2022 May 3;37(5):1030-1036. doi: 10.1093/humrep/deac014.

PMID- 34137105
OWN - NLM
STAT- MEDLINE
DCOM- 20220324
LR  - 20240403
IS  - 1750-3639 (Electronic)
IS  - 1015-6305 (Print)
IS  - 1015-6305 (Linking)
VI  - 31
IP  - 6
DP  - 2021 Nov
TI  - Double-edged effects of tamoxifen-in-oil-gavage on an infectious murine model for 
      multiple sclerosis.
PG  - e12994
LID - 10.1111/bpa.12994 [doi]
LID - e12994
AB  - Tamoxifen gavage is a commonly used method to induce genetic modifications in 
      cre-loxP systems. As a selective estrogen receptor modulator (SERM), the compound 
      is known to have immunomodulatory and neuroprotective properties in 
      non-infectious central nervous system (CNS) disorders. It can even cause complete 
      prevention of lesion development as seen in experimental autoimmune encephalitis 
      (EAE). The effect on infectious brain disorders is scarcely investigated. In this 
      study, susceptible SJL mice were infected intracerebrally with Theiler's murine 
      encephalomyelitis virus (TMEV) and treated three times with a 
      tamoxifen-in-oil-gavage (TOG), resembling an application scheme for genetically 
      modified mice, starting at 0, 18, or 38 days post infection (dpi). All mice 
      developed 'TMEV-induced demyelinating disease' (TMEV-IDD) resulting in 
      inflammation, axonal loss, and demyelination of the spinal cord. TOG had a 
      positive effect on the numbers of oligodendrocytes and oligodendrocyte progenitor 
      cells, irrespective of the time point of application, whereas late application 
      (starting 38 dpi) was associated with increased demyelination of the spinal cord 
      white matter 85 dpi. Furthermore, TOG had differential effects on the CD4(+) and 
      CD8(+) T cell infiltration into the CNS, especially a long lasting increase of 
      CD8(+) cells was detected in the inflamed spinal cord, depending of the time 
      point of TOG application. Number of TMEV-positive cells, astrogliosis, astrocyte 
      phenotype, apoptosis, clinical score, and motor function were not measurably 
      affected. These data indicate that tamoxifen gavage has a double-edged effect on 
      TMEV-IDD with the promotion of oligodendrocyte differentiation and proliferation, 
      but also increased demyelination, depending on the time point of application. The 
      data of this study suggest that tamoxifen has also partially protective functions 
      in infectious CNS disease. These effects should be considered in experimental 
      studies using the cre-loxP system, especially in models investigating 
      neuropathologies.
CI  - © 2021 The Authors. Brain Pathology published by John Wiley & Sons Ltd on behalf 
      of International Society of Neuropathology.
FAU - Hülskötter, Kirsten
AU  - Hülskötter K
AUID- ORCID: 0000-0003-1577-5856
AD  - Department of Pathology, University of Veterinary Medicine Hannover, Hannover, 
      Germany.
AD  - Center for Systems Neuroscience, Hannover, Germany.
FAU - Jin, Wen
AU  - Jin W
AD  - Department of Pathology, University of Veterinary Medicine Hannover, Hannover, 
      Germany.
AD  - Center for Systems Neuroscience, Hannover, Germany.
FAU - Allnoch, Lisa
AU  - Allnoch L
AD  - Department of Pathology, University of Veterinary Medicine Hannover, Hannover, 
      Germany.
AD  - Center for Systems Neuroscience, Hannover, Germany.
FAU - Hansmann, Florian
AU  - Hansmann F
AUID- ORCID: 0000-0001-6064-7728
AD  - Department of Pathology, University of Veterinary Medicine Hannover, Hannover, 
      Germany.
AD  - Center for Systems Neuroscience, Hannover, Germany.
AD  - Institute of Veterinary Pathology, Leipzig University, Leipzig, Germany.
FAU - Schmidtke, Daniel
AU  - Schmidtke D
AD  - Center for Systems Neuroscience, Hannover, Germany.
AD  - Institute of Zoology, University of Veterinary Medicine Hannover, Hannover, 
      Germany.
FAU - Rohn, Karl
AU  - Rohn K
AD  - Institute of Biometry, Epidemiology, and Information Processing, University of 
      Veterinary Medicine Hannover, Hannover, Germany.
FAU - Flügel, Alexander
AU  - Flügel A
AD  - Center for Systems Neuroscience, Hannover, Germany.
AD  - Institute for Neuroimmunology and Multiple Sclerosis Research, University Medical 
      Center Göttingen, Göttingen, Germany.
FAU - Lühder, Fred
AU  - Lühder F
AD  - Institute for Neuroimmunology and Multiple Sclerosis Research, University Medical 
      Center Göttingen, Göttingen, Germany.
FAU - Baumgärtner, Wolfgang
AU  - Baumgärtner W
AUID- ORCID: 0000-0001-8151-5644
AD  - Department of Pathology, University of Veterinary Medicine Hannover, Hannover, 
      Germany.
AD  - Center for Systems Neuroscience, Hannover, Germany.
FAU - Herder, Vanessa
AU  - Herder V
AD  - Department of Pathology, University of Veterinary Medicine Hannover, Hannover, 
      Germany.
AD  - Center for Systems Neuroscience, Hannover, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210617
PL  - Switzerland
TA  - Brain Pathol
JT  - Brain pathology (Zurich, Switzerland)
JID - 9216781
RN  - 094ZI81Y45 (Tamoxifen)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Brain/*pathology
MH  - Cardiovirus Infections/pathology
MH  - Demyelinating Diseases/pathology
MH  - Disease Models, Animal
MH  - Female
MH  - Mice
MH  - Multiple Sclerosis/*pathology
MH  - Spinal Cord/*pathology
MH  - Tamoxifen/*administration & dosage
MH  - Theilovirus
PMC - PMC8549030
OTO - NOTNLM
OT  - Tamoxifen-in-oil-gavage (TOG)
OT  - Theiler's murine encephalomyelitis virus (TMEV)
OT  - cre-loxP
OT  - demyelination
OT  - neuropathology
OT  - oligodendrocytes
COIS- The authors declare that they have no conflict of interest.
EDAT- 2021/06/18 06:00
MHDA- 2022/03/25 06:00
PMCR- 2021/06/17
CRDT- 2021/06/17 07:08
PHST- 2021/05/05 00:00 [revised]
PHST- 2021/02/05 00:00 [received]
PHST- 2021/05/06 00:00 [accepted]
PHST- 2021/06/18 06:00 [pubmed]
PHST- 2022/03/25 06:00 [medline]
PHST- 2021/06/17 07:08 [entrez]
PHST- 2021/06/17 00:00 [pmc-release]
AID - BPA12994 [pii]
AID - 10.1111/bpa.12994 [doi]
PST - ppublish
SO  - Brain Pathol. 2021 Nov;31(6):e12994. doi: 10.1111/bpa.12994. Epub 2021 Jun 17.

PMID- 27710141
OWN - NLM
STAT- MEDLINE
DCOM- 20170310
LR  - 20231213
IS  - 1473-0804 (Electronic)
IS  - 1369-7137 (Linking)
VI  - 19
IP  - 6
DP  - 2016 Dec
TI  - Effects of phytoestrogens on bone mineral density during the menopause 
      transition: a systematic review of randomized, controlled trials.
PG  - 535-545
AB  - INTRODUCTION: Menopause is associated with increased bone resorption and 
      decreased bone mineral density (BMD). Phytoestrogens are believed to prevent bone 
      loss. This study reviewed relevant randomized, controlled trials to determine the 
      effects of phytoestrogens on BMD in postmenopausal women. METHODS: In order to 
      perform this systematic review, PubMed, Science Direct, Scopus, Cochrane Library, 
      ISI Web of Knowledge, and ProQuest databases were searched for articles published 
      during 2005-2016. The main keywords used during the searches were "phytoestrogen" 
      and "bone mineral density" and "menopause". The Cochrane Risk of Bias Assessment 
      Tool was used to evaluate the quality of the selected studies and to assess the 
      risk of bias. RESULTS: A total of 23 eligible studies were included in this 
      systematic review. Most selected studies used a double-blind, placebo-controlled 
      design. In total, 3494 participants were enrolled in the selected trials. 
      Different types of soy isoflavone extracts, including genistein extracts (either 
      alone or in combination with daidzein), dietary products containing different 
      amounts of phytoestrogens, and red clover extracts were used in the designed 
      interventions. The duration of the interventions ranged from 7 weeks to 3 years. 
      In most studies, the primary outcome was the efficacy of the designed 
      intervention which was assessed through measuring whole body or regional BMD or 
      bone mineral content, T-scores, and biomarkers of bone metabolism. CONCLUSIONS: 
      Isoflavones probably have beneficial effects on bone health in menopausal women. 
      Nevertheless, there were controversial reports about changes in BMD. 
      Supplementation with a phytoestrogen can probably prevent the reduction in BMD 
      and maintain a healthy bone structure during menopause.
FAU - Abdi, F
AU  - Abdi F
AD  - a PhD Candidate, Students' Research Office, Nursing and Midwifery Faculty , 
      Shahid Beheshti University of Medical Sciences , Tehran , Iran.
FAU - Alimoradi, Z
AU  - Alimoradi Z
AD  - b PhD Candidate, Department of Midwifery and Reproductive Health, Nursing and 
      Midwifery Faculty , Shahid Beheshti University of Medical Sciences , Tehran , 
      Iran.
FAU - Haqi, P
AU  - Haqi P
AD  - c MS of Midwifery, Students' Research Office, Nursing and Midwifery Faculty , 
      Shahid Beheshti University of Medical Sciences , Tehran , Iran.
FAU - Mahdizad, F
AU  - Mahdizad F
AD  - c MS of Midwifery, Students' Research Office, Nursing and Midwifery Faculty , 
      Shahid Beheshti University of Medical Sciences , Tehran , Iran.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20161006
PL  - England
TA  - Climacteric
JT  - Climacteric : the journal of the International Menopause Society
JID - 9810959
RN  - 0 (Isoflavones)
RN  - 0 (Phytoestrogens)
RN  - 0 (Placebos)
RN  - 0 (Plant Extracts)
RN  - 6287WC5J2L (daidzein)
RN  - DH2M523P0H (Genistein)
SB  - IM
MH  - Bone Density/*drug effects
MH  - Diet
MH  - Double-Blind Method
MH  - Female
MH  - Genistein/administration & dosage
MH  - Humans
MH  - Isoflavones/administration & dosage
MH  - *Menopause
MH  - Phytoestrogens/administration & dosage/*pharmacology
MH  - Phytotherapy
MH  - Placebos
MH  - Plant Extracts/administration & dosage
MH  - *Randomized Controlled Trials as Topic
MH  - Glycine max/chemistry
OTO - NOTNLM
OT  - Phytoestrogen
OT  - bone mineral density
OT  - menopause
EDAT- 2016/10/07 06:00
MHDA- 2017/03/11 06:00
CRDT- 2016/10/07 06:00
PHST- 2016/10/07 06:00 [pubmed]
PHST- 2017/03/11 06:00 [medline]
PHST- 2016/10/07 06:00 [entrez]
AID - 10.1080/13697137.2016.1238451 [doi]
PST - ppublish
SO  - Climacteric. 2016 Dec;19(6):535-545. doi: 10.1080/13697137.2016.1238451. Epub 
      2016 Oct 6.

PMID- 33066585
OWN - NLM
STAT- MEDLINE
DCOM- 20210225
LR  - 20210225
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 21
IP  - 20
DP  - 2020 Oct 14
TI  - Raloxifene as Treatment for Various Types of Brain Injuries and Neurodegenerative 
      Diseases: A Good Start.
LID - 10.3390/ijms21207586 [doi]
LID - 7586
AB  - Recent studies have shown that the selective estrogen receptor modulator (SERM) 
      raloxifene had pronounced protective effects against progressing brain damage 
      after traumatic brain injury (TBI) in mice. These studies, indicating beneficial 
      effects of raloxifene for brain health, prompted the study of the history and 
      present state of knowledge of this topic. It appears that, apart from raloxifene, 
      to date, four nonrelated compounds have shown comparable beneficial 
      effects-fucoidan, pifithrin, SMM-189 (5-dihydroxy-phenyl]-phenyl-methanone), and 
      translocator protein (TSPO) ligands. Raloxifene, however, is ahead of the field, 
      as for more than two decades it has been used in medical practice for various 
      chronic ailments in humans. Thus, apart from different types of animal and cell 
      culture studies, it has also been assessed in various human clinical trials, 
      including assaying its effects on mild cognitive impairments. Regarding cell 
      types, raloxifene protects neurons from cell death, prevents glial activation, 
      ameliorates myelin damage, and maintains health of endothelial cells. At whole 
      central nervous system (CNS) levels, raloxifene ameliorated mild cognitive 
      impairments, as seen in clinical trials, and showed beneficial effects in animal 
      models of Parkinson's disease. Moreover, with stroke and TBI in animal models, 
      raloxifene showed curative effects. Furthermore, raloxifene showed healing 
      effects regarding multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) 
      in cell culture. The adverse biological signals typical of these conditions 
      relate to neuronal activity, neurotransmitters and their receptors, plasticity, 
      inflammation, oxidative stress, nitric oxide, calcium homeostasis, cell death, 
      behavioral impairments, etc. Raloxifene favorably modulates these signals toward 
      cell health-on the one hand, by modulating gene expression of the relevant 
      proteins, for example by way of its binding to the cell nuclear estrogen 
      receptors ERα and ERβ (genomic effects) and, on the other hand (nongenomic 
      effects) by modulation of mitochondrial activity, reduction of oxidative stress 
      and programmed cell death, maintaining metabolic balance, degradation of Abeta, 
      and modulation of intracellular cholesterol levels. More specifically regarding 
      Alzheimer's disease, raloxifene may not cure diagnosed Alzheimer's disease. 
      However, the onset of Alzheimer's disease may be delayed or arrested by 
      raloxifene's capability to attenuate mild cognitive impairment. Mild cognitive 
      impairment is a condition that may precede diagnosis of Alzheimer's disease. In 
      this review, relatively new insights are addressed regarding the notion that 
      Alzheimer's disease can be caused by bacterial (as well as viral) infections, 
      together with the most recent findings that raloxifene can counteract infections 
      of at least some bacterial and viral strains. Thus, here, an overview of 
      potential treatments of neurodegenerative disease by raloxifene is presented, and 
      attention is paid to subcellular molecular biological pathways that may be 
      involved.
FAU - Veenman, Leo
AU  - Veenman L
AD  - Israel Institute of Technology, Faculty of Medicine, Rappaport Institute of 
      Medical Research, 1 Efron Street, P.O. Box 9697, Haifa 31096, Israel.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201014
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Selective Estrogen Receptor Modulators)
RN  - 4F86W47BR6 (Raloxifene Hydrochloride)
SB  - IM
MH  - Animals
MH  - Brain Injuries/*drug therapy/metabolism
MH  - Humans
MH  - Neurodegenerative Diseases/*drug therapy/metabolism
MH  - Neuroprotective Agents/*therapeutic use
MH  - Raloxifene Hydrochloride/*therapeutic use
MH  - Selective Estrogen Receptor Modulators/*therapeutic use
PMC - PMC7589740
OTO - NOTNLM
OT  - Alzheimer
OT  - Parkinson
OT  - Raloxifene
OT  - cure
OT  - gene expression
OT  - mitochondrial activity
OT  - selective estrogen receptor modulator(s), FDA approved
OT  - stroke
OT  - traumatic brain injury (TBI), neurodegeneration
COIS- The author declares no conflict of interest.
EDAT- 2020/10/18 06:00
MHDA- 2021/02/26 06:00
PMCR- 2020/10/01
CRDT- 2020/10/17 01:04
PHST- 2020/09/01 00:00 [received]
PHST- 2020/10/10 00:00 [revised]
PHST- 2020/10/12 00:00 [accepted]
PHST- 2020/10/17 01:04 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/02/26 06:00 [medline]
PHST- 2020/10/01 00:00 [pmc-release]
AID - ijms21207586 [pii]
AID - ijms-21-07586 [pii]
AID - 10.3390/ijms21207586 [doi]
PST - epublish
SO  - Int J Mol Sci. 2020 Oct 14;21(20):7586. doi: 10.3390/ijms21207586.

PMID- 39379960
OWN - NLM
STAT- MEDLINE
DCOM- 20241009
LR  - 20241206
IS  - 1741-7015 (Electronic)
IS  - 1741-7015 (Linking)
VI  - 22
IP  - 1
DP  - 2024 Oct 8
TI  - Physical activity levels are positively related to progression-free survival and 
      reduced adverse events in advanced ER(+) breast cancer.
PG  - 442
LID - 10.1186/s12916-024-03671-x [doi]
LID - 442
AB  - BACKGROUND: Increased levels of physical activity are associated with a reduction 
      of breast cancer mortality, especially in postmenopausal women with positive 
      hormone receptor status. So far, previous observational case-control and cohort 
      studies have focused on associations between overall leisure time physical 
      activity and survival of women with breast cancer in general. METHODS: In this 
      multicenter prospective cohort study, conducted in Germany between 30th August 
      2012 to 29th December 2017, we investigated general physical activity in a 
      homogenous sample of n = 1440 postmenopausal women with advanced (inoperable 
      locally advanced or metastatic), hormone receptor-positive breast cancer 
      receiving the same therapy (everolimus and exemestane). Self-reported physical 
      activity was assessed using the Godin Leisure Time Exercise Questionnaire (GLTEQ) 
      before and every 3 months during treatment. Participants were then classified 
      into "active" and "insufficiently active" to screen their activity behavior the 
      week prior to medical treatment. In addition, changes in physical activity 
      patterns were assessed. Adjusted Cox regression analyses were performed for the 
      activity categories to determine hazard ratios (HR). Besides progression-free 
      survival (PFS), adverse events (AEs), QoL, and fatigue were assessed every 
      3 months until study termination. RESULTS: Compared to "insufficiently active" 
      patients, "active" individuals indicated a significantly longer PFS (HR: 0.84 
      [0.74; 0.984], p = .0295). No significant differences were observed for changes 
      of physical activity behavior. Patients who reported to be "active" at baseline 
      revealed significantly fewer AEs compared to "insufficiently" active patients. In 
      detail, both severe and non-severe AEs occurred less frequently in the "active" 
      patients group. In line with that, QoL and fatigue were better in physical 
      "active" patients compared to their insufficient active counterparts at the last 
      post-baseline assessment. Participants who remained or become active indicated 
      less AEs, a higher QoL, and reduced fatigue levels. CONCLUSIONS: Physical 
      activity behavior prior to medical treatment might have prognostic value in 
      patients with advanced breast cancer in terms of extending the PFS. Moreover, 
      physical activity before and during treatment may reduce treatment-related side 
      effects and improve patients' QoL and fatigue. TRIAL REGISTRATION: EUPAS9462. 
      Registered 30th October 2012 "retrospectively registered."
CI  - © 2024. The Author(s).
FAU - Zimmer, Philipp
AU  - Zimmer P
AD  - Institute for Sport and Sport Science, Division of Performance and Health (Sports 
      Medicine), TU Dortmund University, Dortmund, Germany. 
      philipp.zimmer@tu-dortmund.de.
FAU - Esser, Tobias
AU  - Esser T
AD  - Institute for Sport and Sport Science, Division of Performance and Health (Sports 
      Medicine), TU Dortmund University, Dortmund, Germany.
FAU - Lueftner, Diana
AU  - Lueftner D
AD  - Immanuel Hospital Märkische Schweiz, AND Medical University of Brandenburg 
      Theodor Fontane, BuckowRüdersdorf Bei Berlin, Germany.
FAU - Schuetz, Florian
AU  - Schuetz F
AD  - Department of Obstetrics and Gynecology, University Hospital Heidelberg, 
      Heidelberg, Germany.
FAU - Baumann, Freerk T
AU  - Baumann FT
AD  - Department I of Internal Medicine, Center for Integrated Oncology, University 
      Hospital of Cologne, Cologne, Germany.
FAU - Rody, Achim
AU  - Rody A
AD  - Department of Obstetrics and Gynecology, University Hospital Schleswig-Holstein, 
      Lübeck, Germany.
FAU - Schneeweiss, Andreas
AU  - Schneeweiss A
AD  - National Center for Tumor Diseases (NCT), Heidelberg University Hospital and 
      German Cancer Research Center, Heidelberg, Germany.
FAU - Hartkopf, Andreas D
AU  - Hartkopf AD
AD  - Dpt. of Women's Health, University Hospital Tuebingen, Tuebingen, Germany.
FAU - Decker, Thomas
AU  - Decker T
AD  - Medical Center for Hematology and Oncology Ravensburg, Ravensburg, Germany.
FAU - Uleer, Christoph
AU  - Uleer C
AD  - Gynecologic Group Practice, Hildesheim, Germany.
FAU - Stoetzer, Oliver J
AU  - Stoetzer OJ
AD  - Medical Center for Hematology and Oncology Munich, Munich, Germany.
FAU - Foerster, Frank
AU  - Foerster F
AD  - Poliklinik GmbH Chemnitz, Chemnitz, Germany.
FAU - Schmidt, Marcus
AU  - Schmidt M
AD  - Dpt. of Obstetrics and Gynecology, Dpt. of Conservative and Molecular 
      Gynecological Oncology, University Medical Center Mainz, Mainz, Germany.
FAU - Mundhenke, Christoph
AU  - Mundhenke C
AD  - Department of Obstetrics and Gynecology, Bayreuth Hospital, Bayreuth, Germany.
FAU - Steindorf, Karen
AU  - Steindorf K
AD  - German Cancer Research Center, Division of Physical Activity, Prevention and 
      Cancer, Heidelberg, Germany.
FAU - Tesch, Hans
AU  - Tesch H
AD  - Center for Hematology and Oncology Bethanien, Frankfurt, Germany.
FAU - Jackisch, Christian
AU  - Jackisch C
AD  - Dpt. of Obstetrics and Gynecology, Sana Klinikum Offenbach, Offenbach, Germany.
FAU - Fischer, Thomas
AU  - Fischer T
AD  - Winicker Norimed GmbH Medical Research, Nuernberg, Germany.
FAU - Hanson, Sven
AU  - Hanson S
AD  - Novartis Pharma GmbH, Nuernberg, Germany.
FAU - Kreuzeder, Julia
AU  - Kreuzeder J
AD  - Novartis Pharma GmbH, Nuernberg, Germany.
FAU - Guderian, Gernot
AU  - Guderian G
AD  - Novartis Pharma GmbH, Nuernberg, Germany.
FAU - Fasching, Peter A
AU  - Fasching PA
AD  - Department of Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, 
      Germany.
FAU - Bloch, Wilhelm
AU  - Bloch W
AD  - Dpt. for Molecular and Cellular Sports Medicine, German Sport University Cologne, 
      Cologne, Germany.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20241008
PL  - England
TA  - BMC Med
JT  - BMC medicine
JID - 101190723
RN  - NY22HMQ4BX (exemestane)
RN  - 0 (Androstadienes)
RN  - 9HW64Q8G6G (Everolimus)
RN  - 0 (Receptors, Estrogen)
SB  - IM
MH  - Humans
MH  - Female
MH  - *Breast Neoplasms
MH  - *Exercise/physiology
MH  - Prospective Studies
MH  - Middle Aged
MH  - Aged
MH  - Germany
MH  - Progression-Free Survival
MH  - Androstadienes/therapeutic use
MH  - Everolimus/therapeutic use
MH  - Quality of Life
MH  - Receptors, Estrogen/metabolism
MH  - Postmenopause
MH  - Fatigue
PMC - PMC11462731
OTO - NOTNLM
OT  - Adverse events
OT  - Breast cancer
OT  - Exercise
OT  - Fatigue
OT  - Physical activity
OT  - Quality of life
OT  - Survival
COIS- PZ reports personal fees from Novartis Pharma GmbH (https://www.novartis.de) 
      (talks and traveling fees to present an interims analysis at the SABCS 2015) and 
      IPSEN (https://www.ipsen.com/germany) (advisory board). DL, AS, TD, CM, CJ, and 
      WB report personal fees from Novartis Pharma GmbH (https://www.novartis.de). AH 
      and TF report grants from Novartis Pharma GmbH (https://www.novartis.de) during 
      the conduct of the study. SH, GG, and JK report other non-financial support from 
      Novartis Pharma GmbH (https://www.novartis.de) during the conduct of the study. 
      MS reports grants and personal fees from Novartis Pharma GmbH 
      (https://www.novartis.de). HT reports personal fees and non-financial support 
      from Novartis Pharma GmbH (https://www.novartis.de). PAF reports grants from 
      Biontech (https://biontech.de) and Cepheid (https://www.cepheid.com), personal 
      fees from Roche (https://www.roche.de), Pfizer (https://www.pfizer.de), Celgene 
      (https://www.celgene.de), Daiichi-Sankyo (https://www.daiichi-sankyo.de), Astra 
      Zeneca (https://www.astrazeneca.de), MSD (https://www.msd.de), Myelo Therapeutics 
      (http://www.myelotherapeutics.com), Macrogenics (https://www.macrogenics.com), 
      Eisai (https://www.eisai.de), Lilly (https://www.lilly-pharma.de), and Puma 
      (https://eu.puma.com) and grants and personal fees from Novartis Pharma GmbH 
      (https://www.novartis.de) during the conduct of the study. WB reports personal 
      fees from Novartis Pharma GmbH (https://www.novartis.de) during the conduct of 
      the study. FS, KS, TE, FTB, AR, CU, and FF have nothing to disclose.
EDAT- 2024/10/09 00:23
MHDA- 2024/10/09 10:18
PMCR- 2024/10/08
CRDT- 2024/10/08 23:52
PHST- 2024/02/14 00:00 [received]
PHST- 2024/09/30 00:00 [accepted]
PHST- 2024/10/09 10:18 [medline]
PHST- 2024/10/09 00:23 [pubmed]
PHST- 2024/10/08 23:52 [entrez]
PHST- 2024/10/08 00:00 [pmc-release]
AID - 10.1186/s12916-024-03671-x [pii]
AID - 3671 [pii]
AID - 10.1186/s12916-024-03671-x [doi]
PST - epublish
SO  - BMC Med. 2024 Oct 8;22(1):442. doi: 10.1186/s12916-024-03671-x.

PMID- 31561001
OWN - NLM
STAT- MEDLINE
DCOM- 20200114
LR  - 20231113
IS  - 1879-1220 (Electronic)
IS  - 0960-0760 (Print)
IS  - 0960-0760 (Linking)
VI  - 195
DP  - 2019 Dec
TI  - Simultaneous quantification of estrogens and glucocorticoids in human adipose 
      tissue by liquid-chromatography-tandem mass spectrometry.
PG  - 105476
LID - S0960-0760(19)30090-1 [pii]
LID - 10.1016/j.jsbmb.2019.105476 [doi]
LID - 105476
AB  - The presence of estrogens, androgens and glucocorticoids as well as their 
      receptors and steroid converting enzymes in adipose tissue has been established. 
      Their contribution to diseases such as obesity, diabetes and hormone-dependent 
      cancers is an active area of research. Our objective was to develop a LC-MS/MS 
      method to quantify bioactive estrogens and glucocorticoids simultaneously in 
      human adipose tissue. Estrogens and glucocorticoids were extracted from adipose 
      tissue samples using solid-phase extraction. Estrogens were derivatized using 
      1-(2,4-dinitro-5-fluorophenyl)-4-methylpiperazine (PPZ) and methyl iodide to 
      generate a permanently charged molecule (MPPZ). Steroids were separated and 
      quantified by LC-MS/MS. The limit of quantitation for the steroids was between 15 
      and 100 pg per sample. Accuracy and precision were acceptable (<20%). Using this 
      method, estradiol, estrone, cortisone and cortisol were quantified in adipose 
      tissue from women with and without breast cancer. This novel assay of estrogens 
      and glucocorticoids by LC-MS/MS coupled with derivatization allowed simultaneous 
      quantification of a panel of steroids in human adipose tissue across the 
      endogenous range of concentrations encountered in health and disease.
CI  - Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Laforest, Sofia
AU  - Laforest S
AD  - CHU de Québec-Université Laval Research Center (Endocrinology and Nephrology 
      Division), School of Nutrition, Faculty of Agriculture and Food Sciences, 
      Université Laval, Québec, Canada; Quebec Heart Lung Institute, Québec, Canada.
FAU - Pelletier, Mélissa
AU  - Pelletier M
AD  - CHU de Québec-Université Laval Research Center (Endocrinology and Nephrology 
      Division), School of Nutrition, Faculty of Agriculture and Food Sciences, 
      Université Laval, Québec, Canada; Quebec Heart Lung Institute, Québec, Canada.
FAU - Denver, Nina
AU  - Denver N
AD  - Mass Spectrometry Core, Edinburgh Clinical Research Facility, Queen's Medical 
      Research Institute, Edinburgh, United Kingdom; Institute of Cardiovascular and 
      Medical Sciences, College of Medical, Veterinary and Life Sciences, University of 
      Glasgow, University Avenue, Glasgow, United Kingdom; Strathclyde Institute of 
      Pharmacy and Biomedical Sciences, University of Strathclyde, Cathedral Street, 
      Glasgow, United Kingdom.
FAU - Poirier, Brigitte
AU  - Poirier B
AD  - CHU de Québec-Université Laval Research Center (Oncology Division), Université 
      Laval Cancer Research Center and Department of Surgery, Faculty of Medicine, 
      Université Laval, Québec, Canada; Centre des maladies du sein Deschênes-Fabia, 
      Hôpital Saint-Sacrement, Québec, Canada.
FAU - Nguyen, Sébastien
AU  - Nguyen S
AD  - CHU de Québec-Université Laval Research Center (Oncology Division), Université 
      Laval Cancer Research Center and Department of Surgery, Faculty of Medicine, 
      Université Laval, Québec, Canada.
FAU - Walker, Brian R
AU  - Walker BR
AD  - University/BHF Centre for Cardiovascular Science, Queen's Medical Research 
      Institute, University of Edinburgh, 47, Little France Crescent, Edinburgh, EH16 
      4TJ, UK; Newcastle University, Newcastle upon Tyne, NE1 7RU, UK.
FAU - Durocher, Francine
AU  - Durocher F
AD  - CHU de Québec-Université Laval Research Center (Endocrinology and Nephrology 
      Division), Université Laval Cancer Research Center and Department of Molecular 
      Medicine, Faculty of Medicine, Université Laval, Québec, Canada.
FAU - Homer, Natalie Z M
AU  - Homer NZM
AD  - Mass Spectrometry Core, Edinburgh Clinical Research Facility, Queen's Medical 
      Research Institute, Edinburgh, United Kingdom; University/BHF Centre for 
      Cardiovascular Science, Queen's Medical Research Institute, University of 
      Edinburgh, 47, Little France Crescent, Edinburgh, EH16 4TJ, UK.
FAU - Diorio, Caroline
AU  - Diorio C
AD  - Centre des maladies du sein Deschênes-Fabia, Hôpital Saint-Sacrement, Québec, 
      Canada; CHU de Québec-Université Laval Research Center (Oncology Division), 
      Université Laval Cancer Research Center and Department of Social and Preventive 
      Medicine, Faculty of Medicine, Université Laval, Québec, Canada.
FAU - Tchernof, André
AU  - Tchernof A
AD  - CHU de Québec-Université Laval Research Center (Endocrinology and Nephrology 
      Division), School of Nutrition, Faculty of Agriculture and Food Sciences, 
      Université Laval, Québec, Canada; Quebec Heart Lung Institute, Québec, Canada.
FAU - Andrew, Ruth
AU  - Andrew R
AD  - Mass Spectrometry Core, Edinburgh Clinical Research Facility, Queen's Medical 
      Research Institute, Edinburgh, United Kingdom; University/BHF Centre for 
      Cardiovascular Science, Queen's Medical Research Institute, University of 
      Edinburgh, 47, Little France Crescent, Edinburgh, EH16 4TJ, UK. Electronic 
      address: ruth.andrew@ed.ac.uk.
LA  - eng
GR  - MC_PC_12014/MRC_/Medical Research Council/United Kingdom
GR  - BB/N503691/1/BB_/Biotechnology and Biological Sciences Research Council/United 
      Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190924
PL  - England
TA  - J Steroid Biochem Mol Biol
JT  - The Journal of steroid biochemistry and molecular biology
JID - 9015483
RN  - 0 (Estrogens)
RN  - 0 (Glucocorticoids)
RN  - 2DI9HA706A (Estrone)
RN  - 4TI98Z838E (Estradiol)
RN  - V27W9254FZ (Cortisone)
RN  - WI4X0X7BPJ (Hydrocortisone)
SB  - IM
MH  - Adipose Tissue/*chemistry
MH  - Breast Neoplasms
MH  - Chromatography, Liquid
MH  - Cortisone/analysis
MH  - Estradiol/analysis
MH  - Estrogens/*analysis
MH  - Estrone/analysis
MH  - Female
MH  - Glucocorticoids/*analysis
MH  - Humans
MH  - Hydrocortisone/analysis
MH  - Spectrometry, Mass, Electrospray Ionization
MH  - Tandem Mass Spectrometry
PMC - PMC7099401
OTO - NOTNLM
OT  - Adipose
OT  - Cortisol
OT  - Cortisone
OT  - Derivatization
OT  - Estradiol
OT  - Estrone
COIS- AT is the recipient of research grant support from Johnson & Johnson Medical 
      Companies and Medtronic for studies unrelated to this publication.
EDAT- 2019/09/29 06:00
MHDA- 2020/01/15 06:00
PMCR- 2019/12/01
CRDT- 2019/09/28 06:00
PHST- 2019/03/21 00:00 [received]
PHST- 2019/08/30 00:00 [revised]
PHST- 2019/09/18 00:00 [accepted]
PHST- 2019/09/29 06:00 [pubmed]
PHST- 2020/01/15 06:00 [medline]
PHST- 2019/09/28 06:00 [entrez]
PHST- 2019/12/01 00:00 [pmc-release]
AID - S0960-0760(19)30090-1 [pii]
AID - 105476 [pii]
AID - 10.1016/j.jsbmb.2019.105476 [doi]
PST - ppublish
SO  - J Steroid Biochem Mol Biol. 2019 Dec;195:105476. doi: 
      10.1016/j.jsbmb.2019.105476. Epub 2019 Sep 24.

PMID- 35671973
OWN - NLM
STAT- MEDLINE
DCOM- 20220707
LR  - 20230513
IS  - 2212-8778 (Electronic)
IS  - 2212-8778 (Linking)
VI  - 62
DP  - 2022 Aug
TI  - Sphingosine kinase 1 mediates sexual dimorphism in fibrosis in a mouse model of 
      NASH.
PG  - 101523
LID - S2212-8778(22)00092-8 [pii]
LID - 10.1016/j.molmet.2022.101523 [doi]
LID - 101523
AB  - OBJECTIVE: Men with non-alcoholic fatty liver disease (NAFLD) are more likely to 
      progress to non-alcoholic steatohepatitis (NASH) and liver fibrosis than women. 
      However, the underlying molecular mechanisms of this dimorphism is unclear. We 
      have previously shown that mice with global deletion of SphK1, the enzyme that 
      produces the bioactive sphingolipid metabolite sphingosine 1-phosphate (S1P), 
      were protected from development of NASH. The aim of this study was to elucidate 
      the role of hepatocyte-specific SphK1 in development of NASH and to compare its 
      contribution to hepatosteatosis in male and female mice. METHODS: We assessed 
      mouse livers in early-stage fibrosis induced by high fat feeding, using single 
      harmonic generation microscopy, LC-MS/MS analysis of hydroxyproline levels, and 
      expression of fibrosis markers. We identified an antifibrotic intercellular 
      signaling mechanism by culturing primary mouse hepatocytes alongside, and in 
      co-culture with, LX2 hepatic stellate cells. RESULTS: We generated 
      hepatocyte-specific SphK1 knockout mice (SphK1-hKO). Unlike the global knockout, 
      SphK1-hKO male mice were not protected from diet-induced steatosis, inflammation, 
      or fibrogenesis. In contrast, female SphK1-hKO mice were protected from 
      inflammation. Surprisingly, however, in these female mice, there was a ∼10-fold 
      increase in the fibrosis markers Col1α1 and 2-3 fold induction of alpha smooth 
      muscle actin and the pro-fibrotic chemokine CCL5. Because increased fibrosis in 
      female SphK1-hKO mice occurred despite an attenuated inflammatory response, we 
      investigated the crosstalk between hepatocytes and hepatic stellate cells, 
      central players in fibrosis. We found that estrogen stimulated release of S1P 
      from female hepatocytes preventing TGFβ-induced expression of Col1α1 in HSCs via 
      S1PR3. CONCLUSIONS: The results revealed a novel pathway of estrogen-mediated 
      cross-talk between hepatocytes and HSCs that may contribute to sex differences in 
      NAFLD through an anti-fibrogenic function of the S1P/S1PR3 axis. This pathway is 
      susceptible to pharmacologic manipulation, which may lead to novel therapeutic 
      strategies.
CI  - Copyright © 2022 The Authors. Published by Elsevier GmbH.. All rights reserved.
FAU - Montefusco, David
AU  - Montefusco D
AD  - Virginia Commonwealth University, Department of Biochemistry and Molecular 
      Biology, VA, USA. Electronic address: david.montefusco@vcuhealth.org.
FAU - Jamil, Maryam
AU  - Jamil M
AD  - Virginia Commonwealth University, Department of Biochemistry and Molecular 
      Biology, VA, USA.
FAU - Maczis, Melissa A
AU  - Maczis MA
AD  - Virginia Commonwealth University, Department of Biochemistry and Molecular 
      Biology, VA, USA.
FAU - Schroeder, William
AU  - Schroeder W
AD  - Virginia Commonwealth University, Department of Biochemistry and Molecular 
      Biology, VA, USA.
FAU - Levi, Moshe
AU  - Levi M
AD  - Department of Biochemistry and Molecular & Cellular Biology, Georgetown 
      University, USA.
FAU - Ranjit, Suman
AU  - Ranjit S
AD  - Department of Biochemistry and Molecular & Cellular Biology, Georgetown 
      University, USA.
FAU - Allegood, Jeremy
AU  - Allegood J
AD  - Virginia Commonwealth University, Department of Biochemistry and Molecular 
      Biology, VA, USA.
FAU - Bandyopadhyay, Dipankar
AU  - Bandyopadhyay D
AD  - Virginia Commonwealth University Department of Biostatistics, VA, USA.
FAU - Retnam, Reuben
AU  - Retnam R
AD  - Virginia Commonwealth University Department of Biostatistics, VA, USA.
FAU - Spiegel, Sarah
AU  - Spiegel S
AD  - Virginia Commonwealth University, Department of Biochemistry and Molecular 
      Biology, VA, USA.
FAU - Cowart, L Ashley
AU  - Cowart LA
AD  - Virginia Commonwealth University, Department of Biochemistry and Molecular 
      Biology, VA, USA; Hunter Holmes McGuire VAMC, Richmond, VA, USA.
LA  - eng
GR  - R01 HL151243/HL/NHLBI NIH HHS/United States
GR  - P30 GM103339/GM/NIGMS NIH HHS/United States
GR  - R01 GM043880/GM/NIGMS NIH HHS/United States
GR  - I01 BX000200/BX/BLRD VA/United States
GR  - P30 CA016059/CA/NCI NIH HHS/United States
GR  - R01 HL117233/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20220606
PL  - Germany
TA  - Mol Metab
JT  - Molecular metabolism
JID - 101605730
RN  - 0 (Estrogens)
RN  - EC 2.7.1.- (Phosphotransferases (Alcohol Group Acceptor))
RN  - EC 2.7.1.- (Sphk1 protein, mouse)
RN  - EC 2.7.1.- (sphingosine kinase)
SB  - IM
MH  - Animals
MH  - Chromatography, Liquid
MH  - Disease Models, Animal
MH  - Estrogens/pharmacology
MH  - Female
MH  - Humans
MH  - Liver Cirrhosis/enzymology/metabolism
MH  - Male
MH  - Mice
MH  - Mice, Knockout
MH  - *Non-alcoholic Fatty Liver Disease/enzymology/metabolism
MH  - *Phosphotransferases (Alcohol Group Acceptor)/metabolism
MH  - Sex Characteristics
MH  - Tandem Mass Spectrometry
PMC - PMC9194589
OTO - NOTNLM
OT  - Fibrosis
OT  - NAFLD
OT  - NASH
OT  - Sphingolipid
OT  - Sphingosine kinase
OT  - Sphingosine-1-phosphate
EDAT- 2022/06/08 06:00
MHDA- 2022/07/08 06:00
PMCR- 2022/06/06
CRDT- 2022/06/07 19:26
PHST- 2022/01/05 00:00 [received]
PHST- 2022/05/04 00:00 [revised]
PHST- 2022/05/25 00:00 [accepted]
PHST- 2022/06/08 06:00 [pubmed]
PHST- 2022/07/08 06:00 [medline]
PHST- 2022/06/07 19:26 [entrez]
PHST- 2022/06/06 00:00 [pmc-release]
AID - S2212-8778(22)00092-8 [pii]
AID - 101523 [pii]
AID - 10.1016/j.molmet.2022.101523 [doi]
PST - ppublish
SO  - Mol Metab. 2022 Aug;62:101523. doi: 10.1016/j.molmet.2022.101523. Epub 2022 Jun 
      6.

PMID- 33592471
OWN - NLM
STAT- MEDLINE
DCOM- 20210406
LR  - 20210406
IS  - 1879-1026 (Electronic)
IS  - 0048-9697 (Linking)
VI  - 773
DP  - 2021 Jun 15
TI  - Integrated recombinant gene yeast bioassay and HPLC-MS analysis for detection of 
      low-dose multi-component residue of hormone-like compounds in environment.
PG  - 145569
LID - S0048-9697(21)00637-9 [pii]
LID - 10.1016/j.scitotenv.2021.145569 [doi]
AB  - Illegal addition of low-dose multi-component residue of hormone-like compounds 
      have sprung up in human activities and production as a cunning strategy to escape 
      from sanitation monitoring, sowing a horrible seed for accidents in food 
      security. Hence, combined strategies with accuracy and efficiency are urgently 
      needed to overcome current circumstance and practical hurdles. Herein, an 
      integrated analysis that compromises recombinant gene yeast bioassay (V400E-YES) 
      and high-performance liquid chromatography-mass spectrometry (HPLC-MS) 
      determination was developed promptly with distinguishing advantage as optimized 
      V400E-YES provides a sum of hormone-like compounds in sample, and subsequent 
      HPLC-MS analysis can accurately quantify the concentration of compounds. In terms 
      of V400E-YES, large-scale random mutagenesis was performed to obtain higher 
      sensitivity hormone receptors. Excitingly, single mutation of estrogen receptor 
      (ER) at V400E and amphimutation of androgen receptor (AR) at G581R/D831E 
      conferred the highest detection sensitivity with a more than 10-fold increase. 
      Subsequently, sensitive HPLC-MS methods for simultaneous detection of eleven 
      estrogens and nine androgens, respectively, were well-constructed. Utilizing this 
      integrated and validated methods, we successfully investigated the hormone 
      residue in environmental samples from farms in Jiangsu, China. Collectively, with 
      multiple estrogens and androgens residue are being widely detected in soil and 
      sewage samples, the feasibility of this method is highlighted, as well as the 
      increasing lurking peril of hormone-like substance residues in environment.
CI  - Copyright © 2021 Elsevier B.V. All rights reserved.
FAU - Zhang, Haijie
AU  - Zhang H
AD  - College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, China.
FAU - Cui, Zihe
AU  - Cui Z
AD  - College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, China.
FAU - Yang, Bingqing
AU  - Yang B
AD  - College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, China.
FAU - Fang, Dan
AU  - Fang D
AD  - College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, China.
FAU - Liu, Yuan
AU  - Liu Y
AD  - College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, China; 
      Institute of Comparative Medicine, Yangzhou University, Yangzhou 225009, China; 
      Jiangsu Co-innovation Center for Prevention and Control of Important Animal 
      Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou 225009, China; 
      Joint International Research Laboratory of Agriculture and Agri-Product Safety, 
      Ministry of Education of China, Yangzhou University, Yangzhou 225009, China. 
      Electronic address: liuyuan2018@yzu.edu.cn.
FAU - Wang, Zhiqiang
AU  - Wang Z
AD  - College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, China; 
      Jiangsu Co-innovation Center for Prevention and Control of Important Animal 
      Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou 225009, China; 
      Joint International Research Laboratory of Agriculture and Agri-Product Safety, 
      Ministry of Education of China, Yangzhou University, Yangzhou 225009, China. 
      Electronic address: zqwang@yzu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20210204
PL  - Netherlands
TA  - Sci Total Environ
JT  - The Science of the total environment
JID - 0330500
RN  - 0 (Estrogens)
SB  - IM
MH  - *Biological Assay
MH  - China
MH  - Chromatography, High Pressure Liquid
MH  - Estrogens
MH  - Humans
MH  - *Saccharomyces cerevisiae/genetics
OTO - NOTNLM
OT  - Androgen
OT  - Detection
OT  - Estrogen
OT  - Hormone-like compounds
OT  - Residue
COIS- Declaration of competing interest The authors declare that they have no conflict 
      of interest.
EDAT- 2021/02/17 06:00
MHDA- 2021/04/07 06:00
CRDT- 2021/02/16 20:12
PHST- 2020/11/23 00:00 [received]
PHST- 2021/01/27 00:00 [revised]
PHST- 2021/01/28 00:00 [accepted]
PHST- 2021/02/17 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
PHST- 2021/02/16 20:12 [entrez]
AID - S0048-9697(21)00637-9 [pii]
AID - 10.1016/j.scitotenv.2021.145569 [doi]
PST - ppublish
SO  - Sci Total Environ. 2021 Jun 15;773:145569. doi: 10.1016/j.scitotenv.2021.145569. 
      Epub 2021 Feb 4.

PMID- 34388645
OWN - NLM
STAT- MEDLINE
DCOM- 20211022
LR  - 20211022
IS  - 1879-1026 (Electronic)
IS  - 0048-9697 (Linking)
VI  - 800
DP  - 2021 Dec 15
TI  - An analytical survey of benzotriazole UV stabilizers in plastic products and 
      their endocrine-disrupting potential via human estrogen and androgen receptors.
PG  - 149374
LID - S0048-9697(21)04447-8 [pii]
LID - 10.1016/j.scitotenv.2021.149374 [doi]
AB  - Benzotriazole UV stabilizers (BUVSs) are added to various materials to prevent 
      damage from UV-irradiation. Recently, there has been great concern regarding the 
      endocrine-disrupting effects of exposure to microplastic-derivative BUVSs in 
      particular. In this study, we measured the concentrations of nine representative 
      BUVSs in the plastic bottle caps of 10 beverages, 4 food packages, and 4 plastic 
      shopping bags purchased from Japanese grocery stores by GC-MS analysis, and found 
      that eight BUVSs, except for 
      2-(3,5-di-tert-butyl-2-hydroxyphenyl)-2H-benzotriazole (UV-320), were detected 
      from these plastic products. In particular, 2-(2-hydroxy-5-methylphenyl) 
      benzotriazole (UV-P) and 
      2-(2-hydroxy-3-tert-butyl-5-methylphenyl)-5-chlorobenzotriazole (UV-326) were 
      detected from all the bottle caps at concentrations in the order of ng/g. In 
      addition, we characterized the agonistic and/or antagonistic activities against 
      human estrogen receptors (ERα/β) and androgen receptor (AR) of 13 BUVSs. Results 
      revealed that, among the 13 BUVSs, UV-P, 2-(5-tert-butyl-2-hydroxyphenyl) 
      benzotriazole (UV-PS), 
      2-[2-hydroxy-5-[2-(methacryloyloxy)ethyl]phenyl]-2H-benzotriazole (UV-090) and 
      2-(2-hydroxy-5-tert-octylphenyl)-benzotriazole (UV-329) showed ERα and/or ERβ 
      agonistic activity, with UV-P being the most potent based on these assays. On the 
      other hand, UV-320 and 2-(3-s-butyl-5-tert-butyl-2-hydroxyphenyl) benzotriazole 
      (UV-350) showed both ERα and ERβ antagonistic activities, and 
      2-(3,5-di-tert-amyl-2-hydroxylphenyl) benzotriazole (UV-328) and UV-329 acted as 
      ERβ antagonists. In the AR assay, UV-P and 
      2-(3-allyl-2-hydroxy-5-methylphenyl)-2H-benzotriazole (UV-9) showed AR 
      antagonistic activity although none of the test compounds showed AR agonistic 
      activity. Taken together, our findings suggest that a series of BUVSs are present 
      in our environments via plastic materials and several of these compounds possess 
      endocrine-disrupting potential, such as ERα/β agonistic and/or antagonistic 
      activity and AR antagonistic activity. UV-P and its structurally similar 
      compounds, in particular, appear to be a cause for concern.
CI  - Copyright © 2021 Elsevier B.V. All rights reserved.
FAU - Sakuragi, Yuuta
AU  - Sakuragi Y
AD  - School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, 1757 
      Kanazawa, Ishikari-Tobetsu, Hokkaido 061-0293, Japan.
FAU - Takada, Hideshige
AU  - Takada H
AD  - Laboratory of Organic Geochemistry, Faculty of Agriculture, Tokyo University of 
      Agriculture and Technology, Fuchu, Tokyo 183-8509, Japan.
FAU - Sato, Hiroya
AU  - Sato H
AD  - Laboratory of Organic Geochemistry, Faculty of Agriculture, Tokyo University of 
      Agriculture and Technology, Fuchu, Tokyo 183-8509, Japan.
FAU - Kubota, Atsuhito
AU  - Kubota A
AD  - School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, 1757 
      Kanazawa, Ishikari-Tobetsu, Hokkaido 061-0293, Japan.
FAU - Terasaki, Masaru
AU  - Terasaki M
AD  - School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, 1757 
      Kanazawa, Ishikari-Tobetsu, Hokkaido 061-0293, Japan.
FAU - Takeuchi, Shinji
AU  - Takeuchi S
AD  - Hokkaido Institute of Public Health, Kita-19, Nishi-12, Kita-ku, Sapporo 
      060-0819, Japan.
FAU - Ikeda-Araki, Atsuko
AU  - Ikeda-Araki A
AD  - Hokkaido University Faculty of Health Sciences, Kita-12, Nishi-7, Kita-ku, 
      Sapporo 060-0812, Japan; Center for Environmental and Health Sciences, Hokkaido 
      University, Kita-12, Nishi-7, Kita-ku, Sapporo 060-0812, Japan.
FAU - Watanabe, Yoko
AU  - Watanabe Y
AD  - Nihon Pharmaceutical University, 10281 Komuro, Ina-machi, Kitaadachi-gun, Saitama 
      362-0806, Japan.
FAU - Kitamura, Shigeyuki
AU  - Kitamura S
AD  - Nihon Pharmaceutical University, 10281 Komuro, Ina-machi, Kitaadachi-gun, Saitama 
      362-0806, Japan.
FAU - Kojima, Hiroyuki
AU  - Kojima H
AD  - School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, 1757 
      Kanazawa, Ishikari-Tobetsu, Hokkaido 061-0293, Japan. Electronic address: 
      hirokojima@hoku-iryo-u.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20210731
PL  - Netherlands
TA  - Sci Total Environ
JT  - The Science of the total environment
JID - 0330500
RN  - 0 (Estrogens)
RN  - 0 (Plastics)
RN  - 0 (Receptors, Androgen)
RN  - 0 (Triazoles)
RN  - 0 (UV328)
RN  - 86110UXM5Y (benzotriazole)
SB  - IM
MH  - Estrogens
MH  - Humans
MH  - *Plastics
MH  - *Receptors, Androgen
MH  - Triazoles
OTO - NOTNLM
OT  - Androgen receptor
OT  - Benzotriazole UV stabilizer
OT  - Endocrine disruption
OT  - Estrogen receptor
OT  - Plastic additive
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2021/08/14 06:00
MHDA- 2023/02/25 06:00
CRDT- 2021/08/13 20:21
PHST- 2021/04/30 00:00 [received]
PHST- 2021/06/30 00:00 [revised]
PHST- 2021/07/27 00:00 [accepted]
PHST- 2021/08/14 06:00 [pubmed]
PHST- 2023/02/25 06:00 [medline]
PHST- 2021/08/13 20:21 [entrez]
AID - S0048-9697(21)04447-8 [pii]
AID - 10.1016/j.scitotenv.2021.149374 [doi]
PST - ppublish
SO  - Sci Total Environ. 2021 Dec 15;800:149374. doi: 10.1016/j.scitotenv.2021.149374. 
      Epub 2021 Jul 31.

PMID- 32663100
OWN - NLM
STAT- MEDLINE
DCOM- 20201026
LR  - 20201026
IS  - 1522-1555 (Electronic)
IS  - 0193-1849 (Linking)
VI  - 319
IP  - 2
DP  - 2020 Aug 1
TI  - Ovariectomy modifies lipid metabolism of retroperitoneal white fat in rats: a 
      proteomic approach.
PG  - E427-E437
LID - 10.1152/ajpendo.00094.2020 [doi]
AB  - Menopause is often accompanied by visceral obesity. With the aim of exploring the 
      consequences of ovarian failure on visceral fat, we evaluated the effects of 
      ovariectomy and estrogen replacement on the proteome/phosphoproteome and on the 
      fatty acid profile of the retroperitoneal adipose depot (RAT) of rats. Eighteen 
      3-mo-old female Wistar rats were either ovariectomized or sham operated and fed 
      with standard chow for 3 mo. A subgroup of ovariectomized rats received estradiol 
      replacement. RAT samples were analyzed with data-independent acquisitions 
      LC-MS/MS, and pathway analysis was performed with the differentially 
      expressed/phosphorylated proteins. RAT lipid profile was analyzed by gas 
      chromatography. Ovariectomy induced high adiposity and insulin resistance and 
      promoted alterations in protein expression and phosphorylation. Pathway analysis 
      showed that five pathways were significantly affected by ovariectomy, namely, 
      metabolism of lipids (including fatty acid metabolism and mitochondrial fatty 
      acid β-oxidation), fatty acyl-CoA biosynthesis, innate immune system (including 
      neutrophil degranulation), metabolism of vitamins and cofactors, and integration 
      of energy metabolism (including ChREBP activates metabolic gene expression). 
      Lipid profile analysis showed increased palmitic and palmitoleic acid content. 
      The analysis of the data indicated that ovariectomy favored lipogenesis whereas 
      it impaired fatty acid oxidation and induced a proinflammatory state in the 
      visceral adipose tissue. These effects are consistent with the findings of high 
      adiposity, hyperleptinemia, and impaired insulin sensitivity. The observed 
      alterations were partially attenuated by estradiol replacement. The data point to 
      a role of disrupted lipid metabolism in adipose tissue in the genesis of obesity 
      after menopause.
FAU - Boldarine, Valter T
AU  - Boldarine VT
AUID- ORCID: 0000-0003-2686-7430
AD  - Departamento de Fisiologia, Escola Paulista de Medicina, Universidade Federal de 
      São Paulo, São Paulo, Brazil.
FAU - Pedroso, Amanda P
AU  - Pedroso AP
AD  - Departamento de Fisiologia, Escola Paulista de Medicina, Universidade Federal de 
      São Paulo, São Paulo, Brazil.
FAU - Brandão-Teles, Caroline
AU  - Brandão-Teles C
AD  - Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, 
      Institute of Biology, University of Campinas (UNICAMP), Campinas, Brazil.
FAU - LoTurco, Edson G
AU  - LoTurco EG
AD  - Divisão de Urologia e Reprodução Humana, Departamento de Cirurgia, Escola 
      Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.
FAU - Nascimento, Cláudia M O
AU  - Nascimento CMO
AD  - Departamento de Fisiologia, Escola Paulista de Medicina, Universidade Federal de 
      São Paulo, São Paulo, Brazil.
FAU - Oyama, Lila M
AU  - Oyama LM
AD  - Departamento de Fisiologia, Escola Paulista de Medicina, Universidade Federal de 
      São Paulo, São Paulo, Brazil.
FAU - Bueno, Allain A
AU  - Bueno AA
AD  - Department of Biological Sciences, College of Health, Life and Environmental 
      Sciences, University of Worcester, Worcester, United Kingdom.
FAU - Martins-de-Souza, Daniel
AU  - Martins-de-Souza D
AD  - Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, 
      Institute of Biology, University of Campinas (UNICAMP), Campinas, Brazil.
AD  - Instituto Nacional de Biomarcadores em Neuropsiquiatria (INBION) Conselho 
      Nacional de Desenvolvimento Científico e Tecnológico, São Paulo, Brazil.
AD  - Experimental Medicine Research Cluster (EMRC), University of Campinas, Campinas, 
      Brazil.
AD  - D'Or Institute for Research and Education (IDOR), São Paulo, Brazil.
FAU - Ribeiro, Eliane B
AU  - Ribeiro EB
AD  - Departamento de Fisiologia, Escola Paulista de Medicina, Universidade Federal de 
      São Paulo, São Paulo, Brazil.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200714
PL  - United States
TA  - Am J Physiol Endocrinol Metab
JT  - American journal of physiology. Endocrinology and metabolism
JID - 100901226
RN  - 0 (Fatty Acids)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Adipose Tissue, White/*metabolism
MH  - Adiposity/physiology
MH  - Animals
MH  - Estradiol/administration & dosage
MH  - Estrogen Replacement Therapy
MH  - Fatty Acids/analysis
MH  - Female
MH  - Insulin Resistance/physiology
MH  - Intra-Abdominal Fat/chemistry/*metabolism
MH  - Lipid Metabolism/*physiology
MH  - Obesity
MH  - *Ovariectomy
MH  - Postmenopause
MH  - *Proteomics
MH  - Rats
MH  - Rats, Wistar
OTO - NOTNLM
OT  - estrogen replacement
OT  - lipid profile
OT  - menopause
OT  - proteome/phosphoproteome
OT  - retroperitoneal adipose tissue
EDAT- 2020/07/15 06:00
MHDA- 2020/10/27 06:00
CRDT- 2020/07/15 06:00
PHST- 2020/07/15 06:00 [pubmed]
PHST- 2020/10/27 06:00 [medline]
PHST- 2020/07/15 06:00 [entrez]
AID - 10.1152/ajpendo.00094.2020 [doi]
PST - ppublish
SO  - Am J Physiol Endocrinol Metab. 2020 Aug 1;319(2):E427-E437. doi: 
      10.1152/ajpendo.00094.2020. Epub 2020 Jul 14.

PMID- 36166661
OWN - NLM
STAT- MEDLINE
DCOM- 20221012
LR  - 20221222
IS  - 1520-6882 (Electronic)
IS  - 0003-2700 (Linking)
VI  - 94
IP  - 40
DP  - 2022 Oct 11
TI  - Robust ERα-Targeted Near-Infrared Fluorescence Probe for Selective Hydrazine 
      Imaging in Breast Cancer.
PG  - 14012-14020
LID - 10.1021/acs.analchem.2c03395 [doi]
AB  - Breast cancer is the most common malignancy in women and may become worse when a 
      high concentration of hydrazine is absorbed from the environment or drug 
      metabolite. Therefore, rapid and sensitive detection of hydrazine in vivo is 
      beneficial for people's health. In this work, a novel estrogen receptor α 
      (ERα)-targeted near-infrared fluorescence probe was designed to detect hydrazine 
      levels. The probe showed good ERα affinity and an excellent fluorescence response 
      toward hydrazine. Selectivity experiments demonstrated that the probe had a 
      strong anti-interference ability. Mechanistic studies, including mass 
      spectrometry (MS) and density functional theory (DFT) calculation, indicated that 
      intermolecular charge transfer (ICT) progress was hindered when the probe reacted 
      with hydrazine, resulting in fluorescent quenching. In addition, the probe could 
      selectively bind to MCF-7 breast cancer cells with excellent biocompatibility. 
      The in vivo and ex vivo imaging studies demonstrated that the probe could rapidly 
      visualize hydrazine with high contrast in MCF-7 xenograft tumors. Therefore, this 
      probe can serve as a potential tool to robustly monitor hydrazine levels in vivo.
FAU - Tang, Chu
AU  - Tang C
AD  - Engineering Research Center of Molecular and Neuro Imaging, Ministry of 
      Education, School of Life Science and Technology, Xidian University, Xi'an, 
      Shaanxi 710126, China.
AD  - Xianyang Key Laboratory of Molecular Imaging and Drug Synthesis, School of 
      Pharmacy, Shaanxi Institute of International Trade &amp; Commerce, Xianyang 
      712046, Shaanxi, China.
FAU - Tong, Hongjuan
AU  - Tong H
AD  - Xianyang Key Laboratory of Molecular Imaging and Drug Synthesis, School of 
      Pharmacy, Shaanxi Institute of International Trade &amp; Commerce, Xianyang 
      712046, Shaanxi, China.
FAU - Liu, Bin
AU  - Liu B
AD  - Xianyang Key Laboratory of Molecular Imaging and Drug Synthesis, School of 
      Pharmacy, Shaanxi Institute of International Trade &amp; Commerce, Xianyang 
      712046, Shaanxi, China.
FAU - Wang, Xinan
AU  - Wang X
AD  - Engineering Research Center of Molecular and Neuro Imaging, Ministry of 
      Education, School of Life Science and Technology, Xidian University, Xi'an, 
      Shaanxi 710126, China.
FAU - Jin, Yushen
AU  - Jin Y
AD  - Beijing Key Laboratory of Diagnostic and Traceability Technologies for Food 
      Poisoning, Beijing Center for Disease Prevention and Control, Beijing 100013, 
      China.
FAU - Tian, Erli
AU  - Tian E
AD  - College of Life Sciences and Agronomy, Zhoukou Normal University, Zhoukou 466001, 
      China.
FAU - Wang, Fu
AU  - Wang F
AD  - Engineering Research Center of Molecular and Neuro Imaging, Ministry of 
      Education, School of Life Science and Technology, Xidian University, Xi'an, 
      Shaanxi 710126, China.
AD  - Xianyang Key Laboratory of Molecular Imaging and Drug Synthesis, School of 
      Pharmacy, Shaanxi Institute of International Trade &amp; Commerce, Xianyang 
      712046, Shaanxi, China.
AD  - School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an 710061, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220927
PL  - United States
TA  - Anal Chem
JT  - Analytical chemistry
JID - 0370536
RN  - 0 (Estrogen Receptor alpha)
RN  - 0 (Fluorescent Dyes)
RN  - 0 (Hydrazines)
RN  - 27RFH0GB4R (hydrazine)
SB  - IM
MH  - *Breast Neoplasms/diagnostic imaging
MH  - *Estrogen Receptor alpha
MH  - Female
MH  - Fluorescent Dyes/chemistry
MH  - Humans
MH  - Hydrazines/chemistry
MH  - Spectrometry, Fluorescence
EDAT- 2022/09/28 06:00
MHDA- 2022/10/13 06:00
CRDT- 2022/09/27 15:03
PHST- 2022/09/28 06:00 [pubmed]
PHST- 2022/10/13 06:00 [medline]
PHST- 2022/09/27 15:03 [entrez]
AID - 10.1021/acs.analchem.2c03395 [doi]
PST - ppublish
SO  - Anal Chem. 2022 Oct 11;94(40):14012-14020. doi: 10.1021/acs.analchem.2c03395. 
      Epub 2022 Sep 27.

PMID- 29511040
OWN - NLM
STAT- MEDLINE
DCOM- 20190522
LR  - 20240620
IS  - 1538-7755 (Electronic)
IS  - 1055-9965 (Print)
IS  - 1055-9965 (Linking)
VI  - 27
IP  - 5
DP  - 2018 May
TI  - Estrogen Metabolism in Premenopausal Women Is Related to Early Life Body Fatness.
PG  - 585-593
LID - 10.1158/1055-9965.EPI-17-0595 [doi]
AB  - Background: Estrogen metabolism in premenopausal women may be related to early 
      life body fatness.Methods: Premenopausal women participating in the Nurses' 
      Health Study II recalled their body fatness at ages 5, 10, and 20 years using a 
      validated 9-level pictogram. Fifteen estrogens and estrogen metabolites (EM) were 
      measured using LC/MS-MS in luteal phase urines from 603 women ages 32-54 years. 
      Geometric means of individual EM, metabolic pathway groups, and pathway ratios 
      were examined by body fatness categories using linear mixed models.Results: Body 
      fatness at each age was inversely associated with adult concentrations of all EM 
      combined, parent estrogens (estrone, estradiol), and the 2-hydroxylation pathway. 
      Women in the top (vs. bottom) category of body fatness at age 10 had 21% lower 
      levels of all EM (P(trend) = 0.003), 24% lower parent estrogens (P(trend) = 
      0.002), and 36% lower 2-pathway (P(trend) = 0.0003). Body fatness at age 10 was 
      inversely associated with 2-catechols (35% lower, P(trend) = 0.0004) and 
      2-methylated catechols (30% lower, P(trend) = 0.002). After adjusting for 
      premenopausal body mass index (BMI), these associations remained inverse but were 
      attenuated; only parent estrogens remained statistically significant (21% lower, 
      P(trend) = 0.01). Body fatness at ages 5 and 20 were similarly, but more weakly, 
      associated with estrogen pathways.Conclusions: Estimates of body fatness during 
      early life were inversely associated with premenopausal levels of all EM 
      combined, parent estrogens, and 2-pathway estrogen metabolites. These 
      relationships were not fully explained by adult BMI.Impact: These findings inform 
      investigations of diseases linked to early life body fatness and estrogen 
      metabolism. Cancer Epidemiol Biomarkers Prev; 27(5); 585-93. ©2018 AACR.
CI  - ©2018 American Association for Cancer Research.
FAU - Houghton, Lauren C
AU  - Houghton LC
AD  - Department of Epidemiology, Columbia University Mailman School of Public Health, 
      New York, New York. lh2746@cumc.columbia.edu.
FAU - Sisti, Julia S
AU  - Sisti JS
AD  - Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, 
      Massachusetts.
AD  - Channing Division of Network Medicine, Department of Medicine, Brigham and 
      Women's Hospital and Harvard Medical School, Boston, Massachusetts.
FAU - Hankinson, Susan E
AU  - Hankinson SE
AD  - Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, 
      Massachusetts.
AD  - Channing Division of Network Medicine, Department of Medicine, Brigham and 
      Women's Hospital and Harvard Medical School, Boston, Massachusetts.
AD  - Department of Biostatistics and Epidemiology, School of Public Health and Health 
      Sciences, University of Massachusetts, Amherst, Massachusetts.
FAU - Xie, Jing
AU  - Xie J
AD  - Sanofi, Bridgewater, New Jersey.
FAU - Xu, Xia
AU  - Xu X
AD  - Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick 
      National Laboratory for Cancer Research, Frederick, Maryland.
FAU - Hoover, Robert N
AU  - Hoover RN
AD  - Department of Epidemiology, Columbia University Mailman School of Public Health, 
      New York, New York.
FAU - Eliassen, A Heather
AU  - Eliassen AH
AD  - Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, 
      Massachusetts.
AD  - Channing Division of Network Medicine, Department of Medicine, Brigham and 
      Women's Hospital and Harvard Medical School, Boston, Massachusetts.
FAU - Ziegler, Regina G
AU  - Ziegler RG
AD  - Department of Epidemiology, Columbia University Mailman School of Public Health, 
      New York, New York.
LA  - eng
GR  - P01 CA087969/CA/NCI NIH HHS/United States
GR  - UM1 CA176726/CA/NCI NIH HHS/United States
GR  - U01 CA067262/CA/NCI NIH HHS/United States
GR  - R25 CA098566/CA/NCI NIH HHS/United States
GR  - UM1 CA186107/CA/NCI NIH HHS/United States
GR  - HHSN261200800001E/CA/NCI NIH HHS/United States
GR  - K07 CA218166/CA/NCI NIH HHS/United States
GR  - R01 CA067262/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, N.I.H., Intramural
DEP - 20180306
PL  - United States
TA  - Cancer Epidemiol Biomarkers Prev
JT  - Cancer epidemiology, biomarkers & prevention : a publication of the American 
      Association for Cancer Research, cosponsored by the American Society of 
      Preventive Oncology
JID - 9200608
RN  - 0 (Estrogens)
SB  - IM
MH  - Adiposity/*physiology
MH  - Adolescent
MH  - Adult
MH  - Body Mass Index
MH  - Breast Neoplasms/metabolism/*prevention & control
MH  - Child
MH  - Chromatography, High Pressure Liquid/methods
MH  - Estrogens/metabolism/*urine
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Premenopause/*metabolism/urine
MH  - Prospective Studies
MH  - Risk Factors
MH  - Tandem Mass Spectrometry/methods
MH  - Young Adult
PMC - PMC5932230
MID - NIHMS946487
COIS- The authors declare no potential conflicts of interest
EDAT- 2018/03/08 06:00
MHDA- 2019/05/23 06:00
PMCR- 2019/05/01
CRDT- 2018/03/08 06:00
PHST- 2017/06/28 00:00 [received]
PHST- 2017/10/04 00:00 [revised]
PHST- 2018/02/19 00:00 [accepted]
PHST- 2018/03/08 06:00 [pubmed]
PHST- 2019/05/23 06:00 [medline]
PHST- 2018/03/08 06:00 [entrez]
PHST- 2019/05/01 00:00 [pmc-release]
AID - 1055-9965.EPI-17-0595 [pii]
AID - 10.1158/1055-9965.EPI-17-0595 [doi]
PST - ppublish
SO  - Cancer Epidemiol Biomarkers Prev. 2018 May;27(5):585-593. doi: 
      10.1158/1055-9965.EPI-17-0595. Epub 2018 Mar 6.

PMID- 33322050
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20240805
IS  - 2072-6651 (Electronic)
IS  - 2072-6651 (Linking)
VI  - 12
IP  - 12
DP  - 2020 Dec 10
TI  - Determination of Zearalenone and Trichothecenes, Including Deoxynivalenol and Its 
      Acetylated Derivatives, Nivalenol, T-2 and HT-2 Toxins, in Wheat and Wheat 
      Products by LC-MS/MS: A Collaborative Study.
LID - 10.3390/toxins12120786 [doi]
LID - 786
AB  - An analytical method for the simultaneous determination of trichothecenes-namely, 
      nivalenol (NIV), deoxynivalenol (DON) and its acetylated derivatives (3- and 
      15-acetyl-DON), T-2 and HT-2 toxins-and zearalenone (ZEN) in wheat, wheat flour, 
      and wheat crackers was validated through a collaborative study involving 15 
      participants from 10 countries. The validation study, performed within the M/520 
      standardization mandate of the European Commission, was carried out according to 
      the IUPAC (International Union of Pure and Applied Chemistry) International 
      Harmonized Protocol. The method was based on mycotoxin extraction from the 
      homogenized sample material with a mixture of acetonitrile-water followed by 
      purification and concentration on a solid phase extraction column. 
      High-performance liquid chromatography coupled with tandem mass spectrometry was 
      used for mycotoxin detection, using isotopically labelled mycotoxins as internal 
      standards. The tested contamination ranges were from 27.7 to 378 μg/kg for NIV, 
      from 234 to 2420 μg/kg for DON, from 18.5 to 137 μg/kg for 3-acetyl-DON, from 
      11.4 to 142 μg/kg for 15-acetyl-DON, from 2.1 to 37.6 μg/kg for T-2 toxin, from 
      6.6 to 134 μg/kg for HT-2 toxin, and from 31.6 to 230 μg/kg for ZEN. Recoveries 
      were in the range 71-97% with the lowest values for NIV, the most polar 
      mycotoxin. The relative standard deviation for repeatability (RSD(r)) was in the 
      range of 2.2-34%, while the relative standard deviation for reproducibility 
      (RSD(R)) was between 6.4% and 45%. The HorRat values ranged from 0.4 to 2.0. The 
      results of the collaborative study showed that the candidate method is fit for 
      the purpose of enforcing the legislative limits of the major Fusarium toxins in 
      wheat and wheat-based products.
FAU - Girolamo, Annalisa De
AU  - Girolamo A
AUID- ORCID: 0000-0002-3155-8002
AD  - Institute of Sciences of Food Production, National Research Council of Italy, via 
      Amendola 122/O, 70126 Bari, Italy.
FAU - Ciasca, Biancamaria
AU  - Ciasca B
AD  - Institute of Sciences of Food Production, National Research Council of Italy, via 
      Amendola 122/O, 70126 Bari, Italy.
FAU - Pascale, Michelangelo
AU  - Pascale M
AUID- ORCID: 0000-0002-3898-1030
AD  - Institute of Sciences of Food Production, National Research Council of Italy, via 
      Amendola 122/O, 70126 Bari, Italy.
FAU - Lattanzio, Veronica M T
AU  - Lattanzio VMT
AUID- ORCID: 0000-0002-2354-4436
AD  - Institute of Sciences of Food Production, National Research Council of Italy, via 
      Amendola 122/O, 70126 Bari, Italy.
LA  - eng
GR  - SA/CEN/ENTR/520/2013-17, Contract item: 2013-17.4./European 
      Commission/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201210
PL  - Switzerland
TA  - Toxins (Basel)
JT  - Toxins
JID - 101530765
RN  - 0 (Trichothecenes)
RN  - 5W827M159J (Zearalenone)
RN  - 5WOP02RM1U (nivalenol)
RN  - I3FL5NM3MO (T-2 Toxin)
RN  - JT37HYP23V (deoxynivalenol)
RN  - NC6C26RM46 (HT-2 toxin)
SB  - IM
MH  - Chromatography, Liquid/methods
MH  - Flour/analysis/toxicity
MH  - Food Contamination/analysis/prevention & control
MH  - Humans
MH  - Intersectoral Collaboration
MH  - Mass Spectrometry/methods
MH  - T-2 Toxin/*analogs & derivatives/*analysis/toxicity
MH  - Tandem Mass Spectrometry/methods
MH  - Trichothecenes/*analysis/toxicity
MH  - Triticum/chemistry/toxicity
MH  - Whole Grains/chemistry/toxicity
MH  - Zearalenone/*analysis/toxicity
PMC - PMC7763284
OTO - NOTNLM
OT  - Fusarium toxins
OT  - collaborative study
OT  - liquid chromatography–mass spectrometry
OT  - official control
OT  - trichothecenes
OT  - wheat
OT  - zearalenone
COIS- The authors declare no conflict of interest.
EDAT- 2020/12/17 06:00
MHDA- 2021/06/24 06:00
PMCR- 2020/12/10
CRDT- 2020/12/16 01:02
PHST- 2020/11/12 00:00 [received]
PHST- 2020/12/04 00:00 [revised]
PHST- 2020/12/08 00:00 [accepted]
PHST- 2020/12/16 01:02 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2020/12/10 00:00 [pmc-release]
AID - toxins12120786 [pii]
AID - toxins-12-00786 [pii]
AID - 10.3390/toxins12120786 [doi]
PST - epublish
SO  - Toxins (Basel). 2020 Dec 10;12(12):786. doi: 10.3390/toxins12120786.

PMID- 36541329
OWN - NLM
STAT- MEDLINE
DCOM- 20230130
LR  - 20240924
IS  - 1552-8618 (Electronic)
IS  - 0730-7268 (Print)
IS  - 0730-7268 (Linking)
VI  - 42
IP  - 2
DP  - 2023 Feb
TI  - Comparison of Two Estrogen Chemically Activated Luciferase Expression Cell 
      Bioassays to Liquid Chromatography-Mass Spectrometry for Quantifying Estrone in 
      Water Samples.
PG  - 333-339
LID - 10.1002/etc.5541 [doi]
AB  - Chemically activated luciferase expression (CALUX) cell bioassays are popular 
      tools for assessing endocrine activity of chemicals such as certain environmental 
      contaminants. Although activity equivalents can be obtained from CALUX analysis, 
      directly comparing these equivalents to those obtained from analytical chemistry 
      methods can be problematic because of the complexity of endocrine active 
      pathways. We explored the suitability of two estrogen CALUX bioassays (the 
      Organisation for Economic Co-operation and Development-approved VM7Luc4E2 cell 
      bioassay and the VM7LucERβc9 cell bioassay) for quantitation of estrogen. 
      Quadrupole-time of flight ultraperformance liquid chromatography-mass 
      spectrometry (LC/MS) was selected as a comparative method. Regression analysis of 
      measured estrone (E1) calibration samples showed all three methods to be highly 
      predictive of nominal concentrations (p ≤ 7.5 × 10(-51) ). Extracts of water 
      sampled from laboratory dilutor tanks containing E1 at 0, 20, and 200 ng/L alone 
      and in combination with atrazine were selected to test the quantitative 
      capabilities of the CALUX assays. Process controls (0 and 100 ng E1/L) and a 
      separate E1 standard (10 ng/ml, used to prepare the E1 process control) were also 
      tested. Levels of E1 determined by LC/MS analysis and bioanalytical equivalents 
      (ng E1/L) determined by CALUX analyses were comparable except in certain 
      instances where the samples required dilution prior to CALUX analyses (e.g., the 
      E1 process control and E1 standard). In those instances, measurements by CALUX 
      were slightly but significantly decreased relative to LC/MS. Atrazine had no 
      effect on the ability of either LC/MS or the CALUX bioassays to quantify E1. The 
      present study illustrates the CALUX bioassays as successful in quantifying an 
      estrogen in simple water samples and further characterizes their utility for 
      screening. Environ Toxicol Chem 2023;42:333-339. Published 2022. This article is 
      a U.S. Government work and is in the public domain in the USA.
CI  - Published 2022. This article is a U.S. Government work and is in the public 
      domain in the USA.
FAU - Brennan, Jennifer
AU  - Brennan J
AUID- ORCID: 0000-0003-0386-3496
AD  - Columbia Environmental Research Center, US Geological Survey, Columbia, Missouri.
AD  - Office of Pollution Prevention and Toxics, US Environmental Protection Agency, 
      Research Triangle Park, North Carolina.
FAU - Henke, Abigail
AU  - Henke A
AUID- ORCID: 0000-0002-8182-4639
AD  - Columbia Environmental Research Center, US Geological Survey, Columbia, Missouri.
AD  - Biology Department, Baylor University, Waco, Texas, USA.
FAU - Gale, Robert
AU  - Gale R
AUID- ORCID: 0000-0002-8533-141X
AD  - Columbia Environmental Research Center, US Geological Survey, Columbia, Missouri.
FAU - Nicks, Diane
AU  - Nicks D
AUID- ORCID: 0000-0001-8080-2449
AD  - Columbia Environmental Research Center, US Geological Survey, Columbia, Missouri.
FAU - Tillitt, Donald
AU  - Tillitt D
AUID- ORCID: 0000-0002-8278-3955
AD  - Columbia Environmental Research Center, US Geological Survey, Columbia, Missouri.
LA  - eng
GR  - EPA999999/ImEPA/Intramural EPA/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20230113
PL  - United States
TA  - Environ Toxicol Chem
JT  - Environmental toxicology and chemistry
JID - 8308958
RN  - 2DI9HA706A (Estrone)
RN  - QJA9M5H4IM (Atrazine)
RN  - 0 (Estrogens)
RN  - 059QF0KO0R (Water)
RN  - EC 1.13.12.- (Luciferases)
RN  - 0 (Water Pollutants, Chemical)
SB  - IM
MH  - Estrone/analysis
MH  - *Atrazine/toxicity/analysis
MH  - Estrogens/analysis
MH  - Mass Spectrometry
MH  - Chromatography, Liquid
MH  - Water
MH  - Biological Assay/methods
MH  - Luciferases/genetics/metabolism
MH  - *Water Pollutants, Chemical/toxicity/analysis
MH  - Environmental Monitoring/methods
PMC - PMC11418611
MID - NIHMS2014624
OTO - NOTNLM
OT  - Analytical chemistry
OT  - CALUX
OT  - bioassay
OT  - chemically activated luciferase expression
OT  - estrogenic compounds
OT  - in vitro toxicology
COIS- Competing Interests The authors declare no conflicts of interest.
EDAT- 2022/12/22 06:00
MHDA- 2023/01/31 06:00
PMCR- 2024/09/23
CRDT- 2022/12/21 06:03
PHST- 2022/08/19 00:00 [revised]
PHST- 2022/07/11 00:00 [received]
PHST- 2022/12/11 00:00 [accepted]
PHST- 2022/12/22 06:00 [pubmed]
PHST- 2023/01/31 06:00 [medline]
PHST- 2022/12/21 06:03 [entrez]
PHST- 2024/09/23 00:00 [pmc-release]
AID - 10.1002/etc.5541 [doi]
PST - ppublish
SO  - Environ Toxicol Chem. 2023 Feb;42(2):333-339. doi: 10.1002/etc.5541. Epub 2023 
      Jan 13.

PMID- 30424806
OWN - NLM
STAT- MEDLINE
DCOM- 20190320
LR  - 20190713
IS  - 2049-2618 (Electronic)
IS  - 2049-2618 (Linking)
VI  - 6
IP  - 1
DP  - 2018 Nov 13
TI  - Estrogen-mediated gut microbiome alterations influence sexual dimorphism in 
      metabolic syndrome in mice.
PG  - 205
LID - 10.1186/s40168-018-0587-0 [doi]
LID - 205
AB  - BACKGROUND: Understanding the mechanism of the sexual dimorphism in 
      susceptibility to obesity and metabolic syndrome (MS) is important for the 
      development of effective interventions for MS. RESULTS: Here we show that gut 
      microbiome mediates the preventive effect of estrogen (17β-estradiol) on 
      metabolic endotoxemia (ME) and low-grade chronic inflammation (LGCI), the 
      underlying causes of MS and chronic diseases. The characteristic profiles of gut 
      microbiome observed in female and 17β-estradiol-treated male and ovariectomized 
      mice, such as decreased Proteobacteria and lipopolysaccharide biosynthesis, were 
      associated with a lower susceptibility to ME, LGCI, and MS in these animals. 
      Interestingly, fecal microbiota-transplant from male mice transferred the MS 
      phenotype to female mice, while antibiotic treatment eliminated the sexual 
      dimorphism in MS, suggesting a causative role of the gut microbiome in this 
      condition. Moreover, estrogenic compounds such as isoflavones exerted 
      microbiome-modulating effects similar to those of 17β-estradiol and reversed 
      symptoms of MS in the male mice. Finally, both expression and activity of 
      intestinal alkaline phosphatase (IAP), a gut microbiota-modifying non-classical 
      anti-microbial peptide, were upregulated by 17β-estradiol and isoflavones, 
      whereas inhibition of IAP induced ME and LGCI in female mice, indicating a 
      critical role of IAP in mediating the effects of estrogen on these parameters. 
      CONCLUSIONS: In summary, we have identified a previously uncharacterized 
      microbiome-based mechanism that sheds light upon sexual dimorphism in the 
      incidence of MS and that suggests novel therapeutic targets and strategies for 
      the management of obesity and MS in males and postmenopausal women.
FAU - Kaliannan, Kanakaraju
AU  - Kaliannan K
AD  - Laboratory of Lipid Medicine and Technology, Department of Medicine, 
      Massachusetts General Hospital and Harvard Medical School, 149 -13th Street, 
      Boston, MA, 02129, USA.
FAU - Robertson, Ruairi C
AU  - Robertson RC
AD  - School of Microbiology, University College Cork, Cork, Ireland.
AD  - Teagasc Moorepark Food Research Centre, Fermoy, Co., Cork, Ireland.
AD  - APC Microbiome Institute, University College Cork, Cork, Ireland.
FAU - Murphy, Kiera
AU  - Murphy K
AD  - School of Microbiology, University College Cork, Cork, Ireland.
FAU - Stanton, Catherine
AU  - Stanton C
AD  - School of Microbiology, University College Cork, Cork, Ireland.
AD  - Teagasc Moorepark Food Research Centre, Fermoy, Co., Cork, Ireland.
AD  - APC Microbiome Institute, University College Cork, Cork, Ireland.
FAU - Kang, Chao
AU  - Kang C
AD  - Research Center for Nutrition and Food Safety, Institute of Military Preventive 
      Medicine, Third Military Medical University, Chongqing Key Laboratory of 
      Nutrition and Food Safety, Chongqing Medical Nutrition Research Center, 
      Chongqing, People's Republic of China.
FAU - Wang, Bin
AU  - Wang B
AD  - Research Center for Nutrition and Food Safety, Institute of Military Preventive 
      Medicine, Third Military Medical University, Chongqing Key Laboratory of 
      Nutrition and Food Safety, Chongqing Medical Nutrition Research Center, 
      Chongqing, People's Republic of China.
FAU - Hao, Lei
AU  - Hao L
AD  - Laboratory of Lipid Medicine and Technology, Department of Medicine, 
      Massachusetts General Hospital and Harvard Medical School, 149 -13th Street, 
      Boston, MA, 02129, USA.
FAU - Bhan, Atul K
AU  - Bhan AK
AD  - Department of Pathology, Massachusetts General Hospital and Harvard Medical 
      School, Boston, MA, 02114, USA.
FAU - Kang, Jing X
AU  - Kang JX
AD  - Laboratory of Lipid Medicine and Technology, Department of Medicine, 
      Massachusetts General Hospital and Harvard Medical School, 149 -13th Street, 
      Boston, MA, 02129, USA. kang.jing@mgh.harvard.edu.
LA  - eng
GR  - P30 DK043351/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20181113
PL  - England
TA  - Microbiome
JT  - Microbiome
JID - 101615147
RN  - 0 (Estrogens)
RN  - 0 (Isoflavones)
RN  - 0 (Lipopolysaccharides)
RN  - 4TI98Z838E (Estradiol)
RN  - EC 3.1.3.1 (Alkaline Phosphatase)
SB  - IM
MH  - Alkaline Phosphatase/biosynthesis
MH  - Animals
MH  - Bacterial Load
MH  - Estradiol/*pharmacology
MH  - Estrogens/*pharmacology
MH  - Fecal Microbiota Transplantation
MH  - Female
MH  - Gastrointestinal Microbiome/*physiology
MH  - Isoflavones/pharmacology
MH  - Lipopolysaccharides/biosynthesis
MH  - Male
MH  - Metabolic Syndrome/*prevention & control
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Proteobacteria/*metabolism
MH  - *Sex Characteristics
PMC - PMC6234624
OTO - NOTNLM
OT  - Chronic inflammation
OT  - Estrogen
OT  - Gut microbiome
OT  - Isoflavones
OT  - Metabolic syndrome
OT  - Obesity
COIS- ETHICS APPROVAL: All animal procedures in this study were performed in accordance 
      with the ethical guidelines approved by the MGH Subcommittee on Research Animal 
      Care. COMPETING INTERESTS: The authors declare that they have no competing 
      interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to 
      jurisdictional claims in published maps and institutional affiliations.
EDAT- 2018/11/15 06:00
MHDA- 2019/03/21 06:00
PMCR- 2018/11/13
CRDT- 2018/11/15 06:00
PHST- 2018/06/23 00:00 [received]
PHST- 2018/10/30 00:00 [accepted]
PHST- 2018/11/15 06:00 [entrez]
PHST- 2018/11/15 06:00 [pubmed]
PHST- 2019/03/21 06:00 [medline]
PHST- 2018/11/13 00:00 [pmc-release]
AID - 10.1186/s40168-018-0587-0 [pii]
AID - 587 [pii]
AID - 10.1186/s40168-018-0587-0 [doi]
PST - epublish
SO  - Microbiome. 2018 Nov 13;6(1):205. doi: 10.1186/s40168-018-0587-0.

PMID- 33269975
OWN - NLM
STAT- MEDLINE
DCOM- 20211021
LR  - 20211021
IS  - 1477-0970 (Electronic)
IS  - 1352-4585 (Linking)
VI  - 27
IP  - 9
DP  - 2021 Aug
TI  - Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing 
      post-partum relapses in multiple sclerosis: The POPARTMUS study.
PG  - 1458-1463
LID - 10.1177/1352458520978218 [doi]
AB  - BACKGROUND: Sex steroids could explain the course of multiple sclerosis (MS) in 
      pregnancy. OBJECTIVE: To compare the annualized relapse rate (ARR) 12 weeks 
      post-partum in women treated with nomegestrol acetate (NOMAc) and 
      17-beta-estradiol (E2) versus placebo. METHODS: POPARTMUS is a randomized, 
      proof-of-concept trial in women with MS, receiving oral NOMAc 10 mg/day and 
      transdermal estradiol 75 µg/week, or placebo. RESULTS: Recruitment was stopped 
      prematurely due to slow inclusions (n = 202). No treatment effect was observed on 
      ARR after 12 weeks (sex steroids = 0.90 (0.58-1.39), placebo = 0.97 (0.63-1.50) 
      (p = 0.79)). CONCLUSION: POPARTMUS failed showing efficacy of a NOMAc-E2 
      combination in preventing post-partum relapses.
FAU - Vukusic, Sandra
AU  - Vukusic S
AUID- ORCID: 0000-0001-7337-7122
AD  - Service de neurologie, sclérose en plaques, pathologies de la myéline et 
      neuro-inflammation et Fondation Eugène Devic EDMUS pour la Sclérose en Plaques, 
      Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon-Bron, 
      France/Centre des Neurosciences de Lyon, INSERM 1028 et CNRS UMR5292, 
      Observatoire Français de la Sclérose en Plaques, Lyon, France/Université Claude 
      Bernard Lyon 1, Villeurbanne, France.
FAU - Ionescu, Iuliana
AU  - Ionescu I
AD  - Service de neurologie, sclérose en plaques, pathologies de la myéline et 
      neuro-inflammation et Fondation Eugène Devic EDMUS pour la Sclérose en Plaques, 
      Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon-Bron, 
      France.
FAU - Cornu, Catherine
AU  - Cornu C
AD  - Centre d'Investigation Clinique INSERM1407, Hospices Civils de Lyon, Lyon, 
      France/Service de Pharmaco-toxicologie, Lyon, France/UMR5558, Claude Bernard 
      University, Lyon, France.
FAU - Bossard, Nadine
AU  - Bossard N
AD  - Hospices Civils de Lyon, Pôle Santé Publique, Service de 
      Biostatistique-Bioinformatique, Lyon, France/Université de Lyon, Université Lyon 
      1, CNRS, UMR 5558, Laboratoire de Biométrie et Biologie Évolutive, Équipe 
      Biostatistique-Santé, Villeurbanne, France.
FAU - Durand-Dubief, Françoise
AU  - Durand-Dubief F
AD  - Service de neurologie, sclérose en plaques, pathologies de la myéline et 
      neuro-inflammation et Fondation Eugène Devic EDMUS pour la Sclérose en Plaques, 
      Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon-Bron, 
      France/CREATIS, UMR 5220 CNRS & U1044 Inserm, Université Claude Bernard Lyon1, 
      Université de Lyon, Villeurbanne, France.
FAU - Cotton, François
AU  - Cotton F
AUID- ORCID: 0000-0003-0046-2478
AD  - CREATIS, UMR 5220 CNRS & U1044 Inserm, Université Claude Bernard Lyon1, 
      Université de Lyon, Villeurbanne, France/Service de Radiologie, Centre 
      Hospitalier Lyon-Sud, Hospices Civils de Lyon, Lyon, France.
FAU - Durelli, Luca
AU  - Durelli L
AD  - Clinical and Biological Sciences Department, University of Torino, Turin, Italy.
FAU - Marignier, Romain
AU  - Marignier R
AD  - Service de neurologie, sclérose en plaques, pathologies de la myéline et 
      neuro-inflammation et Fondation Eugène Devic EDMUS pour la Sclérose en Plaques, 
      Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon-Bron, 
      France/Université Claude Bernard Lyon 1, Villeurbanne, France/Centre des 
      Neurosciences de Lyon, INSERM 1028 et CNRS UMR5292, Fluid team, Lyon, France.
FAU - Gignoux, Laurence
AU  - Gignoux L
AD  - Service de neurologie, sclérose en plaques, pathologies de la myéline et 
      neuro-inflammation et Fondation Eugène Devic EDMUS pour la Sclérose en Plaques, 
      Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon-Bron, 
      France.
FAU - Laplaud, David-Axel
AU  - Laplaud DA
AD  - CHU de Nantes, Service de Neurologie & CIC015 INSERM, Nantes, France, INSERM 
      CR1064, Nantes, France.
FAU - Moreau, Thibault
AU  - Moreau T
AD  - Department of Neurology, EA4184, University Hospital of Dijon, Dijon, France.
FAU - Clavelou, Pierre
AU  - Clavelou P
AD  - Service de Neurologie, CHU Clermont-Ferrand, Clermont-Ferrand, France/Inserm 
      U1107, Clermont Université, Université d'Auvergne, Neuro-Dol, Clermont-Ferrand, 
      France.
FAU - De Seze, Jérôme
AU  - De Seze J
AD  - Department of Neurology and Clinical Investigation Center, CHU de Strasbourg, 
      INSERM, Strasbourg, France.
FAU - Debouverie, Marc
AU  - Debouverie M
AD  - EA 4360 Apemac, Lorraine University, Nancy, France/Department of Neurology, Nancy 
      University Hospital, Nancy, France.
FAU - Brassat, David
AU  - Brassat D
AD  - Pôle Neurosciences, CHU Toulouse Purpan, Toulouse, France/INSERM U1043-CNRS UMR 
      5282, Université Toulouse III, Toulouse, France.
FAU - Pelletier, Jean
AU  - Pelletier J
AD  - Aix Marseille Univ, APHM, Hôpital de la Timone, Pôle de Neurosciences Cliniques, 
      Service de Neurologie, Marseille, France.
FAU - Lebrun-Frenay, Christine
AU  - Lebrun-Frenay C
AD  - CRCSEP Department of Neurology, UR2CA URRIS, Nice, France.
FAU - Le Page, Emmanuelle
AU  - Le Page E
AD  - Clinical Neuroscience Centre, CIC-P 1414 INSERM, Rennes University Hospital, 
      Rennes, France.
FAU - Castelnovo, Giovanni
AU  - Castelnovo G
AD  - Department of Neurology, CHU Nîmes, Hôpital Caremeau, Nîmes Cedex, France.
FAU - Berger, Eric
AU  - Berger E
AD  - Department of Neurology, CHU Besançon, Besançon, France.
FAU - Hautecoeur, Patrick
AU  - Hautecoeur P
AD  - Service de Neurologie, Groupe Hospitalier de l'Institut Catholique de Lille, 
      Lille Cedex, France.
FAU - Heinzlef, Olivier
AU  - Heinzlef O
AD  - Neurology Department, Hospital of Poissy-St-Germain en Laye, Paris, France.
FAU - Trojano, Maria
AU  - Trojano M
AD  - Department of Basic Medical Sciences, Neurosciences and Sense Organs, University 
      of Bari, Bari, Italy.
FAU - Patti, Francesco
AU  - Patti F
AUID- ORCID: 0000-0002-6923-0846
AD  - Department of Medical and Surgical Sciences, and Advanced Technologies, GF 
      Ingrassia, Multiple Sclerosis Center, University of Catania, Catania, Italy.
FAU - Baulieu, Etienne-Emile
AU  - Baulieu EE
AD  - INSERM U 1195, Le Kremlin-Bicêtre, France.
FAU - Remontet, Laurent
AU  - Remontet L
AD  - Hospices Civils de Lyon, Pôle Santé Publique, Service de 
      Biostatistique-Bioinformatique, Lyon, France/Université de Lyon, Université Lyon 
      1, CNRS, UMR 5558, Laboratoire de Biométrie et Biologie Évolutive, Équipe 
      Biostatistique-Santé, Villeurbanne, France.
FAU - El-Etr, Martine
AU  - El-Etr M
AD  - INSERM U 1195, Le Kremlin-Bicêtre, France.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201203
PL  - England
TA  - Mult Scler
JT  - Multiple sclerosis (Houndmills, Basingstoke, England)
JID - 9509185
RN  - 0 (Norpregnadienes)
RN  - 4TI98Z838E (Estradiol)
RN  - 83J78V5W05 (nomegestrol acetate)
RN  - EA6LD1M70M (Megestrol)
SB  - IM
MH  - *Estradiol
MH  - Female
MH  - Humans
MH  - Megestrol
MH  - *Multiple Sclerosis/drug therapy
MH  - Norpregnadienes
MH  - Postpartum Period
MH  - Pregnancy
MH  - Recurrence
OTO - NOTNLM
OT  - Multiple sclerosis
OT  - estradiol
OT  - post-partum
OT  - progesterone
OT  - relapses
OT  - sex hormones
EDAT- 2020/12/04 06:00
MHDA- 2023/02/25 06:00
CRDT- 2020/12/03 12:08
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2023/02/25 06:00 [medline]
PHST- 2020/12/03 12:08 [entrez]
AID - 10.1177/1352458520978218 [doi]
PST - ppublish
SO  - Mult Scler. 2021 Aug;27(9):1458-1463. doi: 10.1177/1352458520978218. Epub 2020 
      Dec 3.

PMID- 37378907
OWN - NLM
STAT- MEDLINE
DCOM- 20231106
LR  - 20231106
IS  - 1432-119X (Electronic)
IS  - 0948-6143 (Linking)
VI  - 160
IP  - 5
DP  - 2023 Nov
TI  - Naringenin stimulates aromatase expression and alleviates the clinical and 
      histopathological findings of experimental autoimmune encephalomyelitis in C57bl6 
      mice.
PG  - 477-490
LID - 10.1007/s00418-023-02217-1 [doi]
AB  - This study was conducted to demonstrate the possible protective and therapeutic 
      effects of naringenin, an estrogenically effective flavonoid, in experimental 
      autoimmune encephalomyelitis (EAE), which is the rodent model of multiple 
      sclerosis. For this purpose, 50 12-week-old C57BL6 male mice were divided into 
      five groups; control, naringenin, EAE, prophylactic naringenin + EAE, and 
      EAE + therapeutic naringenin. The EAE model was induced with myelin 
      oligodendrocyte glycoprotein((35-55)), and naringenin (50 mg/kg) was administered 
      by oral gavage. The prophylactic and therapeutic effects of naringenin were 
      examined according to clinical, histopathological, immunohistochemical, electron 
      microscopic, and RT-PCR (aromatase, 3βHSD, estrogen receptors, and progesterone 
      receptor expression) parameters. The acute EAE model was successfully induced, 
      along with its clinical and histopathological findings. RT-PCR showed that 
      expression of aromatase, 3βHSD, estrogen receptor-β, and progesterone receptor 
      gene decreased, while estrogen receptor-α increased after EAE induction. Electron 
      microscopic analysis showed mitochondrial damage and degenerative changes in 
      myelinated axons and neurons in EAE, which could be behind the downregulation in 
      the expressions of neurosteroid enzymes. Aromatase immunopositivity rates also 
      decreased in EAE, while estrogen receptor α and β, and progesterone receptor 
      immunopositivity rates increased. Naringenin improved aromatase immunopositivity 
      rates and gene expression in both prophylactic and therapeutic use. Clinical and 
      histopathological findings revealed that EAE findings were alleviated in both 
      prophylactic and therapeutic groups, along with significantly decreased 
      inflammatory cell infiltrations in the white matter of the spinal cords. In 
      conclusion, naringenin could provide long-term beneficial effects even in 
      prophylactic use due to stimulating aromatase expression, but it could not 
      prevent or eliminate the EAE model's lesions completely.
CI  - © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Karaca, Efe
AU  - Karaca E
AUID- ORCID: 0000-0003-4109-6013
AD  - Department of Veterinary Pathology, Faculty of Veterinary Medicine, Ondokuz Mayıs 
      University, 55200, Atakum, Samsun, Turkey. efe.karaca@omu.edu.tr.
FAU - Yarim, Murat
AU  - Yarim M
AUID- ORCID: 0000-0002-0636-4214
AD  - Department of Veterinary Pathology, Faculty of Veterinary Medicine, Ondokuz Mayıs 
      University, 55200, Atakum, Samsun, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20230628
PL  - Germany
TA  - Histochem Cell Biol
JT  - Histochemistry and cell biology
JID - 9506663
RN  - 0 (Receptors, Progesterone)
RN  - HN5425SBF2 (naringenin)
RN  - 0 (Receptors, Estrogen)
RN  - EC 1.14.14.1 (Aromatase)
SB  - IM
MH  - Male
MH  - Animals
MH  - Mice
MH  - *Encephalomyelitis, Autoimmune, Experimental
MH  - Receptors, Progesterone/therapeutic use
MH  - Receptors, Estrogen
MH  - Aromatase/genetics
MH  - Mice, Inbred C57BL
MH  - Spinal Cord/metabolism
OTO - NOTNLM
OT  - 3βHSD
OT  - Aromatase
OT  - Estrogen receptor
OT  - Experimental autoimmune encephalomyelitis
OT  - Naringenin
EDAT- 2023/06/28 13:08
MHDA- 2023/11/06 06:43
CRDT- 2023/06/28 11:16
PHST- 2023/06/02 00:00 [accepted]
PHST- 2023/11/06 06:43 [medline]
PHST- 2023/06/28 13:08 [pubmed]
PHST- 2023/06/28 11:16 [entrez]
AID - 10.1007/s00418-023-02217-1 [pii]
AID - 10.1007/s00418-023-02217-1 [doi]
PST - ppublish
SO  - Histochem Cell Biol. 2023 Nov;160(5):477-490. doi: 10.1007/s00418-023-02217-1. 
      Epub 2023 Jun 28.

PMID- 37334310
OWN - NLM
STAT- MEDLINE
DCOM- 20230620
LR  - 20230620
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 14
DP  - 2023
TI  - The therapeutic role and potential mechanism of EGCG in obesity-related 
      precocious puberty as determined by integrated metabolomics and network 
      pharmacology.
PG  - 1159657
LID - 10.3389/fendo.2023.1159657 [doi]
LID - 1159657
AB  - OBJECTIVE: (-)-Epigallocatechin-3-gallate (EGCG) has preventive effects on 
      obesity-related precocious puberty, but its underlying mechanism remains unclear. 
      The aim of this study was to integrate metabolomics and network pharmacology to 
      reveal the mechanism of EGCG in the prevention of obesity-related precocious 
      puberty. MATERIALS AND METHODS: A high-performance liquid 
      chromatography-electrospray ionization ion-trap tandem mass spectrometry 
      (LC-ESI-MS/MS) was used to analyze the impact of EGCG on serum metabolomics and 
      associated metabolic pathways in a randomized controlled trial. Twelve weeks of 
      EGCG capsules were given to obese girls in this trail. Additionally, the targets 
      and pathways of EGCG in preventing obesity-related precocious puberty network 
      pharmacology were predicted using network pharmacology. Finally, the mechanism of 
      EGCG prevention of obesity-related precocious puberty was elucidated through 
      integrated metabolomics and network pharmacology. RESULTS: Serum metabolomics 
      screened 234 endogenous differential metabolites, and network pharmacology 
      identified a total of 153 common targets. These metabolites and targets mainly 
      enrichment pathways involving endocrine-related pathways (estrogen signaling 
      pathway, insulin resistance, and insulin secretion), and signal transduction 
      (PI3K-Akt, MAPK, and Jak-STAT signaling pathways). The integrated metabolomics 
      and network pharmacology indicated that AKT1, EGFR, ESR1, STAT3, IGF1, and MAPK1 
      may be key targets for EGCG in preventing obesity-related precocious puberty. 
      CONCLUSION: EGCG may contribute to preventing obesity-related precocious puberty 
      through targets such as AKT1, EGFR, ESR1, STAT3, IGF1, and MAPK1 and multiple 
      signaling pathways, including the estrogen, PI3K-Akt, MAPK, and Jak-STAT 
      pathways. This study provided a theoretical foundation for future research.
CI  - Copyright © 2023 Gu, Xia, Du, Shao, He, Wu, Liang and Shen.
FAU - Gu, Qiuyun
AU  - Gu Q
AD  - Department of Nutrition, Shanghai General Hospital, Shanghai Jiao Tong University 
      School of Medicine, Shanghai, China.
FAU - Xia, Lina
AU  - Xia L
AD  - Department of Nutrition, Shanghai General Hospital, Shanghai Jiao Tong University 
      School of Medicine, Shanghai, China.
FAU - Du, Qiuju
AU  - Du Q
AD  - Department of Nutrition, Shanghai General Hospital, Shanghai Jiao Tong University 
      School of Medicine, Shanghai, China.
FAU - Shao, Ying
AU  - Shao Y
AD  - Department of Nutrition, Shanghai General Hospital, Shanghai Jiao Tong University 
      School of Medicine, Shanghai, China.
FAU - He, Jieyi
AU  - He J
AD  - Department of Nutrition, Shanghai General Hospital, Shanghai Jiao Tong University 
      School of Medicine, Shanghai, China.
FAU - Wu, Peiying
AU  - Wu P
AD  - Department of Nutrition, Shanghai General Hospital, Shanghai Jiao Tong University 
      School of Medicine, Shanghai, China.
FAU - Liang, Lingwei
AU  - Liang L
AD  - Department of Nutrition, Shanghai General Hospital, Shanghai Jiao Tong University 
      School of Medicine, Shanghai, China.
FAU - Shen, Xiuhua
AU  - Shen X
AD  - Department of Nutrition, School of Public Health, Shanghai Jiao Tong University 
      School of Medicine, Shanghai, China.
AD  - Department of Clinical Nutrition, College of Health Science and Technology, 
      Shanghai Jiao Tong University School of Medicine, Shanghai, China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20230602
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - BQM438CTEL (epigallocatechin gallate)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - 0 (Estrogens)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Humans
MH  - Female
MH  - *Network Pharmacology
MH  - Phosphatidylinositol 3-Kinases
MH  - Proto-Oncogene Proteins c-akt
MH  - *Puberty, Precocious/drug therapy/etiology
MH  - Tandem Mass Spectrometry
MH  - Metabolomics
MH  - Estrogens
MH  - ErbB Receptors
PMC - PMC10272822
OTO - NOTNLM
OT  - EGCG
OT  - metabolomics
OT  - network pharmacology
OT  - obesity
OT  - precocious puberty
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/06/19 06:42
MHDA- 2023/06/20 06:41
PMCR- 2023/01/01
CRDT- 2023/06/19 03:05
PHST- 2023/02/12 00:00 [received]
PHST- 2023/05/10 00:00 [accepted]
PHST- 2023/06/20 06:41 [medline]
PHST- 2023/06/19 06:42 [pubmed]
PHST- 2023/06/19 03:05 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2023.1159657 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2023 Jun 2;14:1159657. doi: 
      10.3389/fendo.2023.1159657. eCollection 2023.

PMID- 37958552
OWN - NLM
STAT- MEDLINE
DCOM- 20231115
LR  - 20231117
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 24
IP  - 21
DP  - 2023 Oct 25
TI  - Hyaluronic Acid Conjugated with 17β-Estradiol Effectively Alleviates 
      Estropause-Induced Cognitive Deficits in Rats.
LID - 10.3390/ijms242115569 [doi]
LID - 15569
AB  - Women are at a higher risk of cognitive impairments and Alzheimer's disease (AD), 
      particularly after the menopause, when the estrous cycle becomes irregular and 
      diminishes. Numerous studies have shown that estrogen deficiency, especially 
      estradiol (E2) deficiency, plays a key role in this phenomenon. Recently, a novel 
      polymeric drug, hyaluronic acid-17β-estradiol conjugate (HA-E2), has been 
      introduced for the delivery of E2 to brain tissues. Studies have indicated that 
      HA-E2 crosses the blood-brain barrier (BBB) and facilitates a prolonged E2 
      release profile while lowering the risk of estrogen-supplement-related side 
      effects. In this study, we used ovariohysterectomy (OHE) rats, a postmenopausal 
      cognitive deficit model, to explore the effect of a 2-week HA-E2 treatment (210 
      ng/kg body weight, twice a week) on the cholinergic septo-hippocampal innervation 
      system, synaptic transmission in hippocampal pyramidal neurons and cognitive 
      improvements. Our study revealed an 11% rise in choline acetyltransferase (ChAT) 
      expression in both the medial septal nucleus (MS nucleus) and the hippocampus, 
      along with a 14-18% increase in dendritic spine density in hippocampal pyramidal 
      neurons, following HA-E2 treatment in OHE rats. These enhancements prompted the 
      recovery of cognitive functions such as spatial learning and memory. These 
      findings suggest that HA-E2 may prevent and improve estrogen-deficiency-induced 
      cognitive impairment and AD.
FAU - Chen, Mu-Hsuan
AU  - Chen MH
AUID- ORCID: 0000-0001-7434-1391
AD  - Department of Veterinary Medicine, College of Veterinary Medicine, National 
      Chung-Hsing University, No. 145, Xingda Rd., Taichung 402202, Taiwan.
FAU - Lin, Hsiao-Chun
AU  - Lin HC
AUID- ORCID: 0000-0002-7401-3694
AD  - Department of Veterinary Medicine, College of Veterinary Medicine, National 
      Chung-Hsing University, No. 145, Xingda Rd., Taichung 402202, Taiwan.
FAU - Chao, Tzu
AU  - Chao T
AD  - Department of Veterinary Medicine, College of Veterinary Medicine, National 
      Chung-Hsing University, No. 145, Xingda Rd., Taichung 402202, Taiwan.
FAU - Lee, Viola Szu-Yuan
AU  - Lee VS
AD  - Basic Research Division, Holy Stone Healthcare Co., Ltd., Taipei 11493, Taiwan.
FAU - Hou, Chia-Lung
AU  - Hou CL
AD  - Basic Research Division, Holy Stone Healthcare Co., Ltd., Taipei 11493, Taiwan.
FAU - Wang, Tsyr-Jiuan
AU  - Wang TJ
AD  - Department of Nursing, National Taichung University of Science and Technology, 
      No. 193, Section 1, Sanmin Rd., Taichung 403027, Taiwan.
FAU - Chen, Jeng-Rung
AU  - Chen JR
AUID- ORCID: 0000-0002-4429-283X
AD  - Department of Veterinary Medicine, College of Veterinary Medicine, National 
      Chung-Hsing University, No. 145, Xingda Rd., Taichung 402202, Taiwan.
LA  - eng
GR  - MOST 109-2313-B-005-016/National science and Technology Council of Taiwan/
GR  - 111D570/National Chung-Hsing University/
GR  - 111109F/National Taichung University of Science and Technology/
PT  - Journal Article
DEP - 20231025
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 9004-61-9 (Hyaluronic Acid)
RN  - 4TI98Z838E (Estradiol)
RN  - 0 (Estrogens)
SB  - IM
MH  - Humans
MH  - Rats
MH  - Female
MH  - Animals
MH  - Hyaluronic Acid/pharmacology
MH  - Estradiol/pharmacology/metabolism
MH  - Estrogens/pharmacology
MH  - *Alzheimer Disease
MH  - *Cognitive Dysfunction/drug therapy/etiology
MH  - Cognition
PMC - PMC10649161
OTO - NOTNLM
OT  - Alzheimer’s disease
OT  - Morris water maze
OT  - cholinergic septo-hippocampal innervation system
OT  - cognitive deficit
OT  - dendritic spine
OT  - hippocampus
COIS- The authors declare no conflict of interest.
EDAT- 2023/11/14 06:42
MHDA- 2023/11/15 06:42
PMCR- 2023/10/25
CRDT- 2023/11/14 02:08
PHST- 2023/09/28 00:00 [received]
PHST- 2023/10/18 00:00 [revised]
PHST- 2023/10/18 00:00 [accepted]
PHST- 2023/11/15 06:42 [medline]
PHST- 2023/11/14 06:42 [pubmed]
PHST- 2023/11/14 02:08 [entrez]
PHST- 2023/10/25 00:00 [pmc-release]
AID - ijms242115569 [pii]
AID - ijms-24-15569 [pii]
AID - 10.3390/ijms242115569 [doi]
PST - epublish
SO  - Int J Mol Sci. 2023 Oct 25;24(21):15569. doi: 10.3390/ijms242115569.

PMID- 31453957
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20240229
IS  - 1530-0374 (Electronic)
IS  - 1072-3714 (Print)
IS  - 1072-3714 (Linking)
VI  - 26
IP  - 9
DP  - 2019 Sep
TI  - Determination of estradiol and progesterone content in capsules and creams from 
      compounding pharmacies.
PG  - 966-971
LID - 10.1097/GME.0000000000001356 [doi]
AB  - OBJECTIVES: To analytically characterize the doses of estradiol and progesterone 
      found in compounded combined forms of oral capsule and transdermal cream 
      formulations, and determine the consistency of the hormone formulations within a 
      batch. METHODS: Prescriptions for combined estradiol/progesterone capsules (0.5 
      and 100 mg, respectively) and creams (0.5 and 100 mg/g, respectively) were sent 
      to 15 custom-compounding pharmacies. Estradiol and progesterone levels were 
      measured by radioimmunoassays. Hormone levels were measured in 2 capsules and 2 
      creams from each pharmacy; 10 capsules from 3 pharmacies; and top/middle/bottom 
      layer of cream containers to assess consistency. The magnitude and sources of 
      variation for the measurements were examined by analysis of variance models. 
      RESULTS: Thirteen pharmacies filled the prescriptions. Measured estradiol levels 
      were 0.365 to 0.551 mg for capsules and 0.433 to 0.55 mg/g for creams, and 
      progesterone levels were 90.8 to 135 mg for capsules and 93 to 118 mg/g for 
      creams. Greater variations in estradiol levels were observed between pharmacies 
      for estradiol in capsules than in creams; however, measured estradiol levels 
      within pharmacies were more consistent in the capsules than the creams. Similar 
      results were obtained for progesterone levels. CONCLUSION: The variations in 
      estradiol and progesterone levels observed in compounded hormone therapy 
      formulations justify concerns regarding risks as a result of variability, which 
      have been outlined by The North American Menopause Society, the American College 
      of Obstetricians and Gynecologists, and the US Food and Drug Administration (FDA) 
      in their statements regarding compounded hormone use. These data support the need 
      for an US FDA-approved bioidentical hormone therapy. : Video Summary: 
      Supplemental Digital Content 1, http://links.lww.com/MENO/A425.
FAU - Stanczyk, Frank Z
AU  - Stanczyk FZ
AD  - Department of Obstetrics and Gynecology, Keck School of Medicine, University of 
      Southern California, Los Angeles, CA.
AD  - Department of Preventive Medicine, Keck School of Medicine, University of 
      Southern California, Los Angeles, CA.
FAU - Niu, Chunying
AU  - Niu C
AD  - Department of Obstetrics and Gynecology, Keck School of Medicine, University of 
      Southern California, Los Angeles, CA.
FAU - Azen, Colleen
AU  - Azen C
AD  - Department of Preventive Medicine, Keck School of Medicine, University of 
      Southern California, Los Angeles, CA.
FAU - Mirkin, Sebastian
AU  - Mirkin S
AD  - TherapeuticsMD, Boca Raton, FL.
FAU - Amadio, Julia M
AU  - Amadio JM
AD  - TherapeuticsMD, Boca Raton, FL.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Menopause
JT  - Menopause (New York, N.Y.)
JID - 9433353
RN  - 0 (Capsules)
RN  - 4G7DS2Q64Y (Progesterone)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
CIN - Menopause. 2019 Sep;26(9):945-946. doi: 10.1097/GME.0000000000001400. PMID: 
      31453954
MH  - Capsules
MH  - Drug Compounding/standards
MH  - Estradiol/*chemistry
MH  - *Estrogen Replacement Therapy
MH  - Female
MH  - Humans
MH  - *Menopause
MH  - Pharmacies/*standards
MH  - Progesterone/*chemistry
MH  - Skin Cream
MH  - United States
PMC - PMC6738624
COIS- Financial disclosure/conflicts of interest: Dr Stanczyk consults for Agile 
      Therapeutics, Mithra, and TherapeuticsMD. Chunying Niu has no conflicts of 
      interest. Colleen Azen consults for TherapeuticsMD. Dr Mirkin is an employee of 
      TherapeuticsMD with stock/stock options. Ms Amadio is an employee of 
      TherapeuticsMD with stock/stock options.
EDAT- 2019/08/28 06:00
MHDA- 2020/07/17 06:00
PMCR- 2019/09/11
CRDT- 2019/08/28 06:00
PHST- 2019/08/28 06:00 [entrez]
PHST- 2019/08/28 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
PHST- 2019/09/11 00:00 [pmc-release]
AID - 00042192-201909000-00005 [pii]
AID - MENO-D-18-00417 [pii]
AID - 10.1097/GME.0000000000001356 [doi]
PST - ppublish
SO  - Menopause. 2019 Sep;26(9):966-971. doi: 10.1097/GME.0000000000001356.

PMID- 28257993
OWN - NLM
STAT- MEDLINE
DCOM- 20180503
LR  - 20250103
IS  - 1879-176X (Electronic)
IS  - 0300-5712 (Linking)
VI  - 60
DP  - 2017 May
TI  - Release of monomers from composite dust.
PG  - 56-62
LID - S0300-5712(17)30057-X [pii]
LID - 10.1016/j.jdent.2017.02.016 [doi]
AB  - OBJECTIVES: Dental personnel are more at risk to develop asthmatic disease, but 
      the exact reason is so far unknown. During abrasive procedures, dental personnel 
      are exposed to nano-sized dust particles released from dental composite. The aim 
      of this study was to investigate whether respirable composite dust may also 
      release monomers. METHODS: Respirable (<5μm) composite dust was collected and the 
      release of methacrylate monomers and Bisphenol A (BPA) in water and ethanol was 
      evaluated by liquid chromatography/mass spectroscopy (LC-MS/MS). The dust was 
      ultra-morphologically and chemically analyzed by transmission electron microscopy 
      and energy-dispersive X-ray spectroscopy (TEM-EDS). RESULTS: LC-MS/MS analysis 
      revealed that, irrespective of the type of composite, the respirable fraction of 
      composite dust may release relatively high concentrations of unpolymerized 
      methacrylate monomers, both in water and ethanol. Higher release was observed in 
      ethanol. The endocrine disruptor BPA also emanated from the composite dust 
      particles. TEM showed that most particles were nano-sized, although particle size 
      ranged between 6nm and 5μm with a mode value between 12 and 39nm. Most particles 
      consisted of several filler particles in resin matrix, although single 
      nano-filler particles could also be observed. Elemental analysis by TEM-EDS 
      proved that the particles collected on the filters originated from the dental 
      composites. CONCLUSION: Theoretically, composite dust may function as a vehicle 
      to transport monomers deeply into the respiratory system. The results of this 
      study may shed another light on the increasing incidence of respiratory disease 
      among dental personnel, and more care should be taken to prevent inhalation of 
      composite dust. CLINICAL SIGNIFICANCE: Special care should be taken to prevent 
      inhalation of composite dust, as the dust particles may release methacrylate 
      monomers.
CI  - Copyright © 2017 Elsevier Ltd. All rights reserved.
FAU - Cokic, S M
AU  - Cokic SM
AD  - KU Leuven BIOMAT, Department of Oral Health Sciences, University of Leuven & 
      Dentistry University Hospitals Leuven, Kapucijnenvoer 7, 3000 Leuven, Belgium.
FAU - Duca, R C
AU  - Duca RC
AD  - Centre for Environmental and Health, Department of Public Health and Primary 
      Care, University of Leuven, Kapucijnenvoer 35, 3000 Leuven, Belgium.
FAU - Godderis, L
AU  - Godderis L
AD  - Centre for Environmental and Health, Department of Public Health and Primary 
      Care, University of Leuven, Kapucijnenvoer 35, 3000 Leuven, Belgium; IDEWE, 
      External Service for Prevention and Protection at Work, Heverlee, Belgium.
FAU - Hoet, P H
AU  - Hoet PH
AD  - Centre for Environmental and Health, Department of Public Health and Primary 
      Care, University of Leuven, Kapucijnenvoer 35, 3000 Leuven, Belgium.
FAU - Seo, J W
AU  - Seo JW
AD  - Surface and Interface Engineered Materials, Department of Materials Engineering, 
      University of Leuven, Kasteelpark Arenberg 44, 3001 Heverlee, Belgium.
FAU - Van Meerbeek, B
AU  - Van Meerbeek B
AD  - KU Leuven BIOMAT, Department of Oral Health Sciences, University of Leuven & 
      Dentistry University Hospitals Leuven, Kapucijnenvoer 7, 3000 Leuven, Belgium.
FAU - Van Landuyt, K L
AU  - Van Landuyt KL
AD  - KU Leuven BIOMAT, Department of Oral Health Sciences, University of Leuven & 
      Dentistry University Hospitals Leuven, Kapucijnenvoer 7, 3000 Leuven, Belgium. 
      Electronic address: kirsten.vanlanduyt@med.kuleuven.be.
LA  - eng
PT  - Journal Article
DEP - 20170301
PL  - England
TA  - J Dent
JT  - Journal of dentistry
JID - 0354422
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Biocompatible Materials)
RN  - 0 (Composite Resins)
RN  - 0 (Dust)
RN  - 0 (Filtek Supreme)
RN  - 0 (Gradia)
RN  - 0 (Grandio)
RN  - 0 (Methacrylates)
RN  - 0 (Phenols)
RN  - 0 (Polymethacrylic Acids)
RN  - 0 (Z100 composite resin)
RN  - 059QF0KO0R (Water)
RN  - 3K9958V90M (Ethanol)
RN  - 454I75YXY0 (Bisphenol A-Glycidyl Methacrylate)
RN  - 7631-86-9 (Silicon Dioxide)
RN  - C6V6S92N3C (Zirconium)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - Benzhydryl Compounds/*chemistry
MH  - Biocompatible Materials
MH  - Bisphenol A-Glycidyl Methacrylate/chemistry
MH  - Composite Resins/adverse effects/*chemistry/classification
MH  - *Dust
MH  - Ethanol/chemistry
MH  - Humans
MH  - Inhalation Exposure/adverse effects
MH  - Materials Testing
MH  - Methacrylates/*chemistry
MH  - Microscopy, Electron, Transmission
MH  - Nanoparticles/adverse effects/chemistry/ultrastructure
MH  - Occupational Exposure/adverse effects
MH  - Particle Size
MH  - Phenols/*chemistry
MH  - Polymethacrylic Acids/chemistry
MH  - Silicon Dioxide/chemistry
MH  - Water/chemistry
MH  - Zirconium/chemistry
OTO - NOTNLM
OT  - Biocompatibility
OT  - Dust
OT  - Filler
OT  - Monomer release
OT  - Nanoparticle
OT  - Occupational
EDAT- 2017/03/05 06:00
MHDA- 2018/05/04 06:00
CRDT- 2017/03/05 06:00
PHST- 2016/09/18 00:00 [received]
PHST- 2017/02/21 00:00 [revised]
PHST- 2017/02/27 00:00 [accepted]
PHST- 2017/03/05 06:00 [pubmed]
PHST- 2018/05/04 06:00 [medline]
PHST- 2017/03/05 06:00 [entrez]
AID - S0300-5712(17)30057-X [pii]
AID - 10.1016/j.jdent.2017.02.016 [doi]
PST - ppublish
SO  - J Dent. 2017 May;60:56-62. doi: 10.1016/j.jdent.2017.02.016. Epub 2017 Mar 1.

PMID- 34679005
OWN - NLM
STAT- MEDLINE
DCOM- 20220222
LR  - 20220222
IS  - 2072-6651 (Electronic)
IS  - 2072-6651 (Linking)
VI  - 13
IP  - 10
DP  - 2021 Oct 9
TI  - Biological Transformation of Zearalenone by Some Bacterial Isolates Associated 
      with Ruminant and Food Samples.
LID - 10.3390/toxins13100712 [doi]
LID - 712
AB  - Zearalenone (ZEA) is a secondary metabolite produced by Fusarium spp., the 
      filamentous fungi. Food and feed contamination with zearalenone has adverse 
      effects on health and economy. ZEA degradation through microorganisms is 
      providing a promising preventive measure. The current study includes isolation of 
      47 bacterial strains from 100 different food and rumen samples. Seventeen 
      isolates showed maximum activity of ZEA reduction. A bacterial isolate, RS-5, 
      reduced ZEA concentration up to 78.3% through ELISA analysis and 74.3% as 
      determined through HPLC. Ten of the most efficient strains were further selected 
      for comparison of their biodegradation activity in different conditions such as 
      incubation period, and different growth media. The samples were analyzed after 24 
      h, 48 h, and 72 h of incubation. De Man Rogosa Sharp (MRS) broth, Tryptic soy 
      broth, and nutrient broth were used as different carbon sources for comparison of 
      activity through ELISA. The mean degradation % ± SD through ELISA and HPLC were 
      70.77% ± 3.935 and 69.11% ± 2.768, respectively. Optimum reducing activity was 
      detected at 72 h of incubation, and MRS broth is a suitable medium. Phylogenetic 
      analysis based on 16S rRNA gene nucleotide sequences confirmed that one of the 
      bacterial isolate RS-5 bacterial isolates with higher mycotoxin degradation is 
      identified as Bacillus subtilis isolated from rumen sample. B05 (FSL-8) bacterial 
      isolate of yogurt belongs to the genus Lactobacillus with 99.66% similarity with 
      Lactobacillus delbrukii. Similarly, three other bacterial isolates, D05, H05 and 
      F04 (FS-17, FSL-2 and FS-20), were found to be the sub-species/strains 
      Pseudomonas gessardii of genus Pseudomonas based on their similarity level of 
      (99.2%, 96% and 96.88%) and positioning in the phylogenetic tree. Promising 
      detoxification results were revealed through GC-MS analysis of RS-5 and FSL-8 
      activity.
FAU - Zada, Sharif
AU  - Zada S
AD  - Department of Microbiology, Hazara University, Mansehra 21120, Pakistan.
FAU - Alam, Sadia
AU  - Alam S
AD  - Department of Microbiology, The University of Haripur, Haripur 22620, Pakistan.
FAU - Ayoubi, Samha Al
AU  - Ayoubi SA
AD  - College of Humanities and Sciences, Prince Sultan University, Riyadh 11586, Saudi 
      Arabia.
FAU - Shakeela, Qismat
AU  - Shakeela Q
AD  - Department of Microbiology, Abbottabad University of Science and Technology, 
      Havelian 22060, Pakistan.
FAU - Nisa, Sobia
AU  - Nisa S
AUID- ORCID: 0000-0002-4541-1490
AD  - Department of Microbiology, The University of Haripur, Haripur 22620, Pakistan.
FAU - Niaz, Zeeshan
AU  - Niaz Z
AD  - Department of Microbiology, Hazara University, Mansehra 21120, Pakistan.
FAU - Khan, Ibrar
AU  - Khan I
AUID- ORCID: 0000-0003-4860-9344
AD  - Department of Microbiology, Abbottabad University of Science and Technology, 
      Havelian 22060, Pakistan.
FAU - Ahmed, Waqas
AU  - Ahmed W
AD  - Department of Microbiology, The University of Haripur, Haripur 22620, Pakistan.
FAU - Bibi, Yamin
AU  - Bibi Y
AD  - Department of Botany, PMAS-Arid Agriculture University Rawalpindi, Rawalpindi 
      46300, Pakistan.
FAU - Ahmed, Shehzad
AU  - Ahmed S
AD  - Department of Microbiology, Hazara University, Mansehra 21120, Pakistan.
FAU - Qayyum, Abdul
AU  - Qayyum A
AUID- ORCID: 0000-0001-5322-7936
AD  - Department of Agronomy, The University of Haripur, Haripur 22620, Pakistan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20211009
PL  - Switzerland
TA  - Toxins (Basel)
JT  - Toxins
JID - 101530765
RN  - 5W827M159J (Zearalenone)
RN  - Pseudomonas gessardii
SB  - IM
MH  - Bacillus subtilis/drug effects/*metabolism
MH  - Biotransformation
MH  - Food Microbiology
MH  - Lactobacillus/drug effects/*metabolism
MH  - Pseudomonas/drug effects/*metabolism
MH  - Zearalenone/*metabolism
PMC - PMC8540131
OTO - NOTNLM
OT  - 16SrRNA
OT  - ELISA
OT  - HPLC
OT  - fusarium
OT  - ruminants
OT  - zearalenone
COIS- The authors declare no conflict of interest.
EDAT- 2021/10/23 06:00
MHDA- 2022/02/23 06:00
PMCR- 2021/10/09
CRDT- 2021/10/22 21:03
PHST- 2021/09/03 00:00 [received]
PHST- 2021/10/05 00:00 [revised]
PHST- 2021/10/06 00:00 [accepted]
PHST- 2021/10/22 21:03 [entrez]
PHST- 2021/10/23 06:00 [pubmed]
PHST- 2022/02/23 06:00 [medline]
PHST- 2021/10/09 00:00 [pmc-release]
AID - toxins13100712 [pii]
AID - toxins-13-00712 [pii]
AID - 10.3390/toxins13100712 [doi]
PST - epublish
SO  - Toxins (Basel). 2021 Oct 9;13(10):712. doi: 10.3390/toxins13100712.

PMID- 34071776
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20210714
IS  - 2072-6651 (Electronic)
IS  - 2072-6651 (Linking)
VI  - 13
IP  - 6
DP  - 2021 May 27
TI  - Mycotoxins Exposure of French Grain Elevator Workers: Biomonitoring and Airborne 
      Measurements.
LID - 10.3390/toxins13060382 [doi]
LID - 382
AB  - It is now recognized that additional exposure to mycotoxins may occur through 
      inhalation of contaminated dust at a workplace. The aim of this study was to 
      characterize the multi-mycotoxin exposure of French grain elevator workers using 
      biomonitoring and airborne measurements. Eighteen workers participated in the 
      study. Personal airborne dust samples were analyzed for their mycotoxin 
      concentrations. Workers provided multiple urine samples including pre-shift, 
      post-shift and first morning urine samples or 24 h urine samples. Mycotoxin 
      urinary biomarkers (aflatoxin B1, aflatoxin M1, ochratoxin A, ochratoxin α, 
      deoxynivalenol, zearalenone, α-zearalenol, β-zearalenol, fumonisin B1, HT-2 toxin 
      and T-2 toxin) were measured using a liquid chromatography-high-resolution mass 
      spectrometry method. Grain elevator workers were highly exposed to organic 
      airborne dust (median 4.92 mg.m(-3)). DON, ZEN and FB1 were frequent contaminants 
      in 54, 76 and 72% of air samples, respectively. The mycotoxin biomarkers 
      quantified were DON (98%), ZEN (99%), α-ZEL (52%), β-ZEL (33%), OTA (76%), T-2 
      (4%) and HT-2 (4%). DON elimination profiles showed highest concentrations in 
      samples collected after the end of the work shift and the urinary DON 
      concentrations were significantly higher in post-shift than in pre-shift-samples 
      (9.9 and 22.1 µg/L, respectively). ZEN and its metabolites concentrations did not 
      vary according to the sampling time. However, the levels of α-/β-ZEL were 
      consistent with an additional occupational exposure. These data provide valuable 
      information on grain worker exposure to mycotoxins. They also highlight the 
      usefulness of multi-mycotoxin methods in assessing external and internal 
      exposures, which shed light on the extent and pathways of exposure occurring in 
      occupational settings.
FAU - Ndaw, Sophie
AU  - Ndaw S
AUID- ORCID: 0000-0002-7518-2465
AD  - Toxicology and Biomonitoring Department, INRS-French National Research and Safety 
      Institute for the Prevention of Occupational Accidents and Diseases, 54500 
      Vandoeuvre-Lés-Nancy, France.
FAU - Remy, Aurélie
AU  - Remy A
AD  - Toxicology and Biomonitoring Department, INRS-French National Research and Safety 
      Institute for the Prevention of Occupational Accidents and Diseases, 54500 
      Vandoeuvre-Lés-Nancy, France.
FAU - Jargot, Danièle
AU  - Jargot D
AD  - Pollutant Metrology Department, INRS-French National Research and Safety 
      Institute for the Prevention of Occupational Accidents and Diseases, 54500 
      Vandoeuvre-Lés-Nancy, France.
FAU - Antoine, Guillaume
AU  - Antoine G
AD  - Toxicology and Biomonitoring Department, INRS-French National Research and Safety 
      Institute for the Prevention of Occupational Accidents and Diseases, 54500 
      Vandoeuvre-Lés-Nancy, France.
FAU - Denis, Flavien
AU  - Denis F
AD  - Toxicology and Biomonitoring Department, INRS-French National Research and Safety 
      Institute for the Prevention of Occupational Accidents and Diseases, 54500 
      Vandoeuvre-Lés-Nancy, France.
FAU - Robert, Alain
AU  - Robert A
AD  - Toxicology and Biomonitoring Department, INRS-French National Research and Safety 
      Institute for the Prevention of Occupational Accidents and Diseases, 54500 
      Vandoeuvre-Lés-Nancy, France.
LA  - eng
PT  - Journal Article
DEP - 20210527
PL  - Switzerland
TA  - Toxins (Basel)
JT  - Toxins
JID - 101530765
RN  - 0 (Air Pollutants, Occupational)
RN  - 0 (Biomarkers)
RN  - 0 (Fumonisins)
RN  - 0 (Mycotoxins)
RN  - 0 (Ochratoxins)
RN  - 1779SX6LUY (ochratoxin A)
RN  - 3ZZM97XZ32 (fumonisin B1)
RN  - 5W827M159J (Zearalenone)
SB  - IM
MH  - Adult
MH  - Air Pollutants, Occupational/*analysis
MH  - Biological Monitoring/*methods
MH  - Biomarkers/urine
MH  - Fumonisins/analysis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mycotoxins/*analysis
MH  - *Occupational Exposure
MH  - Ochratoxins/analysis
MH  - Zearalenone/analysis
PMC - PMC8229223
OTO - NOTNLM
OT  - HR-MS/MS
OT  - air
OT  - biomonitoring
OT  - dust
OT  - exposure assessment
OT  - grain workers
OT  - mycotoxins
OT  - occupational exposure
COIS- The authors declare no conflict of interest.
EDAT- 2021/06/03 06:00
MHDA- 2021/07/06 06:00
PMCR- 2021/05/27
CRDT- 2021/06/02 01:33
PHST- 2021/04/13 00:00 [received]
PHST- 2021/05/19 00:00 [revised]
PHST- 2021/05/22 00:00 [accepted]
PHST- 2021/06/02 01:33 [entrez]
PHST- 2021/06/03 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
PHST- 2021/05/27 00:00 [pmc-release]
AID - toxins13060382 [pii]
AID - toxins-13-00382 [pii]
AID - 10.3390/toxins13060382 [doi]
PST - epublish
SO  - Toxins (Basel). 2021 May 27;13(6):382. doi: 10.3390/toxins13060382.

PMID- 32622129
OWN - NLM
STAT- MEDLINE
DCOM- 20200908
LR  - 20221207
IS  - 1879-2448 (Electronic)
IS  - 0043-1354 (Linking)
VI  - 182
DP  - 2020 Sep 1
TI  - Trace determination of eleven natural estrogens and insights from their 
      occurrence in a municipal wastewater treatment plant and river water.
PG  - 115976
LID - S0043-1354(20)30513-3 [pii]
LID - 10.1016/j.watres.2020.115976 [doi]
AB  - As endocrine disruptors, natural estrogens including estrone (E1), 17β-estradiol 
      (E2), and estriol (E3) in wastewaters of municipal wastewater treatment plant 
      (WWTP) as well as other environmental matrix have been widely studied. However, 
      the far-less studied natural estrogens such as 2-hydroxyestrone (2OHE1), 
      16α-hydroxyestrone (16α-OHE1), 4-hydroxyestrone (4OHE1), etc., found in human 
      urine have been almost ignored. Therefore, it is important to investigate the 
      occurrence of these far-less studied natural estrogens in municipal WWTP and 
      other environment. In this study, a GC-MS analytical method was firstly 
      established and validated for trace determination of eleven natural estrogens in 
      waste and surface waters, including E1, E2, E3, 2OHE1, 16α-OHE1, 4OHE1, 
      2-hydroxyestradiol (2OHE2), 4-hydroxyestradiol (4OHE2), 17-epiestriol (17epiE3), 
      16-epiestriol (16epiE3), and 16keto-estradiol (16ketoE2). All the eleven natural 
      estrogens were detected in the influent of one municipal WWTP, which ranged from 
      7.9 to 62.9 ng/L. The top five natural estrogens in the influent were E1, E3, 
      16α-OHE1, 16ketoE2, and 2OHE1 with respective concentrations of 62.9, 62.6, 46.9, 
      32.7, and 28.8 ng/L. Most of them were detected in both the effluent and river 
      water, in which their detected concentrations were n.d-14.7 and n.d-51.7 ng/L, 
      respectively. This work is the first to indicate that the so far less commonly 
      studied natural estrogens in the environment likely pose adverse health effect on 
      humans and wildlife due to their relative strong estrogenic potencies and high 
      levels in wastewater and river water. More work should be done to understand 
      their removals in municipal WWTPs and their occurrence in surface waters.
CI  - Copyright © 2020 Elsevier Ltd. All rights reserved.
FAU - Tang, Zhao
AU  - Tang Z
AD  - School of Environment and Energy, South China University of Technology, 
      Guangzhou, 510006, Guangdong, China.
FAU - Liu, Ze-Hua
AU  - Liu ZH
AD  - School of Environment and Energy, South China University of Technology, 
      Guangzhou, 510006, Guangdong, China; Key Lab Pollution Control & Ecosystem 
      Restoration in Industry Cluster, Ministry of Education, Guangzhou, 510006, 
      Guangdong, China; Guangdong Provincial Key Laboratory of Solid Wastes Pollution 
      Control and Recycling, Guangzhou, 510006, Guangdong, China; Guangdong Provincial 
      Engineering and Technology Research Center for Environment Risk Prevention and 
      Emergency Disposal, South China University of Technology, Guangzhou, 510006, 
      Guangdong, China. Electronic address: zehualiu@scut.edu.cn.
FAU - Wang, Hao
AU  - Wang H
AD  - Key Lab Pollution Control & Ecosystem Restoration in Industry Cluster, Ministry 
      of Education, Guangzhou, 510006, Guangdong, China.
FAU - Dang, Zhi
AU  - Dang Z
AD  - Key Lab Pollution Control & Ecosystem Restoration in Industry Cluster, Ministry 
      of Education, Guangzhou, 510006, Guangdong, China.
FAU - Yin, Hua
AU  - Yin H
AD  - School of Environment and Energy, South China University of Technology, 
      Guangzhou, 510006, Guangdong, China.
FAU - Zhou, Yan
AU  - Zhou Y
AD  - Advanced Environmental Biotechnology Center, Nanyang Environment and Water 
      Research Institute, Nanyang Technological University, CleanTech One, 637141, 
      Singapore; School of Civil and Engineering, Nanyang Technological University, 
      639798, Singapore.
FAU - Liu, Yu
AU  - Liu Y
AD  - Advanced Environmental Biotechnology Center, Nanyang Environment and Water 
      Research Institute, Nanyang Technological University, CleanTech One, 637141, 
      Singapore; School of Civil and Engineering, Nanyang Technological University, 
      639798, Singapore.
LA  - eng
PT  - Journal Article
DEP - 20200527
PL  - England
TA  - Water Res
JT  - Water research
JID - 0105072
RN  - 0 (Estrogens)
RN  - 0 (Waste Water)
RN  - 0 (Water Pollutants, Chemical)
RN  - 2DI9HA706A (Estrone)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Environmental Monitoring
MH  - Estradiol/analysis
MH  - Estrogens/analysis
MH  - Estrone/analysis
MH  - Humans
MH  - Rivers
MH  - *Wastewater
MH  - Water Pollutants, Chemical/*analysis
OTO - NOTNLM
OT  - 16keto-estadiol
OT  - 16α-hydroxyestrone
OT  - Endocrine disruption
OT  - GC-MS
OT  - River water
OT  - Wastewater
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/07/06 06:00
MHDA- 2020/09/09 06:00
CRDT- 2020/07/05 06:00
PHST- 2020/02/03 00:00 [received]
PHST- 2020/05/17 00:00 [revised]
PHST- 2020/05/23 00:00 [accepted]
PHST- 2020/07/06 06:00 [pubmed]
PHST- 2020/09/09 06:00 [medline]
PHST- 2020/07/05 06:00 [entrez]
AID - S0043-1354(20)30513-3 [pii]
AID - 10.1016/j.watres.2020.115976 [doi]
PST - ppublish
SO  - Water Res. 2020 Sep 1;182:115976. doi: 10.1016/j.watres.2020.115976. Epub 2020 
      May 27.

PMID- 32585486
OWN - NLM
STAT- MEDLINE
DCOM- 20200827
LR  - 20200827
IS  - 1090-2414 (Electronic)
IS  - 0147-6513 (Linking)
VI  - 202
DP  - 2020 Oct 1
TI  - Amelioration of PM(2.5)-induced lung toxicity in rats by nutritional 
      supplementation with biochanin A.
PG  - 110878
LID - S0147-6513(20)30717-X [pii]
LID - 10.1016/j.ecoenv.2020.110878 [doi]
AB  - Epidemiological studies have shown that particulate matter with an aerodynamic 
      diameter less than 2.5 μm (PM(2.5)) is closely associated with human health 
      issues, especially pulmonary diseases such as chronic obstructive pulmonary 
      disease (COPD), asthma and lung cancer. In this study, particles were 
      characterized by scanning electron microscopy (SEM), microbeam energy-dispersive 
      X-ray spectroscopy (EDS), inductively coupled plasma mass spectrometry (ICP-MS) 
      and high-performance liquid chromatography (HPLC). A rat model of PM(2.5) 
      exposure was established by nonsurgical intratracheal instillation, and the 
      effects of biochanin A (BCA) treatment were examined. BCA showed a protective 
      effect; it reduced PM(2.5)-induced apoptosis and the production of 
      proinflammatory factors, such as tumor necrosis factor-α (TNF-α), interleukin-2 
      (IL-2), interleukin-6 (IL-6), and the chemokine interleukin-8 (IL-8), as measured 
      using ELISA. These effects were accompanied by increases in the levels of 
      antioxidant enzymes and decreases in the levels of malondialdehyde (MDA), lactate 
      dehydrogenase (LDH) and alkaline phosphatase (AKP). Furthermore, isobaric tag for 
      relative and absolute quantitation (iTRAQ)-based analytical techniques and 
      bioinformatics tools were used to identify putative biomarkers, including XRCC1, 
      MP2K5, IGJ, and F1LQ12, and the results were verified by Western blot analysis. 
      In conclusion, our findings have scientific significance for the application of 
      flavonoids in preventive and therapeutic strategies for PM(2.5)-associated 
      pulmonary diseases and for the promotion of human health.
CI  - Copyright © 2020 Elsevier Inc. All rights reserved.
FAU - Xue, Zhaohui
AU  - Xue Z
AD  - School of Chemical Engineering and Technology, Tianjin University, Tianjin, 
      300072, China.
FAU - Li, Ang
AU  - Li A
AD  - School of Chemical Engineering and Technology, Tianjin University, Tianjin, 
      300072, China.
FAU - Zhang, Xueya
AU  - Zhang X
AD  - School of Chemical Engineering and Technology, Tianjin University, Tianjin, 
      300072, China.
FAU - Yu, Wancong
AU  - Yu W
AD  - Medical Plant Lab, Tianjin Research Center of Agricultural Biotechnology, 
      Tianjin, 300381, China.
FAU - Wang, Junyu
AU  - Wang J
AD  - School of Chemical Engineering and Technology, Tianjin University, Tianjin, 
      300072, China.
FAU - Li, Yong
AU  - Li Y
AD  - Key Laboratory of Water Resources and Environment, Tianjin Normal University, 
      Tianjin, 300387, China.
FAU - Chen, Kui
AU  - Chen K
AD  - Tianjin Eco-Environmental Monitoring Center, Tianjin, 300191, China.
FAU - Wang, Zhongliang
AU  - Wang Z
AD  - Key Laboratory of Water Resources and Environment, Tianjin Normal University, 
      Tianjin, 300387, China.
FAU - Kou, Xiaohong
AU  - Kou X
AD  - School of Chemical Engineering and Technology, Tianjin University, Tianjin, 
      300072, China. Electronic address: kouxiaohong@tju.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20200622
PL  - Netherlands
TA  - Ecotoxicol Environ Saf
JT  - Ecotoxicology and environmental safety
JID - 7805381
RN  - 0 (Air Pollutants)
RN  - 0 (Antioxidants)
RN  - 0 (Particulate Matter)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (X-ray Repair Cross Complementing Protein 1)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - DH2M523P0H (Genistein)
RN  - U13J6U390T (biochanin A)
SB  - IM
MH  - Air Pollutants/*toxicity
MH  - Animals
MH  - Antioxidants/pharmacology
MH  - *Dietary Supplements
MH  - *Genistein
MH  - Lung/drug effects
MH  - Lung Injury/pathology
MH  - Male
MH  - Malondialdehyde/pharmacology
MH  - Particulate Matter/*toxicity
MH  - Rats
MH  - Tumor Necrosis Factor-alpha/metabolism
MH  - X-ray Repair Cross Complementing Protein 1
OTO - NOTNLM
OT  - Antioxidant enzymes
OT  - Biochanin A
OT  - Lung toxicity
OT  - Oxidative stress
OT  - PM(2.5)
EDAT- 2020/06/26 06:00
MHDA- 2020/08/28 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/02/15 00:00 [received]
PHST- 2020/05/03 00:00 [revised]
PHST- 2020/06/08 00:00 [accepted]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/08/28 06:00 [medline]
PHST- 2020/06/26 06:00 [entrez]
AID - S0147-6513(20)30717-X [pii]
AID - 10.1016/j.ecoenv.2020.110878 [doi]
PST - ppublish
SO  - Ecotoxicol Environ Saf. 2020 Oct 1;202:110878. doi: 10.1016/j.ecoenv.2020.110878. 
      Epub 2020 Jun 22.

PMID- 39378034
OWN - NLM
STAT- MEDLINE
DCOM- 20241008
LR  - 20241123
IS  - 2574-3805 (Electronic)
IS  - 2574-3805 (Linking)
VI  - 7
IP  - 10
DP  - 2024 Oct 1
TI  - Reproductive Risk Factor Patterns in Caribbean Women With Breast Cancer Across 4 
      Generations.
PG  - e2438091
LID - 10.1001/jamanetworkopen.2024.38091 [doi]
LID - e2438091
AB  - IMPORTANCE: Breast cancer (BC) is commonly diagnosed among Caribbean women. 
      Shifts in reproductive patterns modify the incidence of BC diagnosis and age at 
      BC diagnosis in population-based studies; however, reproductive patterns in 
      Caribbean women remain understudied. OBJECTIVE: To describe the temporal trends 
      in reproductive patterns and age at BC diagnosis in Caribbean-born women. DESIGN, 
      SETTING, AND PARTICIPANTS: A cross-sectional observational study-the Caribbean 
      Women's Cancer Study-was conducted, with data on reproductive patterns known to 
      affect BC risk collected in The Bahamas, Barbados, Cayman Islands, Dominica, 
      Haiti, Jamaica, and Trinidad and Tobago. Participants were recruited 
      prospectively. The sample included women born in Caribbean countries and 
      diagnosed with invasive BC and/or ovarian cancer from June 1, 2010, to June 30, 
      2018, and was divided into 4 birth cohorts (born before 1950, 1950-1959, 
      1960-1969, and in or after 1970). Data were analyzed between August 1, 2023, and 
      July 31, 2024. EXPOSURES: Receipt of a BC diagnosis and birth in a Caribbean 
      country. MAIN OUTCOMES AND MEASURES: Change in reproductive patterns between 
      birth cohorts, including age at BC diagnosis, family history of cancer, age at 
      first pregnancy, number of pregnancies, number of full-term pregnancies, number 
      of siblings, age at menarche and menopause, estrogen receptor status, and 
      germline pathogenic/likely pathogenic variants. RESULTS: Of 1015 participants 
      diagnosed with BC and ovarian cancer, 995 women (mean [SD] age, 46.6 [10.8] 
      years; 605 [81.8%] Afro-Caribbean, 98 [13.2%] East Indian, 22 [3.0%] White, and 
      12 [1.6%] >1 race) received a diagnosis of invasive BC. Comparison from older to 
      younger birth cohorts (presented in the order of born before 1950, 1950-1959, 
      1960-1969 and in or after 1970) showed an increased proportion of women 
      experiencing menarche at age 12 years or younger (33.0% vs 47.3% vs 45.5% vs 
      57.9%; P < .001), women with no pregnancies (6.8% vs 6.8% vs 10.5% vs 22.8%; 
      P < .001), and nulliparous women (8.6% vs 9.2% vs 13.9% vs 27.6%; P < .001). 
      Younger age at BC diagnosis was observed in women experiencing menarche at age 12 
      years or younger (mean [SD], 45.0 [10.5] years) vs 15 years or older (mean [SD], 
      49.1 [11.2] years) and in nulliparous women (mean [SD], 42.1 [11.2] years) vs 3 
      or more full-term pregnancies (mean [SD], 49.9 [10.6] years; P < .001). For every 
      year of first pregnancy delay, women had a 4% increased chance of being diagnosed 
      with estrogen receptor-positive tumors (odds ratio, 1.04; 95% CI, 1.01-1.08; 
      P = .02). CONCLUSIONS AND RELEVANCE: In this cross-sectional study, between each 
      10-year birth cohort, women diagnosed with BC had a lower age at menarche, number 
      of pregnancies, and number of full-term pregnancies. These findings suggest that 
      interventions targeting other BC risk factors need to be implemented.
FAU - Sanchez-Covarrubias, Alex P
AU  - Sanchez-Covarrubias AP
AD  - Cancer Biology Graduate Program, Miller School of Medicine, University of Miami, 
      Miami, Florida.
AD  - Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and 
      Reproductive Sciences, Miller School of Medicine, University of Miami, Miami, 
      Florida.
AD  - Sylvester Comprehensive Cancer Center, Miami, Florida.
FAU - Chery, Maurice J
AU  - Chery MJ
AD  - Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and 
      Reproductive Sciences, Miller School of Medicine, University of Miami, Miami, 
      Florida.
AD  - Sylvester Comprehensive Cancer Center, Miami, Florida.
AD  - Division of Prevention Science, Department of Public Health Sciences, Miller 
      School of Medicine, University of Miami, Miami, Florida.
FAU - Barreto-Coehlo, Priscilla
AU  - Barreto-Coehlo P
AD  - Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and 
      Reproductive Sciences, Miller School of Medicine, University of Miami, Miami, 
      Florida.
AD  - Division of Medical Oncology, Department of Medicine, Miller School of Medicine, 
      University of Miami, Miami, Florida.
FAU - Alexis, Cheryl
AU  - Alexis C
AD  - University of the West Indies-Cave Hill, Bridgetown, Barbados.
FAU - Ali, Jameel
AU  - Ali J
AD  - St James Medical Complex, North Northwest Regional Health Authority, 
      Port-of-Spain, Trinidad and Tobago.
FAU - Diaz-Barbe, Alexandra
AU  - Diaz-Barbe A
AD  - Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and 
      Reproductive Sciences, Miller School of Medicine, University of Miami, Miami, 
      Florida.
AD  - Sylvester Comprehensive Cancer Center, Miami, Florida.
FAU - Butler, Raleigh
AU  - Butler R
AD  - Department of Obstetrics and Gynecology, School of Clinical Medicine and 
      Research, Princess Margaret Hospital, University of the West Indies, Nassau, The 
      Bahamas.
FAU - Bowe, Saida
AU  - Bowe S
AD  - Department of Obstetrics and Gynecology, School of Clinical Medicine and 
      Research, Princess Margaret Hospital, University of the West Indies, Nassau, The 
      Bahamas.
FAU - Curling, DuVaughn
AU  - Curling D
AD  - Department of Obstetrics and Gynecology, School of Clinical Medicine and 
      Research, Princess Margaret Hospital, University of the West Indies, Nassau, The 
      Bahamas.
FAU - DeGennaro, Vincent
AU  - DeGennaro V
AD  - Innovating Health International, Port au Prince, Haiti.
FAU - Dodds, Leah V
AU  - Dodds LV
AD  - Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and 
      Reproductive Sciences, Miller School of Medicine, University of Miami, Miami, 
      Florida.
AD  - Sylvester Comprehensive Cancer Center, Miami, Florida.
AD  - Division of Prevention Science, Department of Public Health Sciences, Miller 
      School of Medicine, University of Miami, Miami, Florida.
FAU - Dyer, Hedda
AU  - Dyer H
AD  - Ross University School of Medicine, St Michael, Barbados.
FAU - Halliday, Darron
AU  - Halliday D
AD  - Department of Obstetrics and Gynecology, School of Clinical Medicine and 
      Research, Princess Margaret Hospital, University of the West Indies, Nassau, The 
      Bahamas.
FAU - Jeudin, Patricia
AU  - Jeudin P
AD  - Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and 
      Reproductive Sciences, Miller School of Medicine, University of Miami, Miami, 
      Florida.
AD  - Sylvester Comprehensive Cancer Center, Miami, Florida.
FAU - Lowe, Dwight
AU  - Lowe D
AD  - University of the West Indies-Mona, Kingston, Jamaica.
FAU - Samaroo, Kristy
AU  - Samaroo K
AD  - St James Medical Complex, North Northwest Regional Health Authority, 
      Port-of-Spain, Trinidad and Tobago.
FAU - Wharfe, Gillian
AU  - Wharfe G
AD  - University of the West Indies-Mona, Kingston, Jamaica.
AD  - Cayman Islands Cancer Society, Grand Cayman, Cayman Islands.
FAU - Schlumbrecht, Matthew
AU  - Schlumbrecht M
AD  - Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and 
      Reproductive Sciences, Miller School of Medicine, University of Miami, Miami, 
      Florida.
AD  - Sylvester Comprehensive Cancer Center, Miami, Florida.
FAU - Reis, Isildinha M
AU  - Reis IM
AD  - Sylvester Comprehensive Cancer Center, Miami, Florida.
AD  - Division of Statistics, Department of Public Health Sciences, Miller School of 
      Medicine, University of Miami, Miami, Florida.
FAU - Hurley, Judith
AU  - Hurley J
AD  - Sylvester Comprehensive Cancer Center, Miami, Florida.
AD  - Division of Medical Oncology, Department of Medicine, Miller School of Medicine, 
      University of Miami, Miami, Florida.
FAU - George, Sophia
AU  - George S
AD  - Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and 
      Reproductive Sciences, Miller School of Medicine, University of Miami, Miami, 
      Florida.
AD  - Sylvester Comprehensive Cancer Center, Miami, Florida.
LA  - eng
GR  - L60 MD014321/MD/NIMHD NIH HHS/United States
GR  - P30 CA240139/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Observational Study
DEP - 20241001
PL  - United States
TA  - JAMA Netw Open
JT  - JAMA network open
JID - 101729235
SB  - IM
MH  - Humans
MH  - Female
MH  - *Breast Neoplasms/epidemiology
MH  - Cross-Sectional Studies
MH  - Middle Aged
MH  - Risk Factors
MH  - Caribbean Region/epidemiology
MH  - Adult
MH  - Aged
MH  - Reproductive History
MH  - Age Factors
MH  - Pregnancy
PMC - PMC11581535
COIS- Conflict of Interest Disclosures: Ms Dodds reported receiving grants from the 
      National Institutes of Health (NIH) National Heart, Lung, and Blood Institute 
      outside the submitted work. Dr George reported receiving grants from Pfizer, 
      Advenchen, Akoya, and GSK during the conduct of the study. No other disclosures 
      were reported.
EDAT- 2024/10/08 12:23
MHDA- 2024/10/08 12:24
PMCR- 2024/10/08
CRDT- 2024/10/08 11:33
PHST- 2024/10/08 12:24 [medline]
PHST- 2024/10/08 12:23 [pubmed]
PHST- 2024/10/08 11:33 [entrez]
PHST- 2024/10/08 00:00 [pmc-release]
AID - 2824546 [pii]
AID - zoi241101 [pii]
AID - 10.1001/jamanetworkopen.2024.38091 [doi]
PST - epublish
SO  - JAMA Netw Open. 2024 Oct 1;7(10):e2438091. doi: 
      10.1001/jamanetworkopen.2024.38091.

PMID- 35359633
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220402
IS  - 1664-2295 (Print)
IS  - 1664-2295 (Electronic)
IS  - 1664-2295 (Linking)
VI  - 13
DP  - 2022
TI  - Effect of Seasonal Variation on Relapse Rate in Patients With Relapsing-Remitting 
      Multiple Sclerosis in Saudi Arabia.
PG  - 862120
LID - 10.3389/fneur.2022.862120 [doi]
LID - 862120
AB  - Multiple sclerosis (MS) is becoming a global subject of study in which some 
      demographic variations are thought to be correlated with its activity. 
      Relapsing-remitting multiple sclerosis (RRMS) is the most common demyelinating 
      disorder, characterized by periods of exacerbating attacks, followed by partial 
      or complete remission. Several factors might play a role in disease progression 
      and relapse frequency, such as vitamin D, ultraviolet B radiation, estrogen 
      levels, smoking, obesity, and unhealthy lifestyles. In this study, we identified 
      the relationship between seasonal variation and relapse rate and correlated the 
      latter with sex, age, and vitamin D levels in patients with RRMS in Jeddah, Saudi 
      Arabia. We retrospectively collected data from 182 RRMS patients between 2016 and 
      2021. A total of 219 relapses were documented in 106 patients (58.2 %). The 
      relapse per patient ratio showed a sinusoidal pattern, peaking in January at a 
      rate of 0.49 and troughed in June at a rate of 0.18. There was no difference in 
      relapse rates between men and women (p =0.280). There was a significant negative 
      correlation between vitamin D levels and relapse rate (r = -0.312, p =0.024). 
      Therefore, the relapse rate was higher during the winter and was correlated with 
      low vitamin D levels. However, relapses are likely multifactorial, and more 
      population-based studies are needed to understand the role of environmental 
      variables in MS exacerbation. A better understanding of this relationship will 
      allow for improved treatment and possibly better prevention of relapse.
CI  - Copyright © 2022 Makkawi, Aljabri, Bin Lajdam, Albakistani, Aljohani, Labban and 
      Felemban.
FAU - Makkawi, Seraj
AU  - Makkawi S
AD  - College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, 
      Jeddah, Saudi Arabia.
AD  - King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.
AD  - Department of Medicine, Ministry of the National Guard-Health Affairs, Jeddah, 
      Saudi Arabia.
FAU - Aljabri, Ammar
AU  - Aljabri A
AD  - College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, 
      Jeddah, Saudi Arabia.
AD  - King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.
FAU - Bin Lajdam, Ghassan
AU  - Bin Lajdam G
AD  - College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, 
      Jeddah, Saudi Arabia.
AD  - King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.
FAU - Albakistani, Ammar
AU  - Albakistani A
AD  - College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, 
      Jeddah, Saudi Arabia.
AD  - King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.
FAU - Aljohani, Abdulrahman
AU  - Aljohani A
AD  - College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, 
      Jeddah, Saudi Arabia.
AD  - King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.
FAU - Labban, Suhail
AU  - Labban S
AD  - College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, 
      Jeddah, Saudi Arabia.
AD  - King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.
FAU - Felemban, Razaz
AU  - Felemban R
AD  - College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, 
      Jeddah, Saudi Arabia.
AD  - King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.
LA  - eng
PT  - Journal Article
DEP - 20220314
PL  - Switzerland
TA  - Front Neurol
JT  - Frontiers in neurology
JID - 101546899
PMC - PMC8964008
OTO - NOTNLM
OT  - multiple sclerosis
OT  - neuroinflammation
OT  - relapse
OT  - seasonal variation
OT  - vitamin D
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/04/02 06:00
MHDA- 2022/04/02 06:01
PMCR- 2022/03/14
CRDT- 2022/04/01 05:11
PHST- 2022/01/25 00:00 [received]
PHST- 2022/02/14 00:00 [accepted]
PHST- 2022/04/01 05:11 [entrez]
PHST- 2022/04/02 06:00 [pubmed]
PHST- 2022/04/02 06:01 [medline]
PHST- 2022/03/14 00:00 [pmc-release]
AID - 10.3389/fneur.2022.862120 [doi]
PST - epublish
SO  - Front Neurol. 2022 Mar 14;13:862120. doi: 10.3389/fneur.2022.862120. eCollection 
      2022.

PMID- 37062485
OWN - NLM
STAT- MEDLINE
DCOM- 20230607
LR  - 20230611
IS  - 1541-6100 (Electronic)
IS  - 0022-3166 (Linking)
VI  - 153
IP  - 6
DP  - 2023 Jun
TI  - Time-Restricted Feeding Ameliorates Uterine Epithelial Estrogen Receptor α 
      Transcriptional Activity at the Time of Embryo Implantation in Mice Fed a 
      High-Fat Diet.
PG  - 1753-1761
LID - S0022-3166(23)37555-2 [pii]
LID - 10.1016/j.tjnut.2023.04.012 [doi]
AB  - BACKGROUND: More than 30% of reproductive-age women are obese or overweight. 
      Obesity and exposure to a high-fat diet (HFD) detrimentally affect endometrial 
      development and embryo implantation. We previously reported that time-restricted 
      feeding (TRF) improved ovarian follicular development, but whether and how TRF 
      modulates embryo implantation are poorly understood. OBJECTIVE: We investigated 
      the effect of TRF on embryo implantation. METHODS: In TRF group, mice had 10 h of 
      food free access from 9 pm to 7 am, and fed a normal diet or a HFD. Tail vein 
      injection of Chicago blue dye was used to examine embryo implantation sites at 
      day 5.5 (D5.5) of pregnancy. Serum collected at D0.5 and D4.5 of pregnancy was 
      used to examine the level of estradiol (E2) and progesterone. Uterine estrogen 
      receptor (ER) and progesterone receptor levels and their targeted aquaporins 
      (AQPs) were measured. LC-MS was used to analyze bile acid (BA) composition, and 
      primary hepatocytes were used to test the effects of BA on the expression level 
      of SULT1E1, a key enzyme in estrogen inactivation and elimination. RESULTS: We 
      found that TRF prevented HFD-induced embryo loss and alleviated the defect in 
      luminal closure on D4.5 of pregnancy. The cyclic changes of E2 level were lost in 
      mice fed ad libitum but not in TRF mice on the HFD. The HFD increased ER-α 
      expression and transcriptional activity, which induced AQP3 and AQP5 expression 
      on D4.5 of pregnancy. TRF prevented the negative effect of the HFD on uterine 
      luminal closure. Furthermore, in vitro and in vivo results showed that BA 
      suppressed estrogen degradation by activating liver SULT1E1 expression. 
      CONCLUSIONS: Our findings demonstrated that TRF prevented HFD-induced defects in 
      luminal closure, thereby improving embryonic implantation, and provide novel 
      insights into the effects of dietary intervention on obesity and associated 
      infertility.
CI  - Copyright © 2023 American Society for Nutrition. Published by Elsevier Inc. All 
      rights reserved.
FAU - Liu, Luting
AU  - Liu L
AD  - Animal Nutrition Institute, Chengdu, PR China; Key Laboratory for Animal 
      Disease-Resistant Nutrition of the Ministry of Education of China, Chengdu, PR 
      China; Key Laboratory of Animal Disease-Resistant Nutrition of Sichuan Province, 
      Sichuan Agricultural University, Chengdu, PR China.
FAU - Zhuo, Yong
AU  - Zhuo Y
AD  - Animal Nutrition Institute, Chengdu, PR China; Key Laboratory for Animal 
      Disease-Resistant Nutrition of the Ministry of Education of China, Chengdu, PR 
      China; Key Laboratory of Animal Disease-Resistant Nutrition of Sichuan Province, 
      Sichuan Agricultural University, Chengdu, PR China.
FAU - Zhang, Haoqi
AU  - Zhang H
AD  - Animal Nutrition Institute, Chengdu, PR China; Key Laboratory for Animal 
      Disease-Resistant Nutrition of the Ministry of Education of China, Chengdu, PR 
      China; Key Laboratory of Animal Disease-Resistant Nutrition of Sichuan Province, 
      Sichuan Agricultural University, Chengdu, PR China.
FAU - Li, Jing
AU  - Li J
AD  - Animal Nutrition Institute, Chengdu, PR China; Key Laboratory for Animal 
      Disease-Resistant Nutrition of the Ministry of Education of China, Chengdu, PR 
      China; Key Laboratory of Animal Disease-Resistant Nutrition of Sichuan Province, 
      Sichuan Agricultural University, Chengdu, PR China.
FAU - Jiang, Xuemei
AU  - Jiang X
AD  - Animal Nutrition Institute, Chengdu, PR China; Key Laboratory for Animal 
      Disease-Resistant Nutrition of the Ministry of Education of China, Chengdu, PR 
      China; Key Laboratory of Animal Disease-Resistant Nutrition of Sichuan Province, 
      Sichuan Agricultural University, Chengdu, PR China.
FAU - Han, Xingfa
AU  - Han X
AD  - School of Life Sciences, Sichuan Agricultural University, Chengdu, PR China.
FAU - Chao, Jin
AU  - Chao J
AD  - Animal Nutrition Institute, Chengdu, PR China; Key Laboratory for Animal 
      Disease-Resistant Nutrition of the Ministry of Education of China, Chengdu, PR 
      China; Key Laboratory of Animal Disease-Resistant Nutrition of Sichuan Province, 
      Sichuan Agricultural University, Chengdu, PR China.
FAU - Feng, Bin
AU  - Feng B
AD  - Animal Nutrition Institute, Chengdu, PR China; Key Laboratory for Animal 
      Disease-Resistant Nutrition of the Ministry of Education of China, Chengdu, PR 
      China; Key Laboratory of Animal Disease-Resistant Nutrition of Sichuan Province, 
      Sichuan Agricultural University, Chengdu, PR China.
FAU - Che, Lianqiang
AU  - Che L
AD  - Animal Nutrition Institute, Chengdu, PR China; Key Laboratory for Animal 
      Disease-Resistant Nutrition of the Ministry of Education of China, Chengdu, PR 
      China; Key Laboratory of Animal Disease-Resistant Nutrition of Sichuan Province, 
      Sichuan Agricultural University, Chengdu, PR China.
FAU - Xu, Shengyu
AU  - Xu S
AD  - Animal Nutrition Institute, Chengdu, PR China; Key Laboratory for Animal 
      Disease-Resistant Nutrition of the Ministry of Education of China, Chengdu, PR 
      China; Key Laboratory of Animal Disease-Resistant Nutrition of Sichuan Province, 
      Sichuan Agricultural University, Chengdu, PR China.
FAU - Lin, Yan
AU  - Lin Y
AD  - Animal Nutrition Institute, Chengdu, PR China; Key Laboratory for Animal 
      Disease-Resistant Nutrition of the Ministry of Education of China, Chengdu, PR 
      China; Key Laboratory of Animal Disease-Resistant Nutrition of Sichuan Province, 
      Sichuan Agricultural University, Chengdu, PR China.
FAU - Li, Jian
AU  - Li J
AD  - Animal Nutrition Institute, Chengdu, PR China; Key Laboratory for Animal 
      Disease-Resistant Nutrition of the Ministry of Education of China, Chengdu, PR 
      China; Key Laboratory of Animal Disease-Resistant Nutrition of Sichuan Province, 
      Sichuan Agricultural University, Chengdu, PR China.
FAU - Fang, Zhengfeng
AU  - Fang Z
AD  - Animal Nutrition Institute, Chengdu, PR China; Key Laboratory for Animal 
      Disease-Resistant Nutrition of the Ministry of Education of China, Chengdu, PR 
      China; Key Laboratory of Animal Disease-Resistant Nutrition of Sichuan Province, 
      Sichuan Agricultural University, Chengdu, PR China.
FAU - Sun, Mengmeng
AU  - Sun M
AD  - College of Science, Sichuan Agricultural University, Xin Kang Road, Yucheng 
      District, Ya'an, PR China.
FAU - Luo, Ting
AU  - Luo T
AD  - State Key Laboratory of Food Science and Technology, Nanchang University, 
      Nanchang, Jiangxi, PR China.
FAU - Wu, De
AU  - Wu D
AD  - Animal Nutrition Institute, Chengdu, PR China; Key Laboratory for Animal 
      Disease-Resistant Nutrition of the Ministry of Education of China, Chengdu, PR 
      China; Key Laboratory of Animal Disease-Resistant Nutrition of Sichuan Province, 
      Sichuan Agricultural University, Chengdu, PR China. Electronic address: 
      wude@sicau.edu.cn.
FAU - Hua, Lun
AU  - Hua L
AD  - Animal Nutrition Institute, Chengdu, PR China; Key Laboratory for Animal 
      Disease-Resistant Nutrition of the Ministry of Education of China, Chengdu, PR 
      China; Key Laboratory of Animal Disease-Resistant Nutrition of Sichuan Province, 
      Sichuan Agricultural University, Chengdu, PR China. Electronic address: 
      hualun@sicau.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230414
PL  - United States
TA  - J Nutr
JT  - The Journal of nutrition
JID - 0404243
RN  - 0 (Estrogen Receptor alpha)
RN  - 0 (Estrogens)
SB  - IM
MH  - Pregnancy
MH  - Mice
MH  - Female
MH  - Animals
MH  - *Estrogen Receptor alpha/genetics
MH  - *Diet, High-Fat
MH  - Obesity
MH  - Embryo Implantation/physiology
MH  - Estrogens
MH  - Mice, Inbred C57BL
OTO - NOTNLM
OT  - SULT1E1
OT  - bile acid
OT  - implantation
OT  - luminal closure
OT  - time-restricted feeding (TRF)
EDAT- 2023/04/17 06:00
MHDA- 2023/06/07 06:42
CRDT- 2023/04/16 19:25
PHST- 2023/02/17 00:00 [received]
PHST- 2023/04/06 00:00 [revised]
PHST- 2023/04/12 00:00 [accepted]
PHST- 2023/06/07 06:42 [medline]
PHST- 2023/04/17 06:00 [pubmed]
PHST- 2023/04/16 19:25 [entrez]
AID - S0022-3166(23)37555-2 [pii]
AID - 10.1016/j.tjnut.2023.04.012 [doi]
PST - ppublish
SO  - J Nutr. 2023 Jun;153(6):1753-1761. doi: 10.1016/j.tjnut.2023.04.012. Epub 2023 
      Apr 14.

PMID- 34266369
OWN - NLM
STAT- MEDLINE
DCOM- 20220201
LR  - 20220201
IS  - 1944-0057 (Electronic)
IS  - 1944-0057 (Linking)
VI  - 38
IP  - 11
DP  - 2021 Nov
TI  - Depletion of clomiphene residues in eggs and muscle after oral administration to 
      laying hens.
PG  - 1875-1882
LID - 10.1080/19440049.2021.1949497 [doi]
AB  - The selective oestrogen receptor modulator (SERM) clomiphene is therapeutically 
      used to induce ovulation. While prohibited as a doping agent in sports, it is 
      frequently detected in sports drug testing urine samples. Few reports exist on 
      clomiphene's (illicit) use in the farming industry to increase the egg production 
      rate of laying hens, which creates a risk that eggs as well as edible tissue of 
      these hens contain residues of clomiphene. To investigate the potential transfer 
      of clomiphene into eggs and muscle tissue, laying hens were orally administered 
      with clomiphene citrate at 10 mg/day for 28 days. To determine clomiphene 
      residues in eggs, chicken breast and chicken thigh, the target analyte was 
      extracted from homogenised material with acetonitrile and subjected to ultra-high 
      performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) 
      analysis. The test method reached a limit of quantification (LOQ) of 1 µg/kg and 
      was characterised concerning specificity, precision, trueness and linearity. 
      Analyses were performed on whole egg, egg white and yolk separately, and chicken 
      muscle from breast and thigh. Clomiphene was detectable in eggs two days after 
      the beginning of the drug administration period. The drug concentrations 
      increased to 10-20 µg per egg within one week, and after withdrawal of 
      clomiphene, residues decreased after 4 days, but traces of clomiphene were still 
      detectable until the end of the study (14 days after the last administration). In 
      the chicken's muscle tissue, clomiphene levels up to 150 µg/kg (thigh) and 
      36 µg/kg (breast) were found. Six days after the last dose, tissue clomiphene 
      concentrations fell below the LOQ. Overall, these results underline the concerns 
      that clomiphene may be transferred into animal-derived food and future research 
      will therefore need to focus on assessing and minimising the risk of 
      unintentional adverse analytical findings in doping controls.
FAU - Seyerlein, Luisa
AU  - Seyerlein L
AD  - Institute of Biochemistry, Center for Preventive Doping Research, German Sport 
      University Cologne, Cologne, Germany.
FAU - Gillard, Nathalie
AU  - Gillard N
AD  - CER Groupe, Marloie, Belgium.
FAU - Delahaut, Philippe
AU  - Delahaut P
AD  - CER Groupe, Marloie, Belgium.
FAU - Pierret, Gilles
AU  - Pierret G
AD  - CER Groupe, Marloie, Belgium.
FAU - Thomas, Andreas
AU  - Thomas A
AD  - Institute of Biochemistry, Center for Preventive Doping Research, German Sport 
      University Cologne, Cologne, Germany.
FAU - Thevis, Mario
AU  - Thevis M
AUID- ORCID: 0000-0002-1535-6451
AD  - Institute of Biochemistry, Center for Preventive Doping Research, German Sport 
      University Cologne, Cologne, Germany.
AD  - European Monitoring Center for Emerging Doping Agents (EuMoCEDA), Cologne/Bonn, 
      Germany.
LA  - eng
PT  - Journal Article
DEP - 20210715
PL  - England
TA  - Food Addit Contam Part A Chem Anal Control Expo Risk Assess
JT  - Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & 
      risk assessment
JID - 101485040
RN  - 0 (Estrogen Antagonists)
RN  - 1HRS458QU2 (Clomiphene)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Chickens
MH  - Clomiphene/chemistry/metabolism/*pharmacokinetics
MH  - Drug Residues/*chemistry
MH  - Eggs/*analysis
MH  - Estrogen Antagonists/chemistry/*pharmacokinetics
MH  - Female
MH  - Food Contamination
MH  - Meat/*analysis
MH  - Muscle, Skeletal/*chemistry
MH  - Oviposition
OTO - NOTNLM
OT  - HPLC-MS/MS
OT  - SERMs
OT  - clomiphene
OT  - doping
OT  - eggs
OT  - residues
EDAT- 2021/07/17 06:00
MHDA- 2022/02/02 06:00
CRDT- 2021/07/16 05:32
PHST- 2021/07/17 06:00 [pubmed]
PHST- 2022/02/02 06:00 [medline]
PHST- 2021/07/16 05:32 [entrez]
AID - 10.1080/19440049.2021.1949497 [doi]
PST - ppublish
SO  - Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2021 
      Nov;38(11):1875-1882. doi: 10.1080/19440049.2021.1949497. Epub 2021 Jul 15.

PMID- 34433458
OWN - NLM
STAT- MEDLINE
DCOM- 20210927
LR  - 20250103
IS  - 1476-069X (Electronic)
IS  - 1476-069X (Linking)
VI  - 20
IP  - 1
DP  - 2021 Aug 25
TI  - Human-Biomonitoring derived exposure and Daily Intakes of Bisphenol A and their 
      associations with neurodevelopmental outcomes among children of the Polish Mother 
      and Child Cohort Study.
PG  - 95
LID - 10.1186/s12940-021-00777-0 [doi]
LID - 95
AB  - BACKGROUND: Bisphenol A (BPA) is an industrial chemical mostly used in the 
      manufacture of plastics, resins and thermal paper. Several studies have reported 
      adverse health effects with BPA exposures, namely metabolic disorders and altered 
      neurodevelopment in children, among others. The aim of this study was to explore 
      BPA exposure, its socio-demographic and life-style related determinants, and its 
      association with neurodevelopmental outcomes in early school age children from 
      Poland. METHODS: A total of 250 urine samples of 7 year-old children from the 
      Polish Mother and Child Cohort Study (REPRO_PL) were analyzed for BPA 
      concentrations using high performance liquid chromatography with online sample 
      clean-up coupled to tandem mass spectrometry (online-SPE-LC-MS/MS). 
      Socio-demographic and lifestyle-related data was collected by questionnaires or 
      additional biomarker measurements. Emotional and behavioral symptoms in children 
      were assessed using mother-reported Strengths and Difficulties Questionnaire 
      (SDQ). Cognitive and psychomotor development was evaluated by Polish adaptation 
      of the Intelligence and Development Scales (IDS) performed by trained 
      psychologists. RESULTS: Urinary BPA concentrations and back-calculated daily 
      intakes (medians of 1.8 μg/l and 46.3 ng/kg bw/day, respectively) were similar to 
      other European studies. Urinary cotinine levels and body mass index, together 
      with maternal educational level and socio-economic status, were the main 
      determinants of BPA levels in Polish children. After adjusting for confounding 
      factors, BPA has been found to be positively associated with emotional symptoms 
      (β: 0.14, 95% CI: 0.022; 0.27). Cognitive and psychomotor development were not 
      found to be related to BPA levels. CONCLUSIONS: This study represents the first 
      report of BPA levels and their determinants in school age children in Poland. The 
      exposure level was found to be related to child emotional condition, which can 
      have long-term consequences including social functioning and scholastic 
      achievements. Further monitoring of this population in terms of overall chemical 
      exposure is required.
CI  - © 2021. The Author(s).
FAU - Garí, Mercè
AU  - Garí M
AUID- ORCID: 0000-0001-6903-0732
AD  - Institute and Clinic for Occupational, Social and Environmental Medicine, 
      University Hospital, LMU Munich. Institute of Computational Biology, Helmholtz 
      Zentrum München, Munich, Germany. merce.gari@helmholtz-muenchen.de.
FAU - Moos, Rebecca
AU  - Moos R
AD  - Institute for Prevention and Occupational Medicine of the German Social Accident 
      Insurance, Institute of the Ruhr-University Bochum (IPA), Bochum, Germany.
FAU - Bury, Daniel
AU  - Bury D
AD  - Institute for Prevention and Occupational Medicine of the German Social Accident 
      Insurance, Institute of the Ruhr-University Bochum (IPA), Bochum, Germany.
FAU - Kasper-Sonnenberg, Monika
AU  - Kasper-Sonnenberg M
AD  - Institute for Prevention and Occupational Medicine of the German Social Accident 
      Insurance, Institute of the Ruhr-University Bochum (IPA), Bochum, Germany.
FAU - Jankowska, Agnieszka
AU  - Jankowska A
AD  - Department of Environmental and Occupational Health Hazards, Nofer Institute of 
      Occupational Medicine (NIOM), Lodz, Poland.
FAU - Andysz, Aleksandra
AU  - Andysz A
AD  - Department of Health and Work Psychology, Nofer Institute of Occupational 
      Medicine (NIOM), Lodz, Poland.
FAU - Hanke, Wojciech
AU  - Hanke W
AD  - Department of Environmental Epidemiology, Nofer Institute of Occupational 
      Medicine (NIOM), Lodz, Poland.
FAU - Nowak, Dennis
AU  - Nowak D
AD  - Institute and Clinic for Occupational, Social and Environmental Medicine, 
      University Hospital, LMU Munich, Munich, Germany.
FAU - Bose-O'Reilly, Stephan
AU  - Bose-O'Reilly S
AD  - Institute and Clinic for Occupational, Social and Environmental Medicine, 
      University Hospital, LMU Munich, Munich, Germany.
FAU - Koch, Holger M
AU  - Koch HM
AD  - Institute for Prevention and Occupational Medicine of the German Social Accident 
      Insurance, Institute of the Ruhr-University Bochum (IPA), Bochum, Germany.
FAU - Polanska, Kinga
AU  - Polanska K
AD  - Department of Environmental and Occupational Health Hazards, Nofer Institute of 
      Occupational Medicine (NIOM), Lodz, Poland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210825
PL  - England
TA  - Environ Health
JT  - Environmental health : a global access science source
JID - 101147645
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Endocrine Disruptors)
RN  - 0 (Environmental Pollutants)
RN  - 0 (Phenols)
RN  - 0 (Tobacco Smoke Pollution)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
EIN - Environ Health. 2023 Mar 13;22(1):24. doi: 10.1186/s12940-023-00977-w. PMID: 
      36927715
MH  - Adult
MH  - Benzhydryl Compounds/*urine
MH  - Biological Monitoring
MH  - Body Weight
MH  - Child
MH  - Cohort Studies
MH  - Emotions
MH  - Endocrine Disruptors/*urine
MH  - Environmental Pollutants/*urine
MH  - Female
MH  - Humans
MH  - Infant
MH  - Life Style
MH  - Male
MH  - Maternal-Fetal Exchange
MH  - Mothers
MH  - Neurodevelopmental Disorders/*epidemiology
MH  - Phenols/*urine
MH  - Poland/epidemiology
MH  - Pregnancy
MH  - Social Class
MH  - Surveys and Questionnaires
MH  - Tobacco Smoke Pollution
PMC - PMC8390261
OTO - NOTNLM
OT  - Birth cohort
OT  - Bisphenol A
OT  - Children
OT  - Daily Intake
OT  - Neurodevelopment
OT  - Poland
COIS- The authors declare that they have no competing interests.
EDAT- 2021/08/27 06:00
MHDA- 2021/09/28 06:00
PMCR- 2021/08/25
CRDT- 2021/08/26 05:31
PHST- 2020/10/26 00:00 [received]
PHST- 2021/07/29 00:00 [accepted]
PHST- 2021/08/26 05:31 [entrez]
PHST- 2021/08/27 06:00 [pubmed]
PHST- 2021/09/28 06:00 [medline]
PHST- 2021/08/25 00:00 [pmc-release]
AID - 10.1186/s12940-021-00777-0 [pii]
AID - 777 [pii]
AID - 10.1186/s12940-021-00777-0 [doi]
PST - epublish
SO  - Environ Health. 2021 Aug 25;20(1):95. doi: 10.1186/s12940-021-00777-0.

PMID- 28737831
OWN - NLM
STAT- MEDLINE
DCOM- 20180423
LR  - 20180423
IS  - 1791-2431 (Electronic)
IS  - 1021-335X (Linking)
VI  - 38
IP  - 3
DP  - 2017 Sep
TI  - Royal jelly lipophilic fraction induces antiproliferative effects on SH-SY5Y 
      human neuroblastoma cells.
PG  - 1833-1844
LID - 10.3892/or.2017.5851 [doi]
AB  - Royal jelly (RJ) is one the most important bee product because it strongly 
      influences the larval development in the hive, including the queen bee. In 
      literature, RJ is known for its antioxidant, immunoregulatory, antifungal, 
      antibiotical, erythropoietic, hypoglycemic, anticholesteremic, antithyroidic, 
      anti-osteoporotic and estrogenic properties. However, it is surprising how rare 
      the scientific evidence about RJ antineoplastic capacity are. That being said, we 
      investigated, for the first time, the in vitro bioactivity of six different RJs 
      on the growth of three different mammalian cell lines: immortalized murine 
      myoblasts (C2C12), human prostate cancer (PC3) and human neuroblastoma (SH-SY5Y). 
      These studies were performed treating the cells with the only lipophilic, or 
      hydrophilic, fraction of the RJs, a scientific approach never performed before. 
      Moreover, chemical and protein profiles of all RJs were finely characterized, in 
      qualitative and quantitative terms, by GC-MS and 1D-SDS-PAGE, respectively, in 
      order to give a complete framework to the research. Despite the deep differences 
      we found in the composition of each sample, unexpectedly, RJs showed comparable 
      or very similar biological effects. In particular, our attention was captured by 
      the extraordinary antiproliferative activity of the lipophilic extract of all RJs 
      against SH-SY5Y cells, suggesting a potential medical application of this bee 
      product to prevent the onset and slow down the growth of human neuroblastoma.
FAU - Gismondi, Angelo
AU  - Gismondi A
AD  - Department of Biology, University of Rome 'Tor Vergata', I-00133 Rome, Italy.
FAU - Trionfera, Eleonora
AU  - Trionfera E
AD  - Department of Biology, University of Rome 'Tor Vergata', I-00133 Rome, Italy.
FAU - Canuti, Lorena
AU  - Canuti L
AD  - Department of Biology, University of Rome 'Tor Vergata', I-00133 Rome, Italy.
FAU - Di Marco, Gabriele
AU  - Di Marco G
AD  - Department of Biology, University of Rome 'Tor Vergata', I-00133 Rome, Italy.
FAU - Canini, Antonella
AU  - Canini A
AD  - Department of Biology, University of Rome 'Tor Vergata', I-00133 Rome, Italy.
LA  - eng
PT  - Journal Article
DEP - 20170724
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Fatty Acids)
RN  - L497I37F0C (royal jelly)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology
MH  - Cell Line
MH  - Cell Line, Tumor
MH  - Cell Proliferation/*drug effects
MH  - Fatty Acids/*pharmacology
MH  - Humans
MH  - Mice
MH  - Neuroblastoma/*drug therapy
EDAT- 2017/07/25 06:00
MHDA- 2018/04/24 06:00
CRDT- 2017/07/25 06:00
PHST- 2017/02/07 00:00 [received]
PHST- 2017/06/26 00:00 [accepted]
PHST- 2017/07/25 06:00 [pubmed]
PHST- 2018/04/24 06:00 [medline]
PHST- 2017/07/25 06:00 [entrez]
AID - 10.3892/or.2017.5851 [doi]
PST - ppublish
SO  - Oncol Rep. 2017 Sep;38(3):1833-1844. doi: 10.3892/or.2017.5851. Epub 2017 Jul 24.

PMID- 35359845
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220402
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - Hypericum lanceolatum Lam. Medicinal Plant: Potential Toxicity and Therapeutic 
      Effects Based on a Zebrafish Model.
PG  - 832928
LID - 10.3389/fphar.2022.832928 [doi]
LID - 832928
AB  - Hypericum lanceolatum Lam. (H. lanceolatum) is a traditional medicinal plant from 
      Reunion Island used for its pleiotropic effects mainly related to its antioxidant 
      activity. The present work aimed to 1) determine the potential toxicity of the 
      plant aqueous extract in vivo and 2) investigate its putative biological 
      properties using several zebrafish models of oxidative stress, regeneration, 
      estrogenicity, neurogenesis and metabolic disorders. First, we characterized the 
      polyphenolic composition by liquid chromatography-tandem mass spectrometry 
      (LC-MS/MS) and identified chlorogenic acid isomers, quercetin and kaempferol 
      derivatives as the major compounds. We then evaluated for the first time the 
      toxicity of an aqueous extract of H. lanceolatum and determined a maximum 
      non-toxic concentration (MNTC) in zebrafish eleutheroembryos from 0 to 96 hpf 
      following OECD (Organization for Economic Cooperation and Development) 
      guidelines. This MNTC test was also determined on hatched eleutheroembryos after 
      2 days of treatment (from 3 to 5 dpf). In our study, the anti-estrogenic effects 
      of H. lanceolatum are supported by the data from the EASZY assay. In a tail 
      amputation model, we showed that H. lanceolatum at its MNTC displays antioxidant 
      properties, favors immune cell recruitment and tissue regeneration. Our results 
      also highlighted its beneficial effects in metabolic disorders. Indeed, H. 
      lanceolatum efficiently reduces lipid accumulation and body mass index in overfed 
      larva- and adult-models, respectively. In addition, we show that H. lanceolatum 
      did not improve fasting blood glucose levels in a hyperglycemic zebrafish model 
      but surprisingly inhibited neurogenesis impairment observed in diabetic 
      conditions. In conclusion, our study highlights the antioxidant, 
      pro-regenerative, anti-lipid accumulation and pro-neurogenic effects of H. 
      lanceolatum in vivo and supports the use of this traditional medicinal plant as a 
      potential alternative in the prevention and/or treatment of metabolic disorders.
CI  - Copyright © 2022 Gence, Fernezelian, Bringart, Veeren, Christophe, Brion, 
      Meilhac, Bascands and Diotel.
FAU - Gence, Laura
AU  - Gence L
AD  - Université de La Réunion, INSERM, Diabéte athérothrombose Thérapies Réunion Océan 
      Indien (DéTROI), Saint-Denis de La Réunion, France.
FAU - Fernezelian, Danielle
AU  - Fernezelian D
AD  - Université de La Réunion, INSERM, Diabéte athérothrombose Thérapies Réunion Océan 
      Indien (DéTROI), Saint-Denis de La Réunion, France.
FAU - Bringart, Matthieu
AU  - Bringart M
AD  - Université de La Réunion, INSERM, Diabéte athérothrombose Thérapies Réunion Océan 
      Indien (DéTROI), Saint-Denis de La Réunion, France.
FAU - Veeren, Bryan
AU  - Veeren B
AD  - Université de La Réunion, INSERM, Diabéte athérothrombose Thérapies Réunion Océan 
      Indien (DéTROI), Saint-Denis de La Réunion, France.
FAU - Christophe, Armelle
AU  - Christophe A
AD  - Unité D'Écotoxicologie des Substances et des Milieux (ESMI), Institut National de 
      L'Environnement Industriel et des Risques (INERIS), Verneuil-en-Halatte, France.
FAU - Brion, François
AU  - Brion F
AD  - Unité D'Écotoxicologie des Substances et des Milieux (ESMI), Institut National de 
      L'Environnement Industriel et des Risques (INERIS), Verneuil-en-Halatte, France.
FAU - Meilhac, Olivier
AU  - Meilhac O
AD  - Université de La Réunion, INSERM, Diabéte athérothrombose Thérapies Réunion Océan 
      Indien (DéTROI), Saint-Denis de La Réunion, France.
AD  - CHU de La Réunion, Saint-Denis, France.
FAU - Bascands, Jean-Loup
AU  - Bascands JL
AD  - Université de La Réunion, INSERM, Diabéte athérothrombose Thérapies Réunion Océan 
      Indien (DéTROI), Saint-Denis de La Réunion, France.
FAU - Diotel, Nicolas
AU  - Diotel N
AD  - Université de La Réunion, INSERM, Diabéte athérothrombose Thérapies Réunion Océan 
      Indien (DéTROI), Saint-Denis de La Réunion, France.
LA  - eng
PT  - Journal Article
DEP - 20220311
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC8963451
OTO - NOTNLM
OT  - LC MS/MS
OT  - Toxicity
OT  - Zebrafish
OT  - diabetes
OT  - neurogenesis
OT  - obesity
OT  - regeneration
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/04/02 06:00
MHDA- 2022/04/02 06:01
PMCR- 2022/03/11
CRDT- 2022/04/01 05:14
PHST- 2021/12/10 00:00 [received]
PHST- 2022/02/04 00:00 [accepted]
PHST- 2022/04/01 05:14 [entrez]
PHST- 2022/04/02 06:00 [pubmed]
PHST- 2022/04/02 06:01 [medline]
PHST- 2022/03/11 00:00 [pmc-release]
AID - 832928 [pii]
AID - 10.3389/fphar.2022.832928 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Mar 11;13:832928. doi: 10.3389/fphar.2022.832928. 
      eCollection 2022.

PMID- 32632955
OWN - NLM
STAT- MEDLINE
DCOM- 20210226
LR  - 20231213
IS  - 1750-3841 (Electronic)
IS  - 0022-1147 (Linking)
VI  - 85
IP  - 8
DP  - 2020 Aug
TI  - Lipopolysaccharide neutralizing protein in Miso, Japanese fermented soybean 
      paste.
PG  - 2498-2505
LID - 10.1111/1750-3841.15315 [doi]
AB  - Miso, a fermented paste made from soybeans, is used traditionally for seasoning 
      of food. It has been a protein and nitrogen source since ancient times in Japan 
      because of its high nutritional value. Furthermore, it has important health 
      functions such as the estrogen-like activity of isoflavones, anti-oxidation, and 
      angiotensin-converting-enzyme inhibition activity. Moreover, it has activity for 
      neutralization of lipopolysaccharide (LPS) from Escherichia coli. Nevertheless, 
      the mechanisms of that activity remain unclear. For this study, we purified and 
      identified the proteins responsible for LPS-neutralization. After proteins were 
      isolated from a miso extract using Blue native polyacrylamide gel 
      electrophoresis, a protein found at 10 to 30 kDa on the polyacrylamide gel was 
      identified using nano LC-MS/MS as 2S albumin in soybean (Glycine max). The 
      protein had two LPS binding motifs: SKWQHQ (22 amino acid residues) and 
      EKQKKKMEKE (131 amino acid residues). The protein in miso was found to have LPS 
      neutralization activity, as assayed by prostaglandin D(2) (PGD(2) ) production 
      from macrophage cells. The PGD(2) production by macrophage cells was inhibited by 
      LPS-neutralizing protein (LNP) from miso. Particularly, 50 mg/mL of LNP solution 
      and LPS (10 µg/mL) inhibited production of PGD(2) from the cells. The data were 
      inferred as significantly different (P < 0.05) from statistical analyses by 
      analysis of variance testing and Tukey tests. The 2S albumin in soybean is LNP, 
      an LPS-neutralizing protein, produced in miso. PRACTICAL APPLICATION: A protein 
      from miso fermented soy paste neutralizes an Escherichia coli intestinal 
      bacterial product, lipopolysaccharide (LPS), which causes intestinal 
      inflammation. Miso and its protein are anticipated for use as a probiotic agent 
      to prevent intestinal inflammation in humans and domestic animals. Miso is useful 
      not only as a seasoning for food, but also as a health-functional food because it 
      is an LPS-neutralizing agent.
CI  - © 2020 Institute of Food Technologists®.
FAU - Sasaki, Hitomi
AU  - Sasaki H
AD  - School of Food, Agricultural and Environmental Sciences, Miyagi University, 2-2-1 
      Hatatate, Taihaku-ku, Sendai, Miyagi, Japan.
FAU - Pham Thi Ngoc, Diep
AU  - Pham Thi Ngoc D
AD  - School of Food, Agricultural and Environmental Sciences, Miyagi University, 2-2-1 
      Hatatate, Taihaku-ku, Sendai, Miyagi, Japan.
FAU - Nishikawa, Masazumi
AU  - Nishikawa M
AD  - School of Food, Agricultural and Environmental Sciences, Miyagi University, 2-2-1 
      Hatatate, Taihaku-ku, Sendai, Miyagi, Japan.
FAU - Kanauchi, Makoto
AU  - Kanauchi M
AD  - School of Food, Agricultural and Environmental Sciences, Miyagi University, 2-2-1 
      Hatatate, Taihaku-ku, Sendai, Miyagi, Japan.
LA  - eng
GR  - Kobayashi International Scholarship Foundation, Japan/
PT  - Journal Article
DEP - 20200706
PL  - United States
TA  - J Food Sci
JT  - Journal of food science
JID - 0014052
RN  - 0 (Isoflavones)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Soybean Proteins)
SB  - IM
MH  - Functional Food/analysis
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Isoflavones/analysis
MH  - Japan
MH  - Lipopolysaccharides/*analysis
MH  - Soy Foods/*analysis
MH  - Soybean Proteins/*analysis
MH  - Glycine max/*chemistry
MH  - Tandem Mass Spectrometry
OTO - NOTNLM
OT  - Escherichia coli
OT  - fermentation
OT  - lipopolysaccharide
OT  - protein
OT  - soybean
EDAT- 2020/07/08 06:00
MHDA- 2021/02/27 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/03/10 00:00 [received]
PHST- 2020/05/08 00:00 [revised]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2021/02/27 06:00 [medline]
PHST- 2020/07/08 06:00 [entrez]
AID - 10.1111/1750-3841.15315 [doi]
PST - ppublish
SO  - J Food Sci. 2020 Aug;85(8):2498-2505. doi: 10.1111/1750-3841.15315. Epub 2020 Jul 
      6.

PMID- 30655513
OWN - NLM
STAT- MEDLINE
DCOM- 20190219
LR  - 20231213
IS  - 2041-1723 (Electronic)
IS  - 2041-1723 (Linking)
VI  - 10
IP  - 1
DP  - 2019 Jan 17
TI  - Interferon lambda protects the female reproductive tract against Zika virus 
      infection.
PG  - 280
LID - 10.1038/s41467-018-07993-2 [doi]
LID - 280
AB  - Although Zika virus (ZIKV) can be transmitted sexually and cause congenital birth 
      defects, immune control mechanisms in the female reproductive tract (FRT) are not 
      well characterized. Here we show that treatment of primary human vaginal and 
      cervical epithelial cells with interferon (IFN)-α/β or IFN-λ induces host defense 
      transcriptional signatures and inhibits ZIKV infection. We also assess the 
      effects of IFNs on intravaginal infection of the FRT using ovariectomized mice 
      treated with reproductive hormones. We find that mice receiving estradiol are 
      protected against intravaginal ZIKV infection, independently of IFN-α/β or IFN-λ 
      signaling. In contrast, mice lacking IFN-λ signaling sustain greater FRT 
      infection when progesterone is administered. Exogenous IFN-λ treatment confers an 
      antiviral effect when mice receive both estradiol and progesterone, but not 
      progesterone alone. Our results identify a hormonal stage-dependent role for 
      IFN-λ in controlling ZIKV infection in the FRT and suggest a path for minimizing 
      sexual transmission of ZIKV in women.
FAU - Caine, Elizabeth A
AU  - Caine EA
AUID- ORCID: 0000-0002-7548-7330
AD  - Departments of Medicine, Washington University School of Medicine, Saint Louis, 
      MO, 63110, USA.
FAU - Scheaffer, Suzanne M
AU  - Scheaffer SM
AD  - Obstetrics and Gynecology, Washington University School of Medicine, Saint Louis, 
      MO, 63110, USA.
FAU - Arora, Nitin
AU  - Arora N
AD  - Departments of Pediatrics, University of Pittsburgh School of Medicine, 
      Pittsburgh, PA, 15224, USA.
AD  - The Center for Microbial Pathogenesis, Children's Hospital, University of 
      Pittsburgh School of Medicine, Pittsburgh, PA, 15224, USA.
AD  - Department of Pediatrics, The University of Alabama at Birmingham, Birmingham, 
      AL, 35233, USA.
FAU - Zaitsev, Konstantin
AU  - Zaitsev K
AUID- ORCID: 0000-0003-3749-0886
AD  - Department of Pathology and Immunology, Washington University School of Medicine, 
      Saint Louis, MO, 63110, USA.
AD  - Computer Technologies Department, ITMO University, St. Petersburg, 197101, 
      Russia.
FAU - Artyomov, Maxim N
AU  - Artyomov MN
AD  - Department of Pathology and Immunology, Washington University School of Medicine, 
      Saint Louis, MO, 63110, USA.
AD  - The Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy 
      Programs, Washington University School of Medicine, Saint Louis, MO, 63110, USA.
FAU - Coyne, Carolyn B
AU  - Coyne CB
AUID- ORCID: 0000-0002-1884-6309
AD  - Departments of Pediatrics, University of Pittsburgh School of Medicine, 
      Pittsburgh, PA, 15224, USA. coynec2@pitt.edu.
AD  - The Center for Microbial Pathogenesis, Children's Hospital, University of 
      Pittsburgh School of Medicine, Pittsburgh, PA, 15224, USA. coynec2@pitt.edu.
FAU - Moley, Kelle H
AU  - Moley KH
AD  - Obstetrics and Gynecology, Washington University School of Medicine, Saint Louis, 
      MO, 63110, USA. moleyk@wustl.edu.
AD  - Department of Cell Biology and Physiology, Washington University School of 
      Medicine, Saint Louis, MO, 63110, USA. moleyk@wustl.edu.
FAU - Diamond, Michael S
AU  - Diamond MS
AUID- ORCID: 0000-0002-8791-3165
AD  - Departments of Medicine, Washington University School of Medicine, Saint Louis, 
      MO, 63110, USA. diamond@wusm.wustl.edu.
AD  - Department of Pathology and Immunology, Washington University School of Medicine, 
      Saint Louis, MO, 63110, USA. diamond@wusm.wustl.edu.
AD  - The Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy 
      Programs, Washington University School of Medicine, Saint Louis, MO, 63110, USA. 
      diamond@wusm.wustl.edu.
AD  - Department of Molecular Microbiology, Washington University School of Medicine, 
      Saint Louis, MO, 63110, USA. diamond@wusm.wustl.edu.
LA  - eng
GR  - R01 AI081759/AI/NIAID NIH HHS/United States
GR  - R01 AI073755/AI/NIAID NIH HHS/United States
GR  - R01 HD083895/HD/NICHD NIH HHS/United States
GR  - R01 HD075665/HD/NICHD NIH HHS/United States
GR  - U54 HD087011/HD/NICHD NIH HHS/United States
GR  - R01 AI145296/AI/NIAID NIH HHS/United States
GR  - T32 AI055397/AI/NIAID NIH HHS/United States
GR  - R01 AI127828/AI/NIAID NIH HHS/United States
GR  - R01 HD091218/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20190117
PL  - England
TA  - Nat Commun
JT  - Nature communications
JID - 101528555
RN  - 0 (Antiviral Agents)
RN  - 0 (interferon-lambda, human)
RN  - 0 (Interferon-alpha)
RN  - 0 (Interleukins)
RN  - 4G7DS2Q64Y (Progesterone)
RN  - 4TI98Z838E (Estradiol)
RN  - 77238-31-4 (Interferon-beta)
SB  - IM
MH  - Administration, Intravaginal
MH  - Animals
MH  - Antiviral Agents/*pharmacology/therapeutic use
MH  - Cervix Uteri/cytology/virology
MH  - Disease Models, Animal
MH  - Epithelial Cells
MH  - Estradiol/pharmacology
MH  - Female
MH  - Host-Pathogen Interactions/drug effects/immunology
MH  - Humans
MH  - Interferon-alpha/pharmacology/therapeutic use
MH  - Interferon-beta/pharmacology/therapeutic use
MH  - Interleukins/*pharmacology/therapeutic use
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Primary Cell Culture
MH  - Progesterone/pharmacology
MH  - Sexually Transmitted Diseases, Viral/immunology/*prevention & 
      control/transmission/virology
MH  - Vagina/cytology/virology
MH  - Virus Replication/drug effects
MH  - Zika Virus/drug effects/immunology/*pathogenicity
MH  - Zika Virus Infection/immunology/*prevention & control/transmission/virology
PMC - PMC6336786
COIS- M.S.D. is a consultant for Inbios and Sanofi-Pasteur and is on the Scientific 
      Advisory Board of Moderna. The remaining authors declare no competing interests.
EDAT- 2019/01/19 06:00
MHDA- 2019/03/21 06:00
PMCR- 2019/01/17
CRDT- 2019/01/19 06:00
PHST- 2018/09/04 00:00 [received]
PHST- 2018/11/30 00:00 [accepted]
PHST- 2019/01/19 06:00 [entrez]
PHST- 2019/01/19 06:00 [pubmed]
PHST- 2019/03/21 06:00 [medline]
PHST- 2019/01/17 00:00 [pmc-release]
AID - 10.1038/s41467-018-07993-2 [pii]
AID - 7993 [pii]
AID - 10.1038/s41467-018-07993-2 [doi]
PST - epublish
SO  - Nat Commun. 2019 Jan 17;10(1):280. doi: 10.1038/s41467-018-07993-2.

PMID- 38432464
OWN - NLM
STAT- MEDLINE
DCOM- 20240408
LR  - 20240418
IS  - 1879-1298 (Electronic)
IS  - 0045-6535 (Linking)
VI  - 354
DP  - 2024 Apr
TI  - Assessment of occurrence, partitioning and ecological risk for 144 steroid 
      hormones in Taihu Lake using UPLC-MS/MS with machine learning model.
PG  - 141598
LID - S0045-6535(24)00491-0 [pii]
LID - 10.1016/j.chemosphere.2024.141598 [doi]
AB  - Steroid hormones (SHs) have attracted mounting attention due to their 
      endocrine-disrupting effects on humans and aquatic organisms. However, the lack 
      of analytical methods and toxicity data for a large number of SHs has limited the 
      effective management of SH contamination in the water-sediment systems. In this 
      study, we developed a highly sensitive analytical method for the simultaneous 
      quantification of 144 SHs to investigate their occurrence, spatial distribution 
      and partitioning in the water and sediment in Taihu Lake. The results showed that 
      the total concentrations of SHs in water and sediment were 366.88-998.23 ng/L 
      (mean: 612.84 ng/L) and 17.46-150.20 ng/g (mean: 63.41 ng/g), respectively. The 
      spatial distribution of SHs in Taihu Lake might be simultaneously influenced by 
      the pollution sources, lake hydrodynamics, and sediment properties. The 
      sediment-water partitioning result implied that 28 SHs were in dynamic 
      equilibrium at the water-water interface. In addition, 22 and 12 SHs tended to 
      spread to water and settle into sediment, respectively. To assess the ecological 
      risk of all SHs, a robust random forest model (R(2) = 0.801) was developed to 
      predict the acute toxicity of SHs for which toxicity data were not available from 
      publications. Risk assessment showed that SHs posed a high ecological risk 
      throughout Taihu Lake, with the highest risk in the northwestern areas. Estrone, 
      17β-estradiol and 17α-ethynylestradiol were the dominant risk contributors and 
      were therefore recommended as the priority SHs in Taihu Lake. This work provided 
      a valuable dataset for Taihu Lake, which would help to provide guidance and 
      suggestions for future studies and be useful for the government to develop the 
      mitigation and management measures.
CI  - Copyright © 2024 Elsevier Ltd. All rights reserved.
FAU - Zhao, Li
AU  - Zhao L
AD  - Beijing Key Lab for Source Control Technology of Water Pollution, College of 
      Environmental Sciences & Engineering, Beijing Forestry University, Beijing, 
      100083, China.
FAU - Wang, Chao
AU  - Wang C
AD  - China CDC Key Laboratory of Environment and Human Health, National Institute of 
      Environmental Health, Chinese Center for Disease Control and Prevention, Beijing, 
      100021, China.
FAU - Sun, Fuhong
AU  - Sun F
AD  - State Key Laboratory of Environmental Criteria and Risk Assessment, Chinese 
      Research Academy of Environmental Sciences, Beijing, 100012, China.
FAU - Liao, Haiqing
AU  - Liao H
AD  - State Key Laboratory of Environmental Criteria and Risk Assessment, Chinese 
      Research Academy of Environmental Sciences, Beijing, 100012, China.
FAU - Chang, Hong
AU  - Chang H
AD  - Beijing Key Lab for Source Control Technology of Water Pollution, College of 
      Environmental Sciences & Engineering, Beijing Forestry University, Beijing, 
      100083, China. Electronic address: changh@bjfu.edu.cn.
FAU - Jia, Xudong
AU  - Jia X
AD  - NHC Key Laboratory of Food Safety Risk Assessment, China National Center for Food 
      Safety Risk Assessment, Beijing, 100021, China. Electronic address: 
      jiaxudong@cfsa.net.cn.
LA  - eng
PT  - Journal Article
DEP - 20240301
PL  - England
TA  - Chemosphere
JT  - Chemosphere
JID - 0320657
RN  - 0 (Water Pollutants, Chemical)
RN  - 059QF0KO0R (Water)
RN  - 4TI98Z838E (Estradiol)
RN  - 2DI9HA706A (Estrone)
SB  - IM
MH  - Humans
MH  - *Lakes/analysis
MH  - Chromatography, Liquid
MH  - Liquid Chromatography-Mass Spectrometry
MH  - *Water Pollutants, Chemical/analysis
MH  - Environmental Monitoring
MH  - Tandem Mass Spectrometry
MH  - Water
MH  - Risk Assessment
MH  - Estradiol
MH  - Estrone
MH  - China
MH  - Geologic Sediments
OTO - NOTNLM
OT  - Emerging contaminants
OT  - Endocrine disruptors
OT  - Machine learning
OT  - Risk assessment
OT  - Steroid contamination
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2024/03/04 00:43
MHDA- 2024/04/08 06:43
CRDT- 2024/03/03 19:16
PHST- 2024/01/11 00:00 [received]
PHST- 2024/02/25 00:00 [revised]
PHST- 2024/02/29 00:00 [accepted]
PHST- 2024/04/08 06:43 [medline]
PHST- 2024/03/04 00:43 [pubmed]
PHST- 2024/03/03 19:16 [entrez]
AID - S0045-6535(24)00491-0 [pii]
AID - 10.1016/j.chemosphere.2024.141598 [doi]
PST - ppublish
SO  - Chemosphere. 2024 Apr;354:141598. doi: 10.1016/j.chemosphere.2024.141598. Epub 
      2024 Mar 1.

PMID- 35148282
OWN - NLM
STAT- MEDLINE
DCOM- 20220413
LR  - 20220413
IS  - 1945-4589 (Electronic)
IS  - 1945-4589 (Linking)
VI  - 14
IP  - 3
DP  - 2022 Feb 11
TI  - Binding of the angiogenic/senescence inducer CCN1/CYR61 to integrin α(6)β(1) 
      drives endocrine resistance in breast cancer cells.
PG  - 1200-1213
LID - 10.18632/aging.203882 [doi]
AB  - CCN1/CYR61 promotes angiogenesis, tumor growth and chemoresistance by binding to 
      its integrin receptor α(v)β(3) in endothelial and breast cancer (BC) cells. CCN1 
      controls also tissue regeneration by engaging its integrin receptor α(6)β(1) to 
      induce fibroblast senescence. Here, we explored if the ability of CCN1 to drive 
      an endocrine resistance phenotype in estrogen receptor-positive BC cells relies 
      on interactions with either α(v)β(3) or α(6)β(1). First, we took advantage of 
      site-specific mutagenesis abolishing the CCN1 receptor-binding sites to α(v)β(3) 
      and α(6)β(1) to determine the integrin partner responsible for CCN1-driven 
      endocrine resistance. Second, we explored a putative nuclear role of CCN1 in 
      regulating ERα-driven transcriptional responses. Retroviral forced expression of 
      a CCN1 derivative with a single amino acid change (D125A) that abrogates binding 
      to α(v)β(3) partially phenocopied the endocrine resistance phenotype induced upon 
      overexpression of wild-type (WT) CCN1. Forced expression of the CCN1 mutant TM, 
      which abrogates all the T1, H1, and H2 binding sites to α(6)β(1), failed to 
      bypass the estrogen requirement for anchorage-independent growth or to promote 
      resistance to tamoxifen. Wild-type CCN1 promoted estradiol-independent 
      transcriptional activity of ERα and enhanced ERα agonist response to tamoxifen. 
      The α(6)β(1)-binding-defective TM-CCN1 mutant lost the ERα co-activator-like 
      behavior of WT-CCN1. Co-immunoprecipitation assays revealed a direct interaction 
      between endogenous CCN1 and ERα, and in vitro approaches confirmed the ability of 
      recombinant CCN1 to bind ERα. CCN1 signaling via α(6)β(1), but not via α(v)β(3), 
      drives an endocrine resistance phenotype that involves a direct binding of CCN1 
      to ERα to regulate its transcriptional activity in ER+ BC cells.
FAU - Espinoza, Ingrid
AU  - Espinoza I
AD  - Department of Laboratory Medicine and Pathology, Division of Experimental 
      Pathology, Mayo Clinic, Rochester, 55905 MN, USA.
AD  - Current address: Department of Preventive Medicine, John D. Bower School of 
      Population Health, University of Mississippi Medical Center, Jackson, MS 39216, 
      USA.
AD  - Current address: Cancer Institute, School of Medicine, University of Mississippi 
      Medical Center, Jackson, MS 39216, USA.
FAU - Yang, Lin
AU  - Yang L
AD  - Department of Laboratory Medicine and Pathology, Division of Experimental 
      Pathology, Mayo Clinic, Rochester, 55905 MN, USA.
FAU - Steen, Travis Vander
AU  - Steen TV
AD  - Department of Laboratory Medicine and Pathology, Division of Experimental 
      Pathology, Mayo Clinic, Rochester, 55905 MN, USA.
FAU - Vellon, Luciano
AU  - Vellon L
AD  - Stem Cells Laboratory, Institute of Biology and Experimental Medicine 
      (IBYME-CONICET), Buenos Aires C1428ADN, Argentina.
FAU - Cuyàs, Elisabet
AU  - Cuyàs E
AD  - Program Against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer 
      Group, Catalan Institute of Oncology, Girona 17005, Spain.
AD  - Girona Biomedical Research Institute, Salt, Girona 17190, Spain.
FAU - Verdura, Sara
AU  - Verdura S
AD  - Program Against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer 
      Group, Catalan Institute of Oncology, Girona 17005, Spain.
AD  - Girona Biomedical Research Institute, Salt, Girona 17190, Spain.
FAU - Lau, Lester
AU  - Lau L
AD  - Department of Biochemistry and Molecular Genetics, College of Medicine, The 
      University of Illinois at Chicago, Chicago, IL 60607, USA.
FAU - Menendez, Javier A
AU  - Menendez JA
AD  - Program Against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer 
      Group, Catalan Institute of Oncology, Girona 17005, Spain.
AD  - Girona Biomedical Research Institute, Salt, Girona 17190, Spain.
FAU - Lupu, Ruth
AU  - Lupu R
AD  - Department of Laboratory Medicine and Pathology, Division of Experimental 
      Pathology, Mayo Clinic, Rochester, 55905 MN, USA.
AD  - Department of Biochemistry and Molecular Biology Laboratory, Mayo Clinic 
      Minnesota, Rochester, MN 55905, USA.
AD  - Mayo Clinic Cancer Center, Rochester, MN 55905, USA.
LA  - eng
GR  - R01 CA116623/CA/NCI NIH HHS/United States
GR  - R01 CA118975/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20220211
PL  - United States
TA  - Aging (Albany NY)
JT  - Aging
JID - 101508617
RN  - 0 (Cysteine-Rich Protein 61)
RN  - 0 (Estrogen Receptor alpha)
RN  - 0 (Integrin alpha6beta1)
RN  - 0 (Integrins)
RN  - 094ZI81Y45 (Tamoxifen)
SB  - IM
MH  - *Breast Neoplasms/genetics
MH  - Cysteine-Rich Protein 61/genetics/metabolism
MH  - *Estrogen Receptor alpha/genetics
MH  - Female
MH  - Humans
MH  - Integrin alpha6beta1/metabolism
MH  - Integrins
MH  - Tamoxifen/pharmacology
PMC - PMC8876916
OTO - NOTNLM
OT  - CYR61
OT  - estrogen receptor
OT  - integrins
OT  - matricellular proteins
OT  - tamoxifen
COIS- CONFLICTS OF INTEREST: The authors declare that the research was conducted in the 
      absence of any commercial or financial relationships that could be construed as a 
      potential conflict of interest.
EDAT- 2022/02/12 06:00
MHDA- 2022/04/14 06:00
PMCR- 2022/02/15
CRDT- 2022/02/11 17:11
PHST- 2021/03/05 00:00 [received]
PHST- 2022/01/29 00:00 [accepted]
PHST- 2022/02/12 06:00 [pubmed]
PHST- 2022/04/14 06:00 [medline]
PHST- 2022/02/11 17:11 [entrez]
PHST- 2022/02/15 00:00 [pmc-release]
AID - 203882 [pii]
AID - 10.18632/aging.203882 [doi]
PST - ppublish
SO  - Aging (Albany NY). 2022 Feb 11;14(3):1200-1213. doi: 10.18632/aging.203882. Epub 
      2022 Feb 11.

PMID- 30529907
OWN - NLM
STAT- MEDLINE
DCOM- 20200317
LR  - 20200317
IS  - 1873-3360 (Electronic)
IS  - 0306-4530 (Linking)
VI  - 102
DP  - 2019 Apr
TI  - Detection of estradiol in rat brain tissues: Contribution of local versus 
      systemic production.
PG  - 84-94
LID - S0306-4530(18)30252-X [pii]
LID - 10.1016/j.psyneuen.2018.11.037 [doi]
AB  - Estrogens play important roles in regulating brain development, brain function, 
      and behavior. Many studies have evaluated these effects using ovariectomized 
      (OVX) rats or mice with different doses of estrogen replacement, assuming that 
      estradiol levels in all regions of the brain are the same as levels achieved in 
      the serum. It is well known, however, that the brain contains all the enzymes 
      necessary to produce estrogens, and that estrogen levels in the brain are 
      determined by both systemic and local production and are region-specific. The 
      present study conducted a detailed analysis of the relationship between systemic 
      levels of 17-β-estradiol (E2) achieved by estrogen replacement and levels 
      achieved in specific regions of the brain. Levels of E2 were measured in both 
      brain and serum in OVX rats treated with different doses of estradiol benzoate 
      (EB) using a novel and recently validated UPLC-MS/MS method. Results confirmed 
      significantly higher levels of E2 in the brain than in serum in brain regions 
      known to contain aromatase (ARO) activity, both in OVX controls and in rats 
      treated with physiological doses of EB. Additional studies compared the level of 
      E2 and testosterone (T) in the brain and serum between testosterone propionate 
      (TP) treated OVX and male. This demonstrated higher levels of E2 in certain brain 
      regions of males than in TP treated OVX females even though T levels in the brain 
      and serum were similar between the two groups. Studies also demonstrated that the 
      differences between serum and brain levels of E2 can be eliminated by letrozole 
      (ARO inhibitor) treatment, which indicates that the differences are due to local 
      ARO activity. Collectively the results provide a detailed analysis of brain 
      region-specific E2 concentrations in OVX, E2-, and T-treated rats and demonstrate 
      the degree to which these concentrations are ARO-dependent.
CI  - Copyright © 2018 Elsevier Ltd. All rights reserved.
FAU - Li, Junyi
AU  - Li J
AD  - Department of Pharmaceutical Sciences, School of Pharmacy, University of 
      Pittsburgh, Pittsburgh, PA 15261, USA.
FAU - Gibbs, Robert B
AU  - Gibbs RB
AD  - Department of Pharmaceutical Sciences, School of Pharmacy, University of 
      Pittsburgh, Pittsburgh, PA 15261, USA. Electronic address: gibbsr@pitt.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20181201
PL  - England
TA  - Psychoneuroendocrinology
JT  - Psychoneuroendocrinology
JID - 7612148
RN  - 0 (Aromatase Inhibitors)
RN  - 0 (Estrogens)
RN  - 3XMK78S47O (Testosterone)
RN  - 4TI98Z838E (Estradiol)
RN  - 7LKK855W8I (Letrozole)
RN  - EC 1.14.14.1 (Aromatase)
RN  - WI93Z9138A (Testosterone Propionate)
SB  - IM
MH  - Amygdala/drug effects/metabolism
MH  - Animals
MH  - Aromatase/metabolism
MH  - Aromatase Inhibitors/metabolism
MH  - Brain/drug effects/*metabolism
MH  - Cerebellum/drug effects/metabolism
MH  - Chromatography/methods
MH  - Chromatography, Liquid/methods
MH  - Estradiol/*analysis/*metabolism/pharmacology
MH  - Estrogen Replacement Therapy
MH  - Estrogens
MH  - Female
MH  - Frontal Lobe/drug effects/metabolism
MH  - Hippocampus/drug effects/metabolism
MH  - Letrozole/pharmacology
MH  - Male
MH  - Preoptic Area/drug effects/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Tandem Mass Spectrometry/methods
MH  - Testosterone/pharmacology
MH  - Testosterone Propionate
OTO - NOTNLM
OT  - Aromatase
OT  - Letrozole
OT  - Mass spectroscopy
OT  - Testosterone
EDAT- 2018/12/12 06:00
MHDA- 2020/03/18 06:00
CRDT- 2018/12/12 06:00
PHST- 2018/03/22 00:00 [received]
PHST- 2018/11/22 00:00 [revised]
PHST- 2018/11/25 00:00 [accepted]
PHST- 2018/12/12 06:00 [pubmed]
PHST- 2020/03/18 06:00 [medline]
PHST- 2018/12/12 06:00 [entrez]
AID - S0306-4530(18)30252-X [pii]
AID - 10.1016/j.psyneuen.2018.11.037 [doi]
PST - ppublish
SO  - Psychoneuroendocrinology. 2019 Apr;102:84-94. doi: 
      10.1016/j.psyneuen.2018.11.037. Epub 2018 Dec 1.

PMID- 26848802
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20161230
IS  - 1557-7600 (Electronic)
IS  - 1096-620X (Linking)
VI  - 19
IP  - 3
DP  - 2016 Mar
TI  - The Natural Substance MS-10 Improves and Prevents Menopausal Symptoms, Including 
      Colpoxerosis, in Clinical Research.
PG  - 228-37
LID - 10.1089/jmf.2015.3547 [doi]
AB  - Many natural substances were screened to develop nutraceuticals that reduce 
      menopausal symptoms. A complex of Cirsium japonicum var. maackii and Thymus 
      vulgaris extracts, named MS-10, had significant positive effects. Under a low 
      concentration of estrogen, which represents postmenopausal physiological 
      conditions, MS-10 had beneficial effects on estrogen receptor-expressing MCF-7 
      cells by reversibly enhancing estrogen activity. In addition, in the 
      ovariectomized rat model, changes in bone-specific alkaline phosphatase activity 
      and osteocalcin, as well as low-density lipoprotein cholesterol and triglyceride 
      levels were significantly decreased by MS-10. These results show that MS-10 
      protected bone health and reduced metabolic disturbances. Furthermore, in a 
      clinical study, all menopausal symptoms, including hot flushes, parenthesis, 
      insomnia, nervousness, melancholia, vertigo, fatigue, rheumatic pain, 
      palpitations, formication, and headache, as well as colpoxerosis, were 
      significantly improved by taking MS-10 for 90 days. Therefore, the evidence 
      supports that MS-10 is an effective natural substance that can safely improve 
      menopausal symptoms, including colpoxerosis.
FAU - Noh, Yoo-Hun
AU  - Noh YH
AD  - 1 Department of Anatomy and Cell Biology and Neurology, College of Medicine, 
      Chung-Ang University , Seoul, Korea.
AD  - 2 Famenity Biomedical Research Center, Famenity, Inc. , Gyeonggi, Korea.
FAU - Kim, Do-Hee
AU  - Kim DH
AD  - 3 Natural Pharmaceutical R&D Center, Naturesense, Inc. , Gyeonggi, Korea.
FAU - Lee, Seung-Ah
AU  - Lee SA
AD  - 1 Department of Anatomy and Cell Biology and Neurology, College of Medicine, 
      Chung-Ang University , Seoul, Korea.
FAU - Yin, Xing Fu
AU  - Yin XF
AD  - 2 Famenity Biomedical Research Center, Famenity, Inc. , Gyeonggi, Korea.
FAU - Park, Jiae
AU  - Park J
AD  - 1 Department of Anatomy and Cell Biology and Neurology, College of Medicine, 
      Chung-Ang University , Seoul, Korea.
FAU - Lee, Moo Yeol
AU  - Lee MY
AD  - 4 Department of Physiology, College of Medicine, Chung-Ang University , Seoul, 
      Korea.
FAU - Lee, Won Bok
AU  - Lee WB
AD  - 1 Department of Anatomy and Cell Biology and Neurology, College of Medicine, 
      Chung-Ang University , Seoul, Korea.
FAU - Lee, Sang Hyung
AU  - Lee SH
AD  - 5 Department of Neurosurgery, SMG-SNU Boramae Medical Center, Seoul National 
      University College of Medicine , Seoul, Korea.
FAU - Kim, Jae Kwang
AU  - Kim JK
AD  - 6 Department of Internal Medicine, The Catholic University of Korea College of 
      Medicine , Gyeonggi, Korea.
FAU - Kim, Sung-Su
AU  - Kim SS
AD  - 7 Department of Food Science and Nutrition, College of Natural Science, Dankook 
      University , Chungnam, Korea.
FAU - Jeong, Yoonhwa
AU  - Jeong Y
AD  - 7 Department of Food Science and Nutrition, College of Natural Science, Dankook 
      University , Chungnam, Korea.
FAU - Myung, Soon-Chul
AU  - Myung SC
AD  - 8 Department of Urology, College of Medicine, Chung-Ang University , Seoul, 
      Korea.
FAU - Kim, Tae Jin
AU  - Kim TJ
AD  - 9 Division of Immunobiology, Department of Molecular Cell Biology and Samsung 
      Biomedical Research Institute, Sungkyunkwan University School of Medicine , 
      Gyeonggi, Korea.
FAU - Kang, Il-Jun
AU  - Kang IJ
AD  - 10 Department of Food Science and Nutrition, College of Natural Science, Hallym 
      University , Gangwon, Korea.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20160205
PL  - United States
TA  - J Med Food
JT  - Journal of medicinal food
JID - 9812512
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (Plant Extracts)
RN  - 104982-03-8 (Osteocalcin)
SB  - IM
MH  - Animals
MH  - Cirsium/*chemistry
MH  - Female
MH  - Hot Flashes/drug therapy/metabolism/prevention & control
MH  - Humans
MH  - Lipoproteins, LDL/metabolism
MH  - Menopause/*drug effects/metabolism
MH  - Middle Aged
MH  - Osteocalcin/metabolism
MH  - Plant Extracts/*administration & dosage
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Thymus Plant/*chemistry
MH  - Vaginal Diseases/drug therapy/metabolism/*prevention & control
OTO - NOTNLM
OT  - Kupperman's Index
OT  - MS-10
OT  - colpoxerosis
OT  - menopause
OT  - ovariectomized rat
EDAT- 2016/02/06 06:00
MHDA- 2016/12/15 06:00
CRDT- 2016/02/06 06:00
PHST- 2016/02/06 06:00 [entrez]
PHST- 2016/02/06 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - 10.1089/jmf.2015.3547 [doi]
PST - ppublish
SO  - J Med Food. 2016 Mar;19(3):228-37. doi: 10.1089/jmf.2015.3547. Epub 2016 Feb 5.

PMID- 33484998
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240222
IS  - 1873-6424 (Electronic)
IS  - 0269-7491 (Linking)
VI  - 273
DP  - 2021 Jan 15
TI  - Possible overestimation of bisphenol analogues in municipal wastewater analyzed 
      with GC-MS.
PG  - 116505
LID - S0269-7491(21)00083-X [pii]
LID - 10.1016/j.envpol.2021.116505 [doi]
AB  - This work for the first time showed that sulfated BPA could be directly analyzed 
      as BPA with GC-MS after the derivatization with N,O-bis-(trimethylsilyl) 
      trifluoroacetamide (BSTFA)+1% trimethylchlorosilane (TMCS), i.e. the 
      deconjugation step was not necessary. This was because sulfated BPA indeed could 
      be simultaneously deconjugated and derivatized to BPA derivative during 
      derivatization, suggesting that any co-elution of BPA and sulfated BPA during 
      sample extraction led to BPA overestimation in the GC-MS method with BSTFA +1% 
      TMCS as the derivative reagent. Using BPA 4,4'-disulfates (BPA diS) as the pure 
      standard, the co-elution phenomena of sulfated BPA was confirmed with two widely 
      used elution solvents (i.e. methanol and ethyl acetate) or their mixed solutions 
      with different ratios, which further suggested if only sulfated BPA existed in 
      any wastewater sample, BPA was likely over-determined. To further confirm this 
      finding, both influent and effluent samples collected from a local municipal 
      wastewater treatment plant were analyzed, which clearly showed the overestimation 
      of BPA in the two wastewaters due to co-existence of sulfated BPA in the 
      wastewater samples. In addition to BPA, the results also showed the 
      overestimation of other nine bisphenol analogues. As sulfated micropollutants 
      including estrogens, androgens, phytoestrogens, etc., have been widely found in 
      municipal wastewater, the overestimating phenomenon observed in this study may 
      also be extended to determination of other micropollutants, which should be 
      addressed in future.
CI  - Copyright © 2021 Elsevier Ltd. All rights reserved.
FAU - Wang, Hao
AU  - Wang H
AD  - School of Environment and Energy, South China University of Technology, 
      Guangzhou, 510006, Guangdong, China.
FAU - Liu, Ze-Hua
AU  - Liu ZH
AD  - School of Environment and Energy, South China University of Technology, 
      Guangzhou, 510006, Guangdong, China; Key Lab Pollution Control & Ecosystem 
      Restoration in Industry Cluster, Ministry of Education, Guangzhou, 510006; 
      Guangdong, China; Guangdong Provincial Key Laboratory of Solid Wastes Pollution 
      Control and Recycling, Guangzhou, 510006, Guangdong, China; Guangdong Provincial 
      Engineering and Technology Research Center for Environment Risk Prevention and 
      Emergency Disposal, South China University of Technology, Guangzhou, 510006, 
      Guangdong, China. Electronic address: zehualiu@scut.edu.cn.
FAU - Tang, Zhao
AU  - Tang Z
AD  - School of Environment and Energy, South China University of Technology, 
      Guangzhou, 510006, Guangdong, China.
FAU - Zhang, Jun
AU  - Zhang J
AD  - School of Environment and Energy, South China University of Technology, 
      Guangzhou, 510006, Guangdong, China.
FAU - Dang, Zhi
AU  - Dang Z
AD  - School of Environment and Energy, South China University of Technology, 
      Guangzhou, 510006, Guangdong, China.
FAU - Liu, Yu
AU  - Liu Y
AD  - Advanced Environmental Biotechnology Center, Nanyang Environment and Water 
      Research Institute, Nanyang Technological University, CleanTech One, 637141, 
      Singapore; School of Civil and Engineering, Nanyang Technological University, 
      639798, Singapore.
LA  - eng
PT  - Journal Article
DEP - 20210115
PL  - England
TA  - Environ Pollut
JT  - Environmental pollution (Barking, Essex : 1987)
JID - 8804476
SB  - IM
OTO - NOTNLM
OT  - BSTFA+1% TMCS
OT  - Bisphenol analogues
OT  - GC-MS
OT  - Municipal wastewater
OT  - Overestimation
OT  - Sulfated BPA
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2021/01/24 06:00
MHDA- 2021/01/24 06:01
CRDT- 2021/01/23 20:11
PHST- 2020/11/15 00:00 [received]
PHST- 2020/12/23 00:00 [revised]
PHST- 2021/01/11 00:00 [accepted]
PHST- 2021/01/24 06:01 [medline]
PHST- 2021/01/24 06:00 [pubmed]
PHST- 2021/01/23 20:11 [entrez]
AID - S0269-7491(21)00083-X [pii]
AID - 10.1016/j.envpol.2021.116505 [doi]
PST - aheadofprint
SO  - Environ Pollut. 2021 Jan 15;273:116505. doi: 10.1016/j.envpol.2021.116505.

PMID- 30664162
OWN - NLM
STAT- MEDLINE
DCOM- 20190523
LR  - 20211021
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Linking)
VI  - 19
IP  - 3
DP  - 2019 Mar
TI  - Estradiol induces cell proliferation in MCF‑7 mammospheres through HER2/COX‑2.
PG  - 2341-2349
LID - 10.3892/mmr.2019.9879 [doi]
AB  - Cluster of differentiation (CD)44+/CD24- breast cancer cells have stem cell‑like 
      characteristics and are potent initiators of tumorigenesis. Mammosphere cells can 
      partially initiate breast tumorigenesis by inducing estradiol (E2)‑dependent 
      breast cancer cells. However, the mechanisms by which E2 mediates cancer 
      formation in MCF‑7 mammosphere (MS) cells have remained elusive. In the present 
      study, MS cells were isolated by sphere culture. It was possible to maintain 
      these MS cells in culture for long periods of time, while retaining the 
      CD44+/CD24- stem cell marker status. The CD44+/CD24- status was confirmed by flow 
      cytometry. Furthermore, the stem‑cell markers Musashi‑1, cytokeratin (CK)7 and 
      CK19 were identified by immunofluorescence microscopy. It was revealed that 
      treatment of MS cells with E2 increased the expression of CD44, whereas decreased 
      the expression of CD24 on MS cells. In addition, treatment with E2 increased 
      colony formation by MS cells. E2 also induced cyclooxygenase‑2 (COX‑2) expression 
      in MS cells, which promoted their proliferation through the estrogen 
      receptor/human epidermal growth factor receptor 2 (HER2)/mitogen‑activated 
      protein kinase/phosphoinositide‑3 kinase signaling pathway. The results suggested 
      a tumorigenic mechanism by which E2 promotes tumor cell proliferation via 
      HER2/COX‑2 signaling. The present study provided evidence for the molecular 
      impact of E2 on breast tumorigenesis, and suggested possible strategies for 
      preventing and treating human breast cancer.
FAU - Wu, Chin-Hu
AU  - Wu CH
AD  - Department of Obstetrics and Gynecology, Kaohsiung Medical University Hospital, 
      Sanmin, Kaohsiung 807, Taiwan R.O.C.
FAU - Chuang, Hui-Yu
AU  - Chuang HY
AD  - Department of Obstetrics and Gynecology, Kaohsiung Medical University Hospital, 
      Sanmin, Kaohsiung 807, Taiwan R.O.C.
FAU - Wang, Chiu-Lin
AU  - Wang CL
AD  - Department of Obstetrics and Gynecology, Kaohsiung Medical University Hospital, 
      Sanmin, Kaohsiung 807, Taiwan R.O.C.
FAU - Hsu, Chia-Yi
AU  - Hsu CY
AD  - Department of Obstetrics and Gynecology, Kaohsiung Medical University Hospital, 
      Sanmin, Kaohsiung 807, Taiwan R.O.C.
FAU - Long, Cheng-Yu
AU  - Long CY
AD  - Department of Obstetrics and Gynecology, Kaohsiung Medical University Hospital, 
      Sanmin, Kaohsiung 807, Taiwan R.O.C.
FAU - Hsieh, Tsung-Hua
AU  - Hsieh TH
AD  - Department of Obstetrics and Gynecology, Kaohsiung Medical University Hospital, 
      Sanmin, Kaohsiung 807, Taiwan R.O.C.
FAU - Tsai, Eing-Mei
AU  - Tsai EM
AD  - Department of Obstetrics and Gynecology, Kaohsiung Medical University Hospital, 
      Sanmin, Kaohsiung 807, Taiwan R.O.C.
LA  - eng
PT  - Journal Article
DEP - 20190118
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (Antigens, CD)
RN  - 0 (CD24 Antigen)
RN  - 0 (Hyaluronan Receptors)
RN  - 4TI98Z838E (Estradiol)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Antigens, CD/genetics
MH  - Breast Neoplasms/*genetics/metabolism/pathology
MH  - CD24 Antigen/genetics
MH  - Carcinogenesis/*genetics
MH  - Cell Proliferation/drug effects
MH  - Cyclooxygenase 2/*genetics
MH  - Estradiol/metabolism/pharmacology
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/genetics
MH  - Humans
MH  - Hyaluronan Receptors/genetics
MH  - MCF-7 Cells
MH  - Neoplastic Stem Cells/metabolism/pathology
MH  - Receptor, ErbB-2/*genetics
OTO - NOTNLM
OT  - breast cancer
OT  - COX-2
OT  - estradiol
OT  - HER2
OT  - mammosphere cell
EDAT- 2019/01/22 06:00
MHDA- 2019/05/24 06:00
CRDT- 2019/01/22 06:00
PHST- 2018/03/08 00:00 [received]
PHST- 2018/10/02 00:00 [accepted]
PHST- 2019/01/22 06:00 [pubmed]
PHST- 2019/05/24 06:00 [medline]
PHST- 2019/01/22 06:00 [entrez]
AID - 10.3892/mmr.2019.9879 [doi]
PST - ppublish
SO  - Mol Med Rep. 2019 Mar;19(3):2341-2349. doi: 10.3892/mmr.2019.9879. Epub 2019 Jan 
      18.

PMID- 31384769
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220409
IS  - 2661-801X (Electronic)
IS  - 2661-801X (Linking)
VI  - 13
IP  - 1
DP  - 2019 Dec
TI  - Evaluating urinary estrogen and progesterone metabolites using dried filter paper 
      samples and gas chromatography with tandem mass spectrometry (GC-MS/MS).
PG  - 20
LID - 10.1186/s13065-019-0539-1 [doi]
LID - 20
AB  - BACKGROUND: Measuring concentrations of metabolites of estradiol and progesterone 
      in urine, instead of measuring serum concentrations, is common in research and 
      also is used in patient care. The primary aim of this study was to demonstrate 
      that analysis of urine samples dried on filter paper by gas chromatography with 
      tandem mass spectrometry (GC-MS/MS) provides results similar to serum analyzed by 
      radioimmunoassay (RIA). Secondary aims were to show that collection of four 
      samples during the day (4-spot method) can be substituted for a 24-h collection, 
      and that analysis of urine from dried samples is equivalent to liquid urine 
      samples. METHODS: This prospective observational study compared results of urine 
      and serum analyses. Urine samples from women throughout the menstrual cycle and 
      single samples from postmenopausal women were evaluated. Urine was collected onto 
      filter paper and dried. Dried urine was extracted, hydrolyzed, and derivatized 
      prior to analysis by GC-MS/MS. Hormone concentrations were normalized to 
      creatinine. Single samples were used to compare results of 24-h urine collection 
      to the 4-spot method from a separate population of women and men. A subset of 
      these samples were used to compare results from dried urine to liquid urine. 
      RESULTS: The primary study showed good reliability in the comparisons between the 
      dried urine and serum assays. During the menstrual cycles of a subset of four 
      women, urine metabolite concentrations followed the same pattern as serum 
      concentrations. Comparison of 4-spot to 24-h urine collections and of dried to 
      liquid urine measurements had intraclass correlation coefficients (ICC) greater 
      than 0.95, indicating excellent agreement. CONCLUSIONS: For estradiol and 
      progesterone, the dried urine assay is a good surrogate for serum testing. The 
      4-spot method can be used instead of 24-h urine collections and dried urine 
      results are comparable to liquid urine. The dried urine assay is useful for some 
      clinical assessments of hormone disorders and may be useful in large 
      epidemiologic studies due to ease of sample handling.
FAU - Newman, Mark
AU  - Newman M
AD  - Precision Analytical Inc., 3138 NE Rivergate Street #301C, McMinnville, OR 97128 
      USA.
FAU - Pratt, Suzanne M
AU  - Pratt SM
AD  - Suzanne Pratt Works LLC, 7114 SE 18th Avenue, Portland, OR 97202 USA.
FAU - Curran, Desmond A
AU  - Curran DA
AD  - Precision Analytical Inc., 3138 NE Rivergate Street #301C, McMinnville, OR 97128 
      USA.
FAU - Stanczyk, Frank Z
AU  - Stanczyk FZ
AD  - 3Department of Obstetrics and Gynecology, and Preventive Medicine, University of 
      Southern California, Keck School of Medicine, Los Angeles, CA USA. ISNI: 0000 
      0001 2156 6853. GRID: grid.42505.36
LA  - eng
PT  - Journal Article
DEP - 20190204
PL  - Switzerland
TA  - BMC Chem
JT  - BMC chemistry
JID - 101741142
PMC - PMC6661742
OTO - NOTNLM
OT  - DUTCH
OT  - Dried filter paper
OT  - Estradiol
OT  - GC–MS/MS
OT  - Hormone replacement therapy
OT  - Pregnanediol
OT  - Progesterone
OT  - Reproductive hormones
OT  - Subfertility
COIS- Precision Analytical, Inc. is a commercial laboratory offering hormone testing to 
      medical practitioners and individuals. All statistics were calculated and 
      interpreted by an independent agent.
EDAT- 2019/08/07 06:00
MHDA- 2019/08/07 06:01
PMCR- 2019/02/04
CRDT- 2019/08/07 06:00
PHST- 2018/05/17 00:00 [received]
PHST- 2019/01/25 00:00 [accepted]
PHST- 2019/08/07 06:00 [entrez]
PHST- 2019/08/07 06:00 [pubmed]
PHST- 2019/08/07 06:01 [medline]
PHST- 2019/02/04 00:00 [pmc-release]
AID - 539 [pii]
AID - 10.1186/s13065-019-0539-1 [doi]
PST - epublish
SO  - BMC Chem. 2019 Feb 4;13(1):20. doi: 10.1186/s13065-019-0539-1. eCollection 2019 
      Dec.

PMID- 25756335
OWN - NLM
STAT- MEDLINE
DCOM- 20160105
LR  - 20220409
IS  - 1538-9235 (Electronic)
IS  - 1040-5488 (Linking)
VI  - 92
IP  - 9
DP  - 2015 Sep
TI  - Risk Factors for Dry Eye Syndrome: A Retrospective Case-Control Study.
PG  - e199-205
LID - 10.1097/OPX.0000000000000541 [doi]
AB  - PURPOSE: To investigate the independent risk factors of dry eye syndrome (DES) in 
      Chinese. METHODS: A hospital-based age- and sex-matched population was enrolled 
      with a case-control ratio of 1:2, with 789 DES case patients and 1119 healthy 
      family members. Both groups underwent standard ophthalmologic examinations, 
      including slit-lamp evaluation of the anterior segment, measurement of tear film 
      breakup time, Schirmer test, and corneal fluorescein staining. Data on 
      demographic characteristics and lifestyle habits were collected using a 
      questionnaire. Dry eye syndrome risk factors were identified by univariate and 
      multivariate logistic regression analyses. RESULTS: The following independent 
      risk factors showed significant association with DES: diabetes (odds ratio [OR], 
      1.408; 95% confidence interval [CI], 1.031 to 1.924), hepatitis C (OR, 3.326; 95% 
      CI, 1.632 to 6.776); connective tissue disease (OR, 2.157; 95% CI, 1.679 to 
      2.771), benign prostatic hyperplasia (OR, 3.892; 95% CI, 2.476 to 6.116), rosacea 
      (OR, 3.747; 95% CI, 1.972 to 7.120), posttraumatic stress disorder (OR, 1.449; 
      95% CI, 1.043 to 2.013), hematopoietic stem cell transplantation (OR, 7.269; 95% 
      CI, 2.312 to 22.849), head and neck radiotherapy (OR, 8.776; 95% CI, 3.096 to 
      24.873), postmenopausal estrogen therapy (OR, 1.912; 95% CI, 1.160 to 3.151), 
      antihistamines (OR, 2.040; 95% CI, 1.516 to 2.746), antidepressants (OR, 1.982; 
      95% CI, 1.077 to 3.647), contact lenses (OR, 2.366; 95% CI, 1.266 to 4.423), and 
      video display terminal exposure for more than 6 h/d (OR, 2.275; 95% CI, 1.451 to 
      3.568). Potentially protective factors against DES were vitamin supplements (OR, 
      0.716; 95% CI, 0.528 to 0.972) and Ω-3 fatty acid-rich diet (OR, 0.514; 95% CI, 
      0.332 to 0.796). CONCLUSION: Several known risk factors of DES are applicable to 
      Chinese, and some distinctive dietary factors may be protective in this 
      population.
FAU - Yang, Wan-ju
AU  - Yang WJ
AD  - *MD †PhD ‡MS Eye Center, Renmin Hospital of Wuhan University, Wuhan, China (all 
      authors); and Department of Ophthalmology, Central Hospital of Wuhan, Tongji 
      Medical College of Huazhong University of Science and Technology, Wuhan, China 
      (W-JY).
FAU - Yang, Yan-Ning
AU  - Yang YN
FAU - Cao, Jin
AU  - Cao J
FAU - Man, Zi-Hui
AU  - Man ZH
FAU - Yuan, Jing
AU  - Yuan J
FAU - Xiao, Xuan
AU  - Xiao X
FAU - Xing, Yi-Qiao
AU  - Xing YQ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Optom Vis Sci
JT  - Optometry and vision science : official publication of the American Academy of 
      Optometry
JID - 8904931
RN  - 0 (Fatty Acids, Omega-3)
SB  - IM
MH  - Adult
MH  - Age Distribution
MH  - Aged
MH  - Aged, 80 and over
MH  - Case-Control Studies
MH  - Dietary Supplements
MH  - Dry Eye Syndromes/*epidemiology/etiology/prevention & control
MH  - Fatty Acids, Omega-3
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Sex Distribution
MH  - Surveys and Questionnaires
EDAT- 2015/03/11 06:00
MHDA- 2016/01/06 06:00
CRDT- 2015/03/11 06:00
PHST- 2015/03/11 06:00 [entrez]
PHST- 2015/03/11 06:00 [pubmed]
PHST- 2016/01/06 06:00 [medline]
AID - 10.1097/OPX.0000000000000541 [doi]
PST - ppublish
SO  - Optom Vis Sci. 2015 Sep;92(9):e199-205. doi: 10.1097/OPX.0000000000000541.

PMID- 30679747
OWN - NLM
STAT- MEDLINE
DCOM- 20200722
LR  - 20200722
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 9
IP  - 1
DP  - 2019 Jan 24
TI  - Analogues of ERβ ligand chloroindazole exert immunomodulatory and remyelinating 
      effects in a mouse model of multiple sclerosis.
PG  - 503
LID - 10.1038/s41598-018-37420-x [doi]
LID - 503
AB  - Pharmaceutical agents currently approved for the treatment of multiple sclerosis 
      reduce relapse rates, but do not reverse or prevent neurodegeneration nor 
      initiate myelin repair. The highly selective estrogen receptor (ER) β ligand 
      chloroindazole (IndCl) shows particular promise promoting both remyelination 
      while reducing inflammatory cytokines in the central nervous system of mice with 
      experimental autoimmune encephalomyelitis. To optimize these benefits, we 
      developed and screened seven novel IndCl analogues for their efficacy in 
      promoting primary oligodendrocyte (OL) progenitor cell survival, proliferation, 
      and differentiation in vitro by immunohistochemistry. Two analogues, 
      IndCl-o-chloro and IndCl-o-methyl, induced proliferation and differentiation 
      equivalent to IndCl and were selected for subsequent in vivo evaluation for their 
      impact on clinical disease course, white matter pathology, and inflammation. Both 
      compounds ameliorated disease severity, increased mature OLs, and improved 
      overall myelination in the corpus callosum and white matter tracts of the spinal 
      cord. These effects were accompanied by reduced production of the OL toxic 
      molecules interferon-γ and chemokine (C-X-C motif) ligand, CXCL10 by splenocytes 
      with no discernable effect on central nervous system-infiltrating leukocyte 
      numbers, while IndCl-o-methyl also reduced peripheral interleukin (IL)-17. In 
      addition, expression of the chemokine CXCL1, which is associated with 
      developmental oligodendrogenesis, was upregulated by IndCl and both analogues. 
      Furthermore, callosal compound action potential recordings from analogue-treated 
      mice demonstrated a larger N1 component amplitude compared to vehicle, suggesting 
      more functionally myelinated fibers. Thus, the o-Methyl and o-Chloro IndCl 
      analogues represent a class of ERβ ligands that offer significant remyelination 
      and neuroprotection as well as modulation of the immune system; hence, they 
      appear appropriate to consider further for therapeutic development in multiple 
      sclerosis and other demyelinating diseases.
FAU - Karim, Hawra
AU  - Karim H
AD  - Division of Biomedical Sciences, UCR School of Medicine, Riverside, CA, 92521, 
      USA.
FAU - Kim, Sung Hoon
AU  - Kim SH
AD  - Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL, 
      61801, USA.
FAU - Lauderdale, Kelli
AU  - Lauderdale K
AD  - Division of Biomedical Sciences, UCR School of Medicine, Riverside, CA, 92521, 
      USA.
FAU - Lapato, Andrew S
AU  - Lapato AS
AD  - Division of Biomedical Sciences, UCR School of Medicine, Riverside, CA, 92521, 
      USA.
FAU - Atkinson, Kelley
AU  - Atkinson K
AD  - Division of Biomedical Sciences, UCR School of Medicine, Riverside, CA, 92521, 
      USA.
FAU - Yasui, Norio
AU  - Yasui N
AD  - Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL, 
      61801, USA.
FAU - Yamate-Morgan, Hana
AU  - Yamate-Morgan H
AD  - Division of Biomedical Sciences, UCR School of Medicine, Riverside, CA, 92521, 
      USA.
FAU - Sekyi, Maria
AU  - Sekyi M
AD  - Division of Biomedical Sciences, UCR School of Medicine, Riverside, CA, 92521, 
      USA.
FAU - Katzenellenbogen, John A
AU  - Katzenellenbogen JA
AD  - Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL, 
      61801, USA.
FAU - Tiwari-Woodruff, Seema K
AU  - Tiwari-Woodruff SK
AD  - Division of Biomedical Sciences, UCR School of Medicine, Riverside, CA, 92521, 
      USA. seema.tiwari-woodruff@medsch.ucr.edu.
AD  - Center for Glia Neuronal Interaction, UCR School of Medicine, Riverside, CA, 
      92521, USA. seema.tiwari-woodruff@medsch.ucr.edu.
LA  - eng
GR  - R01 DK015556/DK/NIDDK NIH HHS/United States
GR  - R01 NS081141/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20190124
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Cytokines)
RN  - 0 (Estrogen Receptor beta)
RN  - 0 (Immunologic Factors)
RN  - 0 (Indazoles)
RN  - 0 (Ligands)
SB  - IM
MH  - Animals
MH  - Cell Proliferation/drug effects
MH  - Cell Survival/drug effects
MH  - *Corpus Callosum/metabolism/pathology
MH  - Cytokines/metabolism
MH  - Estrogen Receptor beta/*agonists/metabolism
MH  - Female
MH  - Immunologic Factors/*pharmacology
MH  - Indazoles/*pharmacology
MH  - Ligands
MH  - Male
MH  - Mice
MH  - *Multiple Sclerosis/drug therapy/metabolism/pathology
MH  - Oligodendroglia/metabolism/pathology
MH  - Remyelination/*drug effects
PMC - PMC6345788
COIS- The authors declare no competing interests.
EDAT- 2019/01/27 06:00
MHDA- 2020/07/23 06:00
PMCR- 2019/01/24
CRDT- 2019/01/26 06:00
PHST- 2018/07/05 00:00 [received]
PHST- 2018/11/27 00:00 [accepted]
PHST- 2019/01/26 06:00 [entrez]
PHST- 2019/01/27 06:00 [pubmed]
PHST- 2020/07/23 06:00 [medline]
PHST- 2019/01/24 00:00 [pmc-release]
AID - 10.1038/s41598-018-37420-x [pii]
AID - 37420 [pii]
AID - 10.1038/s41598-018-37420-x [doi]
PST - epublish
SO  - Sci Rep. 2019 Jan 24;9(1):503. doi: 10.1038/s41598-018-37420-x.

PMID- 38733803
OWN - NLM
STAT- MEDLINE
DCOM- 20240524
LR  - 20240524
IS  - 1090-2414 (Electronic)
IS  - 0147-6513 (Linking)
VI  - 278
DP  - 2024 Jun 15
TI  - Associations among neighborhood walkability, metal exposure, and sex steroid 
      hormone levels: Results from Hangzhou Birth Cohort Study Ⅱ.
PG  - 116427
LID - S0147-6513(24)00503-7 [pii]
LID - 10.1016/j.ecoenv.2024.116427 [doi]
AB  - BACKGROUND: Neighborhood walkability may influence maternal-fetal exposure to 
      environmental hazards and maternal-fetal health (e.g., fetal growth restriction, 
      reproductive toxicity). However, few studies have explored the association 
      between neighborhood walkability and hormones in pregnant women. METHODS: We 
      included 533 pregnant women from the Hangzhou Birth Cohort Study II (HBCS-II) 
      with testosterone (TTE) and estradiol (E2) measured for analysis. Neighborhood 
      walkability was evaluated by calculating a walkability index based on geo-coded 
      addresses. Placental metals were measured using inductively coupled plasma mass 
      spectrometry (ICP-MS). TTE and E2 levels in umbilical cord blood were measured 
      using chemiluminescence microparticle immunoassay (CMIA). Linear regression model 
      was used to estimate the relationship between the walkability index, placental 
      metals, and sex steroid hormones. Effect modification was also assessed to 
      estimate the effect of placental metals on the associations of neighborhood 
      walkability with TTE and E2. RESULTS: Neighborhood walkability was significantly 
      linked to increased E2 levels (P trend=0.023). Compared with participants at the 
      first quintile (Q1) of walkability index, those at the third quintiles (Q3) had 
      lower chromium (Cr) levels (β = -0.212, 95% CI = -0.421 to -0.003). Arsenic (As), 
      cobalt (Co), manganese (Mn), molybdenum (Mo), nickel (Ni), lead (Pb), antimony 
      (Sb), selenium (Se), tin (Sn), and vanadium (V) were linked to decreased TTE 
      levels, and cadmium (Cd) was linked to increased TTE levels. No metal was 
      significantly associated with E2 levels in trend analysis. In the analysis of 
      effect modification, the associations of neighborhood walkability with TTE and E2 
      were significantly modified by Mn (P = 0.005) and Cu (P = 0.049) respectively. 
      CONCLUSION: Neighborhood walkability could be a favorable factor for E2 
      production during pregnancy, which may be inhibited by maternal exposure to heavy 
      metals.
CI  - Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Fang, Jiawei
AU  - Fang J
AD  - Department of Public Health, Zhejiang University School of 
      Medicine, Hangzhou, Zhejiang 310058, China; Key Laboratory of Reproductive 
      Genetics (Zhejiang University), Ministry of Education, Hangzhou, Zhejiang 
      310006, China.
FAU - Zhou, Yexinyi
AU  - Zhou Y
AD  - Department of Public Health, Zhejiang University School of 
      Medicine, Hangzhou, Zhejiang 310058, China; Key Laboratory of Reproductive 
      Genetics (Zhejiang University), Ministry of Education, Hangzhou, Zhejiang 
      310006, China.
FAU - He, Yinyin
AU  - He Y
AD  - Department of Public Health, Zhejiang University School of 
      Medicine, Hangzhou, Zhejiang 310058, China; Key Laboratory of Reproductive 
      Genetics (Zhejiang University), Ministry of Education, Hangzhou, Zhejiang 
      310006, China.
FAU - Zhou, Jiena
AU  - Zhou J
AD  - Department of Public Health, Zhejiang University School of 
      Medicine, Hangzhou, Zhejiang 310058, China; Key Laboratory of Reproductive 
      Genetics (Zhejiang University), Ministry of Education, Hangzhou, Zhejiang 
      310006, China.
FAU - Tang, Jun
AU  - Tang J
AD  - Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang 
      310052, China.
FAU - Luo, Qiong
AU  - Luo Q
AD  - Department of Obstetrics, Women's Hospital, Zhejiang University School of 
      Medicine, Hangzhou, Zhejiang 310006, China.
FAU - Guo, Jing
AU  - Guo J
AD  - Zhejiang Provincial Key Laboratory of Precision Diagnosis and Therapy for Major 
      Gynecological Diseases, Women's Hospital, Zhejiang University School of 
      Medicine, Hangzhou, Zhejiang 310006, China.
FAU - Chen, Guangdi
AU  - Chen G
AD  - Department of Public Health, Zhejiang University School of 
      Medicine, Hangzhou, Zhejiang 310058, China; Key Laboratory of Reproductive 
      Genetics (Zhejiang University), Ministry of Education, Hangzhou, Zhejiang 
      310006, China. Electronic address: chenguangdi@zju.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20240510
PL  - Netherlands
TA  - Ecotoxicol Environ Saf
JT  - Ecotoxicology and environmental safety
JID - 7805381
RN  - 4TI98Z838E (Estradiol)
RN  - 3XMK78S47O (Testosterone)
RN  - 0 (Environmental Pollutants)
RN  - 0 (Metals)
RN  - 0 (Gonadal Steroid Hormones)
RN  - 0 (Metals, Heavy)
SB  - IM
MH  - Humans
MH  - Female
MH  - Pregnancy
MH  - Adult
MH  - *Walking
MH  - China
MH  - *Residence Characteristics
MH  - Cohort Studies
MH  - Estradiol/blood/analysis
MH  - Testosterone/blood
MH  - Fetal Blood/chemistry
MH  - Maternal Exposure/statistics & numerical data
MH  - Environmental Pollutants/analysis/blood
MH  - Metals/analysis/blood
MH  - Gonadal Steroid Hormones/blood/analysis
MH  - Placenta/chemistry/drug effects
MH  - Metals, Heavy/analysis
MH  - Young Adult
OTO - NOTNLM
OT  - Estradiol
OT  - Metals
OT  - Neighborhood walkability
OT  - Pregnant women
OT  - Testosterone
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper
EDAT- 2024/05/12 00:44
MHDA- 2024/05/25 05:43
CRDT- 2024/05/11 18:08
PHST- 2024/01/31 00:00 [received]
PHST- 2024/05/01 00:00 [revised]
PHST- 2024/05/02 00:00 [accepted]
PHST- 2024/05/25 05:43 [medline]
PHST- 2024/05/12 00:44 [pubmed]
PHST- 2024/05/11 18:08 [entrez]
AID - S0147-6513(24)00503-7 [pii]
AID - 10.1016/j.ecoenv.2024.116427 [doi]
PST - ppublish
SO  - Ecotoxicol Environ Saf. 2024 Jun 15;278:116427. doi: 
      10.1016/j.ecoenv.2024.116427. Epub 2024 May 10.

PMID- 30482205
OWN - NLM
STAT- MEDLINE
DCOM- 20190213
LR  - 20190215
IS  - 1476-069X (Electronic)
IS  - 1476-069X (Linking)
VI  - 17
IP  - 1
DP  - 2018 Nov 27
TI  - Breast cancer risk and serum levels of per- and poly-fluoroalkyl substances: a 
      case-control study nested in the California Teachers Study.
PG  - 83
LID - 10.1186/s12940-018-0426-6 [doi]
LID - 83
AB  - BACKGROUND: Per- and poly- fluoroalkyl substances (PFASs) are a large family of 
      synthetic chemicals, some of which are mammary toxicants and endocrine 
      disruptors. Their potential as breast carcinogens is unclear. Our objective was 
      to evaluate the risk of breast cancer associated with serum PFAS concentrations 
      in a nested case-control study within the California Teachers Study. METHODS: 
      Participants were 902 women with invasive breast cancer (cases) and 858 with no 
      such diagnosis (controls) who provided 10 mL of blood and were interviewed during 
      2011-2015, an average of 35 months after case diagnosis. PFASs were measured 
      using automated online SPE-HPLC-MS/MS methods. Statistical analyses were 
      restricted to six PFASs with detection frequencies ≥ 95%: PFOA (Perfluorooctanoic 
      acid), PFNA (Perfluorononanoic acid), PFUnDA (Perfluoroundecanoic acid), PFHxS 
      (Perfluorohexane sulfonic acid), PFOS (Perfluorooctane sulfonic acid), and 
      MeFOSAA (2-(N-Methyl-perfluorooctane sulfonamido) acetic acid. Unconditional 
      logistic regression was used to calculate adjusted odds ratios (ORs), estimating 
      the breast cancer risk associated with each PFAS. RESULTS: For all cases of 
      invasive breast cancer, none of the adjusted ORs were statistically significant 
      but marginally significant ORs < 1.0 were observed for PFUnDA and PFHxS 
      (p-trend = 0.08). Adjusted ORs < 1.0 for PFUnDA and PFHxS were statistically 
      significant (p ≤ 0.05) among the 107 cases with hormone-negative tumors but not 
      the 743 with hormone-positive tumors. CONCLUSION: Overall, these findings do not 
      provide evidence that serum PFAS levels measured after diagnosis are related to 
      breast cancer risk. The few inverse associations found may be due to chance or 
      may be artifacts of study design. Future studies should incorporate information 
      about genetic susceptibility, endogenous estrogen levels, and measurements of 
      PFASs prior to diagnosis and treatment.
FAU - Hurley, Susan
AU  - Hurley S
AUID- ORCID: 0000-0002-5582-1741
AD  - Cancer Prevention Institute of California, Berkeley, CA, USA. 
      susan.hurley@ucsf.edu.
AD  - Department of Epidemiology and Biostatistics, University of California San 
      Francisco, 2001 Center Street, Suite 700, Berkeley, 94704, California, USA. 
      susan.hurley@ucsf.edu.
FAU - Goldberg, Debbie
AU  - Goldberg D
AD  - Cancer Prevention Institute of California, Berkeley, CA, USA.
AD  - Department of Epidemiology and Biostatistics, University of California San 
      Francisco, 2001 Center Street, Suite 700, Berkeley, 94704, California, USA.
FAU - Wang, Miaomiao
AU  - Wang M
AD  - Environmental Chemistry Laboratory, Department of Toxic Substances Control, 
      Berkeley, CA, USA.
FAU - Park, June-Soo
AU  - Park JS
AD  - Environmental Chemistry Laboratory, Department of Toxic Substances Control, 
      Berkeley, CA, USA.
FAU - Petreas, Myrto
AU  - Petreas M
AD  - Environmental Chemistry Laboratory, Department of Toxic Substances Control, 
      Berkeley, CA, USA.
FAU - Bernstein, Leslie
AU  - Bernstein L
AD  - Department of Population Sciences, Beckman Research Institute of the City of 
      Hope, Duarte, CA, USA.
FAU - Anton-Culver, Hoda
AU  - Anton-Culver H
AD  - Department of Epidemiology, School of Medicine, University of California Irvine, 
      Irvine, CA, USA.
FAU - Nelson, David O
AU  - Nelson DO
AD  - Cancer Prevention Institute of California, Berkeley, CA, USA.
FAU - Reynolds, Peggy
AU  - Reynolds P
AD  - Cancer Prevention Institute of California, Berkeley, CA, USA.
AD  - Department of Epidemiology and Biostatistics, University of California San 
      Francisco, 2001 Center Street, Suite 700, Berkeley, 94704, California, USA.
AD  - Department of Health Research and Policy, Stanford University School of Medicine, 
      Stanford, CA, USA.
LA  - eng
GR  - R01 CA77398/CP/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20181127
PL  - England
TA  - Environ Health
JT  - Environmental health : a global access science source
JID - 101147645
RN  - 0 (Alkanesulfonic Acids)
RN  - 0 (Environmental Pollutants)
RN  - 0 (Fatty Acids)
RN  - 0 (Fluorocarbons)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Alkanesulfonic Acids/*blood
MH  - Breast Neoplasms/*blood/*epidemiology
MH  - California/epidemiology
MH  - Case-Control Studies
MH  - Environmental Monitoring
MH  - Environmental Pollutants/*blood
MH  - Fatty Acids/*blood
MH  - Female
MH  - Fluorocarbons/*blood
MH  - Humans
MH  - Middle Aged
MH  - Odds Ratio
MH  - Risk
MH  - Young Adult
PMC - PMC6260688
OTO - NOTNLM
OT  - Breast cancer risk
OT  - Case control
OT  - PFAS
OT  - Perfluoroalkyl substances
OT  - Polyfluoroalkyl substances
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Upon entry into the study, all 
      participants provided their informed consent to use the data and biospecimens 
      collected for research purposes such as this one. The use of human subjects was 
      reviewed and approved by the California Health and Human Services Agency, 
      Committee for the Protection of Human Subjects and the Institutional Review 
      Boards of participating study institutions. CONSENT FOR PUBLICATION: As part of 
      their informed consent, participants agreed to the publication of research 
      findings based on the data and biospecimens they provided. COMPETING INTERESTS: 
      The authors declare that they have no competing interests. PUBLISHER’S NOTE: 
      Springer Nature remains neutral with regard to jurisdictional claims in published 
      maps and institutional affiliations.
EDAT- 2018/11/30 06:00
MHDA- 2019/02/14 06:00
PMCR- 2018/11/27
CRDT- 2018/11/29 06:00
PHST- 2018/05/10 00:00 [received]
PHST- 2018/11/13 00:00 [accepted]
PHST- 2018/11/29 06:00 [entrez]
PHST- 2018/11/30 06:00 [pubmed]
PHST- 2019/02/14 06:00 [medline]
PHST- 2018/11/27 00:00 [pmc-release]
AID - 10.1186/s12940-018-0426-6 [pii]
AID - 426 [pii]
AID - 10.1186/s12940-018-0426-6 [doi]
PST - epublish
SO  - Environ Health. 2018 Nov 27;17(1):83. doi: 10.1186/s12940-018-0426-6.

PMID- 32320758
OWN - NLM
STAT- MEDLINE
DCOM- 20201104
LR  - 20201104
IS  - 1879-1220 (Electronic)
IS  - 0960-0760 (Linking)
VI  - 201
DP  - 2020 Jul
TI  - The 2-/16α-Hydroxylated Estrogen Ratio-Breast Cancer Risk Hypothesis: 
      Insufficient Evidence for its Support.
PG  - 105685
LID - S0960-0760(20)30175-8 [pii]
LID - 10.1016/j.jsbmb.2020.105685 [doi]
AB  - During the past 25 years or so a number of studies have been carried out to 
      address the hypothesis that the ratio of 2-hydroxyestrone (2-hydroxy-E(1)) to 
      16α-hydroxyestrone (16α-hydroxy-E(1)) is associated with breast cancer risk. The 
      rationale for this hypothesis is based on data from studies that suggest a 
      tumorigenic and genotoxic effect of 16α-hydroxy-E(1) and a protective effect of 
      2-hydroxy-E(1) regarding breast cancer risk. The adverse effect of 
      16α-hydroxy-E(1) has been attributed to its potential to form covalent adducts 
      with macromolecules. Initial studies used radiometric assays and enzyme 
      immunoassays to test the hypothesis. However, concerns about the accuracy of 
      these assays led to the development of a liquid chromatography-tandem mass 
      spectrometry (LC-MS/MS) assay that is capable of measuring 5 unconjugated and 15 
      conjugated endogenous estrogens, which include 2- and 16-hydroxylated estrogen 
      metabolites, in serum or urine. The conjugated estrogens are quantified following 
      a deconjugation (hydrolysis) step to remove the sulfate and glucuronide groups. 
      Epidemiologic studies have been using the LC-MS/MS assay to determine whether 
      there is an association between breast cancer risk and the ratio of the sum of 
      the concentrations of metabolites in the 2-hydroxylated estrogen pathway and in 
      the 16-hydroxylated estrogen pathway. However, the validity of the pathways as 
      biomarkers was not evaluated. The 16-hydroxylated estrogen pathway includes 
      estriol, 16-epiestriol, 17-epiestriol and 16-ketoestradiol, in addition to 
      16α-hydroxy-E(1). However, with the exception of 16α-hydroxy-E(1), there is no 
      evidence that any of the other estrogens in the pathway have tumorigenic or 
      genotoxic properties, and they do not form covalent adducts with macromolecules. 
      Another deficiency in the epidemiological studies pertains to the accuracy of 
      estrogen metabolite measurements obtained after the hydrolysis step in the 
      LC-MS/MS assays. No validation was performed to demonstrate that a constant 
      efficiency of hydrolysis is found for all the different structural forms of 
      sulfated and glucuronidated conjugates. Other deficiencies in the assays include 
      the need for greater sensitivity so that the very low concentrations of 
      unconjugated 2-hydroxy-E(1), 2-hydroxy-E(2), and 16α-hydroxy-E(1) can be measured 
      in serum. There is also a need to develop assays to measure intact forms of 
      conjugated estrogens in both serum and urine, particularly the sulfates and 
      glucuronides of 2-hydroxylated, 2-methoxylated, and 16α-hydroxylated E(1) and 
      E(2). This will avoid inaccuracies that stem from hydrolysis procedures. 
      Improvements in LC-MS/MS assay methodology to obtain accurate measurements of 
      unconjugated and conjugated 2-hydroxylated, 2-methoxylated, and 16α-hydroxylated 
      estrogen metabolites are needed. This should provide valuable data for testing 
      the 2-/16α-hydroxylated estrogen-breast cancer risk hypothesis.
CI  - Copyright © 2020. Published by Elsevier Ltd.
FAU - Stanczyk, Frank Z
AU  - Stanczyk FZ
AD  - Departments of Obstetrics and Gynecology, and Preventive Medicine, Keck School of 
      Medicine, University of Southern California, Los Angeles, California, U.S.A.. 
      Electronic address: fstanczyk@att.net.
LA  - eng
PT  - Journal Article
DEP - 20200419
PL  - England
TA  - J Steroid Biochem Mol Biol
JT  - The Journal of steroid biochemistry and molecular biology
JID - 9015483
RN  - 0 (Hydroxyestrones)
RN  - 18186-49-7 (16-hydroxyestrone)
RN  - UQS3A06ILY (2-hydroxyestrone)
SB  - IM
MH  - Animals
MH  - Breast Neoplasms/*metabolism
MH  - Chromatography, Liquid
MH  - Female
MH  - Humans
MH  - Hydroxyestrones/*metabolism
MH  - Immunoenzyme Techniques
MH  - Radioligand Assay
MH  - Risk
MH  - Tandem Mass Spectrometry
OTO - NOTNLM
OT  - 16α-hydroxyestrone
OT  - 2-hydroxyestrone
OT  - Breast cancer
OT  - Estrogen metabolism
OT  - Estrogens
OT  - Mass spectrometry
EDAT- 2020/04/23 06:00
MHDA- 2020/11/05 06:00
CRDT- 2020/04/23 06:00
PHST- 2020/04/12 00:00 [received]
PHST- 2020/04/16 00:00 [revised]
PHST- 2020/04/17 00:00 [accepted]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2020/11/05 06:00 [medline]
PHST- 2020/04/23 06:00 [entrez]
AID - S0960-0760(20)30175-8 [pii]
AID - 10.1016/j.jsbmb.2020.105685 [doi]
PST - ppublish
SO  - J Steroid Biochem Mol Biol. 2020 Jul;201:105685. doi: 
      10.1016/j.jsbmb.2020.105685. Epub 2020 Apr 19.

PMID- 37589832
OWN - NLM
STAT- MEDLINE
DCOM- 20240117
LR  - 20240130
IS  - 1559-1182 (Electronic)
IS  - 0893-7648 (Print)
IS  - 0893-7648 (Linking)
VI  - 61
IP  - 1
DP  - 2024 Jan
TI  - 2-Methoxyestradiol and Hydrogen Peroxide as Promising Biomarkers in Parkinson's 
      Disease.
PG  - 148-166
LID - 10.1007/s12035-023-03575-6 [doi]
AB  - Estrogens function in numerous physiological processes including controlling 
      brain cell growth and differentiation. 2-Methoxestradiol (2-ME2), a 17β-estradiol 
      (E2) metabolite, is known for its anticancer effects as observed both in vivo and 
      in vitro. 2-ME2 affects all actively dividing cells, including neurons. The study 
      aimed to determine whether 2-ME2 is a potentially cancer-protective or rather 
      neurodegenerative agent in a specific tissue culture model as well as a clinical 
      setup. In this study, 2-ME2 activity was determined in a Parkinson's disease (PD) 
      in vitro model based on the neuroblastoma SH-SY5Y cell line. The obtained results 
      suggest that 2-ME2 generates nitro-oxidative stress and controls heat shock 
      proteins (HSP), resulting in DNA strand breakage and apoptosis. On the one hand, 
      it may affect intensely dividing cells preventing cancer development; however, on 
      the other hand, this kind of activity within the central nervous system may 
      promote neurodegenerative diseases like PD. Thus, the translational value of 
      2-ME2's neurotoxic activity in a PD in vitro model was also investigated. 
      LC-MS/MS technique was used to evaluate estrogens and their derivatives, namely, 
      hydroxy and methoxyestrogens, in PD patients' blood, whereas the stopped-flow 
      method was used to assess hydrogen peroxide (H(2)O(2)) levels. Methoxyestrogens 
      and H(2)O(2) levels were increased in patients' blood as compared to control 
      subjects, but hydoxyestrogens were simultaneously decreased. From the above, we 
      suggest that the determination of plasma levels of methoxyestrogens and H(2)O(2) 
      may be a novel PD biomarker. The presented research is the subject of the pending 
      patent application "The use of hydrogen peroxide and 17β-estradiol and its 
      metabolites as biomarkers in the diagnosis of neurodegenerative diseases," no. 
      P.441360.
CI  - © 2023. The Author(s).
FAU - Bastian, Paulina
AU  - Bastian P
AUID- ORCID: 0000-0003-3875-2534
AD  - Department of Medical Chemistry, Medical University of Gdansk, 80-210, Gdansk, 
      Poland. paulina.bastian@gumed.edu.pl.
FAU - Konieczna, Lucyna
AU  - Konieczna L
AD  - Department of Pharmaceutical Chemistry, Medical University of Gdansk, 80-416, 
      Gdansk, Poland.
FAU - Dulski, Jarosław
AU  - Dulski J
AD  - Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.
AD  - Department of Neurological-Psychiatric Nursing, Medical University of Gdansk, 
      80-211, Gdansk, Poland.
AD  - Neurology & Stroke Dpt. St. Adalbert Hospital, "Copernicus" Ltd, 80-462, Gdansk, 
      Poland.
FAU - Daca, Agnieszka
AU  - Daca A
AD  - Department of Pathology and Experimental Rheumatology, Medical University of 
      Gdansk, 80-210, Gdansk, Poland.
FAU - Jacewicz, Dagmara
AU  - Jacewicz D
AD  - Department of Environmental Technology, Faculty of Chemistry, University of 
      Gdansk, Wita Stwosza 63, 80-308, Gdansk, Poland.
FAU - Płoska, Agata
AU  - Płoska A
AD  - Department of Medical Laboratory Diagnostics-Fahrenheit Biobank BBMRI.pl, Faculty 
      of Pharmacy, Medical University of Gdansk, 80-211, Gdansk, Poland.
FAU - Knap, Narcyz
AU  - Knap N
AD  - Department of Medical Chemistry, Medical University of Gdansk, 80-210, Gdansk, 
      Poland.
FAU - Sławek, Jarosław
AU  - Sławek J
AD  - Department of Neurological-Psychiatric Nursing, Medical University of Gdansk, 
      80-211, Gdansk, Poland.
AD  - Neurology & Stroke Dpt. St. Adalbert Hospital, "Copernicus" Ltd, 80-462, Gdansk, 
      Poland.
FAU - Bączek, Tomasz
AU  - Bączek T
AD  - Department of Pharmaceutical Chemistry, Medical University of Gdansk, 80-416, 
      Gdansk, Poland.
FAU - Kalinowski, Leszek
AU  - Kalinowski L
AD  - Department of Medical Laboratory Diagnostics-Fahrenheit Biobank BBMRI.pl, Faculty 
      of Pharmacy, Medical University of Gdansk, 80-211, Gdansk, Poland.
AD  - BioTechMed Centre, Department of Mechanics of Materials and Structures, Gdansk 
      University of Technology, Narutowicza Street 11/12, 80-233, Gdansk, Poland.
FAU - Drzeżdżon, Joanna
AU  - Drzeżdżon J
AD  - Department of Environmental Technology, Faculty of Chemistry, University of 
      Gdansk, Wita Stwosza 63, 80-308, Gdansk, Poland.
FAU - Roszmann, Anna
AU  - Roszmann A
AD  - Department of Neurological-Psychiatric Nursing, Medical University of Gdansk, 
      80-211, Gdansk, Poland.
AD  - Neurology & Stroke Dpt. St. Adalbert Hospital, "Copernicus" Ltd, 80-462, Gdansk, 
      Poland.
FAU - Belka, Mariusz
AU  - Belka M
AD  - Department of Pharmaceutical Chemistry, Medical University of Gdansk, 80-416, 
      Gdansk, Poland.
FAU - Górska-Ponikowska, Magdalena
AU  - Górska-Ponikowska M
AUID- ORCID: 0000-0002-7366-8429
AD  - Department of Medical Chemistry, Medical University of Gdansk, 80-210, Gdansk, 
      Poland. magdalena.gorska-ponikowska@gumed.edu.pl.
AD  - Department of Biophysics, Institute of Biomaterials and Biomolecular Systems, 
      University of Stuttgart, 70569, Stuttgart, Germany. 
      magdalena.gorska-ponikowska@gumed.edu.pl.
AD  - Euro-Mediterranean Institute of Science and Technology, 90139, Palermo, Italy. 
      magdalena.gorska-ponikowska@gumed.edu.pl.
LA  - eng
GR  - ST 46/Gdański Uniwersytet Medyczny/
PT  - Journal Article
DEP - 20230817
PL  - United States
TA  - Mol Neurobiol
JT  - Molecular neurobiology
JID - 8900963
RN  - 6I2QW73SR5 (2-Methoxyestradiol)
RN  - BBX060AN9V (Hydrogen Peroxide)
RN  - 0 (Reactive Oxygen Species)
RN  - 4TI98Z838E (Estradiol)
RN  - 0 (Estrogens)
SB  - IM
MH  - Humans
MH  - 2-Methoxyestradiol
MH  - Hydrogen Peroxide
MH  - *Parkinson Disease/metabolism
MH  - Reactive Oxygen Species/metabolism
MH  - Chromatography, Liquid
MH  - *Neuroblastoma/metabolism
MH  - Tandem Mass Spectrometry
MH  - Oxidative Stress
MH  - Estradiol
MH  - Apoptosis
MH  - Estrogens
MH  - Cell Line, Tumor
PMC - PMC10791893
OTO - NOTNLM
OT  - 2-Methoxestradiol
OT  - Biomarkers
OT  - Hydrogen peroxide
OT  - Oxidative stress
OT  - Parkinson’s disease
OT  - Reactive oxygen species
COIS- The authors declare no competing interests.
EDAT- 2023/08/17 12:41
MHDA- 2024/01/17 06:42
PMCR- 2023/08/17
CRDT- 2023/08/17 11:09
PHST- 2023/05/04 00:00 [received]
PHST- 2023/08/12 00:00 [accepted]
PHST- 2024/01/17 06:42 [medline]
PHST- 2023/08/17 12:41 [pubmed]
PHST- 2023/08/17 11:09 [entrez]
PHST- 2023/08/17 00:00 [pmc-release]
AID - 10.1007/s12035-023-03575-6 [pii]
AID - 3575 [pii]
AID - 10.1007/s12035-023-03575-6 [doi]
PST - ppublish
SO  - Mol Neurobiol. 2024 Jan;61(1):148-166. doi: 10.1007/s12035-023-03575-6. Epub 2023 
      Aug 17.

PMID- 38604550
OWN - NLM
STAT- MEDLINE
DCOM- 20240601
LR  - 20250104
IS  - 1872-8057 (Electronic)
IS  - 0303-7207 (Print)
IS  - 0303-7207 (Linking)
VI  - 589
DP  - 2024 Aug 1
TI  - Sexual Dimorphism's impact on adipogenesis: A three-dimensional in vitro model 
      treated with 17β-estradiol and testosterone.
PG  - 112249
LID - S0303-7207(24)00105-9 [pii]
LID - 10.1016/j.mce.2024.112249 [doi]
AB  - Using a three-dimensional (3-D) in vitro culture model, we report the dose 
      dependent effect of 17β-estradiol and testosterone on the adipogenic 
      differentiation and maturation of human adipose derived stem cells (hASCs) 
      obtained from female and male patients. Considering sexual dimorphism, we 
      expected male and female adipocytes to respond differently to the sex steroids. 
      Both male and female hASC spheroids were exposed to 100 nM and 500 nM of 
      17β-estradiol and testosterone either at the beginning of the adipogenic 
      maturation (Phase I) to discourage intracellular triglyceride accumulation or 
      exposed after adipogenic maturation (Phase II) to reduce the intracellular 
      triglyceride accumulation. The results show that 17β-estradiol leads to a dose 
      dependent reduction in intracellular triglyceride accumulation in female hASC 
      spheroids compared to the both untreated and testosterone-treated cells. 
      Affirming our hypothesis, 17β-estradiol prevented intracellular triglyceride 
      accumulation during Phase I, while it stimulated lipolysis during Phase II. 
      PPAR-γ and adiponectin gene expression also reduced upon 17β-estradiol treatment 
      in female cells. Interestingly, 17β-estradiol and testosterone had only a modest 
      effect on the male hASC spheroids. Collectively, our findings suggest that 
      17β-estradiol can prevent fat accumulation in adipocytes during early and late 
      stages of maturation in females.
CI  - Copyright © 2024 Elsevier B.V. All rights reserved.
FAU - Pal, Pallabi
AU  - Pal P
AD  - Department of Biomedical Materials Science, School of Dentistry, University of 
      Mississippi Medical Center, 2500 N State St, Jackson, MS, 39216, USA.
FAU - Maranon, Rodrigo O
AU  - Maranon RO
AD  - Department of Physiology, Faculty of Medicine, Universidad Nacional de Tucuman, 
      San Miguel de Tucumán, Argentina; National Council on Scientific and Technical 
      Research (CONICET), Tucuman, Argentina.
FAU - Rivera Gonzales, Osvaldo J
AU  - Rivera Gonzales OJ
AD  - Department of Physiology and Biophysics, University of Mississippi Medical 
      Center, 2500 N State St, Jackson, MS, 39216, USA.
FAU - Speed, Joshua S
AU  - Speed JS
AD  - Department of Physiology and Biophysics, University of Mississippi Medical 
      Center, 2500 N State St, Jackson, MS, 39216, USA.
FAU - Janorkar, Amol V
AU  - Janorkar AV
AD  - Department of Biomedical Materials Science, School of Dentistry, University of 
      Mississippi Medical Center, 2500 N State St, Jackson, MS, 39216, USA. Electronic 
      address: ajanorkar@umc.edu.
LA  - eng
GR  - R01 DK124327/DK/NIDDK NIH HHS/United States
GR  - R01 EB020006/EB/NIBIB NIH HHS/United States
PT  - Journal Article
DEP - 20240409
PL  - Ireland
TA  - Mol Cell Endocrinol
JT  - Molecular and cellular endocrinology
JID - 7500844
RN  - 4TI98Z838E (Estradiol)
RN  - 3XMK78S47O (Testosterone)
RN  - 0 (Adiponectin)
RN  - 0 (Triglycerides)
RN  - 0 (PPAR gamma)
SB  - IM
MH  - Humans
MH  - *Adipogenesis/drug effects
MH  - Male
MH  - Female
MH  - *Estradiol/pharmacology
MH  - *Testosterone/pharmacology
MH  - *Sex Characteristics
MH  - *Adiponectin/metabolism
MH  - Triglycerides/metabolism
MH  - Spheroids, Cellular/drug effects/metabolism/cytology
MH  - Cells, Cultured
MH  - PPAR gamma/metabolism/genetics
MH  - Adipocytes/drug effects/metabolism/cytology
MH  - Stem Cells/metabolism/drug effects/cytology
MH  - Adipose Tissue/cytology/metabolism/drug effects
MH  - Lipolysis/drug effects
PMC - PMC11144096
MID - NIHMS1988385
OTO - NOTNLM
OT  - 3-D spheroids
OT  - Adiponectin
OT  - Female adipocyte
OT  - Male adipocyte
OT  - PPAR-γ
OT  - triglyceride
COIS- Declaration of competing interest Declarations of interest: none.
EDAT- 2024/04/12 00:43
MHDA- 2024/06/02 05:42
PMCR- 2025/08/01
CRDT- 2024/04/11 19:35
PHST- 2023/12/07 00:00 [received]
PHST- 2024/03/28 00:00 [revised]
PHST- 2024/04/08 00:00 [accepted]
PHST- 2025/08/01 00:00 [pmc-release]
PHST- 2024/06/02 05:42 [medline]
PHST- 2024/04/12 00:43 [pubmed]
PHST- 2024/04/11 19:35 [entrez]
AID - S0303-7207(24)00105-9 [pii]
AID - 10.1016/j.mce.2024.112249 [doi]
PST - ppublish
SO  - Mol Cell Endocrinol. 2024 Aug 1;589:112249. doi: 10.1016/j.mce.2024.112249. Epub 
      2024 Apr 9.

PMID- 37977386
OWN - NLM
STAT- MEDLINE
DCOM- 20231204
LR  - 20250103
IS  - 1879-1026 (Electronic)
IS  - 0048-9697 (Linking)
VI  - 910
DP  - 2024 Feb 1
TI  - Bisphenol analogues in infant foods in south China and implications for infant 
      exposure.
PG  - 168509
LID - S0048-9697(23)07137-1 [pii]
LID - 10.1016/j.scitotenv.2023.168509 [doi]
AB  - Bisphenol analogues (BPs) are commonly used as modifiers, stabilizers and 
      photo-initiators in polymer materials, including those used in food packaging. 
      Compared to adults, infants are more sensitive to chemicals because their bodies 
      are growing and not fully developed. Therefore, it is essential to determine the 
      concentrations of BPs in common infant foods to assess infant exposure and 
      prevent hazards. We collected 54 infant formula (IF) samples, 90 complementary 
      food (CMF) samples and 62 breastmilk samples from breastfeeding women in south 
      China. Tandem mass spectrometry coupled to liquid chromatography separation 
      (HPLC-MS/MS) was used to detect the concentrations of 8 BPs in the three types of 
      food samples. The estimated daily intake (EDI) of infants was also assessed. The 
      results showed that the detection frequency of bisphenol F (BPF), bisphenol S 
      (BPS), bisphenol AF (BPAF) and bisphenol AP (BPAP) were relatively high among the 
      different infant foods. BPF, BPP and BPS were predominant among the detected BPs. 
      The lowest 95th EDI for BPA was 0.67 ng kg-bw(-1) day(-1), exceeding the 
      tolerable daily intake (TDI) limit for BPA set by the European Food Safety 
      Authority in 2023. Thus, BP exposure is a significant risk to infants. More 
      attention should be paid to the presence of BPs in daily use products and food, 
      and intake limits should be set for BPs other than BPA.
CI  - Copyright © 2023 Elsevier B.V. All rights reserved.
FAU - Zheng, Quanzhi
AU  - Zheng Q
AD  - School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen 518107, 
      China.
FAU - Xiao, Jinqiu
AU  - Xiao J
AD  - School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen 518107, 
      China.
FAU - Zhang, Duo
AU  - Zhang D
AD  - School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen 518107, 
      China.
FAU - Li, Xiangyu
AU  - Li X
AD  - School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen 518107, 
      China.
FAU - Xu, Jiayi
AU  - Xu J
AD  - School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen 518107, 
      China.
FAU - Ma, Jiaojiao
AU  - Ma J
AD  - School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen 518107, 
      China.
FAU - Xiao, Qinru
AU  - Xiao Q
AD  - School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen 518107, 
      China.
FAU - Fu, Jinfeng
AU  - Fu J
AD  - School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen 518107, 
      China.
FAU - Guo, Zhihui
AU  - Guo Z
AD  - School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen 518107, 
      China.
FAU - Zhu, Yue
AU  - Zhu Y
AD  - School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen 518107, 
      China.
FAU - Ji, Jiajia
AU  - Ji J
AD  - Shenzhen Center for Disease Control and Prevention, Shenzhen 518055, China.
FAU - Lu, Shaoyou
AU  - Lu S
AD  - School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen 518107, 
      China. Electronic address: lushy23@mail.sysu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20231117
PL  - Netherlands
TA  - Sci Total Environ
JT  - The Science of the total environment
JID - 0330500
RN  - 3OX4RR782R (bisphenol S)
RN  - RW57K3X12M (bisphenol A)
RN  - 0 (bisphenol F)
RN  - 0 (Benzhydryl Compounds)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Infant
MH  - Female
MH  - *Tandem Mass Spectrometry
MH  - Chromatography, Liquid
MH  - Chromatography, High Pressure Liquid
MH  - *Infant Food/analysis
MH  - Benzhydryl Compounds/analysis
MH  - China
OTO - NOTNLM
OT  - Bisphenol
OT  - Breastmilk
OT  - Complementary food
OT  - Estimated daily intake
OT  - Infant exposure
OT  - Infant formula
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/11/18 11:41
MHDA- 2023/12/04 12:43
CRDT- 2023/11/17 19:38
PHST- 2023/07/27 00:00 [received]
PHST- 2023/10/26 00:00 [revised]
PHST- 2023/11/09 00:00 [accepted]
PHST- 2023/12/04 12:43 [medline]
PHST- 2023/11/18 11:41 [pubmed]
PHST- 2023/11/17 19:38 [entrez]
AID - S0048-9697(23)07137-1 [pii]
AID - 10.1016/j.scitotenv.2023.168509 [doi]
PST - ppublish
SO  - Sci Total Environ. 2024 Feb 1;910:168509. doi: 10.1016/j.scitotenv.2023.168509. 
      Epub 2023 Nov 17.

PMID- 30951973
OWN - NLM
STAT- MEDLINE
DCOM- 20201104
LR  - 20201104
IS  - 1873-4847 (Electronic)
IS  - 0955-2863 (Linking)
VI  - 67
DP  - 2019 May
TI  - N-acetylcysteine and alpha-lipoic acid improve antioxidant defenses and decrease 
      oxidative stress, inflammation and serum lipid levels in ovariectomized rats via 
      estrogen-independent mechanisms.
PG  - 190-200
LID - S0955-2863(19)30012-9 [pii]
LID - 10.1016/j.jnutbio.2019.02.012 [doi]
AB  - Sexual hormone deficiency has been associated with metabolic changes, oxidative 
      stress and subclinical inflammation in postmenopausal women. Hormone replacement 
      therapies are effective in many instances, even though some patients either do 
      not respond or are not eligible. The aim of this study was to evaluate the impact 
      of short- (15 days) versus long-term (60 days) sexual hormone depletion and 
      whether antioxidant supplementation with N-acetylcysteine (NAC) and alpha-lipoic 
      acid (LA) improves oxidative stress, metabolic, and inflammatory parameters in 
      ovariectomized (OVX) rats. Short-term OVX rapidly depleted circulating estrogen, 
      causing uterine atrophy and body weight gain without affecting oxidative damage, 
      inflammatory and lipid metabolism markers. In contrast, long-term OVX augmented 
      oxidative damage in serum and peripheral tissues as well as increased serum total 
      cholesterol, TNF-α and IL6 levels. Triglycerides, glucose and HDL cholesterol 
      were not altered. Long-term OVX-induced oxidative stress was associated with 
      depletion of GSH and total non-enzymatic antioxidants as well as decreased 
      activity of Glutathione Peroxidase (GPx) and Glutathione Reductase (GR), but not 
      Superoxide Dismutase (SOD) and Catalase (CAT). NAC and LA supplementation 
      prevented GSH and total non-enzymatic antioxidants depletion as well as restored 
      GPx and GR activities, TNF-α, IL6 and cholesterol in OVX rats. NAC and LA effects 
      appear to be independent on NRF2 activation and estrogen-like activity, since 
      NAC/LA did not promote NRF2 activation and were not able to emulate estrogen 
      effects in OVX rats and estrogen-receptor-positive cells. The herein presented 
      data suggest that NAC and LA may improve some deleterious effects of sexual 
      hormone depletion via estrogen-independent mechanisms.
CI  - Copyright © 2019 Elsevier Inc. All rights reserved.
FAU - Delgobo, Marina
AU  - Delgobo M
AD  - Laboratório de Farmacologia Bioquímica e Molecular, Departamento de Farmacologia, 
      Centro de Ciências Biológicas, Universidade Federal de Santa Catarina (UFSC), 
      Florianópolis, SC, Brazil.
FAU - Agnes, Jonathan Paulo
AU  - Agnes JP
AD  - Laboratório de Farmacologia Bioquímica e Molecular, Departamento de Farmacologia, 
      Centro de Ciências Biológicas, Universidade Federal de Santa Catarina (UFSC), 
      Florianópolis, SC, Brazil.
FAU - Gonçalves, Rosângela Mayer
AU  - Gonçalves RM
AD  - Laboratório de Farmacologia Bioquímica e Molecular, Departamento de Farmacologia, 
      Centro de Ciências Biológicas, Universidade Federal de Santa Catarina (UFSC), 
      Florianópolis, SC, Brazil.
FAU - Dos Santos, Vitória Wibbelt
AU  - Dos Santos VW
AD  - Laboratório de Farmacologia Bioquímica e Molecular, Departamento de Farmacologia, 
      Centro de Ciências Biológicas, Universidade Federal de Santa Catarina (UFSC), 
      Florianópolis, SC, Brazil.
FAU - Parisotto, Eduardo Benedetti
AU  - Parisotto EB
AD  - Faculdade de Ciências Farmacêuticas, Alimentos e Nutrição, Universidade Federal 
      de Mato Grosso do Sul (UFMS), Campo Grande, MS, Brazil; Departamento de 
      Bioquímica, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina 
      (UFSC), Florianópolis, SC, Brazil.
FAU - Zamoner, Ariane
AU  - Zamoner A
AD  - Departamento de Bioquímica, Centro de Ciências Biológicas, Universidade Federal 
      de Santa Catarina (UFSC), Florianópolis, SC, Brazil.
FAU - Zanotto-Filho, Alfeu
AU  - Zanotto-Filho A
AD  - Laboratório de Farmacologia Bioquímica e Molecular, Departamento de Farmacologia, 
      Centro de Ciências Biológicas, Universidade Federal de Santa Catarina (UFSC), 
      Florianópolis, SC, Brazil. Electronic address: alfeu.zanotto@ufsc.br.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190310
PL  - United States
TA  - J Nutr Biochem
JT  - The Journal of nutritional biochemistry
JID - 9010081
RN  - 0 (Antioxidants)
RN  - 0 (Cytokines)
RN  - 0 (Estrogens)
RN  - 0 (Lipids)
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (Nfe2l2 protein, rat)
RN  - 73Y7P0K73Y (Thioctic Acid)
RN  - GAN16C9B8O (Glutathione)
RN  - WYQ7N0BPYC (Acetylcysteine)
SB  - IM
MH  - Acetylcysteine/*pharmacology
MH  - Animals
MH  - Antioxidants/metabolism
MH  - Cytokines/metabolism
MH  - Dietary Supplements
MH  - Estrogens/metabolism
MH  - Female
MH  - Glutathione/metabolism
MH  - Inflammation/*drug therapy/metabolism
MH  - Lipids/*blood
MH  - NF-E2-Related Factor 2/metabolism
MH  - Ovariectomy
MH  - Oxidative Stress/*drug effects
MH  - Rats, Wistar
MH  - Thioctic Acid/*pharmacology
OTO - NOTNLM
OT  - Aging
OT  - Antioxidants
OT  - Cytokines
OT  - Estrogen
OT  - Menopause
EDAT- 2019/04/06 06:00
MHDA- 2020/11/05 06:00
CRDT- 2019/04/06 06:00
PHST- 2019/01/09 00:00 [received]
PHST- 2019/02/18 00:00 [revised]
PHST- 2019/02/28 00:00 [accepted]
PHST- 2019/04/06 06:00 [pubmed]
PHST- 2020/11/05 06:00 [medline]
PHST- 2019/04/06 06:00 [entrez]
AID - S0955-2863(19)30012-9 [pii]
AID - 10.1016/j.jnutbio.2019.02.012 [doi]
PST - ppublish
SO  - J Nutr Biochem. 2019 May;67:190-200. doi: 10.1016/j.jnutbio.2019.02.012. Epub 
      2019 Mar 10.

PMID- 33684679
OWN - NLM
STAT- MEDLINE
DCOM- 20210420
LR  - 20210420
IS  - 1873-6424 (Electronic)
IS  - 0269-7491 (Linking)
VI  - 278
DP  - 2021 Jun 1
TI  - Mediated relationships between multiple metals exposure and fasting blood glucose 
      by reproductive hormones in Chinese men.
PG  - 116791
LID - S0269-7491(21)00371-7 [pii]
LID - 10.1016/j.envpol.2021.116791 [doi]
AB  - Previous studies have reported metals exposure contribute to the change of 
      fasting blood glucose (FBG) level. However, the roles of reproductive hormones in 
      their associations have not been fully elucidated. The aim of the study is to 
      investigate the associations of multiple serum metals with reproductive hormones, 
      and to further explore potential roles of reproductive hormones in relationships 
      between metals exposure and FBG level. A total of 1911 Chinese Han men were 
      analyzed by a cross-sectional study. We measured serum levels of 22 metals by 
      inductively coupled plasma mass spectrometer (ICP-MS). FBG, total testosterone 
      (TT), estradiol (E2), follicle stimulating hormone (FSH), and sex hormone-binding 
      globulin (SHBG) levels were determined. Least absolute shrinkage and selection 
      operator (LASSO) regression models were conducted to select important metals, and 
      restricted cubic spline models were then used to estimate dose-response 
      relationships between selected metals and reproductive hormones. We also 
      conducted mediation analyses to evaluate whether reproductive hormones played 
      mediating roles in the associations between metals and FBG. We found significant 
      inverse dose-dependent trends of copper, tin and zinc with E2; zinc with SHBG; 
      copper and nickel with TT, while significant positive dose-dependent trend of 
      iron with E2, respectively. Moreover, approximately inverted U-shaped 
      associations existed between lead and SHBG, iron and TT. In addition, E2, SHBG 
      and TT were negatively associated with FBG level. In mediation analyses, the 
      association of copper with FBG was mediated by E2 and TT, with a mediation ratio 
      of 10.4% and 22.1%, respectively. Furthermore, E2 and SHBG mediated the 
      relationship of zinc with FBG, with a mediation ratio of 7.8% and 14.5%, 
      respectively. E2 mediated 11.5% of positive relationship between tin with FBG. 
      Our study suggested that the associations of metals exposure with FBG may be 
      mediated by reproductive hormones.
CI  - Copyright © 2021 Elsevier Ltd. All rights reserved.
FAU - Zan, Gaohui
AU  - Zan G
AD  - Department of Occupational Health and Environmental Health, School of Public 
      Health, Guangxi Medical University, Nanning, Guangxi, China; Center for Genomic 
      and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, China; 
      Guangxi Key Laboratory for Genomic and Personalized Medicine, Nanning, Guangxi, 
      China; Guangxi Collaborative Innovation Center for Genomic and Personalized 
      Medicine, Nanning, Guangxi, China.
FAU - Li, Longman
AU  - Li L
AD  - Center for Genomic and Personalized Medicine, Guangxi Medical University, 
      Nanning, Guangxi, China; Guangxi Key Laboratory for Genomic and Personalized 
      Medicine, Nanning, Guangxi, China; Guangxi Collaborative Innovation Center for 
      Genomic and Personalized Medicine, Nanning, Guangxi, China.
FAU - Cheng, Hong
AU  - Cheng H
AD  - Department of Occupational Health and Environmental Health, School of Public 
      Health, Guangxi Medical University, Nanning, Guangxi, China; Center for Genomic 
      and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, China; 
      Guangxi Key Laboratory for Genomic and Personalized Medicine, Nanning, Guangxi, 
      China; Guangxi Collaborative Innovation Center for Genomic and Personalized 
      Medicine, Nanning, Guangxi, China.
FAU - Huang, Lulu
AU  - Huang L
AD  - Department of Occupational Health and Environmental Health, School of Public 
      Health, Guangxi Medical University, Nanning, Guangxi, China; Center for Genomic 
      and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, China; 
      Guangxi Key Laboratory for Genomic and Personalized Medicine, Nanning, Guangxi, 
      China; Guangxi Collaborative Innovation Center for Genomic and Personalized 
      Medicine, Nanning, Guangxi, China.
FAU - Huang, Sifang
AU  - Huang S
AD  - Department of Occupational Health and Environmental Health, School of Public 
      Health, Guangxi Medical University, Nanning, Guangxi, China; Center for Genomic 
      and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, China; 
      Guangxi Key Laboratory for Genomic and Personalized Medicine, Nanning, Guangxi, 
      China; Guangxi Collaborative Innovation Center for Genomic and Personalized 
      Medicine, Nanning, Guangxi, China.
FAU - Luo, Xiaoyu
AU  - Luo X
AD  - Department of Occupational Health and Environmental Health, School of Public 
      Health, Guangxi Medical University, Nanning, Guangxi, China; Center for Genomic 
      and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, China; 
      Guangxi Key Laboratory for Genomic and Personalized Medicine, Nanning, Guangxi, 
      China; Guangxi Collaborative Innovation Center for Genomic and Personalized 
      Medicine, Nanning, Guangxi, China.
FAU - Xiao, Lili
AU  - Xiao L
AD  - Department of Occupational Health and Environmental Health, School of Public 
      Health, Guangxi Medical University, Nanning, Guangxi, China.
FAU - Liu, Chaoqun
AU  - Liu C
AD  - Department of Nutrition and Food Hygiene, School of Public Health, Guangxi 
      Medical University, Nanning, Guangxi, China.
FAU - Zhang, Haiying
AU  - Zhang H
AD  - Department of Occupational Health and Environmental Health, School of Public 
      Health, Guangxi Medical University, Nanning, Guangxi, China; Center for Genomic 
      and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, China; 
      Guangxi Key Laboratory for Genomic and Personalized Medicine, Nanning, Guangxi, 
      China; Guangxi Collaborative Innovation Center for Genomic and Personalized 
      Medicine, Nanning, Guangxi, China.
FAU - Mo, Zengnan
AU  - Mo Z
AD  - Center for Genomic and Personalized Medicine, Guangxi Medical University, 
      Nanning, Guangxi, China; Guangxi Key Laboratory for Genomic and Personalized 
      Medicine, Nanning, Guangxi, China; Guangxi Collaborative Innovation Center for 
      Genomic and Personalized Medicine, Nanning, Guangxi, China.
FAU - Yang, Xiaobo
AU  - Yang X
AD  - Department of Occupational Health and Environmental Health, School of Public 
      Health, Guangxi Medical University, Nanning, Guangxi, China; Center for Genomic 
      and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, China; 
      Guangxi Key Laboratory for Genomic and Personalized Medicine, Nanning, Guangxi, 
      China; Guangxi Collaborative Innovation Center for Genomic and Personalized 
      Medicine, Nanning, Guangxi, China; Guangxi Colleges and Universities Key 
      Laboratory of Prevention and Control of Highly Prevalent Diseases, Guangxi 
      Medical University, Nanning, Guangxi, China; Department of Public Health, School 
      of Medicine, Guangxi University of Science and Technology, Liuzhou, Guangxi, 
      China. Electronic address: yangx@gxmu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20210219
PL  - England
TA  - Environ Pollut
JT  - Environmental pollution (Barking, Essex : 1987)
JID - 8804476
RN  - 0 (Blood Glucose)
RN  - 0 (Sex Hormone-Binding Globulin)
RN  - 3XMK78S47O (Testosterone)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - *Blood Glucose
MH  - China
MH  - Cross-Sectional Studies
MH  - Estradiol
MH  - *Fasting
MH  - Humans
MH  - Male
MH  - Sex Hormone-Binding Globulin
MH  - Testosterone
OTO - NOTNLM
OT  - Fasting blood glucose
OT  - Mediation
OT  - Multiple serum metals
OT  - Reproductive hormones
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2021/03/09 06:00
MHDA- 2021/04/21 06:00
CRDT- 2021/03/08 20:13
PHST- 2020/07/19 00:00 [received]
PHST- 2021/02/16 00:00 [revised]
PHST- 2021/02/17 00:00 [accepted]
PHST- 2021/03/09 06:00 [pubmed]
PHST- 2021/04/21 06:00 [medline]
PHST- 2021/03/08 20:13 [entrez]
AID - S0269-7491(21)00371-7 [pii]
AID - 10.1016/j.envpol.2021.116791 [doi]
PST - ppublish
SO  - Environ Pollut. 2021 Jun 1;278:116791. doi: 10.1016/j.envpol.2021.116791. Epub 
      2021 Feb 19.

PMID- 29157823
OWN - NLM
STAT- MEDLINE
DCOM- 20180426
LR  - 20181202
IS  - 1618-095X (Electronic)
IS  - 0944-7113 (Linking)
VI  - 36
DP  - 2017 Dec 1
TI  - Lespedeza bicolor ameliorates endothelial dysfunction induced by methylglyoxal 
      glucotoxicity.
PG  - 26-36
LID - S0944-7113(17)30123-X [pii]
LID - 10.1016/j.phymed.2017.09.005 [doi]
AB  - BACKGROUND: Lespedeza species have been used as a traditional medicine to treat 
      nephritis, azotemia, inflammation, energy depletion, diabetes, and diuresis. 
      PURPOSE: The purpose of this study is to screen the most potent Lespedeza species 
      against methylglyoxal (MGO)-induced glucotoxicity, and to elucidate the 
      mechanisms of action. Also, we will attempt to identify small chemical 
      metabolites that might be responsible for such anti-glucotoxicity effects. 
      METHODS: Firstly, the protective effect of 26 different Lespedeza species against 
      MGO-induced toxicity in human umbilical vein endothelial cells was investigated. 
      The chemical metabolites of the most potent species (Lespedeza bicolor 1 (LB1) 
      were identified by high pressure liquid chromatography quadrupole time-of-flight 
      tandem mass spectrometry (HPLC-Q-TOF-MS/MS), then quantified by HPLC. The effects 
      of LB1 on MGO-induced apoptosis were measured by annexin V-FITC staining and 
      western blot. Inhibitory effects of LB1 on MGO-induced ROS generation, and effect 
      of LB1 on advanced glycation end products (AGEs) inhibitor or a glycated 
      cross-link breaker are also measured. RESULTS: Among different Lespedeza species, 
      LB1 extract was shown to reduce intracellular reactive oxidative species, exhibit 
      anti-apoptotic effects, strongly inhibit all the mitogen-activated protein kinase 
      signals, inhibit MGO-induced AGEs formation, and break down preformed AGEs. We 
      tentatively identified 17 chemical constituents of LB1 by HPLC-Q-TOF-MS/MS. Among 
      those, some components, such as genistein and quercetin, significantly reduced 
      the AGEs formation and increased the AGEs-breaking activity, resulting in the 
      reduction of glucotoxicity. CONCLUSION: LB1 extract has shown to be effective in 
      preventing or treating MGO-induced endothelial dysfunction.
CI  - Copyright © 2017 Elsevier GmbH. All rights reserved.
FAU - Do, Moon Ho
AU  - Do MH
AD  - College of Pharmacy, Gachon University, #191, Hambakmoero, Yeonsu-gu, Incheon 
      21936, Republic of Korea.
FAU - Lee, Jae Hyuk
AU  - Lee JH
AD  - College of Pharmacy, Gachon University, #191, Hambakmoero, Yeonsu-gu, Incheon 
      21936, Republic of Korea.
FAU - Wahedi, Hussain Mustatab
AU  - Wahedi HM
AD  - College of Pharmacy, Gachon University, #191, Hambakmoero, Yeonsu-gu, Incheon 
      21936, Republic of Korea.
FAU - Pak, Chaeho
AU  - Pak C
AD  - College of Pharmacy, Gachon University, #191, Hambakmoero, Yeonsu-gu, Incheon 
      21936, Republic of Korea.
FAU - Lee, Choong Hwan
AU  - Lee CH
AD  - Department of Bioscience and Biotechnology, Konkuk University, 120 Neungdong-ro, 
      Gwangjin-gu, Seoul 05029, Republic of Korea.
FAU - Yeo, Eui-Ju
AU  - Yeo EJ
AD  - Department of Biochemistry, Gachon University College of Medicine, #155 
      Gaetbeal-ro, Yeonsu-gu, Incheon 21999, Republic of Korea.
FAU - Lim, Yunsook
AU  - Lim Y
AD  - Department of Food and Nutrition, Kyung Hee University, Seoul, Republic of Korea.
FAU - Ha, Sang Keun
AU  - Ha SK
AD  - Division of Functional Food Research, Korea Food Research Institute, Sungnam, 
      Gyeonggi-do, Republic of Korea.
FAU - Choi, Inwook
AU  - Choi I
AD  - Division of Functional Food Research, Korea Food Research Institute, Sungnam, 
      Gyeonggi-do, Republic of Korea.
FAU - Kim, Sun Yeou
AU  - Kim SY
AD  - College of Pharmacy, Gachon University, #191, Hambakmoero, Yeonsu-gu, Incheon 
      21936, Republic of Korea; Gachon Institute of Pharmaceutical Science, Gachon 
      University, #191, Hambakmoero, Yeonsu-gu, Incheon 21936, Republic of Korea; 
      Gachon Medical Research Institute, Gil Medical Center, 21, Namdong-daero 
      774beon-gil, Namdong-gu, Incheon, 21565, Republic of Korea. Electronic address: 
      sunnykim@gachon.ac.kr.
LA  - eng
PT  - Journal Article
DEP - 20170923
PL  - Germany
TA  - Phytomedicine
JT  - Phytomedicine : international journal of phytotherapy and phytopharmacology
JID - 9438794
RN  - 0 (Glycation End Products, Advanced)
RN  - 0 (Plant Extracts)
RN  - 0 (Reactive Oxygen Species)
RN  - 722KLD7415 (Pyruvaldehyde)
RN  - 9IKM0I5T1E (Quercetin)
RN  - DH2M523P0H (Genistein)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
SB  - IM
MH  - Apoptosis/drug effects
MH  - Chromatography, High Pressure Liquid
MH  - Drug Evaluation, Preclinical/methods
MH  - Genistein/analysis/pharmacology
MH  - Glycation End Products, Advanced/metabolism
MH  - Human Umbilical Vein Endothelial Cells
MH  - Humans
MH  - Lespedeza/*chemistry/metabolism
MH  - Mitogen-Activated Protein Kinases/metabolism
MH  - Plant Extracts/chemistry/*pharmacology
MH  - Plants, Medicinal/chemistry
MH  - Pyruvaldehyde/*toxicity
MH  - Quercetin/analysis/pharmacology
MH  - Reactive Oxygen Species/metabolism
MH  - Tandem Mass Spectrometry
OTO - NOTNLM
OT  - Advanced glycation end products (AGEs)
OT  - Apoptosis
OT  - Human umbilical vein endothelial cells
OT  - Lespedeza bicolor (LB)
OT  - Methylglyoxal (MGO)
OT  - Reactive oxygen species (ROS)
EDAT- 2017/11/22 06:00
MHDA- 2018/04/27 06:00
CRDT- 2017/11/22 06:00
PHST- 2016/10/04 00:00 [received]
PHST- 2017/06/26 00:00 [revised]
PHST- 2017/09/21 00:00 [accepted]
PHST- 2017/11/22 06:00 [entrez]
PHST- 2017/11/22 06:00 [pubmed]
PHST- 2018/04/27 06:00 [medline]
AID - S0944-7113(17)30123-X [pii]
AID - 10.1016/j.phymed.2017.09.005 [doi]
PST - ppublish
SO  - Phytomedicine. 2017 Dec 1;36:26-36. doi: 10.1016/j.phymed.2017.09.005. Epub 2017 
      Sep 23.

PMID- 26298324
OWN - NLM
STAT- MEDLINE
DCOM- 20151110
LR  - 20190130
IS  - 1872-8421 (Electronic)
IS  - 0165-5728 (Linking)
VI  - 286
DP  - 2015 Sep 15
TI  - Vitamin D and estrogen synergy in Vdr-expressing CD4(+) T cells is essential to 
      induce Helios(+)FoxP3(+) T cells and prevent autoimmune demyelinating disease.
PG  - 48-58
LID - S0165-5728(15)00170-8 [pii]
LID - 10.1016/j.jneuroim.2015.06.015 [doi]
AB  - Multiple sclerosis (MS) is a neurodegenerative disease resulting from an 
      autoimmune attack on the axon-myelin unit. A female MS bias becomes evident after 
      puberty and female incidence has tripled in the last half-century, implicating a 
      female sex hormone interacting with a modifiable environmental factor. These 
      aspects of MS suggest that many female MS cases may be preventable. Mechanistic 
      knowledge of this hormone-environment interaction is needed to devise strategies 
      to reduce female MS risk. We previously demonstrated that vitamin D3 (D3) 
      deficiency increases and D3 supplementation decreases experimental autoimmune 
      encephalomyelitis (EAE) risk in a female-biased manner. We also showed that D3 
      acts in an estrogen (E2)-dependent manner, since ovariectomy eliminated and E2 
      restored D3-mediated EAE protection. Here we probed the hypothesis that E2 and D3 
      interact synergistically within CD4(+) T cells to control T cell fate and prevent 
      demyelinating disease. The E2 increased EAE resistance in wild-type (WT) but not 
      T-Vdr(0) mice lacking Vdr gene function in CD4(+) T cells, so E2 action depended 
      entirely on Vdr(+)CD4(+) T cells. The E2 levels were higher in WT than T-Vdr(0) 
      mice, suggesting the Vdr(+)CD4(+) T cells produced E2 or stimulated its 
      production. The E2 decreased Cyp24a1 and increased Vdr transcripts in T cells, 
      prolonging the calcitriol half-life and increasing calcitriol responsiveness. The 
      E2 also increased CD4(+)Helios(+)FoxP3(+) T regulatory (Treg) cells in a 
      Vdr-dependent manner. Thus, CD4(+) T cells have a cooperative amplification loop 
      involving E2 and calcitriol that promotes CD4(+)Helios(+)FoxP3(+) Treg cell 
      development and is disrupted when the D3 pathway is impaired. The global decline 
      in population D3 status may be undermining a similar cooperative E2-D3 
      interaction controlling Treg cell differentiation in women, causing a breakdown 
      in T cell self tolerance and a rise in MS incidence.
CI  - Copyright © 2015 Elsevier B.V. All rights reserved.
FAU - Spanier, Justin A
AU  - Spanier JA
AD  - Department of Medicine, Center for Immunology, University of Minnesota, 
      Minneapolis, MN, USA.
FAU - Nashold, Faye E
AU  - Nashold FE
AD  - Department of Biochemistry, College of Agricultural and Life Sciences, University 
      of Wisconsin-Madison, WI, USA.
FAU - Mayne, Christopher G
AU  - Mayne CG
AD  - Department of Biology, Viterbo University, La Crosse, WI, USA.
FAU - Nelson, Corwin D
AU  - Nelson CD
AD  - Department of Animal Sciences, University of Florida, Gainesville, FL, USA.
FAU - Hayes, Colleen E
AU  - Hayes CE
AD  - Department of Biochemistry, College of Agricultural and Life Sciences, University 
      of Wisconsin-Madison, WI, USA. Electronic address: hayes@biochem.wisc.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150704
PL  - Netherlands
TA  - J Neuroimmunol
JT  - Journal of neuroimmunology
JID - 8109498
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Estrogens)
RN  - 0 (Forkhead Transcription Factors)
RN  - 0 (Foxp3 protein, mouse)
RN  - 0 (Myelin-Oligodendrocyte Glycoprotein)
RN  - 0 (Peptide Fragments)
RN  - 0 (Receptors, Calcitriol)
RN  - 0 (Transcription Factors)
RN  - 0 (Zfpn1a2 protein, mouse)
RN  - 0 (myelin oligodendrocyte glycoprotein (35-55))
RN  - 1406-16-2 (Vitamin D)
SB  - IM
MH  - Animals
MH  - Autoimmune Diseases of the Nervous System/chemically 
      induced/genetics/pathology/*prevention & control
MH  - CD4-Positive T-Lymphocytes/drug effects/*metabolism
MH  - DNA-Binding Proteins/genetics/*metabolism
MH  - Disease Models, Animal
MH  - Drug Synergism
MH  - Estrogens/*administration & dosage
MH  - Female
MH  - Forkhead Transcription Factors/genetics/*metabolism
MH  - Gene Expression Regulation, Developmental/drug effects/genetics
MH  - In Vitro Techniques
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Transgenic
MH  - Myelin-Oligodendrocyte Glycoprotein/toxicity
MH  - Ovariectomy
MH  - Peptide Fragments/toxicity
MH  - Pregnancy
MH  - Receptors, Calcitriol/genetics/*metabolism
MH  - T-Lymphocytes, Regulatory/drug effects/*metabolism
MH  - Time Factors
MH  - Transcription Factors/genetics/*metabolism
MH  - Uterus/pathology
MH  - Vitamin D/*administration & dosage
OTO - NOTNLM
OT  - Estrogen
OT  - Experimental autoimmune encephalomyelitis
OT  - HeliosFoxP3 T cells
OT  - Multiple sclerosis
OT  - Prevention
OT  - Vitamin D
EDAT- 2015/08/25 06:00
MHDA- 2015/11/11 06:00
CRDT- 2015/08/24 06:00
PHST- 2015/03/18 00:00 [received]
PHST- 2015/06/16 00:00 [revised]
PHST- 2015/06/19 00:00 [accepted]
PHST- 2015/08/24 06:00 [entrez]
PHST- 2015/08/25 06:00 [pubmed]
PHST- 2015/11/11 06:00 [medline]
AID - S0165-5728(15)00170-8 [pii]
AID - 10.1016/j.jneuroim.2015.06.015 [doi]
PST - ppublish
SO  - J Neuroimmunol. 2015 Sep 15;286:48-58. doi: 10.1016/j.jneuroim.2015.06.015. Epub 
      2015 Jul 4.

PMID- 26681757
OWN - NLM
STAT- MEDLINE
DCOM- 20160603
LR  - 20240610
IS  - 1524-4636 (Electronic)
IS  - 1079-5642 (Print)
IS  - 1079-5642 (Linking)
VI  - 36
IP  - 2
DP  - 2016 Feb
TI  - Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of 
      Coronary Heart Disease Due To Combined Estrogen Plus Progestin Therapy.
PG  - 418-24
LID - 10.1161/ATVBAHA.115.306905 [doi]
AB  - OBJECTIVE: To examine whether tissue factor pathway inhibitor or acquired 
      activated protein C (APC) resistance influences the increased risk of coronary 
      heart disease (CHD) due to estrogen plus progestin therapy. APPROACH AND RESULTS: 
      Prospective nested case-control study of 205 cases of CHD and 481 matched 
      controls in the Women's Health Initiative randomized trial of estrogen plus 
      progestin therapy. After multivariable covariate adjustment, both baseline tissue 
      factor pathway activity (P=0.01) and APC resistance (P=0.004) were associated 
      positively with CHD risk. Baseline tissue factor pathway activity and APC 
      resistance singly or jointly did not significantly modify the effect of estrogen 
      plus progestin on CHD risk. Compared with placebo, estrogen plus progestin 
      decreased tissue factor pathway inhibitor activity and increased APC resistance 
      but these changes did not seem to modify or mediate the effect of estrogen plus 
      progestin on CHD risk. CONCLUSIONS: Tissue factor pathway inhibitor activity and 
      APC resistance are related to CHD risk in women, but may not explain the 
      increased CHD risk due to estrogen plus progestin therapy. The data from this 
      study do not support the clinical use of measuring these hemostatic factors to 
      help stratify risk before hormone therapy. CLINICAL TRIAL REGISTRATION: URL: 
      http://www.clinicaltrials.gov. Unique identifier: NCT00000611.
CI  - © 2015 American Heart Association, Inc.
FAU - Johnson, Karen C
AU  - Johnson KC
AD  - From the Department of Preventive Medicine, University of Tennessee Health 
      Science Center, Memphis, TN (K.C.J.); Fred Hutchinson Cancer Research Center, 
      Seattle, WA (A.K.A., A.R.); Ohio State University Medical Center, Columbus, OH 
      (R.J.); Oslo University Hospital and University of Oslo, Oslo, Norway (P.M.S., 
      A.E.A.D.); Maastrich University, Maastrich, The Netherlands (J.R.); University of 
      Leiden, Leiden, The Netherlands (F.R.); Brigham and Women's Hospital, Harvard 
      University, Boston, MA (J.E.M.); George Washington University, Washington, DC 
      (L.W.M.); Brown University, Providence, RI (S.L.); University of Pittsburgh, PA 
      (L.H.K.); University of Vermont, Burlington, VT (M.C.); and National Heart, Lung, 
      and Blood Institute, Bethesda, MD (J.E.R.). kjohnson@uthsc.edu.
FAU - Aragaki, Aaron K
AU  - Aragaki AK
AD  - From the Department of Preventive Medicine, University of Tennessee Health 
      Science Center, Memphis, TN (K.C.J.); Fred Hutchinson Cancer Research Center, 
      Seattle, WA (A.K.A., A.R.); Ohio State University Medical Center, Columbus, OH 
      (R.J.); Oslo University Hospital and University of Oslo, Oslo, Norway (P.M.S., 
      A.E.A.D.); Maastrich University, Maastrich, The Netherlands (J.R.); University of 
      Leiden, Leiden, The Netherlands (F.R.); Brigham and Women's Hospital, Harvard 
      University, Boston, MA (J.E.M.); George Washington University, Washington, DC 
      (L.W.M.); Brown University, Providence, RI (S.L.); University of Pittsburgh, PA 
      (L.H.K.); University of Vermont, Burlington, VT (M.C.); and National Heart, Lung, 
      and Blood Institute, Bethesda, MD (J.E.R.).
FAU - Jackson, Rebecca
AU  - Jackson R
AD  - From the Department of Preventive Medicine, University of Tennessee Health 
      Science Center, Memphis, TN (K.C.J.); Fred Hutchinson Cancer Research Center, 
      Seattle, WA (A.K.A., A.R.); Ohio State University Medical Center, Columbus, OH 
      (R.J.); Oslo University Hospital and University of Oslo, Oslo, Norway (P.M.S., 
      A.E.A.D.); Maastrich University, Maastrich, The Netherlands (J.R.); University of 
      Leiden, Leiden, The Netherlands (F.R.); Brigham and Women's Hospital, Harvard 
      University, Boston, MA (J.E.M.); George Washington University, Washington, DC 
      (L.W.M.); Brown University, Providence, RI (S.L.); University of Pittsburgh, PA 
      (L.H.K.); University of Vermont, Burlington, VT (M.C.); and National Heart, Lung, 
      and Blood Institute, Bethesda, MD (J.E.R.).
FAU - Reiner, Alex
AU  - Reiner A
AD  - From the Department of Preventive Medicine, University of Tennessee Health 
      Science Center, Memphis, TN (K.C.J.); Fred Hutchinson Cancer Research Center, 
      Seattle, WA (A.K.A., A.R.); Ohio State University Medical Center, Columbus, OH 
      (R.J.); Oslo University Hospital and University of Oslo, Oslo, Norway (P.M.S., 
      A.E.A.D.); Maastrich University, Maastrich, The Netherlands (J.R.); University of 
      Leiden, Leiden, The Netherlands (F.R.); Brigham and Women's Hospital, Harvard 
      University, Boston, MA (J.E.M.); George Washington University, Washington, DC 
      (L.W.M.); Brown University, Providence, RI (S.L.); University of Pittsburgh, PA 
      (L.H.K.); University of Vermont, Burlington, VT (M.C.); and National Heart, Lung, 
      and Blood Institute, Bethesda, MD (J.E.R.).
FAU - Sandset, Per Morten
AU  - Sandset PM
AD  - From the Department of Preventive Medicine, University of Tennessee Health 
      Science Center, Memphis, TN (K.C.J.); Fred Hutchinson Cancer Research Center, 
      Seattle, WA (A.K.A., A.R.); Ohio State University Medical Center, Columbus, OH 
      (R.J.); Oslo University Hospital and University of Oslo, Oslo, Norway (P.M.S., 
      A.E.A.D.); Maastrich University, Maastrich, The Netherlands (J.R.); University of 
      Leiden, Leiden, The Netherlands (F.R.); Brigham and Women's Hospital, Harvard 
      University, Boston, MA (J.E.M.); George Washington University, Washington, DC 
      (L.W.M.); Brown University, Providence, RI (S.L.); University of Pittsburgh, PA 
      (L.H.K.); University of Vermont, Burlington, VT (M.C.); and National Heart, Lung, 
      and Blood Institute, Bethesda, MD (J.E.R.).
FAU - Rosing, Jan
AU  - Rosing J
AD  - From the Department of Preventive Medicine, University of Tennessee Health 
      Science Center, Memphis, TN (K.C.J.); Fred Hutchinson Cancer Research Center, 
      Seattle, WA (A.K.A., A.R.); Ohio State University Medical Center, Columbus, OH 
      (R.J.); Oslo University Hospital and University of Oslo, Oslo, Norway (P.M.S., 
      A.E.A.D.); Maastrich University, Maastrich, The Netherlands (J.R.); University of 
      Leiden, Leiden, The Netherlands (F.R.); Brigham and Women's Hospital, Harvard 
      University, Boston, MA (J.E.M.); George Washington University, Washington, DC 
      (L.W.M.); Brown University, Providence, RI (S.L.); University of Pittsburgh, PA 
      (L.H.K.); University of Vermont, Burlington, VT (M.C.); and National Heart, Lung, 
      and Blood Institute, Bethesda, MD (J.E.R.).
FAU - Dahm, Anders E A
AU  - Dahm AE
AD  - From the Department of Preventive Medicine, University of Tennessee Health 
      Science Center, Memphis, TN (K.C.J.); Fred Hutchinson Cancer Research Center, 
      Seattle, WA (A.K.A., A.R.); Ohio State University Medical Center, Columbus, OH 
      (R.J.); Oslo University Hospital and University of Oslo, Oslo, Norway (P.M.S., 
      A.E.A.D.); Maastrich University, Maastrich, The Netherlands (J.R.); University of 
      Leiden, Leiden, The Netherlands (F.R.); Brigham and Women's Hospital, Harvard 
      University, Boston, MA (J.E.M.); George Washington University, Washington, DC 
      (L.W.M.); Brown University, Providence, RI (S.L.); University of Pittsburgh, PA 
      (L.H.K.); University of Vermont, Burlington, VT (M.C.); and National Heart, Lung, 
      and Blood Institute, Bethesda, MD (J.E.R.).
FAU - Rosendaal, Frits
AU  - Rosendaal F
AD  - From the Department of Preventive Medicine, University of Tennessee Health 
      Science Center, Memphis, TN (K.C.J.); Fred Hutchinson Cancer Research Center, 
      Seattle, WA (A.K.A., A.R.); Ohio State University Medical Center, Columbus, OH 
      (R.J.); Oslo University Hospital and University of Oslo, Oslo, Norway (P.M.S., 
      A.E.A.D.); Maastrich University, Maastrich, The Netherlands (J.R.); University of 
      Leiden, Leiden, The Netherlands (F.R.); Brigham and Women's Hospital, Harvard 
      University, Boston, MA (J.E.M.); George Washington University, Washington, DC 
      (L.W.M.); Brown University, Providence, RI (S.L.); University of Pittsburgh, PA 
      (L.H.K.); University of Vermont, Burlington, VT (M.C.); and National Heart, Lung, 
      and Blood Institute, Bethesda, MD (J.E.R.).
FAU - Manson, JoAnn E
AU  - Manson JE
AD  - From the Department of Preventive Medicine, University of Tennessee Health 
      Science Center, Memphis, TN (K.C.J.); Fred Hutchinson Cancer Research Center, 
      Seattle, WA (A.K.A., A.R.); Ohio State University Medical Center, Columbus, OH 
      (R.J.); Oslo University Hospital and University of Oslo, Oslo, Norway (P.M.S., 
      A.E.A.D.); Maastrich University, Maastrich, The Netherlands (J.R.); University of 
      Leiden, Leiden, The Netherlands (F.R.); Brigham and Women's Hospital, Harvard 
      University, Boston, MA (J.E.M.); George Washington University, Washington, DC 
      (L.W.M.); Brown University, Providence, RI (S.L.); University of Pittsburgh, PA 
      (L.H.K.); University of Vermont, Burlington, VT (M.C.); and National Heart, Lung, 
      and Blood Institute, Bethesda, MD (J.E.R.).
FAU - Martin, Lisa W
AU  - Martin LW
AD  - From the Department of Preventive Medicine, University of Tennessee Health 
      Science Center, Memphis, TN (K.C.J.); Fred Hutchinson Cancer Research Center, 
      Seattle, WA (A.K.A., A.R.); Ohio State University Medical Center, Columbus, OH 
      (R.J.); Oslo University Hospital and University of Oslo, Oslo, Norway (P.M.S., 
      A.E.A.D.); Maastrich University, Maastrich, The Netherlands (J.R.); University of 
      Leiden, Leiden, The Netherlands (F.R.); Brigham and Women's Hospital, Harvard 
      University, Boston, MA (J.E.M.); George Washington University, Washington, DC 
      (L.W.M.); Brown University, Providence, RI (S.L.); University of Pittsburgh, PA 
      (L.H.K.); University of Vermont, Burlington, VT (M.C.); and National Heart, Lung, 
      and Blood Institute, Bethesda, MD (J.E.R.).
FAU - Liu, Simin
AU  - Liu S
AD  - From the Department of Preventive Medicine, University of Tennessee Health 
      Science Center, Memphis, TN (K.C.J.); Fred Hutchinson Cancer Research Center, 
      Seattle, WA (A.K.A., A.R.); Ohio State University Medical Center, Columbus, OH 
      (R.J.); Oslo University Hospital and University of Oslo, Oslo, Norway (P.M.S., 
      A.E.A.D.); Maastrich University, Maastrich, The Netherlands (J.R.); University of 
      Leiden, Leiden, The Netherlands (F.R.); Brigham and Women's Hospital, Harvard 
      University, Boston, MA (J.E.M.); George Washington University, Washington, DC 
      (L.W.M.); Brown University, Providence, RI (S.L.); University of Pittsburgh, PA 
      (L.H.K.); University of Vermont, Burlington, VT (M.C.); and National Heart, Lung, 
      and Blood Institute, Bethesda, MD (J.E.R.).
FAU - Kuller, Lewis H
AU  - Kuller LH
AD  - From the Department of Preventive Medicine, University of Tennessee Health 
      Science Center, Memphis, TN (K.C.J.); Fred Hutchinson Cancer Research Center, 
      Seattle, WA (A.K.A., A.R.); Ohio State University Medical Center, Columbus, OH 
      (R.J.); Oslo University Hospital and University of Oslo, Oslo, Norway (P.M.S., 
      A.E.A.D.); Maastrich University, Maastrich, The Netherlands (J.R.); University of 
      Leiden, Leiden, The Netherlands (F.R.); Brigham and Women's Hospital, Harvard 
      University, Boston, MA (J.E.M.); George Washington University, Washington, DC 
      (L.W.M.); Brown University, Providence, RI (S.L.); University of Pittsburgh, PA 
      (L.H.K.); University of Vermont, Burlington, VT (M.C.); and National Heart, Lung, 
      and Blood Institute, Bethesda, MD (J.E.R.).
FAU - Cushman, Mary
AU  - Cushman M
AD  - From the Department of Preventive Medicine, University of Tennessee Health 
      Science Center, Memphis, TN (K.C.J.); Fred Hutchinson Cancer Research Center, 
      Seattle, WA (A.K.A., A.R.); Ohio State University Medical Center, Columbus, OH 
      (R.J.); Oslo University Hospital and University of Oslo, Oslo, Norway (P.M.S., 
      A.E.A.D.); Maastrich University, Maastrich, The Netherlands (J.R.); University of 
      Leiden, Leiden, The Netherlands (F.R.); Brigham and Women's Hospital, Harvard 
      University, Boston, MA (J.E.M.); George Washington University, Washington, DC 
      (L.W.M.); Brown University, Providence, RI (S.L.); University of Pittsburgh, PA 
      (L.H.K.); University of Vermont, Burlington, VT (M.C.); and National Heart, Lung, 
      and Blood Institute, Bethesda, MD (J.E.R.).
FAU - Rossouw, Jacques E
AU  - Rossouw JE
AD  - From the Department of Preventive Medicine, University of Tennessee Health 
      Science Center, Memphis, TN (K.C.J.); Fred Hutchinson Cancer Research Center, 
      Seattle, WA (A.K.A., A.R.); Ohio State University Medical Center, Columbus, OH 
      (R.J.); Oslo University Hospital and University of Oslo, Oslo, Norway (P.M.S., 
      A.E.A.D.); Maastrich University, Maastrich, The Netherlands (J.R.); University of 
      Leiden, Leiden, The Netherlands (F.R.); Brigham and Women's Hospital, Harvard 
      University, Boston, MA (J.E.M.); George Washington University, Washington, DC 
      (L.W.M.); Brown University, Providence, RI (S.L.); University of Pittsburgh, PA 
      (L.H.K.); University of Vermont, Burlington, VT (M.C.); and National Heart, Lung, 
      and Blood Institute, Bethesda, MD (J.E.R.).
LA  - eng
SI  - ClinicalTrials.gov/NCT00000611
GR  - HHSN268201100001I/HL/NHLBI NIH HHS/United States
GR  - HHSN271201100004C/AG/NIA NIH HHS/United States
GR  - HHSN268201100046C/HL/NHLBI NIH HHS/United States
GR  - HHSN268201100003C/WH/WHI NIH HHS/United States
GR  - HHSN268201100003C/WH/WHI NIH HHS/United States
GR  - HHSN268201100004C/WH/WHI NIH HHS/United States
GR  - HHSN271201100004C/AG/NIA NIH HHS/United States
GR  - HHSN268201100002C/WH/WHI NIH HHS/United States
GR  - HHSN268201100046C/HL/NHLBI NIH HHS/United States
GR  - HHSN268201100003I/HL/NHLBI NIH HHS/United States
GR  - HHSN268201100002I/HL/NHLBI NIH HHS/United States
GR  - HHSN268201100002C/WH/WHI NIH HHS/United States
GR  - HHSN268201100001C/WH/WHI NIH HHS/United States
GR  - HHSN268201100004C/WH/WHI NIH HHS/United States
GR  - HHSN268201100001C/WH/WHI NIH HHS/United States
GR  - HHSN268201100004I/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20151217
PL  - United States
TA  - Arterioscler Thromb Vasc Biol
JT  - Arteriosclerosis, thrombosis, and vascular biology
JID - 9505803
RN  - 0 (Biomarkers)
RN  - 0 (Estrogens)
RN  - 0 (Lipoproteins)
RN  - 0 (Progestins)
RN  - 0 (lipoprotein-associated coagulation inhibitor)
SB  - IM
MH  - Activated Protein C Resistance/blood/*complications/diagnosis
MH  - Aged
MH  - Biomarkers/blood
MH  - Case-Control Studies
MH  - Coronary Disease/blood/*chemically induced/diagnosis
MH  - Estrogen Replacement Therapy/*adverse effects
MH  - Estrogens/*adverse effects
MH  - Female
MH  - Humans
MH  - Lipoproteins/*metabolism
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Postmenopause
MH  - Progestins/*adverse effects
MH  - Prospective Studies
MH  - Risk Assessment
MH  - Risk Factors
PMC - PMC4732914
MID - NIHMS743435
OTO - NOTNLM
OT  - activated protein C resistance
OT  - coronary disease
OT  - estrogens
OT  - hemostatics
OT  - progestins
OT  - tissue factor pathway inhibitor activity
EDAT- 2015/12/19 06:00
MHDA- 2016/06/04 06:00
PMCR- 2017/02/01
CRDT- 2015/12/19 06:00
PHST- 2015/06/23 00:00 [received]
PHST- 2015/11/23 00:00 [accepted]
PHST- 2015/12/19 06:00 [entrez]
PHST- 2015/12/19 06:00 [pubmed]
PHST- 2016/06/04 06:00 [medline]
PHST- 2017/02/01 00:00 [pmc-release]
AID - ATVBAHA.115.306905 [pii]
AID - 10.1161/ATVBAHA.115.306905 [doi]
PST - ppublish
SO  - Arterioscler Thromb Vasc Biol. 2016 Feb;36(2):418-24. doi: 
      10.1161/ATVBAHA.115.306905. Epub 2015 Dec 17.

PMID- 33444226
OWN - NLM
STAT- MEDLINE
DCOM- 20210226
LR  - 20220420
IS  - 1479-683X (Electronic)
IS  - 0804-4643 (Linking)
VI  - 184
IP  - 3
DP  - 2021 Mar
TI  - Steroid reference intervals in women: influence of menopause, age and metabolism.
PG  - 395-407
LID - EJE-20-1147 [pii]
LID - 10.1530/EJE-20-1147 [doi]
AB  - OBJECTIVE: To investigate the impact of age, obesity and metabolic parameters on 
      13 circulating steroids in reproductive and menopausal age. To define reference 
      intervals (RIs). DESIGN: Cross-sectional. METHODS: Three hundred and twenty five 
      drug-free, healthy and eumenorrheic women were selected from the general 
      population. Independent relationships of LC-MS/MS-determined steroid levels with 
      age, BMI and metabolic parameters were estimated. Reference sub-cohorts were 
      defined for calculating upper and lower limits in reproductive age, menstrual 
      phases and menopause, and these were compared with limits in dysmetabolic 
      sub-cohorts. RESULTS: Lower androgens, pro-androgens and estrogens, but higher 
      cortisol and metabolites were found in menopausal compared to reproductive age 
      women. Androgens and precursors decreased during reproductive age (P < 0.001-P = 
      0.002) but not after menopause. 17OH-progesterone decreased with BMI (P = 0.006) 
      and glucocorticoids with waist circumference (P < 0.001P = 0.002) in reproductive 
      age, but increased with triglycerides (P=0.011P=0.038) after menopause. Inverse 
      associations of dihydrotestosterone with BMI (P=0.004) and HDL-cholesterol 
      (P=0.010), estrone with total cholesterol (P=0.033) and estradiol with 
      triglycerides (P=0.011) were found in reproductive age. After menopause, estrone 
      increased with waist circumference (P<0.001) and decreased with insulin 
      resistance (P=0.012). Ovarian steroid RIs were estimated in menstrual phases and 
      menopause. Age- and reproductive status-specific RIs were generated for 
      androgens, precursors and corticosteroids. Lower limits for reproductive age 
      cortisol (P=0.020) and menopausal 11-deoxycortisol (P=0.003) in dysmetabolic 
      sub-cohorts were reduced and increased, respectively, compared to reference 
      limits. CONCLUSIONS: Obesity and dysmetabolism differently influence circulating 
      steroids in reproductive and menopausal status. Age, menstrual and menopausal 
      status-specific RIs were provided by LC-MS/MS for a broad steroid panel.
FAU - Mezzullo, Marco
AU  - Mezzullo M
AD  - Department of Medical and Surgical Sciences, Unit of Endocrinology and Prevention 
      and Care of Diabetes, Center for Applied Biomedical Research, University of 
      Bologna, S.Orsola Policlinic, Bologna, Italy.
FAU - Gambineri, Alessandra
AU  - Gambineri A
AD  - Department of Medical and Surgical Sciences, Unit of Endocrinology and Prevention 
      and Care of Diabetes, Center for Applied Biomedical Research, University of 
      Bologna, S.Orsola Policlinic, Bologna, Italy.
FAU - Di Dalmazi, Guido
AU  - Di Dalmazi G
AUID- ORCID: 0000-0002-1291-8906
AD  - Department of Medical and Surgical Sciences, Unit of Endocrinology and Prevention 
      and Care of Diabetes, Center for Applied Biomedical Research, University of 
      Bologna, S.Orsola Policlinic, Bologna, Italy.
FAU - Fazzini, Alessia
AU  - Fazzini A
AD  - Department of Medical and Surgical Sciences, Unit of Endocrinology and Prevention 
      and Care of Diabetes, Center for Applied Biomedical Research, University of 
      Bologna, S.Orsola Policlinic, Bologna, Italy.
FAU - Magagnoli, Matteo
AU  - Magagnoli M
AD  - Department of Medical and Surgical Sciences, Unit of Endocrinology and Prevention 
      and Care of Diabetes, Center for Applied Biomedical Research, University of 
      Bologna, S.Orsola Policlinic, Bologna, Italy.
FAU - Baccini, Margherita
AU  - Baccini M
AD  - Department of Medical and Surgical Sciences, Unit of Endocrinology and Prevention 
      and Care of Diabetes, Center for Applied Biomedical Research, University of 
      Bologna, S.Orsola Policlinic, Bologna, Italy.
FAU - Vicennati, Valentina
AU  - Vicennati V
AD  - Department of Medical and Surgical Sciences, Unit of Endocrinology and Prevention 
      and Care of Diabetes, Center for Applied Biomedical Research, University of 
      Bologna, S.Orsola Policlinic, Bologna, Italy.
FAU - Pelusi, Carla
AU  - Pelusi C
AD  - Department of Medical and Surgical Sciences, Unit of Endocrinology and Prevention 
      and Care of Diabetes, Center for Applied Biomedical Research, University of 
      Bologna, S.Orsola Policlinic, Bologna, Italy.
FAU - Pagotto, Uberto
AU  - Pagotto U
AD  - Department of Medical and Surgical Sciences, Unit of Endocrinology and Prevention 
      and Care of Diabetes, Center for Applied Biomedical Research, University of 
      Bologna, S.Orsola Policlinic, Bologna, Italy.
FAU - Fanelli, Flaminia
AU  - Fanelli F
AD  - Department of Medical and Surgical Sciences, Unit of Endocrinology and Prevention 
      and Care of Diabetes, Center for Applied Biomedical Research, University of 
      Bologna, S.Orsola Policlinic, Bologna, Italy.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Eur J Endocrinol
JT  - European journal of endocrinology
JID - 9423848
RN  - 0 (Gonadal Steroid Hormones)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Aging/*blood/metabolism
MH  - Blood Chemical Analysis/methods/*standards
MH  - Chromatography, Liquid/standards
MH  - Cross-Sectional Studies
MH  - Diagnostic Techniques, Endocrine/standards
MH  - Energy Metabolism/*physiology
MH  - Female
MH  - Gonadal Steroid Hormones/analysis/*blood/standards
MH  - Humans
MH  - Menopause/*blood/metabolism
MH  - Middle Aged
MH  - Reference Values
MH  - Sex Factors
MH  - Tandem Mass Spectrometry/standards
MH  - Young Adult
EDAT- 2021/01/15 06:00
MHDA- 2021/02/27 06:00
CRDT- 2021/01/14 17:09
PHST- 2020/10/05 00:00 [received]
PHST- 2021/01/12 00:00 [accepted]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/02/27 06:00 [medline]
PHST- 2021/01/14 17:09 [entrez]
AID - EJE-20-1147 [pii]
AID - 10.1530/EJE-20-1147 [doi]
PST - ppublish
SO  - Eur J Endocrinol. 2021 Mar;184(3):395-407. doi: 10.1530/EJE-20-1147.

PMID- 32441855
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1439-0272 (Electronic)
IS  - 0303-4569 (Linking)
VI  - 52
IP  - 7
DP  - 2020 Aug
TI  - Simultaneous quantification of oestrogens and androgens in the serum of patients 
      with benign prostatic hyperplasia by liquid chromatography-Tandem mass 
      spectrometry.
PG  - e13611
LID - 10.1111/and.13611 [doi]
AB  - Benign prostate hyperplasia (BPH) is a common disease in elderly men. It has been 
      found that the occurrence of BPH was closely related to dysregulated steroid 
      hormones. Here, a rapid, sensitive, accurate and specific method for the 
      quantitative profiling of five androgens in man serum was developed and validated 
      by the use of liquid chromatography-tandem mass spectrometry (LC-MS/MS). Using 
      this method, dehydroepiandrosterone (DHEA), androstenedione (A4), testosterone 
      (T), androsterone (A), dihydrotestosterone (DHT), oestrone (E1) and oestradiol 
      (E2) were quantified in serum from man with and without BPH. BPH patients were 
      characterised by the decreases in DHEA, A4 and T as well as increases in DHT, E2 
      and E1 in serum. Meanwhile, DHEA and DHT in serum were screened as sensitive 
      biomarkers of BPH patients. This study will provide a new perspective of 
      dysregulated steroid hormones for the diagnosis and prevention of BPH.
CI  - © 2020 Blackwell Verlag GmbH.
FAU - Yang, Tingting
AU  - Yang T
AUID- ORCID: 0000-0003-3843-4325
AD  - Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical 
      University, Xuzhou, China.
FAU - Huang, Yuhan
AU  - Huang Y
AD  - Department of Pharmacy, The Affiliated Hospital of Xuzhou Medical University, 
      Xuzhou, China.
FAU - Zhou, Yi
AU  - Zhou Y
AD  - Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical 
      University, Xuzhou, China.
FAU - Chen, Shangxiu
AU  - Chen S
AD  - Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical 
      University, Xuzhou, China.
FAU - Wang, Haiyan
AU  - Wang H
AD  - Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical 
      University, Xuzhou, China.
FAU - Hu, Yinlu
AU  - Hu Y
AD  - Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical 
      University, Xuzhou, China.
FAU - Liu, Junjie
AU  - Liu J
AD  - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, 
      Xuzhou, China.
FAU - Jiang, Zhenzhou
AU  - Jiang Z
AD  - Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, 
      Nanjing, China.
FAU - Lu, Qian
AU  - Lu Q
AD  - Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical 
      University, Xuzhou, China.
FAU - Yin, Xiaoxing
AU  - Yin X
AD  - Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical 
      University, Xuzhou, China.
LA  - eng
GR  - 53681720/the initializing Fund of Xuzhou Medical University/
GR  - 81903689/National Natural Science Foundation of China/
GR  - 81973377/National Natural Science Foundation of China/
GR  - 19KJA460008/Key Natural Science Foundation of Jiangsu Higher Education 
      Institutions of China/
GR  - 19KJB350006/Key Natural Science Foundation of Jiangsu Higher Education 
      Institutions of China/
GR  - BRA2015329/Foundation of Jiangsu Province/
GR  - Jiangsu Overseas Research & Training Program for University Young & Middle-aged 
      Teachers and Presidents/
GR  - Priority Academic Program Development of Jiangsu Higher Education Institutions 
      (PAPD)/
PT  - Journal Article
DEP - 20200522
PL  - Germany
TA  - Andrologia
JT  - Andrologia
JID - 0423506
RN  - 0 (Androgens)
RN  - 0 (Estrogens)
RN  - 08J2K08A3Y (Dihydrotestosterone)
RN  - 3XMK78S47O (Testosterone)
RN  - 409J2J96VR (Androstenedione)
SB  - IM
MH  - Aged
MH  - *Androgens
MH  - Androstenedione
MH  - Chromatography, Liquid
MH  - Dihydrotestosterone
MH  - Estrogens
MH  - Humans
MH  - Male
MH  - *Prostatic Hyperplasia
MH  - Tandem Mass Spectrometry
MH  - Testosterone
OTO - NOTNLM
OT  - LC-MS/MS
OT  - androgens
OT  - benign prostate hyperplasia
OT  - clinical samples
OT  - hormones homeostasis
OT  - oestrogens
EDAT- 2020/05/23 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/05/23 06:00
PHST- 2020/02/15 00:00 [received]
PHST- 2020/03/29 00:00 [revised]
PHST- 2020/04/01 00:00 [accepted]
PHST- 2020/05/23 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/05/23 06:00 [entrez]
AID - 10.1111/and.13611 [doi]
PST - ppublish
SO  - Andrologia. 2020 Aug;52(7):e13611. doi: 10.1111/and.13611. Epub 2020 May 22.

PMID- 29558501
OWN - NLM
STAT- MEDLINE
DCOM- 20180720
LR  - 20221207
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 13
IP  - 3
DP  - 2018
TI  - The associations between plasma phytoestrogens concentration and metabolic 
      syndrome risks in Chinese population.
PG  - e0194639
LID - 10.1371/journal.pone.0194639 [doi]
LID - e0194639
AB  - Metabolic syndrome (MetS) has become an important issue in the healthcare systems 
      of both developed and developing countries. Phytoestrogens have shown estrogenic 
      effects, which may involve in the etiology of MetS. The current study consisted 
      of 293 MetS cases and 264 healthy controls. The concentrations of seven plasma 
      phytoestrogens (daidzein, genistein, glycitein, equol, enterolactone, enterodiol 
      and coumestrol) were detected by UPLC-MS/MS. Adjusted unconditional logistic 
      regression was used to assess the associations between plasma phytoestrogens 
      concentration and risks of MetS, as well as the associations between plasma 
      phytoestrogens concentration and MetS components. Linear regression was used to 
      evaluate the associations between equol concentration in equol-producers and MetS 
      components. Higher concentrations of total isoflavone and equol were associated 
      with decreased risk of MetS. The equol concentration was negatively associated 
      with waist circumference and positively associated with HDL-C level. Increased 
      daidzein was associated with both lower waist circumference and lower fasting 
      blood glucose levels. Our results suggested that higher plasma total isoflavone, 
      equol and daidzein might decrease MetS risk.
FAU - Liu, Jie
AU  - Liu J
AD  - Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, 
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 
      University of Chinese Academy of Sciences, Shanghai, China.
FAU - Mi, Shengquan
AU  - Mi S
AD  - College of Biochemical Engineering, Beijing Union University, Beijing, China.
FAU - Du, Li
AU  - Du L
AD  - Institute of Biostatistics, School of Life Science, Fudan University, Shanghai, 
      China.
FAU - Li, Xiang
AU  - Li X
AD  - Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, 
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 
      University of Chinese Academy of Sciences, Shanghai, China.
FAU - Li, Peiqin
AU  - Li P
AD  - Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, 
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 
      University of Chinese Academy of Sciences, Shanghai, China.
FAU - Jia, Keyu
AU  - Jia K
AD  - Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, 
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 
      University of Chinese Academy of Sciences, Shanghai, China.
FAU - Zhao, Jing
AU  - Zhao J
AD  - Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, 
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 
      University of Chinese Academy of Sciences, Shanghai, China.
FAU - Zhang, Hong
AU  - Zhang H
AD  - Institute of Biostatistics, School of Life Science, Fudan University, Shanghai, 
      China.
FAU - Zhao, Wenhua
AU  - Zhao W
AD  - National Institute for Nutrition and Health, Chinese Center of Disease Control 
      and Prevention, Beijing, China.
FAU - Gao, Ying
AU  - Gao Y
AUID- ORCID: 0000-0003-3943-9048
AD  - Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, 
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 
      University of Chinese Academy of Sciences, Shanghai, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180320
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Phytoestrogens)
SB  - IM
MH  - Adult
MH  - Asian People/statistics & numerical data
MH  - Case-Control Studies
MH  - China/epidemiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Metabolic Syndrome/blood/*epidemiology/etiology
MH  - Middle Aged
MH  - Phytoestrogens/*blood
MH  - Risk Factors
PMC - PMC5860756
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2018/03/21 06:00
MHDA- 2018/07/22 06:00
PMCR- 2018/03/20
CRDT- 2018/03/21 06:00
PHST- 2017/10/10 00:00 [received]
PHST- 2018/03/07 00:00 [accepted]
PHST- 2018/03/21 06:00 [entrez]
PHST- 2018/03/21 06:00 [pubmed]
PHST- 2018/07/22 06:00 [medline]
PHST- 2018/03/20 00:00 [pmc-release]
AID - PONE-D-17-36347 [pii]
AID - 10.1371/journal.pone.0194639 [doi]
PST - epublish
SO  - PLoS One. 2018 Mar 20;13(3):e0194639. doi: 10.1371/journal.pone.0194639. 
      eCollection 2018.

PMID- 25724466
OWN - NLM
STAT- MEDLINE
DCOM- 20160201
LR  - 20250103
IS  - 1096-0953 (Electronic)
IS  - 0013-9351 (Print)
IS  - 0013-9351 (Linking)
VI  - 142
DP  - 2015 Oct
TI  - Bisphenol A exposure and behavioral problems among inner city children at 7-9 
      years of age.
PG  - 739-45
LID - S0013-9351(15)00015-8 [pii]
LID - 10.1016/j.envres.2015.01.014 [doi]
AB  - BACKGROUND: Bisphenol A (BPA) is a ubiquitous endocrine disrupting compound. 
      Several experimental and epidemiological studies suggest that gestational BPA 
      exposure can lead to neurodevelopmental and behavioral problems in early-life, 
      but results have been inconsistent. We previously reported that prenatal BPA 
      exposure may affect child behavior and differently among boys and girls at ages 
      3-5 years. OBJECTIVES: We investigated the association of prenatal and early 
      childhood BPA exposure with behavioral outcomes in 7-9 year old minority children 
      and hypothesized that we would observe the same sex-specific pattern observed at 
      earlier ages. METHODS: African-American and Dominican women enrolled in an 
      inner-city prospective cohort study and their children were followed from 
      mother's pregnancy through children's age 7-9 years. Women during the third 
      trimester of pregnancy and children at ages 3 and 5 years provided spot urine 
      samples. BPA exposure was categorized by tertiles of BPA urinary concentrations. 
      The Child Behavioral Checklist (CBCL) was administered at ages 7 and 9 to assess 
      multiple child behavior domains. Associations between behavior and prenatal 
      (maternal) BPA concentrations and behavior and postnatal (child) BPA 
      concentration were assessed via Poisson regression in models stratified by sex. 
      These models accounted for potential confounders including prenatal or postnatal 
      urinary BPA concentrations, child age at CBCL assessment, ethnicity, gestational 
      age, maternal intelligence, maternal education and demoralization, quality of 
      child's home environment, prenatal environmental tobacco smoke exposure, and 
      prenatal mono-n-butyl phthalate concentration. RESULTS: The direction of the 
      associations differed between boys and girls. Among boys (n=115), high prenatal 
      BPA concentration (upper tertile vs. lower two tertiles) was associated with 
      increased internalizing (β=0.41, p<0.0001) and externalizing composite scores 
      (β=0.40, p<0.0001) and with their corresponding individual syndrome scales. There 
      was a general decrease in scores among girls that was significant for the 
      internalizing composite score (β=-0.17, p=0.04) (n=135). After accounting for 
      possible selection bias, the results remained consistent for boys. Conversely, 
      high postnatal BPA concentration was associated with increased behaviors on both 
      the internalizing composite (β=0.30, p=0.0002) and externalizing composite scores 
      (β=0.33, p<0.0001) and individual subscores in girls but fewer symptoms in boys. 
      These results remained significant in girls after accounting for selection bias. 
      CONCLUSION: These results suggest BPA exposure may affect childhood behavioral 
      outcomes in a sex-specific manner and differently depending on timing of 
      exposure.
CI  - Copyright © 2015 Elsevier Inc. All rights reserved.
FAU - Roen, Emily L
AU  - Roen EL
AD  - Department of Environmental Health Sciences, Mailman School of Public Health, 
      Columbia University, 722W. 168th St., New York, NY 10032, USA; Columbia Center 
      for Children's Environmental Health, Columbia University, 722W. 168th St., New 
      York, NY 10032, USA.
FAU - Wang, Ya
AU  - Wang Y
AD  - Columbia Center for Children's Environmental Health, Columbia University, 722W. 
      168th St., New York, NY 10032, USA; Department of Biostatistics, Mailman School 
      of Public Health, Columbia University, 722W. 168th St., New York, NY 10032, USA.
FAU - Calafat, Antonia M
AU  - Calafat AM
AD  - National Center for Environmental Health, Centers for Disease Control and 
      Prevention, 4770 Buford Hwy, MS F53, Atlanta, GA 30341, USA.
FAU - Wang, Shuang
AU  - Wang S
AD  - Columbia Center for Children's Environmental Health, Columbia University, 722W. 
      168th St., New York, NY 10032, USA; Department of Biostatistics, Mailman School 
      of Public Health, Columbia University, 722W. 168th St., New York, NY 10032, USA.
FAU - Margolis, Amy
AU  - Margolis A
AD  - Columbia Center for Children's Environmental Health, Columbia University, 722W. 
      168th St., New York, NY 10032, USA; Division of Child & Adolescent Psychiatry and 
      the Center for Developmental Neuropsychiatry, Department of Psychiatry, the New 
      York State Psychiatric Institute and the College of Physicians and Surgeons, 
      Columbia University, 1051 Riverside Drive, New York, NY 10032, USA.
FAU - Herbstman, Julie
AU  - Herbstman J
AD  - Department of Environmental Health Sciences, Mailman School of Public Health, 
      Columbia University, 722W. 168th St., New York, NY 10032, USA; Columbia Center 
      for Children's Environmental Health, Columbia University, 722W. 168th St., New 
      York, NY 10032, USA.
FAU - Hoepner, Lori A
AU  - Hoepner LA
AD  - Department of Environmental Health Sciences, Mailman School of Public Health, 
      Columbia University, 722W. 168th St., New York, NY 10032, USA; Columbia Center 
      for Children's Environmental Health, Columbia University, 722W. 168th St., New 
      York, NY 10032, USA.
FAU - Rauh, Virginia
AU  - Rauh V
AD  - Columbia Center for Children's Environmental Health, Columbia University, 722W. 
      168th St., New York, NY 10032, USA; The Heilbrunn Department of Population and 
      Family Health, Columbia University, 60 Haven Avenue, New York, NY 10032, USA.
FAU - Perera, Frederica P
AU  - Perera FP
AD  - Department of Environmental Health Sciences, Mailman School of Public Health, 
      Columbia University, 722W. 168th St., New York, NY 10032, USA; Columbia Center 
      for Children's Environmental Health, Columbia University, 722W. 168th St., New 
      York, NY 10032, USA. Electronic address: fpp1@columbia.edu.
LA  - eng
GR  - P01 ES009600/ES/NIEHS NIH HHS/United States
GR  - P01ES09600/ES/NIEHS NIH HHS/United States
GR  - R01 ES008977/ES/NIEHS NIH HHS/United States
GR  - R01ES08977/ES/NIEHS NIH HHS/United States
GR  - P30 ES009089/ES/NIEHS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20150224
PL  - Netherlands
TA  - Environ Res
JT  - Environmental research
JID - 0147621
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Endocrine Disruptors)
RN  - 0 (Environmental Pollutants)
RN  - 0 (Phenols)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - Benzhydryl Compounds/*toxicity
MH  - Child
MH  - Child Behavior Disorders/*chemically induced
MH  - Endocrine Disruptors/*toxicity
MH  - *Environmental Exposure
MH  - Environmental Pollutants/*toxicity
MH  - Female
MH  - Humans
MH  - Male
MH  - Phenols/*toxicity
MH  - *Urban Population
PMC - PMC4545741
MID - NIHMS656914
OTO - NOTNLM
OT  - Bisphenol A
OT  - Child behavior
OT  - Sex-specific
EDAT- 2015/03/01 06:00
MHDA- 2016/02/02 06:00
PMCR- 2016/10/01
CRDT- 2015/03/01 06:00
PHST- 2014/08/19 00:00 [received]
PHST- 2015/01/14 00:00 [revised]
PHST- 2015/01/16 00:00 [accepted]
PHST- 2015/03/01 06:00 [entrez]
PHST- 2015/03/01 06:00 [pubmed]
PHST- 2016/02/02 06:00 [medline]
PHST- 2016/10/01 00:00 [pmc-release]
AID - S0013-9351(15)00015-8 [pii]
AID - 10.1016/j.envres.2015.01.014 [doi]
PST - ppublish
SO  - Environ Res. 2015 Oct;142:739-45. doi: 10.1016/j.envres.2015.01.014. Epub 2015 
      Feb 24.

PMID- 36851005
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230303
IS  - 2305-6304 (Electronic)
IS  - 2305-6304 (Linking)
VI  - 11
IP  - 2
DP  - 2023 Jan 29
TI  - Determination of Parabens and Their Metabolites in Seminal Plasma from Chinese 
      Men by Ultra High Performance Liquid Chromatography Tandem Mass Spectrometry 
      (UPLC-MS/MS).
LID - 10.3390/toxics11020131 [doi]
LID - 131
AB  - Parabens are endocrine-disrupting chemicals (EDCs) that have estrogen-like 
      activities and may cause male reproductive disorders. Here, we developed a method 
      for the simultaneous determination of four parabens (MeP, EtP, n-PrP, n-BuP) and 
      two metabolites (4-HB and 3,4-DHB) in human seminal plasma by UPLC-MS/MS. The 
      method was used to analyze 144 seminal plasma samples from Chinese males. MeP, 
      EtP, n-PrP, and 4-HB were the dominant compounds. MeP, EtP, and n-PrP were 
      significantly correlated to each other. In addition, 4-HB was significantly 
      correlated to MeP, EtP, n-PrP, and 3,4-DHB, respectively. The results provide 
      direct evidence that parabens and their metabolites are widely distributed in the 
      male reproductive system. The study presents the paraben metabolites levels in 
      human seminal plasma for the first time.
FAU - Dai, Jing
AU  - Dai J
AD  - National Center for Occupational Safety and Health, National Health Commission of 
      the People's Republic of China, Beijing 102308, China.
FAU - Zhang, Linyuan
AU  - Zhang L
AD  - National Institute for Occupational Health and Poison Control, Chinese Center for 
      Disease Control and Prevention, Beijing 100050, China.
FAU - Xu, Jianfeng
AU  - Xu J
AD  - National Research Institute for Family Planning and WHO Collaborating Centre for 
      Research in Human Reproduction, Beijing 100081, China.
AD  - National Health Commission Key Laboratory of Male Reproductive Health, Beijing 
      100730, China.
FAU - Peng, Fangda
AU  - Peng F
AD  - National Center for Occupational Safety and Health, National Health Commission of 
      the People's Republic of China, Beijing 102308, China.
FAU - Wu, Zhijun
AU  - Wu Z
AD  - National Institute for Occupational Health and Poison Control, Chinese Center for 
      Disease Control and Prevention, Beijing 100050, China.
FAU - Fu, Longlong
AU  - Fu L
AD  - National Research Institute for Family Planning and WHO Collaborating Centre for 
      Research in Human Reproduction, Beijing 100081, China.
AD  - National Health Commission Key Laboratory of Male Reproductive Health, Beijing 
      100730, China.
FAU - Guo, Ying
AU  - Guo Y
AD  - National Research Institute for Family Planning and WHO Collaborating Centre for 
      Research in Human Reproduction, Beijing 100081, China.
AD  - National Health Commission Key Laboratory of Male Reproductive Health, Beijing 
      100730, China.
FAU - Chang, Bing
AU  - Chang B
AD  - National Institute for Occupational Health and Poison Control, Chinese Center for 
      Disease Control and Prevention, Beijing 100050, China.
FAU - Lu, Wenhong
AU  - Lu W
AD  - National Research Institute for Family Planning and WHO Collaborating Centre for 
      Research in Human Reproduction, Beijing 100081, China.
AD  - National Health Commission Key Laboratory of Male Reproductive Health, Beijing 
      100730, China.
FAU - Ding, Chunguang
AU  - Ding C
AD  - National Center for Occupational Safety and Health, National Health Commission of 
      the People's Republic of China, Beijing 102308, China.
LA  - eng
GR  - 21907021/National Natural Science Foundation of China/
GR  - 2019009/the Project of National Center for Occupational Safety and Health, 
      National Health Commission of the People's Republic of China/
PT  - Journal Article
DEP - 20230129
PL  - Switzerland
TA  - Toxics
JT  - Toxics
JID - 101639637
PMC - PMC9962888
OTO - NOTNLM
OT  - UPLC-MS/MS
OT  - metabolite
OT  - parabens
OT  - seminal plasma
COIS- The authors declare no conflict of interest.
EDAT- 2023/03/01 06:00
MHDA- 2023/03/01 06:01
PMCR- 2023/01/29
CRDT- 2023/02/28 01:27
PHST- 2022/12/27 00:00 [received]
PHST- 2023/01/14 00:00 [revised]
PHST- 2023/01/19 00:00 [accepted]
PHST- 2023/02/28 01:27 [entrez]
PHST- 2023/03/01 06:00 [pubmed]
PHST- 2023/03/01 06:01 [medline]
PHST- 2023/01/29 00:00 [pmc-release]
AID - toxics11020131 [pii]
AID - toxics-11-00131 [pii]
AID - 10.3390/toxics11020131 [doi]
PST - epublish
SO  - Toxics. 2023 Jan 29;11(2):131. doi: 10.3390/toxics11020131.

PMID- 27999117
OWN - NLM
STAT- MEDLINE
DCOM- 20180222
LR  - 20180408
IS  - 1460-2350 (Electronic)
IS  - 0268-1161 (Linking)
VI  - 32
IP  - 2
DP  - 2017 Feb
TI  - Performance of mass spectrometry steroid profiling for diagnosis of polycystic 
      ovary syndrome.
PG  - 418-422
LID - 10.1093/humrep/dew328 [doi]
AB  - STUDY QUESTION: How well does multi-analyte steroid mass spectrometry (MS) 
      profiling classify women with and without polycystic ovary syndrome (PCOS)? 
      SUMMARY ANSWER: Our liquid chromatography MS (LC-MS) steroid profiling only 
      minimally improves discrimination of women with and without PCOS compared with a 
      direct testosterone immunoassay (T_IA) and the free androgen index (FAI). WHAT IS 
      KNOWN ALREADY: Blood testosterone measured by direct (non-extraction) immunoassay 
      overlaps between women with and without PCOS. Multi-analyte MS provides greater 
      specificity and accuracy for steroid measurement so might improve the 
      classification. STUDY DESIGN, SIZE, DURATION: An observational, cross-sectional 
      study of women with PCOS (n = 152) defined by Rotterdam criteria and matched 
      non-PCOS (n = 45) control women was conducted. PARTICIPANTS/MATERIALS, SETTING, 
      METHODS: Serum steroid profiles of testosterone (T), dihydrotestosterone (DHT), 
      dehydroepiandrosterone (DHEA), androstenedione (A(4)), estradiol (E(2)), estrone 
      (E(1)), 17 hydroxy progesterone (17OHP(4)), progesterone (P(4)) and cortisol were 
      measured by LC-MS; T_IA and sex hormone binding globulin were measured by 
      immunoassay; and FAI, calculated free testosterone (cFT) and total androgen index 
      (TAI) were calculated. Classification was based on logistic regression with 
      corresponding univariate and multivariate C-statistics. MAIN RESULTS AND THE ROLE 
      OF CHANCE: Serum testosterone by immunoassay demonstrated levels more than 100% 
      higher than that measured by LC-MS. Compared with the controls, women with PCOS 
      had higher serum T, DHEA, A(4), TAI, T_IA, cFT, FAI and E(2) but not serum DHT, 
      E(1), P(4), 17OHP(4) or cortisol. Univariate C-statistics were highest for FAI 
      (0.89) and T_IA (0.82) compared with other androgens (T [0.72], DHT [0.40]), 
      pro-androgens (A(4) [0.74], DHEA[0.71]) or derivatives (cFT [0.75], TAI [0.60]). 
      For all multivariate models, the overall correct predictions (81-86%) featured 
      high sensitivity (92-96%) but low specificity (28-43%). and substituting LC-MS 
      steroid measurements for T_IA and FAI produced only minimal improvements in 
      classification. LIMITATIONS REASONS FOR CAUTION: The study cohort is limited in 
      size and only unconjugated steroids were measured. WIDER IMPLICATIONS OF THE 
      FINDINGS: Multi-analyte steroid profiling of unconjugated circulating steroids 
      provides only limited improvement on direct T_IA in classifying women with and 
      without PCOS. STUDY FUNDING/COMPETING INTERESTS: None. TRIAL REGISTRATION NUMBER: 
      N/A.
CI  - © Crown copyright 2016.
FAU - Handelsman, D J
AU  - Handelsman DJ
AD  - ANZAC Research Institute, University of Sydney, Concord Hospital, NSW 2139, 
      Australia djh@anzac.edu.au.
FAU - Teede, H J
AU  - Teede HJ
AD  - Monash Centre for Health Research Implementation, School of Public Health and 
      Preventative Medicine, Monash University, Melbourne 3004, Australia.
FAU - Desai, R
AU  - Desai R
AD  - ANZAC Research Institute, University of Sydney, Concord Hospital, NSW 2139, 
      Australia.
FAU - Norman, R J
AU  - Norman RJ
AD  - The Robinson Research Institute, Discipline of Obstetrics and Gynaecology, 
      University of Adelaide, Adelaide South Australia, Australia.
FAU - Moran, L J
AU  - Moran LJ
AD  - Monash Centre for Health Research Implementation, School of Public Health and 
      Preventative Medicine, Monash University, Melbourne 3004, Australia.
AD  - The Robinson Research Institute, Discipline of Obstetrics and Gynaecology, 
      University of Adelaide, Adelaide South Australia, Australia.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20161219
PL  - England
TA  - Hum Reprod
JT  - Human reproduction (Oxford, England)
JID - 8701199
RN  - 0 (Androgens)
RN  - 0 (Estrogens)
RN  - 0 (Progestins)
RN  - WI4X0X7BPJ (Hydrocortisone)
SB  - IM
EIN - Hum Reprod. 2017 Jul 1;32(7):1540. doi: 10.1093/humrep/dex212. PMID: 28575397
MH  - Adult
MH  - Androgens/*blood
MH  - Cross-Sectional Studies
MH  - Estrogens/*blood
MH  - Female
MH  - Humans
MH  - Hydrocortisone/*blood
MH  - Immunoassay
MH  - Mass Spectrometry/*methods
MH  - Polycystic Ovary Syndrome/blood/*diagnosis
MH  - Progestins/*blood
OTO - NOTNLM
OT  - androgens
OT  - immunoassay
OT  - mass spectrometry
OT  - polycystic ovary syndrome
OT  - testosterone
EDAT- 2016/12/22 06:00
MHDA- 2018/02/23 06:00
CRDT- 2016/12/22 06:00
PHST- 2016/09/21 00:00 [received]
PHST- 2016/11/12 00:00 [revised]
PHST- 2016/12/01 00:00 [accepted]
PHST- 2016/12/22 06:00 [pubmed]
PHST- 2018/02/23 06:00 [medline]
PHST- 2016/12/22 06:00 [entrez]
AID - dew328 [pii]
AID - 10.1093/humrep/dew328 [doi]
PST - ppublish
SO  - Hum Reprod. 2017 Feb;32(2):418-422. doi: 10.1093/humrep/dew328. Epub 2016 Dec 19.

PMID- 37315995
OWN - NLM
STAT- MEDLINE
DCOM- 20240130
LR  - 20240206
IS  - 1538-0254 (Electronic)
IS  - 0739-1102 (Linking)
VI  - 42
IP  - 2
DP  - 2024 Jan-Feb
TI  - Computational investigation of four isoquinoline alkaloids against polycystic 
      ovarian syndrome.
PG  - 734-746
LID - 10.1080/07391102.2023.2222828 [doi]
AB  - Hyperandrogenism, insulin resistance, and estrogen dominance are the prime 
      defining traits of women with polycystic ovarian syndrome which disrupts 
      hormonal, adrenal, or ovarian functions resulting in impaired folliculogenesis 
      and excess androgen production. The purpose of this study is to identify an 
      appropriate bioactive antagonistic ligand from isoquinoline alkaloids [palmatine 
      (PAL), jatrorrhizine (JAT), magnoflorine (MAG) and berberine (BBR)] from stems of 
      Tinospora cordifolia. Phytocomponents inhibit/prevent androgenic, estrogenic, and 
      steroidogenic receptors, insulin binding, and resultant hyperandrogenism. 
      Intending to develop new inhibitors for human androgen receptor (1E3G), insulin 
      receptor (3EKK), estrogen receptor beta (1U3S), and human steroidogenic 
      cytochromeP450 17A1 (6WR0), here we report the docking studies by employing a 
      flexible ligand docking approach using AutodockVina 4.2.6. ADMET screened 
      swissADME and toxicological predictions to identify novel and potent inhibitors 
      against PCOS. Binding affinity was obtained using Schrodinger. Two ligands, 
      mainly BER (-8.23) and PAL (-6.71) showed the best docking score against androgen 
      receptors. A molecular docking study reveals that compounds BBR and PAL were 
      found to be tight binder at the active site of IE3G. Molecular dynamics results 
      suggest that BBR and PAL showed good binding stability of active site residues. 
      The present study corroborates the molecular dynamics of the compound BBR and 
      PAL, potent Inhibitors of IE3G, having therapeutic potential for PCOS. We project 
      that this study's findings will be helpful in drug development efforts targeting 
      PCOS. Hence isoquinoline alkaloids (BER& PAL) have potential roles against 
      androgen receptors, and in specific PCOS, scientific evaluation has been put 
      forth based on virtual screening.Communicated by Ramaswamy H. Sarma.
FAU - Moka, Murali Krishna
AU  - Moka MK
AD  - Department of Pharmacology, SRMIST, Kattankulathur, Tamil Nadu, India.
FAU - S, Ankul Singh
AU  - S AS
AD  - Department of Pharmacology, SRMIST, Kattankulathur, Tamil Nadu, India.
FAU - M, Sumithra
AU  - M S
AD  - Department of Pharmacology, SRMIST, Kattankulathur, Tamil Nadu, India.
LA  - eng
PT  - Journal Article
DEP - 20230614
PL  - England
TA  - J Biomol Struct Dyn
JT  - Journal of biomolecular structure & dynamics
JID - 8404176
RN  - 0 (Receptors, Androgen)
RN  - 0 (Ligands)
RN  - 0 (Alkaloids)
SB  - IM
MH  - Female
MH  - Humans
MH  - *Polycystic Ovary Syndrome/drug therapy/diagnosis
MH  - *Hyperandrogenism
MH  - Receptors, Androgen
MH  - Molecular Docking Simulation
MH  - Ligands
MH  - *Alkaloids/pharmacology
OTO - NOTNLM
OT  - ADMET studies
OT  - DFT analysis
OT  - Tinospora cordifolia
OT  - docking studies
OT  - isoquinoline alkaloids
EDAT- 2023/06/15 01:08
MHDA- 2024/01/30 12:44
CRDT- 2023/06/14 20:53
PHST- 2024/01/30 12:44 [medline]
PHST- 2023/06/15 01:08 [pubmed]
PHST- 2023/06/14 20:53 [entrez]
AID - 10.1080/07391102.2023.2222828 [doi]
PST - ppublish
SO  - J Biomol Struct Dyn. 2024 Jan-Feb;42(2):734-746. doi: 
      10.1080/07391102.2023.2222828. Epub 2023 Jun 14.

PMID- 34684834
OWN - NLM
STAT- MEDLINE
DCOM- 20211117
LR  - 20211117
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 26
IP  - 20
DP  - 2021 Oct 15
TI  - Palmatine, a Bioactive Protoberberine Alkaloid Isolated from Berberis cretica, 
      Inhibits the Growth of Human Estrogen Receptor-Positive Breast Cancer Cells and 
      Acts Synergistically and Additively with Doxorubicin.
LID - 10.3390/molecules26206253 [doi]
LID - 6253
AB  - Palmatine (PLT) is a natural isoquinoline alkaloid that belongs to the class of 
      protoberberines and exhibits a wide spectrum of pharmacological and biological 
      properties, including anti-cancer activity. The aim of our study was to isolate 
      PLT from the roots of Berberis cretica and investigate its cytotoxic and 
      anti-proliferative effects in vitro alone and in combination with doxorubicine 
      (DOX) using human ER(+)/HER2(-) breast cancer cell lines. The alkaloid was 
      purified by column chromatography filled with silica gel NP and Sephadex LH-20 
      resin developed in the mixture of methanol: water (50:50 v/v) that provided 
      high-purity alkaloid for bioactivity studies. The purity of the alkaloid was 
      confirmed by high resolution mass measurement and MS/MS fragmentation analysis in 
      the HPLC-ESI-QTOF-MS/MS-based analysis. It was found that PLT treatment inhibited 
      the viability and proliferation of breast cancer cells in a dose-dependent manner 
      as demonstrated by MTT and BrdU assays. PLT showed a quite similar growth 
      inhibition on breast cancer cells with IC(50) values ranging from 5.126 to 5.805 
      µg/mL. In contrast, growth of normal human breast epithelial cells was not 
      affected by PLT. The growth inhibitory activity of PLT was related to the 
      induction of apoptosis, as determined by Annexin V/PI staining. Moreover, PLT 
      sensitized breast cancer cells to DOX. Isobolographic analysis revealed 
      synergistic and additive interactions between studied agents. Our studies suggest 
      that PLT can be a potential candidate agent for preventing and treating breast 
      cancer.
FAU - Grabarska, Aneta
AU  - Grabarska A
AUID- ORCID: 0000-0002-3823-1467
AD  - Department of Biochemistry and Molecular Biology, Medical University of Lublin, 
      Chodzki 1, 20-093 Lublin, Poland.
FAU - Wróblewska-Łuczka, Paula
AU  - Wróblewska-Łuczka P
AUID- ORCID: 0000-0002-7099-1968
AD  - Department of Pathophysiology, Medical University of Lublin, Jaczewskiego 8b, 
      20-090 Lublin, Poland.
FAU - Kukula-Koch, Wirginia
AU  - Kukula-Koch W
AUID- ORCID: 0000-0001-7076-600X
AD  - Department of Pharmacognosy with Medicinal Plants Garden, Medical University of 
      Lublin, Chodzki 1, 20-093 Lublin, Poland.
FAU - Łuszczki, Jarogniew J
AU  - Łuszczki JJ
AUID- ORCID: 0000-0002-3059-0393
AD  - Department of Pathophysiology, Medical University of Lublin, Jaczewskiego 8b, 
      20-090 Lublin, Poland.
FAU - Kalpoutzakis, Eleftherios
AU  - Kalpoutzakis E
AD  - Laboratory of Pharmacognosy and Natural Products Chemistry, School of Pharmacy, 
      National and Kapodistrian University of Athens, Panepistimioupoli Zografou, 15771 
      Athens, Greece.
FAU - Adamczuk, Grzegorz
AU  - Adamczuk G
AUID- ORCID: 0000-0003-1677-7247
AD  - Independent Medical Biology Unit, Medical University of Lublin, Jaczewskiego 8b, 
      20-090 Lublin, Poland.
FAU - Skaltsounis, Alexios Leandros
AU  - Skaltsounis AL
AD  - Laboratory of Pharmacognosy and Natural Products Chemistry, School of Pharmacy, 
      National and Kapodistrian University of Athens, Panepistimioupoli Zografou, 15771 
      Athens, Greece.
FAU - Stepulak, Andrzej
AU  - Stepulak A
AD  - Department of Biochemistry and Molecular Biology, Medical University of Lublin, 
      Chodzki 1, 20-093 Lublin, Poland.
LA  - eng
PT  - Journal Article
DEP - 20211015
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (Berberine Alkaloids)
RN  - 0 (Receptors, Estrogen)
RN  - 19716-69-9 (protoberberine)
RN  - 80168379AG (Doxorubicin)
RN  - G50C034217 (palmatine)
SB  - IM
MH  - Antineoplastic Agents, Phytogenic/administration & dosage/*pharmacology
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & dosage
MH  - Apoptosis/drug effects
MH  - Berberine Alkaloids/administration & dosage/*pharmacology
MH  - Berberis/chemistry
MH  - Breast Neoplasms/*drug therapy/metabolism/pathology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Cell Survival/drug effects
MH  - Doxorubicin/administration & dosage
MH  - Drug Synergism
MH  - Female
MH  - Humans
MH  - MCF-7 Cells
MH  - Phytotherapy
MH  - Plant Roots/chemistry
MH  - Plants, Medicinal/chemistry
MH  - Receptors, Estrogen/metabolism
PMC - PMC8538708
OTO - NOTNLM
OT  - Berberidaceae
OT  - Berberis cretica
OT  - HPLC-MS
OT  - breast cancer
OT  - isobolographic analysis
OT  - isoquinoline alkaloids
OT  - natural products
OT  - palmatine
COIS- The authors declare no conflict of interest.
EDAT- 2021/10/24 06:00
MHDA- 2021/11/18 06:00
PMCR- 2021/10/15
CRDT- 2021/10/23 01:19
PHST- 2021/09/02 00:00 [received]
PHST- 2021/10/01 00:00 [revised]
PHST- 2021/10/08 00:00 [accepted]
PHST- 2021/10/23 01:19 [entrez]
PHST- 2021/10/24 06:00 [pubmed]
PHST- 2021/11/18 06:00 [medline]
PHST- 2021/10/15 00:00 [pmc-release]
AID - molecules26206253 [pii]
AID - molecules-26-06253 [pii]
AID - 10.3390/molecules26206253 [doi]
PST - epublish
SO  - Molecules. 2021 Oct 15;26(20):6253. doi: 10.3390/molecules26206253.

PMID- 30981845
OWN - NLM
STAT- MEDLINE
DCOM- 20191127
LR  - 20191127
IS  - 1873-3492 (Electronic)
IS  - 0009-8981 (Linking)
VI  - 495
DP  - 2019 Aug
TI  - Estradiol reference intervals in women during the menstrual cycle, postmenopausal 
      women and men using an LC-MS/MS method.
PG  - 198-204
LID - S0009-8981(19)31812-1 [pii]
LID - 10.1016/j.cca.2019.04.062 [doi]
AB  - BACKGROUND: For optimal medical decision-making, harmonized reference intervals 
      for estradiol for different ages and both sexes are needed. Our aim was to 
      establish reference intervals using a highly accurate and traceable LC-MS/MS 
      method and to compare these with reference intervals in literature. METHODS: 
      Estradiol was measured in serum obtained daily during the menstrual cycle of 30 
      healthy premenopausal women and in serum of 64 men and 33 postmenopausal women. 
      The accuracy of our LC-MS/MS method was demonstrated by a method comparison with 
      the CDC reference method. RESULTS: Our LC-MS/MS method was traceable to the 
      reference method. Estradiol reference interval during the early follicular phase 
      (days -15 to -6) was 31-771 pmol/L; during the late follicular phase (days -5 to 
      -1) 104-1742 pmol/L; during the LH peak (day 0) 275-2864 pmol/L; during the early 
      luteal phase (days +1 to +4) 95-1188 pmol/L; during mid luteal phase (days +5 to 
      +9) 151-1941 pmol/L; during late luteal phase (days +10 to +14) 39-1769 pmol/L. 
      The reference interval for men was 12-136 pmol/L and for postmenopausal women 
      <26 pmol/L. CONCLUSIONS: The established estradiol reference intervals can be 
      used for all traceable LC-MS/MS methods for medical-decision making.
CI  - Copyright © 2019 Elsevier B.V. All rights reserved.
FAU - Verdonk, Sara J E
AU  - Verdonk SJE
AD  - Amsterdam UMC, Vrije Universiteit Amsterdam, Endocrine Laboratory, Department of 
      Clinical Chemistry, Amsterdam Gastroenterology & Metabolism, Amsterdam, 
      Netherlands.
FAU - Vesper, Hubert W
AU  - Vesper HW
AD  - Centers of Disease Control and Prevention, 4770 Buford Highway, NE F25, Atlanta 
      30341-3724, Georgia.
FAU - Martens, Frans
AU  - Martens F
AD  - Amsterdam UMC, Vrije Universiteit Amsterdam, Endocrine Laboratory, Department of 
      Clinical Chemistry, Amsterdam Gastroenterology & Metabolism, Amsterdam, 
      Netherlands; Amsterdam UMC, University of Amsterdam, Endocrine Laboratory, 
      Department of Clinical Chemistry, Amsterdam, Netherlands.
FAU - Sluss, Patrick M
AU  - Sluss PM
AD  - Clinical Pathology Core Laboratory, Massachusetts General Hospital, Boston, MA, 
      USA.
FAU - Hillebrand, Jacquelien J
AU  - Hillebrand JJ
AD  - Amsterdam UMC, University of Amsterdam, Endocrine Laboratory, Department of 
      Clinical Chemistry, Amsterdam, Netherlands.
FAU - Heijboer, Annemieke C
AU  - Heijboer AC
AD  - Amsterdam UMC, Vrije Universiteit Amsterdam, Endocrine Laboratory, Department of 
      Clinical Chemistry, Amsterdam Gastroenterology & Metabolism, Amsterdam, 
      Netherlands; Amsterdam UMC, University of Amsterdam, Endocrine Laboratory, 
      Department of Clinical Chemistry, Amsterdam, Netherlands. Electronic address: 
      a.heijboer@amsterdamumc.nl.
LA  - eng
PT  - Journal Article
DEP - 20190411
PL  - Netherlands
TA  - Clin Chim Acta
JT  - Clinica chimica acta; international journal of clinical chemistry
JID - 1302422
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Blood Chemical Analysis/*standards
MH  - Chromatography, Liquid
MH  - Estradiol/*blood
MH  - Female
MH  - Humans
MH  - Male
MH  - *Menstrual Cycle
MH  - Postmenopause/*blood
MH  - Reference Values
MH  - Tandem Mass Spectrometry
MH  - Young Adult
OTO - NOTNLM
OT  - Estrogens
OT  - Liquid chromatography
OT  - Mass spectrometry
OT  - Menstrual cycle
OT  - Premenopausal women
EDAT- 2019/04/15 06:00
MHDA- 2019/11/28 06:00
CRDT- 2019/04/15 06:00
PHST- 2018/09/25 00:00 [received]
PHST- 2019/04/09 00:00 [revised]
PHST- 2019/04/10 00:00 [accepted]
PHST- 2019/04/15 06:00 [pubmed]
PHST- 2019/11/28 06:00 [medline]
PHST- 2019/04/15 06:00 [entrez]
AID - S0009-8981(19)31812-1 [pii]
AID - 10.1016/j.cca.2019.04.062 [doi]
PST - ppublish
SO  - Clin Chim Acta. 2019 Aug;495:198-204. doi: 10.1016/j.cca.2019.04.062. Epub 2019 
      Apr 11.

PMID- 29909149
OWN - NLM
STAT- MEDLINE
DCOM- 20180730
LR  - 20181202
IS  - 1873-376X (Electronic)
IS  - 1570-0232 (Linking)
VI  - 1092
DP  - 2018 Aug 15
TI  - Determination of aflatoxin and zearalenone analogs in edible and medicinal herbs 
      using a group-specific immunoaffinity column coupled to ultra-high-performance 
      liquid chromatography with tandem mass spectrometry.
PG  - 228-236
LID - S1570-0232(18)30637-8 [pii]
LID - 10.1016/j.jchromb.2018.06.012 [doi]
AB  - Six aflatoxins (AFs; AF B(1), B(2), G(1), G(2), M(1) and M(2)) and six 
      zearalenone (ZEN) analogs (ZEN, zearalanone, α-zeralanol, β-zeralanol, 
      α-zearalenol, and β-zearalenol) were simultaneously extracted from edible and 
      medicinal herbs using a group-specific immunoaffinity column (IAC) and then 
      identified by ultra-high-performance liquid chromatography tandem mass 
      spectrometry (UPLC-MS/MS). The IAC was prepared by coupling 
      N-hydroxysuccinimide-activated Sepharose 4B Fast Flow gel with two group-specific 
      monoclonal antibodies. The column capacities to six AFs and six ZEN analogs 
      ranged from 100.2 ng to 167.1 ng and from 59.5 ng to 244.4 ng, respectively. The 
      IAC-UPLC-MS/MS method was developed and validated with three different matrices 
      (Chinese yam [Dioscorea polystachya], Platycodon grandiflorum and coix seed 
      [Semen Coicis]). Recoveries of twelve analytes from edible and medicinal herbs 
      were in the range of 64.7%-112.1%, with relative standard deviations below 13.7%. 
      The limits of quantification were in the range from 0.08 μg kg(-1) to 
      0.2 μg kg(-1). The method was proven to be sensitive and accurate, and suitable 
      for the determination of real samples.
CI  - Copyright © 2018 Elsevier B.V. All rights reserved.
FAU - Sun, Shujuan
AU  - Sun S
AD  - Beijing Advanced Innovation Center for Food Nutrition and Human Health, College 
      of Veterinary Medicine, China Agricultural University, Beijing Key Laboratory of 
      Detection Technology for Animal-Derived Food Safety, Beijing 100193, People's 
      Republic of China.
FAU - Yao, Kai
AU  - Yao K
AD  - Beijing Advanced Innovation Center for Food Nutrition and Human Health, College 
      of Veterinary Medicine, China Agricultural University, Beijing Key Laboratory of 
      Detection Technology for Animal-Derived Food Safety, Beijing 100193, People's 
      Republic of China.
FAU - Zhao, Sijun
AU  - Zhao S
AD  - China Animal Health and Epidemiology Center, Qingdao 266032, People's Republic of 
      China.
FAU - Zheng, Pimiao
AU  - Zheng P
AD  - Beijing Advanced Innovation Center for Food Nutrition and Human Health, College 
      of Veterinary Medicine, China Agricultural University, Beijing Key Laboratory of 
      Detection Technology for Animal-Derived Food Safety, Beijing 100193, People's 
      Republic of China.
FAU - Wang, Sihan
AU  - Wang S
AD  - Beijing Advanced Innovation Center for Food Nutrition and Human Health, College 
      of Veterinary Medicine, China Agricultural University, Beijing Key Laboratory of 
      Detection Technology for Animal-Derived Food Safety, Beijing 100193, People's 
      Republic of China.
FAU - Zeng, Yuyang
AU  - Zeng Y
AD  - Beijing Advanced Innovation Center for Food Nutrition and Human Health, College 
      of Veterinary Medicine, China Agricultural University, Beijing Key Laboratory of 
      Detection Technology for Animal-Derived Food Safety, Beijing 100193, People's 
      Republic of China.
FAU - Liang, Demei
AU  - Liang D
AD  - Beijing Advanced Innovation Center for Food Nutrition and Human Health, College 
      of Veterinary Medicine, China Agricultural University, Beijing Key Laboratory of 
      Detection Technology for Animal-Derived Food Safety, Beijing 100193, People's 
      Republic of China.
FAU - Ke, Yuebin
AU  - Ke Y
AD  - Shenzhen Center for Disease Control and Prevention, Shenzhen 518055, People's 
      Republic of China.
FAU - Jiang, Haiyang
AU  - Jiang H
AD  - Beijing Advanced Innovation Center for Food Nutrition and Human Health, College 
      of Veterinary Medicine, China Agricultural University, Beijing Key Laboratory of 
      Detection Technology for Animal-Derived Food Safety, Beijing 100193, People's 
      Republic of China. Electronic address: haiyang@cau.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20180607
PL  - Netherlands
TA  - J Chromatogr B Analyt Technol Biomed Life Sci
JT  - Journal of chromatography. B, Analytical technologies in the biomedical and life 
      sciences
JID - 101139554
RN  - 0 (Aflatoxins)
RN  - 0 (Plant Extracts)
RN  - 5W827M159J (Zearalenone)
SB  - IM
MH  - Aflatoxins/*analysis
MH  - Chromatography, Affinity/*methods
MH  - Chromatography, High Pressure Liquid/methods
MH  - Linear Models
MH  - Plant Extracts/chemistry
MH  - Plants, Medicinal/*chemistry
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
MH  - Tandem Mass Spectrometry/*methods
MH  - Zearalenone/*analysis
OTO - NOTNLM
OT  - Aflatoxins
OT  - Edible and medicinal herbs
OT  - Group-specific
OT  - Immunoaffinity column
OT  - UPLC–MS/MS
OT  - Zearalenone analogs
EDAT- 2018/06/18 06:00
MHDA- 2018/07/31 06:00
CRDT- 2018/06/18 06:00
PHST- 2018/04/20 00:00 [received]
PHST- 2018/06/04 00:00 [revised]
PHST- 2018/06/06 00:00 [accepted]
PHST- 2018/06/18 06:00 [pubmed]
PHST- 2018/07/31 06:00 [medline]
PHST- 2018/06/18 06:00 [entrez]
AID - S1570-0232(18)30637-8 [pii]
AID - 10.1016/j.jchromb.2018.06.012 [doi]
PST - ppublish
SO  - J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Aug 15;1092:228-236. doi: 
      10.1016/j.jchromb.2018.06.012. Epub 2018 Jun 7.

PMID- 27771018
OWN - NLM
STAT- MEDLINE
DCOM- 20170814
LR  - 20181113
IS  - 1872-8421 (Electronic)
IS  - 0165-5728 (Print)
IS  - 0165-5728 (Linking)
VI  - 304
DP  - 2017 Mar 15
TI  - Bedside to bench to bedside research: Estrogen receptor beta ligand as a 
      candidate neuroprotective treatment for multiple sclerosis.
PG  - 63-71
LID - S0165-5728(16)30308-3 [pii]
LID - 10.1016/j.jneuroim.2016.09.017 [doi]
AB  - Protective effects of pregnancy during MS have led to clinical trials of estriol, 
      the pregnancy estrogen, in MS. Since estriol binds to estrogen receptor (ER) 
      beta, ER beta ligand could represent a "next generation estriol" treatment. Here, 
      ER beta ligand treatment was protective in EAE in both sexes and across genetic 
      backgrounds. Neuroprotection was shown in spinal cord, sparing myelin and axons, 
      and in brain, sparing neurons and synapses. Longitudinal in vivo MRIs showed 
      decreased brain atrophy in cerebral cortex gray matter and cerebellum during EAE. 
      Investigation of ER beta ligand as a neuroprotective treatment for MS is 
      warranted.
CI  - Copyright © 2016 Elsevier B.V. All rights reserved.
FAU - Itoh, Noriko
AU  - Itoh N
AD  - Department of Neurology, University of California, Los Angeles, David Geffen 
      School of Medicine, USA.
FAU - Kim, Roy
AU  - Kim R
AD  - Department of Neurology, University of California, Los Angeles, David Geffen 
      School of Medicine, USA.
FAU - Peng, Mavis
AU  - Peng M
AD  - Department of Neurology, University of California, Los Angeles, David Geffen 
      School of Medicine, USA.
FAU - DiFilippo, Emma
AU  - DiFilippo E
AD  - Department of Neurology, University of California, Los Angeles, David Geffen 
      School of Medicine, USA.
FAU - Johnsonbaugh, Hadley
AU  - Johnsonbaugh H
AD  - Department of Neurology, University of California, Los Angeles, David Geffen 
      School of Medicine, USA.
FAU - MacKenzie-Graham, Allan
AU  - MacKenzie-Graham A
AD  - Department of Neurology, University of California, Los Angeles, David Geffen 
      School of Medicine, USA.
FAU - Voskuhl, Rhonda R
AU  - Voskuhl RR
AD  - Department of Neurology, University of California, Los Angeles, David Geffen 
      School of Medicine, USA. Electronic address: rvoskuhl@ucla.edu.
LA  - eng
GR  - R01 NS051591/NS/NINDS NIH HHS/United States
GR  - R01 NS096748/NS/NINDS NIH HHS/United States
GR  - T32 HD007228/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20161003
PL  - Netherlands
TA  - J Neuroimmunol
JT  - Journal of neuroimmunology
JID - 8109498
RN  - 0 (AC-186)
RN  - 0 (Cyclohexanes)
RN  - 0 (Estrogen Receptor beta)
RN  - 0 (Ligands)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Phenols)
SB  - IM
MH  - Animals
MH  - Cyclohexanes/*administration & dosage/*metabolism
MH  - Estrogen Receptor beta/*metabolism
MH  - Female
MH  - Ligands
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Inbred NOD
MH  - Multiple Sclerosis/*metabolism/prevention & control
MH  - Neuroprotective Agents/*administration & dosage/*metabolism
MH  - Phenols/*administration & dosage/*metabolism
MH  - Treatment Outcome
PMC - PMC5806698
MID - NIHMS824541
OTO - NOTNLM
OT  - Estrogen
OT  - Experimental autoimmune encephalomyelitis
OT  - Multiple sclerosis
OT  - Neuroprotection
OT  - Pregnancy
EDAT- 2016/10/25 06:00
MHDA- 2017/08/15 06:00
PMCR- 2018/03/15
CRDT- 2016/10/25 06:00
PHST- 2016/05/17 00:00 [received]
PHST- 2016/09/28 00:00 [accepted]
PHST- 2016/10/25 06:00 [pubmed]
PHST- 2017/08/15 06:00 [medline]
PHST- 2016/10/25 06:00 [entrez]
PHST- 2018/03/15 00:00 [pmc-release]
AID - S0165-5728(16)30308-3 [pii]
AID - 10.1016/j.jneuroim.2016.09.017 [doi]
PST - ppublish
SO  - J Neuroimmunol. 2017 Mar 15;304:63-71. doi: 10.1016/j.jneuroim.2016.09.017. Epub 
      2016 Oct 3.

PMID- 27801986
OWN - NLM
STAT- MEDLINE
DCOM- 20171010
LR  - 20250103
IS  - 1365-2265 (Electronic)
IS  - 0300-0664 (Linking)
VI  - 86
IP  - 4
DP  - 2017 Apr
TI  - Urinary bisphenol A is associated with insulin resistance and obesity in 
      reproductive-aged women.
PG  - 506-512
LID - 10.1111/cen.13270 [doi]
AB  - BACKGROUND/OBJECTIVES: The prevalence of obesity has markedly increased and is 
      closely related to insulin resistance. Although lifestyle and genetic 
      predisposition are significant factors influencing the pathophysiology within the 
      body, endocrine-disrupting chemicals (EDCs) are also important triggers of 
      metabolic disturbance. We investigated the relationship between exposure to EDCs 
      and insulin resistance and obesity in healthy, reproductive-aged women. 
      SUBJECTS/METHODS: This cross-sectional analysis included 296 healthy, 
      reproductive-aged women between 30 and 49 years. Metabolically healthy was 
      defined as an absence of the components of metabolic syndrome. Urinary levels of 
      bisphenol A (BPA), mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), 
      mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP) and mono-n-butyl phthalate (MnBP) 
      were measured by high-performance liquid chromatography and tandem mass 
      spectroscopy (LC-MS). Homoeostatic model analysis of insulin resistance (HOMA-IR) 
      was utilized as an index of insulin resistance. RESULTS: Urinary BPA levels were 
      positively correlated with BMI, waist circumference, fasting serum insulin and 
      HOMA-IR. MEHHP, MEOHP and MnBP were not associated with any of the above 
      parameters. In the multiple regression analysis, the BPA levels were 
      significantly associated with BMI and waist circumference after adjusting for 
      age, smoking and alcohol consumption status, triglycerides (TG), total 
      cholesterol (TC) and high-density lipoprotein (HDL). Fasting insulin and HOMA-IR 
      values were also significantly related to urinary BPA concentration after 
      adjusting for confounding variables. Metabolically unhealthy women exhibited 
      significantly higher levels of urinary BPA (P = 0·01) compared to metabolically 
      healthy women. CONCLUSIONS: Higher urinary BPA levels are associated with 
      obesity, insulin resistance and metabolic disruption in Korean reproductive-aged 
      women. BPA could play an important role in the pathogenesis of metabolic 
      abnormalities. Further studies are required to elucidate the relationship between 
      EDCs and metabolic disturbances in various age and sex groups.
CI  - © 2016 John Wiley & Sons Ltd.
FAU - Hong, So-Hyeon
AU  - Hong SH
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Ewha 
      Womans University School of Medicine, Seoul, Korea.
FAU - Sung, Yeon-Ah
AU  - Sung YA
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Ewha 
      Womans University School of Medicine, Seoul, Korea.
FAU - Hong, Young Sun
AU  - Hong YS
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Ewha 
      Womans University School of Medicine, Seoul, Korea.
FAU - Ha, Eunhee
AU  - Ha E
AD  - Department of Preventive Medicine, Ewha Womans University School of Medicine, 
      Seoul, Korea.
FAU - Jeong, Kyungah
AU  - Jeong K
AD  - Department of Obstetrics and Gynecology, Ewha Womans University School of 
      Medicine, Seoul, Korea.
FAU - Chung, Hyewon
AU  - Chung H
AD  - Department of Obstetrics and Gynecology, Ewha Womans University School of 
      Medicine, Seoul, Korea.
FAU - Lee, Hyejin
AU  - Lee H
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Ewha 
      Womans University School of Medicine, Seoul, Korea.
LA  - eng
PT  - Journal Article
DEP - 20161202
PL  - England
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Phenols)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - Adult
MH  - Benzhydryl Compounds/*urine
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - *Insulin Resistance
MH  - Metabolic Diseases/etiology
MH  - Middle Aged
MH  - *Obesity/urine
MH  - Phenols/*urine
MH  - Republic of Korea
EDAT- 2016/11/02 06:00
MHDA- 2017/10/11 06:00
CRDT- 2016/11/02 06:00
PHST- 2016/08/31 00:00 [received]
PHST- 2016/10/16 00:00 [revised]
PHST- 2016/10/28 00:00 [accepted]
PHST- 2016/11/02 06:00 [pubmed]
PHST- 2017/10/11 06:00 [medline]
PHST- 2016/11/02 06:00 [entrez]
AID - 10.1111/cen.13270 [doi]
PST - ppublish
SO  - Clin Endocrinol (Oxf). 2017 Apr;86(4):506-512. doi: 10.1111/cen.13270. Epub 2016 
      Dec 2.

PMID- 28054450
OWN - NLM
STAT- MEDLINE
DCOM- 20180618
LR  - 20250103
IS  - 1615-9314 (Electronic)
IS  - 1615-9306 (Linking)
VI  - 40
IP  - 5
DP  - 2017 Mar
TI  - Simultaneous analysis of bisphenol A based compounds and other monomers leaching 
      from resin-based dental materials by UHPLC-MS/MS.
PG  - 1063-1075
LID - 10.1002/jssc.201601153 [doi]
AB  - Resin-based dental materials have raised debates concerning their safety and 
      biocompatibility, resulting in a growing necessity of profound knowledge on the 
      quantity of released compounds into the oral cavity. In this context, the aim of 
      this study was to develop a comprehensive and reliable procedure based on liquid 
      chromatography with mass spectrometry for the simultaneous analysis of various 
      leached compounds (including bisphenol A based compounds) in samples from in 
      vitro experiments. Different experiments were performed to determine the optimal 
      analytical parameters, comprising mass spectrometry parameters, chromatographic 
      separation conditions, and sample preparation. Four internal standards were used 
      as follows: deuterated diethyl phthalate and bisphenol A (commercially 
      available), and deuterated analogues of triethylene glycol dimethacrylate and 
      urethane dimethacrylate (custom-made). The optimized method was validated for 
      linearity of the calibration curves and the associated correlation coefficient, 
      lower limit of quantification, higher limit of quantification, and intra- and 
      interassay accuracy and precision. Additionally, the developed liquid 
      chromatography with tandem mass spectrometry method was applied to the analysis 
      of leaching compounds from four resin-based dental materials. The results 
      indicated that this method is suitable for the analysis of different target 
      compounds leaching from dental materials. This method might serve as a valuable 
      basis for quick and accurate quantification of leached compounds from resin-based 
      dental materials in biological samples.
CI  - © 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Putzeys, Eveline
AU  - Putzeys E
AD  - BIOMAT, Department of Oral Health Sciences, KU Leuven (University of Leuven), 
      Leuven, Belgium.
FAU - Cokic, Stevan M
AU  - Cokic SM
AD  - BIOMAT, Department of Oral Health Sciences, KU Leuven (University of Leuven), 
      Leuven, Belgium.
FAU - Chong, Hui
AU  - Chong H
AD  - Polymer Chemistry and Materials, Department of Chemistry, KU Leuven (University 
      of Leuven), Leuven, Belgium.
FAU - Smet, Mario
AU  - Smet M
AD  - Polymer Chemistry and Materials, Department of Chemistry, KU Leuven (University 
      of Leuven), Leuven, Belgium.
FAU - Vanoirbeek, Jeroen
AU  - Vanoirbeek J
AD  - Environment and Health, Department of Public Health and Primary Care, KU Leuven 
      (University of Leuven), Leuven, Belgium.
FAU - Godderis, Lode
AU  - Godderis L
AD  - Environment and Health, Department of Public Health and Primary Care, KU Leuven 
      (University of Leuven), Leuven, Belgium.
AD  - IDEWE, External Service for Prevention and Protection at Work, Heverlee, Belgium.
FAU - Van Meerbeek, Bart
AU  - Van Meerbeek B
AD  - BIOMAT, Department of Oral Health Sciences, KU Leuven (University of Leuven), 
      Leuven, Belgium.
FAU - Van Landuyt, Kirsten L
AU  - Van Landuyt KL
AD  - BIOMAT, Department of Oral Health Sciences, KU Leuven (University of Leuven), 
      Leuven, Belgium.
FAU - Duca, Radu Corneliu
AU  - Duca RC
AD  - Environment and Health, Department of Public Health and Primary Care, KU Leuven 
      (University of Leuven), Leuven, Belgium.
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - J Sep Sci
JT  - Journal of separation science
JID - 101088554
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Composite Resins)
RN  - 0 (Dental Materials)
RN  - 0 (Phenols)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - Benzhydryl Compounds/*analysis
MH  - Chromatography, High Pressure Liquid
MH  - Composite Resins/*analysis
MH  - Dental Materials/*chemistry
MH  - Phenols/*analysis
MH  - Reproducibility of Results
MH  - Tandem Mass Spectrometry
OTO - NOTNLM
OT  - dental materials
OT  - liquid chromatography
OT  - mass spectrometry
OT  - monomers
OT  - saliva
EDAT- 2017/01/06 06:00
MHDA- 2018/06/19 06:00
CRDT- 2017/01/06 06:00
PHST- 2016/10/10 00:00 [received]
PHST- 2016/12/12 00:00 [revised]
PHST- 2016/12/13 00:00 [accepted]
PHST- 2017/01/06 06:00 [pubmed]
PHST- 2018/06/19 06:00 [medline]
PHST- 2017/01/06 06:00 [entrez]
AID - 10.1002/jssc.201601153 [doi]
PST - ppublish
SO  - J Sep Sci. 2017 Mar;40(5):1063-1075. doi: 10.1002/jssc.201601153.

PMID- 29497942
OWN - NLM
STAT- MEDLINE
DCOM- 20190308
LR  - 20190308
IS  - 1614-7499 (Electronic)
IS  - 0944-1344 (Linking)
VI  - 25
IP  - 14
DP  - 2018 May
TI  - Is there any association between phthalate exposure and precocious puberty in 
      girls?
PG  - 13589-13596
LID - 10.1007/s11356-018-1567-4 [doi]
AB  - Considerable increase in the prevalence of precocious puberty (PP) during the 
      last decade has raised a lot of concerns. Some environmental endocrine disruptor 
      chemicals (EDCs), such as phthalate esters, have intrinsic estrogen activity or 
      increase endogenous sex hormone levels leading to PP. This study was conducted to 
      investigate the association between exposure to phthalate esters and PP in a 
      sample of girls. Plasma levels of seven phthalate ester metabolites were measured 
      in 87 girls with PP and 63 age- and sex-matched controls by dispersive 
      liquid-liquid microextraction and GC/MS analysis. History of exposure to main 
      sources of phthalates was obtained by a checklist. Diethyl hexyl phthalate (DEHP) 
      metabolite levels were significantly higher in those with PP than that in 
      controls (p < 0.05), but this difference was not significant for other phthalate 
      metabolites. 30.1% girls with PP and 12.2% of controls had played for more than 
      2 h/day with plastic toys in their childhood. 65.1% girls with PP and 32.8% of 
      controls have regularly used some cosmetic products. Consumption of bottled water 
      and beverages by those with PP was about twofold higher than that in the control 
      group. A positive correlation was found between bottled ware consumption and 
      plasma concentrations of four phthalate metabolites. The frequency of seafood 
      consumption was not significantly different between the groups studied. Our 
      findings confirm positive association between phthalate exposure and incidence of 
      PP in girls. Control and reduction of children exposure to phthalate esters 
      should be considered as a health priority.
FAU - Hashemipour, Mahin
AU  - Hashemipour M
AD  - Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, 
      Isfahan, Iran.
FAU - Kelishadi, Roya
AU  - Kelishadi R
AD  - Child Growth and Development Research Center, Research Institute for Primordial 
      Prevention of Non-communicable Disease, Isfahan University of Medical Sciences, 
      Isfahan, Iran.
FAU - Amin, Mohammad Mehdi
AU  - Amin MM
AD  - Department of Environmental Health Engineering, School of Health, Isfahan 
      University of Medical Sciences, Hezar-Jarib Avenue, Isfahan, 81745-185, Iran.
FAU - Ebrahim, Karim
AU  - Ebrahim K
AUID- ORCID: 0000-0002-6230-0119
AD  - Department of Environmental Health Engineering, School of Health, Isfahan 
      University of Medical Sciences, Hezar-Jarib Avenue, Isfahan, 81745-185, Iran. 
      k.najafabady@sbmu.ac.ir.
LA  - eng
GR  - (Research project No. 194151)/Research Institute for Primordial Prevention of 
      Non-communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran/
PT  - Journal Article
DEP - 20180301
PL  - Germany
TA  - Environ Sci Pollut Res Int
JT  - Environmental science and pollution research international
JID - 9441769
RN  - 0 (Cosmetics)
RN  - 0 (Drinking Water)
RN  - 0 (Endocrine Disruptors)
RN  - 0 (Esters)
RN  - 0 (Phthalic Acids)
RN  - 6O7F7IX66E (phthalic acid)
RN  - C42K0PH13C (Diethylhexyl Phthalate)
SB  - IM
MH  - Cosmetics/analysis/chemistry
MH  - Diethylhexyl Phthalate/*analysis/chemistry
MH  - Drinking Water/analysis/*chemistry
MH  - Endocrine Disruptors/analysis/*chemistry
MH  - Environmental Exposure/analysis
MH  - Esters
MH  - Female
MH  - Gas Chromatography-Mass Spectrometry
MH  - Humans
MH  - *Phthalic Acids
MH  - Puberty, Precocious
OTO - NOTNLM
OT  - Endocrine disruptor chemicals
OT  - Girls
OT  - Phthalate esters
OT  - Precocious puberty
OT  - Reproductive system
EDAT- 2018/03/03 06:00
MHDA- 2019/03/09 06:00
CRDT- 2018/03/03 06:00
PHST- 2017/11/30 00:00 [received]
PHST- 2018/02/13 00:00 [accepted]
PHST- 2018/03/03 06:00 [pubmed]
PHST- 2019/03/09 06:00 [medline]
PHST- 2018/03/03 06:00 [entrez]
AID - 10.1007/s11356-018-1567-4 [pii]
AID - 10.1007/s11356-018-1567-4 [doi]
PST - ppublish
SO  - Environ Sci Pollut Res Int. 2018 May;25(14):13589-13596. doi: 
      10.1007/s11356-018-1567-4. Epub 2018 Mar 1.

PMID- 32748636
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220426
IS  - 2192-5682 (Print)
IS  - 2192-5690 (Electronic)
IS  - 2192-5682 (Linking)
VI  - 11
IP  - 8
DP  - 2021 Oct
TI  - The Effects of NPY1 Receptor Antagonism on Intervertebral Disc and Bone Changes 
      in Ovariectomized Rats.
PG  - 1166-1175
LID - 10.1177/2192568220939908 [doi]
AB  - STUDY DESIGN: Basic science. OBJECTIVE: To compare the effects of a neuropeptide 
      Y1 receptor antagonist (NPY-1RA) to estrogen on maintaining vertebral bone 
      microarchitecture and disc height in a rat model of menopause. METHODS: This 
      study was an institutional animal care approved randomized control study with 104 
      ovariectomized rats and 32 intact control animals. Comparison of disc height, 
      trabecular bone, body weights, circulating levels of NPY and estrogen, and 
      distribution of Y1 receptors in the intervertebral disc in an established rodent 
      osteoporotic model were made at baseline and after 2, 4, and 8 weeks after 
      receiving either an implant containing estrogen or an antagonist to the 
      neuropeptide Y1 receptor. Data was compared statistically using One-way analysis 
      of variance. RESULTS: Circulating levels of estrogen increased and NPY decreased 
      following estrogen replacement, with values comparable to ovary-intact animals. 
      NPY-1RA-treated animals had low estrogen and high NPY circulating levels and were 
      similar to ovariectomized control rats. Both NPY-1RA and estrogen administration 
      were able reduce, menopause associated weight gain. NPY-1RA appeared to restore 
      bone formation and maintain disc height, while estrogen replacement prevented 
      further bone loss. CONCLUSION: NPY-1RA in osteoporotic rats activates osteoblast 
      production of bone and decreased marrow and body fat more effectively than 
      estrogen replacement when delivered in similar concentrations. Annulus cells had 
      NPY receptors, which may play a role in disc nutrition, extracellular matrix 
      production, and pain signaling cascades.
FAU - Tucci, Michelle
AU  - Tucci M
AUID- ORCID: 0000-0002-2380-9465
AD  - University of Mississippi Medical Center, Jackson, MS, US.
FAU - Wilson, Gerri A
AU  - Wilson GA
AD  - University of Mississippi Medical Center, Jackson, MS, US.
FAU - McGuire, Robert
AU  - McGuire R
AD  - University of Mississippi Medical Center, Jackson, MS, US.
FAU - Benghuzzi, Hamed A
AU  - Benghuzzi HA
AD  - University of Mississippi Medical Center, Jackson, MS, US.
LA  - eng
PT  - Journal Article
DEP - 20200804
PL  - England
TA  - Global Spine J
JT  - Global spine journal
JID - 101596156
PMC - PMC8453679
OTO - NOTNLM
OT  - degenerative disc disease
OT  - disc
OT  - osteoporosis
COIS- Declaration of Conflicting Interests: The author(s) declared the following 
      potential conflicts of interest with respect to the research, authorship, and/or 
      publication of this article: MT received funding for this project from CPP FFOB 
      2010 closed call. RM is president of the AO Spine Foundation and is a consultant 
      for Rehab, Inc and Zavation. HB is executive director for the Mississippi Academy 
      of Sciences and is vice president for Rocky Mountain Bioengineering Symposium.
EDAT- 2020/08/05 06:00
MHDA- 2020/08/05 06:01
PMCR- 2020/08/04
CRDT- 2020/08/05 06:00
PHST- 2020/08/05 06:00 [pubmed]
PHST- 2020/08/05 06:01 [medline]
PHST- 2020/08/05 06:00 [entrez]
PHST- 2020/08/04 00:00 [pmc-release]
AID - 10.1177_2192568220939908 [pii]
AID - 10.1177/2192568220939908 [doi]
PST - ppublish
SO  - Global Spine J. 2021 Oct;11(8):1166-1175. doi: 10.1177/2192568220939908. Epub 
      2020 Aug 4.

PMID- 35495954
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2296-861X (Print)
IS  - 2296-861X (Electronic)
IS  - 2296-861X (Linking)
VI  - 9
DP  - 2022
TI  - Gadus morhua Eggs Sialoglycoprotein Prevent Estrogen Deficiency-Induced High Bone 
      Turnover by Controlling OPG/RANKL/TRAF6 Pathway and Serum Metabolism.
PG  - 871521
LID - 10.3389/fnut.2022.871521 [doi]
LID - 871521
AB  - In recent years, the development of safe and effective anti-osteoporosis factors 
      has attracted extensive attention. In this study, an estrogen-deficient 
      osteoporosis rat model was employed to study the improving mechanism of 
      sialoglycoprotein isolated from Gadus morhua eggs (Gds) against osteoporosis. The 
      results showed that compared with OVX, Gds ameliorated the trabecular 
      microstructure, especially the increased trabecular thickness, decreased 
      trabecular separation, and enhanced the trabecular number. The analysis of 
      qRT-PCR and western blotting found that Gds reduced bone resorption by inhibiting 
      RANKL-induced osteoclastogenesis. The LC-MS/MS was used to investigate serum 
      metabolism, and the enrichment metabolites were analyzed by the KEGG pathway. The 
      results revealed that the Gds significantly altered the fat anabolism pathway, 
      which includes ovarian steroidogenesis pathway and arachidonic acid metabolism 
      pathway. Altogether, Gds could improve osteoporosis by suppressing high bone 
      turnover via controlling OPG/RANKL/TRAF6 pathway, which is implicated with 
      ovarian steroidogenesis pathway and arachidonic acid metabolism pathway. These 
      findings indicated that Gds could be a candidate factor for anti-osteoporosis.
CI  - Copyright © 2022 Zhao, Mei, Lu, Xiang, Xia, Zhang, Liu, Zhang, Shen and Zhong.
FAU - Zhao, Meihui
AU  - Zhao M
AD  - Hainan Engineering Research Center of Aquatic Resources Efficient Utilization in 
      South China Sea, School of Food Science and Engineering, Hainan University, 
      Hainan, China.
AD  - Collaborative Innovation Center of Provincial and Ministerial Co-construction for 
      Marine Food Deep Processing, Dalian Polytechnic University, Dalian, China.
AD  - Key Laboratory of Food Nutrition and Functional Food of Hainan Province, Hainan 
      University, Haikou, China.
FAU - Mei, Fengfeng
AU  - Mei F
AD  - Hainan Engineering Research Center of Aquatic Resources Efficient Utilization in 
      South China Sea, School of Food Science and Engineering, Hainan University, 
      Hainan, China.
AD  - Collaborative Innovation Center of Provincial and Ministerial Co-construction for 
      Marine Food Deep Processing, Dalian Polytechnic University, Dalian, China.
AD  - Key Laboratory of Food Nutrition and Functional Food of Hainan Province, Hainan 
      University, Haikou, China.
FAU - Lu, Jinfeng
AU  - Lu J
AD  - Hainan Engineering Research Center of Aquatic Resources Efficient Utilization in 
      South China Sea, School of Food Science and Engineering, Hainan University, 
      Hainan, China.
FAU - Xiang, Qingying
AU  - Xiang Q
AD  - Hainan Engineering Research Center of Aquatic Resources Efficient Utilization in 
      South China Sea, School of Food Science and Engineering, Hainan University, 
      Hainan, China.
FAU - Xia, Guanghua
AU  - Xia G
AD  - Hainan Engineering Research Center of Aquatic Resources Efficient Utilization in 
      South China Sea, School of Food Science and Engineering, Hainan University, 
      Hainan, China.
AD  - Collaborative Innovation Center of Provincial and Ministerial Co-construction for 
      Marine Food Deep Processing, Dalian Polytechnic University, Dalian, China.
AD  - Key Laboratory of Food Nutrition and Functional Food of Hainan Province, Hainan 
      University, Haikou, China.
FAU - Zhang, Xueying
AU  - Zhang X
AD  - Hainan Engineering Research Center of Aquatic Resources Efficient Utilization in 
      South China Sea, School of Food Science and Engineering, Hainan University, 
      Hainan, China.
AD  - Collaborative Innovation Center of Provincial and Ministerial Co-construction for 
      Marine Food Deep Processing, Dalian Polytechnic University, Dalian, China.
AD  - Key Laboratory of Food Nutrition and Functional Food of Hainan Province, Hainan 
      University, Haikou, China.
FAU - Liu, Zhongyuan
AU  - Liu Z
AD  - Hainan Engineering Research Center of Aquatic Resources Efficient Utilization in 
      South China Sea, School of Food Science and Engineering, Hainan University, 
      Hainan, China.
AD  - Collaborative Innovation Center of Provincial and Ministerial Co-construction for 
      Marine Food Deep Processing, Dalian Polytechnic University, Dalian, China.
AD  - Key Laboratory of Food Nutrition and Functional Food of Hainan Province, Hainan 
      University, Haikou, China.
FAU - Zhang, Chenghui
AU  - Zhang C
AD  - Hainan Engineering Research Center of Aquatic Resources Efficient Utilization in 
      South China Sea, School of Food Science and Engineering, Hainan University, 
      Hainan, China.
AD  - Key Laboratory of Food Nutrition and Functional Food of Hainan Province, Hainan 
      University, Haikou, China.
FAU - Shen, Xuanri
AU  - Shen X
AD  - Hainan Engineering Research Center of Aquatic Resources Efficient Utilization in 
      South China Sea, School of Food Science and Engineering, Hainan University, 
      Hainan, China.
AD  - Collaborative Innovation Center of Provincial and Ministerial Co-construction for 
      Marine Food Deep Processing, Dalian Polytechnic University, Dalian, China.
AD  - Key Laboratory of Food Nutrition and Functional Food of Hainan Province, Hainan 
      University, Haikou, China.
FAU - Zhong, Qiuping
AU  - Zhong Q
AD  - Hainan Engineering Research Center of Aquatic Resources Efficient Utilization in 
      South China Sea, School of Food Science and Engineering, Hainan University, 
      Hainan, China.
AD  - Key Laboratory of Food Nutrition and Functional Food of Hainan Province, Hainan 
      University, Haikou, China.
LA  - eng
PT  - Journal Article
DEP - 20220412
PL  - Switzerland
TA  - Front Nutr
JT  - Frontiers in nutrition
JID - 101642264
PMC - PMC9040668
OTO - NOTNLM
OT  - Gadus morhua
OT  - OPG
OT  - bone resorption
OT  - osteoporosis
OT  - serum metabolism
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/05/03 06:00
MHDA- 2022/05/03 06:01
PMCR- 2022/01/01
CRDT- 2022/05/02 06:46
PHST- 2022/02/08 00:00 [received]
PHST- 2022/03/01 00:00 [accepted]
PHST- 2022/05/02 06:46 [entrez]
PHST- 2022/05/03 06:00 [pubmed]
PHST- 2022/05/03 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fnut.2022.871521 [doi]
PST - epublish
SO  - Front Nutr. 2022 Apr 12;9:871521. doi: 10.3389/fnut.2022.871521. eCollection 
      2022.

PMID- 33168863
OWN - NLM
STAT- MEDLINE
DCOM- 20210430
LR  - 20220809
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Nov 9
TI  - Comparative proteomic analysis of serum from nonhuman primates administered BIO 
      300: a promising radiation countermeasure.
PG  - 19343
LID - 10.1038/s41598-020-76494-4 [doi]
LID - 19343
AB  - Hematopoietic acute radiation syndrome (H-ARS) and delayed effects of acute 
      radiation exposure (DEARE) are detrimental health effects that occur after 
      exposure to high doses of ionizing radiation. BIO 300, a synthetic genistein 
      nanosuspension, was previously proven safe and effective against H-ARS when 
      administered (via the oral (po) or intramuscular (im) route) prior to exposure to 
      lethal doses of total-body radiation. In this study, we evaluated the proteomic 
      changes in serum of nonhuman primates (NHP) after administering BIO 300 by 
      different routes (po and im). We utilized nanoflow-ultra-performance liquid 
      chromatography quadrupole time-of-flight mass spectrometry (NanoUPLC-MS/MS) 
      methods for comprehensive global profiling and quantification of serum proteins. 
      The results corroborate previous findings that suggest a very similar metabolic 
      profile following both routes of drug administration. Furthermore, we observed 
      minor alterations in protein levels, 2 hours after drug administration, which 
      relates to the C(max) of BIO 300 for both routes of administration. Taken 
      together, this assessment may provide an insight into the mechanism of 
      radioprotection of BIO 300 and a reasonable illustration of the pharmacodynamics 
      of this radiation countermeasure.
FAU - Girgis, Michael
AU  - Girgis M
AD  - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown 
      University Medical Center, Washington, DC, USA.
FAU - Li, Yaoxiang
AU  - Li Y
AD  - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown 
      University Medical Center, Washington, DC, USA.
FAU - Ma, Junfeng
AU  - Ma J
AD  - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown 
      University Medical Center, Washington, DC, USA.
FAU - Sanda, Miloslav
AU  - Sanda M
AD  - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown 
      University Medical Center, Washington, DC, USA.
FAU - Wise, Stephen Y
AU  - Wise SY
AD  - Division of Radioprotectants, Department of Pharmacology and Molecular 
      Therapeutics, F. Edward Hébert School of Medicine, Uniformed Services University 
      of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD, 20814, USA.
AD  - Armed Forces Radiobiology Research Institute, Uniformed Services University of 
      the Health Sciences, Bethesda, MD, USA.
FAU - Fatanmi, Oluseyi O
AU  - Fatanmi OO
AD  - Division of Radioprotectants, Department of Pharmacology and Molecular 
      Therapeutics, F. Edward Hébert School of Medicine, Uniformed Services University 
      of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD, 20814, USA.
AD  - Armed Forces Radiobiology Research Institute, Uniformed Services University of 
      the Health Sciences, Bethesda, MD, USA.
FAU - Kaytor, Michael D
AU  - Kaytor MD
AD  - Humanetics Corporation, Edina, MN, 55435, USA.
FAU - Cheema, Amrita K
AU  - Cheema AK
AD  - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown 
      University Medical Center, Washington, DC, USA.
AD  - Department of Biochemistry, Molecular and Cellular Biology, Georgetown University 
      Medical Center, Washington, DC, USA.
FAU - Singh, Vijay K
AU  - Singh VK
AD  - Division of Radioprotectants, Department of Pharmacology and Molecular 
      Therapeutics, F. Edward Hébert School of Medicine, Uniformed Services University 
      of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD, 20814, USA. 
      vijay.singh@usuhs.edu.
AD  - Armed Forces Radiobiology Research Institute, Uniformed Services University of 
      the Health Sciences, Bethesda, MD, USA. vijay.singh@usuhs.edu.
LA  - eng
GR  - P30 CA051008/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20201109
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Radiation-Protective Agents)
RN  - DH2M523P0H (Genistein)
SB  - IM
MH  - Acute Radiation Syndrome/*metabolism/*prevention & control
MH  - Animals
MH  - Chromatography, Liquid
MH  - Female
MH  - Genistein/pharmacology
MH  - Macaca mulatta
MH  - Male
MH  - Metabolome/drug effects
MH  - Metabolomics/methods
MH  - Principal Component Analysis
MH  - Proteomics/*methods
MH  - *Radiation, Ionizing
MH  - Radiation-Protective Agents/pharmacology
MH  - Tandem Mass Spectrometry
MH  - Time Factors
MH  - Whole-Body Irradiation
PMC - PMC7653926
COIS- Michael D. Kaytor is the Vice President of Research and Development of Humanetics 
      Corporation, Edina, MN, USA. The other authors report no conflicts of interest. 
      The authors alone are responsible for the content and writing of this paper.
EDAT- 2020/11/11 06:00
MHDA- 2021/05/01 06:00
PMCR- 2020/11/09
CRDT- 2020/11/10 05:41
PHST- 2020/03/25 00:00 [received]
PHST- 2020/10/28 00:00 [accepted]
PHST- 2020/11/10 05:41 [entrez]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/05/01 06:00 [medline]
PHST- 2020/11/09 00:00 [pmc-release]
AID - 10.1038/s41598-020-76494-4 [pii]
AID - 76494 [pii]
AID - 10.1038/s41598-020-76494-4 [doi]
PST - epublish
SO  - Sci Rep. 2020 Nov 9;10(1):19343. doi: 10.1038/s41598-020-76494-4.

PMID- 32351599
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2020
DP  - 2020
TI  - Lemon Balm Extracts Prevent Breast Cancer Progression In Vitro and In Ovo on 
      Chorioallantoic Membrane Assay.
PG  - 6489159
LID - 10.1155/2020/6489159 [doi]
LID - 6489159
AB  - Breast cancer is the most frequently diagnosed malignant pathology, representing 
      the primary cause of cancer death in women. Natural products are an appealing 
      strategy to limit the progression of the disease. Targeting angiogenesis in 
      breast cancer may positively impact on poor prognosis of breast cancer. As source 
      of natural compounds, we investigated the leaves of Melissa officinalis L. (MO), 
      known as lemon balm, an aromatic plant that spontaneously grows in the South and 
      Western areas of Romania, being traditionally recommended as anxiolytic, 
      antispasmodic, or as digestive remedy. Our aim was to investigate the 
      phytochemical profiling and the antiangiogenic and chemopreventive bioactivity of 
      MO from Banat region, on breast cancer. Two ethanolic extracts of MO (MOE96 and 
      MOE70) and one methanolic extract (MOM80) were subjected to polyphenol and 
      triterpene profiling by HPLC-MS, and the antioxidant capacity was evaluated. The 
      antiangiogenic potential was investigated using the chorioallantoic membrane 
      assay (CAM). The MTT(3-(4,5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium 
      bromide) assay was used to investigate the cytotoxic effects on MCF-7 and 
      MDA-MB-231breast cancer cells, as well as on MCF-10A normal breast epithelial 
      cells, while apoptosis was performed by DAPI staining. Rosmarinic acid (RA) and 
      ursolic acid (UA) were revealed as dominant phytocompounds. The highest 
      concentration in phytochemicals were found in MOM80; MOE96 was more concentrated 
      in UA, while MOE70 extracted more RA. MOE96 inhibited cancer progression and 
      angiogenesis in the in ovo CAM model using MDA-MB-231 cells, inhibiting breast 
      cancer progression and angiogenesis for the MDA-MB-231 breast cancer cell line; 
      no secondary tumoral areas were registered, indicative for a preventive effect 
      against breast tumor cell invasiveness. The highest cell inhibitory activity was 
      also exhibited by MOE96, in particular against the estrogen receptor positive 
      MCF7 breast cancer cell line, with no cytotoxic effect on healthy cells. The 
      estrogen receptor positive MCF7 cell line proved to be more sensitive to the 
      extract antiproliferative activity than the triple negative MDA-MB-231 breast 
      cancer cell line. Nevertheless, the chemopreventive potential of MOE96 extract is 
      phenotype-dependent and is rather related to the apoptosis and antiangiogenic 
      effects suggesting a multitargeted mechanism of action due to its multiple 
      compound composition next to a concentration ratio of RA : UA in favor of UA.
CI  - Copyright © 2020 Roxana Ghiulai et al.
FAU - Ghiulai, Roxana
AU  - Ghiulai R
AD  - Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Victor Babeş 
      University of Medicine and Pharmacy, 2nd EftimieMurgu Sq., Timişoara 300041, 
      Romania.
FAU - Avram, Stefana
AU  - Avram S
AUID- ORCID: 0000-0002-4824-6769
AD  - Department of Pharmacognosy, Faculty of Pharmacy, Victor Babeş University of 
      Medicine and Pharmacy, 2nd EftimieMurgu Sq., Timişoara 300041, Romania.
FAU - Stoian, Dana
AU  - Stoian D
AUID- ORCID: 0000-0002-0926-9511
AD  - Department of Endocrinology, Faculty of Medicine, Victor Babeş University of 
      Medicine and Pharmacy, 2nd EftimieMurgu Sq., Timişoara 300041, Romania.
FAU - Pavel, Ioana Zinuca
AU  - Pavel IZ
AUID- ORCID: 0000-0002-2223-5228
AD  - Department of Pharmacognosy, Faculty of Pharmacy, Victor Babeş University of 
      Medicine and Pharmacy, 2nd EftimieMurgu Sq., Timişoara 300041, Romania.
FAU - Coricovac, Dorina
AU  - Coricovac D
AUID- ORCID: 0000-0002-5760-8872
AD  - Department of Toxicology, Faculty of Pharmacy, Victor Babeş University of 
      Medicine and Pharmacy, 2nd EftimieMurgu Sq., Timişoara 300041, Romania.
FAU - Oprean, Camelia
AU  - Oprean C
AUID- ORCID: 0000-0003-0862-7791
AD  - Department of Environmental and Food Chemistry, Faculty of Pharmacy, Victor Babeş 
      University of Medicine and Pharmacy, 2nd EftimieMurgu Sq., Timişoara 300041, 
      Romania.
FAU - Vlase, Laurian
AU  - Vlase L
AD  - Department of Pharmaceutical Technology and Biopharmaceutics, Faculty of 
      Pharmacy, "Iuliu Haţieganu" University of Medicine and Pharmacy, 12 Ion Creangă 
      Street, Cluj-Napoca 400010, Romania.
FAU - Farcas, Claudia
AU  - Farcas C
AD  - Department of Pharmaceutical Physics, Faculty of Pharmacy, Victor Babeş 
      University of Medicine and Pharmacy, 2nd EftimieMurgu Sq., Timişoara 300041, 
      Romania.
FAU - Mioc, Marius
AU  - Mioc M
AD  - Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Victor Babeş 
      University of Medicine and Pharmacy, 2nd EftimieMurgu Sq., Timişoara 300041, 
      Romania.
FAU - Minda, Daliana
AU  - Minda D
AD  - Department of Pharmacognosy, Faculty of Pharmacy, Victor Babeş University of 
      Medicine and Pharmacy, 2nd EftimieMurgu Sq., Timişoara 300041, Romania.
FAU - Motoc, Andrei
AU  - Motoc A
AD  - Department of Anatomy, Faculty of Medicine, Victor Babeş University of Medicine 
      and Pharmacy, 2nd EftimieMurgu Sq., Timişoara 300041, Romania.
FAU - Szuhanek, Camelia
AU  - Szuhanek C
AUID- ORCID: 0000-0002-3668-2299
AD  - Department of Pedodontics and Orthodontics, Faculty of Dental Medicine, Victor 
      Babeş University of Medicine and Pharmacy, 9 RevolutieiBv., Sq., Timişoara 
      300041, Romania.
FAU - Danciu, Corina
AU  - Danciu C
AUID- ORCID: 0000-0001-5999-1214
AD  - Department of Pharmacognosy, Faculty of Pharmacy, Victor Babeş University of 
      Medicine and Pharmacy, 2nd EftimieMurgu Sq., Timişoara 300041, Romania.
FAU - Soica, Codruta
AU  - Soica C
AD  - Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Victor Babeş 
      University of Medicine and Pharmacy, 2nd EftimieMurgu Sq., Timişoara 300041, 
      Romania.
FAU - Sima, Laurentiu
AU  - Sima L
AD  - Department of Surgical Semiology, Faculty of Medicine, Victor Babeş University of 
      Medicine and Pharmacy, 9 RevolutieiBv., Sq., Timişoara 300041, Romania.
LA  - eng
PT  - Journal Article
DEP - 20200414
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC7178502
COIS- The authors declare no conflicts of interest.
EDAT- 2020/05/01 06:00
MHDA- 2020/05/01 06:01
PMCR- 2020/04/14
CRDT- 2020/05/01 06:00
PHST- 2019/09/30 00:00 [received]
PHST- 2020/01/16 00:00 [revised]
PHST- 2020/02/03 00:00 [accepted]
PHST- 2020/05/01 06:00 [entrez]
PHST- 2020/05/01 06:00 [pubmed]
PHST- 2020/05/01 06:01 [medline]
PHST- 2020/04/14 00:00 [pmc-release]
AID - 10.1155/2020/6489159 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2020 Apr 14;2020:6489159. doi: 
      10.1155/2020/6489159. eCollection 2020.

PMID- 30599221
OWN - NLM
STAT- MEDLINE
DCOM- 20190408
LR  - 20190408
IS  - 1872-7573 (Electronic)
IS  - 0378-8741 (Linking)
VI  - 233
DP  - 2019 Apr 6
TI  - Root bark extract of Calliandra portoricensis (Jacq.) Benth. chemoprevents 
      N-methyl-N-nitrosourea-induced mammary gland toxicity in rats.
PG  - 22-33
LID - S0378-8741(18)31660-X [pii]
LID - 10.1016/j.jep.2018.12.027 [doi]
AB  - ETHNOPHARMACOLOGICAL RELEVANCE: Calliandra portoricensis (CP) is a herb widely 
      used in Nigeria for the treatment of breast engorgement. However, the scientific 
      evidence of this use and its mechanisms of action is not clearly understood. AIM 
      OF THE STUDY: We assessed the chemopreventive effects of methanol extract of CP 
      on N-methyl-N-nitrosourea (NMU)-induced mammary gland toxicity in rats. MATERIALS 
      AND METHODS: Fingerprinting of methanol extract of CP by Gas Chromatography-Mass 
      Spectrometry (GC-MS) was done. Female Wistar rats were assigned into eight 
      groups: Group 1 (control), group 2 received NMU only, groups 3, 4 and 5 received 
      NMU and treated with CP at doses of 100, 200 and 300 mg/kg, respectively. Group 6 
      received CP (300 mg/kg), group 7 received NMU and vincristine, while group 8 
      received vincristine. RESULTS: The weight-gain by rats decreased in all groups 
      that received NMU. Administration of NMU significantly increased organo-somatic 
      weight of mammary gland by 52%. The NMU increased serum nitric oxide, total 
      bilirubin, mammary myeloperoxidase and lipid peroxidation by 76%, 87%, 130% and 
      21%, respectively, as well as activities of serum aspartate aminotransferase and 
      lactate dehydrogenase. Also, NMU-treated rats had decreased total sulphydryl, 
      reduced glutathione and catalase. Immunohistochemistry revealed strong expression 
      of estrogen, progesterone and EGFR-2 proteins in NMU-treated rats. Treatment with 
      CP (200 and 300 mg/kg) attenuated NMU-induced inflammation and oxidative stress. 
      CONCLUSION: CP ameliorated NMU-induced toxicity by modulating different cellular 
      targets.
CI  - Copyright © 2018 Elsevier B.V. All rights reserved.
FAU - Adefisan, Adedoyin
AU  - Adefisan A
AD  - Department of Biochemistry, Faculty of Basic Medical Sciences, College of 
      Medicine, University of Ibadan, Ibadan, Nigeria.
FAU - Owumi, Solomon
AU  - Owumi S
AD  - Department of Biochemistry, Faculty of Basic Medical Sciences, College of 
      Medicine, University of Ibadan, Ibadan, Nigeria.
FAU - Adaramoye, Oluwatosin
AU  - Adaramoye O
AD  - Department of Biochemistry, Faculty of Basic Medical Sciences, College of 
      Medicine, University of Ibadan, Ibadan, Nigeria. Electronic address: 
      ao.adaramoye@ui.edu.ng.
LA  - eng
PT  - Journal Article
DEP - 20181229
PL  - Ireland
TA  - J Ethnopharmacol
JT  - Journal of ethnopharmacology
JID - 7903310
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Carcinogens)
RN  - 0 (Plant Extracts)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - 684-93-5 (Methylnitrosourea)
RN  - EC 1.11.1.6 (Catalase)
RN  - EC 1.11.1.9 (Glutathione Peroxidase)
RN  - EC 2.5.1.18 (Glutathione Transferase)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - GAN16C9B8O (Glutathione)
SB  - IM
MH  - Animals
MH  - Anticarcinogenic Agents/pharmacology/*therapeutic use
MH  - Carcinogens
MH  - Catalase/metabolism
MH  - Chemoprevention
MH  - *Fabaceae
MH  - Female
MH  - Glutathione/metabolism
MH  - Glutathione Peroxidase/metabolism
MH  - Glutathione Transferase/metabolism
MH  - Mammary Neoplasms, Experimental/metabolism/*prevention & control
MH  - Methylnitrosourea
MH  - Plant Extracts/pharmacology/*therapeutic use
MH  - Plant Roots
MH  - Rats, Wistar
MH  - Receptor, ErbB-2/metabolism
MH  - Receptors, Estrogen/metabolism
MH  - Receptors, Progesterone/metabolism
OTO - NOTNLM
OT  - Inflammation
OT  - Mammary gland
OT  - N-methyl-N-nitrosourea
OT  - Oxidative stress
EDAT- 2019/01/02 06:00
MHDA- 2019/04/09 06:00
CRDT- 2019/01/02 06:00
PHST- 2018/04/25 00:00 [received]
PHST- 2018/11/25 00:00 [revised]
PHST- 2018/12/16 00:00 [accepted]
PHST- 2019/01/02 06:00 [pubmed]
PHST- 2019/04/09 06:00 [medline]
PHST- 2019/01/02 06:00 [entrez]
AID - S0378-8741(18)31660-X [pii]
AID - 10.1016/j.jep.2018.12.027 [doi]
PST - ppublish
SO  - J Ethnopharmacol. 2019 Apr 6;233:22-33. doi: 10.1016/j.jep.2018.12.027. Epub 2018 
      Dec 29.

PMID- 34989822
OWN - NLM
STAT- MEDLINE
DCOM- 20220517
LR  - 20220716
IS  - 1432-0827 (Electronic)
IS  - 0171-967X (Print)
IS  - 0171-967X (Linking)
VI  - 110
IP  - 6
DP  - 2022 Jun
TI  - Ibandronate Suppresses Changes in Apatite Orientation and Young's Modulus Caused 
      by Estrogen Deficiency in Rat Vertebrae.
PG  - 736-745
LID - 10.1007/s00223-021-00940-2 [doi]
AB  - Bone material quality is important for evaluating the mechanical integrity of 
      diseased and/or medically treated bones. However, compared to the knowledge 
      accumulated regarding changes in bone mass, our understanding of the quality of 
      bone material is lacking. In this study, we clarified the changes in bone 
      material quality mainly characterized by the preferential orientation of the 
      apatite c-axis associated with estrogen deficiency-induced osteoporosis, and 
      their prevention using ibandronate (IBN), a nitrogen-containing bisphosphonate. 
      IBN effectively prevented bone loss and degradation of whole bone strength in a 
      dose-dependent manner. The estrogen-deficient condition abnormally increased the 
      degree of apatite orientation along the craniocaudal axis in which principal 
      stress is applied; IBN at higher doses played a role in maintaining the normal 
      orientation of apatite but not at lower doses. The bone size-independent Young's 
      modulus along the craniocaudal axis of the anterior cortical shell of the 
      vertebra showed a significant and positive correlation with apatite orientation; 
      therefore, the craniocaudal Young's modulus abnormally increased under 
      estrogen-deficient conditions, despite a significant decrease in volumetric bone 
      mineral density. However, the abnormal increase in craniocaudal Young's modulus 
      did not compensate for the degradation of whole bone mechanical properties due to 
      the bone loss. In conclusion, it was clarified that changes in the material 
      quality, which are hidden in bone mass evaluation, occur with estrogen 
      deficiency-induced osteoporosis and IBN treatment. Here, IBN was shown to be a 
      beneficial drug that suppresses abnormal changes in bone mechanical integrity 
      caused by estrogen deficiency at both the whole bone and material levels.
CI  - © 2021. The Author(s).
FAU - Ishimoto, Takuya
AU  - Ishimoto T
AUID- ORCID: 0000-0003-0081-0591
AD  - Division of Materials and Manufacturing Science, Graduate School of Engineering, 
      Osaka University, 2-1 Yamadaoka, Suita, Osaka, 565-0871, Japan.
FAU - Saito, Mitsuru
AU  - Saito M
AD  - Department of Orthopaedic Surgery, The Jikei University School of Medicine, 
      3-25-8 Nishi-Shinbashi, Minato-ku, Tokyo, 105-8461, Japan.
FAU - Ozasa, Ryosuke
AU  - Ozasa R
AUID- ORCID: 0000-0002-2773-072X
AD  - Division of Materials and Manufacturing Science, Graduate School of Engineering, 
      Osaka University, 2-1 Yamadaoka, Suita, Osaka, 565-0871, Japan.
FAU - Matsumoto, Yoshihiro
AU  - Matsumoto Y
AD  - Product Research Department, Kamakura Research Laboratories, Chugai 
      Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa, 247-8530, Japan.
FAU - Nakano, Takayoshi
AU  - Nakano T
AUID- ORCID: 0000-0001-8052-1698
AD  - Division of Materials and Manufacturing Science, Graduate School of Engineering, 
      Osaka University, 2-1 Yamadaoka, Suita, Osaka, 565-0871, Japan. 
      nakano@mat.eng.osaka-u.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220106
PL  - United States
TA  - Calcif Tissue Int
JT  - Calcified tissue international
JID - 7905481
RN  - 0 (Apatites)
RN  - 0 (Estrogens)
RN  - UMD7G2653W (Ibandronic Acid)
SB  - IM
MH  - Animals
MH  - Apatites
MH  - Bone Density
MH  - *Bone Diseases, Metabolic/drug therapy
MH  - Elastic Modulus
MH  - *Endocrine System Diseases
MH  - Estrogens/pharmacology
MH  - Ibandronic Acid/pharmacology
MH  - *Osteoporosis/drug therapy
MH  - Rats
MH  - Spine
PMC - PMC9108105
OTO - NOTNLM
OT  - Apatite orientation
OT  - Bone quality
OT  - Ibandronate
OT  - Material anisotropy
OT  - Mechanical integrity
OT  - Osteoporosis
COIS- TN and MS have received research support from Chugai Pharmaceutical Co., Ltd. YM 
      is an employee of Chugai Pharmaceutical Co., Ltd. RO and TI have no competing 
      interests to declare that are relevant to the content of this article.
EDAT- 2022/01/07 06:00
MHDA- 2022/05/18 06:00
PMCR- 2022/01/06
CRDT- 2022/01/06 12:27
PHST- 2021/11/05 00:00 [received]
PHST- 2021/12/24 00:00 [accepted]
PHST- 2022/01/07 06:00 [pubmed]
PHST- 2022/05/18 06:00 [medline]
PHST- 2022/01/06 12:27 [entrez]
PHST- 2022/01/06 00:00 [pmc-release]
AID - 10.1007/s00223-021-00940-2 [pii]
AID - 940 [pii]
AID - 10.1007/s00223-021-00940-2 [doi]
PST - ppublish
SO  - Calcif Tissue Int. 2022 Jun;110(6):736-745. doi: 10.1007/s00223-021-00940-2. Epub 
      2022 Jan 6.

PMID- 26342608
OWN - NLM
STAT- MEDLINE
DCOM- 20160511
LR  - 20250103
IS  - 2196-5412 (Electronic)
IS  - 2196-5412 (Linking)
VI  - 2
IP  - 4
DP  - 2015 Dec
TI  - Trends in Exposure to Chemicals in Personal Care and Consumer Products.
PG  - 348-55
LID - 10.1007/s40572-015-0065-9 [doi]
AB  - Synthetic organic chemicals can be used in personal care and consumer products. 
      Data on potential human health effects of these chemicals are limited-sometimes 
      even contradictory-but because several of these chemicals are toxic in 
      experimental animals, alternative compounds are entering consumer markets. 
      Nevertheless, limited information exists on consequent exposure trends to both 
      the original chemicals and their replacements. Biomonitoring (measuring 
      concentrations of chemicals or their metabolites in people) provides invaluable 
      information for exposure assessment. We use phthalates and bisphenol A-known 
      industrial chemicals-and organophosphate insecticides as case studies to show 
      exposure trends to these chemicals and their replacements (e.g., other 
      phthalates, non-phthalate plasticizers, various bisphenols, pyrethroid 
      insecticides) among the US general population. We compare US trends to national 
      trends from Canada and Germany. Exposure to the original compounds is still 
      prevalent among these general populations, but exposures to alternative chemicals 
      may be increasing.
FAU - Calafat, Antonia M
AU  - Calafat AM
AD  - Centers for Disease Control and Prevention, 4770 Buford Hwy, MS F17, Atlanta, GA, 
      30341, USA. aic7@cdc.gov.
FAU - Valentin-Blasini, Liza
AU  - Valentin-Blasini L
AD  - Centers for Disease Control and Prevention, 4770 Buford Hwy, MS F19, Atlanta, GA, 
      30341, USA. lbv5@cdc.gov.
FAU - Ye, Xiaoyun
AU  - Ye X
AD  - Centers for Disease Control and Prevention, 4770 Buford Hwy, MS F53, Atlanta, GA, 
      30341, USA. xay5@cdc.gov.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Switzerland
TA  - Curr Environ Health Rep
JT  - Current environmental health reports
JID - 101629387
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Cosmetics)
RN  - 0 (Endocrine Disruptors)
RN  - 0 (Insecticides)
RN  - 0 (Organophosphates)
RN  - 0 (Parabens)
RN  - 0 (Phenols)
RN  - 0 (Phthalic Acids)
RN  - 0 (Plasticizers)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - Animals
MH  - Benzhydryl Compounds/*analysis
MH  - Canada
MH  - Consumer Product Safety/standards
MH  - Cosmetics/adverse effects/*chemistry
MH  - Endocrine Disruptors/analysis
MH  - Environmental Exposure/*analysis
MH  - Environmental Monitoring/methods
MH  - Germany
MH  - Household Products/adverse effects/*analysis
MH  - Humans
MH  - Insecticides/analysis
MH  - Organophosphates/*analysis
MH  - Parabens/analysis
MH  - Phenols/*analysis
MH  - Phthalic Acids/*analysis
MH  - Plasticizers/analysis
MH  - Surveys and Questionnaires
MH  - United States
OTO - NOTNLM
OT  - Biomonitoring
OT  - Bisphenol
OT  - DINCH
OT  - Endocrine disruptors
OT  - Exposure
OT  - Insecticides
OT  - Pesticides
OT  - Phthalates
EDAT- 2015/09/08 06:00
MHDA- 2016/05/12 06:00
CRDT- 2015/09/07 06:00
PHST- 2015/09/07 06:00 [entrez]
PHST- 2015/09/08 06:00 [pubmed]
PHST- 2016/05/12 06:00 [medline]
AID - 10.1007/s40572-015-0065-9 [pii]
AID - 10.1007/s40572-015-0065-9 [doi]
PST - ppublish
SO  - Curr Environ Health Rep. 2015 Dec;2(4):348-55. doi: 10.1007/s40572-015-0065-9.

PMID- 33251666
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1473-2165 (Electronic)
IS  - 1473-2130 (Linking)
VI  - 20
IP  - 3
DP  - 2021 Mar
TI  - Study on the skin status of mid-pregnancy women based on lipidomics.
PG  - 955-963
LID - 10.1111/jocd.13866 [doi]
AB  - BACKGROUND: Pregnancy is a complex physiological state and its unique changes in 
      skin state have been discussed. Skin surface lipid (SSL) is an important 
      molecular basis for this skin condition, and it affects skin condition in a 
      number of ways, but there are no complete research data on it. OBJECTIVES: To 
      analyze the lipidome profiles of SSL in pregnancies and controls in order to 
      understand SSL changes in pregnancy. It will provide theoretical data of SSL on 
      skin care and prevention of skin diseases during pregnancy. METHODS: Ultra-high 
      performance liquid chromatography quadrupole time-of-flight mass spectrometry 
      (UPLC-QTOF-MS) and multivariate statistics were used to investigate the changes 
      of SSL in pregnancy. RESULTS: Results showed that there were significant 
      differences (P < .05) in the lipidome between pregnancies and controls. 
      Multivariate data analysis indicated that there were 20 important individual 
      lipid species identified, and triglycerides (TGs) were the majority of 
      differentiating lipid species. CONCLUSIONS: The increase of estrogen level in 
      pregnancies antagonizes and inhibits the regulation of androgen on sebaceous 
      gland, resulting in the decrease of sebum secretion and the weakening of skin 
      barrier function. Besides, the decrease of saturated fatty acid content may be 
      the main factor of the decrease of skin barrier function during pregnancy. 
      Additionally, skin cells perform their self-regulation function to reduce or 
      counteract abnormal state of the skin during pregnancy through the synthesis and 
      secretion of more glycerophospholipids and ceramides.
CI  - © 2020 Wiley Periodicals LLC.
FAU - Chen, Feng
AU  - Chen F
AD  - Beijing Technology and Business University, Beijing, China.
FAU - Huang, Dianchao
AU  - Huang D
AD  - Beijing Technology and Business University, Beijing, China.
LA  - eng
GR  - Z171100001517006/Science and Technology Planning Project of Beijing/
PT  - Journal Article
DEP - 20201209
PL  - England
TA  - J Cosmet Dermatol
JT  - Journal of cosmetic dermatology
JID - 101130964
RN  - 0 (Lipids)
SB  - IM
MH  - Chromatography, High Pressure Liquid
MH  - Female
MH  - Humans
MH  - *Lipidomics
MH  - *Lipids
MH  - Mass Spectrometry
MH  - Pregnancy
MH  - Sebaceous Glands
OTO - NOTNLM
OT  - UPLC-QTOF-MS
OT  - lipidomics
OT  - pregnancy
OT  - skin barrier
OT  - skin surface lipid
EDAT- 2020/12/01 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/30 05:58
PHST- 2020/11/03 00:00 [received]
PHST- 2020/11/20 00:00 [accepted]
PHST- 2020/12/01 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/11/30 05:58 [entrez]
AID - 10.1111/jocd.13866 [doi]
PST - ppublish
SO  - J Cosmet Dermatol. 2021 Mar;20(3):955-963. doi: 10.1111/jocd.13866. Epub 2020 Dec 
      9.

PMID- 28689297
OWN - NLM
STAT- MEDLINE
DCOM- 20180723
LR  - 20181113
IS  - 1573-7365 (Electronic)
IS  - 0885-7490 (Print)
IS  - 0885-7490 (Linking)
VI  - 32
IP  - 5
DP  - 2017 Oct
TI  - Estrogen protects both sexes against EAE by promoting common regulatory cell 
      subtypes independent of endogenous estrogen.
PG  - 1747-1754
LID - 10.1007/s11011-017-0063-8 [doi]
AB  - Autoimmune diseases including multiple sclerosis predominantly affect females. 
      Although high levels of sex hormones, particularly estrogen (E2), can reduce 
      proinflammatory immune responses, it remains unclear if a lack of endogenous sex 
      hormones might affect treatment with exogenous sex hormones. Pretreatment with E2 
      almost completely prevents intact female and male mice from developing clinical 
      and histological signs of experimental autoimmune encephalomyelitis (EAE) by 
      promoting various regulatory immune cell phenotypes. To evaluate the effects of 
      exogenous estrogen in the absence of endogenous sex hormones, the current study 
      compared EAE severity and the emergence of different immunoregulatory cell 
      populations after E2 pretreatment of ovariectomized (OVX) female versus male 
      mice. We found that E2 equally protected both OVX females and males from EAE over 
      a 21 day observation period concomitant with reduced total cell numbers in spleen 
      and spinal cord (males only), but enhanced percentages of CD19(+)CD5(+)CD1d(hi), 
      CD19(+)CD138(+)CD44(hi) and CD19(+)Tim-1(+) Breg cells, CD8(+)CD122(+) Treg cells 
      and CD11b(+)CD 206(+)ARG-1(+) anti-inflammatory M2-like monocytes/macrophages in 
      both groups. In contrast, E2 decreased the percentage of CD4(+)CD25(+)FoxP3(+) 
      Treg cells in OVX females but increased these Treg cells in males and intact 
      female mice. These data suggest that with the exception of CD4(+)CD25(+)FoxP3(+) 
      Treg cells, E2 protection against EAE promotes highly overlapping 
      immunoregulatory subsets in OVX females and males.
FAU - Seifert, Hilary A
AU  - Seifert HA
AD  - Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson 
      Park Rd, Portland, OR, USA.
AD  - Neuroimmunology Research, R&D-31, VA Portland Health Care System, 3710 SW US 
      Veterans Hospital Rd, Portland, OR, 97239, USA.
FAU - Benedek, Gil
AU  - Benedek G
AD  - Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson 
      Park Rd, Portland, OR, USA.
AD  - Neuroimmunology Research, R&D-31, VA Portland Health Care System, 3710 SW US 
      Veterans Hospital Rd, Portland, OR, 97239, USA.
FAU - Nguyen, Ha
AU  - Nguyen H
AD  - Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson 
      Park Rd, Portland, OR, USA.
AD  - Neuroimmunology Research, R&D-31, VA Portland Health Care System, 3710 SW US 
      Veterans Hospital Rd, Portland, OR, 97239, USA.
FAU - Kent, Gail
AU  - Kent G
AD  - Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson 
      Park Rd, Portland, OR, USA.
AD  - Neuroimmunology Research, R&D-31, VA Portland Health Care System, 3710 SW US 
      Veterans Hospital Rd, Portland, OR, 97239, USA.
FAU - Vandenbark, Arthur A
AU  - Vandenbark AA
AD  - Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson 
      Park Rd, Portland, OR, USA.
AD  - Neuroimmunology Research, R&D-31, VA Portland Health Care System, 3710 SW US 
      Veterans Hospital Rd, Portland, OR, 97239, USA.
AD  - Department of Molecular Microbiology & Immunology, Oregon Health & Science 
      University, 3181 SW Sam Jackson Park Rd, Portland, OR, USA.
FAU - Offner, Halina
AU  - Offner H
AD  - Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson 
      Park Rd, Portland, OR, USA. offnerva@ohsu.edu.
AD  - Neuroimmunology Research, R&D-31, VA Portland Health Care System, 3710 SW US 
      Veterans Hospital Rd, Portland, OR, 97239, USA. offnerva@ohsu.edu.
AD  - Department of Anesthesiology & Perioperative Medicine, Oregon Health & Science 
      University, 3181 SW Sam Jackson Park Rd, Portland, OR, USA. offnerva@ohsu.edu.
LA  - eng
GR  - R01 NS080890/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20170708
PL  - United States
TA  - Metab Brain Dis
JT  - Metabolic brain disease
JID - 8610370
RN  - 0 (Antigens, CD)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Animals
MH  - Antigens, CD/metabolism
MH  - B-Lymphocytes, Regulatory/metabolism
MH  - Encephalomyelitis, Autoimmune, Experimental/pathology/*prevention & control
MH  - Estradiol/metabolism/*therapeutic use
MH  - Female
MH  - Macrophages/drug effects/immunology
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Ovariectomy
MH  - Spinal Cord/pathology
MH  - Spleen/pathology
MH  - T-Lymphocytes, Regulatory
PMC - PMC5650507
MID - NIHMS891494
OTO - NOTNLM
OT  - Anti-inflammatory macrophages
OT  - EAE
OT  - Estrogen
OT  - Ovariectomized
OT  - Regulatory B cells
OT  - Sex Differences
COIS- Conflict of Interest: The authors declare that they have no conflict of interest.
EDAT- 2017/07/10 06:00
MHDA- 2018/07/24 06:00
PMCR- 2018/10/01
CRDT- 2017/07/10 06:00
PHST- 2017/05/31 00:00 [received]
PHST- 2017/06/22 00:00 [accepted]
PHST- 2017/07/10 06:00 [pubmed]
PHST- 2018/07/24 06:00 [medline]
PHST- 2017/07/10 06:00 [entrez]
PHST- 2018/10/01 00:00 [pmc-release]
AID - 10.1007/s11011-017-0063-8 [pii]
AID - 10.1007/s11011-017-0063-8 [doi]
PST - ppublish
SO  - Metab Brain Dis. 2017 Oct;32(5):1747-1754. doi: 10.1007/s11011-017-0063-8. Epub 
      2017 Jul 8.

PMID- 30051530
OWN - NLM
STAT- MEDLINE
DCOM- 20191104
LR  - 20210109
IS  - 1476-5381 (Electronic)
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 175
IP  - 20
DP  - 2018 Oct
TI  - 17β-Estradiol reduces mitochondrial cAMP content and cytochrome oxidase activity 
      in a phosphodiesterase 2-dependent manner.
PG  - 3876-3890
LID - 10.1111/bph.14455 [doi]
AB  - BACKGROUND AND PURPOSE: Mitochondria possess their own source of cAMP, that is, 
      soluble adenylyl cyclase (sAC). Activation or expression of mitochondrial sAC 
      promotes mitochondrial function. Oestrogen receptor signalling plays an essential 
      role in the regulation of mitochondrial function. Here we aimed to determine 
      whether 17β-estradiol may affect mitochondrial cAMP signalling. EXPERIMENTAL 
      APPROACH: Expression of the intra-mitochondrial proteins (Western blot), 
      mitochondrial cAMP content (FRET-based live imaging and MS assay), mitochondrial 
      membrane potential and cytochrome oxidase activity were analysed in H9C2 and 
      C2C12 cells. KEY RESULTS: A 24 h treatment with 17β-estradiol significantly 
      reduced the basal level of mitochondrial cAMP, without affecting the 
      intra-mitochondrial content of sAC, phosphodiesterase 2 (PDE2) or PKA and the 
      activity of the intra-mitochondrial sAC. The effect of 17β-estradiol on 
      mitochondrial cAMP was prevented by inhibition of a cGMP-activated PDE2 or 
      soluble guanylyl cyclase (sGC), suggesting a role of NO signalling. Indeed, 
      17β-estradiol raised cellular levels of cGMP and the intra-mitochondrial 
      expression of the catalytic subunit β of sGC was found. The 17β-estradiol-induced 
      reduction of the mitochondrial cAMP level was accompanied by decreased cytochrome 
      oxidase activity and mitochondrial membrane potential in a PDE2-dependent manner. 
      CONCLUSIONS AND IMPLICATIONS: 17β-estradiol reduced the basal level of 
      mitochondrial cAMP content and cytochrome oxidase activity in a sAC-independent 
      but in a PDE2-dependent manner. The results suggest a role of 
      17β-estradiol-induced activation of NO signalling in the regulation of 
      mitochondrial cAMP content. Our study adds a new aspect to the complex action of 
      oestrogens on mitochondrial biology, that is relevant to hormone replacement 
      therapy.
CI  - © 2018 The British Pharmacological Society.
FAU - Pozdniakova, Sofya
AU  - Pozdniakova S
AD  - Charité - Universitätsmedizin Berlin, Institute of Gender in Medicine, Center for 
      Cardiovascular Research, Berlin, Germany.
AD  - DZHK (German Center for Cardiovascular Research), partner site Berlin, Berlin, 
      Germany.
FAU - Guitart-Mampel, Mariona
AU  - Guitart-Mampel M
AD  - Muscle Research and Mitochondrial Function Laboratory, Cellex - IDIBAPS, Faculty 
      of Medicine and Health Science, University of Barcelona, Internal Medicine 
      Service - Hospital Clínic of Barcelona, Barcelona, Spain.
AD  - CIBERER, Madrid, Spain.
FAU - Garrabou, Gloria
AU  - Garrabou G
AD  - Muscle Research and Mitochondrial Function Laboratory, Cellex - IDIBAPS, Faculty 
      of Medicine and Health Science, University of Barcelona, Internal Medicine 
      Service - Hospital Clínic of Barcelona, Barcelona, Spain.
AD  - CIBERER, Madrid, Spain.
FAU - Di Benedetto, Giulietta
AU  - Di Benedetto G
AD  - Neuroscience Institute, Italian National Research Council, Venetian Institute of 
      Molecular Medicine, Padova, Italy.
FAU - Ladilov, Yury
AU  - Ladilov Y
AUID- ORCID: 0000-0002-9836-8801
AD  - Charité - Universitätsmedizin Berlin, Institute of Gender in Medicine, Center for 
      Cardiovascular Research, Berlin, Germany.
AD  - DZHK (German Center for Cardiovascular Research), partner site Berlin, Berlin, 
      Germany.
FAU - Regitz-Zagrosek, Vera
AU  - Regitz-Zagrosek V
AD  - Charité - Universitätsmedizin Berlin, Institute of Gender in Medicine, Center for 
      Cardiovascular Research, Berlin, Germany.
AD  - DZHK (German Center for Cardiovascular Research), partner site Berlin, Berlin, 
      Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180908
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Estrogens)
RN  - 4TI98Z838E (Estradiol)
RN  - E0399OZS9N (Cyclic AMP)
RN  - EC 1.9.3.1 (Electron Transport Complex IV)
RN  - EC 3.1.4.- (Phosphoric Diester Hydrolases)
RN  - H2D2X058MU (Cyclic GMP)
SB  - IM
MH  - Animals
MH  - Cell Line
MH  - Cyclic AMP/*metabolism
MH  - Cyclic GMP/metabolism
MH  - Electron Transport Complex IV/*metabolism
MH  - Estradiol/*pharmacology
MH  - Estrogens/*pharmacology
MH  - Mice
MH  - Mitochondria/*drug effects/physiology
MH  - Phosphoric Diester Hydrolases/metabolism
MH  - Rats
PMC - PMC6151328
EDAT- 2018/07/28 06:00
MHDA- 2019/11/05 06:00
PMCR- 2019/10/01
CRDT- 2018/07/28 06:00
PHST- 2017/09/28 00:00 [received]
PHST- 2018/07/10 00:00 [revised]
PHST- 2018/07/11 00:00 [accepted]
PHST- 2018/07/28 06:00 [pubmed]
PHST- 2019/11/05 06:00 [medline]
PHST- 2018/07/28 06:00 [entrez]
PHST- 2019/10/01 00:00 [pmc-release]
AID - BPH14455 [pii]
AID - 10.1111/bph.14455 [doi]
PST - ppublish
SO  - Br J Pharmacol. 2018 Oct;175(20):3876-3890. doi: 10.1111/bph.14455. Epub 2018 Sep 
      8.

PMID- 29901777
OWN - NLM
STAT- MEDLINE
DCOM- 20190927
LR  - 20190927
IS  - 1529-7268 (Electronic)
IS  - 0006-3363 (Linking)
VI  - 99
IP  - 5
DP  - 2018 Nov 1
TI  - Uterine TPPP3 plays important role in embryo implantation via modulation of 
      β-catenin.
PG  - 982-999
LID - 10.1093/biolre/ioy136 [doi]
AB  - Tubulin polymerization promoting protein 3 (TPPP3) is known to be expressed in 
      the endometrium in a cyclic manner, and its functional role in the physiology of 
      implantation remains unknown. Here we demonstrate a novel function of TPPP3 
      during the window of implantation and in the establishment of pregnancy using a 
      mouse model. The increased protein expression of TPPP3 and β-catenin during 
      peri-implantation period, i.e. D5 (receptive phase, 0800 h), was observed as 
      compared to that on D1 (nonreceptive phase, 0800 h). SiRNATPPP3-mediated 
      knockdown of uterine TPPP3 resulted in implantation failure and inhibited the 
      expression of receptivity markers: LIF, Integrin-β3, IHH, and Wnt4. TPPP3 
      silencing in mouse endometrial epithelial cells also prevented blastocyst 
      attachment and the adhesion reaction. In delayed implantation experiment, 
      expression of TPPP3 was increased in active implantation group (E2 + P4) compared 
      to delayed implantation group (P4). The increased expression of TPPP3 in 
      E2 + P4-treated Ishikawa cells compared to vehicle or P4 or E2 alone-treated 
      Ishikawa cells also revealed its upregulation by E2. The suppression of β-catenin 
      in uterus under the condition of transient knockdown of TPPP3 and the 
      co-immunoprecipitation experiment revealed that regulation of β-catenin was 
      mediated via TPPP3 during implantation. Additionally, in order to gain insight 
      into TPPP3 collaborators, we identified TPPP3 interacting proteins by nanoLC-MS 
      analysis in mouse uterus which might be involved during implantation. In 
      conclusion, our study suggests that TPPP3 is important for embryo implantation 
      and for the establishment of early pregnancy through modulation of β-catenin.
FAU - Shukla, Vinay
AU  - Shukla V
AD  - Division of Endocrinology, CSIR- Central Drug Research Institute, Lucknow-226031, 
      UP, India.
AD  - Academy of Scientific and Innovative Research (AcSIR), CSIR-CDRI Campus, Lucknow, 
      India.
FAU - Popli, Pooja
AU  - Popli P
AD  - Division of Endocrinology, CSIR- Central Drug Research Institute, Lucknow-226031, 
      UP, India.
FAU - Kaushal, Jyoti Bala
AU  - Kaushal JB
AD  - Division of Endocrinology, CSIR- Central Drug Research Institute, Lucknow-226031, 
      UP, India.
AD  - Academy of Scientific and Innovative Research (AcSIR), CSIR-CDRI Campus, Lucknow, 
      India.
FAU - Gupta, Kanchan
AU  - Gupta K
AD  - Division of Endocrinology, CSIR- Central Drug Research Institute, Lucknow-226031, 
      UP, India.
FAU - Dwivedi, Anila
AU  - Dwivedi A
AD  - Division of Endocrinology, CSIR- Central Drug Research Institute, Lucknow-226031, 
      UP, India.
AD  - Academy of Scientific and Innovative Research (AcSIR), CSIR-CDRI Campus, Lucknow, 
      India.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Biol Reprod
JT  - Biology of reproduction
JID - 0207224
RN  - 0 (Ceacam9 protein, mouse)
RN  - 0 (Cell Adhesion Molecules)
RN  - 0 (beta Catenin)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Animals
MH  - Blastocyst
MH  - Cell Adhesion Molecules/*genetics/*physiology
MH  - Cell Line, Tumor
MH  - Embryo Implantation/*genetics/*physiology
MH  - Estradiol/pharmacology
MH  - Female
MH  - Gene Knockdown Techniques
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Pregnancy
MH  - Pseudopregnancy/genetics/metabolism
MH  - Uterus/*metabolism
MH  - beta Catenin/*metabolism
EDAT- 2018/06/15 06:00
MHDA- 2019/09/29 06:00
CRDT- 2018/06/15 06:00
PHST- 2017/09/19 00:00 [received]
PHST- 2018/06/11 00:00 [accepted]
PHST- 2018/06/15 06:00 [pubmed]
PHST- 2019/09/29 06:00 [medline]
PHST- 2018/06/15 06:00 [entrez]
AID - 5036514 [pii]
AID - 10.1093/biolre/ioy136 [doi]
PST - ppublish
SO  - Biol Reprod. 2018 Nov 1;99(5):982-999. doi: 10.1093/biolre/ioy136.

PMID- 29353804
OWN - NLM
STAT- MEDLINE
DCOM- 20180509
LR  - 20250103
IS  - 1873-6424 (Electronic)
IS  - 0269-7491 (Linking)
VI  - 235
DP  - 2018 Apr
TI  - Sensitive analysis of steroid estrogens and bisphenol a in small volumes of water 
      using isotope-dilution ultra-performance liquid chromatography-tandem mass 
      spectrometry.
PG  - 881-888
LID - S0269-7491(17)33735-1 [pii]
LID - 10.1016/j.envpol.2018.01.003 [doi]
AB  - An isotope-dilution ultra-performance liquid chromatography-electrospray tandem 
      mass spectrometry method combined with dansylation was established to sensitively 
      quantify four steroid estrogens (estrone, 17α-estradiol, 17β-estradiol and 
      17α-ethynylestradiol) and bisphenol A in sewage influent and effluent. A simple 
      hexane extraction was performed from a small volume (10 mL), followed by dansyl 
      chloride derivatization and purification with a silica cartridge. The method 
      effectively reduced the matrix effects in sample extract and permitted the 
      selective and sensitive determination of target compounds from complicated 
      matrices. The detection limits of the method for steroid estrogens were 
      0.20-0.90 ng L(-1) in influent and 0.10-0.20 ng L(-1) in effluent samples. For 
      bisphenol A, the limits detection of the method were 20 and 0.80 for influent and 
      effluent samples, respectively. Recoveries of 85%-96% were observed in all 
      matrices. The method was applied to analyze residual estrogens and bisphenol A in 
      sewage influent and effluent samples from Beijing, China. The concentrations of 
      bisphenol A (636-1200 ng L(-1)) were up to 250 times higher than those of steroid 
      estrogens. Estrone was the dominant estrogen in influent and effluent samples, 
      while similar concentrations of 17α-estradiol and 17β-estradiol were detected in 
      all samples.
CI  - Copyright © 2018 Elsevier Ltd. All rights reserved.
FAU - Chang, Hong
AU  - Chang H
AD  - Beijing Key Lab for Source Control Technology of Water Pollution, College of 
      Environmental Sciences & Engineering, Beijing Forestry University, Beijing 
      100083, China. Electronic address: changh@bjfu.edu.cn.
FAU - Shen, Xiaoyan
AU  - Shen X
AD  - Beijing Key Lab for Source Control Technology of Water Pollution, College of 
      Environmental Sciences & Engineering, Beijing Forestry University, Beijing 
      100083, China.
FAU - Shao, Bing
AU  - Shao B
AD  - Beijing Key Laboratory of Diagnostic and Traceability Technologies for Food 
      Poisoning, Beijing Center for Disease Prevention and Control, Beijing 100013, 
      China.
FAU - Wu, Fengchang
AU  - Wu F
AD  - State Key Laboratory of Environmental Criteria and Risk Assessment, Chinese 
      Research Academy of Environmental Sciences, Beijing 100012, China.
LA  - eng
PT  - Journal Article
DEP - 20180221
PL  - England
TA  - Environ Pollut
JT  - Environmental pollution (Barking, Essex : 1987)
JID - 8804476
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Dansyl Compounds)
RN  - 0 (Estrogens)
RN  - 0 (Isotopes)
RN  - 0 (Phenols)
RN  - 0 (Sewage)
RN  - 0 (Water Pollutants, Chemical)
RN  - 059QF0KO0R (Water)
RN  - 2DI9HA706A (Estrone)
RN  - 423D2T571U (Ethinyl Estradiol)
RN  - 4TI98Z838E (Estradiol)
RN  - RW57K3X12M (bisphenol A)
RN  - QMU9166TJ4 (dansyl chloride)
SB  - IM
MH  - Beijing
MH  - Benzhydryl Compounds/*analysis
MH  - Chromatography, High Pressure Liquid/*methods
MH  - Dansyl Compounds/chemistry
MH  - Estradiol/analysis
MH  - Estrogens/*analysis
MH  - Estrone/analysis
MH  - Ethinyl Estradiol/analysis
MH  - Indicator Dilution Techniques
MH  - Isotopes/analysis
MH  - Limit of Detection
MH  - Phenols/*analysis
MH  - Sewage/chemistry
MH  - Tandem Mass Spectrometry/*methods
MH  - Water/*chemistry
MH  - Water Pollutants, Chemical/*analysis
OTO - NOTNLM
OT  - Bisphenol A
OT  - Derivatization
OT  - Sewage
OT  - Steroid estrogens
OT  - UPLC-MS/MS
EDAT- 2018/01/23 06:00
MHDA- 2018/05/10 06:00
CRDT- 2018/01/23 06:00
PHST- 2017/09/20 00:00 [received]
PHST- 2017/12/21 00:00 [revised]
PHST- 2018/01/02 00:00 [accepted]
PHST- 2018/01/23 06:00 [pubmed]
PHST- 2018/05/10 06:00 [medline]
PHST- 2018/01/23 06:00 [entrez]
AID - S0269-7491(17)33735-1 [pii]
AID - 10.1016/j.envpol.2018.01.003 [doi]
PST - ppublish
SO  - Environ Pollut. 2018 Apr;235:881-888. doi: 10.1016/j.envpol.2018.01.003. Epub 
      2018 Feb 21.

PMID- 37802873
OWN - NLM
STAT- MEDLINE
DCOM- 20231009
LR  - 20231009
IS  - 1001-5302 (Print)
IS  - 1001-5302 (Linking)
VI  - 48
IP  - 16
DP  - 2023 Aug
TI  - [Relationship between promoting effect of Zuogui Pills on angiogenesis of 
      reproductive organs and mobilization factors GM-CSF, SDF-1, and their receptors 
      of EPCs in early-aging rats].
PG  - 4467-4474
LID - 10.19540/j.cnki.cjcmm.20230413.703 [doi]
AB  - This study aimed to investigate the relationship between the promoting effect of 
      Zuogui Pills on ovarian and vaginal angiogenesis in early-aging rats and 
      mobilization factors granulocyte-macrophage colony-stimulating factor(GM-CSF), 
      stromal cell-derived factor-1(SDF-1), and their receptors of endothelial 
      progenitor cells(EPCs) and explore the mechanism of Zuogui Pills in improving 
      reproductive hypofunction in early-aging rats. Ultra-high performance liquid 
      chromatography-tandem mass spectrometry(UHPLC-MS/MS) was used to analyze the 
      chemical components of the extract of Zuogui Pills. Forty 14-month-old female 
      early-aging rats with estrous cycle disorder were randomly divided into a blank 
      group, a conjugated estrogen group(conjugated estrogen suspension, 65 
      μg·kg~(-1)), and low-(11 g·kg~(-1)) and high-dose(33 g·kg~(-1)) Zuogui Pills 
      groups, with 10 rats in each group. In addition, 10 4-month-old female rats were 
      assigned to the youth control group. The rats in the blank group and the youth 
      control group were treated with 20 g·kg~(-1) distilled water by gavage, while 
      those in the groups with drug intervention were treated with corresponding drugs 
      by gavage, once a day for 15 days. Enzyme-linked immunosorbent assay(ELISA) was 
      used to detect the levels of SDF-1 and GM-CSF in the mobilization of EPCs in 
      serum. Hematoxylin-eosin(HE) staining was used to observe the changes in the 
      number of ovarian follicles at all levels and corpus luteum, the number of 
      vaginal epithelial layers, the number of vaginal folds, and the blood vessels of 
      ovarian and vaginal tissues in the groups with drug intervention. Western blot 
      was used to detect the expression of ER, GM-CSFR, CXCR4, and CXCR7 proteins in 
      ovarian and vaginal tissues. As revealed by the results, the blank group showed 
      decreased number of corpus luteum, gro-wing follicles at all levels, and blood 
      vessels(P&lt;0.05), decreased thickness of vaginal mucosa, the number of 
      epithelial layers, the number of vaginal folds, and the number of vessels in the 
      lamina propria(P&lt;0.05), reduced content of SDF-1 and GM-CSF in the peripheral 
      blood(P&lt;0.05), and down-regulated levels of ER, CXCR4, CXCR7, and GM-CSFR 
      proteins in ovarian and vaginal tissues(P&lt;0.05). The groups with drug 
      intervention showed increased number of growing follicles at all levels, corpus 
      luteum, and blood vessels(P&lt;0.05), decreased number of atresia 
      follicles(P&lt;0.05), increased thickness of vaginal mucosa, the number of 
      epithelial layers, the number of vaginal mucosal folds, and the number of blood 
      vessels in the lamina propria(P&lt;0.05), increased content of SDF-1 and GM-CSF 
      in the peripheral blood(P&lt;0.05), and up-regulated levels of ER, CXCR4, CXCR7, 
      and GM-CSFR proteins in ovarian and vaginal tissues(P&lt;0.05). This experiment 
      suggests that Zuogui Pills may promote ovarian and vaginal angiogenesis and 
      improve the reproductive function of early-aging rats by up-regulating the levels 
      of mobilization factors SDF-1, GM-CSF, and their receptors of EPCs.
FAU - Song, Qian-Qian
AU  - Song QQ
AD  - Chongqing Key Laboratory of Traditional Chinese Medicine Prevention and Treatment 
      of Metabolic Diseases,College of Traditional Chinese Medicine,Chongqing Medical 
      University Chongqing 400016,China.
FAU - Duan, Heng
AU  - Duan H
AD  - Chongqing Key Laboratory of Traditional Chinese Medicine Prevention and Treatment 
      of Metabolic Diseases,College of Traditional Chinese Medicine,Chongqing Medical 
      University Chongqing 400016,China.
FAU - Peng, Wan-Chun
AU  - Peng WC
AD  - Chongqing Key Laboratory of Traditional Chinese Medicine Prevention and Treatment 
      of Metabolic Diseases,College of Traditional Chinese Medicine,Chongqing Medical 
      University Chongqing 400016,China.
FAU - Wei, Xiao-Jing
AU  - Wei XJ
AD  - Chongqing Key Laboratory of Traditional Chinese Medicine Prevention and Treatment 
      of Metabolic Diseases,College of Traditional Chinese Medicine,Chongqing Medical 
      University Chongqing 400016,China.
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhongguo Zhong Yao Za Zhi
JT  - Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese 
      materia medica
JID - 8913656
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
RN  - 0 (zuogui)
RN  - 0 (Estrogens, Conjugated (USP))
SB  - IM
MH  - Rats
MH  - Female
MH  - Animals
MH  - *Granulocyte-Macrophage Colony-Stimulating Factor
MH  - *Estrogens, Conjugated (USP)
MH  - Tandem Mass Spectrometry
MH  - Aging
MH  - Genitalia
OTO - NOTNLM
OT  - Zuogui Pills
OT  - angiogenesis of reproductive organs
OT  - endothelial progenitor cells
OT  - granulocyte-macrophage colony-stimulating factor
OT  - stromal cell-derived factor-1
EDAT- 2023/10/07 00:42
MHDA- 2023/10/09 06:42
CRDT- 2023/10/06 22:03
PHST- 2023/10/09 06:42 [medline]
PHST- 2023/10/07 00:42 [pubmed]
PHST- 2023/10/06 22:03 [entrez]
AID - 10.19540/j.cnki.cjcmm.20230413.703 [doi]
PST - ppublish
SO  - Zhongguo Zhong Yao Za Zhi. 2023 Aug;48(16):4467-4474. doi: 
      10.19540/j.cnki.cjcmm.20230413.703.

PMID- 39516319
OWN - NLM
STAT- MEDLINE
DCOM- 20241108
LR  - 20241116
IS  - 2399-3642 (Electronic)
IS  - 2399-3642 (Linking)
VI  - 7
IP  - 1
DP  - 2024 Nov 8
TI  - Sulfated galactofucan from Sargassum fusiforme protects against postmenopausal 
      osteoporosis by regulating bone remodeling.
PG  - 1471
LID - 10.1038/s42003-024-07097-2 [doi]
LID - 1471
AB  - Osteoporosis is a degenerative bone disease highly prevalent in older women, 
      causing high morbidity and mortality rates. Fourteen kinds of fucoidan were 
      isolated from Sargassum fusiforme through acid (named as SFS), alkaline (SFJ) and 
      water (SFW). SFW was passed through an anion exchange column to obtain SFW-0, 
      SFW-0.5 and SFW-2. SFW-0.5 and SFW-2 were degraded to obtain different sulfate 
      group contents SFW-x-M/S/O (x for 0.5 or 2). We further confirmed SFW-0.5-O was 
      the most effective fraction of SFW. SFW-0.5-O may have alternating backbones of 
      (Gal)n and (Fuc)n, and the main sulfation may be at C2/C3 of the Fuc/Gal 
      residues. SFW-0.5-O inhibition of OC differentiation was associated with IRF-8 
      signaling; meanwhile, SFW-0.5-O promoted osteoblast differentiation and bone 
      mineral nodule formation. SFW-0.5-O also effectively ameliorated osteoporosis 
      symptom caused by estrogen deprivation in vivo. We uncovered that the fucoidan 
      active fraction SFW-0.5-O demonstrated effective bone protection, may be 
      exploited for osteoporosis therapy.
CI  - © 2024. The Author(s).
FAU - Yizhong, Bao
AU  - Yizhong B
AUID- ORCID: 0009-0001-2935-7121
AD  - Zhejiang Key Laboratory of Geriatrics and Geriatrics Institute of Zhejiang 
      Province, Zhejiang Hospital, Hangzhou, PR China.
FAU - Chen, Fen
AU  - Chen F
AD  - College of Biotechnology and Bioengineering, Zhejiang University of Technology, 
      Hangzhou, PR China.
FAU - Jin, Weihua
AU  - Jin W
AD  - College of Biotechnology and Bioengineering, Zhejiang University of Technology, 
      Hangzhou, PR China.
FAU - Dai, Jihua
AU  - Dai J
AD  - Zhejiang Key Laboratory of Geriatrics and Geriatrics Institute of Zhejiang 
      Province, Zhejiang Hospital, Hangzhou, PR China.
FAU - Mao, Genxiang
AU  - Mao G
AD  - Zhejiang Key Laboratory of Geriatrics and Geriatrics Institute of Zhejiang 
      Province, Zhejiang Hospital, Hangzhou, PR China. maogenxiang@163.com.
FAU - Song, Boshan
AU  - Song B
AD  - Department of Orthopaedic Surgery, Zhejiang Hospital, Hangzhou, PR China. 
      735395261@qq.com.
LA  - eng
GR  - 81801397/National Natural Science Foundation of China (National Science 
      Foundation of China)/
PT  - Journal Article
DEP - 20241108
PL  - England
TA  - Commun Biol
JT  - Communications biology
JID - 101719179
RN  - 0 (Polysaccharides)
RN  - 9072-19-9 (fucoidan)
RN  - 0 (Sulfates)
RN  - Sargassum fusiforme
SB  - IM
MH  - *Sargassum/chemistry
MH  - Animals
MH  - *Osteoporosis, Postmenopausal/prevention & control/drug therapy
MH  - *Polysaccharides/pharmacology/chemistry
MH  - Female
MH  - *Bone Remodeling/drug effects
MH  - Humans
MH  - Mice
MH  - Cell Differentiation/drug effects
MH  - Osteoblasts/drug effects/metabolism
MH  - Sulfates/pharmacology
MH  - Edible Seaweeds
PMC - PMC11549216
COIS- The authors declare no competing interests.
EDAT- 2024/11/13 13:47
MHDA- 2024/11/14 03:55
PMCR- 2024/11/08
CRDT- 2024/11/08 23:26
PHST- 2024/04/18 00:00 [received]
PHST- 2024/10/17 00:00 [accepted]
PHST- 2024/11/14 03:55 [medline]
PHST- 2024/11/13 13:47 [pubmed]
PHST- 2024/11/08 23:26 [entrez]
PHST- 2024/11/08 00:00 [pmc-release]
AID - 10.1038/s42003-024-07097-2 [pii]
AID - 7097 [pii]
AID - 10.1038/s42003-024-07097-2 [doi]
PST - epublish
SO  - Commun Biol. 2024 Nov 8;7(1):1471. doi: 10.1038/s42003-024-07097-2.

PMID- 29671029
OWN - NLM
STAT- MEDLINE
DCOM- 20180629
LR  - 20250103
IS  - 1618-2650 (Electronic)
IS  - 1618-2642 (Linking)
VI  - 410
IP  - 16
DP  - 2018 Jun
TI  - Rapid and sensitive determination of nine bisphenol analogues, three amphenicol 
      antibiotics, and six phthalate metabolites in human urine samples using 
      UHPLC-MS/MS.
PG  - 3871-3883
LID - 10.1007/s00216-018-1062-2 [doi]
AB  - Bisphenol analogues, amphenicol antibiotics, and phthalate have widely aroused 
      public concerns due to their adverse effects on human health. In this study, a 
      rapid and sensitive method for determination of nine bisphenol analogues, three 
      amphenicol antibiotics, and six phthalate metabolites in the urine based on 
      ultra-high-performance liquid chromatography coupled with triple quadrupole 
      tandem mass spectrometry was developed and validated. The sample pretreatment 
      condition on the base of mixed-mode anion-exchange (Oasis MAX) SPE was optimized 
      to separate bisphenol analogues and amphenicol antibiotics from phthalate 
      metabolites: the former were detected with a mobile phase of 0.1% ammonium water 
      solution/methanol containing 0.1% ammonium water solution in negative mode, 
      whereas the latter were determined with a mobile phase of 0.1% acetic acid 
      solution/acetonitrile containing 0.1% acetic acid in negative mode. The limits of 
      detection were less than 0.26 ng/mL for bisphenol analogues, 0.12 ng/mL for 
      amphenicol antibiotics, and 0.14 ng/mL for phathalate metabolites. The recoveries 
      of all target analytes in three fortification levels ranged from 72.02 to 117.64% 
      with the relative standard deviations of no larger than 14.51%. The matrix effect 
      was adjusted by isotopically labeled internal standards. This proposed method was 
      successfully applied to analyze 40 actual urines and 13 out of 18 studied 
      compounds were detected. Graphical abstract Simultaneous determination of nine 
      bisphenol analogues, three amphenicol antibiotics, and six phthalate metabolites 
      in human urine samples.
FAU - Yao, Yuan
AU  - Yao Y
AD  - Key Laboratory of Public Health Security, School of Public Health, Ministry of 
      Education, Fudan University, Shanghai, 200032, China.
AD  - Department of Chemistry in Public Health, School of Public Health, Fudan 
      University, 130 Dong-an Road, Xuhui District, Shanghai, 200032, China.
FAU - Shao, Yijun
AU  - Shao Y
AD  - Key Laboratory of Public Health Security, School of Public Health, Ministry of 
      Education, Fudan University, Shanghai, 200032, China.
AD  - Department of Chemistry in Public Health, School of Public Health, Fudan 
      University, 130 Dong-an Road, Xuhui District, Shanghai, 200032, China.
FAU - Zhan, Ming
AU  - Zhan M
AD  - Pudong New Area for Disease Control and Prevention, Fudan University Pudong 
      Institute of Preventive Medicine, Shanghai, 200136, China.
FAU - Zou, Xiaoli
AU  - Zou X
AD  - Department of Sanitary Technology, West China School of Public Health, University 
      of Sichuan, Chengdu, 610041, Sichuan, China.
FAU - Qu, Weidong
AU  - Qu W
AD  - Key Laboratory of Public Health Security, School of Public Health, Ministry of 
      Education, Fudan University, Shanghai, 200032, China.
AD  - Department of Environmental Health, School of Public Health, Fudan University, 
      Shanghai, 200032, China.
FAU - Zhou, Ying
AU  - Zhou Y
AD  - Key Laboratory of Public Health Security, School of Public Health, Ministry of 
      Education, Fudan University, Shanghai, 200032, China. yingchou@fudan.edu.cn.
AD  - Department of Chemistry in Public Health, School of Public Health, Fudan 
      University, 130 Dong-an Road, Xuhui District, Shanghai, 200032, China. 
      yingchou@fudan.edu.cn.
AD  - Pudong New Area for Disease Control and Prevention, Fudan University Pudong 
      Institute of Preventive Medicine, Shanghai, 200136, China. yingchou@fudan.edu.cn.
LA  - eng
GR  - No. 81325017/National Science Fund for Distinguished Young Scholars of China/
GR  - No. 81630088/Key Program of National Natural Science Foundation of China/
GR  - No. 201540053/Scientific Research Foundation of Shanghai Municipal Commission of 
      Health and Family Planning/
GR  - No. 81373089/National Natural Science Foundation of China/
PT  - Evaluation Study
PT  - Journal Article
PT  - Validation Study
DEP - 20180419
PL  - Germany
TA  - Anal Bioanal Chem
JT  - Analytical and bioanalytical chemistry
JID - 101134327
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Phenols)
RN  - 0 (Phthalic Acids)
RN  - 66974FR9Q1 (Chloramphenicol)
RN  - 6O7F7IX66E (phthalic acid)
RN  - 9J97307Y1H (florfenicol)
RN  - FLQ7571NPM (Thiamphenicol)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - Anti-Bacterial Agents/metabolism/*urine
MH  - Benzhydryl Compounds/metabolism/*urine
MH  - Child
MH  - Chloramphenicol/metabolism/*urine
MH  - Chromatography, High Pressure Liquid/methods
MH  - Female
MH  - Humans
MH  - Limit of Detection
MH  - Male
MH  - Phenols/metabolism/*urine
MH  - Phthalic Acids/metabolism/*urine
MH  - Solid Phase Extraction/methods
MH  - Tandem Mass Spectrometry/*methods
MH  - Thiamphenicol/*analogs & derivatives/metabolism/*urine
OTO - NOTNLM
OT  - Amphenicol antibiotics
OT  - Bisphenol analogues
OT  - Mixed-mode solid-phase extraction
OT  - Phthalate metabolites
OT  - Ultra performance liquid chromatography-tandem mass spectrometry
OT  - Urine sample
EDAT- 2018/04/20 06:00
MHDA- 2018/06/30 06:00
CRDT- 2018/04/20 06:00
PHST- 2017/12/28 00:00 [received]
PHST- 2018/04/03 00:00 [accepted]
PHST- 2018/02/28 00:00 [revised]
PHST- 2018/04/20 06:00 [pubmed]
PHST- 2018/06/30 06:00 [medline]
PHST- 2018/04/20 06:00 [entrez]
AID - 10.1007/s00216-018-1062-2 [pii]
AID - 10.1007/s00216-018-1062-2 [doi]
PST - ppublish
SO  - Anal Bioanal Chem. 2018 Jun;410(16):3871-3883. doi: 10.1007/s00216-018-1062-2. 
      Epub 2018 Apr 19.

PMID- 37905559
OWN - NLM
STAT- MEDLINE
DCOM- 20240125
LR  - 20250103
IS  - 1552-8618 (Electronic)
IS  - 0730-7268 (Linking)
VI  - 43
IP  - 2
DP  - 2024 Feb
TI  - Contamination of Bisphenol A, Nonylphenol, Octylphenol, and Estrone in Major 
      Rivers of Mega Manila, Philippines.
PG  - 259-266
LID - 10.1002/etc.5778 [doi]
AB  - Endocrine-disrupting compounds (EDCs) such as natural and synthetic hormones as 
      well as phenolic industrial chemicals are considered contaminants of emerging 
      concern in environmental waters. While EDCs carried through rivers may impact 
      ecosystem health and productivity, these compounds are still not widely studied 
      nor regulated. In the present study, we report the occurrence of EDCs in urban 
      rivers in Mega Manila, namely, the Marikina, Pasig, Angat, and Pampanga Rivers 
      that drain into Manila Bay. Endocrine-disrupting compounds may have reached these 
      rivers through domestic wastewater and industrial effluents. Water samples from 
      the rivers were extracted by solid-phase extraction before instrumental analysis 
      using a liquid chromatograph coupled to a mass spectrometer. The analytical 
      method exhibited good linear response (>99% in the concentration range of 
      1-50 µg/L) and low instrument detection limits (0.14-1.46 µg/L) for the hormones 
      estrone (E1), estradiol, ethinylestradiol, progesterone, and testosterone, and 
      the industrial chemicals bisphenol A, nonylphenol, and octylphenol. Of the 
      hormones, E1 was detected up to 11 ng/L. Bisphenol A, nonylphenol, and 
      octylphenol were measured up to 54, 1878, and 62 ng/L, respectively. 
      Endocrine-disrupting compounds are not yet monitored in water bodies in the 
      Philippines and there are no local guidelines yet on occurrence, pollution 
      prevention, and mitigation. Environ Toxicol Chem 2024;43:259-266. © 2023 SETAC.
CI  - © 2023 SETAC.
FAU - Sta Ana, Katrina Marie
AU  - Sta Ana KM
AD  - Institute of Chemistry, University of the Philippines, Diliman, Quezon City, 
      Philippines.
FAU - Galera, Kate Coleen
AU  - Galera KC
AD  - Institute of Chemistry, University of the Philippines, Diliman, Quezon City, 
      Philippines.
FAU - Espino, Maria Pythias
AU  - Espino MP
AUID- ORCID: 0000-0003-2265-6249
AD  - Institute of Chemistry, University of the Philippines, Diliman, Quezon City, 
      Philippines.
LA  - eng
GR  - DOST-GIA Project No. 10324/Department of Science and Technology, Philippines/
PT  - Journal Article
DEP - 20231205
PL  - United States
TA  - Environ Toxicol Chem
JT  - Environmental toxicology and chemistry
JID - 8308958
RN  - 2DI9HA706A (Estrone)
RN  - RW57K3X12M (bisphenol A)
RN  - 0 (octylphenol)
RN  - 79F6A2ILP5 (nonylphenol)
RN  - 4TI98Z838E (Estradiol)
RN  - 0 (Benzhydryl Compounds)
RN  - 059QF0KO0R (Water)
RN  - 0 (Water Pollutants, Chemical)
RN  - 0 (Endocrine Disruptors)
RN  - 0 (Phenols)
SB  - IM
MH  - Estrone/analysis
MH  - Philippines
MH  - Ecosystem
MH  - Estradiol
MH  - Benzhydryl Compounds
MH  - Rivers/chemistry
MH  - Water
MH  - *Water Pollutants, Chemical/analysis
MH  - *Endocrine Disruptors/analysis
MH  - Environmental Monitoring/methods
MH  - *Phenols
OTO - NOTNLM
OT  - Alkylphenols
OT  - Bisphenol A
OT  - Hormones
OT  - River water
OT  - liquid chromatography tandem mass spectrometry (LC-MS/MS)
EDAT- 2023/10/31 12:42
MHDA- 2024/01/25 06:44
CRDT- 2023/10/31 07:15
PHST- 2023/10/04 00:00 [revised]
PHST- 2023/08/15 00:00 [received]
PHST- 2023/10/25 00:00 [accepted]
PHST- 2024/01/25 06:44 [medline]
PHST- 2023/10/31 12:42 [pubmed]
PHST- 2023/10/31 07:15 [entrez]
AID - 10.1002/etc.5778 [doi]
PST - ppublish
SO  - Environ Toxicol Chem. 2024 Feb;43(2):259-266. doi: 10.1002/etc.5778. Epub 2023 
      Dec 5.

PMID- 31241065
OWN - NLM
STAT- MEDLINE
DCOM- 20200109
LR  - 20231213
IS  - 2042-650X (Electronic)
IS  - 2042-6496 (Linking)
VI  - 10
IP  - 7
DP  - 2019 Jul 17
TI  - Soybean soluble polysaccharides enhance bioavailability of genistein and its 
      prevention against obesity and metabolic syndrome of mice with chronic high fat 
      consumption.
PG  - 4153-4165
LID - 10.1039/c8fo02379d [doi]
AB  - This study aimed to explore a novel strategy for the simultaneous consumption of 
      soluble soybean polysaccharides (SSPS) and insoluble genistein to improve the 
      bioavailability of genistein and its prevention against obesity and metabolic 
      syndrome in high-fat diet (HFD)-induced obese mice. C57BL/6J mice were fed a 
      normal diet and HFD supplemented or not (n = 8) with SSPS (2.5%), genistein 
      (0.5%) and their mixture (S + G) for 12 weeks. The UPLC-qTOP/MS assay showed that 
      SSPS observably enhanced the urinary concentration of genistein and its 
      metabolites compared to that of single genistein in mice. Supplementation of 
      SSPS, genistein or their combination prevented HFD-induced gain weight, 
      dyslipidemia, oxidative stress and inflammation in obese mice. Interestingly, the 
      combined S + G ingestion exhibited more effective alleviation of dyslipidemia by 
      modulating hepatic FAS, ACC, SREBP-1C and ADRP expressions relative to that of 
      individual SSPS or genistein. Furthermore, S + G activated the energy metabolism 
      pathway AMPK in the liver, and the hepatic PPAR-α/PPAR-γ pathways were doubly 
      activated to alleviate lipogenesis, inflammation, obesity and metabolic syndrome. 
      Moreover, S + G supplementation dramatically modified the gut microbial species 
      at the phylum level with a decrease in Firmicutes and increase in Bacteroidetes. 
      These findings support that the combined supplementation of SSPS and genistein is 
      a novel couple to prevent obesity and metabolic syndrome.
FAU - Lu, Yalong
AU  - Lu Y
AD  - Shaanxi Engineering Laboratory for Food Green Processing and Safety Control, and 
      Shaanxi Key Laboratory for Hazard Factors Assessment in Processing and Storage of 
      Agricultural Products, College of Food Engineering and Nutritional Science, 
      Shaanxi Normal University, Xi'an 710119, China. aiqing_zhao@hotmail.com 
      xbyang@snnu.edu.cn.
FAU - Zhao, Aiqing
AU  - Zhao A
FAU - Wu, Yingmei
AU  - Wu Y
FAU - Zhao, Yan
AU  - Zhao Y
FAU - Yang, Xingbin
AU  - Yang X
LA  - eng
PT  - Journal Article
PL  - England
TA  - Food Funct
JT  - Food & function
JID - 101549033
RN  - 0 (Fas protein, mouse)
RN  - 0 (PPAR alpha)
RN  - 0 (PPAR gamma)
RN  - 0 (Perilipin-2)
RN  - 0 (Plant Extracts)
RN  - 0 (Plin2 protein, mouse)
RN  - 0 (Polysaccharides)
RN  - 0 (RNA, Ribosomal, 16S)
RN  - 0 (Sterol Regulatory Element Binding Protein 1)
RN  - 0 (fas Receptor)
RN  - DH2M523P0H (Genistein)
SB  - IM
MH  - Animals
MH  - Bacteria/classification/drug effects
MH  - *Biological Availability
MH  - Diet, High-Fat/adverse effects
MH  - Dietary Supplements
MH  - Dyslipidemias/metabolism
MH  - Feces/microbiology
MH  - Gastrointestinal Microbiome/drug effects
MH  - Genistein/*pharmacology/therapeutic use
MH  - Inflammation
MH  - Liver/metabolism
MH  - Male
MH  - Metabolic Syndrome/*prevention & control
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Obese
MH  - Obesity/*prevention & control
MH  - Oxidative Stress
MH  - PPAR alpha/metabolism
MH  - PPAR gamma/metabolism
MH  - Perilipin-2/metabolism
MH  - Plant Extracts/pharmacology
MH  - Polysaccharides/*pharmacology/therapeutic use
MH  - RNA, Ribosomal, 16S/genetics
MH  - Glycine max/*chemistry
MH  - Sterol Regulatory Element Binding Protein 1/metabolism
MH  - Weight Gain/drug effects
MH  - fas Receptor/metabolism
EDAT- 2019/06/27 06:00
MHDA- 2020/01/10 06:00
CRDT- 2019/06/27 06:00
PHST- 2019/06/27 06:00 [pubmed]
PHST- 2020/01/10 06:00 [medline]
PHST- 2019/06/27 06:00 [entrez]
AID - 10.1039/c8fo02379d [doi]
PST - ppublish
SO  - Food Funct. 2019 Jul 17;10(7):4153-4165. doi: 10.1039/c8fo02379d.

PMID- 31398002
OWN - NLM
STAT- MEDLINE
DCOM- 20200928
LR  - 20200928
IS  - 1520-6882 (Electronic)
IS  - 0003-2700 (Linking)
VI  - 91
IP  - 17
DP  - 2019 Sep 3
TI  - A Generic Liquid Chromatography-Tandem Mass Spectrometry Exposome Method for the 
      Determination of Xenoestrogens in Biological Matrices.
PG  - 11334-11342
LID - 10.1021/acs.analchem.9b02446 [doi]
AB  - We are constantly exposed to a variety of environmental contaminants and 
      hormones, including those mimicking endogenous estrogens. These highly 
      heterogeneous molecules are collectively referred to as xenoestrogens and hold 
      the potential to affect and alter the delicate hormonal balance of the human 
      body. To monitor exposure and investigate potential health implications, 
      comprehensive analytical methods covering all major xenoestrogen classes are 
      needed but not available to date. Herein, we describe a liquid 
      chromatography-tandem mass spectrometry (LC-MS/MS) method for the simultaneous 
      determination of multiple classes of endogenous as well as exogenous estrogens in 
      human urine, serum, and breast milk to enable proper exposure and risk 
      assessment. In total, 75 analytes were included, whereof a majority was 
      successfully in-house validated in the three matrices. Extraction recoveries of 
      validated analytes ranged from 71% to 110% and limits of quantification from 
      0.015 to 5 μg/L, 0.03 to 14 μg/L, and 0.03 to 4.6 μg/L in urine, serum, and 
      breast milk, respectively. The applicability of the novel method was demonstrated 
      in proof-of-principle experiments by analyzing urine from Austrian individuals 
      and breast milk from Austrian and Nigerian individuals. Thereby, we proved the 
      methods' feasibility to identify and quantify different classes of xenoestrogens 
      simultaneously. The results illustrate the general importance of multiclass 
      exposure assessment in the context of the exposome paradigm. Specifically, they 
      highlight the need for estimating total estrogenic burden rather than single 
      analyte or chemical class measurements and its potential impact in endocrine 
      disruption and hormone related diseases including cancers.
FAU - Preindl, Karin
AU  - Preindl K
AD  - University of Vienna , Faculty of Chemistry, Department of Food Chemistry and 
      Toxicology , Währingerstraße 38 , 1090 Vienna , Austria.
FAU - Braun, Dominik
AU  - Braun D
AUID- ORCID: 0000-0002-9232-4285
AD  - University of Vienna , Faculty of Chemistry, Department of Food Chemistry and 
      Toxicology , Währingerstraße 38 , 1090 Vienna , Austria.
FAU - Aichinger, Georg
AU  - Aichinger G
AUID- ORCID: 0000-0003-1691-7609
AD  - University of Vienna , Faculty of Chemistry, Department of Food Chemistry and 
      Toxicology , Währingerstraße 38 , 1090 Vienna , Austria.
FAU - Sieri, Sabina
AU  - Sieri S
AD  - Epidemiology and Prevention Unit , Fondazione IRCCS Istituto Nazionale dei Tumori 
      , 20133 Milan , Italy.
FAU - Fang, Mingliang
AU  - Fang M
AUID- ORCID: 0000-0002-2204-9783
AD  - Nanyang Technological University , School of Civil and Environmental Engineering 
      , 50 Nanyang Avenue , Singapore 639798 , Singapore.
FAU - Marko, Doris
AU  - Marko D
AUID- ORCID: 0000-0001-6568-2944
AD  - University of Vienna , Faculty of Chemistry, Department of Food Chemistry and 
      Toxicology , Währingerstraße 38 , 1090 Vienna , Austria.
FAU - Warth, Benedikt
AU  - Warth B
AUID- ORCID: 0000-0002-6104-0706
AD  - University of Vienna , Faculty of Chemistry, Department of Food Chemistry and 
      Toxicology , Währingerstraße 38 , 1090 Vienna , Austria.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190822
PL  - United States
TA  - Anal Chem
JT  - Analytical chemistry
JID - 0370536
RN  - 0 (Endocrine Disruptors)
RN  - 0 (Environmental Pollutants)
RN  - 0 (Estrogens)
RN  - 0 (Xenobiotics)
SB  - IM
MH  - Austria
MH  - Chromatography, Liquid/methods
MH  - Endocrine Disruptors/analysis
MH  - Environmental Exposure/analysis
MH  - Environmental Pollutants/analysis
MH  - Estrogens/*analysis/urine
MH  - *Exposome
MH  - Humans
MH  - Milk, Human/chemistry
MH  - Nigeria
MH  - Risk Assessment
MH  - Tandem Mass Spectrometry/methods
MH  - Xenobiotics/*analysis
EDAT- 2019/08/10 06:00
MHDA- 2020/09/29 06:00
CRDT- 2019/08/10 06:00
PHST- 2019/08/10 06:00 [pubmed]
PHST- 2020/09/29 06:00 [medline]
PHST- 2019/08/10 06:00 [entrez]
AID - 10.1021/acs.analchem.9b02446 [doi]
PST - ppublish
SO  - Anal Chem. 2019 Sep 3;91(17):11334-11342. doi: 10.1021/acs.analchem.9b02446. Epub 
      2019 Aug 22.

PMID- 36064063
OWN - NLM
STAT- MEDLINE
DCOM- 20220928
LR  - 20250103
IS  - 1873-6424 (Electronic)
IS  - 0269-7491 (Linking)
VI  - 312
DP  - 2022 Nov 1
TI  - Determination of multiple bisphenol analogues and their metabolites in human 
      serum by liquid chromatography tandem mass spectrometry.
PG  - 120092
LID - S0269-7491(22)01306-9 [pii]
LID - 10.1016/j.envpol.2022.120092 [doi]
AB  - To date, knowledge of internal human exposure to BPA and its analogues 
      (particularly bisphenol S and bisphenol F, etc.) remains limited. In the present 
      study, a method involving dispersive solid-phase extraction and LC/MS was 
      proposed to investigate the contamination levels of 28 precursor bisphenols and 9 
      major metabolites in serum. The critical variables of preparation method were 
      screened out by Plackett-Burman design and further optimized by central composite 
      design. Left in optimal conditions, a total of 286 samples consisting of 153 
      males and 133 females were analyzed. The results showed that BPA dominated over 
      all the cases with the highest positive rate (82.2% of all the surveyed people), 
      and totally four metabolites (BPA β-D-glucuronide, BPA monosulfate, BPA 
      bis-(β-D-glucuronide) and BPS monosulfate) were detectable. The occurrence of BPA 
      bis-(β-D-glucuronide) in serum is reported for the first time and its higher 
      positive rate and contamination concentrations suggested that it may be a more 
      important metabolite of BPA than others. Negligible potential risk of health 
      effects to blood donors was observed, since the estimated exposure levels (mean 
      32.1 ng/kg bw/day, 95th 123.2 ng/kg bw/day) were well below far less than the 
      temporary tolerable reference dose of BPA that recommended by the European Food 
      Safety Authority (4 μg/kg bw/day by). The reference level of BPA for healthy 
      population was determined to be 4.09 μg/L via the percentile method.
CI  - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Zhou, Jian
AU  - Zhou J
AD  - Key Laboratory of Health Risk Appraisal for Trace Toxic Chemicals of Zhejiang 
      Province, Ningbo Municipal Center for Disease Control and Prevention, Ningbo, 
      Zhejiang, 315010, China; Ningbo Key Laboratory of Poison Research and Control, 
      Ningbo Municipal Center for Disease Control and Prevention, Ningbo, 315010, 
      China. Electronic address: zhoujian3781@163.com.
FAU - Chen, Xiao-Hong
AU  - Chen XH
AD  - Key Laboratory of Health Risk Appraisal for Trace Toxic Chemicals of Zhejiang 
      Province, Ningbo Municipal Center for Disease Control and Prevention, Ningbo, 
      Zhejiang, 315010, China; Ningbo Key Laboratory of Poison Research and Control, 
      Ningbo Municipal Center for Disease Control and Prevention, Ningbo, 315010, 
      China.
FAU - Zhang, Dan-Dan
AU  - Zhang DD
AD  - Key Laboratory of Health Risk Appraisal for Trace Toxic Chemicals of Zhejiang 
      Province, Ningbo Municipal Center for Disease Control and Prevention, Ningbo, 
      Zhejiang, 315010, China; Ningbo Key Laboratory of Poison Research and Control, 
      Ningbo Municipal Center for Disease Control and Prevention, Ningbo, 315010, 
      China.
FAU - Jin, Mi-Cong
AU  - Jin MC
AD  - Key Laboratory of Health Risk Appraisal for Trace Toxic Chemicals of Zhejiang 
      Province, Ningbo Municipal Center for Disease Control and Prevention, Ningbo, 
      Zhejiang, 315010, China; Ningbo Key Laboratory of Poison Research and Control, 
      Ningbo Municipal Center for Disease Control and Prevention, Ningbo, 315010, 
      China.
FAU - Zhuang, Li
AU  - Zhuang L
AD  - Ningbo Municipal Center Blood Station, Ningbo Blood Management Center, Ningbo, 
      315010, China.
FAU - Du, Yong
AU  - Du Y
AD  - Ningbo Municipal Center Blood Station, Ningbo Blood Management Center, Ningbo, 
      315010, China.
LA  - eng
PT  - Journal Article
DEP - 20220902
PL  - England
TA  - Environ Pollut
JT  - Environmental pollution (Barking, Essex : 1987)
JID - 8804476
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Glucuronides)
RN  - 0 (Phenols)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - Benzhydryl Compounds/analysis
MH  - Chromatography, Liquid
MH  - Female
MH  - *Glucuronides
MH  - Humans
MH  - Male
MH  - Phenols
MH  - Solid Phase Extraction
MH  - *Tandem Mass Spectrometry
OTO - NOTNLM
OT  - Bisphenol analogues
OT  - Blood donors
OT  - Chemometrics
OT  - Estimated daily intake
OT  - Glucuronide and sulfate
OT  - Serum
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2022/09/06 06:00
MHDA- 2022/09/28 06:00
CRDT- 2022/09/05 19:25
PHST- 2022/04/27 00:00 [received]
PHST- 2022/07/12 00:00 [revised]
PHST- 2022/08/29 00:00 [accepted]
PHST- 2022/09/06 06:00 [pubmed]
PHST- 2022/09/28 06:00 [medline]
PHST- 2022/09/05 19:25 [entrez]
AID - S0269-7491(22)01306-9 [pii]
AID - 10.1016/j.envpol.2022.120092 [doi]
PST - ppublish
SO  - Environ Pollut. 2022 Nov 1;312:120092. doi: 10.1016/j.envpol.2022.120092. Epub 
      2022 Sep 2.

PMID- 37331146
OWN - NLM
STAT- MEDLINE
DCOM- 20230719
LR  - 20230719
IS  - 1873-7072 (Electronic)
IS  - 0308-8146 (Linking)
VI  - 426
DP  - 2023 Nov 15
TI  - Multiple mycotoxins in commonly used edible oils: Occurrence and evaluation of 
      potential health risks.
PG  - 136629
LID - S0308-8146(23)01247-5 [pii]
LID - 10.1016/j.foodchem.2023.136629 [doi]
AB  - In this study, the contamination of 51 mycotoxins in 416 edible oils were 
      determined by UPLC-MS/MS. Totally, twenty-four mycotoxins were detected and 
      nearly half of the samples (46.9%, n = 195) were contaminated simultaneously with 
      six to nine kinds of mycotoxins. The predominant mycotoxins and contamination 
      characteristics varied depending on the type of oils. More specifically, four 
      enniatins, alternariol monomethyl ether (AME) and zearalenone were the most 
      frequent combination. Overall, peanut and sesame oils (10.7-11.7 mycotoxins on 
      average) were found to be the most contaminated matrices whereas camellia and 
      sunflower seed oils (1.8-2.7 species) were the opposite. Dietary exposure risks 
      of mycotoxins were acceptable in most cases, however, the ingestion of aflatoxins 
      (especially aflatoxin B(1)) through peanut and sesame oil (margin of exposure: 
      239.4-386.3 < 10000) exceeded the acceptable carcinogenic risk level. Meanwhile, 
      the risks of cumulative ingestion through the food chain should be of great 
      concern, especially sterigmatocystin, ochratoxin A, AME and zearalenone.
CI  - Copyright © 2023 Elsevier Ltd. All rights reserved.
FAU - Zhou, Jian
AU  - Zhou J
AD  - Key Laboratory of Health Risk Appraisal for Trace Toxic Chemicals of Zhejiang 
      Province, Ningbo Municipal Center for Disease Control and Prevention, Ningbo, 
      Zhejiang 315010, China; Ningbo Key Laboratory of Poison Research and Control, 
      Ningbo Municipal Center for Disease Control and Prevention, Ningbo 315010, China. 
      Electronic address: zhoujian3781@163.com.
FAU - Yao, Shan-Shan
AU  - Yao SS
AD  - Key Laboratory of Health Risk Appraisal for Trace Toxic Chemicals of Zhejiang 
      Province, Ningbo Municipal Center for Disease Control and Prevention, Ningbo, 
      Zhejiang 315010, China; Ningbo Key Laboratory of Poison Research and Control, 
      Ningbo Municipal Center for Disease Control and Prevention, Ningbo 315010, China.
FAU - Wang, Jian-Mei
AU  - Wang JM
AD  - Key Laboratory of Health Risk Appraisal for Trace Toxic Chemicals of Zhejiang 
      Province, Ningbo Municipal Center for Disease Control and Prevention, Ningbo, 
      Zhejiang 315010, China; Ningbo Key Laboratory of Poison Research and Control, 
      Ningbo Municipal Center for Disease Control and Prevention, Ningbo 315010, China.
FAU - Chen, Xiao-Hong
AU  - Chen XH
AD  - Key Laboratory of Health Risk Appraisal for Trace Toxic Chemicals of Zhejiang 
      Province, Ningbo Municipal Center for Disease Control and Prevention, Ningbo, 
      Zhejiang 315010, China; Ningbo Key Laboratory of Poison Research and Control, 
      Ningbo Municipal Center for Disease Control and Prevention, Ningbo 315010, China.
FAU - Qin, Chen
AU  - Qin C
AD  - Key Laboratory of Health Risk Appraisal for Trace Toxic Chemicals of Zhejiang 
      Province, Ningbo Municipal Center for Disease Control and Prevention, Ningbo, 
      Zhejiang 315010, China; Ningbo Key Laboratory of Poison Research and Control, 
      Ningbo Municipal Center for Disease Control and Prevention, Ningbo 315010, China.
FAU - Jin, Mi-Cong
AU  - Jin MC
AD  - Key Laboratory of Health Risk Appraisal for Trace Toxic Chemicals of Zhejiang 
      Province, Ningbo Municipal Center for Disease Control and Prevention, Ningbo, 
      Zhejiang 315010, China; Ningbo Key Laboratory of Poison Research and Control, 
      Ningbo Municipal Center for Disease Control and Prevention, Ningbo 315010, China. 
      Electronic address: jmcjc@163.com.
FAU - Zhang, Dan-Dan
AU  - Zhang DD
AD  - Key Laboratory of Health Risk Appraisal for Trace Toxic Chemicals of Zhejiang 
      Province, Ningbo Municipal Center for Disease Control and Prevention, Ningbo, 
      Zhejiang 315010, China; Ningbo Key Laboratory of Poison Research and Control, 
      Ningbo Municipal Center for Disease Control and Prevention, Ningbo 315010, China.
FAU - Xu, Jiao-Jiao
AU  - Xu JJ
AD  - Lab of Physicochemical Research, Department of Physicochemical & Toxicology, 
      Zhejiang Provincial Centre for Disease Control and Prevention, Zhejiang 310051, 
      China.
FAU - Cai, Zeng-Xuan
AU  - Cai ZX
AD  - Lab of Physicochemical Research, Department of Physicochemical & Toxicology, 
      Zhejiang Provincial Centre for Disease Control and Prevention, Zhejiang 310051, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20230614
PL  - England
TA  - Food Chem
JT  - Food chemistry
JID - 7702639
RN  - 0 (Mycotoxins)
RN  - 5W827M159J (Zearalenone)
RN  - 0 (Oils)
SB  - IM
MH  - *Mycotoxins/analysis
MH  - *Zearalenone/analysis
MH  - Chromatography, Liquid
MH  - Tandem Mass Spectrometry
MH  - Food Contamination/analysis
MH  - Oils
OTO - NOTNLM
OT  - Chemometrics technique
OT  - Dietary exposure risk
OT  - Distribution characteristics
OT  - Edible oil
OT  - Identification
OT  - Mycotoxins
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/06/19 00:42
MHDA- 2023/07/19 06:42
CRDT- 2023/06/18 18:04
PHST- 2023/03/02 00:00 [received]
PHST- 2023/06/11 00:00 [revised]
PHST- 2023/06/12 00:00 [accepted]
PHST- 2023/07/19 06:42 [medline]
PHST- 2023/06/19 00:42 [pubmed]
PHST- 2023/06/18 18:04 [entrez]
AID - S0308-8146(23)01247-5 [pii]
AID - 10.1016/j.foodchem.2023.136629 [doi]
PST - ppublish
SO  - Food Chem. 2023 Nov 15;426:136629. doi: 10.1016/j.foodchem.2023.136629. Epub 2023 
      Jun 14.

PMID- 31848906
OWN - NLM
STAT- MEDLINE
DCOM- 20210726
LR  - 20250103
IS  - 1937-6995 (Electronic)
IS  - 1556-9039 (Print)
IS  - 1556-9039 (Linking)
VI  - 16
IP  - 3
DP  - 2020 Jul
TI  - Urine Bisphenol A and Arsenic Levels in Residents of the Cheyenne River Sioux 
      Tribe, South Dakota, with and without Diabetes.
PG  - 276-283
LID - 10.1007/s13181-019-00748-5 [doi]
AB  - INTRODUCTION: Diabetes disproportionately affects American Indians/Alaskan 
      Natives (AI/AN). Bisphenol A (BPA) and arsenic (As), environmental toxicants 
      which may be associated with diabetes, have not been well studied in this 
      population. Our objectives were to determine if urinary BPA and As are associated 
      with diabetes among adults in the Cheyenne River Sioux Tribe (CRST), and to 
      compare their urinary levels with the general US population. METHODS: We 
      performed a case-control study among 276 volunteers. We matched our cases 
      (persons with diabetes) and controls (persons without diabetes) using age. We 
      collected questionnaire data and urine samples which were tested for BPA and 
      speciated As analytes. We used paired t tests and McNemar's chi-square test to 
      compare continuous and categorical variables, respectively, between cases and 
      controls and linear regression to assess the association between self-reported 
      exposures and BPA and As levels. We used conditional logistic regression to 
      investigate the association between case status and BPA and As levels. BPA and As 
      levels among participants were compared with those from the 2011-2012 National 
      Health and Nutrition Examination Survey (NHANES). RESULTS: The average age of 
      participants was 46 years. The majority identified as AI/AN race (97%) and 58% 
      were female. The geometric means from CRST participant urine specimens were 1.83 
      ug/L for BPA and 3.89 ug/L for total As. BPA geometric means of CRST participants 
      were higher than NHANES participants while total As geometric means were lower. 
      BPA and As were not associated with case status. CONCLUSION: The results of this 
      study are consistent with others that have reported no association between 
      diabetes and exposure to BPA or As.
FAU - Chang, Arthur
AU  - Chang A
AD  - Division of Environmental Health Science and Practice, National Center for 
      Environmental Health (NCEH), Centers for Disease Control and Prevention (CDC), 
      4770 Buford Highway NE, MS S106-6, Chamblee, GA, 30341, USA. ctn7@cdc.gov.
FAU - Ridpath, Alison
AU  - Ridpath A
AD  - Division of Sexually Transmitted Disease Prevention, National Center for 
      HIV/AIDS, Viral Hepatitis, STD and TB Prevention (NCHHSTP), CDC, Atlanta, GA, 
      USA.
FAU - Carpenter, Joseph
AU  - Carpenter J
AD  - Division of Environmental Health Science and Practice, National Center for 
      Environmental Health (NCEH), Centers for Disease Control and Prevention (CDC), 
      4770 Buford Highway NE, MS S106-6, Chamblee, GA, 30341, USA.
FAU - Kieszak, Stephanie
AU  - Kieszak S
AD  - Division of Environmental Health Science and Practice, National Center for 
      Environmental Health (NCEH), Centers for Disease Control and Prevention (CDC), 
      4770 Buford Highway NE, MS S106-6, Chamblee, GA, 30341, USA.
FAU - Sircar, Kanta
AU  - Sircar K
AD  - Division of Environmental Health Science and Practice, NCEH, CDC, Chamblee, GA, 
      USA.
FAU - Espinosa-Bode, Andres
AU  - Espinosa-Bode A
AD  - Division of Global Health Protection, Center for Global Health (CGH), CDC, 
      Atlanta, GA, USA.
FAU - Nelson, David
AU  - Nelson D
AD  - Department of Environmental and Natural Resources, Cheyenne River Sioux Tribe, 
      Eagle Butte, SD, USA.
FAU - Martin, Colleen
AU  - Martin C
AD  - Division of Environmental Health Science and Practice, National Center for 
      Environmental Health (NCEH), Centers for Disease Control and Prevention (CDC), 
      4770 Buford Highway NE, MS S106-6, Chamblee, GA, 30341, USA.
LA  - eng
PT  - Journal Article
DEP - 20191217
PL  - United States
TA  - J Med Toxicol
JT  - Journal of medical toxicology : official journal of the American College of 
      Medical Toxicology
JID - 101284598
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Biomarkers)
RN  - 0 (Phenols)
RN  - RW57K3X12M (bisphenol A)
RN  - N712M78A8G (Arsenic)
SB  - IM
MH  - Adult
MH  - Arsenic/adverse effects/*urine
MH  - Benzhydryl Compounds/adverse effects/*urine
MH  - Biomarkers/urine
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/diagnosis/*ethnology/*urine
MH  - Environmental Exposure/adverse effects
MH  - Female
MH  - Humans
MH  - *Indians, North American
MH  - Male
MH  - Middle Aged
MH  - Phenols/adverse effects/*urine
MH  - Risk Assessment
MH  - Risk Factors
MH  - South Dakota/epidemiology
PMC - PMC7320107
OTO - NOTNLM
OT  - Arsenic
OT  - Bisphenol A
OT  - Diabetes
OT  - Native Americans
COIS- None
EDAT- 2019/12/19 06:00
MHDA- 2021/07/27 06:00
PMCR- 2021/07/01
CRDT- 2019/12/19 06:00
PHST- 2019/07/01 00:00 [received]
PHST- 2019/11/07 00:00 [accepted]
PHST- 2019/10/25 00:00 [revised]
PHST- 2019/12/19 06:00 [pubmed]
PHST- 2021/07/27 06:00 [medline]
PHST- 2019/12/19 06:00 [entrez]
PHST- 2021/07/01 00:00 [pmc-release]
AID - 10.1007/s13181-019-00748-5 [pii]
AID - 748 [pii]
AID - 10.1007/s13181-019-00748-5 [doi]
PST - ppublish
SO  - J Med Toxicol. 2020 Jul;16(3):276-283. doi: 10.1007/s13181-019-00748-5. Epub 2019 
      Dec 17.

PMID- 35577875
OWN - NLM
STAT- MEDLINE
DCOM- 20220519
LR  - 20230513
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 12
IP  - 1
DP  - 2022 May 16
TI  - Prediction of gestational age using urinary metabolites in term and preterm 
      pregnancies.
PG  - 8033
LID - 10.1038/s41598-022-11866-6 [doi]
LID - 8033
AB  - Assessment of gestational age (GA) is key to provide optimal care during 
      pregnancy. However, its accurate determination remains challenging in low- and 
      middle-income countries, where access to obstetric ultrasound is limited. Hence, 
      there is an urgent need to develop clinical approaches that allow accurate and 
      inexpensive estimations of GA. We investigated the ability of urinary metabolites 
      to predict GA at time of collection in a diverse multi-site cohort of healthy and 
      pathological pregnancies (n = 99) using a broad-spectrum liquid chromatography 
      coupled with mass spectrometry (LC-MS) platform. Our approach detected a myriad 
      of steroid hormones and their derivatives including estrogens, progesterones, 
      corticosteroids, and androgens which were associated with pregnancy progression. 
      We developed a restricted model that predicted GA with high accuracy using three 
      metabolites (rho = 0.87, RMSE = 1.58 weeks) that was validated in an independent 
      cohort (n = 20). The predictions were more robust in pregnancies that went to 
      term in comparison to pregnancies that ended prematurely. Overall, we 
      demonstrated the feasibility of implementing urine metabolomics analysis in 
      large-scale multi-site studies and report a predictive model of GA with a 
      potential clinical value.
CI  - © 2022. The Author(s).
FAU - Contrepois, Kévin
AU  - Contrepois K
AD  - Department of Genetics, Stanford University School of Medicine, Stanford, CA, 
      USA.
AD  - Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA.
FAU - Chen, Songjie
AU  - Chen S
AD  - Department of Genetics, Stanford University School of Medicine, Stanford, CA, 
      USA.
FAU - Ghaemi, Mohammad S
AU  - Ghaemi MS
AD  - Department of Anesthesiology, Perioperative and Pain Medicine, Stanford 
      University School of Medicine, Stanford, CA, USA.
AD  - Digital Technologies Research Centre, National Research Council Canada, Toronto, 
      ON, Canada.
FAU - Wong, Ronald J
AU  - Wong RJ
AD  - Department of Pediatrics, Division of Neonatal and Developmental Medicine, 
      Stanford University School of Medicine, Stanford, CA, USA.
FAU - Jehan, Fyezah
AU  - Jehan F
AD  - Department of Pediatrics and Child Health, Aga Khan University, Karachi, 
      Pakistan.
AD  - Biorepository and Omics Research Group, Faculty of Health Sciences, Medical 
      College, Aga Khan University, Karachi, Pakistan.
FAU - Sazawal, Sunil
AU  - Sazawal S
AD  - Center for Public Health Kinetics, New Delhi, India.
AD  - Public Health Laboratory IdC, Pemba, Zanzibar, Tanzania.
FAU - Baqui, Abdullah H
AU  - Baqui AH
AD  - International Center for Maternal and Newborn Health, Department of International 
      Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
FAU - Stringer, Jeffrey S A
AU  - Stringer JSA
AD  - Department of Obstetrics and Gynecology, University of North Carolina at Chapel 
      Hill, Chapel Hill, NC, USA.
FAU - Rahman, Anisur
AU  - Rahman A
AD  - Maternal and Child Health Division, International Centre for Diarrhoeal Disease 
      Research, Dhaka, Bangladesh.
FAU - Nisar, Muhammad I
AU  - Nisar MI
AD  - Department of Pediatrics and Child Health, Aga Khan University, Karachi, 
      Pakistan.
AD  - Biorepository and Omics Research Group, Faculty of Health Sciences, Medical 
      College, Aga Khan University, Karachi, Pakistan.
FAU - Dhingra, Usha
AU  - Dhingra U
AD  - Center for Public Health Kinetics, New Delhi, India.
FAU - Khanam, Rasheda
AU  - Khanam R
AD  - International Center for Maternal and Newborn Health, Department of International 
      Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
FAU - Ilyas, Muhammad
AU  - Ilyas M
AD  - Department of Pediatrics and Child Health, Aga Khan University, Karachi, 
      Pakistan.
FAU - Dutta, Arup
AU  - Dutta A
AD  - Center for Public Health Kinetics, New Delhi, India.
FAU - Mehmood, Usma
AU  - Mehmood U
AD  - Department of Pediatrics and Child Health, Aga Khan University, Karachi, 
      Pakistan.
FAU - Deb, Saikat
AU  - Deb S
AD  - Center for Public Health Kinetics, New Delhi, India.
AD  - Public Health Laboratory IdC, Pemba, Zanzibar, Tanzania.
FAU - Hotwani, Aneeta
AU  - Hotwani A
AD  - Department of Pediatrics and Child Health, Aga Khan University, Karachi, 
      Pakistan.
FAU - Ali, Said M
AU  - Ali SM
AD  - Public Health Laboratory IdC, Pemba, Zanzibar, Tanzania.
FAU - Rahman, Sayedur
AU  - Rahman S
AD  - Projahnmo Research Foundation, Abanti, Banani, Dhaka, Bangladesh.
FAU - Nizar, Ambreen
AU  - Nizar A
AD  - Department of Pediatrics and Child Health, Aga Khan University, Karachi, 
      Pakistan.
FAU - Ame, Shaali M
AU  - Ame SM
AD  - Public Health Laboratory IdC, Pemba, Zanzibar, Tanzania.
FAU - Muhammad, Sajid
AU  - Muhammad S
AD  - Department of Pediatrics and Child Health, Aga Khan University, Karachi, 
      Pakistan.
FAU - Chauhan, Aishwarya
AU  - Chauhan A
AD  - Center for Public Health Kinetics, New Delhi, India.
FAU - Khan, Waqasuddin
AU  - Khan W
AD  - Department of Pediatrics and Child Health, Aga Khan University, Karachi, 
      Pakistan.
AD  - Biorepository and Omics Research Group, Faculty of Health Sciences, Medical 
      College, Aga Khan University, Karachi, Pakistan.
FAU - Raqib, Rubhana
AU  - Raqib R
AD  - International Center for Diarroheal Disease Research, Mohakhali, Dhaka, 
      Bangladesh.
FAU - Das, Sayan
AU  - Das S
AD  - Center for Public Health Kinetics, New Delhi, India.
FAU - Ahmed, Salahuddin
AU  - Ahmed S
AD  - Projahnmo Research Foundation, Abanti, Banani, Dhaka, Bangladesh.
FAU - Hasan, Tarik
AU  - Hasan T
AD  - Projahnmo Research Foundation, Abanti, Banani, Dhaka, Bangladesh.
FAU - Khalid, Javairia
AU  - Khalid J
AD  - Department of Pediatrics and Child Health, Aga Khan University, Karachi, 
      Pakistan.
AD  - Biorepository and Omics Research Group, Faculty of Health Sciences, Medical 
      College, Aga Khan University, Karachi, Pakistan.
FAU - Juma, Mohammed H
AU  - Juma MH
AD  - Public Health Laboratory IdC, Pemba, Zanzibar, Tanzania.
FAU - Chowdhury, Nabidul H
AU  - Chowdhury NH
AD  - Projahnmo Research Foundation, Abanti, Banani, Dhaka, Bangladesh.
FAU - Kabir, Furqan
AU  - Kabir F
AD  - Department of Pediatrics and Child Health, Aga Khan University, Karachi, 
      Pakistan.
FAU - Aftab, Fahad
AU  - Aftab F
AD  - Center for Public Health Kinetics, New Delhi, India.
FAU - Quaiyum, Abdul
AU  - Quaiyum A
AD  - International Center for Diarroheal Disease Research, Mohakhali, Dhaka, 
      Bangladesh.
FAU - Manu, Alexander
AU  - Manu A
AD  - Maternal, Newborn, Child and Adolescent Health Research, World Health 
      Organization, Geneva, Switzerland.
FAU - Yoshida, Sachiyo
AU  - Yoshida S
AD  - Maternal, Newborn, Child and Adolescent Health Research, World Health 
      Organization, Geneva, Switzerland.
FAU - Bahl, Rajiv
AU  - Bahl R
AD  - Maternal, Newborn, Child and Adolescent Health Research, World Health 
      Organization, Geneva, Switzerland.
FAU - Pervin, Jesmin
AU  - Pervin J
AD  - Maternal and Child Health Division, International Centre for Diarrhoeal Disease 
      Research, Dhaka, Bangladesh.
FAU - Price, Joan T
AU  - Price JT
AD  - Department of Obstetrics and Gynecology, University of North Carolina at Chapel 
      Hill, Chapel Hill, NC, USA.
FAU - Rahman, Monjur
AU  - Rahman M
AD  - Maternal and Child Health Division, International Centre for Diarrhoeal Disease 
      Research, Dhaka, Bangladesh.
FAU - Kasaro, Margaret P
AU  - Kasaro MP
AD  - UNC Global Projects Zambia, Lusaka, Zambia.
FAU - Litch, James A
AU  - Litch JA
AD  - Global Alliance to Prevent Prematurity and Stillbirth, Seattle, USA.
FAU - Musonda, Patrick
AU  - Musonda P
AD  - Department of Biostatistics, University of Zambia, Lusaka, Zambia.
FAU - Vwalika, Bellington
AU  - Vwalika B
AD  - Department of Obstetrics and Gynecology, University of Zambia School of Medicine, 
      Lusaka, Zambia.
CN  - Alliance for Maternal and Newborn Health Improvement (AMANHI)
CN  - Global Alliance to Prevent Prematurity and Stillbirth (GAPPS)
FAU - Shaw, Gary
AU  - Shaw G
AD  - Department of Pediatrics, Division of Neonatal and Developmental Medicine, 
      Stanford University School of Medicine, Stanford, CA, USA.
FAU - Stevenson, David K
AU  - Stevenson DK
AD  - Department of Pediatrics, Division of Neonatal and Developmental Medicine, 
      Stanford University School of Medicine, Stanford, CA, USA.
FAU - Aghaeepour, Nima
AU  - Aghaeepour N
AD  - Department of Anesthesiology, Perioperative and Pain Medicine, Stanford 
      University School of Medicine, Stanford, CA, USA. naghaeep@stanford.edu.
FAU - Snyder, Michael P
AU  - Snyder MP
AD  - Department of Genetics, Stanford University School of Medicine, Stanford, CA, 
      USA. mpsnyder@stanford.edu.
AD  - Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA. 
      mpsnyder@stanford.edu.
LA  - eng
GR  - T32 HD075731/HD/NICHD NIH HHS/United States
GR  - R35GM138353/NH/NIH HHS/United States
GR  - OPP1203327/GATES/Bill & Melinda Gates Foundation/United States
GR  - OPP1113682/GATES/Bill & Melinda Gates Foundation/United States
GR  - R35 GM138353/GM/NIGMS NIH HHS/United States
GR  - 2RM1HG00773506/NH/NIH HHS/United States
GR  - T32 HD075731/NH/NIH HHS/United States
GR  - P30AI050410/AI/NIAID NIH HHS/United States
GR  - P30 AI050410/AI/NIAID NIH HHS/United States
GR  - K01 TW010857/TW/FIC NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20220516
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
SB  - IM
EIN - Sci Rep. 2022 Nov 17;12(1):19753. doi: 10.1038/s41598-022-23715-7. PMID: 36396676
MH  - Chromatography, Liquid
MH  - Cohort Studies
MH  - Female
MH  - Gestational Age
MH  - Humans
MH  - Infant, Newborn
MH  - *Metabolomics
MH  - Pregnancy
MH  - *Ultrasonography, Prenatal
PMC - PMC9110694
COIS- M.P.S. is a cofounder and on the advisory board of Personalis, SensOmics, 
      January, Filtricine, Qbio, Protos and Mirive. M.P.S. is on the advisory board of 
      Genapsys and Tailai. The other authors declare no competing interests.
FIR - Jehan, Fyezah
IR  - Jehan F
FIR - Sazawal, Sunil
IR  - Sazawal S
FIR - Baqui, Abdullah H
IR  - Baqui AH
FIR - Nisar, Muhammad I
IR  - Nisar MI
FIR - Dhingra, Usha
IR  - Dhingra U
FIR - Khanam, Rasheda
IR  - Khanam R
FIR - Ilyas, Muhammad
IR  - Ilyas M
FIR - Dutta, Arup
IR  - Dutta A
FIR - Mehmood, Usma
IR  - Mehmood U
FIR - Deb, Saikat
IR  - Deb S
FIR - Hotwani, Aneeta
IR  - Hotwani A
FIR - Ali, Said M
IR  - Ali SM
FIR - Rahman, Sayedur
IR  - Rahman S
FIR - Nizar, Ambreen
IR  - Nizar A
FIR - Ame, Shaali M
IR  - Ame SM
FIR - Muhammad, Sajid
IR  - Muhammad S
FIR - Chauhan, Aishwarya
IR  - Chauhan A
FIR - Khan, Waqasuddin
IR  - Khan W
FIR - Raqib, Rubhana
IR  - Raqib R
FIR - Das, Sayan
IR  - Das S
FIR - Ahmed, Salahuddin
IR  - Ahmed S
FIR - Hasan, Tarik
IR  - Hasan T
FIR - Khalid, Javairia
IR  - Khalid J
FIR - Juma, Mohammed H
IR  - Juma MH
FIR - Chowdhury, Nabidul H
IR  - Chowdhury NH
FIR - Kabir, Furqan
IR  - Kabir F
FIR - Aftab, Fahad
IR  - Aftab F
FIR - Quaiyum, Abdul
IR  - Quaiyum A
FIR - Manu, Alexander
IR  - Manu A
FIR - Yoshida, Sachiyo
IR  - Yoshida S
FIR - Bahl, Rajiv
IR  - Bahl R
FIR - Rahman, Anisur
IR  - Rahman A
FIR - Pervin, Jesmin
IR  - Pervin J
FIR - Price, Joan T
IR  - Price JT
FIR - Rahman, Monjur
IR  - Rahman M
FIR - Kasaro, Margaret P
IR  - Kasaro MP
FIR - Litch, James A
IR  - Litch JA
FIR - Musonda, Patrick
IR  - Musonda P
FIR - Vwalika, Bellington
IR  - Vwalika B
FIR - Stringer, Jeffrey S A
IR  - Stringer JSA
EDAT- 2022/05/17 06:00
MHDA- 2022/05/20 06:00
PMCR- 2022/05/16
CRDT- 2022/05/16 23:21
PHST- 2021/08/12 00:00 [received]
PHST- 2022/04/25 00:00 [accepted]
PHST- 2022/05/16 23:21 [entrez]
PHST- 2022/05/17 06:00 [pubmed]
PHST- 2022/05/20 06:00 [medline]
PHST- 2022/05/16 00:00 [pmc-release]
AID - 10.1038/s41598-022-11866-6 [pii]
AID - 11866 [pii]
AID - 10.1038/s41598-022-11866-6 [doi]
PST - epublish
SO  - Sci Rep. 2022 May 16;12(1):8033. doi: 10.1038/s41598-022-11866-6.

PMID- 30623888
OWN - NLM
STAT- MEDLINE
DCOM- 20191218
LR  - 20250103
IS  - 1096-0953 (Electronic)
IS  - 0013-9351 (Linking)
VI  - 170
DP  - 2019 Mar
TI  - Determination of bisphenol A and bisphenol S concentrations and assessment of 
      estrogen- and anti-androgen-like activities in thermal paper receipts from 
      Brazil, France, and Spain.
PG  - 406-415
LID - S0013-9351(18)30682-0 [pii]
LID - 10.1016/j.envres.2018.12.046 [doi]
AB  - Bisphenol A (BPA) is a high-production-volume chemical with endocrine disrupting 
      properties commonly used as color developer in thermal paper. Concerns about the 
      potential hazards of human BPA exposure have led to the increasing utilization of 
      alternatives such as bisphenol S (BPS) and bisphenol F (BPF). This study was 
      designed to assess: (i) BPA, BPS, and BPF concentrations in 112 thermal paper 
      receipts from Brazil, France, and Spain by liquid chromatography coupled to mass 
      spectrometry (LC-MS); and (ii) hormone-like activities of these receipts using 
      two receptor-specific bioassays, the E-Screen for (anti-)estrogenicity and PALM 
      luciferase assay for (anti-)androgenicity. BPA was present in 95.3% of receipts 
      from Spain, 90.9% of those from Brazil, and 51.1% of those from France at 
      concentrations up to 20.27 mg/g of paper. Only two samples from Brazil, two from 
      Spain, and ten from France had a BPS concentration ranging from 6.46 to 
      13.29 mg/g; no BPA or BPS was detected in 27.7% of French samples. No BPF was 
      detected in any receipt. Estrogenic activity was observed in all samples from 
      Brazil and Spain and in 74.5% of those from France. Anti-androgenic activity was 
      observed in > 90% of samples from Brazil and Spain and in 53.2% of those from 
      France. Only 25.5% of French samples were negative for both estrogenic and 
      anti-androgenic activity. Estrogenic and anti-androgenic activities per gram of 
      paper were up to 1.411 µM estradiol (E(2)) equivalent units (E(2)eq) and up to 
      359.5 mM procymidone equivalent units (Proceq), respectively. BPA but not BPS 
      concentrations were positively correlated with both estrogenic and 
      anti-androgenic activities. BPA still dominates the thermal paper market in 
      Brazil and Spain, and BPS appears to be one of the main alternatives in France. 
      There is an urgent need to evaluate the safety of alternatives proposed to 
      replace BPA as developer in thermal printing. The large proportion of samples 
      with hormonal activity calls for the adoption of preventive measures.
CI  - Copyright © 2018 Elsevier Inc. All rights reserved.
FAU - Molina-Molina, J M
AU  - Molina-Molina JM
AD  - Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada 
      E-18012, Spain; CIBER de Epidemiología y Salud Pública (CIBERESP), Granada 
      E-18071, Spain; Biomedical Research Centre (CIBM) and School of Medicine, 
      University of Granada, Granada E-18071, Spain.
FAU - Jiménez-Díaz, I
AU  - Jiménez-Díaz I
AD  - Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada 
      E-18012, Spain; CIBER de Epidemiología y Salud Pública (CIBERESP), Granada 
      E-18071, Spain.
FAU - Fernández, M F
AU  - Fernández MF
AD  - Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada 
      E-18012, Spain; CIBER de Epidemiología y Salud Pública (CIBERESP), Granada 
      E-18071, Spain; Biomedical Research Centre (CIBM) and School of Medicine, 
      University of Granada, Granada E-18071, Spain. Electronic address: 
      marieta@ugr.es.
FAU - Rodriguez-Carrillo, A
AU  - Rodriguez-Carrillo A
AD  - Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada 
      E-18012, Spain; Biomedical Research Centre (CIBM) and School of Medicine, 
      University of Granada, Granada E-18071, Spain.
FAU - Peinado, F M
AU  - Peinado FM
AD  - Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada 
      E-18012, Spain.
FAU - Mustieles, V
AU  - Mustieles V
AD  - Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada 
      E-18012, Spain; Biomedical Research Centre (CIBM) and School of Medicine, 
      University of Granada, Granada E-18071, Spain.
FAU - Barouki, R
AU  - Barouki R
AD  - INSERM UMR-S 1124, Université Paris Descartes, Paris, France; Service de 
      Biochimie Métabolomique et Protéomique, Hôpital Necker Enfants Malades, AP-HP, 
      Paris, France.
FAU - Piccoli, C
AU  - Piccoli C
AD  - National School of Public Health, Oswaldo Cruz Foundation, CEP: 21041-210, Rio de 
      Janeiro, Brazil.
FAU - Olea, N
AU  - Olea N
AD  - Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada 
      E-18012, Spain; CIBER de Epidemiología y Salud Pública (CIBERESP), Granada 
      E-18071, Spain; Biomedical Research Centre (CIBM) and School of Medicine, 
      University of Granada, Granada E-18071, Spain; UGC Medicina Nuclear, Hospital 
      Universitario San Cecilio, Granada E-18016, Spain. Electronic address: 
      nolea@ugr.es.
FAU - Freire, C
AU  - Freire C
AD  - Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada 
      E-18012, Spain; CIBER de Epidemiología y Salud Pública (CIBERESP), Granada 
      E-18071, Spain; Biomedical Research Centre (CIBM) and School of Medicine, 
      University of Granada, Granada E-18071, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20181221
PL  - Netherlands
TA  - Environ Res
JT  - Environmental research
JID - 0147621
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Estrogens)
RN  - 0 (Phenols)
RN  - 0 (Sulfones)
RN  - 3OX4RR782R (bisphenol S)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - Benzhydryl Compounds/*analysis
MH  - Brazil
MH  - Environmental Monitoring
MH  - Estrogens
MH  - France
MH  - Humans
MH  - *Paper
MH  - Phenols/*analysis
MH  - Spain
MH  - Sulfones/*analysis
OTO - NOTNLM
OT  - Bisphenol A (BPA)
OT  - Bisphenol S (BPS)
OT  - E-screen
OT  - PALM assay
OT  - Thermal paper
EDAT- 2019/01/10 06:00
MHDA- 2019/12/19 06:00
CRDT- 2019/01/10 06:00
PHST- 2018/09/25 00:00 [received]
PHST- 2018/11/20 00:00 [revised]
PHST- 2018/12/20 00:00 [accepted]
PHST- 2019/01/10 06:00 [pubmed]
PHST- 2019/12/19 06:00 [medline]
PHST- 2019/01/10 06:00 [entrez]
AID - S0013-9351(18)30682-0 [pii]
AID - 10.1016/j.envres.2018.12.046 [doi]
PST - ppublish
SO  - Environ Res. 2019 Mar;170:406-415. doi: 10.1016/j.envres.2018.12.046. Epub 2018 
      Dec 21.

PMID- 32430006
OWN - NLM
STAT- MEDLINE
DCOM- 20210317
LR  - 20210317
IS  - 1476-511X (Electronic)
IS  - 1476-511X (Linking)
VI  - 19
IP  - 1
DP  - 2020 May 19
TI  - The imbalance in the aortic ceramide/sphingosine-1-phosphate rheostat in 
      ovariectomized rats and the preventive effect of estrogen.
PG  - 95
LID - 10.1186/s12944-020-01279-7 [doi]
LID - 95
AB  - BACKGROUND: The prevalence of hypertension in young women is lower than that in 
      age-matched men while the prevalence of hypertension in women is significantly 
      increased after the age of 50 (menopause) and is greater than that in men. It is 
      already known that sphingosine-1-phosphate (S1P) and ceramide regulate vascular 
      tone with opposing effects. This study aimed to explore the effects of 
      ovariectomy and estrogen supplementation on the ceramide/S1P rheostat of the 
      aorta in rats, and to explore a potential mechanism for perimenopausal 
      hypertension and a brand-new target for menopausal hormone therapy to protect 
      vessels. METHODS: In total, 30 female adult SD rats were randomly divided into 
      three groups: The sham operation group (SHAM), ovariectomy group (OVX) and 
      ovariectomy plus estrogen group (OVX + E). After 4 weeks of treatment, the blood 
      pressure (BP) of the rats was monitored by a noninvasive system; the sphingolipid 
      content (e.g., ceramide and S1P) was detected by liquid chromatography-mass 
      spectrometry (LC-MS); the expression of the key enzymes involved in ceramide 
      anabolism and catabolism was measured by real-time fluorescence quantitative 
      polymerase chain reaction (qPCR); and the expression of key enzymes and proteins 
      in the sphingosine kinase 1/2 (SphK1/2)-S1P-S1P receptor 1/2/3 (S1P1/2/3) 
      signaling pathway was detected by qPCR and western blotting. RESULTS: In the OVX 
      group compared with the SHAM group, the systolic BP (SBP), diastolic BP (DBP) and 
      pulse pressure (PP) increased significantly, especially the SBP and PP 
      (P < 0.001). For aortic ceramide metabolism, the mRNA level of key enzymes 
      involved in anabolism and catabolism decreased in parallel 2-3 times, while the 
      contents of total ceramide and certain long-chain subtypes increased 
      significantly (P < 0.05). As for the S1P signaling pathway, SphK1/2, the key 
      enzymes involved in S1P synthesis, decreased significantly, and the content of 
      S1P decreased accordingly (P < 0.01). The S1P receptors showed various trends: 
      S1P1 was significantly down-regulated, S1P2 was significantly up-regulated, and 
      S1P3 showed no significant difference. No significant difference existed between 
      the SHAM and OVX + E groups for most of the above parameters (P > 0.05). 
      CONCLUSIONS: Ovariectomy resulted in the imbalance of the aortic ceramide/S1P 
      rheostat in rats, which may be a potential mechanism underlying the increase in 
      SBP and PP among perimenopausal women. Besides, the ceramide/S1P rheostat may be 
      a novel mechanism by which estrogen protects vessels.
FAU - Li, Yao
AU  - Li Y
AD  - Department of Cardiology, Peking University People's Hospital, No. 11 South 
      Avenue, Beijing, 100044, Xi Zhi Men Xicheng District, China.
FAU - Zhang, Wei
AU  - Zhang W
AD  - Department of Urology, Peking University Fifth School of Clinical Medicine, 
      Beijing, 100730, China.
FAU - Li, Junlei
AU  - Li J
AD  - Department of Cardiology, Peking University People's Hospital, No. 11 South 
      Avenue, Beijing, 100044, Xi Zhi Men Xicheng District, China.
FAU - Sun, Yanrong
AU  - Sun Y
AD  - Department of Anatomy and Embryology, Peking University Health Science Center, 
      No. 38, Xueyuan Road, Beijing, 100191, Haidian District, China.
FAU - Yang, Qiyue
AU  - Yang Q
AD  - Department of Anatomy and Embryology, Peking University Health Science Center, 
      No. 38, Xueyuan Road, Beijing, 100191, Haidian District, China.
FAU - Wang, Sinan
AU  - Wang S
AD  - Department of Stomatology, General Hospital of Armed Police, Beijing, 100039, 
      China.
FAU - Luo, Xiaofeng
AU  - Luo X
AD  - Department of Stomatology, General Hospital of Armed Police, Beijing, 100039, 
      China.
FAU - Wang, Wenjuan
AU  - Wang W
AD  - Department of Anatomy and Embryology, Peking University Health Science Center, 
      No. 38, Xueyuan Road, Beijing, 100191, Haidian District, China.
FAU - Wang, Ke
AU  - Wang K
AD  - Department of Anatomy and Embryology, Peking University Health Science Center, 
      No. 38, Xueyuan Road, Beijing, 100191, Haidian District, China.
FAU - Bai, Wenpei
AU  - Bai W
AD  - Department of Obstetrics and Gynecology, Shijitan Hospital, Beijing, 100038, 
      China.
FAU - Zhang, Haicheng
AU  - Zhang H
AD  - Department of Cardiology, Peking University People's Hospital, No. 11 South 
      Avenue, Beijing, 100044, Xi Zhi Men Xicheng District, China. 
      haichengzhang@bjmu.edu.cn.
FAU - Qin, Lihua
AU  - Qin L
AD  - Department of Anatomy and Embryology, Peking University Health Science Center, 
      No. 38, Xueyuan Road, Beijing, 100191, Haidian District, China. 
      qinlihua88@163.com.
LA  - eng
GR  - 81873818/National Natural Science Foundation of China/
PT  - Journal Article
DEP - 20200519
PL  - England
TA  - Lipids Health Dis
JT  - Lipids in health and disease
JID - 101147696
RN  - 0 (Ceramides)
RN  - 0 (Estrogens)
RN  - 0 (Lysophospholipids)
RN  - 26993-30-6 (sphingosine 1-phosphate)
RN  - NGZ37HRE42 (Sphingosine)
SB  - IM
MH  - Animals
MH  - Aorta/chemistry/*metabolism
MH  - Ceramides/analysis/*metabolism
MH  - Estrogens/pharmacology/*therapeutic use
MH  - Female
MH  - Hypertension/drug therapy/etiology/metabolism/*prevention & control
MH  - Lysophospholipids/analysis/*metabolism
MH  - Models, Animal
MH  - Ovariectomy
MH  - Postmenopause/*drug effects
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Sphingosine/*analogs & derivatives/analysis/metabolism
PMC - PMC7236922
OTO - NOTNLM
OT  - Aorta
OT  - Ceramide
OT  - Estrogen
OT  - Ovariectomized rats
OT  - Sphingosine 1-phosphate
COIS- The authors declare that they have no competing interests.
EDAT- 2020/05/21 06:00
MHDA- 2021/03/18 06:00
PMCR- 2020/05/19
CRDT- 2020/05/21 06:00
PHST- 2020/02/10 00:00 [received]
PHST- 2020/05/05 00:00 [accepted]
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2021/03/18 06:00 [medline]
PHST- 2020/05/19 00:00 [pmc-release]
AID - 10.1186/s12944-020-01279-7 [pii]
AID - 1279 [pii]
AID - 10.1186/s12944-020-01279-7 [doi]
PST - epublish
SO  - Lipids Health Dis. 2020 May 19;19(1):95. doi: 10.1186/s12944-020-01279-7.

PMID- 29687146
OWN - NLM
STAT- MEDLINE
DCOM- 20181012
LR  - 20181114
IS  - 1420-908X (Electronic)
IS  - 1023-3830 (Linking)
VI  - 67
IP  - 7
DP  - 2018 Jul
TI  - Genistein modulates the expression of Toll-like receptors in experimental 
      autoimmune encephalomyelitis.
PG  - 597-608
LID - 10.1007/s00011-018-1146-7 [doi]
AB  - OBJECTIVE AND DESIGN: The present work investigates the modulation of 
      experimental autoimmune encephalomyelitis (EAE) using genistein before the EAE 
      induction. MATERIAL: Female C57BL/6 mice (n = 96 mice/experiment), 4-6 weeks old, 
      were used to induce the EAE. The mice were divided into three experimental 
      groups: non-immunized group, immunized group (EAE), and immunized and treated 
      with genistein group (Genistein). TREATMENT: Genistein was used at a dose of 
      200 mg/kg s.c. and were initiated 2 days before the immunization and continued 
      daily until day 6 postimmunization. METHODS: Animals were monitored daily for 
      clinical signs of EAE up to day 21. Inflammatory infiltration, demyelination, 
      Toll-like receptor (TLR) expression, cytokines and transcription factors were 
      analyzed in spinal cords. RESULTS: The present study demonstrates, for the first 
      time, the genistein ability to modulate the factors involved in the innate immune 
      response in the early stages of EAE. The genistein therapy delayed the onset of 
      the disease, with reduced inflammatory infiltration and demyelination. In 
      addition, the expression of TLR3, TLR9 and IFN-β were increased in genistein 
      group, with reduction in the factors of TH1 and Th17 cells. CONCLUSION: These 
      findings shed light on the potential of genistein as a prophylactic strategy for 
      multiple sclerosis (MS) prevention.
FAU - Dias, Alyria Teixeira
AU  - Dias AT
AD  - IMUNOCET, Department of Parasitology, Microbiology and Immunology, Institute of 
      Biological Sciences, Federal University of Juiz de Fora, Juiz de Fora, Minas 
      Gerais, 36036-900, Brazil.
FAU - de Castro, Sandra Bertelli Ribeiro
AU  - de Castro SBR
AD  - Department of Pharmacy, Federal University of Juiz de Fora, Governador Valadares, 
      Brazil.
FAU - de Souza Alves, Caio César
AU  - de Souza Alves CC
AD  - Faculty of Medicine, Federal University of the Valleys of Jequitinhonha and 
      Mucuri, Teófilo Otoni, Brazil.
FAU - Evangelista, Marcilene Gomes
AU  - Evangelista MG
AD  - IMUNOCET, Department of Parasitology, Microbiology and Immunology, Institute of 
      Biological Sciences, Federal University of Juiz de Fora, Juiz de Fora, Minas 
      Gerais, 36036-900, Brazil.
FAU - da Silva, Luan Cristian
AU  - da Silva LC
AD  - IMUNOCET, Department of Parasitology, Microbiology and Immunology, Institute of 
      Biological Sciences, Federal University of Juiz de Fora, Juiz de Fora, Minas 
      Gerais, 36036-900, Brazil.
FAU - Reis, Daniele Ribeiro de Lima
AU  - Reis DRL
AD  - Empresa Brasileira de Pesquisa Agropecuária, Juiz de Fora, Brazil.
FAU - Machado, Marco Antonio
AU  - Machado MA
AD  - Empresa Brasileira de Pesquisa Agropecuária, Juiz de Fora, Brazil.
FAU - Juliano, Maria Aparecida
AU  - Juliano MA
AD  - Department of Biophysics, Federal University of São Paulo, São Paulo, Brazil.
FAU - Ferreira, Ana Paula
AU  - Ferreira AP
AUID- ORCID: 0000-0002-0020-1828
AD  - IMUNOCET, Department of Parasitology, Microbiology and Immunology, Institute of 
      Biological Sciences, Federal University of Juiz de Fora, Juiz de Fora, Minas 
      Gerais, 36036-900, Brazil. ana.paula@ufjf.edu.br.
LA  - eng
GR  - 481459/2009-0/Conselho Nacional de Desenvolvimento Científico e Tecnológico/
GR  - 303369/2009-4/Conselho Nacional de Desenvolvimento Científico e Tecnológico/
GR  - 306575/2012-4/Conselho Nacional de Desenvolvimento Científico e Tecnológico/
GR  - 470768/2013-4/Conselho Nacional de Desenvolvimento Científico e Tecnológico/
GR  - 306768/2015-1/Conselho Nacional de Desenvolvimento Científico e Tecnológico/
GR  - 02236/10/Fundação de Amparo à Pesquisa do Estado de Minas Gerais/
GR  - PPM 0216/10/Fundação de Amparo à Pesquisa do Estado de Minas Gerais/
GR  - PPM 00269-14/Fundação de Amparo à Pesquisa do Estado de Minas Gerais/
GR  - PNPD-2882/2011/Coordenação de Aperfeiçoamento de Pessoal de Nível Superior/
PT  - Journal Article
DEP - 20180423
PL  - Switzerland
TA  - Inflamm Res
JT  - Inflammation research : official journal of the European Histamine Research 
      Society ... [et al.]
JID - 9508160
RN  - 0 (Cytokines)
RN  - 0 (Immunologic Factors)
RN  - 0 (Toll-Like Receptors)
RN  - DH2M523P0H (Genistein)
SB  - IM
MH  - Animals
MH  - Cytokines/genetics/immunology
MH  - Dendritic Cells/drug effects/immunology
MH  - Encephalomyelitis, Autoimmune, Experimental/*immunology/pathology/prevention & 
      control
MH  - Female
MH  - Genistein/*pharmacology/*therapeutic use
MH  - Immunologic Factors/*pharmacology/*therapeutic use
MH  - Macrophages/drug effects/immunology
MH  - Mice, Inbred C57BL
MH  - Multiple Sclerosis/prevention & control
MH  - Myelin Sheath/drug effects
MH  - Spinal Cord/drug effects/immunology/pathology
MH  - Toll-Like Receptors/*immunology
OTO - NOTNLM
OT  - Experimental autoimmune encephalomyelitis
OT  - IFN-β
OT  - Immune response
OT  - Multiple sclerosis
OT  - Toll-like
EDAT- 2018/04/25 06:00
MHDA- 2018/10/13 06:00
CRDT- 2018/04/25 06:00
PHST- 2017/12/06 00:00 [received]
PHST- 2018/03/27 00:00 [accepted]
PHST- 2018/03/25 00:00 [revised]
PHST- 2018/04/25 06:00 [pubmed]
PHST- 2018/10/13 06:00 [medline]
PHST- 2018/04/25 06:00 [entrez]
AID - 10.1007/s00011-018-1146-7 [pii]
AID - 10.1007/s00011-018-1146-7 [doi]
PST - ppublish
SO  - Inflamm Res. 2018 Jul;67(7):597-608. doi: 10.1007/s00011-018-1146-7. Epub 2018 
      Apr 23.

PMID- 30524952
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 2211-5463 (Print)
IS  - 2211-5463 (Electronic)
IS  - 2211-5463 (Linking)
VI  - 8
IP  - 12
DP  - 2018 Dec
TI  - Sulforaphane-induced metabolomic responses with epigenetic changes in estrogen 
      receptor positive breast cancer cells.
PG  - 2022-2034
LID - 10.1002/2211-5463.12543 [doi]
AB  - Estrogen is a risk factor for breast cancer. The isothiocyanate sulforaphane 
      (SFN), found in cruciferous vegetables, has been identified as an effective 
      chemopreventive agent, and may prevent or treat breast cancer by reversing 
      estrogen-induced metabolic changes. Here, we investigated metabolic changes in 
      estrogen receptor-positive breast cancer (MCF-7) cells treated with estradiol 
      (E(2)) and/or SFN to identify key metabolite panels that might provide new 
      insights into the underlying mechanisms of the antitumor effects of SFN. Gas 
      chromatography-mass spectrometry and ultra performance liquid chromatography-mass 
      spectrometry (UPLC-Orbitrap- MS) were used to obtain the metabolic profiles of 
      MCF-7 cells. The data were analyzed using Student's t-test and multivariate 
      statistics, including principal component analysis and partial least squares 
      discriminant analysis. Hydroxymethylation was detected by UPLC-Orbitrap- MS and 
      verified by immunofluorescence assay. We report that significant changes in 
      metabolites induced by E(2) and SFN were associated with differences in 
      glycolysis and energy metabolism, and also amino acid, purine, and folic acid 
      metabolism. E(2) may alter methylation and hydroxymethylation status via the 
      folic acid pathway. We also identified biomarkers that may be of use in 
      interpretation of the metabolic pathways evoked by the effects of E(2) and SFN on 
      breast cancer cells. The identified biomarkers associated with metabolic pathways 
      provide new insight into the chemopreventive mechanisms of SFN.
FAU - Cao, Shuyuan
AU  - Cao S
AD  - Department of Hygienic Analysis and Detection and Ministry of Education Key Lab 
      for Modern Toxicology School of Public Health Nanjing Medical University China.
FAU - Wang, Li
AU  - Wang L
AD  - Department of Hygienic Analysis and Detection and Ministry of Education Key Lab 
      for Modern Toxicology School of Public Health Nanjing Medical University China.
FAU - Zhang, Zhan
AU  - Zhang Z
AD  - Department of Hygienic Analysis and Detection and Ministry of Education Key Lab 
      for Modern Toxicology School of Public Health Nanjing Medical University China.
FAU - Chen, Feng
AU  - Chen F
AD  - Department of Epidemiology and Biostatistics and Ministry of Education Key Lab 
      for Modern Toxicology School of Public Health Nanjing Medical University China.
FAU - Wu, Qian
AU  - Wu Q
AD  - Department of Hygienic Analysis and Detection and Ministry of Education Key Lab 
      for Modern Toxicology School of Public Health Nanjing Medical University China.
FAU - Li, Lei
AU  - Li L
AD  - Department of Hygienic Analysis and Detection and Ministry of Education Key Lab 
      for Modern Toxicology School of Public Health Nanjing Medical University China.
LA  - eng
PT  - Journal Article
DEP - 20181114
PL  - England
TA  - FEBS Open Bio
JT  - FEBS open bio
JID - 101580716
PMC - PMC6275259
OTO - NOTNLM
OT  - breast cancer
OT  - estrogen
OT  - hydroxymethylation
OT  - metabolism
OT  - methylation
OT  - sulforaphane
EDAT- 2018/12/14 06:00
MHDA- 2018/12/14 06:01
PMCR- 2018/11/14
CRDT- 2018/12/08 06:00
PHST- 2018/02/11 00:00 [received]
PHST- 2018/10/09 00:00 [revised]
PHST- 2018/10/19 00:00 [accepted]
PHST- 2018/12/08 06:00 [entrez]
PHST- 2018/12/14 06:00 [pubmed]
PHST- 2018/12/14 06:01 [medline]
PHST- 2018/11/14 00:00 [pmc-release]
AID - FEB412543 [pii]
AID - 10.1002/2211-5463.12543 [doi]
PST - epublish
SO  - FEBS Open Bio. 2018 Nov 14;8(12):2022-2034. doi: 10.1002/2211-5463.12543. 
      eCollection 2018 Dec.

PMID- 32763416
OWN - NLM
STAT- MEDLINE
DCOM- 20210226
LR  - 20210226
IS  - 1872-7573 (Electronic)
IS  - 0378-8741 (Linking)
VI  - 264
DP  - 2021 Jan 10
TI  - In vivo and in vitro evaluation of the osteogenic potential of Davallia mariesii 
      T. Moore ex Baker.
PG  - 113126
LID - S0378-8741(20)33007-5 [pii]
LID - 10.1016/j.jep.2020.113126 [doi]
AB  - ETHNOPHARMACOLOGICAL RELEVANCE: Postmenopausal osteoporosis is a major bone 
      health issue worldwide. There is an unmet medical need for osteoporosis 
      treatments, a disease which disproportionately impacts women. Exploring 
      botanicals to prevent or treat osteoporosis is currently an interest of 
      investigations. Rhizomes of Davallia mariesii T. Moore ex Baker (Davalliacea) are 
      used an indigenous herbal medicine in Asia for injuries due to fractures, 
      contusions, and strains. AIM OF THE STUDY: In the present study, we investigated 
      the osteogenic effect of the water extract of rhizomes of D. mariesii (DMH) on 
      bone loss induced by an ovariectomy (OVX) in mice and also its impact on 
      osteogenesis in primary human osteoblasts (HObs). Additionally, we performed a 
      quantitative analysis of compounds in the DMH extract. MATERIALS AND METHODS: OVX 
      C57BL/6J mice were orally administrated DMH extract for 12 weeks, and 
      microarchitecture parameters were examined by microcomputed tomography. DMH 
      extract was fractionated in a bio-guided manner, and fractions were isolated to 
      obtain active compounds using HObs. Cell viability was evaluated by an MTT assay. 
      Characteristics of early and late osteogenesis were analyzed by alkaline 
      phosphatase activity and a mineralization assay. Molecular mechanisms were 
      explored by a real-time quantitative PCR. Compounds in the DMH extract were 
      identified and quantified using liquid chromatography tandem mass spectroscopy 
      (LC-MS/MS). RESULTS: DMH improved bone mineral densities of vertebrae and the 
      femur. Through microarchitectural observations, DMH significantly decreased the 
      bone surface/volume ratio and trabecular separation, and also increased the 
      connectivity density in the OVX group. Additionally, DMH inhibited osteoclast 
      differentiation in receptor activator of nuclear factor-κB ligand-induced 
      osteoclasts and increased bone formation in HObs. After bio-guided fractionation 
      and isolation, we found that eriodictyol-7-O-β-d-glucuronide (2) significantly 
      increased alkaline phosphatase activity, and 
      5-O-β-d-(6-O-vanilloylglucopyranosyl)gentisic acid (3) substantially enhanced 
      mineral deposition. In HObs, compound 3 was more potent in upregulating 
      expressions of bone morphogenetic protein-2, bone sialoprotein, osteopontin, 
      osterix, and estrogen receptor-α. The amount of bioactive compound 3 in DMH was 
      5.68 ± 0.64 mg/g of dry weight according to LC-MS/MS. CONCLUSION: For the first 
      time we report that D. mariesii and its isolated compounds demonstrated potent 
      osteogenic activities. Quantitative results of D. mariesii could be a reference 
      for phytochemical analyses.
CI  - Copyright © 2020 Elsevier B.V. All rights reserved.
FAU - Lin, Yi-Tzu
AU  - Lin YT
AD  - Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical 
      University, 250 Wuxing Street, Taipei, 11031, Taiwan. Electronic address: 
      d339102003@tmu.edu.tw.
FAU - Peng, Shih-Wen
AU  - Peng SW
AD  - Graduate Institute of Pharmacognosy, College of Pharmacy, Taipei Medical 
      University, 250 Wuxing Street, Taipei, 11031, Taiwan. Electronic address: 
      erica200480@gmail.com.
FAU - Imtiyaz, Zuha
AU  - Imtiyaz Z
AD  - Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical 
      University, 250 Wuxing Street, Taipei, 11031, Taiwan. Electronic address: 
      d339105004@tmu.edu.tw.
FAU - Ho, Chin-Wen
AU  - Ho CW
AD  - Department of Bioengineering, College of Engineering, Tatung University, 40 
      Zhongshan North Road, Section 3, Taipei, 10452, Taiwan. Electronic address: 
      cwho@ttu.edu.tw.
FAU - Chiou, Wen-Fei
AU  - Chiou WF
AD  - National Research Institute of Chinese Medicine, Ministry of Health and Welfare, 
      155-1 Linong Street, Section 2, Beitou, Taipei, 11221, Taiwan. Electronic 
      address: wfchiou@nricm.edu.tw.
FAU - Lee, Mei-Hsien
AU  - Lee MH
AD  - Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical 
      University, 250 Wuxing Street, Taipei, 11031, Taiwan; Graduate Institute of 
      Pharmacognosy, College of Pharmacy, Taipei Medical University, 250 Wuxing Street, 
      Taipei, 11031, Taiwan; Center for Reproductive Medicine & Sciences, Taipei 
      Medical University Hospital, 252 Wuxing Street, Taipei, 11031, Taiwan. Electronic 
      address: lmh@tmu.edu.tw.
LA  - eng
PT  - Journal Article
DEP - 20200805
PL  - Ireland
TA  - J Ethnopharmacol
JT  - Journal of ethnopharmacology
JID - 7903310
RN  - 0 (Plant Extracts)
SB  - IM
MH  - Animals
MH  - Cells, Cultured
MH  - Drug Evaluation, Preclinical/methods
MH  - Female
MH  - Humans
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Middle Aged
MH  - Osteoblasts/*drug effects/metabolism
MH  - Osteogenesis/*drug effects/physiology
MH  - Osteoporosis/diagnostic imaging/*drug therapy/metabolism
MH  - Ovariectomy/adverse effects
MH  - Plant Extracts/isolation & purification/pharmacology/*therapeutic use
MH  - *Plants, Medicinal
MH  - RAW 264.7 Cells
MH  - X-Ray Microtomography/methods
OTO - NOTNLM
OT  - 5-O-β-d-(6-O-Vanilloylglucopyranosyl)gentisic acid
OT  - Davallia mariesii
OT  - Osteoporosis
OT  - Ovariectomy
OT  - Primary human osteoblasts
EDAT- 2020/08/09 06:00
MHDA- 2021/02/27 06:00
CRDT- 2020/08/09 06:00
PHST- 2020/01/02 00:00 [received]
PHST- 2020/06/18 00:00 [revised]
PHST- 2020/06/19 00:00 [accepted]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2021/02/27 06:00 [medline]
PHST- 2020/08/09 06:00 [entrez]
AID - S0378-8741(20)33007-5 [pii]
AID - 10.1016/j.jep.2020.113126 [doi]
PST - ppublish
SO  - J Ethnopharmacol. 2021 Jan 10;264:113126. doi: 10.1016/j.jep.2020.113126. Epub 
      2020 Aug 5.

PMID- 25855707
OWN - NLM
STAT- MEDLINE
DCOM- 20150427
LR  - 20240210
IS  - 1460-2105 (Electronic)
IS  - 0027-8874 (Print)
IS  - 0027-8874 (Linking)
VI  - 107
IP  - 5
DP  - 2015 May
TI  - Prediction of breast cancer risk based on profiling with common genetic variants.
LID - djv036 [pii]
LID - 10.1093/jnci/djv036 [doi]
AB  - BACKGROUND: Data for multiple common susceptibility alleles for breast cancer may 
      be combined to identify women at different levels of breast cancer risk. Such 
      stratification could guide preventive and screening strategies. However, 
      empirical evidence for genetic risk stratification is lacking. METHODS: We 
      investigated the value of using 77 breast cancer-associated single nucleotide 
      polymorphisms (SNPs) for risk stratification, in a study of 33 673 breast cancer 
      cases and 33 381 control women of European origin. We tested all possible 
      pair-wise multiplicative interactions and constructed a 77-SNP polygenic risk 
      score (PRS) for breast cancer overall and by estrogen receptor (ER) status. 
      Absolute risks of breast cancer by PRS were derived from relative risk estimates 
      and UK incidence and mortality rates. RESULTS: There was no strong evidence for 
      departure from a multiplicative model for any SNP pair. Women in the highest 1% 
      of the PRS had a three-fold increased risk of developing breast cancer compared 
      with women in the middle quintile (odds ratio [OR] = 3.36, 95% confidence 
      interval [CI] = 2.95 to 3.83). The ORs for ER-positive and ER-negative disease 
      were 3.73 (95% CI = 3.24 to 4.30) and 2.80 (95% CI = 2.26 to 3.46), respectively. 
      Lifetime risk of breast cancer for women in the lowest and highest quintiles of 
      the PRS were 5.2% and 16.6% for a woman without family history, and 8.6% and 
      24.4% for a woman with a first-degree family history of breast cancer. 
      CONCLUSIONS: The PRS stratifies breast cancer risk in women both with and without 
      a family history of breast cancer. The observed level of risk discrimination 
      could inform targeted screening and prevention strategies. Further discrimination 
      may be achievable through combining the PRS with lifestyle/environmental factors, 
      although these were not considered in this report.
CI  - © The Author 2015. Published by Oxford University Press.
FAU - Mavaddat, Nasim
AU  - Mavaddat N
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Pharoah, Paul D P
AU  - Pharoah PD
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Michailidou, Kyriaki
AU  - Michailidou K
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Tyrer, Jonathan
AU  - Tyrer J
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Brook, Mark N
AU  - Brook MN
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Bolla, Manjeet K
AU  - Bolla MK
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Wang, Qin
AU  - Wang Q
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Dennis, Joe
AU  - Dennis J
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Dunning, Alison M
AU  - Dunning AM
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Shah, Mitul
AU  - Shah M
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Luben, Robert
AU  - Luben R
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Brown, Judith
AU  - Brown J
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Bojesen, Stig E
AU  - Bojesen SE
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Nordestgaard, Børge G
AU  - Nordestgaard BG
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Nielsen, Sune F
AU  - Nielsen SF
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Flyger, Henrik
AU  - Flyger H
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Czene, Kamila
AU  - Czene K
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Darabi, Hatef
AU  - Darabi H
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Eriksson, Mikael
AU  - Eriksson M
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Peto, Julian
AU  - Peto J
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Dos-Santos-Silva, Isabel
AU  - Dos-Santos-Silva I
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Dudbridge, Frank
AU  - Dudbridge F
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Johnson, Nichola
AU  - Johnson N
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Schmidt, Marjanka K
AU  - Schmidt MK
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Broeks, Annegien
AU  - Broeks A
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Verhoef, Senno
AU  - Verhoef S
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Rutgers, Emiel J
AU  - Rutgers EJ
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Swerdlow, Anthony
AU  - Swerdlow A
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Ashworth, Alan
AU  - Ashworth A
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Orr, Nick
AU  - Orr N
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Schoemaker, Minouk J
AU  - Schoemaker MJ
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Figueroa, Jonine
AU  - Figueroa J
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Chanock, Stephen J
AU  - Chanock SJ
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Brinton, Louise
AU  - Brinton L
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Lissowska, Jolanta
AU  - Lissowska J
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Couch, Fergus J
AU  - Couch FJ
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Olson, Janet E
AU  - Olson JE
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Vachon, Celine
AU  - Vachon C
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Pankratz, Vernon S
AU  - Pankratz VS
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Lambrechts, Diether
AU  - Lambrechts D
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Wildiers, Hans
AU  - Wildiers H
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Van Ongeval, Chantal
AU  - Van Ongeval C
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - van Limbergen, Erik
AU  - van Limbergen E
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Kristensen, Vessela
AU  - Kristensen V
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Grenaker Alnæs, Grethe
AU  - Grenaker Alnæs G
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Nord, Silje
AU  - Nord S
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Borresen-Dale, Anne-Lise
AU  - Borresen-Dale AL
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Nevanlinna, Heli
AU  - Nevanlinna H
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Muranen, Taru A
AU  - Muranen TA
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Aittomäki, Kristiina
AU  - Aittomäki K
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Blomqvist, Carl
AU  - Blomqvist C
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Chang-Claude, Jenny
AU  - Chang-Claude J
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Rudolph, Anja
AU  - Rudolph A
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Seibold, Petra
AU  - Seibold P
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Flesch-Janys, Dieter
AU  - Flesch-Janys D
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Fasching, Peter A
AU  - Fasching PA
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Haeberle, Lothar
AU  - Haeberle L
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Ekici, Arif B
AU  - Ekici AB
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Beckmann, Matthias W
AU  - Beckmann MW
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Burwinkel, Barbara
AU  - Burwinkel B
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Marme, Frederik
AU  - Marme F
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Schneeweiss, Andreas
AU  - Schneeweiss A
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Sohn, Christof
AU  - Sohn C
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Trentham-Dietz, Amy
AU  - Trentham-Dietz A
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Newcomb, Polly
AU  - Newcomb P
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Titus, Linda
AU  - Titus L
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Egan, Kathleen M
AU  - Egan KM
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Hunter, David J
AU  - Hunter DJ
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Lindstrom, Sara
AU  - Lindstrom S
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Tamimi, Rulla M
AU  - Tamimi RM
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Kraft, Peter
AU  - Kraft P
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Rahman, Nazneen
AU  - Rahman N
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Turnbull, Clare
AU  - Turnbull C
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Renwick, Anthony
AU  - Renwick A
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Seal, Sheila
AU  - Seal S
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Li, Jingmei
AU  - Li J
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Liu, Jianjun
AU  - Liu J
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Humphreys, Keith
AU  - Humphreys K
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Benitez, Javier
AU  - Benitez J
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Pilar Zamora, M
AU  - Pilar Zamora M
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Arias Perez, Jose Ignacio
AU  - Arias Perez JI
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Menéndez, Primitiva
AU  - Menéndez P
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Jakubowska, Anna
AU  - Jakubowska A
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Lubinski, Jan
AU  - Lubinski J
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Jaworska-Bieniek, Katarzyna
AU  - Jaworska-Bieniek K
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Durda, Katarzyna
AU  - Durda K
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Bogdanova, Natalia V
AU  - Bogdanova NV
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Antonenkova, Natalia N
AU  - Antonenkova NN
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Dörk, Thilo
AU  - Dörk T
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Anton-Culver, Hoda
AU  - Anton-Culver H
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Neuhausen, Susan L
AU  - Neuhausen SL
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Ziogas, Argyrios
AU  - Ziogas A
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Bernstein, Leslie
AU  - Bernstein L
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Devilee, Peter
AU  - Devilee P
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Tollenaar, Robert A E M
AU  - Tollenaar RA
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Seynaeve, Caroline
AU  - Seynaeve C
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - van Asperen, Christi J
AU  - van Asperen CJ
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Cox, Angela
AU  - Cox A
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Cross, Simon S
AU  - Cross SS
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Reed, Malcolm W R
AU  - Reed MW
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Khusnutdinova, Elza
AU  - Khusnutdinova E
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Bermisheva, Marina
AU  - Bermisheva M
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Prokofyeva, Darya
AU  - Prokofyeva D
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Takhirova, Zalina
AU  - Takhirova Z
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Meindl, Alfons
AU  - Meindl A
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Schmutzler, Rita K
AU  - Schmutzler RK
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Sutter, Christian
AU  - Sutter C
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Yang, Rongxi
AU  - Yang R
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Schürmann, Peter
AU  - Schürmann P
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Bremer, Michael
AU  - Bremer M
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Christiansen, Hans
AU  - Christiansen H
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Park-Simon, Tjoung-Won
AU  - Park-Simon TW
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Hillemanns, Peter
AU  - Hillemanns P
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Guénel, Pascal
AU  - Guénel P
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Truong, Thérèse
AU  - Truong T
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Menegaux, Florence
AU  - Menegaux F
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Sanchez, Marie
AU  - Sanchez M
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Radice, Paolo
AU  - Radice P
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Peterlongo, Paolo
AU  - Peterlongo P
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Manoukian, Siranoush
AU  - Manoukian S
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Pensotti, Valeria
AU  - Pensotti V
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Hopper, John L
AU  - Hopper JL
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Tsimiklis, Helen
AU  - Tsimiklis H
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Apicella, Carmel
AU  - Apicella C
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Southey, Melissa C
AU  - Southey MC
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Brauch, Hiltrud
AU  - Brauch H
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Brüning, Thomas
AU  - Brüning T
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Ko, Yon-Dschun
AU  - Ko YD
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Sigurdson, Alice J
AU  - Sigurdson AJ
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Doody, Michele M
AU  - Doody MM
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Hamann, Ute
AU  - Hamann U
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Torres, Diana
AU  - Torres D
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Ulmer, Hans-Ulrich
AU  - Ulmer HU
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Försti, Asta
AU  - Försti A
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Sawyer, Elinor J
AU  - Sawyer EJ
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Tomlinson, Ian
AU  - Tomlinson I
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Kerin, Michael J
AU  - Kerin MJ
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Miller, Nicola
AU  - Miller N
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Andrulis, Irene L
AU  - Andrulis IL
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Knight, Julia A
AU  - Knight JA
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Glendon, Gord
AU  - Glendon G
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Marie Mulligan, Anna
AU  - Marie Mulligan A
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Chenevix-Trench, Georgia
AU  - Chenevix-Trench G
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Balleine, Rosemary
AU  - Balleine R
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Giles, Graham G
AU  - Giles GG
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Milne, Roger L
AU  - Milne RL
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - McLean, Catriona
AU  - McLean C
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Lindblom, Annika
AU  - Lindblom A
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Margolin, Sara
AU  - Margolin S
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Haiman, Christopher A
AU  - Haiman CA
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Henderson, Brian E
AU  - Henderson BE
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Schumacher, Fredrick
AU  - Schumacher F
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Le Marchand, Loic
AU  - Le Marchand L
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Eilber, Ursula
AU  - Eilber U
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Wang-Gohrke, Shan
AU  - Wang-Gohrke S
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Hooning, Maartje J
AU  - Hooning MJ
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Hollestelle, Antoinette
AU  - Hollestelle A
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - van den Ouweland, Ans M W
AU  - van den Ouweland AM
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Koppert, Linetta B
AU  - Koppert LB
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Carpenter, Jane
AU  - Carpenter J
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Clarke, Christine
AU  - Clarke C
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Scott, Rodney
AU  - Scott R
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Mannermaa, Arto
AU  - Mannermaa A
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Kataja, Vesa
AU  - Kataja V
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Kosma, Veli-Matti
AU  - Kosma VM
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Hartikainen, Jaana M
AU  - Hartikainen JM
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Brenner, Hermann
AU  - Brenner H
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Arndt, Volker
AU  - Arndt V
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Stegmaier, Christa
AU  - Stegmaier C
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Karina Dieffenbach, Aida
AU  - Karina Dieffenbach A
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Winqvist, Robert
AU  - Winqvist R
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Pylkäs, Katri
AU  - Pylkäs K
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Jukkola-Vuorinen, Arja
AU  - Jukkola-Vuorinen A
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Grip, Mervi
AU  - Grip M
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Offit, Kenneth
AU  - Offit K
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Vijai, Joseph
AU  - Vijai J
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Robson, Mark
AU  - Robson M
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Rau-Murthy, Rohini
AU  - Rau-Murthy R
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Dwek, Miriam
AU  - Dwek M
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Swann, Ruth
AU  - Swann R
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Annie Perkins, Katherine
AU  - Annie Perkins K
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Goldberg, Mark S
AU  - Goldberg MS
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Labrèche, France
AU  - Labrèche F
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Dumont, Martine
AU  - Dumont M
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Eccles, Diana M
AU  - Eccles DM
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Tapper, William J
AU  - Tapper WJ
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Rafiq, Sajjad
AU  - Rafiq S
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - John, Esther M
AU  - John EM
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Whittemore, Alice S
AU  - Whittemore AS
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Slager, Susan
AU  - Slager S
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Yannoukakos, Drakoulis
AU  - Yannoukakos D
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Toland, Amanda E
AU  - Toland AE
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Yao, Song
AU  - Yao S
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Zheng, Wei
AU  - Zheng W
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Halverson, Sandra L
AU  - Halverson SL
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - González-Neira, Anna
AU  - González-Neira A
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Pita, Guillermo
AU  - Pita G
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Rosario Alonso, M
AU  - Rosario Alonso M
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Álvarez, Nuria
AU  - Álvarez N
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Herrero, Daniel
AU  - Herrero D
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Tessier, Daniel C
AU  - Tessier DC
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Vincent, Daniel
AU  - Vincent D
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Bacot, Francois
AU  - Bacot F
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Luccarini, Craig
AU  - Luccarini C
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Baynes, Caroline
AU  - Baynes C
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Ahmed, Shahana
AU  - Ahmed S
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Maranian, Mel
AU  - Maranian M
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Healey, Catherine S
AU  - Healey CS
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Simard, Jacques
AU  - Simard J
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Hall, Per
AU  - Hall P
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Easton, Douglas F
AU  - Easton DF
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
FAU - Garcia-Closas, Montserrat
AU  - Garcia-Closas M
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK (NM, PDPP, KM, MKB, QW, JD, RL, JBr, 
      DFE); Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
      of Cambridge, Cambridge, UK (PDPP, JT, AMD, MS, CL, CB, SA, MM, CSH, DFE); 
      Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK (MNB, ASw, MJS); Copenhagen General Population Study, Herlev Hospital, 
      Copenhagen University Hospital, Copenhagen, Denmark (SEB, BGN, SFN); Department 
      of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (SEB, BGN, SFN); Faculty of Health and Medical 
      Sciences, Copenhagen University Hospital, Copenhagen, Herlev, Denmark (SEB, BGN); 
      Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 
      Copenhagen, Herlev, Denmark (HF); Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden (KC, HD, ME, KH, PHa); 
      Department of Non-communicable Disease Epidemiology, London School of Hygiene and 
      Tropical Medicine, London, UK (JP, IdSS, FD); Breakthrough Breast Cancer Research 
      Centre, The Institute of Cancer Research, London, UK (NJ, AA, NO, MGC); 
      Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, the 
      Netherlands (MKS, AB, SV, EJR); Division of Breast Cancer Research, Institute of 
      Cancer Research, London, UK (ASw); Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, Rockville, MD (JF, SJC, LB, ASi, MD); Department of 
      Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center 
      and Institute of Oncology, Warsaw, Poland (JLis); Department of Laboratory 
      Medicine and Pathology, Mayo Clinic, Rochester, MN (FJC); Department of Health 
      Sciences Research, Mayo Clinic, Rochester, MN (JEO, CV, VSP, SS); Vesalius 
      Research Center, VIB, Leuven, Belgium (DL); Laboratory for Translational 
      Genetics, Department of Oncology, University of
LA  - eng
GR  - CA128978/CA/NCI NIH HHS/United States
GR  - P30 CA68485/CA/NCI NIH HHS/United States
GR  - C8197/A10123/CRUK_/Cancer Research UK/United Kingdom
GR  - R01 CA100374/CA/NCI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - 1U19CA148537/CA/NCI NIH HHS/United States
GR  - UM1 CA182910/CA/NCI NIH HHS/United States
GR  - CA54281/CA/NCI NIH HHS/United States
GR  - MR/K006215/1/MRC_/Medical Research Council/United Kingdom
GR  - 16563/CRUK_/Cancer Research UK/United Kingdom
GR  - 10124/CRUK_/Cancer Research UK/United Kingdom
GR  - CA116201/CA/NCI NIH HHS/United States
GR  - P30 CA016056/CA/NCI NIH HHS/United States
GR  - C1287/A10710/CRUK_/Cancer Research UK/United Kingdom
GR  - P01 CA087969/CA/NCI NIH HHS/United States
GR  - UM1 CA164920/CA/NCI NIH HHS/United States
GR  - P30 CA016056-32/CA/NCI NIH HHS/United States
GR  - R01 CA092447/CA/NCI NIH HHS/United States
GR  - R01CA47305/CA/NCI NIH HHS/United States
GR  - CA122340/CA/NCI NIH HHS/United States
GR  - CA63464/CA/NCI NIH HHS/United States
GR  - C490/A10124/CRUK_/Cancer Research UK/United Kingdom
GR  - 16565/CRUK_/Cancer Research UK/United Kingdom
GR  - 15106/CRUK_/Cancer Research UK/United Kingdom
GR  - C1287/A12014/CRUK_/Cancer Research UK/United Kingdom
GR  - P01 CA87969/CA/NCI NIH HHS/United States
GR  - R01CA69664/CA/NCI NIH HHS/United States
GR  - 16561/CRUK_/Cancer Research UK/United Kingdom
GR  - CRN-87521/CAPMC/CIHR/Canada
GR  - 1U19CA148065/CA/NCI NIH HHS/United States
GR  - C8620/A8372/CRUK_/Cancer Research UK/United Kingdom
GR  - P30 CA068485/CA/NCI NIH HHS/United States
GR  - R01 CA77398/CA/NCI NIH HHS/United States
GR  - K05 CA152715/CA/NCI NIH HHS/United States
GR  - CA132839/CA/NCI NIH HHS/United States
GR  - CA-58860/CA/NCI NIH HHS/United States
GR  - CA098758/CA/NCI NIH HHS/United States
GR  - MC_PC_14105/MRC_/Medical Research Council/United Kingdom
GR  - G0700491/MRC_/Medical Research Council/United Kingdom
GR  - C8620/A8857/CRUK_/Cancer Research UK/United Kingdom
GR  - C1287/A10118/CRUK_/Cancer Research UK/United Kingdom
GR  - R01 CA47147/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20150408
PL  - United States
TA  - J Natl Cancer Inst
JT  - Journal of the National Cancer Institute
JID - 7503089
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Receptors, Estrogen)
SB  - IM
CIN - BMJ. 2015 Apr 09;350:h1879. doi: 10.1136/bmj.h1879. PMID: 25858913
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/analysis
MH  - Breast Neoplasms/chemistry/*epidemiology/*genetics
MH  - Europe/epidemiology
MH  - Female
MH  - *Gene Expression Profiling
MH  - Gene Expression Regulation, Neoplastic
MH  - Genetic Predisposition to Disease
MH  - Genotype
MH  - Humans
MH  - Middle Aged
MH  - Odds Ratio
MH  - *Polymorphism, Single Nucleotide
MH  - Predictive Value of Tests
MH  - Receptors, Estrogen/analysis
MH  - Risk Assessment
MH  - Risk Factors
PMC - PMC4754625
EDAT- 2015/04/10 06:00
MHDA- 2015/04/29 06:00
PMCR- 2015/04/02
CRDT- 2015/04/10 06:00
PHST- 2014/03/28 00:00 [received]
PHST- 2015/01/26 00:00 [accepted]
PHST- 2015/04/10 06:00 [entrez]
PHST- 2015/04/10 06:00 [pubmed]
PHST- 2015/04/29 06:00 [medline]
PHST- 2015/04/02 00:00 [pmc-release]
AID - djv036 [pii]
AID - 10.1093/jnci/djv036 [doi]
PST - epublish
SO  - J Natl Cancer Inst. 2015 Apr 8;107(5):djv036. doi: 10.1093/jnci/djv036. Print 
      2015 May.

PMID- 34384109
OWN - NLM
STAT- MEDLINE
DCOM- 20220110
LR  - 20220110
IS  - 1439-4286 (Electronic)
IS  - 0018-5043 (Linking)
VI  - 53
IP  - 8
DP  - 2021 Aug
TI  - Impact of Clomiphene Citrate on the Steroid Profile in Dysmetabolic Men with Low 
      Testosterone Levels.
PG  - 520-528
LID - 10.1055/a-1542-8763 [doi]
AB  - Clomiphene citrate (CC) in male hypogonadism increases testosterone (T) and 
      estrogen levels by stimulating pituitary gonadotropin release. Our group 
      confirmed these hormonal changes in a randomized, cross-over, double-blind trial 
      of CC versus placebo in addition to metformin, conducted in 21 obese dysmetabolic 
      men with low T levels. However, we hypothesize that based on its mechanism of 
      action, CC may directly or indirectly affect adrenal steroidogenesis. The aim of 
      this sub-study was to better understand the changes in steroid levels and 
      metabolism induced by CC treatment. We assessed 17α-hydroxypregnelone (17αOH-P5), 
      dehydroepiandrosterone (DHEA), progesterone (P4), 17α-hydroxyprogesterone 
      (17αOH-P4), androstenedione (A), T, dihydrotestosterone (DHT), estrone (E1), 
      17β-estradiol (E2), 11-deoxycortisol (11 S), cortisol (F), and cortisone (E) by 
      LC-MS/MS, and corticosteroid binding globulin (CBG) by ELISA, before and after 
      each treatment. In addition, free-F and steroid product/precursor ratios were 
      calculated. We observed a significant change in serum levels induced by CC 
      compared with placebo for 17αOH-P4, DHT, T, E2, E1, F, E, and CBG, but not 
      free-F. In addition, compared to placebo, CC induced higher 17αOH-P4/P4, E2/E1, 
      17αOH-P4/17αOH-P5, A/17αOH-P4, T/A, E1/A, F/11 S, and F/E ratios. Therefore, 
      besides the CC stimulating effect on testis steroidogenesis, our study showed 
      increased F, E, but not free-F, levels, indicating changes in steroid metabolism 
      rather than adrenal secretion stimulation. The steroid profiling also revealed 
      the CC stimulation of the Δ5 rather than the Δ4 pathway, thus indicating 
      considerable testicular involvement in the increased androgen secretion.
CI  - Thieme. All rights reserved.
FAU - Pelusi, Carla
AU  - Pelusi C
AD  - Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda 
      Ospedaliero-Universitaria di Bologna, Bologna, Italy.
FAU - Fanelli, Flamina
AU  - Fanelli F
AD  - Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda 
      Ospedaliero-Universitaria di Bologna, Bologna, Italy.
FAU - Baccini, Margherita
AU  - Baccini M
AD  - Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda 
      Ospedaliero-Universitaria di Bologna, Bologna, Italy.
FAU - De Pergola, Giovanni
AU  - De Pergola G
AD  - Nutrition Outpatient Clinic, Clinical Oncology Unit, University of Bari, Bari, 
      Italy.
FAU - Triggiani, Vincenzo
AU  - Triggiani V
AD  - Interdisciplinary Department of Medicine, Internal Medicine, Geriatrics, 
      Endocrinology and Rare Diseases, University of Bari, Bari, Italy.
FAU - Mezzullo, Marco
AU  - Mezzullo M
AD  - Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda 
      Ospedaliero-Universitaria di Bologna, Bologna, Italy.
FAU - Fazzini, Alessia
AU  - Fazzini A
AD  - Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda 
      Ospedaliero-Universitaria di Bologna, Bologna, Italy.
FAU - Di Dalmazi, Guido
AU  - Di Dalmazi G
AD  - Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda 
      Ospedaliero-Universitaria di Bologna, Bologna, Italy.
FAU - Petrovic, Biljana
AU  - Petrovic B
AD  - Center for Applied Biomedical Research, Department of Medical & Surgical Sciences 
      (DIMEC), Alma Mater Studiorum University of Bologna, Bologna, Italy.
FAU - Paterini, Paola
AU  - Paterini P
AD  - Center for Applied Biomedical Research, Department of Medical & Surgical Sciences 
      (DIMEC), Alma Mater Studiorum University of Bologna, Bologna, Italy.
FAU - Labate, Antonio Maria Morselli
AU  - Labate AMM
AD  - Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda 
      Ospedaliero-Universitaria di Bologna, Bologna, Italy.
FAU - Pagotto, Uberto
AU  - Pagotto U
AD  - Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda 
      Ospedaliero-Universitaria di Bologna, Bologna, Italy.
FAU - Giagulli, Vito Angelo
AU  - Giagulli VA
AD  - Interdisciplinary Department of Medicine, Internal Medicine, Geriatrics, 
      Endocrinology and Rare Diseases, University of Bari, Bari, Italy.
AD  - Outpatients Clinic of Endocrinology and Metabolic Disease, Conversano Hospital, 
      Bari, Italy.
LA  - eng
GR  - Italian Research Project of Relevant Interest/PRIN 2010-2011/
GR  - Emilia-Romagna Region-University Program grant for Young Investigators 
      "Alessandro Liberati"/PRUA 1-2012-004/
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20210812
PL  - Germany
TA  - Horm Metab Res
JT  - Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et 
      metabolisme
JID - 0177722
RN  - 0 (Steroids)
RN  - 1HRS458QU2 (Clomiphene)
RN  - 3XMK78S47O (Testosterone)
RN  - 9010-38-2 (Transcortin)
SB  - IM
MH  - Adult
MH  - Chromatography, Liquid
MH  - Clomiphene/*pharmacology
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Obesity/metabolism
MH  - Steroids/*blood/metabolism
MH  - Tandem Mass Spectrometry
MH  - Testosterone/*blood
MH  - Transcortin/analysis
COIS- The authors declare that they have no conflict of interest.
EDAT- 2021/08/13 06:00
MHDA- 2022/01/11 06:00
CRDT- 2021/08/12 20:06
PHST- 2021/08/12 20:06 [entrez]
PHST- 2021/08/13 06:00 [pubmed]
PHST- 2022/01/11 06:00 [medline]
AID - 10.1055/a-1542-8763 [doi]
PST - ppublish
SO  - Horm Metab Res. 2021 Aug;53(8):520-528. doi: 10.1055/a-1542-8763. Epub 2021 Aug 
      12.

PMID- 25135999
OWN - NLM
STAT- MEDLINE
DCOM- 20150318
LR  - 20220316
IS  - 1758-535X (Electronic)
IS  - 1079-5006 (Print)
IS  - 1079-5006 (Linking)
VI  - 70
IP  - 2
DP  - 2015 Feb
TI  - Strength and function response to clinical interventions of older women 
      categorized by weakness and low lean mass using classifications from the 
      Foundation for the National Institute of Health sarcopenia project.
PG  - 202-9
LID - 10.1093/gerona/glu110 [doi]
AB  - BACKGROUND: The Foundation for the National Institutes of Health Sarcopenia 
      Project developed data-driven cut-points for clinically meaningful weakness and 
      low lean body mass. This analysis describes strength and function response to 
      interventions based on these classifications. METHODS: In data from four 
      intervention studies, 378 postmenopausal women with baseline and 6-month data 
      were evaluated for change in grip strength, appendicular lean mass corrected for 
      body mass index, leg strength and power, and short physical performance battery 
      (SPPB). Clinical interventions included hormones, exercise, and nutritional 
      supplementation. Differences in outcomes were evaluated between (i) those with 
      and without weakness and (ii) those with weakness and low lean mass or with one 
      but not the other. We stratified analyses by slowness (walking speed ≤ 0.8 m/s) 
      and by treatment assignment. RESULTS: The women (72±7 years; body mass index of 
      26±5kg/m(2)) were weak (33%), had low lean mass (14%), or both (6%). Those with 
      weakness increased grip strength, lost less leg power, and gained SPPB score (p < 
      .05) compared with nonweak participants. Stratified analyses were similar for 
      grip strength and SPPB. With lean mass in the analysis, individuals with weakness 
      had larger gains in grip strength and SPPB scores regardless of low lean mass (p 
      < .01). CONCLUSIONS: Older women with clinically meaningful muscle weakness 
      increased grip strength and SPPB, regardless of the presence of low lean mass 
      following treatment with interventions for frailty. Thus, results suggest that 
      muscle weakness, as defined by the Foundation for the National Institutes of 
      Health Sarcopenia Project, appears to be a treatable symptom.
CI  - © The Author 2014. Published by Oxford University Press on behalf of The 
      Gerontological Society of America. All rights reserved. For permissions, please 
      e-mail: journals.permissions@oup.com.
FAU - Fragala, Maren S
AU  - Fragala MS
AD  - University of Central Florida, Orlando.
FAU - Dam, Thuy-Tien L
AU  - Dam TT
AD  - Columbia University College of Physicians and Surgeons, New York.
FAU - Barber, Vanessa
AU  - Barber V
AD  - University of Connecticut Health Center, Farmington.
FAU - Judge, James O
AU  - Judge JO
AD  - University of Connecticut Health Center, Farmington.
FAU - Studenski, Stephanie A
AU  - Studenski SA
AD  - National Institute of Aging, National Institutes of Health, Bethesda, Maryland.
FAU - Cawthon, Peggy M
AU  - Cawthon PM
AD  - California Pacific Medical Center Research Institute, San Francisco.
FAU - McLean, Robert R
AU  - McLean RR
AD  - Hebrew Senior Life Institute for Aging Research, Boston, Massachusetts. Harvard 
      Medical School, Boston, Massachusetts.
FAU - Harris, Tamara B
AU  - Harris TB
AD  - National Institute of Aging, National Institutes of Health, Bethesda, Maryland.
FAU - Ferrucci, Luigi
AU  - Ferrucci L
AD  - National Institute of Aging, National Institutes of Health, Bethesda, Maryland.
FAU - Guralnik, Jack M
AU  - Guralnik JM
AD  - University of Maryland School of Medicine, Baltimore.
FAU - Kiel, Douglas P
AU  - Kiel DP
AD  - Hebrew Senior Life Institute for Aging Research, Boston, Massachusetts. Harvard 
      Medical School, Boston, Massachusetts.
FAU - Kritchevsky, Stephen B
AU  - Kritchevsky SB
AD  - Wake Forest University School of Medicine, Winston-Salem, North Carolina.
FAU - Shardell, Michelle D
AU  - Shardell MD
AD  - University of Maryland School of Medicine, Baltimore.
FAU - Vassileva, Maria T
AU  - Vassileva MT
AD  - Foundation for the National Institutes of Health, Bethesda, Maryland.
FAU - Kenny, Anne M
AU  - Kenny AM
AD  - University of Connecticut Health Center, Farmington. kenny@uchc.edu.
LA  - eng
GR  - MO1-RR06192/RR/NCRR NIH HHS/United States
GR  - 5P60AG13631/AG/NIA NIH HHS/United States
GR  - M01 RR006192/RR/NCRR NIH HHS/United States
GR  - R01 AG018887/AG/NIA NIH HHS/United States
GR  - R01-AG18887/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20140818
PL  - United States
TA  - J Gerontol A Biol Sci Med Sci
JT  - The journals of gerontology. Series A, Biological sciences and medical sciences
JID - 9502837
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Bone Density Conservation Agents)
RN  - 0 (Estrogens)
RN  - 0 (Fish Oils)
RN  - 1406-16-2 (Vitamin D)
RN  - 459AG36T1B (Dehydroepiandrosterone)
RN  - 4TI98Z838E (Estradiol)
RN  - MLM29U2X85 (Calcium Citrate)
SB  - IM
MH  - Absorptiometry, Photon
MH  - Adjuvants, Immunologic/therapeutic use
MH  - Aged
MH  - Body Composition/physiology
MH  - Bone Density Conservation Agents/therapeutic use
MH  - Calcium Citrate/therapeutic use
MH  - Dehydroepiandrosterone/therapeutic use
MH  - Disease Susceptibility
MH  - Estradiol/administration & dosage
MH  - Estrogen Replacement Therapy
MH  - Estrogens/administration & dosage
MH  - Female
MH  - Fish Oils/therapeutic use
MH  - Gait/physiology
MH  - Humans
MH  - Middle Aged
MH  - Muscle Strength/*physiology
MH  - Muscle Weakness/physiopathology
MH  - National Institutes of Health (U.S.)
MH  - Postmenopause/physiology
MH  - Resistance Training
MH  - Sarcopenia/*physiopathology/*therapy
MH  - United States
MH  - Vitamin D/therapeutic use
PMC - PMC4311186
OTO - NOTNLM
OT  - Clinical trials.
OT  - Function
OT  - Gait speed
OT  - Sarcopenia
OT  - Strength
EDAT- 2014/08/20 06:00
MHDA- 2015/03/19 06:00
PMCR- 2016/02/01
CRDT- 2014/08/20 06:00
PHST- 2014/08/20 06:00 [entrez]
PHST- 2014/08/20 06:00 [pubmed]
PHST- 2015/03/19 06:00 [medline]
PHST- 2016/02/01 00:00 [pmc-release]
AID - glu110 [pii]
AID - 10.1093/gerona/glu110 [doi]
PST - ppublish
SO  - J Gerontol A Biol Sci Med Sci. 2015 Feb;70(2):202-9. doi: 10.1093/gerona/glu110. 
      Epub 2014 Aug 18.

PMID- 39330599
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240929
IS  - 2305-6304 (Electronic)
IS  - 2305-6304 (Linking)
VI  - 12
IP  - 9
DP  - 2024 Sep 14
TI  - Multiphase Partitioning of Estrogens in a River Impacted by Feedlot Wastewater 
      Discharge.
LID - 10.3390/toxics12090671 [doi]
LID - 671
AB  - Estrogens in river systems can significantly impact aquatic ecosystems. This 
      study aimed to investigate the multiphase partitioning of estrogens in Wulo 
      Creek, Taiwan, which receives animal feedlot wastewater, to understand their 
      distribution and potential environmental implications. Water samples were 
      separated into suspended particulate matter (SPM), colloidal, and soluble phases 
      using centrifugation and cross-flow ultrafiltration. Concentrations of estrone 
      (E1), 17β-estradiol (E2), and estriol (E3) in each phase were analyzed using 
      LC/MS/MS. Partition coefficients were calculated to assess estrogen distribution 
      among phases. Estrogens were predominantly found in the soluble phase 
      (85.8-87.3%). The risk assessment of estrogen equivalent (EEQ) values suggests 
      that estrogen concentration in water poses a higher risk compared to SPM, with a 
      majority of the samples indicating a high risk to aquatic organisms. The 
      colloidal phase contained 12.7-14.2% of estrogens. The log K(COC) values 
      (4.72-4.77 L/kg-C) were significantly higher than the log K(OC) and log K(POC) 
      values (2.02-3.40 L/kg-C) for all estrogens. Colloids play a critical role in 
      estrogen distribution in river systems, potentially influencing their fate, 
      transport, and biotoxicity. This finding highlights the importance of considering 
      colloidal interactions in assessing estrogen behavior in aquatic environments.
FAU - Yang, Kuo-Hui
AU  - Yang KH
AD  - Department of Environmental Science and Engineering, National Pingtung University 
      of Science and Technology, Pingtung 91201, Taiwan.
FAU - Hung, Hao-Shen
AU  - Hung HS
AUID- ORCID: 0000-0002-4494-2433
AD  - Department of Environmental Science and Engineering, National Pingtung University 
      of Science and Technology, Pingtung 91201, Taiwan.
FAU - Huang, Wei-Hsiang
AU  - Huang WH
AD  - Department of Environmental Science and Engineering, National Pingtung University 
      of Science and Technology, Pingtung 91201, Taiwan.
AD  - Disaster Prevention and Mitigation Technology Research Center, General Research 
      Service Center, National Pingtung University of Science and Technology, Pingtung 
      91201, Taiwan.
FAU - Hsieh, Chi-Ying
AU  - Hsieh CY
AD  - Department of Environmental Science and Engineering, National Pingtung University 
      of Science and Technology, Pingtung 91201, Taiwan.
FAU - Chen, Ting-Chien
AU  - Chen TC
AD  - Department of Environmental Science and Engineering, National Pingtung University 
      of Science and Technology, Pingtung 91201, Taiwan.
AD  - Disaster Prevention and Mitigation Technology Research Center, General Research 
      Service Center, National Pingtung University of Science and Technology, Pingtung 
      91201, Taiwan.
LA  - eng
GR  - MOST 103-2221-E-020 -008/National Science and Technology Council, R.O.C./
PT  - Journal Article
DEP - 20240914
PL  - Switzerland
TA  - Toxics
JT  - Toxics
JID - 101639637
PMC - PMC11436132
OTO - NOTNLM
OT  - colloid
OT  - estrogens
OT  - multiphase partitioning
OT  - soluble
OT  - suspended particulate matter (SPM)
COIS- The authors declare no conflicts of interest.
EDAT- 2024/09/27 16:17
MHDA- 2024/09/27 16:18
PMCR- 2024/09/14
CRDT- 2024/09/27 09:43
PHST- 2024/07/18 00:00 [received]
PHST- 2024/09/08 00:00 [revised]
PHST- 2024/09/10 00:00 [accepted]
PHST- 2024/09/27 16:18 [medline]
PHST- 2024/09/27 16:17 [pubmed]
PHST- 2024/09/27 09:43 [entrez]
PHST- 2024/09/14 00:00 [pmc-release]
AID - toxics12090671 [pii]
AID - toxics-12-00671 [pii]
AID - 10.3390/toxics12090671 [doi]
PST - epublish
SO  - Toxics. 2024 Sep 14;12(9):671. doi: 10.3390/toxics12090671.

PMID- 33597715
OWN - NLM
STAT- MEDLINE
DCOM- 20210927
LR  - 20230522
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Print)
IS  - 0007-0920 (Linking)
VI  - 124
IP  - 9
DP  - 2021 Apr
TI  - Recommendations from the European Commission Initiative on Breast Cancer for 
      multigene testing to guide the use of adjuvant chemotherapy in patients with 
      early breast cancer, hormone receptor positive, HER-2 negative.
PG  - 1503-1512
LID - 10.1038/s41416-020-01247-z [doi]
AB  - BACKGROUND: Predicting the risk of recurrence and response to chemotherapy in 
      women with early breast cancer is crucial to optimise adjuvant treatment. Despite 
      the common practice of using multigene tests to predict recurrence, existing 
      recommendations are inconsistent. Our aim was to formulate healthcare 
      recommendations for the question "Should multigene tests be used in women who 
      have early invasive breast cancer, hormone receptor-positive, HER2-negative, to 
      guide the use of adjuvant chemotherapy?" METHODS: The European Commission 
      Initiative on Breast Cancer (ECIBC) Guidelines Development Group (GDG), a 
      multidisciplinary guideline panel including experts and three patients, developed 
      recommendations informed by systematic reviews of the evidence. Grading of 
      Recommendations Assessment, Development and Evaluation (GRADE) Evidence to 
      Decision frameworks were used. Four multigene tests were evaluated: the 21-gene 
      recurrence score (21-RS), the 70-gene signature (70-GS), the PAM50 risk of 
      recurrence score (PAM50-RORS), and the 12-gene molecular score (12-MS). RESULTS: 
      Five studies (2 marker-based design RCTs, two treatment interaction design RCTs 
      and 1 pooled individual data analysis from observational studies) were included; 
      no eligible studies on PAM50-RORS or 12-MS were identified and the GDG did not 
      formulate recommendations for these tests. CONCLUSIONS: The ECIBC GDG suggests 
      the use of the 21-RS for lymph node-negative women (conditional recommendation, 
      very low certainty of evidence), recognising that benefits are probably larger in 
      women at high risk of recurrence based on clinical characteristics. The ECIBC GDG 
      suggests the use of the 70-GS for women at high clinical risk (conditional 
      recommendation, low certainty of evidence), and recommends not using 70-GS in 
      women at low clinical risk (strong recommendation, low certainty of evidence).
FAU - Giorgi Rossi, Paolo
AU  - Giorgi Rossi P
AD  - Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
FAU - Lebeau, Annette
AU  - Lebeau A
AD  - Department of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, 
      Germany.
FAU - Canelo-Aybar, Carlos
AU  - Canelo-Aybar C
AD  - Iberoamerican Cochrane Center, Biomedical Research Institute (IIB Sant 
      Pau-CIBERESP), Barcelona, Spain.
AD  - Department of Paediatrics, Obstetrics and Gynaecology, Preventive Medicine, and 
      Public Health, PhD Programme in Methodology of Biomedical Research and Public 
      Health, Universitat Autònoma de Barcelona, Bellaterra, Spain.
FAU - Saz-Parkinson, Zuleika
AU  - Saz-Parkinson Z
AUID- ORCID: 0000-0002-3518-5899
AD  - European Commission, Joint Research Centre (JRC), Ispra, Italy. 
      zuleika.saz-parkinson@ec.europa.eu.
AD  - Instituto de Salud Carlos III, Health Technology Assessment Agency, Avenida 
      Monforte de Lemos 5, Madrid, Spain. zuleika.saz-parkinson@ec.europa.eu.
FAU - Quinn, Cecily
AU  - Quinn C
AD  - St. Vincent's University Hospital, Dublin, Ireland.
FAU - Langendam, Miranda
AU  - Langendam M
AD  - Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam 
      UMC, University of Amsterdam, Amsterdam Public Health Institute, Amsterdam, The 
      Netherlands.
FAU - Mcgarrigle, Helen
AU  - Mcgarrigle H
AD  - Cardiff and Vale UHB - General Surgery, Cardiff, UK.
FAU - Warman, Sue
AU  - Warman S
AD  - Havyatt Lodge, Havyatt Road, Langford, North Somerset, UK.
FAU - Rigau, David
AU  - Rigau D
AD  - Iberoamerican Cochrane Center, Biomedical Research Institute (IIB Sant 
      Pau-CIBERESP), Barcelona, Spain.
FAU - Alonso-Coello, Pablo
AU  - Alonso-Coello P
AD  - Iberoamerican Cochrane Center, Biomedical Research Institute (IIB Sant 
      Pau-CIBERESP), Barcelona, Spain.
FAU - Broeders, Mireille
AU  - Broeders M
AD  - Department for Health Evidence, Radboud University Medical Center, Nijmegen, the 
      Netherlands.
AD  - Dutch Expert Centre for Screening, Nijmegen, the Netherlands.
FAU - Graewingholt, Axel
AU  - Graewingholt A
AD  - Radiologie am Theater, Paderborn, NRW, Germany.
FAU - Posso, Margarita
AU  - Posso M
AD  - Iberoamerican Cochrane Center, Biomedical Research Institute (IIB Sant 
      Pau-CIBERESP), Barcelona, Spain.
AD  - Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical 
      Research Institute), Barcelona, Spain.
AD  - Research Network on Health Services in Chronic Diseases (REDISSEC), Barcelona, 
      Spain.
FAU - Duffy, Stephen
AU  - Duffy S
AUID- ORCID: 0000-0003-4901-7922
AD  - Centre for Cancer Prevention, Queen Mary University of London, Charterhouse 
      Square, London, UK.
FAU - Schünemann, Holger J
AU  - Schünemann HJ
AD  - Michael G. DeGroote Cochrane Canada and McGRADE Centres; Department of Health 
      Research Methods, Evidence and Impact, McMaster University Health Sciences 
      Centre, Hamilton, Ontario, Canada.
CN  - ECIBC Contributor Group
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20210218
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Biomarkers, Tumor/*genetics
MH  - Breast Neoplasms/drug therapy/*genetics/pathology
MH  - Chemotherapy, Adjuvant/*methods
MH  - Europe
MH  - Female
MH  - Gene Expression Profiling
MH  - Humans
MH  - Neoplasm Recurrence, Local/drug therapy/*genetics/pathology
MH  - Practice Guidelines as Topic/*standards
MH  - Prognosis
MH  - Receptor, ErbB-2/metabolism
MH  - Receptors, Estrogen/metabolism
MH  - Receptors, Progesterone/metabolism
PMC - PMC8076250
COIS- Members of the Guideline Development Group (GDG) do not receive financial 
      compensation for their work but are reimbursed by the E.C. for travel-related 
      expenses for the meetings organised by the JRC. Dr. Giorgi Rossi as former-PI of 
      an independent study on HPV-based cervical cancer screening, funded by the 
      Italian Ministry of Health, data owner, conducted negotiations with Roche 
      diagnostics, Hologic-Genprobe, Becton-Dickinson to obtain reagents at reduced 
      price or for free; the reagents obtained were not used in his institution. Dr. 
      Lebeau reports grants and reimbursement for travel-related expenses related to 
      consultancy from Roche Pharma AG, reimbursement for travel-related expenses 
      related to consultancy from Novartis Oncology, and grants from BioNTech 
      Diagnostics GmbH outside the submitted work. Dr. Saz-Parkinson was employed by 
      the European Commission, coordinating the ECIBC Guidelines Development Group. Dr. 
      Quinn is Chair of the European Working Group for Breast Screening Pathology 
      (EWGBSP). Various companies have provided some sponsorship to the EWGBSP for 
      group meetings. Dr. Gräwingholt is the responsible radiologist for screening unit 
      Paderborn, Germany, consultant radiologist for screening programs in Switzerland, 
      and consultant radiologist for Hellenic School of Senology. Dr. Canelo-Aybar, Dr. 
      Rigau, Dr. Posso Rivera, and Dr. Alonso-Coello reports that his institution 
      received payments from the European Commission to develop the systematic reviews 
      informing the recommendations. Authors not named here have disclosed no conflicts 
      of interest. Disclosures can also be viewed at 
      www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M18-3445.
FIR - Autelitano, Mariangela
IR  - Autelitano M
FIR - Borisch, Bettina
IR  - Borisch B
FIR - Castells, Xavier
IR  - Castells X
FIR - Colzani, Edoardo
IR  - Colzani E
FIR - Daneš, Jan
IR  - Daneš J
FIR - Fitzpatrick, Patricia
IR  - Fitzpatrick P
FIR - Giordano, Livia
IR  - Giordano L
FIR - Hofvind, Solveig
IR  - Hofvind S
FIR - Ioannidou-Mouzaka, Lydia
IR  - Ioannidou-Mouzaka L
FIR - Knox, Susan
IR  - Knox S
FIR - Nystrom, Lennarth
IR  - Nystrom L
FIR - Parmelli, Elena
IR  - Parmelli E
FIR - Perez, Elsa
IR  - Perez E
FIR - Torresin, Alberto
IR  - Torresin A
FIR - Van Engen, Ruben
IR  - Van Engen R
FIR - Van Landsveld-Verhoeven, Cary
IR  - Van Landsveld-Verhoeven C
FIR - Young, Ken
IR  - Young K
EDAT- 2021/02/19 06:00
MHDA- 2021/09/28 06:00
PMCR- 2021/02/18
CRDT- 2021/02/18 06:06
PHST- 2020/10/01 00:00 [received]
PHST- 2020/12/17 00:00 [accepted]
PHST- 2020/12/10 00:00 [revised]
PHST- 2021/02/19 06:00 [pubmed]
PHST- 2021/09/28 06:00 [medline]
PHST- 2021/02/18 06:06 [entrez]
PHST- 2021/02/18 00:00 [pmc-release]
AID - 10.1038/s41416-020-01247-z [pii]
AID - 1247 [pii]
AID - 10.1038/s41416-020-01247-z [doi]
PST - ppublish
SO  - Br J Cancer. 2021 Apr;124(9):1503-1512. doi: 10.1038/s41416-020-01247-z. Epub 
      2021 Feb 18.

PMID- 30967597
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20220420
IS  - 1473-1150 (Electronic)
IS  - 1470-269X (Linking)
VI  - 20
IP  - 1
DP  - 2020 Feb
TI  - Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized 
      trial for endocrine-responsive postmenopausal breast cancer.
PG  - 19-26
LID - 10.1038/s41397-019-0087-z [doi]
AB  - Polymorphisms of genes involved in estrogen synthesis have been linked to breast 
      cancer risk, prognosis, and treatment response. We investigated the prognostic 
      impact of a deletion spanning the entire UGT2B17 gene (UGT2B17*2) and genetic 
      variants of the aromatase CYP19A1 and estrogen receptor α (ESR1) in 125 
      postmenopausal women with ER-positive breast cancer enrolled in a randomized 
      pre-surgical trial. The UGT2B17*2 was estimated by copy number variation assays 
      and the CYP19A1 rs10046/rs4646 and ESR1 rs2077647/rs2234693/rs9340799 by TaqMan 
      allelic discrimination assays. Serum exemestane/17-hydroxy exemestane were 
      determined by MS and estrone (E1)/estradiol (E2)/ by GC-MS/MS. The association of 
      genetic polymorphisms with "any event" was assessed by the Cox proportional 
      hazards models adjusted for confounders. The UGT2B17*2 was associated with higher 
      levels of 17-hydroxy exemestane (P = 0.04) and better prognosis (HR = 0.45; 95% 
      CI: 0.20-1.01; P = 0.05) compared with homozygote UGT2B17 wt. The CYP19A1 rs10046 
      A and rs4646 C alleles were associated with higher estrogen levels: rs10046 AA 
      vs. AG/GG genotypes had median E1 of 35.9 vs. 27.4 pg/mL (P = 0.05) and E2 of 
      7.57 vs. 3.9 pg/mL (P < 0.004). After a median follow-up of 7 years, women 
      carrying the "low estrogen" alleles rs10046 G and rs4646 A had a better prognosis 
      compared with homozygote wt for both polymorphisms (HR = 0.40; 95% CI: 0.17-0.93; 
      P = 0.03). Our analysis points to an impact of UGT2B17 and CYP19A1 in 
      postmenopausal endocrine responsive breast cancer. Carriers of UGT2B17*2 and 
      CYP19A1 low estrogen variants may have better prognosis, supporting studies 
      addressing the role of these polymorphisms in optimizing endocrine therapy. Trial 
      registration: http://www.isrctn.com/ISRCTN86894592.
FAU - Johansson, Harriet
AU  - Johansson H
AD  - Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology 
      IRCCS, Milan, Italy. harriet.johansson@ieo.it.
FAU - Aristarco, Valentina
AU  - Aristarco V
AD  - Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology 
      IRCCS, Milan, Italy.
FAU - Gandini, Sara
AU  - Gandini S
AD  - Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, 
      Milan, Italy.
FAU - Gjerde, Jennifer
AU  - Gjerde J
AD  - Department of Clinical Science, University of Bergen, Bergen, Norway.
AD  - Hormone Laboratory, Haukeland University Hospital, Bergen, Norway.
FAU - Macis, Debora
AU  - Macis D
AD  - Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology 
      IRCCS, Milan, Italy.
FAU - Guerrieri-Gonzaga, Aliana
AU  - Guerrieri-Gonzaga A
AD  - Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology 
      IRCCS, Milan, Italy.
FAU - Serrano, Davide
AU  - Serrano D
AD  - Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology 
      IRCCS, Milan, Italy.
FAU - Lazzeroni, Matteo
AU  - Lazzeroni M
AUID- ORCID: 0000-0002-2162-4002
AD  - Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology 
      IRCCS, Milan, Italy.
FAU - Rajasekaran, Agnita
AU  - Rajasekaran A
AD  - Syneos Health, Princeton, NJ, 08540, USA.
FAU - Williard, Clark V
AU  - Williard CV
AD  - Syneos Health, Princeton, NJ, 08540, USA.
FAU - Mellgren, Gunnar
AU  - Mellgren G
AD  - Department of Clinical Science, University of Bergen, Bergen, Norway.
AD  - Hormone Laboratory, Haukeland University Hospital, Bergen, Norway.
FAU - DeCensi, Andrea
AU  - DeCensi A
AD  - Division of Medical Oncology, E.O. Ospedali Galliera, Genoa, Italy.
AD  - Wolfson Institute of Preventive Medicine, Queen Mary University of London, 
      London, UK.
FAU - Bonanni, Bernardo
AU  - Bonanni B
AD  - Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology 
      IRCCS, Milan, Italy.
LA  - eng
SI  - ISRCTN/ISRCTN86894592
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20190410
PL  - United States
TA  - Pharmacogenomics J
JT  - The pharmacogenomics journal
JID - 101083949
RN  - 0 (Androstadienes)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Minor Histocompatibility Antigens)
RN  - EC 1.14.14.1 (Aromatase)
RN  - EC 1.14.14.1 (CYP19A1 protein, human)
RN  - EC 2.4.1.17 (Glucuronosyltransferase)
RN  - EC 2.4.1.17 (UGT2B17 protein, human)
RN  - JCX84Q7J1L (Celecoxib)
RN  - NY22HMQ4BX (exemestane)
SB  - IM
MH  - Aged
MH  - Androstadienes/administration & dosage
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage
MH  - Antineoplastic Agents/administration & dosage
MH  - Aromatase/blood/*genetics
MH  - Breast Neoplasms/blood/*diagnosis/*genetics/therapy
MH  - Celecoxib/administration & dosage
MH  - Female
MH  - Genetic Variation/drug effects/*genetics
MH  - Glucuronosyltransferase/blood/*genetics
MH  - Humans
MH  - Middle Aged
MH  - Minor Histocompatibility Antigens/blood/*genetics
MH  - Polymorphism, Single Nucleotide/genetics
MH  - Postmenopause/blood/drug effects/*genetics
MH  - Prognosis
EDAT- 2019/04/11 06:00
MHDA- 2021/01/05 06:00
CRDT- 2019/04/11 06:00
PHST- 2018/08/14 00:00 [received]
PHST- 2019/03/27 00:00 [accepted]
PHST- 2019/01/11 00:00 [revised]
PHST- 2019/04/11 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2019/04/11 06:00 [entrez]
AID - 10.1038/s41397-019-0087-z [pii]
AID - 10.1038/s41397-019-0087-z [doi]
PST - ppublish
SO  - Pharmacogenomics J. 2020 Feb;20(1):19-26. doi: 10.1038/s41397-019-0087-z. Epub 
      2019 Apr 10.

PMID- 29725047
OWN - NLM
STAT- MEDLINE
DCOM- 20191009
LR  - 20250103
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 8
IP  - 1
DP  - 2018 May 3
TI  - A novel high sensitivity UPLC-MS/MS method for the evaluation of bisphenol A 
      leaching from dental materials.
PG  - 6981
LID - 10.1038/s41598-018-24815-z [doi]
LID - 6981
AB  - There is a growing necessity to acquire more profound knowledge on the quantity 
      of eluates from resin-based dental materials, especially with regard to bisphenol 
      A (BPA). The aim of the present study was to develop a highly sensitive method to 
      characterize the short-term release of BPA in saliva with ultra-performance 
      liquid chromatography-tandem mass spectrometry (UPLC-MS/MS), using an extraction 
      step and additional derivatization of BPA with pyridine-3-sulfonyl chloride. 
      Light-cured resin-based composites were incubated at 37 °C in 1 mL artificial 
      saliva, which was refreshed daily for one week. The final protocol allows 
      accurate quantification of very low levels of BPA in samples of artificial saliva 
      (i.e. 1.10 pmol BPA/mL or 250 pg/mL). The daily BPA-release from dental 
      composites, ranging from 1.10 to 7.46 pmol BPA/mL, was characterized over a 
      period of 7 days. The highest total amount of BPA was released from Solitaire 2 
      (24.72 ± 2.86 pmol), followed by G-ænial Posterior (15.51 ± 0.88 pmol) and Filtek 
      Supreme XTE (12.00 ± 1.31 pmol). In contrast, only trace amounts of BPA were 
      released from Ceram.x Universal. This UPLC-MS/MS method might be used for 
      clinical research focusing on the evaluation of the clinical relevance of BPA 
      release from dental materials.
FAU - De Nys, Siemon
AU  - De Nys S
AUID- ORCID: 0000-0003-1201-1367
AD  - KU Leuven (University of Leuven), Department of Oral Health Sciences, BIOMAT & 
      University Hospitals Leuven (UZ Leuven), Dentistry, Leuven, Belgium.
FAU - Putzeys, Eveline
AU  - Putzeys E
AD  - KU Leuven (University of Leuven), Department of Oral Health Sciences, BIOMAT & 
      University Hospitals Leuven (UZ Leuven), Dentistry, Leuven, Belgium.
FAU - Vervliet, Philippe
AU  - Vervliet P
AUID- ORCID: 0000-0003-2644-6820
AD  - Toxicological Centre, University of Antwerp, Universiteitsplein 1, D.S.551, 2610, 
      Wilrijk, Belgium.
FAU - Covaci, Adrian
AU  - Covaci A
AD  - Toxicological Centre, University of Antwerp, Universiteitsplein 1, D.S.551, 2610, 
      Wilrijk, Belgium.
FAU - Boonen, Imke
AU  - Boonen I
AD  - Department of Analytical, Environmental and Geo-Chemistry, Vrije Universiteit 
      Brussel, Pleinlaan 2, 1050, Ixelles, Belgium.
FAU - Elskens, Marc
AU  - Elskens M
AD  - Department of Analytical, Environmental and Geo-Chemistry, Vrije Universiteit 
      Brussel, Pleinlaan 2, 1050, Ixelles, Belgium.
FAU - Vanoirbeek, Jeroen
AU  - Vanoirbeek J
AUID- ORCID: 0000-0001-5508-3518
AD  - Environment and Health, Department of Public Health and Primary Care, KU Leuven, 
      Kapucijnenvoer 35, 3000, Leuven, Belgium.
FAU - Godderis, Lode
AU  - Godderis L
AD  - Environment and Health, Department of Public Health and Primary Care, KU Leuven, 
      Kapucijnenvoer 35, 3000, Leuven, Belgium.
AD  - IDEWE, External service for prevention and protection at work, Heverlee, Belgium.
FAU - Van Meerbeek, Bart
AU  - Van Meerbeek B
AD  - KU Leuven (University of Leuven), Department of Oral Health Sciences, BIOMAT & 
      University Hospitals Leuven (UZ Leuven), Dentistry, Leuven, Belgium.
FAU - Van Landuyt, Kirsten L
AU  - Van Landuyt KL
AD  - KU Leuven (University of Leuven), Department of Oral Health Sciences, BIOMAT & 
      University Hospitals Leuven (UZ Leuven), Dentistry, Leuven, Belgium.
FAU - Duca, Radu Corneliu
AU  - Duca RC
AD  - Environment and Health, Department of Public Health and Primary Care, KU Leuven, 
      Kapucijnenvoer 35, 3000, Leuven, Belgium. radu.duca@kuleuven.be.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180503
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Dental Materials)
RN  - 0 (Phenols)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - Benzhydryl Compounds/*analysis
MH  - Chromatography, High Pressure Liquid/*methods
MH  - Dental Materials/*chemistry
MH  - Light
MH  - Phenols/*analysis
MH  - Saliva/chemistry
MH  - Sensitivity and Specificity
MH  - Tandem Mass Spectrometry/*methods
MH  - Temperature
PMC - PMC5934439
COIS- The authors declare no competing interests.
EDAT- 2018/05/05 06:00
MHDA- 2019/10/11 06:00
PMCR- 2018/05/03
CRDT- 2018/05/05 06:00
PHST- 2017/12/20 00:00 [received]
PHST- 2018/04/10 00:00 [accepted]
PHST- 2018/05/05 06:00 [entrez]
PHST- 2018/05/05 06:00 [pubmed]
PHST- 2019/10/11 06:00 [medline]
PHST- 2018/05/03 00:00 [pmc-release]
AID - 10.1038/s41598-018-24815-z [pii]
AID - 24815 [pii]
AID - 10.1038/s41598-018-24815-z [doi]
PST - epublish
SO  - Sci Rep. 2018 May 3;8(1):6981. doi: 10.1038/s41598-018-24815-z.

PMID- 30257855
OWN - NLM
STAT- MEDLINE
DCOM- 20190527
LR  - 20200714
IS  - 1521-009X (Electronic)
IS  - 0090-9556 (Print)
IS  - 0090-9556 (Linking)
VI  - 46
IP  - 12
DP  - 2018 Dec
TI  - Identification and Quantification of Novel Major Metabolites of the Steroidal 
      Aromatase Inhibitor, Exemestane.
PG  - 1867-1878
LID - 10.1124/dmd.118.081166 [doi]
AB  - Exemestane (EXE) is an aromatase inhibitor used for the prevention and treatment 
      of estrogen receptor-positive breast cancer. Although the known major metabolic 
      pathway for EXE is reduction to form the active 17β-dihydro-EXE (17β-DHE) and 
      subsequent glucuronidation to 17β-hydroxy-EXE-17-O-β-D-glucuronide 
      (17β-DHE-Gluc), previous studies have suggested that other major metabolites 
      exist for exemestane. In the present study, a liquid chromatography-mass 
      spectrometry (LC-MS) approach was used to acquire accurate mass data in MS(E) 
      mode, in which precursor ion and fragment ion data were obtained simultaneously 
      to screen novel phase II EXE metabolites in urine specimens from women taking 
      EXE. Two major metabolites predicted to be cysteine conjugates of EXE and 17β-DHE 
      by elemental composition were identified. The structures of the two metabolites 
      were confirmed to be 6-methylcysteinylandrosta-1,4-diene-3,17-dione (6-EXE-cys) 
      and 6-methylcysteinylandrosta-1,4-diene-17β-hydroxy-3-one (6-17β-DHE-cys) after 
      comparison with their chemically synthesized counterparts. Both underwent 
      biosynthesis in vitro in three stepwise enzymatic reactions, with the first 
      involving glutathione conjugation. The cysteine conjugates of EXE and 17β-DHE 
      were subsequently quantified by liquid chromatography-mass spectrometry in the 
      urine and matched plasma samples of 132 subjects taking EXE. The combined 
      6-EXE-cys plus 6-17β-DHE-cys made up 77% of total EXE metabolites in urine (vs. 
      1.7%, 0.14%, and 21% for EXE, 17β-DHE, and 17β-DHE-Gluc, respectively) and 35% in 
      plasma (vs. 17%, 12%, and 36% for EXE, 17β-DHE, and 17β-DHE-Gluc, respectively). 
      Therefore, cysteine conjugates of EXE and 17β-DHE appear to be major metabolites 
      of EXE in both urine and plasma.
CI  - Copyright © 2018 The Author(s).
FAU - Luo, Shaman
AU  - Luo S
AD  - Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical 
      Sciences, Washington State University, Spokane, Washington (S.L., G.C., Z.X., 
      P.L.); Department of Medicine, Penn State University College of Medicine, 
      Hershey, Pennsylvania (C.I.T., C.C.B.); and Alkali Soil Natural Environmental 
      Science Center, Northeast Forestry University, Harbin, Heilongjiang, China 
      (S.L.).
FAU - Chen, Gang
AU  - Chen G
AUID- ORCID: 0000-0002-4353-3806
AD  - Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical 
      Sciences, Washington State University, Spokane, Washington (S.L., G.C., Z.X., 
      P.L.); Department of Medicine, Penn State University College of Medicine, 
      Hershey, Pennsylvania (C.I.T., C.C.B.); and Alkali Soil Natural Environmental 
      Science Center, Northeast Forestry University, Harbin, Heilongjiang, China 
      (S.L.).
FAU - Truica, Cristina I
AU  - Truica CI
AD  - Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical 
      Sciences, Washington State University, Spokane, Washington (S.L., G.C., Z.X., 
      P.L.); Department of Medicine, Penn State University College of Medicine, 
      Hershey, Pennsylvania (C.I.T., C.C.B.); and Alkali Soil Natural Environmental 
      Science Center, Northeast Forestry University, Harbin, Heilongjiang, China 
      (S.L.).
FAU - Baird, Cynthia C
AU  - Baird CC
AD  - Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical 
      Sciences, Washington State University, Spokane, Washington (S.L., G.C., Z.X., 
      P.L.); Department of Medicine, Penn State University College of Medicine, 
      Hershey, Pennsylvania (C.I.T., C.C.B.); and Alkali Soil Natural Environmental 
      Science Center, Northeast Forestry University, Harbin, Heilongjiang, China 
      (S.L.).
FAU - Xia, Zuping
AU  - Xia Z
AD  - Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical 
      Sciences, Washington State University, Spokane, Washington (S.L., G.C., Z.X., 
      P.L.); Department of Medicine, Penn State University College of Medicine, 
      Hershey, Pennsylvania (C.I.T., C.C.B.); and Alkali Soil Natural Environmental 
      Science Center, Northeast Forestry University, Harbin, Heilongjiang, China 
      (S.L.).
FAU - Lazarus, Philip
AU  - Lazarus P
AD  - Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical 
      Sciences, Washington State University, Spokane, Washington (S.L., G.C., Z.X., 
      P.L.); Department of Medicine, Penn State University College of Medicine, 
      Hershey, Pennsylvania (C.I.T., C.C.B.); and Alkali Soil Natural Environmental 
      Science Center, Northeast Forestry University, Harbin, Heilongjiang, China (S.L.) 
      phil.lazarus@wsu.edu.
LA  - eng
GR  - R01 CA164366/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20180926
PL  - United States
TA  - Drug Metab Dispos
JT  - Drug metabolism and disposition: the biological fate of chemicals
JID - 9421550
RN  - 0 (Androstadienes)
RN  - 0 (Aromatase Inhibitors)
RN  - 0 (Glucuronides)
RN  - K848JZ4886 (Cysteine)
RN  - NY22HMQ4BX (exemestane)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Androstadienes/administration & dosage/blood/*metabolism/urine
MH  - Aromatase Inhibitors/administration & dosage/blood/*metabolism/urine
MH  - *Breast Neoplasms/blood/urine
MH  - Chromatography, Liquid
MH  - Cysteine/metabolism
MH  - Female
MH  - Glucuronides/metabolism
MH  - Humans
MH  - Metabolic Detoxication, Phase II
MH  - Middle Aged
MH  - Tandem Mass Spectrometry
PMC - PMC7333658
EDAT- 2018/09/28 06:00
MHDA- 2019/05/28 06:00
PMCR- 2018/12/01
CRDT- 2018/09/28 06:00
PHST- 2018/02/28 00:00 [received]
PHST- 2018/09/14 00:00 [accepted]
PHST- 2018/09/28 06:00 [pubmed]
PHST- 2019/05/28 06:00 [medline]
PHST- 2018/09/28 06:00 [entrez]
PHST- 2018/12/01 00:00 [pmc-release]
AID - dmd.118.081166 [pii]
AID - DMD_081166 [pii]
AID - 10.1124/dmd.118.081166 [doi]
PST - ppublish
SO  - Drug Metab Dispos. 2018 Dec;46(12):1867-1878. doi: 10.1124/dmd.118.081166. Epub 
      2018 Sep 26.

PMID- 35216968
OWN - NLM
STAT- MEDLINE
DCOM- 20220707
LR  - 20230703
IS  - 1097-6868 (Electronic)
IS  - 0002-9378 (Print)
IS  - 0002-9378 (Linking)
VI  - 227
IP  - 1
DP  - 2022 Jul
TI  - Effect of risk-reducing salpingo-oophorectomy on sex steroid hormone serum levels 
      among postmenopausal women: an NRG Oncology/Gynecologic Oncology Group study.
PG  - 61.e1-61.e18
LID - S0002-9378(22)00124-7 [pii]
LID - 10.1016/j.ajog.2022.02.022 [doi]
AB  - BACKGROUND: Risk-reducing salpingo-oophorectomy is an effective ovarian cancer 
      risk reduction strategy. However, bilateral oophorectomy has also been associated 
      with increased long-term nonneoplastic sequelae, effects suggested to be mediated 
      through reductions in systemic sex steroid hormone levels. Currently, it is 
      unclear whether the postmenopausal ovary contributes to the systemic hormonal 
      milieu or whether postmenopausal ovarian volume or other factors, such as body 
      mass index and age, affect systemic hormone levels. OBJECTIVE: We examined the 
      impact of oophorectomy on sex steroid hormone levels in postmenopausal women. 
      Furthermore, we explored how well ovarian volume measured by transvaginal 
      ultrasound correlated with direct ovarian measures obtained during surgical 
      pathology evaluation and investigated the association between hormone levels and 
      ovarian volumes. STUDY DESIGN: Postmenopausal women who underwent risk-reducing 
      salpingo-oophorectomy (180 cases) or ovarian cancer screening (38 controls) 
      enrolled in an international, prospective study of risk-reducing 
      salpingo-oophorectomy and risk of ovarian cancer algorithm-based screening among 
      women at increased risk of ovarian cancer (Gynecologic Oncology Group-0199) were 
      included in this analysis. Controls were frequency matched to the cases on age at 
      menopause, age at study entry, and time interval between blood draws. Ovarian 
      volume was calculated using measurements obtained from transvaginal ultrasound in 
      both cases and controls and measurements recorded in surgical pathology reports 
      from cases. Serum hormone levels of testosterone, androstenedione, 
      androstenediol, dihydrotestosterone, androsterone, dehydroepiandrosterone, 
      estrone, estradiol, and sex hormone-binding globulin were measured at baseline 
      and follow-up. Spearman correlation coefficients were used to compare ovarian 
      volumes as measured on transvaginal ultrasound and pathology examinations. 
      Correlations between ovarian volumes by transvaginal ultrasound and measured 
      hormone levels were examined using linear regression models. All models were 
      adjusted for age. Paired t tests were performed to evaluate individual 
      differences in hormone levels before and after risk-reducing 
      salpingo-oophorectomy. RESULTS: Ovarian volumes measured by transvaginal 
      ultrasound were only moderately correlated with those reported on pathology 
      reports (Spearman rho [ρ]=0.42). The median time interval between risk-reducing 
      salpingo-oophorectomy and follow-up for the cases was 13.3 months (range, 
      6.0-19.3), and the median time interval between baseline and follow-up for the 
      controls was 12.7 months (range, 8.7-13.4). Sex steroid levels decreased with age 
      but were not correlated with transvaginal ultrasound ovarian volume, body mass 
      index, or time since menopause. Estradiol levels were significantly lower after 
      risk-reducing salpingo-oophorectomy (percentage change, -61.9 post-risk-reducing 
      salpingo-oophorectomy vs +15.2 in controls; P=.02), but no significant 
      differences were seen for the other hormones. CONCLUSION: Ovarian volumes 
      measured by transvaginal ultrasound were moderately correlated with volumes 
      directly measured on pathology specimens and were not correlated with sex steroid 
      hormone levels in postmenopausal women. Estradiol was the only hormone that 
      declined significantly after risk-reducing salpingo-oophorectomy. Thus, it 
      remains unclear whether the limited post-risk-reducing salpingo-oophorectomy 
      changes in sex steroid hormones among postmenopausal women impact long-term 
      adverse outcomes.
CI  - Copyright © 2022 Elsevier Inc. All rights reserved.
FAU - Mai, Phuong L
AU  - Mai PL
AD  - Center for Clinical Genetics and Genomics, Department of Obstetrics, Gynecology, 
      and Reproductive Sciences, University of Pittsburgh Medical Center Magee-Womens 
      Hospital, Pittsburgh, PA. Electronic address: maip@upmc.edu.
FAU - Miller, Austin
AU  - Miller A
AD  - NRG Oncology, Clinical Trial Development Division, Department of Biostatistics 
      and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
FAU - Black, Amanda
AU  - Black A
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, 
      Bethesda, MD.
FAU - Falk, Roni T
AU  - Falk RT
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, 
      Bethesda, MD.
FAU - Boggess, John F
AU  - Boggess JF
AD  - Department of Obstetrics and Gynecology, The University of North Carolina at 
      Chapel Hill, Chapel Hill, NC.
FAU - Tucker, Katherine
AU  - Tucker K
AD  - Hereditary Cancer Centre, Nelune Comprehensive Cancer Centre, Department of 
      Medical Oncology, Prince of Wales Hospital and Community Health Services, Prince 
      of Wales Clinical School, University of New South Wales, Sydney, Australia.
FAU - Stuckey, Ashley R
AU  - Stuckey AR
AD  - Department of Obstetrics and Gynecology, Women & Infants Hospital, Providence, 
      RI.
FAU - Rodriguez, Gustavo C
AU  - Rodriguez GC
AD  - Division of Gynecologic Oncology, NorthShore University Health System, Evanston, 
      IL.
FAU - Wong, Cheung
AU  - Wong C
AD  - Division of Gynecologic Oncology, University of Vermont Medical Center, 
      Burlington, VT.
FAU - Amatruda, Thomas T
AU  - Amatruda TT
AD  - Metro-Minnesota Community Oncology Research Consortium, Fridley Clinic, Fridley, 
      MN.
FAU - Wilkinson, Kelly J
AU  - Wilkinson KJ
AD  - Department of Medicine, University of Mississippi Medical Center, Jackson, MS.
FAU - Modesitt, Susan C
AU  - Modesitt SC
AD  - Division of Gynecologic Oncology, University of Virginia Health, Charlottesville, 
      VA.
FAU - Yamada, S Diane
AU  - Yamada SD
AD  - Division of Gynecologic Oncology, The University of Chicago Medicine, Chicago, 
      IL.
FAU - Bixel, Kristin L
AU  - Bixel KL
AD  - Division of Gynecologic Oncology, The Ohio State University Comprehensive Cancer 
      Center, Columbus, OH.
FAU - Glaser, Gretchen E
AU  - Glaser GE
AD  - Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN.
FAU - Rose, Peter G
AU  - Rose PG
AD  - Division of Gynecologic Oncology, Case Comprehensive Cancer Center, Cleveland 
      Clinic, Cleveland, OH.
FAU - Greene, Mark H
AU  - Greene MH
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, 
      Bethesda, MD.
FAU - Sherman, Mark E
AU  - Sherman ME
AD  - Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, 
      Jacksonville, FL.
LA  - eng
SI  - ClinicalTrials.gov/NCT00043472
GR  - U10 CA180822/CA/NCI NIH HHS/United States
GR  - U10 CA180868/CA/NCI NIH HHS/United States
GR  - UG1 CA189867/CA/NCI NIH HHS/United States
GR  - UG1 CA233191/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20220222
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 0 (Gonadal Steroid Hormones)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Estradiol
MH  - Female
MH  - Gonadal Steroid Hormones
MH  - Humans
MH  - *Ovarian Neoplasms/prevention & control
MH  - Postmenopause
MH  - Prospective Studies
MH  - *Salpingo-oophorectomy
PMC - PMC9253062
MID - NIHMS1783348
OTO - NOTNLM
OT  - ovarian volume
OT  - postmenopausal sex steroid hormones
OT  - risk-reducing salpingo-oophorectomy
COIS- CONFLICTS OF INTEREST Phuong Mai, Austin Miller, Amanda Black, Roni Falk, John 
      Boggess, Katherine Tucker, Ashley Stuckey, Gustavo Rodriguez, Cheung Wong, Thomas 
      Amatruda, Susan C. Modesitt, S Diane Yamada, Kristen Bixel, Gretchen Glaser, 
      Peter Rose, Mark Greene and Mark Sherman report no conflicts to report relevant 
      to this study. Kelly Wilkinson would like to report serving as a member of GSK 
      Speaker Bureau for Niraparib from 2019- present.
EDAT- 2022/02/27 06:00
MHDA- 2022/07/08 06:00
PMCR- 2023/07/01
CRDT- 2022/02/26 05:33
PHST- 2021/11/22 00:00 [received]
PHST- 2022/02/14 00:00 [revised]
PHST- 2022/02/17 00:00 [accepted]
PHST- 2022/02/27 06:00 [pubmed]
PHST- 2022/07/08 06:00 [medline]
PHST- 2022/02/26 05:33 [entrez]
PHST- 2023/07/01 00:00 [pmc-release]
AID - S0002-9378(22)00124-7 [pii]
AID - 10.1016/j.ajog.2022.02.022 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 2022 Jul;227(1):61.e1-61.e18. doi: 
      10.1016/j.ajog.2022.02.022. Epub 2022 Feb 22.

PMID- 37499804
OWN - NLM
STAT- MEDLINE
DCOM- 20230824
LR  - 20250103
IS  - 1879-1298 (Electronic)
IS  - 0045-6535 (Linking)
VI  - 339
DP  - 2023 Oct
TI  - Caffeic acid accelerated the Fe(II) reinvention in Fe(III)/PMS system for 
      bisphenol A degradation: Oxidation intermediates and inherent mechanism.
PG  - 139608
LID - S0045-6535(23)01875-1 [pii]
LID - 10.1016/j.chemosphere.2023.139608 [doi]
AB  - Fe(II)-catalyzed PMS process was widely used in the degradation of refractory 
      pollutants in wastewater, while its performance was restricted by the slow 
      regeneration efficiency of Fe(II). Herein, caffeic acid (CFA), a representative 
      of hydroxycinnamic acids, was introduced into Fe(III)/PMS system to accelerate 
      the transformation of Fe(III) to Fe(II) and promote the removal of bisphenol A 
      (BPA). Under optimum condition of 0.1 mM CFA, 0.05 mM Fe(III), and 0.5 mM PMS, 
      almost complete removal of BPA can be achieved within 20 min, which was roughly 
      6.2 times higher than that in Fe(III)/PMS system. As the addition of CFA into 
      Fe(III)/PMS system, pH application range was widened from acidic to alkaline 
      conditions. The reduction and chelation of CFA expedited the Fe(III)/Fe(II) cycle 
      by forming CFA-Fe chelate, thereby facilitating the PMS activation. Based on 
      LC-MS analysis and DFT calculation, the intermediate products of CFA were found 
      to play a decisive role in boosting the regeneration of Fe(II), and the toxicity 
      of these intermediates towards organisms was evaluated by ECOSAR. The 
      alcohol-scavenging and chemical probe tests certified that hydroxyl radical 
      (•OH), sulfate radical (SO(4)(•-)), and Fe(IV) coexisted in Fe(III)/CFA/PMS 
      system, and the second-order reaction rate constants of •OH and SO(4)(•-) reacted 
      with CFA were calculated to be 3.16✕10(9) and 2.30✕10(10) M(-1) s(-1), 
      respectively. Two major degradation pathways of BPA, •OH addition and SO(4)(•-) 
      induced hydroxylation reaction, were proposed. This work presented a novel green 
      phenolic compound that expedited the Fe(II)-catalyzed PMS activation process for 
      the treatment of organic contaminants.
CI  - Copyright © 2023 Elsevier Ltd. All rights reserved.
FAU - Ding, Chunsheng
AU  - Ding C
AD  - College of Civil Engineering, Zhejiang University of Technology, Hangzhou, 
      310023, China; Zhejiang Key Laboratory of Civil Engineering Structures & Disaster 
      Prevention and Mitigation Technology, Hangzhou, 310023, China.
FAU - Song, Xinze
AU  - Song X
AD  - College of Civil Engineering, Zhejiang University of Technology, Hangzhou, 
      310023, China.
FAU - Zheng, Zhongyi
AU  - Zheng Z
AD  - College of Civil Engineering, Zhejiang University of Technology, Hangzhou, 
      310023, China.
FAU - Wang, Hainan
AU  - Wang H
AD  - College of Civil Engineering, Zhejiang University of Technology, Hangzhou, 
      310023, China.
FAU - Pan, Yuqiang
AU  - Pan Y
AD  - College of Civil Engineering, Zhejiang University of Technology, Hangzhou, 
      310023, China.
FAU - Zhang, Hangtian
AU  - Zhang H
AD  - College of Civil Engineering, Zhejiang University of Technology, Hangzhou, 
      310023, China.
FAU - Li, Xueyan
AU  - Li X
AD  - School of Environmental Science and Engineering, Suzhou University of Science and 
      Technology, Suzhou, 215009, China.
FAU - Deng, Jing
AU  - Deng J
AD  - College of Civil Engineering, Zhejiang University of Technology, Hangzhou, 
      310023, China; Zhejiang Key Laboratory of Civil Engineering Structures & Disaster 
      Prevention and Mitigation Technology, Hangzhou, 310023, China. Electronic 
      address: zjut_djing@163.com.
LA  - eng
PT  - Journal Article
DEP - 20230725
PL  - England
TA  - Chemosphere
JT  - Chemosphere
JID - 0320657
RN  - RW57K3X12M (bisphenol A)
RN  - 0 (Ferric Compounds)
RN  - 0 (Peroxides)
RN  - 0 (Water Pollutants, Chemical)
RN  - 0 (Ferrous Compounds)
SB  - IM
MH  - *Ferric Compounds
MH  - Peroxides/chemistry
MH  - *Water Pollutants, Chemical/analysis
MH  - Oxidation-Reduction
MH  - Ferrous Compounds
OTO - NOTNLM
OT  - Bisphenol A
OT  - Caffeic acid
OT  - Degradation
OT  - Fe(Ⅲ)/Fe(Ⅱ) cycle
OT  - Peroxymonosulfate
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/07/28 01:08
MHDA- 2023/08/24 06:42
CRDT- 2023/07/27 19:14
PHST- 2023/04/29 00:00 [received]
PHST- 2023/06/24 00:00 [revised]
PHST- 2023/07/20 00:00 [accepted]
PHST- 2023/08/24 06:42 [medline]
PHST- 2023/07/28 01:08 [pubmed]
PHST- 2023/07/27 19:14 [entrez]
AID - S0045-6535(23)01875-1 [pii]
AID - 10.1016/j.chemosphere.2023.139608 [doi]
PST - ppublish
SO  - Chemosphere. 2023 Oct;339:139608. doi: 10.1016/j.chemosphere.2023.139608. Epub 
      2023 Jul 25.

PMID- 36249769
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221019
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - Sagacious confucius' pillow elixir ameliorates Dgalactose induced cognitive 
      injury in mice via estrogenic effects and synaptic plasticity.
PG  - 971385
LID - 10.3389/fphar.2022.971385 [doi]
LID - 971385
AB  - Alzheimer's disease (AD) is a growing concern in modern society, and there is 
      currently a lack of effective therapeutic drugs. Sagacious Confucius' Pillow 
      Elixir (SCPE) has been studied for the treatment of neurodegenerative diseases 
      such as AD. This study aimed to reveal the key components and mechanisms of 
      SCPE's anti-AD effect by combining Ultra-high Performance Liquid 
      Chromatography-electrostatic field Orbitrap combined high-resolution Mass 
      Spectrometry (UPLC-LTQ/Orbitrap-MS) with a network pharmacology approach. And the 
      mechanism was verified by in vivo experiments. Based on UPLC-LTQ/Orbitrap-MS 
      technique identified 9 blood components from rat serum containing SCPE, 
      corresponding to 113 anti-AD targets, and 15 of the 113 targets had high 
      connectivity. KEGG pathway enrichment analysis showed that estrogen signaling 
      pathway and synaptic signaling pathway were the most significantly enriched 
      pathways in SCPE anti-AD, which has been proved by in vivo experiments. SCPE can 
      exert estrogenic effects in the brain by increasing the amount of estrogen in the 
      brain and the expression of ERα receptors. SCPE can enhance the synaptic 
      structure plasticity by promoting the release of brain-derived neurotrophic 
      factor (BDNF) secretion and improving actin polymerization and coordinates 
      cofilin activity. In addition, SCPE also enhances synaptic functional plasticity 
      by increasing the density of postsynaptic densified 95 (PSD95) proteins and the 
      expression of functional receptor AMPA. SCPE is effective for treatment of AD and 
      the mechanism is related to increasing estrogenic effects and improving synaptic 
      plasticity. Our study revealed the synergistic effect of SCPE at the system level 
      and showed that SCPE exhibits anti-AD effects in a multi-component, multi-target 
      and multi-pathway manner. All these provide experimental support for the clinical 
      application and drug development of SCPE in the prevention and treatment of AD.
CI  - Copyright © 2022 Zhao, Lei, Wang, Xue, Zhao, Xu, Zhang, Liu, Geng, Xu and Zhang.
FAU - Zhao, De-Ping
AU  - Zhao DP
AD  - College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, 
      Heilongjiang, China.
FAU - Lei, Xia
AU  - Lei X
AD  - Institute of Traditional Chinese Medicine, Wuxi Traditional Chinese Medicine 
      Hospital, Jiangsu, Wuxi, China.
FAU - Wang, Yue-Ying
AU  - Wang YY
AD  - College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, 
      Heilongjiang, China.
FAU - Xue, Ao
AU  - Xue A
AD  - College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, 
      Heilongjiang, China.
FAU - Zhao, Chen-Yu
AU  - Zhao CY
AD  - College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, 
      Heilongjiang, China.
FAU - Xu, Yan-Ming
AU  - Xu YM
AD  - College of Jiamusi, Heilongjiang University of Chinese Medicine, Jiamusi, 
      Heilongjiang, China.
FAU - Zhang, Yue
AU  - Zhang Y
AD  - College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, 
      Heilongjiang, China.
FAU - Liu, Guo-Liang
AU  - Liu GL
AD  - College of Jiamusi, Heilongjiang University of Chinese Medicine, Jiamusi, 
      Heilongjiang, China.
FAU - Geng, Fang
AU  - Geng F
AD  - Key Laboratory of Photochemistry Biomaterials and Energy Storage Materials of 
      Heilongjiang Province, College of Chemistry and Chemical Engineering, Harbin 
      Normal University, Harbin, Heilongjiang, China.
FAU - Xu, Hong-Dan
AU  - Xu HD
AD  - College of Jiamusi, Heilongjiang University of Chinese Medicine, Jiamusi, 
      Heilongjiang, China.
AD  - College of Pharmacy, Wuxi Higher Health Vocational Technology School, Wuxi, 
      Jiangsu, China.
FAU - Zhang, Ning
AU  - Zhang N
AD  - College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, 
      Heilongjiang, China.
AD  - College of Jiamusi, Heilongjiang University of Chinese Medicine, Jiamusi, 
      Heilongjiang, China.
LA  - eng
PT  - Journal Article
DEP - 20220928
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9555387
OTO - NOTNLM
OT  - Alzheimer’s disease
OT  - Sagacious Confucius’ Pillow Elixir
OT  - blood component
OT  - estrogen receptor
OT  - synaptic plasticity
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/10/18 06:00
MHDA- 2022/10/18 06:01
PMCR- 2022/09/28
CRDT- 2022/10/17 05:28
PHST- 2022/06/17 00:00 [received]
PHST- 2022/08/23 00:00 [accepted]
PHST- 2022/10/17 05:28 [entrez]
PHST- 2022/10/18 06:00 [pubmed]
PHST- 2022/10/18 06:01 [medline]
PHST- 2022/09/28 00:00 [pmc-release]
AID - 971385 [pii]
AID - 10.3389/fphar.2022.971385 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Sep 28;13:971385. doi: 10.3389/fphar.2022.971385. 
      eCollection 2022.

PMID- 30067244
OWN - NLM
STAT- MEDLINE
DCOM- 20181004
LR  - 20250103
IS  - 1477-8920 (Print)
IS  - 1477-8920 (Linking)
VI  - 16
IP  - 4
DP  - 2018 Aug
TI  - Investigation of estrogen activity in the raw and treated waters of riverbank 
      infiltration using a yeast estrogen screen and chemical analysis.
PG  - 635-645
LID - 10.2166/wh.2018.049 [doi]
AB  - Exposure to various endocrine disrupting chemicals (EDCs) can lead to adverse 
      effects on reproductive physiology and behavior in both animals and humans. An 
      adequate strategy for the prevention of environmental contamination and 
      eliminating the effects of them must be established. Chemicals with estrogenic 
      activity were selected, and the effectiveness of their removal during the 
      purification processes in two drinking water treatment plants (DWTPs) using 
      riverbank infiltrated water was determined. Thirty-five water samples in two 
      sampling campaigns throughout different seasons were collected and screened with 
      a yeast estrogen test; furthermore, bisphenol A (BPA), 17ß-estradiol (E2) and 
      ethinyl-estradiol (EE2) content were measured using high-performance liquid 
      chromatography-mass spectrometry (HPLC-MS). Our results confirm that estrogenic 
      compounds are present in sewage effluents and raw surface river water of DWTPs. 
      Very low estrogen activity and pg/L concentrations of BPA and E2 were detected 
      during drinking water processing and occasionally in drinking water. Based on 
      this study, applied riverbank filtration and water treatment procedures do not 
      seem to be suitable for the total removal of estrogenic chemicals. Local 
      contamination could play an important role in increasing the BPA content of the 
      drinking water at the consumer endpoint.
FAU - Plutzer, Judit
AU  - Plutzer J
AD  - National Public Health Institute, Budapest, Hungary E-mail: plujud@yahoo.com.
FAU - Avar, Péter
AU  - Avar P
AD  - MTA-ÖK BLI NAP_B Adaptive Neuroethology, Department of Experimental Zoology, 
      Balaton Limnological Institute, Center for Ecological Research, Tihany, Hungary; 
      NAP-B-Molecular Neuroendocrinology Research Group, Center for Neuroscience, 
      Szentágothai Research Center, Institute of Physiology, Medical School, University 
      of Pécs, Pécs, Hungary.
FAU - Keresztes, Dóra
AU  - Keresztes D
AD  - National Public Health Institute, Budapest, Hungary E-mail: plujud@yahoo.com.
FAU - Sári, Zsófia
AU  - Sári Z
AD  - National Public Health Institute, Budapest, Hungary E-mail: plujud@yahoo.com.
FAU - Kiss-Szarvák, Ildikó
AU  - Kiss-Szarvák I
AD  - National Public Health Institute, Budapest, Hungary E-mail: plujud@yahoo.com.
FAU - Vargha, Márta
AU  - Vargha M
AD  - National Public Health Institute, Budapest, Hungary E-mail: plujud@yahoo.com.
FAU - Maász, Gábor
AU  - Maász G
AD  - MTA-ÖK BLI NAP_B Adaptive Neuroethology, Department of Experimental Zoology, 
      Balaton Limnological Institute, Center for Ecological Research, Tihany, Hungary.
FAU - Pirger, Zsolt
AU  - Pirger Z
AD  - MTA-ÖK BLI NAP_B Adaptive Neuroethology, Department of Experimental Zoology, 
      Balaton Limnological Institute, Center for Ecological Research, Tihany, Hungary.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Water Health
JT  - Journal of water and health
JID - 101185420
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Endocrine Disruptors)
RN  - 0 (Phenols)
RN  - 0 (Water Pollutants, Chemical)
RN  - 4TI98Z838E (Estradiol)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - Benzhydryl Compounds/chemistry/*pharmacology
MH  - Endocrine Disruptors/*chemistry/pharmacology
MH  - Estradiol/chemistry/*pharmacology
MH  - Phenols/chemistry/*pharmacology
MH  - Rivers/*chemistry
MH  - Water Pollutants, Chemical/chemistry/*pharmacology
MH  - Yeasts/*drug effects
EDAT- 2018/08/02 06:00
MHDA- 2018/10/05 06:00
CRDT- 2018/08/02 06:00
PHST- 2018/08/02 06:00 [entrez]
PHST- 2018/08/02 06:00 [pubmed]
PHST- 2018/10/05 06:00 [medline]
AID - 10.2166/wh.2018.049 [doi]
PST - ppublish
SO  - J Water Health. 2018 Aug;16(4):635-645. doi: 10.2166/wh.2018.049.

PMID- 27497082
OWN - NLM
STAT- MEDLINE
DCOM- 20170508
LR  - 20250103
IS  - 1096-0953 (Electronic)
IS  - 0013-9351 (Print)
IS  - 0013-9351 (Linking)
VI  - 151
DP  - 2016 Nov
TI  - Bisphenol A exposure and symptoms of anxiety and depression among inner city 
      children at 10-12 years of age.
PG  - 195-202
LID - S0013-9351(16)30315-2 [pii]
LID - 10.1016/j.envres.2016.07.028 [doi]
AB  - BACKGROUND: Experimental and epidemiological studies suggest that gestational 
      exposure to Bisphenol A (BPA), an ubiquitous endocrine disrupting chemical, may 
      lead to neurobehavioral problems in childhood; however, not all results have been 
      consistent. We previously reported a positive association between prenatal BPA 
      exposure and symptoms of anxiety/depression reported by the mother at child age 
      7-9 years in boys, but not girls. OBJECTIVES: Here, in the same birth cohort, we 
      investigated the association of prenatal BPA exposure with symptoms of depression 
      and anxiety self-reported by the 10-12 year olds, hypothesizing that we would 
      observe sex-specific differences in anxiety and depressive symptoms. METHODS: 
      African-American and Dominican women living in Northern Manhattan and their 
      children were followed from mother's pregnancy through children's age 10-12 
      years. BPA was quantified in maternal urine collected during the third trimester 
      of pregnancy and in child urine collected at ages 3 and 5 years. Children were 
      evaluated using the Revised Children's Manifest Anxiety Scale (RCMAS) and 
      Children's Depression Rating Scale (CDRS). We compared the children in the 
      highest tertile of BPA concentration to those in the lower two tertiles. 
      Associations between behavior and prenatal (maternal) BPA concentration or 
      postnatal (child) BPA concentration were assessed in regression models stratified 
      by sex. RESULTS: Significant positive associations between prenatal BPA and 
      symptoms of depression and anxiety were observed among boys. Postnatal BPA 
      exposure was not significantly associated with outcomes. There was substantial 
      co-occurrence of anxiety and depressive symptoms in this sample. CONCLUSION: 
      These results provide evidence that prenatal BPA exposure is associated with more 
      symptoms of anxiety and depression in boys but not in girls at age 10-12 years.
CI  - Copyright © 2016 Elsevier Inc. All rights reserved.
FAU - Perera, Frederica
AU  - Perera F
AD  - Department of Environmental Health Sciences, Mailman School of Public Health, 
      Columbia University, 722 W. 168th St., New York, NY 10032, USA; Columbia Center 
      for Children's Environmental Health, Columbia University, 722 W. 168th St., New 
      York, NY 10032, USA. Electronic address: fpp1@columbia.edu.
FAU - Nolte, Emily L Roen
AU  - Nolte ELR
AD  - Department of Environmental Health Sciences, Mailman School of Public Health, 
      Columbia University, 722 W. 168th St., New York, NY 10032, USA; Columbia Center 
      for Children's Environmental Health, Columbia University, 722 W. 168th St., New 
      York, NY 10032, USA.
FAU - Wang, Ya
AU  - Wang Y
AD  - Columbia Center for Children's Environmental Health, Columbia University, 722 W. 
      168th St., New York, NY 10032, USA; Department of Biostatistics, Mailman School 
      of Public Health, Columbia University, 722 W. 168th St., New York, NY 10032, USA.
FAU - Margolis, Amy E
AU  - Margolis AE
AD  - Columbia Center for Children's Environmental Health, Columbia University, 722 W. 
      168th St., New York, NY 10032, USA; Division of Child & Adolescent Psychiatry and 
      the Center for Developmental Neuropsychiatry, Department of Psychiatry, The New 
      York State Psychiatric Institute and the College of Physicians and Surgeons, 
      Columbia University, 1051 Riverside Drive, New York, NY 10032, USA.
FAU - Calafat, Antonia M
AU  - Calafat AM
AD  - National Center for Environmental Health, Centers for Disease Control and 
      Prevention, 4770 Buford Hwy, MS F17, Atlanta, GA 30341, USA.
FAU - Wang, Shuang
AU  - Wang S
AD  - Columbia Center for Children's Environmental Health, Columbia University, 722 W. 
      168th St., New York, NY 10032, USA; Department of Biostatistics, Mailman School 
      of Public Health, Columbia University, 722 W. 168th St., New York, NY 10032, USA.
FAU - Garcia, Wanda
AU  - Garcia W
AD  - Columbia Center for Children's Environmental Health, Columbia University, 722 W. 
      168th St., New York, NY 10032, USA; The Heilbrunn Department of Population and 
      Family Health, Columbia University, 60 Haven Avenue, New York, NY 10032, USA.
FAU - Hoepner, Lori A
AU  - Hoepner LA
AD  - Department of Environmental Health Sciences, Mailman School of Public Health, 
      Columbia University, 722 W. 168th St., New York, NY 10032, USA; Columbia Center 
      for Children's Environmental Health, Columbia University, 722 W. 168th St., New 
      York, NY 10032, USA.
FAU - Peterson, Bradley S
AU  - Peterson BS
AD  - Institute for the Developing Mind, Children's Hospital Los Angeles and Keck 
      School of Medicine at the University of Southern California, USA.
FAU - Rauh, Virginia
AU  - Rauh V
AD  - Columbia Center for Children's Environmental Health, Columbia University, 722 W. 
      168th St., New York, NY 10032, USA; The Heilbrunn Department of Population and 
      Family Health, Columbia University, 60 Haven Avenue, New York, NY 10032, USA.
FAU - Herbstman, Julie
AU  - Herbstman J
AD  - Department of Environmental Health Sciences, Mailman School of Public Health, 
      Columbia University, 722 W. 168th St., New York, NY 10032, USA; Columbia Center 
      for Children's Environmental Health, Columbia University, 722 W. 168th St., New 
      York, NY 10032, USA.
LA  - eng
GR  - P01 ES009600/ES/NIEHS NIH HHS/United States
GR  - R01 ES008977/ES/NIEHS NIH HHS/United States
GR  - P30 ES009089/ES/NIEHS NIH HHS/United States
GR  - R01 DA027100/DA/NIDA NIH HHS/United States
GR  - R01 ES015579/ES/NIEHS NIH HHS/United States
PT  - Journal Article
DEP - 20160803
PL  - Netherlands
TA  - Environ Res
JT  - Environmental research
JID - 0147621
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Phenols)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - Adult
MH  - Black or African American
MH  - Anxiety/*chemically induced
MH  - Benzhydryl Compounds/*toxicity
MH  - Child
MH  - Depression/*chemically induced
MH  - Dominican Republic/ethnology
MH  - Female
MH  - Humans
MH  - Male
MH  - New York City
MH  - Phenols/*toxicity
MH  - Pregnancy
MH  - *Prenatal Exposure Delayed Effects
MH  - Urban Population
PMC - PMC5071142
MID - NIHMS808270
OTO - NOTNLM
OT  - Bisphenol A
OT  - Child behavior
OT  - Prenatal
OT  - Sex-specific
EDAT- 2016/10/21 06:00
MHDA- 2017/05/10 06:00
PMCR- 2017/11/01
CRDT- 2016/08/07 06:00
PHST- 2016/02/24 00:00 [received]
PHST- 2016/06/28 00:00 [revised]
PHST- 2016/07/19 00:00 [accepted]
PHST- 2016/10/21 06:00 [pubmed]
PHST- 2017/05/10 06:00 [medline]
PHST- 2016/08/07 06:00 [entrez]
PHST- 2017/11/01 00:00 [pmc-release]
AID - S0013-9351(16)30315-2 [pii]
AID - 10.1016/j.envres.2016.07.028 [doi]
PST - ppublish
SO  - Environ Res. 2016 Nov;151:195-202. doi: 10.1016/j.envres.2016.07.028. Epub 2016 
      Aug 3.

PMID- 31009049
OWN - NLM
STAT- MEDLINE
DCOM- 20200527
LR  - 20200527
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Print)
IS  - 0021-972X (Linking)
VI  - 104
IP  - 10
DP  - 2019 Oct 1
TI  - Plasma Free Cortisol in States of Normal and Altered Binding Globulins: 
      Implications for Adrenal Insufficiency Diagnosis.
PG  - 4827-4836
LID - 10.1210/jc.2019-00022 [doi]
AB  - CONTEXT: Accurate diagnosis of adrenal insufficiency is critical because there 
      are risks associated with overdiagnosis and underdiagnosis. Data using liquid 
      chromatography tandem mass spectrometry (LC/MS/MS) free cortisol (FC) assays in 
      states of high or low cortisol-binding globulin (CBG) levels, including 
      cirrhosis, critical illness, and oral estrogen use, are needed. DESIGN: 
      Cross-sectional. OBJECTIVE: Determine the relationship between CBG and albumin as 
      well as total cortisol (TC) and FC in states of normal and abnormal CBG. 
      Establish the FC level by LC/MS/MS that best predicts TC of <18 μg/dL (497 
      nmol/L) (standard adrenal insufficiency diagnostic cutoff) in healthy 
      individuals. SUBJECTS: This study included a total of 338 subjects in four 
      groups: healthy control (HC) subjects (n = 243), patients with cirrhosis (n = 
      38), intensive care unit patients (ICU) (n = 26), and oral contraceptive (OCP) 
      users (n = 31). MAIN OUTCOME MEASURE(S): FC and TC by LC/MS/MS, albumin by 
      spectrophotometry, and CBG by ELISA. RESULTS: TC correlated with FC in the ICU (R 
      = 0.91), HC (R = 0.90), cirrhosis (R = 0.86), and OCP (R = 0.70) groups (all P < 
      0.0001). In receiver operator curve analysis in the HC group, FC of 0.9 μg/dL 
      (24.8 nmol/L) predicted TC of <18 μg/dL (497 nmol/L; 98% sensitivity, 91% 
      specificity; AUC, 0.98; P < 0.0001). Decreasing the cutoff to 0.7 μg/dL led to a 
      small decrease in sensitivity (92%) with similar specificity (91%). CONCLUSIONS: 
      A cutoff FC of <0.9 μg/dL (25 nmol/L) in this LC/MS/MS assay predicts TC of <18 
      μg/dL (497 nmol/L) with excellent sensitivity and specificity. This FC cutoff may 
      be helpful in ruling out adrenal insufficiency in patients with binding globulin 
      derangements.
CI  - Copyright © 2019 Endocrine Society.
FAU - Dichtel, Laura E
AU  - Dichtel LE
AD  - Neuroendocrine Unit, Massachusetts General Hospital, Boston, Massachusetts.
AD  - Harvard Medical School, Boston, Massachusetts.
FAU - Schorr, Melanie
AU  - Schorr M
AD  - Neuroendocrine Unit, Massachusetts General Hospital, Boston, Massachusetts.
AD  - Harvard Medical School, Boston, Massachusetts.
FAU - Loures de Assis, Claudia
AU  - Loures de Assis C
AD  - Neuroendocrine Unit, Massachusetts General Hospital, Boston, Massachusetts.
FAU - Rao, Elizabeth M
AU  - Rao EM
AD  - Neuroendocrine Unit, Massachusetts General Hospital, Boston, Massachusetts.
FAU - Sims, Jessica K
AU  - Sims JK
AD  - Neuroendocrine Unit, Massachusetts General Hospital, Boston, Massachusetts.
FAU - Corey, Kathleen E
AU  - Corey KE
AD  - Harvard Medical School, Boston, Massachusetts.
AD  - Division of Gastroenterology, Massachusetts General Hospital, Boston, 
      Massachusetts.
FAU - Kohli, Puja
AU  - Kohli P
AD  - Harvard Medical School, Boston, Massachusetts.
AD  - Division of Pulmonology and Critical Care Medicine, Massachusetts General 
      Hospital, Boston, Massachusetts.
FAU - Sluss, Patrick M
AU  - Sluss PM
AD  - Harvard Medical School, Boston, Massachusetts.
AD  - Clinical Pathology, Massachusetts General Hospital, Boston, Massachusetts.
FAU - McPhaul, Michael J
AU  - McPhaul MJ
AD  - Endocrinology, Quest Diagnostics Nichols Institute, San Juan Capistrano, 
      California.
FAU - Miller, Karen K
AU  - Miller KK
AD  - Neuroendocrine Unit, Massachusetts General Hospital, Boston, Massachusetts.
AD  - Harvard Medical School, Boston, Massachusetts.
LA  - eng
GR  - K23 DK113220/DK/NIDDK NIH HHS/United States
GR  - K23 DK115903/DK/NIDDK NIH HHS/United States
GR  - K24 HL092902/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Carrier Proteins)
RN  - 0 (Contraceptives, Oral, Hormonal)
RN  - 0 (Estrogens)
RN  - 0 (Globulins)
RN  - 0 (cortisol binding globulin)
RN  - WI4X0X7BPJ (Hydrocortisone)
SB  - IM
MH  - Administration, Oral
MH  - Adrenal Insufficiency/blood/*diagnosis
MH  - Adult
MH  - Aged
MH  - Carrier Proteins/*blood
MH  - Chromatography, Liquid
MH  - Cohort Studies
MH  - *Contraceptives, Oral, Hormonal/administration & dosage/adverse effects
MH  - *Critical Illness
MH  - Cross-Sectional Studies
MH  - Estrogens/*administration & dosage/blood
MH  - Female
MH  - Globulins/analysis/metabolism
MH  - Hormonal Contraception/adverse effects
MH  - Hormone Replacement Therapy/adverse effects/methods
MH  - Humans
MH  - Hydrocortisone/*blood
MH  - Liver Cirrhosis/*blood
MH  - Male
MH  - Middle Aged
MH  - Pituitary-Adrenal Function Tests/standards
MH  - Sensitivity and Specificity
MH  - Tandem Mass Spectrometry
MH  - Young Adult
PMC - PMC6735741
EDAT- 2019/04/23 06:00
MHDA- 2020/05/28 06:00
PMCR- 2020/04/22
CRDT- 2019/04/23 06:00
PHST- 2019/01/04 00:00 [received]
PHST- 2019/04/16 00:00 [accepted]
PHST- 2019/04/23 06:00 [pubmed]
PHST- 2020/05/28 06:00 [medline]
PHST- 2019/04/23 06:00 [entrez]
PHST- 2020/04/22 00:00 [pmc-release]
AID - 5475551 [pii]
AID - jcem_201900022 [pii]
AID - 10.1210/jc.2019-00022 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2019 Oct 1;104(10):4827-4836. doi: 
      10.1210/jc.2019-00022.

PMID- 30731088
OWN - NLM
STAT- MEDLINE
DCOM- 20190318
LR  - 20191210
IS  - 1873-3492 (Electronic)
IS  - 0009-8981 (Linking)
VI  - 492
DP  - 2019 May
TI  - Development and validation of a LC-MS/MS assay for quantification of serum 
      estradiol using calibrators with values assigned by the CDC reference measurement 
      procedure.
PG  - 45-49
LID - S0009-8981(19)30055-5 [pii]
LID - 10.1016/j.cca.2019.02.003 [doi]
AB  - BACKGROUND: Estradiol was historically measured by gas chromatography-mass 
      spectrometry before development of immunoassays. Although immunoassays were fast 
      requiring low sample volume, they had specificity issues. More recently, liquid 
      chromatography-tandem mass spectrometry became the methodology of choice for 
      estradiol quantitation in serum. However, one thing all methods have in common is 
      lack of standardization. METHODS: A LC-MS/MS assay was developed and clinically 
      validated using calibrators with concentrations assigned by a Reference 
      Measurement Procedure in an effort to increase accuracy of calibration. RESULTS: 
      Two hundred microliters of serum was subjected to liquid-liquid extraction using 
      hexane:ethyl acetate followed by derivatization using dansyl chloride. Gradient 
      elution had a run time of 6.5 min. The analytical measurement range was 2 to 
      1000 pg/mL with between-run imprecision of <10%. Method comparisons with two 
      reference laboratories showed acceptable bias and so did Reference Materials from 
      the European Commission Joint Research Center, Institute for Reference Materials 
      and Measurements and the College of American Pathologist Accuracy-Based survey 
      samples. CONCLUSIONS: A LC-MS/MS assay for serum estradiol was developed and 
      clinically validated with calibrator concentrations assigned by the CDC RMP to 
      help improve accuracy.
CI  - Copyright © 2019 Elsevier B.V. All rights reserved.
FAU - Dowis, Justin
AU  - Dowis J
AD  - University of California San Francisco Medical Center, San Francisco, CA, United 
      States.
FAU - Woroniecki, Witold
AU  - Woroniecki W
AD  - SafeBridge Consultants, Inc., Mountain View, CA, United States.
FAU - French, Deborah
AU  - French D
AD  - Department of Laboratory Medicine, University of California San Francisco, San 
      Francisco, CA, United States. Electronic address: deborah.french@ucsf.edu.
LA  - eng
PT  - Journal Article
PT  - Validation Study
DEP - 20190204
PL  - Netherlands
TA  - Clin Chim Acta
JT  - Clinica chimica acta; international journal of clinical chemistry
JID - 1302422
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Blood Chemical Analysis/*standards
MH  - Calibration
MH  - *Centers for Disease Control and Prevention, U.S.
MH  - Chromatography, Liquid/*standards
MH  - Estradiol/*blood
MH  - Humans
MH  - Linear Models
MH  - Reference Standards
MH  - Tandem Mass Spectrometry/*standards
MH  - United States
OTO - NOTNLM
OT  - Estradiol
OT  - LC-MS/MS
OT  - Standardization
OT  - Steroid hormones
EDAT- 2019/02/08 06:00
MHDA- 2019/03/19 06:00
CRDT- 2019/02/08 06:00
PHST- 2019/01/08 00:00 [received]
PHST- 2019/01/31 00:00 [revised]
PHST- 2019/02/02 00:00 [accepted]
PHST- 2019/02/08 06:00 [pubmed]
PHST- 2019/03/19 06:00 [medline]
PHST- 2019/02/08 06:00 [entrez]
AID - S0009-8981(19)30055-5 [pii]
AID - 10.1016/j.cca.2019.02.003 [doi]
PST - ppublish
SO  - Clin Chim Acta. 2019 May;492:45-49. doi: 10.1016/j.cca.2019.02.003. Epub 2019 Feb 
      4.

PMID- 29709864
OWN - NLM
STAT- MEDLINE
DCOM- 20190122
LR  - 20221207
IS  - 1879-1026 (Electronic)
IS  - 0048-9697 (Linking)
VI  - 636
DP  - 2018 Sep 15
TI  - Identification, contribution, and estrogenic activity of potential EDCs in a 
      river receiving concentrated livestock effluent in Southern Taiwan.
PG  - 464-476
LID - S0048-9697(18)31189-6 [pii]
LID - 10.1016/j.scitotenv.2018.04.031 [doi]
AB  - We assessed 22 selected endocrine-disrupting compounds (EDCs) and other emerging, 
      potentially endocrine-active compounds with estrogenic activity from the waters 
      of the Wuluo River, southern Taiwan. This watershed receives high amounts of 
      livestock and untreated household wastewaters. The river is surrounded by 
      concentrated animal feedlot operations (CAFOs). River water samples were analyzed 
      for selected compounds by liquid chromatography-tandem mass spectrometry 
      (LC-MS/MS), T47D-KBluc reporter gene assay, and E-screen cell proliferation in 
      vitro bioassay. Total concentrations of ∑alkylphenolic compounds (bisphenol A, 
      4-nonylphenol, t-nonylphenol, octylphenol, nonylphenol mono-ethoxylate, 
      nonylphenol di-ethoxylate) were much higher than ∑estrogens (estrone, 17 
      β-estradiol, estriol, 17ß-ethynylestradiol, diethylstilbestrol), ∑preservatives 
      (methyl paraben, ethyl paraben, propyl paraben, butyl paraben), ∑UV-filters 
      (benzophenone, methyl benzylidene camphor, benzophenone-3), ∑antimicrobials 
      (triclocarben, triclosan, chloroxylenol), and an insect repellent 
      (diethyltoluamide) over four seasonal sampling periods. The highest concentration 
      was found for bisphenol A with a mean of 302 ng/L. However, its contribution to 
      estrogenic activity was not significant due to its relatively low estrogenic 
      potency. Lower detection rates were found for BP, EE2, TCS, and PCMX, while DES 
      and EP were not detected. E1 and E2 levels in raw water samples were 50% higher 
      than the predicted no-effect concentrations (PNEC) for aquatic organisms of 6 and 
      2 ng/L, respectively. The potency of estrogenic activity ranged from 11.7 to 
      190.1 ng/L E2(T47D-Kbluc) and 6.63 to 84.5 ng/L E2(E-Screen) for extracted 
      samples. Importantly, estrone contributed 50% of the overall activity in 60% and 
      44% of the samples based on T47D-KBluc and MCF-7 bioassays, followed by 17 
      ß-estradiol, highlighting the importance of total steroid estrogen loading. This 
      study demonstrates that the estrogenic activity of target chemicals was 
      comparable to levels found in different countries worldwide. More intense 
      wastewater treatment is required in areas of intensive agriculture in order to 
      prevent adverse impacts on the ambient environment and aquatic ecosystems.
CI  - Copyright © 2018 Elsevier B.V. All rights reserved.
FAU - Liu, Yung-Yu
AU  - Liu YY
AD  - Department of Environmental Science and Engineering, National Pingtung University 
      of Science and Technology, Pingtung 91201, Taiwan, ROC.
FAU - Lin, Yi-Siou
AU  - Lin YS
AD  - Department of Environmental Science and Engineering, National Pingtung University 
      of Science and Technology, Pingtung 91201, Taiwan, ROC.
FAU - Yen, Chia-Hung
AU  - Yen CH
AD  - Department of Biological Science and Technology, National Pingtung University of 
      Science and Technology, Pingtung 91201, Taiwan, ROC.
FAU - Miaw, Chang-Ling
AU  - Miaw CL
AD  - Department of Nursing, Tajen University, Pingtung 90741, Taiwan, ROC.
FAU - Chen, Ting-Chien
AU  - Chen TC
AD  - Department of Environmental Science and Engineering, National Pingtung University 
      of Science and Technology, Pingtung 91201, Taiwan, ROC.
FAU - Wu, Meng-Chun
AU  - Wu MC
AD  - Department of Environmental Science and Engineering, National Pingtung University 
      of Science and Technology, Pingtung 91201, Taiwan, ROC.
FAU - Hsieh, Chi-Ying
AU  - Hsieh CY
AD  - Department of Environmental Science and Engineering, National Pingtung University 
      of Science and Technology, Pingtung 91201, Taiwan, ROC. Electronic address: 
      chiying@mail.npust.edu.tw.
LA  - eng
PT  - Journal Article
DEP - 20180427
PL  - Netherlands
TA  - Sci Total Environ
JT  - The Science of the total environment
JID - 0330500
RN  - 0 (Endocrine Disruptors)
RN  - 0 (Estrogens)
RN  - 0 (Waste Water)
RN  - 0 (Water Pollutants, Chemical)
SB  - IM
MH  - *Animal Husbandry
MH  - Animals
MH  - Endocrine Disruptors/*analysis
MH  - *Environmental Monitoring
MH  - Estrogens
MH  - Livestock
MH  - Rivers
MH  - Taiwan
MH  - Wastewater/*analysis/statistics & numerical data
MH  - Water Pollutants, Chemical/*analysis
OTO - NOTNLM
OT  - Alkylphenolic compounds
OT  - E1 and E2 levels
OT  - EDCs
OT  - LC-MS/MS
OT  - Livestock discharge
OT  - MCF-7 bioassays
OT  - T47D-KBluc
EDAT- 2018/05/02 06:00
MHDA- 2019/01/23 06:00
CRDT- 2018/05/01 06:00
PHST- 2018/01/31 00:00 [received]
PHST- 2018/04/02 00:00 [revised]
PHST- 2018/04/03 00:00 [accepted]
PHST- 2018/05/02 06:00 [pubmed]
PHST- 2019/01/23 06:00 [medline]
PHST- 2018/05/01 06:00 [entrez]
AID - S0048-9697(18)31189-6 [pii]
AID - 10.1016/j.scitotenv.2018.04.031 [doi]
PST - ppublish
SO  - Sci Total Environ. 2018 Sep 15;636:464-476. doi: 10.1016/j.scitotenv.2018.04.031. 
      Epub 2018 Apr 27.

PMID- 34630615
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211012
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2021
DP  - 2021
TI  - Estrogenic and Antioxidant Activities of Pterocarpus soyauxii (Fabaceae) 
      Heartwood Aqueous Extract in Bilateral Oophorectomized Wistar Rat.
PG  - 6759000
LID - 10.1155/2021/6759000 [doi]
LID - 6759000
AB  - Phytoestrogens are used to ease postmenopausal symptoms, a property probably due 
      to estrogenic and antioxidant effects. Pterocarpus soyauxii (P. soyauxii) is 
      empirically used in Cameroon to treat among others primary and secondary 
      amenorrhea. The aim of this study is to evaluate estrogenic and antioxidant 
      activities of P. soyauxii heartwood aqueous extract in bilateral oophorectomized 
      Wistar rats. Firstly, a characterization of the extract was carried out. For 
      that, flavonoids, phenols, and tannins levels in P. soyauxii extract were 
      evaluated by colorimetric assays and UHPLC-MS analysis was realized. In vitro 
      antioxidant analysis of P. soyauxii was conducted using DPPH, ABTS, and FRAP 
      assays. Secondly, 2 sets of pharmacologic tests were carried out. The results 
      revealed that P. soyauxii aqueous extract contains, respectively, 
      229.42 ± 3.62 mg EAG/g, 63.42 ± 2.16 mg EQ/g, and 27.88 ± 0.23 mg ETA/g of 
      polyphenols, flavonoids, and tannins. UHPLC-MS enabled identifying seven 
      components including mono(2-ethylhexyl) phthalate, cembrene, 
      3',5'-dimethoxy-4-stilbenol, and linoleic acid. DPPH, ABTS, and FRAP assays 
      revealed that P. soyauxii extract possessed a high antioxidant activity with 
      IC(50) value of 730.20 µg/mL, 892.90 µg/mL, and 765.75 mEAG/g of extract, 
      respectively. In the uterotrophic assay, P. soyauxii extract induced significant 
      increase of fresh uterine weight, uterine and vaginal epithelial size, and 
      mammary glands differentiation compared to Ovx control. In the postmenopausal 
      model, compared to the sham control, vagina and uterine dystrophies were observed 
      in Ovx rats treated with distilled water. P. soyauxii aqueous extract expressed 
      estrogenic-like effects on vagina and did not affect uterine epithelial height 
      compared with vehicle groups. On the back of these vaginotrophic effects, the 
      extract displayed antiatherogenic properties by reducing (p < 0.001) AI and LDL 
      cholesterol level as compared to Ovx control group. The extract at 200 mg/kg 
      significantly prevented the increase of MDA (p < 0.01) level and decreased 
      nitrites (p < 0.001) and GSH (p < 0.01) levels compared to Ovx rats. These 
      beneficial effects are related at least in part to the presence of compound such 
      as mono(2-ethylhexyl) phthalate, 3',5'-dimethoxy-4-stilbenol, and linoleic acid. 
      Overall, P. soyauxii aqueous extract exhibits estrogenic and antioxidant effects 
      which can inhibit postmenopausal symptoms by providing vaginal stratification, 
      improving lipid profile and insulin sensitivity, and reducing oxidative stress 
      without side effects on the endometrium and mammary gland in 84-day Ovx rats.
CI  - Copyright © 2021 Yolande Sandrine Mengue Ngadena et al.
FAU - Mengue Ngadena, Yolande Sandrine
AU  - Mengue Ngadena YS
AD  - Department of Psychology, Faculty of Arts, Letters and Social Science, University 
      of Yaoundé 1, P.O. Box 812, Yaoundé, Cameroon.
AD  - Department of Animal Biology and Physiology, Laboratory of Animal Physiology, 
      Faculty of Science, University of Yaoundé 1, P.O. Box 812, Yaoundé, Cameroon.
FAU - Owona, Pascal Emmanuel
AU  - Owona PE
AD  - Department of Animal Biology and Physiology, Laboratory of Animal Physiology, 
      Faculty of Science, University of Yaoundé 1, P.O. Box 812, Yaoundé, Cameroon.
FAU - Noubom, Michel
AU  - Noubom M
AD  - Department of Biological Sciences, Faculty de Medicine and Pharmaceutical 
      Sciences, University of Dschang, P.O. Box, 67, Dschang, Cameroon.
FAU - Mbock, Michel Arnaud
AU  - Mbock MA
AD  - Department of Animal Biology and Physiology, Laboratory of Animal Physiology, 
      Faculty of Science, University of Yaoundé 1, P.O. Box 812, Yaoundé, Cameroon.
FAU - MbolangNguegan, Lohik
AU  - MbolangNguegan L
AD  - Department of Animal Biology and Physiology, Laboratory of Animal Physiology, 
      Faculty of Science, University of Yaoundé 1, P.O. Box 812, Yaoundé, Cameroon.
FAU - Chantal Ngoungouré, Madeleine
AU  - Chantal Ngoungouré M
AD  - Department of Animal Biology and Physiology, Laboratory of Animal Physiology, 
      Faculty of Science, University of Yaoundé 1, P.O. Box 812, Yaoundé, Cameroon.
FAU - Fifen, Rodrigue Ngapout
AU  - Fifen RN
AD  - Department of Animal Biology and Physiology, Laboratory of Animal Physiology, 
      Faculty of Science, University of Yaoundé 1, P.O. Box 812, Yaoundé, Cameroon.
FAU - Bidingha A Goufani, Ronald
AU  - Bidingha A Goufani R
AD  - Department of Animal Biology and Physiology, Laboratory of Animal Physiology, 
      Faculty of Science, University of Yaoundé 1, P.O. Box 812, Yaoundé, Cameroon.
FAU - Kahou Tadah, Rivaldo Bernes
AU  - Kahou Tadah RB
AD  - Department of Animal Biology and Physiology, Laboratory of Animal Physiology, 
      Faculty of Science, University of Yaoundé 1, P.O. Box 812, Yaoundé, Cameroon.
FAU - Claude Bilanda, Danielle
AU  - Claude Bilanda D
AD  - Department of Animal Biology and Physiology, Laboratory of Animal Physiology, 
      Faculty of Science, University of Yaoundé 1, P.O. Box 812, Yaoundé, Cameroon.
FAU - Kamtchouing, Pierre
AU  - Kamtchouing P
AD  - Department of Animal Biology and Physiology, Laboratory of Animal Physiology, 
      Faculty of Science, University of Yaoundé 1, P.O. Box 812, Yaoundé, Cameroon.
FAU - Dzeufiet Djomeni, Paul Désiré
AU  - Dzeufiet Djomeni PD
AUID- ORCID: 0000-0001-5315-6285
AD  - Department of Animal Biology and Physiology, Laboratory of Animal Physiology, 
      Faculty of Science, University of Yaoundé 1, P.O. Box 812, Yaoundé, Cameroon.
LA  - eng
PT  - Journal Article
DEP - 20210930
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC8497103
COIS- The authors declare that there are no conflicts of interest.
EDAT- 2021/10/12 06:00
MHDA- 2021/10/12 06:01
PMCR- 2021/09/30
CRDT- 2021/10/11 05:57
PHST- 2021/04/20 00:00 [received]
PHST- 2021/09/17 00:00 [accepted]
PHST- 2021/10/11 05:57 [entrez]
PHST- 2021/10/12 06:00 [pubmed]
PHST- 2021/10/12 06:01 [medline]
PHST- 2021/09/30 00:00 [pmc-release]
AID - 10.1155/2021/6759000 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2021 Sep 30;2021:6759000. doi: 
      10.1155/2021/6759000. eCollection 2021.

PMID- 35253085
OWN - NLM
STAT- MEDLINE
DCOM- 20220805
LR  - 20220809
IS  - 1432-0711 (Electronic)
IS  - 0932-0067 (Print)
IS  - 0932-0067 (Linking)
VI  - 306
IP  - 2
DP  - 2022 Aug
TI  - Care reality of menopausal women in Germany: healthcare research using 
      quantitative (SHI claims data) and qualitative (survey) data collection.
PG  - 513-521
LID - 10.1007/s00404-022-06457-9 [doi]
AB  - PURPOSE: The transition from the fertile phase of life to menopause is associated 
      with numerous physical changes. Hormone replacement therapy (HRT), as the most 
      effective and efficient form of drug treatment, involves the use of oestrogens 
      and progestins with the aim of increasing health-related quality of life through 
      symptom reduction, sleep improvement and affect enhancement. METHODS: The medical 
      care situation and disease burden of menopausal women was investigated by means 
      of a survey of 1000 women aged 45-60 years on the topics of quality of life, 
      menopause and HRT and a quantitative, longitudinal healthcare study based on an 
      anonymised and age- and sex-adjusted Statutory Health Insurance (SHI) routine 
      data set with approximately four million anonymous insured persons per year. 
      RESULTS: Out of more than half a million women aged 35-70 years, and with 
      statutory health insurance, (n = 613,104), 14% (n = 82,785) had climacteric 
      disorder documented as a first diagnosis in 2014. The proportion of women with 
      the climacteric disorder, who were prescribed HRT on an outpatient basis, was 
      21%; according to the forsa survey, 50% of the women surveyed felt moderate to 
      poorly/very poorly informed about treatment options. CONCLUSION: Findings from 
      the health insurance research conducted with different data sources (survey and 
      SHI claims data) indicate the need for increasing awareness and providing an 
      early and informative education on HRT and its risks and benefits.
CI  - © 2022. The Author(s).
FAU - Stute, Petra
AU  - Stute P
AUID- ORCID: 0000-0002-5591-1552
AD  - Gynaecological Endocrinology and Reproductive Medicine, University Women's 
      Hospital Inselspital, Friedbuehlstrasse 19, 3010, Bern, Switzerland. 
      petra.stute@insel.ch.
FAU - Eversheim, Helena
AU  - Eversheim H
AD  - Besins Healthcare Germany GmbH, Ullsteinhaus, Mariendorfer Damm 3, 12099, Berlin, 
      Germany.
FAU - Ortius-Lechner, Diethe
AU  - Ortius-Lechner D
AD  - Besins Healthcare Germany GmbH, Ullsteinhaus, Mariendorfer Damm 3, 12099, Berlin, 
      Germany.
FAU - May, Melanie
AU  - May M
AD  - HGC Healthcare Consultants GmbH, Graf-Adolf-Platz 15, 40213, Düsseldorf, Germany.
FAU - Feig, Chiara
AU  - Feig C
AD  - HGC Healthcare Consultants GmbH, Graf-Adolf-Platz 15, 40213, Düsseldorf, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220307
PL  - Germany
TA  - Arch Gynecol Obstet
JT  - Archives of gynecology and obstetrics
JID - 8710213
SB  - IM
MH  - *Estrogen Replacement Therapy
MH  - Female
MH  - Germany
MH  - Health Services Research
MH  - Humans
MH  - Menopause
MH  - *Quality of Life
MH  - Surveys and Questionnaires
PMC - PMC9349310
OTO - NOTNLM
OT  - Forsa survey
OT  - Hormone replacement therapy (HRT)
OT  - Menopause
OT  - Real-world evidence (RWE)
OT  - Statutory Health Insurance (SHI) claims data
COIS- Prof. Stute MD is employed by Inselspital Bern and received fees for consulting 
      work from Besins Healthcare Germany GmbH. Ms May and Ms Feig are employed by HGC 
      Healthcare Consultants GmbH and received honoraria for consulting work from 
      Besins Healthcare Germany GmbH. Dr Eversheim and Dr Ortius-Lechner are employed 
      by Besins Healthcare Germany GmbH.
EDAT- 2022/03/08 06:00
MHDA- 2022/08/06 06:00
PMCR- 2022/03/07
CRDT- 2022/03/07 06:11
PHST- 2021/10/30 00:00 [received]
PHST- 2022/02/12 00:00 [accepted]
PHST- 2022/03/08 06:00 [pubmed]
PHST- 2022/08/06 06:00 [medline]
PHST- 2022/03/07 06:11 [entrez]
PHST- 2022/03/07 00:00 [pmc-release]
AID - 10.1007/s00404-022-06457-9 [pii]
AID - 6457 [pii]
AID - 10.1007/s00404-022-06457-9 [doi]
PST - ppublish
SO  - Arch Gynecol Obstet. 2022 Aug;306(2):513-521. doi: 10.1007/s00404-022-06457-9. 
      Epub 2022 Mar 7.

PMID- 27927075
OWN - NLM
STAT- MEDLINE
DCOM- 20170310
LR  - 20241112
IS  - 1744-5116 (Electronic)
IS  - 1388-0209 (Print)
IS  - 1388-0209 (Linking)
VI  - 55
IP  - 1
DP  - 2017 Dec
TI  - Soy isoflavones exert beneficial effects on letrozole-induced rat polycystic 
      ovary syndrome (PCOS) model through anti-androgenic mechanism.
PG  - 242-251
AB  - CONTEXT: Soy is the main source of phytoestrogens, which has long been used as 
      traditional food. One major subtype of phytoestrogens includes isoflavones and 
      they are scientifically validated for their beneficial actions on many 
      hormone-dependent conditions. OBJECTIVE: The present study examines the effect of 
      soy isoflavones on letrozole-induced polycystic ovary syndrome (PCOS) rat model. 
      MATERIALS AND METHODS: PCOS was induced in Sprague-Dawley rats with of 1 mg/kg 
      letrozole, p.o. once daily for 21 consecutive days. Soy isoflavones (50 and 
      100 mg/kg) was administered for 14 days after PCOS induction. Physical parameters 
      (body weight, oestrous cycle determination, ovary and uterus weight) metabolic 
      parameters (oral glucose tolerance test, total cholesterol), steroidal hormone 
      profile (testosterone and 17β-oestradiol), steroidogenic enzymes (3β-hydroxy 
      steroid dehydrogenase (HSD) and 17β-HSD), oxidative stress and histopathology of 
      ovary were studied. RESULTS: Soy isoflavones (100 mg/kg) treatment significantly 
      altered the letrozole-induced PCOS symptoms as observed by decreased body weight 
      gain (p < 0.05), percentage diestrous phase (p < 0.001), testosterone 
      (p < 0.001), 3β-HSD (p < 0.01) and 17β-HSD (p < 0.001) enzyme activity and 
      oxidative stress. Histological results reveal that soy isoflavones treatment in 
      PCOS rats resulted in well-developed antral follicles and normal granulosa cell 
      layer in rat ovary. DISCUSSION: Treatment with soy isoflavones exerts beneficial 
      effects in PCOS rats (with decreased aromatase activity) which might be due to 
      their ability to decrease testosterone concentration in the peripheral blood. 
      CONCLUSION: Analysis of physical, biochemical and histological evidences shows 
      that soy isoflavones may be beneficial in PCOS.
FAU - Rajan, Ravi Kumar
AU  - Rajan RK
AD  - a Department of Pharmacology , PSG College of Pharmacy , Coimbatore , Tamil Nadu 
      , India.
FAU - M, Siva Selva Kumar
AU  - M SS
AD  - b Department of Pharmaceutical Analysis , PSG College of Pharmacy , Coimbatore , 
      Tamil Nadu , India.
FAU - Balaji, Bhaskar
AU  - Balaji B
AD  - a Department of Pharmacology , PSG College of Pharmacy , Coimbatore , Tamil Nadu 
      , India.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Pharm Biol
JT  - Pharmaceutical biology
JID - 9812552
RN  - 0 (Androgen Antagonists)
RN  - 0 (Antioxidants)
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Isoflavones)
RN  - 0 (Nitriles)
RN  - 0 (Phytoestrogens)
RN  - 0 (Triazoles)
RN  - 3XMK78S47O (Testosterone)
RN  - 4TI98Z838E (Estradiol)
RN  - 7LKK855W8I (Letrozole)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - EC 1.1.- (17-Hydroxysteroid Dehydrogenases)
RN  - EC 1.1.- (3-Hydroxysteroid Dehydrogenases)
SB  - IM
MH  - 17-Hydroxysteroid Dehydrogenases/metabolism
MH  - 3-Hydroxysteroid Dehydrogenases/metabolism
MH  - Androgen Antagonists/isolation & purification/*pharmacology
MH  - Animals
MH  - Antioxidants/isolation & purification/pharmacology
MH  - Biomarkers/blood
MH  - Blood Glucose/drug effects/metabolism
MH  - Cholesterol/blood
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Estradiol/blood
MH  - Estrous Cycle/drug effects
MH  - Female
MH  - Isoflavones/isolation & purification/*pharmacology
MH  - Letrozole
MH  - *Nitriles
MH  - Ovary/*drug effects/metabolism/pathology
MH  - Oxidative Stress/drug effects
MH  - Phytoestrogens/isolation & purification/*pharmacology
MH  - Phytotherapy
MH  - Plants, Medicinal
MH  - Polycystic Ovary Syndrome/blood/chemically induced/pathology/*prevention & 
      control
MH  - Rats, Sprague-Dawley
MH  - Glycine max/*chemistry
MH  - Testosterone/blood
MH  - Time Factors
MH  - *Triazoles
MH  - Uterus/*drug effects/metabolism/pathology
MH  - Weight Gain/drug effects
PMC - PMC6130471
OTO - NOTNLM
OT  - Genistein
OT  - daidzein
OT  - oestradiol
OT  - oestrogen beta
OT  - phytoestrogen
OT  - testosterone
EDAT- 2016/12/09 06:00
MHDA- 2017/03/11 06:00
PMCR- 2016/12/07
CRDT- 2016/12/09 06:00
PHST- 2016/12/09 06:00 [entrez]
PHST- 2016/12/09 06:00 [pubmed]
PHST- 2017/03/11 06:00 [medline]
PHST- 2016/12/07 00:00 [pmc-release]
AID - 1258425 [pii]
AID - 10.1080/13880209.2016.1258425 [doi]
PST - ppublish
SO  - Pharm Biol. 2017 Dec;55(1):242-251. doi: 10.1080/13880209.2016.1258425.

PMID- 37150113
OWN - NLM
STAT- MEDLINE
DCOM- 20230515
LR  - 20250103
IS  - 1873-7072 (Electronic)
IS  - 0308-8146 (Linking)
VI  - 422
DP  - 2023 Oct 1
TI  - Multi-immunoaffinity column for the simultaneous analysis of bisphenol A and its 
      analogues in Chinese foods by liquid chromatography tandem mass spectrometry.
PG  - 136295
LID - S0308-8146(23)00913-5 [pii]
LID - 10.1016/j.foodchem.2023.136295 [doi]
AB  - Bisphenol A (BPA) and its four analogues have been receiving considerable 
      attention owing to their potential endocrine disrupting effects. The European 
      Food Safety Authority has proposed 0.04 ng/kg·body weight/day of thetemporary 
      tolerable daily intake for BPA. Therefore, a more sensitive analytical method was 
      urgently needed for the necessity of the risk reassessment of bisphenols (BPs). 
      The matrix effect of Chinese foods is a challenge for the analysis of ultra-trace 
      analytes due to the presence of various spices. A multi-immunoaffinity column 
      (mIAC) was prepared for the purification of BPA, BPB, BPF, BPS, and BPAF in 
      Chinese foods following ultra-high-performance liquid chromatography tandem mass 
      spectrometry detection (UHLPC-MS/MS). The recoveries of each of BPs were ranged 
      from 84.6% to 116.7%, and the intra-day precision and inter-day precision were 
      ranged from 1.6% to 12.4%, and from 4.1% to 14.0%, respectively. This is the 
      first report on the mIACs for simultaneous clean-up and analysis of BPs in 
      complex Chinese foods.
CI  - Copyright © 2023 Elsevier Ltd. All rights reserved.
FAU - Yao, Kai
AU  - Yao K
AD  - Beijing Key Laboratory of Diagnostic and Traceability Technologies for Food 
      Poisoning, Beijing Center for Disease Prevention and Control, Beijing 100013, 
      People's Republic of China.
FAU - Zhang, Jing
AU  - Zhang J
AD  - Beijing Key Laboratory of Diagnostic and Traceability Technologies for Food 
      Poisoning, Beijing Center for Disease Prevention and Control, Beijing 100013, 
      People's Republic of China.
FAU - Niu, Yumin
AU  - Niu Y
AD  - Beijing Key Laboratory of Diagnostic and Traceability Technologies for Food 
      Poisoning, Beijing Center for Disease Prevention and Control, Beijing 100013, 
      People's Republic of China.
FAU - Zhang, Xin
AU  - Zhang X
AD  - Beijing Key Laboratory of Diagnostic and Traceability Technologies for Food 
      Poisoning, Beijing Center for Disease Prevention and Control, Beijing 100013, 
      People's Republic of China.
FAU - Yang, Yunjia
AU  - Yang Y
AD  - Beijing Key Laboratory of Diagnostic and Traceability Technologies for Food 
      Poisoning, Beijing Center for Disease Prevention and Control, Beijing 100013, 
      People's Republic of China.
FAU - Wu, Yige
AU  - Wu Y
AD  - College of Veterinary Medicine, China Agricultural University, Beijing 100193, 
      People's Republic of China.
FAU - Wen, Kai
AU  - Wen K
AD  - College of Veterinary Medicine, China Agricultural University, Beijing 100193, 
      People's Republic of China.
FAU - Shao, Bing
AU  - Shao B
AD  - Beijing Key Laboratory of Diagnostic and Traceability Technologies for Food 
      Poisoning, Beijing Center for Disease Prevention and Control, Beijing 100013, 
      People's Republic of China; College of Veterinary Medicine, China Agricultural 
      University, Beijing 100193, People's Republic of China. Electronic address: 
      shaobingch@sina.com.
LA  - eng
PT  - Journal Article
DEP - 20230502
PL  - England
TA  - Food Chem
JT  - Food chemistry
JID - 7702639
RN  - RW57K3X12M (bisphenol A)
RN  - 0 (Phenols)
RN  - 0 (Benzhydryl Compounds)
SB  - IM
MH  - *Tandem Mass Spectrometry/methods
MH  - Chromatography, Liquid
MH  - Chromatography, High Pressure Liquid
MH  - *Phenols/analysis
MH  - Benzhydryl Compounds/analysis
OTO - NOTNLM
OT  - Bisphenols
OT  - Chinese foods
OT  - Multi-immunoaffinity column
OT  - UHPLC-MS/MS
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/05/08 00:41
MHDA- 2023/05/15 06:42
CRDT- 2023/05/07 18:09
PHST- 2022/11/27 00:00 [received]
PHST- 2023/01/26 00:00 [revised]
PHST- 2023/04/30 00:00 [accepted]
PHST- 2023/05/15 06:42 [medline]
PHST- 2023/05/08 00:41 [pubmed]
PHST- 2023/05/07 18:09 [entrez]
AID - S0308-8146(23)00913-5 [pii]
AID - 10.1016/j.foodchem.2023.136295 [doi]
PST - ppublish
SO  - Food Chem. 2023 Oct 1;422:136295. doi: 10.1016/j.foodchem.2023.136295. Epub 2023 
      May 2.

PMID- 35341524
OWN - NLM
STAT- MEDLINE
DCOM- 20220331
LR  - 20220401
IS  - 1873-4324 (Electronic)
IS  - 0003-2670 (Linking)
VI  - 1202
DP  - 2022 Apr 15
TI  - Assessing human urinary clomiphene metabolites after consumption of eggs from 
      clomiphene-treated laying hens using chromatographic-mass spectrometric 
      approaches.
PG  - 339661
LID - S0003-2670(22)00232-X [pii]
LID - 10.1016/j.aca.2022.339661 [doi]
AB  - The anti-estrogen clomiphene is prohibited in sports at all times. Yet, adverse 
      analytical findings (AAFs) have increased since 2011. This is possibly due to 
      improved analytical sensitivity, but also contamination of food of animal origin 
      needs to be taken into consideration as a potential source of drug exposure. For 
      instance, studies with laying hens that received orally administered clomiphene 
      have shown a significantly increased egg production rate but, as a consequence, 
      eggs were found to incorporate residues of clomiphene. In order to evaluate if 
      the consumption of clomiphene-contaminated eggs can cause an AAF of a doping 
      control sample, eggs obtained from an animal administration study with clomiphene 
      were consumed by human volunteers. Each volunteer ate two eggs, and urine samples 
      were collected and analyzed using routine doping control procedures. 
      Subsequently, additional volunteers received a microdosed clomiphene capsule to 
      compare the excretion profiles. Maximum urinary concentrations of 
      hydroxy-clomiphene (HC) between 80 and 300 pg mL(-1) were detected following the 
      consumption of clomiphene-containing eggs, which would constitute AAFs if 
      observed in athletes' doping control samples. In order to support the 
      differentiation of potential routes of drug exposure, a method was developed 
      which allows for the chromatographic separation of (E)-3-, (Z)-3-, (E)-4-, and 
      (Z)-4-HC using a derivatization step. By comparing the peak areas of these 
      metabolites, characteristic relative distribution patterns were found that assist 
      in identifying AAFs resulting from clomiphene ingested via contaminated eggs and, 
      thus, enable to distinguish clomiphene intake via contaminated eggs from the 
      intake of microdoses or therapeutic dosages, e.g. for doping purposes.
CI  - Copyright © 2022 Elsevier B.V. All rights reserved.
FAU - Euler, Luisa
AU  - Euler L
AD  - Institute of Biochemistry, Center for Preventive Doping Research, German Sport 
      University Cologne, Cologne, Germany.
FAU - Gillard, Nathalie
AU  - Gillard N
AD  - CER Groupe, Marloie, Belgium.
FAU - Delahaut, Philippe
AU  - Delahaut P
AD  - CER Groupe, Marloie, Belgium.
FAU - Pierret, Gilles
AU  - Pierret G
AD  - CER Groupe, Marloie, Belgium.
FAU - Mürdter, Thomas
AU  - Mürdter T
AD  - Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology and University 
      Tübingen, Stuttgart, Germany.
FAU - Schwab, Matthias
AU  - Schwab M
AD  - Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, 
      Germany; Department of Clinical Pharmacology, Department of Biochemistry and 
      Pharmacy, University Tübingen, Tübingen, Germany.
FAU - Döhmen, Georg
AU  - Döhmen G
AD  - Fertility Center Niederrhein, Mönchengladbach, Germany.
FAU - Thomas, Andreas
AU  - Thomas A
AD  - Institute of Biochemistry, Center for Preventive Doping Research, German Sport 
      University Cologne, Cologne, Germany.
FAU - Thevis, Mario
AU  - Thevis M
AD  - Institute of Biochemistry, Center for Preventive Doping Research, German Sport 
      University Cologne, Cologne, Germany; European Monitoring Center for Emerging 
      Doping Agents (EuMoCEDA), Cologne, Bonn, Germany. Electronic address: 
      thevis@dshs-koeln.de.
LA  - eng
PT  - Journal Article
DEP - 20220301
PL  - Netherlands
TA  - Anal Chim Acta
JT  - Analytica chimica acta
JID - 0370534
RN  - 1HRS458QU2 (Clomiphene)
SB  - IM
MH  - Animals
MH  - *Chickens
MH  - Clomiphene/analysis
MH  - *Doping in Sports
MH  - Eggs/analysis
MH  - Female
MH  - Humans
OTO - NOTNLM
OT  - Clomiphene
OT  - Doping
OT  - Eggs
OT  - HPLC-MS/MS
OT  - Residues
OT  - SERMs
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2022/03/29 06:00
MHDA- 2022/04/01 06:00
CRDT- 2022/03/28 05:25
PHST- 2022/01/07 00:00 [received]
PHST- 2022/02/21 00:00 [revised]
PHST- 2022/02/25 00:00 [accepted]
PHST- 2022/03/28 05:25 [entrez]
PHST- 2022/03/29 06:00 [pubmed]
PHST- 2022/04/01 06:00 [medline]
AID - S0003-2670(22)00232-X [pii]
AID - 10.1016/j.aca.2022.339661 [doi]
PST - ppublish
SO  - Anal Chim Acta. 2022 Apr 15;1202:339661. doi: 10.1016/j.aca.2022.339661. Epub 
      2022 Mar 1.

PMID- 29404595
OWN - NLM
STAT- MEDLINE
DCOM- 20190103
LR  - 20210319
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 168
IP  - 3
DP  - 2018 Feb 6
TI  - Should This Patient Receive Hormone Therapy for Her Menopausal Symptoms?: Grand 
      Rounds Discussion From Beth Israel Deaconess Medical Center.
PG  - 203-209
LID - 10.7326/M17-3320 [doi]
AB  - Hormone therapy (HT) was widely prescribed in the 1980s and 1990s and has been 
      controversial since the initial results of the Women's Health Initiative (WHI) 
      trial in the early 2000s suggested that it increased risk for breast cancer and 
      coronary heart disease and did not prolong life. However, more recent data and 
      reexamination of the WHI results suggest that HT is safe and effective for many 
      women when used around the time of menopause. Two experts debate the 2017 Hormone 
      Therapy Position Statement of The North American Menopause Society, which 
      recommends HT as first-line treatment of vasomotor symptoms, and apply it to the 
      care of Ms. R, a 52-year-old woman with severe hot flashes, sleep disturbance, 
      and irritability.
FAU - Reynolds, Eileen E
AU  - Reynolds EE
AD  - Beth Israel Deaconess Medical Center, Boston, Massachusetts (E.E.R., C.B., M.R., 
      R.B.B.).
FAU - Bates, Carol
AU  - Bates C
AD  - Beth Israel Deaconess Medical Center, Boston, Massachusetts (E.E.R., C.B., M.R., 
      R.B.B.).
FAU - Richardson, Martha
AU  - Richardson M
AD  - Beth Israel Deaconess Medical Center, Boston, Massachusetts (E.E.R., C.B., M.R., 
      R.B.B.).
FAU - Burns, Risa B
AU  - Burns RB
AD  - Beth Israel Deaconess Medical Center, Boston, Massachusetts (E.E.R., C.B., M.R., 
      R.B.B.).
LA  - eng
PT  - Clinical Conference
PT  - Journal Article
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Antidepressive Agents, Second-Generation)
RN  - 7D7RX5A8MO (Venlafaxine Hydrochloride)
SB  - IM
CIN - Ann Intern Med. 2018 Aug 7;169(3):203. doi: 10.7326/L18-0238. PMID: 30083711
CIN - Ann Intern Med. 2018 Aug 7;169(3):203. doi: 10.7326/L18-0239. PMID: 30083712
MH  - Antidepressive Agents, Second-Generation/*therapeutic use
MH  - Estrogen Replacement Therapy/*methods
MH  - Female
MH  - Hot Flashes/*drug therapy
MH  - Humans
MH  - *Menopause
MH  - Middle Aged
MH  - Quality of Life
MH  - Risk Assessment
MH  - Sleep Wake Disorders/*drug therapy
MH  - Venlafaxine Hydrochloride/*therapeutic use
EDAT- 2018/02/07 06:00
MHDA- 2019/01/04 06:00
CRDT- 2018/02/07 06:00
PHST- 2018/02/07 06:00 [entrez]
PHST- 2018/02/07 06:00 [pubmed]
PHST- 2019/01/04 06:00 [medline]
AID - 2671912 [pii]
AID - 10.7326/M17-3320 [doi]
PST - ppublish
SO  - Ann Intern Med. 2018 Feb 6;168(3):203-209. doi: 10.7326/M17-3320.

PMID- 32854385
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201023
IS  - 1999-4923 (Print)
IS  - 1999-4923 (Electronic)
IS  - 1999-4923 (Linking)
VI  - 12
IP  - 9
DP  - 2020 Aug 25
TI  - Efficacy of Emu Oil Transfersomes for Local Transdermal Delivery of 4-OH 
      Tamoxifen in the Treatment of Breast Cancer.
LID - 10.3390/pharmaceutics12090807 [doi]
LID - 807
AB  - Oral tamoxifen used in the prevention and treatment of ductal carcinoma in situ 
      (DCIS) (estrogen-positive) patients has limited acceptance, due to its adverse 
      side effects. The efficacy of tamoxifen is related to its major metabolite, 
      4-hydroxytamoxifen. Local transdermal therapy of 4-hydroxytamoxifen to the breast 
      might avert the toxicity of oral tamoxifen, while maintaining efficacy. We aim to 
      study the skin irritancy, as well as to evaluate the efficacy of the developed 
      transfersome formulations, with/without emu oil, using a syngeneic mouse model of 
      breast cancer. We also quantified tamoxifen/4-hydroxytamoxifen concentrations in 
      blood plasma and performed histopathology. The skin irritancy test showed that 
      the pure emu oil and transfersome formulations with or without the emu oil did 
      not cause skin irritancy in the animals studied. A sensitive and specific 
      LC-MS/MS method for the quantification of tamoxifen and 4-hydroxytamoxifen was 
      developed and validated. Studies on tumor volume and necrosis (histopathology) 
      using the breast cancer mouse model showed that the 4-OHT transfersomal 
      formulations, with and without emu oil, showed comparable efficacy with that of 
      orally administered tamoxifen. However, the transfersomal formulations, with and 
      without emu oil, resulted in significantly lower (10.24 ± 0.07 and 32.45 ± 0.48 
      ng/mL, respectively) plasma concentrations of 4-hydroxytamoxifen, compared to the 
      oral tamoxifen (TAMX) group (634.42 ± 7.54 ng/mL). This study demonstrated the 
      potential use of emu oil in a local transdermal formulation for the treatment of 
      breast cancer and its reduced adverse effects.
FAU - Sundralingam, Usha
AU  - Sundralingam U
AUID- ORCID: 0000-0002-1610-2189
AD  - School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, Bandar 
      Sunway, Selangor Darul Ehsan 47500, Malaysia.
AD  - Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, 
      Jalan Lagoon Selatan, Bandar Sunway, Selangor Darul Ehsan 47500, Malaysia.
FAU - Chakravarthi, Srikumar
AU  - Chakravarthi S
AD  - Faculty of Medicine, Bioscience and Nursing, MAHSA University, Jalan SP 2, Bandar 
      Saujana Putra, Jenjarom Selangor 42610, Malaysia.
FAU - Radhakrishnan, Ammu Kutty
AU  - Radhakrishnan AK
AUID- ORCID: 0000-0003-2638-907X
AD  - Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, 
      Jalan Lagoon Selatan, Bandar Sunway, Selangor Darul Ehsan 47500, Malaysia.
FAU - Muniyandy, Saravanan
AU  - Muniyandy S
AD  - Fatima College of Health Sciences, Al Maqam, Al Ain 24162, UAE.
FAU - Palanisamy, Uma D
AU  - Palanisamy UD
AD  - Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, 
      Jalan Lagoon Selatan, Bandar Sunway, Selangor Darul Ehsan 47500, Malaysia.
LA  - eng
GR  - BCHH-SM-2-02-2010/Monash University Malaysia/
PT  - Journal Article
DEP - 20200825
PL  - Switzerland
TA  - Pharmaceutics
JT  - Pharmaceutics
JID - 101534003
PMC - PMC7558379
OTO - NOTNLM
OT  - 4-hydroxytamoxifen
OT  - DCIS
OT  - emu oil
OT  - local transdermal therapy
OT  - tamoxifen
COIS- The authors declare no conflict of interests.
EDAT- 2020/08/29 06:00
MHDA- 2020/08/29 06:01
PMCR- 2020/09/01
CRDT- 2020/08/29 06:00
PHST- 2020/07/10 00:00 [received]
PHST- 2020/08/14 00:00 [revised]
PHST- 2020/08/20 00:00 [accepted]
PHST- 2020/08/29 06:00 [entrez]
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2020/08/29 06:01 [medline]
PHST- 2020/09/01 00:00 [pmc-release]
AID - pharmaceutics12090807 [pii]
AID - pharmaceutics-12-00807 [pii]
AID - 10.3390/pharmaceutics12090807 [doi]
PST - epublish
SO  - Pharmaceutics. 2020 Aug 25;12(9):807. doi: 10.3390/pharmaceutics12090807.

PMID- 28980160
OWN - NLM
STAT- MEDLINE
DCOM- 20181031
LR  - 20250103
IS  - 1614-7499 (Electronic)
IS  - 0944-1344 (Linking)
VI  - 24
IP  - 35
DP  - 2017 Dec
TI  - Exposure assessment to bisphenol A (BPA) in Portuguese children by human 
      biomonitoring.
PG  - 27502-27514
LID - 10.1007/s11356-017-0358-7 [doi]
AB  - Exposure to bisphenol A (BPA) is known to be widespread and available data 
      suggests that BPA can act as an endocrine disruptor. Diet is generally regarded 
      as the dominant BPA exposure source, namely through leaching to food from 
      packaging materials. The aim of this study was to evaluate the exposure of 110 
      Portuguese children (4-18 years old), divided in two groups: the regular diet 
      group (n = 43) comprised healthy normal weight/underweight children with no 
      dietary control; the healthy diet group (n = 67) comprised children diagnosed for 
      obesity/overweight (without other known associated diseases) that were set on a 
      healthy diet for weight control. First morning urine samples were collected and 
      total urinary BPA was analyzed after enzymatic hydrolysis via on-line HPLC-MS/MS 
      with isotope dilution quantification. Virtually, all the children were exposed to 
      BPA, with 91% of the samples above the LOQ (limit of quantification) of 0.1 μg/L. 
      The median (95th percentile) urinary BPA levels for non-normalized and 
      creatinine-corrected values were 1.89 μg/L (16.0) and 1.92 μg/g creatinine 
      (14.4), respectively. BPA levels in the regular diet group were higher than in 
      the healthy diet group, but differences were not significant. Calculated daily 
      BPA intakes, however, were significantly higher in children of the regular diet 
      group than in children of healthy diet group. Median (95th percentile) daily 
      intakes amounted to 41.6 (467) ng/kg body weight/day in the regular diet group, 
      and 23.2 (197) ng/kg body weight/day in the healthy diet group. Multiple logistic 
      regression analysis revealed that children in the healthy diet group had 33% 
      lower intakes than children in the regular diet group (OR 0.67; 95% CI 
      0.51-0.89). For both groups, however, urinary BPA levels and daily BPA intakes 
      were within the range reported for other children's populations and were well 
      below health guidance values such as the European Food Safety Authority (EFSA) 
      temporary tolerable daily intake (t-TDI) of 4 μg/kg body weight/day. In addition, 
      lower daily BPA intakes were more likely linked with the inherent dietary 
      approach rather than with high BMI or obesity.
FAU - Correia-Sá, Luísa
AU  - Correia-Sá L
AD  - REQUIMTE/LAQV - Instituto Superior de Engenharia do Porto do Instituto 
      Politécnico do Porto, Rua Dr. António Bernardino de Almeida, 431, 4200-072, 
      Porto, Portugal.
AD  - CINTESIS - Centro de Investigação em Tecnologias e Sistemas de Informação em 
      Saúde, Centro de Investigação Médica, Faculdade de Medicina da Universidade do 
      Porto, 2° piso, edif. Nascente, Rua Dr. Plácido da Costa s/n, 4200-450, Porto, 
      Portugal.
FAU - Kasper-Sonnenberg, Monika
AU  - Kasper-Sonnenberg M
AD  - Institute for Prevention and Occupational Medicine of the German Social Accident 
      Insurance - Institute of the Ruhr-University Bochum (IPA), 
      Bürkle-de-la-Camp-Platz 1, 44789, Bochum, Germany.
FAU - Schütze, André
AU  - Schütze A
AD  - Institute for Prevention and Occupational Medicine of the German Social Accident 
      Insurance - Institute of the Ruhr-University Bochum (IPA), 
      Bürkle-de-la-Camp-Platz 1, 44789, Bochum, Germany.
FAU - Pälmke, Claudia
AU  - Pälmke C
AD  - Institute for Prevention and Occupational Medicine of the German Social Accident 
      Insurance - Institute of the Ruhr-University Bochum (IPA), 
      Bürkle-de-la-Camp-Platz 1, 44789, Bochum, Germany.
FAU - Norberto, Sónia
AU  - Norberto S
AD  - CINTESIS - Centro de Investigação em Tecnologias e Sistemas de Informação em 
      Saúde, Centro de Investigação Médica, Faculdade de Medicina da Universidade do 
      Porto, 2° piso, edif. Nascente, Rua Dr. Plácido da Costa s/n, 4200-450, Porto, 
      Portugal.
FAU - Calhau, Conceição
AU  - Calhau C
AD  - CINTESIS - Centro de Investigação em Tecnologias e Sistemas de Informação em 
      Saúde, Centro de Investigação Médica, Faculdade de Medicina da Universidade do 
      Porto, 2° piso, edif. Nascente, Rua Dr. Plácido da Costa s/n, 4200-450, Porto, 
      Portugal.
FAU - Domingues, Valentina F
AU  - Domingues VF
AD  - REQUIMTE/LAQV - Instituto Superior de Engenharia do Porto do Instituto 
      Politécnico do Porto, Rua Dr. António Bernardino de Almeida, 431, 4200-072, 
      Porto, Portugal.
FAU - Koch, Holger M
AU  - Koch HM
AUID- ORCID: 0000-0002-8328-2837
AD  - Institute for Prevention and Occupational Medicine of the German Social Accident 
      Insurance - Institute of the Ruhr-University Bochum (IPA), 
      Bürkle-de-la-Camp-Platz 1, 44789, Bochum, Germany. koch@ipa-dguv.de.
LA  - eng
GR  - SFRH/BD/87019/2012/Fundação para a Ciência e a Tecnologia (PT)/
GR  - NORTE-01-0145-FEDER-000011/Qualidade e Segurança Alimentar - uma abordagem 
      (nano)tecnológica/
PT  - Journal Article
DEP - 20171004
PL  - Germany
TA  - Environ Sci Pollut Res Int
JT  - Environmental science and pollution research international
JID - 9441769
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Endocrine Disruptors)
RN  - 0 (Phenols)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - Adolescent
MH  - Benzhydryl Compounds/*urine
MH  - Child
MH  - Child, Preschool
MH  - Diet
MH  - Endocrine Disruptors/*urine
MH  - Environmental Exposure/*analysis
MH  - Environmental Monitoring/methods
MH  - Female
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Obesity/urine
MH  - Overweight/urine
MH  - Phenols/*urine
MH  - Portugal
OTO - NOTNLM
OT  - Bisphenol A
OT  - Children
OT  - Diet
OT  - Exposure assessment
OT  - Human biomonitoring
OT  - Urine
EDAT- 2017/10/06 06:00
MHDA- 2018/11/01 06:00
CRDT- 2017/10/06 06:00
PHST- 2017/07/05 00:00 [received]
PHST- 2017/09/26 00:00 [accepted]
PHST- 2017/10/06 06:00 [pubmed]
PHST- 2018/11/01 06:00 [medline]
PHST- 2017/10/06 06:00 [entrez]
AID - 10.1007/s11356-017-0358-7 [pii]
AID - 10.1007/s11356-017-0358-7 [doi]
PST - ppublish
SO  - Environ Sci Pollut Res Int. 2017 Dec;24(35):27502-27514. doi: 
      10.1007/s11356-017-0358-7. Epub 2017 Oct 4.

PMID- 28961176
OWN - NLM
STAT- MEDLINE
DCOM- 20190116
LR  - 20191210
IS  - 2072-6643 (Electronic)
IS  - 2072-6643 (Linking)
VI  - 9
IP  - 10
DP  - 2017 Sep 29
TI  - Phytoestrogen Concentrations in Human Urine as Biomarkers for Dietary 
      Phytoestrogen Intake in Mexican Women.
LID - 10.3390/nu9101078 [doi]
LID - 1078
AB  - There has been substantial interest in phytoestrogens, because of their potential 
      effect in reducing cancer and heart disease risk. Measuring concentrations of 
      phytoestrogens in urine is an alternative method for conducting epidemiological 
      studies. Our objective was to evaluate the urinary excretion of phytoestrogens as 
      biomarkers for dietary phytoestrogen intake in Mexican women. Participants were 
      100 healthy women from 25 to 80 years of age. A food frequency questionnaire 
      (FFQ) and a 24 h recall were used to estimate habitual and recent intakes of 
      isoflavones, lignans, flavonols, coumestrol, resveratrol, naringenin, and 
      luteolin. Urinary concentrations were measured by liquid chromatography (HPLC) 
      coupled to mass spectrometry (MS) using the electrospray ionization interface 
      (ESI) and diode array detector (DAD) (HPLC-DAD-ESI-MS). Spearman correlation 
      coefficients were used to evaluate associations between dietary intake and urine 
      concentrations. The habitual consumption (FFQ) of total phytoestrogens was 37.56 
      mg/day. In urine, the higher compounds were naringenin (60.1 µg/L) and 
      enterolactone (41.7 µg/L). Recent intakes (24 h recall) of isoflavones (r = 
      0.460, p < 0.001), lignans (r = 0.550, p < 0.0001), flavonoids (r = 0.240, p < 
      0.05), and total phytoestrogens (r = 0.410, p < 0.001) were correlated to their 
      urinary levels. Total phytoestrogen intakes estimated by the FFQ showed higher 
      correlations to urinary levels (r = 0.730, p < 0.0001). Urinary phytoestrogens 
      may be useful as biomarkers of phytoestrogen intake, and as a tool for evaluating 
      the relationship of intake and disease risk in Mexican women.
FAU - Chávez-Suárez, Karina M
AU  - Chávez-Suárez KM
AD  - Department of Nutrition, Section of Public Nutrition and Health, Centro de 
      Investigación en Alimentación y Desarrollo, A.C. (CIAD), Carretera a La Victoria 
      km 0.6, 83304 Hermosillo, Sonora, Mexico. kamachasu@gmail.com.
FAU - Ortega-Vélez, María I
AU  - Ortega-Vélez MI
AD  - Department of Nutrition, Section of Public Nutrition and Health, Centro de 
      Investigación en Alimentación y Desarrollo, A.C. (CIAD), Carretera a La Victoria 
      km 0.6, 83304 Hermosillo, Sonora, Mexico. iortega@ciad.mx.
FAU - Valenzuela-Quintanar, Ana I
AU  - Valenzuela-Quintanar AI
AD  - Department of Food Sciences, Centro de Investigación en Alimentación y 
      Desarrollo, A.C. (CIAD), Carretera a La Victoria km 0.6, 83304 Hermosillo, 
      Sonora, Mexico. aquintanar@ciad.mx.
FAU - Galván-Portillo, Marcia
AU  - Galván-Portillo M
AD  - Center for Population Health Research, Instituto Nacional de Salud Pública, 
      Universidad No. 655, Colonia Santa María Ahuacatitlán, Cerrada Los Pinos y 
      Caminera, 62100 Cuernavaca, Morelos, Mexico. mgalvan@insp.mx.
FAU - López-Carrillo, Lizbeth
AU  - López-Carrillo L
AD  - Center for Population Health Research, Instituto Nacional de Salud Pública, 
      Universidad No. 655, Colonia Santa María Ahuacatitlán, Cerrada Los Pinos y 
      Caminera, 62100 Cuernavaca, Morelos, Mexico. lizbeth@insp.mx.
FAU - Esparza-Romero, Julián
AU  - Esparza-Romero J
AD  - Department of Nutrition, Section of Public Nutrition and Health, Centro de 
      Investigación en Alimentación y Desarrollo, A.C. (CIAD), Carretera a La Victoria 
      km 0.6, 83304 Hermosillo, Sonora, Mexico. julian@ciad.mx.
FAU - Saucedo-Tamayo, María S
AU  - Saucedo-Tamayo MS
AD  - Department of Nutrition, Section of Public Nutrition and Health, Centro de 
      Investigación en Alimentación y Desarrollo, A.C. (CIAD), Carretera a La Victoria 
      km 0.6, 83304 Hermosillo, Sonora, Mexico. coco@ciad.mx.
FAU - Robles-Burgueño, María R
AU  - Robles-Burgueño MR
AD  - Department of Food Sciences, Centro de Investigación en Alimentación y 
      Desarrollo, A.C. (CIAD), Carretera a La Victoria km 0.6, 83304 Hermosillo, 
      Sonora, Mexico. cuquis@ciad.mx.
FAU - Palma-Durán, Susana A
AU  - Palma-Durán SA
AD  - Department of Food Sciences, Centro de Investigación en Alimentación y 
      Desarrollo, A.C. (CIAD), Carretera a La Victoria km 0.6, 83304 Hermosillo, 
      Sonora, Mexico. sussypalmaa@gmail.com.
FAU - Gutiérrez-Coronado, María L
AU  - Gutiérrez-Coronado ML
AD  - Department of Food Sciences, Centro de Investigación en Alimentación y 
      Desarrollo, A.C. (CIAD), Carretera a La Victoria km 0.6, 83304 Hermosillo, 
      Sonora, Mexico. lulu@ciad.mx.
FAU - Campa-Siqueiros, Melissa M
AU  - Campa-Siqueiros MM
AD  - Department of Nutrition, Section of Public Nutrition and Health, Centro de 
      Investigación en Alimentación y Desarrollo, A.C. (CIAD), Carretera a La Victoria 
      km 0.6, 83304 Hermosillo, Sonora, Mexico. melita379@hotmail.com.
FAU - Grajeda-Cota, Patricia
AU  - Grajeda-Cota P
AD  - Department of Food Sciences, Centro de Investigación en Alimentación y 
      Desarrollo, A.C. (CIAD), Carretera a La Victoria km 0.6, 83304 Hermosillo, 
      Sonora, Mexico. grajeda@ciad.mx.
FAU - Caire-Juvera, Graciela
AU  - Caire-Juvera G
AD  - Department of Nutrition, Section of Public Nutrition and Health, Centro de 
      Investigación en Alimentación y Desarrollo, A.C. (CIAD), Carretera a La Victoria 
      km 0.6, 83304 Hermosillo, Sonora, Mexico. gcaire@ciad.mx.
LA  - eng
PT  - Journal Article
DEP - 20170929
PL  - Switzerland
TA  - Nutrients
JT  - Nutrients
JID - 101521595
RN  - 0 (Biomarkers)
RN  - 0 (Phytoestrogens)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers/urine
MH  - Body Mass Index
MH  - Cross-Sectional Studies
MH  - *Diet, Healthy/ethnology
MH  - Female
MH  - Heart Diseases/epidemiology/ethnology/*prevention & control/urine
MH  - Humans
MH  - Mexico/epidemiology
MH  - Middle Aged
MH  - Neoplasms/epidemiology/ethnology/*prevention & control/urine
MH  - Nutrition Surveys
MH  - Obesity/epidemiology/ethnology/prevention & control/urine
MH  - Overweight/epidemiology/ethnology/prevention & control/urine
MH  - *Patient Compliance/ethnology
MH  - Phytoestrogens/*administration & dosage/*urine
MH  - Prevalence
MH  - Risk
PMC - PMC5691695
OTO - NOTNLM
OT  - Mexican women
OT  - biomarker
OT  - phytoestrogen intake
OT  - urinary excretion
COIS- The authors declare no conflict of interest.
EDAT- 2017/09/30 06:00
MHDA- 2019/01/17 06:00
PMCR- 2017/09/29
CRDT- 2017/09/30 06:00
PHST- 2017/08/15 00:00 [received]
PHST- 2017/09/07 00:00 [revised]
PHST- 2017/09/13 00:00 [accepted]
PHST- 2017/09/30 06:00 [entrez]
PHST- 2017/09/30 06:00 [pubmed]
PHST- 2019/01/17 06:00 [medline]
PHST- 2017/09/29 00:00 [pmc-release]
AID - nu9101078 [pii]
AID - nutrients-09-01078 [pii]
AID - 10.3390/nu9101078 [doi]
PST - epublish
SO  - Nutrients. 2017 Sep 29;9(10):1078. doi: 10.3390/nu9101078.

PMID- 34067838
OWN - NLM
STAT- MEDLINE
DCOM- 20210702
LR  - 20250103
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 22
IP  - 10
DP  - 2021 May 17
TI  - Resveratrol Butyrate Esters Inhibit BPA-Induced Liver Damage in Male Offspring 
      Rats by Modulating Antioxidant Capacity and Gut Microbiota.
LID - 10.3390/ijms22105273 [doi]
LID - 5273
AB  - Resveratrol can affect the physiology or biochemistry of offspring in the 
      maternal-fetal animal model. However, it exhibits low bioavailability in humans 
      and animals. Fifteen-week SD pregnant female rats were orally administered 
      bisphenol A (BPA) and/or resveratrol butyrate ester (RBE), and the male offspring 
      rats (n = 4-8 per group) were evaluated. The results show that RBE treatment (BPA 
      + R30) compared with the BPA group can reduce the damage caused by BPA (p < 
      0.05). RBE enhanced the expression of selected genes and induced extramedullary 
      hematopoiesis and mononuclear cell infiltration. RBE increased the abundance of 
      S24-7 and Adlercreutzia in the intestines of the male offspring rats, as well as 
      the concentrations of short-chain fatty acids (SCFAs) in the feces. RBE also 
      increased the antioxidant capacity of the liver by inducing Nrf2, promoting the 
      expression of HO-1, SOD, and CAT. It also increased the concentration of 
      intestinal SCFAs, enhancing the barrier formed by intestinal cells, thereby 
      preventing BPA-induced metabolic disruption in the male offspring rats, and 
      reduced liver inflammation. This study identified a potential mechanism 
      underlying the protective effects of RBE against the liver damage caused by BPA 
      exposure during the peri-pregnancy period, and the influence of the gut 
      microbiota on the gut-liver axis in the offspring.
FAU - Liao, Jin-Xian
AU  - Liao JX
AD  - Department of Seafood Science, National Kaohsiung University of Science and 
      Technology, Kaohsiung 811, Taiwan.
FAU - Chen, Yu-Wei
AU  - Chen YW
AD  - Department of Medicine, Chang Gung University, Linkow 333, Taiwan.
FAU - Shih, Ming-Kuei
AU  - Shih MK
AUID- ORCID: 0000-0001-5830-8591
AD  - Graduate Institute of Food Culture and Innovation, National Kaohsiung University 
      of Hospitality and Tourism, 812301 No.1, Songhe Rd., Xiaogang Dist., Kaohsiung 
      833, Taiwan.
FAU - Tain, You-Lin
AU  - Tain YL
AUID- ORCID: 0000-0002-7059-6407
AD  - Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung 
      University College of Medicine, Kaohsiung 833, Taiwan.
AD  - Institute for Translational Research in Biomedicine, Kaohsiung Chang Gung 
      Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 833, 
      Taiwan.
FAU - Yeh, Yao-Tsung
AU  - Yeh YT
AD  - Aging and Disease Prevention Research Center, Fooyin University, Kaohsiung 83102, 
      Taiwan.
AD  - Biomed Analysis Center, Fooyin University Hospital, Pingtung 92849, Taiwan.
FAU - Chiu, Min-Hsi
AU  - Chiu MH
AD  - Aging and Disease Prevention Research Center, Fooyin University, Kaohsiung 83102, 
      Taiwan.
AD  - Biomed Analysis Center, Fooyin University Hospital, Pingtung 92849, Taiwan.
FAU - Chang, Sam K C
AU  - Chang SKC
AD  - Experimental Seafood Processing Laboratory, Costal Research and Extension Center, 
      Mississippi State University, Pascagoula, MS 39567, USA.
AD  - Department of Food Science, Nutrition and Health Promotion, Mississippi State 
      University, Starkville, MS 39762, USA.
FAU - Hou, Chih-Yao
AU  - Hou CY
AUID- ORCID: 0000-0002-8007-6077
AD  - Department of Seafood Science, National Kaohsiung University of Science and 
      Technology, Kaohsiung 811, Taiwan.
LA  - eng
GR  - 108-2221-E-992 -046/Ministry of Science and Technology, Republic of China/
GR  - 109-2221-E-992-051/Ministry of Science and Technology, Republic of China/
GR  - SCA 5860667081/USDA-ARS/
GR  - CORPG8L0301/Kaohsiung Chang Gung Memorial Hospital , Taiwan/
PT  - Journal Article
DEP - 20210517
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Antioxidants)
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Butyrates)
RN  - 0 (Esters)
RN  - 0 (Fatty Acids, Volatile)
RN  - 0 (Phenols)
RN  - RW57K3X12M (bisphenol A)
RN  - Q369O8926L (Resveratrol)
SB  - IM
MH  - Animals
MH  - Antioxidants/metabolism
MH  - Benzhydryl Compounds/*adverse effects/pharmacology
MH  - Butyrates/metabolism
MH  - Esters/metabolism
MH  - Fatty Acids, Volatile/metabolism
MH  - Female
MH  - Gastrointestinal Microbiome
MH  - Liver/metabolism/pathology
MH  - Liver Diseases/metabolism/*prevention & control
MH  - Male
MH  - Phenols/*adverse effects/pharmacology
MH  - Pregnancy
MH  - Prenatal Exposure Delayed Effects/chemically induced
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Resveratrol/analogs & derivatives/*pharmacology
PMC - PMC8156118
OTO - NOTNLM
OT  - bisphenol A (BPA)
OT  - gut microbiota
OT  - maternal/fetal animal model
OT  - offspring
OT  - resveratrol butyrate esters (RBE)
OT  - short-chain fatty acids (SCFAs)
COIS- The authors declare no conflict of interest.
EDAT- 2021/06/03 06:00
MHDA- 2021/07/03 06:00
PMCR- 2021/05/17
CRDT- 2021/06/02 01:20
PHST- 2021/04/21 00:00 [received]
PHST- 2021/05/08 00:00 [revised]
PHST- 2021/05/14 00:00 [accepted]
PHST- 2021/06/02 01:20 [entrez]
PHST- 2021/06/03 06:00 [pubmed]
PHST- 2021/07/03 06:00 [medline]
PHST- 2021/05/17 00:00 [pmc-release]
AID - ijms22105273 [pii]
AID - ijms-22-05273 [pii]
AID - 10.3390/ijms22105273 [doi]
PST - epublish
SO  - Int J Mol Sci. 2021 May 17;22(10):5273. doi: 10.3390/ijms22105273.

PMID- 31926314
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20201109
IS  - 1872-7573 (Electronic)
IS  - 0378-8741 (Linking)
VI  - 252
DP  - 2020 Apr 24
TI  - Liuwei Dihuang prevents postmenopausal atherosclerosis and endothelial cell 
      apoptosis via inhibiting DNMT1-medicated ERα methylation.
PG  - 112531
LID - S0378-8741(19)31733-7 [pii]
LID - 10.1016/j.jep.2019.112531 [doi]
AB  - ETHNOPHARMACOLOGICAL RELEVANCE: The classical and traditional Chinese medicine 
      prescription, Liuwei Dihuang (LWDH), has been commonly used to treat the 
      menopausal syndrome. It has been reported that LWDH could improve estrogen 
      receptor α (ERα) expression to prevent atherosclerosis (AS), while the mechanism 
      of LWDH on regulating ERα expression was still unknown. AIM OF THE STUDY: To 
      reveal the mechanism of LWDH on regulating the ERα expression. MATERIALS AND 
      METHODS: The protective effect of LWDH on Hcy-induced apoptosis of human 
      umbilical vein endothelial cells (HUVECs) was examined. The expression of ERα and 
      DNA methyltransferases 1 (DNMT1) were detected by Western blot and real-time 
      polymerase chain reaction (RT-PCR). The methylation rate of the ERα gene was 
      assayed by the bisulfite sequencing PCR (BSP). High-performance liquid 
      chromatography-tandem mass spectrometry (HPLC-MS) was applied to determine the 
      level of S-Adenosyl methionine (SAM) and S-Adenosyl homocysteine (SAH). In vivo, 
      the ApoE(-/-) mice were ovariectomized to establish postmenopausal 
      atherosclerosis (AS) model. RESULTS: In vitro study showed that LWDH protects 
      HUVECs from Hcy-induced apoptosis. Treatment with LWDH significantly increased 
      the ERα expression and reduced the methylation rate of the ERα gene by inhibiting 
      the DNMT1 expression. The level of main methyl donor SAM and the ration of 
      SAM/SAH were reduced by LWDH. In vivo, LWDH prevented the formation of plaque and 
      reduced the concentration of Hcy. In addition, LWDH upregulated the ERα 
      expression, as well as inhibiting the expression of DNMT1 in atherosclerotic 
      mice. CONCLUSIONS: LWDH exerted protective effects on postmenopausal AS mice, and 
      HUVECs treated with Hcy. LWDH increased of ERα expression via inhibiting 
      DNMT1-dependent ERα methylation.
CI  - Copyright © 2020 Elsevier B.V. All rights reserved.
FAU - Chen, Qi
AU  - Chen Q
AD  - School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, 
      China. Electronic address: qchen10@qub.ac.uk.
FAU - Zhang, Yuhan
AU  - Zhang Y
AD  - School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, 
      China. Electronic address: 876498449@qq.com.
FAU - Meng, Qinghai
AU  - Meng Q
AD  - School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, 
      China. Electronic address: junmoyan@163.com.
FAU - Wang, Suyun
AU  - Wang S
AD  - School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, 
      China. Electronic address: 1272884802@qq.com.
FAU - Yu, Xichao
AU  - Yu X
AD  - School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, 
      China. Electronic address: 1776021742@qq.com.
FAU - Cai, Danfeng
AU  - Cai D
AD  - School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, 
      China. Electronic address: 1276384610@qq.com.
FAU - Cheng, Peng
AU  - Cheng P
AD  - School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, 
      China. Electronic address: 1020422949@qq.com.
FAU - Li, Yu
AU  - Li Y
AD  - School of Medicine and Life Sciences, Nanjing University of Chinese Medicine, 
      Nanjing, 210023, China. Electronic address: liyu@njucm.edu.cn.
FAU - Bian, Huimin
AU  - Bian H
AD  - School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, 
      China; Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese 
      Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China. 
      Electronic address: 320561@njucm.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20200108
PL  - Ireland
TA  - J Ethnopharmacol
JT  - Journal of ethnopharmacology
JID - 7903310
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Estrogen Receptor alpha)
RN  - 0 (Liuwei Dihuang Decoction)
RN  - EC 2.1.1.37 (DNA (Cytosine-5-)-Methyltransferase 1)
SB  - IM
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Atherosclerosis/*drug therapy/metabolism
MH  - Cells, Cultured
MH  - DNA (Cytosine-5-)-Methyltransferase 1/genetics/*metabolism
MH  - DNA Methylation/drug effects
MH  - Diet, High-Fat
MH  - Drugs, Chinese Herbal/*pharmacology/*therapeutic use
MH  - Estrogen Receptor alpha/genetics/*metabolism
MH  - Female
MH  - Human Umbilical Vein Endothelial Cells/*drug effects/physiology
MH  - Humans
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout, ApoE
MH  - Postmenopause
MH  - Rats, Sprague-Dawley
OTO - NOTNLM
OT  - ApoE(−/-) mice
OT  - Atherosclerosis
OT  - DNA methylation
OT  - Estrogen receptor α
OT  - HUVECs
OT  - Liuwei Dihuang
COIS- Declaration of competing interest All authors declare that they have no conflict 
      of interest.
EDAT- 2020/01/12 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/01/12 06:00
PHST- 2019/05/05 00:00 [received]
PHST- 2019/08/13 00:00 [revised]
PHST- 2019/12/25 00:00 [accepted]
PHST- 2020/01/12 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2020/01/12 06:00 [entrez]
AID - S0378-8741(19)31733-7 [pii]
AID - 10.1016/j.jep.2019.112531 [doi]
PST - ppublish
SO  - J Ethnopharmacol. 2020 Apr 24;252:112531. doi: 10.1016/j.jep.2019.112531. Epub 
      2020 Jan 8.

PMID- 27744701
OWN - NLM
STAT- MEDLINE
DCOM- 20180817
LR  - 20191008
IS  - 1520-6882 (Electronic)
IS  - 0003-2700 (Print)
IS  - 0003-2700 (Linking)
VI  - 88
IP  - 22
DP  - 2016 Nov 15
TI  - Evaluation of an Isotope Dilution HPLC Tandem Mass Spectrometry Candidate 
      Reference Measurement Procedure for Total 17-β Estradiol in Human Serum.
PG  - 11123-11129
AB  - The inaccuracy of 17-β estradiol (E2) measurements affects its use as a biomarker 
      in patient care and research. Clinical and research communities called for 
      accurate and standardized E2 measurements. Reference Measurement Procedures 
      (RMPs), part of the CDC Hormone Standardization Program (HoSt), are essential in 
      addressing this need and ensuring that methods are accurate and comparable across 
      testing systems, laboratories, and over time. A candidate RMP (cRMP) was 
      developed for the measurement of total E2 in serum using liquid 
      chromatography-tandem mass spectrometry (LC-MS/MS) without derivatization. The 
      cRMP meets suggested performance criteria for accuracy and precision through the 
      use of isotope dilution, calibrator bracketing, and gravimetric measurements. The 
      cRMP demonstrated high agreement with certified reference materials (no 
      significant bias to BCR576, 577, and 578) and established RMPs (slope 1.00, 95% 
      CI 1.00-1.01; intercept 0.02, 95% CI -0.01 to 0.06). The cRMP is highly precise 
      with intra-assay, interassay, and total percent CVs of 2.7%, 1.3%, and 2.4%, 
      respectively. A higher specificity was achieved by measuring E2 without 
      derivatization, compared to methods using derivatization agents. The cRMP can 
      serve as a higher-order standard for establishing measurement traceability and 
      provides an accuracy base against which routine methods can be compared in HoSt.
FAU - Botelho, Julianne Cook
AU  - Botelho JC
AD  - Centers For Disease Control And Prevention , National Center For Environmental 
      Health, Division of Laboratory Sciences, Clinical Chemistry Branch, 4770 Buford 
      Highway NE, Atlanta, Georgia 30341, United States.
FAU - Ribera, Ashley
AU  - Ribera A
AD  - Centers For Disease Control And Prevention , National Center For Environmental 
      Health, Division of Laboratory Sciences, Clinical Chemistry Branch, 4770 Buford 
      Highway NE, Atlanta, Georgia 30341, United States.
FAU - Cooper, Hans C
AU  - Cooper HC
AD  - Centers For Disease Control And Prevention , National Center For Environmental 
      Health, Division of Laboratory Sciences, Clinical Chemistry Branch, 4770 Buford 
      Highway NE, Atlanta, Georgia 30341, United States.
FAU - Vesper, Hubert W
AU  - Vesper HW
AD  - Centers For Disease Control And Prevention , National Center For Environmental 
      Health, Division of Laboratory Sciences, Clinical Chemistry Branch, 4770 Buford 
      Highway NE, Atlanta, Georgia 30341, United States.
LA  - eng
GR  - CC999999/Intramural CDC HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20161027
PL  - United States
TA  - Anal Chem
JT  - Analytical chemistry
JID - 0370536
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Chromatography, High Pressure Liquid/standards
MH  - Estradiol/*blood
MH  - Humans
MH  - Indicator Dilution Techniques/standards
MH  - Tandem Mass Spectrometry/standards
PMC - PMC5709807
MID - NIHMS920583
COIS- Notes The authors declare no competing financial interest.
EDAT- 2016/10/18 06:00
MHDA- 2018/08/18 06:00
PMCR- 2017/12/01
CRDT- 2016/10/18 06:00
PHST- 2016/10/18 06:00 [pubmed]
PHST- 2018/08/18 06:00 [medline]
PHST- 2016/10/18 06:00 [entrez]
PHST- 2017/12/01 00:00 [pmc-release]
AID - 10.1021/acs.analchem.6b03220 [doi]
PST - ppublish
SO  - Anal Chem. 2016 Nov 15;88(22):11123-11129. doi: 10.1021/acs.analchem.6b03220. 
      Epub 2016 Oct 27.

PMID- 39634415
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20241207
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Electronic)
IS  - 2405-8440 (Linking)
VI  - 10
IP  - 22
DP  - 2024 Nov 30
TI  - Development of a monoclonal antibody-based indirect competitive enzyme-linked 
      immunosorbent assay for screening of diethylstilbestrol in animal-derived foods.
PG  - e39769
LID - 10.1016/j.heliyon.2024.e39769 [doi]
LID - e39769
AB  - Diethylstilbestrol (DES), a synthetic non-steroid estrogen, it has been 
      prohibited from being added to animal feed for any purposes. Herein, an indirect 
      competitive enzyme-linked immunosorbent assay (ic-ELISA) based on a specific 
      monoclonal antibody (mAb) was developed for the rapid screening of DES. 
      Primarily, conjugates of mono-O-3-carboxypropyl diethylstilbestrol with keyhole 
      limpet hemocyanin were used to raise a specific mAb, 1B7, which had IC(50) value 
      for DES of 213.0 ng L(-1). The limits of detection and limits of quantification 
      value for DES in animal-derived foods ranged from 68.1 to 103.1 ng L(-1) and 
      100.8-192.7 ng L(-1), respectively. The DES recovery ranged from 70.1 % to 
      103.1 %, with coefficients of variation below 13.9 %. A positive correlation 
      (R(2) = 0.997) was observed between the results of ic-ELISA and HPLC-MS/MS for 
      milk. In order to inspect its detection effect, milk and animal-derived foods 
      were chosen as the testing object. The results showed that this ic-ELISA method 
      (specific mAb, 1B7) can effectively examine for DES residues.
CI  - © 2024 The Authors.
FAU - Fu, Bofei
AU  - Fu B
AD  - Jiulongpo Center for Disease Control and Prevention, Chongqing, 400039, China.
FAU - Gao, Haijiao
AU  - Gao H
AD  - National Reference Laboratory of Veterinary Drug Residues (HZAU) and MOA Key 
      Laboratory for the Detection of Veterinary Drug Residues, Huazhong Agricultural 
      University, Wuhan, Hubei, 430070, China.
AD  - Fengdu Animal Disease Prevention and Control Center, Chongqing, 408200, China.
FAU - Fang, Cuilan
AU  - Fang C
AD  - Jiulongpo Center for Disease Control and Prevention, Chongqing, 400039, China.
FAU - Cheng, Guyue
AU  - Cheng G
AD  - National Reference Laboratory of Veterinary Drug Residues (HZAU) and MOA Key 
      Laboratory for the Detection of Veterinary Drug Residues, Huazhong Agricultural 
      University, Wuhan, Hubei, 430070, China.
FAU - Wang, Hui
AU  - Wang H
AD  - National Reference Laboratory of Veterinary Drug Residues (HZAU) and MOA Key 
      Laboratory for the Detection of Veterinary Drug Residues, Huazhong Agricultural 
      University, Wuhan, Hubei, 430070, China.
FAU - Wang, Yulian
AU  - Wang Y
AD  - National Reference Laboratory of Veterinary Drug Residues (HZAU) and MOA Key 
      Laboratory for the Detection of Veterinary Drug Residues, Huazhong Agricultural 
      University, Wuhan, Hubei, 430070, China.
FAU - Hao, Haihong
AU  - Hao H
AD  - National Reference Laboratory of Veterinary Drug Residues (HZAU) and MOA Key 
      Laboratory for the Detection of Veterinary Drug Residues, Huazhong Agricultural 
      University, Wuhan, Hubei, 430070, China.
FAU - Wang, Xu
AU  - Wang X
AD  - National Reference Laboratory of Veterinary Drug Residues (HZAU) and MOA Key 
      Laboratory for the Detection of Veterinary Drug Residues, Huazhong Agricultural 
      University, Wuhan, Hubei, 430070, China.
FAU - Huang, Lingli
AU  - Huang L
AD  - National Reference Laboratory of Veterinary Drug Residues (HZAU) and MOA Key 
      Laboratory for the Detection of Veterinary Drug Residues, Huazhong Agricultural 
      University, Wuhan, Hubei, 430070, China.
FAU - Peng, Dapeng
AU  - Peng D
AD  - Center for Veterinary Sciences, Zhejiang University, Hangzhou, Zhejiang, 310058, 
      China.
AD  - National Reference Laboratory of Veterinary Drug Residues (HZAU) and MOA Key 
      Laboratory for the Detection of Veterinary Drug Residues, Huazhong Agricultural 
      University, Wuhan, Hubei, 430070, China.
LA  - eng
PT  - Journal Article
DEP - 20241031
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC11615517
OTO - NOTNLM
OT  - Animal-derived foods
OT  - Diethylstilbestrol
OT  - Indirect competitive enzyme-linked immunosorbent assay
OT  - Monoclonal antibody
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2024/12/05 06:23
MHDA- 2024/12/05 06:24
PMCR- 2024/10/31
CRDT- 2024/12/05 05:37
PHST- 2024/07/05 00:00 [received]
PHST- 2024/10/22 00:00 [revised]
PHST- 2024/10/23 00:00 [accepted]
PHST- 2024/12/05 06:24 [medline]
PHST- 2024/12/05 06:23 [pubmed]
PHST- 2024/12/05 05:37 [entrez]
PHST- 2024/10/31 00:00 [pmc-release]
AID - S2405-8440(24)15800-8 [pii]
AID - e39769 [pii]
AID - 10.1016/j.heliyon.2024.e39769 [doi]
PST - epublish
SO  - Heliyon. 2024 Oct 31;10(22):e39769. doi: 10.1016/j.heliyon.2024.e39769. 
      eCollection 2024 Nov 30.

PMID- 39110531
OWN - NLM
STAT- MEDLINE
DCOM- 20241210
LR  - 20250129
IS  - 1460-2105 (Electronic)
IS  - 0027-8874 (Print)
IS  - 0027-8874 (Linking)
VI  - 116
IP  - 12
DP  - 2024 Dec 1
TI  - Drug and biomarker tissue levels in a randomized presurgical trial on exemestane 
      alternative schedules.
PG  - 1979-1982
LID - 10.1093/jnci/djae183 [doi]
AB  - The drug's activity at the target tissue could help to define the minimal 
      effective dose to promote cancer preventive therapy. Here we present exemestane 
      and sex hormone concentrations within breast tissue from a presurgical study of 
      alternative exemestane schedules. Postmenopausal women candidates for breast 
      surgery for estrogen receptor-positive breast cancer were randomly assigned to 
      exemestane 25 mg once daily (QD), 25 mg 3 times/week (TIW), or 25 mg per week 
      (QW) for 4-6 weeks before surgery. Drug and sex hormones were analyzed from 
      homogenized frozen tissue using a QTRAP 6500+ LC-MS/MS System. Tissue drug 
      concentrations were detectable only in the QD arm with higher concentrations in 
      nonmalignant tissue. Estradiol was nearly suppressed in all groups in the 
      nonmalignant tissue (QD vs TIW P = .364 and QD vs QW P = .693). In contrast, a 
      dose-response trend was observed in cancer tissue. Based on estradiol suppression 
      in nonmalignant tissue, lower exemestane schedules should be explored for breast 
      cancer preventive therapy. Trial Registration: Clinical Trials.gov NCT02598557 
      and EudraCT 2015-005063-1.
CI  - © The Author(s) 2024. Published by Oxford University Press.
FAU - Serrano, Davide
AU  - Serrano D
AUID- ORCID: 0000-0002-2945-4108
AD  - Division of Cancer Prevention and Genetics, European Institute of Oncology IRCCS, 
      Milan, Italy.
FAU - Johansson, Harriet
AU  - Johansson H
AD  - Division of Cancer Prevention and Genetics, European Institute of Oncology IRCCS, 
      Milan, Italy.
FAU - Bertelsen, Bjørn-Erik
AU  - Bertelsen BE
AUID- ORCID: 0000-0001-8455-2176
AD  - Hormone Laboratory, Department of Medical Biochemistry and Pharmacology, 
      Haukeland University Hospital, Bergen, Norway.
FAU - Gandini, Sara
AU  - Gandini S
AD  - Division of Cancer Prevention and Genetics, European Institute of Oncology IRCCS, 
      Milan, Italy.
FAU - Mellgren, Gunnar
AU  - Mellgren G
AD  - Hormone Laboratory, Department of Medical Biochemistry and Pharmacology, 
      Haukeland University Hospital, Bergen, Norway.
AD  - Department of Clinical Science, University of Bergen, Bergen, Norway.
FAU - Thomas, Parijatham
AU  - Thomas P
AD  - Department of Clinical Cancer Prevention, University of Texas, MD Anderson Cancer 
      Center, Houston, TX, USA.
FAU - Crew, Katherine D
AU  - Crew KD
AD  - Clinical Breast Cancer Prevention Program, Columbia University Irving Medical 
      Center, New York, NY, USA.
FAU - Kumar, Nagi B
AU  - Kumar NB
AD  - Departments Cancer Epidemiology, Genitourinary and Breast Oncology, Moffitt 
      Cancer Center, University of South Florida, Tampa, FL, USA.
FAU - Macis, Debora
AU  - Macis D
AD  - Division of Cancer Prevention and Genetics, European Institute of Oncology IRCCS, 
      Milan, Italy.
FAU - Aristarco, Valentina
AU  - Aristarco V
AD  - Division of Cancer Prevention and Genetics, European Institute of Oncology IRCCS, 
      Milan, Italy.
FAU - Guerrieri-Gonzaga, Aliana
AU  - Guerrieri-Gonzaga A
AD  - Division of Cancer Prevention and Genetics, European Institute of Oncology IRCCS, 
      Milan, Italy.
FAU - Lazzeroni, Matteo
AU  - Lazzeroni M
AUID- ORCID: 0000-0002-2162-4002
FAU - D'Amico, Mauro
AU  - D'Amico M
AD  - Medical Oncology, Ospedali Galliera, Genoa, Italy.
FAU - Buttiron-Webber, Tania
AU  - Buttiron-Webber T
AD  - Medical Oncology, Ospedali Galliera, Genoa, Italy.
FAU - Briata, Irene Maria
AU  - Briata IM
AD  - Medical Oncology, Ospedali Galliera, Genoa, Italy.
FAU - Spinaci, Stefano
AU  - Spinaci S
AD  - Breast Unit, Ospedale Villa Scassi ASL3, Genoa, Italy.
FAU - Galimberti, Viviana
AU  - Galimberti V
AD  - Division of Cancer Prevention and Genetics, European Institute of Oncology IRCCS, 
      Milan, Italy.
FAU - Vornik, Lana A
AU  - Vornik LA
AD  - Department of Clinical Cancer Prevention, University of Texas, MD Anderson Cancer 
      Center, Houston, TX, USA.
FAU - Villar-Sanchez, Eduardo
AU  - Villar-Sanchez E
AD  - Department of Clinical Cancer Prevention, University of Texas, MD Anderson Cancer 
      Center, Houston, TX, USA.
FAU - Brown, Powel H
AU  - Brown PH
AD  - Department of Clinical Cancer Prevention, University of Texas, MD Anderson Cancer 
      Center, Houston, TX, USA.
FAU - Heckman-Stoddard, Brandy M
AU  - Heckman-Stoddard BM
AD  - Division of Cancer Prevention, NCI, Bethesda, MD, USA.
FAU - Szabo, Eva
AU  - Szabo E
AD  - Division of Cancer Prevention, NCI, Bethesda, MD, USA.
FAU - Bonanni, Bernardo
AU  - Bonanni B
AD  - Division of Cancer Prevention and Genetics, European Institute of Oncology IRCCS, 
      Milan, Italy.
FAU - DeCensi, Andrea
AU  - DeCensi A
AD  - Medical Oncology, Ospedali Galliera, Genoa, Italy.
AD  - Wolfson Institute of Population Health, Queen Mary University of London, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT02598557
GR  - HHSN261201200034C/CA/NCI NIH HHS/United States
GR  - 5X1000/Italian Ministry of Health/
GR  - HHSN261201200034I/BC/NCI NIH HHS/United States
GR  - The University of Texas MD Anderson Cancer Center Duncan Family Institute for 
      Cancer Prevention and Risk Assessment/
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Natl Cancer Inst
JT  - Journal of the National Cancer Institute
JID - 7503089
RN  - NY22HMQ4BX (exemestane)
RN  - 0 (Androstadienes)
RN  - 4TI98Z838E (Estradiol)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Aromatase Inhibitors)
RN  - 0 (Receptors, Estrogen)
SB  - IM
EIN - J Natl Cancer Inst. 2025 Jan 28:djaf018. doi: 10.1093/jnci/djaf018. PMID: 
      39873670
MH  - Humans
MH  - Female
MH  - *Breast Neoplasms/surgery/chemistry/prevention & control/drug therapy
MH  - *Androstadienes/administration & dosage
MH  - Middle Aged
MH  - Aged
MH  - *Estradiol/administration & dosage
MH  - Biomarkers, Tumor/analysis
MH  - Postmenopause
MH  - Drug Administration Schedule
MH  - Aromatase Inhibitors/administration & dosage
MH  - Tandem Mass Spectrometry
MH  - Receptors, Estrogen/analysis/metabolism
PMC - PMC11630545
COIS- Dr Brown is the principal investigator of the National Cancer Institute grant 
      that supported this clinical trial and received partial salary support from this 
      grant during the conduct of the study; he also holds stock from GeneTex, an 
      antibody reagent company. No other disclosures were reported.
EDAT- 2024/08/07 18:42
MHDA- 2024/12/11 05:29
PMCR- 2024/08/07
CRDT- 2024/08/07 12:03
PHST- 2024/07/29 00:00 [accepted]
PHST- 2024/04/17 00:00 [received]
PHST- 2024/06/19 00:00 [revised]
PHST- 2024/12/11 05:29 [medline]
PHST- 2024/08/07 18:42 [pubmed]
PHST- 2024/08/07 12:03 [entrez]
PHST- 2024/08/07 00:00 [pmc-release]
AID - 7729127 [pii]
AID - djae183 [pii]
AID - 10.1093/jnci/djae183 [doi]
PST - ppublish
SO  - J Natl Cancer Inst. 2024 Dec 1;116(12):1979-1982. doi: 10.1093/jnci/djae183.

PMID- 32247153
OWN - NLM
STAT- MEDLINE
DCOM- 20201120
LR  - 20201120
IS  - 1096-0953 (Electronic)
IS  - 0013-9351 (Linking)
VI  - 185
DP  - 2020 Jun
TI  - Associations between functional polychlorinated biphenyls in adipose tissues and 
      prognostic biomarkers of breast cancer patients.
PG  - 109441
LID - S0013-9351(20)30334-0 [pii]
LID - 10.1016/j.envres.2020.109441 [doi]
AB  - BACKGROUND: Exposure to polychlorinated biphenyls (PCBs) has been shown to 
      influence expression of some biomarkers that are predictive/prognostic for breast 
      cancer. Therefore, our study was conducted to further investigating associations 
      of different functional PCBs in adipose tissue with breast cancer prognostic 
      biomarkers. METHODS: Two hundred and five breast cancer patients were recruited 
      in Shantou, China. Breast adipose tissues were collected during their resection 
      surgery and levels of 7 PCB congeners were analyzed by gas chromatography-mass 
      spectrometry (GC-MS). The PCB congeners were divided into 4 groups according to 
      structure-activity. Socio-demographic, clinical and pathological information were 
      obtained from questionnaire and digital medical records. Odds ratios (ORs) for 
      associations between prognostic biomarkers and PCB levels (tertile 3 [T3], 
      tertile 2 [T2] vs. tertile 1) were estimated from logistic regression models. 
      RESULTS: Most PCB congeners were detectable, with a highest level (22.06 ng/g 
      lipid) of PCB153. As for estrogenic PCBs, increased PCB52 exposure was positively 
      associated with PR expression (OR(T2) = 2.36, P(trend) = 0.054), but higher 
      PCB101 level was negatively associated with HER-2 (OR(T3) = 0.24, 
      P(trend) = 0.029) and tumor size (OR = 0.43). Limited dioxin-like PCB138 exposure 
      was positively associated with ER (OR(T2) = 3.23, OR(T3) = 3.77, 
      P(trend) = 0.047) but negatively with Top-IIα expression (OR(T2) = 0.35, 
      OR(T3) = 0.28, P(trend) = 0.080). Higher PCB153 (CYP inducer) level was 
      negatively associated with ER (OR(T2) = 0.32, OR(T3) = 0.19, P(trend) = 0.038) 
      but positively with Ki-67 expression (OR(T2) = 1.43, OR(T3) = 3.60, 
      P(trend) = 0.055). Higher neurotoxic PCB28 was positively associated with HER-2 
      (OR(T3) = 5.43, P(trend) = 0.006) and tumor size (OR = 2.37). Moreover, total 
      PCBs exposure was positively associated with VEGF-C (OR(T2) = 76.91, 
      OR(T3) = 97.96, P(trend) = 0.041) and tumor metastasis (OR = 2.25). CONCLUSIONS: 
      Different functional PCB congeners have different associations (both positive and 
      negative) with breast cancer prognostic biomarkers, as well as tumor 
      classification stage. Therefore, the development and aggressiveness of breast 
      cancer may depend upon exposure to specific structure-activity of PCBs.
CI  - Copyright © 2020 Elsevier Inc. All rights reserved.
FAU - Qiu, Zhaolong
AU  - Qiu Z
AD  - Department of Preventive Medicine, Shantou University Medical College, Shantou, 
      515041, Guangdong Province, China.
FAU - Xiao, Jiefeng
AU  - Xiao J
AD  - Department of Preventive Medicine, Shantou University Medical College, Shantou, 
      515041, Guangdong Province, China.
FAU - Zheng, Shukai
AU  - Zheng S
AD  - Department of Preventive Medicine, Shantou University Medical College, Shantou, 
      515041, Guangdong Province, China.
FAU - Huang, Wenlong
AU  - Huang W
AD  - Department of Preventive Medicine, Shantou University Medical College, Shantou, 
      515041, Guangdong Province, China.
FAU - Du, Taifeng
AU  - Du T
AD  - Department of Preventive Medicine, Shantou University Medical College, Shantou, 
      515041, Guangdong Province, China.
FAU - Au, William W
AU  - Au WW
AD  - University of Medicine, Pharmacy, Science and Technology, Targu Mures, Romania.
FAU - Wu, Kusheng
AU  - Wu K
AD  - Department of Preventive Medicine, Shantou University Medical College, Shantou, 
      515041, Guangdong Province, China. Electronic address: kswu@stu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200329
PL  - Netherlands
TA  - Environ Res
JT  - Environmental research
JID - 0147621
RN  - DFC2HB4I0K (Polychlorinated Biphenyls)
SB  - IM
MH  - Adipose Tissue/chemistry
MH  - *Breast Neoplasms
MH  - China
MH  - Humans
MH  - *Polychlorinated Biphenyls/analysis
MH  - Prognosis
OTO - NOTNLM
OT  - Breast cancer
OT  - Estrogen receptor (ER)
OT  - Human epidermal growth factor receptor-2 (HER-2)
OT  - Ki-67
OT  - Polychlorinated biphenyls (PCBs)
OT  - Progesterone receptor (PR)
OT  - Prognostic biomarkers
OT  - Topoisomerase-IIα (Top-IIα)
OT  - Vascular endothelial growth factor-c (VEGF-C)
COIS- Declaration of competing interest The authors declare that they have no competing 
      interests.
EDAT- 2020/04/05 06:00
MHDA- 2020/11/21 06:00
CRDT- 2020/04/05 06:00
PHST- 2019/12/14 00:00 [received]
PHST- 2020/03/23 00:00 [revised]
PHST- 2020/03/24 00:00 [accepted]
PHST- 2020/04/05 06:00 [pubmed]
PHST- 2020/11/21 06:00 [medline]
PHST- 2020/04/05 06:00 [entrez]
AID - S0013-9351(20)30334-0 [pii]
AID - 10.1016/j.envres.2020.109441 [doi]
PST - ppublish
SO  - Environ Res. 2020 Jun;185:109441. doi: 10.1016/j.envres.2020.109441. Epub 2020 
      Mar 29.

PMID- 33515877
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20250103
IS  - 1879-1026 (Electronic)
IS  - 0048-9697 (Linking)
VI  - 770
DP  - 2021 May 20
TI  - Hepatoprotective effects of oridonin against bisphenol A induced liver injury in 
      rats via inhibiting the activity of xanthione oxidase.
PG  - 145301
LID - S0048-9697(21)00367-3 [pii]
LID - 10.1016/j.scitotenv.2021.145301 [doi]
AB  - Bisphenol A (BPA) is widely used to manufacture packaging materials for various 
      daily necessities and causes harmful effects in organs, especially liver injury, 
      by generating oxidative stress. Oridonin, an active diterpenoid isolated from 
      Rabdosia rubescens (Hemsl.) Hara, has been reported to possess a wide range of 
      pharmacological activities including anti-inflammatory, antioxidative and 
      antiapoptotic effects. However, the role of oridonin in BPA--induced liver injury 
      and its potential protective mechanism have not been well characterized. In this 
      research, we explored the metabolic alterations in the liver tissue of rats after 
      exposure to BPA with or without pretreatment with oridonin for 14 days by 
      metabolomics analysis based on UPLC-MS/MS. Rats were randomly divided into groups 
      as follows: Control, Vehicle, Oridonin (10 mg/kg), Bisphenol A (500 mg/kg), 
      bisphenol A + Oridonin (500 + 10 mg/kg), Bisphenol A + Diammonium glycyrrhizinate 
      (500 + 40 mg/kg). The biochemical results showed that oridonin significantly 
      reduced the levels of AST and ALT (P < 0.05), ameliorated the abnormal 
      histopathological changes and reduced hepatic apoptosis compared with the BPA 
      group. Furthermore, metabolomics results revealed that purine metabolism, 
      phenylalanine, tyrosine and tryptophan biosynthesis and phenylalanine metabolism 
      were reprogrammed, based on 28 identified significant differential metabolites 
      among the Vehicle, BPA and BPA + oridonin groups. In-depth studies demonstrated 
      that pretreatment with oridonin may play a protective role by restoring 
      BPA-induced changes in oxidative stress and the activity of oxidase (XOD) 
      (P < 0.05). Additionally, oridonin could inhibit the activity of XOD by binding 
      to it, therefore decreasing the reactive oxygen species (ROS) level, upregulating 
      the content of hypoxanthine and xanthine, and reducing the level of uric acid in 
      the liver (P < 0.05). This research presents the potential protective mechanisms 
      of oridonin on BPA-induced liver injury at the metabolic level, which might be 
      used to identify new protective agents that prevent BPA-induced liver injury.
CI  - Copyright © 2021. Published by Elsevier B.V.
FAU - Wang, Xinying
AU  - Wang X
AD  - Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education 
      of China, Co-innovation Center of Henan Province for New drug R & D and 
      preclinical Safety, School of Pharmaceutical Sciences, Zhengzhou University, 
      Zhengzhou, Henan 450001, PR China.
FAU - Gao, Ming
AU  - Gao M
AD  - Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education 
      of China, Co-innovation Center of Henan Province for New drug R & D and 
      preclinical Safety, School of Pharmaceutical Sciences, Zhengzhou University, 
      Zhengzhou, Henan 450001, PR China.
FAU - Wang, Zihan
AU  - Wang Z
AD  - Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education 
      of China, Co-innovation Center of Henan Province for New drug R & D and 
      preclinical Safety, School of Pharmaceutical Sciences, Zhengzhou University, 
      Zhengzhou, Henan 450001, PR China.
FAU - Cui, Weiqi
AU  - Cui W
AD  - Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education 
      of China, Co-innovation Center of Henan Province for New drug R & D and 
      preclinical Safety, School of Pharmaceutical Sciences, Zhengzhou University, 
      Zhengzhou, Henan 450001, PR China.
FAU - Zhang, Jingxian
AU  - Zhang J
AD  - Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education 
      of China, Co-innovation Center of Henan Province for New drug R & D and 
      preclinical Safety, School of Pharmaceutical Sciences, Zhengzhou University, 
      Zhengzhou, Henan 450001, PR China.
FAU - Zhang, Weijie
AU  - Zhang W
AD  - Henan Joint International Research Laboratory of Chronic Liver Injury, Henan Key 
      Laboratory of Rehabilitation Medicine, Department of Pediatrics, the Fifth 
      Affiliated Hospital, Zhengzhou University, Kangfuqian Street, Zhengzhou, Henan 
      450052, PR China.
FAU - Xia, Yu
AU  - Xia Y
AD  - Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education 
      of China, Co-innovation Center of Henan Province for New drug R & D and 
      preclinical Safety, School of Pharmaceutical Sciences, Zhengzhou University, 
      Zhengzhou, Henan 450001, PR China.
FAU - Wei, Bo
AU  - Wei B
AD  - Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education 
      of China, Co-innovation Center of Henan Province for New drug R & D and 
      preclinical Safety, School of Pharmaceutical Sciences, Zhengzhou University, 
      Zhengzhou, Henan 450001, PR China. Electronic address: weibozz101@163.com.
FAU - Tang, Youcai
AU  - Tang Y
AD  - Henan Joint International Research Laboratory of Chronic Liver Injury, Henan Key 
      Laboratory of Rehabilitation Medicine, Department of Pediatrics, the Fifth 
      Affiliated Hospital, Zhengzhou University, Kangfuqian Street, Zhengzhou, Henan 
      450052, PR China. Electronic address: tangyoucai@hotmail.com.
FAU - Xu, Xia
AU  - Xu X
AD  - Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education 
      of China, Co-innovation Center of Henan Province for New drug R & D and 
      preclinical Safety, School of Pharmaceutical Sciences, Zhengzhou University, 
      Zhengzhou, Henan 450001, PR China. Electronic address: xuxia@zzu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20210121
PL  - Netherlands
TA  - Sci Total Environ
JT  - The Science of the total environment
JID - 0330500
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Diterpenes, Kaurane)
RN  - 0 (Phenols)
RN  - 0APJ98UCLQ (oridonin)
RN  - EC 1.- (Oxidoreductases)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - Animals
MH  - Benzhydryl Compounds/metabolism/toxicity
MH  - *Chemical and Drug Induced Liver Injury, Chronic/metabolism
MH  - Chromatography, Liquid
MH  - Diterpenes, Kaurane
MH  - Liver/metabolism
MH  - Oxidative Stress
MH  - Oxidoreductases/metabolism
MH  - Phenols
MH  - Rats
MH  - Tandem Mass Spectrometry
OTO - NOTNLM
OT  - Bisphenol A
OT  - Liver injury
OT  - Metabolomics
OT  - Oridonin
OT  - Xanthione oxidase
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2021/01/31 06:00
MHDA- 2021/03/19 06:00
CRDT- 2021/01/30 20:11
PHST- 2020/10/10 00:00 [received]
PHST- 2021/01/05 00:00 [revised]
PHST- 2021/01/16 00:00 [accepted]
PHST- 2021/01/31 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
PHST- 2021/01/30 20:11 [entrez]
AID - S0048-9697(21)00367-3 [pii]
AID - 10.1016/j.scitotenv.2021.145301 [doi]
PST - ppublish
SO  - Sci Total Environ. 2021 May 20;770:145301. doi: 10.1016/j.scitotenv.2021.145301. 
      Epub 2021 Jan 21.

PMID- 34209270
OWN - NLM
STAT- MEDLINE
DCOM- 20210714
LR  - 20250103
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 26
IP  - 13
DP  - 2021 Jun 30
TI  - Resveratrol Butyrate Esters Inhibit Obesity Caused by Perinatal Exposure to 
      Bisphenol A in Female Offspring Rats.
LID - 10.3390/molecules26134010 [doi]
LID - 4010
AB  - Resveratrol butyrate esters (RBE) are derivatives of resveratrol (RSV) and 
      butyric acid and exhibit biological activity similar to that of RSV but with 
      higher bioavailability. The aim of this study was designed as an animal 
      experiment to explore the effects of RBE on the serum biochemistry, and fat 
      deposits in the offspring rats exposed to bisphenol A (BPA), along with the 
      growth and decline of gut microbiota. We constructed an animal model of perinatal 
      Bisphenol A (BPA) exposure to observe the effects of RBE supplementation on 
      obesity, blood lipids, and intestinal microbiota in female offspring rats. 
      Perinatal exposure to BPA led to weight gain, lipid accumulation, high levels of 
      blood lipids, and deterioration of intestinal microbiota in female offspring 
      rats. RBE supplementation reduced the weight gain and lipid accumulation caused 
      by BPA, optimised the levels of blood lipids, significantly reduced the 
      Firmicutes/Bacteroidetes (F/B) ratio, and increased and decreased the abundance 
      of S24-7 and Lactobacillus, respectively. The analysis of faecal short-chain 
      fatty acid (SCFA) levels revealed that BPA exposure increased the faecal 
      concentration of acetate, which could be reduced via RBE supplementation. 
      However, the faecal concentrations of propionate and butyrate were not only 
      significantly lower than that of acetate, but also did not significantly change 
      in response to BPA exposure or RBE supplementation. Hence, RBE can suppress 
      BPA-induced obesity in female offspring rats, and it demonstrates excellent 
      modulatory activity on intestinal microbiota, with potential applications in 
      perinatological research.
FAU - Shih, Ming-Kuei
AU  - Shih MK
AUID- ORCID: 0000-0001-5830-8591
AD  - Graduate Institute of Food Culture and Innovation, National Kaohsiung University 
      of Hospitality and Tourism, No.1, Songhe Rd., Xiaogang Dist., Kaohsiung City 812, 
      Taiwan.
FAU - Tain, You-Lin
AU  - Tain YL
AUID- ORCID: 0000-0002-7059-6407
AD  - Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung 
      University College of Medicine, Kaohsiung 833, Taiwan.
AD  - Institute for Translational Research in Biomedicine, Kaohsiung Chang Gung 
      Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 833, 
      Taiwan.
FAU - Chen, Yu-Wei
AU  - Chen YW
AD  - Department of Medicine, Chang Gung University, Linkow 333, Taiwan.
FAU - Hsu, Wei-Hsuan
AU  - Hsu WH
AUID- ORCID: 0000-0002-6598-6435
AD  - Department of Food Safety/Hygiene and Risk Management, College of Medicine, 
      National Cheng Kung University, Tainan 704, Taiwan.
FAU - Yeh, Yao-Tsung
AU  - Yeh YT
AD  - Aging and Disease Prevention Research Center, Fooyin University, Kaohsiung 831, 
      Taiwan.
AD  - Biomed Analysis Center, Fooyin University Hospital, Pingtung 928, Taiwan.
FAU - Chang, Sam K C
AU  - Chang SKC
AD  - Experimental Seafood Processing Laboratory, Costal Research and Extension Center, 
      Mississippi State University, Starkville, MS 39567, USA.
AD  - Department of Food Science, Nutrition and Health Promotion, Mississippi State 
      University, Starkville, MS 39762, USA.
FAU - Liao, Jin-Xian
AU  - Liao JX
AD  - Department of Seafood Science, National Kaohsiung University of Science and 
      Technology, Kaohsiung 824, Taiwan.
FAU - Hou, Chih-Yao
AU  - Hou CY
AUID- ORCID: 0000-0002-8007-6077
AD  - Department of Seafood Science, National Kaohsiung University of Science and 
      Technology, Kaohsiung 824, Taiwan.
LA  - eng
GR  - 108-2221-E-992-046/Ministry of Science and Technology, Republic of China/
GR  - 109-2221-E-992-051/Ministry of Science and Technology, Republic of China/
GR  - grant no. CORPG8L0301/Kaohsiung Chang Gung Memorial Hospital, Taiwan/
GR  - SCA 5860667081/USDA-ARS/
PT  - Journal Article
DEP - 20210630
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Fatty Acids, Volatile)
RN  - 0 (Phenols)
RN  - 107-92-6 (Butyric Acid)
RN  - RW57K3X12M (bisphenol A)
RN  - Q369O8926L (Resveratrol)
SB  - IM
MH  - Animals
MH  - Benzhydryl Compounds/*toxicity
MH  - Butyric Acid/*pharmacology
MH  - Fatty Acids, Volatile/metabolism
MH  - Female
MH  - Gastrointestinal Microbiome/drug effects
MH  - *Obesity/chemically induced/drug therapy/metabolism
MH  - Phenols/*toxicity
MH  - Pregnancy
MH  - *Prenatal Exposure Delayed Effects/chemically induced/drug therapy/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Resveratrol/*pharmacology
PMC - PMC8271435
OTO - NOTNLM
OT  - Firmicutes/Bacteroidetes (F/B) ratio
OT  - bisphenol A (BPA)
OT  - obesity
OT  - perinatal exposure
OT  - resveratrol butyrate esters (RBEs)
COIS- The authors declare no conflict of interest.
EDAT- 2021/07/03 06:00
MHDA- 2021/07/15 06:00
PMCR- 2021/06/30
CRDT- 2021/07/02 01:37
PHST- 2021/06/02 00:00 [received]
PHST- 2021/06/17 00:00 [revised]
PHST- 2021/06/28 00:00 [accepted]
PHST- 2021/07/02 01:37 [entrez]
PHST- 2021/07/03 06:00 [pubmed]
PHST- 2021/07/15 06:00 [medline]
PHST- 2021/06/30 00:00 [pmc-release]
AID - molecules26134010 [pii]
AID - molecules-26-04010 [pii]
AID - 10.3390/molecules26134010 [doi]
PST - epublish
SO  - Molecules. 2021 Jun 30;26(13):4010. doi: 10.3390/molecules26134010.

PMID- 27668549
OWN - NLM
STAT- MEDLINE
DCOM- 20170227
LR  - 20220409
IS  - 1873-2933 (Electronic)
IS  - 0009-9120 (Linking)
VI  - 50
IP  - 3
DP  - 2017 Feb
TI  - Salivary estradiol as a surrogate marker for serum estradiol in assisted 
      reproduction treatment.
PG  - 145-149
LID - S0009-9120(16)30325-3 [pii]
LID - 10.1016/j.clinbiochem.2016.09.016 [doi]
AB  - INTRODUCTION: Controlled ovarian hyper-stimulation for in vitro fertilization or 
      intra cytoplasmatic sperm injection necessitates close monitoring using 
      ultrasound and estradiol measurements. Monitoring is also important to prevent or 
      limit the severity of ovarian hyper stimulation syndrome, an iatrogenic and 
      potentially life-threatening complication. Self-operated endovaginal 
      telemonitoring has been shown to offer an attractive and less costly alternative 
      to classic consultation and saliva estradiol measurements could be a stress-free 
      and practical alternative to serial blood determinations. Objectives were to 
      evaluate whether saliva can be a surrogate marker for serum estradiol and its 
      potential applicability in assisted reproduction treatment monitoring. MATERIAL 
      AND METHODS: Serial blood and saliva samples were collected from 31 patients 
      undergoing ovarian hyper-stimulation. All patients were followed-up using 
      in-house serial vaginal sonograms and immunoassay serum estradiol measurements. 
      Afterwards estradiol was determined in saliva and serum by LC-MS/MS. For a subset 
      equilibrium dialysis and measurement of free serum estradiol was performed. 
      RESULTS: About 1% of estradiol is present in serum in its free, unbound, form. 
      Salivary estradiol correlates well to both serum free estradiol and serum total 
      estradiol (r=0.80). The concentration of salivary estradiol corresponds to the 
      unbound concentration in serum. The dynamics observed in serum monitoring during 
      treatment are closely mimicked in saliva. ROC analysis on the current limited 
      dataset suggested a saliva cut-off of 22pg/mL (81pmol/L) could help predict risk 
      for OHSS. CONCLUSIONS: Salivary E2 can be considered a surrogate marker for free 
      serum estradiol and total serum estradiol in assisted reproduction treatment. 
      Additionally there might be a role as a prediction marker for OHSS although this 
      finding has to be validated in larger datasets.
CI  - Copyright © 2016 The Canadian Society of Clinical Chemists. Published by Elsevier 
      Inc. All rights reserved.
FAU - Fiers, Tom
AU  - Fiers T
AD  - UZ Gent, Clinical Pathology Dept., Belgium. Electronic address: 
      tom.fiers@uzgent.be.
FAU - Dielen, Caroline
AU  - Dielen C
AD  - UZ Gent, Gynecology Dept., Belgium.
FAU - Somers, Sara
AU  - Somers S
AD  - UZ Gent, Gynecology Dept., Belgium.
FAU - Kaufman, Jean-Marc
AU  - Kaufman JM
AD  - UZ Gent, Endocrinology Dept., Belgium.
FAU - Gerris, Jan
AU  - Gerris J
AD  - UZ Gent, Gynecology Dept., Belgium.
LA  - eng
PT  - Journal Article
DEP - 20160923
PL  - United States
TA  - Clin Biochem
JT  - Clinical biochemistry
JID - 0133660
RN  - 0 (Biomarkers)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Biomarkers/analysis/*blood
MH  - Estradiol/analysis/*blood
MH  - Female
MH  - Humans
MH  - Reproductive Techniques, Assisted
MH  - Saliva/*chemistry
MH  - Tandem Mass Spectrometry
OTO - NOTNLM
OT  - Equilibrium dialysis
OT  - Estradiol
OT  - LC-MS/MS
OT  - Ovarian hyper stimulation syndrome
OT  - Saliva
EDAT- 2016/09/27 06:00
MHDA- 2017/02/28 06:00
CRDT- 2016/09/27 06:00
PHST- 2016/07/07 00:00 [received]
PHST- 2016/09/06 00:00 [revised]
PHST- 2016/09/20 00:00 [accepted]
PHST- 2016/09/27 06:00 [pubmed]
PHST- 2017/02/28 06:00 [medline]
PHST- 2016/09/27 06:00 [entrez]
AID - S0009-9120(16)30325-3 [pii]
AID - 10.1016/j.clinbiochem.2016.09.016 [doi]
PST - ppublish
SO  - Clin Biochem. 2017 Feb;50(3):145-149. doi: 10.1016/j.clinbiochem.2016.09.016. 
      Epub 2016 Sep 23.

PMID- 37595429
OWN - NLM
STAT- MEDLINE
DCOM- 20230918
LR  - 20230918
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 166
DP  - 2023 Oct
TI  - Aikeqing, a kidney- and spleen-tonifying compound Chinese medicine granule, 
      prevented ovariectomy-induced bone loss in rats via the suppression of 
      osteoclastogenesis.
PG  - 115339
LID - S0753-3322(23)01130-7 [pii]
LID - 10.1016/j.biopha.2023.115339 [doi]
AB  - Postmenopausal women are prone to osteoporosis due to increased osteoclast 
      activation and bone resorption caused by oestrogen deficiency. In Traditional 
      Chinese Medicine theory, medicines with spleen- and kidney-nourishing effects are 
      commonly used in postmenopausal osteoporosis (PMOP) treatment. Aikeqing (AKQ) is 
      a compound Chinese medicinal granule with spleen- and kidney-nourishing effects. 
      Herein, we investigate the in vitro and in vivo anti-osteoporotic effects of AKQ, 
      its underlying mechanisms and pharmacodynamic basis. In vitro antiosteoporotic 
      effects of AKQ were assessed by its ability to promote osteoblastogenesis in 
      MC3T3-E1 and/or inhibit RANKL-induced osteoclastogenesis in murine bone marrow 
      monocytes (BMMs). The protective effect of AKQ on bone loss induced by oestrogen 
      deficiency was evaluated in ovariectomized rats. The underlying mechanisms were 
      studied in BMMs by detecting the effects of AKQ on the RANKL-induced expression 
      of genes and proteins involved in the regulation of osteoclastogenesis. The main 
      chemical constituents of AKQ in the granule were analyzed by UPLC-QTOF-MS. Our 
      findings show that AKQ did not affect osteoblastogenesis, but it inhibited 
      RANKL-induced osteoclastogenesis. In the ovariectomized rats, oral administration 
      of AKQ (4 g/kg/d) for 90 d effectively prevented oestrogen deficiency-induced 
      bone loss. Mechanistic studies in BMMs revealed that AKQ inhibited RNAKL-induced 
      activation of NF-κB (p65) and MAPKs (p38 and JNK) via blocking the RANK-TRAF6 
      interaction, subsequently suppressing the translocation and expression of NFATc1 
      and c-Fos. UPLC-QTOF-MS analysis quantified the 123 main components of AKQ. Taken 
      together, AKQ was demonstrated for the first time as a novel alternative therapy 
      for osteoclast-associated bone diseases.
CI  - Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Liu, Zhi-Wen
AU  - Liu ZW
AD  - Science and Technology Innovation Center, Guangzhou University of Chinese 
      Medicine, Guangzhou, Guangdong, China.
FAU - Xi, Xiu-Li
AU  - Xi XL
AD  - Science and Technology Innovation Center, Guangzhou University of Chinese 
      Medicine, Guangzhou, Guangdong, China.
FAU - Wu, Tao-Rui
AU  - Wu TR
AD  - Science and Technology Innovation Center, Guangzhou University of Chinese 
      Medicine, Guangzhou, Guangdong, China.
FAU - Lu, Yuan-Yuan
AU  - Lu YY
AD  - Science and Technology Innovation Center, Guangzhou University of Chinese 
      Medicine, Guangzhou, Guangdong, China.
FAU - Zhong, Peng-Cheng
AU  - Zhong PC
AD  - Science and Technology Innovation Center, Guangzhou University of Chinese 
      Medicine, Guangzhou, Guangdong, China.
FAU - Hu, Ying-Jie
AU  - Hu YJ
AD  - Science and Technology Innovation Center, Guangzhou University of Chinese 
      Medicine, Guangzhou, Guangdong, China. Electronic address: 
      yingjiehu@gzucm.edu.cn.
FAU - Shen, Xiao-Ling
AU  - Shen XL
AD  - Science and Technology Innovation Center, Guangzhou University of Chinese 
      Medicine, Guangzhou, Guangdong, China. Electronic address: xshen2@gzucm.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20230816
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Estrogens)
SB  - IM
MH  - Female
MH  - Rats
MH  - Mice
MH  - Animals
MH  - Humans
MH  - *Spleen
MH  - Osteogenesis
MH  - Medicine, Chinese Traditional
MH  - Kidney
MH  - *Bone Diseases, Metabolic
MH  - Estrogens
OTO - NOTNLM
OT  - Aikeqing
OT  - MAPKs
OT  - NF-κB
OT  - Osteoclastogenesis
OT  - Postmenopausal osteoporosis
OT  - TRAF6
COIS- Declaration of Competing Interest There is no conflict of interest declared.
EDAT- 2023/08/19 11:42
MHDA- 2023/09/18 12:43
CRDT- 2023/08/18 18:06
PHST- 2023/07/10 00:00 [received]
PHST- 2023/08/14 00:00 [accepted]
PHST- 2023/09/18 12:43 [medline]
PHST- 2023/08/19 11:42 [pubmed]
PHST- 2023/08/18 18:06 [entrez]
AID - S0753-3322(23)01130-7 [pii]
AID - 10.1016/j.biopha.2023.115339 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2023 Oct;166:115339. doi: 10.1016/j.biopha.2023.115339. Epub 
      2023 Aug 16.

PMID- 32036289
OWN - NLM
STAT- MEDLINE
DCOM- 20200406
LR  - 20200408
IS  - 1879-2448 (Electronic)
IS  - 0043-1354 (Linking)
VI  - 173
DP  - 2020 Apr 15
TI  - Ecotoxicological characterization of emissions from steel coatings in contact 
      with water.
PG  - 115525
LID - S0043-1354(20)30061-0 [pii]
LID - 10.1016/j.watres.2020.115525 [doi]
AB  - In order to prevent corrosion damage, steel structures need to be protected. 
      Coating systems achieve this by the isolation of the steel from its environment. 
      Common binding agents are epoxide and polyurethane resins which harden by 
      polyaddition reactions. In contact with water, various organic substances might 
      be leached out and released into the aquatic environment potentially causing 
      adverse effects. So far, no legal requirements are mandatory for the 
      environmental sustainability of coating systems. To characterize emissions from 
      steel coatings, recommendations for the ecotoxicological assessment of 
      construction products were utilized. Seven different coating systems based on 
      epoxide or polyurethane resins were leached in 8 steps (6 h-64 d), followed by 
      the testing of acute toxic effects on bacteria and algae as well as estrogen-like 
      and mutagenic effects. In addition, chemical analysis by GC-MS was performed to 
      identify potentially toxic compounds released from the coating systems. Two 
      systems tested did not show any significant effects in the bioassays. One coating 
      system caused significant algal toxicity, none was found to cause mutagenic 
      effects. The other coating systems mainly showed estrogenic effects and bacterial 
      toxicity. The effects increased with increasing leaching time. 
      4-tert-butylphenol, which is used in epoxy resins as a hardener, was identified 
      as the main contributor to acute and estrogenic effects in two coatings. The 
      release mechanism of 4-tert-butylphenol was characterized by two different 
      modelling approaches. It was found that the release from the most toxic coating 
      is not explainable by an elevated content of 4-tert-butylphenol but more likely 
      by the release mechanism that - in contrast to the less toxic coating - is 
      controlled not only by diffusion. This finding might indicate a sub-optimal 
      formulation of this coating system resulting in a less stable layer and thus an 
      increased release of toxic compounds.
CI  - Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Bell, Anna Maria
AU  - Bell AM
AD  - Federal Institute of Hydrology, Am Mainzer Tor 1, 56068, Koblenz, Germany.
FAU - Baier, Roland
AU  - Baier R
AD  - Federal Waterways Engineering and Research Institute, Section B2 - Steel 
      Structures and Corrosion Protection, Kußmaulstr. 17, 76187, Karlsruhe, Germany.
FAU - Kocher, Birgit
AU  - Kocher B
AD  - Federal Highway Research Institute, Department V3 - Environmental Protection, 
      Brüderstr. 53, 51427, Bergisch Gladbach, Germany.
FAU - Reifferscheid, Georg
AU  - Reifferscheid G
AD  - Federal Institute of Hydrology, Am Mainzer Tor 1, 56068, Koblenz, Germany.
FAU - Buchinger, Sebastian
AU  - Buchinger S
AD  - Federal Institute of Hydrology, Am Mainzer Tor 1, 56068, Koblenz, Germany. 
      Electronic address: Buchinger@bafg.de.
FAU - Ternes, Thomas
AU  - Ternes T
AD  - Federal Institute of Hydrology, Am Mainzer Tor 1, 56068, Koblenz, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200123
PL  - England
TA  - Water Res
JT  - Water research
JID - 0105072
RN  - 0 (Water Pollutants, Chemical)
RN  - 059QF0KO0R (Water)
RN  - 12597-69-2 (Steel)
SB  - IM
MH  - Corrosion
MH  - Ecotoxicology
MH  - Steel
MH  - *Water
MH  - *Water Pollutants, Chemical
OTO - NOTNLM
OT  - 4-tert-Butylphenol
OT  - Diffusion
OT  - Epoxide
OT  - Leaching
OT  - Polyurethane
OT  - Toxicity
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/02/10 06:00
MHDA- 2020/04/09 06:00
CRDT- 2020/02/10 06:00
PHST- 2019/11/12 00:00 [received]
PHST- 2020/01/14 00:00 [revised]
PHST- 2020/01/19 00:00 [accepted]
PHST- 2020/02/10 06:00 [pubmed]
PHST- 2020/04/09 06:00 [medline]
PHST- 2020/02/10 06:00 [entrez]
AID - S0043-1354(20)30061-0 [pii]
AID - 10.1016/j.watres.2020.115525 [doi]
PST - ppublish
SO  - Water Res. 2020 Apr 15;173:115525. doi: 10.1016/j.watres.2020.115525. Epub 2020 
      Jan 23.

PMID- 26370252
OWN - NLM
STAT- MEDLINE
DCOM- 20160201
LR  - 20240610
IS  - 1475-2662 (Electronic)
IS  - 0007-1145 (Print)
IS  - 0007-1145 (Linking)
VI  - 114
IP  - 10
DP  - 2015 Nov 28
TI  - Urinary isoflavonoids and risk of type 2 diabetes: a prospective investigation in 
      US women.
PG  - 1694-701
LID - 10.1017/S0007114515003359 [doi]
AB  - To examine the association between urinary excretion of isoflavonoids and risk of 
      type 2 diabetes (T2D), we conducted a nested case-control study among 1111 T2D 
      pairs identified during 1995-2008 in the Nurses' Health Study (NHS) and NHSII, 
      who were free of diabetes, CVD and cancer at urine sample collection. Urinary 
      excretion of daidzein and genistein, as well as their metabolites 
      O-desmethylangolensin (O-DMA), dihydrogenistein (DHGE) and dihydrodaidzein (DHDE) 
      was assayed using liquid chromatography MS. Self-reported T2D incident cases were 
      confirmed using a validated questionnaire. Higher urinary excretion of daidzein 
      and genistein was associated with a lower risk of T2D in the combined cohorts. 
      Comparing extreme tertiles of the urinary markers, the OR of T2D were 0·71 (95 % 
      CI 0·55, 0·93) for daidzein and 0·74 (95 % CI 0·56, 0·97) for genistein, although 
      the test for linear trend was not significant for genistein (P trend=0·03 and 
      0·15, respectively). DMA, DHDE and DHGE were non-significantly associated with a 
      lower T2D risk. The inverse association of daidzein with T2D risk was stronger 
      among post-menopausal women who did not use hormone replacement therapy (P 
      interaction=0·001): the OR was 0·58 (95 % CI 0·34, 0·97) comparing extreme 
      tertiles among these women. In conclusion, urinary excretion of isoflavones was 
      associated with a lower T2D risk in US women, especially among post-menopausal 
      women who did not use hormone. Further research is warranted to replicate these 
      observations among western populations with similarly low overall isoflavone 
      intake.
FAU - Ding, Ming
AU  - Ding M
AD  - 1Department of Nutrition,Harvard School of Public Health,Boston,MA 02115,USA.
FAU - Franke, Adrian A
AU  - Franke AA
AD  - 2Department of Food Science and Human Nutrition,College of Tropical Agriculture 
      and Human Resources,University of Hawai'i Cancer Center,Honolulu,HI 96813,USA.
FAU - Rosner, Bernard A
AU  - Rosner BA
AD  - 3Channing Division of Network Medicine,Brigham and Women's Hospital and Harvard 
      Medical School,Boston,MA 02115,USA.
FAU - Giovannucci, Edward
AU  - Giovannucci E
AD  - 1Department of Nutrition,Harvard School of Public Health,Boston,MA 02115,USA.
FAU - van Dam, Rob M
AU  - van Dam RM
AD  - 1Department of Nutrition,Harvard School of Public Health,Boston,MA 02115,USA.
FAU - Tworoger, Shelley S
AU  - Tworoger SS
AD  - 3Channing Division of Network Medicine,Brigham and Women's Hospital and Harvard 
      Medical School,Boston,MA 02115,USA.
FAU - Hu, Frank B
AU  - Hu FB
AD  - 1Department of Nutrition,Harvard School of Public Health,Boston,MA 02115,USA.
FAU - Sun, Qi
AU  - Sun Q
AD  - 1Department of Nutrition,Harvard School of Public Health,Boston,MA 02115,USA.
LA  - eng
GR  - R01 CA050385/CA/NCI NIH HHS/United States
GR  - R01 DK058785/DK/NIDDK NIH HHS/United States
GR  - R01 DK058845/DK/NIDDK NIH HHS/United States
GR  - P01 CA087969/CA/NCI NIH HHS/United States
GR  - UM1 CA176726/CA/NCI NIH HHS/United States
GR  - CA49449/CA/NCI NIH HHS/United States
GR  - U01 CA067262/CA/NCI NIH HHS/United States
GR  - CA67262/CA/NCI NIH HHS/United States
GR  - DK58785/DK/NIDDK NIH HHS/United States
GR  - UM1 CA186107/CA/NCI NIH HHS/United States
GR  - R01 DK082486/DK/NIDDK NIH HHS/United States
GR  - U01 CA049449/CA/NCI NIH HHS/United States
GR  - CA176726/CA/NCI NIH HHS/United States
GR  - P30 CA71789/CA/NCI NIH HHS/United States
GR  - R56 DK058785/DK/NIDDK NIH HHS/United States
GR  - R01 CA067262/CA/NCI NIH HHS/United States
GR  - R00HL098459/HL/NHLBI NIH HHS/United States
GR  - R00 HL098459/HL/NHLBI NIH HHS/United States
GR  - U01 CA176726/CA/NCI NIH HHS/United States
GR  - CA87969/CA/NCI NIH HHS/United States
GR  - DK58845/DK/NIDDK NIH HHS/United States
GR  - R01 CA049449/CA/NCI NIH HHS/United States
GR  - CA50385/CA/NCI NIH HHS/United States
GR  - CA186107/CA/NCI NIH HHS/United States
GR  - DK082486/DK/NIDDK NIH HHS/United States
GR  - P30 CA071789/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20150915
PL  - England
TA  - Br J Nutr
JT  - The British journal of nutrition
JID - 0372547
RN  - 0 (Isoflavones)
RN  - 6287WC5J2L (daidzein)
RN  - DH2M523P0H (Genistein)
SB  - IM
MH  - Adult
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/*urine
MH  - Diet
MH  - Estrogen Replacement Therapy
MH  - Female
MH  - Genistein/urine
MH  - Humans
MH  - Isoflavones/administration & dosage/*urine
MH  - Middle Aged
MH  - Nurses
MH  - Postmenopause
MH  - Prospective Studies
MH  - Risk Factors
MH  - *Women's Health
PMC - PMC4762594
MID - NIHMS759993
OTO - NOTNLM
OT  - DHDE dihydrodaidzein
OT  - DHGE dihydrogenistein
OT  - Diabetes
OT  - Isoflavones
OT  - Menopausal status
OT  - NHS Nurses’ Health Study
OT  - Nested case–control studies
OT  - O-DMA O-desmethylangolensin
OT  - T2D type 2 diabetes
COIS- Competing Interests None of the authors had any financial or personal conflict of 
      interest to disclose.
EDAT- 2015/09/16 06:00
MHDA- 2016/02/02 06:00
PMCR- 2016/05/28
CRDT- 2015/09/16 06:00
PHST- 2015/09/16 06:00 [entrez]
PHST- 2015/09/16 06:00 [pubmed]
PHST- 2016/02/02 06:00 [medline]
PHST- 2016/05/28 00:00 [pmc-release]
AID - S0007114515003359 [pii]
AID - 10.1017/S0007114515003359 [doi]
PST - ppublish
SO  - Br J Nutr. 2015 Nov 28;114(10):1694-701. doi: 10.1017/S0007114515003359. Epub 
      2015 Sep 15.

PMID- 34379355
OWN - NLM
STAT- MEDLINE
DCOM- 20211102
LR  - 20250103
IS  - 1473-2165 (Electronic)
IS  - 1473-2130 (Linking)
VI  - 20
IP  - 11
DP  - 2021 Nov
TI  - Could endocrine disruptors be a new player for acne pathogenesis? The effect of 
      bisphenol A on the formation and severity of acne vulgaris: A prospective, 
      case-controlled study.
PG  - 3573-3579
LID - 10.1111/jocd.14364 [doi]
AB  - BACKGROUND: Acne is one of the most common skin diseases in the adolescent 
      period. Bisphenol A (BPA) is the most frequently observed endocrine-disrupting 
      chemicals that we are exposed to in daily life. BPA can affect acne pathogenesis 
      with similar biological activity on androgenic receptors. AIMS: To investigate 
      whether BPA levels play a role in the development and severity of acne in adults. 
      METHODS: Fifty-one adults with acne and 50 healthy controls, whose ages varied 
      between 18 and 25 years and applied to our dermatology outpatient clinic, were 
      evaluated. A questionnaire containing dietary and lifestyle habits for BPA 
      exposure was filled. BPA and BPA glucuronides were analyzed in the LC-MS/MS 
      system in the first-morning urine samples of the patients. Statistical 
      significance was set at p < 0.05. RESULTS: The median levels of total BPA were 
      significantly higher in the acne group compared with the control group (7.94 
      (4.69-20.32) vs. 5.62 (1.52-21.05) µg/g creatinine, respectively; p = 0.04)). The 
      acne severity was positively associated with the BPA values (p = 0.00 
      rs = 0.534). Higher BPA level was noticed in younger acne onset age (p = 0.012 
      r = -0.349) When the inquiry questions were evaluated, no difference was found 
      between the study groups regarding BPA exposure risk (p > 0.05). CONCLUSION: BPA 
      could be a factor in acne development and its severity. Therefore, it may be 
      beneficial to prevent BPA exposure and raise awareness in the adolescence and 
      post-adolescence period, in which industrial products such as junk food and 
      plastic bottled water are used more frequently.
CI  - © 2021 Wiley Periodicals LLC.
FAU - Kaya Ozden, Hatice
AU  - Kaya Ozden H
AUID- ORCID: 0000-0003-0203-272X
AD  - Department of Dermatology, Derince Training and Research Hospital, Kocaeli, 
      Turkey.
FAU - Karadag, Ayse Serap
AU  - Karadag AS
AD  - Department of Dermatology, Memorial Atasehir Hospital, Istanbul, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20210811
PL  - England
TA  - J Cosmet Dermatol
JT  - Journal of cosmetic dermatology
JID - 101130964
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Endocrine Disruptors)
RN  - 0 (Phenols)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - *Acne Vulgaris
MH  - Adolescent
MH  - Adult
MH  - Benzhydryl Compounds/adverse effects/analysis
MH  - Chromatography, Liquid
MH  - *Endocrine Disruptors/adverse effects/analysis
MH  - Humans
MH  - Phenols
MH  - Prospective Studies
MH  - Tandem Mass Spectrometry
MH  - Young Adult
OTO - NOTNLM
OT  - Acne vulgaris
OT  - acne severity
OT  - adult
OT  - bisphenol A
OT  - endocrine disruptors
EDAT- 2021/08/12 06:00
MHDA- 2021/11/03 06:00
CRDT- 2021/08/11 12:34
PHST- 2021/07/30 00:00 [revised]
PHST- 2021/06/24 00:00 [received]
PHST- 2021/07/19 00:00 [accepted]
PHST- 2021/08/12 06:00 [pubmed]
PHST- 2021/11/03 06:00 [medline]
PHST- 2021/08/11 12:34 [entrez]
AID - 10.1111/jocd.14364 [doi]
PST - ppublish
SO  - J Cosmet Dermatol. 2021 Nov;20(11):3573-3579. doi: 10.1111/jocd.14364. Epub 2021 
      Aug 11.

PMID- 33439749
OWN - NLM
STAT- MEDLINE
DCOM- 20210817
LR  - 20210817
IS  - 2325-8306 (Electronic)
IS  - 2325-8292 (Linking)
VI  - 8
IP  - 2
DP  - 2021 Feb-Mar
TI  - Sublingual Estradiol Is Associated with Higher Estrone Concentrations than 
      Transdermal or Injectable Preparations in Transgender Women and Gender Nonbinary 
      Adults.
PG  - 125-132
LID - 10.1089/lgbt.2020.0249 [doi]
AB  - Purpose: Serum hormone profiles among different feminizing gender-affirming 
      hormone therapies (GAHT) are poorly characterized. To address this gap, we 
      described the serum estrogen profiles of three 17β-estradiol preparations, taken 
      with or without an antiandrogen, using a novel liquid chromatography-mass 
      spectrometry (LC-MS/MS) assay in adults taking feminizing GAHT. Methods: This was 
      a secondary analysis of 93 healthy transgender women and gender nonbinary adults 
      taking feminizing GAHT in a prospective cross-sectional study. Eligible 
      participants took 17β-estradiol (sublingual tablet, transdermal patch, or 
      intramuscular/subcutaneous injection) with or without oral spironolactone for ≥12 
      months before study entry. We determined serum estrone and estradiol 
      concentrations for each hormone preparation and described the association between 
      estrone and (1) clinically relevant estradiol concentration ranges (≤200 and 
      >200 pg/mL) and (2) antiandrogen use. To achieve our objectives, we described our 
      protocol for developing an LC-MS/MS assay to measure estrone and estradiol 
      concentrations. Results: Estrone concentrations were higher among participants 
      taking sublingual 17β-estradiol tablets compared with transdermal or injectable 
      preparations (p < 0.0001). Estradiol concentrations were higher for injectable 
      versus transdermal preparations (p = 0.0201), but both were similar to sublingual 
      tablet concentrations (p > 0.05). Estradiol >200 pg/mL (vs. ≤200 pg/mL) was 
      associated with higher estrone concentrations among participants taking 
      sublingual 17β-estradiol, but not transdermal or injectable 17β-estradiol. We 
      observed no association between spironolactone and estrone concentrations 
      (p > 0.5). Conclusion: Estrone concentrations were higher among transgender women 
      and gender nonbinary adults taking sublingual 17β-estradiol compared with 
      transdermal or injectable preparations. The role of estrone in clinical 
      monitoring and the influence of other antiandrogens (e.g., cyproterone acetate) 
      on the estrogen profile remain to be determined.
FAU - Cirrincione, Lauren R
AU  - Cirrincione LR
AD  - Department of Pharmacy, University of Washington, Seattle, Washington, USA.
FAU - Winston McPherson, Gabrielle
AU  - Winston McPherson G
AD  - Department of Laboratory Medicine, University of Washington, Seattle, Washington, 
      USA.
FAU - Rongitsch, Jessica
AU  - Rongitsch J
AD  - Capitol Hill Medical, Seattle, Washington, USA.
FAU - Sadilkova, Katerina
AU  - Sadilkova K
AD  - Department of Laboratories, Seattle Children's Hospital, Seattle, Washington, 
      USA.
FAU - Drees, Julia C
AU  - Drees JC
AD  - The Permanente Medical Group Regional Laboratories, Berkeley, California, USA.
FAU - Krasowski, Matthew D
AU  - Krasowski MD
AD  - Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, 
      Iowa, USA.
FAU - Dickerson, Jane A
AU  - Dickerson JA
AD  - Department of Laboratory Medicine, University of Washington, Seattle, Washington, 
      USA.
AD  - Department of Laboratories, Seattle Children's Hospital, Seattle, Washington, 
      USA.
FAU - Greene, Dina N
AU  - Greene DN
AD  - Department of Laboratory Medicine, University of Washington, Seattle, Washington, 
      USA.
LA  - eng
PT  - Journal Article
DEP - 20210113
PL  - United States
TA  - LGBT Health
JT  - LGBT health
JID - 101616707
RN  - 2DI9HA706A (Estrone)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Administration, Cutaneous
MH  - Administration, Sublingual
MH  - Adult
MH  - Cross-Sectional Studies
MH  - Estradiol/*administration & dosage
MH  - *Estrogen Replacement Therapy
MH  - Estrone/*blood
MH  - Female
MH  - Humans
MH  - Injections
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Sexual and Gender Minorities/*statistics & numerical data
MH  - Transgender Persons/*statistics & numerical data
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - estradiol
OT  - estrone
OT  - gender-affirming hormone therapy
OT  - transgender
OT  - transgender women
EDAT- 2021/01/14 06:00
MHDA- 2021/08/18 06:00
CRDT- 2021/01/13 17:09
PHST- 2021/01/14 06:00 [pubmed]
PHST- 2021/08/18 06:00 [medline]
PHST- 2021/01/13 17:09 [entrez]
AID - 10.1089/lgbt.2020.0249 [doi]
PST - ppublish
SO  - LGBT Health. 2021 Feb-Mar;8(2):125-132. doi: 10.1089/lgbt.2020.0249. Epub 2021 
      Jan 13.

PMID- 31955091
OWN - NLM
STAT- MEDLINE
DCOM- 20200325
LR  - 20250103
IS  - 1879-1026 (Electronic)
IS  - 0048-9697 (Linking)
VI  - 713
DP  - 2020 Apr 15
TI  - Bisphenol analogues in Chinese bottled water: Quantification and potential risk 
      analysis.
PG  - 136583
LID - S0048-9697(20)30093-0 [pii]
LID - 10.1016/j.scitotenv.2020.136583 [doi]
AB  - Polycarbonate (PC) and polyethylene terephthalate (PET) as the package materials 
      have been widely used for Chinese bottled water, from which estrogenic bisphenol 
      analogues might migrate into bottled water. Therefore, there is a strong need to 
      investigate the occurrence and potential risk of such estrogenic bisphenol 
      analogues in Chinese bottled waters. In this study, a GC-MS method was first 
      established and validated for determination of trace-level ten kinds of bisphenol 
      analogues, including bisphenol A (BPA), bisphenol B (BPB), bisphenol C (BPC), 
      bisphenol E (BPE), bisphenol F (BPF), bisphenol P (BPP), bisphenol S (BPS), 
      bisphenol Z (BPZ), bisphenol AP (BPAP), and bisphenol AF (BPAF). BPA was detected 
      in all eleven brands of PET bottled waters with concentrations of 12.4-44.9 ng/L. 
      Some bisphenol analogues were detected in PET bottled waters, and the average 
      concentrations of BPA, BPE, and BPAF in PET bottled waters were found to be 20.8, 
      1.8, and 2.2 ng/L, respectively. The other eight bisphenol analogues were not 
      detected in PET bottled waters. On the other hand, BPA was detected with high 
      concentrations of 111.8 to 6452.8 ng/L in ten brands of PC bottled water. The 
      average concentrations of BPA, BPS, BPAP, and BPAF were determined to be 1394.3, 
      1.9, 1.4 and 1.0 ng/L, respectively, while the other seven bisphenol analogues 
      were not detected. High BPA concentration detected in PC bottled waters would 
      remarkably increase human BPA daily intake through daily consumption of such 
      bottled waters. Meanwhile, high estrogen equivalence (EEQ) in PC bottled waters 
      of China is mainly due to the presence of BPA, which may imply adverse effect on 
      human. Therefore, further investigation should be dedicated to assess PC bottled 
      water-associated BPA risks in a more holistic manner.
CI  - Copyright © 2020 Elsevier B.V. All rights reserved.
FAU - Wang, Hao
AU  - Wang H
AD  - School of Environment and Energy, South China University of Technology, Guangzhou 
      510006, Guangdong, China.
FAU - Liu, Ze-Hua
AU  - Liu ZH
AD  - School of Environment and Energy, South China University of Technology, Guangzhou 
      510006, Guangdong, China; Key Lab Pollution Control & Ecosystem Restoration in 
      Industry Cluster, Ministry of Education, Guangzhou 510006, Guangdong, China; 
      Guangdong Environmental Protection Key Laboratory of Solid Waste Treatment and 
      Recycling, Guangzhou 510006, Guangdong, China; Guangdong Provincial Engineering 
      and Technology Research Center for Environment Risk Prevention and Emergency 
      Disposal, South China University of Technology, Guangzhou 510006, Guangdong, 
      China. Electronic address: zehualiu@scut.edu.cn.
FAU - Tang, Zhao
AU  - Tang Z
AD  - School of Environment and Energy, South China University of Technology, Guangzhou 
      510006, Guangdong, China.
FAU - Zhang, Jun
AU  - Zhang J
AD  - School of Environment and Energy, South China University of Technology, Guangzhou 
      510006, Guangdong, China.
FAU - Yin, Hua
AU  - Yin H
AD  - School of Environment and Energy, South China University of Technology, Guangzhou 
      510006, Guangdong, China.
FAU - Dang, Zhi
AU  - Dang Z
AD  - School of Environment and Energy, South China University of Technology, Guangzhou 
      510006, Guangdong, China.
FAU - Wu, Ping-Xiao
AU  - Wu PX
AD  - School of Environment and Energy, South China University of Technology, Guangzhou 
      510006, Guangdong, China.
FAU - Liu, Yu
AU  - Liu Y
AD  - Advanced Environmental Biotechnology Center, Nanyang Environment and Water 
      Research Institute, Nanyang Technological University, CleanTech one, 637141, 
      Singapore; School of Civil and Engineering, Nanyang Technological University, 
      639798, Singapore.
LA  - eng
PT  - Journal Article
DEP - 20200110
PL  - Netherlands
TA  - Sci Total Environ
JT  - The Science of the total environment
JID - 0330500
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Drinking Water)
RN  - 0 (Estrogens)
RN  - 0 (Phenols)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - Benzhydryl Compounds
MH  - China
MH  - Drinking Water/*chemistry
MH  - Estrogens
MH  - Phenols
OTO - NOTNLM
OT  - Analogues
OT  - BPA
OT  - Bottled water
OT  - GC–MS
OT  - Human daily intake
OT  - Risk assessment
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/01/20 06:00
MHDA- 2020/03/26 06:00
CRDT- 2020/01/20 06:00
PHST- 2019/11/26 00:00 [received]
PHST- 2020/01/05 00:00 [revised]
PHST- 2020/01/06 00:00 [accepted]
PHST- 2020/01/20 06:00 [pubmed]
PHST- 2020/03/26 06:00 [medline]
PHST- 2020/01/20 06:00 [entrez]
AID - S0048-9697(20)30093-0 [pii]
AID - 10.1016/j.scitotenv.2020.136583 [doi]
PST - ppublish
SO  - Sci Total Environ. 2020 Apr 15;713:136583. doi: 10.1016/j.scitotenv.2020.136583. 
      Epub 2020 Jan 10.

PMID- 27729163
OWN - NLM
STAT- MEDLINE
DCOM- 20180205
LR  - 20250103
IS  - 1873-6750 (Electronic)
IS  - 0160-4120 (Linking)
VI  - 98
DP  - 2017 Jan
TI  - Higher dermal exposure of cashiers to BPA and its association with DNA oxidative 
      damage.
PG  - 69-74
LID - S0160-4120(16)30534-7 [pii]
LID - 10.1016/j.envint.2016.10.001 [doi]
AB  - Bisphenol A (BPA) is a widely used chemical in the production of many 
      polycarbonate plastics, epoxy resin linings for food and beverage containers and 
      thermal papers. Oral intakes from the contaminated diets were considered as the 
      predominant source of BPA exposure for humans. However, due to the high levels of 
      BPA on thermal receipts and their wide applications in our daily life, the amount 
      of BPA be transferred to the skin after holding thermal paper should not be 
      underestimated, particularly for cashiers. To investigate the contribution of BPA 
      exposure levels via the dermal contact route and the relationship between BPA 
      exposure level and oxidative DNA damage, six male volunteers were recruited and 
      required to simulate the cashiers' work and handle the thermal receipts during 
      the study period. Triclosan (TCS, an antimicrobial compound used widely in 
      personal health and skin care products) was applied as a reference compound. 
      Their urinary BPA, TCS and 8-hydroxy-2'-deoxyguanosine (8-OHdG) concentrations 
      were determined by high performance liquid chromatography/ tandem spectrometer 
      (LC/MS/MS). The results showed that after handling the thermal receipts, the 
      urinary BPA concentrations of volunteers increased 3 times of those before the 
      experimental period. But TCS levels in urine kept stable. There existed a 
      correlation between BPA exposure and 8-OHdG (R(2)=0.237, p<0.001), but not 
      between TCS and 8-OHdG concentrations (R(2)=0.026, p<0.777), indicating that more 
      BPA exposure could lead to higher oxidative DNA damage. That the increases in 
      8-OHdG levels in urine being almost consistent with those of BPA suggested that 
      handling thermal receipts resulted in the increasing BPA intakes and BPA exposure 
      was correlated with DNA oxidative damage. After 48h of the end of handling 
      thermal receipts, the urinary BPA levels did not descend to the levels before 
      experiment, suggesting that the excretion of BPA via dermal contact was over 48h. 
      BPA exposure through dermal contact route contributed 51.9% to 84% to urinary BPA 
      levels with the GM ratio of 70.9% for cashiers, indicating that it might be 
      seriously underestimated for cashiers according to the previous studies. More 
      attentions should be paid on the exposure of BPA via dermal penetration for 
      cashiers.
CI  - Copyright Â© 2016 Elsevier Ltd. All rights reserved.
FAU - Lv, Yanshan
AU  - Lv Y
AD  - Guangzhou Key Laboratory of Subtropical Biodiversity and Biomonitoring, School of 
      Life Science, South China Normal University, Guangzhou 510631, China.
FAU - Lu, Shaoyou
AU  - Lu S
AD  - Shenzhen Centers for Disease Control and Prevention, Shenzhen 518055, China.
FAU - Dai, Yanyan
AU  - Dai Y
AD  - Guangzhou Key Laboratory of Subtropical Biodiversity and Biomonitoring, School of 
      Life Science, South China Normal University, Guangzhou 510631, China.
FAU - Rui, Caiyan
AU  - Rui C
AD  - Guangzhou Key Laboratory of Subtropical Biodiversity and Biomonitoring, School of 
      Life Science, South China Normal University, Guangzhou 510631, China.
FAU - Wang, Yongjun
AU  - Wang Y
AD  - Guangzhou Key Laboratory of Subtropical Biodiversity and Biomonitoring, School of 
      Life Science, South China Normal University, Guangzhou 510631, China.
FAU - Zhou, Yuanxiu
AU  - Zhou Y
AD  - Guangzhou Key Laboratory of Subtropical Biodiversity and Biomonitoring, School of 
      Life Science, South China Normal University, Guangzhou 510631, China.
FAU - Li, Yanru
AU  - Li Y
AD  - Guangzhou Key Laboratory of Subtropical Biodiversity and Biomonitoring, School of 
      Life Science, South China Normal University, Guangzhou 510631, China.
FAU - Pang, Qihua
AU  - Pang Q
AD  - Guangzhou Key Laboratory of Subtropical Biodiversity and Biomonitoring, School of 
      Life Science, South China Normal University, Guangzhou 510631, China.
FAU - Fan, Ruifang
AU  - Fan R
AD  - Guangzhou Key Laboratory of Subtropical Biodiversity and Biomonitoring, School of 
      Life Science, South China Normal University, Guangzhou 510631, China; Guangzhou 
      Key Laboratory of Environmental Exposure and Health, School of Environment, Jinan 
      University, Guangzhou 510632, China. Electronic address: 20001047@m.scnu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20161008
PL  - Netherlands
TA  - Environ Int
JT  - Environment international
JID - 7807270
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Phenols)
RN  - 4NM5039Y5X (Triclosan)
RN  - 88847-89-6 (8-Hydroxy-2'-Deoxyguanosine)
RN  - G9481N71RO (Deoxyguanosine)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - 8-Hydroxy-2'-Deoxyguanosine
MH  - Adult
MH  - *Benzhydryl Compounds/administration & dosage/urine
MH  - Chromatography, High Pressure Liquid
MH  - *DNA Damage
MH  - Deoxyguanosine/analogs & derivatives/urine
MH  - Humans
MH  - Male
MH  - Occupational Exposure/*analysis
MH  - Oxidation-Reduction
MH  - Paper
MH  - *Phenols/administration & dosage/urine
MH  - *Skin Absorption
MH  - Tandem Mass Spectrometry
MH  - Triclosan/administration & dosage/urine
MH  - Young Adult
OTO - NOTNLM
OT  - *8-hydroxy-2′-deoxyguanosine
OT  - *Bisphenol A
OT  - *Dermal absorption
OT  - *Urine
EDAT- 2016/10/13 06:00
MHDA- 2018/02/06 06:00
CRDT- 2016/10/13 06:00
PHST- 2016/07/16 00:00 [received]
PHST- 2016/10/01 00:00 [revised]
PHST- 2016/10/02 00:00 [accepted]
PHST- 2016/10/13 06:00 [pubmed]
PHST- 2018/02/06 06:00 [medline]
PHST- 2016/10/13 06:00 [entrez]
AID - S0160-4120(16)30534-7 [pii]
AID - 10.1016/j.envint.2016.10.001 [doi]
PST - ppublish
SO  - Environ Int. 2017 Jan;98:69-74. doi: 10.1016/j.envint.2016.10.001. Epub 2016 Oct 
      8.

PMID- 32279280
OWN - NLM
STAT- MEDLINE
DCOM- 20201201
LR  - 20240210
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Print)
IS  - 0167-6806 (Linking)
VI  - 181
IP  - 2
DP  - 2020 Jun
TI  - Prediction of contralateral breast cancer: external validation of risk 
      calculators in 20 international cohorts.
PG  - 423-434
LID - 10.1007/s10549-020-05611-8 [doi]
AB  - BACKGROUND: Three tools are currently available to predict the risk of 
      contralateral breast cancer (CBC). We aimed to compare the performance of the 
      Manchester formula, CBCrisk, and PredictCBC in patients with invasive breast 
      cancer (BC). METHODS: We analyzed data of 132,756 patients (4682 CBC) from 20 
      international studies with a median follow-up of 8.8 years. Prediction 
      performance included discrimination, quantified as a time-dependent 
      Area-Under-the-Curve (AUC) at 5 and 10 years after diagnosis of primary BC, and 
      calibration, quantified as the expected-observed (E/O) ratio at 5 and 10 years 
      and the calibration slope. RESULTS: The AUC at 10 years was: 0.58 (95% confidence 
      intervals [CI] 0.57-0.59) for CBCrisk; 0.60 (95% CI 0.59-0.61) for the Manchester 
      formula; 0.63 (95% CI 0.59-0.66) and 0.59 (95% CI 0.56-0.62) for PredictCBC-1A 
      (for settings where BRCA1/2 mutation status is available) and PredictCBC-1B (for 
      the general population), respectively. The E/O at 10 years: 0.82 (95% CI 
      0.51-1.32) for CBCrisk; 1.53 (95% CI 0.63-3.73) for the Manchester formula; 1.28 
      (95% CI 0.63-2.58) for PredictCBC-1A and 1.35 (95% CI 0.65-2.77) for 
      PredictCBC-1B. The calibration slope was 1.26 (95% CI 1.01-1.50) for CBCrisk; 
      0.90 (95% CI 0.79-1.02) for PredictCBC-1A; 0.81 (95% CI 0.63-0.99) for 
      PredictCBC-1B, and 0.39 (95% CI 0.34-0.43) for the Manchester formula. 
      CONCLUSIONS: Current CBC risk prediction tools provide only moderate 
      discrimination and the Manchester formula was poorly calibrated. Better 
      predictors and re-calibration are needed to improve CBC prediction and to 
      identify low- and high-CBC risk patients for clinical decision-making.
FAU - Giardiello, Daniele
AU  - Giardiello D
AD  - Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni Van 
      Leeuwenhoek Hospital, Amsterdam, The Netherlands.
AD  - Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, 
      The Netherlands.
FAU - Hauptmann, Michael
AU  - Hauptmann M
AD  - Brandenburg Medical School, Institute of Biostatistics and Registry Research, 
      Neuruppin, Germany.
AD  - Department of Epidemiology and Biostatistics, The Netherlands Cancer Institute - 
      Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
FAU - Steyerberg, Ewout W
AU  - Steyerberg EW
AD  - Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, 
      The Netherlands.
AD  - Department of Public Health, Erasmus MC Cancer Institute, Rotterdam, The 
      Netherlands.
FAU - Adank, Muriel A
AU  - Adank MA
AD  - Family Cancer Clinic, The Netherlands Cancer Institute - Antoni Van Leeuwenhoek 
      Hospital, Amsterdam, The Netherlands.
FAU - Akdeniz, Delal
AU  - Akdeniz D
AD  - Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer 
      Institute, Rotterdam, The Netherlands.
FAU - Blom, Jannet C
AU  - Blom JC
AD  - Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer 
      Institute, Rotterdam, The Netherlands.
FAU - Blomqvist, Carl
AU  - Blomqvist C
AD  - Department of Oncology, Helsinki University Hospital, University of Helsinki, 
      Helsinki, Finland.
AD  - Department of Oncology, Örebro University Hospital, Örebro, Sweden.
FAU - Bojesen, Stig E
AU  - Bojesen SE
AD  - Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen 
      University Hospital, Herlev, Denmark.
AD  - Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen 
      University Hospital, Herlev, Denmark.
AD  - Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, 
      Denmark.
FAU - Bolla, Manjeet K
AU  - Bolla MK
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK.
FAU - Brinkhuis, Mariël
AU  - Brinkhuis M
AD  - Laboratory for Pathology, East-Netherlands, Hengelo, The Netherlands.
FAU - Chang-Claude, Jenny
AU  - Chang-Claude J
AD  - Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 
      Heidelberg, Germany.
AD  - University Medical Center Hamburg-Eppendorf, Cancer Epidemiology, University 
      Cancer Center Hamburg (UCCH), Hamburg, Germany.
FAU - Czene, Kamila
AU  - Czene K
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 
      Stockholm, Sweden.
FAU - Devilee, Peter
AU  - Devilee P
AD  - Department of Pathology, Leiden University Medical Center, Leiden, The 
      Netherlands.
AD  - Department of Human Genetics, Leiden University Medical Center, Leiden, The 
      Netherlands.
FAU - Dunning, Alison M
AU  - Dunning AM
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of 
      Cambridge, Cambridge, UK.
FAU - Easton, Douglas F
AU  - Easton DF
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK.
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of 
      Cambridge, Cambridge, UK.
FAU - Eccles, Diana M
AU  - Eccles DM
AD  - Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, 
      Southampton, UK.
FAU - Fasching, Peter A
AU  - Fasching PA
AD  - David Geffen School of Medicine, Department of Medicine Division of Hematology 
      and Oncology, University of California At Los Angeles, Los Angeles, CA, USA.
AD  - University Hospital Erlangen, Department of Gynecology and Obstetrics, 
      Comprehensive Cancer Center ER-EMN, Friedrich-Alexander-University 
      Erlangen-Nuremberg, Erlangen, Germany.
FAU - Figueroa, Jonine
AU  - Figueroa J
AD  - The University of Edinburgh Medical School, Usher Institute of Population Health 
      Sciences and Informatics, Edinburgh, UK.
AD  - Cancer Research UK Edinburgh Centre, Edinburgh, UK.
AD  - Department of Health and Human Services, Division of Cancer Epidemiology and 
      Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, 
      USA.
FAU - Flyger, Henrik
AU  - Flyger H
AD  - Department of Breast Surgery, Herlev and Gentofte Hospital, Copenhagen University 
      Hospital, Herlev, Denmark.
FAU - García-Closas, Montserrat
AU  - García-Closas M
AD  - Department of Health and Human Services, Division of Cancer Epidemiology and 
      Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, 
      USA.
AD  - Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
FAU - Haeberle, Lothar
AU  - Haeberle L
AD  - University Hospital Erlangen, Department of Gynecology and Obstetrics, 
      Comprehensive Cancer Center ER-EMN, Friedrich-Alexander-University 
      Erlangen-Nuremberg, Erlangen, Germany.
FAU - Haiman, Christopher A
AU  - Haiman CA
AD  - Department of Preventive Medicine, Keck School of Medicine, University of 
      Southern California, Los Angeles, CA, USA.
FAU - Hall, Per
AU  - Hall P
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 
      Stockholm, Sweden.
AD  - Department of Oncology, Södersjukhuset, Stockholm, Sweden.
FAU - Hamann, Ute
AU  - Hamann U
AD  - Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), 
      Heidelberg, Germany.
FAU - Hopper, John L
AU  - Hopper JL
AD  - Centre for Epidemiology and Biostatistics, Melbourne School of Population and 
      Global Health, The University of Melbourne, Melbourne, VIC, Australia.
FAU - Jager, Agnes
AU  - Jager A
AD  - Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The 
      Netherlands.
FAU - Jakubowska, Anna
AU  - Jakubowska A
AD  - Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, 
      Poland.
AD  - Independent Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian 
      Medical University, Szczecin, Poland.
FAU - Jung, Audrey
AU  - Jung A
AD  - Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 
      Heidelberg, Germany.
FAU - Keeman, Renske
AU  - Keeman R
AD  - Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni Van 
      Leeuwenhoek Hospital, Amsterdam, The Netherlands.
FAU - Koppert, Linetta B
AU  - Koppert LB
AD  - Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, The 
      Netherlands.
FAU - Kramer, Iris
AU  - Kramer I
AD  - Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni Van 
      Leeuwenhoek Hospital, Amsterdam, The Netherlands.
FAU - Lambrechts, Diether
AU  - Lambrechts D
AD  - VIB Center for Cancer Biology, Leuven, Belgium.
AD  - Laboratory for Translational Genetics, Department of Human Genetics, University 
      of Leuven, Leuven, Belgium.
FAU - Le Marchand, Loic
AU  - Le Marchand L
AD  - Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA.
FAU - Lindblom, Annika
AU  - Lindblom A
AD  - Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, 
      Sweden.
AD  - Department of Clinical Genetics, Karolinska University Hospital, Stockholm, 
      Sweden.
FAU - Lubiński, Jan
AU  - Lubiński J
AD  - Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, 
      Poland.
FAU - Manoochehri, Mehdi
AU  - Manoochehri M
AD  - Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), 
      Heidelberg, Germany.
FAU - Mariani, Luigi
AU  - Mariani L
AD  - Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto 
      Nazionale Dei Tumori, Milan, Italy.
FAU - Nevanlinna, Heli
AU  - Nevanlinna H
AD  - Department of Obstetrics and Gynecology, Helsinki University Hospital, University 
      of Helsinki, Helsinki, Finland.
FAU - Oldenburg, Hester S A
AU  - Oldenburg HSA
AD  - Department of Surgical Oncology, The Netherlands Cancer Institute - Antoni Van 
      Leeuwenhoek Hospital, Amsterdam, The Netherlands.
FAU - Pelders, Saskia
AU  - Pelders S
AD  - Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer 
      Institute, Rotterdam, The Netherlands.
FAU - Pharoah, Paul D P
AU  - Pharoah PDP
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK.
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of 
      Cambridge, Cambridge, UK.
FAU - Shah, Mitul
AU  - Shah M
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of 
      Cambridge, Cambridge, UK.
FAU - Siesling, Sabine
AU  - Siesling S
AD  - Department of Research, Netherlands Comprehensive Cancer Organisation, Utrecht, 
      The Netherlands.
FAU - Smit, Vincent T H B M
AU  - Smit VTHBM
AD  - Department of Pathology, Leiden University Medical Center, Leiden, The 
      Netherlands.
FAU - Southey, Melissa C
AU  - Southey MC
AD  - Precision Medicine, School of Clinical Sciences at Monash Health, Monash 
      University, Clayton, VIC, Australia.
AD  - Department of Clinical Pathology, The University of Melbourne, Melbourne, VIC, 
      Australia.
FAU - Tapper, William J
AU  - Tapper WJ
AD  - Faculty of Medicine, University of Southampton, Southampton, UK.
FAU - Tollenaar, Rob A E M
AU  - Tollenaar RAEM
AD  - Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
FAU - van den Broek, Alexandra J
AU  - van den Broek AJ
AD  - Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni Van 
      Leeuwenhoek Hospital, Amsterdam, The Netherlands.
FAU - van Deurzen, Carolien H M
AU  - van Deurzen CHM
AD  - Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
FAU - van Leeuwen, Flora E
AU  - van Leeuwen FE
AD  - Division of Psychosocial Research and Epidemiology, The Netherlands Cancer 
      Institute - Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
FAU - van Ongeval, Chantal
AU  - van Ongeval C
AD  - Leuven Cancer Institute, Leuven Multidisciplinary Breast Center, Department of 
      Oncology, University Hospitals Leuven, Leuven, Belgium.
FAU - Van't Veer, Laura J
AU  - Van't Veer LJ
AD  - Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni Van 
      Leeuwenhoek Hospital, Amsterdam, The Netherlands.
FAU - Wang, Qin
AU  - Wang Q
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK.
FAU - Wendt, Camilla
AU  - Wendt C
AD  - Department of Clinical Science and Education, Karolinska Institutet, 
      Södersjukhuset, Stockholm, Sweden.
FAU - Westenend, Pieter J
AU  - Westenend PJ
AD  - Laboratory for Pathology, Dordrecht, The Netherlands.
FAU - Hooning, Maartje J
AU  - Hooning MJ
AD  - Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer 
      Institute, Rotterdam, The Netherlands.
FAU - Schmidt, Marjanka K
AU  - Schmidt MK
AD  - Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni Van 
      Leeuwenhoek Hospital, Amsterdam, The Netherlands. mk.schmidt@nki.nl.
AD  - Division of Psychosocial Research and Epidemiology, The Netherlands Cancer 
      Institute - Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands. 
      mk.schmidt@nki.nl.
AD  - Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The 
      Netherlands. mk.schmidt@nki.nl.
LA  - eng
GR  - 16563/CRUK_/Cancer Research UK/United Kingdom
GR  - UM1 CA164973/CA/NCI NIH HHS/United States
GR  - UM1 CA164920/CA/NCI NIH HHS/United States
GR  - R01 CA063464/CA/NCI NIH HHS/United States
GR  - U01 CA098758/CA/NCI NIH HHS/United States
GR  - 16565/CRUK_/Cancer Research UK/United Kingdom
GR  - Z99 CA999999/ImNIH/Intramural NIH HHS/United States
GR  - R01 CA054281/CA/NCI NIH HHS/United States
GR  - U01 CA063464/CA/NCI NIH HHS/United States
GR  - R01 CA132839/CA/NCI NIH HHS/United States
GR  - U01 CA164973/CA/NCI NIH HHS/United States
GR  - R37 CA054281/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20200411
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (Receptors, Estrogen)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Breast Neoplasms/metabolism/*pathology/surgery
MH  - *Clinical Decision-Making
MH  - Cohort Studies
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - International Agencies
MH  - Mastectomy
MH  - Neoplasms, Second Primary/metabolism/*pathology/surgery
MH  - Prognosis
MH  - Receptor, ErbB-2/metabolism
MH  - Receptors, Estrogen/metabolism
MH  - Risk Assessment/*methods
MH  - Risk Factors
PMC - PMC8380991
MID - NIHMS1625493
OTO - NOTNLM
OT  - Clinical decision-making
OT  - Contralateral breast cancer
OT  - Risk prediction
OT  - Validation
COIS- Conflict of interest Author DG, MH, EW, MAA, DA, JCB, CB, SEB, MKB, JCC, KC, PD, 
      AMD, DFE, JF, HF, MGC, LH, CAH, PH, UH, JLH, AJ, AJ2, AJ3, RK, LBK, IK, DL, LLN, 
      AL, JL, MM, LM, HN, HSAO, SP, PDPP, MS, SS, VTHBMS, MCS, WJT, RAEMT, AJvdB, 
      CHMvD, FEvL, CvO, LvV, QW, CW, PJW, MJH declares that he has no conflict of 
      interest. Author DMM declares that she receives a lecture fee from Pierre Fabre 
      and personal fees for consultancy from Astra Zeneca. Author PAF reports grants 
      from Novartis, grants from Biontech, personal fees from Novartis, personal fees 
      from Roche, personal fees from Pfizer, personal fees from Celgene, personal fees 
      from Daiichi-Sankyo, personal fees from TEVA, personal fees from Astra Zeneca, 
      personal fees from Merck Sharp & Dohme, personal fees from Myelo Therapeutics, 
      personal fees from Macrogenics, personal fees from Eisai, personal fees from 
      Puma, grants from Cepheid.
EDAT- 2020/04/13 06:00
MHDA- 2020/12/02 06:00
PMCR- 2021/08/23
CRDT- 2020/04/13 06:00
PHST- 2019/12/17 00:00 [received]
PHST- 2020/03/21 00:00 [accepted]
PHST- 2020/04/13 06:00 [pubmed]
PHST- 2020/12/02 06:00 [medline]
PHST- 2020/04/13 06:00 [entrez]
PHST- 2021/08/23 00:00 [pmc-release]
AID - 10.1007/s10549-020-05611-8 [pii]
AID - 10.1007/s10549-020-05611-8 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2020 Jun;181(2):423-434. doi: 
      10.1007/s10549-020-05611-8. Epub 2020 Apr 11.

PMID- 31475403
OWN - NLM
STAT- MEDLINE
DCOM- 20200629
LR  - 20200629
IS  - 1615-9861 (Electronic)
IS  - 1615-9853 (Linking)
VI  - 19
IP  - 19
DP  - 2019 Oct
TI  - Protective Cellular Mechanism of Estrogen Against Kidney Stone Formation: A 
      Proteomics Approach and Functional Validation.
PG  - e1900095
LID - 10.1002/pmic.201900095 [doi]
AB  - Females have less incidence/prevalence of kidney stone disease than males. 
      Estrogen thus may serve as the protective factor but with unclear mechanism. This 
      study explores cellular mechanism underlying such stone preventive mechanism of 
      estrogen. Madin darby canine kidney (MDCK) renal tubular cells are incubated with 
      or without 20 nm 17β-estradiol for 7 days. Comparative proteomics reveals 58 
      differentially expressed proteins in estrogen-treated versus control cells that 
      are successfully identified by nanoLC-ESI-Q-TOF-MS/MS. Interestingly, these 
      altered proteins are involved mainly in "binding and receptor," "metabolic 
      process," and "migration and healing" networks. Functional investigations 
      demonstrate reduction of calcium oxalate (CaOx) crystal-binding capability of the 
      estrogen-treated cells consistent with the decreased levels of annexin A1 and 
      α-enolase (the known CaOx crystal-binding receptors) on the cell surface. 
      High-calcium and high-oxalate challenge initially enhances surface expression of 
      annexin A1 and α-enolase, respectively, both of which return to their basal 
      levels by estrogen. Additionally, estrogen reduces intracellular ATP level and 
      promotes cell migration and tissue healing. Taken together, estrogen causes 
      changes in cellular proteome of renal tubular cells that lead to decreased 
      surface expression of CaOx crystal receptors, reduced intracellular metabolism, 
      and enhanced cell proliferation and tissue healing, all of which may contribute, 
      at least in part, to stone prevention.
CI  - © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Peerapen, Paleerath
AU  - Peerapen P
AD  - Medical Proteomics Unit, Office for Research and Development, Faculty of Medicine 
      Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.
FAU - Thongboonkerd, Visith
AU  - Thongboonkerd V
AUID- ORCID: 0000-0001-7865-0765
AD  - Medical Proteomics Unit, Office for Research and Development, Faculty of Medicine 
      Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190918
PL  - Germany
TA  - Proteomics
JT  - Proteomics
JID - 101092707
RN  - 0 (Estrogens)
RN  - 0 (Protective Agents)
RN  - 0 (Proteome)
RN  - 2612HC57YE (Calcium Oxalate)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Animals
MH  - Calcium Oxalate/chemistry/metabolism
MH  - Cells, Cultured
MH  - Chromatography, Liquid/methods
MH  - Crystallization
MH  - Dogs
MH  - Estradiol/*pharmacology
MH  - Estrogens/pharmacology
MH  - Kidney Calculi/metabolism/*prevention & control
MH  - Kidney Tubules/cytology/drug effects/metabolism
MH  - Nanotechnology/methods
MH  - Protective Agents/pharmacology
MH  - Proteome/*metabolism
MH  - Proteomics/*methods
MH  - Reproducibility of Results
MH  - Spectrometry, Mass, Electrospray Ionization/methods
MH  - Tandem Mass Spectrometry/methods
OTO - NOTNLM
OT  - estradiol
OT  - female
OT  - gender
OT  - hormone
OT  - kidney stone
OT  - nephrolithiasis
EDAT- 2019/09/03 06:00
MHDA- 2020/07/01 06:00
CRDT- 2019/09/03 06:00
PHST- 2019/03/11 00:00 [received]
PHST- 2019/08/02 00:00 [revised]
PHST- 2019/09/03 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
PHST- 2019/09/03 06:00 [entrez]
AID - 10.1002/pmic.201900095 [doi]
PST - ppublish
SO  - Proteomics. 2019 Oct;19(19):e1900095. doi: 10.1002/pmic.201900095. Epub 2019 Sep 
      18.

PMID- 34445180
OWN - NLM
STAT- MEDLINE
DCOM- 20210924
LR  - 20210924
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 22
IP  - 16
DP  - 2021 Aug 6
TI  - Endometriosis Susceptibility to Dapsone-Hydroxylamine-Induced Alterations Can Be 
      Prevented by Licorice Intake: In Vivo and In Vitro Study.
LID - 10.3390/ijms22168476 [doi]
LID - 8476
AB  - Endometriosis, an estrogen-dependent chronic gynecological disease, is 
      characterized by a systemic inflammation that affects circulating red blood cells 
      (RBC), by reducing anti-oxidant defenses. The aim of this study was to 
      investigate the potential beneficial effects of licorice intake to protect RBCs 
      from dapsone hydroxylamine (DDS-NHOH), a harmful metabolite of dapsone, commonly 
      used in the treatment of many diseases. A control group (CG, n = 12) and a 
      patient group (PG, n = 18) were treated with licorice extract (25 mg/day), for a 
      week. Blood samples before (T(0)) and after (T(1)) treatment were analyzed for: 
      i) band 3 tyrosine phosphorylation and high molecular weight aggregates; and ii) 
      glutathionylation and carbonic anhydrase activity, in the presence or absence of 
      adjunctive oxidative stress induced by DDS-NHOH. Results were correlated with 
      plasma glycyrrhetinic acid (GA) concentrations, measured by HPLC-MS. Results 
      showed that licorice intake decreased the level of DDS-NHOH-related oxidative 
      alterations in RBCs, and the reduction was directly correlated with plasma GA 
      concentration. In conclusion, in PG, the inability to counteract oxidative stress 
      is a serious concern in the evaluation of therapeutic approaches. GA, by 
      protecting RBC from oxidative assault, as in dapsone therapy, might be considered 
      as a new potential tool for preventing further switching into severe 
      endometriosis.
FAU - Sabbadin, Chiara
AU  - Sabbadin C
AD  - Department of Medicine-Endocrinology, University of Padova, 35121 Padova, Italy.
FAU - Andrisani, Alessandra
AU  - Andrisani A
AD  - Department of Women's and Children's Health, University of Padova, 35121 Padova, 
      Italy.
FAU - Donà, Gabriella
AU  - Donà G
AD  - Department of Molecular Medicine-Biological Chemistry, University of Padova, 
      35131 Padova, Italy.
FAU - Tibaldi, Elena
AU  - Tibaldi E
AD  - Department of Molecular Medicine-Biological Chemistry, University of Padova, 
      35131 Padova, Italy.
FAU - Brunati, Anna Maria
AU  - Brunati AM
AD  - Department of Molecular Medicine-Biological Chemistry, University of Padova, 
      35131 Padova, Italy.
FAU - Dall'Acqua, Stefano
AU  - Dall'Acqua S
AUID- ORCID: 0000-0001-8264-6953
AD  - Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 
      35131 Padova, Italy.
FAU - Ragazzi, Eugenio
AU  - Ragazzi E
AUID- ORCID: 0000-0002-0390-6823
AD  - Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 
      35131 Padova, Italy.
FAU - Ambrosini, Guido
AU  - Ambrosini G
AD  - Department of Women's and Children's Health, University of Padova, 35121 Padova, 
      Italy.
FAU - Armanini, Decio
AU  - Armanini D
AD  - Department of Medicine-Endocrinology, University of Padova, 35121 Padova, Italy.
FAU - Bordin, Luciana
AU  - Bordin L
AUID- ORCID: 0000-0003-4238-3153
AD  - Department of Molecular Medicine-Biological Chemistry, University of Padova, 
      35131 Padova, Italy.
LA  - eng
PT  - Journal Article
DEP - 20210806
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Anti-Infective Agents)
RN  - 0 (Antioxidants)
RN  - 0 (Plant Extracts)
RN  - 0 (Protective Agents)
RN  - 8W5C518302 (Dapsone)
SB  - IM
MH  - Adult
MH  - Anti-Infective Agents/*adverse effects
MH  - Antioxidants/therapeutic use
MH  - Dapsone/*adverse effects
MH  - Endometriosis/*chemically induced/prevention & control
MH  - Erythrocytes/drug effects
MH  - Female
MH  - *Glycyrrhiza/chemistry
MH  - Humans
MH  - Oxidative Stress/drug effects
MH  - Plant Extracts/*therapeutic use
MH  - Protective Agents/*therapeutic use
MH  - Young Adult
PMC - PMC8395227
OTO - NOTNLM
OT  - DDS-NHOH
OT  - dapsone
OT  - endometriosis
OT  - glycyrrhetinic acid
OT  - red blood cell
COIS- The authors declare no conflict of interest.
EDAT- 2021/08/28 06:00
MHDA- 2021/09/25 06:00
PMCR- 2021/08/06
CRDT- 2021/08/27 01:23
PHST- 2021/06/30 00:00 [received]
PHST- 2021/07/28 00:00 [revised]
PHST- 2021/08/03 00:00 [accepted]
PHST- 2021/08/27 01:23 [entrez]
PHST- 2021/08/28 06:00 [pubmed]
PHST- 2021/09/25 06:00 [medline]
PHST- 2021/08/06 00:00 [pmc-release]
AID - ijms22168476 [pii]
AID - ijms-22-08476 [pii]
AID - 10.3390/ijms22168476 [doi]
PST - epublish
SO  - Int J Mol Sci. 2021 Aug 6;22(16):8476. doi: 10.3390/ijms22168476.

PMID- 25529278
OWN - NLM
STAT- MEDLINE
DCOM- 20151116
LR  - 20181113
IS  - 1879-0518 (Electronic)
IS  - 0010-7824 (Print)
IS  - 0010-7824 (Linking)
VI  - 91
IP  - 3
DP  - 2015 Mar
TI  - Mass spectrometry identification of potential mediators of progestin-only 
      contraceptive-induced abnormal uterine bleeding in human endometrial stromal 
      cells.
PG  - 253-60
LID - S0010-7824(14)00776-8 [pii]
LID - 10.1016/j.contraception.2014.11.005 [doi]
AB  - OBJECTIVE: Thrombin and hypoxia each target human endometrial stromal cells 
      (HESCs) to mediate long-acting progestin-only contraceptive (LAPC)-induced 
      abnormal uterine bleeding (AUB). Thus, the secretome resulting from treatment of 
      primary cultures of HESCs with thrombin or hypoxia was screened by mass 
      spectrometry (MS) to detect potential protein mediators that lead to AUB. STUDY 
      DESIGN: Cultured HESCs were primed with estradiol±medroxyprogesterone acetate 
      (MPA) or etonogestrel (ETO), the respective progestins in MPA-injected and 
      ETO-implanted LAPCs, and then treated by incubation with thrombin or under 
      hypoxia. Collected conditioned medium supernatants were used for protein 
      identification and quantitation of potential AUB mediators by liquid 
      chromatography combined with tandem mass spectrometry analysis. Microarray 
      analysis of parallel cultures and immunostaining of endometrial biopsies of LAPC 
      users vs. nonusers corroborated MS results. RESULTS: MS identified several 
      proteins displaying changes in expression levels from either thrombin or hypoxia 
      treatments that are integral to angiogenesis or extracellular matrix formation. 
      Several MS-identified proteins were confirmed by mRNA microarray analysis. 
      Overexpressed stanniocalcin-1 (STC-1) was observed in endometrium of LAPC users. 
      Unlike controls, all LAPC users displayed endometrial tubal metaplasia (ETM). 
      CONCLUSIONS: MS analysis identified many proteins that can affect angiogenesis or 
      vessel integrity, thereby contributing to AUB. Confirmation of STC-1 
      overexpression in LAPC users and microarray data supports the validity of the MS 
      data and suggests STC-1 involvement in AUB. The discovery of ETM in LAPC users 
      indicates that LAPC-related side effects extend beyond AUB. The results presented 
      here demonstrate a complex biological response to LAPC use. IMPLICATIONS: MS 
      identified several HESC secreted proteins deregulated by thrombin and hypoxia 
      that may mediate LAPC-induced AUB. The revelation of overexpressed STC-1 by 
      combined in vivo and in vitro observations identifies a potential target for 
      future studies to prevent or minimize LAPC-induced AUB.
CI  - Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Shapiro, John P
AU  - Shapiro JP
AD  - Department of Obstetrics and Gynecology, The Ohio State University College of 
      Medicine, Columbus, OH 43210, USA.
FAU - Basar, Murat
AU  - Basar M
AD  - Department of Obstetrics and Gynecology, The Ohio State University College of 
      Medicine, Columbus, OH 43210, USA.
FAU - Kayisli, Umit A
AU  - Kayisli UA
AD  - Department of Obstetrics and Gynecology, The University of South Florida, Tampa, 
      FL 33606, USA.
FAU - Guzeloglu-Kayisli, Ozlem
AU  - Guzeloglu-Kayisli O
AD  - Department of Obstetrics and Gynecology, The University of South Florida, Tampa, 
      FL 33606, USA.
FAU - Joseph Huang, S
AU  - Joseph Huang S
AD  - Department of Obstetrics and Gynecology, The Ohio State University College of 
      Medicine, Columbus, OH 43210, USA.
FAU - Suarez, Adrian A
AU  - Suarez AA
AD  - Department of Pathology, The Ohio State University College of Medicine, Columbus, 
      OH 43210, USA.
FAU - Ozer, Hatice Gulcin
AU  - Ozer HG
AD  - Biomedical Informatics Shared Resource, The Ohio State University College of 
      Medicine, Columbus, OH 43210, USA.
FAU - Schatz, Frederick
AU  - Schatz F
AD  - Department of Obstetrics and Gynecology, The University of South Florida, Tampa, 
      FL 33606, USA. Electronic address: fschatz@health.usf.edu.
FAU - Lockwood, Charles J
AU  - Lockwood CJ
AD  - Department of Obstetrics and Gynecology, The University of South Florida, Tampa, 
      FL 33606, USA.
LA  - eng
GR  - P51 RR013986/RR/NCRR NIH HHS/United States
GR  - R01 HD033937/HD/NICHD NIH HHS/United States
GR  - 2 RO1 HD 033937/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20141121
PL  - United States
TA  - Contraception
JT  - Contraception
JID - 0234361
RN  - 0 (Contraceptive Agents, Female)
RN  - 0 (Glycoproteins)
RN  - 0 (Progestins)
RN  - 304GTH6RNH (etonogestrel)
RN  - 4TI98Z838E (Estradiol)
RN  - 76687-96-2 (teleocalcin)
RN  - 81K9V7M3A3 (Desogestrel)
RN  - C2QI4IOI2G (Medroxyprogesterone Acetate)
RN  - EC 3.4.21.5 (Thrombin)
SB  - IM
MH  - Cells, Cultured
MH  - Contraceptive Agents, Female/administration & dosage/*adverse effects
MH  - Desogestrel/administration & dosage/adverse effects
MH  - Endometrium/cytology
MH  - Estradiol/administration & dosage/adverse effects
MH  - Female
MH  - Glycoproteins/drug effects
MH  - Humans
MH  - Hypoxia/chemically induced
MH  - *Mass Spectrometry
MH  - Medroxyprogesterone Acetate/administration & dosage/adverse effects
MH  - Progestins/administration & dosage/*adverse effects
MH  - Stromal Cells/*drug effects
MH  - Thrombin/drug effects
MH  - Uterine Hemorrhage/*chemically induced
PMC - PMC4395468
MID - NIHMS650620
OTO - NOTNLM
OT  - Angiogenesis
OT  - Endometrial tubal metaplasia
OT  - Extracellular matrix
OT  - Mass spectrometry
OT  - Stanniocalcin-1
EDAT- 2014/12/23 06:00
MHDA- 2015/11/17 06:00
PMCR- 2016/03/01
CRDT- 2014/12/23 06:00
PHST- 2014/06/06 00:00 [received]
PHST- 2014/11/06 00:00 [revised]
PHST- 2014/11/08 00:00 [accepted]
PHST- 2014/12/23 06:00 [entrez]
PHST- 2014/12/23 06:00 [pubmed]
PHST- 2015/11/17 06:00 [medline]
PHST- 2016/03/01 00:00 [pmc-release]
AID - S0010-7824(14)00776-8 [pii]
AID - 10.1016/j.contraception.2014.11.005 [doi]
PST - ppublish
SO  - Contraception. 2015 Mar;91(3):253-60. doi: 10.1016/j.contraception.2014.11.005. 
      Epub 2014 Nov 21.

PMID- 30565903
OWN - NLM
STAT- MEDLINE
DCOM- 20200601
LR  - 20220105
IS  - 1488-2434 (Electronic)
IS  - 1180-4882 (Print)
IS  - 1180-4882 (Linking)
VI  - 44
IP  - 1
DP  - 2019 Jan 1
TI  - ERβ agonist alters RNA splicing factor expression and has a longer window of 
      antidepressant effectiveness than estradiol after long-term ovariectomy.
PG  - 19
AB  - BACKGROUND: Estrogen therapy (ET), an effective treatment for perimenopausal 
      depression, often fails to ameliorate symptoms when initiated late after the 
      onset of menopause. Our previous work has suggested that alternative splicing of 
      RNA might mediate these differential effects of ET. METHODS: Female 
      Sprague–Dawley rats were treated with estradiol (E2) or vehicle 6 days (early ET) 
      or 180 days (late ET) after ovariectomy (OVX). We investigated the differential 
      expression of RNA splicing factors and tryptophan hydroxylase 2 (TPH2) protein 
      using a customized RT2 Profiler PCR Array, reverse-transcription polymerase chain 
      reaction, immunoprecipitation and behaviour changes in clinically relevant early 
      and late ET. RESULTS: Early ET, but not late ET, prolonged swimming time in the 
      forced swim test and reduced anxiety-like behaviours in the elevated plus maze. 
      It reversed OVX-increased (SFRS7 and SFRS16) or OVX-decreased (ZRSR2 and CTNNB1) 
      mRNA levels of splicing factors and ERβ splicing changes in the brains of OVX 
      rats. Early ET, but not late ET, also increased the expression of TPH2 and 
      decreased monoamine oxidase A levels in the dorsal raphe in the brains of OVX 
      rats. In late ET, only diarylpropionitrile (an ERβ-specific agonist) achieved 
      similar results — not E2 (an ERα and ERβ agonist) or propylpyrazoletriol (an 
      ERα-specific agonist). LIMITATIONS: Our experimental paradigm mimicked early and 
      late ET in the clinical setting, but the contribution of age and OVX might be 
      difficult to distinguish. CONCLUSION: These findings suggest that ERβ alternative 
      splicing and altered responses in the regulatory system for serotonin may mediate 
      the antidepressant efficacy of ET associated with the timing of therapy 
      initiation. It is likely that ERβ-specific ligands would be effective 
      estrogen-based antidepressants late after the onset of menopause.
CI  - © 2019 Joule Inc. or its licensors
FAU - Hou, Xu
AU  - Hou X
AD  - From the Program in Neuroscience, University of Mississippi Medical Center, 
      Jackson, MS, USA (Hou, Wang); the Department of Pathology, University of 
      Mississippi Medical Center, Jackson, MS, USA (Adeosun, Zhao, Zheng, Reddy, Wang); 
      the Department of Psychiatry and Human Behavior, University of Mississippi 
      Medical Center, Jackson, MS, USA (Wang); the Department of Pharmacology and 
      Toxicology, University of Mississippi Medical Center, Jackson, MS, USA (Wang); 
      the Department of Medicine, University of Mississippi Medical Center, Jackson, 
      MS, USA (Mosley); the Centre for Addiction and Mental Health and Department of 
      Psychiatry, University of Toronto, Toronto, Ont., Canada (Meyer); the Basic 
      Medical College of Heilongjiang University of Chinese Medicine, Harbin, 
      Heilongjiang Province, China (Zhao); and the College of Health & Biomedicine, 
      Victoria University, Melbourne, Australia (Su).
FAU - Adeosun, Samuel O
AU  - Adeosun SO
AD  - From the Program in Neuroscience, University of Mississippi Medical Center, 
      Jackson, MS, USA (Hou, Wang); the Department of Pathology, University of 
      Mississippi Medical Center, Jackson, MS, USA (Adeosun, Zhao, Zheng, Reddy, Wang); 
      the Department of Psychiatry and Human Behavior, University of Mississippi 
      Medical Center, Jackson, MS, USA (Wang); the Department of Pharmacology and 
      Toxicology, University of Mississippi Medical Center, Jackson, MS, USA (Wang); 
      the Department of Medicine, University of Mississippi Medical Center, Jackson, 
      MS, USA (Mosley); the Centre for Addiction and Mental Health and Department of 
      Psychiatry, University of Toronto, Toronto, Ont., Canada (Meyer); the Basic 
      Medical College of Heilongjiang University of Chinese Medicine, Harbin, 
      Heilongjiang Province, China (Zhao); and the College of Health & Biomedicine, 
      Victoria University, Melbourne, Australia (Su).
FAU - Zhao, Xueying
AU  - Zhao X
AD  - From the Program in Neuroscience, University of Mississippi Medical Center, 
      Jackson, MS, USA (Hou, Wang); the Department of Pathology, University of 
      Mississippi Medical Center, Jackson, MS, USA (Adeosun, Zhao, Zheng, Reddy, Wang); 
      the Department of Psychiatry and Human Behavior, University of Mississippi 
      Medical Center, Jackson, MS, USA (Wang); the Department of Pharmacology and 
      Toxicology, University of Mississippi Medical Center, Jackson, MS, USA (Wang); 
      the Department of Medicine, University of Mississippi Medical Center, Jackson, 
      MS, USA (Mosley); the Centre for Addiction and Mental Health and Department of 
      Psychiatry, University of Toronto, Toronto, Ont., Canada (Meyer); the Basic 
      Medical College of Heilongjiang University of Chinese Medicine, Harbin, 
      Heilongjiang Province, China (Zhao); and the College of Health & Biomedicine, 
      Victoria University, Melbourne, Australia (Su).
FAU - Hill, Rosanne
AU  - Hill R
AD  - From the Program in Neuroscience, University of Mississippi Medical Center, 
      Jackson, MS, USA (Hou, Wang); the Department of Pathology, University of 
      Mississippi Medical Center, Jackson, MS, USA (Adeosun, Zhao, Zheng, Reddy, Wang); 
      the Department of Psychiatry and Human Behavior, University of Mississippi 
      Medical Center, Jackson, MS, USA (Wang); the Department of Pharmacology and 
      Toxicology, University of Mississippi Medical Center, Jackson, MS, USA (Wang); 
      the Department of Medicine, University of Mississippi Medical Center, Jackson, 
      MS, USA (Mosley); the Centre for Addiction and Mental Health and Department of 
      Psychiatry, University of Toronto, Toronto, Ont., Canada (Meyer); the Basic 
      Medical College of Heilongjiang University of Chinese Medicine, Harbin, 
      Heilongjiang Province, China (Zhao); and the College of Health & Biomedicine, 
      Victoria University, Melbourne, Australia (Su).
FAU - Zheng, Baoying
AU  - Zheng B
AD  - From the Program in Neuroscience, University of Mississippi Medical Center, 
      Jackson, MS, USA (Hou, Wang); the Department of Pathology, University of 
      Mississippi Medical Center, Jackson, MS, USA (Adeosun, Zhao, Zheng, Reddy, Wang); 
      the Department of Psychiatry and Human Behavior, University of Mississippi 
      Medical Center, Jackson, MS, USA (Wang); the Department of Pharmacology and 
      Toxicology, University of Mississippi Medical Center, Jackson, MS, USA (Wang); 
      the Department of Medicine, University of Mississippi Medical Center, Jackson, 
      MS, USA (Mosley); the Centre for Addiction and Mental Health and Department of 
      Psychiatry, University of Toronto, Toronto, Ont., Canada (Meyer); the Basic 
      Medical College of Heilongjiang University of Chinese Medicine, Harbin, 
      Heilongjiang Province, China (Zhao); and the College of Health & Biomedicine, 
      Victoria University, Melbourne, Australia (Su).
FAU - Reddy, Reveena
AU  - Reddy R
AD  - From the Program in Neuroscience, University of Mississippi Medical Center, 
      Jackson, MS, USA (Hou, Wang); the Department of Pathology, University of 
      Mississippi Medical Center, Jackson, MS, USA (Adeosun, Zhao, Zheng, Reddy, Wang); 
      the Department of Psychiatry and Human Behavior, University of Mississippi 
      Medical Center, Jackson, MS, USA (Wang); the Department of Pharmacology and 
      Toxicology, University of Mississippi Medical Center, Jackson, MS, USA (Wang); 
      the Department of Medicine, University of Mississippi Medical Center, Jackson, 
      MS, USA (Mosley); the Centre for Addiction and Mental Health and Department of 
      Psychiatry, University of Toronto, Toronto, Ont., Canada (Meyer); the Basic 
      Medical College of Heilongjiang University of Chinese Medicine, Harbin, 
      Heilongjiang Province, China (Zhao); and the College of Health & Biomedicine, 
      Victoria University, Melbourne, Australia (Su).
FAU - Su, Xiao
AU  - Su X
AD  - From the Program in Neuroscience, University of Mississippi Medical Center, 
      Jackson, MS, USA (Hou, Wang); the Department of Pathology, University of 
      Mississippi Medical Center, Jackson, MS, USA (Adeosun, Zhao, Zheng, Reddy, Wang); 
      the Department of Psychiatry and Human Behavior, University of Mississippi 
      Medical Center, Jackson, MS, USA (Wang); the Department of Pharmacology and 
      Toxicology, University of Mississippi Medical Center, Jackson, MS, USA (Wang); 
      the Department of Medicine, University of Mississippi Medical Center, Jackson, 
      MS, USA (Mosley); the Centre for Addiction and Mental Health and Department of 
      Psychiatry, University of Toronto, Toronto, Ont., Canada (Meyer); the Basic 
      Medical College of Heilongjiang University of Chinese Medicine, Harbin, 
      Heilongjiang Province, China (Zhao); and the College of Health & Biomedicine, 
      Victoria University, Melbourne, Australia (Su).
FAU - Meyer, Jeffrey
AU  - Meyer J
AD  - From the Program in Neuroscience, University of Mississippi Medical Center, 
      Jackson, MS, USA (Hou, Wang); the Department of Pathology, University of 
      Mississippi Medical Center, Jackson, MS, USA (Adeosun, Zhao, Zheng, Reddy, Wang); 
      the Department of Psychiatry and Human Behavior, University of Mississippi 
      Medical Center, Jackson, MS, USA (Wang); the Department of Pharmacology and 
      Toxicology, University of Mississippi Medical Center, Jackson, MS, USA (Wang); 
      the Department of Medicine, University of Mississippi Medical Center, Jackson, 
      MS, USA (Mosley); the Centre for Addiction and Mental Health and Department of 
      Psychiatry, University of Toronto, Toronto, Ont., Canada (Meyer); the Basic 
      Medical College of Heilongjiang University of Chinese Medicine, Harbin, 
      Heilongjiang Province, China (Zhao); and the College of Health & Biomedicine, 
      Victoria University, Melbourne, Australia (Su).
FAU - Mosley, Thomas
AU  - Mosley T
AD  - From the Program in Neuroscience, University of Mississippi Medical Center, 
      Jackson, MS, USA (Hou, Wang); the Department of Pathology, University of 
      Mississippi Medical Center, Jackson, MS, USA (Adeosun, Zhao, Zheng, Reddy, Wang); 
      the Department of Psychiatry and Human Behavior, University of Mississippi 
      Medical Center, Jackson, MS, USA (Wang); the Department of Pharmacology and 
      Toxicology, University of Mississippi Medical Center, Jackson, MS, USA (Wang); 
      the Department of Medicine, University of Mississippi Medical Center, Jackson, 
      MS, USA (Mosley); the Centre for Addiction and Mental Health and Department of 
      Psychiatry, University of Toronto, Toronto, Ont., Canada (Meyer); the Basic 
      Medical College of Heilongjiang University of Chinese Medicine, Harbin, 
      Heilongjiang Province, China (Zhao); and the College of Health & Biomedicine, 
      Victoria University, Melbourne, Australia (Su).
FAU - Wang, Jun Ming
AU  - Wang JM
AD  - From the Program in Neuroscience, University of Mississippi Medical Center, 
      Jackson, MS, USA (Hou, Wang); the Department of Pathology, University of 
      Mississippi Medical Center, Jackson, MS, USA (Adeosun, Zhao, Zheng, Reddy, Wang); 
      the Department of Psychiatry and Human Behavior, University of Mississippi 
      Medical Center, Jackson, MS, USA (Wang); the Department of Pharmacology and 
      Toxicology, University of Mississippi Medical Center, Jackson, MS, USA (Wang); 
      the Department of Medicine, University of Mississippi Medical Center, Jackson, 
      MS, USA (Mosley); the Centre for Addiction and Mental Health and Department of 
      Psychiatry, University of Toronto, Toronto, Ont., Canada (Meyer); the Basic 
      Medical College of Heilongjiang University of Chinese Medicine, Harbin, 
      Heilongjiang Province, China (Zhao); and the College of Health & Biomedicine, 
      Victoria University, Melbourne, Australia (Su).
LA  - eng
GR  - P30 GM103328/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - Canada
TA  - J Psychiatry Neurosci
JT  - Journal of psychiatry & neuroscience : JPN
JID - 9107859
RN  - 0 (2,3-bis(4-hydroxyphenyl)-propionitrile)
RN  - 0 (Antidepressive Agents)
RN  - 0 (Estrogen Receptor beta)
RN  - 0 (Nitriles)
RN  - 0 (Phenols)
RN  - 0 (Propionates)
RN  - 0 (Pyrazoles)
RN  - 0 (RNA Splicing Factors)
RN  - 0T83Y6JZPF (4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol)
RN  - 4TI98Z838E (Estradiol)
RN  - EC 1.14.16.4 (Tryptophan Hydroxylase)
RN  - EC 1.14.16.4 (tph2 protein, rat)
RN  - EC 1.4.3.4 (Monoamine Oxidase)
SB  - IM
MH  - Animals
MH  - Antidepressive Agents/*pharmacology
MH  - Brain/metabolism
MH  - Estradiol/*pharmacology
MH  - Estrogen Receptor beta/antagonists & inhibitors/metabolism
MH  - Female
MH  - Immobility Response, Tonic/*drug effects
MH  - Maze Learning/*drug effects
MH  - Monoamine Oxidase/metabolism
MH  - Nitriles/pharmacology
MH  - Ovariectomy
MH  - Phenols/pharmacology
MH  - Propionates/pharmacology
MH  - Pyrazoles/pharmacology
MH  - RNA Splicing Factors/*biosynthesis
MH  - Rats
MH  - Time Factors
MH  - Tryptophan Hydroxylase/biosynthesis
PMC - PMC6306290
COIS- J. Meyer reports grants from Janssen, outside the submitted work. In addition, he 
      has patents on a brain marker and blood markers of MAO-A for predicting mood 
      disorder and on a dietary supplement to prevent postpartum depression and sad 
      mood during high MAO-A states. No other competing interests declared.
EDAT- 2018/12/20 06:00
MHDA- 2020/06/02 06:00
PMCR- 2019/01/01
CRDT- 2018/12/20 06:00
PHST- 2018/12/20 06:00 [entrez]
PHST- 2018/12/20 06:00 [pubmed]
PHST- 2020/06/02 06:00 [medline]
PHST- 2019/01/01 00:00 [pmc-release]
AID - 44-1-19 [pii]
AID - 10.1503/jpn.170199 [doi]
PST - ppublish
SO  - J Psychiatry Neurosci. 2019 Jan 1;44(1):19. doi: 10.1503/jpn.170199.

PMID- 28132861
OWN - NLM
STAT- MEDLINE
DCOM- 20170714
LR  - 20170714
IS  - 1872-7573 (Electronic)
IS  - 0378-8741 (Linking)
VI  - 199
DP  - 2017 Mar 6
TI  - Global and untargeted metabolomics evidence of the protective effect of different 
      extracts of Dipsacus asper Wall. ex C.B. Clarke on estrogen deficiency after 
      ovariectomia in rats.
PG  - 20-29
LID - S0378-8741(17)30349-5 [pii]
LID - 10.1016/j.jep.2017.01.050 [doi]
AB  - ETHNOPHARMACOLOGICAL RELEVANCE: Dipsacus asper Wall. ex C.B. Clarke (DA) is an 
      effectively traditional Chinese medicine for treating osteoporosis and bone 
      fracture. Until now, studies on pharmacological mechanism of DA mostly centered 
      on cell and gene level, little is known about its metabolic signatures. The aim 
      of this study is to investigate the anti-osteoporosis effects of crude and 
      wine-processed DA by global and untargeted metabolic profiling of rats serum, 
      liver and kidney derived from sham, model and treated groups. METHOD: A total of 
      25 female Wistar rats were divided into five groups: sham group, model group, E2, 
      crude and wine-processed DA treated group. The treatment rats were orally 
      administered 17β-estradiol, crude and wine-processed DA extract at a therapeutic 
      dose once daily throughout the experimental period, while sham group and model 
      group were orally gavaged approximately volume of saline solution. After 16 
      weeks, all serum, liver and kidney samples of five groups were collected and 
      their metabolomic alterations were monitored by gas chromatography-mass 
      spectrometry (GC-MS). The resulting dataset was analyzed by principal component 
      analysis (PCA) and partial least squares discriminant analysis (PLS-DA). The 
      identification of all potential biomarkers was performed using reference standard 
      or NIST library. Moreover, clinical chemistry and biomechanical analysis were 
      also performed to ensure the success of the osteoporosis model and to validate 
      the anti-osteoporosis effect of crude and wine-processed DA. RESULTS: Clear 
      separation trend among sham, model and treatment group was observed in PCA score 
      plot. The anti-osteoporosis effect of DA and wine-processed DA can be indicated 
      in PLS-DA score plots. A total of 80 and 74 metabolite biomarkers were identified 
      for DA and wine-processed DA treated groups, respectively. Pathway analysis 
      revealed that phenylalanine, tyrosine and tryptophan biosynthesis, valine, 
      leucine and isoleucine biosynthesis, methane metabolism, glycine, serine and 
      threonine metabolism, galactose metabolism were the major intervened pathways. 
      Compared with model group, levels of all biomarkers were gradually restored to 
      normal after administration of DA and wine-processed DA. CONCLUSION: The 
      anti-osteoporosis effect of DA and wine-processed DA has been reliably confirmed 
      by the metabolomics approach. The osteoporosis might be prevented by DA and 
      wine-processed DA via intervening amino acid metabolism, carbohydrate metabolism 
      and energy metabolism in vivo in rats.
CI  - Copyright © 2017 Elsevier Ireland Ltd. All rights reserved.
FAU - Tao, Yi
AU  - Tao Y
AD  - School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, PR 
      China; Jiangsu Key Laboratory of Chinese Medicine Processing, Nanjing University 
      of Chinese Medicine, Nanjing 210023, PR China. Electronic address: 
      taoyi1985812@126.com.
FAU - Chen, Xi
AU  - Chen X
AD  - School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, PR 
      China; Jiangsu Key Laboratory of Chinese Medicine Processing, Nanjing University 
      of Chinese Medicine, Nanjing 210023, PR China.
FAU - Li, Weidong
AU  - Li W
AD  - School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, PR 
      China; Jiangsu Key Laboratory of Chinese Medicine Processing, Nanjing University 
      of Chinese Medicine, Nanjing 210023, PR China.
FAU - Cai, Baochang
AU  - Cai B
AD  - School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, PR 
      China; Jiangsu Key Laboratory of Chinese Medicine Processing, Nanjing University 
      of Chinese Medicine, Nanjing 210023, PR China.
FAU - Di, Liuqing
AU  - Di L
AD  - School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, PR 
      China.
FAU - Shi, Liyun
AU  - Shi L
AD  - Department of Microbiology and Immunology, Nanjing University of Chinese 
      Medicine, Nanjing 210023, PR China.
FAU - Hu, Lihong
AU  - Hu L
AD  - State key Laboratory of Drug Research, Shanghai Institute of Materia Medica, 
      University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 
      201203, PR China.
LA  - eng
PT  - Journal Article
DEP - 20170126
PL  - Ireland
TA  - J Ethnopharmacol
JT  - Journal of ethnopharmacology
JID - 7903310
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Estrogens)
RN  - 0 (Protective Agents)
SB  - IM
MH  - Animals
MH  - *Dipsacaceae
MH  - Drugs, Chinese Herbal/isolation & purification/*pharmacology/therapeutic use
MH  - Estrogens/*deficiency
MH  - Female
MH  - Gas Chromatography-Mass Spectrometry
MH  - Metabolomics/*methods
MH  - Osteoporosis/etiology/*metabolism/prevention & control
MH  - Ovariectomy/*adverse effects
MH  - Protective Agents/isolation & purification/pharmacology/therapeutic use
MH  - Rats
MH  - Rats, Wistar
OTO - NOTNLM
OT  - Chemometrics
OT  - Dipsacus asper Wall. ex C.B. Clarke
OT  - GC-MS
OT  - Metabolomics
OT  - Osteoporosis
EDAT- 2017/01/31 06:00
MHDA- 2017/07/15 06:00
CRDT- 2017/01/31 06:00
PHST- 2016/08/25 00:00 [received]
PHST- 2016/11/08 00:00 [revised]
PHST- 2017/01/26 00:00 [accepted]
PHST- 2017/01/31 06:00 [pubmed]
PHST- 2017/07/15 06:00 [medline]
PHST- 2017/01/31 06:00 [entrez]
AID - S0378-8741(17)30349-5 [pii]
AID - 10.1016/j.jep.2017.01.050 [doi]
PST - ppublish
SO  - J Ethnopharmacol. 2017 Mar 6;199:20-29. doi: 10.1016/j.jep.2017.01.050. Epub 2017 
      Jan 26.

PMID- 29042425
OWN - NLM
STAT- MEDLINE
DCOM- 20180611
LR  - 20240715
IS  - 2047-9980 (Electronic)
IS  - 2047-9980 (Linking)
VI  - 6
IP  - 10
DP  - 2017 Oct 17
TI  - Cardiovascular and Metabolic Consequences of Testosterone Supplements in Young 
      and Old Male Spontaneously Hypertensive Rats: Implications for Testosterone 
      Supplements in Men.
LID - 10.1161/JAHA.117.007074 [doi]
LID - e007074
AB  - BACKGROUND: The safety of testosterone supplements in men remains unclear. In the 
      present study, we tested the hypothesis that in young and old male spontaneously 
      hypertensive rats (SHR), long-term testosterone supplements increase blood 
      pressure and that the mechanism is mediated in part by activation of the 
      renin-angiotensin system. METHODS AND RESULTS: In untreated males, serum 
      testosterone exhibited a sustained decrease after 5 months of age, reaching a 
      nadir by 18 to 22 months of age. The reductions in serum testosterone were 
      accompanied by an increase in body weight until very old age (18 months). 
      Testosterone supplements were given for 6 weeks to young (12 weeks-YMSHR) and old 
      (21-22 months-OMSHR) male SHR that increased serum testosterone by 2-fold in 
      young males and by 4-fold in old males. Testosterone supplements decreased body 
      weight, fat mass, lean mass, and plasma leptin, and increased plasma estradiol in 
      YMSHR but had no effect in OMSHR. Mean arterial pressure (MAP) was significantly 
      higher in OMSHR than in YMSHR and testosterone supplements decreased MAP in 
      OMSHR, but significantly increased MAP in YMSHR. Enalapril, the 
      angiotensin-converting enzyme inhibitor, reduced MAP in both control and 
      testosterone-supplemented YMSHR, but had a greater effect on MAP in 
      testosterone-treated rats, suggesting the mechanism responsible for the increase 
      in MAP in YMSHR is mediated at least in part by activation of the 
      renin-angiotensin system. CONCLUSIONS: Taken together with previous studies, 
      these data suggest that testosterone supplements may have differential effects on 
      men depending on age, cardiovascular and metabolic status, and dose and whether 
      given long-term or short-term.
CI  - © 2017 The Authors. Published on behalf of the American Heart Association, Inc., 
      by Wiley.
FAU - Dalmasso, Carolina
AU  - Dalmasso C
AD  - Department of Biochemistry, University of Mississippi Medical Center, Jackson, 
      MS.
AD  - Department of Women's Health Research Center, University of Mississippi Medical 
      Center, Jackson, MS.
FAU - Patil, Chetan N
AU  - Patil CN
AD  - Department of Biochemistry, University of Mississippi Medical Center, Jackson, 
      MS.
AD  - Department of Women's Health Research Center, University of Mississippi Medical 
      Center, Jackson, MS.
FAU - Yanes Cardozo, Licy L
AU  - Yanes Cardozo LL
AD  - Department of Biochemistry, University of Mississippi Medical Center, Jackson, 
      MS.
AD  - Department of Medicine, Divisions of Endocrinology/Nephrology, University of 
      Mississippi Medical Center, Jackson, MS.
AD  - Department of Women's Health Research Center, University of Mississippi Medical 
      Center, Jackson, MS.
FAU - Romero, Damian G
AU  - Romero DG
AD  - Department of Biochemistry, University of Mississippi Medical Center, Jackson, 
      MS.
AD  - Department of Women's Health Research Center, University of Mississippi Medical 
      Center, Jackson, MS.
FAU - Maranon, Rodrigo O
AU  - Maranon RO
AD  - Department of Medicine, Divisions of Endocrinology/Nephrology, University of 
      Mississippi Medical Center, Jackson, MS rmaranon@umc.edu.
AD  - Department of Women's Health Research Center, University of Mississippi Medical 
      Center, Jackson, MS.
LA  - eng
GR  - P20 GM121334/GM/NIGMS NIH HHS/United States
GR  - R21 DK113500/DK/NIDDK NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
DEP - 20171017
PL  - England
TA  - J Am Heart Assoc
JT  - Journal of the American Heart Association
JID - 101580524
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Leptin)
RN  - 3XMK78S47O (Testosterone)
RN  - 4TI98Z838E (Estradiol)
RN  - 69PN84IO1A (Enalapril)
SB  - IM
MH  - Adiposity/drug effects
MH  - Age Factors
MH  - Aging
MH  - Angiotensin-Converting Enzyme Inhibitors/pharmacology
MH  - Animals
MH  - Antihypertensive Agents/pharmacology
MH  - Arterial Pressure/*drug effects
MH  - Disease Models, Animal
MH  - Enalapril/pharmacology
MH  - Estradiol/blood
MH  - Hormone Replacement Therapy/*adverse effects
MH  - Hypertension/blood/drug therapy/*physiopathology
MH  - Leptin/blood
MH  - Male
MH  - Rats, Inbred SHR
MH  - Renin-Angiotensin System/drug effects
MH  - Risk Factors
MH  - Testosterone/administration & dosage/blood/deficiency/*toxicity
MH  - Weight Gain/drug effects
PMC - PMC5721890
OTO - NOTNLM
OT  - aging
OT  - hypertension
OT  - leptin
OT  - testosterone
EDAT- 2017/10/19 06:00
MHDA- 2018/06/12 06:00
PMCR- 2017/10/01
CRDT- 2017/10/19 06:00
PHST- 2017/10/19 06:00 [entrez]
PHST- 2017/10/19 06:00 [pubmed]
PHST- 2018/06/12 06:00 [medline]
PHST- 2017/10/01 00:00 [pmc-release]
AID - JAHA.117.007074 [pii]
AID - JAH32640 [pii]
AID - 10.1161/JAHA.117.007074 [doi]
PST - epublish
SO  - J Am Heart Assoc. 2017 Oct 17;6(10):e007074. doi: 10.1161/JAHA.117.007074.

PMID- 37951091
OWN - NLM
STAT- MEDLINE
DCOM- 20231121
LR  - 20250103
IS  - 1090-2414 (Electronic)
IS  - 0147-6513 (Linking)
VI  - 267
DP  - 2023 Nov 15
TI  - Effects of prenatal single and mixed bisphenol exposure on bone mineral density 
      in preschool children: A population-based prospective cohort study.
PG  - 115665
LID - S0147-6513(23)01169-7 [pii]
LID - 10.1016/j.ecoenv.2023.115665 [doi]
AB  - Exposure to bisphenols can affect bone mineral density (BMD) in animals and 
      humans. However, the effects of maternal exposure to bisphenols during pregnancy 
      on bone health in preschool children remain unknown. We aimed to assess the 
      effects of prenatal exposure to single and multiple bisphenols on bone health in 
      preschool children. A total of 230 mother-child pairs were included in this 
      study. Generalized linear regression, restricted cubic spline (RCS), principal 
      component analysis (PCA), and Bayesian kernel machine regression (BKMR) were 
      utilized to assess the relationship between bisphenol levels and bone health in 
      preschool children. Each natural log (Ln) unit increase in tetrabromobisphenol A 
      was related to a 0.007 m/s (95 % CI: -0.015, 0.000) decrease in Ln-transformed 
      speed of sound (SOS) among girls. Decreased BMD Z scores in preschool children 
      were found only in the high bisphenol S exposure group (β = -0.568; 95 % CI: 
      -1.087, -0.050) in boys. The risk of low BMD (BMDL) was significantly higher in 
      the middle-exposure group (OR = 4.695; 95 % CI: 1.143, 24.381) and high-exposure 
      group of BPS (OR = 6.165, 95 % CI: 1.445, 33.789) compared with the low-exposure 
      group in boys. In girls, the risk of BMDL decreased with increasing bisphenol A 
      concentration (OR = 0.413, 95 % CI: 0.215, 0.721). RCS analysis revealed a 
      U-shaped nonlinear correlation between BPB concentration and BMDL in girls 
      (P-overall = 0.011, P-nonlinear = 0.009). In PCA, a U-shaped dose-response 
      relationship was found between PC2 and the risk of BMDL (P-overall = 0.048, 
      P-nonlinear = 0.032), and a significant association was only noted in girls when 
      stratified by sex. The BKMR model revealed a horizontal S-shaped curve 
      relationship between bisphenol mixtures and BMDL in girls. The results indicated 
      that prenatal exposure to single and mixed bisphenols can affect BMD in preschool 
      children, exerting nonmonotonic and child sex-specific effects.
CI  - Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Liang, Jun
AU  - Liang J
AD  - Department of Epidemiology and Health Statistics, School of Public Health, 
      Guangxi Medical University, Nanning, Guangxi 530021, China.
FAU - Pang, Lixiang
AU  - Pang L
AD  - Department of Sanitary Chemistry, School of Public Health, Guangxi Medical 
      University, Nanning, Guangxi 530021, China.
FAU - Yang, Chunxiu
AU  - Yang C
AD  - The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi 
      530021, China.
FAU - Long, Jinghua
AU  - Long J
AD  - Department of Epidemiology and Health Statistics, School of Public Health, 
      Guangxi Medical University, Nanning, Guangxi 530021, China; The First Affiliated 
      Hospital of Guangxi Medical University, Nanning, Guangxi 530021, China.
FAU - Liao, Qian
AU  - Liao Q
AD  - Department of Epidemiology and Health Statistics, School of Public Health, 
      Guangxi Medical University, Nanning, Guangxi 530021, China.
FAU - Tang, Peng
AU  - Tang P
AD  - Department of Epidemiology and Health Statistics, School of Public Health, 
      Guangxi Medical University, Nanning, Guangxi 530021, China.
FAU - Huang, Huishen
AU  - Huang H
AD  - Department of Epidemiology and Health Statistics, School of Public Health, 
      Guangxi Medical University, Nanning, Guangxi 530021, China.
FAU - Wei, Huanni
AU  - Wei H
AD  - Liuzhou People's Hospital Affiliated to Guangxi Medical University, Liuzhou 
      545006, China.
FAU - Chen, Qian
AU  - Chen Q
AD  - Department of Epidemiology and Health Statistics, School of Public Health, 
      Guangxi Medical University, Nanning, Guangxi 530021, China.
FAU - Yang, Kaiqi
AU  - Yang K
AD  - Department of Sanitary Chemistry, School of Public Health, Guangxi Medical 
      University, Nanning, Guangxi 530021, China.
FAU - Liu, Tao
AU  - Liu T
AD  - Huaihua Center for Disease Control and Prevention, Huaihua, Hunan 418000, China.
FAU - Lv, Fangfang
AU  - Lv F
AD  - Department of Child and Adolescent Health & Maternal and Child Health, School of 
      Public Health, Guangxi Medical University, Nanning, Guangxi 530021, China.
FAU - Liu, Shun
AU  - Liu S
AD  - Department of Child and Adolescent Health & Maternal and Child Health, School of 
      Public Health, Guangxi Medical University, Nanning, Guangxi 530021, China.
FAU - Huang, Dongping
AU  - Huang D
AD  - Department of Sanitary Chemistry, School of Public Health, Guangxi Medical 
      University, Nanning, Guangxi 530021, China. Electronic address: 
      dongpinghuang@gxmu.edu.cn.
FAU - Qiu, Xiaoqiang
AU  - Qiu X
AD  - Department of Epidemiology and Health Statistics, School of Public Health, 
      Guangxi Medical University, Nanning, Guangxi 530021, China. Electronic address: 
      xqqiu9999@163.com.
LA  - eng
PT  - Journal Article
DEP - 20231110
PL  - Netherlands
TA  - Ecotoxicol Environ Saf
JT  - Ecotoxicology and environmental safety
JID - 7805381
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - Animals
MH  - Male
MH  - Female
MH  - Pregnancy
MH  - Humans
MH  - Child, Preschool
MH  - *Bone Density
MH  - Bayes Theorem
MH  - *Prenatal Exposure Delayed Effects
MH  - Prospective Studies
OTO - NOTNLM
OT  - Bisphenol
OT  - Bone mineral density
OT  - Pregnant women
OT  - Preschool children
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/11/12 00:42
MHDA- 2023/11/21 06:42
CRDT- 2023/11/11 18:12
PHST- 2023/08/06 00:00 [received]
PHST- 2023/10/22 00:00 [revised]
PHST- 2023/11/03 00:00 [accepted]
PHST- 2023/11/21 06:42 [medline]
PHST- 2023/11/12 00:42 [pubmed]
PHST- 2023/11/11 18:12 [entrez]
AID - S0147-6513(23)01169-7 [pii]
AID - 10.1016/j.ecoenv.2023.115665 [doi]
PST - ppublish
SO  - Ecotoxicol Environ Saf. 2023 Nov 15;267:115665. doi: 
      10.1016/j.ecoenv.2023.115665. Epub 2023 Nov 10.

PMID- 38114217
OWN - NLM
STAT- MEDLINE
DCOM- 20231221
LR  - 20231221
IS  - 1001-5302 (Print)
IS  - 1001-5302 (Linking)
VI  - 48
IP  - 22
DP  - 2023 Nov
TI  - [Therapeutic effect of Leonuri Herba aqueous decoction on primary dysmenorrhea in 
      rats and its metabolomic analysis].
PG  - 6093-6106
LID - 10.19540/j.cnki.cjcmm.20230803.401 [doi]
AB  - This study aimed to investigate the therapeutic effect of Leonuri Herba aqueous 
      decoction on primary dysmenorrhea(PD) and explore the underlying mechanism in 
      conjunction with untargeted metabolomics. Forty adult female rats were randomly 
      divi-ded into a normal group, a model control group, ibuprofen(0.12 g·kg~(-1)) 
      group, and high-and low-dose Leonuri Herba aqueous decoction(5 and 2.5 g·kg~(-1)) 
      groups, with eight rats in each group. The PD rat model was prepared using 
      intramuscular injection of estradiol benzoate combined with intraperitoneal 
      injection of pitocin. Drugs were administered by gavage from the 4th day of 
      modeling for 7 d. After the last administration, pitocin was injected 
      intraperitoneally, and the writhing latency and writhing times within 30 min were 
      recorded. The uterine and ovarian coefficients were determined. Estradiol(E_2), 
      progesterone(Prog), oxytocin(OT), cyclooxyge-nase 2(COX-2), prostaglandin 
      E_2(PGE_2), prostaglandin F_(2α)(PGF_(2α)), and Ca~(2+) levels in uterine tissues 
      were measured by ELISA and biochemical kits. Morphological changes in uterine and 
      ovarian tissues were observed by hematoxylin-eosin(HE) staining. The protein 
      expression of oxytocin receptor(OTR), prostaglandin E_2 receptor 3(EP3), and 
      estrogen receptor alpha(ERα) in uterine tissues was detected by 
      immunohistochemistry. The mRNA expression of OTR, PGE_2 receptors 1-4(EP1, EP2, 
      EP3, and EP4), and PGF_(2α) receptor(FP) in uterine tissues was detected by 
      quantitative real-time PCR. Untargeted metabolomics analysis was performed by 
      ultra-high-performance liquid chromatography-quadrupole-time-of-flight mass 
      spectrometry(LC-QTOF-MS) technology to screen potential biomarkers and enrich 
      metabolic pathways. The results showed that Leonuri Herba was able to 
      significantly reduce the writhing times in PD rats(P&lt;0.05 or P&lt;0.01), 
      significantly reduce the uterine and ovarian coefficients(P&lt;0.01), and improve 
      their histomorphology. After treatment with Leonuri Herba, PGE_2 content was 
      significantly increased(P&lt;0.05), COX-2, PGF_(2α) and Ca~(2+) content, and 
      PGF_(2α)/PGE_2 was significantly decreased(P&lt;0.05 or P&lt;0.01), and OT 
      content was decreased, while E_2 and Prog content tended to further increase in 
      uterine tissues of PD rats. Correspondingly, OTR and EP3 protein expression was 
      significantly downregulated(P&lt;0.05 or P&lt;0.01) and ERα protein expression 
      was upregulated(P&lt;0.05) in uterine tissues. The mRNA expression of FP and EP4 
      in uterine tissues was significantly downregulated(P&lt;0.01), and the mRNA 
      expression of EP1, EP3, and OTR showed a decreasing trend. The untargeted 
      metabolomics results showed that 10 differential metabolites were restored in the 
      plasma of PD rats after Leonuri Herba treatment. The results indicate that 
      Leonuri Herba is effective in the prevention and treatment of PD, and the 
      underlying mechanism may be attributed to the regulation of PGs synthesis and 
      corresponding receptor binding.
FAU - Wu, Liu-Jun
AU  - Wu LJ
AD  - State Key Laboratory of Southwest Characteristic Traditional Chinese Medicine 
      Resources, School of Pharmacy,Chengdu University of Traditional Chinese Medicine 
      Chengdu 611137, China.
FAU - Chen, Yan
AU  - Chen Y
AD  - State Key Laboratory of Southwest Characteristic Traditional Chinese Medicine 
      Resources, School of Pharmacy,Chengdu University of Traditional Chinese Medicine 
      Chengdu 611137, China.
FAU - Lin, Zi-Wei
AU  - Lin ZW
AD  - State Key Laboratory of Southwest Characteristic Traditional Chinese Medicine 
      Resources, School of Pharmacy,Chengdu University of Traditional Chinese Medicine 
      Chengdu 611137, China.
FAU - Sun, Chen
AU  - Sun C
AD  - State Key Laboratory of Southwest Characteristic Traditional Chinese Medicine 
      Resources, School of Pharmacy,Chengdu University of Traditional Chinese Medicine 
      Chengdu 611137, China.
FAU - Xiong, Liang
AU  - Xiong L
AD  - State Key Laboratory of Southwest Characteristic Traditional Chinese Medicine 
      Resources, School of Pharmacy,Chengdu University of Traditional Chinese Medicine 
      Chengdu 611137, China.
FAU - Xie, Xiao-Fang
AU  - Xie XF
AD  - State Key Laboratory of Southwest Characteristic Traditional Chinese Medicine 
      Resources, School of Pharmacy,Chengdu University of Traditional Chinese Medicine 
      Chengdu 611137, China.
FAU - Peng, Cheng
AU  - Peng C
AD  - State Key Laboratory of Southwest Characteristic Traditional Chinese Medicine 
      Resources, School of Pharmacy,Chengdu University of Traditional Chinese Medicine 
      Chengdu 611137, China.
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhongguo Zhong Yao Za Zhi
JT  - Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese 
      materia medica
JID - 8913656
RN  - 0 (Estrogen Receptor alpha)
RN  - 50-56-6 (Oxytocin)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - 0 (RNA, Messenger)
RN  - B7IN85G1HY (Dinoprost)
SB  - IM
MH  - Humans
MH  - Rats
MH  - Female
MH  - Animals
MH  - *Estrogen Receptor alpha
MH  - *Oxytocin
MH  - Dysmenorrhea/drug therapy/metabolism
MH  - Cyclooxygenase 2
MH  - Dinoprostone
MH  - RNA, Messenger/metabolism
MH  - Dinoprost
OTO - NOTNLM
OT  - Leonuri Herba
OT  - metabolomics
OT  - primary dysmenorrhea
OT  - prostaglandins
OT  - smooth muscle contraction
EDAT- 2023/12/20 06:41
MHDA- 2023/12/21 06:43
CRDT- 2023/12/19 20:45
PHST- 2023/12/21 06:43 [medline]
PHST- 2023/12/20 06:41 [pubmed]
PHST- 2023/12/19 20:45 [entrez]
AID - 10.19540/j.cnki.cjcmm.20230803.401 [doi]
PST - ppublish
SO  - Zhongguo Zhong Yao Za Zhi. 2023 Nov;48(22):6093-6106. doi: 
      10.19540/j.cnki.cjcmm.20230803.401.

PMID- 28697036
OWN - NLM
STAT- MEDLINE
DCOM- 20180517
LR  - 20240610
IS  - 1530-0374 (Electronic)
IS  - 1072-3714 (Print)
IS  - 1072-3714 (Linking)
VI  - 24
IP  - 10
DP  - 2017 Oct
TI  - Comparison of clinical outcomes among users of oral and transdermal estrogen 
      therapy in the Women's Health Initiative Observational Study.
PG  - 1145-1153
LID - 10.1097/GME.0000000000000899 [doi]
AB  - OBJECTIVE: To examine associations of estrogen preparations with an index of 
      health risks versus benefits. METHODS: Using data from 45,112 participants of the 
      Women's Health Initiative Observational Study (average follow-up 5.5 years), we 
      examined associations of estrogen type and oral conjugated equine estrogen (CEE) 
      dose with time to first global index event (GIE), defined as coronary heart 
      disease, breast cancer, stroke, pulmonary embolism, hip fracture, colorectal 
      cancer, endometrial cancer, or death. RESULTS: Oral CEE less than 
      0.625 mg/d + progestogen (P) users had a lower risk of a GIE (adjusted hazard 
      ratio 0.74, 95% confidence interval 0.56-0.97) than oral CEE 0.625 mg/d + P 
      users. GIE risk in oral CEE 0.625 mg/d + P users was greater with at least 5-year 
      use (adjusted hazard ratio 1.22, 95% confidence interval 1.06-1.41) than with 
      less than 5-year use. In women with prior hysterectomy, compared with women 
      taking oral CEE 0.625 mg/d for less than 5 years, GIE risk was similar with oral 
      CEE below 0.625 mg/d, oral estradiol (E2), and transdermal E2, whether used for 
      less than 5 years or for at least 5 years. There was no difference in GIE risk 
      between users of the following: oral CEE + P versus oral E2 + P; oral CEE + P 
      versus transdermal E2 + P; oral E2 + P versus transdermal E2 + P. Findings were 
      similar among women with hysterectomy taking estrogen alone. CONCLUSIONS: The 
      summary index of risks versus benefits was similar for oral CEE versus oral or 
      transdermal E2-containing regimens. CEE + P containing less than 0.625 mg/d of 
      CEE (vs 0.625 mg/d) for less than 5 years appeared safer.
FAU - Crandall, Carolyn J
AU  - Crandall CJ
AD  - 1Department of Medicine, University of California, Los Angeles, Los Angeles, CA 
      2Dept of Epidemiology and Environmental Health, University at Buffalo, The State 
      University of New York, Buffalo, NY 3Department of Ophthalmology and Visual 
      Sciences, University of Michigan, Ann Arbor, MI 4Department of Epidemiology, 
      Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 
      5Department of Medicine, Stanford University School of Medicine, Stanford, CA 
      6Barbra Streisand Women's Heart Center, Cedars-Sinai Heart Institute, Los 
      Angeles, CA 7Division of Public Health Sciences, Fred Hutchinson Cancer Research 
      Center, Seattle, WA 8Department of Obstetrics and Gynecology, University of 
      Florida College of Medicine-Jacksonville, Jacksonville, FL 9Department of Family 
      Medicine and Epidemiology, Brown University Warren Alpert Medical School and 
      School of Public Health, Pawtucket, RI 10Department of Epidemiology and 
      Environmental Health, University at Buffalo, State University of New York, 
      Buffalo, NY 11Division of Preventive Medicine, Brigham and Women's Hospital, 
      Harvard Medical School, Boston, MA.
FAU - Hovey, Kathleen M
AU  - Hovey KM
FAU - Andrews, Christopher
AU  - Andrews C
FAU - Cauley, Jane A
AU  - Cauley JA
FAU - Stefanick, Marcia
AU  - Stefanick M
FAU - Shufelt, Chrisandra
AU  - Shufelt C
FAU - Prentice, Ross L
AU  - Prentice RL
FAU - Kaunitz, Andrew M
AU  - Kaunitz AM
FAU - Eaton, Charles
AU  - Eaton C
FAU - Wactawski-Wende, Jean
AU  - Wactawski-Wende J
FAU - Manson, JoAnn E
AU  - Manson JE
LA  - eng
GR  - HHSN268201100001I/HL/NHLBI NIH HHS/United States
GR  - HHSN268201100004I/HL/NHLBI NIH HHS/United States
GR  - HHSN268201100046C/HL/NHLBI NIH HHS/United States
GR  - HHSN268201100003C/WH/WHI NIH HHS/United States
GR  - HHSN271201100004C/AG/NIA NIH HHS/United States
GR  - HHSN268201100002C/WH/WHI NIH HHS/United States
GR  - HHSN268201100003I/HL/NHLBI NIH HHS/United States
GR  - HHSN268201100002I/HL/NHLBI NIH HHS/United States
GR  - HHSN268201100001C/WH/WHI NIH HHS/United States
GR  - HHSN268201100004C/WH/WHI NIH HHS/United States
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Menopause
JT  - Menopause (New York, N.Y.)
JID - 9433353
RN  - 0 (Estrogens)
RN  - 0 (Estrogens, Conjugated (USP))
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Administration, Cutaneous
MH  - Administration, Oral
MH  - Aged
MH  - Cohort Studies
MH  - Estradiol/*administration & dosage/adverse effects
MH  - Estrogens/*administration & dosage/adverse effects
MH  - Estrogens, Conjugated (USP)/*administration & dosage/adverse effects
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - *Postmenopause
MH  - Proportional Hazards Models
MH  - Risk
MH  - Time Factors
MH  - Treatment Outcome
MH  - Women's Health
PMC - PMC5607093
MID - NIHMS858444
COIS- Conflict of Interest Disclosures: The following authors have no conflicts of 
      interest: CJC, JAC, CBE, RLP, JWW, KH, CA, CS, MS, JEM Andrew Kaunitz: Serves on 
      contraceptive advisory boards for: Allergan, Bayer, Medicines360, Pfizer 
      Department (U of FL) receives research support from: Bayer, Radius, Therapeutics 
      MD Chrisandra Shufelt received honoraria for lectures from the: Cardiometabolic 
      Risk Summit Fall American College of Physicians Southern California Regional 
      Meeting
EDAT- 2017/07/12 06:00
MHDA- 2018/05/18 06:00
PMCR- 2018/10/01
CRDT- 2017/07/12 06:00
PHST- 2017/07/12 06:00 [pubmed]
PHST- 2018/05/18 06:00 [medline]
PHST- 2017/07/12 06:00 [entrez]
PHST- 2018/10/01 00:00 [pmc-release]
AID - 10.1097/GME.0000000000000899 [doi]
PST - ppublish
SO  - Menopause. 2017 Oct;24(10):1145-1153. doi: 10.1097/GME.0000000000000899.

PMID- 39186452
OWN - NLM
STAT- MEDLINE
DCOM- 20240826
LR  - 20241013
IS  - 1530-0374 (Electronic)
IS  - 1072-3714 (Print)
IS  - 1072-3714 (Linking)
VI  - 31
IP  - 9
DP  - 2024 Sep 1
TI  - Treatment satisfaction, unmet needs, and new treatment expectations for vasomotor 
      symptoms due to menopause: women's and physicians' opinions.
PG  - 769-780
LID - 10.1097/GME.0000000000002399 [doi]
AB  - OBJECTIVE: To assess treatment satisfaction, unmet treatment needs, and new 
      vasomotor symptom (VMS) treatment expectations among women with moderate to 
      severe VMS and physicians treating women with VMS. METHODS: This 
      noninterventional, nonrandomized survey included qualitative interviews and 
      quantitative surveys of women and physicians in the US. Participating women had 
      moderate to severe VMS in the past year and received ≥1 hormone therapy (HT), 
      non-HT, or over-the-counter (OTC) treatment for VMS in the past 3 months. 
      Participating physicians were obstetrician-gynecologists (OB-GYNs) and primary 
      care physicians (PCPs) who treated ≥15 women with VMS in the past 3 months. Two 
      online survey questionnaires were developed using insights from literature, 
      qualitative interviews, and clinical experts. Menopause Symptoms Treatment 
      Satisfaction Questionnaire (MS-TSQ) measured treatment satisfaction. Results were 
      summarized descriptively. RESULTS: Questionnaires were completed by 401 women 
      with VMS and 207 physicians treating VMS. Among women, mean total MS-TSQ score 
      ranges were 62.8-67.3 for HT, 59.8-69.7 for non-HT, and 58.0-64.9 for OTC 
      treatments. Among physicians, mean total MS-TSQ scores were considerably higher 
      for HT than for non-HT and OTC treatments (HT: 73.4-75.6; non-HT: 55.6-62.1; OTC: 
      49.2-54.7). Women reported "lack of effectiveness" (41.2%), and physicians 
      reported "long-term safety concerns" (56.5%) as main features that do not meet 
      their current treatment expectations. The majority of women and physicians would 
      consider trying a new non-HT treatment for VMS (75.8 and 75.9%, respectively). 
      CONCLUSIONS: Treatment satisfaction and new treatment expectations were similar 
      but with some differences between women and physicians; the need for additional 
      treatments for VMS was identified.
CI  - Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on 
      behalf of The Menopause Society.
FAU - DePree, Barbara J
AU  - DePree BJ
AD  - From the Holland Hospital, Holland, MI.
FAU - Shiozawa, Aki
AU  - Shiozawa A
AD  - Astellas Pharma, Inc., Northbrook, IL.
FAU - Kim, Janet
AU  - Kim J
AD  - Astellas Pharma, Inc., Northbrook, IL.
FAU - Wang, Yao
AU  - Wang Y
AD  - Analysis Group, Inc., Boston, MA.
FAU - Yang, Hongbo
AU  - Yang H
AD  - Analysis Group, Inc., Boston, MA.
FAU - Mancuso, Shayna
AU  - Mancuso S
AD  - Astellas Pharma, Inc., Northbrook, IL.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Menopause
JT  - Menopause (New York, N.Y.)
JID - 9433353
SB  - IM
MH  - Humans
MH  - Female
MH  - Middle Aged
MH  - *Patient Satisfaction
MH  - *Menopause/psychology/physiology
MH  - *Hot Flashes/drug therapy
MH  - Surveys and Questionnaires
MH  - Adult
MH  - Aged
MH  - Attitude of Health Personnel
MH  - Gynecology
MH  - Physicians, Primary Care
MH  - Estrogen Replacement Therapy
MH  - United States
MH  - Vasomotor System/physiopathology/drug effects
MH  - Physicians/psychology
PMC - PMC11469650
COIS- Financial disclosures/conflicts of interest: B. DePree serves on an advisory 
      council for Astellas Pharma, Inc. A. Shiozawa, J. Kim, and S. Mancuso are 
      employees of Astellas Pharma, Inc. Y. Wang and H. Yang are employees of Analysis 
      Group, Inc., which received funding from Astellas Pharma, Inc., for the current 
      study.
EDAT- 2024/08/26 19:49
MHDA- 2024/08/26 19:50
PMCR- 2024/10/11
CRDT- 2024/08/26 12:33
PHST- 2024/08/26 19:50 [medline]
PHST- 2024/08/26 19:49 [pubmed]
PHST- 2024/08/26 12:33 [entrez]
PHST- 2024/10/11 00:00 [pmc-release]
AID - 00042192-202409000-00007 [pii]
AID - MENO_240417 [pii]
AID - 10.1097/GME.0000000000002399 [doi]
PST - ppublish
SO  - Menopause. 2024 Sep 1;31(9):769-780. doi: 10.1097/GME.0000000000002399.

PMID- 30481135
OWN - NLM
STAT- MEDLINE
DCOM- 20190404
LR  - 20190404
IS  - 1557-2536 (Electronic)
IS  - 0027-5514 (Linking)
VI  - 110
IP  - 6
DP  - 2018 Nov-Dec
TI  - Marasas et al. 1984 "Toxigenic Fusarium Species: Identity and Mycotoxicology" 
      revisited.
PG  - 1058-1080
LID - 10.1080/00275514.2018.1519773 [doi]
AB  - This study was conducted to determine the species identity and mycotoxin 
      potential of 158 Fusarium strains originally archived in the South African 
      Medical Research Council's Mycotoxigenic Fungal Collection (MRC) that were 
      reported to comprise 17 morphologically distinct species in the classic 1984 
      compilation by Marasas et al., Toxigenic Fusarium Species: Identity and 
      Mycotoxicology. Maximum likelihood and maximum parsimony molecular phylogenetic 
      analyses of single and multilocus DNA sequence data indicated that the strains 
      represented 46 genealogically exclusive phylogenetically distinct species 
      distributed among eight species complexes. Moreover, the phylogenetic data 
      revealed that 80/158 strains were received under a name that is not accepted 
      today (ex F. moniliforme) or classified under a different species name. In 
      addition, gas chromatography-mass spectrometry (GC-MS) and/or high-performance 
      liquid chromatography-mass spectrometry (HPLC-MS)-based mycotoxin analyses were 
      conducted to determine which toxins the strains could produce in liquid and/or 
      solid cultures. All of the trichothecene toxin-producing fusaria were nested 
      within the F. sambucinum (FSAMSC) or F. incarnatum-equiseti (FIESC) species 
      complexes. Consistent with this finding, GC-MS analyses detected trichothecenes 
      in agmatine-containing broth or rice culture extracts of all 13 FSAMSC and 10/12 
      FIESC species tested. Species in six and seven of the eight species complexes 
      were able to produce moniliformin and beauvericin, respectively, whereas B-type 
      fumonisins were only detected in extracts of cracked maize kernel cultures of 
      three species in the F. fujikuroi (FFSC) species complex.
FAU - O'Donnell, Kerry
AU  - O'Donnell K
AUID- ORCID: 0000-0001-6507-691X
AD  - a Mycotoxin Prevention and Applied Microbiology Research Unit, National Center 
      for Agricultural Utilization Research, Agricultural Research Service , US 
      Department of Agriculture , Peoria , Illinois 61604-3999.
FAU - McCormick, Susan P
AU  - McCormick SP
AUID- ORCID: 0000-0002-7824-6372
AD  - a Mycotoxin Prevention and Applied Microbiology Research Unit, National Center 
      for Agricultural Utilization Research, Agricultural Research Service , US 
      Department of Agriculture , Peoria , Illinois 61604-3999.
FAU - Busman, Mark
AU  - Busman M
AUID- ORCID: 0000-0001-9750-064X
AD  - a Mycotoxin Prevention and Applied Microbiology Research Unit, National Center 
      for Agricultural Utilization Research, Agricultural Research Service , US 
      Department of Agriculture , Peoria , Illinois 61604-3999.
FAU - Proctor, Robert H
AU  - Proctor RH
AUID- ORCID: 0000-0001-5400-1680
AD  - a Mycotoxin Prevention and Applied Microbiology Research Unit, National Center 
      for Agricultural Utilization Research, Agricultural Research Service , US 
      Department of Agriculture , Peoria , Illinois 61604-3999.
FAU - Ward, Todd J
AU  - Ward TJ
AUID- ORCID: 0000-0001-5880-9919
AD  - a Mycotoxin Prevention and Applied Microbiology Research Unit, National Center 
      for Agricultural Utilization Research, Agricultural Research Service , US 
      Department of Agriculture , Peoria , Illinois 61604-3999.
FAU - Doehring, Gail
AU  - Doehring G
AD  - a Mycotoxin Prevention and Applied Microbiology Research Unit, National Center 
      for Agricultural Utilization Research, Agricultural Research Service , US 
      Department of Agriculture , Peoria , Illinois 61604-3999.
FAU - Geiser, David M
AU  - Geiser DM
AD  - b Department of Plant Pathology and Environmental Microbiology , The Pennsylvania 
      State University, University Park , Pennsylvania 16802.
FAU - Alberts, Johanna F
AU  - Alberts JF
AUID- ORCID: 0000-0002-3290-9847
AD  - c Mycotoxicology and Chemoprevention Research Group, Institute of Biomedical and 
      Microbial Biotechnology (IBMB), Cape Peninsula University of Technology , 
      Bellville 7535 , South Africa.
FAU - Rheeder, John P
AU  - Rheeder JP
AD  - c Mycotoxicology and Chemoprevention Research Group, Institute of Biomedical and 
      Microbial Biotechnology (IBMB), Cape Peninsula University of Technology , 
      Bellville 7535 , South Africa.
LA  - eng
PT  - Journal Article
DEP - 20181127
PL  - England
TA  - Mycologia
JT  - Mycologia
JID - 0400764
RN  - 0 (DNA, Fungal)
RN  - 0 (Mycotoxins)
RN  - 0 (Trichothecenes)
RN  - 5W827M159J (Zearalenone)
RN  - 7OO57LYZ5I (trichothecene)
SB  - IM
MH  - Biological Specimen Banks
MH  - Chromatography, High Pressure Liquid
MH  - DNA, Fungal/genetics
MH  - Fusarium/*classification
MH  - Gas Chromatography-Mass Spectrometry
MH  - Mycological Typing Techniques
MH  - Mycotoxins/*analysis/genetics
MH  - *Phylogeny
MH  - Tandem Mass Spectrometry
MH  - Trichothecenes/analysis
MH  - Zearalenone/analysis
OTO - NOTNLM
OT  - Beauvericin
OT  - fumonisin
OT  - moniliformin
OT  - mycotoxins
OT  - phylogenetics
OT  - trichothecene
OT  - zearalenone
EDAT- 2018/11/28 06:00
MHDA- 2019/04/05 06:00
CRDT- 2018/11/28 06:00
PHST- 2018/11/28 06:00 [pubmed]
PHST- 2019/04/05 06:00 [medline]
PHST- 2018/11/28 06:00 [entrez]
AID - 10.1080/00275514.2018.1519773 [doi]
PST - ppublish
SO  - Mycologia. 2018 Nov-Dec;110(6):1058-1080. doi: 10.1080/00275514.2018.1519773. 
      Epub 2018 Nov 27.

PMID- 30016454
OWN - NLM
STAT- MEDLINE
DCOM- 20200311
LR  - 20200311
IS  - 1460-2105 (Electronic)
IS  - 0027-8874 (Linking)
VI  - 111
IP  - 4
DP  - 2019 Apr 1
TI  - Circulating 27-Hydroxycholesterol and Breast Cancer Risk: Results From the 
      EPIC-Heidelberg Cohort.
PG  - 365-371
LID - 10.1093/jnci/djy115 [doi]
AB  - BACKGROUND: 27-hydroxycholesterol (27HC) was the first identified endogenous 
      selective estrogen receptor modulator (SERM); 27HC promoted growth and metastasis 
      in experimental models of estrogen receptor-positive mammary cancer. There are no 
      data on prediagnosis circulating 27HC and breast cancer risk in women. METHODS: 
      We conducted a nested case-control study in the well-characterized Heidelberg, 
      Germany, cohort of the European Investigation into Cancer and Nutrition (EPIC) 
      including 530 incident invasive breast cancer cases, each matched to up to two 
      control participants (n = 1036). Serum 27HC was analyzed by liquid 
      chromatography-mass spectrometry (LC-MS) in blood samples collected at study 
      recruitment. Multivariable conditional logistic regression models were used to 
      quantify the association between circulating 27HC and breast cancer risk overall, 
      by tumor hormone receptor status (ie estrogen and progesterone receptors), and by 
      menopausal status at blood collection. All statistical tests were two-sided. 
      RESULTS: 27HC was not associated with breast cancer risk overall (relative risk 
      [RR]Quartile4vsQuartile1 [Q4vsQ1] = 0.90, 95% confidence interval [CI] = 0.66 to 
      1.22). The association between 27HC and breast cancer risk differed by menopausal 
      status at blood collection (Phet = .02), but not by age at diagnosis (Phet = 
      .78). Among women who were postmenopausal at blood collection, higher serum 27HC 
      levels were associated with lower breast cancer risk (RRQ4vsQ1 = 0.56, 95% CI = 
      0.36 to 0.87). We observed no association between 27HC and breast cancer risk 
      (RRQ4vsQ1 = 1.33, 95% CI = 0.75 to 2.38) among women who were premenopausal at 
      blood collection. CONCLUSIONS: In this first prospective study, higher 
      circulating 27HC was associated with lower risk of breast cancer in 
      postmenopausal women. Identification of the first endogenous SERM associated with 
      reduced risk of invasive breast cancer in postmenopausal women may offer novel 
      avenues for breast cancer prevention strategies.
CI  - © The Author(s) 2018. Published by Oxford University Press. All rights reserved. 
      For permissions, please email: journals.permissions@oup.com.
FAU - Lu, Da-Lin
AU  - Lu DL
AD  - Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 
      Heidelberg, Germany.
AD  - Medical Faculty Heidelberg, University of Heidelberg, Heidelberg, Germany.
FAU - Le Cornet, Charlotte
AU  - Le Cornet C
AD  - Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 
      Heidelberg, Germany.
FAU - Sookthai, Disorn
AU  - Sookthai D
AD  - Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 
      Heidelberg, Germany.
FAU - Johnson, Theron S
AU  - Johnson TS
AD  - Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 
      Heidelberg, Germany.
FAU - Kaaks, Rudolf
AU  - Kaaks R
AD  - Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 
      Heidelberg, Germany.
FAU - Fortner, Renée T
AU  - Fortner RT
AD  - Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 
      Heidelberg, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Natl Cancer Inst
JT  - Journal of the National Cancer Institute
JID - 7503089
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Hydroxycholesterols)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - 6T2NA6P5SQ (27-hydroxycholesterol)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*blood
MH  - Breast Neoplasms/*blood/*etiology/pathology
MH  - Case-Control Studies
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Hydroxycholesterols/*blood
MH  - Menopause
MH  - Middle Aged
MH  - Prognosis
MH  - Prospective Studies
MH  - Receptors, Estrogen/metabolism
MH  - Receptors, Progesterone/metabolism
MH  - Risk Factors
EDAT- 2018/07/18 06:00
MHDA- 2020/03/12 06:00
CRDT- 2018/07/18 06:00
PHST- 2017/12/13 00:00 [received]
PHST- 2018/05/07 00:00 [revised]
PHST- 2018/06/01 00:00 [accepted]
PHST- 2018/07/18 06:00 [pubmed]
PHST- 2020/03/12 06:00 [medline]
PHST- 2018/07/18 06:00 [entrez]
AID - 5054612 [pii]
AID - 10.1093/jnci/djy115 [doi]
PST - ppublish
SO  - J Natl Cancer Inst. 2019 Apr 1;111(4):365-371. doi: 10.1093/jnci/djy115.

PMID- 30375890
OWN - NLM
STAT- MEDLINE
DCOM- 20200501
LR  - 20200501
IS  - 1532-7914 (Electronic)
IS  - 0163-5581 (Linking)
VI  - 71
IP  - 3
DP  - 2019
TI  - Effect of Dietary Flaxseed Intake on Circulating Sex Hormone Levels among 
      Postmenopausal Women: A Randomized Controlled Intervention Trial.
PG  - 385-398
LID - 10.1080/01635581.2018.1516789 [doi]
AB  - Lignan intake, and its richest food source, flaxseed, have been associated with 
      reduced breast cancer risk. Endogenous sex hormones, such as estrogens, play a 
      role in breast cancer development, and lignans may alter these sex hormone 
      levels. To assess the effect of flaxseed on circulating sex hormones, a 
      randomized controlled trial was conducted among 99 postmenopausal women in 
      Toronto, Canada. The intervention arm consumed 2 tablespoons (15 g) of ground 
      flaxseed daily for 7 weeks; the control arm maintained usual diet. Baseline and 
      week 7 concentrations of 14 serum sex hormones were measured using liquid 
      chromatography-tandem mass spectrometry (LC-MS/MS) and immunoassay, and serum 
      enterolignans (lignan biomarker) using LC-MS/MS. Intervention effects on sex 
      hormone levels were assessed using analysis of covariance. Serum enterolignans 
      increased among the flaxseed arm (+516%). Women consuming flaxseed (vs. controls) 
      had increased serum 2-hydroxyestrone [treatment effect ratio (TER) = 1.54; 95% 
      CI: 1.18-2.00] and 2:16α-hydroxyestrone ratio (TER =1.54; 95% CI: 1.15-2.06); 
      effects on other hormones were not statistically significant. Within the flaxseed 
      arm, change in enterolignan level was positively correlated with changes in 
      2-hydroxyestrone and 2:16α-hydroxyestrone ratio, and negatively with prolactin. 
      Findings suggest flaxseed affects certain circulating sex hormone levels with 
      possible implications for future breast cancer prevention research.
FAU - Chang, Vicky C
AU  - Chang VC
AD  - a Prevention and Cancer Control , Cancer Care Ontario , Toronto , Ontario , 
      Canada.
AD  - b Dalla Lana School of Public Health , University of Toronto , Toronto , Ontario 
      , Canada.
FAU - Cotterchio, Michelle
AU  - Cotterchio M
AD  - a Prevention and Cancer Control , Cancer Care Ontario , Toronto , Ontario , 
      Canada.
AD  - b Dalla Lana School of Public Health , University of Toronto , Toronto , Ontario 
      , Canada.
FAU - Boucher, Beatrice A
AU  - Boucher BA
AD  - c Department of Nutritional Sciences, Faculty of Medicine , University of Toronto 
      , Toronto , Ontario , Canada.
FAU - Jenkins, David J A
AU  - Jenkins DJA
AD  - c Department of Nutritional Sciences, Faculty of Medicine , University of Toronto 
      , Toronto , Ontario , Canada.
AD  - d Clinical Nutrition and Risk Factor Modification Centre , St. Michael's Hospital 
      , Toronto , Ontario , Canada.
FAU - Mirea, Lucia
AU  - Mirea L
AD  - b Dalla Lana School of Public Health , University of Toronto , Toronto , Ontario 
      , Canada.
AD  - e Clinical Research, Phoenix Children's Hospital , Phoenix , Arizona , USA.
FAU - McCann, Susan E
AU  - McCann SE
AD  - f Department of Cancer Prevention and Control , Roswell Park Comprehensive Cancer 
      Center , Buffalo , New York , USA.
FAU - Thompson, Lilian U
AU  - Thompson LU
AD  - c Department of Nutritional Sciences, Faculty of Medicine , University of Toronto 
      , Toronto , Ontario , Canada.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20181030
PL  - United States
TA  - Nutr Cancer
JT  - Nutrition and cancer
JID - 7905040
RN  - 0 (Gonadal Steroid Hormones)
RN  - 0 (Hydroxyestrones)
RN  - 0 (Lignans)
RN  - 18186-49-7 (16-hydroxyestrone)
RN  - 9002-62-4 (Prolactin)
RN  - UQS3A06ILY (2-hydroxyestrone)
SB  - IM
MH  - Breast Neoplasms/prevention & control
MH  - Canada
MH  - *Diet
MH  - Female
MH  - *Flax/adverse effects
MH  - Gonadal Steroid Hormones/*blood
MH  - Humans
MH  - Hydroxyestrones/blood
MH  - Lignans/administration & dosage/blood
MH  - Middle Aged
MH  - Postmenopause/*blood
MH  - Prolactin/blood
EDAT- 2018/10/31 06:00
MHDA- 2020/05/02 06:00
CRDT- 2018/10/31 06:00
PHST- 2018/10/31 06:00 [pubmed]
PHST- 2020/05/02 06:00 [medline]
PHST- 2018/10/31 06:00 [entrez]
AID - 10.1080/01635581.2018.1516789 [doi]
PST - ppublish
SO  - Nutr Cancer. 2019;71(3):385-398. doi: 10.1080/01635581.2018.1516789. Epub 2018 
      Oct 30.

PMID- 29067388
OWN - NLM
STAT- MEDLINE
DCOM- 20180507
LR  - 20231213
IS  - 2042-650X (Electronic)
IS  - 2042-6496 (Linking)
VI  - 8
IP  - 12
DP  - 2017 Dec 13
TI  - Soluble soybean polysaccharides enhance the protective effects of genistein 
      against hepatic injury in high l-carnitine-fed mice.
PG  - 4364-4373
LID - 10.1039/c7fo00907k [doi]
AB  - This study was to develop a novel strategy for the simultaneous consumption of 
      soluble soybean polysaccharides (SSPS) to enhance the absorption of genistein and 
      its protective effects against high l-carnitine-induced hepatic injury in mice. 
      UPLC-qTOP/MS measurements showed that SSPS observably increased the urinary 
      concentration of genistein and its metabolites in mice. The mice fed with 3% 
      l-carnitine water for 12 weeks experienced a disturbance of the hepatic lipid 
      metabolism, oxidative stress and inflammation, which was evidenced by abnormal 
      TC, LDL, RAHFR and MDA levels, unusual AST, ALT, ALP, SOD and GSP-Px activities, 
      and increased IF-1, IF-6 and TNF-α expressions. Interestingly, the 
      co-supplementation of SSPS and genistein was capable of regulating these 
      imbalances more effectively than the administration of SSPS or genistein alone, 
      which was also confirmed by histological observations of the mouse liver. These 
      findings suggest that the co-ingestion of SSPS and genistein is a feasible 
      strategy for improving liver protection in mice.
FAU - Lu, Yalong
AU  - Lu Y
AD  - Shaanxi Engineering Laboratory for Food Green Processing and Safety Control, and 
      Key Laboratory of Ministry of Education for Medicinal Resource and Natural 
      Pharmaceutical Chemistry, College of Food Engineering and Nutritional Science, 
      Shaanxi Normal University, Xi'an 710062, China. DrNaruto@163.com 
      xbyang@snnu.edu.cn.
FAU - Li, Wenfeng
AU  - Li W
FAU - Yang, Xingbin
AU  - Yang X
LA  - eng
PT  - Journal Article
PL  - England
TA  - Food Funct
JT  - Food & function
JID - 101549033
RN  - 0 (Plant Extracts)
RN  - 0 (Polysaccharides)
RN  - 0 (Protective Agents)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - DH2M523P0H (Genistein)
RN  - S7UI8SM58A (Carnitine)
SB  - IM
MH  - Animals
MH  - Carnitine/*adverse effects/metabolism
MH  - Genistein/*administration & dosage
MH  - Humans
MH  - Lipid Metabolism/drug effects
MH  - Liver/drug effects/metabolism
MH  - Liver Diseases/genetics/metabolism/*prevention & control
MH  - Male
MH  - Malondialdehyde/metabolism
MH  - Mice
MH  - Oxidative Stress/drug effects
MH  - Plant Extracts/*administration & dosage
MH  - Polysaccharides/*administration & dosage
MH  - Protective Agents/*administration & dosage
MH  - Glycine max/*chemistry
MH  - Tumor Necrosis Factor-alpha/genetics/metabolism
EDAT- 2017/10/27 06:00
MHDA- 2018/05/08 06:00
CRDT- 2017/10/26 06:00
PHST- 2017/10/27 06:00 [pubmed]
PHST- 2018/05/08 06:00 [medline]
PHST- 2017/10/26 06:00 [entrez]
AID - 10.1039/c7fo00907k [doi]
PST - ppublish
SO  - Food Funct. 2017 Dec 13;8(12):4364-4373. doi: 10.1039/c7fo00907k.

PMID- 26011304
OWN - NLM
STAT- MEDLINE
DCOM- 20160418
LR  - 20250103
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 10
IP  - 5
DP  - 2015
TI  - Higher urinary bisphenol A concentration is associated with unexplained recurrent 
      miscarriage risk: evidence from a case-control study in eastern China.
PG  - e0127886
LID - 10.1371/journal.pone.0127886 [doi]
LID - e0127886
AB  - BACKGROUND: Evidence about the association between Bisphenol A (BPA) and the risk 
      of recurrent miscarriage (RM) in human being is still limited. OBJECTIVE: We 
      evaluated the association of urinary BPA concentrations with RM in human being. 
      METHODS: A hospital-based 1:2 matched case-control study on RM was carried out in 
      Suzhou and Kunshan in Jiangsu Province in China between August 2008 and November 
      2011. Total urinary BPA concentrations in 264 eligible urine samples (102 RM 
      patients and 162 controls) were measured using liquid chromatography-tandem mass 
      spectrometry (LC-MS/MS). The Wilcoxon test and conditional logistic regression 
      were used to estimate the differences between the groups and odds ratios (OR) 
      with 95% confidence intervals (CI), respectively. RESULTS: The median ± IQR 
      (interquartile range) (P75-P25) values of non-creatinine-adjusted total urinary 
      BPA levels in the RM patients and the controls were 1.66 ± 3.69 ng/ml and 0.58 ± 
      1.07 ng/ml, respectively (0.98 ± 2.67 μg/g Cr (creatinine) and 0.40 ± 0.77 μg/g 
      Cr. The adjusted BPA level was significantly higher in the RM patients than in 
      the controls (Wilcoxon test, Z = 4.476, P < 0.001). Higher level of urinary BPA 
      was significantly associated with an increased risk of RM (P-trend < 0.001). 
      Compared to the groups with urinary BPA levels less than 0.16 μg/g Cr, the women 
      with levels of 0.40-0.93 μg/g Cr and 0.93 μg/g Cr or above had a significantly 
      higher risk of RM (OR = 3.91, 95%CI: 1.23-12.45 and OR = 9.34, 95%CI: 3.06-28.44) 
      that persisted after adjusting for confounding factors. The time from recently RM 
      date to recruitment does not significantly influence the urinary BPA level (P = 
      0.090). CONCLUSION: Exposure to BPA may be associated with RM risk.
FAU - Shen, Yueping
AU  - Shen Y
AD  - Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric 
      Diseases, Department of Epidemiology and Health Statistics School of Public 
      Health, Soochow University, Suzhou, 215123, PR China.
FAU - Zheng, Yanmin
AU  - Zheng Y
AD  - Suzhou Center for Disease Prevention and Control, Suzhou 215004, China.
FAU - Jiang, Jingting
AU  - Jiang J
AD  - The Third Affiliated Hospital, Suzhou University, Changzhou 213003, China.
FAU - Liu, Yinmei
AU  - Liu Y
AD  - Department of Nosocomial Infection and Disease Control, Shanghai Tenth People's 
      Hospital, Shanghai 200072, China.
FAU - Luo, Xiaoming
AU  - Luo X
AD  - Maternal and Child Health Bureau of Kunshan, Kunshan 215301, China.
FAU - Shen, Zongji
AU  - Shen Z
AD  - Department of Obstetrics and Gynaecology, First Affiliated Hospital of Soochow 
      University, Suzhou 215006, China.
FAU - Chen, Xin
AU  - Chen X
AD  - Department of Obstetrics and Gynaecology, Second Affiliated Hospital of Soochow 
      University, Suzhou 215004, China.
FAU - Wang, Yan
AU  - Wang Y
AD  - School of Radiation Medicine and Protection, Medical College of Soochow 
      University, Suzhou 215123, China.
FAU - Dai, Yiheng
AU  - Dai Y
AD  - School of Radiation Medicine and Protection, Medical College of Soochow 
      University, Suzhou 215123, China.
FAU - Zhao, Jing
AU  - Zhao J
AD  - School of Radiation Medicine and Protection, Medical College of Soochow 
      University, Suzhou 215123, China.
FAU - Liang, Hong
AU  - Liang H
AD  - Department of Reproductive Epidemiology and Social Science, Shanghai Institute of 
      Planned Parenthood Research, Shanghai 200032, China.
FAU - Chen, Aimin
AU  - Chen A
AD  - Division of Epidemiology and Biostatistics, Department of Environmental Health, 
      University of Cincinnati College of Medicine, Cincinnati, Ohio 45221, United 
      States of America.
FAU - Yuan, Wei
AU  - Yuan W
AD  - Department of Reproductive Epidemiology and Social Science, Shanghai Institute of 
      Planned Parenthood Research, Shanghai 200032, China; NPFPC Laboratory of 
      Contraception and Devices, Shanghai 200032, China; Institute of Reproduction & 
      Development, Fudan University, Shanghai 200032, China.
LA  - eng
GR  - P30 ES006096/ES/NIEHS NIH HHS/United States
GR  - RC4 ES019755/ES/NIEHS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150526
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Phenols)
RN  - AYI8EX34EU (Creatinine)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - Abortion, Habitual/*urine
MH  - Adult
MH  - Benzhydryl Compounds/*urine
MH  - Case-Control Studies
MH  - China
MH  - Creatinine/urine
MH  - Demography
MH  - Female
MH  - Humans
MH  - Phenols/*urine
MH  - Reference Standards
MH  - Risk Factors
MH  - Time Factors
MH  - Young Adult
PMC - PMC4444137
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2015/05/27 06:00
MHDA- 2016/04/19 06:00
PMCR- 2015/05/26
CRDT- 2015/05/27 06:00
PHST- 2014/11/05 00:00 [received]
PHST- 2015/04/20 00:00 [accepted]
PHST- 2015/05/27 06:00 [entrez]
PHST- 2015/05/27 06:00 [pubmed]
PHST- 2016/04/19 06:00 [medline]
PHST- 2015/05/26 00:00 [pmc-release]
AID - PONE-D-14-47850 [pii]
AID - 10.1371/journal.pone.0127886 [doi]
PST - epublish
SO  - PLoS One. 2015 May 26;10(5):e0127886. doi: 10.1371/journal.pone.0127886. 
      eCollection 2015.

PMID- 30557707
OWN - NLM
STAT- MEDLINE
DCOM- 20190213
LR  - 20250103
IS  - 1090-2414 (Electronic)
IS  - 0147-6513 (Linking)
VI  - 170
DP  - 2019 Apr 15
TI  - Metabolic perturbation, proliferation and reactive oxygen species jointly 
      contribute to cytotoxicity of human breast cancer cell induced by tetrabromo and 
      tetrachloro bisphenol A.
PG  - 495-501
LID - S0147-6513(18)31305-8 [pii]
LID - 10.1016/j.ecoenv.2018.12.018 [doi]
AB  - Halogenated bisphenol A analogues (X-BPA) have been widely used in industrial 
      production, such as flame retardant. Although BPA exposure was found to result in 
      cytotoxicity, toxicity of X-BPA and molecular mechanism remain under-explored. In 
      this study, we employed human breast cancer cell as a model to investigate the 
      concentration-dependent toxicity and underlying mechanisms of tetrabromo 
      bisphenol A (TBBPA) and tetrachloro bisphenol A (TCBPA). An integrated method 
      involving molecular toxicology and mass spectrometry (MS)-based global 
      metabolomics was applied to evaluate the toxicity of TCBPA and TBBPA on cell 
      viability, reactive oxygen species (ROS), and metabolic alterations. The results 
      demonstrated that low micromolar levels (0-10 μM) of TCBPA/TBBPA exposure induced 
      cell proliferation and activated the energy metabolism of both glycolysis and 
      amino acid. On the other hand, high micromolar levels (10-50 μM) of TCBPA/TBBPA 
      exposure perturbed the balance between ROS and antioxidative defense process by 
      promoting the ROS generation via the down-regulation of glutathione biosynthesis 
      and up-regulation of nucleotide metabolism. This study, for the first time, 
      provides evidence and mechanism for better understanding the cytotoxicity of 
      TCBPA and TBBPA by regulating the specific metabolic pathways.
CI  - Copyright © 2018 Elsevier Inc. All rights reserved.
FAU - Zhao, Chao
AU  - Zhao C
AD  - State Key Laboratory of Environmental and Biological Analysis, Department of 
      Chemistry, Hong Kong Baptist University, Hong Kong, China; State Key Laboratory 
      of Environmental Chemistry and Ecotoxicology, Research Center for 
      Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing, China.
FAU - Tang, Zhi
AU  - Tang Z
AD  - Shenzhen Center for Disease Control and Prevention, Shenzhen, China.
FAU - Chung, Arthur Chi Kong
AU  - Chung ACK
AD  - State Key Laboratory of Environmental and Biological Analysis, Department of 
      Chemistry, Hong Kong Baptist University, Hong Kong, China.
FAU - Wang, Hailin
AU  - Wang H
AD  - State Key Laboratory of Environmental Chemistry and Ecotoxicology, Research 
      Center for Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing, 
      China.
FAU - Cai, Zongwei
AU  - Cai Z
AD  - State Key Laboratory of Environmental and Biological Analysis, Department of 
      Chemistry, Hong Kong Baptist University, Hong Kong, China. Electronic address: 
      zwcai@hkbu.edu.hk.
LA  - eng
PT  - Journal Article
DEP - 20181214
PL  - Netherlands
TA  - Ecotoxicol Environ Saf
JT  - Ecotoxicology and environmental safety
JID - 7805381
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Chlorophenols)
RN  - 0 (Flame Retardants)
RN  - 0 (Phenols)
RN  - 0 (Polybrominated Biphenyls)
RN  - 0 (Reactive Oxygen Species)
RN  - FO0P9ET4BN (tetrachlorodian)
RN  - FQI02RFC3A (tetrabromobisphenol A)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - Benzhydryl Compounds/*toxicity
MH  - Breast Neoplasms
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Cell Survival/drug effects
MH  - Chlorophenols/*toxicity
MH  - Dose-Response Relationship, Drug
MH  - Flame Retardants/*toxicity
MH  - Humans
MH  - Metabolic Networks and Pathways/*drug effects/genetics
MH  - Oxidative Stress/drug effects
MH  - Phenols/*toxicity
MH  - Polybrominated Biphenyls/*toxicity
MH  - Reactive Oxygen Species/metabolism
OTO - NOTNLM
OT  - Cell proliferation
OT  - Halogenated BPA analogues
OT  - Human breast cancer
OT  - Metabolic perturbation
OT  - Oxidative stress
EDAT- 2018/12/18 06:00
MHDA- 2019/02/14 06:00
CRDT- 2018/12/18 06:00
PHST- 2018/10/28 00:00 [received]
PHST- 2018/12/02 00:00 [revised]
PHST- 2018/12/08 00:00 [accepted]
PHST- 2018/12/18 06:00 [pubmed]
PHST- 2019/02/14 06:00 [medline]
PHST- 2018/12/18 06:00 [entrez]
AID - S0147-6513(18)31305-8 [pii]
AID - 10.1016/j.ecoenv.2018.12.018 [doi]
PST - ppublish
SO  - Ecotoxicol Environ Saf. 2019 Apr 15;170:495-501. doi: 
      10.1016/j.ecoenv.2018.12.018. Epub 2018 Dec 14.

PMID- 27002408
OWN - NLM
STAT- MEDLINE
DCOM- 20161018
LR  - 20181202
IS  - 1618-095X (Electronic)
IS  - 0944-7113 (Linking)
VI  - 23
IP  - 4
DP  - 2016 Apr 15
TI  - An effective identification and quantification method for Ginkgo biloba flavonol 
      glycosides with targeted evaluation of adulterated products.
PG  - 377-87
LID - S0944-7113(16)00035-0 [pii]
LID - 10.1016/j.phymed.2016.02.003 [doi]
AB  - BACKGROUND: Ginkgo biloba L. (Ginkgoaceae) leaf extract is one of the most 
      popular herbal products on the market, as it contains flavone glycosides (≥ 24%) 
      and terpene lactones (≥ 6%), which are proposed to have significant physiological 
      effects. Unfortunately, the challenging financial climate has resulted in a 
      natural health product market containing adulterated ginkgo products. PURPOSE: 42 
      ginkgo samples were analyzed to establish an HPLC profile for authentic ginkgo 
      and common ginkgo adulterants, and to develop a method capable of easily 
      detecting adulteration in ginkgo commercial products. METHOD: In this study an 
      efficient and targeted HPLC analysis method was established that is capable of 
      distinguishing flavonol glycosides and aglycones simultaneously for the 
      evaluation of ginkgo powdered extracts (PEs) and finished products in a single, 
      13 min run. Thirteen ginkgo leaf samples, fifteen standardized powdered extracts, 
      and fourteen commercially available ginkgo products have been analyzed using this 
      new HPLC method. Chromatograms were compared to six standard reference materials: 
      one flavonol glycoside (rutin), three aglycones (quercetin, kaempferol and 
      isorhamnetin), and two isoflavones (genestin and genistein). The quantitative 
      chromatographic data was interpreted by principal component analysis (PCA), which 
      assisted in the detection of unexpected chromatographic features in various 
      adulterated botanical products. RESULTS: Only three of the commercially available 
      ginkgo finished products tested in this study were determined to be authentic, 
      with flavonol glycoside rutin, and aglycones quercetin, kaempferol, and 
      isorhamnetin found to be common adulterants in the ginkgo powdered extract and 
      finished product samples. CONCLUSION: Despite evidence of adulteration in most of 
      the samples, each of the samples discussed herein met most of the current 
      pharmacopeial standards. It is therefore critical that a preliminary evaluation 
      be utilized to detect adulteration in commercial ginkgo products, prior to the 
      acid hydrolysis procedure utilized in the current testing methods.
CI  - Copyright © 2016 Elsevier GmbH. All rights reserved.
FAU - Ma, Yuan-Chun
AU  - Ma YC
AD  - Canadian Phytopharmaceuticals Corp., 12233 Riverside Way, Richmond, BC V6W 1K8, 
      Canada; Canadian Institute of Medicinal Plants, 12233 Riverside Way, Richmond, BC 
      V6W 1K8, Canada; Hubei University of Chinese Medicine, Wuhan 430000, PR China. 
      Electronic address: ycma@canphyto.com.
FAU - Mani, Ana
AU  - Mani A
AD  - Canadian Phytopharmaceuticals Corp., 12233 Riverside Way, Richmond, BC V6W 1K8, 
      Canada. Electronic address: anahitam@canphyto.com.
FAU - Cai, Yaling
AU  - Cai Y
AD  - Canadian Phytopharmaceuticals Corp., 12233 Riverside Way, Richmond, BC V6W 1K8, 
      Canada; Canadian Institute of Medicinal Plants, 12233 Riverside Way, Richmond, BC 
      V6W 1K8, Canada.
FAU - Thomson, Jaclyn
AU  - Thomson J
AD  - Canadian Phytopharmaceuticals Corp., 12233 Riverside Way, Richmond, BC V6W 1K8, 
      Canada.
FAU - Ma, Jie
AU  - Ma J
AD  - Canadian Phytopharmaceuticals Corp., 12233 Riverside Way, Richmond, BC V6W 1K8, 
      Canada; Canadian Institute of Medicinal Plants, 12233 Riverside Way, Richmond, BC 
      V6W 1K8, Canada.
FAU - Peudru, Flavie
AU  - Peudru F
AD  - Canadian Phytopharmaceuticals Corp., 12233 Riverside Way, Richmond, BC V6W 1K8, 
      Canada.
FAU - Chen, Sarah
AU  - Chen S
AD  - Canadian Phytopharmaceuticals Corp., 12233 Riverside Way, Richmond, BC V6W 1K8, 
      Canada.
FAU - Luo, Mai
AU  - Luo M
AD  - Canadian Phytopharmaceuticals Corp., 12233 Riverside Way, Richmond, BC V6W 1K8, 
      Canada; Canadian Institute of Medicinal Plants, 12233 Riverside Way, Richmond, BC 
      V6W 1K8, Canada.
FAU - Zhang, Junzeng
AU  - Zhang J
AD  - Natural Health Products Program, Aquatic and Crop Resource Development, National 
      Research Council of Canada, Halifax, Nova Scotia B3H 3Z1, Canada.
FAU - Chapman, Robert G
AU  - Chapman RG
AD  - Natural Health Products Program, Aquatic and Crop Resource Development, National 
      Research Council of Canada, Halifax, Nova Scotia B3H 3Z1, Canada.
FAU - Shi, Zhen-Tuo
AU  - Shi ZT
AD  - Hubei Nuokete Pharmaceutical Co., Ltd., Xiaochang, Hubei 432900, PR China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160218
PL  - Germany
TA  - Phytomedicine
JT  - Phytomedicine : international journal of phytotherapy and phytopharmacology
JID - 9438794
RN  - 0 (Flavonols)
RN  - 0 (Glycosides)
RN  - 0 (Kaempferols)
RN  - 0 (Lactones)
RN  - 0 (Plant Extracts)
RN  - 0 (Terpenes)
RN  - 07X3IB4R4Z (3-methylquercetin)
RN  - 731P2LE49E (kaempferol)
RN  - 9IKM0I5T1E (Quercetin)
RN  - DH2M523P0H (Genistein)
SB  - IM
MH  - Chromatography, High Pressure Liquid/methods
MH  - Drug Contamination/*prevention & control
MH  - Flavonols/*analysis
MH  - Genistein/analysis
MH  - Ginkgo biloba/*chemistry
MH  - Glycosides/*analysis
MH  - Kaempferols/analysis
MH  - Lactones/analysis
MH  - Plant Extracts/*chemistry
MH  - Plant Leaves/chemistry
MH  - Quercetin/analogs & derivatives/analysis
MH  - Reference Standards
MH  - Terpenes/analysis
OTO - NOTNLM
OT  - Adulteration
OT  - Ginkgo biloba
OT  - Ginkgo supplements
OT  - LC-MS
OT  - PCA
OT  - Pharmacopeia
EDAT- 2016/03/24 06:00
MHDA- 2016/10/19 06:00
CRDT- 2016/03/23 06:00
PHST- 2015/06/30 00:00 [received]
PHST- 2016/02/03 00:00 [revised]
PHST- 2016/02/04 00:00 [accepted]
PHST- 2016/03/23 06:00 [entrez]
PHST- 2016/03/24 06:00 [pubmed]
PHST- 2016/10/19 06:00 [medline]
AID - S0944-7113(16)00035-0 [pii]
AID - 10.1016/j.phymed.2016.02.003 [doi]
PST - ppublish
SO  - Phytomedicine. 2016 Apr 15;23(4):377-87. doi: 10.1016/j.phymed.2016.02.003. Epub 
      2016 Feb 18.

PMID- 27055356
OWN - NLM
STAT- MEDLINE
DCOM- 20170201
LR  - 20191210
IS  - 1944-0057 (Electronic)
IS  - 1944-0057 (Linking)
VI  - 33
IP  - 5
DP  - 2016 May
TI  - Determination of steroid hormones in bovine milk by LC-MS/MS and their levels in 
      Swiss Holstein cow milk.
PG  - 804-16
LID - 10.1080/19440049.2016.1175186 [doi]
AB  - Synthetic and natural steroid hormones have attracted some attention in recent 
      years as endocrine active substances (EAS) that interact or interfere with the 
      endocrine system. Endogenous hormones occur naturally in food of animal origin, 
      among which bovine milk represents an important source. This study was conducted 
      to determine the occurrence of steroid hormones (oestrogens, androgens, 
      progestogens and glucocorticoids) in cow's milk samples from three farms in 
      Switzerland. An isotope dilution liquid chromatography-tandem mass spectrometry 
      (LC-MS/MS) method was developed and validated for the quantification of 12 
      hormones in milk. Some hormonal levels from individual cows showed large 
      variations. The average levels of the hormones analysed 
      (17α-estradiol = 31 ng kg(-)(1), 17β-estradiol = 6 ng kg(-)(1), 
      estrone = 159 ng kg(-)(1), 4-androstenedione = 684 ng kg(-)(1), 
      progesterone = 15486 ng kg(-)(1), 17-hydroxyprogesterone = 214 ng kg(-)(1), 
      cortisone = 112 ng kg(-)(1), and cortisol = 235 ng kg(-)(1)) were comparable with 
      literature data. Estriol, testosterone and androstenediols were not detected at 
      their respective limit of quantification. No significant differences of hormonal 
      content among milk from cows at different lactation/calving numbers were 
      evidenced, except for progesterone and 4-androstenedione. Due to confounding 
      parameters linked to the physiological stage of the animal, like pregnancy and 
      gestational stage (pregnancy trimester), the causal correlation between the 
      variation of the levels for these two hormones and the lactation/calving number 
      could not be unambiguously demonstrated.
FAU - Goyon, Alexandre
AU  - Goyon A
AD  - a Department of Analytical Sciences, Nestlé Research Centre , Lausanne , 
      Switzerland.
FAU - Cai, Julia Zhenzhen
AU  - Cai JZ
AD  - b Nestlé Food Safety Institute, Nestlé R&D (China) Ltd. , Beijing , China.
FAU - Kraehenbuehl, Karin
AU  - Kraehenbuehl K
AD  - a Department of Analytical Sciences, Nestlé Research Centre , Lausanne , 
      Switzerland.
FAU - Hartmann, Christoph
AU  - Hartmann C
AD  - b Nestlé Food Safety Institute, Nestlé R&D (China) Ltd. , Beijing , China.
FAU - Shao, Bing
AU  - Shao B
AD  - c Central Laboratory , Beijing Centre for Disease Prevention and Control , 
      Beijing , China.
FAU - Mottier, Pascal
AU  - Mottier P
AD  - a Department of Analytical Sciences, Nestlé Research Centre , Lausanne , 
      Switzerland.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Validation Study
DEP - 20160504
PL  - England
TA  - Food Addit Contam Part A Chem Anal Control Expo Risk Assess
JT  - Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & 
      risk assessment
JID - 101485040
RN  - 0 (Androgens)
RN  - 0 (Estrogens)
RN  - 0 (Glucocorticoids)
RN  - 0 (Progestins)
SB  - IM
MH  - Androgens/*analysis
MH  - Animals
MH  - Animals, Inbred Strains
MH  - Cattle
MH  - Chromatography, High Pressure Liquid
MH  - Dairying
MH  - Drug Residues/analysis
MH  - Estrogens/*analysis
MH  - Female
MH  - *Food Contamination
MH  - Food Inspection/*methods
MH  - Glucocorticoids/*analysis
MH  - Indicator Dilution Techniques
MH  - Lactation
MH  - Milk/*chemistry
MH  - Pregnancy
MH  - Progestins/*analysis
MH  - Spectrometry, Mass, Electrospray Ionization
MH  - Switzerland
MH  - Tandem Mass Spectrometry
OTO - NOTNLM
OT  - Bovine milk
OT  - LC-MS/MS
OT  - androgens
OT  - endocrine active substances (EAS)
OT  - glucocorticoids
OT  - hormones
OT  - oestrogens
OT  - progestogens
OT  - steroids
EDAT- 2016/04/09 06:00
MHDA- 2017/02/02 06:00
CRDT- 2016/04/09 06:00
PHST- 2016/04/09 06:00 [entrez]
PHST- 2016/04/09 06:00 [pubmed]
PHST- 2017/02/02 06:00 [medline]
AID - 10.1080/19440049.2016.1175186 [doi]
PST - ppublish
SO  - Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2016 
      May;33(5):804-16. doi: 10.1080/19440049.2016.1175186. Epub 2016 May 4.

PMID- 31767906
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20250103
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 9
IP  - 1
DP  - 2019 Nov 25
TI  - Bisphenol-A (BPA) in Foods commonly consumed in Southwest Nigeria and its Human 
      Health Risk.
PG  - 17458
LID - 10.1038/s41598-019-53790-2 [doi]
LID - 17458
AB  - Bisphenol-A (BPA) is a synthetic chemical ubiquitous in the environment and 
      listed as an endocrine disruptor. It has the tendency of migrating into food 
      stored in materials containing it. This study, therefore, determines the 
      concentrations of BPA in foods commonly consumed in Southwest Nigeria by the 
      adult population and also estimates the risk associated with human exposure. 
      Eight different food categories were selected for this study. Standard QuEChERS 
      protocol was used for sample extraction and analysed using gas 
      chromatography-mass spectrometry (GC-MS). Vegetable oil had the highest BPA 
      concentration (28.4 ng/g). This was followed by aquatic canned fish (26.3 ng/g), 
      canned beef (21.3 ng/g) and crayfish (17.5 ng/g). These concentrations were below 
      the 600 ng/g limit of the European Commission for BPA in foods. Bisphenol-A was 
      not detected in raw beef, chicken, cheese, apple, tomatoes, beans and rice; and 
      chicken eggs. The adult population had an average dietary intake of 30.4 ng/kg 
      bw/day. There is no likely occurrence of harmful health effects of BPA in the 
      selected foods with respect to the current concentrations found therein. However, 
      routine monitoring is recommended to prevent human exposure to BPA.
FAU - Adeyi, Adebola A
AU  - Adeyi AA
AUID- ORCID: 0000-0002-6165-7458
AD  - Department of Chemistry, University of Ibadan, Ibadan, Oyo State, Nigeria. 
      bolaoketola@yahoo.com.
AD  - Basel Convention Coordinating Centre for Training and Technology Transfer for 
      Africa Region, University of Ibadan, Ibadan, Oyo State, Nigeria. 
      bolaoketola@yahoo.com.
FAU - Babalola, Babafemi A
AU  - Babalola BA
AD  - Department of Chemistry, University of Ibadan, Ibadan, Oyo State, Nigeria.
AD  - Basel Convention Coordinating Centre for Training and Technology Transfer for 
      Africa Region, University of Ibadan, Ibadan, Oyo State, Nigeria.
LA  - eng
PT  - Journal Article
DEP - 20191125
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Endocrine Disruptors)
RN  - 0 (Phenols)
RN  - 0 (Plant Oils)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Animals
MH  - Benzhydryl Compounds/*analysis/toxicity
MH  - Dairy Products/analysis
MH  - Eggs/analysis
MH  - Endocrine Disruptors/*analysis/toxicity
MH  - Female
MH  - Food Contamination/*analysis
MH  - Food Inspection
MH  - Food, Preserved/analysis
MH  - Gas Chromatography-Mass Spectrometry
MH  - Humans
MH  - Male
MH  - Maximum Allowable Concentration
MH  - Meat Products/analysis
MH  - Middle Aged
MH  - Nigeria
MH  - Phenols/*analysis/toxicity
MH  - Plant Oils/chemistry
MH  - Risk Assessment
MH  - Socioeconomic Factors
MH  - Vegetables/chemistry
PMC - PMC6877615
COIS- The authors declare no competing interests.
EDAT- 2019/11/27 06:00
MHDA- 2020/11/11 06:00
PMCR- 2019/11/25
CRDT- 2019/11/27 06:00
PHST- 2018/12/10 00:00 [received]
PHST- 2019/11/06 00:00 [accepted]
PHST- 2019/11/27 06:00 [entrez]
PHST- 2019/11/27 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2019/11/25 00:00 [pmc-release]
AID - 10.1038/s41598-019-53790-2 [pii]
AID - 53790 [pii]
AID - 10.1038/s41598-019-53790-2 [doi]
PST - epublish
SO  - Sci Rep. 2019 Nov 25;9(1):17458. doi: 10.1038/s41598-019-53790-2.

PMID- 33283964
OWN - NLM
STAT- MEDLINE
DCOM- 20211203
LR  - 20211214
IS  - 1942-7611 (Electronic)
IS  - 1942-7603 (Linking)
VI  - 13
IP  - 5
DP  - 2021 May
TI  - An in vitro assay approach to investigate the potential impact of different 
      doping agents on the steroid profile.
PG  - 916-928
LID - 10.1002/dta.2991 [doi]
AB  - The steroid profile, that is, the urinary concentrations and concentration ratios 
      of selected steroids, is used in sports drug testing to detect the misuse of 
      endogenous steroids such as testosterone. Since several years, not only 
      population-based thresholds are applied but also the steroid profile is monitored 
      via the Athlete Biological Passport whereby the individual reference ranges 
      derived from multiple test results of the same athlete are compared to 
      population-based thresholds. In order to maintain a high probative force of the 
      passport, samples collected or analyzed under suboptimal conditions should not be 
      included in the longitudinal review. This applies to biologically affected or 
      degraded samples and to samples excluded owing to the presence of other 
      substances potentially (or evidently) altering the steroid profile. Nineteen 
      different doping agents comprising anabolic steroids, selective androgen receptor 
      modulators, selective estrogen receptor modulators, ibutamoren, and tibolone were 
      investigated for their effect on the steroid profile using an androgen receptor 
      activation test, an androgen receptor binding assay, an aromatase assay, and a 
      steroidogenesis assay. The in vitro tests were coupled with well-established 
      liquid chromatography/mass spectrometry-based analytical approaches and for a 
      subset of steroidal analytes by gas chromatography/mass spectrometry. The variety 
      of tests employed should produce a comprehensive data set to better understand 
      how a compound under investigation may impact the steroid profile. Although our 
      data set may allow an estimate of whether or not a substance will have an impact 
      on the overall steroid metabolism, predicting which parameter in particular may 
      be influenced remains difficult.
CI  - © 2020 The Authors. Drug Testing and Analysis published by John Wiley & Sons Ltd.
FAU - Piper, Thomas
AU  - Piper T
AUID- ORCID: 0000-0002-7462-6693
AD  - Center for Preventive Doping Research, German Sport University Cologne, Cologne, 
      Germany.
FAU - Heimbach, Sonja
AU  - Heimbach S
AD  - Research & Development, Crop Science, in vitro Toxicology, Bayer AG, Monheim, 
      Germany.
FAU - Adamczewski, Martin
AU  - Adamczewski M
AD  - Research & Development, Crop Science, in vitro Toxicology, Bayer AG, Monheim, 
      Germany.
FAU - Thevis, Mario
AU  - Thevis M
AUID- ORCID: 0000-0002-1535-6451
AD  - Center for Preventive Doping Research, German Sport University Cologne, Cologne, 
      Germany.
AD  - European Monitoring Center for Emerging Doping Agents (EuMoCEDA), Cologne/Bonn, 
      Germany.
LA  - eng
GR  - Federal Ministry of the Interior, Building and Community/
GR  - Manfred-Donike Institute for Doping Analysis/
PT  - Journal Article
DEP - 20201214
PL  - England
TA  - Drug Test Anal
JT  - Drug testing and analysis
JID - 101483449
RN  - 0 (Anabolic Agents)
RN  - 0 (Androgens)
RN  - 0 (Aromatase Inhibitors)
RN  - 0 (Biomarkers)
RN  - 0 (Gonadal Steroid Hormones)
RN  - 0 (Performance-Enhancing Substances)
RN  - 0 (Receptors, Androgen)
RN  - EC 1.13.12.7 (Luciferases, Firefly)
RN  - EC 1.14.14.1 (Aromatase)
RN  - EC 1.14.14.1 (CYP19A1 protein, human)
SB  - IM
MH  - Anabolic Agents/*analysis
MH  - Androgens/*analysis
MH  - Animals
MH  - Aromatase/genetics/metabolism
MH  - Aromatase Inhibitors/*analysis
MH  - *Biological Assay
MH  - Biomarkers/urine
MH  - Chromatography, Liquid
MH  - *Doping in Sports
MH  - Gas Chromatography-Mass Spectrometry
MH  - Genes, Reporter
MH  - Gonadal Steroid Hormones/*biosynthesis
MH  - Humans
MH  - Luciferases, Firefly/biosynthesis/genetics
MH  - Mass Spectrometry
MH  - PC-3 Cells
MH  - Performance-Enhancing Substances/*analysis
MH  - Predictive Value of Tests
MH  - Rats
MH  - Receptors, Androgen/*drug effects/genetics/metabolism
MH  - Reproducibility of Results
MH  - *Substance Abuse Detection
MH  - Urinalysis
OTO - NOTNLM
OT  - GC/MS
OT  - H295R
OT  - LC/MS
OT  - doping agents
OT  - steroidogenesis
EDAT- 2020/12/08 06:00
MHDA- 2021/12/15 06:00
CRDT- 2020/12/07 08:52
PHST- 2020/11/16 00:00 [revised]
PHST- 2020/07/06 00:00 [received]
PHST- 2020/12/03 00:00 [accepted]
PHST- 2020/12/08 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2020/12/07 08:52 [entrez]
AID - 10.1002/dta.2991 [doi]
PST - ppublish
SO  - Drug Test Anal. 2021 May;13(5):916-928. doi: 10.1002/dta.2991. Epub 2020 Dec 14.

PMID- 38064783
OWN - NLM
STAT- MEDLINE
DCOM- 20240103
LR  - 20240106
IS  - 1879-2448 (Electronic)
IS  - 0043-1354 (Linking)
VI  - 249
DP  - 2024 Feb 1
TI  - Deciphering the synergistic effects of photolysis and biofiltration to actuate 
      elimination of estrogens in natural water matrix.
PG  - 120976
LID - S0043-1354(23)01416-1 [pii]
LID - 10.1016/j.watres.2023.120976 [doi]
AB  - The presence of estrogens in water environments has raised concerns for human 
      health and ecosystems balance. These substances possess potent estrogenic 
      properties, causing severe disruptions in endocrine systems and leading to 
      reproductive and developmental problems. Unfortunately, conventional treatment 
      methods struggle to effectively remove estrogens and mitigate their effects, 
      necessitating technological innovation. This study investigates the effectiveness 
      of a novel sequential photolysis-granular activated carbon (GAC) sandwich 
      biofiltration (GSBF) system in removing estrogens (E1, E2, E3, and EE2) and 
      improving general water quality parameters. The results indicate that combining 
      photolysis pre-treatment with GSBF consistently achieved satisfactory performance 
      in terms of turbidity, dissolved organic carbon (DOC), UV(254), and microbial 
      reduction, with over 77.5 %, 80.2 %, 89.7 %, and 92 % reduction, respectively. 
      Furthermore, this approach effectively controlled the growth of microbial biomass 
      under UV irradiation, preventing excessive head loss. To assess estrogen removal, 
      liquid chromatography-tandem mass spectrometry (LC-MS) measured their 
      concentrations, while bioassays determined estrogenicity. The findings 
      demonstrate that GSBF systems, with and without photolysis installation, achieved 
      over 96.2 % removal for estrogens when the spike concentration of each targeted 
      compound was 10 µg L(-1), successfully reducing estrogenicity (EA/EA0) to levels 
      below 0.05. Additionally, the study evaluated the impact of different thicknesses 
      of GAC layer filling (8 cm, 16 cm, and 24 cm) and found no significant difference 
      (p>0.05) in estrogen and estrogenicity removal among them.
CI  - Copyright © 2023. Published by Elsevier Ltd.
FAU - Huang, Fan
AU  - Huang F
AD  - Centre for Urban Sustainability and Resilience, Department of Civil, 
      Environmental and Geomatic Engineering, University College London, London WC1E 
      6BT, United Kingdom; State Key Laboratory of Environmental Aquatic Chemistry, Key 
      Laboratory of Drinking Water Science and Technology, Research Center for 
      Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing, China.
FAU - Tang, Junwang
AU  - Tang J
AD  - Department of Chemical Engineering, University College London, WC1E 6BT, United 
      Kingdom; Industrial Catalysis Center, Department of Chemical Engineering, 
      Tsinghua University, Beijing 100084, China.
FAU - Xu, Like
AU  - Xu L
AD  - Centre for Urban Sustainability and Resilience, Department of Civil, 
      Environmental and Geomatic Engineering, University College London, London WC1E 
      6BT, United Kingdom.
FAU - Campos, Luiza C
AU  - Campos LC
AD  - Centre for Urban Sustainability and Resilience, Department of Civil, 
      Environmental and Geomatic Engineering, University College London, London WC1E 
      6BT, United Kingdom. Electronic address: l.campos@ucl.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20231205
PL  - England
TA  - Water Res
JT  - Water research
JID - 0105072
RN  - 0 (Estrogens)
RN  - 0 (Water Pollutants, Chemical)
RN  - 2DI9HA706A (Estrone)
RN  - 16291-96-6 (Charcoal)
SB  - IM
MH  - Humans
MH  - *Estrogens/chemistry
MH  - Photolysis
MH  - Ecosystem
MH  - *Water Pollutants, Chemical/chemistry
MH  - Estrone
MH  - Charcoal
OTO - NOTNLM
OT  - Adsorption
OT  - Biodegradation
OT  - Estrogenicity
OT  - Photodegradation
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/12/09 05:43
MHDA- 2024/01/03 09:42
CRDT- 2023/12/08 18:01
PHST- 2023/05/25 00:00 [received]
PHST- 2023/11/18 00:00 [revised]
PHST- 2023/12/04 00:00 [accepted]
PHST- 2024/01/03 09:42 [medline]
PHST- 2023/12/09 05:43 [pubmed]
PHST- 2023/12/08 18:01 [entrez]
AID - S0043-1354(23)01416-1 [pii]
AID - 10.1016/j.watres.2023.120976 [doi]
PST - ppublish
SO  - Water Res. 2024 Feb 1;249:120976. doi: 10.1016/j.watres.2023.120976. Epub 2023 
      Dec 5.

PMID- 28223151
OWN - NLM
STAT- MEDLINE
DCOM- 20170704
LR  - 20171207
IS  - 1879-1220 (Electronic)
IS  - 0960-0760 (Linking)
VI  - 168
DP  - 2017 Apr
TI  - Testosterone rapidly increases Ca(2+)-activated K(+) currents causing 
      hyperpolarization in human coronary artery endothelial cells.
PG  - 118-126
LID - S0960-0760(17)30049-3 [pii]
LID - 10.1016/j.jsbmb.2017.02.014 [doi]
AB  - Testosterone has endothelium-dependent vasodilatory effects on the coronary 
      artery, with some reports suggesting endothelial ion channel involvement. This 
      study employed the whole-cell patch clamp technique to investigate the effect of 
      testosterone on ion channels in human coronary artery endothelial cells (HCAECs) 
      and the mechanisms involved. We found that 0.03-3μM testosterone significantly 
      induced a rapid, concentration-dependent increase in total HCAEC current (EC(50), 
      71.96±1.66nM; maximum increase, 59.13±8.37%; mean±SEM). The testosterone-enhanced 
      currents consisted of small- and large-conductance Ca(2+)-activated K(+) currents 
      (SK(Ca) and BK(Ca) currents), but not Cl(-) and nonselective cation currents. 
      Either a non-permeant testosterone conjugate or the non-aromatizable androgen 
      dihydrotestosterone (DHT) could increase HCAEC currents as well. The androgen 
      receptor antagonist flutamide prevented this testosterone, testosterone 
      conjugate, and DHT effect, while the estrogen receptor antagonist fulvestrant did 
      not. Incubating HCAECs with pertussis toxin or protein kinase A inhibitor H-89 
      largely inhibited the testosterone effect, while pre-incubation with 
      phospholipase C inhibitor U-73122, prostacyclin inhibitor indomethacin, nitric 
      oxide synthase inhibitor L-NAME or cytochrome P450 inhibitor MS-PPOH, did not. 
      Finally, testosterone application induced HCAEC hyperpolarization within minutes; 
      this effect was prevented by SK(Ca) and BK(Ca) current inhibitors apamin and 
      iberiotoxin. This is the first electrophysiological demonstration of 
      androgen-induced K(Ca) current increase, leading to hyperpolarization, in any 
      endothelial cell, and the first report of SK(Ca) as a testosterone target. Our 
      data show that testosterone rapidly increased whole-cell HCAEC SK(Ca) and BK(Ca) 
      currents via a surface androgen receptor, G(i/o) protein, and protein kinase A. 
      This mechanism may explain rapid testosterone-induced coronary vasodilation seen 
      in vivo.
CI  - Copyright © 2017 Elsevier Ltd. All rights reserved.
FAU - Ruamyod, Katesirin
AU  - Ruamyod K
AD  - Department of Physiology Faculty of Medicine Siriraj Hospital, Mahidol 
      University, Bangkok, 10700, Thailand. Electronic address: 
      katesirin.ruy@mahidol.ac.th.
FAU - Watanapa, Wattana B
AU  - Watanapa WB
AD  - Department of Physiology Faculty of Medicine Siriraj Hospital, Mahidol 
      University, Bangkok, 10700, Thailand. Electronic address: 
      wattana.wat@mahidol.ac.th.
FAU - Shayakul, Chairat
AU  - Shayakul C
AD  - Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, 
      Bangkok, 10700, Thailand. Electronic address: chairat.sha@mahidol.ac.th.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170220
PL  - England
TA  - J Steroid Biochem Mol Biol
JT  - The Journal of steroid biochemistry and molecular biology
JID - 9015483
RN  - 0 (Androgens)
RN  - 0 (Estrenes)
RN  - 0 (Potassium Channels, Calcium-Activated)
RN  - 0 (Pyrrolidinones)
RN  - 0 (Receptors, Androgen)
RN  - 112648-68-7 
      (1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione)
RN  - 24345-16-2 (Apamin)
RN  - 3XMK78S47O (Testosterone)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase)
RN  - EC 2.7.11.11 (Cyclic AMP-Dependent Protein Kinases)
RN  - EC 3.6.5.1 (GTP-Binding Protein alpha Subunits, Gi-Go)
RN  - V55S2QJN2X (NG-Nitroarginine Methyl Ester)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Androgens/chemistry
MH  - Apamin/chemistry
MH  - Cell Line
MH  - Coronary Vessels/*cytology
MH  - Cyclic AMP-Dependent Protein Kinases/metabolism
MH  - Endothelial Cells/drug effects/*metabolism
MH  - Epoprostenol/antagonists & inhibitors
MH  - Estrenes/chemistry
MH  - GTP-Binding Protein alpha Subunits, Gi-Go/*metabolism
MH  - Humans
MH  - Indomethacin/chemistry
MH  - NG-Nitroarginine Methyl Ester/chemistry
MH  - Nitric Oxide Synthase/chemistry
MH  - Potassium Channels, Calcium-Activated/*metabolism
MH  - Pyrrolidinones/chemistry
MH  - Receptors, Androgen/metabolism
MH  - Signal Transduction
MH  - Testosterone/*blood/chemistry
MH  - Vasodilation
OTO - NOTNLM
OT  - Androgen
OT  - Endothelial ion channel
OT  - Hyperpolarization
OT  - Surface membrane receptor
EDAT- 2017/02/23 06:00
MHDA- 2017/07/05 06:00
CRDT- 2017/02/23 06:00
PHST- 2016/11/21 00:00 [received]
PHST- 2017/02/14 00:00 [revised]
PHST- 2017/02/17 00:00 [accepted]
PHST- 2017/02/23 06:00 [pubmed]
PHST- 2017/07/05 06:00 [medline]
PHST- 2017/02/23 06:00 [entrez]
AID - S0960-0760(17)30049-3 [pii]
AID - 10.1016/j.jsbmb.2017.02.014 [doi]
PST - ppublish
SO  - J Steroid Biochem Mol Biol. 2017 Apr;168:118-126. doi: 
      10.1016/j.jsbmb.2017.02.014. Epub 2017 Feb 20.

PMID- 25825817
OWN - NLM
STAT- MEDLINE
DCOM- 20150824
LR  - 20181113
IS  - 1945-7170 (Electronic)
IS  - 0013-7227 (Print)
IS  - 0013-7227 (Linking)
VI  - 156
IP  - 7
DP  - 2015 Jul
TI  - Neurokinin 3 Receptor-Expressing Neurons in the Median Preoptic Nucleus Modulate 
      Heat-Dissipation Effectors in the Female Rat.
PG  - 2552-62
LID - 10.1210/en.2014-1974 [doi]
AB  - KNDy neurons facilitate tail skin vasodilation and modulate the effects of 
      estradiol on thermoregulation. We hypothesize that KNDy neurons influence 
      cutaneous vasodilation via projections to neurons in the median preoptic nucleus 
      (MnPO) that express the neurokinin 3 receptor (NK3R). In support of this 
      hypothesis, focal microinjections of senktide, an NK3R agonist, into the MnPO 
      lowers core temperature (TCORE) in the female rat. To further study the role of 
      MnPO NK3R neurons in thermoregulation, these neurons were specifically ablated 
      using a conjugate of a selective NK3R agonist and saporin (NK3-SAP). NK3-SAP or 
      blank-SAP (control) was injected into the MnPO/medial septum. Tail skin 
      temperature (TSKIN) and TCORE were measured in ovariectomized rats exposed to 3 
      ambient temperatures (TAMBIENT) before and after estradiol-17β (E2) treatment. 
      Before killing, we injected senktide (sc), monitored TCORE for 70 minutes, and 
      harvested brains for Fos immunohistochemistry. Ablation of MnPO NK3R neurons 
      lowered TSKIN at neutral and subneutral TAMBIENT regardless of E2 treatment. 
      However, ablation did not prevent the effects of E2 on TCORE and TSKIN. In 
      control rats, senktide injections induced hypothermia with numerous 
      Fos-immunoreactive cells in the MnPO. In contrast, in NK3-SAP rats, senktide did 
      not alter TCORE and minimal Fos-immunoreactive neurons were identified in the 
      MnPO. These data show that NK3R neurons in the MnPO are required for the 
      hypothermic effects of senktide but not for the E2 modulation of 
      thermoregulation. The lower TSKIN in NK3-SAP-injected rats suggests that MnPO 
      NK3R neurons, like KNDy neurons, facilitate cutaneous vasodilation, an important 
      heat-dissipation effector.
FAU - Mittelman-Smith, Melinda A
AU  - Mittelman-Smith MA
AD  - Departments of Pathology (M.A.M.-S., S.J.K.-H., N.E.R.), Cellular and Molecular 
      Medicine (N.T.M., N.E.R.), and Neurology (N.E.R.), and the Evelyn F. McKnight 
      Brain Institute (N.E.R.), University of Arizona College of Medicine, Tucson, 
      Arizona 85724.
FAU - Krajewski-Hall, Sally J
AU  - Krajewski-Hall SJ
AD  - Departments of Pathology (M.A.M.-S., S.J.K.-H., N.E.R.), Cellular and Molecular 
      Medicine (N.T.M., N.E.R.), and Neurology (N.E.R.), and the Evelyn F. McKnight 
      Brain Institute (N.E.R.), University of Arizona College of Medicine, Tucson, 
      Arizona 85724.
FAU - McMullen, Nathaniel T
AU  - McMullen NT
AD  - Departments of Pathology (M.A.M.-S., S.J.K.-H., N.E.R.), Cellular and Molecular 
      Medicine (N.T.M., N.E.R.), and Neurology (N.E.R.), and the Evelyn F. McKnight 
      Brain Institute (N.E.R.), University of Arizona College of Medicine, Tucson, 
      Arizona 85724.
FAU - Rance, Naomi E
AU  - Rance NE
AD  - Departments of Pathology (M.A.M.-S., S.J.K.-H., N.E.R.), Cellular and Molecular 
      Medicine (N.T.M., N.E.R.), and Neurology (N.E.R.), and the Evelyn F. McKnight 
      Brain Institute (N.E.R.), University of Arizona College of Medicine, Tucson, 
      Arizona 85724.
LA  - eng
GR  - R01AG047887/AG/NIA NIH HHS/United States
GR  - R01 AG047887/AG/NIA NIH HHS/United States
GR  - R01 AG032315/AG/NIA NIH HHS/United States
GR  - U54 HD028934/HD/NICHD NIH HHS/United States
GR  - U54-HD28934/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20150331
PL  - United States
TA  - Endocrinology
JT  - Endocrinology
JID - 0375040
RN  - 0 (Estrogens)
RN  - 0 (Peptide Fragments)
RN  - 0 (Receptors, Neurokinin-3)
RN  - 106128-89-6 (senktide)
RN  - 33507-63-0 (Substance P)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Animals
MH  - Arcuate Nucleus of Hypothalamus/physiology
MH  - Body Temperature Regulation/drug effects/*physiology
MH  - Estradiol/pharmacology
MH  - Estrogens/pharmacology
MH  - Female
MH  - Hot Flashes/metabolism
MH  - Neurons/drug effects/*physiology
MH  - Peptide Fragments/pharmacology
MH  - Preoptic Area/cytology/drug effects/*physiology
MH  - Rats
MH  - Receptors, Neurokinin-3/agonists/*physiology
MH  - Skin
MH  - Substance P/analogs & derivatives/pharmacology
MH  - Vasodilation/drug effects/*physiology
PMC - PMC4475724
EDAT- 2015/04/01 06:00
MHDA- 2015/08/25 06:00
PMCR- 2016/07/01
CRDT- 2015/04/01 06:00
PHST- 2015/04/01 06:00 [entrez]
PHST- 2015/04/01 06:00 [pubmed]
PHST- 2015/08/25 06:00 [medline]
PHST- 2016/07/01 00:00 [pmc-release]
AID - EN-14-1974 [pii]
AID - 10.1210/en.2014-1974 [doi]
PST - ppublish
SO  - Endocrinology. 2015 Jul;156(7):2552-62. doi: 10.1210/en.2014-1974. Epub 2015 Mar 
      31.

PMID- 38922147
OWN - NLM
STAT- MEDLINE
DCOM- 20240626
LR  - 20240629
IS  - 2072-6651 (Electronic)
IS  - 2072-6651 (Linking)
VI  - 16
IP  - 6
DP  - 2024 May 28
TI  - Actinobacteria as Promising Biocontrol Agents for In Vitro and In Planta 
      Degradation and Detoxification of Zearalenone.
LID - 10.3390/toxins16060253 [doi]
LID - 253
AB  - Zearalenone (ZEN) is a prevalent mycotoxin found in grains and grain-derived 
      products, inducing adverse health effects in both animals and humans. The 
      in-field application of microorganisms to degrade and detoxify ZEN is a promising 
      strategy to enhance the safety of food and feed. In this study, we investigated 
      the potential of three actinobacterial strains to degrade and detoxify ZEN in 
      vitro and in planta on wheat ears. The residual ZEN concentration and toxicity in 
      the samples were analysed with UHPLC-MS/MS and a bioluminescence BLYES assay, 
      respectively. Streptomyces rimosus subsp. rimosus LMG19352 could completely 
      degrade and detoxify 5 mg/L ZEN in LB broth within 24 h, along with significant 
      reductions in ZEN concentration both in a minimal medium (MM) and on wheat ears. 
      Additionally, it was the only strain that showed a significant colonisation of 
      these ears. Rhodococcus sp. R25614 exhibited partial but significant degradation 
      in LB broth and MM, whereas Streptomyces sp. LMG16995 degraded and detoxified ZEN 
      in LB broth after 72 h by 39% and 33%, respectively. Although all three 
      actinobacterial strains demonstrated the metabolic capability to degrade and 
      detoxify ZEN in vitro, only S. rimosus subsp. rimosus LMG19352 showed promising 
      potential to mitigate ZEN in planta. This distinction underscores the importance 
      of incorporating in planta screening assays for assessing the potential of 
      mycotoxin-biotransforming microorganisms as biocontrol agents.
FAU - De Troyer, Larissa
AU  - De Troyer L
AUID- ORCID: 0000-0002-2420-8725
AD  - Laboratory of Applied Mycology and Phenomics, Department of Plants and Crops, 
      Faculty of Bioscience Engineering, Ghent University, 9000 Ghent, Belgium.
FAU - De Zutter, Noémie
AU  - De Zutter N
AUID- ORCID: 0000-0002-5854-9931
AD  - Laboratory of Applied Mycology and Phenomics, Department of Plants and Crops, 
      Faculty of Bioscience Engineering, Ghent University, 9000 Ghent, Belgium.
FAU - De Saeger, Sarah
AU  - De Saeger S
AUID- ORCID: 0000-0002-2160-7253
AD  - Centre of Excellence in Mycotoxicology and Public Health, Department of 
      Bio-Analysis, Faculty of Pharmaceutical Sciences, Ghent University, 9000 Ghent, 
      Belgium.
FAU - Dumoulin, Frédéric
AU  - Dumoulin F
AD  - Centre of Excellence in Mycotoxicology and Public Health, Department of 
      Bio-Analysis, Faculty of Pharmaceutical Sciences, Ghent University, 9000 Ghent, 
      Belgium.
FAU - Croubels, Siska
AU  - Croubels S
AUID- ORCID: 0000-0001-6357-3517
AD  - Laboratory of Pharmacology and Toxicology, Department of Pathobiology, 
      Pharmacology and Zoological Medicine, Faculty of Veterinary Medicine, Ghent 
      University, 9820 Merelbeke, Belgium.
FAU - De Baere, Siegrid
AU  - De Baere S
AUID- ORCID: 0000-0002-1382-5699
AD  - Laboratory of Pharmacology and Toxicology, Department of Pathobiology, 
      Pharmacology and Zoological Medicine, Faculty of Veterinary Medicine, Ghent 
      University, 9820 Merelbeke, Belgium.
FAU - De Gelder, Leen
AU  - De Gelder L
AD  - Laboratory of Environmental Biotechnology, Department of Applied Biosciences, 
      Faculty of Bioscience Engineering, Ghent University, 9000 Ghent, Belgium.
FAU - Audenaert, Kris
AU  - Audenaert K
AUID- ORCID: 0000-0002-8791-1282
AD  - Laboratory of Applied Mycology and Phenomics, Department of Plants and Crops, 
      Faculty of Bioscience Engineering, Ghent University, 9000 Ghent, Belgium.
LA  - eng
GR  - 1S18223N/Research Foundation - Flanders/
GR  - FWO.HMZ.2022.0008.01/Research Foundation - Flanders/
PT  - Journal Article
DEP - 20240528
PL  - Switzerland
TA  - Toxins (Basel)
JT  - Toxins
JID - 101530765
RN  - 5W827M159J (Zearalenone)
RN  - 0 (Biological Control Agents)
SB  - IM
MH  - *Zearalenone/metabolism/toxicity
MH  - *Triticum/microbiology
MH  - *Biological Control Agents/metabolism
MH  - Streptomyces/metabolism
MH  - Actinobacteria/metabolism
MH  - Food Contamination/prevention & control
MH  - Tandem Mass Spectrometry
PMC - PMC11209476
OTO - NOTNLM
OT  - actinobacteria
OT  - biocontrol
OT  - biotransformation
OT  - degradation
OT  - detoxification
OT  - wheat
OT  - zearalenone
COIS- The authors declare no conflicts of interest.
EDAT- 2024/06/26 12:42
MHDA- 2024/06/26 12:43
PMCR- 2024/05/28
CRDT- 2024/06/26 10:04
PHST- 2024/04/19 00:00 [received]
PHST- 2024/05/13 00:00 [revised]
PHST- 2024/05/27 00:00 [accepted]
PHST- 2024/06/26 12:43 [medline]
PHST- 2024/06/26 12:42 [pubmed]
PHST- 2024/06/26 10:04 [entrez]
PHST- 2024/05/28 00:00 [pmc-release]
AID - toxins16060253 [pii]
AID - toxins-16-00253 [pii]
AID - 10.3390/toxins16060253 [doi]
PST - epublish
SO  - Toxins (Basel). 2024 May 28;16(6):253. doi: 10.3390/toxins16060253.

PMID- 29566104
OWN - NLM
STAT- MEDLINE
DCOM- 20190930
LR  - 20190930
IS  - 2374-2445 (Electronic)
IS  - 2374-2437 (Print)
IS  - 2374-2437 (Linking)
VI  - 4
IP  - 7
DP  - 2018 Jul 1
TI  - Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen 
      Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced 
      Breast Cancer: A Clinical Trial.
PG  - 977-984
LID - 10.1001/jamaoncol.2018.0060 [doi]
AB  - IMPORTANCE: Cotargeting the mammalian target of rapamycin pathway and estrogen 
      receptor may prevent or delay endocrine resistance in patients receiving 
      first-line treatment for advanced breast cancer. OBJECTIVE: To investigate the 
      combination of everolimus plus endocrine therapy in first-line and second-line 
      treatment settings for postmenopausal women with estrogen receptor-positive, 
      human epidermal growth receptor 2-negative advanced breast cancer. DESIGN, 
      SETTING, AND PARTICIPANTS: In the multicenter, open-label, single-arm, phase 2 
      BOLERO-4 (Breast Cancer Trials of Oral Everolimus) clinical trial, 245 patients 
      were screened for eligibility; 202 were enrolled between March 7, 2013, and 
      December 17, 2014. A median follow-up of 29.5 months had been achieved by the 
      data cutoff date (December 17, 2016). INTERVENTIONS: Patients received first-line 
      treatment with everolimus, 10 mg/d, plus letrozole, 2.5 mg/d. Second-line 
      treatment with everolimus, 10 mg/d, plus exemestane, 25 mg/d, was offered at the 
      investigator's discretion upon initial disease progression. MAIN OUTCOMES AND 
      MEASURES: The primary end point was investigator-assessed progression-free 
      survival in the first-line setting per Response Evaluation Criteria in Solid 
      Tumors, version 1.0. Safety was assessed in patients who received at least 1 dose 
      of study medication and at least 1 postbaseline safety assessment. RESULTS: A 
      total of 202 women treated in the first-line setting had a median age of 64.0 
      years (interquartile range, 58.0-70.0 years) with metastatic (194 [96.0%]) or 
      locally advanced (8 [4.0%]) breast cancer. Median progression-free survival was 
      22.0 months (95% CI, 18.1-25.1 months) with everolimus and letrozole. Median 
      overall survival was not reached; 24-month estimated overall survival rate was 
      78.7% (95% CI, 72.1%-83.9%). Fifty patients started second-line treatment; median 
      progression-free survival was 3.7 months (95% CI, 1.9-7.4 months). No new safety 
      signals were observed. In the first-line setting, the most common all-grade 
      adverse event was stomatitis (139 [68.8%]); the most common grade 3 to 4 adverse 
      event was anemia (21 [10.4%]). In the second-line setting, the most common 
      adverse events were stomatitis and decreased weight (10 [20.0%] each); the most 
      common grade 3 to 4 adverse event was hypertension (5 [10.0%]). There were 50 
      (24.8%) deaths overall during the study; 40 were due to study indication (breast 
      cancer). CONCLUSIONS AND RELEVANCE: The results of this trial add to the existing 
      body of evidence suggesting that everolimus plus endocrine therapy is a good 
      first-line treatment option for postmenopausal women with estrogen 
      receptor-positive, human epidermal growth factor receptor 2-negative advanced 
      breast cancer. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01698918.
FAU - Royce, Melanie
AU  - Royce M
AD  - University of New Mexico Comprehensive Cancer Center, Albuquerque.
FAU - Bachelot, Thomas
AU  - Bachelot T
AD  - Breast Cancer Unit and the Clinical Trial Unit, Centre Léon Bérard, Lyon, France.
FAU - Villanueva, Cristian
AU  - Villanueva C
AD  - Service d'Oncologie Médicale, Centre Hospitalier Régional Universitaire de 
      Besançon, Besançon, France.
FAU - Özgüroglu, Mustafa
AU  - Özgüroglu M
AD  - Department of Oncology, Cerrahpaşa School of Medicine, Istanbul University, 
      Istanbul, Turkey.
FAU - Azevedo, Sergio J
AU  - Azevedo SJ
AD  - Oncology Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
FAU - Cruz, Felipe Melo
AU  - Cruz FM
AD  - Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil.
FAU - Debled, Marc
AU  - Debled M
AD  - Département d'Oncologie Médicale, Institut Bergonié, Bordeaux, France.
FAU - Hegg, Roberto
AU  - Hegg R
AD  - Centro de Referência da Saúde da Mulher, Hospital Pérola Byington/Faculdade de 
      Medicina da Universidade de São Paulo, São Paulo, Brazil.
FAU - Toyama, Tatsuya
AU  - Toyama T
AD  - Department of Breast Surgery, Nagoya City University Graduate School of Medical 
      Sciences, Nagoya, Japan.
FAU - Falkson, Carla
AU  - Falkson C
AD  - University of Alabama Comprehensive Cancer Center, Birmingham.
FAU - Jeong, Joon
AU  - Jeong J
AD  - Department of Surgery, Breast Cancer Center, Yonsei University Health System, 
      Seoul, Republic of Korea.
FAU - Srimuninnimit, Vichien
AU  - Srimuninnimit V
AD  - Department of Internal Medicine, Siriraj Hospital, Mahidol University, Bangkok, 
      Thailand.
FAU - Gradishar, William J
AU  - Gradishar WJ
AD  - Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern 
      University, Chicago, Illinois.
FAU - Arce, Christina
AU  - Arce C
AD  - Novartis Oncology, Novartis Pharmaceuticals Corporation, East Hanover, New 
      Jersey.
FAU - Ridolfi, Antonia
AU  - Ridolfi A
AD  - Global Medical Affairs Biostatistics, Novartis Pharma S.A.S., Rueil-Malmaison, 
      France.
FAU - Lin, Chinjune
AU  - Lin C
AD  - Novartis Oncology, Novartis Pharmaceuticals Corporation, East Hanover, New 
      Jersey.
FAU - Cardoso, Fatima
AU  - Cardoso F
AD  - Breast Unit, Champalimaud Clinical Centre, Champalimaud Foundation, Lisbon, 
      Portugal.
LA  - eng
SI  - ClinicalTrials.gov/NCT01698918
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - JAMA Oncol
JT  - JAMA oncology
JID - 101652861
RN  - 0 (Antineoplastic Agents)
RN  - 9HW64Q8G6G (Everolimus)
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Breast Neoplasms/*drug therapy/pathology
MH  - Everolimus/pharmacology/*therapeutic use
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Postmenopause
PMC - PMC5885212
COIS- Conflict of Interest Disclosures: Dr Royce received research funding from 
      Novartis Pharmaceuticals Corporation, was a consultant for Celltrion and BCI 
      Pharma, and received honoraria from Novartis Pharmaceuticals Corporation and 
      Syndax. Dr Bachelot received research funding from Roche and Novartis 
      Pharmaceuticals Corporation and was a consultant for and received travel expenses 
      from AstraZeneca, Roche, Novartis Pharmaceuticals Corporation, and Pfizer. Dr 
      Villanueva was an advisory board member for Novartis Pharmaceuticals Corporation. 
      Dr Melo Cruz received research funding from Novartis Pharmaceuticals Corporation, 
      Janssen, Roche, and Celgene; and received travel, accommodation, and expenses 
      from Janssen Pharmaceuticals. Dr Toyama received research funding from Eisai, 
      Chugai, Novartis Pharmaceuticals Corporation, Nippon Kayaku, Kyowa Hakko Kirin, 
      Daiichi Sankyo, and Takeda. Dr Falkson received research funding from Novartis 
      Pharmaceuticals Corporation, Cascadian Therapeutics, Genentech, and EMD Serono, 
      and was a consultant for and received honoraria from Biotheranostics. Dr Jeong 
      received research funding from Dong-A, Boryung, LG Life Sciences, and Antigen, 
      and received honoraria from Roche, Alvogen, Novartis Pharmaceuticals Corporation, 
      Pfizer, and Covidien. Ms Arce is a Novartis Pharmaceuticals Corporation employee 
      and reported stock ownership with BD. Ms Ridolfi is a Novartis Pharma S.A.S. 
      employee. Dr Lin is a Novartis Pharmaceuticals Corporation employee and reported 
      stock ownership with Novartis Pharmaceuticals Corporation. Dr Cardoso received 
      research funding for clinical trials by institution and was a consultant for 
      Astellas/Medivation, AstraZeneca, Celgene, Daiichi Sankyo, Eisai, GE Oncology, 
      Genentech, GSK, MacroGenics, Merck, Merus BV, Novartis Pharmaceuticals 
      Corporation, Pfizer, Pierre Fabre, Roche, Sanofi, and Teva. No other disclosures 
      are reported.
EDAT- 2018/03/23 06:00
MHDA- 2019/10/01 06:00
PMCR- 2018/03/22
CRDT- 2018/03/23 06:00
PHST- 2018/03/23 06:00 [pubmed]
PHST- 2019/10/01 06:00 [medline]
PHST- 2018/03/23 06:00 [entrez]
PHST- 2018/03/22 00:00 [pmc-release]
AID - 2675915 [pii]
AID - coi180003 [pii]
AID - 10.1001/jamaoncol.2018.0060 [doi]
PST - ppublish
SO  - JAMA Oncol. 2018 Jul 1;4(7):977-984. doi: 10.1001/jamaoncol.2018.0060.

PMID- 31066761
OWN - NLM
STAT- MEDLINE
DCOM- 20190909
LR  - 20231003
IS  - 2359-4292 (Electronic)
IS  - 2359-3997 (Print)
IS  - 2359-3997 (Linking)
VI  - 63
IP  - 3
DP  - 2019 May-Jun
TI  - Does having Turner syndrome affect quality of life in Brazilian women compared to 
      common population?
PG  - 208-214
LID - 10.20945/2359-3997000000136 [doi]
AB  - OBJECTIVES: We aimed to measure the quality of life (QoL) of patients with Turner 
      syndrome (PTS) and determine the extent to which their clinical or laboratory 
      alterations influence QoL compared to reference women (RW) of the same age range. 
      SUBJECTS AND METHODS: From Dec-2013 to Dec-2014, 90 participants were recruited. 
      They were 18 years and older: 48 with Turner syndrome (TS) (PTS) and 42 without 
      (RW). Recruited subjects completed the Portuguese version of Short Form 36 
      (SF-36) questionnaire, and blood was drawn to measure LH, FSH, oestradiol (E2), 
      progesterone (P4), SHBG, and SDHEA (by ECLIA) and testosterone (by LC MS/MS). 
      RESULTS: Age and schooling were similar between groups. The most common 
      occupations for PTS were health worker, administration and education, and health 
      worker or cashier for RW. Most participants were Catholic or Evangelical. 
      Eighty-one percent (39/48) of cases used Hormonal Replacement Therapy (HRT), 
      mostly transdermal (23/39). RW and PTS scored similarly on the SF-36 
      questionnaire. RW had higher oestradiol (p = 0,01), lower FSH (p = 0,01) and 
      higher testosterone (p = 0,01) than PTS. Concentrations of P4, LH, SHBG or SDHEA 
      were similar. Significant associations were found among QoL and hormones (E2 with 
      Vitality and LH with Physical Role) only in the PTS group. CONCLUSIONS: PTS do 
      not consider that TS affects their QoL as measured by domains on the SF-36. 
      Oestradiol was related with QoL, emphasising the importance of HRT.
FAU - Estevez, Maria Bernarda
AU  - Estevez MB
AD  - Ambulatório de Endocrinologia, Escola Paulista de Medicina, Universidade Federal 
      de São Paulo (EPM/Unifesp), São Paulo, SP, Brasil.
FAU - Monteagudo, Patricia Teofilo
AU  - Monteagudo PT
AD  - Departamento de Endocrinologia, Escola Paulista de Medicina, Universidade Federal 
      de São Paulo (EPM/Unifesp), São Paulo, SP, Brasil.
FAU - Oliveira, Kelly Christina
AU  - Oliveira KC
AD  - Laboratório de Esteroides, Escola Paulista de Medicina, Universidade Federal de 
      São Paulo (EPM/Unifesp), São Paulo, SP, Brasil.
FAU - Verreschi, Ieda Therezinha do Nascimento
AU  - Verreschi ITDN
AD  - Departamento de Medicina, Escola Paulista de Medicina, Universidade Federal de 
      São Paulo (EPM/Unifesp), São Paulo, SP, Brasil.
LA  - eng
PT  - Journal Article
DEP - 20190502
PL  - Brazil
TA  - Arch Endocrinol Metab
JT  - Archives of endocrinology and metabolism
JID - 101652058
RN  - 3XMK78S47O (Testosterone)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Brazil
MH  - Case-Control Studies
MH  - Estradiol/blood
MH  - Female
MH  - Hormone Replacement Therapy/*psychology
MH  - Humans
MH  - Middle Aged
MH  - *Quality of Life
MH  - Surveys and Questionnaires
MH  - Testosterone/blood
MH  - Turner Syndrome/blood/*psychology
MH  - Young Adult
PMC - PMC10522194
COIS- Disclosure: no potential conflict of interest relevant to this article was 
      reported.
EDAT- 2019/05/09 06:00
MHDA- 2019/09/10 06:00
PMCR- 2019/04/26
CRDT- 2019/05/09 06:00
PHST- 2017/08/24 00:00 [received]
PHST- 2018/03/14 00:00 [accepted]
PHST- 2019/05/09 06:00 [pubmed]
PHST- 2019/09/10 06:00 [medline]
PHST- 2019/05/09 06:00 [entrez]
PHST- 2019/04/26 00:00 [pmc-release]
AID - S2359-39972019005003105 [pii]
AID - 2359-3997000000136 [pii]
AID - 10.20945/2359-3997000000136 [doi]
PST - ppublish
SO  - Arch Endocrinol Metab. 2019 May-Jun;63(3):208-214. doi: 
      10.20945/2359-3997000000136. Epub 2019 May 2.

PMID- 29208899
OWN - NLM
STAT- MEDLINE
DCOM- 20180918
LR  - 20230811
IS  - 2041-1723 (Electronic)
IS  - 2041-1723 (Linking)
VI  - 8
IP  - 1
DP  - 2017 Dec 5
TI  - In vivo transplantation of 3D encapsulated ovarian constructs in rats corrects 
      abnormalities of ovarian failure.
PG  - 1858
LID - 10.1038/s41467-017-01851-3 [doi]
LID - 1858
AB  - Safe clinical hormone replacement (HR) will likely become increasingly important 
      in the growing populations of aged women and cancer patients undergoing 
      treatments that ablate the ovaries. Cell-based HRT (cHRT) is an alternative 
      approach that may allow certain physiological outcomes to be achieved with lower 
      circulating hormone levels than pharmacological means due to participation of 
      cells in the hypothalamus-pituitary-ovary feedback control loop. Here we describe 
      the in vivo performance of 3D bioengineered ovarian constructs that recapitulate 
      native cell-cell interactions between ovarian granulosa and theca cells as an 
      approach to cHRT. The constructs are fabricated using either Ca(++) or Sr(++) to 
      crosslink alginate. Following implantation in ovariectomized (ovx) rats, the 
      Sr(++)-cross-linked constructs achieve stable secretion of hormones during 90 
      days of study. Further, we show these constructs with isogeneic cells to be 
      effective in ameliorating adverse effects of hormone deficiency, including bone 
      health, uterine health, and body composition in this rat model.
FAU - Sittadjody, Sivanandane
AU  - Sittadjody S
AD  - Wake Forest Institute for Regenerative Medicine, Wake Forest School for Medicine, 
      Winston-Salem, NC, 27157, USA.
FAU - Saul, Justin M
AU  - Saul JM
AD  - Department of Chemical, Paper and Biomedical Engineering, Miami University, 
      Oxford, OH, 45056, USA.
FAU - McQuilling, John P
AU  - McQuilling JP
AD  - Wake Forest Institute for Regenerative Medicine, Wake Forest School for Medicine, 
      Winston-Salem, NC, 27157, USA.
AD  - School of Biomedical Engineering and Sciences (SBES), Wake Forest School of 
      Medicine, Winston-Salem, NC, 27157, USA.
FAU - Joo, Sunyoung
AU  - Joo S
AD  - Wake Forest Institute for Regenerative Medicine, Wake Forest School for Medicine, 
      Winston-Salem, NC, 27157, USA.
FAU - Register, Thomas C
AU  - Register TC
AUID- ORCID: 0000-0002-4078-0166
AD  - Department of Pathology, Section on Comparative Medicine, Wake Forest University 
      School of Medicine, Winston-Salem, NC, 27157, USA.
FAU - Yoo, James J
AU  - Yoo JJ
AD  - Wake Forest Institute for Regenerative Medicine, Wake Forest School for Medicine, 
      Winston-Salem, NC, 27157, USA.
AD  - School of Biomedical Engineering and Sciences (SBES), Wake Forest School of 
      Medicine, Winston-Salem, NC, 27157, USA.
FAU - Atala, Anthony
AU  - Atala A
AD  - Wake Forest Institute for Regenerative Medicine, Wake Forest School for Medicine, 
      Winston-Salem, NC, 27157, USA.
AD  - School of Biomedical Engineering and Sciences (SBES), Wake Forest School of 
      Medicine, Winston-Salem, NC, 27157, USA.
FAU - Opara, Emmanuel C
AU  - Opara EC
AUID- ORCID: 0000-0002-3486-1453
AD  - Wake Forest Institute for Regenerative Medicine, Wake Forest School for Medicine, 
      Winston-Salem, NC, 27157, USA. eopara@wakehealth.edu.
AD  - School of Biomedical Engineering and Sciences (SBES), Wake Forest School of 
      Medicine, Winston-Salem, NC, 27157, USA. eopara@wakehealth.edu.
LA  - eng
GR  - R01 AR061391/AR/NIAMS NIH HHS/United States
GR  - R01 DK080897/DK/NIDDK NIH HHS/United States
GR  - T32 EB014836/EB/NIBIB NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20171205
PL  - England
TA  - Nat Commun
JT  - Nature communications
JID - 101528555
RN  - 0 (Alginates)
RN  - 0 (Estrogens)
RN  - 0 (Hormones)
RN  - 104982-03-8 (Osteocalcin)
RN  - SY7Q814VUP (Calcium)
RN  - YZS2RPE8LE (Strontium)
SB  - IM
CIN - Nat Rev Endocrinol. 2018 Feb;14(2):66. doi: 10.1038/nrendo.2017.171. PMID: 
      29242520
MH  - Alginates/chemistry
MH  - Animals
MH  - Bone Density
MH  - Calcium/chemistry
MH  - Cell Transplantation/methods
MH  - Estrogens/metabolism
MH  - Female
MH  - Granulosa Cells/*transplantation
MH  - Hormone Replacement Therapy/*methods
MH  - Hormones/blood
MH  - Osteocalcin/blood
MH  - Ovary/*cytology
MH  - Primary Ovarian Insufficiency/therapy
MH  - Rats, Inbred F344
MH  - Strontium/chemistry
MH  - Theca Cells/transplantation
MH  - Uterus/physiology
PMC - PMC5717171
COIS- The authors declare that there are two patents associated with the technology 
      described in this paper. The patents are (1) E.C.O., J.J.Y., J.M.S., S.S., A.A. 
      US Patent # 9,283,251 B2; Encapsulated cells for hormone replacement therapy 
      (issue date March 15, 2016) and (2) E.C.O., J.J.Y., J.M.S., S.S., A.A. US Patent 
      # US 9,763,986 B2. Encapsulated cells for hormone replacement therapy (issue date 
      9/19/2017). The remaining authors declare no competing financial interests.
EDAT- 2017/12/07 06:00
MHDA- 2018/09/19 06:00
PMCR- 2017/12/05
CRDT- 2017/12/07 06:00
PHST- 2017/05/15 00:00 [received]
PHST- 2017/10/20 00:00 [accepted]
PHST- 2017/12/07 06:00 [entrez]
PHST- 2017/12/07 06:00 [pubmed]
PHST- 2018/09/19 06:00 [medline]
PHST- 2017/12/05 00:00 [pmc-release]
AID - 10.1038/s41467-017-01851-3 [pii]
AID - 1851 [pii]
AID - 10.1038/s41467-017-01851-3 [doi]
PST - epublish
SO  - Nat Commun. 2017 Dec 5;8(1):1858. doi: 10.1038/s41467-017-01851-3.

PMID- 33081219
OWN - NLM
STAT- MEDLINE
DCOM- 20210225
LR  - 20250103
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 21
IP  - 20
DP  - 2020 Oct 16
TI  - Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in 
      Heregulin-Overexpressing Luminal B-Like Breast Cancer.
LID - 10.3390/ijms21207661 [doi]
LID - 7661
AB  - HER2 transactivation by the HER3 ligand heregulin (HRG) promotes an 
      endocrine-resistant phenotype in the estrogen receptor-positive (ER+) luminal-B 
      subtype of breast cancer. The underlying biological mechanisms that link them 
      are, however, incompletely understood. Here, we evaluated the putative role of 
      the lipogenic enzyme fatty acid synthase (FASN) as a major cause of HRG-driven 
      endocrine resistance in ER+/HER2-negative breast cancer cells. MCF-7 cells 
      engineered to stably overexpress HRG (MCF-7/HRG), an in vitro model of 
      tamoxifen/fulvestrant-resistant luminal B-like breast cancer, showed a pronounced 
      up-regulation of FASN gene/FASN protein expression. Autocrine HRG up-regulated 
      FASN expression via HER2 transactivation and downstream activation of PI-3K/AKT 
      and MAPK-ERK1/2 signaling pathways. The HRG-driven FASN-overexpressing phenotype 
      was fully prevented in MCF-7 cells expressing a structural deletion mutant of HRG 
      that is sequestered in a cellular compartment and lacks the ability to promote 
      endocrine-resistance in an autocrine manner. Pharmacological inhibition of FASN 
      activity blocked the estradiol-independent and tamoxifen/fulvestrant-refractory 
      ability of MCF-7/HRG cells to anchorage-independently grow in soft-agar. In vivo 
      treatment with a FASN inhibitor restored the anti-tumor activity of tamoxifen and 
      fulvestrant against fast-growing, hormone-resistant MCF-7/HRG xenograft tumors in 
      mice. Overall, these findings implicate FASN as a key enabler for endocrine 
      resistance in HRG+/HER2- breast cancer and highlight the therapeutic potential of 
      FASN inhibitors for the treatment of endocrine therapy-resistant luminal-B breast 
      cancer.
FAU - Menendez, Javier A
AU  - Menendez JA
AUID- ORCID: 0000-0001-8733-4561
AD  - Program Against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer 
      Group, Catalan Institute of Oncology, 17007 Girona, Spain.
AD  - Girona Biomedical Research Institute (IDIBGI), 17190 Girona, Spain.
FAU - Mehmi, Inderjit
AU  - Mehmi I
AD  - The Angeles Clinic and Research Institute, Cedar Sinai affiliate, Los Angeles, CA 
      90025, USA.
FAU - Papadimitropoulou, Adriana
AU  - Papadimitropoulou A
AD  - Center of Basic Research, Biomedical Research Foundation of the Academy of 
      Athens, 11527 Athens, Greece.
FAU - Vander Steen, Travis
AU  - Vander Steen T
AD  - Mayo Clinic, Division of Experimental Pathology, Department of Laboratory 
      Medicine and Pathology, Rochester, MN 55905, USA.
FAU - Cuyàs, Elisabet
AU  - Cuyàs E
AD  - Program Against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer 
      Group, Catalan Institute of Oncology, 17007 Girona, Spain.
AD  - Girona Biomedical Research Institute (IDIBGI), 17190 Girona, Spain.
FAU - Verdura, Sara
AU  - Verdura S
AUID- ORCID: 0000-0001-8980-0423
AD  - Program Against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer 
      Group, Catalan Institute of Oncology, 17007 Girona, Spain.
AD  - Girona Biomedical Research Institute (IDIBGI), 17190 Girona, Spain.
FAU - Espinoza, Ingrid
AU  - Espinoza I
AD  - School of Population Health, University of Mississippi Medical Center, Jackson, 
      MS 39216, USA.
AD  - Cancer Institute, School of Medicine, University of Mississippi Medical Center, 
      Jackson, MS 39216, USA.
FAU - Vellon, Luciano
AU  - Vellon L
AD  - Stem Cells Laboratory, Institute of Biology and Experimental Medicine 
      (IBYME-CONICET), Buenos Aires C1428ADN, Argentina.
FAU - Atlas, Ella
AU  - Atlas E
AD  - Environmental Health Science and Research Bureau, Health Canada, Ottawa, ON K1A 
      0K9, Canada.
AD  - Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, 
      Ottawa, ON K1N 6N5, Canada.
FAU - Lupu, Ruth
AU  - Lupu R
AD  - Center of Basic Research, Biomedical Research Foundation of the Academy of 
      Athens, 11527 Athens, Greece.
AD  - Mayo Clinic Minnesota, Department of Biochemistry and Molecular Biology 
      Laboratory, Rochester, MN 55905, USA.
AD  - Mayo Clinic Cancer Center, Rochester, MN 55905, USA.
LA  - eng
GR  - R01 CA116623/NH/NIH HHS/United States
GR  - BC151072/U.S. Department of Defense/
GR  - BC151072P1/U.S. Department of Defense/
GR  - SAF2016-80639-P/Ministerio de Ciencia e Innovación/
GR  - PID2019-10455GB-I00/Ministerio de Ciencia e Innovación/
PT  - Journal Article
DEP - 20201016
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 0 (Proteins)
RN  - 0 (Histidine-Rich Glycoprotein)
RN  - 094ZI81Y45 (Tamoxifen)
RN  - 22X328QOC4 (Fulvestrant)
RN  - EC 2.3.1.85 (FASN protein, human)
RN  - EC 2.3.1.85 (Fatty Acid Synthase, Type I)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents, Hormonal/therapeutic use
MH  - Breast Neoplasms/drug therapy/genetics/*metabolism
MH  - *Drug Resistance, Neoplasm
MH  - Fatty Acid Synthase, Type I/genetics/*metabolism
MH  - Female
MH  - Fulvestrant/therapeutic use
MH  - Humans
MH  - MAP Kinase Signaling System
MH  - MCF-7 Cells
MH  - Mice
MH  - Mice, Nude
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Proteins/genetics/*metabolism
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - Receptor, ErbB-2/genetics
MH  - Tamoxifen/therapeutic use
MH  - Histidine-Rich Glycoprotein
PMC - PMC7588883
OTO - NOTNLM
OT  - endocrine resistance
OT  - fulvestrant
OT  - luminal
OT  - tamoxifen
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2020/10/22 06:00
MHDA- 2021/02/26 06:00
PMCR- 2020/10/01
CRDT- 2020/10/21 01:02
PHST- 2020/09/28 00:00 [received]
PHST- 2020/10/12 00:00 [revised]
PHST- 2020/10/14 00:00 [accepted]
PHST- 2020/10/21 01:02 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2021/02/26 06:00 [medline]
PHST- 2020/10/01 00:00 [pmc-release]
AID - ijms21207661 [pii]
AID - ijms-21-07661 [pii]
AID - 10.3390/ijms21207661 [doi]
PST - epublish
SO  - Int J Mol Sci. 2020 Oct 16;21(20):7661. doi: 10.3390/ijms21207661.

PMID- 37001203
OWN - NLM
STAT- MEDLINE
DCOM- 20230501
LR  - 20250103
IS  - 1873-376X (Electronic)
IS  - 1570-0232 (Linking)
VI  - 1221
DP  - 2023 Apr 15
TI  - Metabolomic analysis of the inhibitory effect of phthalates and bisphenol A on 
      the antioxidant activity of vitamin D in human samples using liquid 
      chromatography-mass spectrometry.
PG  - 123687
LID - S1570-0232(23)00097-1 [pii]
LID - 10.1016/j.jchromb.2023.123687 [doi]
AB  - Vitamin D is important because it has roles in maintaining musculoskeletal 
      health, redox homeostasis, and the immune system; however, it is commonly 
      dysregulated by endocrine disrupting chemicals, particularly phthalates and 
      bisphenol A (BPA). Continuous exposure to phthalates and BPA may alter the 
      endogenous metabolite profiles associated with vitamin D activity, although the 
      specific metabolites are yet to be identified. In this study, we identified the 
      endogenous metabolites altered by phthalates and BPA exposure through untargeted 
      metabolic profiling and investigated the role of these metabolites in vitamin D 
      activity. Plasma metabolic profiling using liquid chromatography-mass 
      spectrometry was performed in two groups: severe 25-hydroxyvitamin D (25(OH)D) 
      deficiency and high exposure to phthalates and BPA (Group A) and 25(OH)D 
      deficiency and low exposure to phthalates and BPA (Group B). Multivariate 
      analysis revealed a distinct separation between the two groups. A total of six 
      metabolites were annotated, of which levels of two were significantly different 
      between the two groups: platelet-activating factor (PAF) C16 or 
      lysophosphatidylcholine (lysoPC) 18:0, and 11Z-eicosenamide. Plasma levels of PAF 
      C16 or lysoPC 18:0 were increased in Group A and exhibited an area under the 
      curve of 0.769 with an accuracy of 74.4% in a receiver operating characteristic 
      curve analysis. These metabolites are generated as byproducts of lipid 
      peroxidation, which supports the fact that phthalates and BPA induce oxidative 
      stress in cells. Furthermore, PAF C16 and lysoPC 18:0 may be involved in the 
      network that interferes with the antioxidant activity of vitamin D upon exposure 
      to phthalates and BPA. This study results provide useful information on how the 
      activity of vitamin D on the antioxidant system is inhibited when exposure to 
      phthalates and BPA.
CI  - Copyright © 2023 Elsevier B.V. All rights reserved.
FAU - Lee, Jae Hwa
AU  - Lee JH
AD  - Department of Molecular Medicine, School of Medicine, Kyungpook National 
      University and Department of Clinical Pharmacology and Therapeutics, Kyungpook 
      National University Hospital, 130 Dongdeok-ro, Jung-gu, Daegu 41944, Republic of 
      Korea; BK21 FOUR KNU Convergence Educational Program of Biomedical Sciences for 
      Creative Future Talents, Department of Molecular Medicine, School of Medicine, 
      Kyungpook National University, 680, Gukchaebosang-ro, Jung-gu, Daegu 41944, 
      Republic of Korea. Electronic address: woghk0202@gmail.com.
FAU - Gwon, Mi-Ri
AU  - Gwon MR
AD  - Department of Molecular Medicine, School of Medicine, Kyungpook National 
      University and Department of Clinical Pharmacology and Therapeutics, Kyungpook 
      National University Hospital, 130 Dongdeok-ro, Jung-gu, Daegu 41944, Republic of 
      Korea; Clinical Omics Institute, School of Medicine, Kyungpook National 
      University, 90, Chilgokjungang-daero 136-gil, Buk-gu, Daegu 41405, Republic of 
      Korea. Electronic address: miri.gwon@gmail.com.
FAU - Park, Ji Seo
AU  - Park JS
AD  - Department of Molecular Medicine, School of Medicine, Kyungpook National 
      University and Department of Clinical Pharmacology and Therapeutics, Kyungpook 
      National University Hospital, 130 Dongdeok-ro, Jung-gu, Daegu 41944, Republic of 
      Korea; BK21 FOUR KNU Convergence Educational Program of Biomedical Sciences for 
      Creative Future Talents, Department of Molecular Medicine, School of Medicine, 
      Kyungpook National University, 680, Gukchaebosang-ro, Jung-gu, Daegu 41944, 
      Republic of Korea. Electronic address: jiseopark1108@gmail.com.
FAU - Lee, Hae Won
AU  - Lee HW
AD  - Department of Molecular Medicine, School of Medicine, Kyungpook National 
      University and Department of Clinical Pharmacology and Therapeutics, Kyungpook 
      National University Hospital, 130 Dongdeok-ro, Jung-gu, Daegu 41944, Republic of 
      Korea. Electronic address: haewonbbc@gmail.com.
FAU - Lee, Duk-Hee
AU  - Lee DH
AD  - Department of Preventive Medicine, School of Medicine, Kyungpook National 
      University, 680, Gukchaebosang-ro, Jung-gu, Daegu 41944, Republic of Korea. 
      Electronic address: lee_dh@knu.ac.kr.
FAU - Yoon, Young-Ran
AU  - Yoon YR
AD  - Department of Molecular Medicine, School of Medicine, Kyungpook National 
      University and Department of Clinical Pharmacology and Therapeutics, Kyungpook 
      National University Hospital, 130 Dongdeok-ro, Jung-gu, Daegu 41944, Republic of 
      Korea; BK21 FOUR KNU Convergence Educational Program of Biomedical Sciences for 
      Creative Future Talents, Department of Molecular Medicine, School of Medicine, 
      Kyungpook National University, 680, Gukchaebosang-ro, Jung-gu, Daegu 41944, 
      Republic of Korea; Clinical Omics Institute, School of Medicine, Kyungpook 
      National University, 90, Chilgokjungang-daero 136-gil, Buk-gu, Daegu 41405, 
      Republic of Korea. Electronic address: yry@knu.ac.kr.
FAU - Seong, Sook Jin
AU  - Seong SJ
AD  - Department of Molecular Medicine, School of Medicine, Kyungpook National 
      University and Department of Clinical Pharmacology and Therapeutics, Kyungpook 
      National University Hospital, 130 Dongdeok-ro, Jung-gu, Daegu 41944, Republic of 
      Korea. Electronic address: wintersj@knu.ac.kr.
LA  - eng
PT  - Journal Article
DEP - 20230321
PL  - Netherlands
TA  - J Chromatogr B Analyt Technol Biomed Life Sci
JT  - Journal of chromatography. B, Analytical technologies in the biomedical and life 
      sciences
JID - 101139554
RN  - 0 (Antioxidants)
RN  - RW57K3X12M (bisphenol A)
RN  - 6O7F7IX66E (phthalic acid)
RN  - 0 (Phthalic Acids)
RN  - 1406-16-2 (Vitamin D)
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Vitamins)
SB  - IM
MH  - Humans
MH  - *Antioxidants/pharmacology
MH  - *Phthalic Acids
MH  - Vitamin D
MH  - Benzhydryl Compounds
MH  - Vitamins
MH  - Chromatography, Liquid
MH  - Mass Spectrometry
OTO - NOTNLM
OT  - Bisphenol A
OT  - Oxidative stress conditions
OT  - Phthalates
OT  - UHPLC-QTOF/MS
OT  - Untargeted metabolomics
OT  - Vitamin D deficiency
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/04/01 06:00
MHDA- 2023/05/01 06:41
CRDT- 2023/03/31 18:00
PHST- 2023/01/11 00:00 [received]
PHST- 2023/02/23 00:00 [revised]
PHST- 2023/03/19 00:00 [accepted]
PHST- 2023/05/01 06:41 [medline]
PHST- 2023/04/01 06:00 [pubmed]
PHST- 2023/03/31 18:00 [entrez]
AID - S1570-0232(23)00097-1 [pii]
AID - 10.1016/j.jchromb.2023.123687 [doi]
PST - ppublish
SO  - J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Apr 15;1221:123687. doi: 
      10.1016/j.jchromb.2023.123687. Epub 2023 Mar 21.

PMID- 26198929
OWN - NLM
STAT- MEDLINE
DCOM- 20151016
LR  - 20181113
IS  - 1872-8421 (Electronic)
IS  - 0165-5728 (Print)
IS  - 0165-5728 (Linking)
VI  - 285
DP  - 2015 Aug 15
TI  - IL-10 producing B cells partially restore E2-mediated protection against EAE in 
      PD-L1 deficient mice.
PG  - 129-36
LID - S0165-5728(15)00159-9 [pii]
LID - 10.1016/j.jneuroim.2015.06.002 [doi]
AB  - Women with multiple sclerosis (MS) often experience clinical improvement during 
      pregnancy, indicating that sex hormones might have therapeutic effects in MS. Our 
      previous studies have demonstrated that B cells and PD-L1 are crucial for E2 
      (17β-estradiol)-mediated protection against experimental autoimmune 
      encephalomyelitis (EAE). We here demonstrate that the transfer of IL-10(+) B 
      cells into E2-treated PD-L1(-/-) mice after EAE induction could partially restore 
      E2-mediated protection and decrease the frequency of pro-inflammatory cells in 
      the CNS compared to E2/saline treated PD-L1(-/-) mice. Hence, co-administration 
      of IL-10(+) B cells and E2 might have a powerful therapeutic potential for 
      treatment of EAE.
CI  - Copyright © 2015 Elsevier B.V. All rights reserved.
FAU - Zhang, Jun
AU  - Zhang J
AD  - Neuroimmunology Research, VA Portland Health Care System, Portland, OR, USA; 
      Department of Neurology, Oregon Health & Science University, Portland, OR, USA. 
      Electronic address: zhanju@ohsu.edu.
FAU - Benedek, Gil
AU  - Benedek G
AD  - Neuroimmunology Research, VA Portland Health Care System, Portland, OR, USA; 
      Department of Neurology, Oregon Health & Science University, Portland, OR, USA. 
      Electronic address: benedek@ohsu.edu.
FAU - Bodhankar, Sheetal
AU  - Bodhankar S
AD  - Neuroimmunology Research, VA Portland Health Care System, Portland, OR, USA; 
      Department of Neurology, Oregon Health & Science University, Portland, OR, USA. 
      Electronic address: bodhanka@ohsu.edu.
FAU - Lapato, Andrew
AU  - Lapato A
AD  - Neuroimmunology Research, VA Portland Health Care System, Portland, OR, USA; 
      Department of Neurology, Oregon Health & Science University, Portland, OR, USA. 
      Electronic address: lapato@ohsu.edu.
FAU - Vandenbark, Arthur A
AU  - Vandenbark AA
AD  - Neuroimmunology Research, VA Portland Health Care System, Portland, OR, USA; 
      Department of Neurology, Oregon Health & Science University, Portland, OR, USA; 
      Department of Molecular Microbiology & Immunology, Oregon Health & Science 
      University, Portland, OR, USA. Electronic address: vandenba@ohsu.edu.
FAU - Offner, Halina
AU  - Offner H
AD  - Neuroimmunology Research, VA Portland Health Care System, Portland, OR, USA; 
      Department of Neurology, Oregon Health & Science University, Portland, OR, USA; 
      Department of Anesthesiology and Perioperative Medicine, Oregon Health & Science 
      University, Portland, OR, USA. Electronic address: offnerva@ohsu.edu.
LA  - eng
GR  - R01 NS080890/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20150611
PL  - Netherlands
TA  - J Neuroimmunol
JT  - Journal of neuroimmunology
JID - 8109498
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Cd274 protein, mouse)
RN  - 0 (IL10 protein, mouse)
RN  - 0 (Neuroprotective Agents)
RN  - 130068-27-8 (Interleukin-10)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Animals
MH  - B-Lymphocytes/immunology/*metabolism/transplantation
MH  - B7-H1 Antigen/*deficiency/immunology
MH  - Encephalomyelitis, Autoimmune, Experimental/immunology/*metabolism/*prevention & 
      control
MH  - Estradiol/pharmacology/*therapeutic use
MH  - Female
MH  - Interleukin-10/*biosynthesis/immunology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Neuroprotective Agents/pharmacology/therapeutic use
PMC - PMC4511855
MID - NIHMS699717
OTO - NOTNLM
OT  - EAE
OT  - Estrogen
OT  - IL-10
OT  - PD-L1
OT  - PD-L2
OT  - Regulatory B cell
COIS- Conflict of interest The authors declare that they have no conflict of interest.
EDAT- 2015/07/23 06:00
MHDA- 2015/10/17 06:00
PMCR- 2016/08/15
CRDT- 2015/07/23 06:00
PHST- 2015/05/20 00:00 [received]
PHST- 2015/06/09 00:00 [accepted]
PHST- 2015/07/23 06:00 [entrez]
PHST- 2015/07/23 06:00 [pubmed]
PHST- 2015/10/17 06:00 [medline]
PHST- 2016/08/15 00:00 [pmc-release]
AID - S0165-5728(15)00159-9 [pii]
AID - 10.1016/j.jneuroim.2015.06.002 [doi]
PST - ppublish
SO  - J Neuroimmunol. 2015 Aug 15;285:129-36. doi: 10.1016/j.jneuroim.2015.06.002. Epub 
      2015 Jun 11.

PMID- 30690247
OWN - NLM
STAT- MEDLINE
DCOM- 20190613
LR  - 20190613
IS  - 1873-264X (Electronic)
IS  - 0731-7085 (Linking)
VI  - 166
DP  - 2019 Mar 20
TI  - Metabolomics profiling provides valuable insights into the underlying mechanisms 
      of Morinda officinalis on protecting glucocorticoid-induced osteoporosis.
PG  - 336-346
LID - S0731-7085(18)31838-7 [pii]
LID - 10.1016/j.jpba.2019.01.019 [doi]
AB  - Morinda officinalis (MO) has long been used as a traditional herbal medicine for 
      the treatment of bone fractures and joint diseases in China. Monotropein (Mon) 
      and rubiadin-1-methyl ether (Rub) are major bioactive components in MO. Ample 
      evidence shows that MO and its chemical constituents can prevent osteoporosis 
      induced by estrogen-deficiency and ageing. However, there is no study reporting 
      glucocorticoid-induced osteoporosis (GIOP). The aim of the present study was to 
      explore the protective effect of MO on GIOP modeled rats and osteoblasts, and 
      elucidate the underlying mechanisms via UHPLC-Q-TOF/MS based metabolomics 
      profiling. Eight weeks after dexamethasone (DEX) injection and MO treatment in 
      female SD rats aged 12 weeks, bone mineral density (BMD), the micro-architecture 
      of the trabecular bone, serum level of bone metabolism markers, and urine 
      metabolomics were assayed in vivo. Cultured osteoblasts were injured with DEX, 
      and the effects of MO, Mon and Rub on osteoblastic proliferation, differentiation 
      and mineralization were examined in vitro. The results showed that MO was able to 
      increase BMD, improve the micro-architecture and intervene bone metabolism via 
      regulating alkaline phosphatase (ALP), tartrate resistant acid phosphatase (TRAP) 
      and c-terminal telopeptides of type I collagen (CTX-I) levels in DEX-treated 
      rats. The in vitro experiment showed that MO, Mon and Rub all increased the cell 
      proliferation and ALP activity, and enhanced extracellular matrix mineralization 
      in DEX-injured osteoblasts. Metabolomics profiling identified a total of 37 
      differential metabolites in DEX group vs. the control group, of which 20 were 
      reversed significantly after MO treatment. Further metabolic pathway enrichment 
      and Western blotting analysis showed that MO prevented bone loss mainly by 
      interfering with arachidonic acid metabolism. These results suggested MO had a 
      notable anti-GIOP effect, and the underlying mechanisms might be related to 
      arachidonic acid metabolism.
CI  - Copyright © 2019 Elsevier B.V. All rights reserved.
FAU - Xia, Tianshuang
AU  - Xia T
AD  - Department of Pharmacognosy, Second Military Medical University School of 
      Pharmacy, Shanghai 200433, China.
FAU - Dong, Xin
AU  - Dong X
AD  - Department of Pharmacognosy, Second Military Medical University School of 
      Pharmacy, Shanghai 200433, China.
FAU - Lin, Liuyue
AU  - Lin L
AD  - Department of Pharmacognosy, Second Military Medical University School of 
      Pharmacy, Shanghai 200433, China.
FAU - Jiang, Yiping
AU  - Jiang Y
AD  - Department of Pharmacognosy, Second Military Medical University School of 
      Pharmacy, Shanghai 200433, China.
FAU - Ma, Xueqin
AU  - Ma X
AD  - Ningxia Engineering and Technology Research Center for Modernization of Hui 
      Medicine, Ningxia Medical University, Yinchuan 750004, China.
FAU - Xin, Hailiang
AU  - Xin H
AD  - Department of Pharmacognosy, Second Military Medical University School of 
      Pharmacy, Shanghai 200433, China. Electronic address: hailiangxin@163.com.
FAU - Zhang, Qiaoyan
AU  - Zhang Q
AD  - Department of Pharmacognosy, Second Military Medical University School of 
      Pharmacy, Shanghai 200433, China; Zhejiang Chinese Medical University School of 
      Pharmacy, Hangzhou 310053, China. Electronic address: zqy1965@163.com.
FAU - Qin, Luping
AU  - Qin L
AD  - Department of Pharmacognosy, Second Military Medical University School of 
      Pharmacy, Shanghai 200433, China; Zhejiang Chinese Medical University School of 
      Pharmacy, Hangzhou 310053, China. Electronic address: qinsmmu@126.com.
LA  - eng
PT  - Journal Article
DEP - 20190114
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Drugs, Chinese Herbal)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 7S5I7G3JQL (Dexamethasone)
SB  - IM
MH  - Animals
MH  - Arachidonic Acid/metabolism
MH  - Bone Density/drug effects
MH  - Cancellous Bone/*drug effects/metabolism
MH  - Cell Proliferation/drug effects
MH  - Cells, Cultured
MH  - Dexamethasone/toxicity
MH  - Disease Models, Animal
MH  - Drugs, Chinese Herbal/administration & dosage/*therapeutic use
MH  - Female
MH  - Metabolic Networks and Pathways/*drug effects
MH  - *Metabolomics
MH  - Morinda/*chemistry
MH  - Osteoblasts/drug effects/metabolism
MH  - Osteoporosis/chemically induced/*drug therapy/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
OTO - NOTNLM
OT  - Arachidonic acid metabolism
OT  - Bone metabolism
OT  - Glucocorticoid-induced osteoporosis
OT  - Metabolomics
OT  - Morinda officinalis
OT  - Osteoblasts
EDAT- 2019/01/29 06:00
MHDA- 2019/06/14 06:00
CRDT- 2019/01/29 06:00
PHST- 2018/08/10 00:00 [received]
PHST- 2018/12/27 00:00 [revised]
PHST- 2019/01/12 00:00 [accepted]
PHST- 2019/01/29 06:00 [pubmed]
PHST- 2019/06/14 06:00 [medline]
PHST- 2019/01/29 06:00 [entrez]
AID - S0731-7085(18)31838-7 [pii]
AID - 10.1016/j.jpba.2019.01.019 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2019 Mar 20;166:336-346. doi: 10.1016/j.jpba.2019.01.019. 
      Epub 2019 Jan 14.

PMID- 37959870
OWN - NLM
STAT- MEDLINE
DCOM- 20231115
LR  - 20231117
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 28
IP  - 21
DP  - 2023 Nov 6
TI  - Identification of the Metabolites of Both Formononetin in Rat Hepatic S9 and 
      Ononin in Rat Urine Samples and Preliminary Network Pharmacology Evaluation of 
      Their Main Metabolites.
LID - 10.3390/molecules28217451 [doi]
LID - 7451
AB  - Astragalus membranaceus is a traditional Chinese medicine derived from the roots 
      of Astragalus membranaceus (Fisch.) Bge., which has the same medicinal and edible 
      uses in China. It is also widely used in daily food, and its pharmacological 
      effects mainly include antioxidant effects, vascular softening effects, etc. 
      Currently, it is increasingly widely used in the prevention of hypertension, 
      cerebral ischemia, and stroke in China. Formononetin and its glucopyranoside 
      (ononin) are both important components of Astragalus membranaceuss and may play 
      important roles in the treatment of cardiovascular diseases (CVDs). This study 
      conducted metabolic studies using formononectin and its glucopyranoside (ononin), 
      including a combination of the in vitro metabolism of Formonetin using rat liver 
      S9 and the in vivo metabolism of ononin administered orally to rats. Five 
      metabolites (Sm2, 7, 9, 10, and 12) were obtained from the solution incubated 
      with formononetin and rat hepatic S9 fraction using chromatographic methods. The 
      structures of the five metabolites were elucidated as 
      (Sm2)6,7,4'-trihydroxy-isoflavonoid; (Sm7)7,4'-dihydroxy-isoflavonoid; 
      (Sm9)7,8,4'-trihydroxy-isoflavonoid; 
      (Sm10)7,8,-dihydroxy-4'-methoxy-isoflavonoid; and (Sm12)6,7-dihydroxy-4'-methoxy- 
      isoflavonoid on the basis of UV, NMR, and MS data. Totally, 14 metabolites were 
      identified via HPLC-DAD-ESI-IT-TOF-MS(n) analysis, from which the formononetin 
      was incubated with rat hepatic S9 fraction, and the main metabolic pathways were 
      hydroxylation, demethylation, and glycosylation. Then, 21 metabolites were 
      identified via HPLC-DAD-ESI-IT-TOF-MS(n) analysis from the urine samples from SD 
      rats to which ononin was orally administered, and the main metabolic pathways 
      were glucuronidation, hydroxylation, demethylation, and sulfonation. The main 
      difference between the in vitro metabolism of formononetin and the in vivo 
      metabolism of ononin is that ononin undergoes deglycemic transformation into 
      Formonetin in the rat intestine, while Formonetin is absorbed into the 
      bloodstream for metabolism, and the metabolic products also produce combined 
      metabolites during in vivo metabolism. The six metabolites obtained from the 
      aforementioned separation indicate the primary forms of formononetin metabolism, 
      and due to their higher contents of similar isoflavone metabolites, they are 
      considered the main active compounds that are responsible for pharmacological 
      effects. To investigate the metabolites of the active ingredients of formononetin 
      in the rat liver S9 system, network pharmacology was used to evaluate the 
      cardiovascular disease (CVD) activities of the six primary metabolites that were 
      structurally identified. Additionally, the macromolecular docking results of six 
      main components and two core targets (HSP90AA1 and SRC) related to CVD showed 
      that formononetin and its main metabolites, Sm10 and Sm12, may have roles in CVD 
      treatment due to their strong binding activities with the HSP90AA1 receptor, 
      while the Sm7 metabolite may have a role in CVD treatment due to its strong 
      binding activity with the SRC receptor.
FAU - Yang, Yu-Zhu
AU  - Yang YZ
AD  - College of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang 
      550025, China.
AD  - School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR 999077, 
      China.
FAU - Wang, Tao
AU  - Wang T
AD  - Departments of, Medicine and Biomedical Engineering, Faculty of Medicine and 
      Health Sciences, McGill University, Montreal, QC H3G1Y6, Canada.
FAU - Chen, Qi-Lei
AU  - Chen QL
AD  - School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR 999077, 
      China.
FAU - Chen, Hu-Biao
AU  - Chen HB
AD  - School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR 999077, 
      China.
FAU - He, Qian-Song
AU  - He QS
AD  - First Clinical Medical College, Guizhou University of Traditional Chinese 
      Medicine, Guiyang 550001, China.
FAU - Zhang, Ya-Zhou
AU  - Zhang YZ
AD  - College of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang 
      550025, China.
AD  - School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR 999077, 
      China.
LA  - eng
GR  - [2018]1071/Guizhou Province, Science and Technology Department, Natural Science 
      Fund, Qiankehe Foundation/
GR  - No. [2020]1Z071/Guizhou Province, Science and Technology Department, Natural 
      Science Fund, Qiankehe Foundation/
GR  - No.2018YFC170810501/Guizhou University of Traditional Chinese Medicine, National 
      Nature Supply Fund/
GR  - (MHP/023/20)/Innovation and Technology Fund in Hong Kong/
PT  - Journal Article
DEP - 20231106
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 295DQC67BJ (formononetin)
RN  - 0 (calycosin-7-O-beta-D-glucoside)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Isoflavones)
SB  - IM
MH  - Rats
MH  - Animals
MH  - Rats, Sprague-Dawley
MH  - *Drugs, Chinese Herbal/chemistry
MH  - Network Pharmacology
MH  - *Isoflavones/chemistry
MH  - Chromatography, High Pressure Liquid/methods
MH  - Liver/metabolism
MH  - *Cardiovascular Diseases
PMC - PMC10648658
OTO - NOTNLM
OT  - HPLC-DAD-ESI-IT-TOF-MSn
OT  - hepatic S9
OT  - network pharmacology
COIS- The authors declare no conflict of interest.
EDAT- 2023/11/14 06:42
MHDA- 2023/11/15 06:42
PMCR- 2023/11/06
CRDT- 2023/11/14 02:16
PHST- 2023/09/09 00:00 [received]
PHST- 2023/10/26 00:00 [revised]
PHST- 2023/10/27 00:00 [accepted]
PHST- 2023/11/15 06:42 [medline]
PHST- 2023/11/14 06:42 [pubmed]
PHST- 2023/11/14 02:16 [entrez]
PHST- 2023/11/06 00:00 [pmc-release]
AID - molecules28217451 [pii]
AID - molecules-28-07451 [pii]
AID - 10.3390/molecules28217451 [doi]
PST - epublish
SO  - Molecules. 2023 Nov 6;28(21):7451. doi: 10.3390/molecules28217451.

PMID- 30387337
OWN - NLM
STAT- MEDLINE
DCOM- 20190211
LR  - 20190215
IS  - 1862-1783 (Electronic)
IS  - 1673-1581 (Print)
IS  - 1673-1581 (Linking)
VI  - 19
IP  - 11
DP  - 2018 Nov.
TI  - Dual flow immunochromatographic assay for rapid and simultaneous quantitative 
      detection of ochratoxin A and zearalenone in corn, wheat, and feed samples.
PG  - 871-883
LID - 10.1631/jzus.B1800085 [doi]
AB  - A one-step dual flow immunochromatographic assay (DICGA), based on a competitive 
      format, was developed for simultaneous quantification of ochratoxin A (OTA) and 
      zearalenone (ZEN) in corn, wheat, and feed samples. The limit of detection for 
      OTA was 0.32 ng/ml with a detection range of 0.53‒12.16 ng/ml, while for ZEN it 
      was 0.58 ng/ml with a detection range of 1.06‒39.72 ng/ml. The recovery rates in 
      corn, wheat, and feed samples ranged from 77.3% to 106.3% with the coefficient of 
      variation lower than 15%. Naturally contaminated corn, wheat, and feed samples 
      were analyzed using both DICGA and liquid chromatography-tandem mass spectrometry 
      (LC-MS/MS) and the correlation between the two methods was evaluated using a 
      regression analysis. The DICGA method shows great potential for simple, rapid, 
      sensitive, and cost-effective quantitative detection of OTA and ZEN in food 
      safety control.
FAU - Zhang, Xian
AU  - Zhang X
AD  - China-Australian Joint Laboratory for Animal Health Big Data Analytics, Zhejiang 
      Provincial Engineering Laboratory for Animal Health Inspection and Internet 
      Technology, College of Animal Science and Technology, Zhejiang A&F University, 
      Lin'an 311300, China.
AD  - Zhejiang University Institute of Preventive Veterinary Medicine, Zhejiang 
      Provincial Key Laboratory of Preventive Veterinary Medicine, Hangzhou 310058, 
      China.
FAU - He, Ke
AU  - He K
AD  - China-Australian Joint Laboratory for Animal Health Big Data Analytics, Zhejiang 
      Provincial Engineering Laboratory for Animal Health Inspection and Internet 
      Technology, College of Animal Science and Technology, Zhejiang A&F University, 
      Lin'an 311300, China.
FAU - Fang, Yun
AU  - Fang Y
AD  - Zhejiang Academy of Science and Technology for Inspection and Quarantine, 
      Hangzhou 310012, China.
FAU - Cao, Tong
AU  - Cao T
AD  - Zhejiang University Institute of Preventive Veterinary Medicine, Zhejiang 
      Provincial Key Laboratory of Preventive Veterinary Medicine, Hangzhou 310058, 
      China.
FAU - Paudyal, Narayan
AU  - Paudyal N
AD  - Zhejiang University Institute of Preventive Veterinary Medicine, Zhejiang 
      Provincial Key Laboratory of Preventive Veterinary Medicine, Hangzhou 310058, 
      China.
FAU - Zhang, Xiao-Feng
AU  - Zhang XF
AD  - Zhejiang Academy of Science and Technology for Inspection and Quarantine, 
      Hangzhou 310012, China.
FAU - Song, Hou-Hui
AU  - Song HH
AD  - China-Australian Joint Laboratory for Animal Health Big Data Analytics, Zhejiang 
      Provincial Engineering Laboratory for Animal Health Inspection and Internet 
      Technology, College of Animal Science and Technology, Zhejiang A&F University, 
      Lin'an 311300, China.
FAU - Li, Xiao-Liang
AU  - Li XL
AD  - Zhejiang University Institute of Preventive Veterinary Medicine, Zhejiang 
      Provincial Key Laboratory of Preventive Veterinary Medicine, Hangzhou 310058, 
      China.
FAU - Fang, Wei-Huan
AU  - Fang WH
AD  - China-Australian Joint Laboratory for Animal Health Big Data Analytics, Zhejiang 
      Provincial Engineering Laboratory for Animal Health Inspection and Internet 
      Technology, College of Animal Science and Technology, Zhejiang A&F University, 
      Lin'an 311300, China.
AD  - Zhejiang University Institute of Preventive Veterinary Medicine, Zhejiang 
      Provincial Key Laboratory of Preventive Veterinary Medicine, Hangzhou 310058, 
      China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - J Zhejiang Univ Sci B
JT  - Journal of Zhejiang University. Science. B
JID - 101236535
RN  - 0 (Colloids)
RN  - 0 (Ochratoxins)
RN  - 1779SX6LUY (ochratoxin A)
RN  - 5W827M159J (Zearalenone)
RN  - 7440-57-5 (Gold)
SB  - IM
MH  - Animal Feed
MH  - Calibration
MH  - Chromatography, Affinity
MH  - Chromatography, Liquid
MH  - Colloids
MH  - Food Contamination/*analysis
MH  - Food Safety
MH  - Gold
MH  - Immunoassay/*methods
MH  - Inhibitory Concentration 50
MH  - Limit of Detection
MH  - Metal Nanoparticles
MH  - Ochratoxins/*analysis
MH  - Regression Analysis
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
MH  - *Triticum
MH  - *Zea mays
MH  - Zearalenone/*analysis
PMC - PMC6238117
OTO - NOTNLM
OT  - Immunochromatographic assay; Gold nanoparticles; Ochratoxin A; Zearalenone; 
      Quantification
COIS- Compliance with ethics guidelines: Xian ZHANG, Ke HE, Yun FANG, Tong CAO, Narayan 
      PAUDYAL, Xiao-feng ZHANG, Hou-hui SONG, Xiao-liang LI, and Wei-huan FANG declare 
      that they have no conflict of interest. This article does not contain any studies 
      with human or animal subjects performed by any of the authors.
EDAT- 2018/11/06 06:00
MHDA- 2019/02/12 06:00
PMCR- 2018/11/01
CRDT- 2018/11/03 06:00
PHST- 2018/11/03 06:00 [entrez]
PHST- 2018/11/06 06:00 [pubmed]
PHST- 2019/02/12 06:00 [medline]
PHST- 2018/11/01 00:00 [pmc-release]
AID - 10.1631/jzus.B1800085 [doi]
PST - ppublish
SO  - J Zhejiang Univ Sci B. 2018 Nov.;19(11):871-883. doi: 10.1631/jzus.B1800085.

PMID- 30315102
OWN - NLM
STAT- MEDLINE
DCOM- 20190429
LR  - 20210205
IS  - 1083-351X (Electronic)
IS  - 0021-9258 (Print)
IS  - 0021-9258 (Linking)
VI  - 293
IP  - 48
DP  - 2018 Nov 30
TI  - Identification of the physiological substrates of PDIp, a pancreas-specific 
      protein-disulfide isomerase family member.
PG  - 18421-18433
LID - 10.1074/jbc.RA118.003694 [doi]
AB  - About 20 members of the protein-disulfide isomerase (PDI) family are present in 
      the endoplasmic reticulum of mammalian cells. They are thought to catalyze 
      thiol-disulfide exchange reactions within secretory or membrane proteins to 
      assist in their folding or to regulate their functions. PDIp is a PDI family 
      member highly expressed in the pancreas and known to bind estrogen in vivo and in 
      vitro However, the physiological functions of PDIp remained unclear. In this 
      study, we set out to identify its physiological substrates. By combining acid 
      quenching and thiol alkylation, we stabilized and purified the complexes formed 
      between endogenous PDIp and its target proteins from the mouse pancreas. MS 
      analysis of these complexes helped identify the disulfide-linked PDIp targets in 
      vivo, revealing that PDIp interacts directly with a number of pancreatic 
      digestive enzymes. Interestingly, when pancreatic elastase, one of the identified 
      proteins, was expressed alone in cultured cells, its proenzyme formed 
      disulfide-linked aggregates within cells. However, when pancreatic elastase was 
      co-expressed with PDIp, the latter prevented the formation of these aggregates 
      and enhanced the production and secretion of proelastase in a form that could be 
      converted to an active enzyme upon trypsin treatment. These findings indicate 
      that the main targets of PDIp are digestive enzymes and that PDIp plays an 
      important role in the biosynthesis of a digestive enzyme by assisting with the 
      proper folding of the proenzyme within cells.
CI  - © 2018 Fujimoto et al.
FAU - Fujimoto, Takushi
AU  - Fujimoto T
AD  - From the Institute of Multidisciplinary Research for Advanced Materials, Tohoku 
      University, Aoba-ku, Sendai, Miyagi 980-8577, Japan.
FAU - Nakamura, Orie
AU  - Nakamura O
AD  - From the Institute of Multidisciplinary Research for Advanced Materials, Tohoku 
      University, Aoba-ku, Sendai, Miyagi 980-8577, Japan.
FAU - Saito, Michiko
AU  - Saito M
AD  - the Graduate School of Biological Sciences, Nara Institute of Science and 
      Technology, Ikoma, Nara 630-0192, Japan.
AD  - the Bio-science Research Center, Kyoto Pharmaceutical University, Misasagi, 
      Yamashina, Kyoto 607-8412, Japan.
FAU - Tsuru, Akio
AU  - Tsuru A
AD  - the Graduate School of Biological Sciences, Nara Institute of Science and 
      Technology, Ikoma, Nara 630-0192, Japan.
FAU - Matsumoto, Masaki
AU  - Matsumoto M
AD  - the Medical Institute of Bioregulation, Kyushu University, Higashi-ku, Fukuoka 
      812-8582, Japan.
FAU - Kohno, Kenji
AU  - Kohno K
AUID- ORCID: 0000-0002-3503-6551
AD  - the Graduate School of Biological Sciences, Nara Institute of Science and 
      Technology, Ikoma, Nara 630-0192, Japan.
AD  - the Institute for Research Initiatives, Nara Institute of Science and Technology, 
      Ikoma, Nara 630-0192, Japan, and.
FAU - Inaba, Kenji
AU  - Inaba K
AD  - From the Institute of Multidisciplinary Research for Advanced Materials, Tohoku 
      University, Aoba-ku, Sendai, Miyagi 980-8577, Japan.
AD  - CREST, Japan Science and Technology Agency (JST), Saitama 332-0012, Japan.
FAU - Kadokura, Hiroshi
AU  - Kadokura H
AUID- ORCID: 0000-0001-7308-7141
AD  - From the Institute of Multidisciplinary Research for Advanced Materials, Tohoku 
      University, Aoba-ku, Sendai, Miyagi 980-8577, Japan, 
      hiroshi.kadokura.b3@tohoku.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20181012
PL  - United States
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
RN  - 0 (Disulfides)
RN  - 0 (Enzyme Precursors)
RN  - 0 (Estrogens)
RN  - EC 3.2.1.1 (alpha-Amylases)
RN  - EC 3.4.21.- (proelastase)
RN  - EC 3.4.21.36 (Pancreatic Elastase)
RN  - EC 5.3.4.1 (Protein Disulfide-Isomerases)
SB  - IM
MH  - Animals
MH  - Disulfides/metabolism
MH  - Enzyme Precursors/biosynthesis
MH  - Estrogens/metabolism
MH  - HeLa Cells
MH  - Humans
MH  - Male
MH  - Mass Spectrometry
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Pancreas/cytology/*enzymology
MH  - Pancreatic Elastase/biosynthesis
MH  - Protein Binding
MH  - Protein Disulfide-Isomerases/*metabolism
MH  - Substrate Specificity
MH  - alpha-Amylases/metabolism
PMC - PMC6290160
OTO - NOTNLM
OT  - PDIp
OT  - biosynthesis
OT  - digestive enzyme
OT  - elastase
OT  - exocrine cells
OT  - pancreas
OT  - proenzyme folding
OT  - protein aggregation
OT  - protein folding
OT  - protein-disulfide isomerase
COIS- The authors declare that they have no conflicts of interest with the contents of 
      this article
EDAT- 2018/10/14 06:00
MHDA- 2019/04/30 06:00
PMCR- 2019/11/30
CRDT- 2018/10/14 06:00
PHST- 2018/04/26 00:00 [received]
PHST- 2018/10/10 00:00 [revised]
PHST- 2018/10/14 06:00 [pubmed]
PHST- 2019/04/30 06:00 [medline]
PHST- 2018/10/14 06:00 [entrez]
PHST- 2019/11/30 00:00 [pmc-release]
AID - S0021-9258(20)31153-4 [pii]
AID - RA118.003694 [pii]
AID - 10.1074/jbc.RA118.003694 [doi]
PST - ppublish
SO  - J Biol Chem. 2018 Nov 30;293(48):18421-18433. doi: 10.1074/jbc.RA118.003694. Epub 
      2018 Oct 12.

PMID- 25541436
OWN - NLM
STAT- MEDLINE
DCOM- 20150421
LR  - 20180603
IS  - 1879-1220 (Electronic)
IS  - 0960-0760 (Linking)
VI  - 147
DP  - 2015 Mar
TI  - 17β-estradiol prevents cardiac diastolic dysfunction by stimulating mitochondrial 
      function: a preclinical study in a mouse model of a human hypertrophic 
      cardiomyopathy mutation.
PG  - 92-102
LID - S0960-0760(14)00317-3 [pii]
LID - 10.1016/j.jsbmb.2014.12.011 [doi]
AB  - OBJECTIVE: We investigated the effect of ovariectomy (OVX) and 17β-estradiol (E2) 
      replacement on both mitochondrial and myocardial function in cTnT-Q92 transgenic 
      mice generated by cardiac-restricted expression of a human hypertrophic 
      cardiomyopathy (HCM) mutation. METHODS: The cTnT-Q92 mice were ovariectomized at 
      twenty weeks of age and were treated with either placebo (OVX group) or E2 
      (OVX+E2 group) for twelve weeks before being sacrificed. Wild-type and cTnT-Q92 
      female mice receiving sham operation were used as controls. Indices of diastolic 
      function such as mitral early (E) and late (A) inflow as well as isovolumic 
      relaxation time (IVRT) were measured by echocardiography. A Clark-type electrode 
      was used to detect respiratory control, and ATP levels were determined at the 
      mitochondrial level using HPLC. Key components related to mitochondrial energy 
      metabolism, such as peroxisome proliferator-activated receptor α (PPARα), PPARγ 
      coactivator 1α (PGC-1α) and nuclear respiratory factor-1 (NRF-1), were also 
      analyzed using Western blot and RT-PCR. The levels of oxidative stress markers 
      were determined by measuring malondialdehyde (MDA) using the thiobarbituric acid 
      assay. RESULTS: The cTnT-Q92 mice had impaired diastolic function compared with 
      wild-type mice (E/A ratio, 1.39 ± 0.04 vs. 1.21 ± 0.01, p<0.001; IVRT, 19.17 ± 
      0.85 vs. 22.15 ± 1.43 ms, p=0.028). In response to ovariectomy, cardiac function 
      further decreased compared with that observed in cTnT-Q92 mice that received the 
      sham operation (E/A ratio, 1.15 ± 0.04 vs. 1.21 ± 0.01, p<0.001; IVRT, 28.31 ± 
      0.39 vs. 22.15 ± 1.43 ms, p=0.002). Myocardial energy metabolism, as determined 
      by ATP levels (3.49 ± 0.31 vs. 5.07 ± 0.47 μmol/g, p<0.001), and the 
      mitochondrial respiratory ratio (2.04 ± 0.10 vs. 2.63 ± 0.11, p=0.01) also 
      decreased significantly. By contrast, myocardial concentrations of MDA increased 
      significantly in the OVX group, and PGC-1α, PPARα and NRF-1decreased 
      significantly. E2 supplementation significantly elevated myocardial ATP levels 
      (4.55 ± 0.21 vs. 3.49 ± 0.31 μmol/g, p=0.003) and mitochondrial respiratory 
      function (3.93 ± 0.05 vs. 2.63 ± 0.11, p=0.001); however, it reduced the MDA 
      level (0.21 ± 0.02 vs. 0.36 ± 0.03 nmol/g, p<0.001), which subsequently improved 
      diastolic function (E/A ratio, 1.35 ± 0.06 vs. 1.15 ± 0.04, p<0.001; IVRT, 18.22 
      ± 1.16 vs. 28.31 ± 0.39 ms, p=0.007). CONCLUSIONS: Our study has shown that 
      17β-estradiol improved myocardial diastolic function, prevented myocardial energy 
      dysregulation, and reduced myocardial oxidative stress in cTnT-Q92 mice.
CI  - Copyright © 2014 Elsevier Ltd. All rights reserved.
FAU - Chen, Youzhou
AU  - Chen Y
AD  - Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai 
      Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical 
      Sciences and Peking Union Medical College, China.
FAU - Zhang, Zhuoli
AU  - Zhang Z
AD  - Department of Radiology, Robert H. Lurie Comprehensive Cancer Center, Feinberg 
      School of Medicine, Northwestern University, 737 N Michigan Ave., 16th Floor, 
      Chicago, USA.
FAU - Hu, Fenghuan
AU  - Hu F
AD  - Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai 
      Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical 
      Sciences and Peking Union Medical College, China.
FAU - Yang, Weixian
AU  - Yang W
AD  - Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai 
      Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical 
      Sciences and Peking Union Medical College, China.
FAU - Yuan, Jiansong
AU  - Yuan J
AD  - Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai 
      Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical 
      Sciences and Peking Union Medical College, China.
FAU - Cui, Jingang
AU  - Cui J
AD  - Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai 
      Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical 
      Sciences and Peking Union Medical College, China.
FAU - Hao, Shujing
AU  - Hao S
AD  - Clinical Laboratory of Zhongke, Beijing, China.
FAU - Hu, Jie
AU  - Hu J
AD  - Clinical Laboratory of Zhongke, Beijing, China.
FAU - Zhou, Ying
AU  - Zhou Y
AD  - Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai 
      Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical 
      Sciences and Peking Union Medical College, China.
FAU - Qiao, Shubin
AU  - Qiao S
AD  - Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai 
      Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical 
      Sciences and Peking Union Medical College, China. Electronic address: 
      qsbfw@sina.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141223
PL  - England
TA  - J Steroid Biochem Mol Biol
JT  - The Journal of steroid biochemistry and molecular biology
JID - 9015483
RN  - 0 (Fatty Acids)
RN  - 0 (PPAR alpha)
RN  - 0 (Troponin T)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Animals
MH  - Cardiomyopathy, Hypertrophic/*drug therapy/*genetics/metabolism/physiopathology
MH  - Disease Models, Animal
MH  - Energy Metabolism/drug effects
MH  - Estradiol/*therapeutic use
MH  - Fatty Acids/metabolism
MH  - Female
MH  - Heart/*drug effects/physiopathology
MH  - Humans
MH  - Mice
MH  - Mice, Transgenic
MH  - Mitochondria/*drug effects/metabolism/pathology/ultrastructure
MH  - Mutation
MH  - Ovariectomy
MH  - Oxidative Stress/drug effects
MH  - PPAR alpha
MH  - Troponin T/*genetics
OTO - NOTNLM
OT  - Energy metabolism
OT  - Estrogen replacement
OT  - Hypertrophic cardiomyopathy
EDAT- 2014/12/30 06:00
MHDA- 2015/04/22 06:00
CRDT- 2014/12/27 06:00
PHST- 2014/11/04 00:00 [received]
PHST- 2014/12/01 00:00 [revised]
PHST- 2014/12/18 00:00 [accepted]
PHST- 2014/12/27 06:00 [entrez]
PHST- 2014/12/30 06:00 [pubmed]
PHST- 2015/04/22 06:00 [medline]
AID - S0960-0760(14)00317-3 [pii]
AID - 10.1016/j.jsbmb.2014.12.011 [doi]
PST - ppublish
SO  - J Steroid Biochem Mol Biol. 2015 Mar;147:92-102. doi: 
      10.1016/j.jsbmb.2014.12.011. Epub 2014 Dec 23.

PMID- 28531801
OWN - NLM
STAT- MEDLINE
DCOM- 20180205
LR  - 20201209
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 92
DP  - 2017 Aug
TI  - ACE-2/Ang1-7/Mas cascade mediates ACE inhibitor, captopril, protective effects in 
      estrogen-deficient osteoporotic rats.
PG  - 58-68
LID - S0753-3322(17)31187-3 [pii]
LID - 10.1016/j.biopha.2017.05.062 [doi]
AB  - The local role of the renin angiotensin system (RAS) was documented recently 
      beside its conventional systemic functions. Studies showed that the effector 
      angiotensin II (AngII) alters bone health, while inhibition of the angiotensin 
      converting enzyme (ACE-1) preserved these effects. The newly identified Ang1-7 
      exerts numerous beneficial effects opposing the AngII. Thus, the current study 
      examines the role of Ang1-7 in mediating the osteo-preservative effects of ACEI 
      (captopril) through the G-protein coupled Mas receptor using an ovariectomized 
      (OVX) rat model of osteoporosis. 8 weeks after the surgical procedures, captopril 
      was administered orally (40mgkg(-1) d(-1)), while the specific Mas receptor 
      blocker (A-779) was delivered at infusion rate of 400ngkg(-1)min(-1) for 6 weeks. 
      Bone metabolic markers were measured in serum and urine. Minerals concentrations 
      were quantified in serum, urine and femoral bones by inductive coupled plasma 
      mass spectroscopy (ICP-MS). Trabecular and cortical morphometry was analyzed in 
      the right distal femurs using micro-CT. Finally, the expressions of RAS peptides, 
      enzymes and receptors along with the receptor activator of NF-κB ligand (RANKL) 
      and osteoprotegerin (OPG) were determined femurs heads. OVX animals markedly 
      showed altered bone metabolism and mineralization along with disturbed bone 
      micro-structure. Captopril significantly restored the metabolic bone bio-markers 
      and corrected Ca(2+) and P values in urine and bones of estrogen deficient rats. 
      Moreover, the trabecular and cortical morphometric features were repaired by 
      captopril in OVX groups. Captopril also improved the expressions of ACE-2, 
      Ang1-7, Mas and OPG, while abolished OVX-induced up-regulation of ACE-1, AngII, 
      Ang type 1 receptor (AT1R) and RANKL. Inhibition of Ang1-7 cascade by A-779 
      significantly eradicated captopril protective effects on bone metabolism, 
      mineralization and micro-structure. A-779 also restored OVX effects on RANKL 
      expression and ACE-1/AngII/AT1R cascade and down-regulated OPG expression and 
      ACE-2/Ang1-7/Mas pathway. In line with the clinical observations of the 
      bone-preservative properties following ACE-1 inhibition, local activation of 
      ACE-2/Ang1-7/Mas signaling and suppressed osteoclastogenesis seem responsible for 
      the osteo-preservative effect of captopril, which could offers a potential 
      therapeutic value in treatment of disabling bone and skeletal muscular diseases.
CI  - Copyright © 2017 Elsevier Masson SAS. All rights reserved.
FAU - Abuohashish, Hatem M
AU  - Abuohashish HM
AD  - Department of Pharmacology and Toxicology, College of Pharmacy, King Saud 
      University, Riyadh, Saudi Arabia; Department of Biomedical Dental Sciences, 
      College of Dentistry, University of Dammam, Dammam, Saudi Arabia. Electronic 
      address: hatem.abuohashish@yahoo.com.
FAU - Ahmed, Mohammed M
AU  - Ahmed MM
AD  - Department of Pharmacology and Toxicology, College of Pharmacy, King Saud 
      University, Riyadh, Saudi Arabia.
FAU - Sabry, Dina
AU  - Sabry D
AD  - Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, 
      Cairo University, Cairo, Egypt.
FAU - Khattab, Mahmoud M
AU  - Khattab MM
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, 
      Cairo, Egypt.
FAU - Al-Rejaie, Salim S
AU  - Al-Rejaie SS
AD  - Department of Pharmacology and Toxicology, College of Pharmacy, King Saud 
      University, Riyadh, Saudi Arabia.
LA  - eng
PT  - Journal Article
DEP - 20170519
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (7-Ala-angiotensin (1-7))
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Biomarkers)
RN  - 0 (Bone Density Conservation Agents)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Peptide Fragments)
RN  - 0 (Receptors, G-Protein-Coupled)
RN  - 11128-99-7 (Angiotensin II)
RN  - 9041-90-1 (Angiotensin I)
RN  - 9G64RSX1XD (Captopril)
RN  - EC 3.4.15.1 (Peptidyl-Dipeptidase A)
RN  - EC 3.4.17.23 (ACE2 protein, human)
RN  - EC 3.4.17.23 (Ace2 protein, rat)
RN  - EC 3.4.17.23 (Angiotensin-Converting Enzyme 2)
RN  - IJ3FUK8MOF (angiotensin I (1-7))
SB  - IM
MH  - Administration, Oral
MH  - Angiotensin I/*antagonists & inhibitors/metabolism
MH  - Angiotensin II/administration & dosage/*analogs & derivatives/toxicity
MH  - Angiotensin-Converting Enzyme 2
MH  - Angiotensin-Converting Enzyme Inhibitors/administration & 
      dosage/chemistry/therapeutic use
MH  - Animals
MH  - Biomarkers/blood/urine
MH  - Bone Density Conservation Agents/administration & dosage/*antagonists & 
      inhibitors/therapeutic use
MH  - Bone and Bones/chemistry/diagnostic imaging/*drug effects/metabolism
MH  - Captopril/administration & dosage/*antagonists & inhibitors/therapeutic use
MH  - Delayed-Action Preparations
MH  - Female
MH  - Femur
MH  - Humans
MH  - Osteolysis/chemically induced/prevention & control
MH  - Osteoporosis, Postmenopausal/chemically induced/diagnostic imaging/*drug 
      therapy/metabolism
MH  - Ovariectomy
MH  - Peptide Fragments/administration & dosage/*antagonists & 
      inhibitors/metabolism/*toxicity
MH  - Peptidyl-Dipeptidase A/chemistry/metabolism
MH  - Rats, Wistar
MH  - Receptors, G-Protein-Coupled/antagonists & inhibitors/metabolism
MH  - Signal Transduction/*drug effects
MH  - Spectrophotometry, Atomic
MH  - X-Ray Microtomography
OTO - NOTNLM
OT  - Ang1-7
OT  - Bone metabolism
OT  - Captopril
OT  - Mas receptor
OT  - Micro-CT
OT  - Minerals
OT  - Osteoclastogenesis
OT  - Ovariectomized
EDAT- 2017/05/23 06:00
MHDA- 2018/02/06 06:00
CRDT- 2017/05/23 06:00
PHST- 2017/03/14 00:00 [received]
PHST- 2017/04/25 00:00 [revised]
PHST- 2017/05/12 00:00 [accepted]
PHST- 2017/05/23 06:00 [pubmed]
PHST- 2018/02/06 06:00 [medline]
PHST- 2017/05/23 06:00 [entrez]
AID - S0753-3322(17)31187-3 [pii]
AID - 10.1016/j.biopha.2017.05.062 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2017 Aug;92:58-68. doi: 10.1016/j.biopha.2017.05.062. Epub 
      2017 May 19.

PMID- 29205599
OWN - NLM
STAT- MEDLINE
DCOM- 20191009
LR  - 20191010
IS  - 1460-9568 (Electronic)
IS  - 0953-816X (Linking)
VI  - 47
IP  - 1
DP  - 2018 Jan
TI  - Postnatal separation prevents the development of prenatal stress-induced anxiety 
      in association with changes in oestrogen receptor and oxytocin immunoreactivity 
      in female mandarin vole (Microtus mandarinus) offspring.
PG  - 95-108
LID - 10.1111/ejn.13788 [doi]
AB  - Oestrogen has both anxiogenic and anxiolytic effects because of variation in 
      opposing action on alpha (ERα) and beta (ERβ) estrogen receptors in the medial 
      preoptic area (mPOA), bed nucleus of the stria terminalis (BNST) and medial 
      amygdala (MeA). Oxytocin (OT) reverses some of the anxiogenic effects of 
      oestrogen in the hypothalamic paraventricular nucleus (PVN) and supraoptic 
      nucleus (SON). Because anxiety disorders are twice as common in women as in men, 
      and oestrogen and OT are more important in females, we examined interactions 
      between prenatal restraint stress (GS) and postnatal early short-term maternal 
      separation (MS) and female mandarin vole behaviour, estrogen receptors and OT. 
      The results show that adult female offspring from GS/noMS mothers showed 
      increased anxiety in open-field and elevated plus-maze tests and had lower serum 
      17-beta-oestradiol (E(2) ) levels than female offspring from GS/MS, noGS/MS and 
      noGS/noMS mothers. GS/noMS females had more immunoreactive neurons for ERα in 
      several brain regions and less ERβ- and OT-immunoreactive neurons in brain areas 
      compared to GS/MS, noGS/MS and noGS/noMS offspring. Interestingly, noGS/MS and 
      GS/MS offspring were similar to noGS/noMS offspring in that they did not develop 
      anxiety as adults. We propose that MS alters the serum concentration of E(2) and 
      that the ERβ/ERα ratio and OT level in the brain may be responsible for the 
      decrease in anxiety-like behaviour in adult female offspring initially exposed to 
      anxiety-inducing conditions via an adverse foetal environment.
CI  - © 2017 Federation of European Neuroscience Societies and John Wiley & Sons Ltd.
FAU - He, Fengqin
AU  - He F
AUID- ORCID: 0000-0002-0127-1115
AD  - Genetic Engineering Laboratory, College of Biological and Environmental 
      Engineering, Xi'an University, Xi'an, Shaanxi, 710065, China.
FAU - Wang, Zijian
AU  - Wang Z
AD  - Genetic Engineering Laboratory, College of Biological and Environmental 
      Engineering, Xi'an University, Xi'an, Shaanxi, 710065, China.
FAU - Guo, Guanlin
AU  - Guo G
AD  - Genetic Engineering Laboratory, College of Biological and Environmental 
      Engineering, Xi'an University, Xi'an, Shaanxi, 710065, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20171219
PL  - France
TA  - Eur J Neurosci
JT  - The European journal of neuroscience
JID - 8918110
RN  - 0 (Receptors, Estrogen)
RN  - 50-56-6 (Oxytocin)
SB  - IM
MH  - Animals
MH  - Anxiety/etiology/*metabolism/physiopathology
MH  - Arvicolinae
MH  - Brain/growth & development/*metabolism/physiopathology
MH  - Female
MH  - *Maternal Deprivation
MH  - Oxytocin/*metabolism
MH  - Pregnancy
MH  - Prenatal Exposure Delayed Effects/*metabolism/physiopathology
MH  - Receptors, Estrogen/*metabolism
MH  - Stress, Psychological/complications/*metabolism/physiopathology
OTO - NOTNLM
OT  - 17-beta-oestradiol
OT  - estrogen receptor alpha
OT  - estrogen receptor beta
OT  - oxytocin
OT  - short-term maternal separation
EDAT- 2017/12/06 06:00
MHDA- 2019/10/11 06:00
CRDT- 2017/12/06 06:00
PHST- 2017/02/06 00:00 [received]
PHST- 2017/11/15 00:00 [revised]
PHST- 2017/11/23 00:00 [accepted]
PHST- 2017/12/06 06:00 [pubmed]
PHST- 2019/10/11 06:00 [medline]
PHST- 2017/12/06 06:00 [entrez]
AID - 10.1111/ejn.13788 [doi]
PST - ppublish
SO  - Eur J Neurosci. 2018 Jan;47(1):95-108. doi: 10.1111/ejn.13788. Epub 2017 Dec 19.

PMID- 28284347
OWN - NLM
STAT- MEDLINE
DCOM- 20170817
LR  - 20181113
IS  - 1872-8421 (Electronic)
IS  - 0165-5728 (Print)
IS  - 0165-5728 (Linking)
VI  - 305
DP  - 2017 Apr 15
TI  - Novel feedback loop between M2 macrophages/microglia and regulatory B cells in 
      estrogen-protected EAE mice.
PG  - 59-67
LID - S0165-5728(16)30431-3 [pii]
LID - 10.1016/j.jneuroim.2016.12.018 [doi]
AB  - Immunoregulatory sex hormones, including estrogen and estriol, may prevent 
      relapses in multiple sclerosis during pregnancy. Our previous studies have 
      demonstrated that regulatory B cells are crucial for estrogen-mediated protection 
      against experimental autoimmune encephalomyelitis (EAE). Herein, we demonstrate 
      an estrogen-dependent induction of alternatively activated (M2) 
      macrophages/microglia that results in an increased frequency of regulatory B 
      cells in the spinal cord of estrogen treated mice with EAE. We further 
      demonstrate that cultured M2-polarized microglia promote the induction of 
      regulatory B cells. Our study suggests that estrogen neuroprotection induces a 
      regulatory feedback loop between M2 macrophages/microglia and regulatory B cells.
CI  - Copyright © 2017 Elsevier B.V. All rights reserved.
FAU - Benedek, Gil
AU  - Benedek G
AD  - Neuroimmunology Research, VA Portland Health Care System, 3710 SW U.S. Veterans 
      Hospital Rd., Portland, OR 97239, USA; Department of Neurology, Oregon Health & 
      Science University, 3181 SW Sam Jackson Park Rd., Portland, OR 97239, USA.
FAU - Zhang, Jun
AU  - Zhang J
AD  - Neuroimmunology Research, VA Portland Health Care System, 3710 SW U.S. Veterans 
      Hospital Rd., Portland, OR 97239, USA; Department of Neurology, Oregon Health & 
      Science University, 3181 SW Sam Jackson Park Rd., Portland, OR 97239, USA.
FAU - Nguyen, Ha
AU  - Nguyen H
AD  - Neuroimmunology Research, VA Portland Health Care System, 3710 SW U.S. Veterans 
      Hospital Rd., Portland, OR 97239, USA; Department of Neurology, Oregon Health & 
      Science University, 3181 SW Sam Jackson Park Rd., Portland, OR 97239, USA.
FAU - Kent, Gail
AU  - Kent G
AD  - Neuroimmunology Research, VA Portland Health Care System, 3710 SW U.S. Veterans 
      Hospital Rd., Portland, OR 97239, USA; Department of Neurology, Oregon Health & 
      Science University, 3181 SW Sam Jackson Park Rd., Portland, OR 97239, USA.
FAU - Seifert, Hilary
AU  - Seifert H
AD  - Neuroimmunology Research, VA Portland Health Care System, 3710 SW U.S. Veterans 
      Hospital Rd., Portland, OR 97239, USA; Department of Neurology, Oregon Health & 
      Science University, 3181 SW Sam Jackson Park Rd., Portland, OR 97239, USA.
FAU - Vandenbark, Arthur A
AU  - Vandenbark AA
AD  - Neuroimmunology Research, VA Portland Health Care System, 3710 SW U.S. Veterans 
      Hospital Rd., Portland, OR 97239, USA; Department of Neurology, Oregon Health & 
      Science University, 3181 SW Sam Jackson Park Rd., Portland, OR 97239, USA; 
      Department of Molecular Microbiology & Immunology, Oregon Health & Science 
      University, 3181 SW Sam Jackson Park Rd., Portland, OR, 97239, USA.
FAU - Offner, Halina
AU  - Offner H
AD  - Neuroimmunology Research, VA Portland Health Care System, 3710 SW U.S. Veterans 
      Hospital Rd., Portland, OR 97239, USA; Department of Neurology, Oregon Health & 
      Science University, 3181 SW Sam Jackson Park Rd., Portland, OR 97239, USA; 
      Department of Anesthesiology and Perioperative Medicine, Oregon Health & Science 
      University, 3181 SW Sam Jackson Park Rd., Portland, OR 97239, USA. Electronic 
      address: offnerva@ohsu.edu.
LA  - eng
GR  - R01 NS080890/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20170128
PL  - Netherlands
TA  - J Neuroimmunol
JT  - Journal of neuroimmunology
JID - 8109498
RN  - 0 (Cytokines)
RN  - 0 (Estrogens)
RN  - 0 (Myelin-Oligodendrocyte Glycoprotein)
RN  - 0 (Peptide Fragments)
RN  - 0 (myelin oligodendrocyte glycoprotein (35-55))
RN  - 130068-27-8 (Interleukin-10)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type II)
RN  - EC 1.14.13.39 (Nos2 protein, mouse)
RN  - EC 3.5.3.1 (Arg1 protein, mouse)
RN  - EC 3.5.3.1 (Arginase)
SB  - IM
MH  - Animals
MH  - Arginase/genetics/metabolism
MH  - B-Lymphocytes, Regulatory/drug effects/*physiology
MH  - Cells, Cultured
MH  - Coculture Techniques
MH  - Cytokines/genetics/metabolism
MH  - Disease Models, Animal
MH  - Encephalomyelitis, Autoimmune, Experimental/*drug therapy/etiology
MH  - Estrogens/*therapeutic use
MH  - Female
MH  - Gene Expression Regulation/drug effects
MH  - Interleukin-10/genetics/metabolism
MH  - Macrophages/drug effects/*physiology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Transgenic
MH  - Microglia/drug effects/*physiology
MH  - Myelin-Oligodendrocyte Glycoprotein/toxicity
MH  - Nitric Oxide Synthase Type II/genetics/metabolism
MH  - Peptide Fragments/toxicity
MH  - Spinal Cord/*pathology
MH  - Spleen/pathology
MH  - Time Factors
PMC - PMC5387865
MID - NIHMS850718
OTO - NOTNLM
OT  - EAE
OT  - Estrogen
OT  - IL-10
OT  - M1/2 microglia
OT  - Regulatory B cells
COIS- Competing interests The authors declare that they have no conflict of interest.
EDAT- 2017/03/13 06:00
MHDA- 2017/08/18 06:00
PMCR- 2018/04/15
CRDT- 2017/03/13 06:00
PHST- 2016/11/29 00:00 [received]
PHST- 2016/12/21 00:00 [revised]
PHST- 2016/12/21 00:00 [accepted]
PHST- 2017/03/13 06:00 [entrez]
PHST- 2017/03/13 06:00 [pubmed]
PHST- 2017/08/18 06:00 [medline]
PHST- 2018/04/15 00:00 [pmc-release]
AID - S0165-5728(16)30431-3 [pii]
AID - 10.1016/j.jneuroim.2016.12.018 [doi]
PST - ppublish
SO  - J Neuroimmunol. 2017 Apr 15;305:59-67. doi: 10.1016/j.jneuroim.2016.12.018. Epub 
      2017 Jan 28.

PMID- 29177998
OWN - NLM
STAT- MEDLINE
DCOM- 20181031
LR  - 20181031
IS  - 1614-7499 (Electronic)
IS  - 0944-1344 (Linking)
VI  - 25
IP  - 4
DP  - 2018 Feb
TI  - Fast trace determination of nine odorant and estrogenic chloro- and 
      bromo-phenolic compounds in real water samples through automated solid-phase 
      extraction coupled with liquid chromatography tandem mass spectrometry.
PG  - 3813-3822
LID - 10.1007/s11356-017-0816-2 [doi]
AB  - A fast and reliable method was developed for simultaneous trace determination of 
      nine odorous and estrogenic chloro- and bromo-phenolic compounds (CPs and BPs) in 
      water samples using solid-phase extraction (SPE) coupled with liquid 
      chromatography tandem mass spectrometry (LC-MS/MS). For sample preparation, the 
      extraction efficiencies of two widely applied cartridges Oasis HLB and Sep-Pak 
      C18 were compared, and the Oasis HLB cartridge showed much better extraction 
      performance; pH of water sample also plays important role on extraction, and 
      pH = 2-3 was found to be most appropriate. For separation of the target 
      compounds, small addition of ammonium hydroxide can obviously improve the 
      detection sensitivity, and the optimized addition concentration was determined as 
      0.2%. The developed efficient method was validated and showed excellent linearity 
      (R (2) > 0.995), low limit of detection (LOD, 1.9-6.2 ng/L), and good recovery 
      efficiencies of 57-95% in surface and tap water with low relative standard 
      deviation (RSD, 1.3-17.4%). The developed method was finally applied to one tap 
      and one surface water samples and most of these nine targets were detected, but 
      all of them were below their odor thresholds, and their estrogen equivalent (EEQ) 
      were also very low.
FAU - Yuan, Su-Fen
AU  - Yuan SF
AD  - School of Environment and Energy, South China University of Technology, 
      Guangzhou, Guangdong, 510006, China.
FAU - Liu, Ze-Hua
AU  - Liu ZH
AUID- ORCID: 0000-0003-3293-5356
AD  - School of Environment and Energy, South China University of Technology, 
      Guangzhou, Guangdong, 510006, China. zehualiu@scut.edu.cn.
AD  - Key Lab Pollution Control & Ecosystem Restoration in Industry Cluster, Ministry 
      of Education, Guangzhou, Guangdong, 510006, China. zehualiu@scut.edu.cn.
AD  - Guangdong Environmental Protection Key Laboratory of Solid Waste Treatment and 
      Recycling, Guangzhou, Guangdong, 510006, China. zehualiu@scut.edu.cn.
AD  - Guangdong Provincial Engineering and Technology Research Center for Environment 
      Risk Prevention and Emergency Disposal, South China University of Technology, 
      Guangzhou, Guangdong, 510006, China. zehualiu@scut.edu.cn.
FAU - Lian, Hai-Xian
AU  - Lian HX
AD  - Center of Water Environmental Monitoring, Guangdong Yue Gang Water Supply Co. 
      LTD, Shenzhen, Guangdong, 518021, China.
AD  - Department of Water Technology Research and Development, Guandong GDH Water Co., 
      LTD, Shenzhen, Guangdong, 518021, China.
FAU - Yang, Chuang-Tao
AU  - Yang CT
AD  - Center of Water Environmental Monitoring, Guangdong Yue Gang Water Supply Co. 
      LTD, Shenzhen, Guangdong, 518021, China.
AD  - Department of Water Technology Research and Development, Guandong GDH Water Co., 
      LTD, Shenzhen, Guangdong, 518021, China.
FAU - Lin, Qing
AU  - Lin Q
AD  - Center of Water Environmental Monitoring, Guangdong Yue Gang Water Supply Co. 
      LTD, Shenzhen, Guangdong, 518021, China.
AD  - Department of Water Technology Research and Development, Guandong GDH Water Co., 
      LTD, Shenzhen, Guangdong, 518021, China.
FAU - Yin, Hua
AU  - Yin H
AD  - School of Environment and Energy, South China University of Technology, 
      Guangzhou, Guangdong, 510006, China.
FAU - Lin, Zhang
AU  - Lin Z
AD  - School of Environment and Energy, South China University of Technology, 
      Guangzhou, Guangdong, 510006, China.
FAU - Dang, Zhi
AU  - Dang Z
AD  - School of Environment and Energy, South China University of Technology, 
      Guangzhou, Guangdong, 510006, China.
LA  - eng
GR  - No.21107025;No.21577040/National Natural Science Foundation of China/
GR  - No. 41330639/National Natural Science Foundation of China/
GR  - u1501234/National Natural Science Foundation of China/
GR  - N0.2015a020215003/Public welfare research and capacity building in Guangdong 
      Province/
GR  - No. 201510010162/Science and Technology Program of Guangzhou/
GR  - No. YGSYBMKY17-N11/Network platform construction on odorous compouds in water/
PT  - Journal Article
DEP - 20171124
PL  - Germany
TA  - Environ Sci Pollut Res Int
JT  - Environmental science and pollution research international
JID - 9441769
RN  - 0 (Endocrine Disruptors)
RN  - 0 (Phenols)
RN  - 0 (Water Pollutants, Chemical)
SB  - IM
MH  - Chromatography, Liquid/methods
MH  - Endocrine Disruptors/*analysis
MH  - Environmental Monitoring/*methods
MH  - Limit of Detection
MH  - Odorants/*analysis
MH  - Phenols/*analysis
MH  - Solid Phase Extraction/methods
MH  - Tandem Mass Spectrometry/methods
MH  - Water Pollutants, Chemical/*analysis
OTO - NOTNLM
OT  - Bromophenols
OT  - Estrogenic chlorophenols
OT  - LC-MS/MS
OT  - Odorant
OT  - SPE
OT  - Surface water
OT  - Tap water
OT  - Trace determination
EDAT- 2017/11/28 06:00
MHDA- 2018/11/01 06:00
CRDT- 2017/11/28 06:00
PHST- 2017/08/07 00:00 [received]
PHST- 2017/11/20 00:00 [accepted]
PHST- 2017/11/28 06:00 [pubmed]
PHST- 2018/11/01 06:00 [medline]
PHST- 2017/11/28 06:00 [entrez]
AID - 10.1007/s11356-017-0816-2 [pii]
AID - 10.1007/s11356-017-0816-2 [doi]
PST - ppublish
SO  - Environ Sci Pollut Res Int. 2018 Feb;25(4):3813-3822. doi: 
      10.1007/s11356-017-0816-2. Epub 2017 Nov 24.

PMID- 34215981
OWN - NLM
STAT- MEDLINE
DCOM- 20211116
LR  - 20250103
IS  - 1614-7499 (Electronic)
IS  - 0944-1344 (Linking)
VI  - 28
IP  - 44
DP  - 2021 Nov
TI  - Association of maternal exposure to bisphenol A with her β-hCG level and neonatal 
      anthropometric measures.
PG  - 62809-62815
LID - 10.1007/s11356-021-15094-9 [doi]
AB  - Bisphenol A (BPA) is one of the organic compounds that might interfere with 
      estrogenic receptors, which would make difficulties in pregnancy hormones and 
      fetal growth. Human chorionic gonadotropin (β-hCG) is one of the important 
      pregnancy hormones that might be affected by environmental pollutants. The aim of 
      this study is to investigate the probable impacts of maternal exposure to BPA on 
      anthropometric measures of newborns. This cross-sectional study was conducted in 
      2019-2020 in Isfahan, Iran. During the first trimester of pregnancy, we measured 
      the urinary BPA concentration and serum β-hCG level of 120 pregnant women, who 
      were randomly selected from participants of a birth cohort. BPA concentration was 
      measured using gas chromatography-mass spectrometry (GC-MS). Serum blood sample 
      was derived and used for β-hCG analysis. Anthropometric measurement of neonates 
      was conducted at the time of birth. BPA and β-hCG level were grouped by 
      quartiles, and their associations with birth weight, height, and head 
      circumference were tested using multiple linear regression model. The adjustment 
      was done for urine creatinine, gender, and gestational age, as well as maternal 
      age, body mass index, and education level. Data of 119 pairs of mothers and 
      infants were available for the present study. The mean (SD) age of mothers was 
      29.19 (5.75) years; 56.3% of newborns were boys. Geometric mean of urinary BPA 
      and β-hCG concentrations were 0.36 ng/g crea. (creatinine) and 17736 mIU/ml, 
      respectively. Across the BPA tertiles, the differences in mean values were not 
      significant for none of the anthropometric measurements and gestational age (GA). 
      Furthermore, no significant association existed between unadjusted and adjusted 
      tertiles of BPA and β-hCG with abovementioned birth outcomes. It seems that the 
      non-significant association found in this study is because of low levels of 
      urinary BPA levels than in other studies; the adverse effects on infants might be 
      related to high concentration of BPA passed from placenta. Future longitudinal 
      studies with large sample size are necessary to document the adverse health 
      effects of maternal exposure to endocrine disruptor chemicals including BPA.
CI  - © 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Amin, Mohammad Mehdi
AU  - Amin MM
AD  - Department of Environmental Health Engineering, School of Health, Isfahan 
      University of Medical Sciences, Isfahan, Iran.
AD  - Environment Research Center, Research Institute for Primordial Prevention of 
      Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran.
FAU - Ghasemi, Zahra
AU  - Ghasemi Z
AUID- ORCID: 0000-0003-0212-3525
AD  - Department of Environmental Health Engineering, School of Health, Isfahan 
      University of Medical Sciences, Isfahan, Iran. zahra.ghasemi93@yahoo.com.
AD  - Student Research Committee, Isfahan University of Medical Sciences, Isfahan, 
      Iran. zahra.ghasemi93@yahoo.com.
FAU - Khoshhali, Mehri
AU  - Khoshhali M
AD  - Department of Pediatrics, Child Growth and Development Research Center, Research 
      Institute for Primordial Prevention of Non-Communicable Disease, Isfahan 
      University of Medical Sciences, Isfahan, Iran.
FAU - Taheri, Ensiyeh
AU  - Taheri E
AD  - Department of Environmental Health Engineering, School of Health, Isfahan 
      University of Medical Sciences, Isfahan, Iran.
AD  - Environment Research Center, Research Institute for Primordial Prevention of 
      Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran.
FAU - Dehdashti, Bahare
AU  - Dehdashti B
AD  - Department of Environmental Health Engineering, School of Health, Isfahan 
      University of Medical Sciences, Isfahan, Iran.
AD  - Student Research Committee, Isfahan University of Medical Sciences, Isfahan, 
      Iran.
FAU - Fatehizadeh, Ali
AU  - Fatehizadeh A
AD  - Department of Environmental Health Engineering, School of Health, Isfahan 
      University of Medical Sciences, Isfahan, Iran.
AD  - Environment Research Center, Research Institute for Primordial Prevention of 
      Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran.
FAU - Rafiei, Nasim
AU  - Rafiei N
AD  - Environment Research Center, Research Institute for Primordial Prevention of 
      Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran.
AD  - Student Research Committee, Isfahan University of Medical Sciences, Isfahan, 
      Iran.
FAU - Kelishadi, Roya
AU  - Kelishadi R
AD  - Department of Pediatrics, Child Growth and Development Research Center, Research 
      Institute for Primordial Prevention of Non-Communicable Disease, Isfahan 
      University of Medical Sciences, Isfahan, Iran.
LA  - eng
GR  - 298144/Isfahan University of Medical Sciences/
PT  - Journal Article
DEP - 20210702
PL  - Germany
TA  - Environ Sci Pollut Res Int
JT  - Environmental science and pollution research international
JID - 9441769
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Phenols)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - Adult
MH  - *Benzhydryl Compounds/analysis
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Male
MH  - *Maternal Exposure
MH  - Phenols/analysis
MH  - Pregnancy
OTO - NOTNLM
OT  - Anthropometry
OT  - Bisphenol A
OT  - Fetus
OT  - HCG-beta
OT  - Urine
EDAT- 2021/07/04 06:00
MHDA- 2021/11/17 06:00
CRDT- 2021/07/03 06:14
PHST- 2021/04/08 00:00 [received]
PHST- 2021/06/20 00:00 [accepted]
PHST- 2021/07/04 06:00 [pubmed]
PHST- 2021/11/17 06:00 [medline]
PHST- 2021/07/03 06:14 [entrez]
AID - 10.1007/s11356-021-15094-9 [pii]
AID - 10.1007/s11356-021-15094-9 [doi]
PST - ppublish
SO  - Environ Sci Pollut Res Int. 2021 Nov;28(44):62809-62815. doi: 
      10.1007/s11356-021-15094-9. Epub 2021 Jul 2.

PMID- 28395354
OWN - NLM
STAT- MEDLINE
DCOM- 20171204
LR  - 20250103
IS  - 2398-7316 (Electronic)
IS  - 2398-7308 (Print)
IS  - 2398-7308 (Linking)
VI  - 61
IP  - 2
DP  - 2017 Mar 1
TI  - Urinary Bisphenol A (BPA) Concentrations among Workers in Industries that 
      Manufacture and Use BPA in the USA.
PG  - 164-182
LID - 10.1093/annweh/wxw021 [doi]
AB  - BACKGROUND: Bisphenol A (BPA) toxicity and exposure risk to humans has been the 
      subject of considerable scientific debate; however, published occupational 
      exposure data for BPA are limited. METHODS: In 2013-2014, 77 workers at six US 
      companies making BPA, BPA-based resins, or BPA-filled wax provided seven urine 
      samples over two consecutive work days (151 worker-days, 525 samples). 
      Participant information included industry, job, tasks, personal protective 
      equipment used, hygiene behaviors, and canned food/beverage consumption. Total 
      (free plus conjugated) BPA, quantified in urine by mass spectrometry, was 
      detected in all samples. RESULTS: The geometric mean (GM) creatinine-adjusted 
      total BPA (total BPACR) concentration was 88.0 µg g-1 (range 0.78-18900 µg g-1), 
      ~70 times higher than in US adults in 2013-2014 (1.27 µg g-1). GM total BPACR 
      increased during Day 1 (26.6-127 µg g-1), decreased by pre-shift Day 2 (84.4 µg 
      g-1) then increased during Day 2 to 178 µg g-1. By industry, baseline and 
      post-baseline total BPACR was highest in BPA-filled wax manufacturing/reclaim (GM 
      = 111 µg g-1) and lowest in phenolic resin manufacturing (GM = 6.56 µg g-1). By 
      job, total BPACR was highest at baseline in maintenance workers (GM = 157 µg g-1) 
      and post-baseline in those working with molten BPA-filled wax (GM = 441 µg g-1). 
      Workers in the job of flaking a BPA-based resin had the lowest concentrations at 
      baseline (GM = 4.81 µg g-1) and post-baseline (GM = 23.2 µg g-1). In multiple 
      regression models, at baseline, industry significantly predicted increased total 
      BPACR (P = 0.0248); post-baseline, handling BPA containers (P = 0.0035), taking 
      ≥3 process/bulk samples with BPA (P = 0.0002) and wearing a Tyvek® coverall (P = 
      0.0042) significantly predicted increased total BPACR (after adjusting for total 
      BPACR at baseline, time point, and body mass index). CONCLUSION: Several 
      work-related factors, including industry, job, and certain tasks performed, were 
      associated with increased urinary total BPACR concentrations in this group of 
      manufacturing workers. The potential for BPA-related health effects among these 
      workers is unknown.
CI  - Published by Oxford University Press on behalf of the British Occupational 
      Hygiene Society 2017.
FAU - Hines, Cynthia J
AU  - Hines CJ
AD  - National Institute for Occupational Safety and Health, 1090 Tusculum Ave, R-14, 
      Cincinnati, OH 45226, USA.
FAU - Jackson, Matthew V
AU  - Jackson MV
AD  - URS Professional Solutions/RCS Corporation, 2131 S. Centennial Ave, Aiken, SC 
      29803, USA.
FAU - Deddens, James A
AU  - Deddens JA
AD  - National Institute for Occupational Safety and Health, 1090 Tusculum Ave, R-14, 
      Cincinnati, OH 45226, USA.
FAU - Clark, John C
AU  - Clark JC
AD  - National Institute for Occupational Safety and Health, 1090 Tusculum Ave, R-14, 
      Cincinnati, OH 45226, USA.
FAU - Ye, Xiaoyun
AU  - Ye X
AD  - National Center for Environmental Health, Centers for Disease Control and 
      Prevention, 4770 Buford Hwy. MS F17, Atlanta, GA 30341, USA.
FAU - Christianson, Annette L
AU  - Christianson AL
AD  - National Institute for Occupational Safety and Health, 1090 Tusculum Ave, R-14, 
      Cincinnati, OH 45226, USA.
FAU - Meadows, Juliana W
AU  - Meadows JW
AD  - National Institute for Occupational Safety and Health, 1090 Tusculum Ave, R-14, 
      Cincinnati, OH 45226, USA.
FAU - Calafat, Antonia M
AU  - Calafat AM
AD  - National Center for Environmental Health, Centers for Disease Control and 
      Prevention, 4770 Buford Hwy. MS F17, Atlanta, GA 30341, USA.
LA  - eng
GR  - CC999999/Intramural CDC HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Ann Work Expo Health
JT  - Annals of work exposures and health
JID - 101698454
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Phenols)
RN  - 0 (Polymers)
RN  - 1HG84L3525 (Formaldehyde)
RN  - 9003-35-4 (phenol-formaldehyde resin)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - Adult
MH  - Benzhydryl Compounds/*urine
MH  - Female
MH  - Formaldehyde
MH  - Humans
MH  - Male
MH  - Occupational Exposure/*analysis
MH  - *Occupations
MH  - Phenols/*urine
MH  - Polymers
MH  - United States
PMC - PMC5577557
MID - NIHMS897393
OTO - NOTNLM
OT  - biological monitoring
OT  - bisphenol A
OT  - determinants of exposure
OT  - exposure assessment
OT  - occupational groups
OT  - reproductive health
OT  - urine analysis
EDAT- 2017/04/11 06:00
MHDA- 2017/12/05 06:00
PMCR- 2018/03/01
CRDT- 2017/04/11 06:00
PHST- 2016/08/02 00:00 [received]
PHST- 2016/11/28 00:00 [accepted]
PHST- 2017/04/11 06:00 [entrez]
PHST- 2017/04/11 06:00 [pubmed]
PHST- 2017/12/05 06:00 [medline]
PHST- 2018/03/01 00:00 [pmc-release]
AID - 2769471 [pii]
AID - wxw021 [pii]
AID - 10.1093/annweh/wxw021 [doi]
PST - ppublish
SO  - Ann Work Expo Health. 2017 Mar 1;61(2):164-182. doi: 10.1093/annweh/wxw021.

PMID- 31004886
OWN - NLM
STAT- MEDLINE
DCOM- 20190919
LR  - 20220408
IS  - 1618-095X (Electronic)
IS  - 0944-7113 (Linking)
VI  - 59
DP  - 2019 Jun
TI  - Zhixiong Capsule (ZXC), a traditional Chinese patent medicine, prevents 
      atherosclerotic plaque formation in rabbit carotid artery and the related 
      mechanism investigation based on network pharmacology and biological research.
PG  - 152776
LID - S0944-7113(18)30594-4 [pii]
LID - 10.1016/j.phymed.2018.11.036 [doi]
AB  - BACKGROUND AND AIMS: Chinese patent medicine Zhixiong Capsule (ZXC) has been used 
      in clinical treatment against blood stasis-induced dizziness and headache for 
      many years in China. HYPOTHESIS/PURPOSE: Recent clinical observations 
      demonstrated a good efficacy of ZXC against atherosclerotic plaque formation in 
      carotid arteries. The aims of this study were to verify the plaque-preventing 
      efficacy of ZXC in animals and to investigate the underlying mechanisms. STUDY 
      DESIGN/METHODS: ZXC (185 mg/kg and 370 mg/kg) was administrated to rabbits which 
      received collar implantation accompanied with high fat diet administration (12 
      days). The blood-dissolved components of ZXC were identified by an UPLC-QTOF-MS 
      method. The key components and targets of ZXC were then predicted based on 
      network pharmacology analysis and biological investigations. RESULTS: Compared 
      with vehicle control group, ZXC administration (185 mg/kg) significantly 
      prevented plaque formation and attenuated intima thickening in the 
      collar-implanted carotid arteries, markedly decreased blood lipid level, and 
      increased plasma IL-4 level in rabbits. A total of 23 blood-dissolved components 
      were identified. Four ingredients (namely, kaempferol, daidzein, puerarin, 
      miltirone) along with leech, and three targets (namely, JUN, FOS and TP53) were 
      recognized to play important roles for ZXC bioactivity. CONCLUSION: It could be 
      concluded that ZXC could be applied to prevent atherosclerotic plaque formation 
      and intimal thickening in carotid arteries at the current clinical dose.
CI  - Copyright © 2018. Published by Elsevier GmbH.
FAU - Zhai, Jianxiu
AU  - Zhai J
AD  - School of Traditional Chinese Material, Shenyang Pharmaceutical University, 
      Shenyang 110016, China.
FAU - Song, Zehai
AU  - Song Z
AD  - School of Traditional Chinese Material, Shenyang Pharmaceutical University, 
      Shenyang 110016, China.
FAU - Wang, Yuwei
AU  - Wang Y
AD  - School of Traditional Chinese Material, Shenyang Pharmaceutical University, 
      Shenyang 110016, China.
FAU - Han, Mingshu
AU  - Han M
AD  - School of Traditional Chinese Material, Shenyang Pharmaceutical University, 
      Shenyang 110016, China.
FAU - Ren, Zhaohui
AU  - Ren Z
AD  - School of Traditional Chinese Material, Shenyang Pharmaceutical University, 
      Shenyang 110016, China.
FAU - Han, Na
AU  - Han N
AD  - School of Traditional Chinese Material, Shenyang Pharmaceutical University, 
      Shenyang 110016, China.
FAU - Liu, Zhihui
AU  - Liu Z
AD  - School of Traditional Chinese Material, Shenyang Pharmaceutical University, 
      Shenyang 110016, China.
FAU - Yin, Jun
AU  - Yin J
AD  - School of Traditional Chinese Material, Shenyang Pharmaceutical University, 
      Shenyang 110016, China. Electronic address: yinjun826@126.com.
LA  - eng
PT  - Journal Article
DEP - 20181207
PL  - Germany
TA  - Phytomedicine
JT  - Phytomedicine : international journal of phytotherapy and phytopharmacology
JID - 9438794
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Isoflavones)
RN  - 0 (Kaempferols)
RN  - 207137-56-2 (Interleukin-4)
RN  - 6287WC5J2L (daidzein)
RN  - Z9W8997416 (puerarin)
SB  - IM
MH  - Animals
MH  - Cardiovascular Agents/*chemistry/*pharmacology
MH  - Carotid Arteries/drug effects/*pathology
MH  - Interleukin-4/blood
MH  - Isoflavones/analysis
MH  - Kaempferols/analysis
MH  - Leeches
MH  - Male
MH  - Medicine, Chinese Traditional
MH  - Plaque, Atherosclerotic/*prevention & control
MH  - Rabbits
OTO - NOTNLM
OT  - Atherosclerotic plaque
OT  - FOS
OT  - JUN
OT  - Network pharmacology
OT  - TP53
OT  - Zhixiong Capsule
EDAT- 2019/04/21 06:00
MHDA- 2019/09/20 06:00
CRDT- 2019/04/21 06:00
PHST- 2018/10/15 00:00 [received]
PHST- 2018/11/28 00:00 [revised]
PHST- 2018/11/30 00:00 [accepted]
PHST- 2019/04/21 06:00 [pubmed]
PHST- 2019/09/20 06:00 [medline]
PHST- 2019/04/21 06:00 [entrez]
AID - S0944-7113(18)30594-4 [pii]
AID - 10.1016/j.phymed.2018.11.036 [doi]
PST - ppublish
SO  - Phytomedicine. 2019 Jun;59:152776. doi: 10.1016/j.phymed.2018.11.036. Epub 2018 
      Dec 7.

PMID- 27156842
OWN - NLM
STAT- MEDLINE
DCOM- 20170504
LR  - 20250103
IS  - 1096-0953 (Electronic)
IS  - 0013-9351 (Linking)
VI  - 150
DP  - 2016 Oct
TI  - A study on phthalate metabolites, bisphenol A and nonylphenol in the urine of 
      Chinese women with unexplained recurrent spontaneous abortion.
PG  - 622-628
LID - S0013-9351(16)30127-X [pii]
LID - 10.1016/j.envres.2016.04.003 [doi]
AB  - Humans are widely exposed to phthalates, bisphenol A and nonylphenol owing to the 
      ubiquitous use of these chemicals in consumer products. Increasing attention has 
      been paid to exposure to phthalates, bisphenol A and nonylphenol because of their 
      potential adverse effects on human fertility. A validated method was developed to 
      investigate the three classes of environmental estrogen, mentioned above, in the 
      urine of Chinese women of Nanjing area with unexplained recurrent spontaneous 
      abortion. Solid-phase extraction coupled with ultra performance liquid 
      chromatography-tandem mass spectrometry (UPLC-MS/MS) was used. In this method, 
      amounts of bisphenol A (BPA), nonylphenol (NP) and four phthalate metabolites, 
      mono-n-butyl phthalate (MBP), mono-isobutyl phthalate (MiBP), mono-benzyl 
      phthalate (MBzP) and mono-2-ethylhexyl phthalate (MEHP), along with their isotope 
      labeled internal standards, were measured using UPLC-MS/MS operated in negative 
      electrospray ionization multiple reaction monitoring mode. The limits of 
      detection were 0.3ng/mL for the four phthalate metabolites, and 0.5ng/mL for 
      bisphenol A and nonylphenol. For women with unexplained recurrent spontaneous 
      abortion, the mean concentrations of MBP, MiBP, MBzP, MEHP, BPA and 4-n-NP were 
      6.52±6.04, 5.51±4.19, 0.53±0.42, 10.12±4.16, 7.13±7.42, 0.41±0.49ng/mL (mean±SD), 
      respectively. For the control group, the mean concentrations of the corresponding 
      analytes were 4.15±3.57, 2.96±3.30, 0.46±0.49, 6.50±2.81, 
      4.43±2.23,0.48±0.43ng/mL (mean±SD), respectively. Levels of MiBP and MEHP were 
      significantly different between the two groups, using Wilcoxon rank sum tests. 
      This method can be applied in epidemiological studies to explore the association 
      between exposure to environmental estrogens and relevant adverse outcomes.
CI  - Copyright © 2016 Elsevier Inc. All rights reserved.
FAU - Peng, Fanli
AU  - Peng F
AD  - Key Laboratory of Environmental Medicine Engineering, Ministry of Education, 
      School of Public Health, Southeast University, Nanjing 210009, China.
FAU - Ji, Wenliang
AU  - Ji W
AD  - Jiangsu Center for Disease Control and Prevention, Nanjing 210009, China.
FAU - Zhu, Feng
AU  - Zhu F
AD  - Jiangsu Center for Disease Control and Prevention, Nanjing 210009, China.
FAU - Peng, Danhong
AU  - Peng D
AD  - Department of Obstetrics and Gynecology, Zhong Da Hospital, School of Medicine, 
      Southeast University, Nanjing 210009, China.
FAU - Yang, Miao
AU  - Yang M
AD  - Key Laboratory of Environmental Medicine Engineering, Ministry of Education, 
      School of Public Health, Southeast University, Nanjing 210009, China.
FAU - Liu, Ran
AU  - Liu R
AD  - Key Laboratory of Environmental Medicine Engineering, Ministry of Education, 
      School of Public Health, Southeast University, Nanjing 210009, China.
FAU - Pu, Yuepu
AU  - Pu Y
AD  - Key Laboratory of Environmental Medicine Engineering, Ministry of Education, 
      School of Public Health, Southeast University, Nanjing 210009, China.
FAU - Yin, Lihong
AU  - Yin L
AD  - Key Laboratory of Environmental Medicine Engineering, Ministry of Education, 
      School of Public Health, Southeast University, Nanjing 210009, China. Electronic 
      address: lhyin@seu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160503
PL  - Netherlands
TA  - Environ Res
JT  - Environmental research
JID - 0147621
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Environmental Pollutants)
RN  - 0 (Phenols)
RN  - 0 (Phthalic Acids)
RN  - 79F6A2ILP5 (nonylphenol)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - Abortion, Spontaneous/*urine
MH  - Adult
MH  - Benzhydryl Compounds/*urine
MH  - China
MH  - Chromatography, Liquid/methods
MH  - Environmental Pollutants/*urine
MH  - Female
MH  - Humans
MH  - Phenols/*urine
MH  - Phthalic Acids/*urine
MH  - Pregnancy
MH  - Recurrence
MH  - Tandem Mass Spectrometry
MH  - Young Adult
OTO - NOTNLM
OT  - Bisphenol A
OT  - Nonylphenol
OT  - Phthalate metabolites
OT  - UPLC-MS/MS
OT  - Unexplained recurrent spontaneous abortion
EDAT- 2016/05/10 06:00
MHDA- 2017/05/05 06:00
CRDT- 2016/05/10 06:00
PHST- 2015/08/13 00:00 [received]
PHST- 2016/03/28 00:00 [revised]
PHST- 2016/04/02 00:00 [accepted]
PHST- 2016/05/10 06:00 [entrez]
PHST- 2016/05/10 06:00 [pubmed]
PHST- 2017/05/05 06:00 [medline]
AID - S0013-9351(16)30127-X [pii]
AID - 10.1016/j.envres.2016.04.003 [doi]
PST - ppublish
SO  - Environ Res. 2016 Oct;150:622-628. doi: 10.1016/j.envres.2016.04.003. Epub 2016 
      May 3.

PMID- 33785318
OWN - NLM
STAT- MEDLINE
DCOM- 20211027
LR  - 20211027
IS  - 1879-0518 (Electronic)
IS  - 0010-7824 (Linking)
VI  - 104
IP  - 3
DP  - 2021 Sep
TI  - Segesterone acetate serum levels with a regression model of continuous use of the 
      segesterone acetate/ethinyl estradiol contraceptive vaginal system.
PG  - 229-234
LID - S0010-7824(21)00096-2 [pii]
LID - 10.1016/j.contraception.2021.03.024 [doi]
AB  - OBJECTIVE: To predict serum segesterone (SA) and ethinyl estradiol (EE) levels 
      after 364 days of hypothetical continuous use (without removal) of a cyclic 
      contraceptive vaginal system (CVS) containing 0.15 mg SA and 0.013 mg EE. STUDY 
      DESIGN: We used pharmacokinetic (PK) data (n = 37) from a multicenter, 
      open-label, nonrandomized study of healthy women (18-38 years) that used the CVS 
      for 13 cycles in a 21 days-in/7 days-out regimen to develop a linear regression 
      model to predict daily serum SA and EE levels for 364 days of continuous CVS use. 
      We then determined residual SA/EE levels in vitro from 18 randomly chosen CVS 
      used by women who completed 13 cycles. Serum SA and EE levels were also predicted 
      for 364 days of continuous CVS use in another in vitro study. RESULTS: After a 
      hypothetical 364 days of continuous CVS use, we predicted daily mean serum levels 
      to be 184 pmol/L (95% confidence interval [CI], 102‒332 pmol/L) for SA and 43 
      pmol/L (95% CI, 19‒95 pmol/L) for EE. We did predict that serum EE levels would 
      not accumulate over time. Residual SA and EE in the CVS were 60% and 80% of the 
      original load after 13 cycles, respectively. CONCLUSION: The predicted serum SA 
      level after 364 days of hypothetical continuous CVS use was comparable to 
      reported levels at which no pregnancy occurred (>100 pmol/L), showing the 
      potential of the CVS for one year of continuous use. Clinical trials on 
      continuous CVS use are planned. IMPLICATIONS: Based on statistical modeling, the 
      long-term, user-controlled contraceptive vaginal system containing segesterone 
      acetate and ethinyl estradiol may have the potential to provide effective 
      pregnancy prevention if used continuously (without removal) for one year. Further 
      investigation is warranted.
CI  - Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Liu, James H
AU  - Liu JH
AD  - University Hospitals Cleveland Medical Center, Cleveland, OH, United States. 
      Electronic address: james.liu@uhhospitals.org.
FAU - Plagianos, Marlena
AU  - Plagianos M
AD  - Population Council, New York, NY, United States.
FAU - Archer, David F
AU  - Archer DF
AD  - Clinical Research Center, Department of Obstetrics and Gynecology, Eastern 
      Virginia Medical School, Norfolk, VA, United States.
FAU - Simon, James A
AU  - Simon JA
AD  - George Washington University, School of Medicine, IntimMedicine Specialists, 
      Washington, DC, United States.
FAU - Kaunitz, Andrew M
AU  - Kaunitz AM
AD  - Department of Obstetrics and Gynecology, University of Florida College of 
      Medicine-Jacksonville, Jacksonville, FL, United States.
FAU - Graham, Shelli
AU  - Graham S
AD  - TherapeuticsMD, Boca Raton, FL, United States.
FAU - Bernick, Brian
AU  - Bernick B
AD  - TherapeuticsMD, Boca Raton, FL, United States.
FAU - Mirkin, Sebastian
AU  - Mirkin S
AD  - TherapeuticsMD, Boca Raton, FL, United States.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20210327
PL  - United States
TA  - Contraception
JT  - Contraception
JID - 0234361
RN  - 0 (Contraceptive Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (Pregnenediones)
RN  - 0 (segesterone acetate and ethinyl estradiol vaginal system)
RN  - 423D2T571U (Ethinyl Estradiol)
SB  - IM
MH  - Contraceptive Agents
MH  - *Contraceptive Devices, Female
MH  - Drug Combinations
MH  - Ethinyl Estradiol
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - *Pregnenediones
OTO - NOTNLM
OT  - Continuous use
OT  - Contraceptive vaginal system
OT  - Pharmacokinetics
OT  - Segesterone acetate
OT  - Serum level
OT  - Statistical model
COIS- Declaration of competing interest Dr. Liu consults for Allergan, AMAG, Bayer 
      Healthcare, Daré, Ferring, Lupin, Mitsubishi-Tanabe, Sebela, and TherapeuticsMD 
      and has received research support for clinical trials (paid to UH Cleveland 
      Medical Center) from AbbVie, Allergan, Bayer Healthcare, Femasys, Ferring, and 
      Palatin Technologies. Ms. Plagianos is an employee of Population Council. Dr. 
      Archer has served as a consultant to AbbVie, Agile Therapeutics, Bayer 
      Healthcare, Endoceutics, Evestra, Exeltis, InnovaGyn, Lupin, Mithra, OvsEva and 
      TherapeuticsMD; and has received research support from Actavis, Bayer Healthcare, 
      Endoceutics, Mithra, Myovant, ObsEva and TherapeuticsMD. He has stock in 
      InnovaGyn and stock options from Agile Therapeutics. Dr. Simon (within the past 
      year, or current) has grant/research support from: AbbVie, Inc., Bayer Healthcare 
      LLC., Endoceutics, Inc., Ipsen, Myovant Sciences, ObsEva SA, TherapeuticsMD, 
      Viveve Medical; has been a consultant/advisory boards of: Allergan, AbbVie, Inc., 
      AMAG Pharmaceuticals, Inc., Bayer HealthCare Pharmaceuticals Inc., Camargo 
      Pharmaceutical Services, LLC, CEEK Enterprises, LLC., Covance Inc., Dare´ 
      Bioscience, Duchesnay USA, Hologic Inc., KaNDy/NeRRe Therapeutics Ltd., Madorra 
      Pty Ltd., Mitsubishi Tanabe Pharma Development America, Inc., Sebela 
      Pharmaceuticals Inc., Shionogi Inc., Sprout2 Inc., TherapeuticsMD; has served on 
      the Speaker’s bureaus of: AMAG Pharmaceuticals, Inc., Duchesnay USA, 
      TherapeuticsMD; and is a stockholder (direct purchase) in: Sermonix 
      Pharmaceuticals. Dr. Kaunitz has served as a consultant to or on the advisory 
      board of AMAG, Mithra and Pfizer; and has received research support (to 
      University of FL) from Allergan, Bayer Healthcare, and TherapeuticsMD. Drs. 
      Graham, Bernick, and Mirkin are employees of TherapeuticsMD with stock/stock 
      options.
EDAT- 2021/04/01 06:00
MHDA- 2021/10/28 06:00
CRDT- 2021/03/31 05:52
PHST- 2020/12/15 00:00 [received]
PHST- 2021/03/18 00:00 [revised]
PHST- 2021/03/22 00:00 [accepted]
PHST- 2021/04/01 06:00 [pubmed]
PHST- 2021/10/28 06:00 [medline]
PHST- 2021/03/31 05:52 [entrez]
AID - S0010-7824(21)00096-2 [pii]
AID - 10.1016/j.contraception.2021.03.024 [doi]
PST - ppublish
SO  - Contraception. 2021 Sep;104(3):229-234. doi: 10.1016/j.contraception.2021.03.024. 
      Epub 2021 Mar 27.

PMID- 38647648
OWN - NLM
STAT- MEDLINE
DCOM- 20240530
LR  - 20240530
IS  - 1362-3095 (Electronic)
IS  - 0955-3002 (Linking)
VI  - 100
IP  - 6
DP  - 2024
TI  - Comparative study of the anti-inflammatory activity of etoricoxib and Matcha 
      green tea against acute kidney injury induced by gamma radiation in rats.
PG  - 940-964
LID - 10.1080/09553002.2024.2338515 [doi]
AB  - PURPOSE: The primary objective of this study was to conduct a comparative 
      analysis of the anti-inflammatory activity between Etoricoxib (ETO) and Matcha 
      green tea (MG) in the context of acute kidney injury (AKI) induced by ionizing 
      gamma radiation (IR) in female rats. Furthermore, the potential impact of whole 
      body IR exposure on the intestinal system and serum estradiol levels was 
      investigated. Additionally, it was acknowledged that the ETO and MG treatments 
      might have exerted favorable effects on the intestinal and hormonal responses. 
      MATERIALS AND METHODS: Six groups of rats were assigned to different treatments: 
      control, ETO, MG, irradiation (IRR), ETO + IRR, and MG + IRR. The evaluation 
      included measuring the total phenolic and flavonoid contents of ETO and MG, as 
      well as assessing their antioxidant activity, radical scavenging capacity, 
      reducing power, and total antioxidant capacity. Kidney function was assessed 
      through serum creatinine and urea levels. Oxidative stress markers, including 
      superoxide dismutase, glutathione, malondialdehyde, and catalase, were measured 
      to evaluate the antioxidant effects of ETO and MG. The anti-inflammatory 
      potential of the treatments was evaluated by measuring STAT-3 and interleukins 
      (IL-6, IL-23, and IL-17) using an ELISA assay. Prostaglandin E2 receptor (PGE-2) 
      mRNA expression, histopathological examination, and immunohistochemistry for 
      NF-κB inhibitors were performed to investigate the underlying mechanisms in 
      kidney tissue homogenates. Histopathological changes and DNA fragmentation in the 
      intestinal tissues were determined, and the characterization of Matcha green tea 
      was performed using liquid chromatography-mass spectrometry (LC-MS). This allowed 
      for the identification and quantification of various compounds present in Matcha 
      green tea. Furthermore, the study assessed the effect of IR and treatments on 
      estrogen levels in female rats. RESULTS: Data showed that both ETO and MG had the 
      potential to mitigate the adverse effects of AKI induced by IR. Notably, MG 
      exhibited greater efficacy in attenuating oxidative stress and inflammation 
      associated with renal injury. These findings revealed and compared the effects of 
      ETO and MG in alleviating AKI caused by IR. MG demonstrated greater 
      anti-inflammatory and antioxidant properties, highlighting its potential as a 
      natural therapeutic agent. CONCLUSIONS: These results contribute to the growing 
      evidence supporting the use of MG in managing IR-induced renal complications. 
      Future studies should focus on elucidating the molecular mechanisms and 
      optimizing the application of MG in clinical settings.
FAU - Khateeb, Sahar
AU  - Khateeb S
AUID- ORCID: 0000-0002-1524-7247
AD  - Biochemistry Division, Department of Chemistry, Faculty of Science, Fayoum 
      University, Fayoum, Egypt.
AD  - Department of Biochemistry, Faculty of Science, University of Tabuk, Saudi 
      Arabia.
FAU - Taha, Eman F S
AU  - Taha EFS
AUID- ORCID: 0000-0003-2337-688X
AD  - Health Radiation Research Department, National Centre for Radiation Research and 
      Technology, Egyptian Atomic Energy Authority (EAEA), Cairo, Egypt.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20240422
PL  - England
TA  - Int J Radiat Biol
JT  - International journal of radiation biology
JID - 8809243
RN  - WRX4NFY03R (Etoricoxib)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Tea)
RN  - 0 (Antioxidants)
RN  - 0 (Pyridines)
RN  - 0 (Sulfones)
SB  - IM
MH  - Animals
MH  - Rats
MH  - *Acute Kidney Injury/etiology/prevention & control
MH  - Female
MH  - *Gamma Rays/adverse effects
MH  - *Etoricoxib/pharmacology
MH  - *Anti-Inflammatory Agents/pharmacology
MH  - *Tea/chemistry
MH  - Antioxidants/metabolism/pharmacology
MH  - Oxidative Stress/drug effects/radiation effects
MH  - Rats, Wistar
MH  - Pyridines/pharmacology
MH  - Sulfones/pharmacology
OAB - This study is of significant importance as it compares the therapeutic potential 
      of ETO and MG in mitigating AKI and intestinal damage induced by IR. The findings 
      reveal that MG exhibits greater anti-inflammatory and antioxidant properties 
      compared to ETO. These results provide valuable insights into the potential use 
      of MG as a natural therapeutic agent for managing IR-induced renal and intestinal 
      complications. As radiation therapy is commonly used in cancer treatment, 
      identifying effective agents to protect the kidneys from radiation damage is 
      crucial. The study contributes to the growing evidence supporting the application 
      of MG in clinical settings, offering a promising alternative approach with 
      potential benefits in terms of reduced side effects and improved patient 
      outcomes.
OABL- eng
OTO - NOTNLM
OT  - Matcha green tea
OT  - acute kidney injury
OT  - gamma radiation
OT  - inflammatory markers
OT  - toricoxib
EDAT- 2024/04/22 13:44
MHDA- 2024/05/30 18:43
CRDT- 2024/04/22 11:12
PHST- 2024/05/30 18:43 [medline]
PHST- 2024/04/22 13:44 [pubmed]
PHST- 2024/04/22 11:12 [entrez]
AID - 10.1080/09553002.2024.2338515 [doi]
PST - ppublish
SO  - Int J Radiat Biol. 2024;100(6):940-964. doi: 10.1080/09553002.2024.2338515. Epub 
      2024 Apr 22.

PMID- 28160860
OWN - NLM
STAT- MEDLINE
DCOM- 20170424
LR  - 20181202
IS  - 1618-095X (Electronic)
IS  - 0944-7113 (Linking)
VI  - 24
DP  - 2017 Jan 15
TI  - Novel effect and the mechanistic insights of fruiting body extract of medicinal 
      fungus Antrodia cinnamomea against T47D breast cancer.
PG  - 39-48
LID - S0944-7113(16)30210-0 [pii]
LID - 10.1016/j.phymed.2016.11.006 [doi]
AB  - INTRODUCTION: Tamoxifen, an anti-oestrogenic drug for estrogen receptor positive 
      (ER+) breast cancer, was observed to stimulate tumor growth or drug resistance in 
      patients. Antrodia cinnamomea (AC), a precious medicinal fungus has been 
      traditionally used as a folk remedy for cancers in Asian countries. The objective 
      of this study was to investigate the bioefficacy and the underlying molecular 
      mechanisms of the AC fruiting bodies extracts (AC-3E) against human ER+ T47D 
      breast cancer cells, and compare the effect with that of tamoxifen. METHODS: Cell 
      proliferation, migration, TUNEL assay, western blotting, time-lapse confocal 
      microscopy analyses, chorioallantoic membrane assay, and a xenograft BALB/c nude 
      mouse system were used in this study. Chemical fingerprinting of AC-3E was 
      established using LC-MS. RESULTS: AC-3E attenuated T47D breast cancer cell 
      activity by deregulating the PI3K/Akt/mTOR signaling pathway and key cell-cycle 
      mediators, and inducing apoptosis. AC-3E also effectively inhibited tube-like 
      structures of endothelial cells, blood vessel branching and microvessel formation 
      ex vivo and in vivo. Significant preventive and therapeutic effects against T47D 
      mammary tumor growth of AC-3E was observed comparable or superior to tamoxifen 
      treatment in xenograft BALB/c nude mice. Dehydroeburicoic acid (2) was 
      characterized as the main chemical constituent in AC-3E against breast cancer. 
      CONCLUSION: This study suggests that AC-3E extracts can be employed as a 
      double-barreled approach to treat human ER+ breast cancer by attacking both 
      cancer cells and tumor-associated blood vessel cells.
CI  - Copyright © 2016 Elsevier GmbH. All rights reserved.
FAU - Shang, Kuang-Ming
AU  - Shang KM
AD  - Agricultural Biotechnology Research Center, Academia Sinica, Taipei, Taiwan.
FAU - Su, Tzu-Hsuan
AU  - Su TH
AD  - Agricultural Biotechnology Research Center, Academia Sinica, Taipei, Taiwan.
FAU - Lee, Wai Leng
AU  - Lee WL
AD  - School of Science, Monash University Sunway Campus, Selangor, Malaysia.
FAU - Hsiao, Wen-Wei
AU  - Hsiao WW
AD  - Experimental Forest, College of Bio-Resources and Agriculture, National Taiwan 
      University, Taipei, Taiwan.
FAU - Chiou, Ching-Yi
AU  - Chiou CY
AD  - Agricultural Biotechnology Research Center, Academia Sinica, Taipei, Taiwan.
FAU - Ho, Bing-Ying
AU  - Ho BY
AD  - Agricultural Biotechnology Research Center, Academia Sinica, Taipei, Taiwan.
FAU - Wang, Sheng-Yang
AU  - Wang SY
AD  - Department of Forestry, National Chung Hsing University, Taichung, Taiwan.
FAU - Shyur, Lie-Fen
AU  - Shyur LF
AD  - Agricultural Biotechnology Research Center, Academia Sinica, Taipei, Taiwan; PhD 
      Program in Translational Medicine, College of Medicine, Kaohsiung Medical 
      University, Kaohsiung, Taiwan; Graduate Institute of Pharmacognosy, Taipei 
      Medical University, Taipei, Taiwan. Electronic address: 
      lfshyur@ccvax.sinica.edu.tw.
LA  - eng
PT  - Journal Article
DEP - 20161108
PL  - Germany
TA  - Phytomedicine
JT  - Phytomedicine : international journal of phytotherapy and phytopharmacology
JID - 9438794
RN  - 0 (Plant Extracts)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
SB  - IM
MH  - Animals
MH  - Antrodia/*chemistry
MH  - Apoptosis/drug effects
MH  - Breast Neoplasms/*drug therapy
MH  - Cell Cycle/drug effects
MH  - Cell Line, Tumor/*drug effects
MH  - Cell Proliferation/drug effects
MH  - Female
MH  - Fruiting Bodies, Fungal/*chemistry
MH  - Humans
MH  - Mice
MH  - Mice, Nude
MH  - Phosphatidylinositol 3-Kinases/*metabolism
MH  - Phytotherapy
MH  - Plant Extracts/*therapeutic use
MH  - Plants, Medicinal/chemistry
MH  - Signal Transduction/drug effects
OTO - NOTNLM
OT  - Anti-angiogenesis
OT  - Antrodia cinnamomea
OT  - Dehydroeburicoic acid
OT  - ER+ T47D breast cancer
OT  - Tamoxifen
EDAT- 2017/02/06 06:00
MHDA- 2017/04/25 06:00
CRDT- 2017/02/06 06:00
PHST- 2015/12/07 00:00 [received]
PHST- 2016/10/26 00:00 [revised]
PHST- 2016/11/06 00:00 [accepted]
PHST- 2017/02/06 06:00 [entrez]
PHST- 2017/02/06 06:00 [pubmed]
PHST- 2017/04/25 06:00 [medline]
AID - S0944-7113(16)30210-0 [pii]
AID - 10.1016/j.phymed.2016.11.006 [doi]
PST - ppublish
SO  - Phytomedicine. 2017 Jan 15;24:39-48. doi: 10.1016/j.phymed.2016.11.006. Epub 2016 
      Nov 8.

PMID- 28973422
OWN - NLM
STAT- MEDLINE
DCOM- 20180725
LR  - 20250103
IS  - 1096-0929 (Electronic)
IS  - 1096-0929 (Linking)
VI  - 160
IP  - 2
DP  - 2017 Dec 1
TI  - Elevated Metabolites of Steroidogenesis and Amino Acid Metabolism in 
      Preadolescent Female Children With High Urinary Bisphenol A Levels: A 
      High-Resolution Metabolomics Study.
PG  - 371-385
LID - 10.1093/toxsci/kfx189 [doi]
AB  - Health risks associated with bisphenol A (BPA) exposure are controversially 
      highlighted by numerous studies. High-resolution metabolomics (HRM) can confirm 
      these proposed associations and may provide a mechanistic insight into the 
      connections between BPA exposure and metabolic perturbations. This study was 
      aimed to identify the changes in metabolomics profile due to BPA exposure in 
      urine and serum samples collected from female and male children (n = 18) aged 
      7-9. Urine was measured for BPA concentration, and the children were subsequently 
      classified into high and low BPA groups. HRM, coupled with Liquid 
      chromatography-mass spectrometry/MS, followed by multivariate statistical 
      analysis using MetaboAnalyst 3.0, were performed on urine to discriminate 
      metabolic profiles between high and low BPA children as well as males and 
      females, followed by further validation of our findings in serum samples obtained 
      from same population. Metabolic pathway analysis showed that biosynthesis of 
      steroid hormones and 7 other pathways-amino acid and nucleotide biosynthesis, 
      phenylalanine metabolism, tryptophan metabolism, tyrosine metabolism, lysine 
      degradation, pyruvate metabolism, and arginine biosynthesis-were affected in high 
      BPA children. Elevated levels of metabolites associated with these pathways in 
      urine and serum were mainly observed in female children, while these changes were 
      negligible in male children. Our results suggest that the steroidogenesis pathway 
      and amino acid metabolism are the main targets of perturbation by BPA in 
      preadolescent girls.
CI  - © The Author 2017. Published by Oxford University Press on behalf of the Society 
      of Toxicology. All rights reserved. For Permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Khan, Adnan
AU  - Khan A
AD  - Metabolomics Laboratory, College of Pharmacy, Korea University, Sejong City 
      30019, Republic of Korea.
FAU - Park, Hyesook
AU  - Park H
AD  - Department of Preventive Medicine, College of Medicine, Ewha Womans University, 
      Seoul 07985, Republic of Korea.
FAU - Lee, Hye Ah
AU  - Lee HA
AD  - Department of Preventive Medicine, College of Medicine, Ewha Womans University, 
      Seoul 07985, Republic of Korea.
FAU - Park, Bohyun
AU  - Park B
AD  - Department of Preventive Medicine, College of Medicine, Ewha Womans University, 
      Seoul 07985, Republic of Korea.
FAU - Gwak, Hye Sun
AU  - Gwak HS
AD  - Division of Life and Pharmaceutical Sciences & College of Pharmacy, Ewha Womans 
      University, Seoul 13760, Republic of Korea.
FAU - Lee, Hye-Ra
AU  - Lee HR
AD  - Department of Biotechnology & Bioinformatics, College of Science and Technology, 
      Korea University, Sejong City 30019, Republic of Korea.
FAU - Jee, Sun Ha
AU  - Jee SH
AD  - Department of Epidemiology and Institute for Health Promotion, Graduate School of 
      Public Health, Yonsei University, Seoul 03722, Republic of Korea.
FAU - Park, Youngja H
AU  - Park YH
AD  - Metabolomics Laboratory, College of Pharmacy, Korea University, Sejong City 
      30019, Republic of Korea.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Validation Study
PL  - United States
TA  - Toxicol Sci
JT  - Toxicological sciences : an official journal of the Society of Toxicology
JID - 9805461
RN  - 0 (Amino Acids)
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Biomarkers)
RN  - 0 (Endocrine Disruptors)
RN  - 0 (Phenols)
RN  - 0 (Steroids)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
CIN - Toxicol Sci. 2018 Jul 1;164(1):3-4. doi: 10.1093/toxsci/kfy096. PMID: 29669048
CIN - Toxicol Sci. 2018 Jul 1;164(1):3. doi: 10.1093/toxsci/kfy095. PMID: 29912408
MH  - Age Factors
MH  - Amino Acids/*blood/*urine
MH  - Benzhydryl Compounds/toxicity/*urine
MH  - Biomarkers/blood/urine
MH  - Child
MH  - *Chromatography, High Pressure Liquid
MH  - Endocrine Disruptors/toxicity/*urine
MH  - Female
MH  - Humans
MH  - Male
MH  - Metabolomics/*methods
MH  - Multivariate Analysis
MH  - Phenols/toxicity/*urine
MH  - Reproducibility of Results
MH  - Risk Assessment
MH  - Sex Factors
MH  - *Spectrometry, Mass, Electrospray Ionization
MH  - Steroids/biosynthesis/*blood/*urine
MH  - Up-Regulation
MH  - Urinalysis
OTO - NOTNLM
OT  - endocrine disruptors
OT  - preadolescent toxicity
OT  - sex effects
OT  - steroidogenesis pathway
EDAT- 2017/10/04 06:00
MHDA- 2018/07/26 06:00
CRDT- 2017/10/04 06:00
PHST- 2017/10/04 06:00 [pubmed]
PHST- 2018/07/26 06:00 [medline]
PHST- 2017/10/04 06:00 [entrez]
AID - 4110197 [pii]
AID - 10.1093/toxsci/kfx189 [doi]
PST - ppublish
SO  - Toxicol Sci. 2017 Dec 1;160(2):371-385. doi: 10.1093/toxsci/kfx189.

PMID- 27400969
OWN - NLM
STAT- MEDLINE
DCOM- 20170711
LR  - 20240210
IS  - 1460-2105 (Electronic)
IS  - 0027-8874 (Print)
IS  - 0027-8874 (Linking)
VI  - 108
IP  - 11
DP  - 2016 Nov
TI  - Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for 
      Prediction of Risk of Distant Recurrence After Endocrine Therapy.
LID - 10.1093/jnci/djw149 [doi]
LID - djw149
AB  - BACKGROUND: Estimating distant recurrence (DR) risk among women with estrogen 
      receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative 
      early breast cancer helps decisions on using adjuvant chemotherapy. The 21-gene 
      Oncotype DX recurrence score (RS) is widely used for this. EndoPredict (EPclin) 
      is an alternative test combining prognostic information from an eight-gene 
      signature (EP score) with tumor size and nodal status. We compared the prognostic 
      information provided by RS and EPclin for 10-year DR risk. METHODS: We used 
      likelihood ratio χ² and Kaplan-Meier survival analyses to compare prognostic 
      information provided by EP, EPclin, RS, and the clinical treatment score (CTS) of 
      clinicopathologic parameters in 928 patients with ER+ disease treated with five 
      years' anastrozole or tamoxifen. Comparisons were made for early (0-5 years) and 
      late (5-10 years) DR according to nodal status. All statistical tests were 
      two-sided. RESULTS: In the overall population, EP and EPclin provided 
      substantially more prognostic information than RS (LRχ(2): EP = 49.3; LRχ(2): 
      EPclin = 139.3; LRχ(2): RS = 29.1), with greater differences in late DR and in 
      node-positive patients. EP and EPclin remained statistically significantly 
      prognostic when adjusted for RS (ΔLRχ(2): EP+RS vs RS = 20.2; ΔLRχ(2): EPclin+RS 
      vs RS = 113.8). Using predefined cut-offs, EPclin and RS identified 58.8% and 
      61.7% patients as low risk, with hazard ratios for non-low vs low risk of 5.99 
      (95% confidence interval [CI] = 3.94 to 9.11) and 2.73 (95% CI = 1.91 to 3.89), 
      respectively. CONCLUSIONS: EP and EPclin were highly prognostic for DR in 
      endocrine-treated patients with ER+, HER2-negative disease. EPclin provided more 
      prognostic information than RS. This was partly but not entirely because of 
      EPclin integrating molecular data with nodal status and tumor size.
CI  - © The Author 2016. Published by Oxford University Press.
FAU - Buus, Richard
AU  - Buus R
AD  - Affiliations of authors: The Breast Cancer Now Toby Robins Research Centre, 
      Institute of Cancer Research, London, UK (RB, MD); Academic Department of 
      Biochemistry, Royal Marsden Hospital, London, UK (RB, MD); Centre for Cancer 
      Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of 
      London, London, UK (IS, JC); Sividon Diagnostics GmbH, Cologne, Germany (RK, KK, 
      MS, CP); Institute of Pathology, Charité University Hospital and German Cancer 
      Consortium (DKTK), Berlin, Germany (CD); Department of Surgery and Comprehensive 
      Cancer Center, Medical University of Vienna, Vienna, Austria (PD).
FAU - Sestak, Ivana
AU  - Sestak I
AD  - Affiliations of authors: The Breast Cancer Now Toby Robins Research Centre, 
      Institute of Cancer Research, London, UK (RB, MD); Academic Department of 
      Biochemistry, Royal Marsden Hospital, London, UK (RB, MD); Centre for Cancer 
      Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of 
      London, London, UK (IS, JC); Sividon Diagnostics GmbH, Cologne, Germany (RK, KK, 
      MS, CP); Institute of Pathology, Charité University Hospital and German Cancer 
      Consortium (DKTK), Berlin, Germany (CD); Department of Surgery and Comprehensive 
      Cancer Center, Medical University of Vienna, Vienna, Austria (PD).
FAU - Kronenwett, Ralf
AU  - Kronenwett R
AD  - Affiliations of authors: The Breast Cancer Now Toby Robins Research Centre, 
      Institute of Cancer Research, London, UK (RB, MD); Academic Department of 
      Biochemistry, Royal Marsden Hospital, London, UK (RB, MD); Centre for Cancer 
      Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of 
      London, London, UK (IS, JC); Sividon Diagnostics GmbH, Cologne, Germany (RK, KK, 
      MS, CP); Institute of Pathology, Charité University Hospital and German Cancer 
      Consortium (DKTK), Berlin, Germany (CD); Department of Surgery and Comprehensive 
      Cancer Center, Medical University of Vienna, Vienna, Austria (PD).
FAU - Denkert, Carsten
AU  - Denkert C
AD  - Affiliations of authors: The Breast Cancer Now Toby Robins Research Centre, 
      Institute of Cancer Research, London, UK (RB, MD); Academic Department of 
      Biochemistry, Royal Marsden Hospital, London, UK (RB, MD); Centre for Cancer 
      Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of 
      London, London, UK (IS, JC); Sividon Diagnostics GmbH, Cologne, Germany (RK, KK, 
      MS, CP); Institute of Pathology, Charité University Hospital and German Cancer 
      Consortium (DKTK), Berlin, Germany (CD); Department of Surgery and Comprehensive 
      Cancer Center, Medical University of Vienna, Vienna, Austria (PD).
FAU - Dubsky, Peter
AU  - Dubsky P
AD  - Affiliations of authors: The Breast Cancer Now Toby Robins Research Centre, 
      Institute of Cancer Research, London, UK (RB, MD); Academic Department of 
      Biochemistry, Royal Marsden Hospital, London, UK (RB, MD); Centre for Cancer 
      Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of 
      London, London, UK (IS, JC); Sividon Diagnostics GmbH, Cologne, Germany (RK, KK, 
      MS, CP); Institute of Pathology, Charité University Hospital and German Cancer 
      Consortium (DKTK), Berlin, Germany (CD); Department of Surgery and Comprehensive 
      Cancer Center, Medical University of Vienna, Vienna, Austria (PD).
FAU - Krappmann, Kristin
AU  - Krappmann K
AD  - Affiliations of authors: The Breast Cancer Now Toby Robins Research Centre, 
      Institute of Cancer Research, London, UK (RB, MD); Academic Department of 
      Biochemistry, Royal Marsden Hospital, London, UK (RB, MD); Centre for Cancer 
      Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of 
      London, London, UK (IS, JC); Sividon Diagnostics GmbH, Cologne, Germany (RK, KK, 
      MS, CP); Institute of Pathology, Charité University Hospital and German Cancer 
      Consortium (DKTK), Berlin, Germany (CD); Department of Surgery and Comprehensive 
      Cancer Center, Medical University of Vienna, Vienna, Austria (PD).
FAU - Scheer, Marsel
AU  - Scheer M
AD  - Affiliations of authors: The Breast Cancer Now Toby Robins Research Centre, 
      Institute of Cancer Research, London, UK (RB, MD); Academic Department of 
      Biochemistry, Royal Marsden Hospital, London, UK (RB, MD); Centre for Cancer 
      Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of 
      London, London, UK (IS, JC); Sividon Diagnostics GmbH, Cologne, Germany (RK, KK, 
      MS, CP); Institute of Pathology, Charité University Hospital and German Cancer 
      Consortium (DKTK), Berlin, Germany (CD); Department of Surgery and Comprehensive 
      Cancer Center, Medical University of Vienna, Vienna, Austria (PD).
FAU - Petry, Christoph
AU  - Petry C
AD  - Affiliations of authors: The Breast Cancer Now Toby Robins Research Centre, 
      Institute of Cancer Research, London, UK (RB, MD); Academic Department of 
      Biochemistry, Royal Marsden Hospital, London, UK (RB, MD); Centre for Cancer 
      Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of 
      London, London, UK (IS, JC); Sividon Diagnostics GmbH, Cologne, Germany (RK, KK, 
      MS, CP); Institute of Pathology, Charité University Hospital and German Cancer 
      Consortium (DKTK), Berlin, Germany (CD); Department of Surgery and Comprehensive 
      Cancer Center, Medical University of Vienna, Vienna, Austria (PD).
FAU - Cuzick, Jack
AU  - Cuzick J
AD  - Affiliations of authors: The Breast Cancer Now Toby Robins Research Centre, 
      Institute of Cancer Research, London, UK (RB, MD); Academic Department of 
      Biochemistry, Royal Marsden Hospital, London, UK (RB, MD); Centre for Cancer 
      Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of 
      London, London, UK (IS, JC); Sividon Diagnostics GmbH, Cologne, Germany (RK, KK, 
      MS, CP); Institute of Pathology, Charité University Hospital and German Cancer 
      Consortium (DKTK), Berlin, Germany (CD); Department of Surgery and Comprehensive 
      Cancer Center, Medical University of Vienna, Vienna, Austria (PD).
FAU - Dowsett, Mitch
AU  - Dowsett M
AD  - Affiliations of authors: The Breast Cancer Now Toby Robins Research Centre, 
      Institute of Cancer Research, London, UK (RB, MD); Academic Department of 
      Biochemistry, Royal Marsden Hospital, London, UK (RB, MD); Centre for Cancer 
      Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of 
      London, London, UK (IS, JC); Sividon Diagnostics GmbH, Cologne, Germany (RK, KK, 
      MS, CP); Institute of Pathology, Charité University Hospital and German Cancer 
      Consortium (DKTK), Berlin, Germany (CD); Department of Surgery and Comprehensive 
      Cancer Center, Medical University of Vienna, Vienna, Austria (PD).
LA  - eng
GR  - 16891/CRUK_/Cancer Research UK/United Kingdom
GR  - C569/A16891/CRUK_/Cancer Research UK/United Kingdom
PT  - Comparative Study
PT  - Journal Article
DEP - 20160710
PL  - United States
TA  - J Natl Cancer Inst
JT  - Journal of the National Cancer Institute
JID - 7503089
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 0 (Nitriles)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Triazoles)
RN  - 094ZI81Y45 (Tamoxifen)
RN  - 2Z07MYW1AZ (Anastrozole)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Anastrozole
MH  - Antineoplastic Agents, Hormonal/therapeutic use
MH  - Breast Neoplasms/chemistry/drug therapy/*genetics/*pathology
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Likelihood Functions
MH  - Lymph Nodes/*pathology
MH  - Lymphatic Metastasis
MH  - Nitriles/therapeutic use
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Receptor, ErbB-2/analysis
MH  - Receptors, Estrogen/analysis
MH  - Risk Assessment/methods
MH  - Tamoxifen/therapeutic use
MH  - Triazoles/therapeutic use
MH  - Tumor Burden
PMC - PMC5241904
EDAT- 2016/07/13 06:00
MHDA- 2017/07/14 06:00
PMCR- 2016/07/10
CRDT- 2016/07/13 06:00
PHST- 2015/12/23 00:00 [received]
PHST- 2016/05/09 00:00 [accepted]
PHST- 2016/07/13 06:00 [entrez]
PHST- 2016/07/13 06:00 [pubmed]
PHST- 2017/07/14 06:00 [medline]
PHST- 2016/07/10 00:00 [pmc-release]
AID - djw149 [pii]
AID - 10.1093/jnci/djw149 [doi]
PST - epublish
SO  - J Natl Cancer Inst. 2016 Jul 10;108(11):djw149. doi: 10.1093/jnci/djw149. Print 
      2016 Nov.

PMID- 25924104
OWN - NLM
STAT- MEDLINE
DCOM- 20150824
LR  - 20211203
IS  - 1945-7170 (Electronic)
IS  - 0013-7227 (Linking)
VI  - 156
IP  - 7
DP  - 2015 Jul
TI  - Hippocampal Gene Expression Is Highly Responsive to Estradiol Replacement in 
      Middle-Aged Female Rats.
PG  - 2632-45
LID - 10.1210/en.2015-1109 [doi]
AB  - In the hippocampus, estrogens are powerful modulators of neurotransmission, 
      synaptic plasticity and neurogenesis. In women, menopause is associated with 
      increased risk of memory disturbances, which can be attenuated by timely estrogen 
      therapy. In animal models of menopause, 17β-estradiol (E2) replacement improves 
      hippocampus-dependent spatial memory. Here, we explored the effect of E2 
      replacement on hippocampal gene expression in a rat menopause model. Middle-aged 
      ovariectomized female rats were treated continuously for 29 days with E2, and 
      then, the hippocampal transcriptome was investigated with Affymetrix expression 
      arrays. Microarray data were analyzed by Bioconductor packages and web-based 
      softwares, and verified with quantitative PCR. At standard fold change selection 
      criterion, 156 genes responded to E2. All alterations but 4 were transcriptional 
      activation. Robust activation (fold change > 10) occurred in the case of 
      transthyretin, klotho, claudin 2, prolactin receptor, ectodin, coagulation factor 
      V, Igf2, Igfbp2, and sodium/sulfate symporter. Classification of the 156 genes 
      revealed major groups, including signaling (35 genes), metabolism (31 genes), 
      extracellular matrix (17 genes), and transcription (16 genes). We selected 33 
      genes for further studies, and all changes were confirmed by real-time PCR. The 
      results suggest that E2 promotes retinoid, growth factor, homeoprotein, 
      neurohormone, and neurotransmitter signaling, changes metabolism, extracellular 
      matrix composition, and transcription, and induces protective mechanisms via 
      genomic effects. We propose that these mechanisms contribute to effects of E2 on 
      neurogenesis, neural plasticity, and memory functions. Our findings provide 
      further support for the rationale to develop safe estrogen receptor ligands for 
      the maintenance of cognitive performance in postmenopausal women.
FAU - Sárvári, Miklós
AU  - Sárvári M
AD  - Laboratory of Endocrine Neurobiology (M.S., I.K., E.H., C.V., Z.L.), Institute of 
      Experimental Medicine, Hungarian Academy of Sciences, 1083 Budapest, Hungary; 
      Faculty of Information Technology and Bionics (I.K., Z.L.), Pázmány Péter 
      Catholic University, 1083 Budapest, Hungary; Faculty of Veterinary Science 
      (N.S.), Szent István University, 1078 Budapest, Hungary; Functional Genomics Core 
      (A.R.), Institute for Research in Biomedicine, 08028 Barcelona, Spain; and 
      Functional Genomics Consulting (H.A.), 08780 Palleja, Spain.
FAU - Kalló, Imre
AU  - Kalló I
AD  - Laboratory of Endocrine Neurobiology (M.S., I.K., E.H., C.V., Z.L.), Institute of 
      Experimental Medicine, Hungarian Academy of Sciences, 1083 Budapest, Hungary; 
      Faculty of Information Technology and Bionics (I.K., Z.L.), Pázmány Péter 
      Catholic University, 1083 Budapest, Hungary; Faculty of Veterinary Science 
      (N.S.), Szent István University, 1078 Budapest, Hungary; Functional Genomics Core 
      (A.R.), Institute for Research in Biomedicine, 08028 Barcelona, Spain; and 
      Functional Genomics Consulting (H.A.), 08780 Palleja, Spain.
FAU - Hrabovszky, Erik
AU  - Hrabovszky E
AD  - Laboratory of Endocrine Neurobiology (M.S., I.K., E.H., C.V., Z.L.), Institute of 
      Experimental Medicine, Hungarian Academy of Sciences, 1083 Budapest, Hungary; 
      Faculty of Information Technology and Bionics (I.K., Z.L.), Pázmány Péter 
      Catholic University, 1083 Budapest, Hungary; Faculty of Veterinary Science 
      (N.S.), Szent István University, 1078 Budapest, Hungary; Functional Genomics Core 
      (A.R.), Institute for Research in Biomedicine, 08028 Barcelona, Spain; and 
      Functional Genomics Consulting (H.A.), 08780 Palleja, Spain.
FAU - Solymosi, Norbert
AU  - Solymosi N
AD  - Laboratory of Endocrine Neurobiology (M.S., I.K., E.H., C.V., Z.L.), Institute of 
      Experimental Medicine, Hungarian Academy of Sciences, 1083 Budapest, Hungary; 
      Faculty of Information Technology and Bionics (I.K., Z.L.), Pázmány Péter 
      Catholic University, 1083 Budapest, Hungary; Faculty of Veterinary Science 
      (N.S.), Szent István University, 1078 Budapest, Hungary; Functional Genomics Core 
      (A.R.), Institute for Research in Biomedicine, 08028 Barcelona, Spain; and 
      Functional Genomics Consulting (H.A.), 08780 Palleja, Spain.
FAU - Rodolosse, Annie
AU  - Rodolosse A
AD  - Laboratory of Endocrine Neurobiology (M.S., I.K., E.H., C.V., Z.L.), Institute of 
      Experimental Medicine, Hungarian Academy of Sciences, 1083 Budapest, Hungary; 
      Faculty of Information Technology and Bionics (I.K., Z.L.), Pázmány Péter 
      Catholic University, 1083 Budapest, Hungary; Faculty of Veterinary Science 
      (N.S.), Szent István University, 1078 Budapest, Hungary; Functional Genomics Core 
      (A.R.), Institute for Research in Biomedicine, 08028 Barcelona, Spain; and 
      Functional Genomics Consulting (H.A.), 08780 Palleja, Spain.
FAU - Vastagh, Csaba
AU  - Vastagh C
AD  - Laboratory of Endocrine Neurobiology (M.S., I.K., E.H., C.V., Z.L.), Institute of 
      Experimental Medicine, Hungarian Academy of Sciences, 1083 Budapest, Hungary; 
      Faculty of Information Technology and Bionics (I.K., Z.L.), Pázmány Péter 
      Catholic University, 1083 Budapest, Hungary; Faculty of Veterinary Science 
      (N.S.), Szent István University, 1078 Budapest, Hungary; Functional Genomics Core 
      (A.R.), Institute for Research in Biomedicine, 08028 Barcelona, Spain; and 
      Functional Genomics Consulting (H.A.), 08780 Palleja, Spain.
FAU - Auer, Herbert
AU  - Auer H
AD  - Laboratory of Endocrine Neurobiology (M.S., I.K., E.H., C.V., Z.L.), Institute of 
      Experimental Medicine, Hungarian Academy of Sciences, 1083 Budapest, Hungary; 
      Faculty of Information Technology and Bionics (I.K., Z.L.), Pázmány Péter 
      Catholic University, 1083 Budapest, Hungary; Faculty of Veterinary Science 
      (N.S.), Szent István University, 1078 Budapest, Hungary; Functional Genomics Core 
      (A.R.), Institute for Research in Biomedicine, 08028 Barcelona, Spain; and 
      Functional Genomics Consulting (H.A.), 08780 Palleja, Spain.
FAU - Liposits, Zsolt
AU  - Liposits Z
AD  - Laboratory of Endocrine Neurobiology (M.S., I.K., E.H., C.V., Z.L.), Institute of 
      Experimental Medicine, Hungarian Academy of Sciences, 1083 Budapest, Hungary; 
      Faculty of Information Technology and Bionics (I.K., Z.L.), Pázmány Péter 
      Catholic University, 1083 Budapest, Hungary; Faculty of Veterinary Science 
      (N.S.), Szent István University, 1078 Budapest, Hungary; Functional Genomics Core 
      (A.R.), Institute for Research in Biomedicine, 08028 Barcelona, Spain; and 
      Functional Genomics Consulting (H.A.), 08780 Palleja, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150429
PL  - United States
TA  - Endocrinology
JT  - Endocrinology
JID - 0375040
RN  - 0 (Cation Transport Proteins)
RN  - 0 (Claudins)
RN  - 0 (Cldn2 protein, rat)
RN  - 0 (Estrogens)
RN  - 0 (Igf2 protein, rat)
RN  - 0 (Insulin-Like Growth Factor Binding Protein 2)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (Prealbumin)
RN  - 0 (Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Prolactin)
RN  - 0 (Sodium Sulfate Cotransporter)
RN  - 0 (Sostdc1 protein, rat)
RN  - 0 (Symporters)
RN  - 4TI98Z838E (Estradiol)
RN  - 67763-97-7 (Insulin-Like Growth Factor II)
RN  - 9001-24-5 (Factor V)
RN  - EC 3.2.1.31 (Glucuronidase)
RN  - EC 3.2.1.31 (Klotho Proteins)
SB  - IM
MH  - Animals
MH  - Cation Transport Proteins/drug effects/genetics
MH  - Claudins/drug effects/genetics
MH  - Estradiol/*pharmacology
MH  - *Estrogen Replacement Therapy
MH  - Estrogens/*pharmacology
MH  - Factor V/drug effects/genetics
MH  - Female
MH  - Gene Expression/*drug effects
MH  - Glucuronidase/drug effects/genetics
MH  - Hippocampus/*drug effects
MH  - Insulin-Like Growth Factor Binding Protein 2/drug effects/genetics
MH  - Insulin-Like Growth Factor II/drug effects/genetics
MH  - Intracellular Signaling Peptides and Proteins
MH  - Klotho Proteins
MH  - Menopause/*drug effects
MH  - Models, Animal
MH  - Prealbumin/drug effects/genetics
MH  - Proteins/drug effects/genetics
MH  - RNA, Messenger/*drug effects/metabolism
MH  - Rats
MH  - Receptors, Prolactin/drug effects/genetics
MH  - Sodium Sulfate Cotransporter
MH  - Symporters/drug effects/genetics
EDAT- 2015/04/30 06:00
MHDA- 2015/08/25 06:00
CRDT- 2015/04/30 06:00
PHST- 2015/04/30 06:00 [entrez]
PHST- 2015/04/30 06:00 [pubmed]
PHST- 2015/08/25 06:00 [medline]
AID - 10.1210/en.2015-1109 [doi]
PST - ppublish
SO  - Endocrinology. 2015 Jul;156(7):2632-45. doi: 10.1210/en.2015-1109. Epub 2015 Apr 
      29.

PMID- 26282764
OWN - NLM
STAT- MEDLINE
DCOM- 20160506
LR  - 20150919
IS  - 1879-1026 (Electronic)
IS  - 0048-9697 (Linking)
VI  - 537
DP  - 2015 Dec 15
TI  - Occurrence of benzophenone-3 in indoor air from Albany, New York, USA, and its 
      implications for inhalation exposure.
PG  - 304-8
LID - S0048-9697(15)30525-8 [pii]
LID - 10.1016/j.scitotenv.2015.08.020 [doi]
AB  - Benzophenone-3 (BP-3) is a widespread environmental contaminant and an estrogenic 
      compound. Very little is known with regard to the occurrence in indoor air and 
      the inhalation exposure of humans to BP-3. In this study, 81 indoor air samples 
      were collected from various locations in Albany, New York, USA, in 2014 and 
      analyzed for BP-3 by high performance liquid chromatography-tandem mass 
      spectrometry (HPLC-MS/MS). BP-3 was found in all indoor air samples and the 
      overall concentrations in bulk air (vapor plus particulate phases) were in the 
      range of 0.19-72.0 ng/m(3) (geometric mean: 2.67 ng/m(3)). The highest 
      concentrations (geometric mean: 10.7 ng/m(3)) were found in cars, followed by 
      barber shops (6.57) ˃ public places (5.75)>homes (3.27) ˃ offices (1.96) ˃ 
      garages (1.04) ˃ laboratories (0.47). The estimated geometric mean daily intake 
      (EDI) of BP-3 for infants, toddlers, children, teenagers, and adults through 
      indoor air inhalation from homes was 1.83, 1.74, 1.18, 0.69, and 0.51 
      ng/kg-bw/day, respectively. Although high concentrations of BP-3 were measured in 
      some microenvironments, the estimated contribution of indoor air to total BP-3 
      intake was <5% of the total BP-3 intake in humans. This is the first survey on 
      the occurrence of BP-3 in indoor air.
CI  - Copyright © 2015 Elsevier B.V. All rights reserved.
FAU - Wan, Yanjian
AU  - Wan Y
AD  - Wadsworth Center, New York State Department of Health, and Department of 
      Environmental Health Sciences, School of Public Health, State University of New 
      York at Albany, Empire State Plaza, P.O. Box 509, Albany, NY 12201-0509, United 
      States; Center for Disease Control and Prevention of Yangtze River Administration 
      and Navigational Affairs, General Hospital of the Yangtze River Shipping, Wuhan 
      430019, China.
FAU - Xue, Jingchuan
AU  - Xue J
AD  - Wadsworth Center, New York State Department of Health, and Department of 
      Environmental Health Sciences, School of Public Health, State University of New 
      York at Albany, Empire State Plaza, P.O. Box 509, Albany, NY 12201-0509, United 
      States.
FAU - Kannan, Kurunthachalam
AU  - Kannan K
AD  - Wadsworth Center, New York State Department of Health, and Department of 
      Environmental Health Sciences, School of Public Health, State University of New 
      York at Albany, Empire State Plaza, P.O. Box 509, Albany, NY 12201-0509, United 
      States; Biochemistry Department, Faculty of Science and Experimental Biochemistry 
      Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, 
      Saudi Arabia. Electronic address: kurunthachalam.kannan@health.ny.gov.
LA  - eng
GR  - 1U38EH000464-01/EH/NCEH CDC HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20150815
PL  - Netherlands
TA  - Sci Total Environ
JT  - The Science of the total environment
JID - 0330500
RN  - 0 (Benzophenones)
RN  - 95OOS7VE0Y (oxybenzone)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Air Pollution, Indoor/analysis/*statistics & numerical data
MH  - Benzophenones/*analysis
MH  - Child
MH  - Child, Preschool
MH  - Environmental Monitoring
MH  - Humans
MH  - Infant
MH  - Inhalation Exposure/analysis/*statistics & numerical data
MH  - New York
OTO - NOTNLM
OT  - Benzophenone-3
OT  - Cosmetics
OT  - Human exposure
OT  - Indoor air
OT  - UV filter
EDAT- 2015/08/19 06:00
MHDA- 2016/05/07 06:00
CRDT- 2015/08/19 06:00
PHST- 2015/06/25 00:00 [received]
PHST- 2015/07/30 00:00 [revised]
PHST- 2015/08/05 00:00 [accepted]
PHST- 2015/08/19 06:00 [entrez]
PHST- 2015/08/19 06:00 [pubmed]
PHST- 2016/05/07 06:00 [medline]
AID - S0048-9697(15)30525-8 [pii]
AID - 10.1016/j.scitotenv.2015.08.020 [doi]
PST - ppublish
SO  - Sci Total Environ. 2015 Dec 15;537:304-8. doi: 10.1016/j.scitotenv.2015.08.020. 
      Epub 2015 Aug 15.

PMID- 38367930
OWN - NLM
STAT- MEDLINE
DCOM- 20240526
LR  - 20240526
IS  - 1872-7573 (Electronic)
IS  - 0378-8741 (Linking)
VI  - 331
DP  - 2024 Sep 15
TI  - Chemical profiling, bio-guided purification, and cytotoxic effect of two African 
      spices: Hypodaphnis zenkeri Engl. Stapf (Lauraceae) and Staudtia kamerunensis 
      warb (Myristicaceae) on human prostate cancer cell lines.
PG  - 117843
LID - S0378-8741(24)00142-9 [pii]
LID - 10.1016/j.jep.2024.117843 [doi]
AB  - ETHNOPHARMACOLOGICAL RELEVANCE: Prostate cancer remains a significant burden in 
      low- and middle-income countries and the second leading cause of death around the 
      world. Spices used in daily cuisine contain interesting phytochemical components 
      capable of helping prevent and cure cancer. AIM: This study aims to give 
      sufficient phytochemical information on two understudied species, Staudtia 
      kamerunensis Warb. (Myristicaceae) and Hypodaphnis zenkeri Engl. Stapf. 
      (Lauraceae), and to study their cytotoxicity against prostate cancer cells in its 
      early form and when they have developed metastasis. MATERIALS AND METHODS: To 
      reach this goal, normal procedures for phytochemical analysis were followed; 
      these include collection, drying, crushing and extraction of plant materials 
      using organic solvents. GC-MS (Gas chromatography- Mass Spectrometry) was used to 
      evaluate the volatile phytochemicals contained in the extracts, and open-column 
      chromatography was used to isolate the pure compounds used in this study. A 
      bio-guided exploration of Hypodaphnis zenkeri (Lauraceae) (leaves, seeds, stems) 
      guided us in selecting the extract for further analysis. An established MTT assay 
      was used to measure cell proliferation. Three prostate cancer cell lines were 
      considered in this study, DU145 and PC3, human androgens-independent prostate 
      carcinoma cells and LNCaP, which are cells derived from metastasis of a human 
      prostate and respond to androgens, oestrogens and progestins. The eight compounds 
      isolated were characterized using HREIMS, 1D and 2D NMR. RESULTS: Among the three 
      extracts from Hypodaphnis zenkeri, considered for biological testing, the leaf 
      extract displayed better activities with a CC(50) of 180 μg/mL against DU 
      145 cells, 184 μg/mL against PC3 cells and 194 μg/mL against LNCaP cells. These 
      results were justified when GC-MS analysis of the different extracts was 
      performed. Fifty compounds were identified from the leaves, representing 96.06% 
      of the volatile components, with most displaying anticancer activities or 
      activities against vectors favorizing cancer growth (inflammation, etc.). An 
      attempt to isolate the active principle responsible for the cancer activity led 
      to the isolation of five pure compounds, namely Eicosane [1], Nonacos-1-ene [2], 
      Palmitic acid [3], Glucoside Stigmasterol [4] and Butane-1,2,3,4-tetraol [5]. 
      Eicosane was identified as being responsible in part for the observed activity, 
      even though it exhibited weak cytotoxicity with the lowest CC(50) equal to 
      30 μg/mL against DU 145 cells. Staudtia kamerunensis sap was investigated in our 
      previous studies with the isolation of Oleanan-12-ene-2α,3β -diol [6] and 2α, 3β 
      -dihydroxylup-20-ene [7] among the major components, with significant 
      antibacterial properties. Oleanan-12-ene-2α,3β -diol [7] in this study displayed 
      a CC(50) of 20 μg/mL against DU145 cells, 22 μg/mL against PC3 cells, 18 μg/mL 
      against LNCaP cells, and 32 μg/mL in HMEC affording a selectivity index >2. 
      Contrary to what was observed in our previous study, the activity of 
      Oleanan-12-ene-2α,3β -diol was lost in the presence of 2α, 3β 
      -dihydroxylup-20-ene. CONCLUSION: the cytotoxic effect of extract from Staudtia 
      and Hypodaphnis genera and pure isolates are here reported for the first time, as 
      well as the pure isolates. These studies exhibit the cytotoxic potential of two 
      traditional African spices and, more specifically, Oleanan-12-ene-2α,3β -diol and 
      eicosane, isolated from these plant species.
CI  - Copyright © 2024. Published by Elsevier B.V.
FAU - Tonga, Jordan L
AU  - Tonga JL
AD  - Drug Discovery and Smart Molecules Research Laboratory, Department of Chemical 
      Sciences, University of Johannesburg, P.O. Box 17011 Doornfontein, Johannesburg 
      2028, South Africa; Centre for Natural Product Research (CNPR), Department of 
      Chemical Sciences, University of Johannesburg, Doornfontein, Johannesburg 2028, 
      South Africa; Research Centre for Synthesis and Catalysis, Department of Chemical 
      Sciences, University of Johannesburg-Kingsway Campus, Auckland Park 2008, South 
      Africa.
FAU - Kamdem, Michael H K
AU  - Kamdem MHK
AD  - Drug Discovery and Smart Molecules Research Laboratory, Department of Chemical 
      Sciences, University of Johannesburg, P.O. Box 17011 Doornfontein, Johannesburg 
      2028, South Africa; Centre for Natural Product Research (CNPR), Department of 
      Chemical Sciences, University of Johannesburg, Doornfontein, Johannesburg 2028, 
      South Africa; Research Centre for Synthesis and Catalysis, Department of Chemical 
      Sciences, University of Johannesburg-Kingsway Campus, Auckland Park 2008, South 
      Africa.
FAU - Mphahlele, Precious M
AU  - Mphahlele PM
AD  - Drug Discovery and Smart Molecules Research Laboratory, Department of Chemical 
      Sciences, University of Johannesburg, P.O. Box 17011 Doornfontein, Johannesburg 
      2028, South Africa; Centre for Natural Product Research (CNPR), Department of 
      Chemical Sciences, University of Johannesburg, Doornfontein, Johannesburg 2028, 
      South Africa; Research Centre for Synthesis and Catalysis, Department of Chemical 
      Sciences, University of Johannesburg-Kingsway Campus, Auckland Park 2008, South 
      Africa.
FAU - Jiyane, Pangaman
AU  - Jiyane P
AD  - Drug Discovery and Smart Molecules Research Laboratory, Department of Chemical 
      Sciences, University of Johannesburg, P.O. Box 17011 Doornfontein, Johannesburg 
      2028, South Africa; Centre for Natural Product Research (CNPR), Department of 
      Chemical Sciences, University of Johannesburg, Doornfontein, Johannesburg 2028, 
      South Africa; Research Centre for Synthesis and Catalysis, Department of Chemical 
      Sciences, University of Johannesburg-Kingsway Campus, Auckland Park 2008, South 
      Africa.
FAU - Fonkui, Thierry Y
AU  - Fonkui TY
AD  - Department of Biotechnology and Food Technology, University of Johannesburg, 
      Doornfontein, Johannesburg 2028, South Africa.
FAU - Fotsing, Marthe C D
AU  - Fotsing MCD
AD  - Drug Discovery and Smart Molecules Research Laboratory, Department of Chemical 
      Sciences, University of Johannesburg, P.O. Box 17011 Doornfontein, Johannesburg 
      2028, South Africa; Centre for Natural Product Research (CNPR), Department of 
      Chemical Sciences, University of Johannesburg, Doornfontein, Johannesburg 2028, 
      South Africa.
FAU - Mmutlane, Edwin M
AU  - Mmutlane EM
AD  - Centre for Natural Product Research (CNPR), Department of Chemical Sciences, 
      University of Johannesburg, Doornfontein, Johannesburg 2028, South Africa; 
      Research Centre for Synthesis and Catalysis, Department of Chemical Sciences, 
      University of Johannesburg-Kingsway Campus, Auckland Park 2008, South Africa. 
      Electronic address: edwinm@uj.ac.za.
FAU - Zingue, Stephane
AU  - Zingue S
AD  - Department of Pharmacotoxicology and Pharmacokinetics, Faculty of Medicine and 
      Biomedical Sciences, University of Yaoundé 1, P.O. Box 1364 Yaoundé, Cameroon. 
      Electronic address: stephane.zingue@fmsb-uy1.cm.
FAU - Ndinteh, Derek T
AU  - Ndinteh DT
AD  - Drug Discovery and Smart Molecules Research Laboratory, Department of Chemical 
      Sciences, University of Johannesburg, P.O. Box 17011 Doornfontein, Johannesburg 
      2028, South Africa; Centre for Natural Product Research (CNPR), Department of 
      Chemical Sciences, University of Johannesburg, Doornfontein, Johannesburg 2028, 
      South Africa.
LA  - eng
PT  - Journal Article
DEP - 20240216
PL  - Ireland
TA  - J Ethnopharmacol
JT  - Journal of ethnopharmacology
JID - 7903310
RN  - 0 (Plant Extracts)
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (Phytochemicals)
SB  - IM
MH  - Humans
MH  - Male
MH  - *Prostatic Neoplasms/drug therapy/pathology
MH  - *Spices
MH  - *Plant Extracts/pharmacology/chemistry
MH  - *Antineoplastic Agents, Phytogenic/pharmacology/isolation & 
      purification/chemistry
MH  - Cell Line, Tumor
MH  - Lauraceae/chemistry
MH  - Cell Survival/drug effects
MH  - Phytochemicals/pharmacology/isolation & purification/analysis
MH  - Gas Chromatography-Mass Spectrometry
MH  - PC-3 Cells
OTO - NOTNLM
OT  - Bio-guided fractionation
OT  - Cytotoxicity
OT  - Hypodaphnis zenkeri
OT  - Prostate cancer
OT  - Staudtia kamerunensis
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2024/02/18 00:42
MHDA- 2024/05/27 00:42
CRDT- 2024/02/17 19:18
PHST- 2023/11/20 00:00 [received]
PHST- 2024/01/25 00:00 [revised]
PHST- 2024/01/28 00:00 [accepted]
PHST- 2024/05/27 00:42 [medline]
PHST- 2024/02/18 00:42 [pubmed]
PHST- 2024/02/17 19:18 [entrez]
AID - S0378-8741(24)00142-9 [pii]
AID - 10.1016/j.jep.2024.117843 [doi]
PST - ppublish
SO  - J Ethnopharmacol. 2024 Sep 15;331:117843. doi: 10.1016/j.jep.2024.117843. Epub 
      2024 Feb 16.

PMID- 37087607
OWN - NLM
STAT- MEDLINE
DCOM- 20230425
LR  - 20250103
IS  - 1872-2059 (Electronic)
IS  - 1000-8713 (Print)
IS  - 1000-8713 (Linking)
VI  - 41
IP  - 5
DP  - 2023 May 8
TI  - [Determination of 26 bisphenols in dust by ultra performance liquid 
      chromatography-tandem mass spectrometry].
PG  - 417-425
LID - 10.3724/SP.J.1123.2022.08022 [doi]
AB  - Bisphenol A (BPA) is one of the most widely produced compounds in the world and 
      was listed as a substance of very high concern by the European Chemicals Agency 
      in 2016. Because of its toxicity, many countries and regions, including China, 
      have banned BPA addition in feeding-bottles. And the European Union (EU) has 
      banned BPA use in other food contact materials and thermal paper. Restrictions on 
      BPA have contributed to the widespread use of alternatives. As the toxicity of 
      BPA alternatives continues to be revealed, the alternatives of BPA alternatives 
      are being developing. As the most extensive alternative for BPA, bisphenol S 
      (BPS) was proven to have estrogen-disrupting effects and developmental toxicity 
      of the neuroendocrine system. Therefore, BPS alternatives are used in thermal 
      paper. In this study, alternatives to both BPA and BPS are collectively referred 
      to as bisphenols (BPs). As a pooling matrix of many indoor chemicals, dust is an 
      important pathway for human exposure to BPs. BPA and its alternatives are 
      routinely detected in dust. As BPS alternatives have been detected in recycled 
      paper and sludge, it is also very important to detected in dust. However, common 
      analytical methods for BPs have low sensitivity and contain few BPS alternatives. 
      Therefore, a high-throughput, high-accuracy, and high-sensitivity method must be 
      established for the determination of BPs in dust; this will lay the foundation 
      for subsequent studies on the environmental behavior and exposure risk of BPs. In 
      this study, an ultra performance liquid chromatography-tandem mass spectrometry 
      (UPLC-MS/MS) method was developed for the simultaneous determination of 26 
      variations of BPs in dust. UPLC-MS/MS parameters of the variations were optimized 
      to compare the separation effect and response intensity in different columns and 
      mobile phases. The influence of the extraction solvent and solid phase extraction 
      (SPE) on the extraction efficiency and purification effect of target compounds 
      were optimized by using the isotopic internal standard method, and the 26 
      variations of BPs in dust was quantitatively analyzed. Finally, the dust samples 
      were extracted by using 3 mL of acetonitrile and 3 mL of a 50% methanol aqueous 
      solution in an ultrasound bath. The combined extract was further purified by 
      using an Oasis HLB cartridge (60 mg/3 mL). The cartridge was then washed with a 
      40% methanol aqueous solution (0.5 mL) and eluted with methanol (2 mL). The 
      target compounds were separated on a CORTECS(®) UPLC(®) C(18) column (100 mm×2.1 
      mm, 1.6 μm), with methanol and 1 mmol/L ammonium fluoride solution as mobile 
      phases and a flow rate of 0.3 mL/min. Electrospray ionization (ESI) was applied 
      in the positive, negative, and multiple reaction monitoring (MRM) modes for the 
      mass scan. Under optimized conditions, the linear ranges of the 26 targets 
      behaved well linearly in their respective ranges with correlation coefficients 
      (r(2))>0.999. The limits of detection (LODs) and limits of quantification (LOQs) 
      were assessed using signal-to-noise (S/N) ratios of 3 and 10, respectively. The 
      LODs and LOQs of the method were 0.01-0.75 μg/kg and 0.02-2.50 μg/kg, 
      respectively. The accuracy of the method was evaluated by conducting a recovery 
      test at three spiked levels: LOQ, two times the LOQ, and 10 times the LOQ, with 
      the average recoveries ranging from 83.7% to 114.9%. The precision of the method 
      was evaluated by using the relative standard deviation (RSD). The intra-day RSDs 
      and inter-day RSDs were 0.86%-9.79% (n=6) and 5.16%-19.5% (n=6), respectively. 
      The established method was used to determine 11 dust samples. Fifteen BPs were 
      detected at a detection rate of 9.1%-100.0%. The detection rate for BPA, BPS, 
      bisphenol F (BPF), 4-hydroxy-4'-isopropoxydiphenylsulfone (BPSIP), and diphenyl 
      sulfone (DPS) was 100.0%. BPSIP, 4-allyloxy-4'-hydroxydiphenyl sulfone (BPS-MAE), 
      and bis-(3-allyl-4-hydroxyphenyl) sulfone (TGSA) were first detected in Chinese 
      dust, whereas 4-benzyloxy-4'-hydroxydiphenyl sulfone (BPS-MPE), 4-hydroxybenzoic 
      acid benzyl (PHBB), and DPS were first detected in dust samples worldwide. This 
      method is simple, rapid, and sensitive, and is suitable for the qualitative 
      screening and quantitative analysis of the 26 BPs in dust samples.
FAU - Sun, Jia-Lin
AU  - Sun JL
AD  - School of Public Health, Capital Medical University, Beijing 100069, China.
FAU - Niu, Yu-Min
AU  - Niu YM
AD  - Beijing Key Laboratory of Diagnostic and Traceability Technologies for Food 
      Poisoning, Beijing Center for Disease Prevention and Control, Beijing 100013, 
      China.
FAU - Gao, Qun
AU  - Gao Q
AD  - Department of Emergency Management, Beijing Center for Disease Prevention and 
      Control, Beijing 100013, China.
FAU - Zhang, Jing
AU  - Zhang J
AD  - Beijing Key Laboratory of Diagnostic and Traceability Technologies for Food 
      Poisoning, Beijing Center for Disease Prevention and Control, Beijing 100013, 
      China.
FAU - Shao, Bing
AU  - Shao B
AD  - Beijing Key Laboratory of Diagnostic and Traceability Technologies for Food 
      Poisoning, Beijing Center for Disease Prevention and Control, Beijing 100013, 
      China.
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Se Pu
JT  - Se pu = Chinese journal of chromatography
JID - 9424804
RN  - RW57K3X12M (bisphenol A)
RN  - 0 (Dust)
RN  - Y4S76JWI15 (Methanol)
RN  - 0 (Estrogens)
RN  - 3OX4RR782R (bisphenol S)
RN  - 0 (Sulfones)
SB  - IM
MH  - Humans
MH  - Chromatography, Liquid
MH  - *Tandem Mass Spectrometry
MH  - *Dust
MH  - Methanol/analysis
MH  - Estrogens
MH  - Sulfones/analysis
MH  - Solid Phase Extraction
MH  - Chromatography, High Pressure Liquid
PMC - PMC10122761
OTO - NOTNLM
OT  - bisphenols (BPs)
OT  - dust
OT  - ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS)
EDAT- 2023/04/23 06:41
MHDA- 2023/04/25 06:42
PMCR- 2023/05/08
CRDT- 2023/04/23 03:12
PHST- 2023/04/25 06:42 [medline]
PHST- 2023/04/23 06:41 [pubmed]
PHST- 2023/04/23 03:12 [entrez]
PHST- 2023/05/08 00:00 [pmc-release]
AID - 10.3724/SP.J.1123.2022.08022 [doi]
PST - ppublish
SO  - Se Pu. 2023 May 8;41(5):417-425. doi: 10.3724/SP.J.1123.2022.08022.

PMID- 27567155
OWN - NLM
STAT- MEDLINE
DCOM- 20170307
LR  - 20250103
IS  - 1879-1298 (Electronic)
IS  - 0045-6535 (Linking)
VI  - 163
DP  - 2016 Nov
TI  - Gestational and lactational exposure to bisphenol AF in maternal rats increases 
      testosterone levels in 23-day-old male offspring.
PG  - 552-561
LID - S0045-6535(16)31077-3 [pii]
LID - 10.1016/j.chemosphere.2016.08.059 [doi]
AB  - During prenatal and postnatal development, exposure to environmental chemicals 
      with estrogenic activity, such as bisphenol AF (BPAF), may result in reproductive 
      disorders. Currently, the mechanisms behind such disorders in male offspring 
      induced by gestational and lactational exposure to BPAF remain poorly understood. 
      Here, female rats from gestational day (GD) 3-19 were exposed to 100 mg 
      BPAF/kg/day by oral gavage. On the day of birth (postnatal day (PD) 0), 
      cross-fostering took place between treated and control litters, and 
      cross-fostered mother rats were given BPAF 100 mg/kg/day during the postnatal 
      period (PD 3 to PD 19). HPLC-MS/MS analysis showed that BPAF was transferred via 
      cord blood and lactation, finally bio-accumulating in the offspring testes. Pups 
      exposed to BPAF both prenatally and postnatally showed a significant increase in 
      testis testosterone levels compared with that of the control, while all pups 
      exposed to BPAF showed a significant decrease in testis inhibin B (INHB) levels. 
      Compared with the control, RNA-seq revealed that 279 genes were significantly 
      differentially expressed in the testes of pups exposed to BPAF both prenatally 
      and postnatally, including genes involved in cell differentiation and meiosis. 
      These results indicate that gestational and lactational exposure to BPAF in the 
      mother can impair reproductive function in male offspring.
CI  - Copyright © 2016 Elsevier Ltd. All rights reserved.
FAU - Li, Jing
AU  - Li J
AD  - Key Laboratory of Animal Ecology and Conservation Biology, Institute of Zoology, 
      Chinese Academy of Sciences, Beijing, 100101, PR China.
FAU - Sheng, Nan
AU  - Sheng N
AD  - Key Laboratory of Animal Ecology and Conservation Biology, Institute of Zoology, 
      Chinese Academy of Sciences, Beijing, 100101, PR China.
FAU - Cui, Ruina
AU  - Cui R
AD  - Key Laboratory of Animal Ecology and Conservation Biology, Institute of Zoology, 
      Chinese Academy of Sciences, Beijing, 100101, PR China.
FAU - Feng, Yixing
AU  - Feng Y
AD  - Beijing Key Laboratory of Diagnostic and Traceability Technologies for Food 
      Poisoning, Beijing Centre for Disease Control and Prevention, Beijing, 100013, PR 
      China.
FAU - Shao, Bing
AU  - Shao B
AD  - Beijing Key Laboratory of Diagnostic and Traceability Technologies for Food 
      Poisoning, Beijing Centre for Disease Control and Prevention, Beijing, 100013, PR 
      China.
FAU - Guo, Xuejiang
AU  - Guo X
AD  - State Key Laboratory of Reproductive Medicine, Nanjing Medical University, 
      Nanjing, 210029, PR China.
FAU - Zhang, Hongxia
AU  - Zhang H
AD  - Key Laboratory of Animal Ecology and Conservation Biology, Institute of Zoology, 
      Chinese Academy of Sciences, Beijing, 100101, PR China.
FAU - Dai, Jiayin
AU  - Dai J
AD  - Key Laboratory of Animal Ecology and Conservation Biology, Institute of Zoology, 
      Chinese Academy of Sciences, Beijing, 100101, PR China. Electronic address: 
      daijy@ioz.ac.cn.
LA  - eng
PT  - Journal Article
DEP - 20160825
PL  - England
TA  - Chemosphere
JT  - Chemosphere
JID - 0320657
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Phenols)
RN  - 3XMK78S47O (Testosterone)
RN  - OH7IX8A37J (bisphenol AF)
SB  - IM
MH  - Animals
MH  - Animals, Newborn
MH  - Benzhydryl Compounds/*adverse effects/blood
MH  - Biological Assay
MH  - Blotting, Western
MH  - Breast Feeding
MH  - Female
MH  - Gene Expression Regulation/drug effects
MH  - Lactation/*drug effects
MH  - Male
MH  - Maternal Exposure/*adverse effects
MH  - Phenols/*adverse effects/blood
MH  - Polymerase Chain Reaction
MH  - Pregnancy
MH  - Prenatal Exposure Delayed Effects/*chemically induced
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reproduction
MH  - Tandem Mass Spectrometry
MH  - Testis/*drug effects/metabolism
MH  - Testosterone/*metabolism
OTO - NOTNLM
OT  - Bisphenol A
OT  - Bisphenol AF
OT  - Endocrine-disrupting compounds (EDCs)
OT  - RNA-seq
OT  - Reproductive toxicity
OT  - Testicular function
EDAT- 2016/08/28 06:00
MHDA- 2017/03/08 06:00
CRDT- 2016/08/28 06:00
PHST- 2016/06/26 00:00 [received]
PHST- 2016/08/05 00:00 [revised]
PHST- 2016/08/12 00:00 [accepted]
PHST- 2016/08/28 06:00 [entrez]
PHST- 2016/08/28 06:00 [pubmed]
PHST- 2017/03/08 06:00 [medline]
AID - S0045-6535(16)31077-3 [pii]
AID - 10.1016/j.chemosphere.2016.08.059 [doi]
PST - ppublish
SO  - Chemosphere. 2016 Nov;163:552-561. doi: 10.1016/j.chemosphere.2016.08.059. Epub 
      2016 Aug 25.

PMID- 38171154
OWN - NLM
STAT- MEDLINE
DCOM- 20240124
LR  - 20250114
IS  - 1090-2120 (Electronic)
IS  - 0045-2068 (Linking)
VI  - 143
DP  - 2024 Feb
TI  - Characterization of the metabolites of Eucommiae Cortex in rats provides a 
      further insight into its estrogen-like effective substances.
PG  - 107052
LID - S0045-2068(23)00713-7 [pii]
LID - 10.1016/j.bioorg.2023.107052 [doi]
AB  - Eucommiae Cortex is one of important traditional Chinese medicines (TCMs) used in 
      Asia for preventing and treating osteoporosis induced by estrogen deficiency. 
      However, the low exposure of prototype components in Eucommiae Cortex in vivo is 
      difficult to interpret its efficacy. Under the guidance of UPLC-Q/TOF-MS, 42 
      metabolites including 32 lignans and 10 phenolics, 21 of which were new 
      compounds, were isolated from rat urine and feces after oral administration of 
      aqueous extract of E. ulmoides Oliv. by various chromatographic techniques. Their 
      structures were determined based on extensive physicochemical analyses and 
      spectral data. Their absolute configurations were determined by experimental and 
      calculated ECD spectra, along with the calculated NMR with DP4 evaluation. 
      Additionally, all isolated metabolites were evaluated for their estrogen-like 
      activities, and there are 15 metabolites having estrogen-like effects after 
      assessing influences in MCF-7 cells. Further, Dual Luciferase Reporter Gene Assay 
      was used to determine their activation with estrogen receptor, M10 and M11 
      mixtures, M14, M19, M33, M27, M31, M38-M41 could activate ERα, and M19 and M41 
      could activate ERβ. These results not only clarify the pharmacological substances 
      of Eucommiae Cortex, but also provide a basis for guiding its clinical 
      application.
CI  - Copyright © 2023 Elsevier Inc. All rights reserved.
FAU - Ding, Liqin
AU  - Ding L
AD  - Institute of Traditional Chinese Medicine, Tianjin University of Traditional 
      Chinese Medicine, Tinjin, China; Tianjin Key Laboratory of Therapeutic Substance 
      of Traditional Chinese Medicine, Tianjin University of Traditional Chinese 
      Medicine, Tianjin, China. Electronic address: ruby70303@163.com.
FAU - Qiu, Tianyi
AU  - Qiu T
AD  - Institute of Traditional Chinese Medicine, Tianjin University of Traditional 
      Chinese Medicine, Tinjin, China; School of Chinese Materia Medica, Tianjin 
      University of Traditional Chinese Medicine, Tianjin, China; Tianjin Key 
      Laboratory of Therapeutic Substance of Traditional Chinese Medicine, Tianjin 
      University of Traditional Chinese Medicine, Tianjin, China.
FAU - Sun, Yanwen
AU  - Sun Y
AD  - Institute of Traditional Chinese Medicine, Tianjin University of Traditional 
      Chinese Medicine, Tinjin, China; Tianjin Key Laboratory of Therapeutic Substance 
      of Traditional Chinese Medicine, Tianjin University of Traditional Chinese 
      Medicine, Tianjin, China.
FAU - Ma, Jiantong
AU  - Ma J
AD  - Institute of Traditional Chinese Medicine, Tianjin University of Traditional 
      Chinese Medicine, Tinjin, China; Tianjin Key Laboratory of Therapeutic Substance 
      of Traditional Chinese Medicine, Tianjin University of Traditional Chinese 
      Medicine, Tianjin, China.
FAU - Meng, Zhaojun
AU  - Meng Z
AD  - Institute of Traditional Chinese Medicine, Tianjin University of Traditional 
      Chinese Medicine, Tinjin, China.
FAU - Zhao, Lin
AU  - Zhao L
AD  - Institute of Traditional Chinese Medicine, Tianjin University of Traditional 
      Chinese Medicine, Tinjin, China.
FAU - Zhu, Na
AU  - Zhu N
AD  - Institute of Traditional Chinese Medicine, Tianjin University of Traditional 
      Chinese Medicine, Tinjin, China.
FAU - Zhou, Kun
AU  - Zhou K
AD  - Institute of Traditional Chinese Medicine, Tianjin University of Traditional 
      Chinese Medicine, Tinjin, China. Electronic address: z.k.ken@263.net.
FAU - Qiu, Feng
AU  - Qiu F
AD  - School of Chinese Materia Medica, Tianjin University of Traditional Chinese 
      Medicine, Tianjin, China; Tianjin Key Laboratory of Therapeutic Substance of 
      Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, 
      Tianjin, China. Electronic address: fengqiu20070118@163.com.
LA  - eng
PT  - Journal Article
DEP - 20231220
PL  - United States
TA  - Bioorg Chem
JT  - Bioorganic chemistry
JID - 1303703
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Estrogens)
RN  - 0 (Lignans)
RN  - 0 (eucommiae cortex)
SB  - IM
MH  - Animals
MH  - Rats
MH  - Chromatography, High Pressure Liquid/methods
MH  - *Drugs, Chinese Herbal/pharmacology/analysis
MH  - Estrogens/pharmacology
MH  - *Lignans/pharmacology
MH  - Medicine, Chinese Traditional
OTO - NOTNLM
OT  - Effective substances
OT  - Estrogen-like activity
OT  - Eucommiae Cortex
OT  - Identification
OT  - In vivo
OT  - Isolation
OT  - Metabolites
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2024/01/04 11:43
MHDA- 2024/01/24 06:43
CRDT- 2024/01/03 18:06
PHST- 2023/11/07 00:00 [received]
PHST- 2023/12/09 00:00 [revised]
PHST- 2023/12/18 00:00 [accepted]
PHST- 2024/01/24 06:43 [medline]
PHST- 2024/01/04 11:43 [pubmed]
PHST- 2024/01/03 18:06 [entrez]
AID - S0045-2068(23)00713-7 [pii]
AID - 10.1016/j.bioorg.2023.107052 [doi]
PST - ppublish
SO  - Bioorg Chem. 2024 Feb;143:107052. doi: 10.1016/j.bioorg.2023.107052. Epub 2023 
      Dec 20.

PMID- 35850312
OWN - NLM
STAT- MEDLINE
DCOM- 20220816
LR  - 20220816
IS  - 1872-7573 (Electronic)
IS  - 0378-8741 (Linking)
VI  - 297
DP  - 2022 Oct 28
TI  - Rooibos (Aspalathus linearis) alters secretome trace amine profile of probiotic 
      and commensal microbes in vitro.
PG  - 115548
LID - S0378-8741(22)00587-6 [pii]
LID - 10.1016/j.jep.2022.115548 [doi]
AB  - ETHNOPHARMACOLOGY RELEVANCE: Aspalathus linearis (Burm.f.) R. Dahlgren (rooibos) 
      tea is anecdotally renowned for its calming effect in the context of 
      gastrointestinal discomfort, but little scientific support is available to 
      elucidate potential mechanisms of action. Enhancement of dietary polyphenol 
      content to improve gut health via prebiotic-like modulation of the gut microbiota 
      has gained significant research interest. Given the known high polyphenol content 
      of rooibos, rooibos tea may potentially exert a prebiotic effect in the gut to 
      facilitate an improvement in chronic inflammatory gastrointestinal conditions. 
      AIM OF THE STUDY: This study aimed to determine the prebiotic or 
      health-modulating potential of rooibos tea in terms of its effect on gut 
      microbial growth and secretome trace amine composition, as well as to determine 
      how differential rooibos processing alters this activity. METHODS: Three rooibos 
      preparations (green and fermented leave aqueous extracts, as well as a green leaf 
      ethanol extract) were compared in terms of their phenolic composition 
      (qTOF-LC/MS). Moreover, the effect of rooibos exposure on growth and secretome 
      trace amine levels of probiotic and commensal microbes were assessed (LC/MS). In 
      addition, given the known female bias prevalent for many gastrointestinal 
      disorders, experiments were conducted in the absence and presence of estradiol. 
      RESULTS: Polyphenolic composition of rooibos was drastically reduced by 
      fermentation. Aqueous extracts of both green and fermented rooibos improved 
      microbial growth, although fermented rooibos had the most pronounced effect 
      (p < 0.01). In terms of secretome trace amine profile, both aqueous extracts of 
      rooibos seemed to facilitate increased putrescine secretion (p < 0.0001) and 
      decreased tryptamine production (p < 0.0001). Estradiol seemed to suppress trace 
      amine secretion by bacteria (Lactobacillus plantarum, Lactobacillus reuteri and 
      Enterococcus mundtii) but increased it in yeast (Saccharomyces boulardii). 
      CONCLUSION: Rooibos altered gut probiotic and commensal microbial growth and 
      secretome trace amine profiles in vitro, suggesting it has potential to modulate 
      gut microbial composition and functionality as a prebiotic. Current data suggest 
      that these effects are highly dependent on raw material processing. Finally, 
      rooibos may be able to prevent estradiol-associated alterations in trace amine 
      profile, which may have important implications for patient management in 
      female-predominant gastrointestinal disorders.
CI  - Copyright © 2022 Elsevier B.V. All rights reserved.
FAU - Pretorius, L
AU  - Pretorius L
AD  - Department of Physiological Sciences, Faculty of Science, Stellenbosch 
      University, South Africa. Electronic address: 19058098@sun.ac.za.
FAU - Van Staden, A D
AU  - Van Staden AD
AD  - Department of Microbiology, Faculty of Science, Stellenbosch University, South 
      Africa; Division of Clinical Pharmacology, Department of Medicine, Faculty of 
      Medicine and Health Sciences, Stellenbosch University, South Africa. Electronic 
      address: advanstaden@sun.ac.za.
FAU - Kellermann, T A
AU  - Kellermann TA
AD  - Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine 
      and Health Sciences, Stellenbosch University, South Africa. Electronic address: 
      tkellermann@sun.ac.za.
FAU - Henning, N
AU  - Henning N
AD  - Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine 
      and Health Sciences, Stellenbosch University, South Africa. Electronic address: 
      20688717@sun.ac.za.
FAU - Smith, C
AU  - Smith C
AD  - Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine 
      and Health Sciences, Stellenbosch University, South Africa. Electronic address: 
      csmith@sun.ac.za.
LA  - eng
PT  - Journal Article
DEP - 20220716
PL  - Ireland
TA  - J Ethnopharmacol
JT  - Journal of ethnopharmacology
JID - 7903310
RN  - 0 (Amines)
RN  - 0 (Plant Extracts)
RN  - 0 (Polyphenols)
RN  - 0 (Tea)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Amines
MH  - *Aspalathus
MH  - Estradiol
MH  - Female
MH  - Humans
MH  - Plant Extracts/pharmacology
MH  - Polyphenols
MH  - *Probiotics
MH  - Secretome
MH  - Tea
OTO - NOTNLM
OT  - Aspalathin
OT  - Estradiol
OT  - Gut health
OT  - Polyphenols
OT  - Putrescine
OT  - Tea
OT  - Tyramine
EDAT- 2022/07/20 06:00
MHDA- 2022/08/17 06:00
CRDT- 2022/07/19 07:26
PHST- 2022/06/09 00:00 [received]
PHST- 2022/07/11 00:00 [revised]
PHST- 2022/07/12 00:00 [accepted]
PHST- 2022/07/20 06:00 [pubmed]
PHST- 2022/08/17 06:00 [medline]
PHST- 2022/07/19 07:26 [entrez]
AID - S0378-8741(22)00587-6 [pii]
AID - 10.1016/j.jep.2022.115548 [doi]
PST - ppublish
SO  - J Ethnopharmacol. 2022 Oct 28;297:115548. doi: 10.1016/j.jep.2022.115548. Epub 
      2022 Jul 16.

PMID- 34649346
OWN - NLM
STAT- MEDLINE
DCOM- 20220127
LR  - 20240226
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 143
DP  - 2021 Nov
TI  - Epiphytic Acampe ochracea orchid relieves paracetamol-induced hepatotoxicity by 
      inhibiting oxidative stress and upregulating antioxidant genes in in vivo and 
      virtual screening.
PG  - 112215
LID - S0753-3322(21)00999-9 [pii]
LID - 10.1016/j.biopha.2021.112215 [doi]
AB  - Orchids are basically ornamental, and biological functions are seldom evaluated. 
      This research investigated the effects of Acampe ochracea methanol extract (AOME) 
      in ameliorating the paracetamol (PCM) induced liver injury in Wistar albino rats, 
      evaluating its phytochemical status through UPLC-qTOF-MS analysis. With molecular 
      docking and network pharmacology, virtual screening verified the inevitable 
      interactions between the UPLC-qTOF-MS-characterized compounds and 
      hepatoprotective drug receptors. The AOME has explicit a dose-dependent decrease 
      of liver enzymes acid phosphatase (ACP), aspartate aminotransferase (AST), 
      alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyl 
      transferase (GGT), lactate dehydrogenase (LDH), total bilirubin, as well as an 
      increase of serum total protein and antioxidant enzymes catalase (CAT), 
      superoxide dismutase (SOD), glutathione reductase (GSH) with a virtual 
      normalization (p < 0.05-p < 0.001) and the values were almost equivalent to the 
      reference drug silymarin. After pretreatment with AOME, PCM-induced 
      malondialdehyde (MDA) levels were considerably decreased (p < 0.001). 
      Histopathological examinations corroborated the functional and biochemical 
      findings. The AOME upregulated the genes involved in antioxidative (CAT, SOD, 
      β-actin, PON1, and PFK1) and hepatoprotective mechanisms in PCM intoxicated rats. 
      An array of 103 compounds has been identified from AOME through UPLC-qTOF-MS 
      analysis. The detected compounds were substantially related to the targets of 
      several liver proteins and antioxidative enzymes, according to an in silico 
      study. Virtual prediction by SwissADME and admetSAR showed that AOME has 
      drug-like, non-toxic, and potential pharmacological activities in hepatic damage. 
      Furthermore, VEGFA, CYP19A1, MAPK14, ESR1, and PPARG genes interact with target 
      compounds impacting the significant biological actions to recover PCM-induced 
      liver damage.
CI  - Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Ahmed, A M Abu
AU  - Ahmed AMA
AD  - Department of Genetic Engineering and Biotechnology, University of Chittagong, 
      Chittagong 4331, Bangladesh; Department of Biochemistry and Molecular Biology, 
      University of Chittagong, Chittagong 4331, Bangladesh.
FAU - Rahman, Md Atiar
AU  - Rahman MA
AD  - Department of Biochemistry and Molecular Biology, University of Chittagong, 
      Chittagong 4331, Bangladesh. Electronic address: atiar@cu.ac.bd.
FAU - Hossen, Md Amjad
AU  - Hossen MA
AD  - Department of Pharmacy, International Islamic University Chittagong, Chittagong 
      4318, Bangladesh.
FAU - Reza, A S M Ali
AU  - Reza ASMA
AD  - Department of Biochemistry and Molecular Biology, University of Chittagong, 
      Chittagong 4331, Bangladesh; Department of Pharmacy, International Islamic 
      University Chittagong, Chittagong 4318, Bangladesh.
FAU - Islam, Md Shahidul
AU  - Islam MS
AD  - Department of Biochemistry and Molecular Biology, University of Chittagong, 
      Chittagong 4331, Bangladesh.
FAU - Rashid, Md Mamunur
AU  - Rashid MM
AD  - Department of Biochemistry and Molecular Biology, University of Chittagong, 
      Chittagong 4331, Bangladesh.
FAU - Rafi, Md Khalid Juhani
AU  - Rafi MKJ
AD  - Department of Biochemistry and Molecular Biology, University of Chittagong, 
      Chittagong 4331, Bangladesh.
FAU - Siddiqui, Md Tanvir Ahmed
AU  - Siddiqui MTA
AD  - Department of Biochemistry and Molecular Biology, University of Chittagong, 
      Chittagong 4331, Bangladesh.
FAU - Al-Noman, Abdullah
AU  - Al-Noman A
AD  - Department of Pharmacy, International Islamic University Chittagong, Chittagong 
      4318, Bangladesh.
FAU - Uddin, Md Nazim
AU  - Uddin MN
AD  - Institute of Food Science and Technology, Bangladesh Council of Scientific and 
      Industrial Research, Dhaka 1205, Bangladesh.
LA  - eng
PT  - Journal Article
DEP - 20210928
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Antioxidants)
RN  - 0 (Estrogen Receptor alpha)
RN  - 0 (PPAR gamma)
RN  - 0 (PPAR gamma, rat)
RN  - 0 (Phytochemicals)
RN  - 0 (Plant Extracts)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 0 (vascular endothelial growth factor A, rat)
RN  - 362O9ITL9D (Acetaminophen)
RN  - EC 1.14.14.1 (Aromatase)
RN  - EC 1.14.14.1 (CYP19A1 protein, rat)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 14)
SB  - IM
MH  - Acetaminophen
MH  - Animals
MH  - Antioxidants/isolation & purification/pharmacokinetics/*pharmacology
MH  - Aromatase/genetics/metabolism
MH  - Chemical and Drug Induced Liver Injury/genetics/metabolism/pathology/*prevention 
      & control
MH  - Disease Models, Animal
MH  - Estrogen Receptor alpha/genetics/metabolism
MH  - Gene Expression Regulation
MH  - Liver/*drug effects/metabolism/pathology
MH  - Male
MH  - Mitogen-Activated Protein Kinase 14/genetics/metabolism
MH  - Molecular Docking Simulation
MH  - Network Pharmacology
MH  - *Orchidaceae/chemistry
MH  - Oxidative Stress/*drug effects/genetics
MH  - PPAR gamma/genetics/metabolism
MH  - Phytochemicals/isolation & purification/pharmacokinetics/*pharmacology
MH  - Plant Extracts/isolation & purification/pharmacokinetics/*pharmacology
MH  - Protein Interaction Maps
MH  - Rats, Wistar
MH  - Signal Transduction
MH  - Vascular Endothelial Growth Factor A/genetics/metabolism
MH  - Rats
OTO - NOTNLM
OT  - Acampe ochracea
OT  - Antioxidant
OT  - Biochemical
OT  - Hepatoprotective
OT  - Liver and PCM
OT  - UPLC-qTOF-MS
EDAT- 2021/10/16 06:00
MHDA- 2022/01/28 06:00
CRDT- 2021/10/15 01:01
PHST- 2021/07/15 00:00 [received]
PHST- 2021/09/13 00:00 [revised]
PHST- 2021/09/15 00:00 [accepted]
PHST- 2021/10/15 01:01 [entrez]
PHST- 2021/10/16 06:00 [pubmed]
PHST- 2022/01/28 06:00 [medline]
AID - S0753-3322(21)00999-9 [pii]
AID - 10.1016/j.biopha.2021.112215 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2021 Nov;143:112215. doi: 10.1016/j.biopha.2021.112215. Epub 
      2021 Sep 28.

PMID- 26025473
OWN - NLM
STAT- MEDLINE
DCOM- 20160506
LR  - 20250103
IS  - 1879-1298 (Electronic)
IS  - 0045-6535 (Linking)
VI  - 139
DP  - 2015 Nov
TI  - Dietary exposure to endocrine disrupting chemicals in metropolitan population 
      from China: a risk assessment based on probabilistic approach.
PG  - 2-8
LID - S0045-6535(15)00499-3 [pii]
LID - 10.1016/j.chemosphere.2015.05.036 [doi]
AB  - The intake of contaminated foods is an important exposure pathway for endocrine 
      disrupting chemicals (EDCs). However, data on the occurrence of EDCs in 
      foodstuffs are sporadic and the resultant risk of co-exposure is rarely 
      concerned. In this study, 450 food samples representing 7 food categories (mainly 
      raw and fresh food), collected from three geographic cities in China, were 
      analyzed for eight EDCs using high performance liquid chromatography tandem mass 
      spectrometry (HPLC-MS/MS). Besides estrone (E1), other EDCs including 
      diethylstilbestrol (DES), nonylphenol (NP), bisphenol A (BPA), octylphenol (OP), 
      17β-estradiol (E2), 17α-ethinylestradiol (EE2), and estriol (E3) were ubiquitous 
      in food. Dose-dependent relationships were found between NP and EE2 (r=0.196, 
      p<0.05), BPA (r=0.391, p<0.05). Moreover, there existed a correspondencebetween 
      EDCs congener and food category. Based on the obtained database of EDCs 
      concentration combined with local food consumption, dietary EDCs exposure was 
      estimated using the Monte Carlo Risk Assessment (MCRA) system. The 50th and 95th 
      percentile exposure of any EDCs isomer were far below the tolerable daily intake 
      (TDI) value identically. However, the sum of 17β-estradiol equivalents (∑EEQs) 
      exposure in population was considerably larger than the value of exposure to E2, 
      which implied the underlying resultant risk of multiple EDCs in food should be 
      concern. In conclusion, co-exposure via food consumption should be considered 
      rather than individual EDCs during health risk evaluation.
CI  - Copyright © 2015 Elsevier Ltd. All rights reserved.
FAU - He, Dongliang
AU  - He D
AD  - Department of Nutrition and Food Hygiene, Hubei Key Laboratory of Food Nutrition 
      and Safety, School of Public Health, Tongji Medical College, Huazhong University 
      of Science and Technology, Wuhan 430030, China; Department of Preventive 
      medicine, School of Public Health, University of South China, Hengyang 421001, 
      China. Electronic address: 220000207857@usc.edu.cn.
FAU - Ye, Xiaolei
AU  - Ye X
AD  - School of Environmental Science and Public Health, Wenzhou Medical University, 
      Wenzhou 325000, China. Electronic address: 1098569236@qq.com.
FAU - Xiao, Yonghua
AU  - Xiao Y
AD  - Wuhan Center for Disease Control and Prevention, Wuhan 430015, China. Electronic 
      address: 280114030@qq.com.
FAU - Zhao, Nana
AU  - Zhao N
AD  - School of Environmental Science and Public Health, Wenzhou Medical University, 
      Wenzhou 325000, China. Electronic address: zhaonana582@163.com.
FAU - Long, Jia
AU  - Long J
AD  - Department of Nutrition and Food Hygiene, Hubei Key Laboratory of Food Nutrition 
      and Safety, School of Public Health, Tongji Medical College, Huazhong University 
      of Science and Technology, Wuhan 430030, China. Electronic address: 
      358031666@qq.com.
FAU - Zhang, Piwei
AU  - Zhang P
AD  - Department of Nutrition and Food Hygiene, Hubei Key Laboratory of Food Nutrition 
      and Safety, School of Public Health, Tongji Medical College, Huazhong University 
      of Science and Technology, Wuhan 430030, China. Electronic address: 
      407500399@qq.com.
FAU - Fan, Ying
AU  - Fan Y
AD  - Department of Nutrition and Food Hygiene, Hubei Key Laboratory of Food Nutrition 
      and Safety, School of Public Health, Tongji Medical College, Huazhong University 
      of Science and Technology, Wuhan 430030, China. Electronic address: 
      yfan@hust.edu.cn.
FAU - Ding, Shibin
AU  - Ding S
AD  - Department of Nutrition and Food Hygiene, Hubei Key Laboratory of Food Nutrition 
      and Safety, School of Public Health, Tongji Medical College, Huazhong University 
      of Science and Technology, Wuhan 430030, China. Electronic address: 
      dingshibin@163.com.
FAU - Jin, Xin
AU  - Jin X
AD  - Department of Nutrition and Food Hygiene, Hubei Key Laboratory of Food Nutrition 
      and Safety, School of Public Health, Tongji Medical College, Huazhong University 
      of Science and Technology, Wuhan 430030, China. Electronic address: 
      375039979@qq.com.
FAU - Tian, Chong
AU  - Tian C
AD  - Department of Nutrition and Food Hygiene, Hubei Key Laboratory of Food Nutrition 
      and Safety, School of Public Health, Tongji Medical College, Huazhong University 
      of Science and Technology, Wuhan 430030, China. Electronic address: 
      tianchong0826@aliyun.com.
FAU - Xu, Shunqing
AU  - Xu S
AD  - Ministry of Education Key Laboratory of Environment and Health, School of Public 
      Health, Tongji Medical College, Huazhong University of Science and Technology, 
      Wuhan 430030, China. Electronic address: xust@hust.edu.cn.
FAU - Ying, Chenjiang
AU  - Ying C
AD  - Department of Nutrition and Food Hygiene, Hubei Key Laboratory of Food Nutrition 
      and Safety, School of Public Health, Tongji Medical College, Huazhong University 
      of Science and Technology, Wuhan 430030, China. Electronic address: 
      yingcj@hust.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150526
PL  - England
TA  - Chemosphere
JT  - Chemosphere
JID - 0320657
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Endocrine Disruptors)
RN  - 0 (Environmental Pollutants)
RN  - 0 (Phenols)
RN  - 0 (octylphenol)
RN  - 2DI9HA706A (Estrone)
RN  - 423D2T571U (Ethinyl Estradiol)
RN  - 4TI98Z838E (Estradiol)
RN  - 731DCA35BT (Diethylstilbestrol)
RN  - 79F6A2ILP5 (nonylphenol)
RN  - FB33469R8E (Estriol)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - Adult
MH  - Benzhydryl Compounds/analysis
MH  - China
MH  - Chromatography, High Pressure Liquid
MH  - Cities
MH  - Diet
MH  - Diethylstilbestrol/analysis
MH  - Endocrine Disruptors/*analysis
MH  - Environmental Monitoring
MH  - Environmental Pollutants/analysis
MH  - Estradiol/analysis
MH  - Estriol/analysis
MH  - Estrone/analysis
MH  - Ethinyl Estradiol/analysis
MH  - Food Contamination/*analysis
MH  - Humans
MH  - Monte Carlo Method
MH  - Phenols/analysis
MH  - Risk Assessment
MH  - Tandem Mass Spectrometry
OTO - NOTNLM
OT  - 17β-Estradiol equivalent (∑EEQs)
OT  - Dietary exposure
OT  - Endocrine disrupting chemicals (EDCs)
OT  - Probabilistic modeling
OT  - Risk assessment
EDAT- 2015/05/31 06:00
MHDA- 2016/05/07 06:00
CRDT- 2015/05/31 06:00
PHST- 2014/03/29 00:00 [received]
PHST- 2015/04/16 00:00 [revised]
PHST- 2015/05/14 00:00 [accepted]
PHST- 2015/05/31 06:00 [entrez]
PHST- 2015/05/31 06:00 [pubmed]
PHST- 2016/05/07 06:00 [medline]
AID - S0045-6535(15)00499-3 [pii]
AID - 10.1016/j.chemosphere.2015.05.036 [doi]
PST - ppublish
SO  - Chemosphere. 2015 Nov;139:2-8. doi: 10.1016/j.chemosphere.2015.05.036. Epub 2015 
      May 26.

PMID- 25533387
OWN - NLM
STAT- MEDLINE
DCOM- 20151203
LR  - 20221207
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
VI  - 58
IP  - 4
DP  - 2015 Apr
TI  - Plasma isoflavone concentration is associated with decreased risk of type 2 
      diabetes in Korean women but not men: results from the Korean Genome and 
      Epidemiology Study.
PG  - 726-35
LID - 10.1007/s00125-014-3463-x [doi]
AB  - AIMS/HYPOTHESIS: To examine the association between soybean products and risk of 
      type 2 diabetes, we measured four isoflavone biological markers--genistein, 
      daidzein, glycitein and equol--in a nested case-control study. METHODS: The study 
      population was composed of 693 cases (316 women and 377 men) and 698 matched 
      controls (317 women and 381 men) within the Korean Genome and Epidemiology Study. 
      The concentrations of isoflavone biomarkers were measured using HPLC-MS/MS on 
      plasma samples that were collected at baseline. A stratified analysis was 
      undertaken to examine the association between plasma isoflavone concentrations 
      and risk of type 2 diabetes according to sex and equol production. Logistic 
      regression models were used to compute ORs and 95% CIs adjusted for confounders. 
      RESULTS: In women, compared with the lowest quartile of plasma concentration of 
      genistein, the highest quartile exhibited a significantly decreased risk of 
      diabetes (OR 0.58, 95% CI 0.35, 0.95). When stratified by equol-producing status 
      in women, the OR for diabetes in the highest vs the lowest quartile of genistein 
      concentration was 0.31 (95% CI 0.16, 0.60) in equol producers, but genistein 
      concentration was not associated with risk of diabetes in equol non-producers (p 
      for interaction = 0.013). In men, isoflavone concentrations were not associated 
      with risk of diabetes, regardless of equol-producing status. 
      CONCLUSIONS/INTERPRETATION: High plasma concentrations of genistein were 
      associated with a decreased risk of type 2 diabetes in women. This inverse 
      association was prominent in equol-producing participants. These results suggest 
      a beneficial effect of a high intake of soybean products on risk of type 2 
      diabetes in women.
FAU - Ko, Kwang-Pil
AU  - Ko KP
AD  - Department of Preventive Medicine, Gachon University, Incheon, Korea.
FAU - Kim, Cheong-Sik
AU  - Kim CS
FAU - Ahn, Younjhin
AU  - Ahn Y
FAU - Park, Seon-Joo
AU  - Park SJ
FAU - Kim, Yeon-Jeong
AU  - Kim YJ
FAU - Park, Jae Kyung
AU  - Park JK
FAU - Lim, Young-Khi
AU  - Lim YK
FAU - Yoo, Keun-Young
AU  - Yoo KY
FAU - Kim, Sung Soo
AU  - Kim SS
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141223
PL  - Germany
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
RN  - 0 (Isoflavones)
RN  - 531-95-3 (Equol)
RN  - 6287WC5J2L (daidzein)
RN  - 92M5F28TVF (glycitein)
RN  - DH2M523P0H (Genistein)
SB  - IM
MH  - Asian People/genetics
MH  - Case-Control Studies
MH  - Chi-Square Distribution
MH  - Chromatography, High Pressure Liquid
MH  - Diabetes Mellitus, Type 2/diagnosis/ethnology/genetics/*prevention & control
MH  - *Diet
MH  - Equol/blood
MH  - Female
MH  - Genistein/blood
MH  - Genome, Human
MH  - Humans
MH  - Isoflavones/*blood
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Prospective Studies
MH  - Protective Factors
MH  - Republic of Korea/epidemiology
MH  - Risk Assessment
MH  - Risk Factors
MH  - Sex Factors
MH  - *Soy Foods
MH  - Tandem Mass Spectrometry
EDAT- 2014/12/24 06:00
MHDA- 2015/12/15 06:00
CRDT- 2014/12/24 06:00
PHST- 2014/06/16 00:00 [received]
PHST- 2014/11/05 00:00 [accepted]
PHST- 2014/12/24 06:00 [entrez]
PHST- 2014/12/24 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - 10.1007/s00125-014-3463-x [doi]
PST - ppublish
SO  - Diabetologia. 2015 Apr;58(4):726-35. doi: 10.1007/s00125-014-3463-x. Epub 2014 
      Dec 23.

PMID- 39721436
OWN - NLM
STAT- MEDLINE
DCOM- 20250128
LR  - 20250128
IS  - 1873-7072 (Electronic)
IS  - 0308-8146 (Linking)
VI  - 469
DP  - 2025 Mar 30
TI  - Establishment and application of a high-performance liquid chromatography-mass 
      spectrometry method for analysis of 15 bisphenols and halogenated phenols in tea.
PG  - 142561
LID - S0308-8146(24)04211-0 [pii]
LID - 10.1016/j.foodchem.2024.142561 [doi]
AB  - Using high-performance liquid chromatography-mass spectrometry, fifteen 
      bisphenols and halogenated phenols were simultaneously analyzed in tea for the 
      first time in China. Response surface methodology was used to optimize sample 
      preparation conditions based on QuEChERS. Finally, the limits of detection and 
      the limits of quantification were 0.0200-0.173 μg/kg and 0.0892-0.770 μg/kg, 
      respectively. The recoveries were 70 %-120 % for most compounds (except for some 
      compounds at low spiked concentrations) with RSDs <20 %. Then 135 dried tea 
      samples were analyzed. Bisphenol S, A and F were the predominant bisphenol 
      contaminants with detection rates above 80 %, and the median level of bisphenol F 
      (4.90 μg/kg) was even higher than that of bisphenol A (2.74 μg/kg). Bisphenol A 
      (p < 0.001) and bisphenol F (p = 0.007) were significantly higher in black tea 
      than in green tea. Hazard index was estimated and bisphenols in tea may pose 
      potential risks to human health.
CI  - Copyright © 2024 Elsevier Ltd. All rights reserved.
FAU - Hu, Zifan
AU  - Hu Z
AD  - Department of Public Health Laboratory Science, West China School of Public 
      Health and West China Fourth Hospital, Food Safety Monitoring and Risk Assessment 
      Key Laboratory of Sichuan Province, Chengdu, Sichuan 610041, China.
FAU - Sun, Weiyang
AU  - Sun W
AD  - Department of Public Health Laboratory Science, West China School of Public 
      Health and West China Fourth Hospital, Food Safety Monitoring and Risk Assessment 
      Key Laboratory of Sichuan Province, Chengdu, Sichuan 610041, China.
FAU - Guo, Jiaqi
AU  - Guo J
AD  - Department of Public Health Laboratory Science, West China School of Public 
      Health and West China Fourth Hospital, Food Safety Monitoring and Risk Assessment 
      Key Laboratory of Sichuan Province, Chengdu, Sichuan 610041, China.
FAU - Wang, Xuan
AU  - Wang X
AD  - Department of Public Health Laboratory Science, West China School of Public 
      Health and West China Fourth Hospital, Food Safety Monitoring and Risk Assessment 
      Key Laboratory of Sichuan Province, Chengdu, Sichuan 610041, China.
FAU - Yong, Li
AU  - Yong L
AD  - Sichuan Center for Disease Control and Prevention, Chengdu, Sichuan 610041, 
      China.
FAU - Ren, Lin
AU  - Ren L
AD  - Sichuan Center for Disease Control and Prevention, Chengdu, Sichuan 610041, 
      China.
FAU - Feng, Dejian
AU  - Feng D
AD  - Institute of Biology, National Institute of Measurement and Testing Technology, 
      Chengdu, Sichuan 610021, China.
FAU - Zou, Xiaoli
AU  - Zou X
AD  - Department of Public Health Laboratory Science, West China School of Public 
      Health and West China Fourth Hospital, Food Safety Monitoring and Risk Assessment 
      Key Laboratory of Sichuan Province, Chengdu, Sichuan 610041, China. Electronic 
      address: zouxl_1113@163.com.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20241217
PL  - England
TA  - Food Chem
JT  - Food chemistry
JID - 7702639
RN  - 0 (Phenols)
RN  - 0 (Tea)
RN  - 0 (Benzhydryl Compounds)
RN  - MLT3645I99 (bisphenol A)
RN  - 0 (Bisphenol A Compounds)
SB  - IM
MH  - *Phenols/analysis/chemistry
MH  - Chromatography, High Pressure Liquid
MH  - *Tea/chemistry
MH  - *Food Contamination/analysis
MH  - *Mass Spectrometry
MH  - *Benzhydryl Compounds/analysis/chemistry
MH  - China
MH  - Camellia sinensis/chemistry
MH  - Liquid Chromatography-Mass Spectrometry
MH  - Bisphenol A Compounds
OTO - NOTNLM
OT  - Bisphenols
OT  - HPLC-MS/MS
OT  - Halogenated phenols
OT  - Health risk
OT  - QuEChERS
OT  - Response surface methodology
OT  - Tea
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2024/12/26 00:20
MHDA- 2025/01/28 11:26
CRDT- 2024/12/25 18:12
PHST- 2024/09/08 00:00 [received]
PHST- 2024/12/07 00:00 [revised]
PHST- 2024/12/16 00:00 [accepted]
PHST- 2025/01/28 11:26 [medline]
PHST- 2024/12/26 00:20 [pubmed]
PHST- 2024/12/25 18:12 [entrez]
AID - S0308-8146(24)04211-0 [pii]
AID - 10.1016/j.foodchem.2024.142561 [doi]
PST - ppublish
SO  - Food Chem. 2025 Mar 30;469:142561. doi: 10.1016/j.foodchem.2024.142561. Epub 2024 
      Dec 17.

PMID- 26821009
OWN - NLM
STAT- MEDLINE
DCOM- 20161019
LR  - 20200225
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 21
IP  - 2
DP  - 2016 Jan 26
TI  - Metabolite Profiling Reveals the Effect of Dietary Rubus coreanus Vinegar on 
      Ovariectomy-Induced Osteoporosis in a Rat Model.
PG  - 149
LID - 10.3390/molecules21020149 [doi]
LID - 149
AB  - The study was aimed at exploring the curative effects of Rubus coreanus (RC) 
      vinegar against postmenopausal osteoporosis by using ovariectomized rats as a 
      model. The investigations were performed in five groups: sham, ovariectomized 
      (OVX) rats without treatment, low-dose RC vinegar (LRV)-treated OVX rats, 
      high-dose RC vinegar (HRV)-treated OVX rats and alendronate (ALEN)-treated OVX 
      rats. The efficacy of RC vinegar was evaluated using physical, biochemical, 
      histological and metabolomic parameters. Compared to the OVX rats, the LRV and 
      HRV groups showed positive effects on the aforementioned parameters, indicating 
      estrogen regulation. Plasma metabolome analysis of the groups using gas 
      chromatography-time of flight mass spectrometry (GC-TOF-MS) and ultra-performance 
      liquid chromatography quadrupole-TOF-MS (UPLC-Q-TOF-MS) with multivariate 
      analysis revealed 19 and 16 metabolites, respectively. Notably, the levels of 
      butyric acid, phenylalanine, glucose, tryptophan and some 
      lysophosphatidylcholines were marginally increased in RC vinegar-treated groups 
      compared to OVX. However, the pattern of metabolite levels in RC vinegar-treated 
      groups was found similar to ALEN, but differed significantly from that in sham 
      group. The results highlight the prophylactic and curative potential of dietary 
      vinegar against postmenopausal osteoporosis. RC vinegar could be an effective 
      natural alternative for the prevention of postmenopausal osteoporosis.
FAU - Lee, Mee Youn
AU  - Lee MY
AD  - Department of Bioscience and Biotechnology, Kon-Kuk University, Seoul 143-701, 
      Korea. kkamlice@hanmail.net.
FAU - Kim, Hyang Yeon
AU  - Kim HY
AD  - Department of Bioscience and Biotechnology, Kon-Kuk University, Seoul 143-701, 
      Korea. festivalkim@naver.com.
FAU - Singh, Digar
AU  - Singh D
AD  - Department of Bioscience and Biotechnology, Kon-Kuk University, Seoul 143-701, 
      Korea. singhdigar@gmail.com.
FAU - Yeo, Soo Hwan
AU  - Yeo SH
AD  - Fermented Food Science Division, Department of Agro-food Resource, National 
      Academy of Agricultural Sciences, Rural Development Administration, Jeollabuk-do 
      565-851, Korea. yeobio@rda.go.kr.
FAU - Baek, Seong Yeol
AU  - Baek SY
AD  - Fermented Food Science Division, Department of Agro-food Resource, National 
      Academy of Agricultural Sciences, Rural Development Administration, Jeollabuk-do 
      565-851, Korea. dunkbis@korea.kr.
FAU - Park, Yoo Kyoung
AU  - Park YK
AD  - Department of Medical Nutrition, Graduate School of East-West Medical Science, 
      Kyung Hee University, Gyeonggi-do 446-791, Korea. ypark@khu.ac.kr.
FAU - Lee, Choong Hwan
AU  - Lee CH
AD  - Department of Bioscience and Biotechnology, Kon-Kuk University, Seoul 143-701, 
      Korea. chlee123@konkuk.ac.kr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160126
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Plant Extracts)
RN  - Q40Q9N063P (Acetic Acid)
RN  - X1J18R4W8P (Alendronate)
SB  - IM
MH  - Acetic Acid/*administration & dosage/pharmacology
MH  - Alendronate/administration & dosage
MH  - Animals
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Gas Chromatography-Mass Spectrometry
MH  - Humans
MH  - Metabolome/*drug effects
MH  - Osteoporosis, Postmenopausal/*drug therapy/*metabolism/pathology
MH  - Ovariectomy/adverse effects
MH  - Plant Extracts/administration & dosage/pharmacology
MH  - Rats
MH  - Rubus/*chemistry
PMC - PMC6273122
OTO - NOTNLM
OT  - Rubus coreanus vinegar
OT  - mass spectrometry
OT  - multivariate analysis
OT  - osteoporosis
OT  - ovariectomy
COIS- The authors declare no conflict of interest.
EDAT- 2016/01/29 06:00
MHDA- 2016/11/12 06:00
PMCR- 2016/01/26
CRDT- 2016/01/29 06:00
PHST- 2015/12/10 00:00 [received]
PHST- 2016/01/15 00:00 [revised]
PHST- 2016/01/21 00:00 [accepted]
PHST- 2016/01/29 06:00 [entrez]
PHST- 2016/01/29 06:00 [pubmed]
PHST- 2016/11/12 06:00 [medline]
PHST- 2016/01/26 00:00 [pmc-release]
AID - molecules21020149 [pii]
AID - molecules-21-00149 [pii]
AID - 10.3390/molecules21020149 [doi]
PST - epublish
SO  - Molecules. 2016 Jan 26;21(2):149. doi: 10.3390/molecules21020149.

PMID- 26843154
OWN - NLM
STAT- MEDLINE
DCOM- 20160708
LR  - 20231213
IS  - 1938-3207 (Electronic)
IS  - 0002-9165 (Print)
IS  - 0002-9165 (Linking)
VI  - 103
IP  - 3
DP  - 2016 Mar
TI  - Acute benefits of the microbial-derived isoflavone metabolite equol on arterial 
      stiffness in men prospectively recruited according to equol producer phenotype: a 
      double-blind randomized controlled trial.
PG  - 694-702
LID - 10.3945/ajcn.115.125690 [doi]
AB  - BACKGROUND: There is much speculation with regard to the potential 
      cardioprotective benefits of equol, a microbial-derived metabolite of the 
      isoflavone daidzein, which is produced in the large intestine after soy intake in 
      30% of Western populations. Although cross-sectional and retrospective data 
      support favorable associations between the equol producer (EP) phenotype and 
      cardiometabolic health, few studies have prospectively recruited EPs to confirm 
      this association. OBJECTIVE: The aim was to determine whether the acute vascular 
      benefits of isoflavones differ according to EP phenotype and subsequently 
      investigate the effect of providing commercially produced S-(-)equol to non-EPs. 
      DESIGN: We prospectively recruited male EPs and non-EPs (n = 14/group) at 
      moderate cardiovascular risk into a double-blind, placebo-controlled crossover 
      study to examine the acute effects of soy isoflavones (80-mg aglycone 
      equivalents) on arterial stiffness [carotid-femoral pulse-wave velocity (cfPWV)], 
      blood pressure, endothelial function (measured by using the EndoPAT 2000; Itamar 
      Medical), and nitric oxide at baseline (0 h) and 6 and 24 h after intake. In a 
      separate assessment, non-EPs consumed 40 mg S-(-)equol with identical vascular 
      measurements performed 2 h after intake. RESULTS: After soy intake, cfPWV 
      significantly improved in EPs at 24 h (cfPWV change from 0 h: isoflavone, -0.2 ± 
      0.2 m/s; placebo, 0.6 ± 0.2 m/s; P < 0.01), which was significantly associated 
      with plasma equol concentrations (R = -0.36, P = 0.01). No vascular effects were 
      observed in EPs at 6 h or in non-EPs at any time point. Similarly, no benefit of 
      commercially produced S-(-)equol was observed in non-EPs despite mean plasma 
      equol concentrations reaching 3.2 μmol/L. CONCLUSIONS: Acute soy intake improved 
      cfPWV in EPs, equating to an 11-12% reduced risk of cardiovascular disease if 
      sustained. However, a single dose of commercially produced equol had no 
      cardiovascular benefits in non-EPs. These data suggest that the EP phenotype is 
      critical in unlocking the vascular benefits of equol in men, and long-term trials 
      should focus on confirming the implications of EP phenotype on cardiovascular 
      health. This trial was registered at clinicaltrials.gov as NCT01530893.
FAU - Hazim, Sara
AU  - Hazim S
AD  - Department of Nutrition, Norwich Medical School, University of East Anglia, 
      Norwich, United Kingdom.
FAU - Curtis, Peter J
AU  - Curtis PJ
AD  - Department of Nutrition, Norwich Medical School, University of East Anglia, 
      Norwich, United Kingdom.
FAU - Schär, Manuel Y
AU  - Schär MY
AD  - Department of Nutrition, Norwich Medical School, University of East Anglia, 
      Norwich, United Kingdom.
FAU - Ostertag, Luisa M
AU  - Ostertag LM
AD  - Department of Nutrition, Norwich Medical School, University of East Anglia, 
      Norwich, United Kingdom.
FAU - Kay, Colin D
AU  - Kay CD
AD  - Department of Nutrition, Norwich Medical School, University of East Anglia, 
      Norwich, United Kingdom.
FAU - Minihane, Anne-Marie
AU  - Minihane AM
AD  - Department of Nutrition, Norwich Medical School, University of East Anglia, 
      Norwich, United Kingdom.
FAU - Cassidy, Aedín
AU  - Cassidy A
AD  - Department of Nutrition, Norwich Medical School, University of East Anglia, 
      Norwich, United Kingdom a.cassidy@uea.ac.uk.
LA  - eng
SI  - ClinicalTrials.gov/NCT01530893
GR  - BB/J004545/1/Biotechnology and Biological Sciences Research Council/United 
      Kingdom
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20160203
PL  - United States
TA  - Am J Clin Nutr
JT  - The American journal of clinical nutrition
JID - 0376027
RN  - 0 (Isoflavones)
RN  - 0 (Phytoestrogens)
RN  - 0 (Plant Extracts)
RN  - 531-95-3 (Equol)
RN  - 6287WC5J2L (daidzein)
SB  - IM
MH  - Aged
MH  - Bacteria/*metabolism
MH  - *Cardiovascular Diseases/blood/physiopathology/prevention & control
MH  - Cross-Over Studies
MH  - Cross-Sectional Studies
MH  - Dietary Supplements
MH  - Double-Blind Method
MH  - *Equol/biosynthesis/blood/pharmacology
MH  - Gastrointestinal Microbiome
MH  - Humans
MH  - Isoflavones/metabolism/*pharmacology/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - *Phenotype
MH  - Phytoestrogens/metabolism/pharmacology/therapeutic use
MH  - Phytotherapy
MH  - Plant Extracts/metabolism/pharmacology/therapeutic use
MH  - Prospective Studies
MH  - Pulse Wave Analysis
MH  - Glycine max/*chemistry
MH  - Vascular Stiffness/*drug effects/physiology
PMC - PMC4763500
OTO - NOTNLM
OT  - CVD risk
OT  - arterial stiffness
OT  - equol producer phenotype
OT  - flavonoids
OT  - isoflavone
OT  - vascular function
EDAT- 2016/02/05 06:00
MHDA- 2016/07/09 06:00
PMCR- 2016/02/03
CRDT- 2016/02/05 06:00
PHST- 2015/10/20 00:00 [received]
PHST- 2015/12/28 00:00 [accepted]
PHST- 2016/02/05 06:00 [entrez]
PHST- 2016/02/05 06:00 [pubmed]
PHST- 2016/07/09 06:00 [medline]
PHST- 2016/02/03 00:00 [pmc-release]
AID - S0002-9165(22)06553-4 [pii]
AID - 125690 [pii]
AID - 10.3945/ajcn.115.125690 [doi]
PST - ppublish
SO  - Am J Clin Nutr. 2016 Mar;103(3):694-702. doi: 10.3945/ajcn.115.125690. Epub 2016 
      Feb 3.

PMID- 27836010
OWN - NLM
STAT- MEDLINE
DCOM- 20170807
LR  - 20240210
IS  - 1465-542X (Electronic)
IS  - 1465-5411 (Print)
IS  - 1465-5411 (Linking)
VI  - 18
IP  - 1
DP  - 2016 Nov 11
TI  - Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international 
      sample of 32,295 women.
PG  - 112
LID - 112
AB  - BACKGROUND: Most BRCA1 or BRCA2 mutation carriers have inherited a single 
      (heterozygous) mutation. Transheterozygotes (TH) who have inherited deleterious 
      mutations in both BRCA1 and BRCA2 are rare, and the consequences of 
      transheterozygosity are poorly understood. METHODS: From 32,295 female BRCA1/2 
      mutation carriers, we identified 93 TH (0.3 %). "Cases" were defined as TH, and 
      "controls" were single mutations at BRCA1 (SH1) or BRCA2 (SH2). Matched SH1 
      "controls" carried a BRCA1 mutation found in the TH "case". Matched SH2 
      "controls" carried a BRCA2 mutation found in the TH "case". After matching the TH 
      carriers with SH1 or SH2, 91 TH were matched to 9316 SH1, and 89 TH were matched 
      to 3370 SH2. RESULTS: The majority of TH (45.2 %) involved the three common 
      Jewish mutations. TH were more likely than SH1 and SH2 women to have been ever 
      diagnosed with breast cancer (BC; p = 0.002). TH were more likely to be diagnosed 
      with ovarian cancer (OC) than SH2 (p = 0.017), but not SH1. Age at BC diagnosis 
      was the same in TH vs. SH1 (p = 0.231), but was on average 4.5 years younger in 
      TH than in SH2 (p < 0.001). BC in TH was more likely to be estrogen receptor (ER) 
      positive (p = 0.010) or progesterone receptor (PR) positive (p = 0.013) than in 
      SH1, but less likely to be ER positive (p < 0.001) or PR positive (p = 0.012) 
      than SH2. Among 15 tumors from TH patients, there was no clear pattern of loss of 
      heterozygosity (LOH) for BRCA1 or BRCA2 in either BC or OC. CONCLUSIONS: Our 
      observations suggest that clinical TH phenotypes resemble SH1. However, TH breast 
      tumor marker characteristics are phenotypically intermediate to SH1 and SH2.
FAU - Rebbeck, Timothy R
AU  - Rebbeck TR
AD  - Department Epidemiology, Dana Farber Cancer Institute and Harvard T.H. Chan 
      School of Public Health, 1101 Dana Building, 450 Brookline Avenue, Boston, MA, 
      USA. Timothy_Rebbeck@dfci.harvard.edu.
FAU - Friebel, Tara M
AU  - Friebel TM
AD  - Department Epidemiology, Dana Farber Cancer Institute and Harvard T.H. Chan 
      School of Public Health, 1101 Dana Building, 450 Brookline Avenue, Boston, MA, 
      USA.
FAU - Mitra, Nandita
AU  - Mitra N
AD  - Department of Biostatistics and Epidemiology, Perelman School of Medicine at the 
      University of Pennsylvania, Philadelphia, PA, USA.
FAU - Wan, Fei
AU  - Wan F
AD  - Biostatistics Unit, Group Health Research Institute, Seattle, WA, USA.
FAU - Chen, Stephanie
AU  - Chen S
AD  - Department of Preventive Medicine, Keck School of Medicine, USC/Norris 
      Comprehensive Cancer Center, University of Southern California, California, USA.
FAU - Andrulis, Irene L
AU  - Andrulis IL
AD  - Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, 
      M5G 1X5, Canada.
AD  - Departments of Molecular Genetics and Laboratory Medicine and Pathobiology, 
      University of Toronto, Toronto, Ontario, Canada.
FAU - Apostolou, Paraskevi
AU  - Apostolou P
AD  - Molecular Diagnostics Laboratory, (INRASTES) Institute of Nuclear and 
      Radiological Sciences and Technology, National Centre for Scientific Research 
      "Demokritos", Patriarchou Gregoriou & Neapoleos str. Aghia Paraskevi Attikis, 
      Athens, Greece.
FAU - Arnold, Norbert
AU  - Arnold N
AD  - Department of Gynaecology and Obstetrics, University Hospital of 
      Schleswig-Holstein, Campus Kiel, Christian-Albrechts University, Kiel, Germany.
FAU - Arun, Banu K
AU  - Arun BK
AD  - Department of Breast Medical Oncology and Clinical Cancer Genetics Program, 
      University Of Texas MD Anderson Cancer Center, 1515 Pressler Street, CBP 5, 
      Houston, TX, USA.
FAU - Barrowdale, Daniel
AU  - Barrowdale D
AD  - Department of Genetics and Computational Biology, QIMR Berghofer Institute of 
      Medical Research, Brisbane, Australia.
FAU - Benitez, Javier
AU  - Benitez J
AD  - Human Genetics Group, Spanish National Cancer Centre (CNIO), Madrid, Spain.
AD  - Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain.
AD  - Human Genotyping (CEGEN) Unit, Human Cancer Genetics Program, Spanish National 
      Cancer Research Centre (CNIO), Madrid, Spain.
FAU - Berger, Raanan
AU  - Berger R
AD  - The Institute of Oncology, Chaim Sheba Medical Center, Ramat Gan, 52621, Israel.
FAU - Berthet, Pascaline
AU  - Berthet P
AD  - Centre François Baclesse, 3 avenue Général Harris, Caen, France.
FAU - Borg, Ake
AU  - Borg A
AD  - Department of Oncology, Clinical Sciences, Lund University and Skåne University 
      Hospital, Lund, Sweden.
FAU - Buys, Saundra S
AU  - Buys SS
AD  - Department of Medicine, Huntsman Cancer Institute, 2000 Circle of Hope, Salt Lake 
      City, UT, 84112, USA.
FAU - Caldes, Trinidad
AU  - Caldes T
AD  - Molecular Oncology Laboratory, Hospital Clinico San Carlos, IdISSC (El Instituto 
      de Investigación Sanitaria del Hospital Clínico San Carlos), Martin Lagos s/n, 
      Madrid, Spain.
FAU - Carter, Jonathan
AU  - Carter J
AD  - Gynaecological Oncology, The University of Sydney Cancer Centre, Royal Prince 
      Alfred Hospital, Sydney, Australia.
FAU - Chiquette, Jocelyne
AU  - Chiquette J
AD  - Unité de recherche en santé des populations, Centre des maladies du sein 
      Deschênes-Fabia, Hôpital du Saint-Sacrement, 1050, chemin Sainte-Foy, Québec, 
      Canada.
FAU - Claes, Kathleen B M
AU  - Claes KB
AD  - Center for Medical Genetics, Ghent University, De Pintelaan 185, 9000, Gent, 
      Belgium.
FAU - Couch, Fergus J
AU  - Couch FJ
AD  - Department of Laboratory Medicine and Pathology, and Health Sciences Research, 
      Mayo Clinic, 200 First Street SW, Rochester, Minnesota, USA.
FAU - Cybulski, Cezary
AU  - Cybulski C
AD  - Department of Genetics and Pathology, Pomeranian Medical University, Polabska 4, 
      Szczecin, Poland.
FAU - Daly, Mary B
AU  - Daly MB
AD  - Division of Population Science, Fox Chase Cancer Center, 333 Cottman Avenue, 
      Philadelphia, PA, 19111, USA.
FAU - de la Hoya, Miguel
AU  - de la Hoya M
AD  - Molecular Oncology Laboratory, Hospital Clinico San Carlos, IdISSC (El Instituto 
      de Investigación Sanitaria del Hospital Clínico San Carlos), Martin Lagos s/n, 
      Madrid, Spain.
FAU - Diez, Orland
AU  - Diez O
AD  - Oncogenetics Group, Vall d'Hebron Institute of Oncology (VHIO), Clinical and 
      Molecular Genetics Area, Vall d'Hebron University Hospital, Passeig Vall d'Hebron 
      119-129, Barcelona, Spain.
FAU - Domchek, Susan M
AU  - Domchek SM
AD  - Department of Medicine, Abramson Cancer Center, Perelman School of Medicine at 
      the University of Pennsylvania, Philadelphia, PA, USA.
FAU - Nathanson, Katherine L
AU  - Nathanson KL
AD  - Department of Medicine, Abramson Cancer Center, Perelman School of Medicine at 
      the University of Pennsylvania, Philadelphia, PA, USA.
FAU - Durda, Katarzyna
AU  - Durda K
AD  - Department of Genetics and Pathology, Pomeranian Medical University, Polabska 4, 
      Szczecin, Poland.
FAU - Ellis, Steve
AU  - Ellis S
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, 
      Cambridge, UK.
CN  - EMBRACE
FAU - Evans, D Gareth
AU  - Evans DG
AD  - Genomic Medicine, Manchester Academic Health Sciences Centre, Institute of Human 
      Development, Manchester University, Central Manchester University Hospitals NHS 
      Foundation Trust, Manchester, UK.
FAU - Foretova, Lenka
AU  - Foretova L
AD  - Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer 
      Institute, Zluty kopec 7, Brno, 65653, Czech Republic.
FAU - Friedman, Eitan
AU  - Friedman E
AD  - The Susanne Levy Gertner Oncogenetics Unit, Institute of Human Genetics, Chaim 
      Sheba Medical Center, Ramat Gan, 52621, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, 69978, Israel.
FAU - Frost, Debra
AU  - Frost D
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, 
      Cambridge, UK.
FAU - Ganz, Patricia A
AU  - Ganz PA
AD  - UCLA Schools of Medicine and Public Health, Division of Cancer Prevention & 
      Control Research Jonsson Comprehensive Cancer Center, 650 Charles Young Drive 
      South, Room A2-125 HS, Los Angeles, CA, 90095-6900, USA.
FAU - Garber, Judy
AU  - Garber J
AD  - Department Epidemiology, Dana Farber Cancer Institute and Harvard T.H. Chan 
      School of Public Health, 1101 Dana Building, 450 Brookline Avenue, Boston, MA, 
      USA.
FAU - Glendon, Gord
AU  - Glendon G
AD  - Ontario Cancer Genetics Network: Samuel Lunenfeld Research Institute, Mount Sinai 
      Hospital, Toronto, Ontario, M5G 1X5, Canada.
FAU - Godwin, Andrew K
AU  - Godwin AK
AD  - Department of Pathology and Laboratory Medicine, 3901 Rainbow Boulevard, 4019 
      Wahl Hall East, MS, 3040, Kansas, USA.
AD  - University of Kansas Medical Center, Kansas City, Kansas, USA.
FAU - Greene, Mark H
AU  - Greene MH
AD  - Clinical Genetics Branch, DCEG, NCI, NIH, 9609 Medical Center Drive, Room 6E-454, 
      Bethesda, MD, USA.
FAU - Gronwald, Jacek
AU  - Gronwald J
AD  - Department of Genetics and Pathology, Pomeranian Medical University, Polabska 4, 
      Szczecin, Poland.
FAU - Hahnen, Eric
AU  - Hahnen E
AD  - Center for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology 
      (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, 
      University of Cologne and University Hospital Cologne, Cologne, Germany.
FAU - Hallberg, Emily
AU  - Hallberg E
AD  - Department of Health Sciences Research, Mayo Clinic, 13400 E. Scottsdale Blvd., 
      Scottsdale, AZ, USA.
FAU - Hamann, Ute
AU  - Hamann U
AD  - Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Im 
      Neuenheimer Feld 580, 69120, Heidelberg, Germany.
FAU - Hansen, Thomas V O
AU  - Hansen TV
AD  - Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, 
      Blegdamsvej 9, DK-2100, Copenhagen, Denmark.
CN  - HEBON
FAU - Imyanitov, Evgeny N
AU  - Imyanitov EN
AD  - N.N. Petrov Institute of Oncology, St.-Petersburg, 197758, Russia.
FAU - Isaacs, Claudine
AU  - Isaacs C
AD  - Lombardi Comprehensive Cancer Center, Georgetown University, 3800 Reservoir Road 
      NW, Washington, DC, USA.
FAU - Jakubowska, Anna
AU  - Jakubowska A
AD  - Department of Genetics and Pathology, Pomeranian Medical University, Polabska 4, 
      Szczecin, Poland.
FAU - Janavicius, Ramunas
AU  - Janavicius R
AD  - Department of Molecular and Regenerative Medicine, Vilnius University Hospital 
      Santariskiu Clinics, Hematology, oncology and transfusion medicine center, 
      Santariskiu st, Vilnius, Lithuania.
AD  - State Research Institute Centre for Innovative medicine, Zygymantu st. 9, 
      Vilnius, Lithuania.
FAU - Jaworska-Bieniek, Katarzyna
AU  - Jaworska-Bieniek K
AD  - Department of Genetics and Pathology, Pomeranian Medical University, Polabska 4, 
      Szczecin, Poland.
FAU - John, Esther M
AU  - John EM
AD  - Department of Epidemiology, Cancer Prevention Institute of California, 2201 
      Walnut Avenue, Suite 300, Fremont, CA, 94538, USA.
FAU - Karlan, Beth Y
AU  - Karlan BY
AD  - Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, 
      Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Suite 290W, Los Angeles, CA, 
      USA.
FAU - Kaufman, Bella
AU  - Kaufman B
AD  - The Institute of Oncology, Chaim Sheba Medical Center, Ramat Gan, 52621, Israel.
FAU - Investigators, KConFab
AU  - Investigators K
AD  - Kathleen Cuningham Consortium for Research into Familial Breast Cancer, Peter 
      MacCallum Cancer Center, Melbourne, Australia.
FAU - Kwong, Ava
AU  - Kwong A
AD  - The Hong Kong Hereditary Breast Cancer Family Registry; Cancer Genetics Center, 
      Hong Kong Sanatorium and Hospital, Hong Kong, Hong Kong.
AD  - Department of Surgery, The University of Hong Kong, Hong Kong, Hong Kong.
FAU - Laitman, Yael
AU  - Laitman Y
AD  - The Susanne Levy Gertner Oncogenetics Unit, Institute of Human Genetics, Chaim 
      Sheba Medical Center, Ramat Gan, 52621, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, 69978, Israel.
FAU - Lasset, Christine
AU  - Lasset C
AD  - Unité de Prévention et d'Epidémiologie Génétique, Centre Léon Bérard, 28 rue 
      Laënnec, Lyon, France.
FAU - Lazaro, Conxi
AU  - Lazaro C
AD  - Molecular Diagnostic Unit, Hereditary Cancer Program, IDIBELL (Bellvitge 
      Biomedical Research Institute) Catalan Institute of Oncology, Gran Via de 
      l'Hospitalet, 199-203, 08908, L'Hospitalet Barcelona, Barcelona, Spain.
FAU - Lester, Jenny
AU  - Lester J
AD  - Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, 
      Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Suite 290W, Los Angeles, CA, 
      USA.
FAU - Loman, Niklas
AU  - Loman N
AD  - Department of Oncology, Lund University Hospital, Lund, Sweden.
FAU - Lubinski, Jan
AU  - Lubinski J
AD  - Department of Genetics and Pathology, Pomeranian Medical University, Polabska 4, 
      Szczecin, Poland.
FAU - Manoukian, Siranoush
AU  - Manoukian S
AD  - Unit of Medical Genetics, Department of Preventive and Predictive Medicine, 
      Fondazione IRCCS (Istituto Di Ricovero e Cura a Carattere Scientifico) Istituto 
      Nazionale Tumori (INT), Via Giacomo Venezian 1, 20133, Milan, Italy.
FAU - Mitchell, Gillian
AU  - Mitchell G
AD  - Familial Cancer Centre, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett 
      Street, Melbourne, VIC, 8006, Australia.
AD  - Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, 
      VIC, 3052, Australia.
FAU - Montagna, Marco
AU  - Montagna M
AD  - Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOC - IRCCS, 
      Via Gattamelata 64, Padua, Italy.
FAU - Neuhausen, Susan L
AU  - Neuhausen SL
AD  - Department of Population Sciences, Beckman Research Institute of City of Hope, 
      Duarte, CA, USA.
FAU - Nevanlinna, Heli
AU  - Nevanlinna H
AD  - Department of Obstetrics and Gynecology, University of Helsinki and Helsinki 
      University Hospital, Biomedicum Helsinki, P.O. BOX 700, (Haartmaninkatu 8), 
      00029, HUS, Helsinki, Finland.
FAU - Niederacher, Dieter
AU  - Niederacher D
AD  - Department of Gynaecology and Obstetrics, University Hospital Düsseldorf, 
      Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.
FAU - Nussbaum, Robert L
AU  - Nussbaum RL
AD  - , 513 Parnassus Ave., HSE 901E, San Francisco, CA, 94143-0794, USA.
FAU - Offit, Kenneth
AU  - Offit K
AD  - Clinical Genetics Research Laboratory, Department of Medicine, Cancer Biology and 
      Genetics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 
      10044, USA.
FAU - Olah, Edith
AU  - Olah E
AD  - Department of Molecular Genetics, National Institute of Oncology, Budapest, 
      Hungary.
FAU - Olopade, Olufunmilayo I
AU  - Olopade OI
AD  - , 5841 South Maryland Avenue, MC 2115, Chicago, IL, USA.
FAU - Park, Sue Kyung
AU  - Park SK
AD  - Department of Preventive Medicine, Seoul National University College of Medicine, 
      103 Daehak-ro, Jongno-gu, Seoul, 110-799, Korea.
FAU - Piedmonte, Marion
AU  - Piedmonte M
AD  - NRG Oncology, Statistics and Data Management Center, Roswell Park Cancer 
      Institute, Elm St & Carlton St, Buffalo, NY, 14263, USA.
FAU - Radice, Paolo
AU  - Radice P
AD  - Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of 
      Preventive and Predicted Medicine, Fondazione IRCCS (Istituto Di Ricovero e Cura 
      a Carattere Scientifico) Istituto Nazionale Tumori (INT), c/o Amaedeolab, via GA 
      Amadeo 42, 20133, Milan, Italy.
FAU - Rappaport-Fuerhauser, Christine
AU  - Rappaport-Fuerhauser C
AD  - Department of OB/GYN, Medical University of Vienna, Waehringer Guertel 18-20, A 
      1090, Vienna, Austria.
FAU - Rookus, Matti A
AU  - Rookus MA
AD  - Department of Epidemiology, Netherlands Cancer Institute, P.O. Box 90203, 1000, 
      BE, Amsterdam, The Netherlands.
FAU - Seynaeve, Caroline
AU  - Seynaeve C
AD  - Department of Medical Oncology, Family Cancer Clinic Erasmus University Medical 
      Center Cancer institute, P.O. Box 5201, 3008, AE, Rotterdam, The Netherlands.
FAU - Simard, Jacques
AU  - Simard J
AD  - Genomics Center, Centre Hospitalier Universitaire de Québec Research Center and 
      Laval University, 2705 Laurier Boulevard, Quebec City, Quebec, Canada.
FAU - Singer, Christian F
AU  - Singer CF
AD  - Department of OB/GYN and Comprehensive Cancer Center, Medical University of 
      Vienna, Waehringer Guertel 18-20, A 1090, Vienna, Austria.
FAU - Soucy, Penny
AU  - Soucy P
AD  - Genomics Center, Centre Hospitalier Universitaire de Québec Research Center and 
      Laval University, 2705 Laurier Boulevard, Quebec City, Quebec, Canada.
FAU - Southey, Melissa
AU  - Southey M
AD  - Genetic Epidemiology Laboratory, Department of Pathology, University of 
      Melbourne, Parkville, Victoria, Australia.
FAU - Stoppa-Lyonnet, Dominique
AU  - Stoppa-Lyonnet D
AD  - Service de Génétique Oncologique, Institut Curie, 26, rue d'Ulm, Paris, Cedex 05, 
      France.
FAU - Sukiennicki, Grzegorz
AU  - Sukiennicki G
AD  - Department of Genetics and Pathology, Pomeranian Medical University, Polabska 4, 
      Szczecin, Poland.
FAU - Szabo, Csilla I
AU  - Szabo CI
AD  - National Human Genome Research Institute, National Institutes of Health Building 
      50, Room 5312, 50 South Drive, MSC 004, Bethesda, MD, 20892-8004, USA.
FAU - Tancredi, Mariella
AU  - Tancredi M
AD  - Section of Genetic Oncology, Department of Laboratory Medicine, University and 
      University Hospital of Pisa, Pisa, Italy.
FAU - Teixeira, Manuel R
AU  - Teixeira MR
AD  - Department of Genetics, Portuguese Oncology Institute, Rua Dr. António Bernardino 
      de Almeida, 4200-072, Porto, Portugal.
FAU - Teo, Soo-Hwang
AU  - Teo SH
AD  - Cancer Research Initiatives Foundation, Sime Darby Medical Centre, 1 Jalan 
      SS12/1A, Subang Jaya, 47500, Malaysia.
AD  - University Malaya Cancer Research Institute, University Malaya, 50603, Kuala 
      Lumpur, Malaysia.
FAU - Terry, Mary Beth
AU  - Terry MB
AD  - Department of Epidemiology, Columbia University, New York, NY, USA.
FAU - Thomassen, Mads
AU  - Thomassen M
AD  - Department of Clinical Genetics, Odense University Hospital, Sonder Boulevard 29, 
      Odense C, Denmark.
FAU - Tihomirova, Laima
AU  - Tihomirova L
AD  - Latvian Biomedical Research and Study Centre, Ratsupites str 1, Riga, Latvia.
FAU - Tischkowitz, Marc
AU  - Tischkowitz M
AD  - Program in Cancer Genetics, Departments of Human Genetics and Oncology, McGill 
      University, Montreal, Quebec, Canada.
FAU - Toland, Amanda Ewart
AU  - Toland AE
AD  - Divison of Human Cancer Genetics, Departments of Internal Medicine and Molecular 
      Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio 
      State University, 998 Biomedical Research Tower, Columbus, OH, USA.
FAU - Toloczko-Grabarek, Aleksandra
AU  - Toloczko-Grabarek A
AD  - Department of Genetics and Pathology, Pomeranian Medical University, Polabska 4, 
      Szczecin, Poland.
FAU - Tung, Nadine
AU  - Tung N
AD  - Department of Medical Oncology, Beth Israel Deaconess Medical Center, 330 
      Brookline Avenue, Boston, MA, 02215, USA.
FAU - van Rensburg, Elizabeth J
AU  - van Rensburg EJ
AD  - Cancer Genetics Laboratory, Department of Genetics, University of Pretoria, 
      Private Bag X323, Arcadia, 0007, South Africa.
FAU - Villano, Danylo
AU  - Villano D
AD  - Clinical Cancer Genetics Laboratory, Memorial Sloane Kettering Cancer Center, New 
      York, NY, USA.
FAU - Wang-Gohrke, Shan
AU  - Wang-Gohrke S
AD  - Department of Gynaecology and Obstetrics, University Hospital Ulm, Ulm, Germany.
FAU - Wappenschmidt, Barbara
AU  - Wappenschmidt B
AD  - Center for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology 
      (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, 
      University of Cologne and University Hospital Cologne, Cologne, Germany.
FAU - Weitzel, Jeffrey N
AU  - Weitzel JN
AD  - Clinical Cancer Genetics, City of Hope, 1500 East Duarte Road, Duarte, 
      California, 91010, USA.
FAU - Zidan, Jamal
AU  - Zidan J
AD  - Institute of Oncology, Rivka Ziv Medical Center, 13000, Zefat, Israel.
AD  - The Faculty of Medicine, Bar-Ilan University, Zefat, Israel.
FAU - Zorn, Kristin K
AU  - Zorn KK
AD  - , 4301 West Markham Street, Slot 793, Little Rock, AR, 72205, USA.
FAU - McGuffog, Lesley
AU  - McGuffog L
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK.
FAU - Easton, Douglas
AU  - Easton D
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK.
FAU - Chenevix-Trench, Georgia
AU  - Chenevix-Trench G
AD  - Department of Genetics and Computational Biology, QIMR Berghofer Institute of 
      Medical Research, Brisbane, Australia.
FAU - Antoniou, Antonis C
AU  - Antoniou AC
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Cambridge, UK.
FAU - Ramus, Susan J
AU  - Ramus SJ
AD  - Department of Preventive Medicine, Keck School of Medicine, USC/Norris 
      Comprehensive Cancer Center, University of Southern California, California, USA.
AD  - Present Address: School of Women's and Children's Health, University of New South 
      Wales and The Kinghorn Cancer Centre, Garvan Institute of Medical Research, 384 
      Victoria Street, Darlinghurst, NSW, 2010, Australia.
LA  - eng
GR  - U10 CA180868/CA/NCI NIH HHS/United States
GR  - UG1 CA189867/CA/NCI NIH HHS/United States
GR  - R01 CA140323/CA/NCI NIH HHS/United States
GR  - R01 CA128978/CA/NCI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - U19 CA148065/CA/NCI NIH HHS/United States
GR  - P50 CA116201/CA/NCI NIH HHS/United States
GR  - C12292/A20861/CRUK_/Cancer Research UK/United Kingdom
GR  - R01 CA112520/CA/NCI NIH HHS/United States
GR  - UM1 CA164920/CA/NCI NIH HHS/United States
GR  - R01 CA176785/CA/NCI NIH HHS/United States
GR  - R01 CA142996/CA/NCI NIH HHS/United States
GR  - U19 CA148112/CA/NCI NIH HHS/United States
GR  - U01 CA161032/CA/NCI NIH HHS/United States
GR  - C5047/A8385/CRUK_/Cancer Research UK/United Kingdom
GR  - R01 CA083855/CA/NCI NIH HHS/United States
GR  - P50 CA083638/CA/NCI NIH HHS/United States
GR  - P30 CA168524/CA/NCI NIH HHS/United States
GR  - C5047/A10692/CRUK_/Cancer Research UK/United Kingdom
GR  - 20861/CRUK_/Cancer Research UK/United Kingdom
GR  - 11174/CRUK_/Cancer Research UK/United Kingdom
GR  - U01 CA113916/CA/NCI NIH HHS/United States
GR  - U01 CA116167/CA/NCI NIH HHS/United States
GR  - C5047/A8384/CRUK_/Cancer Research UK/United Kingdom
GR  - C1287/A 10710/CRUK_/Cancer Research UK/United Kingdom
GR  - U10 CA180822/CA/NCI NIH HHS/United States
GR  - P30 CA015083/CA/NCI NIH HHS/United States
GR  - C5047/A15007/CRUK_/Cancer Research UK/United Kingdom
GR  - R01 CA102776/CA/NCI NIH HHS/United States
GR  - C1281/A12014/CRUK_/Cancer Research UK/United Kingdom
GR  - C1287/A11990/CRUK_/Cancer Research UK/United Kingdom
GR  - C8197/A16565/CRUK_/Cancer Research UK/United Kingdom
GR  - U19 CA148537/CA/NCI NIH HHS/United States
GR  - C1287/A10118/CRUK_/Cancer Research UK/United Kingdom
GR  - P30 CA006927/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20161111
PL  - England
TA  - Breast Cancer Res
JT  - Breast cancer research : BCR
JID - 100927353
SB  - IM
MH  - Alleles
MH  - Breast Neoplasms/genetics/pathology
MH  - Exons
MH  - Female
MH  - *Genes, BRCA1
MH  - *Genes, BRCA2
MH  - *Germ-Line Mutation
MH  - Heterozygote
MH  - Humans
MH  - Loss of Heterozygosity
MH  - Phenotype
MH  - *Population Surveillance
MH  - Promoter Regions, Genetic
PMC - PMC5106833
OTO - NOTNLM
OT  - BRCA1
OT  - BRCA2
OT  - Hereditary breast and ovarian cancer
OT  - Transheterozygosity
EDAT- 2016/11/12 06:00
MHDA- 2017/08/08 06:00
PMCR- 2016/11/11
CRDT- 2016/11/13 06:00
PHST- 2016/04/12 00:00 [received]
PHST- 2016/10/07 00:00 [accepted]
PHST- 2016/11/13 06:00 [entrez]
PHST- 2016/11/12 06:00 [pubmed]
PHST- 2017/08/08 06:00 [medline]
PHST- 2016/11/11 00:00 [pmc-release]
AID - 10.1186/s13058-016-0768-3 [pii]
AID - 768 [pii]
AID - 10.1186/s13058-016-0768-3 [doi]
PST - epublish
SO  - Breast Cancer Res. 2016 Nov 11;18(1):112. doi: 10.1186/s13058-016-0768-3.

PMID- 26367200
OWN - NLM
STAT- MEDLINE
DCOM- 20160217
LR  - 20181113
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Print)
IS  - 0021-972X (Linking)
VI  - 100
IP  - 11
DP  - 2015 Nov
TI  - Bone Mineral Density as a Predictor of Subsequent Wrist Fractures: Findings From 
      the Women's Health Initiative Study.
PG  - 4315-24
LID - 10.1210/jc.2015-2568 [doi]
AB  - CONTEXT: Wrist fractures are common among postmenopausal women. Associations of 
      bone mineral density (BMD) and 10-year predicted risk of major osteoporotic 
      fracture (MOF) with wrist fractures are poorly characterized. OBJECTIVE: The 
      objective was to examine associations between the Fracture Risk Assessment Tool 
      (FRAX)-predicted risk of MOF, BMD, BMD change, and wrist fracture. DESIGN: This 
      was a prospective observational study with a mean follow-up of 8.5 years. 
      SETTING: This study included 40 US centers. PARTICIPANTS: A total of 11 392 
      participants from the Women's Health Initiative BMD Cohort aged 50-79 years at 
      baseline were included in this study. INTERVENTIONS: None. MAIN OUTCOME: The goal 
      was to measure incident wrist fracture. RESULTS: A FRAX-predicted MOF risk ≥9.3% 
      identified 17% of the women aged <65 years who subsequently experienced wrist 
      fracture. Each one standard deviation lower BMD was associated with higher wrist 
      fracture risk, with adjusted hazard ratio (95% confidence interval) of 1.66 
      (1.42-1.93) for femoral neck (FN) BMD and 1.45 (1.28-1.64) for lumbar spine BMD. 
      Compared with FN BMD T score ≥ -1.0, wrist fracture adjusted hazard ratios (95% 
      confidence interval) were: 1.51 (1.06-2.16) for a T score between -1.01 and 
      -1.49; 1.93 (1.36-2.72) for T score between -1.50 and -1.99; 2.52 (1.77-3.60) for 
      a T score between -2.00 and -2.49; and 2.65 (1.78-3.95) for a T score ≤ -2.5. 
      Decrease in FN BMD between baseline and year 3 was associated with increased risk 
      of subsequent wrist fracture; however, change in lumbar spine BMD was not. 
      CONCLUSIONS: Lumbar spine and femoral neck BMDs were associated with incident 
      wrist fracture, but the FRAX threshold recommended to identify screening 
      candidates did not identify the majority of women who subsequently experienced 
      wrist fracture. Improved understanding of determinants of wrist fractures is 
      warranted.
FAU - Crandall, Carolyn J
AU  - Crandall CJ
AD  - Department of Medicine (C.J.C.), David Geffen School of Medicine, University of 
      California at Los Angeles, Los Angeles, California 90024; Department of 
      Epidemiology and Environmental Health (K.M.H., J.W.-W.), State University of New 
      York at Buffalo, Buffalo, New York 14260; Department of Ophthalmology and Visual 
      Sciences (C.A.A.), University of Michigan, Ann Arbor, Michigan 48109; Department 
      of Epidemiology (J.A.C.), Graduate School of Public Health, University of 
      Pittsburgh, Pittsburgh, Pennsylvania 15261; Division of Preventive Medicine 
      (J.E.M.) and Department of Medicine, Endocrine, Diabetes and Hypertension 
      Division (M.S.L.), Brigham and Women's Hospital, Harvard Medical School, Boston, 
      Massachusetts 02467; Department of Epidemiology (N.C.W.) and Division of Clinical 
      Immunology and Rheumatology (J.R.C.), University of Alabama at Birmingham, 
      Birmingham, Alabama 35294; Division of Preventive and Behavioral Medicine (W.L.), 
      University of Massachusetts Medical School, Worcester, Massachusetts 01655; and 
      Department of Health and Exercise Science (K.B.), Wake Forest University, 
      Winston-Salem, North Carolina 27106.
FAU - Hovey, Kathleen M
AU  - Hovey KM
AD  - Department of Medicine (C.J.C.), David Geffen School of Medicine, University of 
      California at Los Angeles, Los Angeles, California 90024; Department of 
      Epidemiology and Environmental Health (K.M.H., J.W.-W.), State University of New 
      York at Buffalo, Buffalo, New York 14260; Department of Ophthalmology and Visual 
      Sciences (C.A.A.), University of Michigan, Ann Arbor, Michigan 48109; Department 
      of Epidemiology (J.A.C.), Graduate School of Public Health, University of 
      Pittsburgh, Pittsburgh, Pennsylvania 15261; Division of Preventive Medicine 
      (J.E.M.) and Department of Medicine, Endocrine, Diabetes and Hypertension 
      Division (M.S.L.), Brigham and Women's Hospital, Harvard Medical School, Boston, 
      Massachusetts 02467; Department of Epidemiology (N.C.W.) and Division of Clinical 
      Immunology and Rheumatology (J.R.C.), University of Alabama at Birmingham, 
      Birmingham, Alabama 35294; Division of Preventive and Behavioral Medicine (W.L.), 
      University of Massachusetts Medical School, Worcester, Massachusetts 01655; and 
      Department of Health and Exercise Science (K.B.), Wake Forest University, 
      Winston-Salem, North Carolina 27106.
FAU - Andrews, Christopher A
AU  - Andrews CA
AD  - Department of Medicine (C.J.C.), David Geffen School of Medicine, University of 
      California at Los Angeles, Los Angeles, California 90024; Department of 
      Epidemiology and Environmental Health (K.M.H., J.W.-W.), State University of New 
      York at Buffalo, Buffalo, New York 14260; Department of Ophthalmology and Visual 
      Sciences (C.A.A.), University of Michigan, Ann Arbor, Michigan 48109; Department 
      of Epidemiology (J.A.C.), Graduate School of Public Health, University of 
      Pittsburgh, Pittsburgh, Pennsylvania 15261; Division of Preventive Medicine 
      (J.E.M.) and Department of Medicine, Endocrine, Diabetes and Hypertension 
      Division (M.S.L.), Brigham and Women's Hospital, Harvard Medical School, Boston, 
      Massachusetts 02467; Department of Epidemiology (N.C.W.) and Division of Clinical 
      Immunology and Rheumatology (J.R.C.), University of Alabama at Birmingham, 
      Birmingham, Alabama 35294; Division of Preventive and Behavioral Medicine (W.L.), 
      University of Massachusetts Medical School, Worcester, Massachusetts 01655; and 
      Department of Health and Exercise Science (K.B.), Wake Forest University, 
      Winston-Salem, North Carolina 27106.
FAU - Cauley, Jane A
AU  - Cauley JA
AD  - Department of Medicine (C.J.C.), David Geffen School of Medicine, University of 
      California at Los Angeles, Los Angeles, California 90024; Department of 
      Epidemiology and Environmental Health (K.M.H., J.W.-W.), State University of New 
      York at Buffalo, Buffalo, New York 14260; Department of Ophthalmology and Visual 
      Sciences (C.A.A.), University of Michigan, Ann Arbor, Michigan 48109; Department 
      of Epidemiology (J.A.C.), Graduate School of Public Health, University of 
      Pittsburgh, Pittsburgh, Pennsylvania 15261; Division of Preventive Medicine 
      (J.E.M.) and Department of Medicine, Endocrine, Diabetes and Hypertension 
      Division (M.S.L.), Brigham and Women's Hospital, Harvard Medical School, Boston, 
      Massachusetts 02467; Department of Epidemiology (N.C.W.) and Division of Clinical 
      Immunology and Rheumatology (J.R.C.), University of Alabama at Birmingham, 
      Birmingham, Alabama 35294; Division of Preventive and Behavioral Medicine (W.L.), 
      University of Massachusetts Medical School, Worcester, Massachusetts 01655; and 
      Department of Health and Exercise Science (K.B.), Wake Forest University, 
      Winston-Salem, North Carolina 27106.
FAU - Manson, JoAnn E
AU  - Manson JE
AD  - Department of Medicine (C.J.C.), David Geffen School of Medicine, University of 
      California at Los Angeles, Los Angeles, California 90024; Department of 
      Epidemiology and Environmental Health (K.M.H., J.W.-W.), State University of New 
      York at Buffalo, Buffalo, New York 14260; Department of Ophthalmology and Visual 
      Sciences (C.A.A.), University of Michigan, Ann Arbor, Michigan 48109; Department 
      of Epidemiology (J.A.C.), Graduate School of Public Health, University of 
      Pittsburgh, Pittsburgh, Pennsylvania 15261; Division of Preventive Medicine 
      (J.E.M.) and Department of Medicine, Endocrine, Diabetes and Hypertension 
      Division (M.S.L.), Brigham and Women's Hospital, Harvard Medical School, Boston, 
      Massachusetts 02467; Department of Epidemiology (N.C.W.) and Division of Clinical 
      Immunology and Rheumatology (J.R.C.), University of Alabama at Birmingham, 
      Birmingham, Alabama 35294; Division of Preventive and Behavioral Medicine (W.L.), 
      University of Massachusetts Medical School, Worcester, Massachusetts 01655; and 
      Department of Health and Exercise Science (K.B.), Wake Forest University, 
      Winston-Salem, North Carolina 27106.
FAU - Wactawski-Wende, Jean
AU  - Wactawski-Wende J
AD  - Department of Medicine (C.J.C.), David Geffen School of Medicine, University of 
      California at Los Angeles, Los Angeles, California 90024; Department of 
      Epidemiology and Environmental Health (K.M.H., J.W.-W.), State University of New 
      York at Buffalo, Buffalo, New York 14260; Department of Ophthalmology and Visual 
      Sciences (C.A.A.), University of Michigan, Ann Arbor, Michigan 48109; Department 
      of Epidemiology (J.A.C.), Graduate School of Public Health, University of 
      Pittsburgh, Pittsburgh, Pennsylvania 15261; Division of Preventive Medicine 
      (J.E.M.) and Department of Medicine, Endocrine, Diabetes and Hypertension 
      Division (M.S.L.), Brigham and Women's Hospital, Harvard Medical School, Boston, 
      Massachusetts 02467; Department of Epidemiology (N.C.W.) and Division of Clinical 
      Immunology and Rheumatology (J.R.C.), University of Alabama at Birmingham, 
      Birmingham, Alabama 35294; Division of Preventive and Behavioral Medicine (W.L.), 
      University of Massachusetts Medical School, Worcester, Massachusetts 01655; and 
      Department of Health and Exercise Science (K.B.), Wake Forest University, 
      Winston-Salem, North Carolina 27106.
FAU - Wright, Nicole C
AU  - Wright NC
AD  - Department of Medicine (C.J.C.), David Geffen School of Medicine, University of 
      California at Los Angeles, Los Angeles, California 90024; Department of 
      Epidemiology and Environmental Health (K.M.H., J.W.-W.), State University of New 
      York at Buffalo, Buffalo, New York 14260; Department of Ophthalmology and Visual 
      Sciences (C.A.A.), University of Michigan, Ann Arbor, Michigan 48109; Department 
      of Epidemiology (J.A.C.), Graduate School of Public Health, University of 
      Pittsburgh, Pittsburgh, Pennsylvania 15261; Division of Preventive Medicine 
      (J.E.M.) and Department of Medicine, Endocrine, Diabetes and Hypertension 
      Division (M.S.L.), Brigham and Women's Hospital, Harvard Medical School, Boston, 
      Massachusetts 02467; Department of Epidemiology (N.C.W.) and Division of Clinical 
      Immunology and Rheumatology (J.R.C.), University of Alabama at Birmingham, 
      Birmingham, Alabama 35294; Division of Preventive and Behavioral Medicine (W.L.), 
      University of Massachusetts Medical School, Worcester, Massachusetts 01655; and 
      Department of Health and Exercise Science (K.B.), Wake Forest University, 
      Winston-Salem, North Carolina 27106.
FAU - Li, Wenjun
AU  - Li W
AD  - Department of Medicine (C.J.C.), David Geffen School of Medicine, University of 
      California at Los Angeles, Los Angeles, California 90024; Department of 
      Epidemiology and Environmental Health (K.M.H., J.W.-W.), State University of New 
      York at Buffalo, Buffalo, New York 14260; Department of Ophthalmology and Visual 
      Sciences (C.A.A.), University of Michigan, Ann Arbor, Michigan 48109; Department 
      of Epidemiology (J.A.C.), Graduate School of Public Health, University of 
      Pittsburgh, Pittsburgh, Pennsylvania 15261; Division of Preventive Medicine 
      (J.E.M.) and Department of Medicine, Endocrine, Diabetes and Hypertension 
      Division (M.S.L.), Brigham and Women's Hospital, Harvard Medical School, Boston, 
      Massachusetts 02467; Department of Epidemiology (N.C.W.) and Division of Clinical 
      Immunology and Rheumatology (J.R.C.), University of Alabama at Birmingham, 
      Birmingham, Alabama 35294; Division of Preventive and Behavioral Medicine (W.L.), 
      University of Massachusetts Medical School, Worcester, Massachusetts 01655; and 
      Department of Health and Exercise Science (K.B.), Wake Forest University, 
      Winston-Salem, North Carolina 27106.
FAU - Beavers, Kristen
AU  - Beavers K
AD  - Department of Medicine (C.J.C.), David Geffen School of Medicine, University of 
      California at Los Angeles, Los Angeles, California 90024; Department of 
      Epidemiology and Environmental Health (K.M.H., J.W.-W.), State University of New 
      York at Buffalo, Buffalo, New York 14260; Department of Ophthalmology and Visual 
      Sciences (C.A.A.), University of Michigan, Ann Arbor, Michigan 48109; Department 
      of Epidemiology (J.A.C.), Graduate School of Public Health, University of 
      Pittsburgh, Pittsburgh, Pennsylvania 15261; Division of Preventive Medicine 
      (J.E.M.) and Department of Medicine, Endocrine, Diabetes and Hypertension 
      Division (M.S.L.), Brigham and Women's Hospital, Harvard Medical School, Boston, 
      Massachusetts 02467; Department of Epidemiology (N.C.W.) and Division of Clinical 
      Immunology and Rheumatology (J.R.C.), University of Alabama at Birmingham, 
      Birmingham, Alabama 35294; Division of Preventive and Behavioral Medicine (W.L.), 
      University of Massachusetts Medical School, Worcester, Massachusetts 01655; and 
      Department of Health and Exercise Science (K.B.), Wake Forest University, 
      Winston-Salem, North Carolina 27106.
FAU - Curtis, Jeffrey R
AU  - Curtis JR
AD  - Department of Medicine (C.J.C.), David Geffen School of Medicine, University of 
      California at Los Angeles, Los Angeles, California 90024; Department of 
      Epidemiology and Environmental Health (K.M.H., J.W.-W.), State University of New 
      York at Buffalo, Buffalo, New York 14260; Department of Ophthalmology and Visual 
      Sciences (C.A.A.), University of Michigan, Ann Arbor, Michigan 48109; Department 
      of Epidemiology (J.A.C.), Graduate School of Public Health, University of 
      Pittsburgh, Pittsburgh, Pennsylvania 15261; Division of Preventive Medicine 
      (J.E.M.) and Department of Medicine, Endocrine, Diabetes and Hypertension 
      Division (M.S.L.), Brigham and Women's Hospital, Harvard Medical School, Boston, 
      Massachusetts 02467; Department of Epidemiology (N.C.W.) and Division of Clinical 
      Immunology and Rheumatology (J.R.C.), University of Alabama at Birmingham, 
      Birmingham, Alabama 35294; Division of Preventive and Behavioral Medicine (W.L.), 
      University of Massachusetts Medical School, Worcester, Massachusetts 01655; and 
      Department of Health and Exercise Science (K.B.), Wake Forest University, 
      Winston-Salem, North Carolina 27106.
FAU - LeBoff, Meryl S
AU  - LeBoff MS
AD  - Department of Medicine (C.J.C.), David Geffen School of Medicine, University of 
      California at Los Angeles, Los Angeles, California 90024; Department of 
      Epidemiology and Environmental Health (K.M.H., J.W.-W.), State University of New 
      York at Buffalo, Buffalo, New York 14260; Department of Ophthalmology and Visual 
      Sciences (C.A.A.), University of Michigan, Ann Arbor, Michigan 48109; Department 
      of Epidemiology (J.A.C.), Graduate School of Public Health, University of 
      Pittsburgh, Pittsburgh, Pennsylvania 15261; Division of Preventive Medicine 
      (J.E.M.) and Department of Medicine, Endocrine, Diabetes and Hypertension 
      Division (M.S.L.), Brigham and Women's Hospital, Harvard Medical School, Boston, 
      Massachusetts 02467; Department of Epidemiology (N.C.W.) and Division of Clinical 
      Immunology and Rheumatology (J.R.C.), University of Alabama at Birmingham, 
      Birmingham, Alabama 35294; Division of Preventive and Behavioral Medicine (W.L.), 
      University of Massachusetts Medical School, Worcester, Massachusetts 01655; and 
      Department of Health and Exercise Science (K.B.), Wake Forest University, 
      Winston-Salem, North Carolina 27106.
LA  - eng
GR  - HHSN268201100001I/HL/NHLBI NIH HHS/United States
GR  - HHSN271201100004C/PHS HHS/United States
GR  - HHSN268201100001C/PHS HHS/United States
GR  - HHSN268201100004I/HL/NHLBI NIH HHS/United States
GR  - HHSN268201100046C/HL/NHLBI NIH HHS/United States
GR  - R01 AR059775/AR/NIAMS NIH HHS/United States
GR  - HHSN268201100003C/WH/WHI NIH HHS/United States
GR  - K12 HS023009/HS/AHRQ HHS/United States
GR  - HHSN268201100003C/PHS HHS/United States
GR  - HHSN268201100004C/PHS HHS/United States
GR  - HHSN271201100004C/AG/NIA NIH HHS/United States
GR  - HHSN268201100002C/WH/WHI NIH HHS/United States
GR  - HHSN268201100046C/PHS HHS/United States
GR  - HHSN268201100002I/HL/NHLBI NIH HHS/United States
GR  - HHSN268201100002C/PHS HHS/United States
GR  - HHSN268201100001C/WH/WHI NIH HHS/United States
GR  - HHSN268201100004C/WH/WHI NIH HHS/United States
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, N.I.H., Extramural
DEP - 20150914
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Bone Density/*physiology
MH  - Cohort Studies
MH  - Estrogen Replacement Therapy
MH  - Female
MH  - Femur Neck/anatomy & histology/metabolism
MH  - Follow-Up Studies
MH  - Fractures, Bone/*epidemiology
MH  - Humans
MH  - Incidence
MH  - Middle Aged
MH  - Osteoporosis/epidemiology
MH  - Osteoporotic Fractures
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - Risk Factors
MH  - Spine/anatomy & histology/metabolism
MH  - *Women
MH  - Wrist Injuries/*epidemiology
PMC - PMC4702460
EDAT- 2015/09/15 06:00
MHDA- 2016/02/18 06:00
PMCR- 2016/11/01
CRDT- 2015/09/15 06:00
PHST- 2015/09/15 06:00 [entrez]
PHST- 2015/09/15 06:00 [pubmed]
PHST- 2016/02/18 06:00 [medline]
PHST- 2016/11/01 00:00 [pmc-release]
AID - 15-2568 [pii]
AID - 10.1210/jc.2015-2568 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2015 Nov;100(11):4315-24. doi: 10.1210/jc.2015-2568. 
      Epub 2015 Sep 14.

PMID- 33086721
OWN - NLM
STAT- MEDLINE
DCOM- 20210223
LR  - 20210223
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 21
IP  - 20
DP  - 2020 Oct 19
TI  - Heregulin Drives Endocrine Resistance by Altering IL-8 Expression in ER-Positive 
      Breast Cancer.
LID - 10.3390/ijms21207737 [doi]
LID - 7737
AB  - Sustained HER2/HER3 signaling due to the overproduction of the HER3 ligand 
      heregulin (HRG) is proposed as a key contributor to endocrine resistance in 
      estrogen receptor-positive (ER+) breast cancer. The molecular mechanisms linking 
      HER2 transactivation by HRG-bound HER3 to the acquisition of a 
      hormone-independent phenotype in ER+ breast cancer is, however, largely unknown. 
      Here, we explored the possibility that autocrine HRG signaling drives 
      cytokine-related endocrine resistance in ER+ breast cancer cells. We used human 
      cytokine antibody arrays to semi-quantitatively measure the expression level of 
      60 cytokines and growth factors in the extracellular milieu of MCF-7 cells 
      engineered to overexpress full-length HRGβ2 (MCF-7/HRG cells). Interleukin-8 
      (IL-8), a chemokine closely linked to ER inaction, emerged as one the most 
      differentially expressed cytokines. Cytokine profiling using structural deletion 
      mutants lacking both the N-terminus and the cytoplasmic-transmembrane region of 
      HRGβ2-which is not secreted and cannot transactivate HER2-or lacking a nuclear 
      localization signal at the N-terminus-which cannot localize at the nucleus but is 
      actively secreted and transactivates HER2-revealed that the HRG-driven activation 
      of IL-8 expression in ER+ cells required HRG secretion and transactivation of 
      HER2 but not HRG nuclear localization. The functional blockade of IL-8 with a 
      specific antibody inversely regulated ERα-driven transcriptional activation in 
      endocrine-sensitive MCF-7 cells and endocrine-resistant MCF-7/HRG cells. Overall, 
      these findings suggest that IL-8 participates in the HRG-driven endocrine 
      resistance program in ER+/HER2- breast cancer and might illuminate a potential 
      clinical setting for IL8- or CXCR1/2-neutralizing antibodies.
FAU - Papadimitropoulou, Adriana
AU  - Papadimitropoulou A
AD  - Center of Basic Research, Biomedical Research Foundation of the Academy of 
      Athens, 115 27 Athens, Greece.
FAU - Vellon, Luciano
AU  - Vellon L
AUID- ORCID: 0000-0001-8531-6503
AD  - Stem Cells Laboratory, Institute of Biology and Experimental Medicine 
      (IBYME-CONICET), Buenos Aires C1428ADN, Argentina.
FAU - Atlas, Ella
AU  - Atlas E
AD  - Environmental Health Science and Research Bureau, Health Canada, Ottawa, ON K1A 
      0K9, Canada.
AD  - Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, 
      Ottawa, ON K1N 6N5, Canada.
FAU - Steen, Travis Vander
AU  - Steen TV
AD  - Division of Experimental Pathology, Department of Laboratory Medicine and 
      Pathology, Mayo Clinic, Rochester, MN 55905, USA.
FAU - Cuyàs, Elisabet
AU  - Cuyàs E
AD  - Program Against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer 
      Group, Catalan Institute of Oncology, 17007 Girona, Spain.
AD  - Girona Biomedical Research Institute (IDIBGI), 17190 Salt, Girona, Spain.
FAU - Verdura, Sara
AU  - Verdura S
AUID- ORCID: 0000-0001-8980-0423
AD  - Program Against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer 
      Group, Catalan Institute of Oncology, 17007 Girona, Spain.
AD  - Girona Biomedical Research Institute (IDIBGI), 17190 Salt, Girona, Spain.
FAU - Espinoza, Ingrid
AU  - Espinoza I
AD  - Department of Preventive Medicine, John D. Bower School of Population Health, 
      University of Mississippi Medical Center, Jackson, MS 39216, USA.
AD  - Cancer Institute, School of Medicine, University of Mississippi Medical Center, 
      Jackson, MS 39216, USA.
FAU - Menendez, Javier A
AU  - Menendez JA
AUID- ORCID: 0000-0001-8733-4561
AD  - Program Against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer 
      Group, Catalan Institute of Oncology, 17007 Girona, Spain.
AD  - Girona Biomedical Research Institute (IDIBGI), 17190 Salt, Girona, Spain.
FAU - Lupu, Ruth
AU  - Lupu R
AD  - Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, 
      Ottawa, ON K1N 6N5, Canada.
AD  - Department of Biochemistry and Molecular Biology Laboratory, Mayo Clinic 
      Minnesota, Rochester, MN 55905, USA.
AD  - Mayo Clinic Cancer Center, Rochester, MN 55905, USA.
LA  - eng
GR  - R01 CA116623/NH/NIH HHS/United States
GR  - BC151072/U.S. Department of Defense/
GR  - BC151072P1/U.S. Department of Defense/
GR  - SAF2016-80639-P/Ministerio de Ciencia e Innovación/
GR  - PID2019-10455GB-I00/Ministerio de Ciencia e Innovación/
PT  - Journal Article
DEP - 20201019
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Chemokines)
RN  - 0 (Interleukin-8)
RN  - 0 (Neuregulin-1)
RN  - 0 (Receptors, Estrogen)
RN  - 155646-83-6 (heregulin beta1)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Autocrine Communication
MH  - Breast Neoplasms/*metabolism/pathology
MH  - Chemokines/metabolism
MH  - Endocrine System/*metabolism
MH  - Female
MH  - Humans
MH  - Interleukin-8/*metabolism
MH  - MCF-7 Cells
MH  - Models, Biological
MH  - Neuregulin-1/*metabolism
MH  - Receptor, ErbB-2/metabolism
MH  - Receptors, Estrogen/*metabolism
MH  - Transcription, Genetic
MH  - Up-Regulation
PMC - PMC7589856
OTO - NOTNLM
OT  - IL-8
OT  - autocrine
OT  - cytokines
OT  - luminal
OT  - tamoxifen
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2020/10/23 06:00
MHDA- 2021/02/24 06:00
PMCR- 2020/10/01
CRDT- 2020/10/22 01:02
PHST- 2020/09/28 00:00 [received]
PHST- 2020/10/14 00:00 [revised]
PHST- 2020/10/16 00:00 [accepted]
PHST- 2020/10/22 01:02 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2021/02/24 06:00 [medline]
PHST- 2020/10/01 00:00 [pmc-release]
AID - ijms21207737 [pii]
AID - ijms-21-07737 [pii]
AID - 10.3390/ijms21207737 [doi]
PST - epublish
SO  - Int J Mol Sci. 2020 Oct 19;21(20):7737. doi: 10.3390/ijms21207737.

PMID- 28801832
OWN - NLM
STAT- MEDLINE
DCOM- 20180430
LR  - 20191210
IS  - 1618-2650 (Electronic)
IS  - 1618-2642 (Print)
IS  - 1618-2642 (Linking)
VI  - 409
IP  - 25
DP  - 2017 Oct
TI  - Simultaneous measurement of total estradiol and testosterone in human serum by 
      isotope dilution liquid chromatography tandem mass spectrometry.
PG  - 5943-5954
LID - 10.1007/s00216-017-0529-x [doi]
AB  - Reliable measurement of total testosterone and estradiol is critical for their 
      use as biomarkers of hormone-related disorders in patient care and translational 
      research. We developed and validated a mass spectrometry method to simultaneously 
      quantify these analytes in human serum without chemical derivatization. Serum is 
      equilibrated with isotopic internal standards and treated with acidic buffer to 
      release hormones from their binding proteins. Lipids are isolated and polar 
      impurities are removed by two serial liquid-liquid extraction steps. Total 
      testosterone and estradiol are measured using liquid chromatography tandem mass 
      spectrometry (LC-MS/MS) in combination of positive and negative electrospray 
      ionization modes. The method shows broad analytical measurement range for both 
      testosterone 0.03-48.5 nM (0.75-1400 ng/dL) and estradiol 11.0-5138 pM (2.99-1400 
      pg/mL) and excellent agreement with certified reference materials (mean bias less 
      than 2.1% to SRM 971, BCR 576, 577, and 578) and a high order reference method 
      (mean bias 1.25% for testosterone and -0.84% for estradiol). The high accuracy of 
      the method was monitored and certified by CDC Hormone Standardization (HoSt) 
      Program for 2 years with mean bias -0.7% (95% CI -1.6% to 0.2%) for testosterone 
      and 0.1% (95% CI -2.2% to 2.3%) for estradiol. The method precision over a 2-year 
      period for quality control pools at low, medium, and high concentrations was 
      2.7-2.9% for testosterone and 3.3-5.3% for estradiol. With the consistently 
      excellent accuracy and precision, this method is readily applicable for 
      high-throughput clinical and epidemiological studies.
FAU - Zhou, Hui
AU  - Zhou H
AD  - Centers For Disease Control and Prevention, National Center For Environmental 
      Health, Division of Laboratory Sciences, Clinical Chemistry Branch, 4770 Buford 
      Hwy NE, Atlanta, GA, 30341, USA.
FAU - Wang, Yuesong
AU  - Wang Y
AD  - Centers For Disease Control and Prevention, National Center For Environmental 
      Health, Division of Laboratory Sciences, Clinical Chemistry Branch, 4770 Buford 
      Hwy NE, Atlanta, GA, 30341, USA.
FAU - Gatcombe, Matthew
AU  - Gatcombe M
AD  - Centers For Disease Control and Prevention, National Center For Environmental 
      Health, Division of Laboratory Sciences, Clinical Chemistry Branch, 4770 Buford 
      Hwy NE, Atlanta, GA, 30341, USA.
FAU - Farris, Jacob
AU  - Farris J
AD  - Centers For Disease Control and Prevention, National Center For Environmental 
      Health, Division of Laboratory Sciences, Clinical Chemistry Branch, 4770 Buford 
      Hwy NE, Atlanta, GA, 30341, USA.
FAU - Botelho, Julianne C
AU  - Botelho JC
AD  - Centers For Disease Control and Prevention, National Center For Environmental 
      Health, Division of Laboratory Sciences, Clinical Chemistry Branch, 4770 Buford 
      Hwy NE, Atlanta, GA, 30341, USA.
FAU - Caudill, Samuel P
AU  - Caudill SP
AD  - Centers For Disease Control and Prevention, National Center For Environmental 
      Health, Division of Laboratory Sciences, Clinical Chemistry Branch, 4770 Buford 
      Hwy NE, Atlanta, GA, 30341, USA.
FAU - Vesper, Hubert W
AU  - Vesper HW
AD  - Centers For Disease Control and Prevention, National Center For Environmental 
      Health, Division of Laboratory Sciences, Clinical Chemistry Branch, 4770 Buford 
      Hwy NE, Atlanta, GA, 30341, USA. HVesper@cdc.gov.
LA  - eng
GR  - CC999999/Intramural CDC HHS/United States
PT  - Journal Article
PT  - Validation Study
DEP - 20170811
PL  - Germany
TA  - Anal Bioanal Chem
JT  - Analytical and bioanalytical chemistry
JID - 101134327
RN  - 0 (Isotopes)
RN  - 3XMK78S47O (Testosterone)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Chromatography, Liquid/*methods
MH  - Estradiol/*blood
MH  - Female
MH  - Humans
MH  - Indicator Dilution Techniques
MH  - Isotopes/blood
MH  - Limit of Detection
MH  - Liquid-Liquid Extraction/methods
MH  - Male
MH  - Middle Aged
MH  - Tandem Mass Spectrometry/*methods
MH  - Testosterone/*blood
MH  - Young Adult
PMC - PMC5693763
MID - NIHMS909567
OTO - NOTNLM
OT  - CDC HoSt
OT  - Estradiol
OT  - Hormone
OT  - LC–MS/MS
OT  - Serum
OT  - Testosterone
COIS- Conflict of interest The authors declare that they have no conflict of interest.
EDAT- 2017/08/13 06:00
MHDA- 2018/05/01 06:00
PMCR- 2017/11/17
CRDT- 2017/08/13 06:00
PHST- 2017/05/17 00:00 [received]
PHST- 2017/07/18 00:00 [accepted]
PHST- 2017/07/05 00:00 [revised]
PHST- 2017/08/13 06:00 [pubmed]
PHST- 2018/05/01 06:00 [medline]
PHST- 2017/08/13 06:00 [entrez]
PHST- 2017/11/17 00:00 [pmc-release]
AID - 10.1007/s00216-017-0529-x [pii]
AID - 10.1007/s00216-017-0529-x [doi]
PST - ppublish
SO  - Anal Bioanal Chem. 2017 Oct;409(25):5943-5954. doi: 10.1007/s00216-017-0529-x. 
      Epub 2017 Aug 11.

PMID- 29704771
OWN - NLM
STAT- MEDLINE
DCOM- 20181010
LR  - 20181010
IS  - 1873-264X (Electronic)
IS  - 0731-7085 (Linking)
VI  - 156
DP  - 2018 Jul 15
TI  - New approach based on immunochemical techniques for monitoring of selective 
      estrogen receptor modulators (SERMs) in human urine.
PG  - 147-152
LID - S0731-7085(18)30204-8 [pii]
LID - 10.1016/j.jpba.2018.04.027 [doi]
AB  - Antiestrogenic compounds such as tamoxifen, toremifen and chlomifen are used 
      illegally by athletes to minimize physical impacts such as gynecomastia resulting 
      from the secondary effects of anabolic androgenic steroids, used to increase 
      athletic efficiency unlawfully. The use of these compounds is banned by the World 
      Anti-Doping Agency (WADA) and controls are made through analytical methodologies 
      such as HPLC-MS/MS, which do not fulfil the sample throughput requirements. 
      Moreover, compounds such as tamoxifen are also used to treat hormone 
      receptor-positive breast cancer (ER + ).Therapeutic drug monitoring (TDM) of 
      tamoxifen may also be clinically useful for guiding treatment decisions. An 
      accurate determination of these drugs requires a solid phase extraction of 
      patient serum followed by HPLC-MS/MS. In the context of an unmet need of 
      high-throughput screening (HTS) and quantitative methods for antiestrogenic 
      substances we have approached the development of antibodies and an immunochemical 
      assay for the determination of these antiestrogenic compounds. The strategy 
      applied has taken into consideration that these drugs are metabolized and 
      excreted in urine as the corresponding 4-hydroxylated compounds. A 
      microplate-based ELISA procedure has been developed for the analysis of these 
      metabolites in urine with a LOD of 0.15, 0.16 and 0.63 μg/L for 4OH-tamoxifen, 
      4OH-toremifen and 4OH-clomifen, respectively, much lower than the MRPL 
      established by WADA (20 μg/L).
CI  - Copyright © 2018 Elsevier B.V. All rights reserved.
FAU - Salvador, J-Pablo
AU  - Salvador JP
AD  - Nanobiotechnology for Diagnostics group (Nb4D), IQAC- CSIC, Jordi Girona 18-26, 
      08034 Barcelona, Spain; CIBER de Bioingeniería, Biomateriales y Nanomedicina 
      (CIBER-BBN), Spain. Electronic address: jpablo.salvador@iqac.csic.es.
FAU - Vila-Roca, Ester
AU  - Vila-Roca E
AD  - Nanobiotechnology for Diagnostics group (Nb4D), IQAC- CSIC, Jordi Girona 18-26, 
      08034 Barcelona, Spain; CIBER de Bioingeniería, Biomateriales y Nanomedicina 
      (CIBER-BBN), Spain.
FAU - Monfort, Núria
AU  - Monfort N
AD  - Barcelona Antidoping Laboratory, IMIM (Hospital del Mar Medical Research 
      Institute), Barcelona, Spain.
FAU - Ventura, Rosa
AU  - Ventura R
AD  - Barcelona Antidoping Laboratory, IMIM (Hospital del Mar Medical Research 
      Institute), Barcelona, Spain; Department of Expermerimental and Health Sciences, 
      UPF, Pompeu Fabra University, Barcelona, Spain.
FAU - Marco, M-Pilar
AU  - Marco MP
AD  - Nanobiotechnology for Diagnostics group (Nb4D), IQAC- CSIC, Jordi Girona 18-26, 
      08034 Barcelona, Spain; CIBER de Bioingeniería, Biomateriales y Nanomedicina 
      (CIBER-BBN), Spain.
LA  - eng
PT  - Journal Article
DEP - 20180422
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Selective Estrogen Receptor Modulators)
RN  - 0 (Testosterone Congeners)
RN  - 094ZI81Y45 (Tamoxifen)
RN  - 17197F0KYM (afimoxifene)
RN  - 1HRS458QU2 (Clomiphene)
RN  - 7NFE54O27T (Toremifene)
SB  - IM
MH  - Breast Neoplasms/drug therapy
MH  - Chromatography, High Pressure Liquid
MH  - Clomiphene/metabolism/therapeutic use/urine
MH  - Doping in Sports/*prevention & control
MH  - Drug Monitoring/*methods
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Healthy Volunteers
MH  - High-Throughput Screening Assays/methods
MH  - Humans
MH  - Selective Estrogen Receptor Modulators/metabolism/therapeutic use/*urine
MH  - Solid Phase Extraction
MH  - Tamoxifen/analogs & derivatives/metabolism/therapeutic use/urine
MH  - Tandem Mass Spectrometry
MH  - Testosterone Congeners/*urine
MH  - Toremifene/metabolism/therapeutic use/urine
OTO - NOTNLM
OT  - Antibody
OT  - ELISA
OT  - Human urine
OT  - SERMs metabolites
OT  - Tamoxifen
OT  - Toremifen
EDAT- 2018/04/29 06:00
MHDA- 2018/10/12 06:00
CRDT- 2018/04/29 06:00
PHST- 2018/01/23 00:00 [received]
PHST- 2018/04/16 00:00 [revised]
PHST- 2018/04/17 00:00 [accepted]
PHST- 2018/04/29 06:00 [pubmed]
PHST- 2018/10/12 06:00 [medline]
PHST- 2018/04/29 06:00 [entrez]
AID - S0731-7085(18)30204-8 [pii]
AID - 10.1016/j.jpba.2018.04.027 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2018 Jul 15;156:147-152. doi: 10.1016/j.jpba.2018.04.027. 
      Epub 2018 Apr 22.

PMID- 39869261
OWN - NLM
STAT- Publisher
LR  - 20250127
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Linking)
DP  - 2025 Jan 27
TI  - The Johns Hopkins Hope at Hopkins Clinic: supporting the comprehensive needs of 
      individuals with metastatic breast cancer.
LID - 10.1007/s10549-024-07591-5 [doi]
AB  - PURPOSE: Individuals with metastatic breast cancer (MBC) may live with their 
      disease for many years. We initiated the Johns Hopkins Hope at Hopkins Clinic to 
      assess the needs and optimize the care of these patients. PATIENTS AND METHODS: 
      Patients with MBC who agreed to participate in the Clinic in addition to usual 
      care completed patient-reported outcome (PRO) surveys. They met with a navigator 
      and underwent core consults (cancer rehabilitation, integrative medicine, 
      supportive and palliative care, social work, and nutrition), clinical trial 
      eligibility assessment, and optional services based on PRO responses and 
      selection from a Clinic Menu. A medical oncologist provided a Care Plan during a 
      final consult. Participants were asked to complete 3- and 6-month follow-up PRO 
      surveys. We report on initial Clinic implementation, participant characteristics, 
      and baseline PROs. RESULTS: From 11/2020 to 6/2022, 45 patients completed 
      baseline surveys and participated in the Clinic. Median age was 58 (32-86); the 
      majority (71%) were white and had estrogen receptor-positive (84%) tumors. 
      Baseline physical and mental health were not good for ≥ 14 days of the past month 
      for 22 and 10%, respectively. PROMIS measure scores were > 1 standard deviation 
      worse than average for 32% for Physical Health, 16% for Mental Health, and 23% 
      for Physical Function. PHQ-8 and GAD-7 scores suggested depression and anxiety 
      for 22 and 7%, respectively. More than 80% of participants received specific 
      recommendations from the core consultants. Only 20% of participants completed 
      follow-up surveys. CONCLUSION: Patients living with MBC have multiple needs. We 
      used our results to implement routine PRO assessments and to expand services for 
      patients with MBC. Our experience can serve as a model for coordinated care in 
      other systems.
CI  - © 2025. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Stearns, Vered
AU  - Stearns V
AUID- ORCID: 0000-0003-4018-4708
AD  - Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, 
      MD, USA. ves4007@med.cornell.edu.
AD  - Meyer Cancer Center, Weill Cornell Medicine (VS), 420 East 70 Street, 2 Floor, 
      New York, NY, 10021, USA. ves4007@med.cornell.edu.
FAU - Chen, Ruizhe
AU  - Chen R
AD  - Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, 
      MD, USA.
FAU - Blackford, Amanda L
AU  - Blackford AL
AD  - Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, 
      MD, USA.
FAU - Saylor, Elizabeth
AU  - Saylor E
AD  - Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, 
      MD, USA.
FAU - Mull, Jill
AU  - Mull J
AD  - Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, 
      MD, USA.
FAU - Folmer, Ann
AU  - Folmer A
AD  - Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, 
      MD, USA.
FAU - Jelinek, Jessica
AU  - Jelinek J
AD  - Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, 
      MD, USA.
FAU - Hodgdon, Christine
AU  - Hodgdon C
AD  - Storm Riders Network, Baltimore, MD, USA.
FAU - Bacon, Jacqueline
AU  - Bacon J
AD  - Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, 
      MD, USA.
FAU - Engle, Jessica
AU  - Engle J
AD  - Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, 
      MD, USA.
FAU - Shah, Mirat
AU  - Shah M
AD  - Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, 
      MD, USA.
FAU - Sheinberg, Rosanne
AU  - Sheinberg R
AD  - University of Washington, Seattle, WA, USA.
FAU - Pedraza-Cardozo, Sandra
AU  - Pedraza-Cardozo S
AD  - Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, 
      MD, USA.
AD  - AdventHealth (SPC), Atlanta, GA, USA.
FAU - Wilkinson, Mary
AU  - Wilkinson M
AD  - Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, 
      MD, USA.
FAU - Alvendia, Melissa
AU  - Alvendia M
AD  - Fred Hutchinson Cancer Center, Seattle, WA, USA.
AD  - Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
FAU - Snyder, Claire
AU  - Snyder C
AD  - Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, 
      MD, USA.
AD  - Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
FAU - Smith, Karen L
AU  - Smith KL
AD  - Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, 
      MD, USA.
AD  - Merck (KLS), Rahway, NJ, USA.
LA  - eng
GR  - 5 NU58DP006673/Centers for Disease Control and Prevention Foundation/
GR  - 5 NU58DP006673/Centers for Disease Control and Prevention Foundation/
GR  - 5 NU58DP006673/Centers for Disease Control and Prevention Foundation/
GR  - 5 NU58DP006673/Centers for Disease Control and Prevention Foundation/
GR  - 5 NU58DP006673/Centers for Disease Control and Prevention Foundation/
GR  - 5 NU58DP006673/Centers for Disease Control and Prevention Foundation/
GR  - 5 NU58DP006673/Centers for Disease Control and Prevention Foundation/
GR  - 5 NU58DP006673/Centers for Disease Control and Prevention Foundation/
GR  - 5 NU58DP006673/Centers for Disease Control and Prevention Foundation/
GR  - P30CA006973/Johns Hopkins Cancer Center Support Grant/
GR  - P30CA006973/Johns Hopkins Cancer Center Support Grant/
GR  - P30CA006973/Johns Hopkins Cancer Center Support Grant/
PT  - Journal Article
DEP - 20250127
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
SB  - IM
OTO - NOTNLM
OT  - Metastatic
OT  - Multi-disciplinary care
OT  - Patient-reported outcomes
OT  - Symptom management
COIS- Declarations. Conflict of interest: The authors report the following competing 
      interests, all outside the submitted work. VS: Received research grants to 
      institution from Abbvie, Biocept, Pfizer, Novartis, Puma Biotechnology, and QUE 
      Oncology (previous); In kind clinical trial assays from Foundation Medicine 
      (previous); Chair, Data Safety Monitoring Board, AstraZeneca (current), all 
      outside the submitted work. CS: Research funding from Pfizer (current) and 
      Genentech (previous) and consulting fees from Shionogi, all outside the submitted 
      work. KLS: Received research grants to institution from Pfizer (previous), was 
      previously employed at AstraZeneca, currently employed at Merck, has stock in 
      Merck, and spouse has stock in Abbvie and ABT Labs, all outside the submitted 
      work. The following authors reported no conflicts: RC, ALB, ES, AF, JJ, CH, JB, 
      JE, MS, RS, SPC, MW, MA. Ethical approval: The project was approved as a quality 
      improvement effort by the Johns Hopkins School of Medicine Institutional Review 
      Board.
EDAT- 2025/01/27 12:25
MHDA- 2025/01/27 12:25
CRDT- 2025/01/27 11:19
PHST- 2024/11/02 00:00 [received]
PHST- 2024/12/17 00:00 [accepted]
PHST- 2025/01/27 12:25 [medline]
PHST- 2025/01/27 12:25 [pubmed]
PHST- 2025/01/27 11:19 [entrez]
AID - 10.1007/s10549-024-07591-5 [pii]
AID - 10.1007/s10549-024-07591-5 [doi]
PST - aheadofprint
SO  - Breast Cancer Res Treat. 2025 Jan 27. doi: 10.1007/s10549-024-07591-5.

PMID- 25850566
OWN - NLM
STAT- MEDLINE
DCOM- 20150803
LR  - 20240323
IS  - 1475-2662 (Electronic)
IS  - 0007-1145 (Print)
IS  - 0007-1145 (Linking)
VI  - 113
IP  - 9
DP  - 2015 May 14
TI  - Flaxseed reduces the pro-carcinogenic micro-environment in the ovaries of normal 
      hens by altering the PG and oestrogen pathways in a dose-dependent manner.
PG  - 1384-95
LID - 10.1017/S000711451500029X [doi]
AB  - The objective of the present study was to find the optimum dose of flaxseed that 
      would decrease PG and alter oestrogen pathway endpoints implicated in ovarian 
      cancer. In the study, four groups of fifty 1.5-year-old chickens were fed 
      different amounts of flaxseed (0, 5, 10 or 15% of their total diet) for 4 months 
      and were then killed to collect blood and tissues. Levels of flaxseed lignan 
      metabolites, Enterolactone (EL) and Enterodiol (ED) were measured in the serum, 
      liver and ovaries by liquid chromatography-MS/MS, and n-3 and n-6 fatty acid (FA) 
      levels were measured by GC. The effects of the varied flaxseed doses were 
      assessed by measuring levels of PGE2 and oestrogen metabolites (16-hydroxyestrone 
      (16-OHE1) and 2-hydroxyestrone (2-OHE1)) as well as by analysing the expression 
      of the oestradiol metabolising enzymes CYP3A4 (cytochrome p450, family 3, 
      subfamily A, polypeptide 4), CYP1B1 (cytochrome p450, family 1, subfamily B, 
      polypeptide 1) and CYP1A1 (cytochrome p450, family 1, subfamily A, polypeptide 1) 
      and that of oestrogen receptor α (ERα) in the ovaries. The ratio of n-3:n-FA 
      increased with an increase in flaxseed supplementation and corresponded to a 
      dose-dependent decrease in cyclo-oxygenase-2 protein and PGE2 levels. EL and ED 
      increased in the serum, liver and ovaries with increased concentrations of 
      flaxseed. Flaxseed decreased the expression of ERα in the ovaries. The ratio of 
      2-OHE1:16-OHE1 in the serum increased significantly in the 15% flaxseed diet, and 
      there was a corresponding increase in CYP1A1 in the liver and decrease in CYP3A4 
      in the ovaries. CYP1B1 mRNA also decreased with flaxseed diet in the ovaries. The 
      15% flaxseed-supplemented diet significantly decreased inflammatory PGE2, ERα, 
      CYP3A4, CYP1B1 and 16-OHE1, but it increased CYP1A1 and 2-OHE1, which thus 
      reduced the inflammatory and pro-carcinogenic micro-environment of the ovaries.
FAU - Dikshit, Anushka
AU  - Dikshit A
AD  - Department of Physiology,Southern Illinois School of Medicine (SIUSOM),1125 
      Lincoln Drive, Life Science II, Room 245B,Carbondale,IL62901,USA.
FAU - Gomes Filho, Manoel Adrião
AU  - Gomes Filho MA
AD  - Departamento de Morfologia e Fisiologia Animal,Universidade Federal Rural de 
      Pernambuco,Recife,PE,Brazil.
FAU - Eilati, Erfan
AU  - Eilati E
AD  - Department of Physiology,Southern Illinois School of Medicine (SIUSOM),1125 
      Lincoln Drive, Life Science II, Room 245B,Carbondale,IL62901,USA.
FAU - McGee, Stacey
AU  - McGee S
AD  - Department of Physiology,Southern Illinois School of Medicine (SIUSOM),1125 
      Lincoln Drive, Life Science II, Room 245B,Carbondale,IL62901,USA.
FAU - Small, Carrie
AU  - Small C
AD  - Department of Physiology,Southern Illinois School of Medicine (SIUSOM),1125 
      Lincoln Drive, Life Science II, Room 245B,Carbondale,IL62901,USA.
FAU - Gao, Chunqi
AU  - Gao C
AD  - Department of Physiology,Southern Illinois School of Medicine (SIUSOM),1125 
      Lincoln Drive, Life Science II, Room 245B,Carbondale,IL62901,USA.
FAU - Klug, Thomas
AU  - Klug T
AD  - Immuna Care Corporation,Tampa,FL,USA.
FAU - Hales, Dale Buchanan
AU  - Hales DB
AD  - Department of Physiology,Southern Illinois School of Medicine (SIUSOM),1125 
      Lincoln Drive, Life Science II, Room 245B,Carbondale,IL62901,USA.
LA  - eng
GR  - R01 AT005295/AT/NCCIH NIH HHS/United States
GR  - NIH RO1 AT00408/AT/NCCIH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20150408
PL  - England
TA  - Br J Nutr
JT  - The British journal of nutrition
JID - 0372547
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Estrogen Receptor alpha)
RN  - 0 (Estrogens)
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (Fatty Acids, Omega-6)
RN  - 0 (Hydroxyestrones)
RN  - 0 (Lignans)
RN  - 0 (RNA, Messenger)
RN  - 18186-49-7 (16-hydroxyestrone)
RN  - 76543-16-3 (2,3-bis(3'-hydroxybenzyl)butane-1,4-diol)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP1A1)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP1B1)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP3A)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - OL659KIY4X (4-Butyrolactone)
RN  - UQS3A06ILY (2-hydroxyestrone)
RN  - X01E7E1D6H (2,3-bis(3'-hydroxybenzyl)butyrolactone)
SB  - IM
MH  - 4-Butyrolactone/analogs & derivatives/analysis/blood
MH  - Animals
MH  - Anticarcinogenic Agents/*administration & dosage
MH  - *Chickens
MH  - Cyclooxygenase 1/analysis/genetics
MH  - Cyclooxygenase 2/analysis/genetics
MH  - Cytochrome P-450 CYP1A1/analysis
MH  - Cytochrome P-450 CYP1B1/analysis
MH  - Cytochrome P-450 CYP3A/analysis
MH  - Diet/*veterinary
MH  - Dietary Supplements
MH  - Dinoprostone/analysis
MH  - Estrogen Receptor alpha/analysis
MH  - Estrogens/metabolism
MH  - Fatty Acids, Omega-3/analysis
MH  - Fatty Acids, Omega-6/analysis
MH  - Female
MH  - *Flax
MH  - Hydroxyestrones/analysis
MH  - Lignans/analysis/blood/metabolism
MH  - Liver/chemistry
MH  - Ovarian Neoplasms/*prevention & control
MH  - Ovary/chemistry/*metabolism
MH  - RNA, Messenger/analysis
PMC - PMC4445837
MID - NIHMS691429
OTO - NOTNLM
OT  - Flaxseed
OT  - Oestrogen
OT  - Ovarian cancer prevention
OT  - PG
EDAT- 2015/04/09 06:00
MHDA- 2015/08/04 06:00
PMCR- 2015/11/14
CRDT- 2015/04/09 06:00
PHST- 2015/04/09 06:00 [entrez]
PHST- 2015/04/09 06:00 [pubmed]
PHST- 2015/08/04 06:00 [medline]
PHST- 2015/11/14 00:00 [pmc-release]
AID - S000711451500029X [pii]
AID - 10.1017/S000711451500029X [doi]
PST - ppublish
SO  - Br J Nutr. 2015 May 14;113(9):1384-95. doi: 10.1017/S000711451500029X. Epub 2015 
      Apr 8.

PMID- 30900980
OWN - NLM
STAT- MEDLINE
DCOM- 20190805
LR  - 20190805
IS  - 0946-1965 (Print)
IS  - 0946-1965 (Linking)
VI  - 57
IP  - 6
DP  - 2019 Jun
TI  - Evaluation of folic acid supplementation by concomitant administration of ethinyl 
      estradiol + levonorgestrel in healthy female subjects .
PG  - 290-297
LID - 10.5414/CP203293 [doi]
AB  - OBJECTIVES: Folic acid supplementation prevents 50 - 75% of cases of neural tube 
      defects. This study evaluated the folic acid supplementation after oral 
      administration of the ethinyl estradiol 0.02 mg + levonorgestrel 0.10 mg + folic 
      acid 0.4 mg coated tablet as well as its safety and tolerability in healthy 
      female subjects. MATERIALS AND METHODS: 36 healthy female subjects received 1 
      coated tablet of the test product - ethinyl estradiol 0.02 mg + levonorgestrel 
      0.10 mg + folic acid 0.4 mg for 21 days and a placebo coated tablet containing 
      folic acid 0.4 mg only on the last 7 days of the cycle, in 3 cycles. Blood 
      samples were collected to quantify folate by liquid chromatography coupled to 
      tandem mass spectrometry (LC-MS/MS). The safety was assessed by recording adverse 
      events, monitoring of vital signs, and the evaluation of laboratory tests and 
      ECG. RESULTS: The mean whole blood level of folic acid at baseline (1(st) day of 
      1(st) cycle) was 42.7 ± 22.2 ng/mL, while on the 28(th) day of the 3(rd) cycle it 
      was 47.6 ± 20.1 ng/mL, with a variation of 11.32%. The subjects tolerated the 
      clinical protocol well and reported no clinically significant adverse effects. 
      CONCLUSION: Oral contraceptives may be a good vehicle for folate supplementation 
      in women of reproductive age.
FAU - de Moraes Jacob, Juliana
AU  - de Moraes Jacob J
FAU - de Jesus Antunes, Natalícia
AU  - de Jesus Antunes N
FAU - Moreno, Ronilson
AU  - Moreno R
FAU - De Nucci, Gilberto
AU  - De Nucci G
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Int J Clin Pharmacol Ther
JT  - International journal of clinical pharmacology and therapeutics
JID - 9423309
RN  - 0 (Contraceptives, Oral, Combined)
RN  - 423D2T571U (Ethinyl Estradiol)
RN  - 5W7SIA7YZW (Levonorgestrel)
RN  - 935E97BOY8 (Folic Acid)
MH  - Chromatography, Liquid
MH  - Contraceptives, Oral, Combined/*administration & dosage
MH  - *Dietary Supplements
MH  - Ethinyl Estradiol/*administration & dosage
MH  - Female
MH  - Folic Acid/*administration & dosage/blood
MH  - Humans
MH  - Levonorgestrel/*administration & dosage
MH  - Tandem Mass Spectrometry
EDAT- 2019/03/23 06:00
MHDA- 2019/08/06 06:00
CRDT- 2019/03/23 06:00
PHST- 2019/05/15 00:00 [accepted]
PHST- 2019/03/23 06:00 [pubmed]
PHST- 2019/08/06 06:00 [medline]
PHST- 2019/03/23 06:00 [entrez]
AID - 18205 [pii]
AID - 10.5414/CP203293 [doi]
PST - ppublish
SO  - Int J Clin Pharmacol Ther. 2019 Jun;57(6):290-297. doi: 10.5414/CP203293.

PMID- 34822534
OWN - NLM
STAT- MEDLINE
DCOM- 20220222
LR  - 20240818
IS  - 2072-6651 (Electronic)
IS  - 2072-6651 (Linking)
VI  - 13
IP  - 11
DP  - 2021 Oct 22
TI  - Biomarkers of Deoxynivalenol, Citrinin, Ochratoxin A and Zearalenone in Pigs 
      after Exposure to Naturally Contaminated Feed Close to Guidance Values.
LID - 10.3390/toxins13110750 [doi]
LID - 750
AB  - This study applied multi-mycotoxin liquid chromatography with tandem mass 
      spectrometric detection (LC-MS/MS) methods to determine the biomarkers of 
      exposure in urine and serum samples from a dose-response study with pigs. The 24 
      studied pigs were divided into three groups: a control and two experimental ones 
      (with different levels of feed contamination). They were exposed to feed prepared 
      from cereals contaminated with deoxynivalenol (DON), zearalenone (ZEN), 
      ochratoxin A (OTA) and citrinin (CIT) for 14 days. After that, both experimental 
      groups received the same feed as the control group for the next 14 days to 
      determine the kinetics of the disappearance of mycotoxin biomarkers. Urine 
      samples were collected daily in the morning and blood samples-eight-times during 
      the experiment. The study reported herein was the first prolonged exposure 
      experiment for multiple mycotoxins like OTA and CIT in pigs. The urinary and 
      serum levels of all biomarkers correlated well with the respective toxin intake; 
      thereby demonstrating that they are suitable biomarkers of exposure in pigs. 
      Urine is a good candidate to monitor DON, ZEN, OTA, CIT exposure while serum may 
      be used to monitor DON, OTA and CIT. Additionally, OTA has even been quantified 
      in both matrices in the experimental groups two weeks after changing the 
      contaminated feed back to the control, this result differed from those produced 
      by the other mycotoxins which were only quantified during the first two weeks. 
      Therefore both matrices are suitable candidates to monitor prolonged OTA exposure 
      in pigs.
FAU - Tkaczyk, Agnieszka
AU  - Tkaczyk A
AUID- ORCID: 0000-0003-2929-8077
AD  - Department of Pharmacology and Toxicology, National Veterinary Research 
      Institute, 24-100 Pulawy, Poland.
FAU - Jedziniak, Piotr
AU  - Jedziniak P
AUID- ORCID: 0000-0001-5212-2913
AD  - Department of Pharmacology and Toxicology, National Veterinary Research 
      Institute, 24-100 Pulawy, Poland.
FAU - Zielonka, Łukasz
AU  - Zielonka Ł
AUID- ORCID: 0000-0003-0983-5592
AD  - Department of Veterinary Prevention and Feed Hygiene, Faculty of Veterinary 
      Medicine, University of Warmia and Mazury, 10-718 Olsztyn, Poland.
FAU - Dąbrowski, Michał
AU  - Dąbrowski M
AD  - Department of Veterinary Prevention and Feed Hygiene, Faculty of Veterinary 
      Medicine, University of Warmia and Mazury, 10-718 Olsztyn, Poland.
FAU - Ochodzki, Piotr
AU  - Ochodzki P
AUID- ORCID: 0000-0003-3228-0783
AD  - Department of Plant Pathology, Plant Breeding and Acclimatization 
      Institute-National Research Institute, 05-870 Błonie, Poland.
FAU - Rudawska, Adrianna
AU  - Rudawska A
AD  - Department of Pharmacology and Toxicology, National Veterinary Research 
      Institute, 24-100 Pulawy, Poland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20211022
PL  - Switzerland
TA  - Toxins (Basel)
JT  - Toxins
JID - 101530765
RN  - 0 (Biomarkers)
RN  - 0 (Ochratoxins)
RN  - 0 (Trichothecenes)
RN  - 1779SX6LUY (ochratoxin A)
RN  - 3S697X6SNZ (Citrinin)
RN  - 5W827M159J (Zearalenone)
RN  - JT37HYP23V (deoxynivalenol)
SB  - IM
MH  - Animal Feed/analysis
MH  - Animals
MH  - Biomarkers/analysis
MH  - Citrinin/*analysis
MH  - Female
MH  - Food Contamination/*analysis
MH  - Ochratoxins/*analysis
MH  - Sus scrofa/*microbiology
MH  - Trichothecenes/*analysis
MH  - Zearalenone/*analysis
PMC - PMC8625168
OTO - NOTNLM
OT  - citrinin
OT  - deoxynivalenol
OT  - multi-mycotoxin LC-MS/MS method
OT  - mycotoxin biomarkers
OT  - ochratoxin A
OT  - pig’s exposure
OT  - zearalenone
COIS- The authors declare no conflict of interest.
EDAT- 2021/11/26 06:00
MHDA- 2022/02/23 06:00
PMCR- 2021/10/22
CRDT- 2021/11/25 17:10
PHST- 2021/07/30 00:00 [received]
PHST- 2021/10/13 00:00 [revised]
PHST- 2021/10/20 00:00 [accepted]
PHST- 2021/11/25 17:10 [entrez]
PHST- 2021/11/26 06:00 [pubmed]
PHST- 2022/02/23 06:00 [medline]
PHST- 2021/10/22 00:00 [pmc-release]
AID - toxins13110750 [pii]
AID - toxins-13-00750 [pii]
AID - 10.3390/toxins13110750 [doi]
PST - epublish
SO  - Toxins (Basel). 2021 Oct 22;13(11):750. doi: 10.3390/toxins13110750.

PMID- 38726425
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20250104
IS  - 2048-7177 (Print)
IS  - 2048-7177 (Electronic)
IS  - 2048-7177 (Linking)
VI  - 12
IP  - 5
DP  - 2024 May
TI  - Network medicine-based analysis of the hepatoprotective effects of Amomum 
      villosum Lour. on alcoholic liver disease in rats.
PG  - 3759-3773
LID - 10.1002/fsn3.4046 [doi]
AB  - Alcoholic liver disease (ALD) is characterized by high morbidity and mortality, 
      and mainly results from prolonged and excessive alcohol use. Amomum villosum 
      Lour. (A. villosum), a well-known traditional Chinese medicine (TCM), has 
      hepatoprotective properties. However, its ability to combat alcohol-induced liver 
      injury has not been fully explored. The objective of this study was to 
      investigate the hepatoprotective effects of A. villosum in a rat model of 
      alcohol-induced liver disease, thereby establishing a scientific foundation for 
      the potential preventive use of A. villosum in ALD. We established a Chinese 
      liquor (Baijiu)-induced liver injury model in rats. Hematoxylin and eosin (HE) 
      staining, in combination with biochemical tests, was used to evaluate the 
      protective effects of A. villosum on the liver. The integration of network 
      medicine analysis with experimental validation was used to explore the 
      hepatoprotective effects and potential mechanisms of A. villosum in rats. Our 
      findings showed that A. villosum ameliorated alcohol-induced changes in body 
      weight, liver index, hepatic steatosis, inflammation, blood lipid metabolism, and 
      liver function in rats. Network proximity analysis was employed to identify 18 
      potentially active ingredients of A. villosum for ALD treatment. These 
      potentially active ingredients in the blood were further identified using mass 
      spectrometry (MS). Our results showed that A. villosum plays a hepatoprotective 
      role by modulating the protein levels of estrogen receptor 1 (ESR1), anti-nuclear 
      receptor subfamily 3 group C member 1 (NR3C1), interleukin 6 (IL-6), and tumor 
      necrosis factor-α (TNF-α). In conclusion, the results of the current study 
      suggested that A. villosum potentially exerts hepatoprotective effects on ALD in 
      rats, possibly through regulating the protein levels of ESR1, NR3C1, IL-6, and 
      TNF-α.
CI  - © 2024 The Authors. Food Science & Nutrition published by Wiley Periodicals LLC.
FAU - Wei, Jing
AU  - Wei J
AD  - School of Bioengineering Zhuhai Campus of Zunyi Medical University Zhuhai China.
FAU - Wang, Sihua
AU  - Wang S
AD  - School of Bioengineering Zhuhai Campus of Zunyi Medical University Zhuhai China.
FAU - Huang, Junze
AU  - Huang J
AD  - School of Bioengineering Zhuhai Campus of Zunyi Medical University Zhuhai China.
FAU - Zhou, Xinhua
AU  - Zhou X
AD  - Guangzhou Eighth People's Hospital Guangzhou Medical University Guangzhou China.
FAU - Qian, Zhengming
AU  - Qian Z
AD  - Dongguan HEC Cordyceps R&D Co., Ltd. Dongguan China.
FAU - Wu, Tingbiao
AU  - Wu T
AD  - School of Bioengineering Zhuhai Campus of Zunyi Medical University Zhuhai China.
FAU - Fan, Qing
AU  - Fan Q
AD  - Basic Medical Science Department Zhuhai Campus of Zunyi Medical University Zhuhai 
      China.
FAU - Liang, Yongyin
AU  - Liang Y
AD  - School of Bioengineering Zhuhai Campus of Zunyi Medical University Zhuhai China.
FAU - Cui, Guozhen
AU  - Cui G
AUID- ORCID: 0000-0002-7639-2456
AD  - School of Bioengineering Zhuhai Campus of Zunyi Medical University Zhuhai China.
LA  - eng
PT  - Journal Article
DEP - 20240222
PL  - United States
TA  - Food Sci Nutr
JT  - Food science & nutrition
JID - 101605473
PMC - PMC11077240
OTO - NOTNLM
OT  - Amomum villosum  Lour.
OT  - alcoholic liver disease
OT  - hepatoprotective effects
OT  - network medicine
COIS- The authors declare that there are no conflicts of interest.
EDAT- 2024/05/10 06:42
MHDA- 2024/05/10 06:43
PMCR- 2024/02/22
CRDT- 2024/05/10 04:00
PHST- 2023/11/25 00:00 [received]
PHST- 2024/02/01 00:00 [revised]
PHST- 2024/02/07 00:00 [accepted]
PHST- 2024/05/10 06:43 [medline]
PHST- 2024/05/10 06:42 [pubmed]
PHST- 2024/05/10 04:00 [entrez]
PHST- 2024/02/22 00:00 [pmc-release]
AID - FSN34046 [pii]
AID - 10.1002/fsn3.4046 [doi]
PST - epublish
SO  - Food Sci Nutr. 2024 Feb 22;12(5):3759-3773. doi: 10.1002/fsn3.4046. eCollection 
      2024 May.

PMID- 26297192
OWN - NLM
STAT- MEDLINE
DCOM- 20160119
LR  - 20151012
IS  - 1879-1220 (Electronic)
IS  - 0960-0760 (Linking)
VI  - 154
DP  - 2015 Nov
TI  - Estimation of reference curves for the urinary steroid metabolome in the first 
      year of life in healthy children: Tracing the complexity of human postnatal 
      steroidogenesis.
PG  - 226-36
LID - S0960-0760(15)30036-4 [pii]
LID - 10.1016/j.jsbmb.2015.07.024 [doi]
AB  - CONTEXT: Complex steroid disorders such as P450 oxidoreductase deficiency or 
      apparent cortisone reductase deficiency may be recognized by steroid profiling 
      using chromatographic mass spectrometric methods. These methods are highly 
      specific and sensitive, and provide a complete spectrum of steroid metabolites in 
      a single measurement of one sample which makes them superior to immunoassays. The 
      steroid metabolome during the fetal-neonatal transition is characterized by (a) 
      the metabolites of the fetal-placental unit at birth, (b) the fetal adrenal 
      androgens until its involution 3-6 months postnatally, and (c) the steroid 
      metabolites produced by the developing endocrine organs. All these developmental 
      events change the steroid metabolome in an age- and sex-dependent manner during 
      the first year of life. OBJECTIVE: The aim of this study was to provide normative 
      values for the urinary steroid metabolome of healthy newborns at short time 
      intervals in the first year of life. METHODS: We conducted a prospective, 
      longitudinal study to measure 67 urinary steroid metabolites in 21 male and 22 
      female term healthy newborn infants at 13 time-points from week 1 to week 49 of 
      life. Urine samples were collected from newborn infants before discharge from 
      hospital and from healthy infants at home. Steroid metabolites were measured by 
      gas chromatography-mass spectrometry (GC-MS) and steroid concentrations corrected 
      for urinary creatinine excretion were calculated. RESULTS: 61 steroids showed age 
      and 15 steroids sex specificity. Highest urinary steroid concentrations were 
      found in both sexes for progesterone derivatives, in particular 
      20α-DH-5α-DH-progesterone, and for highly polar 6α-hydroxylated glucocorticoids. 
      The steroids peaked at week 3 and decreased by ∼80% at week 25 in both sexes. The 
      decline of progestins, androgens and estrogens was more pronounced than of 
      glucocorticoids whereas the excretion of corticosterone and its metabolites and 
      of mineralocorticoids remained constant during the first year of life. 
      CONCLUSION: The urinary steroid profile changes dramatically during the first 
      year of life and correlates with the physiologic developmental changes during the 
      fetal-neonatal transition. Thus detailed normative data during this time period 
      permit the use of steroid profiling as a powerful diagnostic tool.
CI  - Copyright © 2015 Elsevier Ltd. All rights reserved.
FAU - Dhayat, Nasser A
AU  - Dhayat NA
AD  - Department of Nephrology, Hypertension and Clinical Pharmacology, University 
      Hospital of Bern, Freiburgstrasse 15, 3010 Bern, Switzerland. Electronic address: 
      nasser.dhayat@insel.ch.
FAU - Frey, Andrea C
AU  - Frey AC
AD  - Department of Nephrology, Hypertension and Clinical Pharmacology, University 
      Hospital of Bern, Freiburgstrasse 15, 3010 Bern, Switzerland. Electronic address: 
      andrea.frey@hispeed.ch.
FAU - Frey, Brigitte M
AU  - Frey BM
AD  - Department of Nephrology, Hypertension and Clinical Pharmacology, University 
      Hospital of Bern, Freiburgstrasse 15, 3010 Bern, Switzerland. Electronic address: 
      brigitte.frey@dkf.unibe.ch.
FAU - d'Uscio, Claudia H
AU  - d'Uscio CH
AD  - Department of Nephrology, Hypertension and Clinical Pharmacology, University 
      Hospital of Bern, Freiburgstrasse 15, 3010 Bern, Switzerland. Electronic address: 
      claudia.d'uscio@insel.ch.
FAU - Vogt, Bruno
AU  - Vogt B
AD  - Department of Nephrology, Hypertension and Clinical Pharmacology, University 
      Hospital of Bern, Freiburgstrasse 15, 3010 Bern, Switzerland. Electronic address: 
      bruno.vogt@insel.ch.
FAU - Rousson, Valentin
AU  - Rousson V
AD  - Division of Biostatistics, Institute of Social and Preventive Medicine (IUMSP), 
      University Hospital of Lausanne, Biopôle 2, Route de la Corniche 10, 1010 
      Lausanne, Switzerland. Electronic address: valentin.rousson@chuv.ch.
FAU - Dick, Bernhard
AU  - Dick B
AD  - Department of Nephrology, Hypertension and Clinical Pharmacology, University 
      Hospital of Bern, Freiburgstrasse 15, 3010 Bern, Switzerland. Electronic address: 
      bernhard.dick@insel.ch.
FAU - Flück, Christa E
AU  - Flück CE
AD  - Department of Pediatrics (Pediatric Endocrinology and Diabetology, University 
      Children's Hospital) and Department of Clinical Research, University of Bern, 
      Freiburgstrasse 15, 3010, Switzerland. Electronic address: 
      christa.flueck@dkf.unibe.ch.
LA  - eng
PT  - Journal Article
DEP - 20150819
PL  - England
TA  - J Steroid Biochem Mol Biol
JT  - The Journal of steroid biochemistry and molecular biology
JID - 9015483
RN  - 0 (Steroids)
SB  - IM
EIN - J Steroid Biochem Mol Biol. 2018 Oct;183:238. doi: 10.1016/j.jsbmb.2018.08.005. 
      PMID: 30121346
MH  - Female
MH  - Gas Chromatography-Mass Spectrometry
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Male
MH  - *Metabolomics
MH  - Reference Values
MH  - Steroids/*urine
OTO - NOTNLM
OT  - Gas chromatography-mass spectrometry
OT  - Newborn infants
OT  - Reference values
OT  - Urinary steroid profile
EDAT- 2015/08/25 06:00
MHDA- 2016/01/20 06:00
CRDT- 2015/08/23 06:00
PHST- 2015/03/13 00:00 [received]
PHST- 2015/07/29 00:00 [revised]
PHST- 2015/07/30 00:00 [accepted]
PHST- 2015/08/23 06:00 [entrez]
PHST- 2015/08/25 06:00 [pubmed]
PHST- 2016/01/20 06:00 [medline]
AID - S0960-0760(15)30036-4 [pii]
AID - 10.1016/j.jsbmb.2015.07.024 [doi]
PST - ppublish
SO  - J Steroid Biochem Mol Biol. 2015 Nov;154:226-36. doi: 
      10.1016/j.jsbmb.2015.07.024. Epub 2015 Aug 19.

PMID- 31669154
OWN - NLM
STAT- MEDLINE
DCOM- 20200407
LR  - 20250103
IS  - 1618-131X (Electronic)
IS  - 1438-4639 (Linking)
VI  - 223
IP  - 1
DP  - 2020 Jan
TI  - Changes in urinary excretion of phthalates, phthalate substitutes, bisphenols and 
      other polychlorinated and phenolic substances in young Danish men; 2009-2017.
PG  - 93-105
LID - S1438-4639(19)30571-1 [pii]
LID - 10.1016/j.ijheh.2019.10.002 [doi]
AB  - During the past two decades human exposure to bisphenol A (BPA) and phthalates 
      such as di-iso-butyl phthalate (DiBP), di-n-butyl phthalate (DnBP), butylbenzyl 
      phthalate (BBzP) and di-(2-ethyl-hexyl) phthalate (DEHP) has received substantial 
      interest due to widespread population exposures and potential endocrine 
      disrupting effects. Therefore, these chemicals have gradually been restricted and 
      phased out through legislation. However, humans are still exposed to a wide range 
      of other less studied phthalates, phthalate substitutes and BPA analogues as well 
      as other polychlorinated and phenolic substances. In this study, we investigated 
      human exposure to these chemicals over the past decade. Three hundred urine 
      samples collected in 2009, 2013 and 2017 (100 samples each year) from young 
      Danish men of the general population, participating in a large on-going 
      cross-sectional study, were selected for the present time trend study. The 
      urinary concentration of metabolites of 15 phthalates, di-2-ethylhexyl 
      terephthalate (DEHTP) and di-iso-nonyl-cyclohexane-1,2-dicarboxylate (DINCH), 
      seven bisphenols including BPA, bisphenol S (BPS) and bisphenol F (BPF), as well 
      as triclosan, triclocarban, benzophenone-3, three chlorophenols and two 
      phenylphenols were analyzed by two new sensitive LC-MS/MS methods developed and 
      validated for the present study. A significant decrease in urinary concentrations 
      over time was observed for the majority of the chemicals. Median concentrations 
      of BPA and the metabolites of DiBP, DnBP, BBzP and DEHP were more than halved 
      from 2009 to 2017. Similar decreases were observed for triclosan and the chloro- 
      and phenylphenols. In contrast, metabolites of the two phthalate substitutes 
      DEHTP and DINCH increased more than 20 and 2 times, respectively. The potential 
      BPA substitutes; BPS and BPF also increased, but only slightly. Despite these new 
      exposure patterns, the exposure to the old well-known chemicals, such as DiBP, 
      DnBP, BBzP, DEHP and BPA was still higher in 2017 compared to the exposure level 
      of the new substitutes such as DEHTP, DINCH, BPS and BPF. A significant decrease 
      in internal exposure to most of the common phthalates and BPA over the past 
      decade was observed, reflecting market changes and regulatory measures 
      implemented in EU. Despite increasing exposures to some of the known phthalate 
      substitutes and BPA analogues, the total amount of each measured chemical group 
      (original and substitute analytes combined) was lower in the more recently 
      collected samples. This indicates only partial direct substitution or 
      substitution by chemicals not covered in this approach, or a general decline in 
      the exposure to these chemical/product groups over the last decade.
CI  - Copyright © 2019 Elsevier GmbH. All rights reserved.
FAU - Frederiksen, Hanne
AU  - Frederiksen H
AD  - Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, 
      Denmark; International Center for Research and Research Training in Endocrine 
      Disruption of Male Reproduction and Child Health (EDMaRC), Rigshospitalet, 
      University of Copenhagen, Denmark. Electronic address: 
      hanne.frederiksen@regionh.dk.
FAU - Nielsen, Ole
AU  - Nielsen O
AD  - Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, 
      Denmark.
FAU - Koch, Holger M
AU  - Koch HM
AD  - Institute for Prevention and Occupational Medicine of the German Social Accident 
      Insurance, Institute of the Ruhr-University Bochum (IPA), Bochum, Germany.
FAU - Skakkebaek, Niels E
AU  - Skakkebaek NE
AD  - Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, 
      Denmark; International Center for Research and Research Training in Endocrine 
      Disruption of Male Reproduction and Child Health (EDMaRC), Rigshospitalet, 
      University of Copenhagen, Denmark.
FAU - Juul, Anders
AU  - Juul A
AD  - Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, 
      Denmark; International Center for Research and Research Training in Endocrine 
      Disruption of Male Reproduction and Child Health (EDMaRC), Rigshospitalet, 
      University of Copenhagen, Denmark.
FAU - Jørgensen, Niels
AU  - Jørgensen N
AD  - Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, 
      Denmark; International Center for Research and Research Training in Endocrine 
      Disruption of Male Reproduction and Child Health (EDMaRC), Rigshospitalet, 
      University of Copenhagen, Denmark.
FAU - Andersson, Anna-Maria
AU  - Andersson AM
AD  - Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, 
      Denmark; International Center for Research and Research Training in Endocrine 
      Disruption of Male Reproduction and Child Health (EDMaRC), Rigshospitalet, 
      University of Copenhagen, Denmark.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20191025
PL  - Germany
TA  - Int J Hyg Environ Health
JT  - International journal of hygiene and environmental health
JID - 100898843
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Endocrine Disruptors)
RN  - 0 (Environmental Pollutants)
RN  - 0 (Phenols)
RN  - 0 (Phthalic Acids)
RN  - 0 (Plasticizers)
RN  - 0 (Sulfones)
RN  - 0 (bisphenol F)
RN  - 2286E5R2KE (Dibutyl Phthalate)
RN  - 6O7F7IX66E (phthalic acid)
RN  - 6S7NKZ40BQ (terephthalic acid)
RN  - 3OX4RR782R (bisphenol S)
RN  - C42K0PH13C (Diethylhexyl Phthalate)
RN  - IZ67FTN290 (diisobutyl phthalate)
RN  - RW57K3X12M (bisphenol A)
RN  - YPC4PJX59M (butylbenzyl phthalate)
SB  - IM
MH  - Adult
MH  - Benzhydryl Compounds/urine
MH  - Denmark
MH  - Dibutyl Phthalate/analogs & derivatives/urine
MH  - Diethylhexyl Phthalate/urine
MH  - Endocrine Disruptors/urine
MH  - Environmental Exposure/*statistics & numerical data
MH  - Environmental Monitoring
MH  - Environmental Pollutants/*urine
MH  - Humans
MH  - Male
MH  - Phenols/urine
MH  - Phthalic Acids/*urine
MH  - Plasticizers/metabolism
MH  - Sulfones/urine
OTO - NOTNLM
OT  - DINCH
OT  - Di-2-ethylhexyl terephthalate (DEHTP)
OT  - Endocrine disruptor
OT  - Human biomonitoring
OT  - Phenol
OT  - Phthalate
EDAT- 2019/11/02 06:00
MHDA- 2020/04/09 06:00
CRDT- 2019/11/01 06:00
PHST- 2019/06/20 00:00 [received]
PHST- 2019/10/06 00:00 [revised]
PHST- 2019/10/06 00:00 [accepted]
PHST- 2019/11/02 06:00 [pubmed]
PHST- 2020/04/09 06:00 [medline]
PHST- 2019/11/01 06:00 [entrez]
AID - S1438-4639(19)30571-1 [pii]
AID - 10.1016/j.ijheh.2019.10.002 [doi]
PST - ppublish
SO  - Int J Hyg Environ Health. 2020 Jan;223(1):93-105. doi: 
      10.1016/j.ijheh.2019.10.002. Epub 2019 Oct 25.

PMID- 25820259
OWN - NLM
STAT- MEDLINE
DCOM- 20160517
LR  - 20181113
IS  - 1613-4133 (Electronic)
IS  - 1613-4125 (Print)
IS  - 1613-4125 (Linking)
VI  - 59
IP  - 8
DP  - 2015 Aug
TI  - Isoflavones in soy flour diet have different effects on whole-genome expression 
      patterns than purified isoflavone mix in human MCF-7 breast tumors in 
      ovariectomized athymic nude mice.
PG  - 1419-30
LID - 10.1002/mnfr.201500028 [doi]
AB  - SCOPE: Soy flour diet (MS) prevented isoflavones from stimulating MCF-7 tumor 
      growth in athymic nude mice, indicating that other bioactive compounds in soy can 
      negate the estrogenic properties of isoflavones. The underlying signal 
      transduction pathways to explain the protective effects of soy flour consumption 
      were studied here. METHODS AND RESULTS: Ovariectomized athymic nude mice 
      inoculated with MCF-7 human breast cancer cells were fed either Soy flour diet 
      (MS) or purified isoflavone mix diet (MI), both with equivalent amounts of 
      genistein. Positive controls received estradiol pellets and negative controls 
      received sham pellets. GeneChip Human Genome U133 Plus 2.0 Array platform was 
      used to evaluate gene expressions, and results were analyzed using bioinformatics 
      approaches. Tumors in MS-fed mice exhibited higher expression of tumor growth 
      suppressing genes ATP2A3 and BLNK and lower expression of oncogene MYC. Tumors in 
      MI-fed mice expressed a higher level of oncogene MYB and a lower level of MHC-I 
      and MHC-II, allowing tumor cells to escape immunosurveillance. MS-induced gene 
      expression alterations were predictive of prolonged survival among 
      estrogen-receptor-positive breast cancer patients, whilst MI-induced gene changes 
      were predictive of shortened survival. CONCLUSION: Our findings suggest that 
      dietary soy flour affects gene expression differently than purified isoflavones, 
      which may explain why soy foods prevent isoflavones-induced stimulation of MCF-7 
      tumor growth in athymic nude mice.
CI  - © 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Liu, Yunxian
AU  - Liu Y
AD  - Department of Food Science and Human Nutrition, University of Illinois, 
      Urbana-Champaign, IL, USA.
FAU - Hilakivi-Clarke, Leena
AU  - Hilakivi-Clarke L
AD  - Department of Oncology, Georgetown University Medical Center, Washington, DC, 
      USA.
FAU - Zhang, Yukun
AU  - Zhang Y
AD  - Department of Food Science and Human Nutrition, University of Illinois, 
      Urbana-Champaign, IL, USA.
FAU - Wang, Xiao
AU  - Wang X
AD  - Bradley Department of Electrical and Computer Engineering, Virginia Polytechnic 
      Institute and State University, Arlington, VA, USA.
FAU - Pan, Yuan-Xiang
AU  - Pan YX
AD  - Department of Food Science and Human Nutrition, University of Illinois, 
      Urbana-Champaign, IL, USA.
FAU - Xuan, Jianhua
AU  - Xuan J
AD  - Bradley Department of Electrical and Computer Engineering, Virginia Polytechnic 
      Institute and State University, Arlington, VA, USA.
FAU - Fleck, Stefanie C
AU  - Fleck SC
AD  - Division of Biochemical Toxicology, National Center for Toxicological Research, 
      U.S. Food and Drug Administration, Jefferson, AR, USA.
FAU - Doerge, Daniel R
AU  - Doerge DR
AD  - Division of Biochemical Toxicology, National Center for Toxicological Research, 
      U.S. Food and Drug Administration, Jefferson, AR, USA.
FAU - Helferich, William G
AU  - Helferich WG
AD  - Department of Food Science and Human Nutrition, University of Illinois, 
      Urbana-Champaign, IL, USA.
LA  - eng
GR  - P50 AT006268/AT/NCCIH NIH HHS/United States
GR  - P50AT006268/AT/NCCIH NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20150626
PL  - Germany
TA  - Mol Nutr Food Res
JT  - Molecular nutrition & food research
JID - 101231818
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (Isoflavones)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Phytoestrogens)
RN  - 6287WC5J2L (daidzein)
RN  - DH2M523P0H (Genistein)
SB  - IM
MH  - Antineoplastic Agents, Phytogenic/*administration & dosage/adverse 
      effects/analysis/therapeutic use
MH  - Breast Neoplasms/*diet therapy/metabolism/pathology
MH  - Cluster Analysis
MH  - Computational Biology
MH  - Female
MH  - Gene Expression Profiling
MH  - *Gene Expression Regulation, Neoplastic
MH  - Genistein/administration & dosage/adverse effects/analysis/therapeutic use
MH  - Humans
MH  - Isoflavones/*administration & dosage/adverse effects/analysis/therapeutic use
MH  - MCF-7 Cells
MH  - Neoplasm Proteins/agonists/antagonists & inhibitors/genetics/*metabolism
MH  - Oligonucleotide Array Sequence Analysis
MH  - Ovariectomy
MH  - Phytoestrogens/*administration & dosage/adverse effects/analysis/therapeutic use
MH  - Random Allocation
MH  - Soy Foods/*analysis
MH  - Tumor Burden
MH  - Xenograft Model Antitumor Assays
PMC - PMC5763549
MID - NIHMS723087
OTO - NOTNLM
OT  - Breast cancer
OT  - Isoflavones
OT  - MCF-7
OT  - Soy
OT  - Whole-genome expression
COIS- Conflict of interest The authors have declared no conflict of interest.
EDAT- 2015/03/31 06:00
MHDA- 2016/05/18 06:00
PMCR- 2018/01/11
CRDT- 2015/03/31 06:00
PHST- 2015/01/14 00:00 [received]
PHST- 2015/03/04 00:00 [revised]
PHST- 2015/04/07 00:00 [accepted]
PHST- 2015/03/31 06:00 [entrez]
PHST- 2015/03/31 06:00 [pubmed]
PHST- 2016/05/18 06:00 [medline]
PHST- 2018/01/11 00:00 [pmc-release]
AID - 10.1002/mnfr.201500028 [doi]
PST - ppublish
SO  - Mol Nutr Food Res. 2015 Aug;59(8):1419-30. doi: 10.1002/mnfr.201500028. Epub 2015 
      Jun 26.

PMID- 26633438
OWN - NLM
STAT- MEDLINE
DCOM- 20160728
LR  - 20250103
IS  - 1660-4601 (Electronic)
IS  - 1661-7827 (Print)
IS  - 1660-4601 (Linking)
VI  - 12
IP  - 12
DP  - 2015 Nov 30
TI  - Occurrence and Profiles of the Artificial Endocrine Disruptor Bisphenol A and 
      Natural Endocrine Disruptor Phytoestrogens in Urine from Children in China.
PG  - 15110-7
LID - 10.3390/ijerph121214964 [doi]
AB  - BACKGROUND: Exposure to artificial or natural endocrine disruptors, such as 
      bisphenol A (BPA) and phytoestrogens has been demonstrated to have health 
      effects, especially in children. Biomonitoring of BPA and phytoestrogens in human 
      urine can be used to assess the intake levels of these compounds. METHODS: In 
      this study, BPA and phytoestrogens in urine specimens (n = 256) collected from 
      children in China were measured by liquid chromatography (LC)-tandem mass 
      spectrometry (MS/MS). RESULTS: BPA was detected in most specimens, with a 
      geometric mean concentration of 1.58 ng/mL. For the first time, levels of urinary 
      phytoestrogens in Chinese children were reported. Daidzein and enterolactone are 
      the typical isoflavones and lignans compounds in urine, respectively. 
      CONCLUSIONS: Relatively high levels of urinary BPA indicate an increasing risk of 
      BPA exposure to Chinese children. Urinary concentrations of daidzein in Chinese 
      children are higher when compared with those reported in the U.S. children, while 
      concentrations of urinary enterolactone and enterodiols are significantly lower. 
      This suggests a significant difference in phytoestrogen intake between the 
      children from China and from the U.S.
FAU - Zhang, Mingyue
AU  - Zhang M
AD  - Tianjin Centers for Disease Control and Prevention, Tianjin 300171, China. 
      cdczhangmy@126.com.
FAU - Duan, Zhenghua
AU  - Duan Z
AD  - Ministry of Education Key Laboratory of Pollution Processes and Environmental 
      Criteria/Tianjin Key Laboratory of Environmental Remediation and Pollution 
      Control, Nankai University, Tianjin 300071, China. 
      duanzhenghua@mail.nankai.edu.cn.
AD  - School of Environmental Science and Safety Engineering, Tianjin University of 
      Technology, Tianjin 300384, China. duanzhenghua@mail.nankai.edu.cn.
FAU - Wu, Yinghong
AU  - Wu Y
AD  - Tianjin Centers for Disease Control and Prevention, Tianjin 300171, China. 
      wuyinghongnk@126.com.
FAU - Liu, Zhen
AU  - Liu Z
AD  - Ministry of Education Key Laboratory of Pollution Processes and Environmental 
      Criteria/Tianjin Key Laboratory of Environmental Remediation and Pollution 
      Control, Nankai University, Tianjin 300071, China. m15822267505@163.com.
FAU - Li, Ke
AU  - Li K
AD  - Ministry of Education Key Laboratory of Pollution Processes and Environmental 
      Criteria/Tianjin Key Laboratory of Environmental Remediation and Pollution 
      Control, Nankai University, Tianjin 300071, China. like1030@mail.nankai.edu.cn.
FAU - Wang, Lei
AU  - Wang L
AD  - Ministry of Education Key Laboratory of Pollution Processes and Environmental 
      Criteria/Tianjin Key Laboratory of Environmental Remediation and Pollution 
      Control, Nankai University, Tianjin 300071, China. wang2007@nankai.edu.cn.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151130
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Endocrine Disruptors)
RN  - 0 (Isoflavones)
RN  - 0 (Lignans)
RN  - 0 (Phenols)
RN  - 0 (Phytoestrogens)
RN  - 6287WC5J2L (daidzein)
RN  - RW57K3X12M (bisphenol A)
RN  - OL659KIY4X (4-Butyrolactone)
RN  - X01E7E1D6H (2,3-bis(3'-hydroxybenzyl)butyrolactone)
SB  - IM
MH  - 4-Butyrolactone/*analogs & derivatives/urine
MH  - Benzhydryl Compounds/*urine
MH  - Child
MH  - China
MH  - Chromatography, Liquid
MH  - Endocrine Disruptors/*urine
MH  - Environmental Monitoring
MH  - Female
MH  - Humans
MH  - Isoflavones/*urine
MH  - Lignans/*urine
MH  - Male
MH  - Phenols/*urine
MH  - Phytoestrogens/*urine
MH  - Risk Assessment
MH  - Tandem Mass Spectrometry
MH  - United States
PMC - PMC4690900
OTO - NOTNLM
OT  - China
OT  - biomonitoring
OT  - bisphenol A
OT  - children
OT  - phytoestrogens
EDAT- 2015/12/04 06:00
MHDA- 2016/07/29 06:00
PMCR- 2015/12/01
CRDT- 2015/12/04 06:00
PHST- 2015/10/17 00:00 [received]
PHST- 2015/11/15 00:00 [revised]
PHST- 2015/11/20 00:00 [accepted]
PHST- 2015/12/04 06:00 [entrez]
PHST- 2015/12/04 06:00 [pubmed]
PHST- 2016/07/29 06:00 [medline]
PHST- 2015/12/01 00:00 [pmc-release]
AID - ijerph121214964 [pii]
AID - ijerph-12-14964 [pii]
AID - 10.3390/ijerph121214964 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2015 Nov 30;12(12):15110-7. doi: 
      10.3390/ijerph121214964.

PMID- 27981482
OWN - NLM
STAT- MEDLINE
DCOM- 20170803
LR  - 20181202
IS  - 1614-7499 (Electronic)
IS  - 0944-1344 (Linking)
VI  - 24
IP  - 5
DP  - 2017 Feb
TI  - Association of breast adipose tissue levels of polychlorinated biphenyls and 
      breast cancer development in women from Chaoshan, China.
PG  - 4778-4790
LID - 10.1007/s11356-016-8208-6 [doi]
AB  - Polychlorinated biphenyls (PCBs) are implied to be potential risk factors for 
      breast cancer in wildlife and in in vivo and in vitro studies. Epidemiological 
      studies revealed some individual or groups of PCB congeners associated with 
      breast cancer risk, but consistent conclusions are scarce. This study aimed to 
      explore the association between PCB exposure and breast cancer development. 
      Breast adipose tissues were collected, and seven PCB congeners were analyzed by 
      gas chromatography-mass spectrometry (GC-MS). Demographic characteristics, basic 
      clinical data, and pathological diagnosis information were obtained from medical 
      records. The differences in PCB exposure levels among different groups and 
      indices were compared, and the correlation among PCB congeners was evaluated. The 
      order of congener profile by molar concentration was PCB-153 > PCB-138 > PCB-180 
      > PCB-118 > PCB-101 > PCB-52 > PCB-28. ∑PCB level differed by occupation and 
      residence and was significantly higher at 55-59-year-old group than at the other 
      age groups. ∑PCB level was higher in postmenopausal than in premenopausal women. 
      Decreasing ∑PCB levels were related with increasing parity among women with 
      progesterone receptor (PR)-positive breast tumors. With increased clinical stage, 
      the ∑PCB level increased significantly. ∑PCB level did not differ by 
      tumor-node-metastasis classification and PR or human epidermal growth factor 
      receptor 2 (HER2) expression but did differ by estrogen receptor (ER) expression 
      (P = 0.04) without a regularly increasing trend in breast adipose tissue. These 
      results suggest a potential association between PCB exposure and breast cancer 
      development. Further in vitro and in vivo studies are needed to confirm these 
      findings and explain the underlying mechanisms. Graphical Abstract Total PCBs 
      level among different clinical stages in breast cancer patients.
FAU - He, Yuanfang
AU  - He Y
AD  - Department of Preventive Medicine, Shantou University Medical College, No. 22, 
      Xinling Rd, Shantou, Guangdong, 515041, China.
FAU - Peng, Lin
AU  - Peng L
AD  - Clinical Laboratory, Cancer Hospital of Shantou University Medical College, 
      Shantou, Guangdong, 515041, China.
FAU - Huang, Yiteng
AU  - Huang Y
AD  - Health Care Center, The First Affiliated Hospital of Shantou University Medical 
      College, Shantou, Guangdong, 515041, China.
FAU - Peng, Xiaodong
AU  - Peng X
AD  - Department of Preventive Medicine, Shantou University Medical College, No. 22, 
      Xinling Rd, Shantou, Guangdong, 515041, China.
FAU - Zheng, Shukai
AU  - Zheng S
AD  - Department of Preventive Medicine, Shantou University Medical College, No. 22, 
      Xinling Rd, Shantou, Guangdong, 515041, China.
FAU - Liu, Caixia
AU  - Liu C
AD  - Department of Preventive Medicine, Shantou University Medical College, No. 22, 
      Xinling Rd, Shantou, Guangdong, 515041, China.
FAU - Wu, Kusheng
AU  - Wu K
AUID- ORCID: 0000-0001-5163-2524
AD  - Department of Preventive Medicine, Shantou University Medical College, No. 22, 
      Xinling Rd, Shantou, Guangdong, 515041, China. kswu@stu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20161215
PL  - Germany
TA  - Environ Sci Pollut Res Int
JT  - Environmental science and pollution research international
JID - 9441769
RN  - 0 (Receptors, Estrogen)
RN  - DFC2HB4I0K (Polychlorinated Biphenyls)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adipose Tissue/*chemistry
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Breast Neoplasms/*chemically induced
MH  - China
MH  - Female
MH  - Gas Chromatography-Mass Spectrometry
MH  - Humans
MH  - Middle Aged
MH  - Polychlorinated Biphenyls/*analysis/toxicity
MH  - Receptor, ErbB-2/analysis
MH  - Receptors, Estrogen/analysis
OTO - NOTNLM
OT  - Breast adipose
OT  - Breast cancer
OT  - Exposure
OT  - Polychlorinated biphenyls
EDAT- 2016/12/17 06:00
MHDA- 2017/08/05 06:00
CRDT- 2016/12/17 06:00
PHST- 2016/08/19 00:00 [received]
PHST- 2016/12/05 00:00 [accepted]
PHST- 2016/12/17 06:00 [pubmed]
PHST- 2017/08/05 06:00 [medline]
PHST- 2016/12/17 06:00 [entrez]
AID - 10.1007/s11356-016-8208-6 [pii]
AID - 10.1007/s11356-016-8208-6 [doi]
PST - ppublish
SO  - Environ Sci Pollut Res Int. 2017 Feb;24(5):4778-4790. doi: 
      10.1007/s11356-016-8208-6. Epub 2016 Dec 15.

PMID- 29852126
OWN - NLM
STAT- MEDLINE
DCOM- 20181112
LR  - 20211122
IS  - 1873-3492 (Electronic)
IS  - 0009-8981 (Print)
IS  - 0009-8981 (Linking)
VI  - 484
DP  - 2018 Sep
TI  - Do metabolites account for higher serum steroid hormone levels measured by RIA 
      compared to mass spectrometry?
PG  - 223-225
LID - S0009-8981(18)30272-9 [pii]
LID - 10.1016/j.cca.2018.05.054 [doi]
AB  - Higher circulating estradiol levels are generally obtained using conventional 
      radioimmunoassays (RIA) compared to liquid chromatography/tandem mass 
      spectrometry (LC-MS/MS) assays, and this has been attributed to the presence of 
      estradiol metabolites that cross-react with the antibody used in the RIA. This 
      study aimed to determine which estradiol metabolites may contribute to this 
      effect. LC-MS/MS analysis was performed on 70 serum samples from premenopausal 
      women, after purification by extraction and Celite column partition 
      chromatography as would be used prior to conventional RIA for estradiol. The 
      metabolites estrone and 2-methoxyestradiol accounted for 6.9% and 2.1% of the 
      estradiol fractions in the purified samples overall, but the extent of 
      contamination with these metabolites was greater in the samples containing 
      <50 pg/mL estradiol (14.6% and 3.8% respectively) than in those containing 
      >50 pg/mL estradiol. However, since these metabolites have a < 1% 
      cross-reactivity to the antibody in the estradiol RIA, this level of 
      contamination is too small to account for the differences between RIA and 
      LC-MS/MS measurements of estradiol.
CI  - Copyright © 2018 Elsevier B.V. All rights reserved.
FAU - Stanczyk, Frank Z
AU  - Stanczyk FZ
AD  - Departments of Obstetrics and Gynecology and Preventive Medicine, Keck School of 
      Medicine of USC, Los Angeles, CA, United States. Electronic address: 
      fstanczyk@att.net.
FAU - Xu, Xia
AU  - Xu X
AD  - Protein Characterization Laboratory, Frederick National Laboratory for Cancer 
      Research, Frederick, MD, United States.
FAU - Sluss, Patrick M
AU  - Sluss PM
AD  - Pathology Service, Massachusetts General Hospital/Harvard Medical School, Boston, 
      MA, United States.
FAU - Brinton, Louise A
AU  - Brinton LA
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, 
      Bethesda, MD, United States.
FAU - McGlynn, Katherine A
AU  - McGlynn KA
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, 
      Bethesda, MD, United States.
LA  - eng
GR  - ZIA CP010126/ImNIH/Intramural NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
DEP - 20180528
PL  - Netherlands
TA  - Clin Chim Acta
JT  - Clinica chimica acta; international journal of clinical chemistry
JID - 1302422
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Chromatography, Liquid
MH  - Estradiol/*blood/*metabolism
MH  - Humans
MH  - *Radioimmunoassay
MH  - *Tandem Mass Spectrometry
PMC - PMC8606038
MID - NIHMS1754852
OTO - NOTNLM
OT  - Estradiol
OT  - Hormones
OT  - Mass spectrometry
OT  - Metabolite
OT  - Radioimmunoassay
COIS- Declarations of Interest: None.
EDAT- 2018/06/01 06:00
MHDA- 2018/11/13 06:00
PMCR- 2021/11/21
CRDT- 2018/06/01 06:00
PHST- 2018/04/30 00:00 [received]
PHST- 2018/05/27 00:00 [accepted]
PHST- 2018/06/01 06:00 [pubmed]
PHST- 2018/11/13 06:00 [medline]
PHST- 2018/06/01 06:00 [entrez]
PHST- 2021/11/21 00:00 [pmc-release]
AID - S0009-8981(18)30272-9 [pii]
AID - 10.1016/j.cca.2018.05.054 [doi]
PST - ppublish
SO  - Clin Chim Acta. 2018 Sep;484:223-225. doi: 10.1016/j.cca.2018.05.054. Epub 2018 
      May 28.

PMID- 39371146
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20241023
DP  - 2024 Sep 16
TI  - Randomized dose-response trial of n-3 fatty acids in hormone receptor negative 
      breast cancer survivors- impact on breast adipose oxylipin and DNA methylation 
      patterns.
LID - 2024.09.16.24313691 [pii]
LID - 10.1101/2024.09.16.24313691 [doi]
AB  - BACKGROUND: Increasing evidence suggests the unique susceptibility of estrogen 
      receptor and progesterone receptor negative (ERPR-) breast cancer to dietary fat 
      amount and type. Dietary n-3 polyunsaturated fatty acids (PUFAs), such as 
      docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), may modulate breast 
      adipose fatty acid profiles and downstream bioactive metabolites to counteract 
      pro-inflammatory, pro-carcinogenic signaling in the mammary microenvironment. 
      OBJECTIVE: To determine effects of ~1 to 5 g/d EPA+DHA over 12 months on breast 
      adipose fatty acid and oxylipin profiles in women with ERPR(-) breast cancer, a 
      high-risk molecular subtype. METHODS: We conducted a 12-month randomized 
      controlled, double-blind clinical trial of ~5g/d vs ~1g/d DHA+EPA supplementation 
      in women within 5 years of completing standard therapy for ERPR(-) breast cancer 
      Stages 0-III. Blood and breast adipose tissue specimens were collected every 3 
      months for biomarker analyses including fatty acids by gas chromatography, 
      oxylipins by LC-MS/MS, and DNA methylation by reduced-representation bisulfite 
      sequencing (RRBS). RESULTS: A total of 51 participants completed the 12-month 
      intervention. Study treatments were generally well-tolerated. While both doses 
      increased n-3 PUFAs from baseline in breast adipose, erythrocytes, and plasma, 
      the 5g/d supplement was more potent (n =51, p <0.001). The 5g/d dose also reduced 
      plasma triglycerides from baseline (p =0.008). Breast adipose oxylipins at 0, 6, 
      and 12 months showed dose-dependent increases in unesterified and esterified DHA 
      and EPA metabolites (n =28). Distinct DNA methylation patterns in adipose tissue 
      after 12 months were identified, with effects unique to the 5g/d dose group (n 
      =17). CONCLUSIONS: Over the course of 1 year, EPA+DHA dose-dependently increased 
      concentrations of these fatty acids and their derivative oxylipin metabolites, 
      producing differential DNA methylation profiles of gene promoters involved in 
      metabolism-related pathways critical to ERPR(-) breast cancer development and 
      progression. These data provide evidence of both metabolic and epigenetic effects 
      of n-3 PUFAs in breast adipose tissue, elucidating novel mechanisms of action for 
      high-dose EPA+DHA-mediated prevention of ERPR(-) breast cancer.
FAU - Frankhouser, David E
AU  - Frankhouser DE
AUID- ORCID: 0000-0002-8233-5853
AD  - Department of Computational and Quantitative Medicine, City of Hope, Duarte, CA 
      91010.
FAU - DeWess, Todd
AU  - DeWess T
AD  - Department of Computational and Quantitative Medicine, City of Hope, Duarte, CA 
      91010.
AD  - Department of Surgery, City of Hope, Duarte CA 91010.
FAU - Snodgrass, Isabel F
AU  - Snodgrass IF
AUID- ORCID: 0009-0008-6036-0530
AD  - University of California Davis West Coast Metabolomics Center, Genome Center, 
      University of California Davis, Davis CA, 95616.
FAU - Cole, Rachel M
AU  - Cole RM
AD  - Department of Food Science and Technology, The Ohio State University, Columbus OH 
      43210.
FAU - Steck, Sarah
AU  - Steck S
AD  - The Ohio State University Comprehensive Cancer Center, Columbus OH 43210.
FAU - Thomas, Danielle
AU  - Thomas D
AD  - Department of Surgery, City of Hope, Duarte CA 91010.
FAU - Kalu, Chidimma
AU  - Kalu C
AD  - Department of Surgery, City of Hope, Duarte CA 91010.
FAU - Belury, Martha A
AU  - Belury MA
AUID- ORCID: 0000-0002-6480-4281
AD  - Department of Food Science and Technology, The Ohio State University, Columbus OH 
      43210.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus OH 43210.
FAU - Clinton, Steven K
AU  - Clinton SK
AD  - The Ohio State University Comprehensive Cancer Center, Columbus OH 43210.
AD  - Department of Internal Medicine, The Ohio State University, Columbus OH 43210.
FAU - Newman, John W
AU  - Newman JW
AD  - University of California Davis West Coast Metabolomics Center, Genome Center, 
      University of California Davis, Davis CA, 95616.
AD  - Department of Nutrition, University of California Davis, Davis CA, 956169.
AD  - United States Department of Agriculture Agricultural Research Service, Western 
      Human Nutrition Research Center, Davis CA, 95616.
FAU - Yee, Lisa D
AU  - Yee LD
AUID- ORCID: 0000-0001-8243-1055
AD  - Department of Surgery, City of Hope, Duarte CA 91010.
AD  - City of Hope Comprehensive Cancer Center, Duarte, CA 91010.
LA  - eng
GR  - R01 CA164019/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Preprint
DEP - 20240916
PL  - United States
TA  - medRxiv
JT  - medRxiv : the preprint server for health sciences
JID - 101767986
PMC - PMC11451633
COIS- The authors declare no potential conflicts of interest.
EDAT- 2024/10/07 11:22
MHDA- 2024/10/07 11:23
PMCR- 2024/10/04
CRDT- 2024/10/07 05:17
PHST- 2024/10/07 11:22 [pubmed]
PHST- 2024/10/07 11:23 [medline]
PHST- 2024/10/07 05:17 [entrez]
PHST- 2024/10/04 00:00 [pmc-release]
AID - 2024.09.16.24313691 [pii]
AID - 10.1101/2024.09.16.24313691 [doi]
PST - epublish
SO  - medRxiv [Preprint]. 2024 Sep 16:2024.09.16.24313691. doi: 
      10.1101/2024.09.16.24313691.

PMID- 35494071
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - Fulvestrant May Falsely Increase 17β-Estradiol Levels in Immunoassays: A Case 
      Report of a 57-Year-Old Postmenopausal Patient With Recurrent Estrogen 
      Receptor-Positive Breast Cancer.
PG  - 832763
LID - 10.3389/fonc.2022.832763 [doi]
LID - 832763
AB  - The prognosis for female patients with locoregionally recurrent breast cancer has 
      improved with the concurrent local and systemic treatment under multiple 
      disciplinary teams. Radiotherapy is a valuable local treatment measure for 
      unresectable locoregional recurrent breast cancer; however, reirradiation in 
      previously irradiated areas is still a matter of debate. Antihormonal therapy 
      achieves an overall survival benefit for most of these patients with estrogen 
      receptor-positive (ER+) breast cancer in both adjuvant and metastatic settings. 
      Fulvestrant is an ER antagonist and selective ER downregulator widely used in 
      antihormonal therapy, especially in recurrent postmenopausal ER+ breast cancers. 
      However, fulvestrant closely resembles 17β-estradiol in its molecular structure 
      which may result in false increases in serum 17β-estradiol levels in commercially 
      available immunoassays leading to incorrect medical decisions. Herein, we report 
      a case of a 57-year-old postmenopausal patient with recurrent ER+ breast cancer 
      treated with concurrent fulvestrant and reirradiation. There was a good clinical 
      response, and the combination treatment was well tolerable. During the quarterly 
      follow-up, we monitored a gradual increase of the serum 17β-estradiol level in 
      immunoassays, unexpectedly, because the patient underwent natural menopause 8 
      years ago. To rule out the suspected fulvestrant cross-reactivity with 
      17β-estradiol in immunoassay, the patient's serum 17β-estradiol levels were 
      subsequently tested with the more sensitive and specific liquid 
      chromatography-mass spectrometry (LC-MS) method, which confirmed 17β-estradiol 
      levels at the postmenopausal level. Concomitant fulvestrant with reirradiation 
      seems to be a safe and effective therapy for locoregionally recurrent ER+ breast 
      cancer. However, a falsely increased 17β-estradiol may result from 
      cross-reactivity between 17β-estradiol and its molecular analog compounds, for 
      example, fulvestrant. Therefore, it is important for the clinicians with the 
      knowledge of this interaction to prevent unnecessary erroneous interpretation of 
      results and avoid wrong medical decisions.
CI  - Copyright © 2022 Ding, Cao and Guo.
FAU - Ding, Jingxian
AU  - Ding J
AD  - Department of Radiation Oncology, The Breast Cancer Institute, Third Hospital of 
      Nanchang, Nanchang, China.
FAU - Cao, Yali
AU  - Cao Y
AD  - Department of Breast Surgery, The Breast Cancer Institute, The Third Hospital of 
      Nanchang, Nanchang, China.
FAU - Guo, Yonghong
AU  - Guo Y
AD  - Department of Radiation Oncology, The Fourth Affiliated Hospital of Nanchang 
      University, Nanchang, China.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20220413
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9045700
OTO - NOTNLM
OT  - 17β-estradiol (E2)
OT  - antihormonal therapy
OT  - breast cancer
OT  - fulvestrant
OT  - reirradiation (re-RT)
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/05/03 06:00
MHDA- 2022/05/03 06:01
PMCR- 2022/01/01
CRDT- 2022/05/02 06:27
PHST- 2021/12/10 00:00 [received]
PHST- 2022/03/16 00:00 [accepted]
PHST- 2022/05/02 06:27 [entrez]
PHST- 2022/05/03 06:00 [pubmed]
PHST- 2022/05/03 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.832763 [doi]
PST - epublish
SO  - Front Oncol. 2022 Apr 13;12:832763. doi: 10.3389/fonc.2022.832763. eCollection 
      2022.

PMID- 32127777
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220216
IS  - 1319-562X (Print)
IS  - 2213-7106 (Electronic)
IS  - 2213-7106 (Linking)
VI  - 27
IP  - 3
DP  - 2020 Mar
TI  - Isolation, purification and characterization of naturally derived Crocetin 
      beta-d-glucosyl ester from Crocus sativus L. against breast cancer and its 
      binding chemistry with ER-alpha/HDAC2.
PG  - 975-984
LID - 10.1016/j.sjbs.2020.01.018 [doi]
AB  - Saffron plant (Crocus sativus L.) is being used as a source of saffron spice and 
      medicine to cure or prevent different types of diseases including cancers. We 
      report the isolation, characterization of bioactive small molecule ([crocetin 
      (β-d-glucosyl) ester] from the leaf biowastes of saffron plant of Kashmir, India. 
      MTTC assay and Bio-autography aided approach were used to assess anti-oxidant 
      activity and anti-cancer properties of crocin (s) against DPPH free radical and 
      breast cancer cell line respectively. Crocetin beta-d-glucosyl ester restrained 
      proliferation of human breast adeno-carcinoma cell model (MCF-7) without 
      significantly affecting normal cell line (L-6). Further studies involving 
      molecular mechanics generalized born surface area and molecular docking showed 
      that crocetin beta-d-glucosyl ester exhibits strong affinity for estrogen 
      receptor alpha and histone deacetylase 2 (crucial receptors involved in breast 
      cancer signalling) as evidenced by the negative docking score and binding free 
      energy (BFE) values. Therefore, crocetin beta-d-glucosyl ester from Crocus 
      sativus biowastes showed antiproliferative effect possibly by inhibiting estrogen 
      receptor alpha and HDAC2 mediated signalling cascade.
CI  - © 2020 The Author(s).
FAU - Mir, Mudasir A
AU  - Mir MA
AD  - Division of Biotechnology, Sher-e-Kashmir University of Agricultural Sciences and 
      Technology of Kashmir, Shalimar, Srinagar 190025, Jammu and Kashmir, India.
FAU - Ganai, Shabir Ahmad
AU  - Ganai SA
AD  - Division of Basic Sciences and Humanities, Faculty of Agriculture, 
      SKUAST-Kashmir, Wadura, Sopore 193201, Jammu & Kashmir, India.
FAU - Mansoor, Sheikh
AU  - Mansoor S
AD  - Division of Biochemistry, Sher-e-Kashmir University of Agricultural Sciences and 
      Technology, Jammu 180009, J&K, India.
FAU - Jan, Sumira
AU  - Jan S
AD  - Division of Basic Science and Humanities, Sher-e-Kashmir University of 
      Agricultural Sciences and Technology of Kashmir, Shalimar, Srinagar 190025, Jammu 
      and Kashmir, India.
FAU - Mani, P
AU  - Mani P
AD  - Department of Biotechnology, Annai College of Arts & Science, Kumbakonam, Tamil 
      Nadu 612503, India.
FAU - Masoodi, Khalid Z
AU  - Masoodi KZ
AD  - Division of Biotechnology, Sher-e-Kashmir University of Agricultural Sciences and 
      Technology of Kashmir, Shalimar, Srinagar 190025, Jammu and Kashmir, India.
FAU - Amin, Henna
AU  - Amin H
AD  - Department of Pharmaceutical Sciences, Faculty of Applied Science and Technology, 
      University of Kashmir, Srinagar, J&K 190006, India.
FAU - Rehman, Muneeb U
AU  - Rehman MU
AD  - Department of Clinical Pharmacy, College of Pharmacy, King Saudi University, P. 
      O. Box. 2460, Riyadh 11451, Saudi Arabia.
FAU - Ahmad, Parvaiz
AU  - Ahmad P
AD  - Botany and Microbiology Department, College of Science, King Saudi University, P. 
      O. Box. 2460, Riyadh 11451, Saudi Arabia.
LA  - eng
PT  - Journal Article
DEP - 20200127
PL  - Saudi Arabia
TA  - Saudi J Biol Sci
JT  - Saudi journal of biological sciences
JID - 101543796
PMC - PMC7042633
OTO - NOTNLM
OT  - Antioxidant
OT  - Breast cancer
OT  - Crocetin beta-d-glucosyl ester
OT  - DMEM, Dulbecco’s Modified Eagle’s Medium
OT  - DPPH, 2,2-diphenyl-1-picrylhydrazyl
OT  - FBS, Fetal Bovine serum
OT  - FTIR, Fourier-transform infrared spectroscopy
OT  - Floral biowastes
OT  - LC-MS/MS, Liquid chromatography–mass spectrometry
OT  - MTT, 3-(4,5–dimethyl thiazol–2–yl)–5–diphenyltetrazolium bromide
OT  - Molecular docking
OT  - NMR, Nuclear magneticresonance
OT  - Saffron
OT  - TLC, Thin layer chromatography
OT  - UV, Ultra violet
EDAT- 2020/03/05 06:00
MHDA- 2020/03/05 06:01
PMCR- 2020/01/27
CRDT- 2020/03/05 06:00
PHST- 2019/12/07 00:00 [received]
PHST- 2020/01/15 00:00 [revised]
PHST- 2020/01/16 00:00 [accepted]
PHST- 2020/03/05 06:00 [entrez]
PHST- 2020/03/05 06:00 [pubmed]
PHST- 2020/03/05 06:01 [medline]
PHST- 2020/01/27 00:00 [pmc-release]
AID - S1319-562X(20)30019-X [pii]
AID - 10.1016/j.sjbs.2020.01.018 [doi]
PST - ppublish
SO  - Saudi J Biol Sci. 2020 Mar;27(3):975-984. doi: 10.1016/j.sjbs.2020.01.018. Epub 
      2020 Jan 27.

PMID- 29477067
OWN - NLM
STAT- MEDLINE
DCOM- 20180323
LR  - 20250103
IS  - 1873-376X (Electronic)
IS  - 1570-0232 (Linking)
VI  - 1080
DP  - 2018 Mar 30
TI  - Development of an immunoaffinity column for the highly sensitive analysis of 
      bisphenol A in 14 kinds of foodstuffs using ultra-high-performance liquid 
      chromatography tandem mass spectrometry.
PG  - 50-58
LID - S1570-0232(18)30038-2 [pii]
LID - 10.1016/j.jchromb.2018.02.013 [doi]
AB  - An immunoaffinity clean-up material based on a monoclonal antibody (mAb) has been 
      prepared for concentrating and purifying bisphenol A (BPA) in 14 kinds of 
      foodstuffs at trace level. Haptens and immunogen of bisphenol A have been 
      synthesized and comprehensively characterized. An mAb towards BPA was prepared 
      and cross-reactivities with 14 BPA analogues were below 5%. The prepared antibody 
      was coupled to N-hydroxysuccinimide-activated Sepharose 4B to manufacture an 
      immunoaffinity column (IAC), which was applied to purify BPA in 14 kinds of 
      foodstuffs. The analyte was then detected by means of ultra-high-performance 
      liquid chromatography tandem mass spectrometry (UPLC-MS/MS). Under the optimized 
      conditions, compared with two traditional SPE clean-up methods, the IAC showed 
      better selectivity (matrix effect <16.8%) and higher sensitivity. The limits of 
      detection for BPA in 14 kinds of foodstuffs ranged from 0.001 μg L(-1) to 
      0.01 μg kg(-1), and the limits of quantification were in the range from 0.003 μg 
      L(-1) to 0.04 μg kg(-1). The recoveries of BPA from spiked samples ranged from 
      82.0% to 104.9%, with RSDs below 13.8%. Besides, the IAC exhibited good 
      reusability, with 40% column capacity remaining and no significant loss of 
      recovery after 25 application cycles in real sample detection. These results 
      demonstrated that the developed IAC-UPLC-MS/MS approach has wide applicability 
      for purifying and detecting BPA in various foodstuffs.
CI  - Copyright © 2018 Elsevier B.V. All rights reserved.
FAU - Yao, Kai
AU  - Yao K
AD  - Beijing Advanced Innovation Center for Food Nutrition and Human Health, College 
      of Veterinary Medicine, China Agricultural University, Beijing 100193, People's 
      Republic of China; Beijing Key Laboratory of Detection Technology for 
      Animal-Derived Food Safety, Beijing 100193, People's Republic of China; Beijing 
      Key Laboratory of Diagnostic and Traceability Technologies for Food Poisoning, 
      Beijing Center for Disease Prevention and Control, 100013, People's Republic of 
      China.
FAU - Wen, Kai
AU  - Wen K
AD  - Beijing Advanced Innovation Center for Food Nutrition and Human Health, College 
      of Veterinary Medicine, China Agricultural University, Beijing 100193, People's 
      Republic of China; Beijing Key Laboratory of Detection Technology for 
      Animal-Derived Food Safety, Beijing 100193, People's Republic of China.
FAU - Shan, Wenchong
AU  - Shan W
AD  - Beijing Advanced Innovation Center for Food Nutrition and Human Health, College 
      of Veterinary Medicine, China Agricultural University, Beijing 100193, People's 
      Republic of China; Beijing Key Laboratory of Detection Technology for 
      Animal-Derived Food Safety, Beijing 100193, People's Republic of China; Beijing 
      Key Laboratory of Diagnostic and Traceability Technologies for Food Poisoning, 
      Beijing Center for Disease Prevention and Control, 100013, People's Republic of 
      China.
FAU - Xie, Sanlei
AU  - Xie S
AD  - Beijing Advanced Innovation Center for Food Nutrition and Human Health, College 
      of Veterinary Medicine, China Agricultural University, Beijing 100193, People's 
      Republic of China; Beijing Key Laboratory of Detection Technology for 
      Animal-Derived Food Safety, Beijing 100193, People's Republic of China.
FAU - Peng, Tao
AU  - Peng T
AD  - Beijing Advanced Innovation Center for Food Nutrition and Human Health, College 
      of Veterinary Medicine, China Agricultural University, Beijing 100193, People's 
      Republic of China; Beijing Key Laboratory of Detection Technology for 
      Animal-Derived Food Safety, Beijing 100193, People's Republic of China.
FAU - Wang, Jianyi
AU  - Wang J
AD  - Beijing Advanced Innovation Center for Food Nutrition and Human Health, College 
      of Veterinary Medicine, China Agricultural University, Beijing 100193, People's 
      Republic of China; Beijing Key Laboratory of Detection Technology for 
      Animal-Derived Food Safety, Beijing 100193, People's Republic of China.
FAU - Jiang, Haiyang
AU  - Jiang H
AD  - Beijing Advanced Innovation Center for Food Nutrition and Human Health, College 
      of Veterinary Medicine, China Agricultural University, Beijing 100193, People's 
      Republic of China; Beijing Key Laboratory of Detection Technology for 
      Animal-Derived Food Safety, Beijing 100193, People's Republic of China. 
      Electronic address: haiyang@cau.edu.cn.
FAU - Shao, Bing
AU  - Shao B
AD  - Beijing Advanced Innovation Center for Food Nutrition and Human Health, College 
      of Veterinary Medicine, China Agricultural University, Beijing 100193, People's 
      Republic of China; Beijing Key Laboratory of Diagnostic and Traceability 
      Technologies for Food Poisoning, Beijing Center for Disease Prevention and 
      Control, 100013, People's Republic of China. Electronic address: 
      shaobingch@sina.com.
LA  - eng
PT  - Journal Article
DEP - 20180213
PL  - Netherlands
TA  - J Chromatogr B Analyt Technol Biomed Life Sci
JT  - Journal of chromatography. B, Analytical technologies in the biomedical and life 
      sciences
JID - 101139554
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Phenols)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - Antibodies, Monoclonal/chemistry/metabolism
MH  - Benzhydryl Compounds/*analysis/isolation & purification/metabolism
MH  - Chromatography, Affinity/*methods
MH  - Chromatography, High Pressure Liquid/methods
MH  - Food Contamination/*analysis
MH  - Limit of Detection
MH  - Linear Models
MH  - Phenols/*analysis/isolation & purification/metabolism
MH  - Reproducibility of Results
MH  - Tandem Mass Spectrometry/*methods
OTO - NOTNLM
OT  - Bisphenol A
OT  - Foodstuffs
OT  - Immunoaffinity column
OT  - Monoclonal antibody
OT  - UPLC-MS/MS
EDAT- 2018/02/25 06:00
MHDA- 2018/03/24 06:00
CRDT- 2018/02/25 06:00
PHST- 2018/01/05 00:00 [received]
PHST- 2018/02/07 00:00 [revised]
PHST- 2018/02/10 00:00 [accepted]
PHST- 2018/02/25 06:00 [pubmed]
PHST- 2018/03/24 06:00 [medline]
PHST- 2018/02/25 06:00 [entrez]
AID - S1570-0232(18)30038-2 [pii]
AID - 10.1016/j.jchromb.2018.02.013 [doi]
PST - ppublish
SO  - J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Mar 30;1080:50-58. doi: 
      10.1016/j.jchromb.2018.02.013. Epub 2018 Feb 13.

PMID- 38755042
OWN - NLM
STAT- MEDLINE
DCOM- 20240616
LR  - 20250103
IS  - 1879-0097 (Electronic)
IS  - 0109-5641 (Linking)
VI  - 40
IP  - 7
DP  - 2024 Jul
TI  - Level of BPA contamination in resin composites determines BPA release.
PG  - 1025-1030
LID - S0109-5641(24)00105-2 [pii]
LID - 10.1016/j.dental.2024.05.006 [doi]
AB  - OBJECTIVES: Resin composites may release bisphenol A (BPA) due to impurities 
      present in the monomers. However, there is a lack of knowledge regarding the 
      leaching characteristics of BPA from resin composites. Therefore, experimental 
      resin composites were prepared with known amounts of BPA. The objective of this 
      study was (1) to determine which amount of BPA initially present in the material 
      leaches out in the short term and, (2) how this release is influenced by the 
      resin composition. METHODS: BPA (0, 0.001, 0.01, or 0.1 wt%) was added to 
      experimental resin composites containing 60 mol% BisGMA, BisEMA(3), or UDMA, 
      respectively, as base monomer and 40 mol% TEGDMA as diluent monomer. Polymerized 
      samples (n = 5) were immersed at 37 °C for 7 days in 1 mL of water, which was 
      collected and refreshed daily. BPA release was quantified with UPLC-MS/MS after 
      derivatization with pyridine-3-sulfonyl chloride. RESULTS: Between 0.47 to 
      0.67 mol% of the originally added BPA eluted from the resin composites after 7 
      days. Similar elution trends were observed irrespective of the base monomer. 
      Two-way ANOVA showed a significant effect of the base monomer on BPA release, but 
      the differences were small and not consistent. SIGNIFICANCE: The released amount 
      of BPA was directly proportional to the quantity of BPA present in the resin 
      composite as an impurity. BPA release was mainly diffusion-based, while polymer 
      composition seemed to play a minor role. Our results underscore the importance 
      for manufacturers only to use monomers of the highest purity in dental resin 
      composites to avoid unnecessary BPA exposure in patients.
CI  - Copyright © 2024 Elsevier Inc. All rights reserved.
FAU - De Nys, Siemon
AU  - De Nys S
AD  - KU Leuven, Department of Oral Health Sciences, BIOMAT & University Hospitals 
      Leuven (UZ Leuven), Dentistry, Leuven, Belgium.
FAU - Turkalj, Marko
AU  - Turkalj M
AD  - KU Leuven, Department of Oral Health Sciences, BIOMAT & University Hospitals 
      Leuven (UZ Leuven), Dentistry, Leuven, Belgium.
FAU - Duca, Radu Corneliu
AU  - Duca RC
AD  - Environment and Health, Department of Public Health and Primary Care, KU Leuven, 
      Kapucijnenvoer 35, 3000 Leuven, Belgium; Unit Environmental Hygiene and Human 
      Biological Monitoring, Department of Health Protection, National Health 
      Laboratory (LNS), 3555 Dudelange, Luxembourg.
FAU - Covaci, Adrian
AU  - Covaci A
AD  - Toxicological Centre, University of Antwerp, Universiteitsplein 1, D.S.551, 2610 
      Wilrijk, Belgium.
FAU - Elskens, Marc
AU  - Elskens M
AD  - Laboratory of Analytical, Environmental and Geo-Chemistry, Vrije Universiteit 
      Brussel, Pleinlaan 2, 1050 Ixelles, Belgium.
FAU - Godderis, Lode
AU  - Godderis L
AD  - Environment and Health, Department of Public Health and Primary Care, KU Leuven, 
      Kapucijnenvoer 35, 3000 Leuven, Belgium; IDEWE, External service for prevention 
      and protection at work, Heverlee, Belgium.
FAU - Vanoirbeek, Jeroen
AU  - Vanoirbeek J
AD  - Environment and Health, Department of Public Health and Primary Care, KU Leuven, 
      Kapucijnenvoer 35, 3000 Leuven, Belgium.
FAU - Van Meerbeek, Bart
AU  - Van Meerbeek B
AD  - KU Leuven, Department of Oral Health Sciences, BIOMAT & University Hospitals 
      Leuven (UZ Leuven), Dentistry, Leuven, Belgium.
FAU - Van Landuyt, Kirsten L
AU  - Van Landuyt KL
AD  - KU Leuven, Department of Oral Health Sciences, BIOMAT & University Hospitals 
      Leuven (UZ Leuven), Dentistry, Leuven, Belgium. Electronic address: 
      kirsten.vanlanduyt@uzleuven.be.
LA  - eng
PT  - Journal Article
DEP - 20240516
PL  - England
TA  - Dent Mater
JT  - Dental materials : official publication of the Academy of Dental Materials
JID - 8508040
RN  - 0 (Phenols)
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Composite Resins)
RN  - RW57K3X12M (bisphenol A)
RN  - 14I47YJ5EY (triethylene glycol dimethacrylate)
RN  - 0 (Polyurethanes)
RN  - 0 (Polymethacrylic Acids)
RN  - 0 (Methacrylates)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
SB  - IM
MH  - *Phenols/analysis/chemistry
MH  - *Benzhydryl Compounds/chemistry
MH  - *Composite Resins/chemistry
MH  - Materials Testing
MH  - Chromatography, High Pressure Liquid
MH  - Tandem Mass Spectrometry
MH  - Polyurethanes/chemistry
MH  - Polymethacrylic Acids/chemistry
MH  - Methacrylates/chemistry/analysis
MH  - Polyethylene Glycols/chemistry
MH  - Polymerization
OTO - NOTNLM
OT  - BPA
OT  - BisEMA
OT  - BisGMA
OT  - Bisphenol A
OT  - Endocrine disruptor
OT  - Experimental composite
OT  - Resin-based dental materials
EDAT- 2024/05/17 00:43
MHDA- 2024/06/17 00:42
CRDT- 2024/05/16 21:57
PHST- 2024/02/02 00:00 [received]
PHST- 2024/04/29 00:00 [revised]
PHST- 2024/05/03 00:00 [accepted]
PHST- 2024/06/17 00:42 [medline]
PHST- 2024/05/17 00:43 [pubmed]
PHST- 2024/05/16 21:57 [entrez]
AID - S0109-5641(24)00105-2 [pii]
AID - 10.1016/j.dental.2024.05.006 [doi]
PST - ppublish
SO  - Dent Mater. 2024 Jul;40(7):1025-1030. doi: 10.1016/j.dental.2024.05.006. Epub 
      2024 May 16.

PMID- 31348763
OWN - NLM
STAT- MEDLINE
DCOM- 20200224
LR  - 20250103
IS  - 1619-3997 (Electronic)
IS  - 0300-5577 (Linking)
VI  - 47
IP  - 7
DP  - 2019 Sep 25
TI  - Simultaneous analysis of bisphenol A fractions in maternal and fetal compartments 
      in early second trimester of pregnancy.
PG  - 765-770
LID - 10.1515/jpm-2019-0040 [doi]
AB  - Background Bisphenol A (BPA) is an estrogenic, endocrine-disrupting compound 
      widely used in the industry. It is also a ubiquitous environmental pollutant. Its 
      presence was confirmed in human fetuses, which results from maternal exposure 
      during pregnancy. The mechanisms behind maternal-fetal transfer, and 
      relationships between pregnant women and fetal exposures remain unclear. The aim 
      of this study was to assess the impact of maternal exposure to BPA on the 
      exposure of the fetus. Methods Maternal plasma and amniotic fluid samples were 
      collected from 52 pregnant women undergoing amniocentesis for prenatal diagnosis 
      of chromosomal abnormalities. BPA was measured by gas chromatography-mass 
      spectrometry (GC-MS). The permeability factor - a ratio of fetal-to-maternal BPA 
      concentration - was used as a measure delineating the transplacental transfer of 
      BPA. Results The median concentration of maternal plasma BPA was 8 times higher 
      than the total BPA concentration in the amniotic fluid (8.69 ng/mL, range: 4.3 
      ng/mL-55.3 ng/mL vs. median 1.03 ng/mL, range: 0.3 ng/mL-10.1 ng/mL). There was 
      no direct relationship between the levels of BPA in maternal plasma and amniotic 
      fluid levels. The permeability factor, in turn, negatively correlated with fetal 
      development (birth weight) (R = -0.54, P < 0.001). Conclusion Our results suggest 
      that the risk of fetal BPA exposure depends on placental BPA permeability rather 
      than the levels of maternal BPA plasma concentration and support general 
      recommendations to become aware and avoid BPA-containing products.
FAU - Zbucka-Krętowska, Monika
AU  - Zbucka-Krętowska M
AD  - Department of Reproduction and Gynaecological Endocrinology, Medical University 
      of Bialystok, Marii Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland.
FAU - Łazarek, Urszula
AU  - Łazarek U
AD  - Department of Pharmaceutical Analysis, Medical University of Bialystok, 
      Mickiewicza 2D, 15-522 Bialystok, Poland.
FAU - Miltyk, Wojciech
AU  - Miltyk W
AD  - Department of Pharmaceutical Analysis, Medical University of Bialystok, 
      Mickiewicza 2D, 15-522 Bialystok, Poland.
FAU - Sidorkiewicz, Iwona
AU  - Sidorkiewicz I
AUID- ORCID: 0000-0003-0254-3095
AD  - Clinical Research Centre, Medical University of Bialystok, Marii 
      Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland.
FAU - Pierzyński, Piotr
AU  - Pierzyński P
AD  - Department of Reproduction and Gynaecological Endocrinology, Medical University 
      of Bialystok, Marii Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland.
FAU - Milewski, Robert
AU  - Milewski R
AD  - Department of Statistics and Medical Informatics, Medical University of 
      Bialystok, Szpitalna 37, 15-295 Bialystok, Poland.
FAU - Wołczyński, Sławomir
AU  - Wołczyński S
AD  - Department of Reproduction and Gynaecological Endocrinology, Medical University 
      of Bialystok, Marii Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland.
FAU - Czerniecki, Jan
AU  - Czerniecki J
AD  - Department of Biology and Pathology of Human Reproduction, Institute of Animal 
      Reproduction and Food Research, Polish Academy of Science, Tuwima 10, 10-748 
      Olsztyn, Poland.
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - J Perinat Med
JT  - Journal of perinatal medicine
JID - 0361031
RN  - 0 (Air Pollutants, Occupational)
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Estrogens, Non-Steroidal)
RN  - 0 (Phenols)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - Adult
MH  - Air Pollutants, Occupational/adverse effects/blood/chemistry
MH  - Amniotic Fluid/*chemistry
MH  - *Benzhydryl Compounds/adverse effects/blood/chemistry
MH  - Birth Weight/*drug effects
MH  - Environmental Exposure/prevention & control
MH  - Estrogens, Non-Steroidal/adverse effects/blood/chemistry
MH  - Female
MH  - Gas Chromatography-Mass Spectrometry/methods
MH  - Humans
MH  - Maternal Exposure/prevention & control
MH  - *Maternal-Fetal Exchange
MH  - Permeability
MH  - *Phenols/adverse effects/blood/chemistry
MH  - *Placenta/metabolism/physiopathology
MH  - Pregnancy
MH  - Pregnancy Trimester, Second
OTO - NOTNLM
OT  - Bisphenol A
OT  - amniotic fluid
OT  - maternal plasma
OT  - prenatal exposure
OT  - second trimester
EDAT- 2019/07/28 06:00
MHDA- 2020/02/25 06:00
CRDT- 2019/07/27 06:00
PHST- 2019/02/06 00:00 [received]
PHST- 2019/07/07 00:00 [accepted]
PHST- 2019/07/28 06:00 [pubmed]
PHST- 2020/02/25 06:00 [medline]
PHST- 2019/07/27 06:00 [entrez]
AID - jpm-2019-0040 [pii]
AID - 10.1515/jpm-2019-0040 [doi]
PST - ppublish
SO  - J Perinat Med. 2019 Sep 25;47(7):765-770. doi: 10.1515/jpm-2019-0040.

PMID- 27145114
OWN - NLM
STAT- MEDLINE
DCOM- 20171127
LR  - 20171201
IS  - 1613-4133 (Electronic)
IS  - 1613-4125 (Linking)
VI  - 60
IP  - 9
DP  - 2016 Sep
TI  - Biochanin A improves hepatic steatosis and insulin resistance by regulating the 
      hepatic lipid and glucose metabolic pathways in diet-induced obese mice.
PG  - 1944-55
LID - 10.1002/mnfr.201500689 [doi]
AB  - SCOPE: Natural compounds that regulate peroxisome proliferator-activated receptor 
      alpha (PPARα) have been reported to have beneficial effects in obesity-mediated 
      metabolic disorders. In this study, we demonstrated that biochanin A (BA), an 
      agonist of PPAR-α, improved hepatic steatosis and insulin resistance by 
      regulating hepatic lipid and glucose metabolism. METHODS AND RESULTS: C57BL/6 
      mice were fed a normal chow diet, a high-fat diet (HFD), and an HFD supplemented 
      with 0.05% BA for 12 weeks. Histological and biochemical examinations indicated 
      that BA prevented obesity-induced hepatic steatosis and insulin resistance in 
      HFD-fed mice. BA stimulated the transcriptional activation of PPAR-α in vitro and 
      increased the expression of PPAR-α and its regulatory proteins in the liver. 
      CE-TOF/MS analyses indicated that BA administration promoted the recovery of 
      metabolites involved in phosphatidylcholine synthesis, lipogenesis, and 
      beta-oxidation in the livers of obese mice. BA also suppressed the levels of 
      gluconeogenesis-related metabolites and the expression of the associated enzymes, 
      glucose 6-phosphatase and pyruvate kinase. CONCLUSION: Taken together, these 
      results showed that BA ameliorated metabolic disorders such as hepatic steatosis 
      and insulin resistance by modulating lipid and glucose metabolism in diet-induced 
      obesity. Thus, BA may be a potential therapeutic agent for the prevention of 
      obesity-mediated hepatic steatosis and insulin resistance.
CI  - © 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Park, Hee-Sook
AU  - Park HS
AD  - Division of Nutrition and Metabolism, Korea Food Research Institute, Seongnam, 
      Republic of Korea.
FAU - Hur, Haeng Jeon
AU  - Hur HJ
AD  - Division of Nutrition and Metabolism, Korea Food Research Institute, Seongnam, 
      Republic of Korea.
FAU - Kim, Soon-Hee
AU  - Kim SH
AD  - Division of Nutrition and Metabolism, Korea Food Research Institute, Seongnam, 
      Republic of Korea.
FAU - Park, Su-Jin
AU  - Park SJ
AD  - Division of Nutrition and Metabolism, Korea Food Research Institute, Seongnam, 
      Republic of Korea.
FAU - Hong, Moon Ju
AU  - Hong MJ
AD  - Division of Nutrition and Metabolism, Korea Food Research Institute, Seongnam, 
      Republic of Korea.
AD  - Department of Food Biotechnology, University of Science & Technology, Seongnam, 
      Republic of Korea.
FAU - Sung, Mi Jeong
AU  - Sung MJ
AD  - Division of Nutrition and Metabolism, Korea Food Research Institute, Seongnam, 
      Republic of Korea.
AD  - Department of Food Biotechnology, University of Science & Technology, Seongnam, 
      Republic of Korea.
FAU - Kwon, Dae Young
AU  - Kwon DY
AD  - Division of Nutrition and Metabolism, Korea Food Research Institute, Seongnam, 
      Republic of Korea.
AD  - Department of Food Biotechnology, University of Science & Technology, Seongnam, 
      Republic of Korea.
FAU - Kim, Myung-Sunny
AU  - Kim MS
AD  - Division of Nutrition and Metabolism, Korea Food Research Institute, Seongnam, 
      Republic of Korea. truka@kfri.re.kr.
AD  - Department of Food Biotechnology, University of Science & Technology, Seongnam, 
      Republic of Korea. truka@kfri.re.kr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160608
PL  - Germany
TA  - Mol Nutr Food Res
JT  - Molecular nutrition & food research
JID - 101231818
RN  - 0 (PPAR alpha)
RN  - 0 (Phosphatidylcholines)
RN  - DH2M523P0H (Genistein)
RN  - IY9XDZ35W2 (Glucose)
RN  - U13J6U390T (biochanin A)
SB  - IM
MH  - Animals
MH  - Diet, High-Fat/adverse effects
MH  - Genistein/*pharmacology
MH  - Glucose/*metabolism
MH  - HEK293 Cells
MH  - Humans
MH  - *Insulin Resistance
MH  - Lipid Metabolism/*drug effects
MH  - Liver/drug effects/metabolism/physiopathology
MH  - Male
MH  - Mice, Inbred C57BL
MH  - Mice, Obese
MH  - Non-alcoholic Fatty Liver Disease/*drug therapy/etiology/metabolism
MH  - Obesity/drug therapy/etiology/*metabolism/physiopathology
MH  - PPAR alpha/genetics/metabolism
MH  - Phosphatidylcholines/metabolism
OTO - NOTNLM
OT  - Biochanin A
OT  - Glucose metabolism
OT  - Hepatic steatosis
OT  - Lipid metabolism
OT  - Metabolomics
EDAT- 2016/05/05 06:00
MHDA- 2017/11/29 06:00
CRDT- 2016/05/05 06:00
PHST- 2015/09/02 00:00 [received]
PHST- 2016/03/28 00:00 [revised]
PHST- 2016/03/31 00:00 [accepted]
PHST- 2016/05/05 06:00 [entrez]
PHST- 2016/05/05 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
AID - 10.1002/mnfr.201500689 [doi]
PST - ppublish
SO  - Mol Nutr Food Res. 2016 Sep;60(9):1944-55. doi: 10.1002/mnfr.201500689. Epub 2016 
      Jun 8.

PMID- 35791606
OWN - NLM
STAT- MEDLINE
DCOM- 20220707
LR  - 20220915
IS  - 1872-2059 (Electronic)
IS  - 1000-8713 (Print)
IS  - 1000-8713 (Linking)
VI  - 40
IP  - 7
DP  - 2022 Jul
TI  - [Simultaneous determination of nine estrogens in bullfrogs using filtered solid 
      phase extraction and ultra-performance liquid chromatography-tandem mass 
      spectrometry].
PG  - 669-676
LID - 10.3724/SP.J.1123.2022.01017 [doi]
AB  - Due to the harmful effects of estrogens and their prevalence in animal foods, 
      accurate analysis of estrogen levels in animal foods is imperative in order to 
      effectively assess food safety risks and ensure consumer safety. Therefore, a 
      rapid and accurate method based on PRiME HLB solid phase extraction (SPE) 
      cartridge purification and ultra-performance liquid chromatography-tandem mass 
      spectrometry (UPLC-MS/MS) was developed to determine nine estrogen residues in 
      bullfrogs. The nine estrogens included estriol (E3), 17β-estradiol (β-E), 
      17α-estradiol (α-E), 17α-ethinylestradiol (EE2), estrone (EI), diethylstilbestrol 
      (DES), dienestrol (DE), hexestrol (HEX), and dienestrol diacetate (DD). This 
      study optimized the mobile phase system, extraction solvent, and SPE cartridges. 
      Because estrogens present weak alkalinity, adding a small amount of alkaline 
      substance to the mobile phase benefits estrogen ionization into the ionic state, 
      eliminates the peak trailing phenomenon, and enhances the signal response of 
      estrogens to improve sensitivity. Estrogens have one or more hydroxyl groups in 
      their chemical structures. According to the principle of similar solubility, 
      polar solvents are chosen as extraction solvents. Based on the complex matrix 
      composition of meat samples, SPE is required for purification to reduce matrix 
      effects. The liquid chromatographic conditions were optimized, and the 0.5 mmol/L 
      ammonium fluoride aqueous solution-acetonitrile system as mobile phases showed 
      better sensitivity than the ammonium acetate aqueous solution-acetonitrile system 
      and the ammonia-acetonitrile system for the nine estrogens. When acetonitrile was 
      used as the extraction solvent, the extraction rates of all nine estrogens 
      exceeded those of methanol and ethyl acetate and increased by 15%-40%. By 
      focusing on the matrix purification effect of four different SPE cartridges, the 
      results showed that the matrix purification ability of the PRiME HLB cartridge 
      outperformed that of the HLB, C(18), and Silica SPE cartridges. After 
      purification by the PRiME HLB cartridge, the recoveries of all compounds were in 
      the range of 70%-125%, and the DD recovery was increased from 47% to 74%, whereas 
      the HEX recovery was reduced from 180% to 123%. Therefore, the PRiME HLB SPE 
      cartridge was selected as the cleanup material for this experiment. Finally, the 
      sample was extracted using acetonitrile, purified by PRiME HLB SPE cartridge, and 
      separated on a Waters Acquity UPLC BEH C(18) column (100 mm×2.1 mm, 1.7 μm) with 
      a mobile phase of 0.5 mmol/L ammonium fluoride aqueous acetonitrile solution at a 
      flow rate of 0.3 mL/min. The detection was conducted in positive and negative ion 
      switching mode (ESI(+)/ESI(-)) and multiple reaction monitoring (MRM) scanning, 
      and it was quantified using a matrix-matched external standard method. Under the 
      optimal experimental conditions, the linear ranges were 0.5-100.0 μg/L for E3, 
      β-E, α-E, EI, DE, HEX, and DD, and 1.0-100.0 μg/L for EE2 and DES. The nine 
      estrogens showed good linearity in all linear ranges, with correlation 
      coefficients of 0.9953-0.9994. The limits of detection were 0.17-0.33 μg/kg, and 
      the limits of quantification were 0.5-1.0 μg/kg. The recoveries of the nine 
      estrogens spiked at the three spiked levels of low (2.0 μg/kg), medium (10.0 
      μg/kg), and high (80.0 μg/kg) were 107.4%-125.3%, 67.0%-123.3%, and 65.1%-128.2%, 
      respectively. The relative standard deviations were 1.9%-17.6%. The method 
      established in this study was applied to detect nine estrogen residues in 50 
      commercially available bullfrog samples, and the results showed that HEX, EI, and 
      DES were detected in few samples. The method is simple, rapid, sensitive, and 
      reproducible, and can be used for the simultaneous, rapid and accurate 
      determination of large quantities of samples.
FAU - Qiu, Qiaoli
AU  - Qiu Q
AD  - Ningbo Municipal Center for Disease Control and Prevention, Key Laboratory of 
      Health Risk Appraisal for Trace Toxic Chemicals of Zhejiang Province, Ningbo 
      315010, China.
FAU - Chen, Xiaohong
AU  - Chen X
AD  - Ningbo Municipal Center for Disease Control and Prevention, Key Laboratory of 
      Health Risk Appraisal for Trace Toxic Chemicals of Zhejiang Province, Ningbo 
      315010, China.
FAU - Pan, Shengdong
AU  - Pan S
AD  - Ningbo Municipal Center for Disease Control and Prevention, Key Laboratory of 
      Health Risk Appraisal for Trace Toxic Chemicals of Zhejiang Province, Ningbo 
      315010, China.
FAU - Jin, Micong
AU  - Jin M
AD  - Ningbo Municipal Center for Disease Control and Prevention, Key Laboratory of 
      Health Risk Appraisal for Trace Toxic Chemicals of Zhejiang Province, Ningbo 
      315010, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Se Pu
JT  - Se pu = Chinese journal of chromatography
JID - 9424804
RN  - 0 (Acetonitriles)
RN  - 0 (Estrogens)
RN  - 0 (Solvents)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Acetonitriles
MH  - Animals
MH  - Chromatography, High Pressure Liquid
MH  - Chromatography, Liquid
MH  - Estradiol
MH  - *Estrogens/analysis
MH  - Rana catesbeiana
MH  - Solid Phase Extraction
MH  - Solvents
MH  - *Tandem Mass Spectrometry/methods
PMC - PMC9404095
OTO - NOTNLM
OT  - bullfrog
OT  - estrogen
OT  - solid phase extraction (SPE)
OT  - ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS)
EDAT- 2022/07/07 06:00
MHDA- 2022/07/08 06:00
PMCR- 2022/07/08
CRDT- 2022/07/06 03:02
PHST- 2022/07/06 03:02 [entrez]
PHST- 2022/07/07 06:00 [pubmed]
PHST- 2022/07/08 06:00 [medline]
PHST- 2022/07/08 00:00 [pmc-release]
AID - 10.3724/SP.J.1123.2022.01017 [doi]
PST - ppublish
SO  - Se Pu. 2022 Jul;40(7):669-676. doi: 10.3724/SP.J.1123.2022.01017.

PMID- 25003624
OWN - NLM
STAT- MEDLINE
DCOM- 20160225
LR  - 20211021
IS  - 1530-0374 (Electronic)
IS  - 1072-3714 (Print)
IS  - 1072-3714 (Linking)
VI  - 22
IP  - 2
DP  - 2015 Feb
TI  - Soy Isoflavones for Reducing Bone Loss Study: effects of a 3-year trial on 
      hormones, adverse events, and endometrial thickness in postmenopausal women.
PG  - 185-97
LID - 10.1097/GME.0000000000000280 [doi]
AB  - OBJECTIVE: This study aims to assess the overall safety and potential 
      endometrium-stimulating effects of soy isoflavone tablets consumed (3 y) by 
      postmenopausal women and to determine endometrial thickness response to treatment 
      among compliant women, taking into account hormone concentrations and other 
      hypothesized modifying factors. METHODS: We randomized healthy postmenopausal 
      women (aged 45.8-65.0 y) to placebo control or two doses (80 or 120 mg/d) of soy 
      isoflavones at two sites. We used intent-to-treat analysis (N = 224) and 
      compliant analysis (>95%; N = 208) to assess circulating hormone concentrations, 
      adverse events, and endometrial thickness (via transvaginal ultrasound). RESULTS: 
      Median values for endometrial thickness (mm) declined from baseline through 36 
      months. Nonparametric analysis of variance for treatment differences among groups 
      showed no differences in absolute (or percentage of change) endometrial thickness 
      (χ(2) P ranged from 0.12 to 0.69) or in circulating hormones at any time point. A 
      greater number of adverse events in the genitourinary system (P = 0.005) were 
      noted in the 80 mg/day group compared with the 120 mg/day group, whereas other 
      systems showed no treatment effects. The model predicting endometrial thickness 
      response (using natural logarithm) to treatment among compliant women across time 
      points was significant (P ≤ 0.0001), indicating that estrogen exposure (P = 
      0.0013), plasma 17β-estradiol (P = 0.0086), and alcohol intake (P = 0.023) 
      contributed significantly to the response. Neither the 80 mg/day dose (P = 0.57) 
      nor the 120 mg/day dose (P = 0.43) exerted an effect on endometrial thickness 
      across time. CONCLUSIONS: Our randomized controlled trial verifies the long-term 
      overall safety of soy isoflavone tablet intake by postmenopausal women who 
      display excellent compliance. We find no evidence of treatment effects on 
      endometrial thickness, adverse events, or circulating hormone concentrations, 
      most notably thyroid function, across a 3-year period.
FAU - Alekel, D Lee
AU  - Alekel DL
AD  - From the 1National Institutes of Health, Bethesda, MD; 2Department of Statistics, 
      Iowa State University, Ames, IA; 3US Department of Agriculture-Agricultural 
      Research Service, Western Human Nutrition Research Center, University of 
      California at Davis, Davis, CA; 4McFarland Clinic, Ames, IA; 5Mayo Validation 
      Support Services, Rochester, MN; 6Center for Devices and Radiological Health, 
      Food and Drug Administration, White Oak, MD; and 7Department of Food Science and 
      Nutrition, University of Minnesota, St Paul, MN.
FAU - Genschel, Ulrike
AU  - Genschel U
FAU - Koehler, Kenneth J
AU  - Koehler KJ
FAU - Hofmann, Heike
AU  - Hofmann H
FAU - Van Loan, Marta D
AU  - Van Loan MD
FAU - Beer, Bonnie S
AU  - Beer BS
FAU - Hanson, Laura N
AU  - Hanson LN
FAU - Peterson, Charles T
AU  - Peterson CT
FAU - Kurzer, Mindy S
AU  - Kurzer MS
LA  - eng
SI  - ClinicalTrials.gov/NCT00043745
GR  - R01AR046922/AR/NIAMS NIH HHS/United States
GR  - R01 AR046922/AR/NIAMS NIH HHS/United States
GR  - UL1 RR024146/RR/NCRR NIH HHS/United States
GR  - M01 RR019975/RR/NCRR NIH HHS/United States
GR  - 1M01RR1997501/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Menopause
JT  - Menopause (New York, N.Y.)
JID - 9433353
RN  - 0 (Estrogens)
RN  - 0 (Isoflavones)
RN  - 0 (Sex Hormone-Binding Globulin)
RN  - 0 (Soybean Proteins)
RN  - 2DI9HA706A (Estrone)
RN  - 4TI98Z838E (Estradiol)
RN  - 9002-71-5 (Thyrotropin)
RN  - QTL48N278K (estrone sulfate)
SB  - IM
MH  - Aged
MH  - Double-Blind Method
MH  - Endometrium/anatomy & histology/diagnostic imaging/*drug effects
MH  - Estradiol/blood
MH  - Estrogens/blood
MH  - Estrone/analogs & derivatives/blood
MH  - Female
MH  - Humans
MH  - Intention to Treat Analysis
MH  - Isoflavones/*administration & dosage/adverse effects
MH  - Middle Aged
MH  - Osteoporosis, Postmenopausal/blood/*prevention & control
MH  - Sex Hormone-Binding Globulin/analysis
MH  - Soybean Proteins/*administration & dosage/adverse effects
MH  - Thyrotropin/blood
MH  - Ultrasonography
PMC - PMC4286538
MID - NIHMS608546
COIS- Conflict of Interest: MS Kurzer is a member of the Soy Nutrition Institute 
      Scientific Advisory Board; otherwise, the authors had no known conflicts of 
      interest.
EDAT- 2014/07/09 06:00
MHDA- 2016/02/26 06:00
PMCR- 2016/02/01
CRDT- 2014/07/09 06:00
PHST- 2014/07/09 06:00 [entrez]
PHST- 2014/07/09 06:00 [pubmed]
PHST- 2016/02/26 06:00 [medline]
PHST- 2016/02/01 00:00 [pmc-release]
AID - 10.1097/GME.0000000000000280 [doi]
PST - ppublish
SO  - Menopause. 2015 Feb;22(2):185-97. doi: 10.1097/GME.0000000000000280.

PMID- 26692419
OWN - NLM
STAT- MEDLINE
DCOM- 20161019
LR  - 20161230
IS  - 1873-6815 (Electronic)
IS  - 0531-5565 (Linking)
VI  - 74
DP  - 2016 Feb
TI  - Chronic vagus nerve stimulation attenuates vascular endothelial impairments and 
      reduces the inflammatory profile via inhibition of the NF-κB signaling pathway in 
      ovariectomized rats.
PG  - 43-55
LID - S0531-5565(15)30104-2 [pii]
LID - 10.1016/j.exger.2015.12.005 [doi]
AB  - Vagus nerve stimulation (VNS), a method for activating cholinergic 
      anti-inflammatory pathways, could suppress endothelial activation and minimize 
      tissue injury during inflammation. The aim of this study was to investigate the 
      effects of chronic VNS on endothelial impairments and the inflammatory profile in 
      ovariectomized (OVX) rats. Sprague-Dawley rats (7-8 months old) were randomly 
      assigned to the following four groups: sham-OVX, OVX, OVX+sham-VNS, and OVX+VNS. 
      Throughout the experimental period, the OVX+VNS group received VNS for 3h (20.0 
      Hz, 1.0 mA, and 10.00 ms pulse width) at the same time every other day. After 12 
      weeks of VNS, blood samples and thoracic aortas were collected for further 
      analyses. Light microscopy and electron microscopy analyses showed that chronic 
      VNS prevented endothelial swelling, desquamation and even necrosis in the OVX 
      rats. In addition, it obviously improved endothelial function in the OVX rats by 
      restoring the endothelial nitric oxide synthase (e-NOS) and serum endothelin-1 
      level. Increased expression of cell adhesion molecules (VCAM-1, ICAM-1 and 
      E-selectin) in the thoracic aortas and increases in the levels of circulating 
      cytokines (TNF-α, IL-6, MCP-1, and CINC/KC) were also observed in the OVX rats. 
      Chronic VNS significantly restored these detrimental changes partly by increasing 
      the ACh concentrations in vascular walls and blocking NF-κB pathway activity. The 
      results of this in vivo study have shown that the administration of chronic VNS 
      during, in the early stage of estrogen deficiency, protects OVX rats from 
      endothelial impairments and the inflammatory profile. These findings indicate 
      that activation of the vagus nerve could be a promising supplemental therapy for 
      reducing the risks of suffering from further CVDs in postmenopausal women.
CI  - Copyright © 2015 Elsevier Inc. All rights reserved.
FAU - Li, Ping
AU  - Li P
AD  - Department of Physiology, Zhongshan School of Medicine, Sun Yat-sen University, 
      Guangzhou, People's Republic of China.
FAU - Liu, Huaipu
AU  - Liu H
AD  - Department of Physiology, Zhongshan School of Medicine, Sun Yat-sen University, 
      Guangzhou, People's Republic of China; Department of Cardiothoracic Surgery, 
      Shenzhen Children's Hospital, Shenzhen, People's Republic of China.
FAU - Sun, Peng
AU  - Sun P
AD  - Department of Physiology, Zhongshan School of Medicine, Sun Yat-sen University, 
      Guangzhou, People's Republic of China.
FAU - Wang, Xiaoyu
AU  - Wang X
AD  - Department of Physiology, Zhongshan School of Medicine, Sun Yat-sen University, 
      Guangzhou, People's Republic of China.
FAU - Wang, Chen
AU  - Wang C
AD  - Department of Physiology, Zhongshan School of Medicine, Sun Yat-sen University, 
      Guangzhou, People's Republic of China.
FAU - Wang, Ling
AU  - Wang L
AD  - Department of Physiology, Zhongshan School of Medicine, Sun Yat-sen University, 
      Guangzhou, People's Republic of China.
FAU - Wang, Tinghuai
AU  - Wang T
AD  - Department of Physiology, Zhongshan School of Medicine, Sun Yat-sen University, 
      Guangzhou, People's Republic of China. Electronic address: 
      wangth@mail.sysu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151209
PL  - England
TA  - Exp Gerontol
JT  - Experimental gerontology
JID - 0047061
RN  - 0 (Cell Adhesion Molecules)
RN  - 0 (Inflammation Mediators)
RN  - 0 (NF-kappa B)
RN  - 0 (Rela protein, rat)
RN  - 0 (Transcription Factor RelA)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type III)
RN  - EC 1.14.13.39 (Nos3 protein, rat)
RN  - N9YNS0M02X (Acetylcholine)
SB  - IM
MH  - Acetylcholine/metabolism
MH  - Animals
MH  - Aorta, Thoracic/innervation/*metabolism/physiopathology/ultrastructure
MH  - Cardiovascular Diseases/metabolism/pathology/physiopathology/*prevention & 
      control
MH  - Cell Adhesion Molecules/metabolism
MH  - Disease Models, Animal
MH  - Endothelial Cells/metabolism/pathology
MH  - Endothelium, Vascular/innervation/*metabolism/physiopathology/ultrastructure
MH  - Female
MH  - Inflammation/metabolism/pathology/physiopathology/*prevention & control
MH  - Inflammation Mediators/*metabolism
MH  - NF-kappa B/*metabolism
MH  - Nitric Oxide/metabolism
MH  - Nitric Oxide Synthase Type III/metabolism
MH  - *Ovariectomy
MH  - Rats, Sprague-Dawley
MH  - *Signal Transduction
MH  - Time Factors
MH  - Transcription Factor RelA/metabolism
MH  - *Vagus Nerve Stimulation
MH  - Vasodilation
OTO - NOTNLM
OT  - Cholinergic anti-inflammatory pathway
OT  - Chronic vagus nerve stimulation
OT  - Endothelial dysfunction
OT  - Inflammation
OT  - Ovariectomy
EDAT- 2015/12/23 06:00
MHDA- 2016/11/12 06:00
CRDT- 2015/12/23 06:00
PHST- 2015/09/22 00:00 [received]
PHST- 2015/11/10 00:00 [revised]
PHST- 2015/12/07 00:00 [accepted]
PHST- 2015/12/23 06:00 [entrez]
PHST- 2015/12/23 06:00 [pubmed]
PHST- 2016/11/12 06:00 [medline]
AID - S0531-5565(15)30104-2 [pii]
AID - 10.1016/j.exger.2015.12.005 [doi]
PST - ppublish
SO  - Exp Gerontol. 2016 Feb;74:43-55. doi: 10.1016/j.exger.2015.12.005. Epub 2015 Dec 
      9.

PMID- 32105339
OWN - NLM
STAT- MEDLINE
DCOM- 20201222
LR  - 20201222
IS  - 1097-0010 (Electronic)
IS  - 0022-5142 (Linking)
VI  - 100
IP  - 7
DP  - 2020 May
TI  - Topical capsaicin cream with moderate exercise protects against hepatic 
      steatosis, dyslipidemia and increased blood pressure in hypoestrogenic obese 
      rats.
PG  - 3212-3219
LID - 10.1002/jsfa.10357 [doi]
AB  - BACKGROUND: The aim of this study was to evaluate the effects of capsaicin (Cap), 
      moderate exercise (Ex), and their combination on arterial blood pressure (BP) and 
      metabolic complications in hypoestrogenic (HE) obese (HEOb) rats. Female Wistar 
      rats were ovariectomized and given 300 g L(-1) sucrose solution (HEOb), or 
      purified water (HE) ad libitum, for 28 weeks. After shaving the abdominal skin, 
      cold cream vehicle was applied to sedentary (Sed) and exercise (Ex) groups, and 
      0.75 g kg(-1) Cap cream was applied to Ex groups. Ex groups ran on a treadmill 
      every day for 20 min at speeds from 0.15 to 0.3 m s(-1) . For combination groups 
      (Cap + Ex), topical Cap was applied 90 min before Ex. The treatments were 
      performed for 6 weeks, and BP was recorded before and at the end of the 
      experimental protocol. The animals were killed by decapitation, and blood and 
      tissues were obtained to perform oxidative profile, as well as to undertake 
      biochemical and histologic studies. RESULTS: Compared with individual treatments, 
      the combined therapy (Cap + Ex) in HEOb rats caused a higher reduction in the 
      caloric intake, body weight, abdominal fat percentage, oxidative stress, and 
      hepatic steatosis. In HEOb groups, Cap was the only treatment that reduced BP and 
      prevented dyslipidemia and oxidative stress. CONCLUSION: The present data show 
      that Cap improves the metabolic alterations induced by obesity and 
      hypoestrogenism, suggesting that Cap can be considered as an excellent candidate 
      for therapy of these clinical conditions. © 2020 Society of Chemical Industry.
CI  - © 2020 Society of Chemical Industry.
FAU - de Lourdes Medina-Contreras, Juana Maria
AU  - de Lourdes Medina-Contreras JM
AD  - Pharmacobiology Department, Cinvestav-IPN Sede Sur, Mexico City, Mexico.
FAU - Mailloux-Salinas, Patrick
AU  - Mailloux-Salinas P
AD  - Pharmacobiology Department, Cinvestav-IPN Sede Sur, Mexico City, Mexico.
FAU - Colado-Velazquez, Juventino Iii
AU  - Colado-Velazquez JI
AD  - Chair of the Department of Health Sciences, Western Autonomous University, 
      Culiacán Regional Unit, Culiacán, Mexico.
FAU - Gómez-Viquez, Norma Leticia Gomez Viquez
AU  - Gómez-Viquez NLGV
AD  - Pharmacobiology Department, Cinvestav-IPN Sede Sur, Mexico City, Mexico.
FAU - Velázquez-Espejel, Rodrigo
AU  - Velázquez-Espejel R
AD  - Phatology Department, National Cardiology Institute "Ignacio Chávez", Mexico 
      City, Mexico.
FAU - Del Carmen Susunaga-Notario, Ana
AU  - Del Carmen Susunaga-Notario A
AD  - Conacyt-ICAT Institute of Applied Sciences and Technology, UNAM, Mexico City, 
      Mexico.
FAU - Arias-Chávez, David Julian
AU  - Arias-Chávez DJ
AD  - Pharmacobiology Department, Cinvestav-IPN Sede Sur, Mexico City, Mexico.
FAU - Bravo, Guadalupe
AU  - Bravo G
AUID- ORCID: 0000-0002-2730-7761
AD  - Pharmacobiology Department, Cinvestav-IPN Sede Sur, Mexico City, Mexico.
LA  - eng
GR  - CONACYT/
PT  - Journal Article
DEP - 20200311
PL  - England
TA  - J Sci Food Agric
JT  - Journal of the science of food and agriculture
JID - 0376334
RN  - 0 (Estrogens)
RN  - S07O44R1ZM (Capsaicin)
SB  - IM
MH  - Animals
MH  - Blood Pressure/drug effects
MH  - Capsaicin/*administration & dosage
MH  - Combined Modality Therapy
MH  - Dyslipidemias/*prevention & control
MH  - Estrogens/*blood
MH  - *Exercise Therapy
MH  - Fatty Liver/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Obesity/blood/*complications/drug therapy/*therapy
MH  - Rats
MH  - Rats, Wistar
MH  - Skin Cream/administration & dosage
OTO - NOTNLM
OT  - capsaicin
OT  - dyslipidemia
OT  - exercise
OT  - hepatic steatosis
OT  - hypoestrogenism
OT  - obesity
EDAT- 2020/02/28 06:00
MHDA- 2020/12/23 06:00
CRDT- 2020/02/28 06:00
PHST- 2019/03/01 00:00 [received]
PHST- 2020/01/17 00:00 [revised]
PHST- 2020/02/27 00:00 [accepted]
PHST- 2020/02/28 06:00 [pubmed]
PHST- 2020/12/23 06:00 [medline]
PHST- 2020/02/28 06:00 [entrez]
AID - 10.1002/jsfa.10357 [doi]
PST - ppublish
SO  - J Sci Food Agric. 2020 May;100(7):3212-3219. doi: 10.1002/jsfa.10357. Epub 2020 
      Mar 11.

PMID- 27713913
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2331-4737 (Print)
IS  - 2331-4737 (Electronic)
IS  - 2331-4737 (Linking)
VI  - 3
IP  - 7-8
DP  - 2016
TI  - The metastasis inducer CCN1 (CYR61) activates the fatty acid synthase 
      (FASN)-driven lipogenic phenotype in breast cancer cells.
PG  - 242-257
AB  - The angiogenic inducer CCN1 (Cysteine-rich 61, CYR61) is differentially activated 
      in metastatic breast carcinomas. However, little is known about the precise 
      mechanisms that underlie the pro-metastatic actions of CCN1. Here, we 
      investigated the impact of CCN1 expression on fatty acid synthase (FASN), a 
      metabolic oncogene thought to provide cancer cells with proliferative and 
      survival advantages. Forced expression of CCN1 in MCF-7 cells robustly 
      up-regulated FASN protein expression and also significantly increased FASN gene 
      promoter activity 2- to 3-fold, whereas deletion of the sterol response 
      element-binding protein (SREBP) binding site in the FASN promoter completely 
      abrogated CCN1-driven transcriptional activation. Pharmacological blockade of 
      MAPK or PI-3'K activation similarly prevented the ability of CCN1 to induce FASN 
      gene activation. Pharmacological inhibition of FASN activity with the mycotoxin 
      cerulenin or the small compound C75 reversed CCN1-induced acquisition of estrogen 
      independence and resistance to hormone therapies such as tamoxifen and 
      fulvestrant in anchorage-independent growth assays. This study uncovers 
      FASNdependent endogenous lipogenesis as a new mechanism controlling the 
      metastatic phenotype promoted by CCN1. Because estrogen independence and 
      progression to a metastatic phenotype are hallmarks of therapeutic resistance and 
      mortality in breast cancer, this previously unrecognized CCN1-driven lipogenic 
      phenotype represents a novel metabolic target to clinically manage metastatic 
      disease progression.
FAU - Menendez, Javier A
AU  - Menendez JA
AD  - ProCURE (Program Against Cancer Therapeutic Resistance), Metabolism and Cancer 
      Group, Catalan Institute of Oncology, Girona, Catalonia, Spain; Girona Biomedical 
      Research Institute (IDIBGI), Girona, Spain.
FAU - Vellon, Luciano
AU  - Vellon L
AD  - IBYME, CONICET-Laboratorio de Immunohematología, Buenos Aires, Argentina.
FAU - Espinoza, Ingrid
AU  - Espinoza I
AD  - Cancer Institute, University of Mississippi, Jackson, MS, USA; Department of 
      Preventive Medicine, University of Mississippi, Jackson, MS, USA.
FAU - Lupu, Ruth
AU  - Lupu R
AD  - Mayo Clinic, Department of Laboratory Medicine and Pathology, Division of 
      Experimental Pathology, Rochester, MN, USA; Mayo Clinic Cancer Center, Rochester, 
      MN, USA.
LA  - eng
GR  - R01 CA118975/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20160722
PL  - United States
TA  - Oncoscience
JT  - Oncoscience
JID - 101636666
PMC - PMC5043073
OTO - NOTNLM
OT  - CCN1
OT  - CYR61
OT  - breast cancer
OT  - fatty acid synthase
OT  - metastasis
COIS- The authors declare no conflicts of interest.
EDAT- 2016/10/08 06:00
MHDA- 2016/10/08 06:01
PMCR- 2016/07/22
CRDT- 2016/10/08 06:00
PHST- 2016/04/05 00:00 [received]
PHST- 2016/07/08 00:00 [accepted]
PHST- 2016/10/08 06:00 [entrez]
PHST- 2016/10/08 06:00 [pubmed]
PHST- 2016/10/08 06:01 [medline]
PHST- 2016/07/22 00:00 [pmc-release]
AID - 314 [pii]
AID - 10.18632/oncoscience.314 [doi]
PST - epublish
SO  - Oncoscience. 2016 Jul 22;3(7-8):242-257. doi: 10.18632/oncoscience.314. 
      eCollection 2016.

PMID- 30842127
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20200716
IS  - 1538-7755 (Electronic)
IS  - 1055-9965 (Linking)
VI  - 28
IP  - 5
DP  - 2019 May
TI  - Circulating 25-Hydroxyvitamin D Concentration and Risk of Breast, Prostate, and 
      Colorectal Cancers: The Melbourne Collaborative Cohort Study.
PG  - 900-908
LID - 10.1158/1055-9965.EPI-18-1155 [doi]
AB  - BACKGROUND: The role of vitamin D in cancer risk remains controversial, and 
      limited data exist on associations between vitamin D and subtypes of specific 
      cancers. We investigated associations between circulating 25-hydroxyvitamin D 
      (25(OH)D) and risk of colorectal, breast, and prostate cancers, including 
      subtypes. METHODS: A case-cohort study within the Melbourne Collaborative Cohort 
      Study included 547 colorectal, 634 breast, and 824 prostate cancers, and a 
      sex-stratified random sample of participants (n = 2,996). Concentration of 
      25(OH)D in baseline-dried blood spots was measured using LC-MS/MS. Cox regression 
      yielded adjusted HRs and 95% confidence intervals (CI) for each cancer in 
      relation to plasma-equivalent 25(OH)D concentration. Associations by stage and 
      BRAF/KRAS status for colorectal cancer, estrogen receptor status for breast 
      cancer, and aggressiveness for prostate cancer were examined in competing risks 
      models. RESULTS: 25(OH)D concentrations were inversely associated with risk of 
      colorectal cancer [highest vs. lowest 25(OH)D quintile: HR, 0.71; 95% confidence 
      interval (CI), 0.51-0.98], which was limited to women (HR, 0.52; 95% CI, 
      0.33-0.82). Circulating 25(OH)D was also inversely associated with BRAF 
      V600E-positive colorectal cancer (per 25 nmol/L increment: HR, 0.71; 95% CI, 
      0.50-1.01). There were no inverse associations with breast cancer (HR, 0.98; 95% 
      CI, 0.70-1.36) or prostate cancer (HR, 1.11; 95% CI, 0.82-1.48). CONCLUSIONS: 
      Circulating 25(OH)D concentration was inversely associated with colorectal cancer 
      risk for women, but not with risk of breast cancer or prostate cancer. IMPACT: 
      Vitamin D might play a role in preventing colorectal cancer. Further studies are 
      required to confirm whether vitamin D is associated with specific tumor subtypes.
CI  - ©2019 American Association for Cancer Research.
FAU - Heath, Alicia K
AU  - Heath AK
AUID- ORCID: 0000-0001-6517-1300
AD  - Centre for Epidemiology and Biostatistics, Melbourne School of Population and 
      Global Health, University of Melbourne, Melbourne, Victoria, Australia.
AD  - Cancer Epidemiology and Intelligence Division, Cancer Council Victoria, 
      Melbourne, Victoria, Australia.
AD  - School of Public Health, Imperial College London, London, United Kingdom.
FAU - Hodge, Allison M
AU  - Hodge AM
AUID- ORCID: 0000-0001-5464-2197
AD  - Centre for Epidemiology and Biostatistics, Melbourne School of Population and 
      Global Health, University of Melbourne, Melbourne, Victoria, Australia.
AD  - Cancer Epidemiology and Intelligence Division, Cancer Council Victoria, 
      Melbourne, Victoria, Australia.
FAU - Ebeling, Peter R
AU  - Ebeling PR
AD  - Department of Medicine, School of Clinical Sciences at Monash Health, Monash 
      University, Clayton, Victoria, Australia.
FAU - Eyles, Darryl W
AU  - Eyles DW
AD  - Queensland Brain Institute, University of Queensland, St Lucia, Queensland, 
      Australia.
AD  - Queensland Centre for Mental Health Research, The Park Centre for Mental Health, 
      Wacol, Queensland, Australia.
FAU - Kvaskoff, David
AU  - Kvaskoff D
AD  - Queensland Brain Institute, University of Queensland, St Lucia, Queensland, 
      Australia.
FAU - Buchanan, Daniel D
AU  - Buchanan DD
AUID- ORCID: 0000-0003-2225-6675
AD  - Colorectal Oncogenomics Group, Department of Clinical Pathology, University of 
      Melbourne, Victorian Comprehensive Cancer Centre, Melbourne, Victoria, Australia.
AD  - University of Melbourne Centre for Cancer Research, Victorian Comprehensive 
      Cancer Centre, Melbourne, Victoria, Australia.
AD  - Genomic Medicine and Family Cancer Clinic, Royal Melbourne Hospital, Melbourne, 
      Victoria, Australia.
FAU - Giles, Graham G
AU  - Giles GG
AUID- ORCID: 0000-0003-4946-9099
AD  - Centre for Epidemiology and Biostatistics, Melbourne School of Population and 
      Global Health, University of Melbourne, Melbourne, Victoria, Australia.
AD  - Cancer Epidemiology and Intelligence Division, Cancer Council Victoria, 
      Melbourne, Victoria, Australia.
FAU - Williamson, Elizabeth J
AU  - Williamson EJ
AUID- ORCID: 0000-0001-6905-876X
AD  - Centre for Epidemiology and Biostatistics, Melbourne School of Population and 
      Global Health, University of Melbourne, Melbourne, Victoria, Australia.
AD  - Cancer Epidemiology and Intelligence Division, Cancer Council Victoria, 
      Melbourne, Victoria, Australia.
AD  - Farr Institute of Health Informatics Research, London, United Kingdom.
AD  - Department of Medical Statistics, London School of Hygiene and Tropical Medicine, 
      London, United Kingdom.
FAU - English, Dallas R
AU  - English DR
AD  - Centre for Epidemiology and Biostatistics, Melbourne School of Population and 
      Global Health, University of Melbourne, Melbourne, Victoria, Australia. 
      d.english@unimelb.edu.au.
AD  - Cancer Epidemiology and Intelligence Division, Cancer Council Victoria, 
      Melbourne, Victoria, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190306
PL  - United States
TA  - Cancer Epidemiol Biomarkers Prev
JT  - Cancer epidemiology, biomarkers & prevention : a publication of the American 
      Association for Cancer Research, cosponsored by the American Society of 
      Preventive Oncology
JID - 9200608
RN  - 0 (Biomarkers, Tumor)
RN  - 1406-16-2 (Vitamin D)
RN  - A288AR3C9H (25-hydroxyvitamin D)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Australia/epidemiology
MH  - Biomarkers, Tumor/*blood
MH  - Breast Neoplasms/*blood/epidemiology/etiology
MH  - Case-Control Studies
MH  - Colorectal Neoplasms/*blood/epidemiology/etiology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Prospective Studies
MH  - Prostatic Neoplasms/*blood/epidemiology/etiology
MH  - Risk Factors
MH  - Vitamin D/*analogs & derivatives/blood
EDAT- 2019/03/08 06:00
MHDA- 2020/07/17 06:00
CRDT- 2019/03/08 06:00
PHST- 2018/10/26 00:00 [received]
PHST- 2018/12/19 00:00 [revised]
PHST- 2019/02/26 00:00 [accepted]
PHST- 2019/03/08 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
PHST- 2019/03/08 06:00 [entrez]
AID - 1055-9965.EPI-18-1155 [pii]
AID - 10.1158/1055-9965.EPI-18-1155 [doi]
PST - ppublish
SO  - Cancer Epidemiol Biomarkers Prev. 2019 May;28(5):900-908. doi: 
      10.1158/1055-9965.EPI-18-1155. Epub 2019 Mar 6.

PMID- 27796716
OWN - NLM
STAT- MEDLINE
DCOM- 20171207
LR  - 20240210
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Print)
IS  - 0167-6806 (Linking)
VI  - 161
IP  - 1
DP  - 2017 Jan
TI  - Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with 
      genetic variants showing differential allelic expression: identification of a 
      modifier of breast cancer risk at locus 11q22.3.
PG  - 117-134
LID - 10.1007/s10549-016-4018-2 [doi]
AB  - PURPOSE: Cis-acting regulatory SNPs resulting in differential allelic expression 
      (DAE) may, in part, explain the underlying phenotypic variation associated with 
      many complex diseases. To investigate whether common variants associated with DAE 
      were involved in breast cancer susceptibility among BRCA1 and BRCA2 mutation 
      carriers, a list of 175 genes was developed based of their involvement in 
      cancer-related pathways. METHODS: Using data from a genome-wide map of SNPs 
      associated with allelic expression, we assessed the association of ~320 SNPs 
      located in the vicinity of these genes with breast and ovarian cancer risks in 
      15,252 BRCA1 and 8211 BRCA2 mutation carriers ascertained from 54 studies 
      participating in the Consortium of Investigators of Modifiers of BRCA1/2. 
      RESULTS: We identified a region on 11q22.3 that is significantly associated with 
      breast cancer risk in BRCA1 mutation carriers (most significant SNP rs228595 
      p = 7 × 10(-6)). This association was absent in BRCA2 carriers (p = 0.57). The 
      11q22.3 region notably encompasses genes such as ACAT1, NPAT, and ATM. Expression 
      quantitative trait loci associations were observed in both normal breast and 
      tumors across this region, namely for ACAT1, ATM, and other genes. In silico 
      analysis revealed some overlap between top risk-associated SNPs and relevant 
      biological features in mammary cell data, which suggests potential functional 
      significance. CONCLUSION: We identified 11q22.3 as a new modifier locus in BRCA1 
      carriers. Replication in larger studies using estrogen receptor (ER)-negative or 
      triple-negative (i.e., ER-, progesterone receptor-, and HER2-negative) cases 
      could therefore be helpful to confirm the association of this locus with breast 
      cancer risk.
FAU - Hamdi, Yosr
AU  - Hamdi Y
AD  - Genomics Center, Centre Hospitalier Universitaire de Québec Research Center and 
      Laval University, 2705 Laurier Boulevard, Quebec, QC, G1V 4G2, Canada.
FAU - Soucy, Penny
AU  - Soucy P
AD  - Genomics Center, Centre Hospitalier Universitaire de Québec Research Center and 
      Laval University, 2705 Laurier Boulevard, Quebec, QC, G1V 4G2, Canada.
FAU - Kuchenbaeker, Karoline B
AU  - Kuchenbaeker KB
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, 
      Cambridge, UK.
AD  - The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus Hinxton, 
      Cambridge, CB10 1HH, UK.
FAU - Pastinen, Tomi
AU  - Pastinen T
AD  - Department of Human Genetics, McGill University, Montreal, QC, H3A 1B1, Canada.
AD  - McGill University and Genome Quebec Innovation Centre, Montreal, QC, H3A 0G1, 
      Canada.
FAU - Droit, Arnaud
AU  - Droit A
AD  - Genomics Center, Centre Hospitalier Universitaire de Québec Research Center and 
      Laval University, 2705 Laurier Boulevard, Quebec, QC, G1V 4G2, Canada.
FAU - Lemaçon, Audrey
AU  - Lemaçon A
AD  - Genomics Center, Centre Hospitalier Universitaire de Québec Research Center and 
      Laval University, 2705 Laurier Boulevard, Quebec, QC, G1V 4G2, Canada.
FAU - Adlard, Julian
AU  - Adlard J
AD  - Yorkshire Regional Genetics Service, Chapel Allerton Hospital, Leeds, LS7 4SA, 
      UK.
FAU - Aittomäki, Kristiina
AU  - Aittomäki K
AD  - Department of Clinical Genetics, Helsinki University Hospital, HUS, Meilahdentie 
      2, P.O. BOX 160, 00029, Helsinki, Finland.
FAU - Andrulis, Irene L
AU  - Andrulis IL
AD  - Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, M5G 
      1X5, Canada.
AD  - Departments of Molecular Genetics and Laboratory Medicine and Pathobiology, 
      University of Toronto, Toronto, ON, Canada.
FAU - Arason, Adalgeir
AU  - Arason A
AD  - Department of Pathology hus 9, Landspitali-LSH v/Hringbraut, 101, Reykjavík, 
      Iceland.
AD  - BMC (Biomedical Centre), Faculty of Medicine, University of Iceland, 
      Vatnsmyrarvegi 16, 101, Reykjavík, Iceland.
FAU - Arnold, Norbert
AU  - Arnold N
AD  - Department of Gynaecology and Obstetrics, University Hospital of 
      Schleswig-Holstein, Christian-Albrechts University Kiel, Campus Kiel, 24105, 
      Kiel, Germany.
FAU - Arun, Banu K
AU  - Arun BK
AD  - Department of Breast Medical Oncology and Clinical Cancer Genetics Program, 
      University of Texas MD Anderson Cancer Center, 1515 Pressler Street CBP 5, 
      Houston, TX, 77030, USA.
FAU - Azzollini, Jacopo
AU  - Azzollini J
AD  - Unit of Medical Genetics, Department of Preventive and Predictive Medicine, 
      Fondazione IRCCS (Istituto Di Ricovero e Cura a Carattere Scientifico) Istituto 
      Nazionale Tumori (INT), Via Giacomo Venezian 1, 20133, Milan, Italy.
FAU - Bane, Anita
AU  - Bane A
AD  - Department of Pathology & Molecular Medicine, Juravinski Hospital and Cancer 
      Centre, McMaster University, 711 Concession Street, Hamilton, ON, L8V 1C3, 
      Canada.
FAU - Barjhoux, Laure
AU  - Barjhoux L
AD  - Bâtiment Cheney D, Centre Léon Bérard, 28 rue Laënnec, 69373, Lyon, France.
FAU - Barrowdale, Daniel
AU  - Barrowdale D
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, 
      Cambridge, UK.
FAU - Benitez, Javier
AU  - Benitez J
AD  - Human Genetics Group, Spanish National Cancer Centre (CNIO), Madrid, Spain.
AD  - Biomedical Network on Rare Diseases (CIBERER), 28029, Madrid, Spain.
AD  - Human Genotyping (CEGEN) Unit, Human Cancer Genetics Program, Spanish National 
      Cancer Research Centre (CNIO), Madrid, Spain.
FAU - Berthet, Pascaline
AU  - Berthet P
AD  - Centre François Baclesse, 3 avenue Général Harris, 14076, Caen, France.
FAU - Blok, Marinus J
AU  - Blok MJ
AD  - Department of Clinical Genetics, Maastricht University Medical Center, P.O. Box 
      5800, 6202 AZ, Maastricht, The Netherlands.
FAU - Bobolis, Kristie
AU  - Bobolis K
AD  - City of Hope Clinical Cancer Genomics Community Research Network, 1500 East 
      Duarte Road, Duarte, CA, 91010, USA.
FAU - Bonadona, Valérie
AU  - Bonadona V
AD  - Unité de Prévention et d'Epidémiologie Génétique, Centre Léon Bérard, 28 rue 
      Laënnec, 69373, Lyon, France.
FAU - Bonanni, Bernardo
AU  - Bonanni B
AD  - Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia (IEO), 
      Via Ripamonti 435, 20141, Milan, Italy.
FAU - Bradbury, Angela R
AU  - Bradbury AR
AD  - Department of Medicine, Abramson Cancer Center, Perelman School of Medicine at 
      the University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA, 
      19104, USA.
FAU - Brewer, Carole
AU  - Brewer C
AD  - Department of Clinical Genetics, Royal Devon & Exeter Hospital, Exeter, EX1 2ED, 
      UK.
FAU - Buecher, Bruno
AU  - Buecher B
AD  - Service de Génétique Oncologique, Institut Curie, 26 rue d'Ulm, 75248, Paris 
      Cedex 05, France.
FAU - Buys, Saundra S
AU  - Buys SS
AD  - Department of Medicine, Huntsman Cancer Institute, 2000 Circle of Hope, Salt Lake 
      City, UT, 84112, USA.
FAU - Caligo, Maria A
AU  - Caligo MA
AD  - Section of Genetic Oncology, Department of Laboratory Medicine, University and 
      University Hospital of Pisa, Pisa, Italy.
FAU - Chiquette, Jocelyne
AU  - Chiquette J
AD  - Unité de recherche en santé des populations, Centre des maladies du sein 
      Deschênes-Fabia, Hôpital du Saint-Sacrement, 1050 chemin Sainte-Foy, Quebec, QC, 
      G1S 4L8, Canada.
FAU - Chung, Wendy K
AU  - Chung WK
AD  - Departments of Pediatrics and Medicine, Columbia University, 1150 St. Nicholas 
      Avenue, New York, NY, 10032, USA.
FAU - Claes, Kathleen B M
AU  - Claes KB
AD  - Center for Medical Genetics, Ghent University, De Pintelaan 185, 9000, Ghent, 
      Belgium.
FAU - Daly, Mary B
AU  - Daly MB
AD  - Division of Population Science, Fox Chase Cancer Center, 333 Cottman Avenue, 
      Philadelphia, PA, 19111, USA.
FAU - Damiola, Francesca
AU  - Damiola F
AD  - Bâtiment Cheney D, Centre Léon Bérard, 28 rue Laënnec, 69373, Lyon, France.
FAU - Davidson, Rosemarie
AU  - Davidson R
AD  - Department of Clinical Genetics, South Glasgow University Hospitals, Glasgow, G51 
      4TF, UK.
FAU - De la Hoya, Miguel
AU  - De la Hoya M
AD  - Molecular Oncology Laboratory, Hospital Clinico San Carlos, IdISSC (El Instituto 
      de Investigación Sanitaria del Hospital Clínico San Carlos), Martin Lagos s/n, 
      Madrid, Spain.
FAU - De Leeneer, Kim
AU  - De Leeneer K
AD  - Center for Medical Genetics, Ghent University, De Pintelaan 185, 9000, Ghent, 
      Belgium.
FAU - Diez, Orland
AU  - Diez O
AD  - Oncogenetics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron 
      University Hospital, Clinical and Molecular Genetics Area, Passeig Vall d'Hebron 
      119-129, 08035, Barcelona, Spain.
FAU - Ding, Yuan Chun
AU  - Ding YC
AD  - Department of Population Sciences, Beckman Research Institute of City of Hope, 
      Duarte, CA, USA.
FAU - Dolcetti, Riccardo
AU  - Dolcetti R
AD  - Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di 
      Riferimento Oncologico, IRCCS (Istituto Di Ricovero e Cura a Carattere 
      Scientifico) National Cancer Institute, Via Franco Gallini 2, 33081, Aviano, PN, 
      Italy.
AD  - University of Queensland Diamantina Institute, Translational Research Institute, 
      Brisbane, QLD, Australia.
FAU - Domchek, Susan M
AU  - Domchek SM
AD  - Department of Medicine, Abramson Cancer Center, Perelman School of Medicine at 
      the University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA, 
      19104, USA.
FAU - Dorfling, Cecilia M
AU  - Dorfling CM
AD  - Cancer Genetics Laboratory, Department of Genetics, University of Pretoria, 
      Private Bag X323, Arcadia, 0007, South Africa.
FAU - Eccles, Diana
AU  - Eccles D
AD  - Faculty of Medicine, University of Southampton, Southampton University Hospitals 
      NHS Trust, Southampton, UK.
FAU - Eeles, Ros
AU  - Eeles R
AD  - Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS 
      Foundation Trust, Sutton, SM2 5NG, UK.
FAU - Einbeigi, Zakaria
AU  - Einbeigi Z
AD  - Department of Oncology, Sahlgrenska University Hospital, 41345, Göteborg, Sweden.
FAU - Ejlertsen, Bent
AU  - Ejlertsen B
AD  - Department of Oncology, Rigshospitalet, Copenhagen University Hospital, 
      Blegdamsvej 9, 2100, Copenhagen, Denmark.
CN  - EMBRACE
FAU - Engel, Christoph
AU  - Engel C
AD  - Institute for Medical Informatics, Statistics and Epidemiology, University of 
      Leipzig, 04107, Leipzig, Germany.
AD  - LIFE, Leipzig Research Centre for Civilization Diseases, University of Leipzig, 
      Leipzig, Germany.
FAU - Gareth Evans, D
AU  - Gareth Evans D
AD  - Genomic Medicine, Manchester Academic Health Sciences Centre, Institute of Human 
      Development, Manchester University, Central Manchester University Hospitals, NHS 
      Foundation Trust, Manchester, M13 9WL, UK.
FAU - Feliubadalo, Lidia
AU  - Feliubadalo L
AD  - Molecular Diagnostic Unit, Hereditary Cancer Program, IDIBELL (Bellvitge 
      Biomedical Research Institute), Catalan Institute of Oncology, Gran Via de 
      l'Hospitalet, 199-203, L'Hospitalet, 08908, Barcelona, Spain.
FAU - Foretova, Lenka
AU  - Foretova L
AD  - Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer 
      Institute, Zluty kopec 7, 65653, Brno, Czech Republic.
FAU - Fostira, Florentia
AU  - Fostira F
AD  - Molecular Diagnostics Laboratory, (INRASTES) Institute of Nuclear and 
      Radiological Sciences and Technology, National Centre for Scientific Research 
      "Demokritos", Patriarchou Gregoriou & Neapoleos str., Aghia Paraskevi Attikis, 
      Athens, Greece.
FAU - Foulkes, William D
AU  - Foulkes WD
AD  - Program in Cancer Genetics, Departments of Human Genetics and Oncology, McGill 
      University, Montreal, QC, Canada.
FAU - Fountzilas, George
AU  - Fountzilas G
AD  - Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of 
      Thessaloniki School of Medicine, Thessaloníki, Greece.
FAU - Friedman, Eitan
AU  - Friedman E
AD  - The Susanne Levy Gertner Oncogenetics Unit, Institute of Human Genetics, Chaim 
      Sheba Medical Center, 52621, Ramat Gan, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, 69978, Ramat Aviv, Israel.
FAU - Frost, Debra
AU  - Frost D
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, 
      Cambridge, UK.
FAU - Ganschow, Pamela
AU  - Ganschow P
AD  - Clinical Cancer Genetics, City of Hope, 1500 East Duarte Road, Duarte, CA, 91010, 
      USA.
FAU - Ganz, Patricia A
AU  - Ganz PA
AD  - UCLA Schools of Medicine and Public Health, Division of Cancer Prevention & 
      Control Research, Jonsson Comprehensive Cancer Center, 650 Charles Young Drive 
      South, Room A2-125 HS, Los Angeles, CA, 90095-6900, USA.
FAU - Garber, Judy
AU  - Garber J
AD  - Cancer Risk and Prevention Clinic, Dana-Farber Cancer Institute, 450 Brookline 
      Avenue, Boston, MA, USA.
FAU - Gayther, Simon A
AU  - Gayther SA
AD  - Department of Preventive Medicine, Keck School of Medicine, University of 
      Southern California, Los Angeles, CA, 90033, USA.
CN  - GEMO Study Collaborators
FAU - Gerdes, Anne-Marie
AU  - Gerdes AM
AD  - Department of Clincial Genetics, Rigshospitalet, Blegdamsvej 9, 4062, Copenhagen, 
      Denmark.
FAU - Glendon, Gord
AU  - Glendon G
AD  - Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, M5G 
      1X5, Canada.
FAU - Godwin, Andrew K
AU  - Godwin AK
AD  - Department of Pathology and Laboratory Medicine, University of Kansas Medical 
      Center, 3901 Rainbow Boulevard, 4019 Wahl Hall East, MS 3040, Kansas City, 
      Kansas, USA.
FAU - Goldgar, David E
AU  - Goldgar DE
AD  - Department of Dermatology, University of Utah School of Medicine, 30 North 1900 
      East, SOM 4B454, Salt Lake City, UT, 84132, USA.
FAU - Greene, Mark H
AU  - Greene MH
AD  - Clinical Genetics Branch, DCEG, NCI NIH, 9609 Medical Center Drive, Room 6E-454, 
      Bethesda, MD, USA.
FAU - Gronwald, Jacek
AU  - Gronwald J
AD  - Department of Genetics and Pathology, Pomeranian Medical University, Polabska 4, 
      70-115, Szczecin, Poland.
FAU - Hahnen, Eric
AU  - Hahnen E
AD  - Centre of Familial Breast and Ovarian Cancer, Department of Gynaecology and 
      Obstetrics and Centre for Integrated Oncology (CIO), Center for Molecular 
      Medicine Cologne (CMMC), University Hospital of Cologne, 50931, Cologne, Germany.
FAU - Hamann, Ute
AU  - Hamann U
AD  - Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Im 
      Neuenheimer Feld 580, 69120, Heidelberg, Germany.
FAU - Hansen, Thomas V O
AU  - Hansen TV
AD  - Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, 
      Blegdamsvej 9, 2100, Copenhagen, Denmark.
FAU - Hart, Steven
AU  - Hart S
AD  - Department of Health Sciences Research, Mayo Clinic, 200 First Street SW, 
      Rochester, MN, 55905, USA.
FAU - Hays, John L
AU  - Hays JL
AD  - Division of Medical Oncology, Department of Internal Medicine, The Ohio State 
      University, Columbus, OH, 43210, USA.
AD  - Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The 
      Ohio State University, Columbus, OH, 43210, USA.
AD  - Comprehensive Cancer Center Arthur C. James Cancer Hospital and Richard J. Solove 
      Research Institute Biomedical Research Tower, Room 588, 460 West 12th Avenue, 
      Columbus, OH, 43210, USA.
CN  - HEBON
FAU - Hogervorst, Frans B L
AU  - Hogervorst FB
AD  - Family Cancer Clinic, Netherlands Cancer Institute, P.O. Box 90203, 1006 BE, 
      Amsterdam, The Netherlands.
FAU - Hulick, Peter J
AU  - Hulick PJ
AD  - Center for Medical Genetics, NorthShore University HealthSystem, University of 
      Chicago Pritzker School of Medicine, 1000 Central Street, Suite 620, Evanston, 
      IL, 60201, USA.
FAU - Imyanitov, Evgeny N
AU  - Imyanitov EN
AD  - N.N. Petrov Institute of Oncology, St. Petersburg, Russia, 197758.
FAU - Isaacs, Claudine
AU  - Isaacs C
AD  - Lombardi Comprehensive Cancer Center, Georgetown University, 3800 Reservoir Road 
      NW, Washington, DC, 20007, USA.
FAU - Izatt, Louise
AU  - Izatt L
AD  - Clinical Genetics, Guy's and St. Thomas' NHS Foundation Trust, London, SE1 9RT, 
      UK.
FAU - Jakubowska, Anna
AU  - Jakubowska A
AD  - Department of Genetics and Pathology, Pomeranian Medical University, Polabska 4, 
      70-115, Szczecin, Poland.
FAU - James, Paul
AU  - James P
AD  - Familial Cancer Centre, Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, 
      Australia.
AD  - Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, 
      VIC, 3010, Australia.
FAU - Janavicius, Ramunas
AU  - Janavicius R
AD  - Hematology, Oncology and Transfusion Medicine Center, Department of Molecular and 
      Regenerative Medicine, Vilnius University Hospital Santariskiu Clinics, 
      Santariskiu st. 2, 08661, Vilnius, Lithuania.
AD  - State Research Institute Centre for Innovative Medicine, Zygymantu st. 9, 
      Vilnius, Lithuania.
FAU - Jensen, Uffe Birk
AU  - Jensen UB
AD  - Department of Clinical Genetics, Aarhus University Hospital, Brendstrupgaardsvej 
      21C, Århus N, Denmark.
FAU - John, Esther M
AU  - John EM
AD  - Department of Epidemiology, Cancer Prevention Institute of California, 2201 
      Walnut Avenue Suite 300, Fremont, CA, 94538, USA.
AD  - Department of Health Research and Policy (Epidemiology) and Stanford Cancer 
      Institute, Stanford University School of Medicine, Stanford, CA, USA.
FAU - Joseph, Vijai
AU  - Joseph V
AD  - Clinical Genetics Research Laboratory, Department of Medicine, Memorial 
      Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10044, USA.
FAU - Just, Walter
AU  - Just W
AD  - Institute of Human Genetics, University of Ulm, 89091, Ulm, Germany.
FAU - Kaczmarek, Katarzyna
AU  - Kaczmarek K
AD  - Department of Genetics and Pathology, Pomeranian Medical University, Polabska 4, 
      70-115, Szczecin, Poland.
FAU - Karlan, Beth Y
AU  - Karlan BY
AD  - Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, 
      Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Suite 290W, Los Angeles, CA, 
      90048, USA.
CN  - KConFab Investigators
FAU - Kets, Carolien M
AU  - Kets CM
AD  - Department of Human Genetics, Radboud University Medical Center, P.O. Box 9101, 
      6500 HB, Nijmegen, The Netherlands.
FAU - Kirk, Judy
AU  - Kirk J
AD  - Westmead Hospital, Familial Cancer Service, Hawkebury Road, P.O. Box 533, 
      Wentworthville, NSW, 2145, Australia.
FAU - Kriege, Mieke
AU  - Kriege M
AD  - Department of Medical Oncology, Family Cancer Clinic, Erasmus University Medical 
      Center, P.O. Box 5201, 3008 AE, Rotterdam, The Netherlands.
FAU - Laitman, Yael
AU  - Laitman Y
AD  - The Susanne Levy Gertner Oncogenetics Unit, Institute of Human Genetics, Chaim 
      Sheba Medical Center, 52621, Ramat Gan, Israel.
FAU - Laurent, Maïté
AU  - Laurent M
AD  - Service de Génétique Oncologique, Institut Curie, 26 rue d'Ulm, 75248, Paris 
      Cedex 05, France.
FAU - Lazaro, Conxi
AU  - Lazaro C
AD  - Molecular Diagnostic Unit, Hereditary Cancer Program, IDIBELL (Bellvitge 
      Biomedical Research Institute), Catalan Institute of Oncology, Gran Via de 
      l'Hospitalet, 199-203, L'Hospitalet, 08908, Barcelona, Spain.
FAU - Leslie, Goska
AU  - Leslie G
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, 
      Cambridge, UK.
FAU - Lester, Jenny
AU  - Lester J
AD  - Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, 
      Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Suite 290W, Los Angeles, CA, 
      90048, USA.
FAU - Lesueur, Fabienne
AU  - Lesueur F
AD  - Genetic Epidemiology of Cancer Team, INSERM U900, Institut Curie Mines ParisTech, 
      PSL University, 26 rue d'Ulm, 75248, Paris Cedex 05, France.
FAU - Liljegren, Annelie
AU  - Liljegren A
AD  - Department of Oncology, Karolinska University Hospital, 17176, Stockholm, Sweden.
FAU - Loman, Niklas
AU  - Loman N
AD  - Department of Oncology, Lund University Hospital, 22185, Lund, Sweden.
FAU - Loud, Jennifer T
AU  - Loud JT
AD  - Clinical Genetics Branch, DCEG, NCI NIH, 9609 Medical Center Drive, Room 6E-454, 
      Bethesda, MD, USA.
FAU - Manoukian, Siranoush
AU  - Manoukian S
AD  - Unit of Medical Genetics, Department of Preventive and Predictive Medicine, 
      Fondazione IRCCS (Istituto Di Ricovero e Cura a Carattere Scientifico) Istituto 
      Nazionale Tumori (INT), Via Giacomo Venezian 1, 20133, Milan, Italy.
FAU - Mariani, Milena
AU  - Mariani M
AD  - Unit of Medical Genetics, Department of Preventive and Predictive Medicine, 
      Fondazione IRCCS (Istituto Di Ricovero e Cura a Carattere Scientifico) Istituto 
      Nazionale Tumori (INT), Via Giacomo Venezian 1, 20133, Milan, Italy.
FAU - Mazoyer, Sylvie
AU  - Mazoyer S
AD  - Lyon Neuroscience Research Center-CRNL, INSERM U1028, CNRS UMR5292, University of 
      Lyon, Lyon, France.
FAU - McGuffog, Lesley
AU  - McGuffog L
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, 
      Cambridge, UK.
FAU - Meijers-Heijboer, Hanne E J
AU  - Meijers-Heijboer HE
AD  - Department of Clinical Genetics, VU University Medical Center, P.O. Box 7057, 
      1007 MB, Amsterdam, The Netherlands.
FAU - Meindl, Alfons
AU  - Meindl A
AD  - Department of Gynaecology and Obstetrics, University Hospital of 
      Schleswig-Holstein, Christian-Albrechts University Kiel, Campus Kiel, 24105, 
      Kiel, Germany.
FAU - Miller, Austin
AU  - Miller A
AD  - NRG Oncology Statistics and Data Management Center, Roswell Park Cancer 
      Institute, Elm St & Carlton St, Buffalo, NY, 14263, USA.
FAU - Montagna, Marco
AU  - Montagna M
AD  - Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, 
      Via Gattamelata 64, 35128, Padua, Italy.
FAU - Mulligan, Anna Marie
AU  - Mulligan AM
AD  - Departments of Molecular Genetics and Laboratory Medicine and Pathobiology, 
      University of Toronto, Toronto, ON, Canada.
AD  - Department of Laboratory Medicine and the Keenan Research Centre of the Li Ka 
      Shing Knowledge Institute, St Michael's Hospital, Toronto, ON, Canada.
FAU - Nathanson, Katherine L
AU  - Nathanson KL
AD  - Department of Medicine, Abramson Cancer Center, Perelman School of Medicine at 
      the University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA, 
      19104, USA.
FAU - Neuhausen, Susan L
AU  - Neuhausen SL
AD  - Department of Population Sciences, Beckman Research Institute of City of Hope, 
      Duarte, CA, USA.
FAU - Nevanlinna, Heli
AU  - Nevanlinna H
AD  - Department of Obstetrics and Gynecology, University of Helsinki and Helsinki 
      University Hospital, Biomedicum Helsinki, Haartmaninkatu 8, HUS, P.O. BOX 700, 
      00029, Helsinki, Finland.
FAU - Nussbaum, Robert L
AU  - Nussbaum RL
AD  - Department of Medicine and Genetics, University of California, 513 Parnassus 
      Ave., HSE 901E, San Francisco, CA, 94143-0794, USA.
FAU - Olah, Edith
AU  - Olah E
AD  - Department of Molecular Genetics, National Institute of Oncology, Budapest, 
      Hungary.
FAU - Olopade, Olufunmilayo I
AU  - Olopade OI
AD  - Department of Medicine, University of Chicago, 5841 South Maryland Avenue, MC 
      2115, Chicago, IL, USA.
FAU - Ong, Kai-Ren
AU  - Ong KR
AD  - West Midlands Regional Genetics Service, Birmingham Women's Hospital Healthcare 
      NHS Trust, Edgbaston, Birmingham, UK.
FAU - Oosterwijk, Jan C
AU  - Oosterwijk JC
AD  - Department of Genetics, University Medical Center Groningen, University of 
      Groningen, 9700 RB, Groningen, The Netherlands.
FAU - Osorio, Ana
AU  - Osorio A
AD  - Human Genetics Group, Spanish National Cancer Centre (CNIO), Madrid, Spain.
AD  - Biomedical Network on Rare Diseases (CIBERER), 28029, Madrid, Spain.
FAU - Papi, Laura
AU  - Papi L
AD  - Unit of Medical Genetics, Department of Biomedical Experimental and Clinical 
      Sciences, University of Florence, Viale Morgagni 50, 50134, Florence, Italy.
FAU - Park, Sue Kyung
AU  - Park SK
AD  - Department of Preventive Medicine, Seoul National University College of Medicine, 
      103 Daehak-ro, Jongno-gu, Seoul, 110-799, Korea.
FAU - Pedersen, Inge Sokilde
AU  - Pedersen IS
AD  - Section of Molecular Diagnostics, Department of Biochemistry, Aalborg University 
      Hospital, Reberbansgade 15, Ålborg, Denmark.
FAU - Peissel, Bernard
AU  - Peissel B
AD  - Unit of Medical Genetics, Department of Preventive and Predictive Medicine, 
      Fondazione IRCCS (Istituto Di Ricovero e Cura a Carattere Scientifico) Istituto 
      Nazionale Tumori (INT), Via Giacomo Venezian 1, 20133, Milan, Italy.
FAU - Segura, Pedro Perez
AU  - Segura PP
AD  - Department of Oncology, Hospital Clinico San Carlos, IdISSC (El Instituto de 
      Investigación Sanitaria del Hospital Clínico San Carlos), Martin Lagos s/n, 
      Madrid, Spain.
FAU - Peterlongo, Paolo
AU  - Peterlongo P
AD  - IFOM, The FIRC (Italian Foundation for Cancer Research) Institute of Molecular 
      Oncology, c/o IFOM-IEO Campus, Via Adamello 16, 20139, Milan, Italy.
FAU - Phelan, Catherine M
AU  - Phelan CM
AD  - Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, 33612, USA.
FAU - Radice, Paolo
AU  - Radice P
AD  - Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of 
      Preventive and Predicted Medicine, Fondazione IRCCS (Istituto Di Ricovero e Cura 
      a Carattere Scientifico) Istituto Nazionale Tumori (INT), c/o Amaedeolab via GA 
      Amadeo 42, 20133, Milan, Italy.
FAU - Rantala, Johanna
AU  - Rantala J
AD  - Department of Clinical Genetics, Karolinska University Hospital, L5:03, 171 76, 
      Stockholm, Sweden.
FAU - Rappaport-Fuerhauser, Christine
AU  - Rappaport-Fuerhauser C
AD  - Department of OB/GYN, Medical University of Vienna, Waehringer Guertel 18-20, A, 
      1090, Vienna, Austria.
FAU - Rennert, Gad
AU  - Rennert G
AD  - Clalit National Israeli Cancer Control Center and Department of Community 
      Medicine and Epidemiology, Carmel Medical Center and B. Rappaport Faculty of 
      Medicine, 7 Michal St., 34362, Haifa, Israel.
FAU - Richardson, Andrea
AU  - Richardson A
AD  - Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, 
      MD, 21205, USA.
FAU - Robson, Mark
AU  - Robson M
AD  - Clinical Genetics, Services Department of Medicine, Memorial Sloan-Kettering 
      Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
FAU - Rodriguez, Gustavo C
AU  - Rodriguez GC
AD  - Division of Gynecologic Oncology, NorthShore University HealthSystem, University 
      of Chicago, 2650 Ridge Avenue, Suite 1507, Walgreens, Evanston, IL, 60201, USA.
FAU - Rookus, Matti A
AU  - Rookus MA
AD  - Department of Epidemiology, Netherlands Cancer Institute, P.O. Box 90203, 1006 
      BE, Amsterdam, The Netherlands.
FAU - Schmutzler, Rita Katharina
AU  - Schmutzler RK
AD  - Centre of Familial Breast and Ovarian Cancer, Department of Gynaecology and 
      Obstetrics and Centre for Integrated Oncology (CIO), Center for Molecular 
      Medicine Cologne (CMMC), University Hospital of Cologne, 50931, Cologne, Germany.
AD  - Center for Hereditary Breast and Ovarian Cancer, Medical Faculty, University 
      Hospital Cologne, 50931, Cologne, Germany.
AD  - Center for Integrated Oncology (CIO), Medical Faculty, University Hospital 
      Cologne, Cologne, Germany.
FAU - Sevenet, Nicolas
AU  - Sevenet N
AD  - Oncogénétique, Institut Bergonié, 229 cours de l'Argonne, 33076, Bordeaux, 
      France.
FAU - Shah, Payal D
AU  - Shah PD
AD  - Department of Medicine, Abramson Cancer Center, Perelman School of Medicine at 
      the University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA, 
      19104, USA.
FAU - Singer, Christian F
AU  - Singer CF
AD  - Department of OB/GYN, Medical University of Vienna, Waehringer Guertel 18-20, A, 
      1090, Vienna, Austria.
FAU - Slavin, Thomas P
AU  - Slavin TP
AD  - Clinical Cancer Genetics, City of Hope, 1500 East Duarte Road, Duarte, CA, 91010, 
      USA.
FAU - Snape, Katie
AU  - Snape K
AD  - Medical Genetics Unit, St George's, University of London, London, SW17 0RE, UK.
FAU - Sokolowska, Johanna
AU  - Sokolowska J
AD  - Laboratoire de génétique médicale Nancy Université, Centre Hospitalier Régional 
      et Universitaire, Rue du Morvan cedex 1, 54511, Vandoeuvre-les-Nancy, France.
FAU - Sønderstrup, Ida Marie Heeholm
AU  - Sønderstrup IM
AD  - Department of Pathology Region Zealand Section Slagelse, Slagelse Hospital, 
      Ingemannsvej 18 Slagelse, Cpoenhagen, Denmark.
FAU - Southey, Melissa
AU  - Southey M
AD  - Genetic Epidemiology Laboratory, Department of Pathology, University of 
      Melbourne, Parkville, VIC, 3010, Australia.
FAU - Spurdle, Amanda B
AU  - Spurdle AB
AD  - Genetics and Computational Biology Department, QIMR Berghofer Medical Research 
      Institute, Herston Road, Brisbane, QLD, 4006, Australia.
FAU - Stadler, Zsofia
AU  - Stadler Z
AD  - Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering 
      Cancer Center, 1275 York Avenue, New York, NY, USA.
FAU - Stoppa-Lyonnet, Dominique
AU  - Stoppa-Lyonnet D
AD  - Service de Génétique Oncologique, Institut Curie, 26 rue d'Ulm, 75248, Paris 
      Cedex 05, France.
FAU - Sukiennicki, Grzegorz
AU  - Sukiennicki G
AD  - Department of Genetics and Pathology, Pomeranian Medical University, Polabska 4, 
      70-115, Szczecin, Poland.
FAU - Sutter, Christian
AU  - Sutter C
AD  - Institute of Human Genetics, Department of Human Genetics, University Hospital 
      Heidelberg, Heidelberg, Germany.
FAU - Tan, Yen
AU  - Tan Y
AD  - Department of OB/GYN, Medical University of Vienna, Waehringer Guertel 18-20, A, 
      1090, Vienna, Austria.
FAU - Tea, Muy-Kheng
AU  - Tea MK
AD  - Department of OB/GYN, Medical University of Vienna, Waehringer Guertel 18-20, A, 
      1090, Vienna, Austria.
FAU - Teixeira, Manuel R
AU  - Teixeira MR
AD  - Department of Genetics, Portuguese Oncology Institute, Rua Dr. António Bernardino 
      de Almeida, 4200-072, Porto, Portugal.
AD  - Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal.
FAU - Teulé, Alex
AU  - Teulé A
AD  - Genetic Counseling Unit, Hereditary Cancer Program, IDIBELL (Bellvitge Biomedical 
      Research Institute), Catalan Institute of Oncology, Gran Via de l'Hospitalet, 
      199-203, L'Hospitalet, 08908, Barcelona, Spain.
FAU - Teo, Soo-Hwang
AU  - Teo SH
AD  - Cancer Research Initiatives Foundation, Sime Darby Medical Centre, 1 Jalan 
      SS12/1A, 47500, Subang Jaya, Malaysia.
AD  - University Malaya Cancer Research Institute, University Malaya, 1 Jalan SS12/1A, 
      50603, Kuala Lumpur, Malaysia.
FAU - Terry, Mary Beth
AU  - Terry MB
AD  - Department of Epidemiology, Columbia University, New York, NY, USA.
FAU - Thomassen, Mads
AU  - Thomassen M
AD  - Department of Clinical Genetics, Odense University Hospital, Sonder Boulevard 29, 
      Odense C, Denmark.
FAU - Tihomirova, Laima
AU  - Tihomirova L
AD  - Latvian Biomedical Research and Study Centre, Ratsupites str 1, Riga, Latvia.
FAU - Tischkowitz, Marc
AU  - Tischkowitz M
AD  - Program in Cancer Genetics, Departments of Human Genetics and Oncology, McGill 
      University, Montreal, QC, Canada.
AD  - Department of Medical Genetics Level 6 Addenbrooke's Treatment Centre, 
      Addenbrooke's Hospital, Hills Road, Box 134, Cambridge, CB2 0QQ, UK.
FAU - Tognazzo, Silvia
AU  - Tognazzo S
AD  - Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, 
      Via Gattamelata 64, 35128, Padua, Italy.
FAU - Toland, Amanda Ewart
AU  - Toland AE
AD  - Division of Human Genetics, Departments of Internal Medicine and Cancer Biology 
      and Genetics Comprehensive Cancer Center, The Ohio State University, 998 
      Biomedical Research Tower, Columbus, OH, 43210, USA.
FAU - Tung, Nadine
AU  - Tung N
AD  - Department of Medical Oncology, Beth Israel Deaconess Medical Center, 330 
      Brookline Avenue, Boston, MA, 02215, USA.
FAU - van den Ouweland, Ans M W
AU  - van den Ouweland AM
AD  - Department of Clinical Genetics, Family Cancer Clinic, Erasmus University Medical 
      Center, 330 Brookline Avenue, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands.
FAU - van der Luijt, Rob B
AU  - van der Luijt RB
AD  - Department of Medical Genetics, University Medical Center Utrecht, 3584 EA, 
      Utrecht, The Netherlands.
FAU - van Engelen, Klaartje
AU  - van Engelen K
AD  - Department of Clinical Genetics, Academic Medical Center, P.O. Box 22700, 1100 
      DE, Amsterdam, The Netherlands.
FAU - van Rensburg, Elizabeth J
AU  - van Rensburg EJ
AD  - Cancer Genetics Laboratory, Department of Genetics, University of Pretoria, 
      Private Bag X323, Arcadia, 0007, South Africa.
FAU - Varon-Mateeva, Raymonda
AU  - Varon-Mateeva R
AD  - Institute of Human Genetics, Charite Berlin, Campus Virchov Klinikum, 13353, 
      Berlin, Germany.
FAU - Wappenschmidt, Barbara
AU  - Wappenschmidt B
AD  - Centre of Familial Breast and Ovarian Cancer, Department of Gynaecology and 
      Obstetrics and Centre for Integrated Oncology (CIO), Center for Molecular 
      Medicine Cologne (CMMC), University Hospital of Cologne, 50931, Cologne, Germany.
FAU - Wijnen, Juul T
AU  - Wijnen JT
AD  - Department of Human Genetics & Department of Clinical Genetics, Leiden University 
      Medical Center, 2300 RC, Leiden, The Netherlands.
FAU - Rebbeck, Timothy
AU  - Rebbeck T
AD  - Department of Medicine, Abramson Cancer Center, Perelman School of Medicine at 
      the University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA, 
      19104, USA.
AD  - Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine 
      at the University of Pennsylvania, Philadelphia, PA, USA.
FAU - Chenevix-Trench, Georgia
AU  - Chenevix-Trench G
AD  - Genetics and Computational Biology Department, QIMR Berghofer Medical Research 
      Institute, Herston Road, Brisbane, QLD, 4006, Australia.
FAU - Offit, Kenneth
AU  - Offit K
AD  - Clinical Genetics Research Laboratory, Department of Medicine, Memorial 
      Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10044, USA.
FAU - Couch, Fergus J
AU  - Couch FJ
AD  - Department of Health Sciences Research, Mayo Clinic, 200 First Street SW, 
      Rochester, MN, 55905, USA.
AD  - Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street 
      SW, Rochester, MN, 55905, USA.
FAU - Nord, Silje
AU  - Nord S
AD  - Department of Cancer Genetics, Institute for Cancer Research, Oslo University 
      Hospital, Radiumhospitalet, 0372, Oslo, Norway.
FAU - Easton, Douglas F
AU  - Easton DF
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, 
      Cambridge, UK.
FAU - Antoniou, Antonis C
AU  - Antoniou AC
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
      Care, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, 
      Cambridge, UK.
FAU - Simard, Jacques
AU  - Simard J
AD  - Genomics Center, Centre Hospitalier Universitaire de Québec Research Center and 
      Laval University, 2705 Laurier Boulevard, Quebec, QC, G1V 4G2, Canada. 
      Jacques.Simard@crchudequebec.ulaval.ca.
LA  - eng
GR  - U10 CA180868/CA/NCI NIH HHS/United States
GR  - UG1 CA189867/CA/NCI NIH HHS/United States
GR  - R01 CA140323/CA/NCI NIH HHS/United States
GR  - R01 CA176785/CA/NCI NIH HHS/United States
GR  - 11174/CRUK_/Cancer Research UK/United Kingdom
GR  - C5047/A15007/CRUK_/Cancer Research UK/United Kingdom
GR  - N02CP65504/CP/NCI NIH HHS/United States
GR  - R01 CA102776/CA/NCI NIH HHS/United States
GR  - R01 CA149429/CA/NCI NIH HHS/United States
GR  - U19 CA148065/CA/NCI NIH HHS/United States
GR  - N02CP11019/CP/NCI NIH HHS/United States
GR  - RC4 CA153828/CA/NCI NIH HHS/United States
GR  - R01 CA142996/CA/NCI NIH HHS/United States
GR  - P50 CA125183/CA/NCI NIH HHS/United States
GR  - UM1 CA164920/CA/NCI NIH HHS/United States
GR  - P30 CA168524/CA/NCI NIH HHS/United States
GR  - U01 CA161032/CA/NCI NIH HHS/United States
GR  - C5047/A8385/CRUK_/Cancer Research UK/United Kingdom
GR  - C12292/A11174/CRUK_/Cancer Research UK/United Kingdom
GR  - U10 CA027469/CA/NCI NIH HHS/United States
GR  - C5047/A10692/CRUK_/Cancer Research UK/United Kingdom
GR  - 20861/CRUK_/Cancer Research UK/United Kingdom
GR  - UL1 TR000124/TR/NCATS NIH HHS/United States
GR  - 17528/CRUK_/Cancer Research UK/United Kingdom
GR  - U01 CA116167/CA/NCI NIH HHS/United States
GR  - C5047/A8384/CRUK_/Cancer Research UK/United Kingdom
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - R01 CA128978/CA/NCI NIH HHS/United States
GR  - C1287/A 10710/CRUK_/Cancer Research UK/United Kingdom
GR  - R01 CA083855/CA/NCI NIH HHS/United States
GR  - U19 CA148537/CA/NCI NIH HHS/United States
GR  - P30 CA051008/CA/NCI NIH HHS/United States
GR  - R01 CA116167/CA/NCI NIH HHS/United States
GR  - P50 CA116201/CA/NCI NIH HHS/United States
GR  - 16565/CRUK_/Cancer Research UK/United Kingdom
GR  - U01 CA113916/CA/NCI NIH HHS/United States
GR  - C12292/A20861/CRUK_/Cancer Research UK/United Kingdom
GR  - U10 CA037517/CA/NCI NIH HHS/United States
GR  - 10118/CRUK_/Cancer Research UK/United Kingdom
GR  - U19 CA148112/CA/NCI NIH HHS/United States
GR  - C1281/A12014/CRUK_/Cancer Research UK/United Kingdom
GR  - C1287/A11990/CRUK_/Cancer Research UK/United Kingdom
GR  - C8197/A16565/CRUK_/Cancer Research UK/United Kingdom
GR  - R01 CA192393/CA/NCI NIH HHS/United States
GR  - C1287/A10118/CRUK_/Cancer Research UK/United Kingdom
GR  - 15007/CRUK_/Cancer Research UK/United Kingdom
GR  - U10 CA180822/CA/NCI NIH HHS/United States
GR  - P30 CA006927/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20161028
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - *Alleles
MH  - Biomarkers, Tumor
MH  - Breast Neoplasms/*epidemiology/*etiology
MH  - Chromosomes, Human, Pair 11
MH  - Female
MH  - Gene Expression
MH  - *Genes, BRCA1
MH  - *Genes, BRCA2
MH  - Genetic Predisposition to Disease
MH  - Genetic Variation
MH  - *Heterozygote
MH  - Humans
MH  - *Mutation
MH  - Quantitative Trait Loci
MH  - Risk
PMC - PMC5222911
MID - NIHMS835924
OTO - NOTNLM
OT  - BRCA1 and BRCA2 mutation carriers
OT  - Breast cancer
OT  - Cis-regulatory variants
OT  - Differential allelic expression
OT  - Genetic modifiers
OT  - Genetic susceptibility
COIS- The authors declare that they have no conflict of interest. Ethical approval 
      Study participants were recruited through the CIMBA Initiative, following the 
      approval of the corresponding protocol by the Institutional Review Board or 
      Ethics Committee at each participating center. Written informed consent was 
      obtained from all study participants.
EDAT- 2016/11/01 06:00
MHDA- 2017/12/08 06:00
PMCR- 2016/10/28
CRDT- 2016/11/01 06:00
PHST- 2016/10/05 00:00 [received]
PHST- 2016/10/08 00:00 [accepted]
PHST- 2016/11/01 06:00 [pubmed]
PHST- 2017/12/08 06:00 [medline]
PHST- 2016/11/01 06:00 [entrez]
PHST- 2016/10/28 00:00 [pmc-release]
AID - 10.1007/s10549-016-4018-2 [pii]
AID - 4018 [pii]
AID - 10.1007/s10549-016-4018-2 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2017 Jan;161(1):117-134. doi: 10.1007/s10549-016-4018-2. 
      Epub 2016 Oct 28.

PMID- 29903136
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20181211
IS  - 1000-8020 (Print)
IS  - 1000-8020 (Linking)
VI  - 45
IP  - 5
DP  - 2016 Sep
TI  - [UPLC-MS / MS for the pharmacokinetics of icariin in rats].
PG  - 807-810
AB  - OBJECTIVE: To establish an ultra-performance liquid chromatographytandem mass 
      spectrometry( UPLC-MS / MS) method for the quantification of icariin( ICA), and 
      investigate pharmacokinetics of ICA in rats following multiple oral 
      administration. METHODS: ICA and an internal standard coumestrol( CMT) were 
      extracted from rat plasma using ethyl acetate and separated on a BEH C18( 50 mm × 
      2. 1mm, 1. 7 μm) column using a gradient mobile phase of acetonitrile containing 
      0. 1%( V / V)formic acid and water containing 2 mmol / L ammonium formate at a 
      flow rate of 0. 3m L / min. In negative electrospray ionization mode, multiple 
      reaction monitoring of the precursor-product ion transitions of m / z 675. 6→351. 
      1 for ICA, 267. 0 →211. 1 for CMT was used for the quantification. Plasma was 
      collected after rats were orally administered with ICA at multiple doses of 50 mg 
      / kg. RESULTS: The linear calibration curve was achieved in a concentration range 
      of 0. 5-50 ng / m L with a lower limit of quantification of0. 5 ng / m L. The 
      value of intra- and inter-day precision was less than 11. 3% and accuracy fell in 
      the ranges of 94. 3%-98. 7%. The recovery ranged from 81. 3% to85. 2% and the 
      matrix effects from 94. 3% to 103. 2%. After oral administration of ICA to rats, 
      t1 /2was( 1. 68 ± 0. 29) h, Cmaxwas( 29. 6 ± 5. 3) ng / m L, tmaxwas( 1. 00 ± 0. 
      00) h, AUC0- twas( 88. 4 ± 13. 9)( h·ng) / m L. CONCLUSION: The method is 
      specific and accurate, suitable for preclinical pharmacokinetics of ICA.
FAU - Zhang, Shuangqing
AU  - Zhang S
AD  - National Institute for Nutrition and Health, Chinese Center for Disease Control 
      and Prevention, Beijing 100050, China.
FAU - He, Mengjie
AU  - He M
AD  - National Institute for Nutrition and Health, Chinese Center for Disease Control 
      and Prevention, Beijing 100050, China.
FAU - Huang, Zhenwu
AU  - Huang Z
AD  - National Institute for Nutrition and Health, Chinese Center for Disease Control 
      and Prevention, Beijing 100050, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Wei Sheng Yan Jiu
JT  - Wei sheng yan jiu = Journal of hygiene research
JID - 9426367
RN  - 0 (Flavonoids)
RN  - V7NW98OB34 (Coumestrol)
RN  - VNM47R2QSQ (icariin)
SB  - IM
MH  - Animals
MH  - Chromatography, High Pressure Liquid/*methods
MH  - Coumestrol/analysis
MH  - Flavonoids/*pharmacokinetics
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reproducibility of Results
MH  - Tandem Mass Spectrometry/*methods
OTO - NOTNLM
OT  - icariin
OT  - pharmacokinetics
OT  - ultra-performance liquid chromatography-tandem mass spectrometry
EDAT- 2016/09/01 00:00
MHDA- 2016/09/01 00:01
CRDT- 2018/06/16 06:00
PHST- 2018/06/16 06:00 [entrez]
PHST- 2016/09/01 00:00 [pubmed]
PHST- 2016/09/01 00:01 [medline]
PST - ppublish
SO  - Wei Sheng Yan Jiu. 2016 Sep;45(5):807-810.

PMID- 31762681
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1337-6853 (Print)
IS  - 1337-9569 (Electronic)
IS  - 1337-6853 (Linking)
VI  - 11
IP  - 4
DP  - 2018 Dec
TI  - Impact of quercetin on tight junctional proteins and BDNF signaling molecules in 
      hippocampus of PCBs-exposed rats.
PG  - 294-305
LID - 10.2478/intox-2018-0029 [doi]
AB  - Polychlorinated biphenyls (PCBs) consist of a range of toxic substances which are 
      directly proportional to carcinogenesis and tumor-promoting factors as well as 
      having neurotoxic properties. Reactive oxygen species, which are produced from 
      PCBs, alter blood-brain barrier (BBB) integrity, which is paralleled by 
      cytoskeletal rearrangements and redistribution and disappearance of tight 
      junction proteins (TJPs) like claudin-5 and occludin. Brain-derived neurotrophic 
      factor (BDNF), plays an important role in the maintenance, survival of neurons 
      and synaptic plasticity. It is predominant in the hippocampal areas vital to 
      learning, memory and higher thinking. Quercetin, a flavonoid, had drawn attention 
      to its neurodefensive property. The study is to assess the role of quercetin on 
      serum PCB, estradiol and testosterone levels and mRNA expressions of estrogen 
      receptor α and β, TJPs and BDNF signaling molecules on the hippocampus of 
      PCBs-exposed rats. Rats were divided into 4 groups of 6 each. Group I rats were 
      intraperitoneally (i.p.) administered corn oil (vehicle). Group II received 
      quercetin 50 mg/kg/bwt (gavage). Group III received PCBs (Aroclor 1254) at 2 
      mg/kg bwt (i.p). Group IV received quercetin 50 mg/kg bwt (gavage) simultaneously 
      with PCBs 2 mg/kg bwt (i.p.). The treatment was given daily for 30 days. The rats 
      were euthanized 24 h after the experimental period. Blood was collected for 
      quantification of serum PCBs estradiol and testosterone. The hippocampus was 
      dissected and processed for PCR and Western blot; serum PCB was observed in PCB 
      treated animals, simultaneously quercetin treated animals showed PCB metabolites. 
      Serum testosterone and estradiol were decreased after PCB exposure. Quercetin 
      supplementation brought back normal levels. mRNA expressions of estrogen α and β 
      were decreased in the hippocampus of PCB treated rats. TJPS and BDNF signalling 
      molecules were decreased in hippocampus of PCB treated rats. Quercetin 
      supplementation retrieved all the parameters. Quercetin alone treated animals 
      showed no alteration. Thus in PCB caused neurotoxicity, quercetin protects and 
      prevents neuronal damage in the hippocampus.
CI  - Copyright © 2018 SETOX & Institute of Experimental Pharmacology and Toxicology, 
      SASc.
FAU - Selvakumar, Kandaswamy
AU  - Selvakumar K
AD  - Department of Endocrinology, Dr. ALM Post Graduate Institute of Basic Medical 
      Sciences, University of Madras, Chennai- 600113, India.
AD  - Department of Biochemistry, Kauvery Hospital, Luz church Road, Chennai 600004, 
      Tamilnadu, India.
FAU - Bavithra, Senthamilselvan
AU  - Bavithra S
AD  - Department of Endocrinology, Dr. ALM Post Graduate Institute of Basic Medical 
      Sciences, University of Madras, Chennai- 600113, India.
FAU - Krishnamoorthy, Gunasekaran
AU  - Krishnamoorthy G
AD  - Department of Biochemistry, Rajas Dental College and Hospital, 
      Tirunelveli-627105, Tamilnadu, India.
FAU - Arunakaran, Jagadeesan
AU  - Arunakaran J
AD  - Department of Endocrinology, Dr. ALM Post Graduate Institute of Basic Medical 
      Sciences, University of Madras, Chennai- 600113, India.
LA  - eng
PT  - Journal Article
DEP - 20191018
PL  - Slovakia
TA  - Interdiscip Toxicol
JT  - Interdisciplinary toxicology
JID - 101528175
PMC - PMC6853011
OTO - NOTNLM
OT  - BDNF
OT  - GC-MS
OT  - PCBs
OT  - Quercetin
OT  - TJPs
EDAT- 2019/11/26 06:00
MHDA- 2019/11/26 06:01
PMCR- 2018/12/01
CRDT- 2019/11/26 06:00
PHST- 2018/01/14 00:00 [received]
PHST- 2018/02/06 00:00 [accepted]
PHST- 2019/11/26 06:00 [entrez]
PHST- 2019/11/26 06:00 [pubmed]
PHST- 2019/11/26 06:01 [medline]
PHST- 2018/12/01 00:00 [pmc-release]
AID - ITX-11-294 [pii]
AID - 10.2478/intox-2018-0029 [doi]
PST - ppublish
SO  - Interdiscip Toxicol. 2018 Dec;11(4):294-305. doi: 10.2478/intox-2018-0029. Epub 
      2019 Oct 18.

PMID- 38668342
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240428
IS  - 2218-1989 (Print)
IS  - 2218-1989 (Electronic)
IS  - 2218-1989 (Linking)
VI  - 14
IP  - 4
DP  - 2024 Apr 11
TI  - Unveiling the Nexus: Cellular Metabolomics Unravels the Impact of Estrogen on 
      Nicotinamide Metabolism in Mitigating Rheumatoid Arthritis Pathogenesis.
LID - 10.3390/metabo14040214 [doi]
LID - 214
AB  - Rheumatoid arthritis (RA) is a metabolic joint disorder influenced by hormonal 
      regulation, notably estrogen, which plays a cytoprotective role against 
      inflammation. While estrogen's impact on RA pathogenesis has been studied, the 
      altered metabolite expression under estrogen's influence remains unexplored. This 
      study investigated the changes in the metabolome of synovial fibroblasts isolated 
      from RA patients under 17β-estradiol (E2) using the liquid chromatography with 
      tandem mass spectrometry (LC-MS/MS) approach followed by multivariate and 
      biological pathway analysis along with in vitro validation. Results identified 
      3624 m/z, among which eight metabolites were significant (p < 0.05). Nicotinate 
      and nicotinamide metabolism was found to be highly correlated with the treatment 
      of E2, with metabolites NAD(+) and 1-methynicotinamide (1-MNA) upregulated by E2 
      induction in RA-FLS. PharmMapper analysis identified potential gene targets of 
      1-MNA, which were further matched with RA gene targets, and thus, STAT1, MAPK14, 
      MMP3, and MMP9 were concluded to be the common targets. E2 treatment affected the 
      expression of these gene targets and ameliorated the development of oxidative 
      stress associated with RA inflammation, which can be attributed to increased 
      concentration of 1-MNA. Thus, an LC-MS/MS-based metabolomics study revealed the 
      prominent role of estrogen in preventing inflammatory progression in RA by 
      altering metabolite concentration, which can support its therapeutic capacity in 
      remitting RA.
FAU - Malik, Swati
AU  - Malik S
AD  - Department of Integrative and Functional Biology, CSIR-Institute of Genomics and 
      Integrative Biology, Mall Road, Delhi 110007, India.
AD  - AcSIR-Academy of Scientific and Innovative Research, Ghaziabad 201002, India.
FAU - Chakraborty, Debolina
AU  - Chakraborty D
AD  - Department of Integrative and Functional Biology, CSIR-Institute of Genomics and 
      Integrative Biology, Mall Road, Delhi 110007, India.
AD  - AcSIR-Academy of Scientific and Innovative Research, Ghaziabad 201002, India.
FAU - Agnihotri, Prachi
AU  - Agnihotri P
AD  - Department of Integrative and Functional Biology, CSIR-Institute of Genomics and 
      Integrative Biology, Mall Road, Delhi 110007, India.
AD  - AcSIR-Academy of Scientific and Innovative Research, Ghaziabad 201002, India.
FAU - Kumar, Vijay
AU  - Kumar V
AD  - Department of Orthopaedics, AIIMS-All India Institute of Medical Sciences, Ansari 
      Nagar, New Delhi 110029, India.
FAU - Biswas, Sagarika
AU  - Biswas S
AUID- ORCID: 0000-0002-2017-1670
AD  - Department of Integrative and Functional Biology, CSIR-Institute of Genomics and 
      Integrative Biology, Mall Road, Delhi 110007, India.
AD  - AcSIR-Academy of Scientific and Innovative Research, Ghaziabad 201002, India.
LA  - eng
GR  - CRG/2019/006398/Department of Science and Technology/
PT  - Journal Article
DEP - 20240411
PL  - Switzerland
TA  - Metabolites
JT  - Metabolites
JID - 101578790
PMC - PMC11052502
OTO - NOTNLM
OT  - 1-methylnicotinamide
OT  - estrogen
OT  - metabolomics
OT  - nicotinate and nicotinamide metabolism
OT  - rheumatoid arthritis
OT  - synovial fibroblast
COIS- The authors declare no conflicts of interest.
EDAT- 2024/04/26 13:21
MHDA- 2024/04/26 13:22
PMCR- 2024/04/11
CRDT- 2024/04/26 09:35
PHST- 2024/03/06 00:00 [received]
PHST- 2024/03/21 00:00 [revised]
PHST- 2024/03/23 00:00 [accepted]
PHST- 2024/04/26 13:22 [medline]
PHST- 2024/04/26 13:21 [pubmed]
PHST- 2024/04/26 09:35 [entrez]
PHST- 2024/04/11 00:00 [pmc-release]
AID - metabo14040214 [pii]
AID - metabolites-14-00214 [pii]
AID - 10.3390/metabo14040214 [doi]
PST - epublish
SO  - Metabolites. 2024 Apr 11;14(4):214. doi: 10.3390/metabo14040214.

PMID- 39877638
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20250129
IS  - 2008-3866 (Print)
IS  - 2008-3874 (Electronic)
IS  - 2008-3866 (Linking)
VI  - 28
IP  - 1
DP  - 2025
TI  - Characteristics of soybean (Glycine max) protein hydrolysate by bromelain and its 
      effect on inflammation and kidney disorders in gentamicin-induced male Wistar 
      rats.
PG  - 56-62
LID - 10.22038/ijbms.2024.78131.16885 [doi]
AB  - OBJECTIVES: Soybeans have various positive effects on health, including 
      anti-inflammatory and preventing kidney damage. There is concern regarding the 
      phytoestrogen content due to the high isoflavone content in soybeans. Various 
      forms of soybean processing have been tried; in this study, the hydrolysis method 
      will be used to obtain the active substance Arginine-Glycine-Aspartate (RGD) 
      tripeptide in soybean protein hydrolyzed by bromelain (SPHB). The research aimed 
      to determine the characteristics and influence of SPHB on kidney function, 
      inflammation, body weight, and estrogen in male Wistar rats induced by 
      gentamicin. MATERIALS AND METHODS: Soybeans (Glycine max) are hydrolyzed using 
      the proteolytic enzyme Bromelain from pineapples. The proteomics was investigated 
      using Liquid-Chromatography Mass Spectroscopy Tandem (LC-MS/MS). SPHB in three 
      doses would be tested for 28 days on male Wistar rats induced by gentamicin. The 
      parameters measured were body weight, high-sensitive cell reactive protein 
      (hs-CRP) levels, urea, creatinine, and estrogen levels. RESULTS: SPHB has a low 
      molecular weight (LMW) of 10 kDa and contains RGD in the lunasin sequence. SPHB 
      showed no effect on body weight (P>0.05). The impact of SPHB on hs-CRP, urea, and 
      creatinine showed differences significantly from the positive control, especially 
      SPHB at a dose of 112 mg/day (P<0.01). Meanwhile, SPHB has almost no effect on 
      estrogen levels. CONCLUSION: The administration of SPHB with LMW and contains 
      lunasin showed decreased inflammation and kidney function parameters but did not 
      affect body weight and estrogen levels in induced gentamicin Wistar rats.
CI  - 2025. This work is openly licensed via CC BY 4.0.
FAU - Hidayat, Meilinah
AU  - Hidayat M
AD  - Faculty of Medicine, Universitas Kristen Maranatha Jalan Prof.Drg. Suria Sumantri 
      65 Bandung 40163, Indonesia.
FAU - Barnas, Amirah
AU  - Barnas A
AD  - Faculty of Medicine, Universitas Kristen Maranatha Jalan Prof.Drg. Suria Sumantri 
      65 Bandung 40163, Indonesia.
FAU - Nussy, Virginia
AU  - Nussy V
AD  - Faculty of Medicine, Universitas Kristen Maranatha Jalan Prof.Drg. Suria Sumantri 
      65 Bandung 40163, Indonesia.
FAU - Wantania, Timothy
AU  - Wantania T
AD  - Faculty of Medicine, Universitas Kristen Maranatha Jalan Prof.Drg. Suria Sumantri 
      65 Bandung 40163, Indonesia.
FAU - Prahastuti, Sijani
AU  - Prahastuti S
AD  - Faculty of Medicine, Universitas Kristen Maranatha Jalan Prof.Drg. Suria Sumantri 
      65 Bandung 40163, Indonesia.
FAU - Sriwidodo, Sriwidodo
AU  - Sriwidodo S
AD  - Faculty of Pharmacy, Universitas Padjadjaran Jl. Ir. Soekarno, KM 21 Jatinangor - 
      Sumedang, 45363, Indonesia.
FAU - Hasan, Khomaini
AU  - Hasan K
AD  - Faculty of Medicine, Universitas Jenderal Achmad Yani, Jalan Terusan Jenderal 
      Sudirman, Cimahi 40531 PO Box 148, Indonesia.
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - Iran J Basic Med Sci
JT  - Iranian journal of basic medical sciences
JID - 101517966
PMC - PMC11771338
OTO - NOTNLM
OT  - Creatinine
OT  - Glycine max
OT  - Phytoestrogen
OT  - Protein hydrolysates
OT  - RGD motif
OT  - Soybean
OT  - hs-CRP
COIS- All authors declare that there are no conflicts of interest.
EDAT- 2025/01/29 11:20
MHDA- 2025/01/29 11:21
PMCR- 2025/01/01
CRDT- 2025/01/29 04:35
PHST- 2024/02/13 00:00 [received]
PHST- 2024/06/05 00:00 [accepted]
PHST- 2025/01/29 11:21 [medline]
PHST- 2025/01/29 11:20 [pubmed]
PHST- 2025/01/29 04:35 [entrez]
PHST- 2025/01/01 00:00 [pmc-release]
AID - 10.22038/ijbms.2024.78131.16885 [doi]
PST - ppublish
SO  - Iran J Basic Med Sci. 2025;28(1):56-62. doi: 10.22038/ijbms.2024.78131.16885.

PMID- 31086672
OWN - NLM
STAT- MEDLINE
DCOM- 20200207
LR  - 20231011
IS  - 2052-1707 (Electronic)
IS  - 2052-1707 (Linking)
VI  - 7
IP  - 3
DP  - 2019 Jun
TI  - Identification of equol-7-glucuronide-4'-sulfate, monoglucuronides and 
      monosulfates in human plasma of 2 equol producers after administration of kinako 
      by LC-ESI-MS.
PG  - e00478
LID - 10.1002/prp2.478 [doi]
LID - e00478
AB  - Equol is a product formed during the biotransformation of the naturally occurring 
      isoflavone daidzein by intestinal bacteria. The role of equol in the prevention 
      of several hormone-dependent diseases such as prostate cancer and osteoporosis as 
      well as vasomotor symptoms has been extensively investigated. Equol primarily 
      occurs in the form of major metabolites such as glucuronides and sulfates, while 
      intact equol has been detected at only ca. 1% in human plasma. However, to date, 
      conjugated metabolites have been evaluated by measuring the free equol obtained 
      after selective enzymatic hydrolysis. Thus, the precise types of conjugates 
      circulating in vivo and the position(s) of the conjugation sites on the equol 
      skeleton have yet to be clarified. Our study describes the identification of 
      polar equol metabolites in the plasma of 2 equol-producers obtained at 8 hours 
      after consuming 50 g of kinako (approximately 37 mg of daidzein). The structural 
      identification of these conjugated metabolites in plasma was performed by 
      comparison to the LC-ESI-MS (n) and (1)H-NMR spectral data of the corresponding 
      chemically synthesized compounds. The results of the LC-ESI-MS/MS analysis 
      indicated that the main conjugated metabolite in plasma was 
      (S)-equol-7-glucuronide-4'-sulfate along with lower amounts of 7- and 
      4'-monoglucuronides as well as 7- and 4'-monosulfates.
FAU - Obara, Aki
AU  - Obara A
AD  - Department of Medical Technology Faculty of Health Sciences Kyorin University 
      Mitaka Tokyo Japan.
FAU - Kinoshita, Mizuki
AU  - Kinoshita M
AD  - Department of Medical Technology Faculty of Health Sciences Kyorin University 
      Mitaka Tokyo Japan.
FAU - Hosoda, Kaori
AU  - Hosoda K
AD  - Department of Medical Technology Faculty of Health Sciences Kyorin University 
      Mitaka Tokyo Japan.
FAU - Yokokawa, Akitomo
AU  - Yokokawa A
AD  - School of Pharmacy Tokyo University of Pharmacy and Life Sciences Hachioji Tokyo 
      Japan.
FAU - Shibasaki, Hiromi
AU  - Shibasaki H
AD  - School of Pharmacy Tokyo University of Pharmacy and Life Sciences Hachioji Tokyo 
      Japan.
FAU - Ishii, Kazuo
AU  - Ishii K
AUID- ORCID: 0000-0002-0846-6548
AD  - Department of Medical Technology Faculty of Health Sciences Kyorin University 
      Mitaka Tokyo Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190509
PL  - United States
TA  - Pharmacol Res Perspect
JT  - Pharmacology research & perspectives
JID - 101626369
RN  - 0 (Glucuronates)
RN  - 0 (Isoflavones)
RN  - 0 (Sulfates)
RN  - 531-95-3 (Equol)
RN  - 6287WC5J2L (daidzein)
SB  - IM
MH  - Chromatography, Liquid
MH  - Equol/blood/chemistry
MH  - Glucuronates/*blood/chemistry
MH  - Humans
MH  - Isoflavones/*administration & dosage/pharmacokinetics
MH  - Proton Magnetic Resonance Spectroscopy
MH  - Sulfates/*blood/chemistry
MH  - Tandem Mass Spectrometry
PMC - PMC6507113
OTO - NOTNLM
OT  - Equol
OT  - LC‐ESI‐MS
OT  - glucuronide
OT  - identification
OT  - sulfate
EDAT- 2019/05/16 06:00
MHDA- 2020/02/08 06:00
PMCR- 2019/05/09
CRDT- 2019/05/16 06:00
PHST- 2019/01/21 00:00 [received]
PHST- 2019/04/09 00:00 [revised]
PHST- 2019/04/11 00:00 [accepted]
PHST- 2019/05/16 06:00 [entrez]
PHST- 2019/05/16 06:00 [pubmed]
PHST- 2020/02/08 06:00 [medline]
PHST- 2019/05/09 00:00 [pmc-release]
AID - PRP2478 [pii]
AID - 10.1002/prp2.478 [doi]
PST - epublish
SO  - Pharmacol Res Perspect. 2019 May 9;7(3):e00478. doi: 10.1002/prp2.478. 
      eCollection 2019 Jun.

PMID- 31981674
OWN - NLM
STAT- MEDLINE
DCOM- 20210817
LR  - 20210817
IS  - 1873-2747 (Electronic)
IS  - 0361-9230 (Print)
IS  - 0361-9230 (Linking)
VI  - 157
DP  - 2020 Apr
TI  - Effects of acute versus recurrent insulin-induced hypoglycemia on ventromedial 
      hypothalamic nucleus metabolic-sensory neuron AMPK activity: Impact of 
      alpha(1)-adrenergic receptor signaling.
PG  - 41-50
LID - S0361-9230(19)30375-2 [pii]
LID - 10.1016/j.brainresbull.2020.01.013 [doi]
AB  - Mechanisms that underlie metabolic sensor acclimation to recurring 
      insulin-induced hypoglycemia (RIIH) are unclear. Norepinephrine (NE) regulates 
      ventromedial hypothalamic nucleus (VMN) gluco-stimulatory nitric oxide (NO) and 
      gluco-inhibitory γ-aminobutryic acid (GABA) neuron signaling. Current research 
      addressed the hypothesis that during RIIH, NE suppresses 5'-AMP-activated protein 
      kinase (AMPK) reactivity in both populations and impedes counter-regulation. The 
      brain is postulated to utilize non-glucose substrates, e.g. amino acids glutamine 
      (Gln), glutamate (Glu), and aspartate (Asp), to produce energy during 
      hypoglycemia. A correlated aim investigated whether NE controls pyruvate 
      recycling pathway marker protein (glutaminase, GLT; malic enzyme, ME-1) 
      expression in either metabolic-sensory cell population. Male rats were injected 
      subcutaneously with vehicle or insulin on days 1-3, then pretreated on day 4 by 
      intracerebroventricular delivery of the alpha(1)-adrenergic receptor (α(1)-AR) 
      reverse-agonist prazocin (PRZ) or vehicle before final insulin therapy. PRZ 
      prevented acute hypoglycemic augmentation of AMPK activation in each cell group. 
      Antecedent hypoglycemic repression of sensor activity was reversed by PRZ in GABA 
      neurons. During RIIH, nitrergic neurons exhibited α(1)-AR - dependent 
      up-regulated GLT and α(2)-AR profiles, while GABA cells showed down-regulated 
      α(1)-AR. LC-ESI-MS analysis documented a decline in VMN Glu, Gln, and Asp 
      concentrations during acute hypoglycemia, and habituation of the former two 
      profiles to RIIH. PRZ attenuated glucagon and corticosterone secretion during 
      acute hypoglycemia, but reversed decrements in output of both hormones during 
      RIIH. Results implicate adjustments in impact of α(1)-AR signaling in repressed 
      VMN metabolic-sensory AMPK activation and counter-regulatory dysfunction during 
      RIIH. Antecedent hypoglycemia may up-regulate NO neuron energy yield via α(1)-AR 
      - mediated up-regulated pyruvate recycling.
CI  - Copyright © 2020 Elsevier Inc. All rights reserved.
FAU - Briski, Karen P
AU  - Briski KP
AD  - School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, 
      University of Louisiana at Monroe, Monroe, LA 71201, United States. Electronic 
      address: briski@ulm.edu.
FAU - Mandal, Santosh K
AU  - Mandal SK
AD  - School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, 
      University of Louisiana at Monroe, Monroe, LA 71201, United States.
FAU - Bheemanapally, Khaggeswar
AU  - Bheemanapally K
AD  - School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, 
      University of Louisiana at Monroe, Monroe, LA 71201, United States.
FAU - Ibrahim, Mostafa M H
AU  - Ibrahim MMH
AD  - School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, 
      University of Louisiana at Monroe, Monroe, LA 71201, United States.
LA  - eng
GR  - R01 DK109382/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200122
PL  - United States
TA  - Brain Res Bull
JT  - Brain research bulletin
JID - 7605818
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Receptors, Estrogen)
RN  - EC 2.7.11.31 (AMP-Activated Protein Kinases)
RN  - X4W3ENH1CV (Norepinephrine)
SB  - IM
MH  - AMP-Activated Protein Kinases/*metabolism
MH  - Animals
MH  - Hypoglycemia/*metabolism/physiopathology
MH  - Hypoglycemic Agents/pharmacology
MH  - Insulin/*metabolism
MH  - Male
MH  - Norepinephrine/metabolism
MH  - Rats, Sprague-Dawley
MH  - Receptors, Estrogen/metabolism
MH  - Rhombencephalon/metabolism
MH  - Ventromedial Hypothalamic Nucleus/cytology/*metabolism
PMC - PMC7332013
MID - NIHMS1556843
OTO - NOTNLM
OT  - Aspartate
OT  - Neuronal nitric oxide synthase
OT  - Prazocin
OT  - Recurrent insulin-induced hypoglycemia
OT  - Ventromedial hypothalamic nucleus
COIS- Conflict of Interest Statement: The authors have no conflicts of interest to 
      declare.
EDAT- 2020/01/26 06:00
MHDA- 2021/08/18 06:00
PMCR- 2021/04/01
CRDT- 2020/01/26 06:00
PHST- 2019/05/14 00:00 [received]
PHST- 2019/12/15 00:00 [revised]
PHST- 2020/01/17 00:00 [accepted]
PHST- 2020/01/26 06:00 [pubmed]
PHST- 2021/08/18 06:00 [medline]
PHST- 2020/01/26 06:00 [entrez]
PHST- 2021/04/01 00:00 [pmc-release]
AID - S0361-9230(19)30375-2 [pii]
AID - 10.1016/j.brainresbull.2020.01.013 [doi]
PST - ppublish
SO  - Brain Res Bull. 2020 Apr;157:41-50. doi: 10.1016/j.brainresbull.2020.01.013. Epub 
      2020 Jan 22.

PMID- 30717353
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2218-1989 (Print)
IS  - 2218-1989 (Electronic)
IS  - 2218-1989 (Linking)
VI  - 9
IP  - 2
DP  - 2019 Feb 2
TI  - Metabolomic Profiling of Cerebral Palsy Brain Tissue Reveals Novel Central 
      Biomarkers and Biochemical Pathways Associated with the Disease: A Pilot Study.
LID - 10.3390/metabo9020027 [doi]
LID - 27
AB  - Cerebral palsy (CP) is one of the most common causes of motor disability in 
      childhood, with complex and heterogeneous etiopathophysiology and clinical 
      presentation. Understanding the metabolic processes associated with the disease 
      may aid in the discovery of preventive measures and therapy. Tissue samples 
      (caudate nucleus) were obtained from post-mortem CP cases (n = 9) and age- and 
      gender-matched control subjects (n = 11). We employed a targeted metabolomics 
      approach using both ¹H NMR and direct injection liquid chromatography-tandem mass 
      spectrometry (DI/LC-MS/MS). We accurately identified and quantified 55 
      metabolites using ¹H NMR and 186 using DI/LC-MS/MS. Among the 222 detected 
      metabolites, 27 showed significant concentration changes between CP cases and 
      controls. Glycerophospholipids and urea were the most commonly selected 
      metabolites used to develop predictive models capable of discriminating between 
      CP and controls. Metabolomics enrichment analysis identified folate, propanoate, 
      and androgen/estrogen metabolism as the top three significantly perturbed 
      pathways. We report for the first time the metabolomic profiling of post-mortem 
      brain tissue from patients who died from cerebral palsy. These findings could 
      help to further investigate the complex etiopathophysiology of CP while 
      identifying predictive, central biomarkers of CP.
FAU - Alpay Savasan, Zeynep
AU  - Alpay Savasan Z
AUID- ORCID: 0000-0002-2121-3721
AD  - Department of Obstetrics and Gynecology, Maternal Fetal Medicine Division, 
      Beaumont Health System, 3811 W. 13 Mile Road, Royal Oak, MI 48073, USA. 
      Zeynep.AlpaySavasan@beaumont.org.
AD  - Oakland University-William Beaumont School of Medicine, Beaumont Health, 3811 W. 
      13 Mile Road, Royal Oak, MI 48073, USA. Zeynep.AlpaySavasan@beaumont.org.
FAU - Yilmaz, Ali
AU  - Yilmaz A
AD  - Beaumont Research Institute, Beaumont Health, 3811 W. 13 Mile Road, Royal Oak, MI 
      48073, USA. Ali.Yilmaz@beaumont.org.
FAU - Ugur, Zafer
AU  - Ugur Z
AD  - Beaumont Research Institute, Beaumont Health, 3811 W. 13 Mile Road, Royal Oak, MI 
      48073, USA. Zafer.Ugur@beaumont.org.
FAU - Aydas, Buket
AU  - Aydas B
AD  - Departments of Mathematics and Computer Sciences, Albion College, 611 E. Porter 
      St., Albion, MI 49224, USA. baydas@albion.edu.
FAU - Bahado-Singh, Ray O
AU  - Bahado-Singh RO
AD  - Department of Obstetrics and Gynecology, Maternal Fetal Medicine Division, 
      Beaumont Health System, 3811 W. 13 Mile Road, Royal Oak, MI 48073, USA. 
      Ray.Bahado-Singh@beaumont.org.
AD  - Oakland University-William Beaumont School of Medicine, Beaumont Health, 3811 W. 
      13 Mile Road, Royal Oak, MI 48073, USA. Ray.Bahado-Singh@beaumont.org.
FAU - Graham, Stewart F
AU  - Graham SF
AUID- ORCID: 0000-0003-1001-0002
AD  - Oakland University-William Beaumont School of Medicine, Beaumont Health, 3811 W. 
      13 Mile Road, Royal Oak, MI 48073, USA. Stewart.Graham@beaumont.org.
AD  - Beaumont Research Institute, Beaumont Health, 3811 W. 13 Mile Road, Royal Oak, MI 
      48073, USA. Stewart.Graham@beaumont.org.
LA  - eng
PT  - Journal Article
DEP - 20190202
PL  - Switzerland
TA  - Metabolites
JT  - Metabolites
JID - 101578790
PMC - PMC6409919
OTO - NOTNLM
OT  - 1H NMR
OT  - cerebral palsy
OT  - metabolic pathways
OT  - metabolomics
OT  - targeted mass spectrometry
COIS- The authors declare no conflict of interest.
EDAT- 2019/02/06 06:00
MHDA- 2019/02/06 06:01
PMCR- 2019/02/01
CRDT- 2019/02/06 06:00
PHST- 2019/01/09 00:00 [received]
PHST- 2019/01/29 00:00 [revised]
PHST- 2019/01/31 00:00 [accepted]
PHST- 2019/02/06 06:00 [entrez]
PHST- 2019/02/06 06:00 [pubmed]
PHST- 2019/02/06 06:01 [medline]
PHST- 2019/02/01 00:00 [pmc-release]
AID - metabo9020027 [pii]
AID - metabolites-09-00027 [pii]
AID - 10.3390/metabo9020027 [doi]
PST - epublish
SO  - Metabolites. 2019 Feb 2;9(2):27. doi: 10.3390/metabo9020027.

PMID- 31408594
OWN - NLM
STAT- MEDLINE
DCOM- 20190820
LR  - 20190820
IS  - 0869-2084 (Print)
IS  - 0869-2084 (Linking)
VI  - 64
IP  - 7
DP  - 2019
TI  - [Nonspecific parameters of the immune inflammatory response as a link in the 
      pathogenesis of remodeling of the vascular wall and destruction of bone tissue in 
      women with arterial hypertension in postmenopausal women.].
PG  - 417-423
LID - 10.18821/0869-2084-2019-64-7-417-423 [doi]
AB  - Recently, they increasingly began to pay attention to the role of a nonspecific 
      immune-inflammatory vascular response as a link in general pathogenetic 
      mechanisms with a change in the elastic properties of arteries and phenomena of 
      destructive bone changes, which at the subclinical level is of great importance 
      for the prevention of the development of socially significant diseases. A total 
      of 104 patients were examined (mean age 57.45 years), which were divided into 
      three groups. The first group included 39 healthy women, the second group 
      included 30 patients with hypertension and osteopenia, and the third group 
      included 35 women with hypertension and osteoporosis. The analysis of markers of 
      the immune inflammatory response, endothelial dysfunction, hormonal and 
      mineral-vitamin status parameters was conducted against the background of the 
      study of parameters of daily monitoring of arterial pressure, study of parameters 
      of vascular wall stiffness and densitometry to clarify the predictors of 
      cardiovascular and degenerative bone changes in postmenopausal women. A 
      significant increase in the concentration of HF-CRP, the level of homocystemine, 
      IL-8, parathyroid hormone, against the background of a significant decrease in 
      the level of estrogen, progesterone, testosterone, with a persistent tendency to 
      increase in total cholesterol, atherogenic lipid fractions, myeloperoxidase, 
      endothelin-1 and decrease was recorded calcitonin, total and ionized calcium, 
      with a significantly minimal value of vitamin D in the 3rd group of patients. The 
      risks of development and progression of bone destructive changes were calculated 
      using the logistic regression method for the group of AH with osteopenia and 
      osteoporosis. Thus, for patients with hypertension and osteopenia, a 
      significantly significant parameter associated with the risk of developing 
      osteoporosis was an indicator of the velocity of the pulse wave, an increase in 
      the level of which exceeds 12.05 m/s is associated with an increased risk of 
      developing osteoporosis by 3.8 times. Increased levels of pro-inflammatory 
      parameters, IL-6 and 8, TNF-α, HB-SRB, parathyroid hormone and reduced levels of 
      progesterone and IL10, took the most active part in aggravating the degree of 
      available bone tissue destruction. Timely specialized multidirectional study of 
      biochemical and instrumental parameters (in particular, the study of the speed of 
      the pulse wave and densitometry) can be the basis for the development of 
      personalized prevention and treatment tactics for women in order to prevent 
      socially dangerous cardiovascular and bone complications.
FAU - Petelina, T I
AU  - Petelina TI
AUID- ORCID: 0000-0001-6251-4179
AD  - Tyumen Cardiology Research Center, Tomsk National Research Medical Center RAS, 
      Tomsk, Russia.
FAU - Avdeeva, K S
AU  - Avdeeva KS
AUID- ORCID: 0000-0002-2134-4107
AD  - Tyumen Cardiology Research Center, Tomsk National Research Medical Center RAS, 
      Tomsk, Russia.
FAU - Bykova, S G
AU  - Bykova SG
AD  - Tyumen Cardiology Research Center, Tomsk National Research Medical Center RAS, 
      Tomsk, Russia.
FAU - Musikhina, N A
AU  - Musikhina NA
AUID- ORCID: 0000-0001-9607-7245
AD  - Tyumen Cardiology Research Center, Tomsk National Research Medical Center RAS, 
      Tomsk, Russia.
FAU - Gapon, L I
AU  - Gapon LI
AUID- ORCID: 0000-0002-3620-0659
AD  - Tyumen Cardiology Research Center, Tomsk National Research Medical Center RAS, 
      Tomsk, Russia.
FAU - Gorbаtenko, E A
AU  - Gorbаtenko EA
AUID- ORCID: 0000-0003-0858-2933
AD  - Tyumen Cardiology Research Center, Tomsk National Research Medical Center RAS, 
      Tomsk, Russia.
FAU - Zueva, E V
AU  - Zueva EV
AUID- ORCID: 0000-0002-8716-7019
AD  - Tyumen Cardiology Research Center, Tomsk National Research Medical Center RAS, 
      Tomsk, Russia.
FAU - Leonovich, S V
AU  - Leonovich SV
AD  - Tyumen Cardiology Research Center, Tomsk National Research Medical Center RAS, 
      Tomsk, Russia.
FAU - Lystsova, N L
AU  - Lystsova NL
AUID- ORCID: 0000-0002-3401-6794
AD  - Tyumen Cardiology Research Center, Tomsk National Research Medical Center RAS, 
      Tomsk, Russia.
LA  - rus
PT  - Journal Article
PL  - Russia (Federation)
TA  - Klin Lab Diagn
JT  - Klinicheskaia laboratornaia diagnostika
JID - 9432021
RN  - 0 (Cytokines)
RN  - 0 (Hormones)
SB  - IM
MH  - Bone Density
MH  - Bone Diseases, Metabolic/immunology/pathology
MH  - Bone and Bones
MH  - Case-Control Studies
MH  - Cytokines/blood
MH  - Female
MH  - Hormones/blood
MH  - Humans
MH  - Hypertension/immunology/*pathology
MH  - Inflammation/*pathology
MH  - Middle Aged
MH  - Osteoporosis/immunology/*pathology
MH  - Postmenopause
OTO - NOTNLM
OT  - arterial hypertension
OT  - hormonal and mineral – vitamin status
OT  - markers of immune inflammatory response
OT  - osteoporosis
OT  - postmenopause
COIS- The authors declare no conflict of interest.
EDAT- 2019/08/14 06:00
MHDA- 2019/08/21 06:00
CRDT- 2019/08/14 06:00
PHST- 2019/05/28 00:00 [received]
PHST- 2019/06/04 00:00 [accepted]
PHST- 2019/08/14 06:00 [entrez]
PHST- 2019/08/14 06:00 [pubmed]
PHST- 2019/08/21 06:00 [medline]
AID - 10.18821/0869-2084-2019-64-7-417-423 [doi]
PST - ppublish
SO  - Klin Lab Diagn. 2019;64(7):417-423. doi: 10.18821/0869-2084-2019-64-7-417-423.

PMID- 29857569
OWN - NLM
STAT- MEDLINE
DCOM- 20190405
LR  - 20190405
IS  - 2072-6651 (Electronic)
IS  - 2072-6651 (Linking)
VI  - 10
IP  - 6
DP  - 2018 Jun 1
TI  - Fructo-Oligosaccharide (DFA III) Feed Supplementation for Mitigation of Mycotoxin 
      Exposure in Cattle-Clinical Evaluation by a Urinary Zearalenone Monitoring 
      System.
LID - 10.3390/toxins10060223 [doi]
LID - 223
AB  - The potential effect of difructose anhydride III (DFA III) supplementation in 
      cattle feed was evaluated using a previously developed urinary-zearalenone (ZEN) 
      monitoring system. Japanese Black cattle from two beef herds aged 9⁻10 months 
      were used. DFA III was supplemented for two weeks. ZEN concentrations in feed 
      were similar in both herds (0.27 and 0.22 mg/kg in roughage and concentrates, 
      respectively), and below the maximum allowance in Japan. ZEN, α-zearalenol 
      (α-ZOL), and β-ZOL concentrations in urine were measured using LC/MS/MS the day 
      before DFA III administration, 9 and 14 days thereafter, and 9 days after 
      supplementation ceased. Significant differences in ZEN, α-ZOL, β-ZOL, and total 
      ZEN were recorded on different sampling dates. The concentration of inorganic 
      phosphate in DFA III-supplemented animals was significantly higher than in 
      controls on day 23 (8.4 vs. 7.7 mg/dL), suggesting a possible role of DFA III in 
      tight junction of intestinal epithelial cells. This is the first evidence that 
      DFA III reduces mycotoxin levels reaching the systemic circulation and excreted 
      in urine. This preventive effect may involve an improved tight-junction-dependent 
      intestinal barrier function. Additionally, our practical approach confirmed that 
      monitoring of urinary mycotoxin is useful for evaluating the effects of dietary 
      supplements to prevent mycotoxin adsorption.
FAU - Toda, Katsuki
AU  - Toda K
AD  - United Graduate School of Veterinary Sciences, Yamaguchi University, Yamaguchi 
      753-8515, Japan. t1643eson@yahoo.co.jp.
AD  - Shepherd Central Livestock Clinic, Kagoshima 899-1611, Japan. 
      t1643eson@yahoo.co.jp.
FAU - Uno, Seiichi
AU  - Uno S
AD  - Faculty of Fisheries, Kagoshima University, Kagoshima 890-0056, Japan. 
      uno@fish.kagoshima-u.ac.jp.
FAU - Kokushi, Emiko
AU  - Kokushi E
AD  - Faculty of Fisheries, Kagoshima University, Kagoshima 890-0056, Japan. 
      kokushi@fish.kagoshima-u.ac.jp.
FAU - Shiiba, Ayaka
AU  - Shiiba A
AD  - United Graduate School of Veterinary Sciences, Yamaguchi University, Yamaguchi 
      753-8515, Japan. shiibaayakahime@yahoo.co.jp.
AD  - Shepherd Central Livestock Clinic, Kagoshima 899-1611, Japan. 
      shiibaayakahime@yahoo.co.jp.
FAU - Hasunuma, Hiroshi
AU  - Hasunuma H
AD  - Shepherd Central Livestock Clinic, Kagoshima 899-1611, Japan. 
      hasu@fa3.so-net.ne.jp.
FAU - Matsumoto, Daisaku
AU  - Matsumoto D
AD  - Shepherd Central Livestock Clinic, Kagoshima 899-1611, Japan. 
      papashepherd@gmail.com.
FAU - Ohtani, Masayuki
AU  - Ohtani M
AD  - Nippon Beet Sugar Manufacturing Co., Ltd., Obihiro 080-0835, Japan. 
      mohtani@nitten.co.jp.
FAU - Yamato, Osamu
AU  - Yamato O
AD  - Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima 890-0062, 
      Japan. osam@vet.kagoshima-u.ac.jp.
FAU - Shinya, Urara
AU  - Shinya U
AD  - Soo Agricultural Mutual Aid Association, Kagoshima 890-8212, Japan. 
      urara@nosai-soo.com.
FAU - Wijayagunawardane, Missaka
AU  - Wijayagunawardane M
AD  - Department of Animal Science, University of Peradeniya, Peradeniya 20400, Sri 
      Lanka. missakaw@pdn.ac.lk.
FAU - Fink-Gremmels, Johanna
AU  - Fink-Gremmels J
AD  - Faculty of Veterinary Medicine, Utrecht University, Yalelaan 104, The 
      Netherlands. J.Fink@uu.nl.
FAU - Taniguchi, Masayasu
AU  - Taniguchi M
AD  - United Graduate School of Veterinary Sciences, Yamaguchi University, Yamaguchi 
      753-8515, Japan. masa0810@yamaguchi-u.ac.jp.
AD  - Laboratory of Theriogenology, Joint Faculty of Veterinary Medicine, Yamaguchi 
      University, Yamaguchi 753-8515, Japan. masa0810@yamaguchi-u.ac.jp.
FAU - Takagi, Mitsuhiro
AU  - Takagi M
AD  - United Graduate School of Veterinary Sciences, Yamaguchi University, Yamaguchi 
      753-8515, Japan. mtakagi@yamaguchi-u.ac.jp.
AD  - Laboratory of Theriogenology, Joint Faculty of Veterinary Medicine, Yamaguchi 
      University, Yamaguchi 753-8515, Japan. mtakagi@yamaguchi-u.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180601
PL  - Switzerland
TA  - Toxins (Basel)
JT  - Toxins
JID - 101530765
RN  - 0 (Disaccharides)
RN  - 0 (Phosphates)
RN  - 5W827M159J (Zearalenone)
RN  - 81129-73-9 (difructose anhydride III)
RN  - I38ZP9992A (Magnesium)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - *Animal Feed
MH  - Animals
MH  - Calcium/blood
MH  - Cattle
MH  - Dietary Exposure/prevention & control
MH  - *Dietary Supplements
MH  - Disaccharides/*administration & dosage
MH  - Environmental Monitoring
MH  - Female
MH  - Intestinal Absorption/*drug effects
MH  - Magnesium/blood
MH  - Phosphates/blood
MH  - Zearalenone/*urine
PMC - PMC6024752
OTO - NOTNLM
OT  - DFA III
OT  - blood
OT  - cattle
OT  - mycotoxin
OT  - tight-junction
OT  - urine
COIS- The authors declare no conflict of interest.
EDAT- 2018/06/03 06:00
MHDA- 2019/04/06 06:00
PMCR- 2018/06/01
CRDT- 2018/06/03 06:00
PHST- 2018/05/01 00:00 [received]
PHST- 2018/05/23 00:00 [revised]
PHST- 2018/05/30 00:00 [accepted]
PHST- 2018/06/03 06:00 [entrez]
PHST- 2018/06/03 06:00 [pubmed]
PHST- 2019/04/06 06:00 [medline]
PHST- 2018/06/01 00:00 [pmc-release]
AID - toxins10060223 [pii]
AID - toxins-10-00223 [pii]
AID - 10.3390/toxins10060223 [doi]
PST - epublish
SO  - Toxins (Basel). 2018 Jun 1;10(6):223. doi: 10.3390/toxins10060223.

PMID- 26018796
OWN - NLM
STAT- MEDLINE
DCOM- 20160314
LR  - 20211203
IS  - 1439-0221 (Electronic)
IS  - 0032-0943 (Linking)
VI  - 81
IP  - 7
DP  - 2015 May
TI  - Anabolic effect of the traditional Chinese medicine compound tanshinone IIA on 
      myotube hypertrophy is mediated by estrogen receptor.
PG  - 578-85
LID - 10.1055/s-0035-1545883 [doi]
AB  - Skeletal muscle loss during menopause is associated with a higher risk of 
      developing diabetes type II and the general development of the metabolic 
      syndrome. Therefore, strategies combining nutritional and training interventions 
      to prevent muscle loss are necessary. Danshen Si Wu is a traditional Chinese 
      medicine used for menopausal complains. One of the main compounds of Danshen Si 
      Wu is tanshinone IIA. Physiological effects of tanshinone IIA have been described 
      as being mediated via the estrogen receptor. Therefore, it was the aim of this 
      study to determine its tissue specific ERα- and ERβ-mediated estrogenic activity, 
      to investigate its antiestrogenic properties, and, particularly, to study 
      estrogen receptor-mediated biological responses to tanshinone IIA on skeletal 
      muscle cells. The purity of tanshinone IIA was analyzed by LC-DAD-MS/MS analysis. 
      ERα/ERβ-mediated activity was dose-dependently analyzed in HEK 239 cells 
      transfected with ERα or ERβ expression vectors and respective reporter genes. 
      Androgenic, antiandrogenic, and antiestrogenic properties of tanshinone IIA were 
      analyzed in a yeast reporter gene assay. The effects of tanshinone IIA on 
      proliferation and cell cycle distribution were investigated in ERα positive T47D 
      breast cancer cells. The ability of tanshinone IIA to stimulate estrogen 
      receptor-mediated myotube hypertrophy was studied in C2C12 myoblastoma cells. Our 
      data show that tanshinone IIA is quite potent at stimulating ERα and ERβ reporter 
      genes with comparable efficacy. Tanshinone IIA displayed antiestrogenic and also 
      antiandrogenic properties in a yeast reporter gene assay. It inhibited the growth 
      of T47D breast cancer cells by suppressing proliferation and arresting the cells 
      in G0/G1. Tanshinone IIA also stimulated the hypertrophy of C2C12 myotubes via an 
      estrogen receptor-mediated mechanism. Summarizing our results, tanshinone IIA can 
      be characterized as an estrogen receptor partial agonist with antiandrogenic 
      properties. It seems to inhibit ERα-mediated cell proliferation but induces 
      ERβ-related biological responses like hypertrophy of myotubes. These findings are 
      interesting with respect to the treatment of a variety of complains of 
      postmenopausal females, including muscle wasting.
CI  - Georg Thieme Verlag KG Stuttgart · New York.
FAU - Zhao, Piwen
AU  - Zhao P
AD  - School of Preclinical Medicine, Beijing University of Chinese Medicine, Beijing, 
      China.
FAU - Soukup, Sebastian Tobias
AU  - Soukup ST
AD  - Department of Safety and Quality of Fruit and Vegetables, Max Rubner-Institut, 
      Karlsruhe, Germany.
FAU - Hegevoss, Jonas
AU  - Hegevoss J
AD  - German Sport University, Cologne, Germany.
FAU - Ngueu, Sandrine
AU  - Ngueu S
AD  - German Sport University, Cologne, Germany.
FAU - Kulling, Sabine Emma
AU  - Kulling SE
AD  - Department of Safety and Quality of Fruit and Vegetables, Max Rubner-Institut, 
      Karlsruhe, Germany.
FAU - Diel, Patrick
AU  - Diel P
AD  - German Sport University, Cologne, Germany.
LA  - eng
PT  - Journal Article
DEP - 20150508
PL  - Germany
TA  - Planta Med
JT  - Planta medica
JID - 0066751
RN  - 0 (Abietanes)
RN  - 0 (Anabolic Agents)
RN  - 0 (Androgen Receptor Antagonists)
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Estrogen Antagonists)
RN  - 0 (Estrogen Receptor alpha)
RN  - 0 (Estrogen Receptor beta)
RN  - 0 (Estrogens)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Selective Estrogen Receptor Modulators)
RN  - 03UUH3J385 (tanshinone)
RN  - 1693AM5SBN (dan-shen root extract)
SB  - IM
MH  - Abietanes/*pharmacology/therapeutic use
MH  - Anabolic Agents/pharmacology/therapeutic use
MH  - Androgen Receptor Antagonists/pharmacology
MH  - Antineoplastic Agents, Phytogenic/pharmacology/therapeutic use
MH  - Breast Neoplasms/drug therapy/metabolism
MH  - Cell Line, Tumor
MH  - Drugs, Chinese Herbal/pharmacology/therapeutic use
MH  - Estrogen Antagonists/pharmacology/therapeutic use
MH  - Estrogen Receptor alpha/*metabolism
MH  - Estrogen Receptor beta/metabolism
MH  - Estrogens/*pharmacology/therapeutic use
MH  - HEK293 Cells
MH  - Humans
MH  - Hypertrophy
MH  - Muscle Fibers, Skeletal/*drug effects
MH  - Muscular Atrophy/*metabolism/prevention & control
MH  - Phytotherapy
MH  - Receptors, Estrogen/*metabolism
MH  - Salvia miltiorrhiza/*chemistry
MH  - Selective Estrogen Receptor Modulators/pharmacology/therapeutic use
EDAT- 2015/05/29 06:00
MHDA- 2016/03/15 06:00
CRDT- 2015/05/29 06:00
PHST- 2015/05/29 06:00 [entrez]
PHST- 2015/05/29 06:00 [pubmed]
PHST- 2016/03/15 06:00 [medline]
AID - 10.1055/s-0035-1545883 [doi]
PST - ppublish
SO  - Planta Med. 2015 May;81(7):578-85. doi: 10.1055/s-0035-1545883. Epub 2015 May 8.

PMID- 27543746
OWN - NLM
STAT- MEDLINE
DCOM- 20180201
LR  - 20250111
IS  - 1460-9568 (Electronic)
IS  - 0953-816X (Print)
IS  - 0953-816X (Linking)
VI  - 44
IP  - 8
DP  - 2016 Oct
TI  - Prenatal testosterone exposure decreases colocalization of insulin receptors in 
      kisspeptin/neurokinin B/dynorphin and agouti-related peptide neurons of the adult 
      ewe.
PG  - 2557-2568
LID - 10.1111/ejn.13373 [doi]
AB  - Insulin serves as a link between the metabolic and reproductive systems, 
      communicating energy availability to the hypothalamus and enabling reproductive 
      mechanisms. Adult Suffolk ewes prenatally exposed to testosterone (T) display an 
      array of reproductive and metabolic dysfunctions similar to those seen in women 
      with polycystic ovarian syndrome (PCOS), including insulin resistance. Moreover, 
      prenatal T treatment alters neuropeptide expression in KNDy (co-expressing 
      kisspeptin, neurokinin B/dynorphin) and agouti-related peptide (AgRP) neurons in 
      the arcuate nucleus, two populations that play key roles in the control of 
      reproduction and metabolism, respectively. In this study, we determined whether 
      prenatal T treatment also altered insulin receptors in KNDy and AgRP neurons, as 
      well as in preoptic area (POA) kisspeptin, pro-opiomelanocortin (POMC), and 
      gonadotropin-releasing hormone (GnRH) neurons of the adult sheep brain. 
      Immunofluorescent detection of the beta subunit of insulin receptor (IRβ) 
      revealed that KNDy, AgRP and POMC neurons, but not GnRH or POA kisspeptin 
      neurons, colocalize IRβ in control females. Moreover, prenatal T treatment 
      decreased the percentage of KNDy and AgRP neurons that colocalized IRβ, 
      consistent with reduced insulin sensitivity. Administration of the anti-androgen 
      drug, Flutamide, during prenatal T treatment, prevented the reduction in IRβ 
      colocalization in AgRP, but not in KNDy neurons, suggesting that these effects 
      are programmed by androgenic and oestrogenic actions, respectively. These 
      findings provide novel insight into the effects of prenatal T treatment on 
      hypothalamic insulin sensitivity and raise the possibility that decreased insulin 
      receptors, specifically within KNDy and AgRP neurons, may contribute to the 
      PCOS-like phenotype of this animal model.
CI  - © 2016 Federation of European Neuroscience Societies and John Wiley & Sons Ltd.
FAU - Cernea, Maria
AU  - Cernea M
AD  - Department of Neurobiology and Anatomical Sciences, The University of Mississippi 
      Medical Center, Jackson, MS, 39232, USA.
AD  - Department of Anatomy & Cell Biology, The University of Western Ontario, London, 
      Canada.
FAU - Phillips, Rebecca
AU  - Phillips R
AD  - Department of Neurobiology and Anatomical Sciences, The University of Mississippi 
      Medical Center, Jackson, MS, 39232, USA.
AD  - Department of Anatomy & Cell Biology, The University of Western Ontario, London, 
      Canada.
FAU - Padmanabhan, Vasantha
AU  - Padmanabhan V
AD  - Department of Obstetrics and Gynecology, Pediatrics, and Reproductive Sciences 
      Program, The University of Michigan, Ann Arbor, MI, USA.
FAU - Coolen, Lique M
AU  - Coolen LM
AD  - Department of Physiology and Biophysics, The University of Mississippi Medical 
      Center, Jackson, MS, USA.
FAU - Lehman, Michael N
AU  - Lehman MN
AD  - Department of Neurobiology and Anatomical Sciences, The University of Mississippi 
      Medical Center, Jackson, MS, 39232, USA. mlehman@umc.edu.
LA  - eng
GR  - P01 HD044232/HD/NICHD NIH HHS/United States
GR  - P30 DK020572/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20160914
PL  - France
TA  - Eur J Neurosci
JT  - The European journal of neuroscience
JID - 8918110
RN  - 0 (Kisspeptins)
RN  - 33515-09-2 (Gonadotropin-Releasing Hormone)
RN  - 3XMK78S47O (Testosterone)
RN  - 74913-18-1 (Dynorphins)
RN  - 86933-75-7 (Neurokinin B)
RN  - EC 2.7.10.1 (Receptor, Insulin)
SB  - IM
MH  - Aging
MH  - Animals
MH  - Arcuate Nucleus of Hypothalamus/drug effects
MH  - Dynorphins/*metabolism
MH  - Female
MH  - Gonadotropin-Releasing Hormone/metabolism
MH  - Hypothalamus/*drug effects/metabolism
MH  - Kisspeptins/*metabolism
MH  - Neurokinin B/*metabolism
MH  - Neurons/drug effects/metabolism
MH  - Receptor, Insulin/*drug effects/metabolism
MH  - Sheep
MH  - Testosterone/*pharmacology
PMC - PMC5067216
MID - NIHMS812125
OTO - NOTNLM
OT  - agouti-related peptide
OT  - insulin receptor
OT  - kisspeptin
OT  - polycystic ovarian syndrome
OT  - sheep
COIS- The authors have no no conflicts of interest to declare.
EDAT- 2016/08/21 06:00
MHDA- 2018/02/02 06:00
PMCR- 2017/10/01
CRDT- 2016/08/21 06:00
PHST- 2016/01/06 00:00 [received]
PHST- 2016/07/26 00:00 [revised]
PHST- 2016/08/17 00:00 [accepted]
PHST- 2016/08/21 06:00 [pubmed]
PHST- 2018/02/02 06:00 [medline]
PHST- 2016/08/21 06:00 [entrez]
PHST- 2017/10/01 00:00 [pmc-release]
AID - 10.1111/ejn.13373 [doi]
PST - ppublish
SO  - Eur J Neurosci. 2016 Oct;44(8):2557-2568. doi: 10.1111/ejn.13373. Epub 2016 Sep 
      14.

PMID- 27301406
OWN - NLM
STAT- MEDLINE
DCOM- 20170130
LR  - 20181113
IS  - 1756-0500 (Electronic)
IS  - 1756-0500 (Linking)
VI  - 9
DP  - 2016 Jun 14
TI  - A case report of QT prolongation with glycopyrronium bromide in a patient with 
      chronic tamoxifen use.
PG  - 310
LID - 10.1186/s13104-016-2105-4 [doi]
LID - 310
AB  - BACKGROUND: Glycopyrronium bromide has recently been approved as a once daily 
      maintenance inhalation therapy for moderate to severe chronic obstructive 
      pulmonary disease (COPD). Efficacy and safety trial data have found rare cases of 
      significant QT prolongation. To our knowledge, we describe the first case report 
      of QT prolongation >600 ms with initiation of glycopyrronium bromide in a real 
      world setting. CASE PRESENTATION: A 78-year-old female with moderate COPD 
      recently started on glycopyrronium bromide, presented to Emergency Department 
      (ED) with syncope. Her past medical history was significant for a left total 
      mastectomy and she had been on Tamoxifen for 9 months. One day prior to her 
      presentation, she had visited a naturopathic clinic for a vitamin infusion 
      resulting in emesis. The following day she continued to feel dizzy and had a 
      witnessed syncopal episode without any reported cardiac or neurological symptoms 
      preceding the event or after regaining consciousness. In the emergency 
      department, she reported dizziness and was found to be hypotensive. Her symptoms 
      completely resolved with intravenous fluids. Lab work was normal however her 
      electrocardiogram (ECG) demonstrated a QTc interval of 603 and 631 ms (Friderica 
      and Bazett's respectively) with a normal QT interval on her baseline ECG prior to 
      initiating Tamoxifen. She was admitted to the Cardiology service for further 
      work-up of QT prolongation. Her syncope was felt to be due to orthostatic 
      hypotension and the QT prolongation secondary to medications, which were both 
      discontinued during her admission. After 2 days, her QT interval normalized 
      consistent with the half-life of Glycopyrronium bromide (13-57 h) compared to 
      Tamoxifen (8-14 days). CONCLUSION: Glycopyrronium bromide is guideline 
      recommended as first line therapy for prevention of exacerbation in moderate to 
      severe COPD however safety data had been limited to select populations. This case 
      report highlights the need for future studies to identify high-risk populations 
      at potential risk of life-threatening arrhythmias who may benefit from periodic 
      ECG surveillance.
FAU - Chiu, Michael H
AU  - Chiu MH
AD  - Division of Cardiology, Libin Cardiovascular Institute, University of Calgary, 
      Calgary, AB, Canada.
FAU - Al-Majed, Nawaf S
AU  - Al-Majed NS
AD  - Division of Cardiology, University of Alberta, Edmonton, AB, Canada.
FAU - Stubbins, Ryan
AU  - Stubbins R
AD  - Department of Internal Medicine, Faculty of Medicine, University of Alberta, 
      Edmonton, AB, Canada.
FAU - Pollmann, Dylan
AU  - Pollmann D
AD  - Department of Pharmacy, Mazankowski Alberta Heart Institute, University of 
      Alberta, Edmonton, AB, Canada.
FAU - Sandhu, Roopinder K
AU  - Sandhu RK
AD  - Division of Cardiology, University of Alberta, Edmonton, AB, Canada. 
      rsandhu2@ualberta.ca.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20160614
PL  - England
TA  - BMC Res Notes
JT  - BMC research notes
JID - 101462768
RN  - 0 (Muscarinic Antagonists)
RN  - 0 (Selective Estrogen Receptor Modulators)
RN  - 094ZI81Y45 (Tamoxifen)
RN  - V92SO9WP2I (Glycopyrrolate)
SB  - IM
MH  - Administration, Inhalation
MH  - Aged
MH  - Electrocardiography
MH  - Female
MH  - Glycopyrrolate/administration & dosage/*adverse effects
MH  - Humans
MH  - Long QT Syndrome/chemically induced/*diagnosis
MH  - Muscarinic Antagonists/administration & dosage/adverse effects
MH  - Pulmonary Disease, Chronic Obstructive/drug therapy
MH  - Selective Estrogen Receptor Modulators/adverse effects
MH  - Syncope/chemically induced/*diagnosis
MH  - Tamoxifen/*adverse effects
PMC - PMC4908703
OTO - NOTNLM
OT  - Chronic obstructive pulmonary disease
OT  - Glycopyrronium bromide (Seebri)
OT  - NVA237
OT  - QT prolongation
EDAT- 2016/06/16 06:00
MHDA- 2017/01/31 06:00
PMCR- 2016/06/14
CRDT- 2016/06/16 06:00
PHST- 2015/11/27 00:00 [received]
PHST- 2016/05/31 00:00 [accepted]
PHST- 2016/06/16 06:00 [entrez]
PHST- 2016/06/16 06:00 [pubmed]
PHST- 2017/01/31 06:00 [medline]
PHST- 2016/06/14 00:00 [pmc-release]
AID - 10.1186/s13104-016-2105-4 [pii]
AID - 2105 [pii]
AID - 10.1186/s13104-016-2105-4 [doi]
PST - epublish
SO  - BMC Res Notes. 2016 Jun 14;9:310. doi: 10.1186/s13104-016-2105-4.

PMID- 29883867
OWN - NLM
STAT- MEDLINE
DCOM- 20180907
LR  - 20250103
IS  - 1879-1298 (Electronic)
IS  - 0045-6535 (Linking)
VI  - 208
DP  - 2018 Oct
TI  - Efficient catalytic degradation of bisphenol A by novel Fe(0)- vermiculite 
      composite in photo-Fenton system: Mechanism and effect of iron oxide shell.
PG  - 335-342
LID - S0045-6535(18)31081-6 [pii]
LID - 10.1016/j.chemosphere.2018.06.008 [doi]
AB  - Novel Fe(0)-vermiculite (Fe-Ver-C-H(2)) composite was synthesized by thermal 
      reduction and acted as catalysts to remove bisphenol A (BPA) in photo-Fenton 
      system. In term of activation ability toward H(2)O(2), separation ability and 
      stability, Fe-Ver-C-H(2) presented obvious advantages over other kinds of 
      Fe(0)-vermiculite composite (Fe-Ver-NaBH(4)), which obtained by traditional 
      liquid reduction. The reason was that iron oxide shells on the surface of Fe(0) 
      were α-Fe(2)O(3) and Fe(3)O(4) for Fe-Ver-NaBH(4) and Fe-Ver-C-H(2), 
      respectively. And for Fe-Ver-C-H(2), the synergistic effect between iron core 
      (Fe(0)) and iron oxide shell (Fe(3)O(4)) is beneficial to catalytic performance. 
      The mechanism and plausible pathway of BPA degradation were also proposed 
      according to the results of radical scavenger studies and gas chromatography-mass 
      spectrometry (GC-MS), respectively. In addition, factorial effects for 
      Fe-Ver-C-H(2) in photo-Fenton system were also investigated and optimized as: pH 
      of 5, dosage of 0.2 g L(-1) and H(2)O(2) concentration of 20 mM. This study 
      presented a facile method to synthesize novel Fe(0)-vermiculite composite and 
      provided a new sight to investigate the effect of iron oxide shell on the 
      catalytic performance when Fe(0)-vermiculite composite acted as catalyst to 
      remove contaminants from the environment in photo-Fenton system.
CI  - Copyright © 2018 Elsevier Ltd. All rights reserved.
FAU - Yang, Shanshan
AU  - Yang S
AD  - School of Environment and Energy, South China University of Technology, 
      Guangzhou, 510006, PR China.
FAU - Wu, Pingxiao
AU  - Wu P
AD  - School of Environment and Energy, South China University of Technology, 
      Guangzhou, 510006, PR China; Guangdong Provincial Engineering and Technology 
      Research Center for Environmental Risk Prevention and Emergency Disposal, South 
      China University of Technology, Guangzhou, 510006, PR China; Guangdong 
      Environmental Protection Key Laboratory of Solid Waste Treatment and Recycling, 
      Guangzhou, 510006, PR China; Guangdong Engineering and Technology Research Center 
      for Environmental Nanomaterials, Guangzhou, 510006, China. Electronic address: 
      pppxwu@scut.edu.cn.
FAU - Ye, Quanyun
AU  - Ye Q
AD  - School of Environment and Energy, South China University of Technology, 
      Guangzhou, 510006, PR China.
FAU - Li, Wen
AU  - Li W
AD  - Guangdong Polytechnic of Environmental Protection Engineering, Foshan, Guangdong, 
      528216, PR China.
FAU - Chen, Meiqing
AU  - Chen M
AD  - School of Environment and Energy, South China University of Technology, 
      Guangzhou, 510006, PR China.
FAU - Zhu, Nengwu
AU  - Zhu N
AD  - School of Environment and Energy, South China University of Technology, 
      Guangzhou, 510006, PR China; Guangdong Environmental Protection Key Laboratory of 
      Solid Waste Treatment and Recycling, Guangzhou, 510006, PR China.
LA  - eng
PT  - Journal Article
DEP - 20180602
PL  - England
TA  - Chemosphere
JT  - Chemosphere
JID - 0320657
RN  - 0 (Aluminum Silicates)
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Fenton's reagent)
RN  - 0 (Ferric Compounds)
RN  - 0 (Phenols)
RN  - 1318-00-9 (vermiculite)
RN  - 1K09F3G675 (ferric oxide)
RN  - BBX060AN9V (Hydrogen Peroxide)
RN  - E1UOL152H7 (Iron)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - Aluminum Silicates/*chemistry
MH  - Benzhydryl Compounds/analysis/*chemistry
MH  - Catalysis
MH  - Ferric Compounds/*chemistry
MH  - Hydrogen Peroxide/*chemistry
MH  - Iron/*chemistry
MH  - Oxidation-Reduction
MH  - Phenols/analysis/*chemistry
MH  - Photolysis
OTO - NOTNLM
OT  - BPA
OT  - Iron oxide shell
OT  - Photo-Fenton
OT  - Vermiculite
OT  - Zero-valent iron
EDAT- 2018/06/09 06:00
MHDA- 2018/09/08 06:00
CRDT- 2018/06/09 06:00
PHST- 2018/01/20 00:00 [received]
PHST- 2018/05/24 00:00 [revised]
PHST- 2018/06/02 00:00 [accepted]
PHST- 2018/06/09 06:00 [pubmed]
PHST- 2018/09/08 06:00 [medline]
PHST- 2018/06/09 06:00 [entrez]
AID - S0045-6535(18)31081-6 [pii]
AID - 10.1016/j.chemosphere.2018.06.008 [doi]
PST - ppublish
SO  - Chemosphere. 2018 Oct;208:335-342. doi: 10.1016/j.chemosphere.2018.06.008. Epub 
      2018 Jun 2.

PMID- 30127828
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1735-0328 (Print)
IS  - 1726-6890 (Electronic)
IS  - 1726-6882 (Linking)
VI  - 17
IP  - 3
DP  - 2018 Summer
TI  - Ethyl Acetate Extract of Licorice Root (Glycyrrhiza glabra) Enhances 
      Proliferation and Osteogenic Differentiation of Human Bone Marrow Mesenchymal 
      Stem Cells.
PG  - 1057-1067
AB  - Glycyrrhiza glabra (G. glabra) has been used as a flavoring and sweetener agent, 
      in addition to its therapeutic properties. It is rich in phytoestrogen and may 
      prevent osteoporosis caused by estrogen deficiency; however, there is no evidence 
      for its effects on proliferation and osteogenesis in mesenchymal stem cells. So, 
      we were encouraged to investigate whether the ethyl acetate extract of licorice 
      root as a source of phytoestrogen can act similar to estrogen in cell culture. 
      Furthermore, the analysis of the licorice extract (LE) based on HPLC-DAD-ESI-MS 
      indicated that LE comprises phytoestrogen compounds, such as glabridin and 
      glabrene. In this study, the effects of LE on proliferation of human bone-marrow 
      mesenchymal stem cells (hBM-MSCs) were investigated using MTT assay. In addition, 
      its effects on the osteogenesis were evaluated using alkaline phosphatase 
      activity (ALP), calcium deposition, and bone specific gene expression such as 
      ALP, osteocalcin, Runx2, and BMP-2. The quantitative gene expression was studied 
      by real-time RT-PCR. Our results showed a significant increase in proliferation 
      in presence of LE in concentration 10-50 µg/mL. The differentiation of hBM-MSCs 
      increased in doses of LE (10-25 µg/mL) compared to the control group. The effects 
      of LE were similar to those of 17β-estradiol (E2) (10(-8) M) and were abolished 
      by ICI 182,780 an antagonist of estrogen receptor (ER) (10(-7)), indicating that 
      the stimulatory effects of LE occur through estrogen receptor-mediated mechanism 
      . Taking these into account, LE may be a potential candidate for prevention of 
      osteoporosis in menopausal women.
FAU - Azizsoltani, Arezou
AU  - Azizsoltani A
AD  - Department of Biotechnology, Faculty of Agriculture, Bu-Ali Sina University, 
      Hamedan, Iran.
AD  - Department of Medical Biotechnology, Faculty of Advanced Sciences, Tabriz 
      University of Medical Sciences, Tabriz, Iran.
FAU - Piri, Khosro
AU  - Piri K
AD  - Department of Biotechnology, Faculty of Agriculture, Bu-Ali Sina University, 
      Hamedan, Iran.
FAU - Behzad, Sahar
AU  - Behzad S
AD  - Department of Pharmacognosy, School of Pharmacy, Shahid Beheshti University of 
      Medical Sciences, Tehran, Iran.
AD  - Evidence-based Phytotherapy and Complementary Medicine Research Center, Alborz 
      University of Medical Sciences, Karaj, Iran.
FAU - Soleimani, Masoud
AU  - Soleimani M
AD  - Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares 
      University, Tehran, Iran.
FAU - Nekouei, Mina
AU  - Nekouei M
AD  - Department of Phytochemistry, Medicinal Plants and Drug Research Institute, 
      Shahid Beheshti University, Tehran, Iran.
FAU - Mahmoudi, Zahra
AU  - Mahmoudi Z
AD  - Department of Life Science Engineering, Faculty of New Science and Technologies, 
      University of Tehran, Tehran, Iran.
FAU - Kazemi, Asad
AU  - Kazemi A
AD  - Department of Biology, Faculty of Sciences, University of Mohaghegh Ardabili, 
      Ardabil, Iran.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Iran J Pharm Res
JT  - Iranian journal of pharmaceutical research : IJPR
JID - 101208407
PMC - PMC6094414
OTO - NOTNLM
OT  - Differentiation
OT  - Fabaceae
OT  - Glycyrrhiza glabra
OT  - Mesenchymal stem cell
OT  - Osteoporosis
OT  - Phytoestrogen
EDAT- 2018/08/22 06:00
MHDA- 2018/08/22 06:01
PMCR- 2018/06/01
CRDT- 2018/08/22 06:00
PHST- 2018/08/22 06:00 [entrez]
PHST- 2018/08/22 06:00 [pubmed]
PHST- 2018/08/22 06:01 [medline]
PHST- 2018/06/01 00:00 [pmc-release]
AID - ijpr-17-1057 [pii]
PST - ppublish
SO  - Iran J Pharm Res. 2018 Summer;17(3):1057-1067.

PMID- 26873198
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20250103
IS  - 1618-2650 (Electronic)
IS  - 1618-2642 (Linking)
VI  - 408
IP  - 10
DP  - 2016 Apr
TI  - Simultaneous determination of urinary parabens, bisphenol A, triclosan, and 
      8-hydroxy-2'-deoxyguanosine by liquid chromatography coupled with electrospray 
      ionization tandem mass spectrometry.
PG  - 2621-9
LID - 10.1007/s00216-016-9372-8 [doi]
AB  - A simple and fast method was developed for the simultaneous determination of five 
      parabens, bisphenol A (BPA), triclosan (TCS), and 8-hydroxy-2'-deoxyguanosine 
      (8-OHdG) in human urine using liquid chromatography coupled with electrospray 
      ionization tandem mass spectrometry (LC-ESI-MS/MS). The solid-phase extraction 
      (SPE) procedure, chromatographic conditions, and MS/MS parameters were optimized 
      to achieve maximum sensitivity and accuracy for the analytes. The validation 
      results showed that the correlation coefficients (R (2)) and recoveries ranged 
      from 0.999 to 1 and 83.9 to 109.9 %, respectively, and the intra-day and 
      inter-day precisions (relative standard deviation, RSD) were within the range of 
      1.3-8.5 % and 1.3-9.0 %, respectively. The limits of detection for the analytes 
      ranged from 0.001 to 0.05 μg/L. The method was successfully employed to determine 
      parabens, BPA, TCS, and 8-OHdG in urine samples from school students in 
      Guangzhou, China. The results showed that methyl, ethyl, n-propyl parabens, BPA, 
      TCS, and 8-OHdG were frequently detected in urine samples. n-Butyl and benzyl 
      parabens were only detected in a part of the samples due to their low 
      concentrations in urine.
FAU - Ren, Lu
AU  - Ren L
AD  - School of Chemistry and Environment, South China Normal University, Guangzhou, 
      Guangdong, 510006, China.
FAU - Fang, Jianzhang
AU  - Fang J
AD  - School of Chemistry and Environment, South China Normal University, Guangzhou, 
      Guangdong, 510006, China.
FAU - Liu, Guihua
AU  - Liu G
AD  - Shenzhen Center for Disease Control and Prevention, Shenzhen, Guangdong, 518055, 
      China.
FAU - Zhang, Jianqing
AU  - Zhang J
AD  - Shenzhen Center for Disease Control and Prevention, Shenzhen, Guangdong, 518055, 
      China.
FAU - Zhu, Zhou
AU  - Zhu Z
AD  - Shenzhen Center for Disease Control and Prevention, Shenzhen, Guangdong, 518055, 
      China.
FAU - Liu, Honghe
AU  - Liu H
AD  - Shenzhen Center for Disease Control and Prevention, Shenzhen, Guangdong, 518055, 
      China.
FAU - Lin, Kai
AU  - Lin K
AD  - Shenzhen Center for Disease Control and Prevention, Shenzhen, Guangdong, 518055, 
      China.
FAU - Zhang, Huimin
AU  - Zhang H
AD  - Shenzhen Center for Disease Control and Prevention, Shenzhen, Guangdong, 518055, 
      China.
FAU - Lu, Shaoyou
AU  - Lu S
AD  - Shenzhen Center for Disease Control and Prevention, Shenzhen, Guangdong, 518055, 
      China. lushaoyou2005@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Validation Study
DEP - 20160212
PL  - Germany
TA  - Anal Bioanal Chem
JT  - Analytical and bioanalytical chemistry
JID - 101134327
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Parabens)
RN  - 0 (Phenols)
RN  - 88847-89-6 (8-Hydroxy-2'-Deoxyguanosine)
RN  - G9481N71RO (Deoxyguanosine)
RN  - RW57K3X12M (bisphenol A)
SB  - IM
MH  - 8-Hydroxy-2'-Deoxyguanosine
MH  - Benzhydryl Compounds/*urine
MH  - Chromatography, Liquid/*methods
MH  - Deoxyguanosine/*analogs & derivatives/urine
MH  - Humans
MH  - Limit of Detection
MH  - Parabens/*analysis
MH  - Phenols/*urine
MH  - Spectrometry, Mass, Electrospray Ionization/*methods
MH  - Tandem Mass Spectrometry/*methods
OTO - NOTNLM
OT  - 8-Hydroxy-2′-deoxyguanosine
OT  - Bisphenol A
OT  - Parabens
OT  - Triclosan
OT  - Urine
EDAT- 2016/02/14 06:00
MHDA- 2016/12/15 06:00
CRDT- 2016/02/14 06:00
PHST- 2015/11/12 00:00 [received]
PHST- 2016/01/27 00:00 [accepted]
PHST- 2016/01/20 00:00 [revised]
PHST- 2016/02/14 06:00 [entrez]
PHST- 2016/02/14 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - 10.1007/s00216-016-9372-8 [pii]
AID - 10.1007/s00216-016-9372-8 [doi]
PST - ppublish
SO  - Anal Bioanal Chem. 2016 Apr;408(10):2621-9. doi: 10.1007/s00216-016-9372-8. Epub 
      2016 Feb 12.

PMID- 26972555
OWN - NLM
STAT- MEDLINE
DCOM- 20160816
LR  - 20160404
IS  - 1879-1220 (Electronic)
IS  - 0960-0760 (Linking)
VI  - 159
DP  - 2016 May
TI  - Serum steroid concentrations remain within normal postmenopausal values in women 
      receiving daily 6.5mg intravaginal prasterone for 12 weeks.
PG  - 142-53
LID - S0960-0760(16)30062-0 [pii]
LID - 10.1016/j.jsbmb.2016.03.016 [doi]
AB  - This study integrates all data obtained in women aged 40-80years enrolled with 
      moderate to severe symptoms of vulvovaginal atrophy (VVA) who received daily 
      intravaginal administration of 0.50% (6.5mg) dehydroepiandrosterone (DHEA; 
      prasterone) for 12weeks (n=723; ITT-S population) as compared with placebo 
      (n=266; ITT-S population). To this end, serum steroid levels (DHEA, DHEA-sulfate 
      (DHEA-S), androst-5-ene-3β, 17β-diol (5-diol), testosterone, dihydrotestosterone 
      (DHT), androstenedione (4-dione), estrone (E1), estradiol (E2), estrone sulfate 
      (E1-S), androsterone glucuronide (ADT-G), and androstane-3α, 17β-diol 
      17-glucuronide (3α-diol-17G)) were measured at Day 1 and Week 12 by liquid 
      chromatography-tandem mass spectrometry (LC-MS/MS) following validation performed 
      according to the FDA guidelines [1-6]. In agreement with the mechanisms of 
      intracrinology where DHEA is exclusively transformed intracellularly into active 
      sex steroids which act and are inactivated locally before being released as 
      glucuronided or sulfated metabolites for elimination by the kidneys and liver, 
      all sex steroids remained well within normal postmenopausal values following 
      administration of intravaginal DHEA. Serum estradiol, the most relevant sex 
      steroid, was measured after 12weeks of treatment at 3.36pg/ml (cITT-S population) 
      or 19% below the normal postmenopausal value of 4.17pg/ml. On the other hand, 
      serum E1-S, the best recognized marker of global estrogenic activity, shows an 
      average value of 209pg/ml at 12 weeks compared to 220pg/ml in normal 
      postmenopausal women. Moreover, serum ADT-G, the main metabolite of androgens, 
      also remains well within normal postmenopausal values. The present data shows 
      that a low daily intravaginal dose (6.5mg) of DHEA (prasterone) which is 
      efficacious on the symptoms and signs of VVA, permits to achieve the desired 
      local efficacy without systemic exposure, in agreement with the stringent 
      mechanisms of menopause established after 500 million years of evolution where 
      each cell in each tissue is the master of its sex steroid exposure.
CI  - Copyright © 2016 Elsevier Ltd. All rights reserved.
FAU - Martel, Céline
AU  - Martel C
AD  - EndoCeutics Inc., Quebec City, QC G1V 4M7, Canada.
FAU - Labrie, Fernand
AU  - Labrie F
AD  - EndoCeutics Inc., Quebec City, QC G1V 4M7, Canada. Electronic address: 
      fernand.labrie@endoceutics.com.
FAU - Archer, David F
AU  - Archer DF
AD  - CONRAD Clinical Research Center, Norfolk, VA, USA.
FAU - Ke, Yuyong
AU  - Ke Y
AD  - EndoCeutics Inc., Quebec City, QC G1V 4M7, Canada.
FAU - Gonthier, Renaud
AU  - Gonthier R
AD  - EndoCeutics Inc., Quebec City, QC G1V 4M7, Canada.
FAU - Simard, Jean-Nicolas
AU  - Simard JN
AD  - EndoCeutics Inc., Quebec City, QC G1V 4M7, Canada.
FAU - Lavoie, Lyne
AU  - Lavoie L
AD  - EndoCeutics Inc., Quebec City, QC G1V 4M7, Canada.
FAU - Vaillancourt, Mario
AU  - Vaillancourt M
AD  - EndoCeutics Inc., Quebec City, QC G1V 4M7, Canada.
FAU - Montesino, Marlene
AU  - Montesino M
AD  - EndoCeutics Inc., Quebec City, QC G1V 4M7, Canada.
FAU - Balser, John
AU  - Balser J
AD  - Veristat, Southborough, MA, USA.
FAU - Moyneur, Érick
AU  - Moyneur É
AD  - StatLog Consulting Inc., Quebec, QC, Canada.
CN  - other participating members of the Prasterone Clinical Research Group
LA  - eng
PT  - Journal Article
DEP - 20160310
PL  - England
TA  - J Steroid Biochem Mol Biol
JT  - The Journal of steroid biochemistry and molecular biology
JID - 9015483
RN  - 3XMK78S47O (Testosterone)
RN  - 459AG36T1B (Dehydroepiandrosterone)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Administration, Intravaginal
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Atrophy/drug therapy
MH  - Dehydroepiandrosterone/*administration & dosage/pharmacokinetics
MH  - Estradiol/*blood
MH  - Female
MH  - Hormone Replacement Therapy
MH  - Humans
MH  - Middle Aged
MH  - Postmenopause/*blood
MH  - Testosterone/*blood
MH  - Vaginal Diseases/*drug therapy
OTO - NOTNLM
OT  - Androgens
OT  - Dehydroepiandrosterone (DHEA)
OT  - Estradiol
OT  - Menopause
OT  - Prasterone
OT  - Vulvovaginal atrophy
FIR - Ackerman, Ronald T
IR  - Ackerman RT
FIR - Andruczyk, Eugene
IR  - Andruczyk E
FIR - Aqua, Keith A
IR  - Aqua KA
FIR - Ayotte, Normand
IR  - Ayotte N
FIR - Bachmann, Gloria A
IR  - Bachmann GA
FIR - Balk, Judith
IR  - Balk J
FIR - Baron, Mira
IR  - Baron M
FIR - Belisle, Serge
IR  - Belisle S
FIR - Belle-Isle, Jasmin
IR  - Belle-Isle J
FIR - Benoit, Gervais
IR  - Benoit G
FIR - Berg, Saul
IR  - Berg S
FIR - Beyer, Roger
IR  - Beyer R
FIR - Blank, Stephen
IR  - Blank S
FIR - Blouin, François
IR  - Blouin F
FIR - Bouchard, Céline
IR  - Bouchard C
FIR - Chavoustie, Steven E
IR  - Chavoustie SE
FIR - Cooper, Theodore A
IR  - Cooper TA
FIR - Cusan, Leonello
IR  - Cusan L
FIR - Derogatis, Leonard R
IR  - Derogatis LR
FIR - Donovan, Arthur
IR  - Donovan A
FIR - Drosman, Steven
IR  - Drosman S
FIR - Eder, Scott E
IR  - Eder SE
FIR - Elfassi, Emile
IR  - Elfassi E
FIR - Eubank, Charles Dale
IR  - Eubank CD
FIR - Fikry, Sameh
IR  - Fikry S
FIR - Frenette, Louise
IR  - Frenette L
FIR - Gallagher, John Christopher
IR  - Gallagher JC
FIR - Gangestad, Angelina
IR  - Gangestad A
FIR - Giguère, Nicole
IR  - Giguère N
FIR - Gilbert, Lucy
IR  - Gilbert L
FIR - Girard, Ginette
IR  - Girard G
FIR - Goldberg, Cynthia C
IR  - Goldberg CC
FIR - Goldstein, Irwin
IR  - Goldstein I
FIR - Goldstein, Steven R
IR  - Goldstein SR
FIR - Grainger, David A
IR  - Grainger DA
FIR - Hauck, Brian A
IR  - Hauck BA
FIR - Janzen, Jeannette
IR  - Janzen J
FIR - Kaunitz, Andrew
IR  - Kaunitz A
FIR - Khaled, Abdelmoula
IR  - Khaled A
FIR - Kirstein, Judith
IR  - Kirstein J
FIR - Koltun, William
IR  - Koltun W
FIR - Komer, Lawrence D
IR  - Komer LD
FIR - Kroll, Robin
IR  - Kroll R
FIR - Lederman, Samuel N
IR  - Lederman SN
FIR - Levine, Bruce J
IR  - Levine BJ
FIR - Levine, Stephen B
IR  - Levine SB
FIR - London, Andrew
IR  - London A
FIR - Lukes, Andrea S
IR  - Lukes AS
FIR - Martens, Mark
IR  - Martens M
FIR - McClinton, Joe
IR  - McClinton J
FIR - Moreau, Michelle
IR  - Moreau M
FIR - O' Mahony, Michael F J
IR  - O' Mahony MF
FIR - O' Mahony, William F
IR  - O' Mahony WF
FIR - Pinkerton, JoAnn
IR  - Pinkerton J
FIR - Poindexter, Alfred 3rd
IR  - Poindexter A 3rd
FIR - Portman, David J
IR  - Portman DJ
FIR - Rice, James
IR  - Rice J
FIR - Simon, James A
IR  - Simon JA
FIR - Sussman, Steven
IR  - Sussman S
FIR - Swanson, Stephen G
IR  - Swanson SG
FIR - Thériault, Guy
IR  - Thériault G
FIR - Thomas, Michael
IR  - Thomas M
FIR - Turner, Mark
IR  - Turner M
FIR - Upp, Linda
IR  - Upp L
FIR - Vachon, Andrée
IR  - Vachon A
FIR - Varano, Susann
IR  - Varano S
FIR - Wade, Anthony
IR  - Wade A
FIR - Waldbaum, Arthur S
IR  - Waldbaum AS
FIR - Weisz, Alla
IR  - Weisz A
FIR - Wine, Alan
IR  - Wine A
FIR - Young, Douglas
IR  - Young D
EDAT- 2016/03/15 06:00
MHDA- 2016/08/17 06:00
CRDT- 2016/03/15 06:00
PHST- 2015/12/10 00:00 [received]
PHST- 2016/02/10 00:00 [revised]
PHST- 2016/03/09 00:00 [accepted]
PHST- 2016/03/15 06:00 [entrez]
PHST- 2016/03/15 06:00 [pubmed]
PHST- 2016/08/17 06:00 [medline]
AID - S0960-0760(16)30062-0 [pii]
AID - 10.1016/j.jsbmb.2016.03.016 [doi]
PST - ppublish
SO  - J Steroid Biochem Mol Biol. 2016 May;159:142-53. doi: 
      10.1016/j.jsbmb.2016.03.016. Epub 2016 Mar 10.

PMID- 39855825
OWN - NLM
STAT- MEDLINE
DCOM- 20250124
LR  - 20250124
IS  - 1875-5364 (Electronic)
IS  - 1875-5364 (Linking)
VI  - 23
IP  - 1
DP  - 2025 Jan
TI  - Tianxiangdan (TXD) alleviates myocardial ischemia reperfusion-induced ferroptosis 
      through the activation of estrogen receptor alpha (ERα).
PG  - 102-110
LID - S1875-5364(25)60811-9 [pii]
LID - 10.1016/S1875-5364(25)60811-9 [doi]
AB  - Tianxiangdan (TXD), a traditional Chinese herbal remedy, demonstrates efficacy in 
      mitigating myocardial ischemia-reperfusion (I/R)-induced damage. This study 
      employed network pharmacology to evaluate the therapeutic targets and mechanisms 
      of TXD in treating I/R. High-performance liquid chromatography-mass spectrometry 
      (HPLC-MS) identified 86 compounds in TXD. Network pharmacological analysis 
      predicted potential target genes and their modes of action. Cardiac function, 
      ischaemic ST changes, lactate dehydrogenase (LDH), malondialdehyde (MDA), 
      superoxide dismutase (SOD) activity, myocardial fiber, and infarct size were 
      assessed using in vivo and in vitro I/R injury models. Estrogen receptor alpha 
      (ERα) protein expression and estradiol (E2) levels were measured to confirm TXD's 
      impact on estrogen levels and ERα expression. To examine if TXD reduces I/R 
      injury through ERα, an AZD group (300 nmol·L(-1) AZD9496 and 15% TXD serum) was 
      compared to a TXD group (15% TXD serum). The study hypothesized that TXD 
      upregulates the ERα-mediated iron metamorphosis pathway. I/R injury-induced 
      ferroptosis was identified using a Fer-1 group (1.0 μmol·L(-1) Fer-1 and 15% TXD 
      serum) to elucidate the potential association between ferroptosis and ERα 
      proteins. A DCFH-DA probe detected reactive oxygen species (ROS) and Fe(2+), 
      while Western blotting assessed target protein expression. Both in vitro and in 
      vivo experiments demonstrated that TXD attenuated I/R injury by reducing elevated 
      ST-segment levels, improving cardiac injury biomarkers (LDH, MDA, and SOD), 
      alleviating pathological features, and preventing I/R-induced loss of cell 
      viability in vitro. The effects and mechanisms of TXD on I/R injury-associated 
      ferroptosis were investigated using I/R-induced H9c2 cells. The TXD group showed 
      significantly decreased ROS and Fe(2+) levels, while the AZ group (treated with 
      AZD9496) exhibited increased levels. The TXD group demonstrated enhanced 
      expression of ERα and glutathione peroxidase 4 (GPX4), with reduced levels of P53 
      protein and ferritin-heavy polypeptide 1 (FTH1). The AZ group exhibited 
      contrasting effects on these expression levels. The literature indicated a novel 
      connection between ERα and ferroptosis. TXD activates the ERα signaling pathway, 
      promoting protection against I/R-induced myocardial cell ferroptosis. This study 
      provides evidence supporting TXD use for myocardial ischemia treatment, 
      particularly in older female patients who may benefit from its therapeutic 
      outcomes.
CI  - Copyright © 2025 China Pharmaceutical University. Published by Elsevier B.V. All 
      rights reserved.
FAU - Yue, Yuanjia
AU  - Yue Y
AD  - Department of Pharmacy, The Fourth College of Clinical Medicine, Xinjiang Medical 
      University, Urumqi 830000, China; Department of Pharmacy, Xinjiang Uygur 
      Autonomous Region Hospital of Traditional Chinese Medicine, Urumqi 830000, China; 
      State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence 
      Diseases in Central Asia, Xinjiang Medical University, Urumqi 830000, China.
FAU - Li, Yu
AU  - Li Y
AD  - Department of Neurosurgery ICU, Xinjiang Uygur Autonomous Region People's 
      Hospital, Urumqi, 830000, China.
FAU - Rong, Xing
AU  - Rong X
AD  - Department of Pharmacy, The Fourth College of Clinical Medicine, Xinjiang Medical 
      University, Urumqi 830000, China.
FAU - Ji, Zhao
AU  - Ji Z
AD  - Department of Pharmacy, The Fourth College of Clinical Medicine, Xinjiang Medical 
      University, Urumqi 830000, China.
FAU - Wang, Huimin
AU  - Wang H
AD  - Department of Pharmacy, The Fourth College of Clinical Medicine, Xinjiang Medical 
      University, Urumqi 830000, China.
FAU - Chen, Liang
AU  - Chen L
AD  - Department of Pharmacy, The Fourth College of Clinical Medicine, Xinjiang Medical 
      University, Urumqi 830000, China; Department of Pharmacy, Xinjiang Uygur 
      Autonomous Region Hospital of Traditional Chinese Medicine, Urumqi 830000, China.
FAU - Jiang, Lin
AU  - Jiang L
AD  - Department of Pharmacy, The Fourth College of Clinical Medicine, Xinjiang Medical 
      University, Urumqi 830000, China; Department of Pharmacy, Xinjiang Uygur 
      Autonomous Region Hospital of Traditional Chinese Medicine, Urumqi 830000, China. 
      Electronic address: 597900175@qq.com.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Chin J Nat Med
JT  - Chinese journal of natural medicines
JID - 101504416
RN  - 0 (Estrogen Receptor alpha)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 4TI98Z838E (Estradiol)
RN  - 0 (Reactive Oxygen Species)
SB  - IM
MH  - *Ferroptosis/drug effects
MH  - Animals
MH  - *Estrogen Receptor alpha/metabolism/genetics
MH  - *Myocardial Reperfusion Injury/drug therapy/metabolism
MH  - *Drugs, Chinese Herbal/pharmacology
MH  - Male
MH  - Mice
MH  - Humans
MH  - Myocytes, Cardiac/drug effects/metabolism
MH  - Estradiol/pharmacology
MH  - Reactive Oxygen Species/metabolism
OTO - NOTNLM
OT  - Estrogen receptor alpha
OT  - Ferroptosis
OT  - Myocardial ischemia-reperfusion injury
OT  - Network pharmacology
OT  - Tianxiangdan
EDAT- 2025/01/25 13:53
MHDA- 2025/01/25 13:54
CRDT- 2025/01/24 21:00
PHST- 2024/03/29 00:00 [received]
PHST- 2024/05/14 00:00 [revised]
PHST- 2024/07/01 00:00 [accepted]
PHST- 2025/01/25 13:54 [medline]
PHST- 2025/01/25 13:53 [pubmed]
PHST- 2025/01/24 21:00 [entrez]
AID - S1875-5364(25)60811-9 [pii]
AID - 10.1016/S1875-5364(25)60811-9 [doi]
PST - ppublish
SO  - Chin J Nat Med. 2025 Jan;23(1):102-110. doi: 10.1016/S1875-5364(25)60811-9.

PMID- 39864850
OWN - NLM
STAT- MEDLINE
DCOM- 20250126
LR  - 20250126
IS  - 1347-5215 (Electronic)
IS  - 0918-6158 (Linking)
VI  - 48
IP  - 1
DP  - 2025
TI  - Impact of Daily High Ergosterol Intake for 14 Weeks in Ovariectomized Rats on 
      Cholesterol and Vitamin D(3) Biosynthesis Pathways.
PG  - 39-45
LID - 10.1248/bpb.b24-00536 [doi]
AB  - Postmenopausal women are at a higher risk of developing dyslipidemia and 
      osteoporosis due to estrogen deficiency, necessitating regular vitamin D 
      supplementation and the use of cholesterol inhibitors, respectively, to prevent 
      these conditions. Despite current treatments, alternatives are needed to address 
      both conditions simultaneously. Ergosterol, a precursor of vitamin D(2), is a 
      fungal sterol converted to brassicasterol by 7-dehydrocholesterol reductase, a 
      cholesterol biosynthesis enzyme that converts 7-dehydrocholesterol (a precursor 
      of vitamin D(3)) into cholesterol. Our previous research demonstrated that 
      ergosterol decreases cholesterol levels and increases 7-dehydrocholesterol levels 
      in human HepG2 hepatoma cells. Furthermore, we reported that ergosterol increases 
      vitamin D(2) levels, inhibits the cholesterol biosynthetic pathway, and 
      potentially promotes vitamin D(3) biosynthesis in male rats fed a high-fat and 
      high-sucrose diet. In this study, we investigated the effects of daily high 
      ergosterol intake on cholesterol, vitamin D(2), and D(3) biosynthetic pathways in 
      ovariectomized (OVX) rats using GC-MS and LC with tandem mass spectrometry. OVX 
      rats treated with ergosterol for 14 weeks exhibited significantly decreased 
      plasma cholesterol levels and markers of cholesterol absorption, such as the 
      plant sterol sitosterol. Furthermore, 7-dehydrocholesterol levels increased in 
      these rats compared to untreated OVX rats. We observed that 1α, 
      25-dihydroxyvitamin D(3) levels slightly increased in OVX rats treated with 
      ergosterol. Additionally, ergosterol improved bone strength and increased 
      OVX-induced bone resorption. These results indicate that daily ergosterol intake 
      may aid in the simultaneous prevention of dyslipidemia and osteoporosis in 
      postmenopausal women.
FAU - Kuwabara, Naoko
AU  - Kuwabara N
AD  - Laboratory of Functional and Analytical Food Sciences, Faculty of Applied Life 
      Sciences, Niigata University of Pharmacy and Medical and Life Sciences, 265-1 
      Higashijima, Akiha-ku, Niigata 956-8603, Japan.
FAU - Kanda, Junkichi
AU  - Kanda J
AD  - Department of Clinical Pharmacotherapy, Faculty of Pharmaceutical Sciences, 
      Niigata University of Pharmacy and Medical and Life Sciences, 265-1 Higashijima, 
      Akiha-ku, Niigata 956-8603, Japan.
FAU - Sato, Shinji
AU  - Sato S
AD  - Laboratory of Functional and Analytical Food Sciences, Faculty of Applied Life 
      Sciences, Niigata University of Pharmacy and Medical and Life Sciences, 265-1 
      Higashijima, Akiha-ku, Niigata 956-8603, Japan.
FAU - Nakagawa, Saori
AU  - Nakagawa S
AD  - Division of Bio-Analytical Chemistry, Faculty of Medical Technology, Niigata 
      University of Pharmacy and Medical and Life Sciences, 265-1 Higashijima, 
      Akiha-ku, Niigata 956-8603, Japan.
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Biol Pharm Bull
JT  - Biological & pharmaceutical bulletin
JID - 9311984
RN  - Z30RAY509F (Ergosterol)
RN  - 1C6V77QF41 (Cholecalciferol)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - BK1IU07GKF (7-dehydrocholesterol)
RN  - 0 (Dehydrocholesterols)
SB  - IM
MH  - Animals
MH  - *Ergosterol/biosynthesis/pharmacology
MH  - Female
MH  - *Ovariectomy
MH  - *Cholecalciferol/pharmacology/administration & dosage
MH  - *Cholesterol/blood/biosynthesis
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Dehydrocholesterols/metabolism
OTO - NOTNLM
OT  - 7-dehydrocholesterol reductase
OT  - cholesterol
OT  - dyslipidemia
OT  - ergosterol
OT  - ovariectomized rat
OT  - vitamin D
EDAT- 2025/01/27 00:20
MHDA- 2025/01/27 00:21
CRDT- 2025/01/26 20:43
PHST- 2025/01/27 00:21 [medline]
PHST- 2025/01/27 00:20 [pubmed]
PHST- 2025/01/26 20:43 [entrez]
AID - 10.1248/bpb.b24-00536 [doi]
PST - ppublish
SO  - Biol Pharm Bull. 2025;48(1):39-45. doi: 10.1248/bpb.b24-00536.

PMID- 33140606
OWN - NLM
STAT- MEDLINE
DCOM- 20210115
LR  - 20240921
IS  - 1001-5515 (Print)
IS  - 1001-5515 (Linking)
VI  - 37
IP  - 5
DP  - 2020 Oct 25
TI  - [Low-magnitude vibration promotes osteogenesis of osteoblasts in ovariectomized 
      osteoporotic rats via the estrogen receptor α].
PG  - 825-833
LID - 10.7507/1001-5515.202006029 [doi]
AB  - The purpose of this study was to investigate the effect of low-magnitude 
      vibration on osteogenesis of osteoblasts in ovariectomized rats with osteoporosis 
      via estrogen receptor α(ERα). The mRNA expression of osteogenic markers were 
      examined with qRT-PCR, based on which the optimal vibration parameter for 
      promoting osteogenesis was determined (45 Hz × 0.9 g, g = 9.8 m/s(2)). Then we 
      loaded the optimal vibration parameter on the osteoblasts of ovariectomized rats 
      with osteoporosis. The protein expression of osteogenic markers and ERα were 
      detected with Western blot; the distribution of ERα was examined with 
      immunofluorescence technique. Finally, through inhibiting the expression of ERα 
      with estrogen receptor inhibitor ICI182780, the protein and mRNA expression of 
      osteogenic markers were examined. First, the results showed that low-magnitude 
      vibration could promote the expression of osteogenic markers and ERα in 
      osteoblasts of ovariectomized rats with osteoporosis (P < 0.05), and make ERα 
      transfer to the nucleus. On the other hand, the results also showed that after 
      inhibiting the expression of ERα in osteoblasts of ovariectomized rats with 
      osteoporosis, the protein and mRNA expression of osteogenic marker were decreased 
      (P < 0.05). In our study, low-magnitude vibration played an important role in the 
      osteogenesis of osteoblasts in ovariectomized rats with osteoporosis through 
      increasing the expression and causing translocation of ERα. Furthermore, it 
      provides a theoretical basis for the application of low-magnitude vibration in 
      the prevention and treatment of postmenopausal osteoporosis.
FAU - Zhu, Guangguang
AU  - Zhu G
AD  - Institute of Biomedical Engineering, West China School of Basic Medical Science & 
      Forensic Medicine, Sichuan University, Chengdu 610041, P.R.China.
FAU - Yu, Xiaoqin
AU  - Yu X
AD  - Institute of Biomedical Engineering, West China School of Basic Medical Science & 
      Forensic Medicine, Sichuan University, Chengdu 610041, P.R.China.
FAU - Wen, Jirui
AU  - Wen J
AD  - Institute of Biomedical Engineering, West China School of Basic Medical Science & 
      Forensic Medicine, Sichuan University, Chengdu 610041, P.R.China.
FAU - Bao, Mingyue
AU  - Bao M
AD  - Institute of Biomedical Engineering, West China School of Basic Medical Science & 
      Forensic Medicine, Sichuan University, Chengdu 610041, P.R.China.
FAU - Tang, Min
AU  - Tang M
AD  - Institute of Biomedical Engineering, West China School of Basic Medical Science & 
      Forensic Medicine, Sichuan University, Chengdu 610041, P.R.China.
FAU - Wang, Jingge
AU  - Wang J
AD  - Institute of Biomedical Engineering, West China School of Basic Medical Science & 
      Forensic Medicine, Sichuan University, Chengdu 610041, P.R.China.
FAU - He, Xueling
AU  - He X
AD  - Laboratory Animal Center, Sichuan University, Chengdu 610041, P.R.China.
FAU - Li, Liang
AU  - Li L
AD  - Institute of Biomedical Engineering, West China School of Basic Medical Science & 
      Forensic Medicine, Sichuan University, Chengdu 610041, P.R.China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Sheng Wu Yi Xue Gong Cheng Xue Za Zhi
JT  - Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = 
      Shengwu yixue gongchengxue zazhi
JID - 9426398
RN  - 0 (Estrogen Receptor alpha)
SB  - IM
MH  - Animals
MH  - Cell Differentiation
MH  - Estrogen Receptor alpha/genetics
MH  - Female
MH  - Osteoblasts
MH  - *Osteogenesis
MH  - *Osteoporosis
MH  - Ovariectomy
MH  - Rats
MH  - Vibration
PMC - PMC10320547
OTO - NOTNLM
OT  - estrogen receptor α
OT  - low-magnitude vibration
OT  - osteoblasts
OT  - ovariectomized osteoporosis
COIS- 利益冲突声明：本文全体作者均声明不存在利益冲突。
EDAT- 2020/11/04 06:00
MHDA- 2021/01/16 06:00
PMCR- 2020/10/25
CRDT- 2020/11/03 05:52
PHST- 2020/11/03 05:52 [entrez]
PHST- 2020/11/04 06:00 [pubmed]
PHST- 2021/01/16 06:00 [medline]
PHST- 2020/10/25 00:00 [pmc-release]
AID - swyxgcxzz-37-5-825 [pii]
AID - 10.7507/1001-5515.202006029 [doi]
PST - ppublish
SO  - Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2020 Oct 25;37(5):825-833. doi: 
      10.7507/1001-5515.202006029.
